# ESC Guidelines 2020

<!-- 2020_ACS_NSTE.md -->

# ESC Guidelines: ACS NSTE (2020)

**Source**: `2020_ACS_NSTE.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 79

---

## Table of Contents

- [tblfn1](#tblfn1) *(p. 13)*
- [tblfn2](#tblfn2) *(p. 13)*
- [tblfn3](#tblfn3) *(p. 13)*
- [tblfn4](#tblfn4) *(p. 13)*
- [tblfn5](#tblfn5) *(p. 15)*
- [tblfn6](#tblfn6) *(p. 15)*
- [tblfn7](#tblfn7) *(p. 18)*
- [tblfn8](#tblfn8) *(p. 18)*
- [tblfn17](#tblfn17) *(p. 19)*
- [tblfn18](#tblfn18) *(p. 19)*
- [tblfn19](#tblfn19) *(p. 19)*
- [tblfn20](#tblfn20) *(p. 19)*
- [tblfn21](#tblfn21) *(p. 19)*
- [tblfn22](#tblfn22) *(p. 19)*
- [tblfn23](#tblfn23) *(p. 19)*
- [tblfn9](#tblfn9) *(p. 20)*
- [tblfn10](#tblfn10) *(p. 20)*
- [tblfn11](#tblfn11) *(p. 20)*
- [tblfn12](#tblfn12) *(p. 21)*
- [tblfn13](#tblfn13) *(p. 21)*
- [tblfn14](#tblfn14) *(p. 21)*
- [tblfn15](#tblfn15) *(p. 21)*
- [tblfn16](#tblfn16) *(p. 21)*
- [tblfn26](#tblfn26) *(p. 23)*
- [tblfn27](#tblfn27) *(p. 23)*
- [tblfn28](#tblfn28) *(p. 23)*
- [tblfn24](#tblfn24) *(p. 24)*
- [tblfn25](#tblfn25) *(p. 24)*
- [tblfn39](#tblfn39) *(p. 26)*
- [tblfn40](#tblfn40) *(p. 26)*
- [tblfn41](#tblfn41) *(p. 26)*
- [tblfn42](#tblfn42) *(p. 28)*
- [tblfn43](#tblfn43) *(p. 28)*
- [tblfn47](#tblfn47) *(p. 28)*
- [tblfn48](#tblfn48) *(p. 28)*
- [tblfn44](#tblfn44) *(p. 29)*
- [tblfn45](#tblfn45) *(p. 29)*
- [tblfn46](#tblfn46) *(p. 29)*
- [tblfn49](#tblfn49) *(p. 30)*
- [tblfn50](#tblfn50) *(p. 30)*
- [tblfn51](#tblfn51) *(p. 30)*
- [tblfn29](#tblfn29) *(p. 31)*
- [tblfn103](#tblfn103) *(p. 31)*
- [tblfn30](#tblfn30) *(p. 33)*
- [tblfn31](#tblfn31) *(p. 33)*
- [tblfn32](#tblfn32) *(p. 33)*
- [tblfn33](#tblfn33) *(p. 34)*
- [tblfn34](#tblfn34) *(p. 34)*
- [tblfn35](#tblfn35) *(p. 34)*
- [tblfn36](#tblfn36) *(p. 41)*
- [tblfn37](#tblfn37) *(p. 41)*
- [tblfn38](#tblfn38) *(p. 41)*
- [tblfn104](#tblfn104) *(p. 42)*
- [tblfn105](#tblfn105) *(p. 42)*
- [tblfn106](#tblfn106) *(p. 43)*
- [tblfn107](#tblfn107) *(p. 43)*
- [tblfn108](#tblfn108) *(p. 43)*
- [tblfn109](#tblfn109) *(p. 44)*
- [tblfn110](#tblfn110) *(p. 44)*
- [tblfn111](#tblfn111) *(p. 44)*
- [tblfn112](#tblfn112) *(p. 45)*
- [tblfn113](#tblfn113) *(p. 45)*
- [tblfn114](#tblfn114) *(p. 45)*
- [tblfn115](#tblfn115) *(p. 45)*
- [tblfn116](#tblfn116) *(p. 45)*
- [tblfn117](#tblfn117) *(p. 45)*
- [tblfn118](#tblfn118) *(p. 46)*
- [tblfn119](#tblfn119) *(p. 46)*
- [tblfn120](#tblfn120) *(p. 47)*
- [tblfn121](#tblfn121) *(p. 47)*
- [tblfn122](#tblfn122) *(p. 47)*
- [tblfn123](#tblfn123) *(p. 48)*
- [tblfn124](#tblfn124) *(p. 48)*
- [tblfn125](#tblfn125) *(p. 48)*
- [tblfn126](#tblfn126) *(p. 48)*
- [tblfn52](#tblfn52) *(p. 51)*
- [tblfn53](#tblfn53) *(p. 51)*
- [tblfn54](#tblfn54) *(p. 51)*
- [tblfn55](#tblfn55) *(p. 51)*
- [tblfn56](#tblfn56) *(p. 55)*
- [tblfn99](#tblfn99) *(p. 59)*
- [tblfn100](#tblfn100) *(p. 59)*
- [tblfn101](#tblfn101) *(p. 59)*
- [tblfn1102](#tblfn1102) *(p. 59)*
- [tblfn1103](#tblfn1103) *(p. 59)*
- [tblfn1104](#tblfn1104) *(p. 59)*
- [tblfn1105](#tblfn1105) *(p. 59)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
Authors/Task Force Members: Jean-Philippe Collet
* (Chairperson) (France),
Holger Thiele
* (Chairperson) (Germany), Emanuele Barbato (Italy),
Olivier Barthe´le´my (France), Johann Bauersachs (Germany), Deepak L. Bhatt
(United States of America), Paul Dendale (Belgium), Maria Dorobantu (Romania),
Thor Edvardsen (Norway), Thierry Folliguet (France), Chris P. Gale
(United Kingdom), Martine Gilard (France), Alexander Jobs (Germany),
Peter Ju¨ni (Canada), Ekaterini Lambrinou (Cyprus), Basil S. Lewis (Israel),
Julinda Mehilli (Germany), Emanuele Meliga (Italy), Be´la Merkely (Hungary),
Christian Mueller (Switzerland), Marco Roffi (Switzerland), Frans H. Rutten
(Netherlands), Dirk Sibbing (Germany), George C.M. Siontis (Switzerland)
* Corresponding authors: Jean-Philippe Collet, Sorbonne Universite´, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hoˆpital Pitie´-Salp^etrie`re (Assistance
Publique- Hoˆpitaux de Paris) (AP-HP), 83, boulevard de l’Hoˆpital, 75013 Paris, France. Tel þ 33 01 42 16 29 62, E-mail: jean-philippe.collet@aphp.fr
Holger Thiele, Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Stru¨mpellstr. 39, 04289 Leipzig, Germany. Tel: þ49 341 865 1428, Fax:
þ49 341 865 1461, E-mail: holger.thiele@medizin.uni-leipzig.de
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers, and Author/Task Force Member afﬁliations: listed in the Appendix.
ESC entities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European
Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice.
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Coronary Pathophysiology and Microcirculation, Thrombosis.
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
V
C The European Society of Cardiology 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehaa575


<!-- PAGE 2 -->

### Page 2

.......................................................................
Document Reviewers: Adnan Kastrati (CPG Review Coordinator) (Germany), Mamas A. Mamas (CPG
Review Coordinator) (United Kingdom), Victor Aboyans (France), Dominick J. Angiolillo (United States of
America), Hector Bueno (Spain), Raffaele Bugiardini (Italy), Robert A. Byrne (Ireland), Silvia Castelletti
(Italy), Alaide Chieffo (Italy), Veronique Cornelissen (Belgium), Filippo Crea (Italy), Victoria Delgado
(Netherlands), Heinz Drexel (Austria), Marek Gierlotka (Poland), Sigrun Halvorsen (Norway), Kristina
Hermann Haugaa (Norway), Ewa A. Jankowska (Poland), Hugo A. Katus (Germany), Tim Kinnaird (United
Kingdom), Jolanda Kluin (Netherlands), Vijay Kunadian (United Kingdom), Ulf Landmesser (Germany),
Christophe Leclercq (France), Maddalena Lettino (Italy), Leena Meinila (Finland), Darren Mylotte
(Ireland), Gjin Ndrepepa (Germany), Elmir Omerovic (Sweden), Roberto F. E. Pedretti (Italy), Steffen E.
Petersen (United Kingdom), Anna Sonia Petronio (Italy), Gianluca Pontone (Italy), Bogdan A. Popescu
(Romania), Tatjana Potpara (Serbia), Kausik K. Ray (United Kingdom), Flavio Luciano Ribichini (Italy),
Dimitrios J. Richter (Greece), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom),
Miguel Sousa-Uva (Portugal), Robert F. Storey (United Kingdom), Rhian M. Touyz (United Kingdom),
Marco Valgimigli (Switzerland), Pascal Vranckx (Belgium), Robert W. Yeh (United States of America)
The disclosure forms of all experts involved in the development of these guidelines are available on the
ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the Guidelines see European Heart Journal online.
...................................................................................................................................................................................................
Keywords
Guidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet
• apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/
IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction
• nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations •
revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable angina
Table of contents
Abbreviations and acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1293
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1295
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296
2.1 Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296
2.1.1 Universal definition of myocardial infarction . . . . . . . . . . . . 1296
2.1.1.1 Type 1 myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . 1296
2.1.1.2 Type 2 myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . 1297
2.1.1.3 Types 35 myocardial infarction . . . . . . . . . . . . . . . . . . 1297
2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1297
2.2 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1297
2.3 What is new? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1297
2.4 Number and breakdown of classes of recommendations (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . 1298
3 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1298
3.1 Clinical presentation (Supplementary Data) . . . . . . . . . . . . . . . . 1298
3.2 Physical examination (Supplementary Data) . . . . . . . . . . . . . . . . 1298
3.3 Diagnostic tools . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1298
3.3.1 Electrocardiogram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1298
3.3.2 Biomarkers: high-sensitivity cardiac troponin . . . . . . . . . . . 1299
3.3.2.1 Central laboratory vs. point-of-care . . . . . . . . . . . . . . . . 1300
3.3.2.2 Other biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
3.3.3 Rapid ‘rule-in’ and ‘rule-out’ algorithms . . . . . . . . . . . . . . . . . 1301
3.3.4 Observe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1303
3.3.4.1 Caveats of using rapid algorithms . . . . . . . . . . . . . . . . . . 1303
3.3.4.2 Confounders of cardiac troponin concentration . . . . 1303
3.3.4.3 Practical guidance on how to implement the
European Society of Cardiology 0 h/1 h algorithm . . . . . . . . . 1304
3.3.4.4 Avoiding misunderstandings: time to decision
= time of blood drawrn-around time . . . . . . . . . . . . . . . . . . . . . 1304
3.3.5 Non-invasive imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
3.3.5.1 Functional evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
3.3.5.2 Anatomical evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
3.4 Differential diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
4 Risk assessment and outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1307
4.1 Electrocardiogram indicators (Supplementary Data) . . . . . . . . 1307
4.2 Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1307
4.3 Clinical scores for risk assessment (Supplementary Data) . . . . 1307
4.4 Bleeding risk assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1308
4.5 Integrating ischaemic and bleeding risks . . . . . . . . . . . . . . . . . . . . . 1309
5 Pharmacological treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
5.1 Antithrombotic treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
5.1.1 Antiplatelet drugs and pre-treatment . . . . . . . . . . . . . . . . . . . 1311
5.1.1.1 Antiplatelet drugs and dual antiplatelet therapy . . . . . 1311


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
5.1.1.2 Pre-treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1312
5.1.2 Peri-interventional anticoagulant treatment . . . . . . . . . . . . . 1314
5.1.3 Peri-interventional antiplatelet treatment . . . . . . . . . . . . . . . 1315
5.1.4 Post-interventional and maintenance treatment . . . . . . . . 1315
5.2 Pharmacological treatment of ischaemia
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318
5.2.1 Supportive pharmacological treatment
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318
5.2.2 Nitrates and beta-blockers (Supplementary Data) . . . . . . 1318
5.3 Managing oral antiplatelet agents in patients requiring long-termoral anticoagulants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318
5.3.1 Patients with atrial fibrillation without mechanical prosthetic heart valves or moderate-to-severe mitral stenosis undergoing percutaneous coronary intervention or managed medically (Supplementary Data) . . . . . . . . . . . . . . . . 1318
5.3.2 Patients requiring vitamin K antagonists or undergoing coronary artery bypass surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1320
5.4 Management of acute bleeding events
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.1 General supportivemeasures
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.2 Bleeding events on antiplatelet agents
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.3 Bleeding events on vitamin K antagonists
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.4 Bleeding events on non-vitamin K antagonist oral anticoagulants (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.5 Non-access-related bleeding events
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.6 Bleeding events related to percutaneous coronary intervention (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.7 Bleeding events related to coronary artery bypass surgery (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.8 Transfusion therapy (Supplementary Data) . . . . . . . . . . . . . 1322
5.4.9 Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients . . . . . . . . . . . . . 1322
6 Invasive treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
6.1 Invasive coronary angiography and revascularization . . . . . . . . 1322
6.1.1 Routine invasive vs. selective invasive approach (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
6.1.2 Timing of invasive strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1323
6.1.2.1 Immediate invasive strategy (<2 h) . . . . . . . . . . . . . . . . . 1323
6.1.2.2 Early invasive strategy (<24 h) . . . . . . . . . . . . . . . . . . . . . 1323
6.1.2.3 Selective invasive strategy . . . . . . . . . . . . . . . . . . . . . . . . . 1324
6.1.3 Pattern of coronary artery disease in non-ST-segment elevation acute coronary syndrome (Supplementary Data) . . . 1325
6.1.4 How to identify the culprit lesion? (Supplementary
Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1325
6.1.5 Spontaneous coronary artery dissection . . . . . . . . . . . . . . . . 1325
6.1.6 Fractional flow reserve, instantaneous wave-free ratio, and other resting indices (Supplementary Data) . . . . . . . . 1326
6.1.6.1 Fractional flow reserve . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.1.6.2 Instantaneous wave-free ratio and other resting indices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.1.7 Intracoronary imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.2 Conservative treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.2.1 Patients who are not candidates for invasive coronary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.2.2 Patients with coronary artery disease not amenable to revascularization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.3 Technical aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.3.1 Technical aspects and challenges . . . . . . . . . . . . . . . . . . . . . . . 1327
6.3.2 Vascular access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.3.3 Revascularization strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.4 Coronary artery bypass grafting . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.5 Percutaneous coronary intervention vs. coronary artery bypass surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.6 Specific situations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1328
6.6.1 Management of patients with ongoing myocardial ischaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1328
6.6.2 Management of patients with cardiac arrest . . . . . . . . . . . . . 1328
6.7 Recommendations for coronary revascularization . . . . . . . . . . 1328
7 Myocardial infarction with non-obstructive coronary arteries and alternative diagnoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1329
8 Special populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1331
8.1 Heart failure and cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . 1331
8.2 Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332
8.3 Chronic kidney disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
8.4 Anaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.5 Thrombocytopenia (Supplementary Data) . . . . . . . . . . . . . . . . . . 1334
8.5.1 Thrombocytopenia related to glycoprotein IIb/IIIa inhibitors (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.5.2 Heparin-induced thrombocytopenia
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.6 The older person . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.7 Frailty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.8 Sex disparities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
9 Long-term management of non-ST-segment elevation acute coronary syndrome (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.1 Lifestyle management (Supplementary Data) . . . . . . . . . . . . . . . 1335
9.1.1 Smoking (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.1.2 Diet and alcohol (Supplementary Data) . . . . . . . . . . . . . . . . 1335
9.1.3 Weight management (Supplementary Data) . . . . . . . . . . . . 1335
9.1.3 Physical activity (Supplementary Data) . . . . . . . . . . . . . . . . . 1335
9.1.4 Cardiac rehabilitation (Supplementary Data) . . . . . . . . . . . 1335
9.1.5 Psychosocial factors (Supplementary Data) . . . . . . . . . . . . . 1335
9.1.6 Environmental factors (Supplementary Data) . . . . . . . . . . . 1335
9.1.7 Sexual activity (Supplementary Data) . . . . . . . . . . . . . . . . . . . 1335
9.1.8 Adherence and sustainability (Supplementary Data) . . . . . 1335
9.1.9 Influenza vaccination (Supplementary Data) . . . . . . . . . . . . 1335
9.2 Pharmacological management (Supplementary Data) . . . . . . . 1335
9.2.1 Anti-ischaemic drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.2.1.1 Beta-blockers (Supplementary Data) . . . . . . . . . . . . . . . 1335
9.2.2 Antithrombotic treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.2.3 Proton pump inhibitors (Supplementary Data) . . . . . . . . . . 1335
9.2.4 Statins and other lipid-lowering agents . . . . . . . . . . . . . . . . . 1335
9.2.5 Glucose-lowering therapy in patients with diabetes . . . . . 1336
9.2.6 Renin-angiotensin-aldosterone system blockers (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
9.2.7 Mineralocorticoid receptor antagonist therapy (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
9.2.8 Antihypertensive therapy (Supplementary Data) . . . . . . . . 1336
9.2.9 Hormone replacement therapy (Supplementary Data) . . 1336
ESC Guidelines
1291


<!-- PAGE 4 -->

### Page 4

........................................................................................................................................................................
10 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1337
11 Management strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1340
12 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1341
13 Gaps in evidence for non-ST-segment elevation acute coronary syndrome care and future research . . . . . . . . . . . . . . . . . . . . . 1342
14 ‘What to do’ and ‘what not to do’messages . . . . . . . . . . . . . . . . . . . . 1343
15 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1347
16 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1347
17 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1348
Tables of Recommendations
Recommendations for diagnosis, risk stratification, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1306
Recommendations on biomarker measurements for prognostic stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1308
Recommendations for antithrombotic treatment in non-STsegment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention . . . . . . . . . . . . . . . . . . 1314
Recommendations for post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1317
Recommendations for anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . 1318
Recommendations for combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation . . . . . . . . . . 1321
Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
Recommendations for coronary revascularization . . . . . . . . . . . . . . . . 1328
Recommendations for myocardial infarction with non-obstructive coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1331
Recommendations for non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock . . . . . . . . . 1332
Recommendations for diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients . . . . . . . . . . . . . . . . . . . . . . 1333
Recommendations for patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome . . . . . . . . . 1333
Recommendations for older persons with non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
Recommendations for lifestyle managements after non-STsegment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
Recommendations for pharmacological long-term management after non-ST-segment elevation acute coronary syndrome
(excluding antithrombotic treatments) . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1295
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296
Table 3 Clinical implications of high-sensitivity cardiac troponin assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
Table 4 Conditions other than acute type 1 myocardial infarction associated with cardiomyocyte injury (= cardiac troponin elevation) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
Table 5 Assay specific cut-off levels in ng/l within the 0 h/1 h and 0 h/2 h algorithms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1303
Table 6 Differential diagnoses of acute coronary syndromes in the setting of acute chest pain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1306
Table 7 Major and minor criteria for high bleeding risk according to the Academic Research Consortium for High
Bleeding Risk at the time of percutaneous coronary intervention
(bleeding risk is high if at least one major or two minor criteria aremet) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
Table 8 Dose regimen of antiplatelet and anticoagulant drugs in non-ST-segment elevation acute coronary syndrome patients . . . . . 1311
Table 9 P2Y12 receptor inhibitors for use in non-ST-segment elevation acute coronary syndrome patients . . . . . . . . . . . . . . . . . . . . . . 1312
Table 10 Treatment options for extended dual antithrombotic or antiplatelet therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1316
Table 11 Risk criteria for extended treatment with a second antithrombotic agent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1316
Table 12 Suggested strategies to reduce bleeding risk related to percutaneous coronary intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1319
Table 13 Randomized controlled trials including patients with non-ST-segment elevation acute coronary syndrome requiring anticoagulation and antiplatelet therapy . . . . . . . . . . . . . . . . . . . . . . . . . . 1319
Table 14 Diagnostic criteria of myocardial infarction with non-obstructive coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330
Table 15 Quality indicators in non-ST-segment elevation acute coronary syndrome care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1337
List of figures
Figure 1 Diagnostic algorithm and triage in acute coronary syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1299
Figure 2 Value of high-sensitivity cardiac troponin. . . . . . . . . . . . . . . . . . 1300
Figure 3 0 h/1 h rule-out and rule-in algorithm using high-sensitivity cardiac troponin assays in haemodynamically stable patients presenting with suspected non-ST-segment elevation acute coronary syndrome to the emergency department. . . . . . . . . . . . . . . . 1302
Figure 4 Timing of the blood draws and clinical decisions when using the European Society of Cardiology 0 h/1 h algorithm. . . . . . . . 1304
Figure 5 Determinants of antithrombotic treatment in coronary artery disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1310
Figure 6 Antithrombotic treatments in non-ST-segment elevation acute coronary syndrome patients: pharmacological targets. . . . . . . . 1310
Figure 7 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients without atrial fibrillation undergoing percutaneous coronary intervention . . . . . . . . . . . . . . . . . . . . . . . . 1313
Figure 8 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients with atrial fibrillation undergoing percutaneous coronary intervention or medical management . . . . . 1320
Figure 9 Selection of non-ST-segment elevation acute coronary syndrome treatment strategy and timing according to initial risk stratification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1323


<!-- PAGE 5 -->

### Page 5

.......................................................................................................................................................................
Figure 10 Time to coronary angiography in the early/immediate invasive and delayed invasive groups of included trials. . . . . . . . . . . . . . 1324
Figure 11 Diagnosis and treatment of patients with non-ST-segment elevation acute coronary syndrome related to spontaneous coronary artery dissection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1325
Figure 12 Diagnostic algorithm for myocardial infarction with non-obstructive coronary arteries using a traffic light scheme. . . . . . 1331
Figure 13 Central illustration. Management strategy for non-ST-segment elevation acute coronary syndrome patients. . . . . . 1340
Abbreviations and acronyms
ACCOAST
Comparison of Prasugrel at the Time of
Percutaneous Coronary Intervention or as
Pretreatment at the Time of Diagnosis in
Patients with Non-ST Elevation Myocardial
Infarction
ACE
Angiotensin-converting enzyme
ACS
Acute coronary syndromes
ACUITY
Acute Catheterization and Urgent
Intervention Triage strategY
ACVC
Association for Acute Cardiovascular Care
ADP
Adenosine diphosphate
AF
Atrial ﬁbrillation
AGRIS
Australian GRACE Risk score Intervention
Study
AHA
American Heart Association
AMI
Acute myocardial infarction
ARB
Angiotensin receptor blocker
ARC-HBR
Academic Research Consortium for High
Bleeding Risk
ATLAS ACS 2
TIMI 51
Anti-Xa Therapy to Lower Cardiovascular
Events in Addition to Standard Therapy in
Subjects with Acute Coronary
SyndromeThrombolysis In Myocardial
Infarction 51
AUGUSTUS
Antithrombotic Therapy after Acute
Coronary Syndrome or PCI in Atrial
Fibrillation
BARC
Bleeding Academic Research Consortium
BEST
Randomized Comparison of Coronary
Artery Bypass Surgery and EverolimusEluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery
Disease b.i.d
.
Bis in die (twice a day)
BNP
B-type natriuretic peptide
CABG
Coronary artery bypass graft(ing)
CAD
Coronary artery disease
CCS
Chronic coronary syndromes
CCTA
Coronary computed tomography angiography
CCU
Coronary care unit
CFR
Coronary ﬂow reserve
CHA2DS2-VASc
Congestive heart failure, Hypertension, Age
>_75 years (2 points), Diabetes, Stroke (2
points)Vascular disease, Age 6574, Sex category (female)
CHAMPION
Cangrelor versus Standard Therapy to
Achieve Optimal Management of Platelet
Inhibition
CI
Conﬁdence interval
CK
Creatine kinase
CKD
Chronic kidney disease
CK-MB
Creatine kinase myocardial band
CMR
Cardiac magnetic resonance
COACT
Coronary Angiography after Cardiac Arrest
COMPASS
Cardiovascular OutcoMes for People using
Anticoagulation StrategieS
CPG
Clinical practice guidelines
CPR
Cardiopulmonary resuscitation
CrCl
Creatinine clearance
CRUSADE
Can Rapid risk stratiﬁcation of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA
guidelines
CS
Cardiogenic shock
CT
Computed tomography
CULPRITSHOCK
Culprit Lesion Only PCI versus Multivessel
PCI in Cardiogenic Shock
CVD
Cardiovascular disease
CYP
Cytochrome P450
DAPT
Dual antiplatelet therapy
DAT
Dual antithrombotic therapy
DES
Drug-eluting stent
EACTS
European Association for Cardio-Thoracic
Surgery
ECG
Electrocardiogram/electrocardiography
Echo
Echocardiogram eGFR
Estimated glomerular ﬁltration rate
ELISA
Early or Late Intervention in unStable Angina
ENTRUSTAF PCI
EdoxabaN TRreatment versUS VKA in paTients with AF undergoing PCI
ESC
European Society of Cardiology
FAMOUSNSTEMI
Fractional ﬂow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction
FFR
Fractional ﬂow reserve
FFR-CT
Fractional ﬂow reserve-computed tomography
GDF-15
Growth differentiation factor 15
GP
Glycoprotein
GRACE
Global Registry of Acute Coronary Events
HAS-BLED
Hypertension, abnormal renal and liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly
(>65 years), drugs and alcohol (1 point each)
HBR
High bleeding risk h-FABP
Heart-type fatty acid-binding protein
ESC Guidelines
1293


<!-- PAGE 6 -->

### Page 6

........................................................................................................................................................................
HIT
Heparin-induced thrombocytopenia
HR
Hazard ratio hs-cTn
High-sensitivity cardiac troponin
IABP
Intra-aortic balloon pump
IABP-SHOCK II
Intraaortic Balloon Pump in cardiogenic shock II
ICA
Invasive coronary angiography iFR
Instantaneous wave-free ratio
IMR
Index of microcirculatory resistance
INR
International normalized ratio
ISAR-REACT
Intracoronary stenting and Antithrombotic regimenRapid Early Action for Coronary
Treatment
ISAR-TRIPLE
Triple Therapy in Patients on Oral
Anticoagulation After Drug Eluting Stent
Implantation i.v.
Intravenous
IVUS
Intravascular ultrasound
LBBB
Left bundle branch block
LD
Loading dose
LDL-C
Low-density lipoprotein cholesterol
LIPSIA-NSTEMI
Leipzig Immediate versus early and late
PercutaneouS coronary Intervention triAl in
NSTEMI
LMWH
Low-molecular-weight heparin
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MACE
Major adverse cardiovascular events
MATRIX
Minimizing Adverse Haemorrhagic Events by
TRansradial Access Site and Systemic
Implementation of angioX
MD
Maintenance dose
MDCT
Multidetector computed tomography
MI
Myocardial infarction
MINOCA
Myocardial infarction with non-obstructive coronary arteries
MRA
Mineralocorticoid receptor antagonist
NOAC
Non-vitamin K antagonist oral anticoagulant
NPV
Negative predictive value
NSTE-ACS
Non-ST-segment elevation acute coronary syndrome
NSTEMI
Non-ST-segment elevation myocardial infarction
NT-proBNP
N-terminal pro-B-type natriuretic peptide
OAC
Oral anticoagulation/anticoagulant
OASIS-5
Fifth Organization to Assess Strategies in
Acute Ischemic Syndromes
OCT
Optical coherence tomography o.d.
Once daily
OR
Odds ratio
P
Prasugrel
PAD
Peripheral artery disease
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin kexin 9
Pd/Pa
Distal coronary to aortic pressure ratio
PEGASUS-TIMI 54
Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a
Background of Aspirin-Thrombolysis in
Myocardial Infarction 54
PLATO
PLATelet inhibition and patient Outcomes
POCT
Point-of-care test
PPV
Positive predictive value
PRECISE-DAPT
PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy
PRECOMBAT
Premier of Randomized Comparison of
Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left
Main Coronary Artery Disease
PROMs
Patient-reported outcome measures
QI
Quality indicator
RBBB
Right bundle branch block
RCT
Randomized controlled trial
RE-DUAL PCI
Randomized Evaluation of Dual
Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in
Patients with Nonvalvular Atrial Fibrillation
Undergoing Percutaneous Coronary
Intervention
REDUCE-IT
Reduction of Cardiovascular Events with
Icosapent EthylIntervention Trial
RFR
Resting full-cycle ratio
RIDDLE-NSTEMI
Randomized Study of Immediate Versus
Delayed Invasive Intervention in Patients
With Non-ST-Segment Elevation Myocardial
Infarction
RIVAL
RadIal Vs femorAL access for coronary intervention
RR
Relative risk
SAPT
Single antiplatelet therapy
SCAAR
Swedish Coronary Angiography and
Angioplasty Registry
SCAD
Spontaneous coronary artery dissection
SISCA
Comparison of Two Treatment Strategies in
Patients With an Acute Coronary Syndrome
Without ST Elevation
SMILE
Impact of Different Treatment in Multivessel
Non ST Elevation Myocardial Infarction
Patients: One Stage Versus Multistaged
Percutaneous Coronary Intervention
SPECT
Single-photon-emission tomography
STEMI
ST-segment elevation myocardial infarction
STS
Society of Thoracic Surgeons
SYNTAX
Synergy between PCI with Taxus and cardiac surgery
TAT
Triple antithrombotic therapy
TIMACS
Timing of Intervention in Patients with Acute
Coronary Syndromes
TIMI
Thrombolysis In Myocardial Infarction


<!-- PAGE 7 -->

### Page 7

.................................................................................................
TRITON-TIMI 38
TRial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet InhibitioN
with PrasugrelThrombolysis In Myocardial
Infarction 38
TROPICAL-ACS
Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute
Coronary Syndromes
TWILIGHT
Ticagrelor With Aspirin or Alone in HighRisk Patients After Coronary Intervention
UFH
Unfractionated heparin
UKGRIS
UK GRACE Risk Score Intervention Study
ULTIMATE
Intravascular Ultrasound Guided Drug Eluting
Stents Implantation in “All-Comers”
Coronary Lesions
VALIDATESWEDEHEART
Swedish Web-system for Enhancement and
Development of Evidence-based care in
Heart disease Evaluated According to
Recommended Therapies
VERDICT
Very EaRly vs Deferred Invasive evaluation using Computerized Tomography
VKA
Vitamin K antagonist
WOEST
What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESCGuidelines). The ESC Guidelines represent the official position of the
ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the Guidelines and may be used by the
ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a
Table 1
Classes of recommendations
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
©ESC 2020
ESC Guidelines
1295


<!-- PAGE 8 -->

### Page 8

..........................................................................................................
comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
2 Introduction
2.1 Definitions
The clinical presentation of acute coronary syndromes (ACS) is broad. It ranges from cardiac arrest, electrical or haemodynamic instability with cardiogenic shock (CS) due to ongoing ischaemia or mechanical complications such as severe mitral regurgitation, to patients who are already pain free again at the time of presentation.1
The leading symptom initiating the diagnostic and therapeutic cascade in patients with suspected ACS is acute chest discomfort described as pain, pressure, tightness, and burning. Chest pain-equivalent symptoms may include dyspnoea, epigastric pain, and pain in the left arm.
Based on the electrocardiogram (ECG), two groups of patients should be differentiated:
• Patients with acute chest pain and persistent (>20 min)
ST-segment elevation. This condition is termed ST-segment elevation ACS and generally reflects an acute total or subtotal coronary occlusion. Most patients will ultimately develop ST-segment elevation myocardial infarction (STEMI). The mainstay of treatment in these patients is immediate reperfusion by primary percutaneous coronary intervention (PCI) or, if not available in a timely manner, by fibrinolytic therapy.2
• Patients with acute chest discomfort but no persistent
ST-segment elevation [non-ST-segment elevation ACS (NSTEACS)]
exhibit
ECG
changes that may include transient
ST-segment elevation, persistent or transient ST-segment depression, T-wave inversion, flat T waves, or pseudonormalization of T waves; or the ECG may be normal.
The pathological correlate at the myocardial level is cardiomyocyte necrosis [non-ST-segment elevation myocardial infarction
(NSTEMI)] or, less frequently, myocardial ischaemia without cell damage (unstable angina). A small proportion of patients may present with ongoing myocardial ischaemia, characterized by one or more of the following: recurrent or ongoing chest pain, marked ST-segment depression on 12-lead ECG, heart failure, and haemodynamic or electrical instability.1 Due to the amount of myocardium in jeopardy and the risk of developing CS and/or malignant ventricular arrhythmias, immediate coronary angiography and, if appropriate, revascularization are indicated (see section 6).
2.1.1 Universal definition of myocardial infarction
Acute myocardial infarction (AMI) defines cardiomyocyte necrosis in a clinical setting consistent with acute myocardial ischaemia.1,3 A
combination of criteria is required to meet the diagnosis of AMI,
namely the detection of an increase and/or decrease of a cardiac biomarker, preferably high-sensitivity cardiac troponin (hs-cTn) T or I,
with at least one value above the 99th percentile of the upper reference limit and at least one of the following:
(1)
Symptoms of myocardial ischaemia.
(2)
New ischaemic ECG changes.
(3)
Development of pathological Q waves on ECG.
(4)
Imaging evidence of loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology.
(5)
Intracoronary thrombus detected on angiography or autopsy.
2.1.1.1 Type 1 myocardial infarction
Type 1 myocardial infarction (MI) is characterized by atherosclerotic plaque rupture, ulceration, fissure, or erosion with resulting
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2020


<!-- PAGE 9 -->

### Page 9

.............................................................................................................................................................................
intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and/or distal embolization and subsequent myocardial necrosis. The patient may have underlying severe coronary artery disease (CAD) but, on occasion
(510% of cases), there may be non-obstructive coronary atherosclerosis or no angiographic evidence of CAD, particularly in women.1,35
2.1.1.2 Type 2 myocardial infarction
Type 2 MI is myocardial necrosis in which a condition other than coronary plaque instability causes an imbalance between myocardial oxygen supply and demand.3 Mechanisms include hypotension,
hypertension, tachyarrhythmias, bradyarrhythmias, anaemia, hypoxaemia, but also by definition, coronary artery spasm, spontaneous coronary artery dissection (SCAD), coronary embolism, and coronary microvascular dysfunction.68
2.1.1.3 Types 35 myocardial infarction
The universal definition of MI also includes type 3 MI (MI resulting in death when biomarkers are not available) and types 4 and 5 MI
[related to PCI and coronary artery bypass grafting (CABG),
respectively].3
2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays
Unstable angina is defined as myocardial ischaemia at rest or on minimal exertion in the absence of acute cardiomyocyte injury/necrosis.
Among unselected patients presenting to the emergency department with suspected NSTE-ACS, the introduction of hs-cTn measurements in place of standard troponin assays resulted in an increase in the detection of MI (4% absolute and 20% relative increases) and a reciprocal decrease in the diagnosis of unstable angina.913
Compared with NSTEMI patients, individuals with unstable angina do not experience acute cardiomyocyte injury/necrosis, have a substantially lower risk of death, and appear to derive less benefit from intensified antiplatelet therapy, as well as an invasive strategy within
72 h.1,35,919 Pathophysiology and epidemiology are discussed in detail elsewhere.1
2.2 Epidemiology
The proportion of patients with NSTEMI in MI surveys increased from one third in 1995 to more than half in 2015, mainly accounted for by a refinement in the operational diagnosis of NSTEMI20. As opposed to STEMI, no significant changes are observed in the baseline characteristics of the NSTEMI population with respect to age and smoking, while diabetes, hypertension, and obesity increased substantially. The use of early angiography (<_72 h from admission)
increased from 9% in 1995 to 60% in 2015 [adjusted odds ratio (OR)
16.4, 95% confidence interval (CI) 12.022.4, P<0.001] and PCI during the initial hospital stay increased from 12.5% to 67%. The main consequences of these changes are a reduction in 6-month mortality from 17.2% to 6.3% and the adjusted hazard ratio (HR) decreased to
0.40 (95% CI 0.300.54) in 2010, remaining stable at 0.40
(0.300.52) in 2015.20
2.3 What is new?
New key recommendations 
Diagnosis
As an alternative to the ESC 0 h/1 h algorithm, it is recommended to use the ESC 0 h/2 h algorithm with blood sampling at 0 h and 2 h, if an hs-cTn test with a validated 0 h/2 h algorithm is available.
For diagnostic purposes, it is not recommended to routinely measure additional biomarkers such 
as CK, CK-MB, h-FABP, or copeptin, in addition to hs-cTn. 
Risk stratification
Measuring BNP or NT-proBNP plasma concentrations should be considered to gain prognostic 
information.
Antithrombotic treatment
In patients with NSTE-ACS who cannot undergo an early invasive strategy, pre-treatment with 
a P2Y12 receptor inhibitor may be considered depending on bleeding risk.
De-escalation of P2Y12 inhibitor treatment (e.g. with a switch from prasugrel or ticagrelor to 
clopidogrel) may be considered as an alternative DAPT strategy, especially for ACS patients 
deemed unsuitable for potent platelet inhibition. De-escalation may be done unguided based on 
clinical judgment, or guided by platelet function testing, or CYP2C19 genotyping depending 
on the patient’s risk profile and availability of respective assays.
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor to 
patients in whom the coronary anatomy is not known and early invasive management is 
planned.
Prasugrel should be considered in preference to ticagrelor for NSTE-ACS patients who proceed to PCI.
In patients with AF (CHA2DS2-VASc score ≥1 in men and ≥2 in women), after a short period 
of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using 
a NOAC at the recommended dose for stroke prevention and single oral antiplatelet agent 
(preferably clopidogrel).
Discontinuation of antiplatelet treatment in patients treated with OACs is recommended after 12 
months.
DAT with an OAC and either ticagrelor or prasugrel may be considered as an alternative to 
TAT with an OAC, aspirin, and clopidogrel in patients with a moderate or high risk of stent 
thrombosis, irrespective of the type of stent used.
Invasive treatment
An early invasive strategy within 24 h is recommended in patients with any of the following 
high-risk criteria: 
•
Diagnosis of NSTEMI.  
•
Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing 
ischaemia. 
•
Transient ST-segment elevation. 
•
GRACE risk score >140. 
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive 
CAD by CCTA is recommended in patients considered at low risk.
Delayed, as opposed to immediate, angiography should be considered in haemodynamically 
stable patients without ST-segment elevation successfully resuscitated after an out-of-hospital 
cardiac arrest.
Complete revascularization should be considered in NSTE-ACS patients without cardiogenic 
shock and with multivessel CAD.
Complete revascularization during index PCI may be considered in NSTE-ACS patients with 
multivessel disease.
FFR-guided revascularization of non-culprit NSTE-ACS lesions may be used during index 
PCI.
Continued
ESC Guidelines
1297


<!-- PAGE 10 -->

### Page 10

.............................................................................................................................................................................
Major changes in recommendations 
0
2
0
2
5
1
0
2
Diagnosis
A rapid rule-out protocol at 0 h and 3 h is 
recommended if hs-cTn tests are available.
A rapid rule-out and rule-in protocol with 
blood sampling at 0 h and 3 h should be 
considered if an hs-cTn test with a validated 
0 h/3 h algorithm is available.
MDCT coronary angiography should be 
considered as an alternative to invasive 
angiography to exclude ACS when there is 
a low-to-intermediate likelihood of CAD 
and when cardiac troponin and/or ECG are 
inconclusive.
CCTA is recommended as an alternative to 
invasive angiography to exclude ACS 
when there is a low-to-intermediate 
likelihood of CAD and when cardiac 
troponin and/or ECG are normal or 
inconclusive. 
Rhythm monitoring up to 24 h or PCI 
(whichever comes first) should be 
considered in NSTEMI patients at low risk 
for cardiac arrhythmias.
Rhythm monitoring up to 24 h or to PCI 
(whichever comes first) is recommended in 
NSTEMI patients at low risk for cardiac 
arrhythmias.
Rhythm monitoring for >24 h should be 
considered in NSTEMI patients at 
intermediate-to-high risk for cardiac 
arrhythmias.
Rhythm monitoring for >24 h is 
recommended in NSTEMI patients at 
increased risk for cardiac arrhythmias.
Risk assessment
It is recommended to use established risk 
scores for prognosis estimation.
GRACE risk score models should be 
considered for estimating prognosis.
Pharmacological treatments
Bivalirudin (0.75 mg/kg i.v. bolus, 
followed by 1.75 mg/kg/h for up to 4 h 
after the procedure) is recommended as an 
alternative to UFH plus GP IIb/IIIa 
inhibitors during PCI.
Bivalirudin may be considered as an 
alternative to UFH.
P2Y12 inhibitor administration in addition 
to aspirin beyond 1 year may be 
considered after careful assessment of the 
ischaemic and bleeding risks of the 
patient. 
Adding a second antithrombotic agent to 
aspirin for extended long-term secondary 
prevention should be considered in 
patients at high risk of ischaemic events 
and without increased risk of major or 
life-threatening bleeding.
Class I 
Class IIa
Class IIb
New sections
•
MINOCA 
•
SCAD 
•
QIs in NSTE-ACS treatment 
New/revised concepts 
•
Rapid rule-in and rule-out algorithms 
•
Risk stratification for an early invasive approach 
•
Definition of high bleeding risk 
•
Definitions of very high and high ischaemic risk 
•
The gap in evidence and corresponding RCTs to be performed 
©ESC 2020
ACS = acute coronary syndromes; AF = atrial fibrillation; BNP = Btype natriuretic peptide; CAD = coronary artery disease; CCTA =
coronary computed tomography angiography; CHA2DS2-VASc =
Congestive heart failure, Hypertension, Age >_75 years (2 points),
Diabetes, Stroke (2 points)Vascular disease, Age 6574, Sex category (female); CK = creatine kinase; CK-MB = creatine kinase myocardial band; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; ECG = electrocardiogram/electrocardiography; ESC = European Society of Cardiology; FFR = fractional flow reserve; GP = glycoprotein; GRACE = Global Registry of Acute
Coronary Events; h-FABP = heart-type fatty acid-binding protein;
hs-cTn = high-sensitivity cardiac troponin; MDCT = multidetector computed tomography; MINOCA = myocardial infarction with nonobstructive coronary arteries; NOAC = non-vitamin K antagonist oral anticoagulant; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; OAC = oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention; QI = quality indicator; RCT = randomized controlled trial; SCAD = spontaneous coronary artery dissection;
TAT = triple antithrombotic therapy; UFH = unfractionated heparin.
2.4 Number and breakdown of classes of recommendations (Supplementary Data)
The total number of recommendations is 131. The breakdown of the recommendations according to ESC classes of recommendations and levels of evidence are summarized in Supplementary Figure 1.
3 Diagnosis
3.1 Clinical presentation (Supplementary
Data)
3.2 Physical examination (Supplementary
Data)
3.3 Diagnostic tools
3.3.1 Electrocardiogram
The resting 12-lead ECG is the first-line diagnostic tool in the assessment of patients with suspected ACS (Figure 1). It is recommended to perform it within 10 min of the patient’s arrival in the emergency room or, ideally, at first contact with the emergency medical services in the pre-hospital setting and to have it immediately interpreted by a qualified physician.21 While the ECG in the setting of NSTE-ACS may be normal in more than 30% of patients, characteristic abnormalities include ST-segment depression, transient ST-segment elevation, and
T-wave changes.68,1013,22
If the standard leads are inconclusive and the patient has signs or symptoms suggestive of ongoing myocardial ischaemia, additional leads should be recorded; left circumflex artery occlusion may be detected only in V7V9 or right ventricular MI only in V3R and
V4R.3 In patients with suggestive signs and symptoms, the finding of persistent ST-segment elevation indicates STEMI, which mandates immediate reperfusion.2 Comparison with previous tracings is valuable, particularly in patients with pre-existing ECG abnormalities. It is recommended to obtain additional 12-lead ECGs in case of persistent or recurrent symptoms or diagnostic uncertainty. In patients with left bundle branch block (LBBB), specific ECG criteria
(Sgarbossa’s criteria) may help in the detection of candidates for immediate coronary angiography.23,24 Patients with a high clinical suspicion of ongoing myocardial ischaemia and LBBB should be managed in a way similar to STEMI patients, regardless of whether the LBBB is


<!-- PAGE 11 -->

### Page 11

................................................
previously known.2 In contrast, haemodynamically stable patients presenting with chest pain and LBBB only have a slightly higher risk of having MI compared to patients without LBBB. Therefore, the result of the hs-cTn T/I measurement at presentation should be integrated into the decision regarding immediate coronary angiography.24
In patients with right bundle brunch block (RBBB), ST-elevation is indicative of STEMI while ST-segment depression in lead I, aVL, and
V56 is indicative of NSTE-ACS.25 In patients with paced ventricular beats, the ECG is often of no help for the diagnosis of NSTE-ACS.
Novel ECG algorithms using digital ECG data are in development.2628 In general, it is advisable to perform ECG interpretation using remote technologies at the pre-hospital stage.
It is important to highlight that more than 50% of patients presenting with acute chest pain and LBBB to the emergency department or chest pain unit will ultimately be found to have a diagnosis other than MI.24 Similarly, more than 50% of patients presenting with acute chest pain and RBBB to the emergency department will ultimately be found to have a diagnosis other than MI and should,
therefore, also await the result of the hs-cTn T/I measurement at presentation.25
3.3.2 Biomarkers: high-sensitivity cardiac troponin
Biomarkers complement clinical assessment and 12-lead ECG in the diagnosis, risk stratification, and treatment of patients with suspected
NSTE-ACS. Measurement of a biomarker of cardiomyocyte injury,
preferably hs-cTn, is mandatory in all patients with suspected NSTEACS.1,3,1013 Cardiac troponins are more sensitive and specific markers of cardiomyocyte injury than creatine kinase (CK), its myocardial band isoenzyme (CK-MB), and myoglobin.1,3,4,1013,29,30 If the clinical presentation is compatible with myocardial ischaemia, then a dynamic elevation of cardiac troponin above the 99th percentile of healthy individuals indicates MI. In patients with MI, levels of cardiac
©ESC 2020
Figure 1 Diagnostic algorithm and triage in acute coronary syndrome. The initial assessment is based on the integration of low likelihood and/or high likelihood features derived from the clinical setting (i.e. symptoms, vital signs), the 12-lead ECG, and the cardiac troponin concentration determined at presentation to the emergency department and serially thereafter. ‘Other cardiac’ includes  among others  myocarditis, Takotsubo syndrome, or congestive heart failure. ‘Noncardiac’ refers to thoracic diseases such as pneumonia or pneumothorax. Cardiac troponin and its change during serial sampling should be interpreted as a quantitative marker: the higher the 0 h level or the absolute change during serial sampling, the higher the likelihood for the presence of MI. In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography should be performed/interpreted by trained physicians immediately following a 12-lead ECG. If the initial evaluation suggests aortic dissection or pulmonary embolism, D-dimers and CCTA are recommended according to dedicated algorithms.1,2933 CPR = cardiopulmonary resuscitation; ECG = electrocardiogram/electrocardiography; MI = myocardial infarction; NSTEMI = nonST-segment elevation myocardial infarction; STEMI = ST-segment elevation myocardial infarction. Listen to the audio guide of this figure online.
ESC Guidelines
1299


<!-- PAGE 12 -->

### Page 12

............................................................................
troponin rise rapidly (i.e. usually within 1 h from symptom onset if using high-sensitivity assays) after symptom onset and remain elevated for a
variable period of time
(usually several days).1,3,4,1013,29,30 Advances in technology have led to a refinement in cardiac troponin assays and have improved the ability to detect and quantify cardiomyocyte injury.1,3,4,68,1013,29,30,3436 Data from large multicentre studies have consistently shown that hs-cTn assays increase diagnostic accuracy for MI at the time of presentation as compared with conventional assays (Figure 2), especially in patients presenting early after chest pain onset, and allow for a more rapid
‘rule-in’
and
‘rule-out’
of
MI
(see section
3.3.3
and
Table 3).1,3,4,68,1013,29,30,35,36 Overall, hs-cTn T and hs-cTn I assays seem to provide comparable diagnostic accuracy in the early diagnosis of MI.3740
3.3.2.1 Central laboratory vs. point-of-care
The vast majority of cardiac troponin assays that are run on automated platforms in the central laboratory are sensitive (i.e. allow for detection of cardiac troponin in 2050% of healthy individuals) or high-sensitivity (detection in 5095% of healthy individuals) assays.
High-sensitivity assays are recommended over less sensitive ones, as they provide higher diagnostic accuracy at identical low cost.1,3,4,68,1013,29,30,33,35,36
The majority of currently used point-of-care tests (POCTs) cannot be considered sensitive or high-sensitivity assays41. Therefore, the obvious advantage of POCTs, namely the shorter turn-around time,
is counterbalanced by lower sensitivity, lower diagnostic accuracy,
and lower negative predictive value (NPV). Overall, automated assays have been more thoroughly evaluated than POCTs and seem to be preferable at this point in time.1,3,4,68,1013,29,30,33,35,36
As these techniques continue to improve, and performance characteristics are both assay and hospital dependent, it is important to re-evaluate this preference once extensively validated high-sensitivity
POCTs become clinically available.42 The first hs-cTn I POCTs have recently been shown to provide comparable performance characteristics to that of central laboratory hs-cTn I/T assays.43,44
Many cardiac pathologies other than MI also result in cardiomyocyte injury and, therefore, cardiac troponin elevations (Table 4).
Tachyarrhythmias, heart failure, hypertensive emergencies, critical illness, myocarditis, Takotsubo syndrome, and valvular heart disease are the most frequent ones. Most often in elderly patients with renal dysfunction, elevations in cardiac troponin should not be primarily attributed to impaired clearance and considered harmless, as cardiac conditions such as chronic coronary syndromes (CCS) or hypertensive heart disease seem to be the most important contributor to cardiac troponin elevation in this setting.35,45 Other life-threatening conditions presenting with chest pain, such as aortic dissection and pulmonary embolism, may also result in elevated cardiac troponin concentrations and should be considered as differential diagnoses
(Table 4).
©ESC 2020
Figure 2 Value of high-sensitivity cardiac troponin. hs-cTn assays (right) are reported in ng/L and provide identical information as conventional assays
(left, reported in lg/L) if the concentration is substantially elevated, e.g. above 100 ng/L. In contrast, only hs-cTn allows a precise differentiation between
‘normal’ and mildly elevated. Therefore, hs-cTn detects a relevant proportion of patients with previously undetectable cardiac troponin concentrations with the conventional assay who have hs-cTn concentrations above the 99th percentile possibly related to AMI. ??? = unknown due to the inability of the assay to measure in the normal range;68,1013,2931 AMI = acute myocardial infarction; CoV = coefficient of variation; hs-cTn = high-sensitivity cardiac troponin; POCT = point-of-care test. aThe limit of detection varies among the different hs-cTn assays between 1 ng/L and 5 ng/L. Similarly, the 99th percentile varies among the different hs-cTn assays, mainly being between 10 ng/L and 20 ng/L. Listen to the audio guide of this figure online.


<!-- PAGE 13 -->

### Page 13

......................................................................................................................
3.3.2.2 Other biomarkers
Among the multitude of additional biomarkers evaluated for the diagnosis of NSTE-ACS, only CK-MB, myosin-binding protein C,46 and copeptin4758 may have clinical relevance in specific clinical settings when used in combination with cardiac troponin T/I. Compared with cardiac troponin, CK-MB shows a more rapid decline after MI and may provide added value for the timing of myocardial injury and the detection of early reinfarction.1 However, it is important to highlight that little is known on how to best diagnose early reinfarction. Detailed clinical assessment including chest pain characteristics (same characteristics as index event), 12-lead ECG for the detection of new STsegment changes or T-wave inversion, as well as serial measurement of cardiac troponin T/I and CK/CK-MB is recommended. Myosin-binding protein C is more abundant than cardiac troponin and may therefore provide value as an alternative to, or in combination with, cardiac troponin.46 Assessment of copeptin, the C-terminal part of the vasopressin prohormone, may quantify the endogenous stress level in multiple medical conditions including MI. As the level of endogenous stress appears to be high at the onset of MI in most patients, the added value of copeptin to conventional (less sensitive) cardiac troponin assays is substantial.49,50,53 Therefore, the routine use of copeptin as an additional biomarker for the early rule-out of MI should be considered in the increasingly uncommon setting where hs-cTn assays are not available. However, copeptin does not have relevant added value for institutions using one of the well-validated hs-cTn-based rapid protocols in the early diagnosis of MI.47,48,51,52,5458 Other widely available laboratory variables, such as estimated glomerular filtration rate (eGFR), glucose, and B-type natriuretic peptide (BNP) provide incremental prognostic information and may therefore help in risk stratification.59
The determination of D-dimer is recommended in outpatients/emergency department patients with low or intermediate clinical probability, or those that are unlikely to have pulmonary embolism, to reduce the need for unnecessary imaging and irradiation. D-dimers are key diagnostic elements whenever pulmonary embolism is suspected.32,60
3.3.3 Rapid ‘rule-in’ and ‘rule-out’ algorithms
Due to the higher sensitivity and diagnostic accuracy for the detection of MI at presentation, the time interval to the second cardiac troponin assessment can be shortened with the use of hs-cTn assays.
This seems to substantially reduce the delay to diagnosis, translating into shorter stays in the emergency department and lower costs.11,56,6166 It is recommended to use the 0 h/1 h algorithm (best option, blood draw at 0 h and 1 h) or the 0 h/2 h algorithm (secondbest option, blood draw at 0 h and 2 h) (Figure 3). These have been
Table 3
Clinical implications of high-sensitivity cardiac troponin assays
Compared with standard cardiac troponin assays, hs-cTn assays:
• Have higher NPV for AMI.
• Reduce the ‘troponin-blind’ interval leading to earlier detection of AMI.
• Result in 4% absolute and 20% relative increases in the detection of type 1 MI and a corresponding decrease in the diagnosis of unstable angina.
• Are associated with a 2-fold increase in the detection of type 2 MI.
Levels of hs-cTn should be interpreted as quantitative markers of cardiomyocyte damage (i.e. the higher the level, the greater the likelihood of MI):
• Elevations beyond 5-fold the upper reference limit have high (>90%) PPV for acute type 1 MI.
• Elevations up to 3-fold the upper reference limit have only limited (5060%) PPV for AMI and may be associated with a broad spectrum of conditions.
• It is common to detect circulating levels of cardiac troponin in healthy individuals.
Rising and/or falling cardiac troponin levels differentiate acute (as in MI) from chronic cardiomyocyte damage (the more pronounced the change, the higher the likelihood of AMI).
AMI = acute myocardial infarction; hs-cTn = high-sensitivity cardiac troponin; MI = myocardial infarction; NPV = negative predictive value; PPV = positive predictive value.
Table 4
Conditions other than acute type 1 myocardial infarction associated with cardiomyocyte injury
(5 cardiac troponin elevation)
Tachyarrhythmias
Heart failure
Hypertensive emergencies
Critical illness (e.g. shock/sepsis/burns)
Myocarditisa
Takotsubo syndrome
Valvular heart disease (e.g. aortic stenosis)
Aortic dissection
Pulmonary embolism, pulmonary hypertension
Renal dysfunction and associated cardiac disease
Acute neurological event (e.g. stroke or subarachnoid haemorrhage)
Cardiac contusion or cardiac procedures (CABG, PCI, ablation, pacing,
cardioversion, or endomyocardial biopsy)
Hypo- and hyperthyroidism
Inﬁltrative diseases (e.g. amyloidosis, haemochromatosis, sarcoidosis,
scleroderma)
Myocardial drug toxicity or poisoning (e.g. doxorubicin, 5-ﬂuorouracil,
herceptin, snake venoms)
Extreme endurance efforts
Rhabdomyolysis
Bold = most frequent conditions.
CABG = coronary artery bypass graft(ing); PCI = percutaneous coronary intervention.
aIncludes myocardial extension of endocarditis or pericarditis.
ESC Guidelines
1301


<!-- PAGE 14 -->

### Page 14

...................................................................
derived and well-validated in large multicentre diagnostic studies using central adjudication of the final diagnosis for all currently available hs-cTn assays.33,35,36,39,6769 Optimal thresholds for rule-out were selected to allow for a minimal sensitivity and NPV of 99%.
Optimal thresholds for rule-in were selected to allow for a minimal positive predictive value (PPV) of 70%. The algorithms were developed in large derivation cohorts and then validated in large independent validation cohorts. As an alternative, the previous European
Society of Cardiology (ESC) 0 h/3 h algorithm70 should be considered.1 However, three recent large diagnostic studies have suggested that the ESC 0 h/3 h algorithm seems to balance efficacy and safety less well in comparison to more rapid protocols using lower rule-out concentrations including the ESC 0 h/1 h algorithm.7173 Moreover,
the very high safety and high efficacy of applying the ESC 0 h/1 h algorithm has recently been confirmed in three real-life implementation studies, including one randomized controlled trial (RCT) .66,73,74
The 0 h/1 h and 0 h/2 h algorithms rely on two concepts: first, hscTn is a continuous variable and the probability of MI increases with increasing hs-cTn values,35,36,39,68,69,75,76 second, early absolute changes of the levels within 1 h or 2 h can be used as surrogates for absolute changes over 3 h or 6 h and provide incremental diagnostic value to the cardiac troponin assessment at presentation.33,35,36,39,68,69,75,76 The cut-off concentrations within the
0
h/1
h and
0
h/2
h algorithms are assay specific
(Table 5).33,35,36,39,68,69,75,76 The NPV for MI in patients assigned ‘ruleout’ exceeded 99% in several large validation cohorts.35,36,39,68,69,77
Used in conjunction with clinical and ECG findings, the 0 h/1 h and 0
h/2 h algorithm will allow the identification of appropriate candidates for early discharge and outpatient management. Even after the ruleout of MI, elective non-invasive or invasive imaging may be indicated according to clinical assessment. Invasive coronary angiography (ICA)
will still be the best option in patients with very high clinical likelihood of unstable angina, even after NSTEMI has been ruled out. In contrast,
stress testing with imaging or coronary computed tomography angiography (CCTA) will be the best option in patients with low-tomodest clinical likelihood of unstable angina. No testing is necessary in patients with a clear alternative diagnosis.
The PPV for MI in patients meeting the ‘rule-in’ criteria is about
7075%.35,36,39,69 Most of the ‘rule-in’ patients with diagnoses other than MI did have conditions that usually still require ICA or cardiac magnetic resonance (CMR) imaging for accurate diagnosis, including
Takotsubo syndrome and myocarditis.35,36,39,68,69,75,76 Therefore, the vast majority of patients triaged towards the rule-in group are candidates for early ICA and admission to a coronary care unit (CCU).
©ESC 2020
Figure 3 0 h/1 h rule-out and rule-in algorithm using high-sensitivity cardiac troponin assays in haemodynamically stable patients presenting with suspected non-ST-segment elevation acute coronary syndrome to the emergency department. 0 h and 1 h refer to the time from first blood test. NSTEMI
can be ruled out at presentation if the hs-cTn concentration is very low. NSTEMI can also be ruled out by the combination of low baseline levels and the lack of a relevant increase within 1 h (no 1hD). Patients have a high likelihood of NSTEMI if the hs-cTn concentration at presentation is at least moderately elevated or hs-cTn concentrations show a clear rise within the first hour (1hD).1,68,1013,2931,33 Cut-offs are assay specific (see Table 3) and derived to meet predefined criteria for sensitivity and specificity for NSTEMI. CCU = coronary care unit; CCTA = coronary computed tomography angiography;
CPO = chest pain onset; hs-cTn = high-sensitivity cardiac troponin; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = nonST-segment elevation myocardial infarction. aOnly applicable if CPO >3 h. Listen to the audio guide of this figure online.


<!-- PAGE 15 -->

### Page 15

...........................................................................................
These algorithms should always be integrated with a detailed clinical assessment and 12-lead ECG, and repeat blood sampling is mandatory in case of ongoing or recurrent chest pain.
The same concept applies to the 0 h/2 h algorithm. Cut-off levels are assay-specific and shown in Table 5. Cut-off levels for other hscTn assays are in development.
3.3.4 Observe
Patients who do not qualify for ‘rule-out’ or ‘rule-in’, are assigned to observe. They represent a heterogeneous group that usually requires a third measurement of cardiac troponin at 3 h and echocardiography as the next steps.85 ICA should be considered in patients for whom there is a high degree of clinical suspicion of NSTE-ACS (e.g. relevant increase in cardiac troponin from presentation to 3 h), while in patients with low-to-intermediate likelihood for this condition according to clinical judgment, non-invasive imaging using CCTA or stress testing
[stress echocardiography, positron emission tomography, singlephoton-emission tomography (SPECT), or CMR for the detection of
ACS features (oedema, late gadolinium enhancement, perfusion defect,
etc.)] should be considered after discharge from the emergency department to the ward. No further diagnostic testing is indicated when alternative conditions, such as rapid ventricular rate response to atrial fibrillation (AF) or hypertensive emergency, have been identified.
3.3.4.1 Caveats of using rapid algorithms. When using any algorithm,
three main caveats apply i.
Algorithms should only be used in conjunction with all available clinical information, including detailed assessment of chest pain characteristics and ECG.
ii. The ESC 0 h/1h and 0 h/2 h algorithms apply to all patients irrespective of chest pain onset. The safety (as quantified by the NPV) and sensitivity are very high (>99%), including in the subgroup of patients presenting very early (e.g. <2 h).69 However, due to the time dependency of troponin release and the only moderate number of patients presenting <1 h after chest pain onset in previous studies, obtaining an additional cardiac troponin concentration at 3 h in patients presenting <1 h and triaged towards rule-out should be considered.
iii. As late increases in cardiac troponin have been described in 1% of patients, serial cardiac troponin testing should be pursued if the clinical suspicion remains high or whenever the patient develops recurrent chest pain.35,36,39,68,69,75,76,86
3.3.4.2 Confounders of cardiac troponin concentration. In patients presenting with suspected NSTE-ACS, beyond the presence or absence of
MI,
four clinical variables affect hs-cTn concentrations:35,36,39,69,79,8793
i. Age (to a large extent as a surrogate for pre-existing cardiac disease).
ii. Renal dysfunction (to a large extent as a surrogate for pre-existing cardiac disease).
iii. Time from chest pain onset.
iv. Sex.
The effect of age (differences in concentration between healthy very young vs. healthy very old individuals up to 300%), renal dysfunction
(differences in concentration between otherwise healthy patients with very high vs. very low eGFR up to 300%), and chest pain onset
(>300%)
is substantial,
and modest for sex
(40%).11,35,36,39,69,79,8893 Until information technology tools that allow the incorporation of the effect of all four variables are available,
Table 5
Assay speciﬁc cut-off levels in ng/l within the 0 h/1 h and 0 h/2 h algorithms
0 h/1 h algorithm
Very low
Low
No 1hD
High
1hD
hs-cTn T (Elecsys; Roche)
<5
<12
<3
>_52
>_5
hs-cTn I (Architect; Abbott)
<4
<5
<2
>_64
>_6
hs-cTn I (Centaur; Siemens)
<3
<6
<3
>_120
>_12
hs-cTn I (Access; Beckman Coulter)
<4
<5
<4
>_50
>_15
hs-cTn I (Clarity; Singulex)
<1
<2
<1
>_30
>_6
hs-cTn I (Vitros; Clinical Diagnostics)
<1
<2
<1
>_40
>_4
hs-cTn I (Pathfast; LSI Medience)
<3
<4
<3
>_90
>_20
hs-cTn I (TriageTrue; Quidel)
<4
<5
<3
>_60
>_8
0 h/2 h algorithm
Very low
Low
No 2hD
High
2hD
hs-cTn T (Elecsys; Roche)
<5
<14
<4
>_52
>_10
hs-cTn I (Architect; Abbott)
<4
<6
<2
>_64
>_15
hs-cTn I (Centaur; Siemens)
<3
<8
<7
>_120
>_20
hs-cTn I (Access; Beckman Coulter)
<4
<5
<5
>_50
>_20
hs-cTn I (Clarity; Singulex)
<1
TBD
TBD
>_30
TBD
hs-cTn I (Vitros; Clinical Diagnostics)
<1
TBD
TBD
>_40
TBD
hs-cTn I (Pathfast; LSI Medience)
<3
TBD
TBD
>_90
TBD
hs-cTn I (TriageTrue; Quidel)
<4
TBD
TBD
>_60
TBD
These cut-offs apply irrespective of age and renal function. Optimized cut-offs for patients above 75 years of age and patients with renal dysfunction have been evaluated, but not consistently shown to provide better balance between safety and efﬁcacy as compared to these universal cut-offs.35,36,69 The algorithms for additional assays are in development.
hs-cTn = high-sensitivity cardiac troponin; TBD = to be determined.3537,39,40,68,69,7584
ESC Guidelines
1303


<!-- PAGE 16 -->

### Page 16

.................................
the use of uniform cut-off concentrations should remain the standard of care in the early diagnosis of MI.35,36,39,68,69,75,76
3.3.4.3 Practical guidance on how to implement the European Society of
Cardiology 0 h/1 h algorithm
In order to maximize the safety and feasibility of the process, the nursing team should, in general, obtain blood samples for hs-cTn at
0 h and 1 h irrespective of other clinical details and pending results.
This introduces unnecessary cardiac troponin measurements in perhaps 1015% of patients with very low 0 h concentrations and chest pain onset >3 h, but substantially facilitates the process and thereby further increases patient safety. Documentation of the time of the 0 h blood draw allows exact determination of the time window
(± 10 min) of the 1 h blood draw. If the 1 h (± 10 min) blood draw was not feasible, then blood should be drawn at 2 h and the ESC
0 h/2 h algorithm applied.
3.3.4.4 Avoiding misunderstandings: time to decision ¼ time of blood draw þ turn-around time
The use of the ESC 0 h/1 h algorithm is irrespective of the local turnaround time. 0 h and 1 h refer to the time point at which blood is taken (Figure 4).
©ESC 2020
Figure 4 Timing of the blood draws and clinical decisions when using the European Society of Cardiology 0 h/1 h algorithm. 0 h and 1 h refer to the time points at which blood is taken. The turn-around time is the time period from blood draw to reporting back the results to the clinician. It is usually about
1 h using an automated platform in the central laboratory. It includes transport of the blood tube to the lab, scanning of the probe, centrifugation, putting plasma on the automated platform, the analysis itself, and the reporting of the test result to the hospital information technology/electronic patient record.
The turn-around time is identical whether using a hs-cTn assay vs. a conventional assay, as long as both are run on an automated platform. Adding the local turn-around time to the time of blood draw determines the earliest time point for clinical decision making based on hs-cTn concentrations. e.g. for the 0 h time point, time to decision is at 1 h if the local turn-around time is 1 h. For the blood drawn at 1 h, the results are reported back at 2 h (1 h þ 1 h) if the local turn-around time is 1 h. Relevant 1 h changes are assay dependent and listed in Table 3. CPO = chest pain onset; CPR = cardiopulmonary resuscitation; ECG = electrocardiogram/electrocardiography; hs-cTn = high-sensitivity cardiac troponin; MACE = major adverse cardiovascular events; MI = myocardial infarction. Listen to the audio guide of this figure online.


<!-- PAGE 17 -->

### Page 17

.............................................................................................................................................................................
The clinical and economic benefit of the ESC 0 h/1 h algorithm vs.
the ESC 0 h/3 h algorithm or other algorithms with the second blood draw later than 1 h is therefore independent of the local turn-around time.61
3.3.5 Non-invasive imaging
3.3.5.1 Functional evaluation
Transthoracic echocardiography should be routinely available in emergency rooms and chest pain units and performed/interpreted by trained physicians in all patients during hospitalization for NSTE-ACS.
This imaging modality is useful to identify abnormalities suggestive of myocardial ischaemia or necrosis (i.e. segmental hypokinesia or akinesia). In the absence of significant wall motion abnormalities, impaired myocardial perfusion detected by contrast echocardiography or reduced regional function using strain and strain rate imaging might improve the diagnostic and prognostic value of conventional echocardiography.9496 Moreover, echocardiography can help in detecting alternative pathologies associated with chest pain, such as acute aortic dissection, pericardial effusion, aortic valve stenosis, hypertrophic cardiomyopathy, mitral valve prolapse, or right ventricular dilatation suggestive of acute pulmonary embolism.
Similarly,
echocardiography is the diagnostic tool of choice for patients with haemodynamic instability of suspected cardiac origin.96,97 Evaluation of left ventricular (LV) systolic function, at the latest by the time of hospital discharge, is important to estimate prognosis, and echocardiography
(as well as other imaging modalities) can provide this information.
In patients without ischaemic changes on 12-lead ECGs and normal hs-cTn, who are free from chest pain for several hours, stress imaging can be performed during hospitalization or shortly after discharge.
Stress imaging is preferred over exercise ECG due to its greater diagnostic accuracy.98 Various studies have shown that normal exercise or dobutamine or dipyridamole stress echocardiograms have high NPV
for ischaemia and are associated with excellent patient outcomes.99,100
Moreover, stress echocardiography has demonstrated superior prognostic value over exercise ECG.101 If the acoustic window is not adequate to assess regional wall motion abnormalities, the use of echocardiographic contrast is recommended to improve the accuracy of such an assessment and facilitate the detection of ischaemia.98,101103
CMR can assess both perfusion and wall motion abnormalities, and patients presenting with acute chest pain with a normal stress CMR
have an excellent short- and mid-term prognosis.104 Additionally,
CMR permits detection of scar tissue (using late gadolinium enhancement) and can differentiate this from recent infarction (using T2weighted imaging to delineate myocardial oedema).98 Moreover,
CMR can facilitate the differential diagnosis between infarction, myocarditis, or Takotsubo syndrome, among others.98 In a recent randomized trial in patients with unclear NSTEMI diagnosis, upfront imaging with CMR reduced the need for ICA and provided an alternative diagnosis in a relevant proportion of patients.105
Similarly, SPECT has been shown to be useful for the risk stratification of patients with acute chest pain suggestive of ACS. Resting myocardial scintigraphy, by detecting fixed perfusion defects suggestive of myocardial necrosis, can be helpful for the initial triage of patients presenting with chest pain without ECG changes or elevated cardiac troponins.98 Combined stressrest imaging and/or stress-only imaging may further enhance assessment of ischaemia, while a normal study is associated with an excellent outcome.106,107 Stressrest imaging modalities are usually not widely available on 24 h service and some (e.g. SPECT) are associated with substantial radiation exposure.
3.3.5.2 Anatomical evaluation
CCTA allows visualization of the coronary arteries and a normal scan excludes CAD. CCTA has a high NPV to exclude ACS (by excluding
CAD) and an excellent outcome in patients presenting to the emergency department with low-to-intermediate pre-test probability for
ACS and a normal CCTA.108 Seven RCTs have tested CCTA vs.
usual care in the triage of low-to-intermediate-risk patients presenting with acute chest pain to emergency departments without signs of ischaemia on ECG and normal cardiac troponins.109 However, the majority of studies used only conventional,
less sensitive assays.110113 At a follow-up of 16 months, there were no deaths,
and a meta-analysis demonstrated comparable outcomes with the two approaches (i.e. no difference in the incidence of MI, postdischarge emergency department visits, or re-hospitalizations) and showed that CCTA was associated with a reduction in emergency department costs and length of stay.114 However, none of these studies used hs-cTn assays, which also reduce hospital stay. In a randomized study, in which the standard of care included hs-cTn, CCTA was no longer able to improve patient flow.115 It was also noted that
CCTA was associated with an increase in the use of invasive angiography.114 In contrast, in a recent randomized trial of unclear NSTEMI
diagnosis, upfront imaging with CCTA reduced the need for ICA105
Similar results were observed in a sub-analysis of the Very EaRly vs
Deferred Invasive evaluation using Computerized Tomography
(VERDICT) trial, where upfront CCTA in NSTE-ACS patients had an
NPV of 90.9%.116 However, a relatively large patient group had to be excluded for specific reasons and an NPV of 90.9% is not entirely perfect.116 Accordingly, CCTA can be used to exclude CAD and is thus less useful in patients with known CAD. Other factors limiting CCTA
include severe calcifications (high calcium score) and elevated or irregular heart rate; in addition, a 24 h service is currently not widely available. Finally, the use of CCTA in the acute setting in patients with stents or previous CABG has not been validated. Importantly, computed tomography (CT) imaging can effectively exclude other causes of acute chest pain that, if untreated, are associated with high mortality, namely pulmonary embolism and aortic dissection.
3.4 Differential diagnosis
Among unselected patients presenting with acute chest pain to the emergency department, disease prevalence can be expected to be the following: 510% STEMI, 1520% NSTEMI, 10% unstable angina, 15% other cardiac conditions, and 50% non-cardiac diseases.35,36,39,69,79,8793 Several cardiac and non-cardiac conditions may mimic NSTE-ACS (Table 6).
Conditions that should always be considered in the differential diagnosis of NSTE-ACS because they are potentially life-threatening but also treatable include aortic dissection, pulmonary embolism, and tension pneumothorax. Echocardiography should be performed urgently in all patients with haemodynamic instability of suspected cardiovascular origin. Takotsubo syndrome has recently been
ESC Guidelines
1305


<!-- PAGE 18 -->

### Page 18

.....................
observed more often as a differential diagnosis and usually requires coronary angiography to rule out ACS.117
Chest X-ray is recommended in all patients in whom NSTEACS is considered unlikely in order to detect pneumonia, pneumothorax, rib fractures, or other thoracic disorders. Stroke may be accompanied by ECG changes, myocardial wall motion abnormalities, and cardiomyocyte injury (= increase in cardiac troponin concentrations). The majority of patients presenting to the emergency department with acute chest pain have non-cardiac conditions causing the chest discomfort.35,36,39,69,79,8793 In many instances, the pain is musculoskeletal and is therefore benign, selflimiting, and does not require hospitalization. Chest pain characteristics help  to some extent  in the early identification of these patients.
Table 6
Differential diagnoses of acute coronary syndromes in the setting of acute chest pain
Cardiac
Pulmonary
Vascular
Gastro-intestinal
Orthopaedic
Other
Myopericarditis
Pulmonary embolism
Aortic dissection
Oesophagitis,
reﬂux, or spasm
Musculoskeletal disorders
Anxiety disorders
Cardiomyopathiesa
(Tension)-
pneumothorax
Symptomatic aortic aneurysm
Peptic ulcer, gastritis
Chest trauma
Herpes zoster
Tachyarrhythmias
Bronchitis, pneumonia
Stroke
Pancreatitis
Muscle injury/inﬂammation
Anaemia
Acute heart failure
Pleuritis
Cholecystitis
Costochondritis
Hypertensive emergencies
Cervical spine pathologies
Aortic valve stenosis
Takotsubo syndrome
Coronary spasm
Cardiac trauma
Bold = common and/or important differential diagnoses.
aDilated, hypertrophic and restrictive cardiomyopathies may cause angina or chest discomfort.
Recommendations for diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Diagnosis and risk stratiﬁcation
It is recommended to base diagnosis and initial short-term risk stratiﬁcation on a combination of clinical history, symptoms,
vital signs, other physical ﬁndings, ECG, and laboratory results including hs-cTn.3
I
B
It is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within 60 min of blood sampling.3,1013,2931,34
I
B
It is recommended to obtain a 12-lead ECG within 10 min after ﬁrst medical contact and to have it immediately interpreted by an experienced physician.21
I
B
It is recommended to obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty.
I
C
The ESC 0 h/1 h algorithm with blood sampling at 0 h and 1 h is recommended if an hs-cTn test with a validated 0 h/1 h algorithm is available.30,33,35,36,39,68,69,75,76
I
B
Additional testing after 3 h is recommended if the ﬁrst two cardiac troponin measurements of the 0 h/1 h algorithm are not conclusive and the clinical condition is still suggestive of ACS.85
I
B
As an alternative to the ESC 0 h/1 h algorithm, it is recommended to use the ESC 0 h/2 h algorithm with blood sampling at 0
h and 2 h, if an hs-cTn test with a validated 0 h/2 h algorithm is available.33,39,75,78,84
I
B
Additional ECG leads (V3R, V4R, V7V9) are recommended if ongoing ischaemia is suspected when standard leads are inconclusive.
I
C
As an alternative to the ESC 0 h/1 h algorithm, a rapid rule-out and rule-in protocol with blood sampling at 0 h and 3 h should be considered, if a high-sensitivity (or sensitive) cardiac troponin test with a validated 0 h/3 h algorithm is available.7073
IIa
B
The routine use of copeptin as an additional biomarker for the early rule-out of MI should be considered where hs-cTn assays are not available.
IIa
B
It should be considered to use established risk scores for prognosis estimation.
IIa
C
For initial diagnostic purposes, it is not recommended to routinely measure additional biomarkers such as h-FABP or copeptin, in addition to hs-cTn.47,48,51,52,54,118
III
B
Continued


<!-- PAGE 19 -->

### Page 19

.................................................................................
4 Risk assessment and outcomes
4.1 Electrocardiogram indicators
(Supplementary Data)
4.2 Biomarkers
Beyond diagnostic utility, initial cardiac troponin levels add prognostic information in terms of short- and long-term mortality to clinical and
ECG variables. While hs-cTn T and I have comparable diagnostic accuracy, hs-cTn T has greater prognostic accuracy.38,119 Serial measurements are useful to identify peak levels of cardiac troponin for risk stratification purposes in patients with established MI. The higher the hs-cTn levels, the greater the risk of death.12,76,120 However, evidence is limited regarding the optimal time points of serial hs-cTn measurement. Serum creatinine and eGFR should also be determined in all patients with NSTE-ACS because they affect prognosis and are key elements of the Global Registry of Acute Coronary
Events (GRACE) risk score (see section 4.3). Similarly, natriuretic peptides [BNP and N-terminal pro-BNP (NT-proBNP)] provide prognostic information regarding the risk of death, acute heart failure, as well as the development of AF in addition to cardiac troponin.121 In addition, quantifying the presence and severity of haemodynamic stress and heart failure using BNP or NT-proBNP concentrations in patients with left main CAD or three-vessel CAD without NSTEACS may help the heart team to select either PCI or CABG as the revascularization strategy of choice.122124 However, this needs confirmation in randomized trials and has not been tested in NSTEACS patients so far. Similarly, natriuretic peptides provide prognostic information on top of cardiac troponin.121,125,126 Other biomarkers,
such as high-sensitivity C-reactive protein, mid-regional pro-adrenomedullin, growth differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (h-FABP), and copeptin may also have some prognostic value.50,118,127132 However, the assessment of these markers has, so far, not been shown to improve patient management and their added value in risk assessment on top of the GRACE risk calculation and/or BNP/NT-proBNP seems marginal. At the present time, the routine use of these biomarkers for prognostic purposes is not recommended.
4.3 Clinical scores for risk assessment
(Supplementary Data)
A number of prognostic models that aim to estimate the future risk of all-cause mortality or the combined risk of all-cause mortality or MI have been developed. These models have been formulated into clinical risk scores and, among these, the GRACE risk score offers the best discriminative performance.133135 It is important to recognize, however, that there are several GRACE
risk scores, and each refers to different patient groups and predicts different outcomes.136139 The GRACE risk score models have been externally validated using observational data.140
Further information concerning the GRACE risk scores is presented in Supplementary Data section 4.3, Supplementary Table 1,
Imaging
In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography is recommended and should be performed by trained physicians immediately following a 12-lead ECG.
I
C
In patients with no recurrence of chest pain, normal ECG ﬁndings, and normal levels of cardiac troponin (preferably high sensitivity), but still with a suspected ACS, a non-invasive stress test (preferably with imaging) for inducible ischaemia or CCTA is recommended before deciding on an invasive approach.91,92,98,101,105108
I
B
Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.c
I
C
CCTA is recommended as an alternative to ICA to exclude ACS when there is a low-to-intermediate likelihood of CAD and when cardiac troponin and/or ECG are normal or inconclusive.105,108,110114
I
A
Monitoring
Continuous rhythm monitoring is recommended until the diagnosis of NSTEMI has been established or ruled out.
I
C
It is recommended to admit NSTEMI patients to a monitored unit.
I
C
Rhythm monitoring up to 24 h or to PCI (whichever comes ﬁrst) is recommended in NSTEMI patients at low risk for cardiac arrhythmias.d
I
C
Rhythm monitoring for >24 h is recommended in NSTEMI patients at increased risk for cardiac arrhythmias.e
I
C
In the absence of signs or symptoms of ongoing ischaemia, rhythm monitoring in unstable angina may be considered in selected patients (e.g. suspicion of coronary spasm or associated symptoms suggestive of arrhythmic events).
IIb
C
0 h = time of ﬁrst blood test; 1 h, 2 h, 3 h = 1, 2, or 3 h after the ﬁrst blood test.
ACS = acute coronary syndromes; CAD = coronary artery disease; CCTA = coronary computed tomography angiography; ECG = electrocardiogram/electrocardiography;
ESC = European Society of Cardiology; GRACE = Global Registry of Acute Coronary Events; h-FABP = heart-type fatty acid-binding protein; hs-cTn = high-sensitivity cardiac troponin; ICA = invasive coronary angiography; LV = left ventricular; LVEF = left ventricular ejection fraction; NSTEMI = non-ST-segment elevation myocardial infarction; PCI =
percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
cDoes not apply to patients discharged the same day in whom NSTEMI has been ruled out.
dIf none of the following criteria: haemodynamically unstable, major arrhythmias, LVEF <40%, failed reperfusion, additional critical coronary stenoses of major vessels, complications related to percutaneous revascularization, or GRACE risk score >140 if assessed.
eIf one or more of the above criteria are present.
ESC Guidelines
1307


<!-- PAGE 20 -->

### Page 20

.......................................................................................................
and Supplementary Figure 3. The nomogram to calculate the original GRACE risk score, which estimates the risk of in-hospital death, is shown in Supplementary Figure 3 and online risk calculators are available for other GRACE risk scores: https://www.out comes-umassmed.org/risk_models_grace_orig.aspx for the
GRACE risk score 1.0 and www.outcomes-umassmed.org/grace/
acs_risk2/index.html for the GRACE risk score 2.0.
Given that the GRACE risk score predicts clinical outcomes, it is possible to stratify patients according to their estimated risk of future ischaemic events. A GRACE risk score-based risk assessment has been found to be superior to (subjective) physician assessment for the occurrence of death or MI.141,142 Moreover, it is well recognized that the delivery of guideline-directed care is inversely related to the estimated risk of the patient with NSTE-ACS143
 the so called ‘risk-treatment paradox’.144,145 Guideline-directed care is associated with proportionally greater survival gains among those with higher baseline risk, therefore objective risk assessment may help to identify NSTE-ACS patients who would benefit from risk-determined care interventions.144,145 The Australian GRACE
Risk score Intervention Study (AGRIS)146 and the ongoing UK
GRACE Risk score Intervention Study (UKGRIS)147 have  or are for the first time  investigating the impact of the utilization of the
GRACE risk score on outcomes of patients with NSTE-ACS in a randomized manner. The AGRIS cluster-randomized trial failed to demonstrate any add-on value, especially for the guideline-directed treatments with the routine implementation of the GRACE risk score. This was largely explained by better-than-expected performance of the control hospitals. Given temporal improvements in early mortality from NSTE-ACS,148 the prediction of long-term risk is important. Deaths in the early phase following NSTE-ACS are more attributable to ischaemia/thrombosis-related events, whereas in the later phase they are more likely to be associated with the progression of atherosclerosis and non-cardiovascular causes.149152
4.4 Bleeding risk assessment
Major bleeding events are associated with increased mortality in
NSTE-ACS.157 In order to estimate bleeding risk in this setting,
scores such as the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/American Heart Association (AHA)
guidelines
(CRUSADE;
https://www.mdcalc.com/crusade-score-post-mibleeding-risk)
and the
Acute
Catheterization and
Urgent
Intervention Triage strategY (ACUITY) bleeding risk scores have been developed. Overall, the two scores have reasonable predictive value for major bleeding in ACS patients undergoing coronary angiography, with CRUSADE being the most discriminatory.155157
Changes in interventional practice, such as the use of radial access for coronary angiography and PCI, as well as in antithrombotic treatment, may modify the predictive value of risk scores. In addition, in medically treated patients or those on oral anticoagulants
(OACs), the predictive value of these scores has not been established. Given these limitations, the use of the CRUSADE bleeding risk score may be considered in patients undergoing coronary angiography to quantify bleeding risk.
An alternative to these scores may be the assessment of bleeding risk according to the Academic Research Consortium for High
Bleeding Risk (ARC-HBR) (Table 7).158 This consensus definition of patients at high bleeding risk (HBR) was recently developed to provide consistency for clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing PCI.158
This proposed ARC-HBR represents a pragmatic approach that includes the most recent trials performed in HBR patients, who were previously excluded from clinical trials of dual antiplatelet therapy
(DAPT) duration or intensity (Table 7).159161 However, bleeding risk assessment based on ARC-HBR criteria may be difficult to apply in routine clinical practice as several of the criteria are quite detailed and so far, this score has not been validated.
Recommendations on biomarker measurements for prognostic stratiﬁcation
Recommendations
Classa
Levelb
Beyond its diagnostic role, it is recommended to measure hs-cTn serially for the estimation of prognosis.12,13,119,120
I
B
Measuring BNP or NT-proBNP plasma concentrations should be considered to gain prognostic information.121,125,126
IIa
B
The measurement of additional biomarkers, such as mid-regional pro-A-type natriuretic peptide, high-sensitivity
C-reactive protein, mid-regional pro-adrenomedullin, GDF-15, copeptin, and h-FABP is not recommended for routine risk or prognosis assessment.50,127,129
III
B
Score to risk stratify in NSTE-ACS
GRACE risk score models should be considered for estimating prognosis.137139
IIa
B
The use of risk scores designed to evaluate the beneﬁts and risks of different DAPT durations may be considered.153,154
IIb
A
To estimate bleeding risk, the use of scores may be considered in patients undergoing coronary angiography.155,156
IIb
B
BNP = B-type natriuretic peptide; DAPT = dual antiplatelet therapy; GDF-15 = growth differentiation factor 15; GRACE = Global Registry of Acute Coronary Events; h-FABP
= heart-type fatty acid-binding protein; hs-cTn = high-sensitivity cardiac troponin; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NT-proBNP = N-terminal pro-B-type natriuretic peptide.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 21 -->

### Page 21

...................................................................................
4.5 Integrating ischaemic and bleeding risks
Major bleeding events affect prognosis in a similar way to spontaneous ischaemic complications.163,164 Given the trade-off between ischaemic vs. bleeding risks for any antithrombotic regimen, the use of scores might prove useful to tailor antithrombotic duration,
as well as intensity, to maximize ischaemic protection and minimize bleeding risk in the individual patient. Specific risk scores have been developed for patients on DAPT following PCI, in the setting of both CCS as well as ACS. To date, no risk score has been tested in patients requiring long-term anticoagulation. The DAPT and the
PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent
Dual
Anti
Platelet
Therapy
(PRECISE-DAPT) scores have been designed to guide and inform decision making on DAPT duration.153,154 The applicability of the
PRECISE-DAPT score is at patient discharge, while the DAPT
score is a bleeding risk estimation to be calculated at 1 year from the index event. The usefulness of the PRECISE-DAPT score was retrospectively assessed within patients randomized to different
DAPT durations (n = 10 081) to identify the effect on bleeding and ischaemia of a long (1224 months) or short (36 months) treatment duration in relation to baseline bleeding risk.154 Among HBR
patients based on PRECISE-DAPT (i.e. PRECISE-DAPT score
>_25), prolonged DAPT was associated with no ischaemic benefit but a large bleeding burden.154 Conversely, longer treatment in patients without HBR (i.e. PRECISE-DAPT score <25) was associated with no increase in bleeding and a significant reduction in the composite ischaemic endpoint of MI, definite stent thrombosis,
stroke, and target vessel revascularization. The findings remained valid in analyses restricted to ACS. However, for the majority of patients in the study, DAPT consisted of aspirin and clopidogrel.
An external validation of the PRECISE-DAPT score  in 4424
ACS patients undergoing PCI and treated with prasugrel or ticagrelor  showed a modest predictive value for major bleeding at a median follow-up of 14 months (c-statistic = 0.653).165 In addition,
none of these risk prediction models have been prospectively tested in RCTs, therefore, their value in improving patient outcomes remains unclear. The DAPT study has been less well validated, with a retrospective analysis in 1970 patients and a score calculation at a different time point (6 vs. 12 months) than in the derivation cohort used to generate the score.166
5 Pharmacological treatments
5.1 Antithrombotic treatment
Antithrombotic treatment is mandatory in NSTE-ACS patients with and without invasive management. Its choice, the combination, the time point of initiation, and the treatment duration depend on various intrinsic and extrinsic (procedural) factors (Figure 5). Notably,
both ischaemic and bleeding complications significantly influence the outcome of NSTE-ACS patients and their overall mortality risk.167
Thus, the choice of treatment should equally reflect the ischaemic and bleeding risk of the patient.
Table 7
Major and minor criteria for high bleeding risk according to the Academic Research Consortium for High
Bleeding Risk at the time of percutaneous coronary intervention (bleeding risk is high if at least one major or two minor criteria are met)
Major
Minor
• Anticipated use of long-term OACa
• Age >_ 75 years
• Severe or end-stage CKD (eGFR <30 mL/min)
• Moderate CKD (eGFR 3059 mL/min)
• Haemoglobin <11 g/dL
• Haemoglobin 1112.9 g/dL for men or 1111.9 g/dL for women
• Spontaneous bleeding requiring hospitalization and/or transfusion in the past 6 months or at any time, if recurrent
• Spontaneous bleeding requiring hospitalization and/or transfusion within the past 12 months not meeting the major criterion
• Moderate or severe baseline thrombocytopeniab
(platelet count <100  109/L)
• Chronic use of oral non-steroidal anti-inﬂammatory drugs or steroids
• Chronic bleeding diathesis
• Any ischaemic stroke at any time not meeting the major criterion
• Liver cirrhosis with portal hypertension
• Active malignancyc (excluding non-melanoma skin cancer)
within the past 12 months
• Previous spontaneous intracranial haemorrhage (at any time)
• Previous traumatic intracranial haemorrhage within the past 12 months
• Presence of a brain arteriovenous malformation
• Moderate or severe ischaemic stroked within the past 6 months
• Recent major surgery or major trauma within 30 days prior to PCI
• Non-deferrable major surgery on DAPT
CKD = chronic kidney disease; DAPT = dual antiplatelet therapy; eGFR = estimated glomerular ﬁltration rate; OAC = oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention.
aThis excludes vascular protection doses.162
bBaseline thrombocytopenia is deﬁned as thrombocytopenia before PCI.
cActive malignancy is deﬁned as diagnosis within 12 months and/or ongoing requirement for treatment (including surgery, chemotherapy, or radiotherapy).
dNational Institutes of Health Stroke Scale score >5.
ESC Guidelines
1309


<!-- PAGE 22 -->

### Page 22

©ESC 2020
Figure 5 Determinants of antithrombotic treatment in coronary artery disease. Intrinsic (in blue: patient’s characteristics, clinical presentation & comorbidities) and extrinsic (in yellow: co-medication & procedural aspects) variables influencing the choice, dosing, and duration of antithrombotic treatment.
ACS = acute coronary syndromes; CABG = coronary artery bypass graft(ing); CCS = chronic coronary syndromes; CKD = chronic kidney disease;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI =
ST-segment elevation myocardial infarction.
©ESC 2020
Figure 6 Antithrombotic treatments in non-ST-segment elevation acute coronary syndrome patients: pharmacological targets. Drugs with oral administration are shown in black letters and drugs with preferred parenteral administration in red. Abciximab (in brackets) is not supplied anymore. ADP =
adenosine diphosphate; DAPT = dual antiplatelet therapy; FXa = factor Xa; GP = glycoprotein; TxA2 = thromboxane A2; UFH = unfractionated heparin;
VKA = vitamin K antagonist.


<!-- PAGE 23 -->

### Page 23

............................................................
Recommended anticoagulant and antiplatelet drugs and their dosing (for use during and after NSTE-ACS) are summarized in Figure 6
and Table 8.
5.1.1 Antiplatelet drugs and pre-treatment
5.1.1.1 Antiplatelet drugs and dual antiplatelet therapy
Activation of blood platelets and the coagulation cascade play a key role in the initial phase and evolution of NSTE-ACS. Hence, sufficient platelet inhibition and (temporary) anticoagulation is essential in
NSTE-ACS patients, especially in those undergoing myocardial revascularization by PCI. Aspirin is considered to be the cornerstone of treatment for inhibition of thromboxane A2 generation (Figure 6),
which is normally complete with a dose >_75 mg/d. Aspirin treatment is started with a loading dose (LD) followed by maintenance treatment (Table 8). Current evidence supports a maintenance dose (MD)
of 75100 mg once daily (o.d.).169 Based on the results of the phase
III PLATelet inhibition and patient Outcomes (PLATO) and TRial to
Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet InhibitioN with PrasugrelThrombolysis In Myocardial
Infarction 38 (TRITON-TIMI 38) trials,170,171 DAPT including aspirin and a potent P2Y12 receptor inhibitor (ticagrelor or prasugrel) is the recommended standard treatment for
NSTE-ACS
patients.
Clopidogrel, characterized by less potent and variable platelet inhibition,172,173 should only be used when prasugrel or ticagrelor are contraindicated, not available, or cannot be tolerated due to an unacceptable HBR. P2Y12 receptor inhibitors differ with respect to their pharmacokinetic and pharmacodynamic properties. Table 9
summarizes the essential features of the available oral and intravenous (i.v.) drugs. For further details on recent DAPT trials, please refer to the 2017 ESC focused update on DAPT in CAD.169
Trial data on the head-to-head comparison of prasugrel vs. ticagrelor became available with the open-label randomized Intracoronary stenting and Antithrombotic regimenRapid Early Action for
Coronary Treatment (ISAR-REACT) 5 trial.174 This study was conducted in 4018 ACS patients (NSTE-ACS and STEMI) for whom an invasive evaluation was planned. The trial demonstrated that treatment with prasugrel vs. ticagrelor significantly reduced the composite rate of death, MI, or stroke (6.9 vs. 9.3%, P=0.006) without any increase in bleeding complications (4.8 vs. 5.4%, P=0.46). Limitations
Table 8
Dose regimen of antiplatelet and anticoagulant drugs in non-ST-segment elevation acute coronary syndrome patientsa
I. Antiplatelet drugs
Aspirin
LD of 150300 mg orally or 75250 mg i.v. if oral ingestion is not possible, followed by oral MD of 75100 mg o.d.
P2Y12 receptor inhibitors (oral or i.v.)
Clopidogrel
LD of 300600 mg orally, followed by a MD of 75 mg o.d., no speciﬁc dose adjustment in CKD patients.
Prasugrel
LD of 60 mg orally, followed by a MD of 10 mg o.d. In patients with body weight <60 kg, a MD of 5 mg o.d. is recommended.
In patients aged >_75 years, prasugrel should be used with caution, but a dose of 5 mg o.d. should be used if treatment is deemed necessary. No speciﬁc dose adjustment in CKD patients. Prior stroke is a contraindication for prasugrel.
Ticagrelor
LD of 180 mg orally, followed by a MD of 90 mg b.i.d., no speciﬁc dose adjustment in CKD patients.
Cangrelor
Bolus of 30 mg/kg i.v. followed by 4 mg/kg/min infusion for at least 2 h or the duration of the procedure (whichever is longer).
GP IIb/IIIa receptor inhibitors (i.v.)
Abciximab
Bolus of 0.25 mg/kg i.v. and 0.125 lg/kg/min infusion (maximum 10 lg/min) for 12 h (drug is not supplied anymore).
Eptiﬁbatide
Double bolus of 180 lg/kg i.v. (given at a 10-min interval) followed by an infusion of 2.0 lg/kg/min for up to18 h.
Tiroﬁban
Bolus of 25 lg/kg i.v. over 3 min, followed by an infusion of 0.15 lg/kg/min for up to 18 h.
II. Anticoagulant drugs (for use before and during PCI)
UFH
70100 U/kg i.v. bolus when no GP IIb/IIIa inhibitor is planned followed up by an IV infusion until the invasive procedure. 5070 U/kg i.v. bolus with GP IIb/IIIa inhibitors.
Enoxaparin
0.5 mg/kg i.v. bolus.
Bivalirudin
0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for up to 4 h after the procedure as clinically warranted.
Fondaparinux
2.5 mg/d subcutaneously (only before PCI).
III. Oral anticoagulant drugsb
Rivaroxaban
Very low MD of 2.5 mg b.i.d. (in combination with aspirin) for long-term extended antithrombotic treatment in a secondary prevention setting of CAD patients.
AF = atrial ﬁbrillation; b.i.d. = bis in die (twice a day); CAD = coronary artery disease; CKD = chronic kidney disease; GP = glycoprotein; i.v. = intravenous; MD = maintenance dose; LD = loading dose; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation/anticoagulant; o.d. = once daily; PCI = percutaneous coronary intervention; UFH = unfractionated heparin; VKA = vitamin K antagonist.
aAll dosing regimens refer to doses given for the respective drugs for protection against thrombosis within the arterial system.
bSection III lists the dosing for rivaroxaban in a secondary prevention setting in CAD patients. For a comprehensive summary on dosing of OACs (NOACs and VKAs) in a setting of full-dose anticoagulation please see: The 2018 European Heart Rhythm Association Practical Guide on the use of NOACs in patients with AF.168
ESC Guidelines
1311


<!-- PAGE 24 -->

### Page 24

........................................................................................
of the study, amongst multiple others, include its open-label design and the limited data on medically managed or CABG-treated patients, which were more prominent in the PLATO trial.170
Ticagrelor also led to more patients stopping medication because of side effects. The actual treatment strategy was PCI in >80% of randomized patients and, consequently, prasugrel should be considered the preferred P2Y12 receptor inhibitor for NSTE-ACS patients who proceed to PCI. The possible benefit of prasugrel, in comparison with ticagrelor or clopidogrel, may be related to improved endothelial function.175 Recommended treatment algorithms and treatment durations, as well as options for extended treatment (>12 months) in
NSTE-ACS patients, are shown in Figure 7.
5.1.1.2 Pre-treatment
Pre-treatment defines a strategy according to which antiplatelet drugs, usually a P2Y12 receptor inhibitor, are given before coronary angiography and when the coronary anatomy is unknown.176
Although a rationale for pre-treatment in NSTE-ACS may seem obvious, for achieving sufficient platelet inhibition at the time of
PCI, large-scale randomized trials supporting a routine pretreatment strategy with either clopidogrel or the potent P2Y12
receptor inhibitors  prasugrel and ticagrelor  are lacking. The randomized Comparison of Prasugrel at the Time of Percutaneous
Coronary Intervention or as Pretreatment at the Time of
Diagnosis in Patients with Non-ST Elevation Myocardial Infarction
(ACCOAST) trial177 demonstrated a lack of any ischaemic benefit for pre-treatment in NSTE-ACS patients, but instead, a substantially higher bleeding risk with prasugrel pre-treatment. In line with these results, observational data on pre-treatment with ticagrelor,
prasugrel, and clopidogrel were reported from the Swedish
Coronary Angiography and Angioplasty Registry (SCAAR) in 64
857 NSTE-ACS patients.178 In this large dataset on pre-treatment,
the authors reported that P2Y12 receptor inhibitor pre-treatment in NSTE-ACS patients was not associated with improved ischaemic outcomes, but instead, with a significantly increased risk of bleeding events. With respect to pre-treatment data for ticagrelor,
the recently published ISAR-REACT 5 trial showed that a prasugrel-based strategy with deferred loading after knowledge of coronary anatomy in NSTE-ACS patients was superior to a ticagrelor-based strategy that implied a routine pre-treatment strategy.174 Importantly, there was no apparent benefit of a pretreatment strategy (that utilized ticagrelor) in that study.
Based upon the available evidence,174,177 it is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in
NSTE-ACS patients in whom coronary anatomy is not known and an early invasive management is planned. For patients with a delayed invasive management, pre-treatment with a P2Y12 receptor inhibitor may be considered in selected cases and according to the bleeding risk of the patient.
Fortunately, the recommended standard treatment with potent
P2Y12 receptor inhibitors (ticagrelor or prasugrel) exhibits a fast onset of action (Table 9), thereby allowing LD administration after diagnostic coronary angiography and directly before PCI. Of note, a routine pre-treatment strategy may be deleterious for a relevant proportion of patients with diagnoses other than NSTE-ACS (e.g. aortic dissection or bleeding complications including intracranial bleeding)
and may increase bleeding risk or delay procedures in patients scheduled for CABG after diagnostic angiography.
Table 9
P2Y12 receptor inhibitors for use in non-ST-segment elevation acute coronary syndrome patients
Oral administration i.v. administration
Clopidogrel
Prasugrel
Ticagrelor
Cangrelor
Drug class
Thienopyridine
Thienopyridine
Cyclopentyl-triazolopyrimidine
Adenosine triphosphate analogue
Reversibility
Irreversible
Irreversible
Reversible
Reversible
Bioactivation
Yes (pro-drug, CYP
dependent, 2 steps)
Yes (pro-drug, CYP
dependent, 1 step)
Noa
No
(Pretreatment)-Dose
600 mg LD, 75 mg MD
60 mg LD, 10 (5) mg MD
180 mg LD, 2  90 (60) mg MD
30 mg/kg i.v. bolus, 4 mg/kg/min i.v.
infusion for PCI
Onset of effect
Delayed: 26 h
Rapid: 0.54 h
Rapid: 0.52 h
Immediate: 2 min
Offset of effect
310 days
510 days
34 days
3060 min
Delay to surgery
5 days
7 days
5 days
No signiﬁcant delay
Kidney failure
No dose adjustment
No dose adjustment
No dose adjustment
No dose adjustment
Dialysis or CrCl
<15 mL/min
Limited data
Limited data
Limited data
Limited data
CrCl = creatine clearance; CYP = cytochrome P450; i.v. = intravenous; LD = loading dose, MD = maintenance dose, PCI = percutaneous coronary intervention.
aFollowing intestinal absorption, ticagrelor does not need to be metabolized to inhibit platelets. Of note, a metabolite (AR-C124910XX) of ticagrelor is also active.


<!-- PAGE 25 -->

### Page 25

©ESC 2020
Figure 7 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients without atrial fibrillation undergoing percutaneous coronary intervention. HBR is considered as an increased risk of spontaneous bleeding during DAPT (e.g. PRECISE-DAPT score >_25 or
ARC-HBR158). Colour-coding refers to the ESC classes of recommendations (green = class I; yellow = IIa; orange = Class IIb). Very HBR is defined as recent bleeding in the past month and/or not deferrable planned surgery. A = aspirin; ARC-HBR = Academic Research Consortium  High Bleeding Risk;
C = clopidogrel; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy (here: aspirin þ rivaroxaban); eGFR = estimated glomerular filtration rate; ESC = European Society of Cardiology; HBR = high bleeding risk; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; P = prasugrel; PCI = percutaneous coronary intervention; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; R = rivaroxaban; T = ticagrelor; UFH = unfractionated heparin. aClopidogrel during 12 months DAPT if patient is not eligible for treatment with prasugrel or ticagrelor or in a setting of DAPT de-escalation with a switch to clopidogrel (class IIb). bClopidogrel or prasugrel if patient is not eligible for treatment with ticagrelor. cClass IIa indication for DAT or DAPT >12 months in patients at high risk for ischaemic events (see
Table 11 for definitions) and without increased risk of major bleeding (= prior history of intracranial haemorrhage or ischaemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, renal failure requiring dialysis, or with eGFR <15
mL/min/1.73 m2); Class IIb indication for DAT or DAPT >12 months in patients with moderately increased risk of ischaemic events (see Table 11 for definitions)
and without increased risk of major bleeding. Listen to the audio guide of this figure online.
ESC Guidelines
1313


<!-- PAGE 26 -->

### Page 26

....................................
5.1.2 Peri-interventional anticoagulant treatment
Peri-interventional treatment for NSTE-ACS patients consists of anticoagulation to inhibit thrombin generation and thrombin activity
(Figure 6). Anticoagulation is recommended for all patients in addition to antiplatelet therapy during invasive management for NSTEACS.192 Table 8 provides an overview of the relevant drugs and their dosing in NSTE-ACS patients. Unfractionated heparin (UFH) is the standard of care for NSTE-ACS patients due to its favourable riskbenefit profile. In general, a crossover between anticoagulants should be avoided [especially between UFH and low-molecular-weight heparin (LMWH)], with the exception of adding UFH to fondaparinux when a patient proceeds to PCI after fondaparinux treatment.196,199
The respective drugs should be discontinued immediately after PCI,
except in specific clinical settings such as the confirmed presence of
LV aneurysm with thrombus formation or AF requiring anticoagulation, which is usually done with UFH in (per)-acute settings.
Adjunctive treatment [e.g. glycoprotein (GP) IIb/IIIa inhibitors] and procedural aspects (radial vs. femoral access) have been subject to change in recent years. In contrast to older studies, recent and contemporary trials have pursued a balanced and more selective use of
GP IIb/IIIa inhibitors, with both bivalirudin and UFH. These trials have been reviewed extensively in a number of meta-analyses.200203 A
recent meta-analysis, which included the Minimizing Adverse
Haemorrhagic Events by TRansradial Access Site and Systemic
Recommendations for antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention
Recommendations
Classa
Levelb
Antiplatelet treatment
Aspirin is recommended for all patients without contraindications at an initial oral LD of 150300 mg (or 75250 mg i.v.), and at a
MD of 75100 mg o.d. for long-term treatment.179181
I
A
A P2Y12 receptor inhibitor is recommended in addition to aspirin, and maintained over 12 months unless there are contraindications or an excessive risk of bleeding.170,171,182
Options are:
I
A
 Prasugrel in P2Y12 receptor inhibitor-naı¨ve patients proceeding to PCI (60 mg LD, 10 mg/d as standard dose, 5 mg/d for patients aged >_75 years or with a body weight <60 kg).171
I
B
 Ticagrelor irrespective of the planned treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d.).170
I
B
 Clopidogrel (300600 mg LD, 75 mg daily dose), only when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.182,183
I
C
Prasugrel should be considered in preference to ticagrelor for NSTE-ACS patients who proceed to PCI.174
IIa
B
GP IIb/IIIa antagonists should be considered for bail-out if there is evidence of no-reﬂow or a thrombotic complication.
IIa
C
Cangrelor may be considered in P2Y12 receptor inhibitor-naı¨ve patients undergoing PCI.184187
IIb
A
Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients with NSTE-ACS who are not planned to undergo an early invasive strategy and do not have an HBR.
IIb
C
Treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known is not recommended.188,189
III
A
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned.174,177,178,190,191
III
A
Peri-interventional anticoagulant treatment
Parenteral anticoagulation is recommended for all patients, in addition to antiplatelet treatment, at the time of diagnosis and, especially, during revascularization procedures according to both ischaemic and bleeding risks.192,193
I
A
UFH (weight-adjusted i.v. bolus during PCI of 70100 IU/kg, or 5070 IU/kg in combination with a GP IIb/IIIa inhibitor; activated clotting time target range of 250350 s, or 200250 s if a GP IIb/IIIa inhibitor is given) is recommended in patients undergoing PCI.
I
A
In cases of medical treatment or logistical constraints for transferring the patient to PCI within the required time frame, fondaparinux is recommended and, in such cases, a single bolus of UFH is recommended at the time of PCI.183
I
B
It is recommended to select anticoagulation according to both ischaemic and bleeding risks, and according to the efﬁcacysafety proﬁle of the chosen agent.
I
C
Enoxaparin (i.v.) should be considered in patients pre-treated with subcutaneous enoxaparin.194196
IIa
B
Discontinuation of parenteral anticoagulation should be considered immediately after an invasive procedure.
IIa
C
Bivalirudin may be considered as an alternative to UFH.189,197,198
IIb
A
Crossover of UFH and LMWH is not recommended.196
III
B
b.i.d. = bis in die (twice a day); GP = glycoprotein; HBR = high bleeding risk; i.v. = intravenous; LD = loading dose; LMWH = low-molecular-weight heparin; MD = maintenance dose; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; o.d. = once daily; PCI = percutaneous coronary intervention; UFH = unfractionated heparin.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 27 -->

### Page 27

.............................................................................................................................................................................
Implementation of angioX (MATRIX) trial,197 showed no significant benefit of bivalirudin vs. UFH for ischaemic outcomes.202 Bivalirudin was associated with a significant increase in the risk of stent thrombosis and a significant decrease in bleeding risk. Bleeding risk reduction was linked to unbalanced use of GP IIb/IIIa inhibitors, predominantly with UFH. Recently, the Swedish Web-system for Enhancement and
Development of Evidence-based care in Heart disease Evaluated
According to
Recommended
Therapies
(VALIDATESWEDEHEART) study204 compared UFH vs. bivalirudin on a background of radial access and limited use of GP IIb/IIIa inhibitors. The study demonstrated similar risks for both ischaemia and bleeding when comparing the two drugs. Another meta-analysis, updated with the results of the VALIDATE-SWEDEHEART study, confirmed that bivalirudin vs. UFH was associated with a similar incidence of allcause death and ischaemic events after PCI in ACS.203 A significant association between bivalirudin and decreased risk of bleeding was only found with unbalanced use of GP IIb/IIIa inhibitors in conjunction with UFH.
In summary, and based on the aforementioned trials, UFH is primarily recommended as an anticoagulant for PCI. Due to its short half-life and favourable results in some of the studies, bivalirudin may be considered as an alternative to UFH in selected cases. For a more detailed description and a historical summary of the older clinical trials (with unbalanced use of GP IIb/IIIa inhibitors) comparing UFH
with bivalirudin, please refer to the 2018 ESC/EACTS Guidelines on myocardial revascularization.205
Patients may undergo cardiac catheterization after a conservative treatment phase and these patients might be treated with fondaparinux during this period. This regimen is based on the Fifth
Organization to Assess Strategies in Acute Ischemic Syndromes
(OASIS-5) trial.206 Of note, catheter thrombus formation was an issue with fondaparinux and, therefore, full-dose UFH must be added to prevent thrombus formation when the patient proceeds to PCI.
Enoxaparin, a LMWH with a predictable dose-effect relationship and a lower risk for heparin-induced thrombocytopenia (HIT) compared to UFH, should be considered as an anticoagulant for PCI in patients pre-treated with subcutaneous enoxaparin. A benefit of enoxaparin over UFH reduced mortality and bleeding complications  was reported in a meta-analysis that included NSTE-ACS
patients,194 but dedicated large-scale trials comparing enoxaparin vs.
UFH in NSTE-ACS are lacking.
5.1.3 Peri-interventional antiplatelet treatment
Drugs for peri-interventional i.v. antiplatelet treatment include cangrelor and GP IIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban).
Most of the trials evaluating GP IIb/IIIa inhibitors in PCI-treated ACS
patients predated the era of routine DAPT with early DAPT initiation including a P2Y12 receptor inhibitor LD.205,207 Today, with routine and potent oral P2Y12 receptor inhibitors, there is no compelling evidence for an additional benefit of routine upstream use of GP IIb/IIIa inhibitors in NSTE-ACS patients scheduled for coronary angiography.188,189 Even more so, in a setting of potent platelet inhibition with ticagrelor or prasugrel, where randomized data on GP IIb/IIIa use is limited, routine use of these agents cannot be recommended.
Nevertheless, use should be considered for bail-out situations or thrombotic complications and may be considered for high-risk PCI in patients without pre-treatment with P2Y12 receptor inhibitors (see
2018 ESC/EACTS Guidelines on myocardial revascularization for more details).205
Cangrelor is a direct reversible, short-acting P2Y12 receptor inhibitor that has been evaluated during PCI for stable CCS and ACS in clinical trials comparing cangrelor with clopidogrel, administered before PCI [Cangrelor versus Standard Therapy to Achieve Optimal
Management of Platelet Inhibition (CHAMPION)] or after PCI
(CHAMPION PLATFORM and CHAMPION PHOENIX).185187 A
meta-analysis of these trials showed a benefit with respect to major ischaemic endpoints that was counter-balanced by an increase in minor bleeding complications.184 Moreover, the benefit of cangrelor with respect to ischaemic endpoints was attenuated in CHAMPION
PCI with upfront administration of clopidogrel, while data for its use in conjunction with ticagrelor or prasugrel treatment are limited.
Due to its proven efficacy in preventing intra-procedural and postprocedural stent thrombosis in P2Y12 receptor inhibitor-naı¨ve patients, cangrelor may be considered on a case-by-case basis in
P2Y12 receptor inhibitor-naı¨ve NSTE-ACS patients undergoing PCI
(see 2018 ESC/EACTS Guidelines on myocardial revascularization for more details).205
5.1.4 Post-interventional and maintenance treatment
Following PCI for NSTE-ACS, DAPT consisting of a potent P2Y12
receptor inhibitor in addition to aspirin is generally recommended for 12 months, irrespective of the stent type, unless there are contraindications.170,171,182 In specific clinical scenarios, DAPT duration can be shortened (<12 months), extended (>12 months, see Figure 7 and
Tables 10 and 11), or modified (switching DAPT, DAPT deescalation) and these decisions depend on individual clinical judgement being driven by the patient’s ischaemic and bleeding risk, the occurrence of adverse events, comorbidities, co-medications, and the availability of the respective drugs. For a detailed description of the pertinent and numerous trials that have compared different
DAPT treatment durations (especially 36 vs. 12 months in NSTEACS patients), please refer to the 2017 ESC focused update on
DAPT in CAD169 and recent trial publications.208,209 In patients with
NSTE-ACS and stent implantation who are at high risk of bleeding
(e.g. PRECISE-DAPT >_25 or ARC-HBR criteria met), discontinuation of P2Y12 receptor inhibitor therapy after 36 months should be considered.154 In patients at very high risk of bleeding, defined as a recent bleeding episode in the past month or planned, not deferrable surgery in the near future, 1 month of aspirin and clopidogrel should be considered.
Four recent trials (n = 29 089) have explored the benefit of a shortened DAPT duration of 13 months.208211 Low-to-intermediate ischaemic risk and low bleeding risk patients were included and early monotherapy with clopidogrel/ticagrelor was used. All bleeding events were reduced, with a favourable trend towards less ischaemic events including MI. Importantly, more than 50% had ACS
as an inclusion criterion. In particular, the Ticagrelor With Aspirin or
Alone in
High-Risk
Patients
After
Coronary
Intervention
(TWILIGHT) trial211 examined the effect of ticagrelor alone vs. ticagrelor plus aspirin with regard to clinically relevant bleeding among patients at high risk for bleeding or ischaemic events who had undergone PCI, according to the inclusion criteria. However, these patients
ESC Guidelines
1315


<!-- PAGE 28 -->

### Page 28

...........................
were not at HBR according to current HBR criteria and event rates at follow-up. Based on this, these patients were more a low bleeding and ischaemic risk cohort even though more than two thirds had an
ACS. After 3 months of treatment with ticagrelor plus aspirin,
patients who did not have a major bleeding or ischaemic event continued to take ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. The primary endpoint of Bleeding
Academic Research Consortium (BARC) type 2, 3, or 5 bleeding was significantly reduced by omitting aspirin (4.0 vs. 7.1%; HR 0.56, 95%
CI 0.450.68, P<0.001), with a significant interaction according to
ACS at presentation. The trial was not powered for the composite endpoint of death from any cause, non-fatal MI, or non-fatal stroke.
However, in exploratory non-inferiority hypothesis testing, there was no signal of increased ischaemic risk.211 It should be acknowledged that the actual ischaemic event rate in TWILIGHT was low compared to other trials for deemed high-risk PCI patients.
Contrary to this, and based on the results of the DAPT and
Prevention of Cardiovascular Events in Patients With Prior Heart
Table 10
Treatment options for extended dual antithrombotic or antiplatelet therapies
Drug
Dose
Indication
NNT
(ischaemic outcomes)
NNH
(bleeding outcomes)
DAT regimens for extended treatment (including aspirin 75100 mg o.d.)
Rivaroxaban (COMPASS trial)
2.5 mg b.i.d.
Patients with CAD or symptomatic
PAD at high risk of ischaemic events
77
84
DAPT regimens for extended treatment (including aspirin 75100 mg o.d.)
Clopidogrel (DAPT trial)
75 mg/d
Post MI in patients who have tolerated DAPT for 1 year
63
105
Prasugrel (DAPT trial)
10 mg/d (5 mg/d if body weight
<60 kg or age >75 years)
Post PCI for MI in patients who have tolerated DAPT for 1 year
63
105
Ticagrelor (PEGASUS-TIMI 54)
60/90 mg b.i.d.
Post MI in patients who have tolerated DAPT for 1 year
84
81
Drugs (in addition to aspirin 75100 mg/d) for extended DAPT treatment options are in alphabetical order. For indications and deﬁnitions for high/moderately increased risk and bleeding risk see Table 9 and Figure 7. NNT refers to the primary ischaemic endpoints of the respective trials and NNH refers to the key safety (bleeding) endpoints. NNT
and NNH numbers from the DAPT trial are pooled numbers for clopidogrel and prasugrel.
b.i.d. = bis in die (twice a day); CAD = coronary artery disease; COMPASS = Cardiovascular OutcoMes for People using Anticoagulation StrategieS; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; MI = myocardial infarction; NNH = number needed to harm; NNT = number needed to treat; o.d. = once daily; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; PEGASUS-TIMI 54 = Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54.
Table 11
Risk criteria for extended treatment with a second antithrombotic agent
High thrombotic risk (Class IIa)
Moderate thrombotic risk (Class IIb)
Complex CAD and at least 1 criterion
Non-complex CAD and at least 1 criterion
Risk enhancers
Diabetes mellitus requiring medication
Diabetes mellitus requiring medication
History of recurrent MI
History of recurrent MI
Any multivessel CAD
Polyvascular disease (CAD plus PAD)
Polyvascular disease (CAD plus PAD)
CKD with eGFR 1559 mL/min/1.73 m2
Premature (<45 years) or accelerated (new lesion within a 2-year time frame) CAD
Concomitant systemic inﬂammatory disease (e.g. human immunodeﬁciency virus,
systemic lupus erythematosus, chronic arthritis)
CKD with eGFR 1559 mL/min/1.73 m2
Technical aspects
At least 3 stents implanted
At least 3 lesions treated
Total stent length >60 mm
History of complex revascularization (left main, bifurcation stenting with >_2 stents implanted, chronic total occlusion, stenting of last patent vessel)
History of stent thrombosis on antiplatelet treatment
In line with guideline recommendations, CAD patients are stratiﬁed into two different risk groups (high vs. moderately increased thrombotic or ischaemic risk). Stratiﬁcation of patients towards complex vs. non-complex CAD is based on individual clinical judgement with knowledge of patients’ cardiovascular history and/or coronary anatomy.
Selection and composition of risk-enhancing factors are based on the combined evidence of clinical trials on extended antithrombotic treatment in CAD patients162,212,214 and on data from related registries.228230
CAD = coronary artery disease; CKD = chronic kidney disease; eGFR = estimated glomerular ﬁltration rate; MI = myocardial infarction; PAD = peripheral artery disease.


<!-- PAGE 29 -->

### Page 29

Attack Using Ticagrelor Compared to Placebo on a Background of
Aspirin-Thrombolysis in Myocardial Infarction (PEGASUS-TIMI)
54 trials, in patients with ACS who have tolerated DAPT without a bleeding complication, a prolonged DAPT course >12 months should be considered in those with high thrombotic risk and without an increased risk for major or life-threatening bleeding, and may be considered in patients with moderately elevated thrombotic risk (see Figure 7 and Tables 10 and 11).212,213 Of note, the
60 mg bis in die [b.i.d. (twice a day)] dose for ticagrelor was better tolerated than the 90 mg b.i.d dose214,215 and this dose is now approved in many (albeit not all) countries for this indication.
Switching between oral P2Y12 receptor inhibitors is common and triggers may include bleeding complications (or concerns for bleeding), non-bleeding side effects (e.g. dyspnoea on ticagrelor, allergic reactions), as well as socio-economic factors.216,217 Switching between oral P2Y12 receptor inhibitors may be considered in selected cases, and for a more detailed description on switching antiplatelet drugs, please refer to the International Expert Consensus on
Switching Platelet P2Y12 Receptor-Inhibiting Therapies217 and the
2017 ESC DAPT focused update.169
DAPT de-escalation (switch from potent drugs like prasugrel or ticagrelor to clopidogrel) in NSTE-ACS patients may be considered as an alternative treatment regimen.216,217 However, it is important to note that there is a potential for increased ischaemic risk with a uniform de-escalation of P2Y12 receptor inhibiting therapy after PCI, particularly if performed early (<30 days) after the index event. Indeed, dedicated large-scale trials on a uniform and unguided DAPT de-escalation are lacking and the available data on uniform de-escalation are conflicting.218,219 Based on the results of the Testing Responsiveness to Platelet Inhibition on Chronic
Antiplatelet
Treatment for
Acute
Coronary
Syndromes
(TROPICAL-ACS)
and
POPULAR
Genetics trials,220,221
an approach of DAPT de-escalation guided by either platelet function testing
(TROPICAL-ACS:
NSTE-ACS
and
STEMI
patients)
or CYP2C19-directed genotyping (POPULAR Genetics: STEMI
patients) may be considered in selected NSTE-ACS patients as an alternative to 12 months of potent platelet inhibition,
especially for patients deemed unsuitable for maintained potent platelet inhibition. For further details, please refer to the updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in
PCI.222
Recently, data on a novel strategy of dual antithrombotic therapy (DAT) consisting of factor-Xa inhibition with a very low dose of rivaroxaban (2.5 mg b.i.d.) plus aspirin has emerged, and such a regimen should be considered as a treatment option for maintenance treatment beyond 12 months post ACS PCI. In a secondary prevention setting, the Cardiovascular OutcoMes for People using
Anticoagulation StrategieS (COMPASS) trial162,223 investigated very low-dose rivaroxaban (2.5 mg b.i.d.) in combination with aspirin vs. aspirin alone or rivaroxaban 5 mg b.i.d. alone.
Rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d. reduced the risk of the combined ischaemic endpoint, overall mortality (without reaching the threshold P-value according to the Hochberg procedure), and cardiovascular mortality alone, while this combination increased the risk for major bleeding complications without a
Recommendations for post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
In patients with NSTE-ACS treated with coronary stent implantation, DAPT with a P2Y12 receptor inhibitor on top of aspirin is recommended for 12
months unless there are contraindications such as excessive risk of bleeding.170,171,225
I
A
Prolonging antithrombotic treatment duration
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be considered in patients with a high risk of ischaemic events and without increased risk of major or life-threatening bleeding (see
Tables 9 and 11 for options).162,212,213,214,223
IIa
A
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention may be considered in patients with moderately increased risk of ischaemic events and without increased risk of major or life-threatening bleeding
(see Tables 9 and 11 for options).162,212,213,214,223
IIb
A
In ACS patients with no prior stroke/transient ischaemic attack who are at high ischaemic risk and low bleeding risk and are receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg b.i.d. for approximately 1 year) may be considered after discontinuation of parenteral anticoagulation.224
IIb
B
Shortening antithrombotic treatment duration
After stent implantation with high risk of bleeding (e.g. PRECISE-DAPT >_25 or ARC-HBR criteria met), discontinuation of P2Y12 receptor inhibitor therapy after 3 months should be considered.154,226
IIa
B
After stent implantation in patients undergoing a strategy of DAPT, stopping aspirin after 36
months should be considered, depending on the balance between the ischaemic and bleeding risk.208,209,227
IIa
A
De-escalation of P2Y12 receptor inhibitor treatment (e.g. with a switch from prasugrel or ticagrelor to clopidogrel) may be considered as an alternative DAPT strategy, especially for ACS
patients deemed unsuitable for potent platelet inhibition. De-escalation may be done unguided based on clinical judgment or guided by platelet function testing or CYP2C19 genotyping,
depending on patient’s risk proﬁle and availability of respective assays.218,220,221
IIb
A
ACS = acute coronary syndromes; ARC-HBR = Academic Research Consortium
 High Bleeding Risk; b.i.d. = bis in die (twice a day); DAPT = dual antiplatelet therapy; NSTE-ACS = non-ST-segment elevation acute coronary syndrome;
PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing
Stent implantation and subsEquent Dual Anti Platelet Therapy.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1317


<!-- PAGE 30 -->

### Page 30

......................................................................................................................................................................
significant increase in the risk of fatal, intracranial, or critical organ bleeding events. Greater absolute risk reductions were seen in high-risk patients, including those with diabetes or polyvascular disease [CAD plus peripheral artery disease (PAD)]. Thus, rivaroxaban (2.5 mg b.i.d.) should be considered, in addition to aspirin
75 - 100 mg/d in patients at high thrombotic risk and without an increased risk for major or life-threatening bleeding, and may be considered in patients with moderately elevated thrombotic risk
(see Figure 7 and Tables 10 and 11 for selection criteria and for ischaemic and bleeding risk definitions).
Rivaroxaban has also been studied in the Anti-Xa Therapy to
Lower Cardiovascular Events in Addition to Standard Therapy in
Subjects with Acute Coronary Syndrome 2Thrombolysis In
Myocardial Infarction 51 (ATLAS ACS 2TIMI 51) trial on a background of clopidogrel treatment. The study showed a reduction of ischaemic events and cardiovascular mortality along with a higher risk for bleeding.224 However, data are lacking on a background of ticagrelor or prasugrel treatment and it is therefore difficult to extrapolate trial results to contemporary practice including the use of potent
P2Y12 receptor inhibitors.
5.2 Pharmacological treatment of ischaemia (Supplementary Data)
5.2.1 Supportive pharmacological treatment
(Supplementary Data)
5.2.2 Nitrates and beta-blockers (Supplementary
Data)
5.3 Managing oral antiplatelet agents in patients requiring long-term oral anticoagulants
5.3.1 Patients with atrial fibrillation without mechanical prosthetic heart valves or moderate-to-severe mitral stenosis undergoing percutaneous coronary intervention or managed medically (Supplementary Data)
In 68% of patients undergoing PCI, long-term OAC is indicated and should also be continued during the procedure because its interruption and bridging with parenteral anticoagulants may lead to increased thromboembolic episodes and bleeds.232234 In patients undergoing PCI, it is unknown whether it is safe to bridge non-vitamin K antagonist (VKA) OACs (NOACs) with parenteral anticoagulants or continue NOACs without additional parenteral anticoagulation, while no parenteral anticoagulation is needed if the international normalized ratio (INR) is >2.5 in VKA-treated patients.235237 Strategies to minimize PCI-related complications in patients on OACs are listed in Table 12.
In NSTE-ACS patients, evidence on the management of patients undergoing PCI requiring long-term OAC is derived from subgroups of RCTs (see Table 13 and Supplementary Data section 5.3.1).238242
Overall, in patients with AF without mechanical prosthetic valves or moderate-to-severe mitral stenosis, the evidence supports the use of NOACs over VKA in terms of safety (i.e. lower bleeding risk).
DAT with a NOAC at the recommended dose for stroke prevention and single antiplatelet therapy (SAPT) (preferably clopidogrel, chosen in more than 90% of cases in available trials) is recommended as the default strategy up to 12 months after a short period (up to 1 week)
of triple antithrombotic therapy (TAT) (with NOAC and DAPT)
(Figure 8). Although none of the available RCTs were designed to detect subtle differences in ischaemic events, the numerically higher risk of stent thrombosis or MIs observed in some trials might have been offset by the higher risk of bleeding, resulting in a neutral effect on major adverse cardiovascular events (MACE) or overall death.243,244 At variance with the default strategy, in patients with
HBR, DAT should be shortened to 6 months by withdrawing the ongoing antiplatelet therapy; while in patients with high coronary ischaemic risk, TAT should be prolonged up to 1 month, followed by
DAT for up to 12 months. There is currently limited evidence to support the use of OACs with ticagrelor or prasugrel as dual therapy after PCI as an alternative to TAT.241,245 Following coronary stenting,
DAPT with aspirin and ticagrelor or prasugrel, without OAC, may be considered as an alternative to TAT in patients with high ischaemic risk NSTE-ACS and AF and one non-sex stroke risk factor within the first 4 weeks. Regarding the need to continue with any antiplatelet agent beyond 12 months, the AFIRE trial randomized 2236 AF
patients treated with PCI or CABG more than 1 year earlier or with documented CAD to receive either monotherapy with rivaroxaban or combination therapy with rivaroxaban plus a single antiplatelet agent.246 Rivaroxaban monotherapy (15 mg o.d. or 10 mg o.d. with creatinine clearance (CrCl) 1549 mL/min) was non-inferior to combination therapy for the primary efficacy composite endpoint of stroke, systemic embolism, MI, unstable angina requiring revascularization,
or overall death
(HR
0.72,
95%
CI
0.550.95).
Recommendations for anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Sublingual or i.v. nitrates and early initiation of beta-blocker treatment are recommended in patients with ongoing ischaemic symptoms and without contraindications.
I
C
It is recommended to continue chronic betablocker therapy unless the patient is in overt heart failure.
I
C
i.v. nitrates are recommended in patients with uncontrolled hypertension or signs of heart failure.
I
C
In patients with suspected/conﬁrmed vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided.231
IIa
B
i.v. = intravenous.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 31 -->

### Page 31

Table 12
Suggested strategies to reduce bleeding risk related to percutaneous coronary intervention
• Anticoagulant doses adjusted to body weight and renal function, especially in women and older patients
• Radial artery approach as default vascular access
• Proton pump inhibitors in patients on DAPT at higher-than-average risk of gastrointestinal bleeds (i.e. history of gastrointestinal ulcer/haemorrhage, anticoagulant therapy, chronic non-steroidal anti-inﬂammatory drugs/corticosteroid use, or two or more of:
a.
Age >_65 years b.
Dyspepsia c.
Gastro-oesophageal reﬂux disease d.
Helicobacter pylori infection e.
Chronic alcohol use
• In patients on OAC
a.
PCI performed without interruption of VKAs or NOACs b.
In patients on VKAs, do not administer UFH if INR >2.5
c.
In patients on NOACs, regardless of the timing of the last administration of NOACs, add low-dose parenteral anticoagulation
(e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg)
• Aspirin is indicated but avoid pre-treatment with P2Y12 receptor inhibitors
• GP IIb/IIIa inhibitors only for bailout or periprocedural complications
DAPT = dual antiplatelet therapy; GP = glycoprotein; INR = international normalized ratio; i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; OAC =
oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention; UFH = unfractionated heparin; VKA = vitamin K antagonist.
Table 13
Randomized controlled trials including patients with non-ST-segment elevation acute coronary syndrome requiring anticoagulation and antiplatelet therapy
RCT
n
Comparison
Primary Endpoint
Secondary endpoints
WOEST239
573
DAT (VKA þ C) for 12 months vs.
TAT (VKA þ A þ C) for
12 months
TIMI bleeding lower with DAT vs. TAT
at 1 year (HR 0.36, 95% CI 0.260.50)
MI þ stroke þ target vessel revascularization þ stent thrombosis: no difference.
All-cause mortality lower with DAT vs. TAT
at 1 year (HR 0.39, 95% CI 0.160.93)
ISAR-TRIPLE250
614
6 weeks TAT (VKA þ A þ C) followed by DAT (VKA þ A) vs.
6 months TAT (VKA þ A þ C)
Death þ MI þ stent thrombosis þ
stroke or TIMI major bleeds at
9 months: no difference
Cardiac death þ MIþ stent thrombosis
þ stroke: no difference. TIMI major bleeding: no difference
PIONEER
AF-PCI240
2124
DAT (rivaroxaban 15 mg/day þ C)
for 12 months) vs. modiﬁed TAT
(rivaroxaban 2.5 mg b.i.d. þ A þ C
for 1, 6, or 12 months) vs. TAT (VKA
þ A þ C for 1, 6, or 12 months)
Clinically signiﬁcant bleeding lower with DAT (HR 0.59, 95% CI
0.470.76) or modiﬁed TAT (HR 0.63,
95% CI 0.500.80) vs. TAT
Cardiovascular death þ MI þ stroke:
no difference. All-cause death þ rehospitalization lower with DAT (HR 0.79,
CI 0.690.94) or modiﬁed TAT (HR
0.75, CI 0.620.90) vs. TAT
RE-DUAL PCI238
2725
TAT (VKA þ A þ C) up to 3
months vs. DAT (dabigatran 110 or
150 mg b.i.d. þ C or T)
Major or clinically relevant non-major bleeding lower in DAT 110 mg (HR 0.52,
95% CI 0.420.63) or DAT 150 mg (HR
0.72, 95% CI 0.580.88) vs. TAT
MI þ stroke þ systemic embolism,
death, unplanned revascularization: no difference
AUGUSTUS241
4614
DAT1 (apixaban 5 mg b.i.d. þ C or T
or P) vs. DAT2 (VKA þ C or T or P)
vs. TAT1 (apixaban 5 mg b.i.d. þ A þ
C or T or P) vs. TAT2 (VKA þ A þ
C or T or P)
Major or clinically relevant non-major bleeds lower with DAT1 (HR 0.69,
95% CI 0.580.81) vs. other regimens
Death þ hospitalization lower with apixaban (HR 0.83, 95% CI 0.740.93)
No difference with aspirin
ENTRUSTAF PCI251
1506
DAT (edoxaban 60 mg þ C or T or
P) vs. TAT (VKA þ A þ C or T or
P)
Major or clinically relevant non-major bleeds non-inferior between DAT or
TAT (HR 0.83, 95% CI 0.651.05,
P=0.0010 for non-inferiority)
Cardiovascular death þ stroke þ systemic embolism þ MI þ stent thrombosis not different between DAT and
TAT
A = aspirin; AF = atrial ﬁbrillation; AUGUSTUS = Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation; b.i.d. = bis in die (twice a day); C = clopidogrel; CI = conﬁdence interval; DAT = dual antithrombotic therapy; ENTRUST-AF PCI = EdoxabaN TRreatment versUS VKA in paTients with AF undergoing PCI; HR =
hazard ratio; ISAR-TRIPLE = Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation; MI = myocardial infarction; OAC = oral anticoagulation/
anticoagulant; P = prasugrel; PIONEER AF-PCI = Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a DoseAdjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention; RCT = randomized controlled trial; RE-DUAL PCI = Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial
Fibrillation Undergoing Percutaneous Coronary Intervention; T = ticagrelor; TAT = triple antithrombotic therapy; TIMI = Thrombolysis In Myocardial Infarction; VKA = vitamin
K antagonist; WOEST = What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing.
ESC Guidelines
1319


<!-- PAGE 32 -->

### Page 32

......................................................
Rivaroxaban monotherapy was superior for the primary safety endpoint of major bleeding (HR 0.59, 95% CI 0.390.89).
In NSTE-ACS patients managed medically, available data support
DAT over TAT, with a single antiplatelet agent (most commonly clopidogrel) for at least 6 months.247 In a registry, bleeding risk was increased on TAT compared to VKA plus a single antiplatelet agent at 90 days, but not at 1 year, without differences in ischaemic events.248 In addition, warfarin plus clopidogrel resulted in a nonsignificant reduction in major bleeds compared with TAT, with a non-significant reduction in MI or cardiovascular death.249 In the randomized
Antithrombotic
Therapy after
Acute
Coronary
Syndrome or PCI in Atrial Fibrillation (AUGUSTUS) trial,241 approximately 23% of enrolled patients presented with medically managed
ACS. In these patients, apixaban significantly reduced bleeding events vs. VKA (HR 0.44, 95% CI 0.280.68) and death or hospitalization
(HR 0.71, 95% CI 0.540.92), while no significant differences were observed in death or ischaemic events (HR 0.71, 95% CI
0.461.09]). Aspirin vs. placebo presented a strong trend towards higher bleeding events (HR 1.49, 95% CI 0.982.26), but no significant differences in death or hospitalization (HR 1.16, 95% CI
0.901.51) or ischaemic events (HR 1.01, 95% CI 0.661.55).
5.3.2 Patients requiring vitamin K antagonists or undergoing coronary artery bypass surgery
In patients where VKA is mandated (e.g. patients with mechanical prosthetic valves), DAT with VKA and SAPT (preferably clopidogrel)
is indicated after a short in-hospital period of TAT (with aspirin and clopidogrel).239 Compared with TAT (consisting of VKA plus aspirin and clopidogrel), DAT (VKA plus clopidogrel) was associated with a trend towards a reduction in Thrombolysis In Myocardial Infarction
(TIMI) major bleeding (OR 0.58, 95% CI 0.311.08) in a network meta-analysis, while no significant difference was observed in MACE
(OR 0.96, 95% CI 0.601.46).243
CABG in fully anticoagulated patients is associated with an increased bleeding risk, thus interruption of VKA prior to CABG is recommended in non-emergent cases. In emergency surgery, a
©ESC 2020
Figure 8 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients with atrial fibrillation undergoing percutaneous coronary intervention or medical management. Green (class I) and yellow (class IIa) colours denote the classes of recommendation. OAC: preference for a NOAC over VKA for the default strategy and in all other scenarios if no contraindications. For both TAT and DAT regimens, the recommended doses for the NOACs are as follows:
1) Apixaban 5 mg b.i.d.241
2) Dabigatran 110 mg or 150 mg b.i.d.238
3) Edoxaban 60 mg/d
4) Rivaroxaban 15 mg or 20 mg/d240
NOAC dose reductions are recommended in patients with renal failure and may be considered in patients with ARC-HBR (see Table 7).158 SAPT: preference for a P2Y12 receptor inhibitor over aspirin. Ticagrelor may be considered in patients with high ischaemic risk and low bleeding risk. Treatment >1
month: OAC þ DAPT (TAT) may be considered for up to 6 months in selected patients with high ischaemic risk (IIa C). Treatment >12 months: OAC þ
SAPT may be considered in selected patients with high ischaemic risk. ARC-HBR = see Table 7 and in addition with a PRECISE-DAPT score of >_25. High thrombotic or ischaemic risk is defined in Table 11. AF = atrial fibrillation; ARC-HBR = Academic Research Consortium  High Bleeding Risk; b.i.d. = bis in die (twice a day); DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; NOAC = non-vitamin K antagonist oral anticoagulant; NSTEACS = non-ST-segment elevation acute coronary syndrome; OAC = oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention;
PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; SAPT = single antiplatelet therapy; TAT = triple antithrombotic therapy; VKA = vitamin K antagonist. Listen to the audio guide of this figure online.


<!-- PAGE 33 -->

### Page 33

......................
combination of prothrombin complex concentrate of four inactivated factors (25 IU/kg) and oral vitamin K is required to obtain fast and sustained restoration of haemostasis at the time of surgery.252
While experience with urgent major surgery in patients treated with
NOACs is limited, it has been suggested to use prothrombin complex concentrate of activated factors to restore haemostasis.253
Reversal agents might represent an additional option in these patients.254 In the setting of planned CABG, a 48-h interruption of
NOACs is recommended (a longer period might be necessary in patients with impaired renal function). In ACS patients with an established indication for OAC, anticoagulation should be resumed after
CABG as soon as the bleeding is controlled, possibly with a combination with SAPT, while TAT should be avoided. For antithrombotic therapy and CABG, see Valgimigli et al.169
Recommendations for combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation
Recommendations
Classa
Levelb
Stroke prevention is recommended to AF patients with >_1 non-sex CHA2DS2-VASc stroke risk factors (score of >_1 in males or
>_2 in females).For patients with >_2 non-sex stroke risk factors, OAC is recommended.255259
I
A
For patients with 1 non-sex stroke risk factor, OAC should be considered and treatment may be individualized based on net clinical beneﬁt and consideration of patient values and preferences.260263
IIa
B
An early ICA should be considered in HBR patients, irrespective of OAC exposure, to expedite treatment allocation (medical vs.
PCI vs. CABG) and to determine the optimal antithrombotic regimen.
IIa
C
Patients undergoing coronary stenting
Anticoagulation
During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all NOACs and if
INR is <2.5 in VKA-treated patients.
I
C
In patients with an indication for OAC with VKA in combination with aspirin and/or clopidogrel, the dose intensity of VKA should be carefully regulated with a target INR of 2.02.5 and a time in the therapeutic range >70%.236,238241
IIa
B
Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase.
IIa
C
Antiplatelet treatment
In patients with AF and CHA2DS2-VASc score >_1 in men and >_2 in women, after a short period of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel).238241,244,245
I
A
Periprocedural DAPT administration consisting of aspirin and clopidogrel up to 1 week is recommended.238241,244,245
I
A
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.236239,246
I
B
In patients treated with a VKA (e.g. mechanical prosthetic valves), clopidogrel alone should be considered in selected patients
(HAS-BLED >_3 or ARC-HBR met and low risk of stent thrombosis) for up to 12 months.236
IIa
B
When rivaroxaban is used and concerns about HBR prevail over stent thrombosis or ischaemic stroke, rivaroxaban 15 mg o.d.
should be considered in preference to rivaroxaban 20 mg o.d. for the duration of concomitant SAPT or DAPT.240,245
IIa
B
In patients at HBR (HAS-BLED >_3), dabigatran 110 mg b.i.d. should be considered in preference to dabigatran 150 mg b.i.d. for the duration of concomitant SAPT or DAPT to mitigate bleeding risk.238
IIa
B
In patients treated with an OAC, aspirin plus clopidogrel for longer than 1 week and up to 1 month should be considered in those with high ischaemic risk or other anatomical/procedural characteristics which outweigh the bleeding risk (Table 11).
IIa
C
DAT (with an OAC and either ticagrelor or prasugrel) may be considered as an alternative to TAT (with an OAC, aspirin, and clopidogrel) in patients with a moderate or high risk of stent thrombosis, irrespective of the type of stent used.
IIb
C
The use of ticagrelor or prasugrel as part of TAT is not recommended.
III
C
Medically managed patients
One antiplatelet agent in addition to an OAC should be considered for up to 1 year.241,247
IIa
C
In patients with AF, apixaban 5 mg b.i.d. and SAPT (clopidogrel) for at least 6 months may be considered.241,247
IIb
B
AF = atrial ﬁbrillation; ARC-HBR = Academic Research Consortium  High Bleeding Risk; b.i.d. = bis in die (twice a day); CABG = coronary artery bypass graft(ing);
CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years (2 points), Diabetes, Stroke (2 points)Vascular disease, Age 6574, Sex category (female); DAPT =
dual antiplatelet therapy; DAT = dual antithrombotic therapy; HAS-BLED = hypertension, abnormal renal and liver function (1 point each), stroke, bleeding history or predisposition, labile INR, older patients (>65 years), drugs and alcohol (1 point each); HBR = high bleeding risk (see Table 7); ICA = invasive coronary angiography; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation/anticoagulant; o.d. = once daily; PCI = percutaneous coronary intervention;
SAPT = single antiplatelet therapy; TAT = triple antithrombotic therapy; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1321


<!-- PAGE 34 -->

### Page 34

........................................................................................
5.4 Management of acute bleeding events
(Supplementary Data)
5.4.1 General supportive measures (Supplementary Data)
5.4.2 Bleeding events on antiplatelet agents
(Supplementary Data)
5.4.3 Bleeding events on vitamin K antagonists
(Supplementary Data)
5.4.4 Bleeding events on non-vitamin K antagonist oral anticoagulants (Supplementary Data)
5.4.5 Non-access-related bleeding events (Supplementary
Data)
5.4.6 Bleeding events related to percutaneous coronary intervention (Supplementary Data)
5.4.7 Bleeding events related to coronary artery bypass surgery (Supplementary Data)
5.4.8 Transfusion therapy (Supplementary Data)
5.4.9 Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients
6 Invasive treatments
6.1 Invasive coronary angiography and revascularization
Coronary angiography facilitates clarification as to whether presumed anginal chest pain originates from myocardial ischaemia, as a consequence of a culprit lesion, or not. In the former case, the culprit lesion can subsequently be treated by means of PCI within the same procedure or by CABG, depending on lesion morphology and the patient’s risk profile (see section 6.4). In the latter case, exclusion of a culprit lesion paves the way to subsequent diagnostic investigations ultimately revealing the cause of chest pain and/or myocardial injury
(see section 7). However, ICA carries a certain risk for procedurerelated complications, which has to be considered in management decisions.
6.1.1 Routine invasive vs. selective invasive approach
(Supplementary Data)
Routine invasive strategy means the patient is deemed to undergo
ICA. Following a selective invasive strategy, ICA will only be performed after recurrent symptoms, objective evidence of inducible ischaemia on non-invasive testing, or detection of obstructive CAD
by CCTA. Multiple RCTs comparing a routine invasive with a selective invasive strategy have been conducted and their results have been pooled in several meta-analyses.266270 The available evidence
(Supplementary Table 2) indicates that a routine invasive strategy:
• Does not reduce all-cause mortality risk in the overall population of NSTE-ACS patients.
Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients
Recommendations
Classa
Levelb
In patients with dabigatran-associated ongoing life-threatening bleeding, the administration of the speciﬁc antidote for dabigatran
 idarucizumab  should be considered.264
IIa
B
In patients with VKA-associated life-threatening bleeding events, rapid reversal of anticoagulation with four-factor prothrombin complex concentrate rather than with fresh frozen plasma or recombinant activated factor VII should be considered.
In addition, repetitive 10 mg i.v. doses of vitamin K should be administered by slow injection.
IIa
C
In patients with NOAC-associated ongoing life-threatening bleeding, the administration of prothrombin complex concentrates or activated prothrombin complex concentrates should be considered when the speciﬁc antidote is unavailable.
IIa
C
In patients with rivaroxaban-, apixaban-, or edoxaban-associated ongoing life-threatening bleeding, the administration of the speciﬁc antidote  andexanet-alpha  may be considered.265
IIb
B
In patients with anaemia and no evidence of active bleeding, blood transfusion may be considered in case of compromised haemodynamic status, haematocrit <25%, or haemoglobin level <8 g/dL.
IIb
C
i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 35 -->

### Page 35

.......................................................................
• Increases the risk of periprocedural complications such as periprocedural MI and bleeding.
• Reduces the risk of composite ischaemic endpoints, particularly in high-risk patients.
However, the currently available evidence is based on old RCTs that were conducted before critical improvements such as radial access, modern drug-eluting stents (DES), complete functional revascularization for multivessel CAD, modern DAPT, intensified lipid lowering therapy, and contemporary biomarker assays and/or cut-off values for diagnosing spontaneous/periprocedural MI
became available.
In summary, the results of RCTs and their meta-analyses highlight the role of risk stratification in the decision process and support a routine invasive strategy in high-risk patients.
6.1.2 Timing of invasive strategy
6.1.2.1 Immediate invasive strategy (<2 h)
Very high-risk NSTE-ACS patients (i.e. with at least one very highrisk criterion according to Figure 9) have generally been excluded from RCTs. Owing to a poor short- and long-term prognosis if left untreated, an immediate invasive strategy (i.e. <2 h from hospital admission, analogous to STEMI management) with the intent to perform revascularization is recommended, irrespective of ECG or biomarker findings. Centres without 24/7 PCI availability must transfer the patient immediately.
6.1.2.2 Early invasive strategy (<24 h)
An early invasive strategy is defined as coronary angiography performed within 24 h of hospital admission. It is recommended in high-risk patients defined according to Figure 9. Multiple RCTs have investigated the optimal timing of ICA and revascularization in NSTEACS (Figure 10, Supplementary Table 3). A main limitation for the interpretation of these RCTs is the calculation of time to ICA, which rather than being based on pain onset or on hospital admission time,
was based on randomization time. While ICA was virtually always performed within 24 h of randomization in the early invasive strategy groups, the time from randomization to ICA was more heterogeneous in the delayed invasive groups (Figure 10). The two largest RCTs,
with more than 1000 patients in each treatment group, are Timing of
Intervention in Patients with Acute Coronary Syndromes (TIMACS)
and the more contemporary VERDICT trial.271,272 There are several important messages that can be derived from these RCTs:
(1)
Among unselected NSTE-ACS patients, an early invasive strategy is not superior over a delayed invasive strategy with regard to composite clinical endpoints (Supplementary Table 3).271,272
©ESC 2020
Figure 9 Selection of non-ST-segment elevation acute coronary syndrome treatment strategy and timing according to initial risk stratification. EMS =
emergency medical services; GRACE = Global Registry of Acute Coronary Events; MI = myocardial infarction; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention. Listen to the audio guide of this figure online.
ESC Guidelines
1323


<!-- PAGE 36 -->

### Page 36

............................................................................
(2)
Benefit with an early invasive strategy is strongly associated with the patient’s risk profile. In a pre-specified subgroup analysis, patients with a GRACE risk score >140 benefited from an early invasive strategy while those with a GRACE risk score <140 did not
(TIMACS trial: HR 0.65, 95% CI 0.480.89 vs. HR 1.12, 95% CI
0.811.56, Pinteraction = 0.01;271 VERDICT trial: HR 0.81, 95% CI
0.671.00 vs. HR 1.21, 95% CI 0.921.60; Pinteraction = 0.02).272
With regard to the GRACE risk score, it must be highlighted that both RCTs calculated the original GRACE risk score for in-hospital death (see Supplementary Figure 3).139 Due to different weighting of variables, scores of other GRACE risk scores (see Supplementary
Table 1 for more details) might be considerably different for the same patient, possibly leading to different treatment decisions.
Furthermore, in both studies, GRACE risk score calculation was based on elevations of CK-MB or conventional troponin. The value of a GRACE risk score >140 to guide timing of ICA and revascularization in the era of hs-cTn has not been determined.
(3)
Benefit with an early invasive strategy is not modified by STsegment/T-wave changes, despite the fact that ST-segment depression has been consistently identified as a predictor for an adverse outcome (Supplementary Figure 2).
In patients with transient ST-segment elevation and relief of symptoms, an immediate invasive strategy did not reduce CMR-assessed infarct size compared to an early invasive strategy.273
Several meta-analyses have pooled data of multiple RCTs assessing different timing intervals of ICA (Supplementary Table 4). None of them observed a benefit with an early invasive strategy with respect to the endpoints death, non-fatal MI, or stroke among unselected
NSTE-ACS patients.274278 However, a collaborative meta-analysis comparing an early/immediate invasive to a delayed invasive strategy using a modified individual patient data approach observed a survival benefit in high-risk patients, although tests for interaction were inconclusive.277 Only the VERDICT trial studied the impact of timing on the endpoint hospital admission for heart failure and observed a trend towards less heart failure hospitalization in favour of an early invasive strategy (HR 0.78, 95% CI 0.601.01).272Meta-analyses have consistently reported that an early invasive strategy is associated with a lower risk of recurrent/refractory ischaemia and a shorter length of hospital stay.274276,278 Taken together, an early invasive strategy is recommended in patients with at least one high-risk criterion
(Figure 9).
6.1.2.3 Selective invasive strategy
Patients with no recurrence of symptoms and none of the very highor high-risk criteria listed in the recommendation table regarding timing of invasive strategy are to be considered at low risk of short-term acute ischaemic events (Figure 9). These patients should be managed according to the 2019 ESC Guidelines for the diagnosis and management of CCS.231 In this setting, stress echocardiography or stress
Figure 10 Time to coronary angiography in the early/immediate invasive and delayed invasive groups of included trials.271,272,279287 Bars depict interquartile ranges and median times from randomization to coronary angiography in the early invasive group (red) and delayed invasive group (blue). In addition, description of the main finding of the primary endpoint with an early vs. delayed invasive strategy. Adapted and updated from Jobs et al.277 Based on the individual patient-based meta-analysis patients with elevated biomarkers, GRACE score >140, age >75 years, and diabetes showed a mortality benefit from an early invasive approach.277 ABOARD = Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention; CK-MB = creatine kinase myocardial band; EARLY = Early or Delayed Revascularization for Intermediate- and High-Risk NonST-Segment Elevation Acute Coronary Syndromes?; ELISA = Early or Late Intervention in unStable Angina; GRACE = Global Registry of Acute Coronary
Events; ISAR-COOL = Intracoronary Stenting and Antithrombotic Regimen - Cooling off strategy; LIPSIA-NSTEMI = Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI; MACE = major adverse cardiovascular events; MI = myocardial infarction; PCI = percutaneous coronary intervention; RIDDLE-NSTEMI = Randomized Study of Immediate Versus Delayed Invasive Intervention in Patients With Non-ST-Segment
Elevation Myocardial Infarction; SISCA = Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation;
TIMACS = Timing of Intervention in Patients with Acute Coronary Syndromes; VERDICT = Very EaRly vs Deferred Invasive evaluation using
Computerized Tomography.


<!-- PAGE 37 -->

### Page 37

........................................................................................
CMR may be preferred over non-invasive anatomical testing.109 With routine use of hs-cTn and established diagnostic algorithms for
NSTE-ACS assessment, ongoing myocardial injury  even low level
 can be identified. Therefore, patients previously regarded to be at intermediate risk (e.g. those with a history of revascularization or diabetes mellitus), but ruled out according to a diagnostic algorithm using hs-cTn, should be regarded as low risk and follow a selective invasive strategy.1
6.1.3 Pattern of coronary artery disease in non-ST-segment elevation acute coronary syndrome
(Supplementary Data)
6.1.4 How to identify the culprit lesion? (Supplementary
Data)
6.1.5 Spontaneous coronary artery dissection
Spontaneous coronary artery dissection (SCAD) is defined as a non-atherosclerotic, non-traumatic, or iatrogenic separation of the coronary arterial tunics secondary to vasa vasorum haemorrhage or intimal tear, which creates a false lumen, coronary compression, and downstream myocardial ischaemia.288,289
SCAD accounts for up to 4% of all ACS, but the incidence is reported to be much higher (2235% of ACS) in women <60 years of age, in pregnancy-related MI, and in patients with a history of fibromuscular dysplasia, anxiety, depression, or previous neuropsychiatric disorders.290,291 Clinical presentations can vary considerably, but elevation of cardiac biomarkers associated with chest discomfort is the most common presentation.292 There are three angiographic types of SCAD, which range from no obstruction to complete occlusion of the affected coronaries. SCAD Type 1 (contrast dye staining of the arterial wall with multiple radiolucent lumen) and SCAD Type 2
(long diffuse and smooth narrowing) with non-obstructive coronary arteries (stenosis <50%) are described as possible causes of MI with non-obstructive coronary arteries (MINOCA) (see section 7), while
SCAD Type 2 with severe coronary obstruction (>50%) and SCAD
Type 3 (focal or tubular stenosis that mimics atherosclerosis) should be considered separately. As SCAD may be missed or not be detectable on CCTA, a negative CCTA should not exclude a diagnosis of
SCAD.293 Intracoronary imaging [optical coherence tomography
(OCT) and intravascular ultrasound (IVUS)] might be the most accurate options in unclear situations to prove the presence of intramural haematoma or double lumen.294 This may be fundamental to making a proper diagnosis.294
The optimal management of SCAD is still unclear, since no RCTs have compared medical therapy to revascularization strategies.
According to available data, with the exception of very high-risk profile patients, a conservative approach should be the preferred strategy.295297 The decision to treat either with a conservative medical approach or to perform PCI or CABG surgery must be individualized and based on both clinical and angiographic factors. A possible treatment algorithm is shown in Figure 11. Optimal medical treatment for patients with SCAD is still undetermined, but because hypertension is an independent predictor of recurrent SCAD,292,295,298 an aggressive anti-hypertensive therapy should be considered to ensure optimal blood pressure control. Beta-blockers, which have been reported to be significantly associated with a reduced risk of
©ESC 2020
Figure 11 Diagnosis and treatment of patients with non-ST-segment elevation acute coronary syndrome related to spontaneous coronary artery dissection. CABG = coronary artery bypass graft(ing); CAD = coronary artery disease; CCTA = coronary computed tomography angiography; DAPT = dual antiplatelet therapy; ICA = invasive coronary angiography; IVUS = intravascular ultrasound; OCT = optical coherence tomography; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; SCAD = spontaneous coronary artery dissection. aSelection of revascularization strategy for highrisk anatomy according to local expertise. bBeta-blocker recommended while benefit of DAPT is questionable. cLeft main or proximal left anterior descendent or circumflex or right coronary artery, multivessel SCAD. Listen to the audio guide of this figure online.
ESC Guidelines
1325


<!-- PAGE 38 -->

### Page 38

.............................................................................................................................................................................
recurrent events, should be the preferred antihypertensive class in this subset of patients.298 There is controversy regarding the benefit of antithrombotic therapy among these patients,292,298 however,
among PCI-treated patients, the DAPT algorithms stated in section 5
should be used. Among SCAD patients treated medically and having persistent or recurrent symptoms, even in the absence of recurrent
MI or ischaemia, CCTA might be considered for follow-up.
6.1.6 Fractional flow reserve, instantaneous wave-free ratio, and other resting indices (Supplementary Data)
6.1.6.1 Fractional flow reserve
Fractional flow reserve (FFR) is the current standard for the functional assessment of lesion severity in patients with intermediategrade stenosis (4090%) without evidence of ischaemia in noninvasive testing, or in those with multivessel disease. Due to microvascular obstruction,299 the haemodynamic relevance of the culprit lesion in NSTE-ACS may be underestimated.300 However, it appears reliable for non-culprit lesion estimation when compared to postponed repeat FFR, CMR perfusion, or SPECT.301304 In ACS
patients, deferred revascularization based on FFR or instantaneous wave-free ratio (iFR) is associated with worse clinical outcome compared to patients with stable CAD.305308 Persistent instability of non-haemodynamically significant stenoses or presence of more than one unstable lesion may account for the higher risk.
The majority of the evidence relating to the value of FFR in NSTEACS is derived from small subgroups of registries and randomized trials (Supplementary Table 5). In the small Fractional flow reserve versus angiography in guiding management to optimize outcomes in nonST-elevation myocardial infarction (FAMOUS-NSTEMI) randomized trial,309 significantly more NSTEMI patients were treated medically with FFR vs. an angio-guided PCI strategy (22.7 vs. 13.2%, P¼0.022).
This strategy of functional revascularization seems to be safe without any impact on clinical outcomes in NSTE-ACS. However, adequately powered dedicated randomized trials are still lacking.
6.1.6.2 Instantaneous wave-free ratio and other resting indices
There has been renewed interest in resting indices derived from resting gradients alone [distal coronary to aortic pressure ratio (Pd/Pa),
iFR, coronary flow reserve (CFR), resting full-cycle ratio (RFR), or the index of microcirculatory resistance (IMR)]. Two large-scale randomized trials showed broadly comparable results between FFRguided and iFR-guided revascularization strategies in patients with intermediate-grade stenosis.310,311 In these trials, the proportion of
ACS patients was 1517%, the non-culprit lesions were investigated,
and follow-up was limited to a 1-year duration. For resting indices other than iFR, randomized clinical outcome data are not available.
6.1.7 Intracoronary imaging
Both intracoronary imaging methods, IVUS and OCT, allow real-time tomographic assessment of vessel size, lumen area, plaque composition and volume, as well as stent coverage and expansion.312
IVUS-guided PCI has been reported to reduce target vessel failure
12 months after PCI compared to angio-guided PCI in the
Intravascular Ultrasound Guided Drug Eluting Stents Implantation in
“All-Comers” Coronary Lesions (ULTIMATE) randomized trial: 2.9
vs. 5.4%, respectively (HR 0.53, 95% CI 0.310.90, P¼0.019).313
Clinically driven target lesion revascularization or definite stent thrombosis was lower with the IVUS-guided strategy [1.2 vs. 2.6%,
relative risk (RR) 0.46, 95% CI 0.211.03, P¼0.05]. However, only
12% of the enrolled patients presented with STEMI or NSTE-ACS,
limiting its validity in NSTE-ACS settings.313
OCT-guided PCI is safe and results in a similar minimum stent area to that of IVUS-guided PCI.314 In addition, OCT-guided PCI has been shown to lead to higher post-PCI FFR compared to angio-guided PCI
among NSTE-ACS patients.315 Adequately powered trials for clinical endpoints, however, are lacking. Additionally, in patients with
MINOCA (see section 7), OCT is a diagnostic tool for evaluating
SCAD, erosions, and plaque ruptures.312
6.2 Conservative treatment
The established benefit associated with coronary revascularization in
NSTE-ACS patients has led to a significant reduction of medical management alone, from 60% two decades ago down to 1030% in the contemporary era of PCI.170,225,316319 Medical management comprises patients not undergoing coronary angiography, but also those with extensive CAD not amenable to revascularization or those without obstructive CAD (see MINOCA, section 7).
6.2.1 Patients who are not candidates for invasive coronary angiography
This group represents a small subgroup, where data indicating a hypothetical advantage of an invasive strategy are scarce. Depending on country and world region specific differences, advanced age,
female sex, chronic kidney disease (CKD), diabetes mellitus, prior heart failure/revascularization, history of cancer, and frailty are the major reported reasons accounting for withholding diagnostic
ICA.170,225,316,318,319 These features largely overlap with the predictors of bleeding and ischaemic adverse events320 and explain the poor prognosis of this population, with in-hospital mortality of 69%
that rises up to 20 and 50% at 6 months and 3 years, respectively.321
Medical management should be chosen after careful risk assessment,
keeping in mind that ICA using the radial approach is a low-risk procedure, that impaired LV function increases mortality risk, and that coronary anatomy and presence of diabetes may refine the risk stratification and the choice of pharmacological therapy (see Figures 57).
Advanced age or female sex alone, in the absence of severe comorbidities or frailty, should not be considered as a sufficient reason not to perform ICA and, likewise, ICA should not be denied for logistical reasons.322,323
6.2.2 Patients with coronary artery disease not amenable to revascularization
Patients diagnosed with severe CAD who are not amenable to any type of revascularization are at very high risk of recurrent ischaemic events.324 Frequently, these patients are women, old and/or suffering from severe CKD, with multivessel CAD, and a history of MI or prior revascularization. The decision not to perform PCI is an independent predictor of increased cardiovascular mortality, both in-hospital and long-term.188,318 Accordingly, the decision not to perform revascularization should be made in very selected patients only, where there is consensus that risk outweighs the benefit for clinical or anatomical reasons. These patients should undergo an aggressive secondary


<!-- PAGE 39 -->

### Page 39

.............................................................................................................................................................................
prevention treatment with potent antiplatelet therapy
(see
Figures 58) and anti-anginal agents, taking their comorbidities into account.325,326
6.3 Technical aspects
6.3.1 Technical aspects and challenges
The principal technical aspects of PCI in NSTE-ACS patients do not differ from the invasive assessment and revascularization strategies for other manifestations of CAD. In patients presenting with NSTEACS who are deemed eligible for PCI in one or more vessels, implantation of new-generation DES is the standard of care,159,327,328 while routine thrombectomy has not been proven beneficial in this setting.329,330 The combination and duration of antithrombotic treatment are explained in section 5.
6.3.2 Vascular access
A timely performance of PCI and the use of potent antithrombotic drugs have reduced ischaemic risk in patients with NSTE-ACS.
However, this strategy is also invariably associated with an increased bleeding risk, which affects prognosis at least as much as ischaemic complications and is associated with impaired survival.331333 Among patients undergoing PCI, access-related bleeding accounts for
3070% of total bleeding events.334 There is accumulative evidence showing that reducing access-site bleeding events with the use of radial access translates into significant clinical benefits. Two large randomized trials, the RadIal Vs femorAL access for coronary intervention (RIVAL) trial (n=7021 ACS patients) and the MATRIX trial
(n=8404 ACS patients)335,336 have demonstrated significantly lower rates of access site-related bleeding, surgical access site repair, and blood transfusion with radial compared to femoral access. A pairwise meta-analysis comparing radial vs. femoral access in the whole spectrum of patients with CAD, including 30-day follow-up of the
MATRIX trial, showed a significant reduction in major bleeds; death,
MI, or stroke; and all-cause mortality favouring radial vs. femoral access.337 Although this effect was diluted at 1-year follow-up, net clinical adverse events remained lower with a radial vs. femoral access site.336 Therefore, radial access is recommended as the preferred approach in NSTE-ACS patients undergoing invasive assessment with or without PCI. However, dependent on their haemodynamic situation during index PCI and procedural technical aspects, femoral access might be selectively chosen instead of radial access.
6.3.3 Revascularization strategies
Based on observational studies of patients with NSTE-ACS, the benefit of early intervention  when compared to a conservative approach  may mandate a complete revascularization strategy, irrespective of the possibility to identify and/or treat the culprit lesion.268,277,338340
Recently,
data from the
British
Cardiac
Intervention Society PCI database showed significantly lower cumulative mortality rates with single-stage complete revascularization compared to culprit-lesion-only PCI (22.5 vs. 25.9%, P=0.0005) at a median follow-up of 4.1 years (interquartile range 2.25.8) among
21 857 NSTE-ACS patients with multivessel CAD undergoing PCI.
This long-term benefit was observed despite an initial increase in inhospital mortality with single-stage complete revascularization (2.3
vs. 1.5%, P¼0.002).341 Whether this initial increased risk with singlestage complete revascularization can be reduced by staged complete revascularization needs to be further evaluated.
In contrast to the STEMI setting,342344 there is only one dedicated randomized trial examining the role of single vs. staged multivessel PCI in NSTE-ACS patients [Impact of Different Treatment in
Multivessel Non ST Elevation Myocardial Infarction Patients: One
Stage Versus Multistaged Percutaneous Coronary Intervention
(SMILE) trial].345 The complete single-stage coronary revascularization resulted in less major adverse cardiovascular and cerebrovascular events
(defined as cardiac death,
death,
reinfarction,
rehospitalization for unstable angina, repeat coronary revascularization, and stroke at 1 year) compared to complete coronary revascularization in multistage PCI during the index hospitalization (HR 0.55,
95% CI 0.360.83, P¼0.004).345 This benefit was largely determined by a significant reduction in repeat revascularization with single-stage multivessel PCI (HR 0.52, 95% CI 0.310.88, P¼0.01).345 However,
since pursuing completeness of revascularization for some patients with complex coronary anatomy may increase the risk of PCI or require CABG, it is reasonable, in the absence of robust clinical data,
to tailor the need for, and timing of, complete revascularization to functional relevance of all stenoses, age, general patient condition and comorbidities, and LV function. Furthermore, selection of the revascularization modality may rely on patient preference. For NSTE-ACS
patients presenting with CS, randomized evidence does not support routine immediate multivessel PCI (see details in section 8.1).346
6.4 Coronary artery bypass grafting
Approximately 510% of NSTE-ACS patients require CABG347 and these represent a challenging subgroup given their high-risk characteristics compared with patients undergoing elective CABG. In the absence of randomized data, optimal timing for non-emergency
CABG in NSTE-ACS patients should be determined individually.348
The risk of ischaemic events, possibly related to suboptimal antiplatelet therapy while awaiting surgery, is less than 0.1%, while perioperative bleeding complications associated with platelet inhibitors is higher than 10%.349 In patients with ongoing ischaemia or haemodynamic instability and with an indication for CABG, emergency surgery should be performed and not postponed as a consequence of antiplatelet treatment exposure.
If CABG is to be performed, every effort should be made to minimize aortic manipulation, work off-pump if there is a calcified aorta or the patient is high risk, achieve complete revascularization, and use graft flow measurement.
6.5 Percutaneous coronary intervention vs. coronary artery bypass surgery
There is no randomized comparison of PCI vs. CABG surgery in the specific setting of NSTE-ACS. In the individual patient data analysis from the Randomized Comparison of Coronary Artery Bypass
Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery (BEST), Premier of
Randomized Comparison of Bypass Surgery versus Angioplasty
Using Sirolimus-Eluting Stent in Patients with Left Main Coronary
Artery Disease (PRECOMBAT), and Synergy between PCI with
Taxus and cardiac surgery (SYNTAX) trials, which compared PCI
with CABG, of the 3280 patients with multivessel CAD or left main
ESC Guidelines
1327


<!-- PAGE 40 -->

### Page 40

.........................................................
disease, only 77 patients (2.2%) presented with NSTEMI and 1169
patients (35.7%) presented with unstable angina.350 Among NSTEACS patients, at 5-year follow-up, the risk of death, MI, or stroke was significantly reduced with CABG compared to PCI (HR 0.74, 95% CI
0.560.98, P¼0.036). The difference was driven by a reduction in MI
rates with CABG (3.8% vs. 7.5%, HR 0.50, 95% CI 0.310.82,
P¼0.006).350 In a population-based analysis, the benefit of CABG
over PCI was confirmed in patients with diabetes who presented with ACS. At 3-year follow-up, the combined incidence of all-cause death, non-fatal MI, or non-fatal stroke was lower with CABG compared with PCI (20.8 vs. 33.4%, P<0.01).351 Taken together, evidence is limited from these aforementioned RCTs to support one revascularization strategy over the other, especially in NSTEMI patients.
Thus, the currently available evidence indirectly suggests that the criteria applied in patients with stable CAD to guide the choice of revascularization modality (2018 ESC/EACTS Guidelines on myocardial revascularization)205 should also be applied to stabilized patients with NSTE-ACS, particularly for patients with diabetes.350354
For complex cases, Heart Team discussion and use of the
SYNTAX score are recommended, particularly given its ability to predict death, MI, and revascularization in multivessel CAD NSTEACS patients undergoing PCI.355 Furthermore, calculation of a
Society of Thoracic Surgeons (STS) score is recommended to assess in-hospital or 30-day mortality, and in-hospital morbidity after CABG
among high-risk patients.356 Clinical and anatomical characteristics in favour of CABG are considered to be diabetes, reduced LV ejection fraction (LVEF) (<40%), contraindications to DAPT, recurrent diffuse in-stent restenosis, anatomical and technical aspects likely resulting in incomplete revascularization with PCI, and the need for concomitant cardiovascular surgery. Those in favour of PCI are clinical and anatomical characteristics, such as presence of severe comorbidity (not reflected by scores), advanced age/frailty or reduced life expectancy,
restricted mobility, conditions that affect the rehabilitation process,
anatomical and technical aspects likely resulting in incomplete revascularization with CABG surgery due to poor quality or missing conduits, severe chest deformation or scoliosis, sequelae of chest radiation, and porcelain aorta.
6.6 Specific situations
6.6.1 Management of patients with ongoing myocardial ischaemia
These patients are characterized by an overwhelming risk of developing STEMI, onset of life-threatening arrhythmias, acute heart failure,
and CS. They should undergo coronary angiography within 2 h of hospital admission with intent to perform revascularization. Based on published data, this approach reduces in-hospital mortality and mortality at early and mid-term follow-up,281,357 as well as reducing the risk of new MI in the pre-catheterization period and the length of hospital stay.278
6.6.2 Management of patients with cardiac arrest
The management of patients presenting with resuscitated cardiac arrest and concomitant NSTE-ACS needs to be individualized according to their haemodynamic and neurological status.
In out-of-hospital cardiac arrest and no ST-elevation without CS,
an unselected immediate invasive strategy is not superior over a delayed invasive strategy, as recently shown in the randomized
Coronary Angiography after Cardiac Arrest (COACT) trial.278 This trial enrolled 552 patients who had been successfully resuscitated after out-of-hospital cardiac arrest and had no signs of STEMI. No difference in 90-day survival was observed between these two strategies, 64.5% in the immediate vs. 67.2% in the delayed angiography strategy (OR 0.89, 95% CI 0.621.27, P=0.51).358 Therefore, it appears reasonable to delay performance of ICA among NSTE-ACS
patients.358 However, several ongoing trials will further define a possible benefit of an early invasive approach.359
In comatose survivors, echocardiography should be performed immediately for further evaluation of differential diagnoses. If aortic dissection or pulmonary embolism is suspected,
CT
is recommended.360,361
6.7 Recommendations for coronary revascularization
Recommendations for coronary revascularization
Recommendations
Classa
Levelb
Timing of invasive strategy
An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very high-risk criteria:
• Haemodynamic instability or CS.
• Recurrent or refractory chest pain despite medical treatment.
• Life-threatening arrhythmias.
• Mechanical complications of MI.
• Heart failure clearly related to NSTE-ACS.
• Presence of ST-segment depression >1 mm in >_6 leads additional to ST-segment elevation in aVR and/or V1.
I
C
An early invasive strategy within 24 h is recommended in patients with any of the following highrisk criteria:
• Diagnosis of NSTEMI suggested by the diagnostic algorithm recommended in section 3.
• Dynamic or presumably new contiguous
ST/T-segment changes suggesting ongoing ischaemia.
• Transient ST-segment elevation.273,362
• GRACE risk score >140.271,272,277
I
A
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive CAD
by CCTA is recommended in patients considered at low risk.267,268,363
I
A
Delayed as opposed to immediate angiography should be considered among haemodynamically stable patients without ST-segment elevation successfully resuscitated after out-of-hospital cardiac arrest.358,364
IIa
B
Continued


<!-- PAGE 41 -->

### Page 41

.............................................................................................................................................................................
7 Myocardial infarction with non-obstructive coronary arteries and alternative diagnoses
Although the occurrence of an AMI without significant CAD was initially reported almost 80 years ago,367 and outcomes were definitely described 13 years ago,368 the term MINOCA has only been used recently to describe these patients.369 Accordingly, MINOCA is initially considered at the time of angiography as a working diagnosis until further assessment excludes other possible causes for troponin elevation. This incorporates a heterogeneous group of underlying causes that may involve both coronary and non-coronary pathological conditions, with the latter including cardiac and extracardiac disorders.370 Compared with patients with obstructive CAD,
NSTE-ACS patients diagnosed with MINOCA are more likely to be younger and female, and less likely diabetic, hypertensive, or dyslipidaemic,371,372 suggesting a predominant role of non-atheroscleroticrelated aetiologies and of unusual or usual risk factors like psychosocial aspects, insulin-resistance, and inflammation.373 However, all studies assessing prognosis in patients with MINOCA are considerably heterogeneous in terms of inclusion criteria, outcomes measurements, and length of follow-up; some report the prevalence of hard endpoints like mortality or reinfarction,374,375 but few report outcomes for both MINOCA and CAD populations.376 Although associated with better prognosis compared to patients with ACS patients with obstructive CAD,371,372,376379 MINOCA patients have a lower survival rate than healthy individuals matched for age and sex.371,372,376379 Of importance, this excess of adverse events has been reported at both early and late follow-up.371,372,376379
The term MINOCA has been broadly used in the past and is often misclassified, limiting all aspects of disease description, management,
and treatment. Despite having a contemporary position statement from the ESC and the AHA, great variability exists in the manner in which patients with suspected MINOCA are evaluated and treated.380,381 The extent of the diagnostic and therapeutic strategies implemented often depends on local non-standardized practices and varies widely.
The ESC position statement on MINOCA proposed the following
MINOCA criteria:380
(1)
AMI criteria as defined by the ‘Third universal definition of MI’.369
(2)
Non-obstructive coronary arteries as per angiographic guidelines,
with no lesions >_50% in a major epicardial vessel.
(3)
No other clinically overt specific cause that can serve an alternative cause for the acute presentation.
Based on this ESC definition, myocarditis and Takotsubo syndrome patients, among other non-ischaemic conditions, were labelled as MINOCA.380
However, fundamental to the definition of MINOCA is the diagnosis of MI with elevated cardiac biomarkers, typically cardiac troponin
>99th percentile of the upper reference level with a rise or fall in the level on serial assessment. Although elevated troponin levels are indicative of myocyte injury with release of this intracellular protein into the systemic circulation, the process is not disease specific and can result from either ischaemic or non-ischaemic mechanisms.
Therefore, the most recent scientific statement from the AHA
provides a formal and updated definition for the broadly labelled term MINOCA incorporating the Fourth Universal Definition of
Myocardial Infarction.381 Table 14 provides the current criteria for the MINOCA definition, which by consensus now excludes myocarditis and
Takotsubo syndrome from the final diagnosis of
MINOCA.381 Interestingly, in some patients, Takotsubo syndrome may be triggered by NSTEMI or STEMI.382 Furthermore, with regard to Takotsubo syndrome, there are no RCTs to support a specific treatment and, therefore, all recommendations so far are based on expert opinions.383
It also provides a clinically useful framework and algorithms pertaining to the diagnostic evaluation and management of these
Technical aspects
Radial access is recommended as the standard approach, unless there are overriding procedural considerations.336,337
I
A
DES are recommended over bare-metal stents for any PCI irrespective of:
• Clinical presentation.
• Lesion type.
• Planned non-cardiac surgery.
• Anticipated duration of DAPT.
• Concomitant anticoagulant therapy.354,365,366
I
A
It is recommended to base the revascularization strategy (ad hoc culprit lesion PCI/multivessel PCI/
CABG) on the patient’s clinical status and comorbidities, as well as their disease severity [i.e. the distribution and angiographic lesion characteristics
(e.g. SYNTAX score)], according to the principles for stable CAD.350 However, the decision on immediate PCI of the culprit stenosis does not require Heart Team consultation.
I
B
Complete revascularization should be considered in NSTE-ACS patients without CS and with multivessel CAD.
IIa
C
Intracoronary imaging should be considered to diagnose SCAD if suspected.
IIa
C
Complete revascularization during index PCI may be considered in NSTE-ACS patients with multivessel disease.345
IIb
B
FFR-guided revascularization of a non-culprit
NSTE-ACS lesion may be used during index
PCI.302
IIb
B
CABG = coronary artery bypass graft(ing); CAD = coronary artery disease;
CCTA = coronary computed tomography angiography; CS = cardiogenic shock;
DAPT = dual antiplatelet therapy; DES = drug-eluting stent; FFR = fractional ﬂow reserve; GRACE = Global Registry of Acute Coronary Events; MI = myocardial infarction; NSTEMI = non-ST-segment elevation myocardial infarction; NSTEACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; SCAD = spontaneous coronary artery dissection;
SYNTAX = Synergy between PCI with Taxus and cardiac surgery.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1329


<!-- PAGE 42 -->

### Page 42

.............................................................................................
patients, which mainly includes a ‘traffic light’ clinical algorithm
(Figure 12).
Based on the initial working diagnosis, proper initial assessment of
LV wall motion should be promptly performed in the acute setting using LV angiography, depending on renal function, or echocardiography. Regional wall motion abnormalities may indicate an epicardial cause of MINOCA or other specific causes, which may lead to the exclusion of MINOCA. CMR is one of the key diagnostic tools in this algorithm for the differential diagnosis of Takotsubo syndrome,384
myocarditis,385,386 or true MI.387 CMR has the ability to identify the underlying cause in as many as 87% of patients with MINOCA.388 In the sub-endocardium, late gadolinium enhancement may indicate an ischaemic cause, while sub-epicardial localization may indicate cardiomyopathies or myocarditis, and the absence of relevant late gadolinium enhancement with oedema and associated specific wall motion abnormalities is a hallmark of Takotsubo syndrome.387,388 In a metaanalysis of five studies involving 556 patients with an initial diagnosis of MINOCA, CMR identified myocarditis as the primary cause in 33%
of patients.389
Intracoronary acetylcholine or ergonovine testing may be performed when coronary or microvascular spasm is suspected.390,391
Intracoronary imaging with IVUS392 or OCT393,394 may also be valuable for the detection of unrecognized causes at coronary angiography, especially when thrombus, plaque rupture or erosion, or SCAD
are suspected.
Pulmonary embolism should also be considered as an alternative diagnosis as a possible cause of myocardial injury, and this diagnosis may be excluded with additional D-dimer testing, BNP, and/or CT
pulmonary angiography,361 as appropriate. Furthermore, other conditions with an imbalance between myocardial oxygen supply and demand or elevation of cardiac troponin should be considered as potential causes of myocardial injury, such as hypertensive crisis,
tachyarrhythmias, sepsis, severe anaemia, and cardiac contusion,
among others.
Patients with an initial diagnosis of MINOCA, and an underlying cause identified during the diagnostic work-up, should be treated and followed up according to the guidelines of the specific diagnosis. For example, MINOCA patients discharged with a final diagnosis of
NSTE-ACS or MINOCA of unknown cause should be followed up as
ACS patients with obstructive CAD.
However, despite optimal work-up, the cause of MINOCA
remains undetermined in 825% of patients.5,380,395 This condition, identified as ‘myocardial infarction of unknown/unclear causes’, represents a therapeutic dilemma. Treatment should target the most probable causes of MINOCA, with negative provocative tests and CMR, namely vasospastic angina, coronary plaque disruption, and thromboembolism. The benefit of DAPT (aspirin
þ P2Y12 receptor inhibitor) should be considered based on pathophysiological considerations. However, evidence is scarce.
Pharmacological therapy with aspirin,
statins,
angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), and calcium channel blockers (in case vasospasm is still suspected) as routine treatment may be suggested.396 These medications have shown significant long-term beneficial effects in terms of all-cause mortality (statins, beta-blockers), cardiovascular death
(statins), AMI (beta-blockers), stroke (statins), and MACE (statins,
ACE inhibitor/ARB) at 12 months in a national registry.397
However, this registry did not apply current MINOCA criteria,397
therefore, the conclusions drawn must be interpreted with caution.
Table 14
Diagnostic criteria of myocardial infarction with non-obstructive coronary arteries
The diagnosis of MINOCA is made in patients with AMI fulﬁlling the following criteria:
1. AMI (modiﬁed from the ‘Fourth Universal Deﬁnition of Myocardial Infarction’ criteria):
• Detection of a rise or fall in cardiac troponin with at least one value above the 99th percentile upper reference limit and
• Corroborative clinical evidence of infarction as shown by at least one of the following:
a.
Symptoms of myocardial ischaemia b.
New ischaemic electrocardiographic changes c.
Development of pathological Q waves d.
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic cause e.
Identiﬁcation of a coronary thrombus by angiography or autopsy
2. Non-obstructive coronary arteries on angiography:
• Deﬁned as the absence of obstructive disease on angiography (i.e. no coronary artery stenosis >_50%) in any major epicardial vessela
This includes patients with:
• Normal coronary arteries (no angiographic stenosis)
• Mild luminal irregularities (angiographic stenosis <30% stenoses)
• Moderate coronary atherosclerotic lesions (stenoses >30% but <50%)
3. No speciﬁc alternate diagnosis for the clinical presentation:
• Alternate diagnoses include, but are not limited to, non-ischaemic causes such as sepsis, pulmonary embolism, and myocarditis
AMI = acute myocardial infarction; MINOCA = myocardial infarction with non-obstructive coronary arteries.
aNote that additional review of the angiogram may be required to ensure the absence of obstructive disease.


<!-- PAGE 43 -->

### Page 43

...............
8 Special populations
8.1 Heart failure and cardiogenic shock
Acute heart failure is a frequent complication of NSTE-ACS and is associated with a two to four-fold higher risk of in-hospital mortality compared with
NSTE-ACS
without acute heart failure.398401
The diagnosis of NSTE-ACS in the context of acute heart failure can be challenging because patients with acute heart failure may present with chest discomfort, myocardial injury with troponin
Figure 12 Diagnostic algorithm for myocardial infarction with non-obstructive coronary arteries using a traffic light scheme. Red indicates immediate alternative diagnosis without further additional testing. Yellow indicates initial working diagnosis that may lead to the final MINOCA diagnosis or alternative diagnoses. Green indicates final MINOCA diagnosis. CAD = coronary artery disease; IVUS = intravascular ultrasound; MINOCA = myocardial infarction with non-obstructive coronary arteries; CMR = cardiac magnetic resonance; Echo = echocardiogram; LV = left ventricular; OCT = optical coherence tomography; SCAD = spontaneous coronary artery dissection; ULN = upper limit of normal. Listen to the audio guide of this figure online.
Recommendations for myocardial infarction with non-obstructive coronary arteries
Recommendations
Classa
Levelb
In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to differentiate true
MINOCA from alternative diagnoses.
I
C
It is recommended to perform CMR in all MINOCA patients without an obvious underlying cause.370
I
B
It is recommended to manage patients with an initial diagnosis of MINOCA and a ﬁnal established underlying cause according to the disease-speciﬁc guidelines.
I
C
Patients with a ﬁnal diagnosis of MINOCA of unknown cause may be treated according to secondary prevention guidelines for atherosclerotic disease.
IIb
C
CMR = cardiac magnetic resonance; MINOCA = myocardial infarction with non-obstructive coronary arteries.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1331


<!-- PAGE 44 -->

### Page 44

.......................................
elevation can occur in the absence of obstructive CAD,3 and the
ECG may not be interpretable (bundle branch block or paced rhythm).402 Consequently, coronary angiography may be required to establish a diagnosis of NSTE-ACS.
The management of acute heart failure should follow current guideline recommendations.403,404 Emergency echocardiography should be performed to gather information about the LVEF, regional wall motion abnormalities, right ventricular function, presence of valvular heart disease, and volume loading.96,205,405 The revascularization strategy should be based on the coronary anatomy, LV function,
comorbidities, functional relevance of stenoses, and estimated surgical risk according to a Heart Team consensus, and based upon current recommendations.205
CS may occur in up to 4% of patients with NSTE-ACS.406,407
Ischaemia-related heart failure, acute severe mitral regurgitation, and mechanical complications are the major precipitating causes. These patients should be transferred, as soon as possible, to a tertiary care centre where ICA can be performed. In hub centres, immediate coronary angiography is indicated and PCI should be performed. Nearly
80% of such patients have multivessel CAD. Based on the Culprit
Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock
(CULPRIT-SHOCK) trial,408 non-culprit lesions should not be routinely treated immediately, and the immediate PCI strategy should be limited to the culprit lesion only. In CULPRIT-SHOCK, culprit-lesiononly PCI led to a significant reduction in all-cause death or renalreplacement therapy at 30-day follow-up, favouring culprit-lesiononly PCI with possible staged revascularization [RR 0.83, (95% CI
0.710.96)].408 The risk of all-cause death in the culprit-lesion-only
PCI strategy was significantly lower compared to immediate multivessel PCI at 30-day follow-up (RR 0.84, 95% CI 0.720.98, P¼0.03).
Results for the composite endpoint were maintained at 1-year follow-up, whereas the mortality difference was mainly confined to the first 30 days.346,408
In patients with a coronary anatomy not suitable for PCI, emergency CABG is indicated.
Percutaneous mechanical circulatory support devices and/or venoarterial extracorporeal membrane oxygenation may be considered in selected patients, depending on age, comorbidities, neurological function, and severity of CS. Several RCTs are ongoing
(Supplementary Table 6). Currently, no survival benefit has been demonstrated for these devices compared with intra-aortic balloon pump (IABP) use.409,410 Moreover, in a large retrospective registry of
48 306 haemodynamically unstable patients (44% NSTEMI) undergoing PCI, higher mortality and bleeding rates were observed with
Impella support compared to IABP.411 Similar results were observed in another registry confined to CS patients where Impella support was also associated with more complications and higher mortality,
even after propensity matching.412
As shown in the Intraaortic Balloon Pump in cardiogenic shock
(IABP-SHOCK) II trial, IABP does not reduce 30-day, 1-year, or 6year mortality.413415 Therefore, IABP is not recommended on a routine basis, while its use in situations of ACS-related mechanical complications should be considered.
For NSTE-ACS and stabilized heart failure, evidence-based pharmacotherapies including beta-blockers, ACE inhibitors or ARBs, and mineralocorticoid receptor antagonists (MRAs) should be offered in keeping with current guidelines.404
8.2 Diabetes mellitus
Patients with diabetes more frequently present with non-typical symptoms than patients without diabetes. They more frequently have multifocal CAD,418 less frequently receive guideline-indicated care, and have worse clinical outcomes.419 Nonetheless, the selection of antithrombotics and an invasive strategy should not differ from those without diabetes. Compared with clopidogrel, more potent platelet inhibitors have higher absolute risk reductions in patients with diabetes.420,421
On admission to hospital, it is recommended that all patients with
NSTE-ACS have their glycaemic status evaluated, regardless of a history of diabetes, and for it to be monitored frequently in patients with diabetes or hyperglycaemia. Given that, during the acute phase
Recommendations for non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock
Recommendations
Classa
Levelb
Emergency coronary angiography is recommended in patients with CS complicating
ACS.205,416,417
I
B
Emergency PCI of the culprit lesion is recommended for patients with CS due to NSTE-ACS, independent of the time delay from symptom onset, if the coronary anatomy is amenable to PCI.205,417
I
B
Emergency CABG is recommended for patients with CS if the coronary anatomy is not amenable to PCI.205,417
I
B
It is recommended to perform emergency echocardiography without delay to assess LV and valvular function and exclude mechanical complications.
I
C
In cases of haemodynamic instability, emergency surgical or catheter-based repair of mechanical complications of ACS is recommended, as decided by the Heart Team.
I
C
For NSTE-ACS-related mechanical complications,
the use of IABP should be considered.
IIa
C
In selected patients with ACS and CS, short-term mechanical circulatory support may be considered, depending on patient age, comorbidities,
neurological function, and the prospects for longterm survival and predicted quality of life.
IIb
C
Routine use of IABP in patients with CS and no mechanical complications due to ACS is not recommended.413,414,415
III
B
Routine immediate revascularization of non-culprit lesions in NSTE-ACS patients with multivessel disease presenting with CS is not recommended.346,408
III
B
ACS = acute coronary syndromes; CABG = coronary artery bypass graft(ing);
CS = cardiogenic shock; IABP = intra-aortic balloon pump; LV = left ventricular;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
.....................................................................................................................................


<!-- PAGE 45 -->

### Page 45

................................................................................
of NSTEMI, there may be hyperglycaemia, there is the potential for a false positive diagnosis of diabetes. Therefore, the diagnosis of diabetes should be confirmed subsequent to the hospital stay. In critically ill patients, there is a risk of hypoglycaemia-related events when using intensive insulin therapy.422 It is not unreasonable to manage hyperglycaemia in patients with NSTE-ACS by keeping their blood glucose concentration <11.0 mmol/L or <200 mg/dL) while avoiding hypoglycaemia, but intensive insulin therapy should not routinely be offered unless clinically indicated. Intensive lipid modification is indicated for secondary prevention.423 A multifactorial approach to diabetes mellitus management, with treatment targets, should be considered in patients with diabetes mellitus and cardiovascular disease (CVD).
8.3 Chronic kidney disease
In all patients with NSTE-ACS, assessment of kidney function by eGFR is recommended for prognostic reasons and to identify patients at risk of contrast-induced nephropathy. Although individuals with CKD have a worse prognosis in the setting of NSTE-ACS than individuals with normal renal function, they less frequently receive evidence-based treatments such as antithrombotic agents and early invasive strategy.437,438
The diagnosis of NSTE-ACS in patients with CKD may be challenging, as both mild elevations in cardiac troponin and ECG abnormalities
(e.g. associated with electrolyte disturbances or hypertensive heart disease) are frequent. Therefore, new ECG changes should be differentiated from pre-existing abnormalities and absolute changes in cardiac troponin (i.e. increase and/or decrease) should be assessed to differentiate MI from conditions associated with chronic cardiac injury.
Hs-cTn assays maintain high diagnostic and prognostic accuracy and, therefore, clinical utility in patients with renal dysfunction.35,89,439
A threshold of <5 ng/L may rule out myocardial injury in this population.89 Moreover, patients with troponin concentrations >99th percentile have a two-fold greater risk of cardiac events at 1 year,
irrespective of the diagnosis.89
Patients with advanced kidney disease are less likely to receive an invasive strategy.440 Whilst the overall 1-year mortality is lower with an invasive strategy, the benefit of such a strategy declines with greater reductions in renal function, and with no impact on mortality among patients with eGFR <15 mL/min/1.73m2 and in those receiving dialysis.
When an invasive strategy is selected, measures should be taken to prevent contrast-induced nephropathy, for which adequate hydration is the main approach.441446 High-dose statins, irrespective of the risk of contrast-induced nephropathy, are indicated for secondary prevention.442 For detailed recommendations for contrast-induced nephropathy prevention, consult the 2018 ESC/EACTS Guidelines on myocardial revascularization, section 10.2.205
The choice and dose of antithrombotic drugs should be carefully considered in patients with CKD, as these patients have an increased risk of bleeding. While most anticoagulants need dose adjustment in patients with renal insufficiency, this is not the case for oral antiplatelet agents.447 However, for patients with stage 5 CKD
(i.e. eGFR <15 mL/min/1.73 m2), there are insufficient safety and efficacy data for the use of P2Y12 receptor inhibitors.
Recommendations for diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients
Recommendations
Classa
Levelb
It is recommended to screen all patients with
NSTE-ACS for diabetes and to monitor blood glucose levels frequently in patients with known diabetes or admission hyperglycaemia.
I
C
Avoidance of hypoglycaemia is recommended.424427
I
B
Glucose-lowering therapy should be considered in ACS patients with blood glucose >10 mmol/L
(>180 mg/dL), with the target adapted to comorbidities, while episodes of hypoglycaemia should be avoided.422,428430
IIa
B
A multifactorial approach to diabetes mellitus management, with treatment targets, should be considered in patients with diabetes and CVD.431436
IIa
B
Less stringent glucose control should be considered, both in the acute phase and at follow-up, in patients with more advanced CVD, older age, longer diabetes duration, and more comorbidities.
IIa
C
ACS = acute coronary syndromes; CVD = cardiovascular disease; NSTE-ACS =
non-ST-segment elevation acute coronary syndrome.
aClass of recommendation.
bLevel of evidence.
Recommendations for patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Risk stratiﬁcation in CKD
It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD
(dose adjustment may be necessary) as for patients with normal renal function.
I
C
It is recommended to assess kidney function by eGFR in all patients.
I
C
Myocardial revascularization in patients with CKD
Use of low- or iso-osmolar contrast media (at lowest possible volume) are recommended in invasive strategies.205,441,442,445,446
I
A
Pre- and post-hydration with isotonic saline should be considered if the expected contrast volume is >100 mL in invasive strategies.
IIa
C
As an alternative to the pre- and post-hydration regimen, tailored hydration regimens may be considered.441,448
IIb
B
CABG should be considered over PCI in patients with multivessel CAD whose surgical risk proﬁle is acceptable and life expectancy is >1 year.449,450
IIa
B
CABG = coronary artery bypass graft(ing); CAD = coronary artery disease; CKD
= chronic kidney disease; eGFR = estimated glomerular ﬁltration rate; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
.............................................................................................
ESC Guidelines
1333


<!-- PAGE 46 -->

### Page 46

....................
8.4 Anaemia
Anaemia is common in patients with NSTE-ACS.451 Persistent or worsening anaemia in patients with NSTE-ACS is associated with increased mortality, recurrent MI, and major bleeding.452 However, it is uncertain whether anaemia itself is the determinant for poorer outcome or rather a marker of comorbidity.
Given that the treatment of NSTE-ACS includes antithrombotic therapy (which may exacerbate bleeding), it is important to identify the cause of anaemia and, in particular, occult bleeds in patients presenting with NSTE-ACS. The indication for ICA, access site choice
(radial approach favoured), and the need for revascularization should be carefully considered to avoid further blood loss.453,454 Equally, the choice of antithrombotic agent requires evaluation of ischaemic and bleeding risks, favouring the use of shorter half-life or reversible agents. In the setting of anaemia related to an unknown/untreatable source, the use of DES should be limited to the new-generation devices with proven safety profiles on short-term DAPT.455 Blood transfusion is discussed in section 5.4.9.
8.5 Thrombocytopenia (Supplementary
Data)
8.5.1 Thrombocytopenia related to glycoprotein IIb/IIIa inhibitors (Supplementary Data)
8.5.2 Heparin-induced thrombocytopenia (Supplementary
Data)
8.6 The older person
The clinical presentation of NSTE-ACS in the older person is more often atypical. Among the atypical presentations, dyspnoea is the leading symptom, while syncope, malaise, and confusion are less frequently encountered.456 Electrocardiographic ST elevation is less frequently present in older than in younger patients.457Hs-cTn assays have an excellent diagnostic performance for diagnosing early MI in the older person. However, the specificity of the test is lower than in younger patients, and elevated troponin levels are more commonly associated with conditions other than ACS.458
For NSTE-ACS, age is a predictor of in-hospital and 6-month mortality.140,457 Decisions as to how to manage older patients should be based on ischaemic and bleeding risks, estimated life expectancy,
comorbidities, the need for non-cardiac surgery, quality of life, frailty,
cognitive and functional impairment, patient values and preferences,
and the estimated risks and benefits of revascularization.459,460
The choice of antithrombotic agent and dosage should be adapted to renal function, as well as specific contraindications.461
Despite the lower rate of revascularization in the older person, its benefit appears to be maintained at older age.462,463 The effectiveness of an invasive strategy in the context of the older patient with NSTEACS is, however, the subject of ongoing research, including the
SENIOR-RITA RCT (NCT03052036). Recent data have shown that,
for patients aged 80 years and over with NSTE-ACS, an invasive strategy was superior to a conservative strategy for the reduction of MI,
urgent revascularisation, stroke, and death, with no increase in bleeding complications.464 In this RCT, the primary composite endpoint was predominantly driven by fewer MIs and urgent revascularisation and was not sufficiently powered to test efficacy for individual endpoints. Furthermore, in the context of revascularization  both
PCI and CABG  procedure-related complications are more frequent in the older patient, including MI, heart failure, stroke, renal failure, and bleeding.457,465
High-intensity lipid modification is indicated for secondary prevention.466
8.7 Frailty
Frailty is a syndrome characterized by reduced biological reserve,
leading to a failure of homeostatic mechanisms following stressors events.468,469 A combination of an aging population, improved disease survival, treatable conditions, and greater awareness has increased the prevalence of frailty.470 Frail patients with NSTE-ACS less frequently receive ACS pharmacotherapies and an invasive strategy,
have more complex CAD,471,472 have longer lengths of hospital stay,
and are at higher risk of death.459,473 Specifically, they are reported to have a higher rate of a composite of all-cause mortality, MI, stroke,
unplanned revascularization, and major bleeding at 1 year.474 In the absence of robust data to inform healthcare professionals about the management of frail people with NSTE-ACS,475 it is recommended that the risk of individual treatments is balanced against their risk of harm, whilst being mindful of potential for healthcare professional aversion to treatment due to misperception of risk. Following risk stratification, it would not be unreasonable to offer optimal medical therapy plus an invasive strategy to frail patients at high risk of future cardiovascular events and low risk of complications, and to offer optimal medical therapy alone to those who are deemed at low risk of future events with a high risk of developing procedural complications.
A systematic review by de Vries et al. identified a range of outcomes instruments to measure frailty (Supplementary Table 7).476
8.8 Sex disparities
Data from registries and studies demonstrate discrepant results with respect to access to healthcare, the use of evidence-based therapy,
and clinical outcome between men and women presenting with
ACS.477483 Moreover, women are often under-represented in many RCTs.
Recommendations for older persons with non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
It is recommended to apply the same diagnostic strategies in older patients as for younger patients.458
I
B
It is recommended to apply the same interventional strategies in older patients as for younger patients.463,467
I
B
The choice of antithrombotic agent and dosage, as well as secondary preventions, should be adapted to renal function, as well as speciﬁc contraindications.461
I
B
aClass of recommendation.
bLevel of evidence.
........................................................................................................................................................


<!-- PAGE 47 -->

### Page 47

............................................................................................................
Although several non-invasive testing techniques exist, which may be more appropriate in the detection of microvascular CAD in women,484 catheterization remains the reference standard for highrisk NSTE-ACS and guidelines should be followed the same for both sexes. Specifically, women who present with NSTE-ACS should be provided with equal access to care, a prompt diagnosis, and treatments at the same rate and intensity as their male counterparts. It should be noted that women with NSTEMI may receive higher antithrombotic medication dosing than appropriate for their weight or renal function (or both), and this is partly responsible for the higher risk of in-hospital bleeds and access-related complications after PCI in women.485 For recommendations regarding the management of women who are pregnant and have NSTE-ACS, we refer the reader to the 2018 ESC Guidelines for the management of CVD during pregnancy.486
9 Long-term management of non-ST-segment elevation acute coronary syndrome
9.1 Lifestyle management
(Supplementary Data)
9.1.1 Smoking (Supplementary Data)
9.1.2 Diet and alcohol (Supplementary Data)
9.1.3 Weight management (Supplementary Data)
9.1.3 Physical activity (Supplementary Data)
9.1.4 Cardiac rehabilitation (Supplementary Data)
9.1.5 Psychosocial factors (Supplementary Data)
9.1.6 Environmental factors (Supplementary Data)
9.1.7 Sexual activity (Supplementary Data)
9.1.8 Adherence and sustainability (Supplementary Data)
9.1.9 Influenza vaccination (Supplementary Data)
9.2 Pharmacological management
(Supplementary Data)
9.2.1 Anti-ischaemic drugs
Often, patients do not continue to experience chest pain after
NSTEMI and revascularization. For anti-ischaemic drug management,
please refer to the 2019 ESC CCS Guidelines.231
9.2.1.1 Beta-blockers (Supplementary Data)
9.2.2 Antithrombotic treatments
Duration of antiplatelet treatment and/or anticoagulation are discussed in section 5.1.4.
9.2.3 Proton pump inhibitors (Supplementary Data)
9.2.4 Statins and other lipid-lowering agents
Dyslipidaemia should be managed, according to lipid guidelines, with pharmacological and lifestyle intervention.512 Patients with established CAD are regarded as being at very high risk for cardiovascular events, and statin treatment must be considered, irrespective of lowdensity lipoprotein cholesterol (LDL-C) levels. The goal of treatment is to lower LDL-C to <1.4 mmol/L (<55 mg/dL) and to reduce it by at least 50% if the baseline LDL-C level is 1.83.5 mmol/L (70135
mg/dL). When this level cannot be achieved, the addition of ezetimibe has been demonstrated to decrease cholesterol and cardiovascular events in post-ACS patients, and in patients with diabetes513
with no further impact on mortality.514 In addition to exercise, diet,
and weight control, which should be recommended to all patients,
dietary supplements including phytosterols may lower LDL-C to a lesser extent, but have not been shown to improve clinical outcomes.515 They may be considered (Class IIb) as an adjunct to pharmacological therapy in high- and very high-risk patients who fail to achieve LDL-C goals on statins and those who cannot be treated with statins.516 Trials published since 2015 have demonstrated that proprotein convertase subtilisin kexin
9
(PCSK9)
inhibitors
Recommendations for lifestyle managements after non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Improvement of lifestyle factors in addition to appropriate pharmacological management is recommended in order to reduce allcause and cardiovascular mortality and morbidity and improve health-related quality of life.487497
I
A
Cognitive behavioural interventions are recommended to help individuals achieve a healthy lifestyle.498500
I
A
Multidisciplinary exercise-based cardiac rehabilitation is recommended as an effective means for patients with CAD to achieve a healthy lifestyle and manage risk factors in order to reduce all-cause and cardiovascular mortality and morbidity, and improve healthrelated quality of life.487,497,501
I
A
Involvement of multidisciplinary healthcare professionals (cardiologists, general practitioners, nurses, dieticians, physiotherapists, psychologists, pharmacists) is recommended in order to reduce all-cause and cardiovascular mortality and morbidity, and improve health-related quality of life.492,499,502,503
I
A
Psychological interventions are recommended to improve symptoms of depression in patients with CAD in order to improve healthrelated quality of life.504,505
I
B
Annual inﬂuenza vaccination is recommended for patients with CAD, especially in the older person, in order to improve morbidity.505511
I
B
CAD = coronary artery disease.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1335


<!-- PAGE 48 -->

### Page 48

(evolocumab517 and alirocumab518520) are very effective at reducing cholesterol, lowering LDL-C in a stable fashion to nearly
50 mg/dL (1.3 mmol/L) or less.521 In outcome trials, these agents have demonstrated a reduction of cardiovascular events, with little or no impact on mortality.522 Very low levels of cholesterol are generally well tolerated and associated with fewer events,523 but the high cost of PCSK9 inhibitors, unaffordable for many health systems,524
and unknown long-term safety have limited widespread use to date.
LDL apheresis and new therapies, such as mipomersen and lomitapide, need further research. For patients undergoing PCI, high-dose atorvastatin has been shown to reduce the frequency of periprocedural events in both statin-naı¨ve patients and those receiving chronic statin therapy.525 The recent Reduction of Cardiovascular Events with Icosapent EthylIntervention Trial (REDUCE-IT),526 which included 8179 participants (70.7% for secondary prevention of cardiovascular events) with a median follow-up of 4.9 years, demonstrated a significant effect of a pure prescription-grade eicosapentaenoic acid omega-3 fatty acid, icosapent ethyl, on a composite of cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, or unstable angina in comparison to placebo (17.2 vs. 22.0%, HR 0.75,
95% CI 0.680.83). Of note, very high doses of icosapent ethyl (two times 2 g daily) were used.526 The 2019 ESC/EAS Guidelines for the management of dyslipidaemias give icosapent ethyl a
IIa recommendation.512
9.2.5 Glucose-lowering therapy in patients with diabetes
This topic is beyond the scope of the present document and was discussed in recent guidelines.231 As a general rule, the more advanced the CVD, the older the patient, the longer the diabetes duration, and the more comorbidities that are present, the less stringent the glucose control should be.
For the first time in the history of diabetes mellitus, there are data from several RCTs indicating cardiovascular benefits from the use of glucose-lowering agents in patients with CVD or at very high/high cardiovascular risk. The results obtained from these trials, using glucagon-like peptide-1-receptor antagonists527529 and sodiumglucose cotransporter-2 inhibitors,530532 strongly suggest that these agents should be recommended in patients with type 2 diabetes mellitus with prevalent atherosclerotic CVD.
9.2.6 Renin-angiotensin-aldosterone system blockers
(Supplementary Data)
9.2.7 Mineralocorticoid receptor antagonist therapy
(Supplementary Data)
9.2.8 Antihypertensive therapy (Supplementary Data)
9.2.9 Hormone replacement therapy (Supplementary
Data)
Recommendations for pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments)
Recommendations
Classa
Levelb
Lipid-lowering drugs
Statins are recommended in all NSTE-ACS patients.
The aim is to reduce LDL-C by >_50% from baseline and to achieve LDL-C <1.4 mmol/L (<55 mg/
dL).533,534
I
A
If the LDL-C goalc is not achieved after 46 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended.514,535
I
B
If the LDL-C goalc is not achieved after 46 weeks despite maximally tolerated statin therapy and ezetimibe, the addition of a PCSK9 inhibitor is recommended.520,535
I
B
If the current NSTE-ACS episode is a recurrence within less than 2 years of a ﬁrst ACS, while taking maximally tolerated statin-based therapy, an LDL-C
goal of <1.0 mmol/L (<40 mg/dL) may be considered.520,535
IIb
B
ACE inhibitors or ARBs
ACE inhibitors (or ARBs in cases of intolerance to
ACE inhibitors) are recommended in patients with heart failure with reduced LVEF (<40%), diabetes, or
CKD unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.) in order to reduce allcause and cardiovascular mortality and cardiovascular morbidity.536538
I
A
Beta-blockers
Beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced
LVEF (<40%).539541
I
A
In patients with prior MI, long-term oral treatment with a beta-blocker should be considered in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.542547
IIa
B
MRAs
MRAs are recommended in patients with heart failure with reduced LVEF (<40%) in order to reduce allcause and cardiovascular mortality and cardiovascular morbidity.548,549
I
A
Proton pump inhibitors
Concomitant use of a proton pump inhibitor is recommended in patients receiving aspirin monotherapy,
DAPT, DAT, TAT, or OAC monotherapy who are at high risk of gastrointestinal bleeding in order to reduce the risk of gastric bleeds.169
I
A
ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; ARB
= angiotensin receptor blocker; CKD = chronic kidney disease; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; LDL-C = low-density lipoprotein cholesterol; LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; MRA = mineralocorticoid receptor antagonist;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome; OAC = oral anticoagulation/anticoagulant; PCSK9 = proprotein convertase subtilisin kexin 9;
TAT = triple antithrombotic therapy.
aClass of recommendation.
bLevel of evidence.
cFor patients at very high cardiovascular risk (such as patients with ACS), an LDLC reduction of at least 50% from baseline and an LDL-C goal <1.4 mmol/L (<55
mg/dL) are recommended.512


<!-- PAGE 49 -->

### Page 49

.............................................................................
10 Quality measures
Quality indicators (QIs) are sets of measures that enable the quantification of adherence to guideline recommendations and provide a mechanism for measuring opportunities to improve cardiovascular care and outcomes.550 QIs are derived from evidence and should be feasible, concretely interpretable, and usable.551 They improve quality by identifying practices that may lead to high-quality care and illustrate how such care was delivered, and have been increasingly used by health authorities, professional organizations, healthcare payers, as well as the public.552555
Typically, QIs are divided into structural, process, and outcome indicators, depending on the aspect of care being measured.556
Although high-quality evidence tends to support process Qis,557 the inclusion of both outcome and process measures enables a more comprehensive evaluation.558 Additionally, patient-reported outcome measures (PROMs), which may not be underpinned by a strong class of recommendation within guidelines, can be seen as having a complementary role alongside other Qis.559
In 2016, the ESC Association for Acute Cardiovascular Care
(ACVC), formerly the Acute Cardiovascular Care Association, developed a suite of QIs for the management of AMI with or without
ST-segment elevation.560 These QIs were externally validated in international clinical registries, and most demonstrated an inverse association with mortality.561563 For this 2020 Guidelines for the management of ACS in patients presenting without persistent STsegment elevation, the QIs have been updated so that they align to the current recommendations, but also take into account the wider
NSTE-ACS pathway of care. Briefly, the ESC ACVC QIs for AMI
comprise seven domains, which include the evaluation of: (1) centre organization, (2) the reperfusion/invasive strategy, (3) in-hospital risk assessment, (4) antithrombotic treatment during hospitalization, (5)
secondary prevention discharge treatments, (6) patient satisfaction,
and (7) composite QI risk-adjusted 30-day mortality. The composite
QIs are combinations of individual indicators into a single number to summarize the multiple dimensions and facilitate comparisons and categorization of the centres and can be used by providers for decision making and benchmarking. In this document, however, only the
QIs relevant to the management of NSTE-ACS are described and are displayed in Table 15.
The QIs defined here are intended for quality improvement and performance measurement through meaningful surveillance, as well as for integration within registries that specifically aim to identify areas for improvement in clinical practice. The main and secondary QIs represent major and complementary components of the quality of
NSTE-ACS care, respectively, and are not intended for ranking healthcare professionals/providers or payment incentives.
Continuous monitoring and update will be required for these QIs based on feedback and ‘downstream’ clinical registries data, as well as according to changes in evidence and guideline recommendations.
Table 15
Quality indicators in non-ST-segment elevation acute coronary syndrome care
1. Centre organization
Classa
Levelb
Main QI: hospital use of hs-cTn.
QI: hs-cTn is available in the centre for testing.
Corresponding ESC CPG recommendation: it is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within 60 min of blood sampling.
I
B
Secondary QI: the centre should participate in a regular registry or programme for quality assessment.
QI: centres participating in a registry.
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
2. Invasive strategy
Main QI (1): rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
Numerator: number of NSTEMI patients who receive ICA within 24 h of their diagnosis.
Denominator: all NSTEMI patients without contraindications.
Corresponding ESC CPG recommendation: an early invasive strategy within 24 h is recommended in patients with any of high-risk criteria, including the diagnosis of NSTEMI suggested by a diagnostic algorithm.
I
A
Main QI (2): use of radial access in case of invasive strategy.
Numerator: number of NSTE-ACS patients who receive ICA via radial access.
Denominator: number of NSTE-ACS patients who receive ICA without overriding procedural considerations against the use of radial access.
Corresponding ESC CPG recommendation: radial access is recommended as the standard approach, unless there are overriding procedural considerations.
I
A
Continued
ESC Guidelines
1337


<!-- PAGE 50 -->

### Page 50

### 3 In-hospital risk assessment

Main QI (1): the proportion of patients who have an assessment of LVEF before hospital discharge. LVEF should be assessed and the numerical value recorded for all patients admitted with NSTE-ACS.
Numerator: number of NSTE-ACS patients who have their LVEF measured before hospital discharge.
Denominator: number of NSTE-ACS patients.
Corresponding ESC CPG recommendation: echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.
I
C
Main QI (2): LDL-C assessment should be performed during hospitalization.
Numerator: number of NSTE-ACS patients who have their LDL-C measured during hospitalization.
Denominator: number of NSTE-ACS patients.
Corresponding ESC CPG recommendation: statins are recommended in all NSTE-ACS patients. The aim is to reduce LDL-C
by at least 50% from baseline and/or achieve LDL-C <1.4 mmol/L (<55 mg/dL).
I
A
4. Anti-thrombotic treatment during hospitalization
Main QI: proportion of patients with ‘adequate P2Y12 receptor inhibition’.
Numerator: number of NSTE-ACS patients prescribed adequate P2Y12 inhibitors at the time of hospital discharge.
Denominator: NSTE-ACS patients alive at the time of hospital discharge with an indication for prasugrel, ticagrelor, or clopidogrel.
Corresponding ESC CPG recommendation: a P2Y12 receptor inhibitor is recommended in addition to aspirin, to be maintained over 12 months unless there are contraindications or an excessive risk of bleeding.
I
A
5. Secondary prevention discharge treatments
Main QI: proportion of patients discharged from hospital on high-intensity statins (deﬁned as atorvastatin >_40 mg or rosuvastatin
>_20 mg) unless contraindicated.
Numerator: number of NSTE-ACS patients who receive high-intensity statin therapy at the time of hospital discharge.
Denominator: number of NSTE-ACS patients alive at the time of hospital discharge and without contraindications, refusal, side effects, allergy, or history of intolerance to high-intensity statin therapy.
Corresponding ESC CPG recommendation: statins are recommended in all NSTE-ACS patients. The aim is to reduce LDL-C
by at least 50% from baseline and/or achieve LDL-C <1.4 mmol/L (<55 mg/dL).
I
A
Secondary QI (1): proportion of patients with LVEF <40% who are discharged from hospital on ACE inhibitor (or ARB if intolerant to ACE inhibitors).
Numerator: number of NSTE-ACS patients with LVEF <40%, prescribed ACE inhibitor/ARB at the time of hospital discharge.
Denominator: number of NSTE-ACS patients with LVEF<40% and alive at the time of hospital discharge who are eligible for ACE
inhibitor/ARB (no severe renal impairment, hyperkalaemia, other contraindication, refusal, side effects, or allergy).
Corresponding ESC CPG recommendation: ACE inhibitors (or ARB in cases of intolerance) are recommended in NSTE-ACS
patients with co-existing hypertension, LVEF <40%, diabetes, or CKD, unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.).
I
A
Secondary QI (2): proportion of patients with LVEF <40% who are discharged from hospital on beta-blockers.
Numerator: number of patients with LVEF <40% prescribed beta-blockers at the time of hospital discharge.
Denominator: patients with LVEF<40% and alive at the time of hospital discharge who are eligible for beta-blockers.
Corresponding ESC CPG recommendation: beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced LVEF (<40%).
I
A
6. Patient satisfaction
Main QI: feedback regarding the patient’s experience should be systematically collected in an organized way from all patients. It should include the following points:
Explanations provided by doctors and nurses (about the coronary disease, the beneﬁt/risk of the discharge treatment, and medical follow-up).
Discharge information regarding what to do in case of recurrence of symptoms and timing of visit.
Numerator: number of NSTE-ACS patients alive at the time of discharge from hospital with feedback collected.
Denominator: number of NSTE-ACS patients discharged from hospital alive.
Corresponding ESC CPG recommendation (1): no ESC CPG recommendation.
NA
NA
Continued


<!-- PAGE 51 -->

### Page 51

Secondary QI: systematic assessment of health-related quality of life in all patients using a validated instrument.
Numerator: number of NSTE-ACS patients alive at the time of hospital discharge who have their health-related quality of life assessed during hospitalization using a validated instrument.
Denominator: number of NSTE-ACS patients discharged from hospital alive.
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
7. CQI
Main CQI (opportunity based): with the following individual QIs (all indicators are weighted equally):
The centre should participate in a regular registry or programme for quality assessment.
Rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
Proportion of patients who have an assessment of LVEF before hospital discharge.
Proportion of patients with ‘adequate P2Y12 receptor inhibition’.
Proportion of patients discharged from hospital on high-intensity statins.
Proportion of patients with LVEF <40% who are discharged from hospital on an ACE inhibitor/ARB.
Proportion of patients with LVEF <40% who are discharged from hospital on beta-blockers.
Feedback regarding the patient’s experience systematically collected in an organized way from all patients.
Numerator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each individual indicator).
Denominator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each applicable indicator, according to patient and centre characteristics).
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
Secondary CQI (all or none): based on three or ﬁve components, according to LVEF:
• Calculated on three individual QIs in patients with LVEF >_40%:
(1)
Rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
(2)
Proportion of patients with ‘adequate P2Y12 receptor inhibition’.
(3)
Proportion of patients discharged from hospital on high-intensity statins.
• Calculated on ﬁve individual QIs in patients with LVEF <40%:
(1)
Rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
(2)
Proportion of patients with ‘adequate P2Y12 receptor inhibition’.
(3)
Proportion of patients discharged from hospital on high-intensity statins.
(4)
Proportion of patients with LVEF <40% who are discharged from hospital on an ACE inhibitor/ARB.
(5)
Proportion of patients with LVEF <40% who are discharged from hospital on beta-blockers.
Numerator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each individual indicator).
Denominator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each applicable indicator, according to patient and centre characteristics).
8. Outcome QI
Secondary QI: risk adjusted 30-day mortality rate.c
Numerator: all NSTE-ACS patients who died within 30 days after admission.
Denominator: all NSTE-ACS patients at 30-day follow-up.
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery disease; CCS = chronic coronary syndromes; CKD = chronic kidney disease; CPG = clinical practice guidelines; CQI = composite quality indicator; ESC = European Society of Cardiology; hs-cTn = high-sensitivity cardiac troponin; ICA = invasive coronary angiography; LDL-C = low-density lipoprotein cholesterol; LV = left ventricular; LVEF = left ventricular ejection fraction; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; QI = quality indicator.
aClass of recommendation.
bLevel of evidence.
cRisk-adjusted 30-day mortality rates (i.e. using a logistic regression model adjusted for the risk score (by a validated risk score assessment), with 30-day mortality as the dependent variable.
ESC Guidelines
1339


<!-- PAGE 52 -->

### Page 52

11 Management strategy
Figure 13 describes an overview and management pathway for NSTE-ACS patients.
Figure 13 Central illustration. Management strategy for non-ST-segment elevation acute coronary syndrome patients. BNP = B-type natriuretic peptide; CABG = coronary artery bypass graft(ing); CCU = coronary care unit; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; ECG = electrocardiogram/electrocardiography; GP = glycoprotein; GRACE = Global Registry of Acute Coronary Events; hs-cTn = high-sensitivity cardiac troponin; NSTEACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; NT-proBNP = N-terminal proB-type natriuretic peptide; PCI = percutaneous coronary intervention; PCSK9 = proprotein convertase subtilisin kexin 9; UFH = unfractionated heparin.
Listen to the audio guide of this figure online.


<!-- PAGE 53 -->

### Page 53

.............................................................................................................................................................................
12 Key messages
• Diagnosis. Chest discomfort without persistent ST-segment elevation (NSTE-ACS) is the leading symptom initiating the diagnostic and therapeutic cascade. The pathological correlate at the myocardial level is cardiomyocyte necrosis, measured by troponin release, or, less frequently, myocardial ischaemia without cell damage (unstable angina). Individuals with unstable angina have a substantially lower risk of death and derive less benefit from an aggressive pharmacological and invasive approach.
• Troponin assays. High-sensitivity troponin assays measurements are recommended over less sensitive ones, as they provide higher diagnostic accuracy at identical low cost. It should be noted that many cardiac pathologies other than MI also result in cardiomyocyte injury and, therefore, cardiac troponin elevations.
• Other biomarkers. Other biomarkers may have clinical relevance in specific clinical settings when used in combination with non hs-cTn T/I. CK-MB shows a more rapid decline after MI and may provide added value for detection of early reinfarction. The routine use of copeptin as an additional biomarker for the early rule-out of MI should be considered in the increasingly uncommon setting where hs-cTn assays are not available.
• Rapid ‘rule-in’ and ‘rule-out’ algorithms. Due to the higher sensitivity and diagnostic accuracy for the detection of MI at presentation, the time interval to the second cTn assessment can be shortened with the use of hs-cTn assays. It is recommended to use the 0 h/1 h algorithm (best option, blood draw at 0 h and 1 h)
or the 0 h/2 h algorithm (second-best option, blood draw at 0 h and 2 h). Optimal thresholds for rule-out and rule-in were selected to allow for a minimal sensitivity and NPV of 99% and a minimal PPV of 70%. Used in conjunction with clinical and ECG
findings, the 0 h/1 h and 0 h/2 h algorithm allows the identification of appropriate candidates for early discharge and outpatient management.
• Confounders of hs-cTn. Beyond the presence or absence of
MI, four clinical variables affect hs-cTn concentrations. The effect of age (differences in concentration between healthy very young vs. ‘healthy’ very old individuals up to 300%), renal dysfunction
(differences in concentration between otherwise healthy patients with very high vs. very low eGFR up to 300%), and chest pain onset (>300%) is substantial, and modest for sex (40%).
• Ischaemic risk assessment. Initial cTn levels add prognostic information in terms of short- and long-term mortality to clinical and ECG variables. The higher the hs-cTn levels, the greater the risk of death. Serum creatinine and eGFR should also be determined in all patients with NSTE-ACS because they affect prognosis and are key elements of the GRACE risk score, which assessment is superior to (subjective) physician assessment for the occurrence of death or MI. Natriuretic peptides may provide incremental prognostic information and may help in risk stratification.
• Bleeding risk assessment. ARC-HBR is a pragmatic approach that includes the most recent trials performed in HBR patients,
who were previously excluded from clinical trials of DAPT duration or intensity. The PRECISE-DAPT score may be used to guide and inform decision making on DAPT duration with a modest predictive value for major bleeding. Their value in improving patient outcomes remains unclear.
• Non-invasive imaging. Even after the rule-out of MI, elective non-invasive or invasive imaging may be indicated according to clinical assessment. CCTA may be an option in patients with lowto-modest clinical likelihood of unstable angina as a normal scan excludes CAD. CCTA has a high NPV to exclude ACS (by excluding CAD) and an excellent outcome in patients presenting to the emergency department with low-to-intermediate pre-test probability for ACS and a normal CCTA. In addition, upfront imaging with CCTA reduces the need for ICA in high risk patients. Stress imaging by cardiac magnetic resonance imaging,
stress echocardiography, or nuclear imaging may also be an option based on risk assessment.
• Risk stratification for an invasive approach. An early routine invasive approach within 24 h of admission is recommended for NSTEMI based on hs-cTn measurements, GRACE risk score
>140, and dynamic new, or presumably new, ST-segment changes as it improves major adverse cardiac events and possibly early survival. Immediate invasive angiography is required in highly unstable patients according to hemodynamic status, arrythmias,
acute heart failure, or persistent chest pain. In all other clinical presentation, a selective invasive approach may be performed according to non-invasive testing or clinical risk assessment.
• Revascularization strategies. The principal technical aspects of PCI in NSTE-ACS patients do not differ from the invasive assessment and revascularization strategies for other manifestations of CAD. Radial access is recommended as the preferred approach in NSTE-ACS patients undergoing invasive assessment with or without PCI. Multivessel disease is frequent in NSTEACS, timing and completeness of revascularization should be decided according to functional relevance of all stenoses, age,
general patient condition, comorbidities, and left ventricular function.
• Myocardial infarction with non-obstructive coronary arteries. MINOCA incorporates a heterogeneous group of underlying causes that may involve both coronary and noncoronary pathological conditions, with the latter including cardiac and extra-cardiac disorders. It excludes by consensus myocarditis and Takotsubo syndrome. Cardiac magnetic resonance imaging is one of the key diagnostic tools as it identifies the underlying cause in more than 85% of patients and the subsequent appropriate treatment.
• Spontaneous coronary artery dissection. Defined as a non-atherosclerotic, non-traumatic, or iatrogenic separation of the coronary arterial tunics secondary to vasa vasorum hemorrhage or intimal tear, it accounts for up to 4% of all ACS, but the incidence is reported to be much higher (2235% of ACS) in women <60 years of age. Intracoronary imaging is very useful for the diagnosis and treatment orientation. Medical treatment remains to be established.
• Pre-treatment with P2Y12 receptor inhibitors. Routine pre-treatment with a P2Y12 receptor inhibitor in NSTE-ACS
patients in whom coronary anatomy is not known and an early invasive management is planned is not recommended given the lack of established benefit. However, it may be considered in selected cases and according to the bleeding risk of the patient.
ESC Guidelines
1341


<!-- PAGE 54 -->

### Page 54

..............................
• Post-treatment antiplatelet therapy. DAPT consisting of a potent P2Y12 receptor inhibitor in addition to aspirin is generally recommended for 12 months, irrespective of the stent type,
unless there are contraindications. New scenarios have been implemented. DAPT duration can be shortened (<12 months),
extended (>12 months), or modified by switching DAPT or deescalation. These decisions depend on individual clinical judgment being driven by the patient’s ischaemic and bleeding risk, the occurrence of adverse events, comorbidities, co-medications,
and the availability of the respective drugs.
• Triple antithrombotic therapy. In at least 68% of patients undergoing PCI, long-term oral anticoagulation is indicated and should be continued. NOACs are preferred over VKAs in terms of safety when patients are eligible. DAT with a NOAC at the recommended dose for stroke prevention and SAPT (preferably clopidogrel, chosen in more than 90% of cases in available trials)
is recommended as the default strategy up to 12 months after a short period up to 1 week of TAT (with NOAC and DAPT).
TAT may be prolonged up to 1 month when the ischaemic risk outweighs the bleeding risk.
13 Gaps in evidence for non-ST-segment elevation acute coronary syndrome care and future research
Gaps in NSTE-ACS Care
Needed RCTs
RISK PREDICTION MODELLING
Whether risk stratiﬁcation of NSTE-ACS patients based on multivariable risk prediction models improves clinical outcomes remains unclear.
Patients randomized to treatment algorithms based on scores calculated at point of care or to usual treatment.
No dedicated RCT has evaluated the value of a management strategy based on a risk-prediction model (i.e. PRECISE-DAPT score, ARC-HBR criteria)
for DAPT duration following PCI for NSTE-ACS.
Patients randomized to management strategies based on risk prediction models for DAPT duration vs. usual care.
MEDICALTREATMENT STRATEGIES
The efﬁcacy and safety of pre-treatment NSTE-ACS patients with oral P2Y12
receptor inhibitors prior to ICA is unknown.
Dedicated RCTs for pre-treatment with ticagrelor (and separately, clopidogrel) vs. placebo as opposed to loading after angiography in PCI patients.
The efﬁcacy and safety of early i.v. beta-blockers before an early or late invasive strategy in NSTE-ACS patients remain under question.
Patients randomized to i.v. beta-blockers or usual care before ICA.
The value of long-term therapy with beta-blockers in patients with LVEF
>40% needs further evaluation.
Patients with LVEF>40% following 1 year of beta-blocker therapy after the event randomized to long-term therapy or not.
BIOMARKERS
The role of platelet function testing or genetic testing to de-escalate oral
P2Y12 receptor inhibitors after the ﬁrst month of therapy following PCI for
NSTE-ACS needs to be deﬁned.
Adequately powered RCTs of a strategy of platelet function testing- or genetic testing-based de-escalation vs. usual guideline-based care.
What is the added value of biomarkers other than hs-cTn for rapid rule-out of NSTE-ACS compared with usual care?
NSTE-ACS patients randomized to diagnostic pathways with or without biomarkers in addition to usual care.
TIMING OF ANGIOGRAPHYAND REVASCULARIZATION STRATEGIES
What is the optimal timing of invasive angiography in high-risk NSTE-ACS
patients?
Further RCTs with different time intervals until angiography within the 72-h window from presentation.
Should low-risk NSTE-ACS patients undergo routine or selective invasive assessment?
Appropriate risk-stratiﬁed patients randomized to routine or selective invasive strategy.
The optimal invasive strategy for women presenting with NSTE-ACS is unknown.
Adequately powered RCTs to identify potential sex differences in treatment strategies in patients presenting with NSTE-ACS.
What is the role of CCTA- or other imaging-based stress testing strategies for low-risk NSTE-ACS patients or uncertain NSTEMI patients?
Diagnostic RCTs of routine non-invasive anatomy- or functional imagingbased strategies prior to an ICA approach powered for clinical endpoints.
What is the value of FFR-CT added to CCTA in evaluating the role of adverse plaque characteristics and adverse haemodynamic characteristics in the determination of ACS?
Diagnostic RCTs comparing the adding value of FFR-CT on a non-invasive anatomical testing strategy (CCTA).
The safety and effectiveness of routine vs. selective invasive assessment of frail patients presenting with NSTE-ACS requires further evaluation.
Frail patients presenting with NSTE-ACS without ongoing ischaemia or haemodynamic instability should be randomized to routine vs. selective ICA.
Mainly due to difﬁculties in enrolment, older patients have been under-represented in clinical trials of invasive strategies for NSTE-ACS patients.
Multicentre RCTs evaluating the safety and effectiveness of different treatment strategies in sufﬁcient numbers of older NSTE-ACS patients.
Continued


<!-- PAGE 55 -->

### Page 55

14 ‘What to do’ and ‘what not to do’ messages
We do not know whether there are additional criteria for not waiting at all in the NSTE-ACS population, apart from those currently listed in the immediate invasive strategy.
Risk stratiﬁcation pathways to identify vulnerable populations having the greatest beneﬁt from an early invasive assessment (and perhaps also immediate invasive assessment) deserve appropriate evaluation.
It remains unclear whether coronary revascularization of the presumed culprit lesion only or complete revascularization in NSTE-ACS patients should be attempted.
RCTs of PCI of the presumed culprit lesion only based on non-invasive imaging and/or coronary angiography vs. complete revascularization with
PCI (or CABG).
The value of haemodynamic assessment based on FFR of non-culprit lesions to guide complete revascularization in the NSTE-ACS setting remains unclear.
Patients presenting with NSTE-ACS and multivessel disease randomized to
PCI as indicated with vs. without FFR of non-culprit lesions.
Should PCI or CABG be the preferred option in multivessel coronary disease in NSTE-ACS?
Dedicated trials focused on NSTE-ACS patients with multivessel coronary disease randomized to PCI vs. CABG including invasive and/or non-invasive assessment.
Should complete revascularization be achieved during the index intervention or as a staged approach?
Immediate vs. staged complete revascularization should be evaluated in
RCTs in patients with multivessel disease.
The role and type of percutaneous mechanical circulatory support device in patients presenting with NSTE-ACS and CS remains uncertain.
Strategies based on percutaneous mechanical circulatory support devices in
NSTE-ACS patients presenting with CS should be evaluated compared to standard of care.
LONG-TERM MANAGEMENT
The optimal mode of training programmes following NSTE-ACS should be determined.
Patients randomized to different modes of rehabilitation programmes after
NSTE-ACS.
It has to be determined whether neprilysin inhibitors  in the speciﬁc group of patients who have suffered NSTE-ACS with systolic LV dysfunction 
improve clinical outcomes and reduce hospitalizations.
NSTE-ACS patients with systolic LV dysfunction should be randomized to therapy with a neprilysin inhibitor vs. standard of care.
What is the value of long-term beta-blocker and long-term ACE inhibitor/
ARB in patients with normal LV function and no other indications for these therapies?
RCTs comparing the long-term continuation of therapy with beta-blockers and ACE inhibitor/ARB to withdrawal in patients with normal LV function in the absence of other indications following NSTE-ACS.
What is the optimal long-term antithrombotic therapy in NSTE-ACS
patients who have undergone percutaneous coronary revascularization?
Dedicated RCTs comparing different combinations of potent antithrombotic agents and examining the beneﬁt-risk balance for ischaemic/bleeding events.
The impact of heart valve disease in patients with CAD and NSTE-ACS is unknown and needs to be investigated.
Strategies based on revascularization only vs. revascularization and heart valve disease treatment should be evaluated (non-severe valvular heart disease including aortic stenosis and mitral regurgitation).
ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; ARB = angiotensin receptor blocker; ARC-HBR = Academic Research Consortium - High Bleeding
Risk; CABG = coronary artery bypass graft(ing); CAD = coronary artery disease; CCTA = coronary computed tomographic angiography; CS = cardiogenic shock; DAPT =
dual antiplatelet therapy; FFR = fractional ﬂow reserve; FFR-CT = fractional ﬂow reserve-computed tomography; hs-cTn = high-sensitivity cardiac troponin ; ICA = invasive coronary angiography; i.v. = intravenous; LV = left ventricular; LVEF = left ventricular ejection fraction; NSTE-ACS = non-ST elevation acute coronary syndrome; NSTEMI = nonST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; RCT = randomized controlled trial.
Recommendations for diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome
Classa
Levelb
Diagnosis and risk stratiﬁcation
It is recommended to base diagnosis and initial short-term risk stratiﬁcation on a combination of clinical history, symptoms, vital signs,
other physical ﬁndings, ECG, and laboratory results including hs-cTn.3
I
B
It is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within
60 min of blood sampling.3,1013,2931,34
I
B
It is recommended to obtain a 12-lead ECG within 10 min after ﬁrst medical contact and to have it immediately interpreted by an experienced physician.21
I
B
It is recommended to obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty.
I
C
Continued
ESC Guidelines
1343


<!-- PAGE 56 -->

### Page 56

The ESC 0 h/1 h algorithm with blood sampling at 0 h and 1 h is recommended if an hs-cTn test with a validated 0 h/1 h algorithm is available.30,33,35,36,39,68,69,75,76
I
B
Additional testing after 3 h is recommended if the ﬁrst two cardiac troponin measurements of the 0 h/1 h algorithm are not conclusive and the clinical condition is still suggestive of ACS.85
I
B
As an alternative to the ESC 0 h/1 h algorithm, it is recommended to use the ESC 0 h/2 h algorithm with blood sampling at 0 h and 2
h, if an hs-cTn test with a validated 0 h/2 h algorithm is available.33,39,75,78,84
I
B
Additional ECG leads (V3R, V4R, V7V9) are recommended if ongoing ischaemia is suspected when standard leads are inconclusive.
I
C
For initial diagnostic purposes, it is not recommended to routinely measure additional biomarkers such as h-FABP or copeptin, in addition to hs-cTn.47,48,51,52,54,118
III
B
Imaging
In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography is recommended and should be performed by trained physicians immediately following a 12-lead ECG.
I
C
In patients with no recurrence of chest pain, normal ECG ﬁndings, and normal levels of cardiac troponin (preferably high sensitivity),
but still with a suspected ACS, a non-invasive stress test (preferably with imaging) for inducible ischaemia or CCTA is recommended before deciding on an invasive approach.91,92,98,101,105108
I
B
Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.c
I
C
CCTA is recommended as an alternative to ICA to exclude ACS when there is a low-to-intermediate likelihood of CAD and when cardiac troponin and/or ECG are normal or inconclusive.105,108,110114
I
A
Monitoring
Continuous rhythm monitoring is recommended until the diagnosis of NSTEMI has been established or ruled out.
I
C
It is recommended to admit NSTEMI patients to a monitored unit.
I
C
Rhythm monitoring up to 24 h or to PCI (whichever comes ﬁrst) is recommended in NSTEMI patients at low risk for cardiac arrhythmias.d
I
C
Rhythm monitoring for >24 h is recommended in NSTEMI patients at increased risk for cardiac arrhythmias.e
I
C
Recommendations on biomarker measurements for prognostic stratiﬁcation
Beyond its diagnostic role, it is recommended to measure hs-cTn serially for the estimation of prognosis.12,13,119,120
I
B
The measurement of additional biomarkers, such as mid-regional pro-A-type natriuretic peptide, high-sensitivity C-reactive protein,
mid-regional pro-adrenomedullin, GDF-15, copeptin, and h-FABP is not recommended for routine risk or prognosis assessment.50,127,129
III
B
Recommendations for antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention
Antiplatelet treatment
Aspirin is recommended for all patients without contraindications at an initial oral LD of 150300 mg (or 75250 mg i.v.), and at a
MD of 75100 mg o.d. for long-term treatment.179181
I
A
A P2Y12 receptor inhibitor is recommended in addition to aspirin, and maintained over 12 months unless there are contraindications or an excessive risk of bleeding.170,171,182
Options are:
I
A
 Prasugrel in P2Y12 receptor inhibitor-naı¨ve patients proceeding to PCI (60 mg LD, 10 mg/d as standard dose, 5 mg/d for patients aged >_75 years or with a body weight <60 kg).171
I
B
 Ticagrelor irrespective of the planned treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d.).170
I
B
 Clopidogrel (300600 mg LD, 75 mg daily dose), only when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.182,183
I
C
Treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known and is not recommended.188,189
III
A
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned.174,177,190,191
III
A
Peri-interventional anticoagulant treatment
Parenteral anticoagulation is recommended for all patients, in addition to antiplatelet treatment, at the time of diagnosis and, especially, during revascularization procedures according to both ischaemic and bleeding risks.192,193
I
A
UFH (weight-adjusted i.v. bolus during PCI of 70100 IU/kg, or 5070 IU/kg in combination with a GP IIb/IIIa inhibitor; activated clotting time target range of 250350 s, or 200250 s if a GP IIb/IIIa inhibitor is given) is recommended in patients undergoing PCI.
I
A
In cases of medical treatment or logistical constraints for transferring the patient to PCI within the required time frame, fondaparinux is recommended and, in such cases, a single bolus of UFH is recommended at the time of PCI.183
I
B
Continued


<!-- PAGE 57 -->

### Page 57

It is recommended to select anticoagulation according to both ischaemic and bleeding risks, and according to the efﬁcacysafety proﬁle of the chosen agent.
I
C
Crossover of UFH and LMWH is not recommended.196
III
B
Recommendations for post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome
In patients with NSTE-ACS treated with coronary stent implantation, DAPT with a P2Y12 receptor inhibitor on top of aspirin is recommended for 12 months unless there are contraindications such as excessive risk of bleeding.170,171,225
I
A
Recommendations for anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome
Sublingual or i.v. nitrates and early initiation of beta-blocker treatment are recommended in patients with ongoing ischaemic symptoms and without contraindications.
I
C
It is recommended to continue chronic beta-blocker therapy unless the patient is in overt heart failure.
I
C
i.v. nitrates are recommended in patients with uncontrolled hypertension or signs of heart failure.
I
C
Recommendations for combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation
Stroke prevention should be offered to AF patients with >_1 non-sex CHA2DS2-VASc stroke risk factors (score of >_1 in males or >_2
in females). For patients with >_2 non-sex stroke risk factors, OAC is recommended.255259
I
A
Patients undergoing coronary stenting
Anticoagulation
During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all NOACs and if INR
is <2.5 in VKA-treated patients.
I
C
Antiplatelet treatment
In patients with AF and CHA2DS2-VASc score >_1 in men and >_2 in women, after a short period of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel).238241,244,245
I
A
Periprocedural DAPT administration consisting of aspirin and clopidogrel up to 1 week is recommended.238241,244,245
I
A
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.236239,246
I
B
The use of ticagrelor or prasugrel as part of TAT is not recommended.
III
C
Recommendations for coronary revascularization
Timing of invasive strategy
An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very high-risk criteria:
• Haemodynamic instability or CS.
• Recurrent or refractory chest pain despite medical treatment.
• Life-threatening arrhythmias.
• Mechanical complications of MI.
• Heart failure clearly related to NSTE-ACS.
• Presence of ST-segment depression >1 mm in >_6 leads additional to ST-segment elevation in aVR and/or V1.
I
C
An early invasive strategy within 24 h is recommended in patients with any of the following high-risk criteria:
• Diagnosis of NSTEMI suggested by the diagnostic algorithm recommended in section 3.
• Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing ischaemia.
• Transient ST-segment elevation.273,362
• GRACE risk score >140.271,272,277
I
A
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive CAD by CCTA is recommended in patients considered at low risk.267,268,363
I
A
Technical aspects
Radial access is recommended as the standard approach, unless there are overriding procedural considerations.336,337
I
A
DES are recommended over bare-metal stents for any PCI irrespective of:
• Clinical presentation.
• Lesion type.
• Planned non-cardiac surgery.
• Anticipated duration of DAPT.
• Concomitant anticoagulant therapy.354,365,366
I
A
Continued
ESC Guidelines
1345


<!-- PAGE 58 -->

### Page 58

It is recommended to base the revascularization strategy (ad hoc culprit lesion PCI/multivessel PCI/CABG) on the patient’s clinical status and comorbidities, as well as their disease severity [i.e. the distribution and angiographic lesion characteristics (e.g. SYNTAX
score)], according to the principles for stable CAD.350 However, the decision on immediate PCI of the culprit stenosis does not require Heart Team consultation.
I
B
Recommendations for myocardial infarction with non-obstructive coronary arteries
In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to differentiate true
MINOCA from alternative diagnoses.
I
C
It is recommended to perform CMR in all MINOCA patients without an obvious underlying cause.370
I
B
It is recommended to manage patients with an initial diagnosis of MINOCA and a ﬁnal established underlying cause according to the disease-speciﬁc guidelines.
I
C
Recommendations for non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock
Emergency coronary angiography is recommended in patients with CS complicating ACS.205,416,417
I
B
Emergency PCI of the culprit lesion is recommended for patients with CS due to NSTE-ACS, independent of the time delay from symptom onset, if the coronary anatomy is amenable to PCI.205,417
I
B
Emergency CABG is recommended for patients with CS if the coronary anatomy is not amenable to PCI.205,417
I
B
It is recommended to perform emergency echocardiography without delay to assess LV and valvular function and exclude mechanical complications.
I
C
In cases of haemodynamic instability, emergency surgical or catheter-based repair of mechanical complications of ACS is recommended, as decided by the Heart Team.
I
C
Routine use of IABP in patients with CS and no mechanical complications due to ACS is not recommended.413,414,415
III
B
Routine immediate revascularization of non-culprit lesions in NSTE-ACS patients with multivessel disease presenting with CS is not recommended.346,408
III
B
Recommendations for diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients
It is recommended to screen all patients with NSTE-ACS for diabetes and to monitor blood glucose levels frequently in patients with known diabetes or admission hyperglycaemia.
I
C
Avoidance of hypoglycaemia is recommended.424427
I
B
Recommendations for patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome
Risk stratiﬁcation in CKD
It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD (dose adjustment may be necessary)
as for patients with normal renal function.
I
C
It is recommended to assess kidney function by eGFR in all patients.
I
C
Myocardial revascularization in patients with CKD
Use of low- or iso-osmolar contrast media (at lowest possible volume) are recommended in invasive strategies.205,441,442,445,446
I
A
Recommendations for older persons with non-ST-segment elevation acute coronary syndrome
It is recommended to apply the same diagnostic strategies in older patients as for younger patients.458
I
B
It is recommended to apply the same interventional strategies in older patients as for younger patients.463,467
I
B
The choice of antithrombotic agent and dosage, as well as secondary preventions, should be adapted to renal function, as well as speciﬁc contraindications.461
I
B
Recommendations for lifestyle managements after non-ST-segment elevation acute coronary syndrome
Improvement of lifestyle factors in addition to appropriate pharmacological management is recommended in order to reduce allcause and cardiovascular mortality and morbidity and improve health-related quality of life.487497
I
A
Cognitive behavioural interventions are recommended to help individuals achieve a healthy lifestyle.498500
I
A
Multidisciplinary exercise-based cardiac rehabilitation is recommended as an effective means for patients with CAD to achieve a healthy lifestyle and manage risk factors in order to reduce all-cause and cardiovascular mortality and morbidity, and improve healthrelated quality of life.487,497,501
I
A
Involvement of multidisciplinary healthcare professionals (cardiologists, general practitioners, nurses, dieticians, physiotherapists, psychologists, pharmacists) is recommended in order to reduce all-cause and cardiovascular mortality and morbidity, and improve health-related quality of life.492,499,502,503
I
A
Psychological interventions are recommended to improve symptoms of depression in patients with CAD in order to improve healthrelated quality of life.504,505
I
B
Annual inﬂuenza vaccination is recommended for patients with CAD, especially in the older person, in order to improve morbidity.505511
I
B
Continued


<!-- PAGE 59 -->

### Page 59

...................................................
15 Supplementary data
Supplementary Data with additional Supplementary Figures, Tables,
and text complementing the full text are available on the European
Heart Journal website and via the ESC website at www.escardio.org/
guidelines.
16 Appendix
Author/Task
Force
Member
Affiliations:
Emanuele
Barbato, Advanced Biomedical Sciences, University Federico II,
Napoli, Italy; Olivier Barthe´le´my, Sorbonne Universite´, ACTION
Study Group, Institut de Cardiologie, Hoˆpital Pitie´-Salp^eetrie`re
(Assistance Publique- Hoˆpitaux de Paris) (AP-HP), Paris, France;
Johann Bauersachs, Department of Cardiology and Angiology,
Hannover Medical School, Hannover, Germany; Deepak L. Bhatt,
Brigham and Women’s Hospital and Harvard Medical School,
Boston, United States of America; Paul Dendale, Faculty of
Medicine and Life Sciences, Hasselt University, Hasselt, Belgium;
Maria Dorobantu, Cardiology, "Carol Davila" University of
Medicine and Pharmacy, Bucharest, Romania; Thor Edvardsen,
Cardiology, Oslo University Hospital, Oslo, Norway; Thierry
Folliguet,
UPEC,
Cardiac surgery,
Hoˆpital
Henri
Mondor
(Assistance Publique Hoˆpitaux de Paris), Cre´teil, France; Chris P.
Gale, Leeds Institute of Cardiovascular and Metabolic Medicine,
University of Leeds, Leeds, United Kingdom; Martine Gilard,
Cardiology, CHU La Cavale Blanche, Brest, France; Alexander
Jobs, Department of Internal Medicine/Cardiology, Heart Center
Leipzig at University of Leipzig, Leipzig, Germany; Peter Ju¨ni, Li Ka
Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Canada;
Ekaterini Lambrinou, Department of Nursing, School of Health
Sciences, Cyprus University of Technology, Limassol, Cyprus; Basil
S. Lewis, Cardiovascular Clinical Trials Institute, Lady Davis Carmel
Medical Center and the Ruth and Bruce Rappaport School of
Recommendations for pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments)
Lipid-lowering drugs
Statins are recommended in all NSTE-ACS patients. The aim is to reduce LDL-C by >_50% from baseline and/or to achieve LDL-C
<1.4 mmol/L (<55 mg/dL).533,534
I
A
If the LDL-C goalf is not achieved after 46 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended.514,535
I
B
If the LDL-C goalf is not achieved after 46 weeks despite maximally tolerated statin therapy and ezetimibe, the addition of a PCSK9
inhibitor is recommended.520,535
I
B
ACE inhibitors or ARBs
ACE inhibitors (or ARBs in cases of intolerance to ACE inhibitors) are recommended in patients with heart failure with reduced
LVEF (<40%), diabetes, or CKD unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.) in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.536538
I
A
Beta-blockers
Beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced LVEF (<40%).539541
I
A
MRAs
MRAs are recommended in patients with heart failure with reduced LVEF (<40%) in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.548,549
I
A
Proton pump inhibitors
Concomitant use of a proton pump inhibitor is recommended in patients receiving aspirin monotherapy, DAPT, DAT, TAT, or OAC
monotherapy who are at high risk of gastrointestinal bleeding in order to reduce the risk of gastric bleeds.169
I
A
ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; AF = atrial ﬁbrillation; ARB = angiotensin receptor blocker; b.i.d. = bis in die (twice a day); CABG =
coronary artery bypass graft(ing); CAD = coronary artery disease; CCTA = coronary computed tomography angiography; CHA2DS2-VASc = Congestive heart failure,
Hypertension, Age >_75 years (2 points), Diabetes, Stroke (2 points)_Vascular disease, Age 65_74, Sex category (female); CKD = chronic kidney disease; CMR = cardiac magnetic resonance; CS = cardiogenic shock; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; DES = drug-eluting stent; ECG = electrocardiogram/electrocardiography; eGFR = estimated glomerular ﬁltration rate; ESC = European Society of Cardiology; FFR = fractional ﬂow reserve; GDF-15 = growth differentiation factor 15;
GP = glycoprotein; GRACE = Global Registry of Acute Coronary Events; h-FABP = heart-type fatty acid-binding protein; hs-cTn = high-sensitivity cardiac troponin; IABP =
intra-aortic balloon pump; ICA = invasive coronary angiography; INR = international normalized ratio; i.v. = intravenous; LD = loading dose; LDL-C = low-density lipoprotein cholesterol; LMWH = low-molecular-weight heparin; LV = left ventricular; LVEF = left ventricular ejection fraction; MD = maintenance dose; MI = myocardial infarction;
MINOCA = myocardial infarction with non-obstructive coronary arteries; MRA = mineralocorticoid receptor antagonist; NOAC = non-vitamin K antagonist oral anticoagulant;
NSTEMI = non-ST-segment elevation myocardial infarction; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; OAC = oral anticoagulation/anticoagulant;
o.d. = once daily; PCI = percutaneous coronary intervention; PCSK9 = proprotein convertase subtilisin kexin 9; TAT = triple antithrombotic therapy; UFH = unfractionated heparin; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cDoes not apply to patients discharged the same day in whom NSTEMI has been ruled out dIf none of the following criteria: haemodynamically unstable, major arrhythmias, LVEF <40%, failed reperfusion, additional critical coronary stenoses of major vessels, complications related to percutaneous revascularization, or GRACE risk score >140 if assessed.
eIf one or more of the above criteria are present.
fFor patients at very high cardiovascular risk (such as patients with ACS), an LDL-C reduction of at least 50% from baseline and an LDL-C goal <1.4 mmol/L (<55 mg/dL) are recommended.512
ESC Guidelines
1347


<!-- PAGE 60 -->

### Page 60

.............................................................................................................................................................................
Medicine, Haifa, Israel; Julinda Mehilli, Munich University Clinic,
Ludwig-Maximilians
University,
Munich,
Germany;
Emanuele
Meliga, Interventional Cardiology, AO Mauriziano Umberto I, Turin,
Italy; Be´la Merkely, Heart and Vascular Center, Semmelweis
University, Budapest, Hungary; Christian Mueller, Cardiovascular
Research Institute Basel (CRIB) and Cardiology, University Hospital
Basel, University of Basel, Basel, Switzerland; Marco Roffi, Geneva
University Hospitals, Geneva, Switzerland; Frans H. Rutten,
General Practice, Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht, Utrecht University, Utrecht,
Netherlands; Dirk Sibbing, Privatklinik Lauterbacher Mu¨hle am
Ostersee, Munich, Germany; and Ludwig-Maximilians Universit€at
Mu¨nchen, Munich, Germany; George C.M. Siontis, Department of
Cardiology, University Hospital of Bern, Inselspital, Bern, Switzerland.
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Colin Baigent (United Kingdom), Jean-Philippe Collet (France),
Veronica Dean (France), Victoria Delgado (Netherlands), Donna
Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom),
Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway),
Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni
(Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany),
Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S.
Lewis
(Israel),
Be´la
Merkely
(Hungary),
Christian
Mueller
(Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia
Petronio
(Italy),
Dimitrios
J.
Richter
(Greece),
Marco
Roffi
(Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A.
Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Rhian M.
Touyz (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation.
Algeria: Algerian Society of Cardiology, Mohammed Chettibi;
Armenia:
Armenian
Cardiologists
Association,
Hamlet
G.
Hayrapetyan; Austria: Austrian Society of Cardiology, Bernhard
Metzler; Azerbaijan: Azerbaijan Society of Cardiology, Ruslan
Najafov; Belarus: Belorussian Scientific Society of Cardiologists,
Valeriy I. Stelmashok; Belgium: Belgian Society of Cardiology, Marc
Claeys; Bosnia and Herzegovina: Association of Cardiologists of
Bosnia and Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian
Society of Cardiology, Plamen Marinov Gatzov; Croatia: Croatian
Cardiac Society, Bosko
Skoric; Cyprus: Cyprus
Society of
Cardiology, Georgios Panayi; Czech Republic: Czech Society of
Cardiology, Martin Mates; Denmark: Danish Society of Cardiology,
Rikke Sorensen; Egypt: Egyptian Society of Cardiology, Khaled
Shokry; Estonia: Estonian Society of Cardiology, Toomas Marandi;
Finland: Finnish Cardiac Society, Olli A. Kajander; France: French
Society of Cardiology, Philippe Commeau; Georgia: Georgian
Society of Cardiology, Alexander Aladashvili; Germany: German
Cardiac Society, Steffen Massberg; Greece: Hellenic Society of
Cardiology, Dimitrios Nikas; Hungary: Hungarian Society of
Cardiology, David Becker; Iceland: Icelandic Society of Cardiology,
Ingibjo¨rg J. Guðmundsdottir; Ireland: Irish Cardiac Society, Aaron J.
Peace; Israel: Israel Heart Society, Roy Beigel; Italy: Italian
Federation of Cardiology, Ciro Indolfi; Kazakhstan: Association of
Cardiologists of
Kazakhstan,
Nazipa
Aidargaliyeva;
Kosovo
(Republic of): Kosovo Society of Cardiology, Shpend Elezi;
Kyrgyzstan: Kyrgyz Society of Cardiology, Medet Beishenkulov;
Latvia: Latvian Society of Cardiology, Aija Maca; Lithuania:
Lithuanian Society of Cardiology, Olivija Gustiene; Luxembourg:
Luxembourg Society of Cardiology, Philippe Degrell; Malta: Maltese
Cardiac Society, Andrew Cassar Maempel; Moldova (Republic of): Moldavian Society of Cardiology, Victoria Ivanov; Netherlands:
Netherlands
Society of
Cardiology,
Peter
Damman;
North
Macedonia: North Macedonian Society of Cardiology, Sasko
Kedev; Norway: Norwegian Society of Cardiology, Terje K. Steigen;
Poland:
Polish
Cardiac
Society,
Jacek
Legutko;
Portugal:
Portuguese
Society of
Cardiology,
Jo~ao
Morais;
Romania:
Romanian Society of Cardiology, Dragos Vinereanu; Russian
Federation: Russian Society of Cardiology, Dmitry Duplyakov; San
Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia:
Cardiology Society of Serbia, Milan Pavlovic; Slovakia: Slovak
Society of Cardiology, Marek Orban; Slovenia: Slovenian Society of
Cardiology, Matjaz Bunc; Spain: Spanish Society of Cardiology, Borja
Iba~nez; Sweden: Swedish Society of Cardiology, Robin Hofmann;
Switzerland: Swiss Society of Cardiology, Oliver Gaemperli;
Syrian Arab Republic: Syrian Cardiovascular Association, Yassin
Bani Marjeh; Tunisia: Tunisian Society of Cardiology and CardioVascular Surgery, Faouzi Addad; Turkey: Turkish Society of
Cardiology,
Eralp
Tutar;
Ukraine:
Ukrainian
Association of
Cardiology, Alexander Parkhomenko; United Kingdom of Great
Britain and Northern Ireland: British Cardiovascular Society,
Nina Karia.
17 References
01. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger
MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P,
Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, ESC Scientific
Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task
Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology
(ESC). Eur Heart J 2016;37:267315.
02. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio
ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ,
Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, ESC
Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task
Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur
Heart J 2018;39:119177.
03. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD,
ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237269.
04. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML,
Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM,
Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin
Therapy (PURSUIT) Trial Investigators. Circulation 2000;102:11011106.
05. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, Pena-Sing I,
Axel L, Attubato MJ, Yatskar L, Kalhorn RT, Wood DA, Lobach IV, Hochman JS.
Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation 2011;124:14141425.
06. Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson P, McAllister DA,
Strachan FE, Newby DE, Mills NL. Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation 2018;137:12361245.


<!-- PAGE 61 -->

### Page 61

.............................................................................................................................................................................
07. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K,
Breitenbucher D, Sabti Z, Puelacher C, Rubini Gimenez M, Kozhuharov N,
Strebel I, Sazgary L, Schneider D, Jann J, du Fay de Lavallaz J, Miro O, MartinSanchez FJ, Morawiec B, Kawecki D, Muzyk P, Keller DI, Geigy N, Osswald S,
Reichlin T, Mueller C, APACE Investigators. Effect of definition on incidence and prognosis of type 2 myocardial infarction. J Am Coll Cardiol 2017;70:15581568.
08. Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Renne T, Qaderi V, Teltrop
E, Kramer S, Quantius L, Zeller T, Karakas M, Blankenberg S, Westermann D.
Discrimination of patients with type 2 myocardial infarction. Eur Heart J
2017;38:35143520.
09. Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation
2013;127:24522457.
10. Reichlin T, Twerenbold R, Maushart C, Reiter M, Moehring B, Schaub N, Balmelli
C, Rubini Gimenez M, Hoeller R, Sakarikos K, Drexler B, Haaf P, Osswald S,
Mueller C. Risk stratification in patients with unstable angina using absolute serial changes of 3 high-sensitive troponin assays. Am Heart J 2013;165:371378 e373.
11. Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, Sandeman D,
Stables CL, Adamson PD, Andrews JPM, Anwar MS, Hung J, Moss AJ, O’Brien R,
Berry C, Findlay I, Walker S, Cruickshank A, Reid A, Gray A, Collinson PO,
Apple FS, McAllister DA, Maguire D, Fox KAA, Newby DE, Tuck C, Harkess R,
Parker RA, Keerie C, Weir CJ, Mills NL, High-STEACS investigators. Highsensitivity troponin in the evaluation of patients with suspected acute coronary syndrome:
a stepped-wedge,
cluster-randomised controlled trial.
Lancet
2018;392:919928.
12. Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J
2014;35:552556.
13. Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, Winkler K,
Kurz S, Stelzig C, Freese M, Drexler B, Haaf P, Zellweger C, Osswald S, Mueller
C. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med 2012;125:12051213 e1201.
14. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH,
Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS,
Braunwald E, TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:24052412.
15. Eggers KM, Jernberg T, Lindahl B. Unstable angina in the era of cardiac troponin assays with improved sensitivity-A
clinical dilemma.
Am
J
Med
2017;130:14231430 e1425.
16. Eggers KM, Jernberg T, Lindhagen L, Lindahl B. High-sensitivity cardiac troponin
T levels identify patients with non-st-segment elevation acute coronary syndrome who benefit from invasive assessment.
JACC
Cardiovasc
Interv
2018;11:16651667.
17. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013;368:20042013.
18. Puelacher C, Gugala M, Adamson PD, Shah A, Chapman AR, Anand A, Sabti Z,
Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Rubini
Gimenez M, Shrestha S, Sazgary L, Mueller D, Schumacher L, Kozhuharov N,
Flores D, du Fay de Lavallaz J, Miro O, Martin-Sanchez FJ, Morawiec B, Fahrni G,
Osswald S, Reichlin T, Mills NL, Mueller C. Incidence and outcomes of unstable angina compared with non-ST-elevation myocardial infarction.
Heart
2019;105:14231431.
19. Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP,
Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S,
Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK, study group PLATO.
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized
Platelet
Inhibition and
Patient
Outcomes
(PLATO)
trial.
Circulation
2014;129:293303.
20. Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, Lemesle G, Motreff P,
Popovic B, Khalife K, Labeque JN, Perret T, Le Ray C, Orion L, Jouve B,
Blanchard D, Peycher P, Silvain J, Steg PG, Goldstein P, Gueret P, Belle L,
Aissaoui N, Ferrieres J, Schiele F, Danchin N, USIK, USIC 2000, and FAST-MI
investigators. Acute myocardial infarction: changes in patient characteristics,
management, and 6-month outcomes over a period of 20 years in the FAST-MI
program
(French
Registry of
Acute
ST-Elevation or
Non-ST-Elevation
Myocardial Infarction) 1995 to 2015. Circulation 2017;136:19081919.
21. Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV, Jr., Kirk JD, Smith
SC, Jr., Gibler WB, Ohman EM, Blomkalns AL, Newby LK, Hochman JS, Peterson
ED, Roe MT. Frequency and consequences of recording an electrocardiogram
>10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). Am J Cardiol
2006;97:437442.
22. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A,
Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S, Euro Heart
Survey Investigators. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006;27:22852293.
23. Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of STelevation myocardial infarction in the presence of left bundle branch block with the ST-elevation to S-wave ratio in a modified Sgarbossa rule. Ann Emerg Med
2012;60:766776.
24. Nestelberger T, Cullen L, Lindahl B, Reichlin T, Greenslade JH, Giannitsis E,
Christ M, Morawiec B, Miro O, Martin-Sanchez FJ, Wussler DN, Koechlin L,
Twerenbold R, Parsonage W, Boeddinghaus J, Rubini Gimenez M, Puelacher C,
Wildi K, Buerge T, Badertscher P, DuFaydeLavallaz J, Strebel I, Croton L, Bendig
G, Osswald S, Pickering JW, Than M, Mueller C, APACE, ADAPT and TRAPIDAMI Investigators. Diagnosis of acute myocardial infarction in the presence of left bundle branch block. Heart 2019;105:15591567.
25. Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Schafer S, Keller T,
Blankenberg S, Clemmensen P, Westermann D. Right bundle branch block in patients with suspected myocardial infarction. Eur Heart J Acute Cardiovasc Care
2019;8:161166.
26. Abacherli R, Twerenbold R, Boeddinghaus J, Nestelberger T, Machler P, Sassi R,
Rivolta MW, Roonizi EK, Mainardi LT, Kozhuharov N, Rubini Gimenez M, Wildi
K, Grimm K, Sabti Z, Hillinger P, Puelacher C, Strebel I, Cupa J, Badertscher P,
Roux I, Schmid R, Leber R, Osswald S, Mueller C, Reichlin T. Diagnostic and prognostic values of the V-index, a novel ECG marker quantifying spatial heterogeneity of ventricular repolarization, in patients with symptoms suggestive of non-ST-elevation myocardial infarction. Int J Cardiol 2017;236:2329.
27. Strebel I, Twerenbold R, Boeddinghaus J, Abacherli R, Rubini Gimenez M, Wildi
K, Grimm K, Puelacher C, Badertscher P, Sabti Z, Breitenbucher D, Jann J,
Selman F, du Fay de Lavallaz J, Schaerli N, Nestelberger T, Stelzig C, Freese M,
Schumacher L, Osswald S, Mueller C, Reichlin T. Diagnostic value of the cardiac electrical biomarker, a novel ECG marker indicating myocardial injury, in patients with symptoms suggestive of non-ST-elevation myocardial infarction. Ann
Noninvasive Electrocardiol 2018;23:e12538.
28. Strebel I, Twerenbold R, Wussler D, Boeddinghaus J, Nestelberger T, du Fay de
Lavallaz J, Abacherli R, Maechler P, Mannhart D, Kozhuharov N, Rubini Gimenez
M, Wildi K, Sazgary L, Sabti Z, Puelacher C, Badertscher P, Keller DI, Miro O,
Fuenzalida C, Calderon S, Martin-Sanchez FJ, Iglesias SL, Osswald S, Mueller C,
Reichlin T. Incremental diagnostic and prognostic value of the QRS-T angle, a
12-lead ECG marker quantifying heterogeneity of depolarization and repolarization, in patients with suspected non-ST-elevation myocardial infarction. Int J
Cardiol 2019;277:815.
29. Mueller C, Giannitsis E, Mockel M, Huber K, Mair J, Plebani M, Thygesen K, Jaffe
AS, Lindahl B, Biomarker Study Group of the ESC Acute Cardiovascular Care
Association. Rapid rule out of acute myocardial infarction: novel biomarkerbased strategies. Eur Heart J Acute Cardiovasc Care 2017;6:218222.
30. Mockel M, Giannitsis E, Mueller C, Huber K, Jaffe AS, Mair J, Plebani M, Thygesen K,
Lindahl B, Biomarker Study Group of the European Society of Cardiology Acute
Cardiovascular Care Association. Editor’s choice-rule-in of acute myocardial infarction: focus on troponin. Eur Heart J Acute Cardiovasc Care 2017;6:212217.
31. Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S,
Blankenberg S, Brueckmann M, Collinson P, Comaniciu D, Crea F, Dinh W,
Ducrocq G, Flachskampf FA, Fox KAA, Friedrich MG, Hebert KA, Himmelmann
A, Hlatky M, Lautsch D, Lindahl B, Lindholm D, Mills NL, Minotti G, Mockel M,
Omland T, Semjonow V. Early diagnosis of acute coronary syndrome. Eur Heart J
2017;38:30493055.
32. Giannitsis E, Mair J, Christersson C, Siegbahn A, Huber K, Jaffe AS, Peacock WF,
Plebani M, Thygesen K, Mockel M, Mueller C, Lindahl B, Biomarker Study Group of the European Society of Cardiology (ESC) Acute Cardiovascular Care
Association (ACCA). How to use D-dimer in acute cardiovascular care. Eur
Heart J Acute Cardiovasc Care 2017;6:6980.
33. Neumann JT, Twerenbold R, Ojeda F, Sorensen NA, Chapman AR, Shah ASV,
Anand A, Boeddinghaus J, Nestelberger T, Badertscher P, Mokhtari A, Pickering
JW, Troughton RW, Greenslade J, Parsonage W, Mueller-Hennessen M, Gori T,
Jernberg T, Morris N, Liebetrau C, Hamm C, Katus HA, Munzel T, Landmesser
U, Salomaa V, Iacoviello L, Ferrario MM, Giampaoli S, Kee F, Thorand B, Peters
A, Borchini R, Jorgensen T, Soderberg S, Sans S, Tunstall-Pedoe H, Kuulasmaa K,
Renne T, Lackner KJ, Worster A, Body R, Ekelund U, Kavsak PA, Keller T,
Lindahl B, Wild P, Giannitsis E, Than M, Cullen LA, Mills NL, Mueller C, Zeller T,
Westermann D, Blankenberg S. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med 2019;380:25292540.
34. Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease.
Nat
Rev
Cardiol
2017;14:472483.
35. Twerenbold R, Badertscher P, Boeddinghaus J, Nestelberger T, Wildi K,
Puelacher C, Sabti Z, Rubini Gimenez M, Tschirky S, du Fay de Lavallaz J,
Kozhuharov N, Sazgary L, Mueller D, Breidthardt T, Strebel I, Flores Widmer D,
Shrestha S, Miro O, Martin-Sanchez FJ, Morawiec B, Parenica J, Geigy N, Keller
ESC Guidelines
1349


<!-- PAGE 62 -->

### Page 62

.............................................................................................................................................................................
DI, Rentsch K, von Eckardstein A, Osswald S, Reichlin T, Mueller C. 0/1-hour triage algorithm for myocardial infarction in patients with renal dysfunction.
Circulation 2018;137:436451.
36. Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B,
Giannitsis E, Sorensen NA, Badertscher P, Jann JE, Wussler D, Puelacher C,
Rubini Gimenez M, Wildi K, Strebel I, Du Fay de Lavallaz J, Selman F, Sabti Z,
Kozhuharov N, Potlukova E, Rentsch K, Miro O, Martin-Sanchez FJ, Morawiec B,
Parenica J, Lohrmann J, Kloos W, Buser A, Geigy N, Keller DI, Osswald S,
Reichlin T, Westermann D, Blankenberg S, Mueller C, APACE, BACC, and
TRAPID-AMI Investigators. Impact of age on the performance of the ESC 0/1halgorithms for early diagnosis of myocardial infarction.
Eur
Heart
J
2018;39:37803794.
37. Boeddinghaus J, Twerenbold R, Nestelberger T, Koechlin L, Wussler D, Meier
M, Troester V, Zimmermann T, Badertscher P, Wildi K, Gimenez Rubini, LopezAyala, M, Potlukova, P, Miro, E, Martin-Sanchez, O, Kawecki, FJ, Geigy, D, Keller,
N, Reichlin, DI, Mueller, T, APACE Investigators, C. Clinical use of a new highsensitivity cardiac troponin i assay in patients with suspected myocardial infarction. Clin Chem 2019;65:14261436.
38. Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M,
Zellweger C, Moehring B, Stallone F, Sou SM, Mueller M, Denhaerynck K,
Mosimann T, Reiter M, Meller B, Freese M, Stelzig C, Klimmeck I, Voegele J,
Hartmann B, Rentsch K, Osswald S, Mueller C. Direct comparison of highsensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J 2014;35:23032311.
39. Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Wildi K,
Puelacher C, du Fay de Lavallaz J, Keser E, Rubini Gimenez M, Wussler D,
Kozhuharov N, Rentsch K, Miro O, Martin-Sanchez FJ, Morawiec B, Stefanelli S,
Geigy N, Keller DI, Reichlin T, Mueller C, APACE Investigators. Clinical validation of a novel high-sensitivity cardiac troponin i assay for early diagnosis of acute myocardial infarction. Clin Chem 2018;64:13471360.
40. Boeddinghaus J, Nestelberger T, Twerenbold R, Koechlin L, Meier M, Troester
V, Wussler D, Badertscher P, Wildi K, Puelacher C, du Fay de Lavallaz J, Rubini
Gimenez M, Zimmermann T, Hafner B, Potlukova E, Miro O, Martin-Sanchez FJ,
Keller DI, Reichlin T, Mueller C, APACE Investigators. High-sensitivity cardiac troponin I assay for early diagnosis of acute myocardial infarction. Clin Chem
2019;65:893904.
41. Collinson PO, Saenger AK, Apple FS, IFCC C-CB. High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the
IFCC Committee on Clinical Application of Cardiac Bio-Markers. Clin Chem Lab
Med 2019;57:623632.
42. Pickering JW, Young JM, George PM, Watson AS, Aldous SJ, Troughton RW,
Pemberton CJ, Richards AM, Cullen LA, Than MP. Validity of a novel point-ofcare troponin assay for single-test rule-out of acute myocardial infarction. JAMA
Cardiol 2018;3:11081112.
43. Sorensen NA, Neumann JT, Ojeda F, Giannitsis E, Spanuth E, Blankenberg S,
Westermann D, Zeller T. Diagnostic evaluation of a high-sensitivity troponin I
point-of-care assay. Clin Chem 2019;65:15921601.
44. Boeddinghaus J, Nestelberger T, Koechlin L, Wussler D, Lopez-Ayala P, Walter
JE, Troester V, Ratmann PD, Seidel F, Zimmermann T, Badertscher P, Wildi K,
Rubini Gimenez M, Potlukova E, Strebel I, Freese M, Miro O, Martin-Sanchez FJ,
Kawecki D, Keller DI, Gualandro DM, Christ M, Twerenbold R, Mueller C,
APACE Investigators. Early diagnosis of myocardial infarction with point-of-care high-sensitivity cardiac troponin I. J Am Coll Cardiol 2020;75:11111124.
45. Eggers KM, Jernberg T, Lindahl B. Cardiac troponin elevation in patients without a specific diagnosis. J Am Coll Cardiol 2019;73:19.
46. Kaier TE, Twerenbold R, Puelacher C, Marjot J, Imambaccus N, Boeddinghaus J,
Nestelberger T, Badertscher P, Sabti Z, Gimenez MR, Wildi K, Hillinger P,
Grimm K, Loeffel S, Shrestha S, Widmer DF, Cupa J, Kozhuharov N, Miro O,
Martin-Sanchez FJ, Morawiec B, Rentsch K, Lohrmann J, Kloos W, Osswald S,
Reichlin T, Weber E, Marber M, Mueller C. Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction. Circulation 2017;136:14951508.
47. Boeddinghaus J, Reichlin T, Nestelberger T, Twerenbold R, Meili Y, Wildi K,
Hillinger P, Gimenez MR, Cupa J, Schumacher L, Schubera M, Badertscher P,
Corbiere S, Grimm K, Puelacher C, Sabti Z, Widmer DF, Schaerli N,
Kozhuharov N, Shrestha S, Burge T, Machler P, Buchi M, Rentsch K, Miro O,
Lopez B, Martin-Sanchez FJ, Rodriguez-Adrada E, Morawiec B, Kawecki D,
Ganovska E, Parenica J, Lohrmann J, Buser A, Keller DI, Osswald S, Mueller C.
Early diagnosis of acute myocardial infarction in patients with mild elevations of cardiac troponin. Clin Res Cardiol 2017;106:457467.
48. Hillinger P, Twerenbold R, Jaeger C, Wildi K, Reichlin T, Rubini Gimenez M,
Engels U, Miro O, Boeddinghaus J, Puelacher C, Nestelberger T, Rothlisberger
M, Ernst S, Rentsch K, Mueller C. Optimizing early rule-out strategies for acute myocardial infarction: utility of 1-hour copeptin. Clin Chem 2015;61:14661474.
49. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C,
Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O,
Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF,
Blankenberg S. Copeptin improves early diagnosis of acute myocardial infarction.
J Am Coll Cardiol 2010;55:20962106.
50. Mockel M, Searle J, Hamm C, Slagman A, Blankenberg S, Huber K, Katus H,
Liebetrau C, Muller C, Muller R, Peitsmeyer P, von Recum J, Tajsic M, Vollert JO,
Giannitsis E. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 2015;36:369376.
51. Mueller C, Mockel M, Giannitsis E, Huber K, Mair J, Plebani M, Thygesen K,
Jaffe AS, Lindahl B, Study ESC Group on Biomarkers in Cardiology of the
Acute Cardiovascular Care Association. Use of copeptin for rapid rule-out of acute myocardial infarction.
Eur
Heart
J
Acute
Cardiovasc
Care
2018;7:570576.
52. Mueller-Hennessen M, Lindahl B, Giannitsis E, Vafaie M, Biener M, Haushofer
AC, Seier J, Christ M, Alquezar-Arbe A, deFilippi CR, McCord J, Body R,
Panteghini M, Jernberg T, Plebani M, Verschuren F, French JK, Christenson RH,
Dinkel C, Katus HA, Mueller C. Combined testing of copeptin and highsensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. Int J Cardiol 2019;276:261267.
53. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG,
Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T,
Merki R, Schaub N, Bingisser R, Christ M, Mueller C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol
2009;54:6068.
54. Stallone F, Schoenenberger AW, Puelacher C, Rubini Gimenez M, Walz B,
Naduvilekoot Devasia A, Bergner M, Twerenbold R, Wildi K, Reichlin T,
Hillinger P, Erne P, Mueller C. Incremental value of copeptin in suspected acute myocardial infarction very early after symptom onset. Eur Heart J Acute
Cardiovasc Care 2016;5:407415.
55. Vargas KG, Kassem M, Mueller C, Wojta J, Huber K. Copeptin for the early ruleout of non-ST-elevation myocardial infarction. Int J Cardiol 2016;223:797804.
56. Wildi K, Boeddinghaus J, Nestelberger T, Twerenbold R, Badertscher P, Wussler
D, Gimenez MR, Puelacher C, du Fay de Lavallaz J, Dietsche S, Walter J,
Kozhuharov N, Morawiec B, Miro O, Javier Martin-Sanchez F, Subramaniam S,
Geigy N, Keller DI, Reichlin T, Mueller C, APACE investigators. Comparison of fourteen rule-out strategies for acute myocardial infarction. Int J Cardiol
2019;283:4147.
57. Wildi K, Zellweger C, Twerenbold R, Jaeger C, Reichlin T, Haaf P, Faoro J,
Gimenez MR, Fischer A, Nelles B, Druey S, Krivoshei L, Hillinger P, Puelacher C,
Herrmann T, Campodarve I, Rentsch K, Steuer S, Osswald S, Mueller C.
Incremental value of copeptin to highly sensitive cardiac Troponin I for rapid rule-out of myocardial infarction. Int J Cardiol 2015;190:170176.
58. Zellweger C, Wildi K, Twerenbold R, Reichlin T, Naduvilekoot A, Neuhaus JD,
Balmelli C, Gabutti M, Al Afify A, Ballarino P, Jager C, Druey S, Hillinger P, Haaf
P, Vilaplana C, Darbouret B, Ebmeyer S, Rubini Gimenez M, Moehring B,
Osswald S, Mueller C. Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction. Int J Cardiol 2015;190:190197.
59. Kavsak PA, Neumann JT, Cullen L, Than M, Shortt C, Greenslade JH, Pickering
JW, Ojeda F, Ma J, Clayton N, Sherbino J, Hill SA, McQueen M, Westermann D,
Sorensen NA, Parsonage WA, Griffith L, Mehta SR, Devereaux PJ, Richards M,
Troughton R, Pemberton C, Aldous S, Blankenberg S, Worster A. Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department. CMAJ 2018;190:E974E984.
60. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP,
Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit
M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P,
Righini M, Torbicki A, Van Belle E, Zamorano JL, ESC Scientific Document
Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory
Society (ERS). Eur Heart J 2020;41:543603.
61. Ambavane A, Lindahl B, Giannitsis E, Roiz J, Mendivil J, Frankenstein L, Body R,
Christ M, Bingisser R, Alquezar A, Mueller C, TRAPID-AMI investigators.
Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department. PLoS One 2017;12:e0187662.
62. Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa
J, Burge T, Machler P, Corbiere S, Grimm K, Gimenez MR, Puelacher C,
Shrestha S, Flores Widmer D, Fuhrmann J, Hillinger P, Sabti Z, Honegger U,
Schaerli N, Kozhuharov N, Rentsch K, Miro O, Lopez B, Martin-Sanchez FJ,
Rodriguez-Adrada E, Morawiec B, Kawecki D, Ganovska E, Parenica J,
Lohrmann J, Kloos W, Buser A, Geigy N, Keller DI, Osswald S, Reichlin T,
Mueller C. Direct comparison of 4 very early rule-out strategies for acute myocardial infarction using high-sensitivity cardiac troponin I. Circulation
2017;135:15971611.


<!-- PAGE 63 -->

### Page 63

.............................................................................................................................................................................
63. Ljung L, Lindahl B, Eggers KM, Frick M, Linder R, Lofmark HB, Martinsson A,
Melki D, Sarkar N, Svensson P, Jernberg T. A rule-out strategy based on highsensitivity troponin and HEART score reduces hospital admissions. Ann Emerg
Med 2019;73:491499.
64. Odqvist M, Andersson PO, Tygesen H, Eggers KM, Holzmann MJ. High-sensitivity troponins and outcomes after myocardial infarction.
J
Am
Coll
Cardiol
2018;71:26162624.
65. Twerenbold R, Jaeger C, Rubini Gimenez M, Wildi K, Reichlin T, Nestelberger T,
Boeddinghaus J, Grimm K, Puelacher C, Moehring B, Pretre G, Schaerli N,
Campodarve I, Rentsch K, Steuer S, Osswald S, Mueller C. Impact of highsensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. Eur Heart J
2016;37:33243332.
66. Stoyanov KM, Hund H, Biener M, Gandowitz J, Riedle C, Lohr J, MuellerHennessen M, Vafaie M, Katus HA, Giannitsis E. RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction.
Eur
Heart
J
Acute
Cardiovasc
Care
2020;9:3951.
67. Mueller C, Giannitsis E, Christ M, Ordonez-Llanos J, deFilippi C, McCord J, Body
R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French J, Christenson R,
Weiser S, Bendig G, Dilba P, Lindahl B, Investigators TRAPID-AMI. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T. Ann Emerg Med 2016;68:7687 e74.
68. Neumann JT, Sorensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, Schaefer
S, Waldeyer C, Sinning C, Renne T, Than M, Parsonage W, Wildi K, Makarova
N, Schnabel RB, Landmesser U, Mueller C, Cullen L, Greenslade J, Zeller T,
Blankenberg S, Karakas M, Westermann D. Diagnosis of myocardial infarction using a
high-sensitivity troponin
I
1-hour algorithm.
JAMA
Cardiol
2016;1:397404.
69. Twerenbold R, Neumann JT, Sorensen NA, Ojeda F, Karakas M, Boeddinghaus J,
Nestelberger T, Badertscher P, Rubini Gimenez M, Puelacher C, Wildi K,
Kozhuharov N, Breitenbuecher D, Biskup E, du Fay de Lavallaz J, Flores D,
Wussler D, Miro O, Martin Sanchez FJ, Morawiec B, Parenica J, Geigy N, Keller
DI, Zeller T, Reichlin T, Blankenberg S, Westermann D, Mueller C. Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarction. J Am
Coll Cardiol 2018;72:620632.
70. Wildi K, Nelles B, Twerenbold R, Rubini Gimenez M, Reichlin T, Singeisen H,
Druey S, Haaf P, Sabti Z, Hillinger P, Jaeger C, Campodarve I, Kreutzinger P,
Puelacher C, Moreno Weidmann Z, Gugala M, Pretre G, Doerflinger S, Wagener
M, Stallone F, Freese M, Stelzig C, Rentsch K, Bassetti S, Bingisser R, Osswald S,
Mueller C. Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. Am Heart J 2016;181:1625.
71. Badertscher P, Boeddinghaus J, Twerenbold R, Nestelberger T, Wildi K, Wussler
D, Schwarz J, Puelacher C, Gimenez Rubini, Kozhuharov, M, du Fay de Lavallaz,
N, Cerminara, J, Potlukova, SE, Rentsch, E, Miro, K, Lopez, O, Martin-Sanchez, B,
Morawiec, FJ, Muzyk, B, Keller, P, Reichlin, DI, Mueller, T, APACE Investigators,
C. Direct comparison of the 0/1h and 0/3h algorithms for early rule-out of acute myocardial infarction. Circulation 2018;137:25362538.
72. Chapman AR, Anand A, Boeddinghaus J, Ferry AV, Sandeman D, Adamson PD,
Andrews J, Tan S, Cheng SF, D’Souza M, Orme K, Strachan FE, Nestelberger T,
Twerenbold R, Badertscher P, Reichlin T, Gray A, Shah ASV, Mueller C, Newby
DE, Mills NL. Comparison of the efficacy and safety of early rule-out pathways for acute myocardial infarction. Circulation 2017;135:15861596.
73. Chapman AR, Fujisawa T, Lee KK, Andrews JP, Anand A, Sandeman D, Ferry AV,
Stewart S, Marshall L, Strachan FE, Gray A, Newby DE, Shah ASV, Mills NL.
Novel high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syndrome. Heart 2019;105:616622.
74. Chew DP, Lambrakis K, Blyth A, Seshadri A, Edmonds MJR, Briffa T, Cullen LA,
Quinn S, Karnon J, Chuang A, Nelson AJ, Wright D, Horsfall M, Morton E,
French JK, Papendick C. A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible Acute
Coronary Syndrome in the Emergency Department With High-Sensitivity
Troponin T Study (RAPID-TnT). Circulation 2019;140:15431556.
75. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H,
Bassetti S, Steuer S, Winkler K, Peter F, Meissner J, Haaf P, Potocki M, Drexler B,
Osswald S, Mueller C. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation
2011;124:136145.
76. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C,
Moehring B, Ziller R, Hoeller R, Rubini Gimenez M, Haaf P, Potocki M, Wildi K,
Balmelli C, Freese M, Stelzig C, Freidank H, Osswald S, Mueller C. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med 2012;172:12111218.
77. Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Schock A, Seddighizadeh P, Zeller
T, Westermann D, Blankenberg S. Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myocardial infarction. Int J Cardiol 2019;283:3540.
78. Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH, Parsonage WA, Hammett
C, Pickering JW, Hawkins T, Aldous S, Twerenbold R, Wildi K, Nestelberger T,
Grimm K, Rubini-Gimenez M, Puelacher C, Kern V, Rentsch K, Than M, Mueller
C. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction by use of high-sensitivity cardiac troponin
I.
Clin
Chem
2016;62:494504.
79. Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W,
Worster A, Kavsak PA, Blankenberg S, Neumann J, Sorensen NA, Westermann
D, Buijs MM, Verdel GJE, Pickering JW, Than MP, Twerenbold R, Badertscher P,
Sabti Z, Mueller C, Anand A, Adamson P, Strachan FE, Ferry A, Sandeman D,
Gray A, Body R, Keevil B, Carlton E, Greaves K, Korley FK, Metkus TS, Sandoval
Y, Apple FS, Newby DE, Shah ASV, Mills NL. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. JAMA 2017;318:19131924.
80. Greenslade J, Cho E, Van Hise C, Hawkins T, Parsonage W, Ungerer J, Tate J,
Pretorius C, Than M, Cullen L. Evaluating rapid rule-out of acute myocardial infarction using a high-sensitivity cardiac troponin I assay at presentation. Clin
Chem 2018;64:820829.
81. Pickering JW, Than MP, Cullen L, Aldous S, Ter Avest E, Body R, Carlton EW,
Collinson P, Dupuy AM, Ekelund U, Eggers KM, Florkowski CM, Freund Y,
George P, Goodacre S, Greenslade JH, Jaffe AS, Lord SJ, Mokhtari A, Mueller C,
Munro A, Mustapha S, Parsonage W, Peacock WF, Pemberton C, Richards AM,
Sanchis J, Staub LP, Troughton R, Twerenbold R, Wildi K, Young J. Rapid ruleout of acute myocardial infarction with a single high-sensitivity cardiac troponin
T measurement below the limit of detection: a collaborative meta-analysis. Ann
Intern Med 2017;166:715724.
82. Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, Chapman AR,
Langdon T, Sandeman D, Vaswani A, Strachan FE, Ferry A, Stirzaker AG, Reid A,
Gray AJ, Collinson PO, McAllister DA, Apple FS, Newby DE, Mills NL, HighSTEACS investigators. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet
2015;386:24812488.
83. Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus J,
Nestelberger T, Sabti Z, Rubini-Gimenez M, Puelacher C, Cupa J, Schumacher L,
Badertscher P, Grimm K, Kozhuharov N, Stelzig C, Freese M, Rentsch K,
Lohrmann J, Kloos W, Buser A, Reichlin T, Pickering JW, Than M, Mueller C.
Direct comparison of 2 rule-out strategies for acute myocardial infarction: 2-h accelerated diagnostic protocol vs 2-h algorithm. Clin Chem 2017;63:12271236.
84. Nestelberger T, Boeddinghaus J, Greenslade J, Parsonage WA, Than M, Wussler
D, Lopez-Ayala P, Zimmermann T, Meier M, Troester V, Badertscher P, Koechlin
L, Wildi K, Anwar M, Freese M, Keller DI, Reichlin T, Twerenbold R, Cullen L,
Mueller C, APACE and ADAPT Investigators. Two-hour algorithm for rapid triage of suspected acute myocardial infarction using a high-sensitivity cardiac troponin I assay. Clin Chem 2019;65:14371447.
85. Nestelberger T, Wildi K, Boeddinghaus J, Twerenbold R, Reichlin T, Gimenez
MR, Puelacher C, Jaeger C, Grimm K, Sabti Z, Hillinger P, Kozhuharov N, du Fay de Lavallaz J, Pinck F, Lopez B, Salgado E, Miro O, Bingisser R, Lohrmann J,
Osswald S, Mueller C. Characterization of the observe zone of the ESC 2015
high-sensitivity cardiac troponin 0h/1h-algorithm for the early diagnosis of acute myocardial infarction. Int J Cardiol 2016;207:238245.
86. Hammarsten O, Fu ML, Sigurjonsdottir R, Petzold M, Said L, Landin-Wilhelmsen
K, Widgren B, Larsson M, Johanson P. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem 2012;58:628637.
87. Azmy C, Guerard S, Bonnet X, Gabrielli F, Skalli W. EOS orthopaedic imaging system to study patellofemoral kinematics: assessment of uncertainty. Orthop
Traumatol Surg Res 2010;96:2836.
88. Hillinger P, Twerenbold R, Wildi K, Rubini Gimenez M, Jaeger C, Boeddinghaus J,
Nestelberger T, Grimm K, Reichlin T, Stallone F, Puelacher C, Sabti Z,
Kozhuharov N, Honegger U, Ballarino P, Miro O, Denhaerynck K, Ekrem T,
Kohler C, Bingisser R, Osswald S, Mueller C. Gender-specific uncertainties in the diagnosis of acute coronary syndrome. Clin Res Cardiol 2017;106:2837.
89. Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, Farrah
T, Halbesma N, Blackmur JP, Newby DE, Mills NL, Dhaun N. High-sensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. Circulation 2018;137:425435.
90. Rubini Gimenez M, Badertscher P, Twerenbold R, Boeddinghaus J, Nestelberger
T, Wussler D, Miro O, Martin-Sanchez FJ, Reichlin T, Mueller C. Impact of the
US food and drug administration-approved sex-specific cutoff values for highsensitivity cardiac troponin T to diagnose myocardial infarction. Circulation
2018;137:18671869.
91. Rubini Gimenez M, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C,
Hillinger P, Wildi K, Jaeger C, Grimm K, Heitzelmann KF, Sabti Z, Badertscher P,
Cupa J, Honegger U, Schaerli N, Kozhuharov N, du Fay de Lavallaz J, Lopez B,
Salgado E, Miro O, Martin-Sanchez FJ, Adrada ER, Morawiec B, Parenica J,
Ganovska E, Neugebauer C, Rentsch K, Lohrmann J, Osswald S, Reichlin T,
ESC Guidelines
1351


<!-- PAGE 64 -->

### Page 64

.............................................................................................................................................................................
Mueller C. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction. JAMA Cardiol 2016;1:912920.
92. Mueller-Hennessen M, Lindahl B, Giannitsis E, Biener M, Vafaie M, deFilippi CR,
Christ M, Santalo-Bel M, Panteghini M, Plebani M, Verschuren F, Jernberg T,
French JK, Christenson RH, Body R, McCord J, Dilba P, Katus HA, Mueller C,
TRAPID-AMI Investigators. Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T - sub-analysis from the TRAPID-AMI study. Int J Cardiol 2016;209:2633.
93. Sorensen NA, Neumann JT, Ojeda F, Schafer S, Magnussen C, Keller T, Lackner
KJ, Zeller T, Karakas M, Munzel T, Blankenberg S, Westermann D, Schnabel RB.
Relations of sex to diagnosis and outcomes in acute coronary syndrome. J Am
Heart Assoc 2018;7:e007297.
94. Dahlslett T, Karlsen S, Grenne B, Eek C, Sjoli B, Skulstad H, Smiseth OA,
Edvardsen T, Brunvand H. Early assessment of strain echocardiography can accurately exclude significant coronary artery stenosis in suspected non-ST-segment elevation acute coronary syndrome. J Am Soc Echocardiogr 2014;27:512519.
95. Grenne B, Eek C, Sjoli B, Dahlslett T, Uchto M, Hol PK, Skulstad H, Smiseth OA,
Edvardsen T, Brunvand H. Acute coronary occlusion in non-ST-elevation acute coronary syndrome: outcome and early identification by strain echocardiography. Heart 2010;96:15501556.
96. Lancellotti P, Price S, Edvardsen T, Cosyns B, Neskovic AN, Dulgheru R,
Flachskampf FA, Hassager C, Pasquet A, Gargani L, Galderisi M, Cardim N,
Haugaa KH, Ancion A, Zamorano JL, Donal E, Bueno H, Habib G. The use of echocardiography in acute cardiovascular care:
recommendations of the
European Association of Cardiovascular Imaging and the Acute Cardiovascular
Care Association. Eur Heart J Acute Cardiovasc Care 2015;4:35.
97. Price S, Platz E, Cullen L, Tavazzi G, Christ M, Cowie MR, Maisel AS, Masip J,
Miro O, McMurray JJ, Peacock WF, Martin-Sanchez FJ, Di Somma S, Bueno H,
Zeymer U, Mueller C, Acute Heart Failure Study Group of the European Society of Cardiology Acute Cardiovascular Care Association. Expert consensus document: echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nat Rev Cardiol 2017;14:427440.
98. Fox K, Achenbach S, Bax J, Cosyns B, Delgado V, Dweck MR, Edvardsen T,
Flachskampf F, Habib G, Lancellotti P, Muraru D, Neglia D, Pontone G,
Schwammenthal E, Sechtem U, Westwood M, Popescu BA. Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality
Imaging of the European Association of Cardiovascular Imaging. Eur Heart J
2019;40:553558.
99. Shah BN, Balaji G, Alhajiri A, Ramzy IS, Ahmadvazir S, Senior R. Incremental diagnostic and prognostic value of contemporary stress echocardiography in a chest pain unit: mortality and morbidity outcomes from a real-world setting. Circ
Cardiovasc Imaging 2013;6:202209.
100. Sicari
R,
Nihoyannopoulos
P,
Evangelista
A,
Kasprzak
J,
Lancellotti
P,
Poldermans
D,
Voigt
JU,
Zamorano
JL,
European
Association of
Echocardiography.
Stress
Echocardiography
Expert
Consensus
StatementExecutive Summary: European Association of Echocardiography
(EAE) (a registered branch of the ESC). Eur Heart J 2009;30:278289.
101. Gaibazzi
N,
Reverberi
C,
Badano
L.
Usefulness of contrast stressechocardiography or exercise-electrocardiography to predict long-term acute coronary syndromes in patients presenting with chest pain without electrocardiographic abnormalities or
12-hour troponin elevation.
Am
J
Cardiol
2011;107:161167.
102. Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL,
Nihoyannopoulos P, Edvardsen T, Lancellotti P, EACVI Scientific Documents
Committee for
201416
and
201618,
EACVI
Scientific
Documents
Committee for 201416 and 201618. Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular
Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 2017;18:12051205af.
103. Senior R, Moreo A, Gaibazzi N, Agati L, Tiemann K, Shivalkar B, von
Bardeleben S, Galiuto L, Lardoux H, Trocino G, Carrio I, Le Guludec D,
Sambuceti G, Becher H, Colonna P, Ten Cate F, Bramucci E, Cohen A, Bezante
G, Aggeli C, Kasprzak JD. Comparison of sulfur hexafluoride microbubble
(SonoVue)-enhanced myocardial contrast echocardiography with gated singlephoton emission computed tomography for detection of significant coronary artery disease:
a large
European multicenter study. J
Am
Coll
Cardiol
2013;62:13531361.
104. Ingkanisorn WP, Kwong RY, Bohme NS, Geller NL, Rhoads KL, Dyke CK,
Paterson DI, Syed MA, Aletras AH, Arai AE. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol 2006;47:14271432.
105. Smulders MW, Kietselaer BLJH, Wildberger JE, Dagnelie PC, Brunner-La Rocca
HP, Mingels AMA, van Cauteren YJM, Theunissen RALJ, Post MJ, Schalla S, van
Kuijk SMJ, Das M, Kim RJ, Crijns HJGM, Bekkers SCAM. Initial imaging-guided strategy versus routine care in patients with non-st-segment elevation myocardial infarction. J Am Coll Cardiol 2019;74:24662477.
106. Lim SH, Anantharaman V, Sundram F, Chan ES, Ang ES, Yo SL, Jacob E, Goh A,
Tan SB, Chua T. Stress myocardial perfusion imaging for the evaluation and triage of chest pain in the emergency department: a randomized controlled trial. J
Nucl Cardiol 2013;20:10021012.
107. Nabi F, Kassi M, Muhyieddeen K, Chang SM, Xu J, Peterson LE, Wray NP,
Shirkey BA, Ashton CM, Mahmarian JJ. Optimizing evaluation of patients with low-to-intermediate-risk acute chest pain: a randomized study comparing stress myocardial perfusion tomography incorporating stress-only imaging versus cardiac CT. J Nucl Med 2016;57:378384.
108. Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, Douglas PS.
A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. J Nucl Cardiol 2012;19:364376.
109. Siontis GC, Mavridis D, Greenwood JP, Coles B, Nikolakopoulou A, Juni P,
Salanti G, Windecker S. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ 2018;360:k504.
110. Goldstein JA, Chinnaiyan KM, Abidov A, Achenbach S, Berman DS, Hayes SW,
Hoffmann U, Lesser JR, Mikati IA, O’Neil BJ, Shaw LJ, Shen MY, Valeti US, Raff
GL, STAT InvestigatorsCT-. The CT-STAT (Coronary Computed Tomographic
Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment)
trial. J Am Coll Cardiol 2011;58:14141422.
111. Goldstein JA, Gallagher MJ, O’Neill WW, Ross MA, O’Neil BJ, Raff GL. A
randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007;49:863871.
112. Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT,
Pope JH, Hauser TH, White CS, Weiner SG, Kalanjian S, Mullins ME, Mikati I,
Peacock WF, Zakroysky P, Hayden D, Goehler A, Lee H, Gazelle GS, Wiviott
SD, Fleg JL, Udelson JE, ROMICAT-II Investigators. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 2012;367:299308.
113. Litt HI, Gatsonis C, Snyder B, Singh H, Miller CD, Entrikin DW, Leaming JM,
Gavin LJ, Pacella CB, Hollander JE. CT angiography for safe discharge of patients with possible acute coronary syndromes.
N
Engl
J
Med
2012;366:13931403.
114. Hulten E, Pickett C, Bittencourt MS, Villines TC, Petrillo S, Di Carli MF,
Blankstein R. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. J Am Coll Cardiol 2013;61:880892.
115. Dedic A, Lubbers MM, Schaap J, Lammers J, Lamfers EJ, Rensing BJ, Braam RL,
Nathoe HM, Post JC, Nielen T, Beelen D, le Cocq d’Armandville MC, Rood PP,
Schultz CJ, Moelker A, Ouhlous M, Boersma E, Nieman K. Coronary CT
angiography for suspected ACS in the era of high-sensitivity troponins: randomized multicenter study. J Am Coll Cardiol 2016;67:1626.
116. Linde JJ, Kelbaek H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J,
Heitmann M, Nielsen OW, Hofsten D, Kuhl JT, Raymond IE, Kristiansen OP,
Svendsen IH, Vall-Lamora MHD, Kragelund C, de Knegt M, Hove JD, Jorgensen
T, Fornitz GG, Steffensen R, Jurlander B, Abdulla J, Lyngbaek S, Elming H,
Therkelsen SK, Jorgensen E, Klovgaard L, Bang LE, Hansen PR, Helqvist S,
Galatius S, Pedersen F, Abildgaard U, Clemmensen P, Saunamaki K, Holmvang
L, Engstrom T, Gislason G, Kober LV, Kofoed KF. Coronary CT angiography in patients with non-st-segment elevation acute coronary syndrome. J Am Coll
Cardiol 2020;75:453463.
117. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL,
Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef
HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D,
Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun
P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H,
Luscher
TF,
Templin
C.
International expert consensus document on
Takotsubo syndrome (part II): diagnostic workup, outcome, and management.
Eur Heart J 2018;39:20472062.
118. O’Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP,
Sabatine MS. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006;114:550557.
119. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger
C, Moehring B, Fischer C, Meller B, Wildi K, Freese M, Stelzig C, Mosimann
T, Reiter M, Mueller M, Hochgruber T, Sou SM, Murray K, Minners J,
Freidank H, Osswald S, Mueller C. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. Eur Heart J
2014;35:365375.
120. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K,
Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M,
Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS, Study Group on Biomarkers in Cardiology of ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care.
Eur
Heart
J
2012;33:22522257.


<!-- PAGE 65 -->

### Page 65

.............................................................................................................................................................................
121. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, Hasin Y, Biasucci
LM, Giannitsis E, Lindahl B, Koenig W, Tubaro M, Collinson P, Katus H, Galvani
M, Venge P, Alpert JS, Hamm C, Jaffe AS, Study Group on Biomarkers in
Cardiology of the
ESC
Working
Group on
Acute
Cardiac
Care.
Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the
ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33:20012006.
122. Redfors B, Chen S, Crowley A, Ben-Yehuda O, Gersh BJ, Lembo NJ, Brown
WM, 3rd, Banning AP, Taggart DP, Serruys PW, Kappetein AP, Sabik JF, 3rd,
Stone GW. B-type natriuretic peptide assessment in patients undergoing revascularization for left main coronary artery disease.
Circulation
2018;138:469478.
123. Michou E, Fahrni G, Mueller C. Quantifying heart failure using natriuretic peptides may help the
HEART
team in decision-making.
Eur
Heart
J
2019;40:34063408.
124. Zhang C, Jiang L, Xu L, Tian J, Liu J, Zhao X, Feng X, Wang D, Zhang Y, Sun K,
Xu B, Zhao W, Hui R, Gao R, Yuan J, Song L. Implications of N-terminal pro-Btype natriuretic peptide in patients with three-vessel disease. Eur Heart J
2019;40:33973405.
125. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH,
Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
N
Engl
J
Med
2001;345:10141021.
126. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA,
DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-STelevation myocardial infarction: B-type natriuretic peptide and prognosis in
TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:12641272.
127. Balmelli C, Meune C, Twerenbold R, Reichlin T, Rieder S, Drexler B, Rubini
MG, Mosimann T, Reiter M, Haaf P, Mueller M, Ernst S, Ballarino P, Alafify AA,
Zellweger C, Wildi K, Moehring B, Vilaplana C, Bernhard D, Merk S, Ebmeyer
S, Freidank H, Osswald S, Mueller C. Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men. Am
Heart J 2013;166:3037.
128. Dhillon OS, Khan SQ, Narayan HK, Ng KH, Struck J, Quinn PA, Morgenthaler
NG, Squire IB, Davies JE, Bergmann A, Ng LL. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-STelevation myocardial infarction:
the
LAMP
(Leicester
Acute
Myocardial
Infarction Peptide) II study. J Am Coll Cardiol 2010;56:125133.
129. Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J,
Nowak RM, Vilke G, Daniels LB, Hollander JE, Apple FS, Cannon C, Nagurney
JT, Schreiber D, deFilippi C, Hogan C, Diercks DB, Stein JC, Headden G,
Limkakeng AT, Jr., Anand I, Wu AHB, Papassotiriou J, Hartmann O, Ebmeyer S,
Clopton P, Jaffe AS, Peacock WF. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial
(Copeptin Helps in the early detection Of Patients with acute myocardial
INfarction). J Am Coll Cardiol 2013;62:150160.
130. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N,
McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
Circulation 2002;105:17601763.
131. Schurtz G, Lamblin N, Bauters C, Goldstein P, Lemesle G. Copeptin in acute coronary syndromes and heart failure management: state of the art and future directions. Arch Cardiovasc Dis 2015;108:398407.
132. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B,
Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM,
Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.
Circulation
2007;115:962971.
133. Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KA, Goodman SG, Eagle
KA, Gurm HS. Does simplicity compromise accuracy in ACS risk prediction? A
retrospective analysis of the TIMI and GRACE risk scores. PLoS One
2009;4:e7947.
134. D’Ascenzo F, Biondi-Zoccai G, Moretti C, Bollati M, Omede P, Sciuto F,
Presutti DG, Modena MG, Gasparini M, Reed MJ, Sheiban I, Gaita F. TIMI,
GRACE and alternative risk scores in acute coronary syndromes: a metaanalysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. Contemp Clin Trials 2012;33:507514.
135. Gale CP, Manda SO, Weston CF, Birkhead JS, Batin PD, Hall AS. Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial
Infarction National Audit Project (MINAP) database. Heart 2009;95:221227.
136. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F,
Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD,
Fox KA, GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:27272733.
137. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F,
Avezum A, Goodman SG, Flather MD, Anderson FA, Jr., Granger CB.
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
138. Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, Coste P,
Monsegu J, Gabriel Steg P, Danchin N, Anderson F. Should patients with acute coronary disease be stratified for management according to their risk?
Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014;4:e004425.
139. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van
De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA, Global Registry of
Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:23452353.
140. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA, GRACE and GRACE2
Investigators. The Global Registry of Acute Coronary Events, 1999 to
2009GRACE. Heart 2010;96:10951101.
141. Bing R, Goodman SG, Yan AT, Fox K, Gale CP, Hyun K, D’Souza M, Shetty P,
Atherton J, Hammett C, Chew D, Brieger D. Use of clinical risk stratification in non-ST
elevation acute coronary syndromes:
an analysis from the
CONCORDANCE
registry.
Eur
Heart
J
Qual
Care
Clin
Outcomes
2018;4:309317.
142. Chew DP, Junbo G, Parsonage W, Kerkar P, Sulimov VA, Horsfall M, Mattchoss
S, Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndrome
Patients (PREDICT) Study Investigators. Perceived risk of ischemic and bleeding events in acute coronary syndromes.
Circ
Cardiovasc
Qual
Outcomes
2013;6:299308.
143. Hall M, Bebb OJ, Dondo TB, Yan AT, Goodman SG, Bueno H, Chew DP,
Brieger D, Batin PD, Farkouh ME, Hemingway H, Timmis A, Fox KAA, Gale
CP. Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST
elevation myocardial infarction.
Eur
Heart
J
2018;39:37983806.
144. Fox KA, Anderson FA, Jr., Dabbous OH, Steg PG, Lopez-Sendon J, Van de
Werf F, Budaj A, Gurfinkel EP, Goodman SG, Brieger D, GRACE investigators.
Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary
Events (GRACE). Heart 2007;93:177182.
145. Saar A, Marandi T, Ainla T, Fischer K, Blondal M, Eha J. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. Int J Cardiol 2018;272:2632.
146. Chew DP, Astley CM, Luker H, Alprandi-Costa B, Hillis G, Chow CK, Quinn S,
Yan AT, Gale CP, Goodman S, Fox KA, Brieger D. A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: rationale and design of the Australian GRACE Risk score Intervention
Study (AGRIS). Am Heart J 2015;170:9951004 e1001.
147. Everett CC, Fox KA, Reynolds C, Fernandez C, Sharples L, Stocken DD,
Carruthers K, Hemingway H, Yan AT, Goodman SG, Brieger D, Chew DP,
Gale CP. Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registrybased trial. BMJ Open 2019;9:e032165.
148. Hall M, Dondo TB, Yan AT, Goodman SG, Bueno H, Chew DP, Brieger D,
Timmis A, Batin PD, Deanfield JE, Hemingway H, Fox KA, Gale CP. Association of clinical factors and therapeutic strategies with improvements in survival following non-st-elevation myocardial infarction, 2003-2013. JAMA 2016;316:10731082.
149. Bricker RS, Valle JA, Plomondon ME, Armstrong EJ, Waldo SW. Causes of mortality after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes
2019;12:e005355.
150. Chang WC, Boersma E, Granger CB, Harrington RA, Califf RM, Simoons ML,
Kleiman NS, Armstrong PW, GUSTO-IIb and PURSUIT Investigators. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from
GUSTO-IIb and PURSUIT. Am Heart J 2004;148:6271.
151. Fox KA, Anderson FA, Jr., Goodman SG, Steg PG, Pieper K, Quill A, Gore JM,
GRACE Investigators. Time course of events in acute coronary syndromes:
implications for clinical practice from the GRACE registry. Nat Clin Pract
Cardiovasc Med 2008;5:580589.
152. Spoon DB, Psaltis PJ, Singh M, Holmes DR, Jr., Gersh BJ, Rihal CS, Lennon RJ,
Moussa ID, Simari RD, Gulati R. Trends in cause of death after percutaneous coronary intervention. Circulation 2014;129:12861294.
153. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ,
Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK,
Song Y, Massaro JM, Mauri L, DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1
year after percutaneous coronary intervention. JAMA 2016;315:17351749.
ESC Guidelines
1353


<!-- PAGE 66 -->

### Page 66

...........................................................................................................................................................................
154. Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK,
Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL,
Stone GW, Windecker S, Steyerberg EW, Valgimigli M, PRECISE-DAPT Study
Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:10251034.
155. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY,
Gibler WB, Ohman EM, Roe MT, Pollack CV, Jr., Peterson ED, Alexander KP.
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients
Suppress ADverse outcomes with Early implementation of the ACC/AHA
Guidelines) bleeding score. Circulation 2009;119:18731882.
156. Abu-Assi E, Raposeiras-Roubin S, Lear P, Cabanas-Grandio P, Girondo M,
Rodriguez-Cordero M, Pereira-Lopez E, Romani SG, Gonzalez-Cambeiro C,
Alvarez-Alvarez B, Garcia-Acuna JM, Gonzalez-Juanatey JR. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2012;1:222231.
157. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H,
Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G,
Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010;55:25562566.
158. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset
T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M,
James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA,
Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N,
Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC.
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for
High Bleeding Risk. Eur Heart J 2019;40:26322653.
159. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J,
Richardt G, Iniguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland
J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll
HP, Morice MC, LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015;373:20382047.
160. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G,
Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga
E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P,
Briguori C, Investigators ZEUS. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015;65:805815.
161. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie D, Hovasse T, Garot
P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, PinarBermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M,
Morice MC, Sinnaeve PR, SENIOR investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
Lancet 2018;391:4150.
162. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O,
Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas
LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, LopezJaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G,
Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ,
Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM,
Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz
F, Chen E, Leong D, Yusuf S, COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease.
N
Engl
J
Med
2017;377:13191330.
163. Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S,
Storey RF, Cannon CP, Becker RC, James SK, Katus HA, Lopes RD, Sorbets E,
Wallentin L, Steg PG. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. Am Heart J 2017;186:9199.
164. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ,
Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington
RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome
(TRACER) randomized trial. Eur Heart J 2017;38:804810.
165. Bianco M, D’Ascenzo F, Raposeiras Roubin S, Kinnaird T, Peyracchia M, ArizaSole A, Cerrato E, Manzano-Fernandez S, Gravinese C, Templin C, Destefanis
P, Velicki L, Luciano A, Xanthopoulou I, Rinaldi M, Rognoni A, Varbella F,
Boccuzzi G, Omede P, Montabone A, Bernardi A, Taha S, Rossini R, Durante A,
Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Giustetto C, Garay A,
Quadri G, Queija BC, Srdanovic I, Paz RC, Fernandez MC, Pousa IM, Gallo D,
Morbiducci
U,
Dominguez-Rodriguez
A,
Lopez-Cuenca
A,
Cequier
A,
Alexopoulos D, Iniguez-Romo A, Pozzi R, Assi EA, Valgimigli M. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int J Cardiol
2020;301:200206.
166. Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, Tumscitz C,
Moschovitis A, Windecker S, Valgimigli M. Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention.
Ann Intern Med 2017;167:1725.
167. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, Kastrati
A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690697.
168. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler
KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R,
Camm AJ, Heidbuchel H, ESC Scientific Document Group. The 2018 European
Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Eur
Heart
J
2018;39:13301393.
169. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati
A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG,
Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC
Committee for Practice Guidelines (CPG), ESC National Cardiac Societies.
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology
(ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J 2018;39:213260.
170. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow
J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG,
Storey RF, Harrington RA, Investigators PLATO. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:10451057.
171. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S,
Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G,
Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes.
N
Engl
J
Med
2007;357:20012015.
172. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK,
ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G,
Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati
A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors:
collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36:17621771.
173. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello
L, Sibbing D, Collet JP, Huber K, Working Group on Thrombosis of the
European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur
Heart J 2014;35:209215.
174. Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J,
Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L,
Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M,
Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer
W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S,
Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A,
Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, ISAR-REACT 5 Trial
Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:15241534.
175. Schnorbus B, Daiber A, Jurk K, Warnke S, Koenig J, Lackner KJ, Munzel T, Gori
T. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function,
inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study. Eur Heart J 2020;ehz917.
176. Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS
patients: who, when, why, and which agent? Eur Heart J 2016;37:12841295.
177. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten
Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J,
Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E,
Widimsky P, ACCOAST Investigators. Pretreatment with prasugrel in non-STsegment elevation acute coronary syndromes.
N
Engl
J
Med
2013;369:9991010.
178. Dworeck C, Redfors B, Angera˚s O, Haraldsson I, Odenstedt J, Ioanes D,
Petursson P, Vo¨lz S, Persson J, Koul S , Venetsanos D, Ulvenstam A, Hofmann
R, Jensen J, Albertsson P, Ra˚munddal T, Jeppsson A, Erlinge D, Omerovic E.
Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. JAMA Netw Open 2020;3:e2018735.
179. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De
Caterina R, Gulba D, Huber K, Husted S, Kristensen SD, Morais J, Neumann FJ,


<!-- PAGE 67 -->

### Page 67

.............................................................................................................................................................................
Rasmussen LH, Siegbahn A, Steg PG, Storey RF, Van de Werf F, Verheugt F.
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur
Heart J 2011;32:29222932.
180. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:7186.
181. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins
R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T,
Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:18491860.
182. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg
K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in
Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Lancet 2001;358:527533.
183. FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D,
Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao
SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S. Low-dose vs standarddose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux:
the
FUTURA/OASIS-8
randomized trial. JAMA 2010;304:13391349.
184. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW,
Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS,
Gruberg L, French WJ, White HD, Harrington RA, Investigators CHAMPION.
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions:
a pooled analysis of patient-level data.
Lancet
2013;382:19811992.
185. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM,
Pollack CV, Jr., Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG,
Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH,
Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing
PCI. N Engl J Med 2009;361:23182329.
186. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price
MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth
J, Spriggs D, McLaurin BT, Angiolillo DJ, Genereux P, Liu T, Prats J, Todd M,
Skerjanec S, White HD, Harrington RA, CHAMPION PHOENIX Investigators.
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N
Engl J Med 2013;368:13031313.
187. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G,
Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Jr., Manoukian
SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J,
Skerjanec S, Harrington RA, CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:23302341.
188. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van
’t Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F,
Braunwald E, Harrington RA, Califf RM, Newby LK, EARLY ACS Investigators.
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N
Engl J Med 2009;360:21762190.
189. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White
HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius
H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra
J, Mehran R, Ohman EM, ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:22032216.
190. Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ,
CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA
2002;288:24112420.
191. Widimsky P, Motovska Z, Simek S, Kala P, Pudil R, Holm F, Petr R, Bilkova D,
Skalicka H, Kuchynka P, Poloczek M, Miklik R, Maly M, Aschermann M,
PRAGUE-8 Trial Investigators. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008;29:14951503.
192. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S.
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:19361942.
193. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A
meta-analysis. JAMA 1996;276:811815.
194. Silvain J, Beygui F, Barthelemy O, Pollack C, Jr., Cohen M, Zeymer U, Huber K,
Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012;344:e553.
195. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald
E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Qwave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
Circulation
1999;100:16021608.
196. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S,
Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A,
Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC,
Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB,
Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, ToroFigueroa L, White H, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:4554.
197. Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P,
Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R,
Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G,
Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N,
Rigattieri S, Zingarelli A, Tosi P, van ’t Hof A, Boccuzzi G, Omerovic E, Sabate
M,
Heg
D,
Juni
P,
Vranckx
P,
MATRIX
Investigators.
Bivalirudin or unfractionated heparin in acute coronary syndromes.
N
Engl
J
Med
2015;373:9971009.
198. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz
KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schomig A,
Berger PB, Mehilli J, ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med
2011;365:19801989.
199. Cohen M, Mahaffey KW, Pieper K, Pollack CV, Jr., Antman EM, Hoekstra J,
Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ, SYNERGY
Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
J Am Coll Cardiol 2006;48:13461354.
200. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014;384:599606.
201. Cassese S, Byrne RA, Laugwitz KL, Schunkert H, Berger PB, Kastrati A.
Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention 2015;11:196203.
202. Zhang S, Gao W, Li H, Zou M, Sun S, Ba Y, Liu Y, Cheng G. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Int J Cardiol
2016;209:8795.
203. Nuhrenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ.
Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. Clin
Res Cardiol 2018;107:807815.
204. Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, Swahn E,
Henareh L, Wagner H, Hardhammar P, Sjogren I, Stewart J, Grimfjard P, Jensen J,
Aasa M, Robertsson L, Lindroos P, Haupt J, Wikstrom H, Ulvenstam A, Bhiladvala
P, Lindvall B, Lundin A, Todt T, Ioanes D, Ramunddal T, Kellerth T, Zagozdzon L,
Gotberg M, Andersson J, Angeras O, Ostlund O, Lagerqvist B, Held C, Wallentin
L, Schersten F, Eriksson P, Koul S, James S. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 2017;377:11321142.
205. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U,
Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD,
Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S,
Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS
Guidelines on myocardial revascularization. Eur Heart J 2019;40:87165.
206. Fifth
Organization to
Assess
Strategies in
Acute
Ischemic
Syndromes
Investigators Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB,
Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med
2006;354:14641476.
207. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F,
de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM,
Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet
2002;359:189198.
208. Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH,
Kim BO, Cho JH, Suh IW, Kim DI, Park HK, Park JS, Choi WG, Lee WS, Kim J,
Choi KH, Park TK, Lee JM, Yang JH, Choi JH, Choi SH, Gwon HC, SMARTDATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Lancet 2018;391:12741284.
ESC Guidelines
1355


<!-- PAGE 68 -->

### Page 68

.............................................................................................................................................................................
209. Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho
BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS,
Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH,
Choi JH, Choi SH, Lee SH, Gwon HC, SMART-CHOICE Investigators.
Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:
the
SMART-CHOICE
randomized clinical trial.
JAMA
2019;321:24282437.
210. Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, van Es GA,
McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Mollmann H,
Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns
RJ, Huber K, Slagboom T, Serruys PW, Windecker S, GLOBAL LEADERS
Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months,
followed by aspirin monotherapy for 12 months after implantation of a drugeluting stent: a multicentre, open-label, randomised superiority trial. Lancet
2018;392:940949.
211. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY,
Collier T, Dangas G, Dudek D, Dzavik V, Escaned J, Gil R, Gurbel P, Hamm
CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian
V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G,
Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S,
Gibson CM. Ticagrelor with or without aspirin in high-risk patients after PCI. N
Engl J Med 2019;381:20322042.
212. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff
MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP,
Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med
2014;371:21552166.
213. Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T,
Budaj A, Goto S, Lopez-Sendon J, Diaz R, Dalby A, Van de Werf F, Ardissino
D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E,
Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from
P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 2016;37:11331142.
214. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G,
Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj, A, Theroux, P,
Ruda, M, Hamm, C, Goto, S, Spinar, J, Nicolau, JC, Kiss, RG, Murphy, SA,
Wiviott, SD, Held, P, Braunwald, E, Sabatine, MS, PEGASUS-TIMI 54 Steering
Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:17911800.
215. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C,
Andersson M, Himmelmann A, Ridderstrale W, Leonsson-Zachrisson M, Liu Y,
Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalan R, Cornel JH,
Widimsky P, Leiter LA, THEMIS Steering Committee and Investigators.
Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med
2019;381:13091320.
216. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker
BA, Messenger JC, Cohen DJ, Wang TY, TRANSLATE-ACS Investigators.
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the Treatment with
Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of
Treatment
Patterns and
Events after
Acute
Coronary
Syndrome
(TRANSLATE-ACS) observational study. Am Heart J 2017;183:6268.
217. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D,
So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L,
Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R,
Mehran R, Montalescot G, Franchi F, Price MJ. International expert consensus on switching platelet
P2Y12
receptor-inhibiting therapies.
Circulation
2017;136:19551975.
218. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G,
Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet
JL. Benefit of switching dual antiplatelet therapy after acute coronary syndrome:
the TOPIC (timing of platelet inhibition after acute coronary syndrome)
randomized study. Eur Heart J 2017;38:30703078.
219. De Luca L, D’Ascenzo F, Musumeci G, Saia F, Parodi G, Varbella F, Marchese A,
De Servi S, Berti S, Bolognese L. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention:
the
SCOPE
registry.
EuroIntervention 2017;13:459466.
220. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M,
Hadamitzky M, Merkely B, Kiss RG, Komocsi A, Dezsi CA, Holdt L, Felix SB,
Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ,
Koltowski L, Mehilli J, Huczek Z, Massberg S, TROPICAL-ACS Investigators.
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention
(TROPICAL-ACS):
a randomised,
open-label,
multicentre trial.
Lancet
2017;390:17471757.
221. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd
A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A,
Boersma C, Deneer VHM, Ten Berg JM. A genotype-guided strategy for oral
P2Y12 inhibitors in primary PCI. N Engl J Med 2019;381:16211631.
222. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP,
Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ,
Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF,
Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12
receptor inhibitor treatment in percutaneous coronary intervention. JACC
Cardiovasc Interv 2019;12:15211537.
223. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K,
O’Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E,
Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori
M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD,
Anand SS, Varigos JD, Fox KAA, Yusuf S, COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international,
randomised,
double-blind,
placebo-controlled trial.
Lancet
2018;391:205218.
224. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,
Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,
Schneider D, Sun X, Verheugt FW, Gibson CM, ATLAS ACS 2TIMI 51
Investigators. Rivaroxaban in patients with a recent acute coronary syndrome.
N Engl J Med 2012;366:919.
225. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in
Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494502.
226. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A,
Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park
KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Genereux P,
Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J
2017;38:10341043.
227. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY,
Collier T, Dangas G, Dudek D, Dzavik V, Escaned J, Gil R, Gurbel P, Hamm
CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian
V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G,
Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S,
Gibson CM. Ticagrelor with or without aspirin in high-risk patients after PCI. N
Engl J Med 2019;381:20322042.
228. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW,
Alberts MJ, D’Agostino R, Liau CS, Mas JL, Rother J, Smith SC, Jr., Salette G,
Contant CF, Massaro JM, Steg PG, REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:13501357.
229. Collet JP, Zeitouni M, Procopi N, Hulot JS, Silvain J, Kerneis M, Thomas D,
Lattuca B, Barthelemy O, Lavie-Badie Y, Esteve JB, Payot L, Brugier D, Lopes I,
Diallo A, Vicaut E, Montalescot G, ACTION Study Group. Long-term evolution of premature coronary artery disease. J Am Coll Cardiol 2019;74:18681878.
230. Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Ohman EM,
Rother J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG, REACH
Registry Investigators. Association of multiple enrichment criteria with ischemic and bleeding risks among COMPASS-eligible patients. J Am Coll Cardiol
2019;73:32813291.
231. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen
T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip
J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document
Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407477.
232. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, Finet G, Le
Breton H, Boschat J, STENTICO Investigators. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting
(from
STENTIng and oral antiCOagulants
[STENTICO]).
Am
J
Cardiol
2009;104:338342.
233. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG,
Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a


<!-- PAGE 69 -->

### Page 69

.............................................................................................................................................................................
joint consensus document of the European Society of Cardiology Working
Group on Thrombosis, European Heart Rhythm Association (EHRA), European
Association of
Percutaneous
Cardiovascular
Interventions
(EAPCI)
and
European Association of Acute Cardiac Care (ACCA) endorsed by the Heart
Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur
Heart J 2014;35:31553179.
234. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR,
Sogorb F, Valdes M, Lip GY. Anticoagulant and antiplatelet therapy use in 426
patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll
Cardiol 2008;51:818825.
235. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S,
Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:18881896.
236. Dewilde
WJ,
Janssen
PW,
Kelder
JC,
Verheugt
FW,
De
Smet
BJ,
Adriaenssens T, Vrolix M, Brueren GB, Van Mieghem C, Cornelis K, Vos J,
Breet NJ, ten Berg JM. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention
2015;11:381390.
237. Kiviniemi T, Karjalainen P, Pietila M, Ylitalo A, Niemela M, Vikman S, Puurunen
M, Biancari F, Airaksinen KE. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. Am J Cardiol 2012;110:3035.
238. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M,
Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J,
Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, RE-DUAL PCI Steering
Committee and Investigators. Dual antithrombotic therapy with dabigatran after
PCI in atrial fibrillation. N Engl J Med 2017;377:15131524.
239. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,
Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ’t Hof AW,
ten Berg JM, WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet
2013;381:11071115.
240. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,
Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip
GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing
PCI.
N
Engl
J
Med
2016;375:24232434.
241. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman
SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A,
Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D,
Granger CB, Alexander JH, AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or pci in atrial fibrillation. N Engl J Med
2019;380:15091524.
242. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin
V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R,
Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet
2019;394:13351343.
243. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger
CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Gibson CM, Alexander JH.
Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol 2019;4:747755.
244. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M.
Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin
K
antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019;40:37573767.
245. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau
D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF,
Valgimigli M, Huber K, ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of
Cardiology
Working
Group on
Thrombosis,
European
Association of
Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS),
Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society
(LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace
2019;21:192193.
246. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K,
Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, Investigators AFIRE.
Antithrombotic therapy for atrial fibrillation with stable coronary disease. N
Engl J Med 2019;381:11031113.
247. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R,
Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura
F, Engstrom T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis
BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J, Potpara TS, Raev D,
Sabate M, de Waha-Thiele S, Welsh RC, Xavier D, Mehran R, Alexander JH,
AUGUSTUS Investigators. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention:
insights from the AUGUSTUS trial. Circulation 2019;140:19211932.
248. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL,
Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012;126:11851193.
249. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM,
Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML.
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
J
Am
Coll
Cardiol
2013;62:981989.
250. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D,
Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg
S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation:
the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:16191629.
251. Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz PE, Eckardt L, Lanz HJ,
Zierhut W, Smolnik R, Goette A. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. Am Heart J
2018;196:105112.
252. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA,
EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008;34:7392.
253. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P,
Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P, Working Group on
Perioperative
Haemostasis,
French
Study
Group on
Thrombosis and
Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors.
Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis
2011;104:669676.
254. Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, TorpPedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip
GYH, Verheugt FWA, Agewall S. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and
European Society of Cardiology Working Group on Thrombosis. Eur Heart J
2017;38:17101716.
255. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J,
Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R,
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering
Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:11391151.
256. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G,
Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A,
Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van
Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans
AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S,
AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806817.
257. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, AlKhalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz
JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo
AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL,
Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE
Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981992.
258. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz
SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883891.
ESC Guidelines
1357


<!-- PAGE 70 -->

### Page 70

.............................................................................................................................................................................
259. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL,
Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y,
Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM,
ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:20932104.
260. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer
C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
261. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol
2015;65:225232.
262. Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
Thromb Haemost 2015;114:826834.
263. Joundi RA, Cipriano LE, Sposato LA, Saposnik G, Stroke Outcomes Research
Working Group. Ischemic stroke risk in patients with atrial fibrillation and
CHA2DS2-VASc score of 1: systematic review and meta-analysis. Stroke
2016;47:13641367.
264. Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA,
Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy
JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L,
Weitz JI. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J
Med 2017;377:431441.
265. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence
JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp
S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk
AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E,
Meeks B, Ahmad S, Nakamya J, Milling TJ, Jr., ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors.
N Engl J Med 2019;380:13261335.
266. O’Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter
RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E,
Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2008;300:7180.
267. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky
P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative metaanalysis of randomized trials. JAMA 2005;293:29082917.
268. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG,
Lagerqvist B, Wallentin L, Collaboration FIR. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll
Cardiol 2010;55:24352445.
269. Fanning JP, Nyong J, Scott IA, Aroney CN, Walters DL. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database Syst Rev
2016:CD004815.
270. Elgendy IY, Mahmoud AN, Wen X, Bavry AA. Meta-analysis of randomized trials of long-term all-cause mortality in patients with non-ST-elevation acute coronary syndrome managed with routine invasive versus selective invasive strategies. Am J Cardiol 2017;119:560564.
271. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R,
Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J,
Natarajan MK, Horsman C, Fox KA, Yusuf S, Investigators TIMACS. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med
2009;360:21652175.
272. Kofoed KF, Kelbaek H, Hansen PR, Torp-Pedersen C, Hofsten D, Klovgaard L,
Holmvang L, Helqvist S, Jorgensen E, Galatius S, Pedersen F, Bang L, Saunamaki
K, Clemmensen P, Linde JJ, Heitmann M, Wendelboe Nielsen O, Raymond IE,
Kristiansen OP, Svendsen IH, Bech J, Dominguez Vall-Lamora MH, Kragelund C,
Hansen TF, Dahlgaard Hove J, Jorgensen T, Fornitz GG, Steffensen R, Jurlander
B, Abdulla J, Lyngbaek S, Elming H, Therkelsen SK, Abildgaard U, Jensen JS,
Gislason G, Kober LV, Engstrom T. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome. Circulation 2018;138:27412750.
273. Lemkes JS, Janssens GN, van der Hoeven NW, van de Ven PM, Marques KMJ,
Nap A, van Leeuwen MAH, Appelman YEA, Knaapen P, Verouden NJW, Allaart
CP, Brinckman SL, Saraber CE, Plomp KJ, Timmer JR, Kedhi E, Hermanides RS,
Meuwissen M, Schaap J, van der Weerdt AP, van Rossum AC, Nijveldt R, van
Royen N. Timing of revascularization in patients with transient ST-segment elevation myocardial infarction:
a randomized clinical trial.
Eur
Heart
J
2019;40:283291.
274. Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M,
Engstrom T, Di Pasquale G, Kochman W, Ardissino D, Kedhi E, Stone GW,
Kubica J. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann
Intern Med 2013;158:261270.
275. Milasinovic D, Milosevic A, Marinkovic J, Vukcevic V, Ristic A, Asanin M,
Stankovic G. Timing of invasive strategy in NSTE-ACS patients and effect on clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. Atherosclerosis 2015;241:4854.
276. Katritsis DG, Siontis GC, Kastrati A, van’t Hof AW, Neumann FJ, Siontis KC,
Ioannidis JP. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes.
Eur
Heart
J
2011;32:3240.
277. Jobs A, Mehta SR, Montalescot G, Vicaut E, Van’t Hof AWJ, Badings EA,
Neumann FJ, Kastrati A, Sciahbasi A, Reuter PG, Lapostolle F, Milosevic A,
Stankovic G, Milasinovic D, Vonthein R, Desch S, Thiele H. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome:
a meta-analysis of randomised trials. Lancet 2017;390:737746.
278. Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, Michelet P,
Roch A, Kerbaul F, Boyer L. Timing of coronary invasive strategy in non-STsegment elevation acute coronary syndromes and clinical outcomes: an updated meta-analysis. JACC Cardiovasc Interv 2016;9:22672276.
279. Reuter PG, Rouchy C, Cattan S, Benamer H, Jullien T, Beruben A, Montely JM,
Assez N, Raphael V, Hennequin B, Boccara A, Javaud N, Soulat L, Adnet F,
Lapostolle F. Early invasive strategy in high-risk acute coronary syndrome without
ST-segment elevation.
The
Sisca randomized trial.
Int
J
Cardiol
2015;182:414418.
280. Sciahbasi A, Madonna M, De Vita M, Agati L, Scioli R, Summaria F, Romagnoli E,
Patrizi R, Lanzillo C, Pendenza G, Canali E, Penco M, Lioy E. Comparison of immediate vs early invasive strategy in patients with first acute non-STelevation myocardial infarction. Clin Cardiol 2010;33:650655.
281. Milosevic A, Vasiljevic-Pokrajcic Z, Milasinovic D, Marinkovic J, Vukcevic V,
Stefanovic B, Asanin M, Dikic M, Stankovic S, Stankovic G. Immediate versus delayed invasive intervention for Non-STEMI patients: the RIDDLE-NSTEMI
study. JACC Cardiovasc Interv 2016;9:541549.
282. Thiele H, Rach J, Klein N, Pfeiffer D, Hartmann A, Hambrecht R, Sick P,
Eitel I, Desch S, Schuler G, LIPSIA-NSTEMI Trial Group. Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the
Leipzig
Immediate versus early and late
PercutaneouS
coronary
Intervention triAl in
NSTEMI
(LIPSIA-NSTEMI
trial).
Eur
Heart
J
2012;33:20352043.
283. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP,
Schmitt C, Seyfarth M, Dirschinger J, Schomig A. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA
2003;290:15931599.
284. Badings EA, The SH, Dambrink JH, van Wijngaarden J, Tjeerdsma G, Rasoul S,
Timmer JR, van der Wielen ML, Lok DJ, van ’t Hof AW. Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the
ELISA-3 trial. EuroIntervention 2013;9:5461.
285. van ’t Hof AW, de Vries ST, Dambrink JH, Miedema K, Suryapranata H,
Hoorntje JC, Gosselink AT, Zijlstra F, de Boer MJ. A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes:
results of the Early or Late Intervention in unStable Angina (ELISA) pilot study.
2b/3a upstream therapy and acute coronary syndromes.
Eur
Heart
J
2003;24:14011405.
286. Lemesle G, Laine M, Pankert M, Boueri Z, Motreff P, Paganelli F, Baumstarck K,
Roch A, Kerbaul F, Puymirat E, Bonello L. Optimal timing of intervention in
NSTE-ACS
without pre-treatment:
the
EARLY
randomized trial.
JACC
Cardiovasc Interv 2020;13:907917.
287. Montalescot G, Cayla G, Collet JP, Elhadad S, Beygui F, Le Breton H, Choussat
R, Leclercq F, Silvain J, Duclos F, Aout M, Dubois-Rande JL, Barthelemy O,
Ducrocq G, Bellemain-Appaix A, Payot L, Steg PG, Henry P, Spaulding C,
Vicaut E, ABOARD Investigators. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 2009;302:947954.
288. Saw J, Mancini GBJ, Humphries KH. Contemporary review on spontaneous coronary artery dissection. J Am Coll Cardiol 2016;68:297312.
289. Vrints CJ. Spontaneous coronary artery dissection. Heart 2010;96:801808.
290. Mortensen KH, Thuesen L, Kristensen IB, Christiansen EH. Spontaneous coronary artery dissection: a Western Denmark Heart Registry study. Catheter
Cardiovasc Interv 2009;74:710717.
291. Nishiguchi T, Tanaka A, Ozaki Y, Taruya A, Fukuda S, Taguchi H, Iwaguro T,
Ueno S, Okumoto Y, Akasaka T. Prevalence of spontaneous coronary artery dissection in patients with acute coronary syndrome. Eur Heart J Acute
Cardiovasc Care 2016;5:263270.


<!-- PAGE 71 -->

### Page 71

...........................................................................................................................................................................
292. Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. Eur Heart J 2018;39:33533368.
293. Eleid MF, Tweet MS, Young PM, Williamson E, Hayes SN, Gulati R.
Spontaneous coronary artery dissection: challenges of coronary computed tomography angiography. Eur Heart J Acute Cardiovasc Care 2018;7:609613.
294. Alfonso F, Paulo M, Gonzalo N, Dutary J, Jimenez-Quevedo P, Lennie V,
Escaned J, Banuelos C, Hernandez R, Macaya C. Diagnosis of spontaneous coronary artery dissection by optical coherence tomography. J Am Coll Cardiol
2012;59:10731079.
295. Mahmoud AN, Taduru SS, Mentias A, Mahtta D, Barakat AF, Saad M, Elgendy
AY, Mojadidi MK, Omer M, Abuzaid A, Agarwal N, Elgendy IY, Anderson RD,
Saw J. Trends of incidence, clinical presentation, and in-hospital mortality among women with acute myocardial infarction with or without spontaneous coronary artery dissection:
a population-based analysis.
JACC
Cardiovasc
Interv
2018;11:8090.
296. Martins JL, Afreixo V, Santos L, Costa M, Santos J, Goncalves L. Medical treatment or revascularisation as the best approach for spontaneous coronary artery dissection: a systematic review and meta-analysis. Eur Heart J Acute
Cardiovasc Care 2018;7:614623.
297. Hassan S, Prakash R, Starovoytov A, Saw J. Natural history of spontaneous coronary artery dissection with spontaneous angiographic healing. JACC Cardiovasc
Interv 2019;12:518527.
298. Saw J, Humphries K, Aymong E, Sedlak T, Prakash R, Starovoytov A, Mancini
GBJ. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol 2017;70:11481158.
299. Cuculi F, De Maria GL, Meier P, Dall’Armellina E, de Caterina AR, Channon
KM, Prendergast BD, Choudhury RP, Forfar JC, Kharbanda RK, Banning AP.
Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after
ST-segment elevation myocardial infarction.
J
Am
Coll
Cardiol
2014;64:18941904.
300. Pijls NH, Tanaka N, Fearon WF. Functional assessment of coronary stenoses:
can we live without it? Eur Heart J 2013;34:13351344.
301. Layland J, Rauhalammi S, Watkins S, Ahmed N, McClure J, Lee MM, Carrick D,
O’Donnell A, Sood A, Petrie MC, May VT, Eteiba H, Lindsay M, McEntegart M,
Oldroyd KG, Radjenovic A, Berry C. Assessment of Fractional Flow Reserve in
Patients
With
Recent
Non-ST-Segment-Elevation
Myocardial
Infarction:
Comparative Study With 3-T Stress Perfusion Cardiac Magnetic Resonance
Imaging. Circ Cardiovasc Interv 2015;8:e002207.
302. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E,
Hamilos M, Mangiacapra F, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne B.
Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv
2010;3:12741281.
303. Samady H, Lepper W, Powers ER, Wei K, Ragosta M, Bishop GG, Sarembock IJ,
Gimple L, Watson DD, Beller GA, Barringhaus KG. Fractional flow reserve of infarct-related arteries identifies reversible defects on noninvasive myocardial perfusion imaging early after myocardial infarction.
J
Am
Coll
Cardiol
2006;47:21872193.
304. Sels JW, Tonino PA, Siebert U, Fearon WF, Van’t Veer M, De Bruyne B, Pijls
NH. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv
2011;4:11831189.
305. Escaned J, Ryan N, Mejia-Renteria H, Cook CM, Dehbi HM, Alegria-Barrero E,
Alghamdi A, Al-Lamee R, Altman J, Ambrosia A, Baptista SB, Bertilsson M,
Bhindi R, Birgander M, Bojara W, Brugaletta S, Buller C, Calais F, Silva PC,
Carlsson J, Christiansen EH, Danielewicz M, Di Mario C, Doh JH, Erglis A,
Erlinge D, Gerber RT, Going O, Gudmundsdottir I, Harle T, Hauer D, Hellig F,
Indolfi C, Jakobsen L, Janssens L, Jensen J, Jeremias A, Karegren A, Karlsson AC,
Kharbanda RK, Khashaba A, Kikuta Y, Krackhardt F, Koo BK, Koul S, Laine M,
Lehman SJ, Lindroos P, Malik IS, Maeng M, Matsuo H, Meuwissen M, Nam CW,
Niccoli G, Nijjer SS, Olsson H, Olsson SE, Omerovic E, Panayi G, Petraco R,
Piek JJ, Ribichini F, Samady H, Samuels B, Sandhall L, Sapontis J, Sen S, Seto AH,
Sezer M, Sharp ASP, Shin ES, Singh J, Takashima H, Talwar S, Tanaka N, Tang K,
Van Belle E, van Royen N, Varenhorst C, Vinhas H, Vrints CJ, Walters D, Yokoi
H, Frobert O, Patel MR, Serruys P, Davies JE, Gotberg M. Safety of the deferral of coronary revascularization on the basis of instantaneous wave-free ratio and fractional flow reserve measurements in stable coronary artery disease and acute coronary syndromes. JACC Cardiovasc Interv 2018;11:14371449.
306. Hakeem A, Edupuganti MM, Almomani A, Pothineni NV, Payne J, Abualsuod
AM, Bhatti S, Ahmed Z, Uretsky BF. Long-term prognosis of deferred acute coronary syndrome lesions based on nonischemic fractional flow reserve. J Am
Coll Cardiol 2016;68:11811191.
307. Lee JM, Choi KH, Koo BK, Shin ES, Nam CW, Doh JH, Hwang D, Park J, Zhang
J, Lim HS, Yoon MH, Tahk SJ. Prognosis of deferred non-culprit lesions according to fractional flow reserve in patients with acute coronary syndrome.
EuroIntervention 2017;13:e1112e1119.
308. Masrani Mehta S, Depta JP, Novak E, Patel JS, Patel Y, Raymer D, Facey G,
Zajarias A, Lasala JM, Singh J, Bach RG, Kurz HI. Association of lower fractional flow reserve values with higher risk of adverse cardiac events for lesions deferred revascularization among patients with acute coronary syndrome. J Am
Heart Assoc 2015;4:e002172.
309. Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, Junejo S,
Ahmed N, Lee MM, Shaukat A, O’Donnell A, Nam J, Briggs A, Henderson R,
McConnachie A, Berry C, FAMOUSNSTEMI investigators. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in nonST-segment elevation myocardial infarction: the British Heart Foundation
FAMOUS-NSTEMI randomized trial. Eur Heart J 2015;36:100111.
310. Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M,
Jakobsen L, Olsson SE, Ohagen P, Olsson H, Omerovic E, Calais F, Lindroos P,
Maeng M, Todt T, Venetsanos D, James SK, Karegren A, Nilsson M, Carlsson J,
Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Frobert O, iFRSWEDEHEART Investigators. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 2017;376:18131823.
311. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R,
Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M,
Van Belle E, Krackhardt F, Bojara W, Going O, Harle T, Indolfi C, Niccoli G,
Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H,
Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES,
Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N,
Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K,
Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK,
Patel MR, Serruys P, Escaned J. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 2017;376:18241834.
312. Johnson TW, Raber L, di Mario C, Bourantas C, Jia H, Mattesini A, Gonzalo N,
de la Torre Hernandez JM, Prati F, Koskinas K, Joner M, Radu MD, Erlinge D,
Regar E, Kunadian V, Maehara A, Byrne RA, Capodanno D, Akasaka T, Wijns
W, Mintz GS, Guagliumi G. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European
Association of
Percutaneous
Cardiovascular
Interventions.
Eur
Heart
J
2019;40:25662584.
313. Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, Tian N, Lin S, Lu Q, Wu X, Li Q,
Liu Z, Chen Y, Qian X, Wang J, Chai D, Chen C, Li X, Gogas BD, Pan T, Shan
S, Ye F, Chen SL. Intravascular ultrasound versus angiography-guided drugeluting stent implantation:
the
ULTIMATE
trial.
J
Am
Coll
Cardiol
2018;72:31263137.
314. Ali ZA, Maehara A, Genereux P, Shlofmitz RA, Fabbiocchi F, Nazif TM,
Guagliumi G, Meraj PM, Alfonso F, Samady H, Akasaka T, Carlson EB, Leesar
MA, Matsumura M, Ozan MO, Mintz GS, Ben-Yehuda O, Stone GW, ILUMIEN
III: OPTIMIZE PCI Investigators. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet
2016;388:26182628.
315. Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P,
Morel O, Lefrancois Y, Descotes-Genon V, Silvain J, Braik N, Chopard R,
Chatot M, Ecarnot F, Tauzin H, Van Belle E, Belle L, Schiele F. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: results of the multicenter, randomized DOCTORS study (Does Optical Coherence Tomography
Optimize Results of Stenting). Circulation 2016;134:906917.
316. De Luca L, Leonardi S, Cavallini C, Lucci D, Musumeci G, Caporale R,
Abrignani MG, Lupi A, Rakar S, Gulizia MM, Bovenzi FM, De Servi S, EYESHOT
Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: the EYESHOT Study.
Eur Heart J Acute Cardiovasc Care 2015;4:441452.
317. Puymirat E, Simon T, Steg PG, Schiele F, Gueret P, Blanchard D, Khalife K,
Goldstein P, Cattan S, Vaur L, Cambou JP, Ferrieres J, Danchin N, USIK USIC
2000 Investigators, FAST MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012;308:9981006.
318. Puymirat E, Taldir G, Aissaoui N, Lemesle G, Lorgis L, Cuisset T, Bourlard P,
Maillier B, Ducrocq G, Ferrieres J, Simon T, Danchin N. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary
Syndrome). JACC Cardiovasc Interv 2012;5:893902.
319. Bueno H, Rossello X, Pocock SJ, Van de Werf F, Chin CT, Danchin N, Lee SW,
Medina J, Huo Y. In-hospital coronary revascularization rates and postESC Guidelines
1359


<!-- PAGE 72 -->

### Page 72

.............................................................................................................................................................................
discharge mortality risk in non-ST-segment elevation acute coronary syndrome.
J Am Coll Cardiol 2019;74:14541461.
320. Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV, Jr., Brindis RG, Smith SC,
Jr., Harrington RA, Fintel D, Fraulo ES, Califf RM, Gibler WB, Ohman EM,
Peterson ED. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch
Intern Med 2006;166:20272034.
321. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG,
Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC,
Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL,
Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR,
Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon
RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS,
Ohman EM, TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
N
Engl
J
Med
2012;367:12971309.
322. Olivari Z, Chinaglia A, Gonzini L, Falsini G, Pilleri A, Valente S, Gregori G, Rollo
R, My L, Scrimieri P, Lanzillo T, Corrado L, Chiti M, Picardi E, BLITZ 4
Investigators. Invasive strategy in non-ST-segment elevation acute coronary syndrome: what should be the benchmark target in the real world patients?
Insights from BLITZ-4 Quality Campaign. Int J Cardiol 2016;220:761767.
323. Van de Werf F, Gore JM, Avezum A, Gulba DC, Goodman SG, Budaj A,
Brieger D, White K, Fox KA, Eagle KA, Kennelly BM, Investigators GRACE.
Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study. BMJ 2005;330:441.
324. Bueno H. Medical management: the dark side of acute coronary syndromes. Eur
Heart J Cardiovasc Pharmacother 2015;1:179181.
325. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya
J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK.
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur
Heart J 2014;35:20832093.
326. Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, Belardinelli L, FarzanehFar R, Walker G, Morrow DA, Scirica BM. Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Clin
Cardiol 2015;38:469475.
327. Garot P, Morice MC, Tresukosol D, Pocock SJ, Meredith IT, Abizaid A, Carrie
D, Naber C, Iniguez A, Talwar S, Menown IBA, Christiansen EH, Gregson J,
Copt S, Hovasse T, Lurz P, Maillard L, Krackhardt F, Ong P, Byrne J, Redwood
S, Windhovel U, Greene S, Stoll HP, Urban P, LEADERS FREE Investigators. 2year outcomes of high bleeding risk patients after polymer-free drug-coated stents. J Am Coll Cardiol 2017;69:162171.
328. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Smits PC,
Kaiser C, D’Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drugeluting and bare-metal stents: evidence from a comprehensive network metaanalysis. J Am Coll Cardiol 2014;63:299307.
329. Meyer-Saraei R, de Waha S, Eitel I, Desch S, Scheller B, Bohm M, Lauer B,
Gawaz M, Geisler T, Gunkel O, Bruch L, Klein N, Pfeiffer D, Schuler G, Zeymer
U, Thiele H. Thrombus aspiration in non-ST-elevation myocardial infarction -
12-month clinical outcome of the randomised TATORT-NSTEMI trial. Eur
Heart J Acute Cardiovasc Care 2017;6:1017.
330. Thiele H, de Waha S, Zeymer U, Desch S, Scheller B, Lauer B, Geisler T,
Gawaz M, Gunkel O, Bruch L, Klein N, Pfeiffer D, Schuler G, Eitel I. Effect of aspiration thrombectomy on microvascular obstruction in NSTEMI patients: the
TATORT-NSTEMI trial. J Am Coll Cardiol 2014;64:11171124.
331. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR, Jr. Bleeding, blood transfusion,
and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009;53:20192027.
332. Kwok CS, Khan MA, Rao SV, Kinnaird T, Sperrin M, Buchan I, de Belder MA,
Ludman PF, Nolan J, Loke YK, Mamas MA. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ
Cardiovasc Interv 2015;8:e001645.
333. Ndrepepa G, Neumann FJ, Richardt G, Schulz S, Tolg R, Stoyanov KM, Gick M,
Ibrahim T, Fiedler KA, Berger PB, Laugwitz KL, Kastrati A. Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention.
Circ Cardiovasc Interv 2013;6:354361.
334. Rao SV, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective,
current concepts,
and future directions.
J
Am
Coll
Cardiol
2010;55:21872195.
335. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, Budaj A, Niemela
M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner
CD, Chrolavicius S, Mehta SR, RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet
2011;377:14091420.
336. Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbuhler M, Tebaldi M,
Varbella F, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Ferrario M,
Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B,
Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare
N, Tosi P, van ’t Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Juni P,
MATRIX Investigators. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet 2018;392:835848.
337. Ferrante G, Rao SV, Juni P, Da Costa BR, Reimers B, Condorelli G, Anzuini A,
Jolly SS, Bertrand OF, Krucoff MW, Windecker S, Valgimigli M. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials. JACC
Cardiovasc Interv 2016;9:14191434.
338. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N,
Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM,
Braunwald E, TACTICS (Treat Angina with Aggrastat and Determine Cost of
Therapy with an
Invasive or
Conservative
Strategy)Thrombolysis in
Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:18791887.
339. Poole-Wilson
PA,
Pocock
SJ,
Fox
KA,
Henderson
RA,
Wheatley
DJ,
Chamberlain DA, Shaw TR, Clayton TC, Randomised Intervention Trial of unstable Angina Investigators. Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA
3 trial. Heart
2006;92:14731479.
340. Wallentin L, Lindhagen L, Arnstrom E, Husted S, Janzon M, Johnsen SP, Kontny
F, Kempf T, Levin LA, Lindahl B, Stridsberg M, Stahle E, Venge P, Wollert KC,
Swahn E, Lagerqvist B, FRISC-II study group. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISCII): 15 year follow-up of a prospective, randomised, multicentre study. Lancet
2016;388:19031911.
341. Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, Kalra SS, Dalby
MC, O’Mahony C, Malik IS, Knight CJ, Mathur A, Redwood S, Sirker A,
MacCarthy PA, Smith EJ, Wragg A, Jones DA. Complete versus culprit-only lesion intervention in patients with acute coronary syndromes. J Am Coll Cardiol
2018;72:19891999.
342. Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L,
Jorgensen E, Pedersen F, Saunamaki K, Clemmensen P, De Backer O, Ravkilde J,
Tilsted HH, Villadsen AB, Aaroe J, Jensen SE, Raungaard B, Kober L, DANAMI3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet 2015;386:665671.
343. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K,
Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R,
Angeras O, Richardt G, Omerovic E, Compare-Acute Investigators. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J
Med 2017;376:12341244.
344. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B,
Di Pasquale G, Lopez-Sendon J, Faxon DP, Mauri L, Rao SV, Feldman L, Steg
PG, Avezum A, Sheth T, Pinilla-Echeverri N, Moreno R, Campo G, Wrigley
B, Kedev S, Sutton A, Oliver R, Rodes-Cabau J, Stankovic G, Welsh R, Lavi
S, Cantor WJ, Wang J, Nakamya J, Bangdiwala SI, Cairns JA, COMPLETE
Trial Steering Committee and Investigators. Complete revascularization with multivessel
PCI
for myocardial infarction.
N
Engl
J
Med
2019;381:14111421.
345. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, Calcagno S,
Ugo F, Boccuzzi G, Fedele F, Mancone M. Single-staged compared with multistaged PCI in multivessel NSTEMI patients: the SMILE trial. J Am Coll Cardiol
2016;67:264272.
346. Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, Eitel
I, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Jobs A, Lapp H, Piek
JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P,
Montalescot G, Barthelemy O, Huber K, Windecker S, Hunziker L, Savonitto S,
Torremante P, Vrints C, Schneider S, Zeymer U, Desch S, Investigators
CULPRIT-SHOCK. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med 2018;379:16991710.
347. Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT,
Lopez-Sendon J, Avezum A, Goodman SG, Granger CB, Brieger D. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007.
Am J Cardiol 2011;108:617624.


<!-- PAGE 73 -->

### Page 73

.............................................................................................................................................................................
348. Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg 2013;145:15771583, 1583
e1571.
349. Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C,
Jeppsson A. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. Br J Anaesth 2016;117:309315.
350. Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, Han M, Park
DW, Kang SJ, Lee SW, Kim YH, Park SW, Serruys PW, Park SJ. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome.
Am
J
Cardiol
2017;120:380386.
351. Ramanathan K, Abel JG, Park JE, Fung A, Mathew V, Taylor CM, Mancini GBJ,
Gao M, Ding L, Verma S, Humphries KH, Farkouh ME. Surgical versus percutaneous coronary revascularization in patients with diabetes and acute coronary syndromes. J Am Coll Cardiol 2017;70:29953006.
352. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M,
Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA,
Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava
B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, 3rd, Bertrand M,
Fuster V, FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367:23752384.
353. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack
MJ, Holmes DR, Jr., Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys
PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5year follow-up of the randomised,
clinical
SYNTAX
trial.
Lancet
2013;381:629638.
354. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M,
Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V,
Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser
U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP,
Torracca
L,
Valgimigli
M,
Wijns
W,
Witkowski
A,
Kolh
P,
Juni
P.
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 2014;348:g3859.
355. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, Dangas G,
Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic value of the
SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and
Urgent
Intervention
Triage
StrategY)
trial.
J
Am
Coll
Cardiol
2011;57:23892397.
356. Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, Rich
JB. Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. Eur J Cardiothorac Surg 2014;46:400408; discussion 408.
357. Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack C,
Jr., Wiviott SD, Elbez Y, Sabatine MS, Steg PG. Timing of angiography and outcomes in high-risk patients with non-ST-segment-elevation myocardial infarction managed invasively: insights from the TAO trial (Treatment of
Acute
Coronary
Syndrome
With
Otamixaban).
Circulation
2017;136:18951907.
358. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA,
Meuwissen M, Rijpstra TA, Bosker HA, Blans MJ, Bleeker GB, Baak R,
Vlachojannis GJ, Eikemans BJW, van der Harst P, van der Horst ICC, Voskuil M,
van der Heijden JJ, Beishuizen A, Stoel M, Camaro C, van der Hoeven H,
Henriques JP, Vlaar APJ, Vink MA, van den Bogaard B, Heestermans T, de
Ruijter W, Delnoij TSR, Crijns H, Jessurun GAJ, Oemrawsingh PV, Gosselink
MTM, Plomp K, Magro M, Elbers PWG, van de Ven PM, Oudemans-van
Straaten HM, van Royen N. Coronary angiography after cardiac arrest without
ST-segment elevation. N Engl J Med 2019;380:13971407.
359. Desch S, Freund A, Graf T, Fichtlscherer S, Haake H, Preusch M, Hammer F,
Akin I, Christ M, Liebetrau C, Skurk C, Steiner S, Voigt I, Schmitz R, Mudra H,
Ledwoch J, Menck N, Horstkotte J, Pels K, Lahmann AL, Otto S, Lenk K,
Ohlow MA, Hassager C, Nordbeck P, Zeymer U, Jobs A, de Waha-Thiele S,
Olbrich D, Konig I, Klinge K, Thiele H. Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: design and rationale of the TOMAHAWK trial. Am
Heart J 2019;209:2028.
360. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H,
Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung
B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U,
Sirnes PA, Allmen RS, Vrints CJ, ESC Committee for Practice Guidelines. 2014
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic
Diseases of the
European
Society of
Cardiology
(ESC).
Eur
Heart
J
2014;35:28732926.
361. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N,
Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J,
Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH,
Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M, Task
Force for the Diagnosis and Management of Acute Pulmonary Embolism of the
European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
Eur
Heart
J
2014;35:30333069, 3069a3069k.
362. Janssens GN, van der Hoeven NW, Lemkes JS, Everaars H, van de Ven PM,
Marques KMJ, Nap A, van Leeuwen MAH, Appelman Y, Knaapen P, Verouden
NJW, Allaart CP, Brinckman SL, Saraber CE, Plomp KJ, Timmer JR, Kedhi E,
Hermanides RS, Meuwissen M, Schaap J, van der Weerdt AP, van Rossum AC,
Nijveldt R, van Royen N. 1-year outcomes of delayed versus immediate intervention in patients with transient ST-segment elevation myocardial infarction.
JACC Cardiovasc Interv 2019;12:22722282.
363. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006;48:13191325.
364. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, Windecker S,
Spaulding
C,
European
Association for
Percutaneous
Cardiovascular
Interventions (EAPCI), Stent for Life (SFL) Group. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the
European association for percutaneous cardiovascular interventions (EAPCI)/
stent for life (SFL) groups. EuroIntervention 2014;10:3137.
365. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo
F, Kimura T, Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC,
Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:13931402.
366. Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M,
Oktay S, Juni P, Kastrati A, Sianos G, Stefanini GG, Wijns W, Windecker S.
Report of a
European
Society of
Cardiology-European
Association of
Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J 2015;36:26082620.
367. Gross H, Sternberg WH. Myocardial infarction without significant lesions of coronary arteries. Arch Intern Med (Chic) 1939;64:249267.
368. Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography.
Arch
Intern
Med
2006;166:13911395.
369. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint tWGobot, Myocardial EAAWTFftUDo, Infarction. Third universal definition of myocardial infarction. Eur Heart J 2012;33:25512567.
370. Pasupathy S, Tavella R, Beltrame JF. Myocardial infarction with nonobstructive coronary arteries (MINOCA): the past, present, and future management.
Circulation 2017;135:14901493.
371. Pizzi C, Xhyheri B, Costa GM, Faustino M, Flacco ME, Gualano MR, Fragassi G,
Grigioni F, Manzoli L. Nonobstructive versus obstructive coronary artery disease in acute coronary syndrome: a meta-analysis.
J
Am
Heart
Assoc
2016;5:e004185.
372. Safdar B, Spatz ES, Dreyer RP, Beltrame JF, Lichtman JH, Spertus JA, Reynolds
HR, Geda M, Bueno H, Dziura JD, Krumholz HM, D’Onofrio G. Presentation,
clinical profile, and prognosis of young patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): results from the VIRGO study. J
Am Heart Assoc 2018;7:e009174.
373. Ciliberti G, Coiro S, Tritto I, Benedetti M, Guerra F, Del Pinto M, Finocchiaro
G, Cavallini C, Capucci A, Kaski JC, Ambrosio G. Predictors of poor clinical outcomes in patients with acute myocardial infarction and non-obstructed coronary arteries (MINOCA). Int J Cardiol 2018;267:4145.
374. Bainey KR, Welsh RC, Alemayehu W, Westerhout CM, Traboulsi D, Anderson
T, Brass N, Armstrong PW, Kaul P. Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA):
insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study. Int J Cardiol 2018;264:1217.
375. Planer D, Mehran R, Ohman EM, White HD, Newman JD, Xu K, Stone GW.
Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the
Acute Catheterization and Urgent Intervention Triage Strategy trial. Circ
Cardiovasc Interv 2014;7:285293.
376. Kang WY, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, Hur SH, Seong IW,
Hong TJ, Choi DH, Cho MC, Kim CJ, Seung KB, Chung WS, Jang YS, Rha SW,
Bae JH, Cho JG, Park SJ, Korea Acute Myocardial Infarction Registry Investigators.
Are patients with angiographically near-normal coronary arteries who present as acute myocardial infarction actually safe? Int J Cardiol 2011;146:207212.
ESC Guidelines
1361


<!-- PAGE 74 -->

### Page 74

.............................................................................................................................................................................
377. Andersson HB, Pedersen F, Engstrom T, Helqvist S, Jensen MK, Jorgensen E, Kelbaek
H, Rader S, Saunamaki K, Bates E, Grande P, Holmvang L, Clemmensen P. Longterm survival and causes of death in patients with ST-elevation acute coronary syndrome without obstructive coronary artery disease. Eur Heart J 2018;39:102110.
378. Grodzinsky A, Arnold SV, Gosch K, Spertus JA, Foody JM, Beltrame J, Maddox
TM, Parashar S, Kosiborod M. Angina frequency after acute myocardial infarction in patients without obstructive coronary artery disease. Eur Heart J Qual
Care Clin Outcomes 2015;1:9299.
379. Larsen AI, Galbraith PD, Ghali WA, Norris CM, Graham MM, Knudtson ML,
APPROACH Investigators. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. Am J
Cardiol 2005;95:261263.
380. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, De
Caterina R, Zimarino, M, Roffi, M, Kjeldsen, K, Atar, D, Kaski, JC, Sechtem, U,
Tornvall, P. WG on Cardiovascular Pharmacotherapy. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur
Heart J 2017;38:143153.
381. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM,
Lerman A, Cushman M, Kumbhani DJ, Arslanian-Engoren C, Bolger AF,
Beltrame JF, American Heart Association Interventional Cardiovascular Care
Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on
Quality of Care and Outcomes Research. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association.
Circulation 2019;139:e891e908.
382. Redfors B, Ramunddal T, Shao Y, Omerovic E. Takotsubo triggered by acute myocardial infarction: a common but overlooked syndrome? J Geriatr Cardiol
2014;11:171173.
383. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR,
Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G,
Mebazaa A, Omerovic E. Current state of knowledge on Takotsubo syndrome:
a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart
Failure Association of the European Society of Cardiology. Eur J Heart Fail
2016;18:827.
384. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K,
Aldrovandi A, Francone M, Desch S, Gutberlet M, Strohm O, Schuler G,
Schulz-Menger J, Thiele H, Friedrich MG. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA
2011;306:277286.
385. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem
U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018;72:31583176.
386. Lurz P, Luecke C, Eitel I, Fohrenbach F, Frank C, Grothoff M, de Waha S,
Rommel KP, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Gutberlet M.
comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-Trial. J Am Coll Cardiol 2016;67:18001811.
387. Eitel I, Behrendt F, Schindler K, Kivelitz D, Gutberlet M, Schuler G, Thiele H.
Differential diagnosis of suspected apical ballooning syndrome using contrastenhanced magnetic resonance imaging. Eur Heart J 2008;29:26512659.
388. Pathik B, Raman B, Mohd Amin NH, Mahadavan D, Rajendran S, McGavigan
AD, Grover S, Smith E, Mazhar J, Bridgman C, Ganesan AN, Selvanayagam JB.
Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging. Eur Heart J
Cardiovasc Imaging 2016;17:11461152.
389. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E,
Leurent G, Meneveau N, Montaudon M, Perez-David E, Sorensson P, Agewall S.
Myocarditis or "true" infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: a meta-analysis of individual patient data. Atherosclerosis 2015;241:8791.
390. Ciliberti G, Seshasai SRK, Ambrosio G, Kaski JC. Safety of intracoronary provocative testing for the diagnosis of coronary artery spasm. Int J Cardiol
2017;244:7783.
391. Montone RA, Niccoli G, Fracassi F, Russo M, Gurgoglione F, Camma G, Lanza
GA, Crea F. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. Eur Heart J 2018;39:9198.
392. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T,
Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007;50:933939.
393. Di Vito L, Prati F, Arbustini E, Crea F, Maseri A. A "stable" coronary plaque rupture documented by repeated
OCT
studies.
JACC
Cardiovasc
Imaging
2013;6:835836.
394. Takahashi T, Okayama H, Matsuda K, Yamamoto T, Hosokawa S, Kosaki T,
Kawamura G, Shigematsu T, Kinoshita M, Kawada Y, Hiasa G, Yamada T,
Kazatani Y. Optical coherence tomography-based diagnosis in a patient with
ST-elevation myocardial infarction and no obstructive coronary arteries. Int J
Cardiol 2016;223:146148.
395. Gerbaud E, Harcaut E, Coste P, Erickson M, Lederlin M, Labeque JN, Perron
JM, Cochet H, Dos Santos P, Durrieu-Jais C, Laurent F, Montaudon M. Cardiac magnetic resonance imaging for the diagnosis of patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Int J Cardiovasc
Imaging 2012;28:783794.
396. Bugiardini R, Cenko E. A short history of vasospastic angina. J Am Coll Cardiol
2017;70:23592362.
397. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjold A, Gard A,
Jernberg T. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease. Circulation 2017;135:14811489.
398. Arrigo M, Gayat E, Parenica J, Ishihara S, Zhang J, Choi DJ, Park JJ, Alhabib KF,
Sato N, Miro O, Maggioni AP, Zhang Y, Spinar J, Cohen-Solal A, Iwashyna TJ,
Mebazaa A, GREAT Network. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J
Heart Fail 2017;19:201208.
399. Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F,
Armstrong PW, Mahaffey KW, Harrington RA, Diaz R, Ohman EM, White HD,
James S, Granger CB. Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC Heart
Fail 2013;1:223229.
400. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG,
Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez
S, Miani D, Filippatos G, Maggioni AP, Heart ESC Failure Long-Term Registry
Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail
2017;19:12421254.
401. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, LopezSendon J, Budaj A, Goldberg RJ, Klein W, Anderson FA, Jr., Global Registry of
Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the
Global
Registry of
Acute
Coronary
Events
(GRACE).
Circulation
2004;109:494499.
402. Harjola VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, Bueno H, Celutkiene
J, Chioncel O, Coats AJS, Collins SP, de Boer RA, Filippatos G, Gayat E, Hill L,
Laine M, Lassus J, Lommi J, Masip J, Mebazaa A, Metra M, Miro O, Mortara A,
Mueller
C,
Mullens
W,
Peacock
WF,
Pentikainen
M,
Piepoli
MF,
Polyzogopoulou E, Rudiger A, Ruschitzka F, Seferovic P, Sionis A, Teerlink JR,
Thum T, Varpula M, Weinstein JM, Yilmaz MB. Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;doi:10.1002/ejhf.1831.
403. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD,
Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP,
Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman
K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos
G. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the
European Society of Cardiology, the European Society of Emergency Medicine and the
Society of
Academic
Emergency
Medicine.
Eur
J
Heart
Fail
2015;17:544558.
404. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V,
Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the
European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail
2016;18:891975.
405. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,
Gonzalez-Juanatey
JR,
Harjola
VP,
Jankowska
EA,
Jessup
M,
Linde
C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group.
ESC. Eur Heart J 2016;37:21292200.
406. Holmes DR, Jr., Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM,
Vahanian A, Bates ER, Topol EJ. Cardiogenic shock in patients with acute


<!-- PAGE 75 -->

### Page 75

.............................................................................................................................................................................
ischemic syndromes with and without
ST-segment elevation.
Circulation
1999;100:20672073.
407. Kolte D, Khera S, Dabhadkar KC, Agarwal S, Aronow WS, Timmermans R, Jain
D, Cooper HA, Frishman WH, Menon V, Bhatt DL, Abbott JD, Fonarow GC,
Panza JA. Trends in coronary angiography, revascularization, and outcomes of cardiogenic shock complicating non-ST-elevation myocardial infarction. Am J
Cardiol 2016;117:19.
408. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck
P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T,
Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G,
Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C,
Schneider S, Desch S, Zeymer U, CULPRIT-SHOCK Investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl
J Med 2017;377:24192432.
409. Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, Eitel I,
Poss J, Fuernau G, de Waha S. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative metaanalysis of randomized trials. Eur Heart J 2017;38:35233531.
410. Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, Pieri M,
Skurk C, Lauten A, Landmesser U, Westenfeld R, Horn P, Pauschinger M,
Eckner D, Twerenbold R, Nordbeck P, Salinger T, Abel P, Empen K, Busch MC,
Felix SB, Sieweke JT, Moller JE, Pareek N, Hill J, MacCarthy P, Bergmann MW,
Henriques JPS, Mobius-Winkler S, Schulze PC, Ouarrak T, Zeymer U,
Schneider S, Blankenberg S, Thiele H, Schafer A, Westermann D. Impella support for acute myocardial infarction complicated by cardiogenic shock.
Circulation 2019;139:12491258.
411. Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, McNeely C, AlBadarin F, House JA, Kulkarni H, Rao SV. The evolving landscape of impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation 2020;141:273284.
412. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP,
Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, Ngufor C, Girotra S,
Amin AP, Shah ND, Desai NR. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2020:323:734745.
413. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt
G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R,
Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K, IABPSHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:12871296.
414. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de
Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I,
Hambrecht R, Lauer B, Bohm M, Ebelt H, Schneider S, Werdan K, Schuler G,
Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013;382:16381645.
415. Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M,
Meyer-Saraei R, Fuernau G, Eitel I, Hambrecht R, Bohm M, Werdan K, Felix
SB, Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S,
IABPSHOCK II Trial (Intraaortic Balloon Pump in Cardiogenic Shock II)
Investigators. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABPSHOCK II trial. Circulation 2019:139:395403..
416. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J,
White HD, SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction.
JAMA
2006;295:25112515.
417. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller
CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK
Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341:625634.
418. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L,
Wallentin L. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004;43:585591.
419. Alabas OA, Hall M, Dondo TB, Rutherford MJ, Timmis AD, Batin PD, Deanfield
JE, Hemingway H, Gale CP. Long-term excess mortality associated with diabetes following acute myocardial infarction: a population-based cohort study. J
Epidemiol Community Health 2017;71:2532.
420. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L,
Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ,
Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:
the
RESPOND study. Circulation 2010;121:11881199.
421. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J,
Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L, PLATO Study Group.
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO)
trial. Eur Heart J 2010;31:30063016.
422. Study Investigators NICE-SUGAR, Finfer S, Chittock DR, Su SY, Blair D, Foster
D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC,
Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA,
Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:12831297.
423. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE ITTIMI 22 trial. Eur Heart J 2006;27:23232329.
424. ORIGIN Trial Investigators Mellbin LG, Ryden L, Riddle MC, Probstfield J,
Rosenstock J, Diaz R, Yusuf S, Gerstein HC. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J
2013;34:31373144.
425. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the
ORIGIN trial. Diabetes Care 2015;38:2228.
426. Iqbal A, Heller S. Managing hypoglycaemia. Best Pract Res Clin Endocrinol Metab
2016;30:413430.
427. Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley
RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J,
Lehmann L, Kvist K, Buse JB, DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018;61:5865.
428. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute
Myocardial Infarction) Study Group. BMJ 1997;314:15121515.
429. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H,
Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI
study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:5765.
430. Ritsinger V, Malmberg K, Martensson A, Ryden L, Wedel H, Norhammar A.
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose
Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes
Endocrinol 2014;2:627633.
431. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R,
Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes
A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L,
Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano
JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De
Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I,
Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P,
Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S,
Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ,
Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N,
Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A, European Society of
Cardiology (ESC), European Association for Cardiovascular Prevention and
Rehabilitation
(EACPR),
Council on
Cardiovascular
Nursing,
European
Association for Study of Diabetes (EASD), International Diabetes Federation
Europe (IDF-Europe), European Stroke Initiative (EUSI), International Society of
Behavioural Medicine (ISBM), European Society of Hypertension (ESH),
European Society of General Practice/Family Medicine (ESGP/FM/WONCA),
European Heart Network (EHN). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl
2:E1E40.
432. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580591.
433. Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L,
Schnell O, Tuomilehto J, Wood D, Ryden L, Amouyel P, Bruthans J, Conde AC,
Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z,
Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S,
Lovic D, Milicic D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N,
Reiner Z,
Stagmo
M, Stork
S,
Tokgozoglu
L, Vulic
D,
EUROASPIRE
Investigators. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the
ESC Guidelines
1363


<!-- PAGE 76 -->

### Page 76

.............................................................................................................................................................................
EuroObservational
Research
Programme of the
European
Society of
Cardiology. Cardiovasc Diabetol 2015;14:133.
434. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M,
Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M,
Kadowaki T, J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (JDOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol
2017;5:951964.
435. Oellgaard J, Gaede P, Rossing P, Rorth R, Kober L, Parving HH, Pedersen O.
Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61:17241733.
436. Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM,
Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjornsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N
Engl J Med 2018;379:633644.
437. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA,
Knudtson ML, APPROACH Investigators. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:15871592.
438. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U,
Wallentin L, Jernberg T, SWEDEHEART. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 2010;268:4049.
439. Twerenbold R, Wildi K, Jaeger C, Gimenez MR, Reiter M, Reichlin T, Walukiewicz
A, Gugala M, Krivoshei L, Marti N, Moreno Weidmann Z, Hillinger P, Puelacher
C, Rentsch K, Honegger U, Schumacher C, Zurbriggen F, Freese M, Stelzig C,
Campodarve I, Bassetti S, Osswald S, Mueller C. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation 2015;131:20412050.
440. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U,
Wallentin L, Jernberg T, SWEDEHEART. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of
Evidence-Based Care in Heart Disease Evaluated According to Recommended
Therapies (SWEDEHEART). Circulation 2009;120:851858.
441. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M,
Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:10381046.
442. Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S, Dangas
G, Kastrati A, Mehran R, Tamburino C, Capodanno D. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical bayesian network metaanalysis of
124
trials and
28
240
patients.
Circ
Cardiovasc
Interv
2017;10:e004383.
443. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ,
Bersin RM, Van Moore A, Simonton CA, 3rd, Rittase RA, Norton HJ, Kennedy
TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:23282334.
444. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U,
Marsch S, Roskamm H. Prevention of contrast media-associated nephropathy:
randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329336.
445. Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren
MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase
3, controlled, open-label, non-inferiority trial. Lancet 2017;389:13121322.
446. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA,
Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson
R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM, PRESERVE Trial
Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018;378:603614.
447. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA,
Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K,
Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and
Patient Outcomes (PLATO) trial. Circulation 2010;122:10561067.
448. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, Dua A,
Short L, Kane K. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014;383:18141823.
449. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC.
Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol 2012;23:20422049.
450. Zheng H, Xue S, Lian F, Huang RT, Hu ZL, Wang YY. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg
2013;43:459467.
451. Younge JO, Nauta ST, Akkerhuis KM, Deckers JW, van Domburg RT. Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes. Am J Cardiol 2012;109:506510.
452. Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, Fox KA, Joyner
CD, Chrolavicius S, Granger CB, Mehta S, Yusuf S, OASIS 5 and OASIS 6
Investigators. Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J 2010;31:5058.
453. Chase AJ, Fretz EB, Warburton WP, Klinke WP, Carere RG, Pi D, Berry B,
Hilton JD. Association of the arterial access site at angioplasty with transfusion and mortality:
the
M.O.R.T.A.L
study
(Mortality benefit
Of
Reduced
Transfusion after percutaneous coronary intervention via the Arm or Leg).
Heart 2008;94:10191025.
454. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi
M, Vassanelli C, Zardini P, Louvard Y, Hamon M. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures;
systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol
2004;44:349356.
455. Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, Colangelo S,
Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo
R, Meliga E, Testa L, Gabriel HM, Ferlini M, Vranckx P, Valgimigli M, ZEUS
Investigators. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv 2016;9:426436.
456. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G,
GRACE Investigators. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004;126:461469.
457. Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, Hasdai D.
Age, clinical presentation, and outcome of acute coronary syndromes in the
Euroheart acute coronary syndrome survey. Eur Heart J 2006;27:789795.
458. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, Hochholzer W,
Stelzig C, Freese M, Heinisch C, Breidthardt T, Freidank H, Winkler K,
Campodarve I, Gea J, Mueller C. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J
2011;32:13791389.
459. Ekerstad N, Swahn E, Janzon M, Alfredsson J, Lofmark R, Lindenberger M,
Carlsson P. Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction. Circulation
2011;124:23972404.
460. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ,
Ferrucci L, Forman DE. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014;63:747762.
461. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW,
Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM,
Ohman EM, American Heart Association Council on Clinical Cardiology,
Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: nonST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on clinical cardiology: in collaboration with the Society of Geriatric Cardiology.
Circulation 2007;115:25492569.
462. Bauer T, Koeth O, Junger C, Heer T, Wienbergen H, Gitt A, Zahn R, Senges J,
Zeymer U, Acute Coronary Syndromes Registry (ACOS) Investigators. Effect of an invasive strategy on in-hospital outcome in elderly patients with non-STelevation myocardial infarction. Eur Heart J 2007;28:28732878.
463. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA,
Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes.
Ann
Intern
Med
2004;141:186195.
464. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, Gjertsen E,
Dahl-Hofseth O, Ranhoff AH, Gullestad L, Bendz B, After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After
Eighty study):
an open-label randomised controlled trial.
Lancet
2016;387:10571065.
465. Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV, Jr., Ohman EM,
Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, management,
and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes:
results from the
CRUSADE
Initiative.
J
Am
Coll
Cardiol
2007;49:17901797.
466. Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf
RM, Braunwald E, Blazing MA. Effect of simvastatin-ezetimibe compared with


<!-- PAGE 77 -->

### Page 77

.............................................................................................................................................................................
simvastatin monotherapy after acute coronary syndrome among patients 75
years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol
2019:4:846-854..
467. Damman P, Clayton T, Wallentin L, Lagerqvist B, Fox KA, Hirsch A,
Windhausen F, Swahn E, Pocock SJ, Tijssen JG, de Winter RJ. Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes:
a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3
(FIR) trials. Heart 2012;98:207213.
468. McDermid RC, Stelfox HT, Bagshaw SM. Frailty in the critically ill: a novel concept. Crit Care 2011;15:301.
469. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people.
Lancet 2013;381:752762.
470. Bell SP, Saraf AA. Epidemiology of multimorbidity in older adults with cardiovascular disease. Clin Geriatr Med 2016;32:215226.
471. Singh M, Rihal CS, Lennon RJ, Spertus JA, Nair KS, Roger VL. Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization. Circ Cardiovasc Qual Outcomes 2011;4:496502.
472. Gu SZ, Qiu W, Batty JA, Sinclair H, Veerasamy M, Brugaletta S, Neely D, Ford
G, Calvert PA, Mintz GS, Kunadian V. Coronary artery lesion phenotype in frail older patients with non-ST-elevation acute coronary syndrome undergoing invasive care. EuroIntervention 2019;15:e261e268.
473. White HD, Westerhout CM, Alexander KP, Roe MT, Winters KJ, Cyr DD, Fox
KA, Prabhakaran D, Hochman JS, Armstrong PW, Ohman EM, TRILOGY ACS
investigators. Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes
(TRILOGY ACS) trial. Eur Heart J Acute Cardiovasc Care 2016;5:231242.
474. Batty J, Qiu W, Gu S, Sinclair H, Veerasamy M, Beska B, Neely D, Ford G,
Kunadian V, ICON-1 Study Investigators. One-year clinical outcomes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: an analysis of the ICON1 study. Int J Cardiol 2019;274:4551.
475. Bebb O, Smith FG, Clegg A, Hall M, Gale CP. Frailty and acute coronary syndrome: a structured literature review. Eur Heart J Acute Cardiovasc Care
2018;7:166175.
476. de Vries NM, Staal JB, van Ravensberg CD, Hobbelen JS, Olde Rikkert MG,
Nijhuis-van der Sanden MW. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev 2011;10:104114.
477. Gargiulo G, Ariotti S, Santucci A, Piccolo R, Baldo A, Franzone A, Magnani G,
Marino M, Esposito G, Windecker S, Valgimigli M. Impact of sex on 2-year clinical outcomes in patients treated with 6-month or 24-month dual-antiplatelet therapy duration: a pre-specified analysis from the PRODIGY trial. JACC
Cardiovasc Interv 2016;9:17801789.
478. Alabas OA, Gale CP, Hall M, Rutherford MJ, Szummer K, Lawesson SS,
Alfredsson J, Lindahl B, Jernberg T. Sex differences in treatments, relative survival,
and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART Registry. J Am Heart Assoc 2017;6:e007123.
479. Gudnadottir GS, Andersen K, Thrainsdottir IS, James SK, Lagerqvist B,
Gudnason T. Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes. Am Heart
J 2017;191:6574.
480. Araujo C, Pereira M, Laszczynska O, Dias P, Azevedo A. Sex-related inequalities in management of patients with acute coronary syndrome-results from the
EURHOBOP study. Int J Clin Pract 2018;72:e13049.
481. Langabeer JR, 2nd, Champagne-Langabeer T, Fowler R, Henry T. Gender-based outcome differences for emergency department presentation ofnon-STEMI
acute coronary syndrome. Am J Emerg Med 2019;37:179182.
482. Rashid M, Fischman DL, Gulati M, Tamman K, Potts J, Kwok CS, Ensor J, Shoaib
A, Mansour H, Zaman A, Savage MP, Mamas MA. Temporal trends and inequalities in coronary angiography utilization in the management of non-ST-Elevation acute coronary syndromes in the U.S. Sci Rep 2019;9:240.
483. Wilkinson C, Bebb O, Dondo TB, Munyombwe T, Casadei B, Clarke S, Schiele
F, Timmis A, Hall M, Gale CP. Sex differences in quality indicator attainment for myocardial infarction: a nationwide cohort study. Heart 2019;105:516523.
484. Mieres JH, Gulati M, Bairey Merz N, Berman DS, Gerber TC, Hayes SN,
Kramer CM, Min JK, Newby LK, Nixon JV, Srichai MB, Pellikka PA, Redberg RF,
Wenger NK, Shaw LJ, American Heart Association Cardiac Imaging Committee of the Council on Clinical Cardiology, Cardiovascular Imaging and Intervention
Committee of the Council on Cardiovascular Radiology and Intervention. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease:
a consensus statement from the
American
Heart
Association. Circulation 2014;130:350379.
485. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM,
Pollack C, Gibler WB, Ohman EM, Peterson ED, CRUSADE Investigators.
Excess dosing of antiplatelet and antithrombin agents in the treatment of nonST-segment elevation acute coronary syndromes. JAMA 2005;294:31083116.
486. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
Cifkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM,
Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini
T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J
2018;39:31653241.
487. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor
RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane
Database Syst Rev 2016:CD001800.
488. Booth JN, 3rd, Levitan EB, Brown TM, Farkouh ME, Safford MM, Muntner P.
Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2014;113:19331940.
489. Cheng W, Zhang Z, Cheng W, Yang C, Diao L, Liu W. Associations of leisuretime physical activity with cardiovascular mortality: A systematic review and metaanalysis of 44 prospective cohort studies. Eur J Prev Cardiol 2018;25:18641872.
490. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750758.
491. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA
2003;290:8697.
492. Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V,
Chieffo C, Gattone M, Griffo R, Schweiger C, Tavazzi L, Urbinati S, Valagussa F,
Vanuzzo D, GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study,
a multicenter,
randomized controlled trial from the
Italian
Cardiac
Rehabilitation Network. Arch Intern Med 2008;168:21942204.
493. Keteyian SJ, Brawner CA, Savage PD, Ehrman JK, Schairer J, Divine G, Aldred H,
Ophaug K, Ades PA. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J 2008;156:292300.
494. Lahtinen M, Toukola T, Junttila MJ, Piira OP, Lepojarvi S, Kaariainen M, Huikuri
HV, Tulppo MP, Kiviniemi AM. Effect of changes in physical activity on risk for cardiac death in patients with coronary artery disease.
Am
J
Cardiol
2018;121:143148.
495. Benzer W, Rauch B, Schmid JP, Zwisler AD, Dendale P, Davos CH, Kouidi E,
Simon A, Abreu A, Pogosova N, Gaita D, Miletic B, Bonner G, Ouarrak T,
McGee H, EuroCaReD study group. Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. Int J Cardiol 2017;228:5867.
496. Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP,
Granger CB, Hagstrom E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG,
Vedin O, Wallentin L, White HD, Investigators STABILITY. Physical activity and mortality in patients with stable coronary heart disease. J Am Coll Cardiol
2017;70:16891700.
497. de Vries H, Kemps HM, van Engen-Verheul MM, Kraaijenhagen RA, Peek N.
Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. Eur Heart J 2015;36:15191528.
498. Aldcroft SA, Taylor NF, Blackstock FC, O’Halloran PD. Psychoeducational rehabilitation for health behavior change in coronary artery disease: a systematic review of controlled trials. J Cardiopulm Rehabil Prev 2011;31:273281.
499. Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L,
Lichtenstein AH, Kumanyika S, Kraus WE, Fleg JL, Redeker NS, Meininger JC,
Banks J, Stuart-Shor EM, Fletcher BJ, Miller TD, Hughes S, Braun LT, Kopin LA,
Berra K, Hayman LL, Ewing LJ, Ades PA, Durstine JL, Houston-Miller N, Burke LE,
American
Heart
Association
Prevention
Committee of the
Council on
Cardiovascular Nursing. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 2010;122:406441.
500. Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2013;20:620640.
501. Rauch B, Davos CH, Doherty P, Saure D, Metzendorf MI, Salzwedel A, Voller
H, Jensen K, Schmid JP, ‘Cardiac Rehabilitation Section’, European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical
Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane Metabolic and Endocrine Disorders Group,
Institute of General Practice, Heinrich-Heine University, Du¨sseldorf, Germany.
The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study
(CROS). Eur J Prev Cardiol 2016;23:19141939.
502. Voogdt-Pruis HR, Beusmans GH, Gorgels AP, Kester AD, Van Ree JW.
Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomised trial. Br J Gen Pract 2010;60:4046.
ESC Guidelines
1365


<!-- PAGE 78 -->

### Page 78

.............................................................................................................................................................................
503. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De
Bacquer D, Collier T, De Backer G, Faergeman O, EUROACTION Study
Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease:
a paired,
cluster-randomised controlled trial.
Lancet
2008;371:19992012.
504. Barth J, Jacob T, Daha I, Critchley JA. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev
2015:CD006886.
505. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database
Syst Rev 2011:CD008012.
506. Caldeira D, Costa J, Vaz-Carneiro A. [Analysis of the Cochrane Review: influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst
Rev. 2015;5:CD005050]. Acta Med Port 2015;28:424426.
507. Caldeira D, Ferreira JJ, Costa J. Influenza vaccination and prevention of cardiovascular disease mortality. Lancet 2018;391:426427.
508. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015:CD005050.
509. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction.
Heart
2016;102:19531956.
510. Udell JA, Farkouh ME, Solomon SD, Vardeny O. Does influenza vaccination influence cardiovascular complications?
Expert
Rev
Cardiovasc
Ther
2015;13:593596.
511. Paules CI, Subbarao K. Influenza vaccination and prevention of cardiovascular disease mortality - authors’ reply. Lancet 2018;391:427428.
512. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman
MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A,
Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS,
Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019
ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111188.
513. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park
JG, White JA, Bohula EA, Braunwald E, IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved
Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation
2018;137:15711582.
514. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius
H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P,
Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA,
Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:
23872397.
515. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, Jr., DePalma
SM, Minissian MB, Orringer CE, Smith SC, Jr. 2017 focused update of the 2016
ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017;70:17851822.
516. Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham
LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P,
Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD.
Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll
Cardiol 2017;70:12901301.
517. Silvestris E, Cafforio P, D’Oronzo S, Felici C, Silvestris F, Loverro G. In vitro differentiation of human oocyte-like cells from oogonial stem cells: single-cell isolation and molecular characterization. Hum Reprod 2018;33:464473.
518. Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH,
Cannon CP. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control.
Circulation 2016;134:19311943.
519. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES,
Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R,
Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med
2015;372:14891499.
520. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM,
Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey
KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci
P,
White
HD,
Zeiher
AM,
ODYSSEY
OUTCOMES
Committees and
Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:20972107.
521. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj
AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V,
Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tunon J, White
HD, Zeiher AM, Schwartz GG, Steg PG, ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:618628.
522. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;4:CD011748.
523. Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, Miller
K, Kastelein JJ. Safety of very low low-density lipoprotein cholesterol levels with alirocumab:
pooled data from randomized trials.
J
Am
Coll
Cardiol
2017;69:471482.
524. Arbel R, Hammerman A, Triki N, Greenberg D. PCSK9 inhibitors may improve cardiovascular outcomes-can we afford them? Int J Cardiol 2016;220:242245.
525. Zhai C, Cong H, Liu Y, Zhang Y, Liu X, Zhang H, Ren Z. Effect of high-dose statin pretreatment on the incidence of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: grading the evidence through a cumulative meta-analysis. Clin Cardiol 2015;38:668678.
526. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT,
Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT
Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:1122.
527. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB,
Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM,
McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators.
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:15191529.
528. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I,
Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson
J, Vilsboll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:18341844.
529. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA,
Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman
B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial
Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl
J Med 2016;375:311322.
530. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw
W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group.
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J
Med 2017;377:644657.
531. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG,
Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding
JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM,
Sabatine MS, DECLARETIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347357.
532. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M,
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG
OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:21172128.
533. Cholesterol Treatment Trialists’ (CTT) Collaborators Kearney PM, Blackwell L,
Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117125.
534. Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent C, Blackwell L,
Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J,
Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet
2010;376:16701681.
535. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA,
Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER
Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:17131722.
536. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C,
Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients.
ACE-Inhibitor
Myocardial
Infarction
Collaborative Group. Lancet 2000;355:15751581.
537. SOLVD Investigators Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293302.
538. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR,
Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J,


<!-- PAGE 79 -->

### Page 79

............................................................................................................................
Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The
SAVE Investigators. N Engl J Med 1992;327:669677.
539. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebocontrolled studiesCIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.
Am Heart J 2002;143:301307.
540. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM,
Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J
Med 1996;334:13491355.
541. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda
M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A,
Skene A, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:713.
542. Hwang D, Lee JM, Kim HK, Choi KH, Rhee TM, Park J, Park TK, Yang JH, Song
YB, Choi JH, Hahn JY, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ,
Gwon HC, Jeong MH, Kim HS, KAMIR Investigators. Prognostic impact of betablocker dose after acute myocardial infarction. Circ J 2019;83:410417.
543. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW,
Montalescot G, Hsu A, Fox KA, Lincoff AM. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7:872881.
544. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, Cottin Y,
Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrieres J,
Juilliere Y, Simon T, Danchin N. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.
545. Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual Outcomes 2018;11:e004356.
546. Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O’Neill WW, Grines CL.
Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43:17731779.
547. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio
JJ, Devereaux PJ, Alexander KP, Wetterslev J, Messerli FH. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014;127:939953.
548. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes
J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N
Engl J Med 1999;341:709717.
549. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R,
Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:13091321.
550. Spertus JA, Eagle KA, Krumholz HM, Mitchell KR, Normand SL, American College of Cardiology, American Heart Association Task Force on Performance
Measures. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. Circulation 2005;111:17031712.
551. National Quality Forum. Measure evaluation criteria. http://www.qualityforum.
org/Measuring_Performance/Submitting_Standards/Measure_Evaluation_
Criteria.aspx#comparison (7 January 2020).
552. Raleigh VS, Root C. Getting the measure of quality: opportunities and challenges. http://www.kingsfund.org.uk/document.rm?id=8550 (4 February 2020).
553. Lindenauer PK, Remus D, Roman S, Rothberg MB, Benjamin EM, Ma A, Bratzler
DW. Public reporting and pay for performance in hospital quality improvement.
N Engl J Med 2007;356:486496.
554. Forster AJ, van Walraven C. The use of quality indicators to promote accountability in health care: the good, the bad, and the ugly. Open Med 2012;6:e75e79.
555. Bhatt DL, Drozda JP, Jr., Shahian DM, Chan PS, Fonarow GC, Heidenreich PA,
Jacobs JP, Masoudi FA, Peterson ED, Welke KF. ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise: A
report of the American College of Cardiology/American Heart Association
Task Force on Performance Measures and The Society of Thoracic Surgeons. J
Am Coll Cardiol 2015;66:22302245.
556. Donabedian
A.
The quality of care.
How can it be assessed?
JAMA
1988;260:17431748.
557. Spertus JA, Bonow RO, Chan P, Diamond GA, Drozda JP, Jr., Kaul S,
Krumholz HM, Masoudi FA, Normand SL, Peterson ED, Radford MJ,
Rumsfeld JS, ACCF/AHA Task Force on Performance Measures. ACCF/AHA
new insights into the methodology of performance measurement: a report of the
American
College of
Cardiology
Foundation/American
Heart
Association Task Force on performance measures. J Am Coll Cardiol
2010;56:17671782.
558. Krumholz HM, Normand SL, Spertus JA, Shahian DM, Bradley EH. Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. Health Aff (Millwood) 2007;26:7585.
559. Arnold SV, Grodzinsky A, Gosch KL, Kosiborod M, Jones PG, Breeding T,
Towheed A, Beltrame J, Alexander KP, Spertus JA. Predictors of physician under-recognition of angina in outpatients with stable coronary artery disease.
Circ Cardiovasc Qual Outcomes 2016;9:554559.
560. Schiele F, Gale CP, Bonnefoy E, Capuano F, Claeys MJ, Danchin N, Fox KA,
Huber K, Iakobishvili Z, Lettino M, Quinn T, Rubini Gimenez M, Botker HE,
Swahn E, Timmis A, Tubaro M, Vrints C, Walker D, Zahger D, Zeymer U,
Bueno H. Quality indicators for acute myocardial infarction: a position paper of the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care
2017;6:3459.
561. Schiele F, Gale CP, Simon T, Fox KAA, Bueno H, Lettino M, Tubaro M,
Puymirat E, Ferrieres J, Meneveau N, Danchin N. Assessment of quality indicators for acute myocardial infarction in the FAST-MI (French Registry of Acute
ST-Elevation or
Non-ST-Elevation
Myocardial
Infarction)
Registries.
Circ
Cardiovasc Qual Outcomes 2017;10.
562. Timoteo AT, Mimoso J, Investigators ProACS. Assessment of quality performance measures in patients with acute coronary syndromes: data from the
Portuguese Registry of Acute Coronary Syndromes (ProACS), a nationwide registry. J Eval Clin Pract 2018;24:439446.
563. Bebb O, Hall M, Fox KAA, Dondo TB, Timmis A, Bueno H, Schiele F, Gale CP.
Performance of hospitals according to the ESC ACCA quality indicators and
30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP)
register. Eur Heart J 2017;38:974982.
ESC Guidelines
1367

<!-- 2020_Adult_Congenital_Heart_Disease.md -->

# ESC Guidelines: Adult Congenital Heart Disease (2020)

**Source**: `2020_Adult_Congenital_Heart_Disease.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 84

---

## Table of Contents

- [l](#l) *(p. 8)*
- [tblfn1](#tblfn1) *(p. 12)*
- [tblfn2](#tblfn2) *(p. 13)*
- [tblfn3](#tblfn3) *(p. 15)*
- [tblfn4](#tblfn4) *(p. 15)*
- [ehaa554-T6](#ehaa554-t6) *(p. 15)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn10](#tblfn10) *(p. 18)*
- [tblfn11](#tblfn11) *(p. 18)*
- [tblfn12](#tblfn12) *(p. 18)*
- [tblfn13](#tblfn13) *(p. 18)*
- [tblfn14](#tblfn14) *(p. 18)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn5](#tblfn5) *(p. 20)*
- [tblfn6](#tblfn6) *(p. 20)*
- [tblfn7](#tblfn7) *(p. 20)*
- [tblfn8](#tblfn8) *(p. 20)*
- [tblfn9](#tblfn9) *(p. 20)*
- [l](#l) *(p. 8)*
- [tblfn24](#tblfn24) *(p. 21)*
- [tblfn25](#tblfn25) *(p. 21)*
- [l](#l) *(p. 8)*
- [tblfn15](#tblfn15) *(p. 22)*
- [tblfn16](#tblfn16) *(p. 22)*
- [tblfn17](#tblfn17) *(p. 22)*
- [tblfn18](#tblfn18) *(p. 22)*
- [tblfn19](#tblfn19) *(p. 22)*
- [tblfn20](#tblfn20) *(p. 22)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn26](#tblfn26) *(p. 25)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn27](#tblfn27) *(p. 28)*
- [tblfn28](#tblfn28) *(p. 28)*
- [tblfn34](#tblfn34) *(p. 28)*
- [ehaa554-T11](#ehaa554-t11) *(p. 28)*
- [tblfn35](#tblfn35) *(p. 28)*
- [tblfn36](#tblfn36) *(p. 28)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn29](#tblfn29) *(p. 30)*
- [tblfn30](#tblfn30) *(p. 30)*
- [tblfn31](#tblfn31) *(p. 30)*
- [tblfn32](#tblfn32) *(p. 30)*
- [tblfn33](#tblfn33) *(p. 30)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn37](#tblfn37) *(p. 33)*
- [tblfn38](#tblfn38) *(p. 33)*
- [tblfn39](#tblfn39) *(p. 33)*
- [tblfn40](#tblfn40) *(p. 33)*
- [tblfn41](#tblfn41) *(p. 33)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn42](#tblfn42) *(p. 35)*
- [tblfn43](#tblfn43) *(p. 35)*
- [tblfn44](#tblfn44) *(p. 35)*
- [tblfn45](#tblfn45) *(p. 35)*
- [tblfn46](#tblfn46) *(p. 35)*
- [l](#l) *(p. 8)*
- [tblfn47](#tblfn47) *(p. 36)*
- [tblfn48](#tblfn48) *(p. 36)*
- [tblfn49](#tblfn49) *(p. 36)*
- [tblfn50](#tblfn50) *(p. 36)*
- [tblfn51](#tblfn51) *(p. 36)*
- [tblfn52](#tblfn52) *(p. 37)*
- [tblfn53](#tblfn53) *(p. 37)*
- [l](#l) *(p. 8)*
- [tblfn66](#tblfn66) *(p. 38)*
- [tblfn67](#tblfn67) *(p. 38)*
- [tblfn68](#tblfn68) *(p. 38)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn54](#tblfn54) *(p. 40)*
- [tblfn55](#tblfn55) *(p. 40)*
- [tblfn56](#tblfn56) *(p. 40)*
- [tblfn57](#tblfn57) *(p. 40)*
- [l](#l) *(p. 8)*
- [tblfn58](#tblfn58) *(p. 41)*
- [tblfn59](#tblfn59) *(p. 41)*
- [tblfn60](#tblfn60) *(p. 41)*
- [tblfn61](#tblfn61) *(p. 41)*
- [tblfn62](#tblfn62) *(p. 41)*
- [l](#l) *(p. 8)*
- [tblfn63](#tblfn63) *(p. 42)*
- [tblfn64](#tblfn64) *(p. 42)*
- [tblfn65](#tblfn65) *(p. 42)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn69](#tblfn69) *(p. 46)*
- [tblfn70](#tblfn70) *(p. 46)*
- [tblfn71](#tblfn71) *(p. 46)*
- [tblfn72](#tblfn72) *(p. 46)*
- [tblfn73](#tblfn73) *(p. 46)*
- [tblfn74](#tblfn74) *(p. 46)*
- [tblfn75](#tblfn75) *(p. 46)*
- [l](#l) *(p. 8)*
- [tblfn76](#tblfn76) *(p. 47)*
- [tblfn77](#tblfn77) *(p. 47)*
- [tblfn78](#tblfn78) *(p. 47)*
- [tblfn79](#tblfn79) *(p. 47)*
- [tblfn80](#tblfn80) *(p. 47)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn81](#tblfn81) *(p. 49)*
- [tblfn82](#tblfn82) *(p. 49)*
- [tblfn83](#tblfn83) *(p. 49)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn84](#tblfn84) *(p. 52)*
- [tblfn85](#tblfn85) *(p. 52)*
- [tblfn86](#tblfn86) *(p. 52)*
- [tblfn87](#tblfn87) *(p. 52)*
- [tblfn88](#tblfn88) *(p. 52)*
- [tblfn89](#tblfn89) *(p. 52)*
- [tblfn90](#tblfn90) *(p. 52)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn91](#tblfn91) *(p. 57)*
- [tblfn92](#tblfn92) *(p. 57)*
- [tblfn93](#tblfn93) *(p. 57)*
- [l](#l) *(p. 8)*
- [tblfn94](#tblfn94) *(p. 58)*
- [tblfn95](#tblfn95) *(p. 58)*
- [tblfn96](#tblfn96) *(p. 58)*
- [tblfn97](#tblfn97) *(p. 58)*
- [l](#l) *(p. 8)*
- [tblfn98](#tblfn98) *(p. 59)*
- [tblfn99](#tblfn99) *(p. 59)*
- [tblfn100](#tblfn100) *(p. 59)*
- [l](#l) *(p. 8)*
- [tblfn101](#tblfn101) *(p. 60)*
- [tblfn102](#tblfn102) *(p. 60)*
- [tblfn103](#tblfn103) *(p. 60)*
- [tblfn104](#tblfn104) *(p. 60)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn105](#tblfn105) *(p. 62)*
- [tblfn106](#tblfn106) *(p. 62)*
- [tblfn107](#tblfn107) *(p. 62)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn108](#tblfn108) *(p. 65)*
- [tblfn109](#tblfn109) *(p. 65)*
- [tblfn110](#tblfn110) *(p. 65)*
- [l](#l) *(p. 8)*
- [tblfn111](#tblfn111) *(p. 66)*
- [tblfn112](#tblfn112) *(p. 66)*
- [tblfn113](#tblfn113) *(p. 66)*
- [tblfn114](#tblfn114) *(p. 66)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [l](#l) *(p. 8)*
- [tblfn21](#tblfn21) *(p. 73)*
- [tblfn22](#tblfn22) *(p. 73)*
- [tblfn23](#tblfn23) *(p. 73)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2020 ESC Guidelines for the management of adult congenital heart disease
The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC)
Endorsed by: Association for European Paediatric and Congenital Cardiology
(AEPC), International Society for Adult Congenital Heart Disease (ISACHD)
Authors/Task Force Members: Helmut Baumgartner* (Chairperson) (Germany),
Julie De Backer* (Chairperson) (Belgium), Sonya V. Babu-Narayan (United
Kingdom), Werner Budts (Belgium), Massimo Chessa 1 (Italy),
Gerhard-Paul Diller (Germany), Bernard Iung (France), Jolanda Kluin
(Netherlands), Irene M. Lang (Austria), Folkert Meijboom (Netherlands), Philip
Moons (Belgium), Barbara J. M. Mulder (Netherlands), Erwin Oechslin (Canada),
Jolien W. Roos-Hesselink (Netherlands), Markus Schwerzmann (Switzerland),
Lars Sondergaard (Denmark), Katja Zeppenfeld (Netherlands)
Document reviewers: Sabine Ernst (CPG Review Coordinator) (United Kingdom), Magalie Ladouceur
(CPG Review Coordinator) (France), Victor Aboyans (France), David Alexander (United Kingdom),
Ruxandra Christodorescu (Romania), Domenico Corrado (Italy), Michele D’Alto (Italy),
* Corresponding authors: Helmut Baumgartner, Department of Cardiology III: Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Albert Schweitzer
Campus 1, Building A1, D-48149, Muenster, Germany. Tel: þ49 251 83 46110, Fax: þ49 251 83 46109, E-mail: helmut.baumgartner@ukmuenster.de. Julie De Backer,
Department of Cardiology, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent. Tel: þ32 9 332 56 27, E-mail: Julie.debacker@ugent.be.
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers, and Author/Task Force Member Afﬁliations: listed in the Appendix.
1Representing the AEPC.
ESC entities having participated in the development of this document:
Associations: Association for Acute Cardiovascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European
Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council of Cardio-Oncology, Council on Valvular Heart Disease.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Development Anatomy and Pathology, e-Cardiology, Pulmonary Circulation and Right Ventricular Function.
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
V
C The European Society of Cardiology 2020. All rights reserved. For permissions please email: journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehaa554


<!-- PAGE 2 -->

### Page 2

.........................................................................................................
Natasja de Groot (Netherlands), Victoria Delgado (Netherlands), Giovanni Di Salvo (United Kingdom),
Laura Dos Subira (Spain), Andreas Eicken1 (Germany), Donna Fitzsimons (United Kingdom), Alexandra A.
Frogoudaki (Greece), Michael Gatzoulis (United Kingdom), Stephane Heymans (Netherlands/Belgium),
Ju¨ rgen Ho¨ rer (Germany), Lucile Houyel (France), Guillaume Jondeau (France), Hugo A. Katus (Germany),
Ulf Landmesser (Germany), Basil S. Lewis (Israel), Alexander Lyon (United Kingdom), Christian E. Mueller
(Switzerland), Darren Mylotte (Ireland), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio
(Italy), Marco Rofﬁ(Switzerland), Raphael Rosenhek (Austria), Evgeny Shlyakhto (Russia), Iain A. Simpson
(United Kingdom), Miguel Sousa-Uva (Portugal), Christian Tobias Torp-Pedersen (Denmark), Rhian M.
Touyz (United Kingdom), Alexander Van De Bruaene (Belgium)
The disclosure forms of all experts involved in the development of these Guidelines are available on the
ESC website www.escardio.org/guidelines
Click here to access the corresponding chapter in Section 17- Congenital heart disease in children and adults
...................................................................................................................................................................................................
Keywords
Guidelines • congenital heart disease • disease • adult • diagnosis • imaging • late complications • medical treatment • congenital cardiac surgery • catheter intervention • patient follow-up • recommendations
Table of contents
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 568
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
2.1 Why do we need new Guidelines on the management of adult congenital heart disease? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
2.2 Content of these Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
2.3 New format of the Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
2.4 How to use these Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
2.5 What is new in the 2020 Guidelines? . . . . . . . . . . . . . . . . . . . . . . . . 570
3 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
3.1 Prevalence of adult congenital heart disease . . . . . . . . . . . . . . . . . 570
3.2 Organization of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
3.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575
3.3.1 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577
3.3.2 Cardiovascular magnetic resonance imaging . . . . . . . . . . . . . 578
3.3.3 Cardiovascular computed tomography . . . . . . . . . . . . . . . . . . 578
3.3.4 Cardiopulmonary exercise testing . . . . . . . . . . . . . . . . . . . . . . 578
3.3.5 Cardiac catheterization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 578
3.3.6 Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 578
3.4 Therapeutic considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579
3.4.1 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579
3.4.2 Arrhythmias and sudden cardiac death . . . . . . . . . . . . . . . . . . 579
3.4.2.1 Arrhythmia substrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579
3.4.2.2 Assessment in patients with suspected/documented arrythmias and arrythmia management . . . . . . . . . . . . . . . . . . . . . . . 580
3.4.2.3 Sinus node dysfunction, atrioventricular block and infra-hisian conduction delay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581
3.4.2.4 Sudden cardiac death and risk stratification . . . . . . . . . . . . . 581
3.4.3 Pulmonary hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 582
3.4.3.1 Introduction and classification . . . . . . . . . . . . . . . . . . . . . . . . . 582
3.4.3.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
3.4.3.2.1 The diagnostic work-up of pulmonary hypertension in adult congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
3.4.3.2.2 Risk assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
3.4.3.3 Therapeutic management of pulmonary hypertension in adult congential heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
3.4.3.3.1 Expert centres . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
3.4.3.3.2 General measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
3.4.3.3.3 Anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
3.4.3.3.4 Shunt repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584
3.4.3.3.5 Pulmonary arterial hypertension-directed medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584
3.4.4 Surgical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584
3.4.5 Catheter intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585
3.4.6 Infective endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585
3.4.7 Antithrombotic treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585
3.4.8 Management of cyanotic patients . . . . . . . . . . . . . . . . . . . . . . . . 585
3.4.8.1 Adoptive mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586
3.4.8.2 Multisystem disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586
3.4.8.3 Clinical presentation and natural history . . . . . . . . . . . . . . . . 586
3.4.8.4 Late complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586
3.4.8.5 Diagnostic aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586
3.4.8.6 Laboratory precautions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587
3.4.8.7 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587
3.4.8.8 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587
3.4.8.9 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 587
3.4.8.10 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588
3.5 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588
3.5.1 Sex differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588
3.5.2 Adult congenital heart disease at more advanced age . . . . . 588
3.5.3 Advance care planning and end-of-life care . . . . . . . . . . . . . . 588
3.5.4 Insurance and employment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588
3.5.5 Exercise and sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589
3.5.6 Non-cardiac surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589
3.5.7 Pregnancy, contraception, and genetic counselling . . . . . . . 589
3.5.7.1 Pregnancy and contraception . . . . . . . . . . . . . . . . . . . . . . . . . 589
3.5.7.2 Genetic counselling and recurrence risk . . . . . . . . . . . . . . . . . 590


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
4 Specific lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591
4.1 Atrial septal defect and anomalous pulmonary venous connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591
4.1.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 591
4.1.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 591
4.1.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591
4.1.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 591
4.1.5 Specific aspects of isolated anomalous pulmonary venous connections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592
4.1.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 593
4.1.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594
4.2 Ventricular septal defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594
4.2.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 594
4.2.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 594
4.2.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594
4.2.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 595
4.2.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 595
4.2.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595
4.3 Atrioventricular septal defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595
4.3.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 595
4.3.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 596
4.3.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 596
4.3.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 596
4.3.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 597
4.3.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597
4.4 Patent ductus arteriosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .597
4.4.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 597
4.4.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 597
4.4.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598
4.4.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 598
4.4.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 598
4.4.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598
4.5 Left ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . 598
4.5.1 Valvular aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598
4.5.1.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 598
4.5.1.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 598
4.5.1.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598
4.5.1.4 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600
4.5.1.5 Surgical/catheter interventional treatment . . . . . . . . . . . . . . 600
4.5.1.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 600
4.5.1.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600
4.5.2 Supravalvular aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601
4.5.2.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 601
4.5.2.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 601
4.5.2.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601
4.5.2.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . 602
4.5.2.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 602
4.5.2.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602
4.5.3 Subaortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602
4.5.3.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 602
4.5.3.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 602
4.5.3.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602
4.5.3.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . 602
4.5.3.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 602
4.5.3.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603
4.6 Coarctation of the aorta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603
4.6.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 603
4.6.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 603
4.6.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603
4.6.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 604
4.6.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 604
4.6.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605
4.7 Aortopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605
4.7.1 Marfan syndrome and related heritable thoracic aortic diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605
4.7.1.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 605
4.7.1.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 606
4.7.1.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606
4.7.1.4 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606
4.7.1.5 Surgical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606
4.7.1.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 607
4.7.1.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607
4.7.2 Bicuspid aortic disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607
4.7.3 Turner syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607
4.8 Right ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . 608
4.8.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 608
4.8.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 608
4.8.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609
4.8.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 609
4.8.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 609
4.8.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609
4.9 Ebstein anomaly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610
4.9.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 610
4.9.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 610
4.9.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611
4.9.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 611
4.9.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 611
4.9.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611
4.10 Tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 612
4.10.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 612
4.10.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 612
4.10.3 Diagnostic work-up of repaired patients . . . . . . . . . . . . . . . 612
4.10.4 Late surgical/catheter interventional treatment . . . . . . . . . 613
4.10.5 Indications for electrophysiological testing and implantable cardioverter defibrillator . . . . . . . . . . . . . . . . . . . . . . . . . 614
4.10.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 615
4.10.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
4.11 Pulmonary atresia with ventricular septal defect . . . . . . . . . . . . 615
4.11.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 615
4.11.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 615
4.11.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
4.11.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . 616
4.11.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 616
4.11.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 616
4.12 Transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . 616
4.12.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 616
4.12.2 Atrial switch operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 616
4.12.2.1 Clinical presentation after atrial switch . . . . . . . . . . . . . . . . 616
4.12.2.2 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618
4.12.2.3 Medical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618
4.12.2.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . 618
4.12.3 Arterial switch operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619
4.12.3.1 Clinical presentation after arterial switch . . . . . . . . . . . . . . 619
4.12.3.2 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619
ESC Guidelines
565


<!-- PAGE 4 -->

### Page 4

.............................................................................................................................................................................
4.12.3.3 Surgical/catheter interventional treatment . . . . . . . . . . . . . 620
4.12.4 Rastelli-type operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620
4.12.4.1 Clinical presentation after Rastelli-type repair . . . . . . . . . . 620
4.12.4.2 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620
4.12.4.3 Surgical/catheter interventional treatment . . . . . . . . . . . . . 620
4.12.5 Follow-up recommendations (irrespective of type of repair) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620
4.12.6 Additional considerations (irrespective of type of repair) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620
4.13 Congenitally corrected transposition of the great arteries . . . 620
4.13.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 620
4.13.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 621
4.13.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621
4.13.4 Medical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621
4.13.5 Surgical/catheter interventional treatment . . . . . . . . . . . . . 621
4.13.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 622
4.13.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622
4.14 Right ventricular to pulmonary artery conduit . . . . . . . . . . . . . . 622
4.14.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 622
4.14.2 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622
4.14.3 Surgical/catheter interventional treatment . . . . . . . . . . . . . 622
4.14.4 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 623
4.14.5 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623
4.15 Univentricular heart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623
4.15.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 623
4.15.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 623
4.15.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624
4.15.4 Conservative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
4.15.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 625
4.15.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
4.16 Patients after Fontan operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
4.16.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 625
4.16.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 625
4.16.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626
4.16.4 Medical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626
4.16.5 Surgical/interventional treatment . . . . . . . . . . . . . . . . . . . . . . 626
4.16.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 627
4.16.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627
4.17 Coronary anomalies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627
4.17.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 627
4.17.1.1 Anomalous coronary artery from the pulmonary artery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627
4.17.1.2 Anomalous aortic origin of a coronary artery . . . . . . . . . . . 627
4.17.1.3 Coronary artery fistulae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628
4.17.2 Diagnostic evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628
4.17.3 Surgical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628
5 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628
6 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.1 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.1.1 Organization of care and patient evaluation . . . . . . . . . . . . . . 629
6.1.2 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.1.3 Arrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.1.4 Pulmonary arterial hypertension . . . . . . . . . . . . . . . . . . . . . . . . 629
6.1.5 Cyanotic patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.2 Specific lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.2.1 Shunt lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.2.2 Left ventricular outflow tract obstruction and coarctation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.2.3 Aortopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629
6.2.4 Right ventricular outflow tract obstruction . . . . . . . . . . . . . . 629
6.2.5 Ebstein anomaly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
6.2.6 Tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
6.2.7 Transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . 630
6.2.8 Congenitally corrected transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
6.2.9 Univentricular heart and Fontan operation . . . . . . . . . . . . . . 630
6.2.10 Coronary anomalies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
7 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
7.1 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
7.1.1 Organization of care and patient evaluation . . . . . . . . . . . . . . 630
7.1.2 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
7.1.3 Arrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630
7.1.4 Pulmonary arterial hypertension . . . . . . . . . . . . . . . . . . . . . . . . 630
7.1.5 Cyanotic patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2 Specific lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2.1 Shunt lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2.2 Left ventricular outflow tract obstruction . . . . . . . . . . . . . . . 631
7.2.3 Aortic coarctation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2.4 Aortopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2.5 Right ventricular outflow tract obstruction . . . . . . . . . . . . . . 631
7.2.6 Ebstein anomaly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2.7 Tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2.8 Transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . 631
7.2.9 Congenitally corrected transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631
7.2.10 Univentricular heart and Fontan operation . . . . . . . . . . . . . 632
7.2.11 Coronary anomalies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632
8 ‘What to do’ and ‘what not to do’ messages . . . . . . . . . . . . . . . . . . . . . . 632
9 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 635
10 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 636
Tables of Recommendations
Recommendations for treatment of arrhythmias in adult congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581
Recommendations for treatment of pulmonary arterial hypertension associated with congenital heart disease . . . . . . . . . . . . . . 584
Recommendations for intervention in atrial septal defect
(native and residual) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592
Recommendations for intervention in ventricular septal defect (native and residual) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595
Recommendations for intervention in atrioventricular septal defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597
Recommendations for intervention in patent ductus arteriosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598
Recommendations for intervention in valvular aortic stenosis . . . . . . . 600
Recommendations for intervention in supravalvular aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602
Recommendations for intervention in subaortic stenosis . . . . . . . . . . . 603
Recommendations for intervention in coarctation and re-coarctation of the aorta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604
Recommendations for aortic surgery in aortopathies . . . . . . . . . . . . . . . 608


<!-- PAGE 5 -->

### Page 5

.............................................................................................................................................................................
Recommendations for intervention in right ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609
Recommendations for intervention in Ebstein anomaly . . . . . . . . . . . . . 611
Recommendations for intervention after repair of tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 614
Recommendations for intervention in transposition of the great arteries after atrial switch operation . . . . . . . . . . . . . . . . . . . . . . . . . 619
Recommendations for intervention in transposition of the great arteries after arterial switch operation . . . . . . . . . . . . . . . . . . . . . . . 620
Recommendations for intervention in congenitally corrected transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621
Recommendations for intervention in right ventricular to pulmonary artery conduits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622
Special considerations and Recommendations for intervention in univentricular heart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624
Special considerations and Recommendations for intervention after Fontan operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627
Recommendations for the management of patients with anomalous coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569
Table 3 Selected revised recommendations, new recommendations, and new concepts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 571
Table 4 Classification of congenital heart disease complexity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575
Table 5 Staff requirements for specialist ACHD centres . . . . . . . . . . . . 577
Table 6 Indications for cardiovascular magnetic resonance imaging in ACHD patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577
Table 7 Risk estimates for arrhythmic events and bradycardias in ACHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580
Table 8 Definitions of pulmonary hypertension subtypes and their occurrence in ACHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583
Table 9 Risk reduction strategies in patients with cyanotic congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587
Table 10 Congenital heart disease with high risk and extremely high risk for pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 590
Table 11 Recurrence rates for various congenital heart lesions according to the sex of the affected parent . . . . . . . . . . . . . . . . . 590
Table 12 Diagnostic criteria for degree of aortic stenosis severity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599
List of figures
Figure 1 Central illustration. Congenital heart disease is a lifelong chronic condition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 576
Figure 2 Management of atrial septal defect . . . . . . . . . . . . . . . . . . . . . . . . 593
Figure 3 Management of ventricular septal defect . . . . . . . . . . . . . . . . . . 596
Figure 4 Management of patent ductus arteriosus . . . . . . . . . . . . . . . . . . 599
Figure 5 Management of left ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601
Figure 6 Management of coarctation and re-coarctation of the aorta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605
Figure 7 Management of right ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610
Figure 8 Management of repaired tetralogy of Fallot:
long-term complications to address during follow-up . . . . . . . . . . . . . . 613
Figure 9 Management of transposition of the great arteries:
long-term complications to address during follow-up . . . . . . . . . . . . . . 617
Abbreviations and acronyms
3D
Three-dimensional
6MWT
6-minute walk test
AAOCA
Anomalous aortic origin of a coronary artery
AAOLCA
Anomalous aortic origin of the left coronary artery
ACAPA
Anomalous coronary artery from the pulmonary artery
ACE
Angiotensin-converting enzyme
ACHD
Adult congenital heart disease
AF
Atrial ﬁbrillation
ALCAPA
Anomalous left coronary artery from the pulmonary artery
AR
Aortic regurgitation
ARB
Angiotensin II receptor blocker
ARCAPA
Anomalous right coronary artery from the pulmonary artery
AS
Aortic stenosis
ASD
Atrial septal defect
ASI
Aortic size index
AT
Atrial tachycardia
AV
Atrioventricular
AVA
Aortic valve area
AVAi
Indexed aortic valve area
AVNRT
Atrioventricular node reentrant tachycardia
AVRT
Atrioventricular reentrant tachycardia
AVSD
Atrioventricular septal defect
BAV
Bicuspid aortic valve
BNP
B-type natriuretic peptide
BSA
Body surface area
CAD
Coronary artery disease
CABG
Coronary artery bypass graft
CCT
Cardiovascular computed tomography ccTGA
Congenitally corrected transposition of the great arteries
CHD
Congenital heart disease
CMR
Cardiovascular magnetic resonance
CoA
Coarctation of the aorta
CONCOR
CONgenital CORvitia
CPET
Cardiopulmonary exercise testing
CRT
Cardiac resynchronization therapy
DCRV
Double-chambered right ventricle
EACVI
European Association of Cardiovascular Imaging
EAT
Ectopic atrial tachycardia
ECG
Electrocardiogram
EF
Ejection fraction
EP
Electrophysiology/electrophysiological
ERA
Endothelin receptor antagonist
ESC
European Society of Cardiology
ESC Guidelines
567


<!-- PAGE 6 -->

### Page 6

..........................................................................................................................................................................
HLHS
Hypoplastic left heart syndrome
HTAD
Heritable thoracic aortic disease
IART
Intraatrial reentrant tachycardia
ICD
Implantable cardioverter deﬁbrillator
IE
Infective endocarditis
INR
International normalized ratio
IVC
Inferior vena cava
LA
Left atrium/atrial
LR
Left-to-right
LV
Left ventricle/ventricular
LVEF
Left ventricular ejection fraction
LVESD
Left ventricular end systolic diameter
LVH
Left ventricular hypertrophy
LVOT
Left ventricular outﬂow tract
LVOTO
Left ventricular outﬂow tract obstruction
MAPCAs
Major aortic pulmonary collaterals
MCV
Mean corpuscular volume mWHO
Modiﬁed World Health Organization
NOAC
Non-vitamin K antagonist oral anticoagulant
NT-pro-BNP
N-terminal-pro-B-type natriuretic peptide
NYHA
New York Heart Association
PA
Pulmonary artery
PAH
Pulmonary arterial hypertension
PAH-CHD
Pulmonary arterial hypertension associated with congenital heart disease
PAP
Pulmonary artery pressure
PDA
Patent ductus arteriosus
PDE-5
Phosphodiesterase type 5
PES
Programmed electrical stimulation
PFO
Patent foramen ovale
PH
Pulmonary hypertension
PM
Pacemaker
PR
Pulmonary regurgitation
PS
Pulmonary stenosis
PVD
Pulmonary vascular disease
PVR
Pulmonary vascular resistance
PVRep
Pulmonary valve replacement
QIs
Quality indicators
Qp:Qs
Pulmonary to systemic ﬂow ratio
RA
Right atrium/atrial
RL
Right-to-left rTOF
Repaired tetralogy of Fallot
RV
Right ventricle/ventricular
RVEDVi
Right ventricular end diastolic volume indexed
RVEF
Right ventricular ejection fraction
RVESVi
Right ventricular end systolic volume indexed
RVH
Right ventricular hypertrophy
RVOT
Right ventricular outﬂow tract
RVOTO
Right ventricular outﬂow tract obstruction
RVSP
Right ventricular systolic pressure
SCD
Sudden cardiac death
SND
Sinus node dysfunction
SubAS
Subaortic stenosis
SupraAS
Supravalvular aortic stenosis
SVC
Superior vena cava
SVT
Supraventricular tachycardia
TGA
Transposition of the great arteries
TOE
Transoesophageal echocardiography
TOF
Tetralogy of Fallot
TPVI
Transcatheter pulmonary valve implantation
TR
Tricuspid regurgitation
TTE
Transthoracic echocardiography
TV
Tricuspid valve
UVH
Univentricular heart
VE/VCO2
Ventilation to carbon dioxide output
VF
Ventricular ﬁbrillation
VKA
Vitamin K antagonist
Vmax
Maximum Doppler velocity
VSD
Ventricular septal defect
VT
Ventricular tachycardia
WHO
World Health Organization
WU
Wood units
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESCGuidelines). The ESC Guidelines represent the official position of the
ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the Guidelines and may be used by the
ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of


<!-- PAGE 7 -->

### Page 7

.....................................
patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
guidelines). This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task
Table 1
Classes of recommendations
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
©ESC 2020
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2020
ESC Guidelines
569


<!-- PAGE 8 -->

### Page 8

.............................................................................................................................................................................
Force. The finalized document is approved by the CPG for publication in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, booklets with essential messages, summary cards for nonspecialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the Guidelines, which is freely available via the ESC website and hosted on the EHJ website. The National Cardiac Societies of the
ESC are encouraged to endorse, adopt, translate and implement all
ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
2 Introduction
2.1 Why do we need new Guidelines on the management of adult congenital heart disease?
Since the previous version of the Guidelines on the management of grown-up congenital heart disease (CHD) was published in 2010,
new evidence has accumulated for this patient group, particularly on percutaneous interventional techniques and risk stratification with regard to timing of surgery and catheter intervention, as well as medical treatment. This made a revision of the recommendations necessary.
Since adult patients with CHD now present in increasing numbers at advanced ages, including the elderly, the term grown-up CHD no longer appears appropriate and was therefore replaced with adult
CHD (ACHD) throughout the document. This is also in accordance with international literature.
2.2 Content of these Guidelines
Decision making in ACHD involves accurate diagnosis, timing of intervention, risk assessment, and selection of the most suitable type of intervention. In addition, specific aspects of medical treatment for conditions such as heart failure, pulmonary hypertension (PH), and anticoagulation are addressed.
These guidelines focus on ACHD, are oriented towards management, and for more details in the topics of endocarditis, isolated valve disease, and aortic disease, refer to the relevant separate guideline documents published by the European Society of Cardiology (ESC).
2.3 New format of the Guidelines
The new Guidelines have been adapted to facilitate their use in clinical practice and to meet the readers’ demands by focusing on condensed, clearly presented recommendations. At the end of the document, section 5 proposes topics for future research and section 6
summarizes the key messages. For more background information please refer to the ESC Textbook of Cardiovascular Medicine.1
2.4 How to use these Guidelines
The Committee emphasizes that many factors ultimately determine the most appropriate treatment in individual patients within a given community. These factors include availability of diagnostic equipment, the expertise of cardiologists and surgeons, especially in the field of congenital heart surgery and percutaneous intervention, and notably, the wishes of well-informed patients. Furthermore, owing to the lack of evidence-based data in the field of ACHD, most recommendations are largely the result of expert consensus based on retrospective and prospective observational studies and registries.
Therefore, deviations from these Guidelines may be appropriate in certain clinical circumstances.
2.5 What is new in the 2020 Guidelines?
Selected revised recommendations, new recommendations, and new concepts are summarized in Table 3.
3 General aspects
3.1 Prevalence of adult congenital heart disease
To date, the prevalence of CHD worldwide is 9 per 1000 newborns, with substantial geographic variation.2,3 While the prevalence of severe congenital heart defects is declining in many Western/
developed countries due to foetal screening and pregnancy termination, overall prevalence on a global scale is increasing.4 Due to medical, surgical, and technological evolutions over the past decades,
>90% of individuals with CHD who are born, now survive into adulthood.5 As a result, the prevalence of CHD in the community has increased and now by far exceeds the number of children with
CHD.6 CHD can be classified as mild, moderate, or severe (see
Table 4).
3.2 Organization of care
When patients with CHD are approaching adulthood, they require transfer to ACHD care. This transfer should be preceded by a preparatory transition phase, which continues into adulthood according to the needs of the patient. Special healthcare organization and training programmes are required to meet the needs of this patient population.7 Importantly, the care for ACHD patients is a lifelong process
(Figure 1) and also requires advance care planning strategies. The ESC
Working Group on Grown-up Congenital Heart Disease published a position paper on recommendations for organization of care and training in the subspecialty of ACHD in Europe.8 The position paper refers to the previous ESC Guidelines9 and stratified patient care into


<!-- PAGE 9 -->

### Page 9

Table 3
Selected revised recommendations (R), new recommendations (N), and new concepts
Arrhythmia
N
There were no formal recommendations on arrhythmia in the 2010 edition  these have now been included  for details see recommendation tables in Sections 3.4.2 and 4.10. Summary of the most important items:
 Emphasizing the importance of understanding the cause, the mechanism of the arrhythmia, and the anatomy of the underlying CHD
 Emphasizing the importance of a multidisciplinary approach for optimal arrhythmia treatment prior to, or concomitant with, percutaneous or surgical interventions
 Consideration of early catheter ablation as an alternative to long-term medical treatment for symptomatic SVT and VT provided that the procedure is performed in experienced centres
 Targeting VT-related anatomical isthmuses in repaired tetralogy of Fallot patients with sustained VTs before percutaneous or surgical reintervention in the RVOT, as these procedures may lead to inaccessibility of the VT substrates
 Recognizing the association between bradycardia and IART and the potential beneﬁt of PM implantation.
Eisenmenger sydrome /pulmonary arterial hypertension
N
It is recommended that patients with CHD and conﬁrmed pre-capillary PH are counselled against pregnancy.
N
Risk assessment is recommended in all patients with PAH-CHD.
N
In low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or sequential combination therapy is recommended, and high-risk patients should be treated with initial combination therapy including parenteral prostanoids.
R
Emphasize the importance of sequential PAH therapy strategy in Eisenmenger syndrome and use of 6MWT for the decision to initiate therapy.
In Eisenmenger patients with reduced exercise capacity
(6MWT distance <450 m), a treatment strategy with initial endothelin receptor antagonist monotherapy should be considered followed by combination therapy if patients fail to improve.
Shunt lesions
N
In patients with shunt lesions and non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory.
N/R
Adjusted recommendations for shunt closure (when Qp:Qs >1.5) according to calculated PVR:
<3 WU: class I for ASD, VSD, and PDA
35 WU: class IIa for ASD, VSD, and PDA
>_5 WU but decreasing to <5 WU after targeted PAH treatment: class IIb for ASD (fenestrated closure only)
>_5 WU for VSD and PDA (careful individual decision in expert centres); class IIb
>_5 WU despite targeted PAH treatment: class III for ASD.
N
In patients with ASD and LV disease, it is recommended to perform balloon testing and carefully weigh the beneﬁt of eliminating LR
shunt against the potential negative impact of ASD closure on outcome due to increase in ﬁlling pressure (taking closure, fenestrated closure, and no closure into consideration).
N
Take older age into account in the decision for surgical ASD
closure.
In elderly patients not suitable for device closure, it is recommended to weigh the surgical risk against the potential beneﬁt of ASD closure.
R
Transcatheter VSD closure has become an alternative to surgery in selected patients, particularly in residual VSD.
Transcatheter VSD closure has become an alternative, particularly in residual VSDs, VSDs poorly accessible by surgery,
and in muscular VSDs centrally located in the interventricular septum.
R
Specify the requirement for a congenital cardiac surgeon for partial AVSD closure.
Surgical closure is recommended in patients with signiﬁcant
RV volume overload and should only be performed by a congenital cardiac surgeon.
R
Specify the presence of atrial ﬁbrillation or PH as requirements for valve repair in AVSD.
In asymptomatic patients with severe left-sided AV valve regurgitation, preserved LV function (LVESD <45 mm and/or
LVEF >60%), high likelihood of successful valve repair, and low surgical risk, intervention should be considered when atrial ﬁbrillation or systolic PAP >50 mmHg is present.
R
Specify the option of fenestrated ASD closure.
In patients with PVR >_5 WU, fenestrated ASD closure may be considered when PVR falls below 5 WU after targeted PAH
treatment and signiﬁcant LR shunt is present (Qp:Qs >1.5).
R
Include desaturation on exercise as a contraindication for
ASD, VSD, AVSD, and PDA closure.
Shunt closure is not recommended in patients with severe
PAH (PVR >_5 WU) presenting with desaturation on exercise.
Continued
ESC Guidelines
571


<!-- PAGE 10 -->

### Page 10

Left ventricular outﬂow tract obstruction and aortopathies
R
Increase the recommendation class from IIa to I in low-ﬂow,
low-gradient AS for intervention.
Intervention is indicated in patients with severe low-ﬂow, lowgradient (mean gradient <40 mmHg) AS with reduced EF and evidence of ﬂow (contractile) reserve excluding pseudosevere
AS.
R
Lower mean Doppler gradient threshold for LVOTO intervention from 50 to 40 mmHg.
In symptomatic patients with valvular, subvalvular, or supravalvular AS and mean Doppler gradient >_40 mmHg surgery is recommended.
R
Include BNP levels and increased PAP in the indication for intervention in valvular AS.
Intervention should be considered in asymptomatic patients with normal EF and no exercise test abnormalities (see
Section 4.5.1) if the surgical risk is low and one of the following
ﬁndings is present:
 Markedly elevated BNP levels (>3-fold age- and sex-corrected normal range) conﬁrmed by repeated measurements without other explanation.
 Severe PH (systolic PAP at rest >60 mmHg conﬁrmed by invasive measurement) without other explanation.
R
Conﬁrm pressure gradients by invasive measurement and prefer stenting in coarctation and re-coarctation when technically feasible.
Repair of coarctation or re-coarctation (surgically or catheter based) is indicated in hypertensive patients with an increased non-invasive gradient between upper and lower limbs conﬁrmed by invasive measurement (peak-to-peak >_20 mmHg),
with preference for catheter treatment (stenting) when technically feasible.
N
Catheter treatment (stenting) of coarctation should be considered in normotensive patients with an increased non-invasive gradient conﬁrmed with invasive measurement (peak-to-peak >_20 mmHg) when technically feasible.
N
In aortopathies, aortic valve repair using the reimplantation or remodelling with aortic annuloplasty technique is recommended in young patients with Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves, when performed by experienced surgeons.
N
Surgery should be considered in patients with a TGFBR1 or TGFBR2 mutation (including LoeysDietz syndrome) who have aortic root disease with maximal aortic sinus diameter >_45 mm.
N
In Turner syndrome, elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered for women who are
>16 years of age, have an ascending ASI >25 mm/m2, and have associated risk factors for aortic dissection.
N
In Turner syndrome, elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women who are
>16 years of age, have an ascending aortic size index >25 mm/m2, and do not have associated risk factors for aortic dissection.
Right ventricular outﬂow tract obstruction / tetralogy of Fallot /Ebstein
R
Adjust recommendations for surgical intervention in RVOTO
according to symptoms.
If surgical valve replacement is the only option, it is indicated in patients with severe stenosis who are symptomatic.
If surgical valve replacement is the only option in patients with severe stenosis who are asymptomatic, it is indicated in the presence of one or more of the following:
 Objective decrease in exercise capacity
 Decreasing RV function and/or progressive TR to at least moderate
 RVSP >80 mmHg
 RL shunting via an ASD or VSD.
R
Include preference for catheter intervention for pulmonary valve implantation in TOF.
In patients with no native outﬂow tract, catheter intervention
(TPVI) should be preferred if anatomically feasible.
R
Specify RV dilatation in the setting of pulmonary valve replacement for TOF and for RVOT conduits.
Pulmonary valve replacement should be considered in asymptomatic patients with severe PR and/or RVOTO, in the presence of progressive RV dilation to RVESVi >_80 mL/m2, and/or
RVEDVi >_160 mL/m2, and/or progression of TR to at least moderate.
Continued


<!-- PAGE 11 -->

### Page 11

R
In case of ASDs in Ebstein anomaly, add caution about RA
pressure rise or fall in cardiac output.
In the case of documented systemic embolism probably caused by paradoxical embolism, isolated device closure of
ASD/PFO should be considered but requires careful evaluation before intervention to exclude induction of RA pressure increase or fall in cardiac output.
If cyanosis (oxygen saturation at rest <90%) is the leading problem, isolated device closure of ASD/PFO may be considered but requires careful evaluation before intervention to exclude induction of RA pressure increase or fall in cardiac output.
Transposition of the great arteries
R
Downgrade level of recommendation for AV valve repair in
TGA/atrial switch from I to IIa in symptomatic patients.
In patients with severe systemic (tricuspid) AV valve regurgitation without signiﬁcant ventricular systolic dysfunction (EF
>40%), valve repair or replacement should be considered regardless of symptoms.
R
In patients with TGA/atrial switch requiring PM/ICD implantation: pay attention to the presence of bafﬂe leaks.
In patients with a bafﬂe leak who require a PM/ICD, closure of the bafﬂe leak should be considered, when technically feasible,
prior to insertion of transvenous leads.
N
In ccTGA, biventricular pacing should be considered in case of complete AV block or >40% ventricular pacing requirement.
R
Revise indications for TV replacement in ccTGA, according to symptoms and systemic ventricular function.
(Upgrade level of recommendation for symptomatic ccTGA
patients from IIa to I).
In symptomatic patients with severe TR and preserved or mildly impaired systemic RV systolic function (EF >40%), TV
replacement is indicated.
In asymptomatic patients with severe TR and progressive systemic RV dilatation and/or mildly impaired systemic RV systolic function (EF >40%), TV replacement should be considered.
In symptomatic patients with severe TR and more than mildly reduced systemic RV systolic function (EF <_40%), TV replacement may be considered.
R
Anatomic repair (atrial þ arterial switch) for ccTGA removed from the recommendations.
Univentricular heart
N
It is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres including multimodality imaging as well as invasive work-up to decide whether they may beneﬁt from surgical or interventional procedures.
Fontan circulation
N
Sustained atrial arrhythmia with rapid AV conduction is a medical emergency and should promptly be treated with electrical cardioversion.
N
Anticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic events.
N
It is recommended that women with a Fontan circulation and any complication are counselled against pregnancy.
N
Cardiac catheterization is recommended at a low threshold in cases of unexplained oedema, exercise deterioration, new-onset arrhythmia, cyanosis, and haemoptysis.
N
In patients with arrhythmias, a proactive approach of electrophysiological evaluation and ablation (where appropriate) should be considered.
N
Regular liver imaging (ultrasound, computed tomography, magnetic resonance) should be considered.
N
Endothelin receptor antagonists and phosphodiesterase-5 inhibitors may be considered in selected patients with elevated pulmonary pressures/resistance in the absence of elevated ventricular end diastolic pressure.
N
In selected patients with signiﬁcant cyanosis, device closure of a fenestration may be considered but requires careful evaluation before intervention to exclude induction of systemic venous pressure increase or fall in cardiac output.
Coronary artery anomalies
N
Non-pharmacological functional imaging (e.g. nuclear study, echocardiography or CMR with physical stress) is recommended in patients with coronary anomalies to conﬁrm/exclude myocardial ischaemia.
A) Anomalous coronary artery from the pulmonary artery (ACAPA)
N
Surgery is recommended in patients with ALCAPA.
N
Surgery is recommended in patients with ARCAPA and symptoms attributable to anomalous coronary artery.
Continued
ESC Guidelines
573


<!-- PAGE 12 -->

### Page 12

.........................................................
three levels: (i) patients who require care exclusively in a specialist centre, (ii) patients for whom shared care can be established with the appropriate general adult cardiac services, and (iii) patients who can be managed in non-specialist clinics (with access to specialized care if required). The proposed staff requirements for specialist centres are described in Table 5. The complexity of the heart defect should not be the only criterion to assign patients to a certain level of care. Although patients with complex defects can easily be assigned to a high level of care, even anatomically simple defects may require specialist care under certain circumstances [e.g. atrial septal defect (ASD) with pulmonary arterial hypertension (PAH)]. Therefore, it is recommended that all ACHD patients are seen once in a specialist centre, allowing
ACHD specialists to determine the most appropriate level of care and follow-up intervals for each individual patient.8 Networks of specialist centres with general adult care should be established for each catchment area. Indeed, with the growing population of adults with CHD,
more patients will first present to general cardiologists for acute conditions, such as arrhythmia, heart failure, or endocarditis. In such cases,
general cardiologists should not delay treatment in haemodynamically unstable patients but ought to liaise with the patient’s ACHD centre immediately to discuss appropriate management strategies or transfer of the patient. Special attention is necessary for patients after Fontan correction presenting with arrhythmia, as even supraventricular arrhythmias are not well tolerated. Detailed advice on emergency care for ACHD patients will follow in a separate future position paper.
Transfer of adolescents to ACHD care is vital as they approach adulthood without gaps in care, and should be preceded by a preparatory transition phase with additional transition support that continues into early adulthood according to the needs of the patient.10
Transition requires a special healthcare organization.10,11 It is recommended that specialist ACHD centres have teams including specialist nurses, psychologists, and social workers given that anxiety, depression, or problems coping with the medical condition are well known concerns in adult patients with CHD.12 They also play a critical role in the transition process by taking over the transitional care of patients after the transfer from paediatric cardiology. Aspects that have to be addressed by allied health professionals include mental health, psychic well-being, and quality of life.12,13 During the ACHD
N
Surgery should be considered for ARCAPA in asymptomatic patients with ventricular dysfunction, or myocardial ischaemia attributable to coronary anomaly.
B) Anomalous aortic origin of a coronary artery (AAOCA)
N
Surgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced myocardial ischaemia in a matching territory or high-risk anatomy.
N
Surgery should be considered in asymptomatic patients with AAOCA (right or left) and evidence of myocardial ischaemia.
N
Surgery should be considered in asymptomatic patients with AAOLCA and no evidence of myocardial ischaemia but a high-risk anatomy.
N
Surgery may be considered for symptomatic patients with AAOCA even if they have neither evidence of myocardial ischaemia nor highrisk anatomy.
N
Surgery may be considered for asymptomatic patients with AAOLCA without myocardial ischaemia and without high-risk anatomy when they present at young age (<35 years).
N
Surgery is not recommended for AAORCA in asymptomatic patients without myocardial ischaemia and without high-risk anatomy.
New concepts
Naming (ACHD).
Disease complexity classiﬁcation.
Stafﬁng requirements for an ACHD expert centre.
Emerging role of biomarkers in follow-up of ACHD.
Detailed and speciﬁc recommendations on arrhythmia management.
More speciﬁc and adjusted recommendations for PAH treatment.
Recommendations on the use of anticoagulants.
Consideration of ageing and advance care planning.
Categories of high-risk pregnancies in accordance with the pregnancy guidelines.
Expand Marfan syndrome section to aortopathies (and include HTAD, Turner syndrome, and bicuspid aortic disease).
Emerging role of catheter intervention in ACHD.
6MWT = 6-minute walk test; AAOCA = anomalous aortic origin of a coronary artery; AAOLCA = anomalous aortic origin of the left coronary artery; ACAPA = anomalous coronary artery from the pulmonary artery; ACHD = adult congenital heart disease; AF = atrial ﬁbrillation; ALCAPA = anomalous left coronary artery from the pulmonary artery; ARCAPA = anomalous right coronary artery from the pulmonary artery; AS = aortic stenosis; ASD = atrial septal defect; AV = atrioventricular; AVSD = atrioventricular septal defect; BNP = B-type natriuretic peptide; ccTGA = congenitally corrected transposition of the great arteries; CHD = congenital heart disease; CMR = cardiovascular magnetic resonance; EF = ejection fraction; HTAD = heritable thoracic aortic disease; IART = intraatrial reentrant tachycardia; ICD = implantable cardioverter deﬁbrillator;
LR = left-to-right; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end systolic diameter; LVOT = left ventricular outﬂow tract; LVOTO = left ventricular outﬂow tract obstruction; N = new recommendation; PAH = pulmonary arterial hypertension; PAH-CHD = pulmonary arterial hypertension associated with congenital heart disease; PAP = pulmonary artery pressure; PDA = patent ductus arteriosus; PFO = patent foramen ovale; PH = pulmonary hypertension; PR =
pulmonary regurgitation; PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio; R = revised recommendation; RA = right atrium/atrial; RL = rightto-left; RV = right ventricle/ventricular; RVEDVi = right ventricular end diastolic volume indexed; RVESVi = right ventricular end systolic volume indexed; RVOT = right ventricular outﬂow tract; RVOTO = right ventricular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; SVT = supraventricular tachycardia; TGA = transposition of the great arteries; TGFBR = transforming growth factor beta receptor; TOF = tetralogy of Fallot; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgitation; TV = tricuspid valve; UVH = univentricular heart; VSD = ventricular septal defect; VT = ventricular tachycardia; WU = Wood units.


<!-- PAGE 13 -->

### Page 13

....................................
care journey, advance care planning choices and strategies relating to end of life also require expert support.
3.3 Diagnostic work-up
Besides a thorough clinical evaluation, the medical history, including detailed information about palliative or reparative surgery and catheter-based interventions, is of critical importance in the work-up of ACHD patients. The aim of analysing patient history is to assess present and past symptoms, as well as to look for intercurrent events and any changes in medication. The most frequent symptoms reported by ACHD patients are exercise intolerance and palpitations. Self-estimated physical capacity corresponds poorly with objective measures of exercise capacity.14 Therefore, cardiopulmonary exercise testing (CPET) has gained importance for objective assessment of exercise intolerance in both apparently asymptomatic and symptomatic patients. In addition, the patient should be questioned about his/her lifestyle to detect progressive changes in daily activity in order to limit the subjectivity of symptom analysis. In symptomatic patients, alternative causes such as anaemia, depression,
weight gain, and physical deconditioning, besides the congenital defect and its sequelae or residuae, should be kept in mind and further excluded if necessary.
Clinical examination plays a major role and includes careful evaluation of any changes in auscultation findings, blood pressure, or
Table 4
Classiﬁcation of congenital heart disease complexity
MILD:
• Isolated congenital aortic valve disease and bicuspid aortic disease
• Isolated congenital mitral valve disease (except parachute valve, cleft leaﬂet)
• Mild isolated pulmonary stenosis (infundibular, valvular, supravalvular)
• Isolated small ASD, VSD, or PDA
• Repaired secundum ASD, sinus venosus defect, VSD, or PDA without residuae or sequellae, such as chamber enlargement, ventricular dysfunction,
or elevated PAP.
MODERATE: (Repaired or unrepaired where not speciﬁed; alphabetical order)
• Anomalous pulmonary venous connection (partial or total)
• Anomalous coronary artery arising from the PA
• Anomalous coronary artery arising from the opposite sinus
• Aortic stenosis - subvalvular or supravalvular
• AVSD, partial or complete, including primum ASD (excluding pulmonary vascular disease)
• ASD secundum, moderate or large unrepaired (excluding pulmonary vascular disease)
• Coarctation of the aorta
• Double chambered right ventricle
• Ebstein anomaly
• Marfan syndrome and related HTAD, Turner Syndrome
• PDA, moderate or large unrepaired (excluding pulmonary vascular disease)
• Peripheral pulmonary stenosis
• Pulmonary stenosis (infundibular, valvular, supravalvular), moderate or severe
• Sinus of Valsalva aneurysm/ﬁstula
• Sinus venosus defect
• Tetralogy of Fallot  repaired
• Transposition of the great arteries after arterial switch operation
• VSD with associated abnormalities (excluding pulmonary vascular disease) and/or moderate or greater shunt.
SEVERE: (Repaired or unrepaired where not speciﬁed; alphabetical order)
• Any CHD (repaired or unrepaired) associated with pulmonary vascular disease (including Eisenmenger syndrome)
• Any cyanotic CHD (unoperated or palliated)
• Double-outlet ventricle
• Fontan circulation
• Interrupted aortic arch
• Pulmonary atresia (all forms)
• Transposition of the great arteries (except for patients with arterial switch operation)
• Univentricular heart (including double inlet left/right ventricle, tricuspid/mitral atresia, hypoplastic left heart syndrome, any other anatomic abnormality with a functionally single ventricle)
• Truncus arteriosus
• Other complex abnormalities of AV and ventriculoarterial connection (i.e. crisscross heart, heterotaxy syndromes, ventricular inversion).
ASD = atrial septal defect; AV = atrioventricular; AVSD = atrioventricular septal defect; CHD = congenital heart disease; HTAD = heritable thoracic aortic disease; LV = left ventricle/ventricular; PA = pulmonary artery; PAP = pulmonary artery pressure; PDA = patent ductus arteriosus; VSD = ventricular septal defect.
ESC Guidelines
575


<!-- PAGE 14 -->

### Page 14

©ESC
Emergency admissions
Need for 
f repeated operations and interventions
Congenital heart disease ~ A lifelong ch f
ronic condition 
Hospitalisations
Recurrence of CHD
Lifelong medical ther f
apy
Pregnancy complications
Maternal mortality
Neonatal complication ions tion
Reduced life expectancy f
Stroke k
Neurological 
complications
Coronary complications
Aortic syndrome
Exercise intolerance
Depressive symptoms
Reduced quality of lifef
Arrhythmia 
Hypertension
Sudden cardiac death
Endocarditis
Figure 1 Central illustration. Congenital heart disease is a lifelong chronic condition.
CHD = congenital heart disease; SCD = sudden cardiac death.


<!-- PAGE 15 -->

### Page 15

...............................................................
development of signs of heart failure. An electrocardiogram
(ECG) and pulse oximetry are routinely carried out alongside clinical examination. A chest X-ray provides information on changes in heart size and configuration, as well as pulmonary vascularization. Noninvasive imaging is routinely performed by transthoracic echocardiography (TTE) involving transoesophageal echocardiography (TOE)
and cardiovascular magnetic resonance (CMR) imaging where indicated. Thus, patients with CHD may particularly benefit from magnetic resonance-conditional/compatible pacemakers and defibrillators.
Echocardiography is superior to CMR in estimating pressure gradients and pulmonary artery (PA) pressure (PAP), and detecting small, highly mobile structures such as vegetations. CMR is ideal for accurate quantification of ventricular volumes, ejection fraction (EF),
valvular regurgitation,15 calculation of pulmonary and systemic blood flow, and myocardial fibrosis assessment. Cardiovascular computed tomography (CCT) with modern single or dual source scanners can be performed with dose-saving protocols and may be required for special indications  as indicated in Table 6. Interdisciplinary expert collaboration is important: imaging CHD experts need to respond to feedback from CHD surgeons, interventionalists, and electrophysiologists to optimize imaging contribution to care, as well as work with each other to enhance appropriate use of multimodality imaging.
Advanced imaging is usually best reserved for when patients are seen in the specialist centre rather than be repeated.
Echocardiography, CMR, and CCT require staff with expertise in
CHD as well as in imaging, which has training and resource implications. Within the ESC, this is recognized by a certification examination of the European Association of Cardiovascular Imaging (EACVI),
separate from the standard TTE, TOE, or CMR examination, and specific to CHD.
3.3.1 Echocardiography
Echocardiography remains the first-line imaging modality.16 M-mode,
two-dimensional, and three-dimensional (3D) echocardiography are all used for imaging, whereas tissue Doppler imaging and deformation imaging, especially longitudinal strain and strain rate, are becoming integral parts of functional assessment.17
Echocardiography provides information on cardiac anatomy, situs
(including orientation and position of the heart), connection of the atria and ventricles, heart valves, and connection of ventricles with the great arteries. For assessment of morphology and function of cardiac valves, TTE and, if necessary, TOE (nowadays often combined with 3D echocardiography), is the preferred imaging modality. This is also true for shunt lesions, such as ASDs or ventricular septal defects
(VSDs): 3D echocardiography enables an en face view, which can be helpful in the assessment of the size and shape of a defect and its relation to surrounding structures.
Ventricular size, shape, volume, and EF can be measured and calculated with TTE. Signs of volume overload, in the case of a shunt or valvular regurgitation, or pressure overload, in the case of increased afterload, are detected in a good-quality TTE. Even older techniques using M-mode for measurement of tricuspid annular plane systolic
Table 5
Staff requirements for specialist ACHD
centresa
Discipline
Required number
Adult/paediatric cardiologist with ACHD certiﬁcation
>_2
ACHD imaging specialist (certiﬁed in TTE/TOE,
CMR, CCT)
>_2
Congenital interventional cardiologist
>_2
CHD surgeon
>_2
Anaesthesiologist with CHD experience and expertise
>_2
Specialist nurse (if national professional nursing bodies allow specialization)
>_2
Invasive electrophysiologist with ACHD experience
>_1
Pulmonary vascular disease expert
>_1
Clinical geneticist
>_1
Psychologist
>_1
Social worker
>_1
Palliative care team
ACHD = adult congenital heart disease; CHD = congenital heart disease; CMR =
cardiovascular magnetic resonance; CCT = cardiovascular computed tomography;
TOE
=
transoesophageal echocardiography;
TTE
=
transthoracic echocardiography.
aModiﬁed from Baumgartner et al.8
Table 6
Indications for cardiovascular magnetic resonance imaging in ACHD patients
Indications for CMR in ACHD patients
• Quantiﬁcation of RV volumes, EF (including subpulmonary RV, systemic RV, and single ventricle)
• Evaluation of RVOTO and RVPA conduits
• Quantiﬁcation of PR
• Evaluation of PAs (stenoses, aneurysms) and the aorta [aneurysm, dissection, coarctation (CCT may be superior)]
• Evaluation of systemic and pulmonary veins (anomalous connection,
obstruction, coronary venous anatomy pre-procedure, etc.)
• Collaterals and arteriovenous malformations (CCT may be superior)
• Coronary anomalies and CAD (CCT is superior for intramural course,
slit-like course, acute angle take-off, myocardial bridging, and plaque assessment)
• Detection and quantiﬁcation of myocardial ischaemia by CMR stress perfusion
• Evaluation of intra- and extracardiac masses
• Quantiﬁcation of myocardial mass (LV and RV)
• Detection and quantiﬁcation of myocardial ﬁbrosis/scar (late gadolinium enhancement, T1 mapping) tissue characterization (ﬁbrosis, fat,
iron, etc.)
• Quantiﬁcation of systemic and pulmonary blood ﬂow to calculate
Qp:Qs
• Quantiﬁcation of perfusion distribution to the right/left lung
• Measurement of pulmonary blood ﬂow in patients with multiple sources of blood supply (i.e. with major aorto-pulmonary collateral arteries)
ACHD = adult congenital heart disease; CAD = coronary artery disease; CMR =
cardiovascular magnetic resonance; CCT = cardiovascular computed tomography; EF = ejection fraction; LV = left ventricle/ventricular; PA = pulmonary artery;
PR = pulmonary regurgitation; Qp:Qs = pulmonary to systemic ﬂow ratio; RV =
right ventricle/ventricular; RVOTO = right ventricular outﬂow tract obstruction.
ESC Guidelines
577


<!-- PAGE 16 -->

### Page 16

.............................................................................................................................................................................
excursion and mitral annular plane systolic excursion are still valid,
especially in longitudinal follow-up. For left ventricular (LV) systolic function,
3D
echocardiography,
tissue
Doppler imaging,
and two-dimensional deformation imaging have proved to be robust tools and deserve to be integrated into clinical practice. Even accounting for newer techniques, echocardiography retains a key role in longitudinal follow-up assessment of systolic function of a right or single ventricle, although for more accurate measurements additional imaging is often needed in the form of CMR.
3.3.2 Cardiovascular magnetic resonance imaging
CMR has become an essential facility in the specialist unit. It enables 3D
anatomical reconstruction, which is not restricted by body size or acoustic windows, and has rapidly improving spatial and temporal resolution.18 CMR requires a regular heart rhythm for optimal image quality,
however, diagnostic CMR studies are often achievable even in patients with irregular heart rhythms [frequent ectopy or atrial fibrillation (AF)]
and metallic artefacts. CMR is the gold-standard imaging method for quantification of volumes. It may be an alternative when echocardiography cannot be obtained with sufficient quality, or used as a second method when echocardiography measurements are borderline or ambiguous. Furthermore, the lack of radiation makes it a useful tool when serial evaluations are needed (e.g. for monitoring aortic dimensions). CMR allows calculation of systemic and pulmonary blood flow in patients with multiple sources of blood supply and, in combination with invasive catheterization, of pulmonary vascular resistance (PVR). Tissue characterisation for myocardial fibrosis is a unique capability of CMR.
Late gadolinium enhancement CMR for focal fibrosis and interstitial fibrosis T1 mapping imaging are increasingly being applied in ACHD for their potential diagnostic and prognostic value. However, large CHD
lesion-specific studies to determine if they predict survival are ongoing.
To mitigate the low risk of nephrogenic systemic fibrosis, gadolinium contrast should be avoided in patients with a low glomerular filtration rate (<30 mL/min/1.73 m2). It is therefore recommended that creatinine levels are checked prior to CMR. Even though clinical repercussions have not yet been seen, long-term brain deposits of gadolinium  regardless of renal function  raised concerns about cumulative lifetime doses in CHD patients who undergo serial CMR
from a young age. It is preferred, therefore, that gadolinium is selectively administered in specialist centres using a macrocyclic, rather than linear chelated, gadolinium contrast, which presents a decreased risk at the lowest dose to achieve image enhancement.19
Adults with CHD with conventional pacemakers (PM) and defibrillators (ICD) can undergo CMR within guidelines where local support is available.20
3D CMR imaging can be integrated into electrophysiology (EP)
procedures to inform and guide them. 3D CCT and CMR reconstructions can also be used for virtual reality rehearsal of interventions or planning from patient-specific 3D prints.
Indications for CMR are summarized in Table 6.
3.3.3 Cardiovascular computed tomography
CCT has high spatial resolution and rapid acquisition time; it is particularly relevant for imaging the great vessels, coronary arteries, and collateral arteries, and for parenchymal lung disease (Table 6). In many institutions, CCT is the preferred imaging modality in planning for transcatheter valve implantation. Ventricular size and function can be assessed, with inferior temporal resolution compared with CMR,
typically with an increased radiation dose, and is therefore not used serially for this indication. Recent rapid developments have substantially reduced the amount of radiation exposure, achieving <5 mSv for a combined CCT coronary, pulmonary, and aortic angiogram. For
ACHD patients, this has made CCT more attractive for specific indications such as assessment, in particular for coronary artery pathology, and detailed assessment of collaterals.21
CCT is particularly useful in emergency settings including dissection, pulmonary embolism, and paravalvular abscess in the setting of endocarditis, where it may have advantages over echocardiography and CMR due to being less susceptible to prosthetic valve artefact.
In patients with prosthetic valves (in situ >3 months), fluorine-18fluorodeoxyglucose positron emission tomography/computed tomography is useful for early diagnosis of inflammation and infection at the site of the valve, and also for identifying infection at secondary sites.22
3.3.4 Cardiopulmonary exercise testing
Formal exercise testing has an important role in the CHD population,
in which quality of life and functional capacity are key measures of the success of intervention. CPET, including assessment of objective exercise capacity (peak oxygen consumption), ventilatory efficiency
[ventilation to carbon dioxide output (VE/VCO2) slope], chronotropic and blood pressure response, as well as exercise-induced arrhythmia and desaturation, gives a broader evaluation of functional capacity and physical fitness, and has endpoints which correlate well with morbidity and mortality in ACHD patients.23 Serial exercise testing should therefore be a part of long-term follow-up protocols.
It plays an important role in the timing of interventions and reinterventions. CPET is also a useful tool for recommending the intensity of physical activity based on an individualized exercise prescription.24
The 6-minute walk test (6MWT) is another simple test for quantification of exercise capacity; it relates to outcome in patients with PAH.
3.3.5
Cardiac catheterization
Cardiac catheterization is mainly reserved for resolution of specific anatomical and physiological questions,
or for intervention.
Indications include assessment of PVR, ventricular diastolic function
(including constrictive and restrictive physiology), pressure gradients,
shunt quantification, coronary angiography, and evaluation of extracardiac vessels such as aortic pulmonary collateral arteries when noninvasive evaluation leaves uncertainty.
In shunt lesions with Doppler echocardiographic signs of PH, catheterization  including testing of vasoreactivity  remains essential in the decision on shunt closure. Inhaled nitric oxide is the most widely used agent for this purpose. Estimation of PVR in shunt lesions requires accurate calculation of pulmonary flow using the Fick principle. This method with measured oxygen consumption allows the most accurate cardiac output quantification.
Before surgery, coronary artery imaging should be performed (by
CCT or invasive coronary angiography) in men >40 years of age,
postmenopausal women, and patients with signs of, or one or more risk factors for, coronary artery disease (CAD).25
3.3.6
Biomarkers
Different classes of biomarkers have been reported to be associated with adverse events in the
CHD
population,
including


<!-- PAGE 17 -->

### Page 17

.............................................................................................................................................................................
neurohormones and markers of myocardial injury (high-sensitivity troponins) or inflammation (high-sensitivity C-reactive protein).
Among the neurohormones, natriuretic peptides [B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP)] are best studied in ACHD patients. They carry important prognostic information, but are less useful to diagnose heart failure across different cardiac lesions due to a cut-off variability depending on the underlying defect and type of repair.26 They are most useful in patients with biventricular circulation and least useful in patients with a Fontan circulation.27 Serial testing of natriuretic peptides plays a role in identifying patients at risk for adverse events. Of note, natriuretic peptides may be increased in cyanotic heart disease simply due to hypoxiainduced peptide secretion.28
3.4 Therapeutic considerations
3.4.1
Heart failure
The development of heart failure is a common problem affecting
2050% of the ACHD population, and is a main cause of death.29 The incidence is increasing and is probably underestimated. Since latent signs and symptoms of heart failure might occur frequently, patients at high risk of developing heart failure require systematic follow-up and diagnostic screening.30 Any haemodynamic abnormalities, including arrhythmias, potentially causing heart failure that can be addressed by intervention or surgery must be excluded and, if possible, treated first.
In the absence of specific guidelines, ACHD practitioners follow the current guidelines for medical treatment for both heart failure and common heart failure-related comorbidities, such as diabetes mellitus,
AF, central sleep apnoea, iron deficiency, and cachexia.31 However, as the pathophysiology of cardiorespiratory dysfunction is often different from the failing circulation in patients with non-congenital (acquired)
heart disease, extrapolation of results from published heart failure studies to ACHD patients are inappropriate, particularly in patients with a systemic right ventricle (RV), a failing subpulmonary ventricle, or in patients with a single ventricle physiology. The pathophysiology of
ACHD heart failure with systolic ventricular dysfunction includes a broad spectrum of causes. Both systemic and subpulmonary ventricles,
whether morphological left or right, single ventricles included, might be chronically overloaded by pressure and/or volume, which leads to progressive ventricular dysfunction. Altered myocardial architecture (noncompaction) and ventricular interdependence can compromise systolic ventricular function. Myocardial injury (limited myocardial protection during bypass, after ventriculotomy, and after chronic hypoxia) may occur in CHD patients. Finally, ischaemic heart disease  mainly related to ageing or congenital coronary anomalies  and persistent tachyarrhythmia might be responsible for impaired systemic and subpulmonary ventricular function.30 The few available data on heart failure treatments, specifically in ACHD patients, are often not conclusive and derived from small patient cohorts. As a consequence, ACHDspecific recommendations are mostly based on clinical experience or position statements.30 In a biventricular circulation, patients with an impaired systemic LV are generally treated with conventional heart failure therapy; this is also applied in symptomatic patients with a failing systemic RV. Diuretics mainly control symptoms; whether the longterm use of inhibitors of the reninangiotensin aldosterone system or beta blockers influences clinical outcome remains unknown. Also, no long-term clinical benefit of conventional heart failure treatment has been shown in a failing subpulmonary ventricle, although diuretics might alleviate symptoms. Treatment of symptomatic patients with a failing single ventricle in a Fontan circulation, or in the case of a persistent right-to-left (RL) shunt, should always be carefully initiated, taking the labile balance of ventricular preload and systemic afterload into account. In ACHD patients with heart failure, there are currently only a few small studies looking at the new drug sacubitril/valsartan, which was found to decrease morbidity and mortality and implemented in the therapy of chronic heart failure in recent ESC Guidelines31, however, no recommendation can be made at this moment. Heart failure with preserved EF is also not uncommon in ACHD patients.
Therapeutic recommendations should follow the general heart failure guidelines. On top of medical treatment, cardiac resynchronization therapy (CRT) has gained increasing interest for use in ACHD patients with congestive heart failure, despite little evidence on indications and outcomes. Efficacy of CRT in CHD may vary with the underlying structural and functional substrate, such as anatomy of the systemic ventricle
(left, right, or functionally single), presence and degree of structural systemic atrioventricular (AV) valve regurgitation, primary myocardial disease or scarring, and type of electrical conduction delay.32
It is expected that the incidence of acute heart failure in ACHD
patients will also increase over time due to increasing age and more complex diseases. The knowledge of correct use of inotropes, the availability of extra-corporal membrane oxygenation, and advanced bridging techniques are the minimum requirements to adequately support ACHD patients with acute heart failure; transfer to an expert centre is recommended.33
Heart transplantation may also be considered as a therapeutic option for end-stage heart failure. Outcome after transplant surgery is continuously improving, particularly in CHD patients, but perioperative mortality still remains higher than in other underlying diseases. This is mainly related to previous cardiac surgery, complex anatomy and pathophysiology, and comorbidities (multisystem disorder). The increased use of ventricular assist devices can bridge patients to transplantation; in selected patients, it may be an option as destination therapy. Some patients may have extreme complex anatomy or high levels of antibodies against the human leucocyte antigens and are not eligible for transplantation.
In some patients, multiorgan transplantation is required. Heartlung transplantation is applied in CHD patients with irreversible PAH
such as Eisenmenger syndrome, however, the lack of donor organs is a major limitation.
Simultaneous heart-liver transplantation is rarely done in liver failure after Fontan palliation or in patients with long-standing hepatic pressure load due to right heart failure [e.g. unrecognized Ebstein’s malformation of the tricuspid valve (TV)]; experience of this kind of surgery is limited.
In all cases, timely evaluation for transplantation by ACHD heart failure specialists in a transplant centre with ACHD expertise is recommended. Advance care planning, eventually including palliative care, should be offered to all advanced heart failure patients.
3.4.2
Arrhythmias and sudden cardiac death
3.4.2.1 Arrhythmia substrates
The entire spectrum of arrhythmias may be encountered in ACHD
patients. However, some congenital arrhythmia substrates are related to the malformation itself (Table 7 and section 4). Longer life expectancy (in conjunction with exposure to conventional risk factors for arrhythmogenic substrates) increases the prevalence of
ESC Guidelines
579


<!-- PAGE 18 -->

### Page 18

..........................................
arrhythmias related to structural remodelling, which may occur at a younger age than in the general population, e.g. AF.
Other arrhythmias are related to the type and timing of the ACHD
repair. Right atrial (RA) incisions, together with cardiac remodelling secondary to haemodynamic overload, contribute to the high prevalence of atrial tachycardias (AT) in various CHDs. Most frequently encountered is late intraatrial reentrant tachycardia (IART), in particular cavotricuspid isthmus-dependent atrial flutter. Atrial rates between
150 and 250 beats per minute may lead to rapid AV conduction, haemodynamic compromise,
and sudden cardiac death
(SCD).
Monomorphic ventricular tachycardia (VT) also depends on the malformation (Table 7) and type of repair,34,35 with the critical part of the macro-reentry circuit typically located within anatomically well-defined isthmuses bordered by surgical scars and patch material. In contrast, in patients with progressive failure of the systemic or subpulmonary ventricle, more complex EP changes may occur. These changes involve ion channel remodelling, alterations in calcium handling, and remodelling of the extracellular matrix leading to different arrythmias including less well-organized fast polymorphic VT and ventricular fibrillation (VF).36
3.4.2.2 Assessment in patients with suspected/documented arrhythmias and arrhythmia management
In symptomatic patients without arrhythmia documentation at presentation, evaluation depends on the frequency [Holter registration,
device interrogation (if present), event recorder] and circumstances
(exercise testing) of symptoms.
The usefulness of periodic evaluation beyond 12-lead ECGs (e.g.
periodic Holter) in asymptomatic patients is less clear. A high
Table 7
Risk estimates for arrhythmic events and bradycardias in ACHD
AF = atrial ﬁbrillation; ASD = atrial septal defect; AV = atrioventricular; AVRT = atrioventricular reentrant tachycardia; AVSD = atrioventricular septal defect; ccTGA = congenitally corrected transposition of the great arteries; CHD = congenital heart disease; EAT = ectopic atrial tachycardia; IART = intraatrial reentrant tachycardia; SCD = sudden cardiac death;
SND = sinus node dysfunction; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; VSD = ventricular septal defect; VT = ventricular tachycardia.
aConsidering the high prevalence of VSD, the overall risk in unselected patients with VSD is considered to be minimal.
bSCD may be due to supraventricular arrhythmias with rapid AV conduction.
cVT higher estimated risk in complex dextro-TGA.
dNon-arrhythmic.


<!-- PAGE 19 -->

### Page 19

....................................................................................
prevalence of asymptomatic findings has been reported that rarely change management.37
In all patients, evaluation for a reversible cause of the arrhythmia
(e.g. hyperthyroidism, inflammatory process) and new or residual haemodynamic abnormalities is important. Arrhythmias causing haemodynamic instability require immediate termination irrespective of duration/anticoagulation following current recommendations.32
Post-conversion, sinus arrest/bradycardia may occur and availability of back-up pacing needs to be considered in patients at risk for sinus node dysfunction (SND) (Table 7). If IART/AF is tolerated and lasting
>_48 h, cardiac thrombus needs to be ruled out (TOE) and/or appropriate anticoagulation (>3 weeks) and pharmacological rate control needs to be initiated before cardioversion using a beta blocker or calcium channel blocker (in patients with normal systemic ventricular function and absent preexcitation).32,37,38 Maintenance of sinus rhythm is the aim in all CHD patients.32,37 Catheter ablation is recommended as first-line therapy and preferred over long-term pharmacological treatment,
in case of amenable,
circumscribed substrates, as antiarrhythmic drugs are often associated with negative inotropic and/or dromotropic effects.32 Antiarrhythmic drugs such as class IC drugs may slow the rate of IART without blocking AV conduction allowing 1:1 conduction with worsening haemodynamics.32
Amiodarone may be considered for AT/AF recurrence prevention in patients with CHD and systemic ventricular dysfunction, hypertrophy of systemic ventricle, or CAD, in whom catheter ablation fails or is otherwise no option. Side effects of amiodarone are frequent and it should be used with caution in cyanotic CHD, low body weight, hepatic, thyroid, or pulmonary disease, or prolonged QT interval. Longterm amiodarone therapy is not advised in young CHD patients.32
For optimal chronic arrhythmia management, referral to a centre with a multidisciplinary team and expertise in CHD-related arrhythmias is mandatory.32,37 For more specifications on anticoagulation see section 3.4.7.
3.4.2.3 Sinus node dysfunction, atrioventricular block, and infra-hisian conduction delay
Periodic Holter for patients at risk for SND and AV block should be considered in asymptomatic patients. Chronic SND/bradycardia with ineffective atrial haemodynamics may affect atrial remodelling and facilitate IART. Patients with post-operative AV block are considered at increased risk for SCD. Accordingly, broader indications for pacemaker implantation compared with patients with structurally normal hearts have been suggested.20,32
In ACHD patients with a biventricular circulation and a systemic
LV, indications for CRT follow standard criteria. Of note, conventional ventricular pacing rather than bundle branch block is the major cause of systemic ventricular dysfunction. Accordingly, CRT is recommended in ACHD with a systemic EF <_35% and intrinsic narrow
QRS, and an anticipated requirement for significant pacing and new device placement. Alternatively, his bundle pacing could be considered. Efficacy of CRT in ACHD may vary across defects and may depend on the individual anatomy and causes of dyssynchrony (e.g.
systemic RV/single ventricle, AV valve regurgitation, scarring). In general, QRS duration alone may not be a sufficient predictor and follow-up data are limited. In addition, thoracotomy or hybrid lead implantation is often required and data on longevity of CRT are lacking.32
3.4.2.4 Sudden cardiac death and risk stratification
SCD related to ventricular arrhythmia is of concern (726% of all deaths in adults).29,39,40 Although the incidence in the CHD population at large is relatively low (<0.1% per year), some defects place patients at higher risk, with occasional disease-specific substrates and risk factors (Table 7). Identifying patients at risk for SCD remains a challenge.
ICD implantation for secondary prevention of SCD and for primary prevention in patients with biventricular physiology and a systemic LV follows standard criteria.37,41 Antiarrhythmic drugs may be used as an adjunct to an ICD in order to reduce the ventricular arrhythmia burden.32 The benefit of ICD therapy in primary prevention for single or systemic RVs is less well established.
Accordingly, with the exception of tetralogy of Fallot (TOF), specific guidelines regarding ICD implantation for primary prevention in
CHD remain elusive.32,37 Transvenous ICD systems have been used,
but in patients with limited venous access to the ventricle or intracardiac shunt, the subcutaneous ICD may be an alternative. However,
not all patients are eligible due to the risk of inappropriate sensing and lack of antitachycardia and antibradycardia pacing.
The usefulness of programmed electrical stimulation (PES) in asymptomatic patients with CHD is unclear. It seems reasonable in patients with ventricular incisions and/or a substrate for ventricular reentry typically, but not exclusively, encountered in repaired TOF
(rTOF). It is important to recognize other causes of SCD due to bradycardia/total AV block and bradycardia-induced ventricular arrhythmia with or without long QT, and IART/AF with rapid conduction.
Recommendations for treatment of arrhythmias in adult congenital heart disease
Recommendations
Classa
Levelb
In patients with moderate and severe CHD complexity (Table 4) and documented arrhythmias,
referral to a centre with a multidisciplinary team and expertise in ACHD patients and ACHDrelated arrhythmia is indicated.
I
C
In CHD patients with documented arrhythmias or at high risk for post-procedural arrhythmias
(e.g. ASD closure at older age) considered for percutaneous or surgical (re)interventions,
referral to a centre with a multidisciplinary team with expertise in these interventions and in invasive treatment of arrhythmias is indicated.
I
C
In mild CHD, catheter ablation is recommended over long-term medical therapy for symptomatic, sustained recurrent SVT (AVNRT, AVRT,
AT, and IART), or if SVT is potentially related to
SCD (Table 7).
I
C
In moderate and severe CHD, catheter ablation should be considered for symptomatic, sustained recurrent SVT (AVNRT, AVRT, AT, and IART),
or if SVT is potentially related to SCD (Table 7),
provided that the procedure is performed in experienced centres.
IIa
C
Continued
ESC Guidelines
581


<!-- PAGE 20 -->

### Page 20

...............................................................................................
3.4.3
Pulmonary hypertension
3.4.3.1 Introduction and classification
PH is an important prognostic factor in patients with CHD,42 requiring particular attention in pregnancy43 or prior to reparative cardiac or other major surgery. Until recently, PH was defined by an increase in invasively measured mean PAP >_25 mmHg at rest.44 While this has now been reduced to >20 mmHg,45 classification as pre-capillary PH
 also called PAH  additionally requires an increase in PVR >_3
Wood units (WU) (Table 8).45 This increase in resistance in this group is due to an obstructive pulmonary vasculopathy which is driven by genetic background, modifier genes, vascular shear stress,
and environmental triggers.44 It is important to separate PAH associated with CHD (PAH-CHD, in group 1 of the PH classification44)
from conditions with an LV filling pressure >15 mmHg (post-capillary
PH due to passive transmission of LV filling pressures in groups 2 and
5 of the PH classification),44 because of the futility of PAH-targeted treatments in post-capillary PH. Clinical subtypes of PAH-CHD are
PAH with congenital systemic-pulmonary shunts, Eisenmenger syndrome, repaired defects, and PAH that appears coincidental with
CHD, frequently with small defects. Fontan circulation is another condition with pulmonary vascular disease (PVD) and sometimes elevated PVR. An increase in PAP in these patients is, however, more frequently caused post-capillary (increase in ventricular filling pressure and/or AV valve regurgitation). In complex CHD, PAH may be restricted to certain segments of the pulmonary vascular bed (segmental PAH).46 This is most frequently encountered in complex pulmonary atresia with VSD.
Although PAH-CHD can occur in males and females of any age, the disease is more frequently encountered in females, and increases with biological age and age at defect closure.47 The sex bias disappears in
PAH-CHD after defect repair.48 More recently, a nationwide CHD
Catheter ablation is indicated as adjunctive therapy to ICDs in patients who present with recurrent monomorphic VT, incessant VT, or electrical storm not manageable by medical therapy or ICD reprogramming.
I
C
Catheter ablation should be considered for symptomatic, monomorphic sustained VT in patients for whom medical therapy is not desired, provided that the procedure is performed in experienced centres.
IIa
C
Implantable cardiac deﬁbrillator
ICD implantation is indicated in adults with
CHD who are survivors of an aborted cardiac arrest due to VF or haemodynamically untolerated VT after evaluation to deﬁne the cause of the event and exclusion of reversible causes.
I
C
ICD implantation is indicated in adults with
CHD and sustained VT after haemodynamic evaluation and repair when indicated. EP evaluation is required to identify patients in whom catheter ablation or surgical ablation may be beneﬁcial as adjunctive treatment or in whom it may offer a reasonable alternative.
I
C
ICD implantation should be considered in adults with CHD with biventricular physiology and a systemic LV presenting with symptomatic heart failure (NYHA II/III) and EF <_35% despite >_ 3
months of optimal medical treatment, provided they are expected to survive substantially longer than one year with good functional status.c
IIa
C
ICD implantation should be considered in patients with CHD and unexplained syncope and suspicion for arrhythmia aetiology and either advanced ventricular dysfunction or inducible VT/VF at programmed electrical stimulation.
IIa
C
ICD implantation should be considered in selected TOF patients with multiple risk factors for SCD, including LV dysfunction, non-sustained, symptomatic VT, QRS duration >_180 ms,
extensive RV scarring on CMR, or inducible VT
at programmed electrical stimulation.
IIa
C
ICD implantation may be considered in patients with advanced single or systemic RV dysfunction
(EF systemic RV <35%) in the presence of additional risk factors.d
IIb
C
Pacemaker
PM implantation should be considered in ACHD
patients with bradycardia-tachycardia syndrome to prevent IART, if ablation fails or is not possible.
IIa
C
PM implantation should be considered for patients with severe CHD and sinus or
IIa
C
Continued junctional bradycardia (daytime heart rate <40
beats per minute or pauses >3 s).
PM implantation should be considered for patients with CHD and compromised haemodynamics due to sinus bradycardia or loss of AV
synchrony.
IIa
C
PM implantation may be considered for patients with moderate CHD and sinus or junctional bradycardia (daytime heart rate <40 beats per minute or pauses >3 s).
IIb
C
ACHD = adult congenital heart disease; ASD = atrial septal defect; AT = atrial tachycardia; AV = atrioventricular; AVNRT = atrioventricular node reentrant tachycardia; AVRT = atrioventricular reentrant tachycardia; CHD = congenital heart disease; CMR = cardiovascular magnetic resonance; EF = ejection fraction;
EP = electrophysiology/electrophysiological; IART = intraatrial reentrant tachycardia; ICD = implantable cardioverter deﬁbrillator; LV = left ventricle/ventricular; NYHA = New York Heart Association; PM = pacemaker; RV = right ventricle/ventricular; SCD = sudden cardiac death; SVT = supraventricular tachycardia; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; VF =
ventricular ﬁbrillation; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cConsidering the broad spectrum of ACHD with LV pathologies that may differ from acquired heart diseases, the potentially higher risk of ICD-related complications in ACHD, and the paucity of data on the beneﬁt of ICDs for primary prevention of SCD in ACHD, a personalized approach seems appropriate.
dData are sparse and risk factors may be lesion speciﬁc, including non-sustained
VT, NYHA II/III, severe AV valve regurgitation, and wide QRS >_140 ms (TGA).


<!-- PAGE 21 -->

### Page 21

............................................................................................................
population study reported a PAH prevalence of 3.2% in CHD patients,
accounting for 100 per million in the general adult population.47
3.4.3.2 Diagnosis
The 2015 guidelines for the diagnosis and treatment of PH presented a haemodynamic algorithm for the diagnosis of PH, highlighting the role of right heart catheterization to differentiate pre- from postcapillary PH.44 The algorithm has recently been modified,45 and
Table 8 illustrates current definitions of different types of PH and the settings in which they may occur in ACHD. In this definition, mean
PAP threshold is >20 instead of >_25 mmHg in the presence of a PVR
>_3 WU to define pre-capillary PH.45
3.4.3.2.1 Diagnostic work-up of pulmonary hypertension in adult congenital heart disease.
The diagnostic work-up includes medical history, physical examination,
lung function tests, arterial blood gas analysis, imaging (especially echocardiography), and laboratory testing (including total blood cell counts,
serum iron levels, haematocrit, infectious diseases, and NT-pro-BNP
measurements). In general, right heart catheterization with compartmental oximetry is required for major decisions such as start and follow-up of vasodilator therapy, pregnancy, or surgery. The threshold for invasive assessment is, however, higher in patients with Eisenmenger syndrome.
Invasive haemodynamic assessment is usually not required for guiding therapeutic interventions over time. Because higher haematocrit levels lead to higher PVR, this may have to be taken into account.49
3.4.3.2.2
Risk assessment.
Outcomes of PAH-CHD patients have improved with the availability of new PAH therapies, advances in surgical and perioperative management, and use of a team-based, multidisciplinary approach.44,50,51
In recent series, outcomes of PAH-CHD patients appear to be better than in idiopathic PAH,48 but depend on the PH subset. Outcomes of
PAH associated with small defects resemble the dismal outcomes of idiopathic PAH, presumably because these conditions are based on a similar vascular proliferative disorder. PAH after defect repair carries even worse prognosis.48
3.4.3.3 Therapeutic management of pulmonary hypertension in adult congenital heart disease
3.4.3.3.1 Expert centres.
Successful management of an ACHD patient with PH requires a multidisciplinary management team comprising experts in imaging, cardiology,
respiratory medicine,
haematology,
infectious diseases,
obstetrics, anaesthesiology, neonatology, PH, thoracic and cardiovascular surgery, nursing, and medical genetics.
3.4.3.3.2
General measures.
The main general measures are social and psychological support, vaccination, and avoidance of excessive physical stress.
Follow-up visits are planned individually. Pregnancy must be avoided in all cases of pre-capillary PH. Continuous supplemental oxygen is recommended when the arterial blood oxygen pressure is consistently <60 mmHg,44 except in Eisenmenger patients in whom it is only recommended when it produces a documented, consistent, and significant increase in oxygen saturation and improvement of symptoms.
3.4.3.3.3 Anticoagulation.
Anticoagulation with vitamin K antagonists (VKAs) in the absence of atrial arrhythmia, mechanical valves, or vascular prosthesis is not generally recommended in PAH-CHD, and has to be decided on an individual basis, e.g. large PA aneurysms with thrombus or previous thromboembolic events. No data exist on the use of non-vitamin K
antagonist oral anticoagulants
(NOACs).
In patients with
Eisenmenger syndrome, data supporting the routine use of anticoagulation are lacking, but oral anticoagulation should be considered in patients with atrial arrhythmias and may be considered in the presence of PA thrombosis or embolism and low bleeding risk. As the risk of bleeding is increased in cyanotic patients, the use of oral
....................................................................................................................................................................................................................
Table 8
Deﬁnitions of pulmonary hypertension subtypes and their occurrence in ACHD
Pulmonary Hypertension in Adult Congenital Heart Disease
Definition
Haemodynamic characteristicsa
Clinical settings
Pulmonary Hypertension (PH)
Mean PAP >20 mmHg
All
Pre-capillary PH (PAH)
Mean PAP >20 mmHg
PAWP <_15 mmHg
PVR >_3 WU
Shunt lesions prior to and after repair (including Eisenmenger syndrome)
Complex CHD (including UVH, segmental PAH)
Isolated post-capillary PH
Mean PAP >20 mmHg
PAWP >15 mmHg
PVR <3 WU
Systemic ventricular dysfunction
Systemic AV valve dysfunction
Pulmonary vein obstruction
Cor triatriatum
Combined pre- and post-capillary PH
Mean PAP >20 mmHg
PAWP >15 mmHg
PVR >_3 WU
Settings listed under isolated post-capillary PH
Settings listed under isolated post-capillary PH in combination with shunt lesions/complex CHD
ACHD = adult congenital heart disease; AV = atrioventricular; CHD = congenital heart disease; PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure;
PAWP = pulmonary artery wedge pressure; PH = pulmonary hypertension; PVR = pulmonary vascular resistance; UVH = univentricular heart; WU = Wood units.
aThe most recent deﬁnition of PH45 lowers mean PAP from >_25 mmHg44 to >20 mmHg but additionally requires a PVR >_3 WU for pre-capillary PH.
ESC Guidelines
583


<!-- PAGE 22 -->

### Page 22

................................................
anticoagulation and antiplatelet agents should be considered carefully on a case-by-case basis.
3.4.3.3.4 Shunt repair.
Because endothelial shear triggers PH,52 surgical/interventional repair of conditions of increased flow are conceptualized to protect the pulmonary vasculature. The threshold PVR permitting reparative surgical closure of a left-to-right (LR) shunt without right heart failure differs for the different shunt lesions (see sections 4.14.4). However, the decision to close a shunt is made using all the available information and is not solely dependent on the haemodynamics obtained at cardiac catheterization;53,54 the decision should only be taken in expert centres.
There is no prospective evidence that a treat-and-repair approach in patients with PAH-CHD confers long-term benefits.44,55 No prospective data are available on the usefulness of vasoreactivity testing,
closure test, or lung biopsy for assessment of operability.53,54,5660
3.4.3.3.5
Pulmonary arterial hypertension-directed medical therapy.
Advanced therapies benefit patients with Eisenmenger syndrome,51
and likely also other PAH-CHD.61,62 According to the 2015 ESC/ERS
Guidelines on PH,44pre-capillary PH (PAH), including Eisenmenger syndrome, is a moderate- to high-risk condition and requires a proactive approach using initial63 or sequential combination treatment,64,65
including parenteral prostacyclins.44 Parenteral prostaglandins work best when started early.66 The presence of a central intravenous catheter for parenteral therapy, however, increases the risk of paradoxical embolism and infection in Eisenmenger patients and those with RL shunt lesions. In this setting, subcutaneous or inhaled forms of administration are therefore generally preferred.
Exclusions to this rule are patients with closed or coincidental defects meeting strict criteria for vasodilator responsiveness (mainly a decrease of mean PAP >10 mmHg and below 40 mmHg acutely under nitric oxide inhalation) who may be treated with calcium channel blocker therapy only. However, such patients are extremely rare among adults with PAH-CHD. General vasoreactivity testing is not recommended in PAH-CHD.44
Long-term home oxygen therapy may improve symptoms but has not been shown to augment survival in Eisenmenger patients. The use of supplemental oxygen should be restricted to those cases in which it produces a documented, consistent, and significant increase in arterial oxygen saturation and improves symptoms.
Secondary erythrocytosis is beneficial for adequate oxygen transport and delivery, and routine phlebotomy should be avoided; for more details see section 3.4.8.
In Eisenmenger patients, the endothelin receptor antagonist (ERA)
bosentan has been shown to improve 6MWT and decrease PVR after
16 weeks of treatment in World Health Organization (WHO) functional class III patients.67 Although a beneficial effect of bosentan has been shown on exercise capacity and quality of life in this group of patients, an effect on mortality is less well documented. Long-term follow-up showed sustained improvement in symptoms. Experiences with other ERAs and the phosphodiesterase type 5 (PDE-5) inhibitors,
sildenafil and tadalafil, show favourable functional and haemodynamic results in patients with PAH-CHD and Eisenmenger syndrome, with less robust evidence. Experience is limited for latest-generation PAH
drugs such as macitentan, selexipag, or riociguat in the setting of
CHD.66 While patients with simple repaired lesions have been included in the landmark studies for these substances, and are likely to benefit similarly to idiopathic PAH patients, data are currently limited for Eisenmenger patients. A recent randomized controlled trial investigating efficacy of macitentan to improve 6MWT in Eisenmenger syndrome was neutral.68 Most centres follow a sequential symptomorientated treatment strategy in Eisenmenger syndrome, generally starting with an oral ERA or PDE-5 inhibitor and escalating therapy if symptoms persist or in the case of clinical deterioration. Should an adequate improvement in symptoms not be achieved with oral therapy, parenteral options should be considered proactively.
The effect of PAH therapy in patients with segmental PAH remains a matter of debate. While some series reported promising results,
there have been cases where therapies were not tolerated.46
Heart-lung or lung transplantation with heart surgery is an option in special cases not responsive to medical treatment but is limited by surgical complexity and organ availability.
3.4.4
Surgical treatment
Cardiac surgery in ACHD patients deserves special attention. Even small operations can carry a high risk due to the dysregulation of the delicate balance in which ACHD patients often thrive. This risk cannot be calculated using conventional surgical risk scores. The adult congenital heart surgery score was derived from the Society of
Recommendations for treatment of pulmonary arterial hypertension associated with congenital heart disease
Recommendations
Classa
Levelb
It is recommended that patients with CHD and conﬁrmed pre-capillary PHc are counselled against pregnancy.
I
C
Risk assessment is recommended in all patients with PAH-CHD.d
I
C
In low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH,
initial oral combination therapy or sequential combination therapy is recommended and highrisk patients should be treated with initial combination therapy including parenteral prostanoids.e 6365
I
A
In Eisenmenger patients with reduced exercise capacity (6MWT distance <450 m), a treatment strategy with initial endothelin receptor antagonist monotherapy should be considered followed by combination therapy if patients fail to improve.6769
IIa
B
6MWT = 6-minute walk test; CHD = congenital heart disease; PAH-CHD = pulmonary arterial hypertension associated with congenital heart disease; PH = pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
cThe risk of pregnancy in patients with pre-capillary PH is very high. It may be less in pregnancies of patients with post-capillary PH, therefore, a right heart catheterization is necessary in all patients with a suspicion of pre-capillary PH to conﬁrm the diagnosis.
dFor details see 2015 ESC/ERS Guidelines for diagnosis and treatment of PH.44
eFor details about choice of drugs and the recommended risk-adjusted treatment algorithm see 2015 ESC/ERS Guidelines for diagnosis and treatment of PH.44


<!-- PAGE 23 -->

### Page 23

.............................................................................................................................................................................
Thoracic Surgeons Congenital Heart Surgery Database as the first evidence-based score, designed specifically for surgery in ACHD.70
Upon evaluation, the score reached a good predictive power in
ACHD, although the corresponding paediatric score performed better in children,71 indicating that in ACHD, individual patients’ comorbidities may play a more important role in determining outcomes.
The ACHD mortality score, an expert-based score that accounts for comorbidities, may therefore also be considered for evaluating the risk of cardiac surgery in ACHD.72
Apart from the need for personalized risk assessment, understanding the specific anatomy and haemodynamics, experience with redo surgery, and special requirements in intensive care units are factors that determine short- and long-term outcomes. When
ACHD patients are operated on by a congenital cardiac surgeon,
outcome is proven to be superior.73 Therefore, the strict recommendation is that all ACHD patients are operated on by a congenital cardiac surgeon in a multidisciplinary environment with expertise in ACHD. This holds true for all ACHD cardiac surgery in the present recommendations except for surgery of uncomplicated bicuspid aortic valve (BAV), heritable thoracic aortic disease
(HTAD) such as Marfan syndrome, and secundum-type ASD without anomalous pulmonary venous connection and/or absence of
PVD. The multidisciplinary expert environment also favours the growing interest in, and need for, hybrid procedures, where (congenital) cardiac surgeons, vascular surgeons, interventional congenital cardiologists, and electrophysiologists collaborate in technically challenging procedures.
3.4.5
Catheter intervention
Catheter-based interventions, either as stand-alone or hybrid procedures, are an appealing alternative to conventional open-heart surgery, obviating the need for redo sternotomy/thoracotomy and cardiopulmonary bypass. The most frequent percutaneous interventions are closure of shunt lesions (in particular secundum-type ASD,
rarely VSD, and persistent arterial duct), fistula, or unusual collaterals;
balloon dilatation of the pulmonary valve and valved grafts; balloon dilatation and/or stenting of narrowed great vessels [e.g. (re-coarctation of the aorta (CoA) and pulmonary arterial stenosis]; and transcatheter pulmonary valve implantation (TPVI). ACHD diagnosis and,
in particular, interventional care should be delivered by people who are trained as CHD caregivers and are part of an ACHD care centre,
where individual procedures are reviewed and discussed within a multidisciplinary team.74 It is of particular importance that a programme performing transcatheter interventions in ACHD patients should be co-located with appropriate congenital cardiac services for the management of procedural complications. In many programmes,
experienced paediatric interventional cardiologists form an important component of ACHD intervention services, but in others (e.g.
those based in a separate paediatric hospital), paediatric interventionalists may be uncomfortable with the interventional management of adults with congenital cardiac problems. Therefore, full collaboration between adult and paediatric cardiology is recommended.
Concentration of ACHD catheterization in a limited number of designated centres allows quality assurance as well as co-location of key cardiovascular services.74 Minimum annual numbers of interventions per centre have been proposed in a recent recommendation paper.74
3.4.6
Infective endocarditis
The risk of infective endocarditis (IE) in ACHD patients is higher than in the general population, with marked variation between lesions.
The 2015 ESC Guidelines on IE maintain the restriction of antibiotic prophylaxis to patients at high risk of IE undergoing at-risk dental procedures.22 High-risk conditions are prosthetic valves, including transcatheter valves, valve repair using a prosthetic ring, previous IE, any cyanotic CHD, and any CHD repaired with prosthetic material up to
6 months after the procedure or lifelong if residual shunt or valvular regurgitation remains.
Non-specific hygiene measures should be applied in all ACHD
patients: good oral and cutaneous hygiene, and aseptic measures during healthcare and any invasive procedure. Piercings and tattoos are discouraged and otherwise should be performed in optimal hygienic conditions.
All patients need to be educated about symptoms of IE and appropriate behaviour (seeking medical advice, importance of blood cultures before starting antibiotic treatment) at occurrence of such symptoms.
Recent studies confirmed the relatively high risk of IE in patients after valve surgery, particularly previous IE and bovine jugular vein conduits.7578 Specific awareness is needed after TPVI using a
Melody valve prosthesis.75
3.4.7
Antithrombotic treatment
Patients with ACHD are at increased risk of thromboembolic events,
but evidence on prevention is limited. In patients with IART or AF,
the CHA2DS2-VASc and HAS-BLED scores have proven beneficial in adult patients with acquired heart disease.38 However, as their validity in the CHD population is uncertain, the scores should only be used in combination with individually assessed risks. Traditionally,
VKAs are used for thromboembolic prevention, but in general cardiology, NOACs are currently recommended in preference to VKA.
Also, in the CHD population, NOACs seem similarly safe and effective, in the absence of mechanical valves or severe mitral valve stenosis.79,80 Anticoagulation therapy is recommended in paroxysmal and persistent AF/IART in patients with moderate or severe CHD, but an individualized approach remains necessary. In patients with mild
CHD, the CHA2DS2-VASc and HAS-BLED scores38 should be used as per general recommendations.81 Whether all Fontan patients benefit from anticoagulation is unclear at the moment. Bleeding risk should also be considered and weighed against thrombogenic risk,
especially in cyanotic patients. For secondary prevention, anticoagulation is recommended in patients with a thromboembolic event or incidental intracardiac or intravascular thrombus (see also 2017 ESC/
EACTS Guidelines on valvular heart disease and 2018 ESC
Guidelines on pregnancy).
3.4.8
Management of cyanotic patients
Cyanosis is caused by RL shunt due to an anatomical communication between the systemic and pulmonary circulation at the atrial,
ventricular, or arterial level. Cyanotic heart disease comprises a heterogeneous group of lesions with different underlying anatomy and pathophysiology: normal or restricted pulmonary blood flow in the presence of an obstruction across the pulmonary outflow tract or increased pulmonary blood flow in the absence of such an obstruction which, in some defects, may result in development of PAH and
ESC Guidelines
585


<!-- PAGE 24 -->

### Page 24

.............................................................................................................................................................................
eventually Eisenmenger syndrome (see sections 3.4.3 and 4.15).
They may present with or without prior palliative intervention.
Cyanotic patients are complex and must be followed by an ACHD
specialist.
3.4.8.1 Adaptive mechanisms
Cyanosis induces adaptive mechanisms to improve oxygen transport and delivery to the tissue: secondary erythrocytosis, rightward shift of the oxyhaemoglobin dissociation curve, and increase in cardiac output.82,83 Erythrocytosis secondary to erythropoietin stimulus is the physiological response to chronic hypoxaemia. Compensated erythrocytosis reflects an equilibrium and decompensated erythrocytosis indicates failure of an equilibrium (excessive red blood cell/haemoglobin increase and unstable, rising haematocrit with major hyperviscosity symptoms).82,84
3.4.8.2 Multisystem disorder
Cyanosis and secondary erythrocytosis imply profound consequences for the entire organ system:82,84,85
• Blood viscosity is increased and is directly related to red blood cell mass.84
• Haemostatic abnormalities are common and complex and are attributed to abnormalities in platelets (thrombocytopaenia and thrombasthenia), coagulation pathways, and other abnormal coagulation mechanisms. Vitamin K-dependent clotting factors and factor V are reduced, fibrinolytic activity is increased, and the largest von Willebrand multimers are depleted.
• Increased turnover of red blood cells/haemoglobin and impaired urate filtration lead to hyperuricaemia.86 The increased concentration of unconjugated bilirubin puts cyanotic patients at risk for calcium bilirubinate gallstones.
• Severe endothelial dysfunction is evident by the striking impairment of endothelium-dependent vasodilation.85
• Chronic hypoxaemia, increased blood viscosity, and endothelial dysfunction affect microcirculation, myocardial function, and the function of other organ systems.
3.4.8.3 Clinical presentation and natural history
Clinical presentation includes central cyanosis, a result of an increased quantity of reduced haemoglobin (>5 g/100 mL blood),
clubbing, and frequently scoliosis. The underlying anatomy/pathophysiology characterizes cardiac findings.
Mortality is significantly higher in cyanotic patients than in acyanotic patients.87 Outcome is determined by the underlying anatomy, pathophysiology, palliative procedures, complications of cyanosis, and preventive measures.88,89 Low platelet count, severe hypoxia, cardiomegaly, and elevated haematocrit during childhood are parameters to predict premature death and adverse events in patients with and without PVD.90 Iron deficiency is associated with adverse late outcome;91,92
BNP can predict outcome in Eisenmenger patients.93,94 However, in a multicentre study,89 only age, pre-tricuspid shunt, absence of sinus rhythm, lower oxygen saturation at rest, and presence of pericardial effusion, but not BNP, were the strongest predictors for death.
3.4.8.4 Late complications
• Hyperviscosity symptoms include headache, faintness, dizziness,
fatigue, tinnitus, blurred vision, paraesthesia of fingers, toes, and lips, muscle pain, and weakness (classified moderate when they interfere with some activities, severe when they interfere with most activities).82,83 Hyperviscosity symptoms are unlikely in an iron-replete patient with haematocrit <65%.
• Bleeding and thrombotic diathesis occur; both cause a therapeutic dilemma (risks of thrombosis and bleeding). Spontaneous bleeding is usually minor, self-limiting (dental bleeding, epistaxis,
easy bruising, menorrhagia). Haemoptysis is the most common major bleeding event and is an external manifestation of an intrapulmonary haemorrhage not reflecting the extent of parenchymal bleeding (reported in up to 100% of Eisenmenger patients).95,96 Thrombosis is caused by coagulation abnormalities,
stasis of blood in dilated chambers and vessels, atherosclerosis and/or endothelial dysfunction, the presence of thrombogenic material (e.g. conduits), and arrhythmias. The haemostatic abnormalities do not protect against thrombotic complications.
Laminated thrombi in large, partially calcified and aneurysmal PAs are common (up to 30%).97100 Female sex, low oxygen saturation, older age, biventricular dysfunction, and dilated PAs have been identified as risk factors.97,100,101
• Cerebrovascular infarctions are common, but underreported.97
They may be caused by thromboembolic events (paradoxical embolism, supraventricular arrhythmia), rheological factors
(microcytosis), endothelial dysfunction, and traditional atherosclerotic risk factors. The severity of secondary erythrocytosis is not in itself a risk factor.102 Microcytosis caused by iron deficiency, due to inappropriate phlebotomies, was the strongest independent predictor for cerebrovascular events in one study.91
Severity of cyanosis and CHD complexity are other risk factors.97
• Paradoxical emboli may be caused by transvenous leads or catheters.
• Iron deficiency is frequently caused by, and may be exacerbated by, inappropriate phlebotomies or heavy menstruation in female patients.
• Arrhythmias  supraventricular and ventricular.
• Infectious complications include endocarditis, cerebral abscess,
and pneumonia. Fever, associated with a new or different headache, raises suspicion of a brain abscess.
• Renal dysfunction is common and is due to functional and structural abnormalities of the kidneys.
• Cholelithiasis is common and can be complicated by cholecystitis/choledocholithiasis.
• Rheumatological complications include gouty arthritis, hypertrophic osteoarthropathy, and kyphoscoliosis.83
3.4.8.5 Diagnostic aspects
Particular attention must be paid to hyperviscosity symptoms and bleeding/ischaemic complications. Oxygen saturation must be obtained with pulse oximetry at rest for at least 5 min, and exercise capacity should be assessed on a regular basis, preferably with a
6MWT.
Blood work must include cellular blood count, mean corpuscular volume (MCV), serum ferritin (serum iron, iron saturation, transferrin, and transferrin saturation may be required for earlier detection of iron deficiency), creatinine, serum uric acid, clotting profile, BNP/
NT-pro-BNP, folic acid, and vitamin B12 in the presence of elevated
MCV or normal MCV and low serum ferritin.


<!-- PAGE 25 -->

### Page 25

..........................................................................................................
3.4.8.6 Laboratory precautions
• Coagulation parameters: plasma volume is reduced due to secondary erythrocytosis; the amount of sodium citrate must be adjusted to haematocrit if haematocrit is >55%.
• Haematocrit determined with automated electronic particle counts (micro-haematocrit centrifugation) results in falsely high haematocrit due to plasma trapping.
• Glucose level can be reduced (increased in vitro glycolysis, which results from the increased number of erythrocytes).
3.4.8.7 Indications for intervention
Risk and benefit must be carefully considered and require expertise.
Cyanotic patients without PAH/Eisenmenger syndrome must be periodically evaluated for any procedure that may improve quality of life and reduce morbidity, or for eligibility for physiological repair (see section 4.15).
3.4.8.8 Medical therapy
• Specific PAH treatment: see section 3.4.3.
• Arrhythmias: sinus rhythm should be maintained whenever possible. Antiarrhythmic therapy must be individualized (medications,
ablation,
epicardial
PM/ICD).
Antiarrhythmic therapy is extremely difficult; drug therapy should be initiated with particular care and generally in a hospital.
• Therapeutic phlebotomy should only be performed in the presence of moderate/severe hyperviscosity symptoms due to secondary erythrocytosis (haematocrit at least >65%), in the absence of dehydration and iron deficiency.82 Isovolumetric fluid replacement (7501000 mL of isotonic saline while removing 400500
mL of blood) should be undertaken.
• Blood transfusion may be required in the presence of ironreplete anaemia
(haemoglobin inadequate to oxygen saturation) and should not be based on conventional indications.
• Iron supplementation should be performed in the presence of iron deficiency (MCV <80 fL, low iron stores) and carefully followed (rebound effect).
• Routine anticoagulation/aspirin: currently available data do not support any benefit in cyanotic patients to prevent thromboembolic complications. There is, however, an increased risk of bleeding.
• Indication for anticoagulation: atrial flutter/AF (target INR 22.5;
higher target INR in the presence of other risk factors). Note laboratory precautions: false high INR values are measured due to the high haematocrit. There are no data and only anecdotal experiences about the use of NOACs (see also section 3.4.7).
• Haemoptysis: requires chest computed tomography if there is an infiltrate on the chest X-ray. Bronchoscopy puts the patient at risk and seldom provides useful information. Therapy includes discontinuation of aspirin,
non-steroidal anti-inflammatory agents, oral anticoagulants; treatment of hypovolaemia and anaemia; reduction of physical activity; and suppression of nonproductive cough. Selective embolization of bronchial arteries may be required for refractory intrapulmonary haemorrhage/
haemoptysis. Antifibrinolytic agents (e.g. inhaled tranexamic acid)
are under investigation and may be a novel approach to treat haemoptysis.103 More trials are needed.
• Hyperuricaemia:
no indication to treat asymptomatic hyperuricaemia.
• Acute gouty arthritis (atypical presentation) is treated with oral or intravenous colchicine, probenecid, and anti-inflammatory drugs, with attention paid to the risk of renal failure and bleeding.
Uricosuric (e.g. probenecid) or uricostatic agents (e.g. allopurinol) avoid recurrence.
3.4.8.9 Follow-up recommendations
All cyanotic patients require lifelong evaluation with follow-up visits every 612 months in a specialized ACHD centre in close collaboration with the family physician. Evaluation includes:
Table 9
Risk reduction strategies in patients with cyanotic congenital heart disease
Prophylactic measures are the mainstay of care to avoid complications.83
The following exposures/activities should be avoided:
Other risk reduction strategies include:
• Pregnancy in patients with Eisenmenger syndrome and in cyanotic patients without PAH, but arterial oxygen saturation <90%
• Use of an air ﬁlter in an intravenous line to prevent air embolism
• Iron deﬁciency and anaemia (no routine, inappropriate phlebotomies to maintain a pre-determined haemoglobin)  treat iron deﬁciency and iron-deﬁcient anaemia
• Consultation with an ACHD cardiologist before administration of any agent and performance of any surgical/interventional procedure
• Inappropriate anticoagulation
• Prompt antibiotic therapy of upper respiratory tract infections
• Dehydration
• Cautious use or avoidance of agents that impair renal function
• Infectious disease: administer inﬂuenza and pneumococcal vaccines
• Contraceptive advice at each clinic visit
• Cigarette smoking, recreational drug abuse including excessive alcohol
• Transvenous PM/ICD leads
• Strenuous exercise
• Acute exposure to heat (sauna, hot tub, or hot shower) or extreme cold
• Oestrogen-containing contraception
CHD = congenital heart disease; ICD = implantable cardioverter deﬁbrillator; PAH = pulmonary arterial hypertension; PM = pacemaker.
ESC Guidelines
587


<!-- PAGE 26 -->

### Page 26

.............................................................................................................................................................................
• Comprehensive evaluation and systematic review of potential complications.
• Blood tests (see section 3.4.8.8)
• Education about risk reduction strategies (Table 9).
3.4.8.10 Additional considerations
• Air flight: commercial air travel is well tolerated.104,105Riskreduction strategies include avoidance of travel- and non-travelrelated stress, dehydration, alcoholic drinks, and measures to prevent deep vein thrombosis.
• Exposure to high altitude: acute exposure to high altitude
(>2500 m) should be avoided. Gradual ascent up to 2500 m may be tolerated.
• Pregnancy: pregnancy in cyanotic patients, without PH, results in significant maternal and foetal complications and requires followup by a Pregnancy Heart Team. Oxygen saturation (>85%) and haemoglobin (<200 g/L) before pregnancy were the strongest predictors for live birth in one series.106 Pregnancy should be strongly discouraged in Eisenmenger syndrome and in cyanotic patients without PAH, but an arterial oxygen saturation <90%43
(see section 3.5.7).
• IE prophylaxis: recommended in all patients (see section 3.4.6).
3.5 Additional considerations
3.5.1
Sex differences
Women have been appropriately included in trials, and sex-stratified analyses are available to some extent. Data regarding sex difference on prevalence of CHD, morbidity, and mortality are conflicting.76,107110 Although no differences in mortality were noted in the CONgenital CORvitia (CONCOR) study, there were significant sex differences in morbidity (increased risk for PH for women, but lower risk for IE, aortic complications, and ICD implantation).111
Whether these differences relate to genetic and inherent biological difference, smaller body size, or other not yet defined differences warrants further exploration.112
Sex differences are important for diagnostic evaluation and clinical decision making. Although recommendations are usually not sex specific, body surface area (BSA)-normalized cut-offs of aortic and cardiac chamber dimensions may correct for smaller BSA in women.113
Personalized counselling is essential in women contemplating pregnancy, as indications for intervention in females may set lower absolute values for aortic surgery
(hereditary/CHD-associated aortopathy) or for pulmonary valve replacement (PVRep) in patients with TOF.112
There are data showing different impacts for men than women for employment,114 gaps in medical care,115 and physical activity.116
Clinical evaluation, decision making, and counselling may require tailoring to the individual to help ensure equity of outcomes.
3.5.2
Adult congenital heart disease at more advanced age
To date, 90% of patients with mild, 75% with moderate, and 40%
with complex heart defects reach the age of 60 years.117 These proportions are expected to rise further in the upcoming decades.
Hence, there is a growing population of older persons with CHD
and unique healthcare needs.
These older patients are characterized by more comorbidities, inherent age-related risk for arrhythmia (especially AF), accelerated ageing, acquired disease,
changed responses to medication, earlier onset of geriatric syndromes (e.g. cognitive decline, immobility/falls, failure to thrive,
sensory alterations), and an altered psychosocial profile.118,119
Dedicated guidelines for older patients with CHD ought to be consulted to provide adequate care to this more vulnerable patient population.120 The onset of acquired diseases starts early in life, therefore, prevention strategies ought to be implemented in the first decades of life (at paediatric cardiology).
3.5.3
Advance care planning and end-of-life care
Most patients, independent of defect complexity, wish to discuss life expectancy prior to being confronted with life-threatening complications.121 Such complications may occur during high-risk interventions or reflect an uncertain illness trajectory. Timely discussion of advance care planning is a critical component of patient-centred, comprehensive care.121,122 Initiation of this demanding conversation is difficult. Unplanned hospital admissions, ICD insertion, or functional decline can serve as a trigger for such conversations. Most patients do not start advance care planning discussions on their own and wait for the provider’s initiative. The content of advance care planning discussions depends on the patient’s physical and psychological health and preferences. Initially, discussion about life expectancy and treatment preferences may be all the patient wants. With deteriorating health, a holistic assessment of the patient’s wishes and values, advance directives, nomination of a surrogate decision maker, and decisions regarding device therapies in ICD patients are required.
During the process of care, active disease-specific treatment may progressively become supported and eventually substituted by palliative care. Involvement of palliative care specialists can be supportive.
At any time, it is important to emphasize that active disease-specific care might continue during the advance care planning process, even near the end of life, keeping in line with patients’ preferences and goals. The role of palliative care and family support continues after the patient’s death in managing bereavement care.123
Whenever possible, family members should be involved in all steps. Patient preferences can change over time and periodic reevaluation of the patient’s wishes is necessary.
3.5.4
Insurance and employment
For ACHD patients, it is often difficult to obtain life-, health-, or travel insurance, and mortgages.124126 If insurance is granted, patients frequently need to pay an extra charge or the heart defect as a preexisting condition excludes them from insurance. In general, obtaining insurance or not, and the higher fee, are mostly unrelated to the complexity of the defect, the functional status of the patient, or the prognosis,124,126 but are rather a function of the policies of insurance companies and reflect a large inter- and intra-country variation.
Patients currently need to shop around, and both clinicians and patient associations may be of help. Insurability is a definite issue that should be discussed during patient counselling. Also, employment, in particular the requirements for specific professions, needs attention.127 Starting in adolescence, choices about education should be


<!-- PAGE 27 -->

### Page 27

.............................................................................................................................................................................
made based on the possibilities to perform heavy exercise and work night shifts, and the use of specific medication such as oral anticoagulation.
3.5.5
Exercise and sports
Recommendations for exercise and sports need to be based on the underlying congenital heart defect and its potential complications, the haemodynamic and EP status of the patient, and their pre-existing fitness.24 Counselling must consider the type of sport and the anticipated effort levels. In general, physicians have been over-conservative in their advice, especially as physical activity has well-documented benefits for fitness, psychological well-being, and social interaction, as well as a positive effect on the future risk of acquired heart disease; symptoms do not exclude physical activity. Dynamic exercise is more suitable than static exercise. In addition, in patients with known cardiac conditions,
complications during exercise,
including
SCD,
are rare.128
Recommendations for participation in low- to high-intensity sports are discussed in the position paper of Budts et al.24 Guidelines on elite sports in athletes with CHD are described in the 2020 ESC Guidelines on sports cardiology.129 Assessment of physical exercise capacity should be done before recommending recreational exercise or sport in order to avoid intense exercise in untrained patients. Most patients with CHD can safely engage in regular, moderate physical activity. A
few conditions, such as systemic ventricular systolic dysfunction, systemic ventricular outflow tract obstruction, PH, haemodynamically significant arrhythmias, or aortic dilation, warrant more caution.
3.5.6
Non-cardiac surgery
The evaluation and management of ACHD patients should follow the principles of the 2014 ESC Guidelines on non-cardiac surgery130
and consider the specificities of CHD. Factors associated with increased risk of perioperative morbidity and mortality are cyanosis,
congestive heart failure, poor general health, younger age, PH, operations on the respiratory and nervous systems, complex CHD, and urgent/emergency procedures. In patients with complex CHD
(Fontan, Eisenmenger syndrome, cyanotic patients), non-cardiac surgical and interventional procedures should be performed in an expert centre.130,131 Issues to consider are endocarditis prophylaxis, complications related to underlying haemodynamics, abnormal venous and/
or arterial anatomy affecting venous and arterial access, persistent shunts, valvular disease, arrhythmias including bradyarrhythmias,
erythrocytosis, pulmonary vascular disease (PVD), prevention of venous thrombosis, monitoring of renal and liver function, periprocedural anticoagulation, possible need for non-conventional drug dosing, increased prevalence of hepatitis C infection because of prior procedures and remote blood transfusions and, finally, developmental disability.
3.5.7
Pregnancy, contraception, and genetic counselling
3.5.7.1 Pregnancy and contraception
The majority of ACHD patients tolerate pregnancy well, but women with complex CHD have higher risks. Detailed ESC
Guidelines on pregnancy and heart disease were published in 2018.43
Pre-pregnancy counselling should be provided to all women with
CHD. Specialist care is best provided in a multidisciplinary team setting by the Pregnancy Heart Team. This team should have input from
ACHD cardiology, obstetrics, and anaesthesia, and where necessary from other specialists, including clinical geneticists. The team should be involved in all patients with at least moderate to complex heart disease before pregnancy for timely counselling and advice during pregnancy in order to plan antenatal care, including delivery and post-partum follow-up and need for cardiac monitoring. Risk estimation should be individualized and based on the modified WHO
(mWHO) classification (Table 10).43
Functional status before pregnancy, ventricular function, severity of the lesions, and history of previous cardiac events are also of prognostic value.132 CPET performed before conception can predict maternal and neonatal outcomes. A blunted heart rate response to exercise is associated with a higher risk of maternal cardiac and neonatal adverse events.
Maternal mortality is 01% and heart failure complicates pregnancy in 11% of women with heart disease, with PAH being associated with the highest risks.133,134 Cyanosis poses a significant risk to the foetus,
with live birth unlikely (<12%) if oxygen saturation is <85%.106
Women with cardiac disease also have an increased risk of obstetric complications, including premature labour, pre-eclampsia, and postpartum haemorrhage.135 The potential for drugs affecting the foetus should always be considered; angiotensin-converting enzyme
(ACE) inhibitors and angiotensin II receptor blockers (ARBs), in particular, should not be used. Women requiring oral anticoagulation deserve special attention. VKAs are teratogenic, especially at higher doses. A dose-adjusted treatment algorithm is proposed in the 2018
ESC Guidelines on pregnancy.43
The pregnancy duration and mode of delivery should be decided by the Pregnancy Heart Team, taking the CHD severity into account.
Contraception should be discussed in a timely fashion with specific attention to effectiveness and safety.136 Barrier methods are safe and protect against sexually transmitted diseases, however, they only have a high contraceptive efficacy with compliant couples. Hormonal contraceptives are highly efficacious, but there are few data on their safety in the ACHD population. The combined oral contraceptive is highly effective (99.9%), but is best avoided in patients with a preexisting thrombotic risk (cyanosis, Fontan physiology, mechanical valves, prior thrombotic events, PAH), especially as there are few data to suggest that concomitant oral anticoagulation therapy will negate this risk. Progesterone-only contraceptives, on the other hand, do not pose such a high thrombosis risk, and newer preparations available for oral administration or with intrauterine implants have a high efficacy (>95%). The risk of endocarditis after insertion of progesterone-coated intrauterine devices is probably low. However,
there is a risk of vasovagal reactions (5%) at the time of insertion or removal. Patients with a fragile physiology (e.g. patients with a Fontan circulation, PH, cyanotic CHD, Eisenmenger syndrome) should have their intrauterine device inserted/removed in a safe environment (i.e.
in an environment with expertise in ACHD). Female sterilization or male partner sterilization should only be considered after careful discussion, with particular reference to long-term prognosis.
Assisted reproduction has added risks above those of pregnancy alone, and consultation with an ACHD specialist must be performed before treatment. Superovulation is prothrombotic and can be complicated by ovarian hyperstimulation syndrome, with marked fluid shifts and an even greater risk of thrombosis.137 The risk of ovarian
ESC Guidelines
589


<!-- PAGE 28 -->

### Page 28

............
hyperstimulation syndrome can be reduced by careful cycle monitoring, using low-dose follicle-stimulating hormone in combination with a gonadotropin-releasing hormone antagonist, freezing all embryos,
and only transferring a single embryo. The last option is strongly advised in women with heart disease, since conceiving a multiple pregnancy is associated with greater cardiovascular changes and more maternal and foetal complications.138 Pregnancy and fertility treatment are contraindicated in women with mWHO classification of maternal cardiovascular risk class IV.43 In women with mWHO
class III, or those who are anticoagulated, the risk of superovulation is very high and the alternative of natural cycle in vitro fertilization should be considered.
Sexuality is an important element of quality of life. The few available data suggest that sexual function is a concern in both women and men and should be discussed more often.139
3.5.7.2 Genetic counselling and recurrence risk
Genetic counselling, whether supplemented with further genetic testing or not, should at least be considered for every ACHD patient.
Demonstrating a genetic abnormality can be important to further adjust the patient’s own management and is evidently also important for family planning. It is estimated that 1030% of all structural CHD
would have a genetic basis. This rate is higher in cases of associated organ disorders and familial occurrence, and lower in isolated cases.
With the rapid technical progress and possibilities of genetic testing,
the reliability of these tests is further improving. Naturally, genetic elaboration in each patient must be multidisciplinary, with integration of necessary clinical data and adequate interpretation of found genetic variants. A detailed consensus document on this subject, providing an algorithm for genetic testing and an overview of the main syndromes to consider, has recently been published.140
One of the important and specific aspects of genetic counselling is the assessment of recurrence risk, which needs consideration in both men and women. The recurrence rate of CHD in offspring ranges from 250% and is higher in affected women than men. The highest recurrence risks are found in single gene disorders and/or chromosomal abnormalities such as Marfan, Noonan, 22q11 deletion syndrome, and Holt-Oram syndrome. Among patients with isolated,
Table 10
Congenital heart disease with high risk and extremely high risk for pregnancy
Significantly increased risk of maternal mortality or severe morbidity (mWHO class III) (cardiac event rate
1927%)
Extremely high risk of maternal mortality or severe morbidity (mWHO class IV)a (cardiac event rate 40100%)
Unrepaired cyanotic heart disease
Pulmonary arterial hypertension
Moderate LV impairment (EF 3045%)
Severe LV impairment (EF <30% or NYHA class IIIIV)
Systemic RV with good or mildly decreased ventricular function
Systemic RV with moderate or severely decreased ventricular function
Fontan circulation. If the patient is otherwise well and the cardiac condition uncomplicated
Fontan with any complication
Severe asymptomatic AS
Severe symptomatic AS
Moderate mitral stenosis
Severe mitral stenosis
Moderate aortic dilatation (4045 mm in Marfan syndrome or other
HTAD; 4550 mm in BAV, 2025 mm/m2 in Turner syndrome)
Severe aortic dilatation (>45 mm in Marfan syndrome or other
HTAD, >50 mm in BAV, >25 mm/m2 in Turner syndrome)
Mechanical valve
Severe (re-)coarctation
AS = aortic stenosis; ASI = aortic size index; BAV = bicuspid aortic valve; CHD = congenital heart defect; EF = ejection fraction; HTAD = heritable thoracic aortic disease; LV
= left ventricle/ventricular; mWHO = modiﬁed World Health Organization; NYHA = New York Heart Association; RV = right ventricle/ventricular; TOF = tetralogy of Fallot.
aPregnancy should deﬁnitely be avoided in women with these conditions.
Modiﬁed from the 2018 ESC guidelines for the management of cardiovascular disease during pregnancy.43
.................................................
Table 11
Recurrence rates for various congenital heart lesions according to the sex of the affected parenta
Recurrence rate (%)*
Women
Men
ASD
46
1.53.5
VSD
610
23.5
AVSD
11.514
14.5
PDA
3.54
22.5
CoA
46.5
23.5
Marfan/HTAD
50b
LVOTO
818
34
RVOTO (PS)
46.5
23.5
Eisenmenger syndrome
6
NR
TOF
22.5
1.5
Pulmonary atresia/VSD
NR
NR
TGA
2b ccTGA
35b
UVH (HLHS)
21b
ASD = atrial septal defect; AVSD = atrioventricular septal defect; ccTGA = congenitally corrected transposition of the great arteries; CHD = congenital heart disease; CoA = coarctation of the aorta; HLHS = hypoplastic left heart syndrome; HTAD = heritable thoracic aortic disease; LVOTO = left ventricular outﬂow tract obstruction; NR = not reported; PDA = patent ductus arteriosus; PS =
pulmonary stenosis; RVOTO = right ventricular outﬂow tract obstruction; TGA
= transposition of the great arteries; TOF = tetralogy of Fallot; UVH = univentricular heart; VSD = ventricular septal defect.
*Except for Marfan syndrome, rates apply to patients with isolated cardiac lesions in whom known genetic/syndromic entities have been excluded.
aModiﬁed from Pierpont et al.141
bSex-speciﬁc data not available or not relevant.


<!-- PAGE 29 -->

### Page 29

.............................................................................................................................................................
non-familial CHD, the recurrence rate varies from 121%,141
according to the underlying lesion. An overview is provided in
Table 11. Foetal echocardiography in affected couples is recommended at 1922 weeks gestation and can be done as early as
1516 weeks gestation.
4 Specific lesions
4.1 Atrial septal defect and anomalous pulmonary venous connection
4.1.1
Introduction and background
ASD can remain undiagnosed until adulthood. ASD types include:
• Secundum ASD (80% of ASDs; located in the region of the fossa ovalis and its surrounding).
• Primum ASD [15%; synonyms: partial AV septal defect [atrioventricular septal defect (AVSD) with communication on the atrial level only], partial AV canal; located near the crux, AV valves are typically malformed, resulting in various degrees of regurgitation
(see section 4.3)].
• Superior sinus venosus defect [5%; located near the superior vena cava (SVC) entry, associated with partial or complete connection of right pulmonary veins to SVC/RA].
• Inferior sinus venosus defect [<1%; located near the inferior vena cava (IVC) entry].
• Unroofed coronary sinus [<1%; separation from the left atrium
(LA) can be partially or completely missing].
Associated lesions include anomalous pulmonary venous connection, persistent left SVC, pulmonary valve stenosis, and mitral valve prolapse. Interatrial defects are the most frequently associated defects in Ebstein anomaly (see section 4.9). Treatment decisions are more complex in the latter combination. The present section deals with isolated ASD.
The shunt volume depends on RV/LV compliance, defect size, and
LA/RA pressure. A simple ASD results in LR shunt because of the higher compliance of the RV compared with the LV (relevant shunt in general with defect sizes >_10 mm), and causes RV volume overload and pulmonary overcirculation. Reduction in LV compliance, or any condition with elevation of LA pressure (hypertension, ischaemic heart disease, cardiomyopathy, aortic and mitral valve disease), increases
LR shunt. As a consequence, an ASD may become haemodynamically more important with age. Reduced RV compliance (pulmonic stenosis, PAH, other RV disease) or TV disease may decrease LR
shunt or eventually cause shunt reversal, resulting in cyanosis.
4.1.2
Clinical presentation and natural history
Patients frequently remain asymptomatic until adulthood. However,
the majority develop symptoms beyond the fourth decade including reduced functional capacity, exertional shortness of breath, and palpitations (supraventricular tachyarrhythmias), and less frequently pulmonary infections and right heart failure. Life expectancy is reduced overall, but survival is much better than previously assumed.142 PAP
can be normal, but on average increases with age. Severe PVD is nevertheless very rare (<5%); its development presumably requires additional factors and the disease course is similar to idiopathic
PAH.48 With increasing age, and with increasing PAP, tachyarrhythmias become more common (atrial flutter, AF).143 Systemic embolism may be caused by paradoxical embolism (rare) or AF and atrial flutter.
4.1.3
Diagnostic work-up
See section 3.3 for general principles.
Key clinical findings include fixed splitting of the second heart sound and a systolic pulmonary flow murmur. ECG typically shows an incomplete right bundle branch block and right-axis deviation
(superior left-axis deviation in partial AVSD). An increased pulmonary vascularity on chest X-ray is frequently overlooked.
• Echocardiography is the first-line diagnostic technique, providing diagnosis and quantification. RV volume overload, which may be the first unexpected finding in a patient with previously undiagnosed ASD, is the key finding and best characterizes the haemodynamic relevance of the defect (preferable to the shunt ratio).
Sinus venosus defects in general require TOE for accurate diagnosis (CMR/CCT is an alternative and superior in case of inferior sinus venosus defects). TOE is also required for precise evaluation of secundum defects before device closure, which should include sizing, exploration of the residual septum’s morphology,
the rim size and quality, exclusion of additional defects, and confirmation of a normal pulmonary venous connection. 3D echocardiography provides visualization of ASD morphology. Other key information to be provided includes PAP and tricuspid regurgitation (TR).
• CMR is rarely required but may be useful for assessment of RV
volume overload, identification of inferior sinus venosus defect,
quantification of pulmonary to systemic flow ratio (Qp:Qs), and evaluation of pulmonary venous connection (alternatively for the latter, use CCT).
• Cardiac catheterization is required in case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine PVR.
• Exercise testing should be performed in patients with PAH to exclude desaturation.
4.1.4
Surgical/catheter interventional treatment
Indications for intervention are summarized in the Recommendations for intervention in atrial septal defect (native and residual) table and in
Figure 2.
Surgical repair has low mortality (<1% in patients without significant comorbidity) and good long-term outcome when performed early (childhood, adolescence) and in the absence of PH.144,145
Although surgical repair can be performed with very low risk, even in the elderly, comorbidities that may affect operative risk need to be considered and then risk weighed against potential benefit.
ESC Guidelines
591


<!-- PAGE 30 -->

### Page 30

.............................................................................................................................................................................
Device closure has become the first choice for secundum defect closure, when feasible, based on the morphology (includes stretched diameter <_38 mm and sufficient rim of 5 mm except towards the aorta). This is the case in 80% of patients. Although it cannot be assumed to be zero, several recent studies have reported no mortality.
Serious complications have been observed in <_1% of patients.148,149
Atrial tachyarrhythmias occurring early after intervention are mostly transient. Erosion of the atrial wall, anterior mitral leaflet, or the aorta,
as well as thromboembolic events, appear to be very rare.150,151
Antiplatelet therapy is required for at least 6 months (aspirin 75 mg o.d. minimum). Potential incidence of late arrhythmias or adverse events still requires investigation. Studies comparing surgery and catheter intervention have reported similar success rates and mortality, but morbidity was lower and hospital stays shorter with catheter intervention while reintervention rate was slightly higher.148,152
Outcome is best with repair at age <25 years.144,145 ASD closure after the age of 40 years appears not to affect the frequency of arrhythmia development during follow-up.146,153 However, the patient’s morbidity benefits from closure at any age (exercise capacity, shortness of breath, right heart failure), particularly when it can be done by catheter intervention.146,153
In patients with impaired LV function (systolic and diastolic), ASD
closure may worsen heart failure. These patients must be carefully evaluated and may require pre-interventional testing (balloon occlusion with reassessment of haemodynamics) to decide between complete,
fenestrated, or no closure, considering that an increase in filling pressure due to ASD closure may worsen symptoms and outcome.154
Patients with PH must be evaluated with particular care.
Calculation of PVR is mandatory. In patients with PVR <5 WU, ASD
closure has been shown to be safe and associated with a decrease in
PAP and improvement of symptoms.60,153,155 However, even in this group, the extent of improvement decreases with increasing PAP.
Patients with PVR >_5 WU are unlikely to improve60 and likely to have an even worse outcome with complete ASD closure.48,156
Vasoreactivity testing is not recommended when making the decision whether to close an ASD in patients with PVR >_5 WU. It appears safer to treat PAH, re-evaluate haemodynamics during follow-up, and consider fenestrated closure only when PVR falls below 5 WU in the presence of significant LR shunt. If this is not the case, ASD closure should be avoided.
In patients with atrial flutter/AF, cryo- or radiofrequency ablation
(modified maze procedure) should be considered at the time of surgery. Device closure may restrict access to the LA for later EP
interventions.
In patients of advanced age with ASDs not suitable for device closure, individual surgical risk due to comorbidities must be carefully weighed against the potential benefits of ASD closure.
4.1.5
Specific aspects of isolated anomalous pulmonary venous connections
Anomalous pulmonary venous connections do not only occur in association with ASD (typically in sinus venous defects) but can also be isolated. This results in volume overload of the right heart, with a physiological effect similar to that of an ASD, but when isolated, differs in that there is no potential for RL shunting, and the magnitude of the LR shunt is not exacerbated by the development of acquired left heart disease. Most common is the connection of the right upper pulmonary vein to the SVC. Other abnormal connections include right pulmonary vein(s) to the IVC (‘scimitar vein’, which may be associated with sequestration of the right lower lobe), left upper
Recommendations for intervention in atrial septal defect (native and residual)
Recommendations
Classa
Levelb
In patients with evidence of RV volume overloadc and no PAH (no non-invasive signs of PAP
elevation or invasive conﬁrmation of PVR <3
WU in case of such signs) or LV disease, ASD
closure is recommended regardless of symptoms.146,147
I
B
Device closure is recommended as the method of choice for secundum ASD closure when technically suitable.
I
C
In elderly patients not suitable for device closure, it is recommended to carefully weigh the surgical risk against the potential beneﬁt of ASD
closure.
I
C
In patients with non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory.
I
C
In patients with LV disease, it is recommended to perform balloon testing and carefully weigh the beneﬁt of eliminating LR shunt against the potential negative impact of ASD closure on outcome due to an increase in ﬁlling pressure
(taking closure, fenestrated closure, and no closure into consideration).
I
C
In patients with suspicion of paradoxical embolism (exclusion of other causes), ASD closure should be considered regardless of size providing there is absence of PAH and LV disease.
IIa
C
In patients with PVR 35 WU, ASD closure should be considered when signiﬁcant LR
shunt is present (Qp:Qs >1.5).
IIa
C
In patients with PVR >_5 WU, fenestrated ASD
closure may be considered when PVR falls below 5 WU after targeted PAH treatment and signiﬁcant LR shunt is present (Qp:Qs >1.5).
IIb
C
ASD closure is not recommended in patients with Eisenmenger physiology, patients with PAH
and PVR >_5 WU despite targeted PAH treatment, or desaturation on exercise.d
III
C
ASD = atrial septal defect; LR = left-to-right; LV = left ventricle/ventricular;
PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure; PVR
= pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio; RV
= right ventricle/ventricular; WU = Wood units.
aClass of recommendation.
bLevel of evidence.
cRV enlargement with increased stroke volume.
dThere are limited data available for a precise cut-off, but by clinical experience,
this would be given by a fall of arterial oxygen saturation <90%.


<!-- PAGE 31 -->

### Page 31

..........................................................
pulmonary vein(s) to the left innominate vein, and right upper pulmonary vein(s) connecting high on the SVC. Long-term sequelae of anomalous pulmonary venous connections reflect the impact of right heart volume overload and are similar to the sequelae of ASDs.
Surgical repair can be challenging as low-velocity venous flow imparts risk of thrombosis of the surgically operated vein, particularly in scimitar syndrome; it should only be performed by a congenital cardiac surgeon.
Indications for surgery follow the principals of recommendation for
ASD closure, but technical suitability for repair and operative risk must be weighed against the potential benefit of intervention. It is unusual for a single anomalous pulmonary venous connection of only one pulmonary lobe to result in a sufficient volume load to justify surgical repair.
4.1.6
Follow-up recommendations
Follow-up evaluation should include assessment of a residual shunt, RV
size and function, TR and PAP by echocardiography, and assessment of arrhythmias by history, ECG, and  only if indicated  Holter monitoring. Patients repaired at age <25 years without relevant sequelae or residua (no residual shunt, normal PAP, normal RV, no arrhythmias) do not require regular follow-up. However, patients and referring physicians should be informed about the possible late occurrence of tachyarrhythmias.
Patients with residual shunt, elevated PAP, or arrhythmias (before or after repair) and those repaired at adult age (particularly >40 years)
should be followed on a regular basis, including evaluation in specialized ACHD centres (intervals depending on the severity of residual problems). After device closure, regular follow-up during the first 2
years and then, depending on results, every 35 years is reasonable.
Late post-operative arrhythmias after surgical repair at age <40 years are most frequently IART or atrial flutter, which can be successfully treated with radiofrequency or cryoablation. Without repair or with repair after age 40 years, AF becomes more common. In patients who undergo ASD closure aged >40 years, the prevalence of atrial arrhythmias is up to 4060%. Access to the LA may be restricted after device closure.
SVC stenosis may occur after repair of a sinus venosus defect, as well as stenoses of redirected pulmonary veins.
©ESC 2020
Figure 2 Management of atrial septal defect.
ASD = atrial septal defect; LR = left-to-right; LV = left ventricle/ventricular; PAH = pulmonary arterial hypertension; PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic flow ratio; RV = right ventricle/ventricular; WU = Wood units.
aRV enlargement with increased stroke volume.
bProviding there is no PAH or LV disease.
cIn elderly patients not suitable for device closure, carefully weigh surgical risk vs. potential benefit of ASD closure.
dCarefully weigh the benefit of eliminating LR shunt against the potential negative impact of ASD closure on outcome due to an increase in filling pressure (taking closure, fenestrated closure, and no closure into consideration).
ESC Guidelines
593


<!-- PAGE 32 -->

### Page 32

.............................................................................................................................................................................
4.1.7
Additional considerations
• Exercise/sports: no restrictions in asymptomatic patients before or after intervention without PH, significant arrhythmias, or RV
dysfunction; limitation to low-intensity recreational sports in
PAH patients (see section 3.5.5).
• Pregnancy: low risk in patients without PH, although there may be an increased risk of paradoxical embolism. Patients with pre-capillary
PH should be counselled against pregnancy (see section 3.5.7).
• IE prophylaxis: recommended for 6 months after device closure
(see section 3.4.6).
4.2 Ventricular septal defect
4.2.1
Introduction and background
VSD is mostly diagnosed and  when indicated  treated before adulthood. Spontaneous closure is frequent in childhood. Several locations of the defect within the interventricular septum are possible, and these can be divided into four groups according to their location within the
RV (nomenclature varies and synonyms are added):157
• Perimembranous/paramembranous/subaortic/conoventricular
(most common, 80% of VSDs; located in the membranous septum with possible extension into inlet, trabecular, or outlet septum; adjacent to tricuspid and aortic valve; so-called aneurysms of the membranous septum  i.e. tissue from the septal leaflet of the
TV  are frequent and may result in partial or complete closure).
• Muscular/trabecular (up to 1520%; completely surrounded by muscle; various locations; frequently multiple; spontaneous closure particularly frequent).
• Outlet (with or without malalignment of the outlet septum)/
supracristal/subarterial/subpulmonary/infundibular/conal/doubly committed juxta-arterial [5%; located beneath the semilunar valves in the conal or outlet septum; may be associated with progressive aortic regurgitation (AR) due to prolapse of the right aortic cusp and aneurysm of the sinus of Valsalva].
• Inlet/AV canal/AVSD type (inlet of the ventricular septum immediately inferior to the AV valve apparatus; associated with a common AV valve; may be associated with AV septal malalignment and straddling TV; typically occurring in Down syndrome).
Often there is one single defect, but multiple defects do occur.
VSD is also a common component of complex anomalies, such as
TOF, transposition of the great arteries (TGA), and congenitally corrected TGA (ccTGA). Spontaneous closure occurs mainly during childhood and is uncommon in outlet defects.158
The direction and magnitude of the shunt are determined by PVR
and systemic vascular resistance, the size of the defect, LV/RV systolic and diastolic function, and the presence of right ventricular outflow tract (RVOT) obstruction (RVOTO) and left ventricular outflow tract (LVOT) obstruction (LVOTO).
4.2.2
Clinical presentation and natural history
The usual clinical presentations in adults include:
• VSD operated on in childhood, without residual VSD and no PH.
• VSD operated on in childhood, with residual VSD. The residual shunt size determines the degree of LV volume overload and the development of PH.
• Small VSD with insignificant LR shunt, without LV volume overload or PH (restrictive VSD), which was not considered for surgery in childhood.
• VSD with LR shunt, PH (various degrees), and various degrees of LV volume overload (rare).
• VSD with RL shunt (Eisenmenger syndrome): large, nonrestrictive, VSD with originally large LR shunt and development of severe PVD eventually resulting in shunt reversal (cyanosis;
see sections 3.4.3 and 3.4.8).
A large majority of patients with a VSD that has been closed entirely in childhood (spontaneously or surgically), or patients with a small VSD who were either never operated on or who had a residual defect after surgical repair with no LV volume overload on echocardiography, usually remain asymptomatic and do not require further surgery.159 However, an unknown percentage of patients with a small residual VSD develop problems later in life.160 Survival 40 years after closure appears to remain slightly lower than in the general population.161
Several possible problems may occur with advancing age:
• A double-chambered RV (DCRV) can develop over time, mostly in perimembranous defects, and may be a result of the jet lesion of the RV endothelium caused by the high-velocity VSD jet.
• In the case of an outlet (supracristal) VSD (less commonly perimembranous), there is a risk for prolapse of the right coronary (or non-coronary) cusp of the aortic valve, resulting in progressive AR and formation of a sinus of Valsalva aneurysm.
• Arrhythmias can occur, but are less frequent than in other forms of CHD162.
• Complete heart block  rare nowadays  was not uncommon in the earlier years of cardiac smurgery, so can occur, especially in older patients. These patients usually require lifelong pacing.
• Late LV dysfunction and heart failure.
• Endocarditis.
4.2.3
Diagnostic work-up
See section 3.3 for general principles.
Specific clinical findings include a holosystolic murmur over the third to fourth left intercostal space, and a precordial thrill may be felt.
• Echocardiography is the key diagnostic technique, in general providing the diagnosis and assessment of disease severity. Key findings to provide are location, number, and size of defects,
severity of LV volume overload, and estimated PAP. AR due to prolapse of the right or non-coronary cusp must be checked for,
especially in the case of outlet (supracristal) and high perimembranous VSDs. DCRV and sinus of Valsalva aneurysm must be excluded.
• CMR can serve as an alternative if echocardiography is insufficient, particularly for assessment of LV volume overload and shunt quantification.
• Cardiac catheterization is required in case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine
PVR.
• Exercise testing should be performed in patients with PAH to exclude desaturation.


<!-- PAGE 33 -->

### Page 33

.........................................................................................................................................................................
4.2.4
Surgical/catheter interventional treatment
Indications for intervention are summarized in the Recommendations for intervention in ventricular septal defect (native and residual) table and in Figure 3.
Surgical closure can be performed with low operative mortality
(12%) and good long-term results.163 Transcatheter closure has become an alternative, particularly in residual VSDs, in VSDs that are poorly accessible for surgical closure, and in muscular VSDs that are located centrally in the interventricular septum. In perimembranous
VSD, it has been shown to be feasible. Whether the risk of complete
AV block and entrapment of TV tissue leading to TR, or the risk of
AR that has been observed in children, is relevant in adults undergoing interventional closure of a perimembranous VSD remains to be seen.
Patients eligible for VSD closure at adult age are rare. Most patients have either small VSDs with insignificant shunt or have already developed PH. The latter must be evaluated with particular caution. Patients with shunt closure and persistent/progressive PAH
appear to have a particularly poor outcome.48
4.2.5
Follow-up recommendations
Development of AR or TR, degree of (residual) shunt, LV dysfunction, elevation of PAP, or development of DCRV, should be excluded or assessed if present by echocardiography.
Possible development of complete AV block requires attention
(patients who develop bifascicular block or transient trifascicular block after VSD closure are at risk in later years for the development of complete AV block).
Patients with more than small residual VSD, valvular lesions, or haemodynamic impairment (LV dysfunction or PAH) should be seen every year, including evaluation in specialized ACHD centres. In patients with a small VSD (native or residual, normal LV, normal PAP,
asymptomatic) and no other lesion, 35-year intervals may be reasonable. After device closure, regular follow-up during the first 2
years and then, depending on the results, every 25 years is reasonable. After surgical closure without residual abnormality, 5-year intervals may be reasonable.
4.2.6
Additional considerations
• Exercise/sports:
no restrictions are required in patients after VSD closure, or with small VSD without PH, significant arrhythmias, or LV dysfunction. Patients with PAH must limit themselves to low-intensity recreational activity/sports (see section 3.5.5).
• Pregnancy: patients with pre-capillary PH (PAH) should be counselled against pregnancy. The risk is low in asymptomatic patients with normal LV and no PAH (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.3 Atrioventricular septal defect
4.3.1
Introduction and background
An AVSD (AV canal or endocardial cushion defect) is characterized by the presence of a common AV junction. The partial AVSD
usually has a defect only at the atrial level (primum ASD) or, in rare cases, only at the ventricular level. The anterior and posterior bridging leaflets are fused centrally, creating separate left- and right-sided orifices. In a complete AVSD, the central fusion is not present and there is only one orifice. A complete AVSD (complete
AV canal) has a septal defect in the crux of the heart, extending into both the interatrial and interventricular septum (non-restrictive inlet VSD). The AV node is positioned posterior and inferior to the coronary sinus. The bundle of His and the left bundle branch are displaced posteriorly. This accounts for an abnormal activation sequence of the ventricles (prolongation of AV conduction time,
left-axis deviation) and is important to recognize during EP studies and catheter ablation.
Most complete AVSDs occur in Down syndrome patients (>75%),
and most partial AVSDs occur in non-Down syndrome patients
(>90%). AVSD may occur in association with TOF and other forms of complex CHD. An AVSD with unequal position of the common
AV valve above the ventricles is accompanied by a variable degree of ventricular hypoplasia (unbalanced AVSD). The following recommendations apply to balanced AVSDs.
Recommendations for intervention in ventricular septal defect (native and residual)
Recommendations
Classa
Levelb
In patients with evidence of LV volume overloadc and no PAH (no non-invasive signs of PAP
elevation or invasive conﬁrmation of PVR <3
WU in case of such signs), VSD closure is recommended regardless of symptoms.
I
C
In patients with no signiﬁcant LR shunt, but a history of repeated episodes of IE, VSD closure should be considered.
IIa
C
In patients with VSD-associated prolapse of an aortic valve cusp causing progressive AR, surgery should be considered.
IIa
C
In patients who have developed PAH with PVR
35 WU, VSD closure should be considered when there is still signiﬁcant LR shunt (Qp:Qs
>1.5).
IIa
C
In patients who have developed PAH with PVR
>_5 WU, VSD closure may be considered when there is still signiﬁcant LR shunt (Qp:Qs >1.5),
but careful individual decision in expert centres is required.
IIb
C
VSD closure is not recommended in patients with Eisenmenger physiology and patients with severe PAH (PVR >_5 WU) presenting with desaturation on exercise.d
III
C
AR = aortic regurgitation; IE = infective endocarditis; LR = left-to-right; LV =
left ventricle/ventricular; PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure; PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio; VSD = ventricular septal defect; WU = Wood units.
aClass of recommendation.
bLevel of evidence.
cLV enlargement with increased stroke volume.
dThere are limited data available for a precise cut-off, but by clinical experience,
this would be given by a fall of arterial oxygen saturation <90%.
ESC Guidelines
595


<!-- PAGE 34 -->

### Page 34

........................................................................
4.3.2
Clinical presentation and natural history
Clinical presentation depends on the presence and size of the ASD
and VSD and competence of the left-sided AV valve. Symptoms are not specific for an AVSD and are caused by intracardiac shunting (LR, RL, or bidirectional), PH, AV valve regurgitation, ventricular dysfunction, or LVOTO. Exercise intolerance, dyspnoea,
arrhythmia, and cyanosis may be present. LVOTO (subvalvular)
may be present or develop over time. Complete AV block may develop late.
The history of unoperated complete
AVSD
is that of
Eisenmenger syndrome unless the VSD is only small (see sections
3.4.3 and 3.4.8).
Unrepaired primum ASD (partial AVSD) is not uncommon in adults. The presenting clinical symptoms are that of an LR shunt at the atrial level (see section 4.1) and/or that of left-sided AV valve regurgitation (‘cleft’). Patients may still be asymptomatic, but symptoms tend to increase with age; most adults are symptomatic by 40
years of age.
4.3.3
Diagnostic work-up
See section 3.3 for general principles.
Clinical findings depend on the individual variant (see sections 4.3.1
and 4.3.2).
• Echocardiography is the key diagnostic technique. It provides assessment of each anatomic component of the AVSD, of the AV
valves and their connections, the severity and exact substrate of
AV valve regurgitation, the magnitude and direction of intracardiac shunting, LV and RV function, PAP, and assessment of the presence/absence of LVOTO.
• CMR is indicated when additional quantification of ventricular volumes and function, AV valve regurgitation, or intracardiac shunting is required for decision making.
• Cardiac catheterization is required in case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine PVR.
• Exercise testing should be performed in patients with PAH to exclude desaturation.
4.3.4
Surgical/catheter interventional treatment
Catheter closure of AVSDs is not feasible, and intervention is therefore surgical (defect closure, valve repair). In cases of residual interatrial or interventricular communications, endocardial pacing causes an elevated risk of paradoxical emboli; this should be taken into account when pacing is indicated. Epicardial pacing may be required.
The expertise of a congenital cardiac surgeon is recommended for all kinds of AVSD defect closures and AV valve repairs.
©ESC 2020
Figure 3 Management of ventricular septal defect.
AR = aortic regurgitation; IE = infective endocarditis; LV = left ventricle/ventricular; Qp:Qs = pulmonary to systemic flow ratio; PAH = pulmonary artery hypertension; PVR = pulmonary vascular resistance; VSD = ventricular septal defect; WU = Wood units.
aLV enlargement with increased stroke volume.
bIncludes all patients with desaturation at rest (Eisenmenger physiology) or on exercise.
cCareful individual decision in expert centres is required.


<!-- PAGE 35 -->

### Page 35

.............................................................................................................................................................................
4.3.5
Follow-up recommendations
Lifelong regular follow-up of all patients with an AVSD, operated and unoperated, is recommended, including evaluation in specialized
ACHD centres. Particular attention should be paid to residual shunt,
AV valve malfunction, LV and RV enlargement and dysfunction, PAP
elevation, LVOTO, and arrhythmias.164 The frequency of outpatient visits depends on the presence and severity of residual abnormalities.
A patient with a surgically repaired AVSD without significant residual abnormalities should be seen at least every 23 years. In the case of residual abnormalities, the intervals should be shorter.
Indications for reoperation for residual abnormalities are comparable with the indications for primary surgery. In operated patients, the most frequently occurring problem is left-sided AV valve regurgitation.165,166 It has to be emphasized that these valves are different from mitral valves and more difficult to repair. Left-sided AV valve stenosis (most often a result of previous repair) that causes symptoms should be operated on.
4.3.6
Additional considerations
• Exercise/sports: for most patients with uncomplicated, repaired
AVSD, physical activity does not need restriction. Many will,
however, have subnormal exercise performance when measured objectively. Patients with important residual problems require individual recommendations (see section 3.5.5).
• Pregnancy: well tolerated in patients with complete repair and no significant residual lesions. An unoperated partial AVSD increases the risk of paradoxical embolization. Patients with pre-capillary
PH should be counselled against pregnancy. As a rule, patients with residual left-sided AV valve regurgitation, who have no indication for surgery, tolerate pregnancy relatively well, although arrhythmias and worsening of AV valve regurgitation may occur167 (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.4 Patent ductus arteriosus
4.4.1
Introduction and background
Patent ductus arteriosus (PDA) is the persistent communication between the proximal left PA and the descending aorta just distal to the left subclavian artery. It can be associated with a variety of CHD
lesions, however, in adults, it is usually an isolated finding.
PDA originally results in LR shunt and LV and LA volume overload. In moderate and large PDA, PAP is elevated. In patients who reach adulthood with a moderate PDA, either LV volume overload or PAH may be predominant. Adult patients with a large PDA have,
in general, developed Eisenmenger physiology.
4.4.2
Clinical presentation and natural history
Presentations of adult patients with PDA include:
• Small duct with no LV volume overload (normal LV) and normal
PAP (generally asymptomatic).
• Moderate PDA with predominant LV volume overload: large LV
with normal or reduced function (may present with left heart failure).
• Moderate PDA with predominant PAH: pressure-overloaded RV
(may present with right heart failure).
• Large PDA: Eisenmenger physiology with differential hypoxaemia and differential cyanosis (lower extremities cyanotic, sometimes left arm too); see sections 3.4.3 and 3.4.8.
Aneurysm formation of the duct is a very rare complication.
Recommendations for intervention in atrioventricular septal defect
Recommendations
Classa
Levelb
Complete AVSD
Surgical repair is not recommended in patients with Eisenmenger physiology, and patients with PAH (PVR >_5 WU) presenting with desaturation on exercise.c
III
C
For recommendations on intervention see also recommendations for intervention in VSD (section 4.2).
Partial AVSD (primum ASD)
Surgical closure is recommended in patients with signiﬁcant RV volume overload and should only be performed by a congenital cardiac surgeon.
I
C
For further details see recommendations for intervention in
ASD (section 4.1).
AV valve regurgitation
Valve surgery, preferably AV valve repair, is recommended in symptomatic patients with moderate to severe AV valve regurgitation and should be performed by a congenital cardiac surgeon.
I
C
In asymptomatic patients with severe leftsided AV valve regurgitation, valve surgery is recommended when LVESD
>_45 mmd and/or LVEF <_60% provided other causes of LV dysfunction are excluded.
I
C
In asymptomatic patients with severe leftsided AV valve regurgitation, preserved LV
function (LVESD <45 mmd and/or LVEF
>60%), high likelihood of successful valve repair, and low surgical risk, intervention should be considered when atrial ﬁbrillation or systolic PAP >50 mmHg is present.
IIa
C
Left ventricular outﬂow tract obstruction
See recommendations for intervention in SubAS (section 4.5.3).
ASD = atrial septal defect; AV = atrioventricular; AVSD = atrioventricular septal defect; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction;
LVESD = left ventricular end systolic diameter; LVOTO = left ventricular outﬂow tract obstruction; PAH = pulmonary artery hypertension; PAP = pulmonary artery pressure; PVR = pulmonary vascular resistance; RV = right ventricle/ventricular; SubAS = subaortic stenosis; VSD = ventricular septal defect; WU =
Wood units.
aClass of recommendation.
bLevel of evidence.
cThere are limited data available for a precise cut-off, but by clinical experience,
this would be given by a fall of arterial oxygen saturation <90%.
dCut-off refers to average-sized adults and may require adaption in patients with unusually small or large stature.
ESC Guidelines
597


<!-- PAGE 36 -->

### Page 36

.............................................................................................................................................................................
4.4.3
Diagnostic work-up
See section 3.3 for general principles.
Specific clinical findings include a continuous murmur that disappears with development of Eisenmenger syndrome (for differential cyanosis, see section 4.4.2; oxygen saturation should be measured at the upper and lower extremities).
• Echocardiography is the key diagnostic technique and provides the diagnosis (may be difficult in patients with Eisenmenger physiology), the degree of LV volume overload, PAP, PA size, and right heart changes.
• CMR is indicated when additional quantification of LV volumes and quantification of shunt (Qp:Qs) is needed.
• CMR/CCT can further evaluate the anatomy where required.
• Cardiac catheterization is required in the case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine PVR. Measurementofpulmonarybloodflowischallenginginthissetting.MeasurementofoxygensaturationinbothleftandrightPAsismandatory.
• Exercise testing should be performed in patients with PAH to exclude desaturation of lower limbs.
4.4.4
Surgical/catheter interventional treatment
Indications for intervention are summarized in the Recommendation for intervention in patent ductus arteriosus table and in Figure 4.
In adults, calcification of the PDA may cause a problem for surgical closure. Device closure is the method of choice, even if cardiac operations are indicated due to other concomitant cardiac lesions, and can be successfully performed in the vast majority of adults with a very low complication rate.168170 Surgery is reserved for the rare patient with a duct too large for device closure or with unsuitable anatomy such as aneurysm formation.
4.4.5
Follow-up recommendations
Echocardiographic evaluation should include LV size and function,
PAP, residual shunt, and associated lesions.
Patients with no residual shunt, normal LV, and normal PAP do not require regular follow-up after 6 months.
Patients with LV dysfunction and patients with residual PAH
should be followed at intervals of 13 years, depending on severity,
including evaluation in specialized ACHD centres.
4.4.6
Additional considerations
• Exercise/sports: no restrictions in asymptomatic patients before or after intervention without PH; limitation to low-intensity sports in PAH patients.
• Pregnancy: no significantly increased risk for patients without PH.
Patients with pre-capillary PH should be counselled against pregnancy (see section 3.5.7).
• IE prophylaxis: limited to high-risk patients (see section 3.4.6).
4.5 Left ventricular outflow tract obstruction
4.5.1
Valvular aortic stenosis
4.5.1.1 Introduction and background
The most common cause for congenital valvular aortic stenosis (AS)
is BAV. Up to 80% of patients with a BAV will develop ascending aortic dilatation, which is discussed in section 4.7.2. For the management of AR associated with BAV, see the 2017 ESC/EACTS
Guidelines on the management of valvular heart disease.25
4.5.1.2 Clinical presentation and natural history
Patients frequently remain asymptomatic for many years. Progression of stenosis varies and depends on initial severity, degree of calcification, age, and atherosclerotic risk factors. In BAV, progression is faster in those patients with greater closure-line eccentricity and an anteroposterior-oriented line of closure.
Prognosis is good and sudden death is rare in asymptomatic patients with good exercise tolerance, even when stenosis is severe.171
Once symptoms (angina pectoris, dyspnoea, or syncope) occur,
the prognosis deteriorates rapidly. In patients with BAV, cardiac mortality has been reported to be 0.3% per patient-year of follow-up, the frequency of aortic dissection 0.03%, and endocarditis 0.3%. Dilated aortic sinuses and/or ascending aorta have been found in 45% of patients after 9 years of follow-up.172
4.5.1.3 Diagnostic work-up
See section 3.3 for general principles. Diagnostic criteria for degree of
AS are summarized in Table 12.
Recommendations for intervention in patent ductus arteriosus
Recommendations
Classa
Levelb
In patients with evidence of LV volume overloadc and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs), PDA closure is recommended regardless of symptoms.
I
C
Device closure is recommended as the method of choice when technically suitable.
I
C
In patients who have developed PAH with PVR
35 WU, PDA closure should be considered when there is still signiﬁcant LR shunt
(Qp:Qs >1.5).
IIa
C
In patients who have developed PAH with PVR
>_5 WU, PDA closure may be considered when there is still signiﬁcant LR shunt (Qp:Qs >1.5)
but careful individual decision in expert centres is required.
IIb
C
PDA closure is not recommended in patients with
Eisenmenger physiology and patients with lower limb desaturation on exercise.d
III
C
LR = left-to-right; LV = left ventricle/ventricular; PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure; PDA = patent ductus arteriosus;
PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio;
WU = Wood units.
aClass of recommendation.
bLevel of evidence.
cLV enlargement with increased stroke volume.
dThere are limited data available for a precise cut-off, but by clinical experience,
this would be given by a fall of arterial oxygen saturation <90%.


<!-- PAGE 37 -->

### Page 37

....................
Specific clinical findings include the typical systolic ejection murmur over the aortic valve, radiating into the carotid arteries. An ejection click can be heard and a thrill may be palpable. The ECG
may show LV hypertrophy (LVH) with or without strain. In patients diagnosed with a BAV, CoA should be excluded (see section 4.6).
• Echocardiography is the gold standard for the diagnosis of AS
and for assessing the degree of calcification, LV function, LVH,
and associated lesions including ascending aortic dilatation. With
Doppler echocardiography, the degree of AS severity is determined from transvalvular peak velocity (Vmax), mean gradient,
and continuity equation-calculated aortic valve area (AVA). For more details, see recent recommendations for the echocardiographic assessment of AS.173
• TOE may occasionally provide more anatomical details about valve dysfunction or AVA planimetry in non-calcified valves.
• Exercise testing is recommended in asymptomatic patients, particularly in moderate-to-severe AS, to confirm asymptomatic status and evaluate exercise tolerance, blood pressure response,
and arrhythmias for risk stratification and timing of surgery.
• Low-dose dobutamine or exercise stress echocardiography is helpful in AS with reduced stroke volume and impaired LV function (classical low-flow, low-gradient AS).173
• CMR/CCT, despite having potential for assessing AS, is mainly required to assess dilation of the ascending aorta, in cases where measurement is unreliable with echocardiography.
• CCT has become particularly important for the quantification of valve calcification when assessing AS severity in lowgradient AS, although it should be noted that aortic valve
©ESC 2020
Figure 4 Management of patent ductus arteriosus.
LV = left ventricle/ventricular; Qp:Qs = pulmonary to systemic flow ratio; PAH = pulmonary artery hypertension; PDA = patent ductus arteriosus; PVR =
pulmonary vascular resistance; WU = Wood units.
aLV enlargement with increased stroke volume.
bIncludes all patients with lower limb desaturation at rest (Eisenmenger physiology) or on exercise.
cCareful individual decision in expert centres is required.
Table 12
Diagnostic criteria for degree of aortic stenosis severity173
Mild AS
Moderate AS
Severe AS
Vmax (m/s)a
2.62.9
3.03.9
>_4.0
Mean gradient (mmHg)a
<20
2039
>_40
AVA (cm2)
>1.5
1.01.5
<1.0
AVAi (cm2/m2 BSA)
>0.85
0.600.85
<0.60
LVOT velocity/aortic valve velocity
>0.50
0.250.50
<0.25
AS = aortic stenosis; AVA = aortic valve area; AVAi = indexed aortic valve area;
BSA = body surface area; LVOT = left ventricular outﬂow tract; Vmax = maximum
Doppler velocity.
aAt normal transvalvular ﬂow.
ESC Guidelines
599


<!-- PAGE 38 -->

### Page 38

.............................................................................................................................................................................
stenosis in young patients is not necessarily associated with significant calcification.
• Cardiac catheterization is only required if non-invasive evaluation yields uncertain results, for evaluation of coronary arteries, or when percutaneous balloon angioplasty is considered.
4.5.1.4 Medical therapy
Symptomatic patients require urgent surgery. Medical treatment for
AS-related heart failure is reserved for non-operable patients.
Neither statin treatment, nor any other medical treatment, has so far been shown to retard progression of AS.
4.5.1.5 Surgical/catheter interventional treatment
Indications for intervention are summarized in the Recommendations for intervention in valvular aortic stenosis table and in Figure 5.
In selected adolescents and young adults with non-calcified valves, balloon valvuloplasty may be considered. This may be the case in haemodynamically unstable patients as a bridge to surgery or to delay valve replacement in women with anatomically suitable valves and desire of pregnancy. In patients with calcified valves, the treatment of choice is valve replacement. Mechanical valves are more durable than biological valves or homografts but require lifelong anticoagulation. The Ross procedure (two-valve operation)
has been suggested for patients of childbearing age and for those wanting to avoid anticoagulation. Progressive degeneration of the homograft after the Ross procedure is the most frequent reason for reintervention during follow-up. Transcatheter pulmonary valve implantation has become an alternative technique for surgical treatment of the degenerated pulmonary valve. Transcatheter aortic valve implantation currently has no place in the treatment of congenital AS, except in very rare cases with high surgical risk,
when technically feasible.
4.5.1.6 Follow-up recommendations
Lifelong and regular follow-up is required, and the intervals depend upon the degree of stenosis severity. It is also necessary after valve intervention at minimum yearly intervals.
Echocardiographic imaging of the aortic valve and aortic root to determine progression of valve stenosis and aortic dilation is mandatory. CMR or CCT of the aorta is recommended in patients with a native BAV, patients with a history of isolated valve replacement where the ascending aorta is not well visualized on TTE, and in patients with root/ascending diameters >40mm.176
4.5.1.7 Additional considerations
• Exercise/sports: patients with severe symptomatic and asymptomatic AS, and those with moderate stenosis due to BAV and dilated aorta, should avoid isometric exercise and high-intensity sports. In mild and moderate AS, more intensive physical activity is allowed. A prior exercise test to guide counselling is recommended.24
• Pregnancy: contraindicated in severe symptomatic AS. Treatment by either balloon valvuloplasty or surgery should be performed before conception. In asymptomatic patients with severe AS and a normal exercise test, pregnancy may be possible in selected patients. The aorta requires particular attention as BAV-related
Recommendations for intervention in valvular aortic stenosis
Recommendations
Classa
Levelb
Symptomatic patients with aortic valve stenosis
In symptomatic patients with severe high-gradient AS (mean gradient >_40 mmHg), intervention is recommended.25,171,174,175
I
B
Intervention is indicated in symptomatic patients with severe low-ﬂow, low-gradient
(mean gradient <40 mmHg) AS with reduced
EF and evidence of ﬂow (contractile) reserve excluding pseudosevere AS.
I
C
Asymptomatic patients with severe aortic valve stenosis
Intervention is indicated in asymptomatic patients with severe AS and an abnormal exercise test showing symptoms on exercise clearly related to AS.
I
C
Intervention is indicated in asymptomatic patients with severe AS and systolic LV dysfunction (LVEF <50%) not due to another cause.
I
C
Intervention should be considered in asymptomatic patients with severe AS when they present with a fall in blood pressure below baseline during exercise testing.
IIa
C
Intervention should be considered in asymptomatic patients with normal EF and none of the above-mentioned exercise test abnormalities if the surgical risk is low and one of the following ﬁndings is present:
• Very severe AS deﬁned by a Vmax >5.5 m/s.
• Severe valve calciﬁcation and a rate of Vmax progression >_0.3 m/s/year.
• Markedly elevated BNP levels (>3-fold ageand sex-corrected normal range) conﬁrmed by repeated measurements without other explanation.
• Severe PH (systolic PAP at rest >60 mmHg conﬁrmed by invasive measurement) without other explanation.
IIa
C
Concomitant aortic valve surgery at the time of other cardiac/
ascending aorta surgery
Surgery is recommended when patients with severe AS undergo surgery of the ascending aorta or of another valve, or CABG.
I
C
Patients with moderate AS undergoing CABG
surgery or surgery of the ascending aorta or another valve should be considered for additional valve replacement.
IIa
C
AS = aortic stenosis; BNP = B-type natriuretic peptide; CABG = coronary artery bypass graft; EF = ejection fraction; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction; PAP = pulmonary artery pressure; PH = pulmonary hypertension; Vmax = maximum Doppler velocity.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 39 -->

### Page 39

...............................................................
aortic dilation may be induced and progress during and after pregnancy; there is a risk of dissection (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.5.2
Supravalvular aortic stenosis
4.5.2.1 Introduction and background
Supravalvular AS (SupraAS) may occur as a characteristic feature of
WilliamsBeuren syndrome or be isolated/familial, which are respectively caused by deletion of the elastin gene located on chromosome 7q11.23 or a mutation in this same gene. These genetic defects lead to obstructive arteriopathy of varying severity, which is most pronounced at the sinotubular junction.177
SupraAS may also be encountered in the setting of familial homozygous hypercholesterolaemia.178 SupraAS occurs as a localized fibrous diaphragm just distal to the coronary ostia or, most commonly, as an external hourglass deformity with a corresponding luminal narrowing of the aorta, or as diffuse stenosis of the ascending aorta. It may be associated with aortic valve abnormalities, hypoplasia of the entire aorta, involvement of coronary ostia, or stenosis of major branches of the aorta or PAs.
4.5.2.2 Clinical presentation and natural history
The majority of patients present in childhood with symptoms of either outflow obstruction or myocardial ischaemia. While progression of
SupraAS is rare in adulthood, adults remain at risk for cardiac complications.179 Sudden death occurs rarely, but it is more common in
SupraAS with WilliamsBeuren syndrome, with diffuse peripheral PA
stenosis, or with CAD, particularly related to anaesthetic procedures.
4.5.2.3 Diagnostic work-up
See section 3.3 for general principles.
Auscultation typically reveals a loud systolic ejection murmur best heard at the left lower sternal border without associated ejection click or diastolic murmur of AR.
• Echocardiography enables the anatomic diagnosis of SupraAS
when the acoustic window allows. Doppler echocardiography provides pressure gradients, but these may over- or underestimate the actual pressure drop across the obstruction. TOE
allows good visualization of the coronary ostia and 3D TOE can be used for detailed evaluation of the stenotic region.180
• For exercise testing, see valvular AS (section 4.5.1).
©ESC 2020
Figure 5 Management of severe left ventricular outflow tract obstruction.
AS = aortic stenosis; LVEF = left ventricular ejection fraction; LVOTO = left ventricular outflow tract obstruction; PAP = pulmonary artery pressure; PH
= pulmonary hypertension; SubAS = subaortic stenosis SupraAS = supravalvular aortic stenosis.
aSee Section 4.5. There are fundamental differences in management decisions compared to valvular AS, particularly because a valve substitute with its consequences is generally not required.
bPeak velocity >5.5m/s; severe calcification þ peak velocity progression >_0.3 m/s/y; markedly elevated neurohormones (>3-fold age- and sex-corrected normal range); severe PH (systolic PAP >60 mmHg without other explanation).
ESC Guidelines
601


<!-- PAGE 40 -->

### Page 40

.............................................................................................................................................................................
• CMR/CCT is useful for detailed evaluation of supravalvular anatomy, in particular, when multilevel LVOTO is present or for
(pre-operative) assessment of coronary artery anatomy and other aortic or aortic branch lesions (e.g. carotid and renal artery stenosis), and central and branch PAs.
• Cardiac catheterization: haemodynamic assessment is recommended when non-invasive quantification remains uncertain.
• Genetic evaluation, with counselling and subsequent testing using micro-array techniques to diagnose WilliamsBeuren syndrome and sequencing of the elastin gene in non-syndromic presentations, is useful.
4.5.2.4 Surgical/catheter interventional treatment
Surgery is the primary treatment: the operative mortality rate for fibrous diaphragm and hourglass deformity is <5%. Since the coronary arteries are under high pressure, surgery might be considered earlier than in patients with valvular AS, particularly when no valve substitute is required. Following operative repair, the survival rate has been reported to be 8085% at 20 years.181 AR may be present in 25% of patients,
but usually it is not progressive after surgical relief of SupraAS.
4.5.2.5 Follow-up recommendations
Lifelong and regular follow-up, including echocardiography, is required to determine progression of obstruction (rare), LV size/
function, and development of symptoms, as well as after surgery to detect late restenosis, development of aneurysm (CMR/CCT), and the occurrence or progression of CAD. Follow-up should include evaluation in specialized ACHD centres.
4.5.2.6 Additional considerations
• Exercise/sports: see valvular AS (section 4.5.1).
• Pregnancy: See valvular AS (section 4.5.1). Male and female patients with WilliamsBeuren syndrome and elastin gene mutations have a 50% transmission risk (family screening recommended).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.5.3
Subaortic stenosis
4.5.3.1 Introduction and background
Subaortic stenosis (SubAS) occurs as an isolated lesion, but is frequently associated with aortic valve disease, VSD, AVSD, or Shone complex
(multilevel left heart obstruction). It may also develop after repair of these lesions. It is caused by a fibrous ridge/ring in the LVOT proximal to the aortic valve or as a fibromuscular narrowing. SubAS has to be differentiated from obstructive hypertrophic cardiomyopathy.
4.5.3.2 Clinical presentation and natural history
The clinical course is highly variable. The presence of associated
CHD, particularly a VSD, is related with SubAS progression; age seems not to play a role in disease. AR is frequent but rarely haemodynamically significant or progressive.182 Although infrequent, sudden death has been reported in SubAS patients.
4.5.3.3 Diagnostic work-up
See section 3.3 for general principles.
Clinical findings mainly include a systolic ejection murmur at the left sternal border without systolic ejection click. A diastolic murmur refers to AR.
• Echocardiography visualizes LVOT anatomy, associated aortic valve abnormality, degree of AR, LV function, LVH, and associated lesions. With Doppler echocardiography, the severity of the subvalvular obstruction is determined, but Doppler-derived gradients may overestimate the obstruction and may require confirmation by cardiac catheterization.
Occasionally,
TOE
is necessary to better demonstrate the membrane or ring. 3D TOE
can be helpful to characterize the complex LVOT anatomy and estimate the area of obstruction by planimetry.
• CMR may be useful to characterize complex LVOTO anatomies,
especially in patients with poor acoustic window.
4.5.3.4 Surgical/catheter interventional treatment
Surgical treatment is the only effective intervention and involves a complete resection of the fibrous ridge/ring and parts of the muscular base along the left septal surface. Fibromuscular or tunnel-type
SubAS requires more extensive resection or a Konno procedure.
Surgical results are good, but restenosis may occur. In patients with low surgical risk and morphologically well suited to repair, the threshold for intervention is lower than in aortic valve stenosis since no valve implant is required. In the case of moderate or severe AR, the aortic valve must be repaired or replaced at the time of surgery.
4.5.3.5 Follow-up recommendations
Lifelong regular follow-up, including echocardiography, is required in the non-operated state to determine progression of obstruction, AR,
and LV hypertrophy, function, and size. Regular post-operative followRecommendations for intervention in supravalvular aortic stenosis
Recommendations
Classa
Levelb
In patients with symptoms (spontaneous or on exercise test) and mean Doppler gradient >_40
mmHg, surgery is recommended.
I
C
In patients with mean Doppler gradient <40
mmHg, surgery is recommended when one or more of the following ﬁndings are present:
 Symptoms attributable to obstruction (exertional dyspnoea, angina, syncope).
 LV systolic dysfunction (EF <50% without other explanation).
 Surgery required for signiﬁcant CAD or valvular disease.
I
C
Patients with mean Doppler gradient >_40
mmHgc  but without symptoms, LV systolic dysfunction, LVH, or abnormal exercise test 
may be considered for repair when the surgical risk is low.
IIb
C
CAD = coronary artery disease; EF = ejection fraction; LV = left ventricle/ventricular; LVH = left ventricular hypertrophy.
aClass of recommendation.
bLevel of evidence.
cDoppler-derived gradients may overestimate the obstruction and may need conﬁrmation by left heart catheterization.


<!-- PAGE 41 -->

### Page 41

.........................................................................................................................................................................
up is also necessary to detect and observe late restenosis, progressive
AR, and complications such as arrhythmias, heart block, and iatrogenic
VSD. Follow-up should include evaluation in specialized ACHD centres,
and the frequency is related to the expected disease progression.
4.5.3.6 Additional considerations
• Exercise/sports: see valvular AS (section 4.5.1).
• Pregnancy: only contraindicated in severe, symptomatic SubAS
where surgery should be performed before pregnancy (even in asymptomatic severe SubAS, surgery should be considered) (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.6 Coarctation of the aorta
4.6.1
Introduction and background
CoA is considered as part of a generalized arteriopathy, and not only as narrowing of the aorta. It occurs as a discrete stenosis or as a long,
hypoplastic aortic (arch) segment. Typically, CoA is located in the area where the ductus arteriosus inserts, and only in rare cases occurs ectopically (ascending, descending, or abdominal aorta).
Associated lesions include BAV (up to 85%), ascending aortic aneurysm, SubAS, or SupraAS, (supra)mitral valve stenosis (including parachute mitral valve), Shone complex, or complex congenital heart defects. CoA can be associated with Turner syndrome and
WilliamsBeuren syndrome. Extracardiac vascular anomalies have been reported in CoA patients including anomalous origin of the right subclavian artery (in 45% of cases), collateral arterial circulation, and intracerebral aneurysms (in up to 10%).
4.6.2
Clinical presentation and natural history
Signs and symptoms depend on the severity of CoA. Patients with severe CoA usually present with signs and symptoms early in life,
while particularly mild cases may not become evident until adulthood, where CoA is detected in the work-up of arterial hypertension.
Key symptoms may include headache, nosebleeds, dizziness,
tinnitus, shortness of breath, abdominal angina, claudication, and cold feet.
Patients with CoA who reach adolescence demonstrate very good long-term survival up to age 60 years. Long-term morbidity is common, however, largely related to aortic complications and longstanding hypertension.183
The natural course may be complicated by left heart failure, intracranial haemorrhage (from berry aneurysm), IE, aortic rupture/dissection, premature coronary and cerebral artery disease, and associated heart defects.
4.6.3
Diagnostic work-up
See section 3.3 for general principles.
Office blood pressure measurement in the upper and lower extremities are the primary studies required in all coarctation patients. A blood pressure gradient between upper and lower extremities (systolic >_20 mmHg) indicates significant CoA. Weak or absent pulses in the lower extremities or radiofemoral pulse delay also indicate significant coarctation.
• Ambulatory blood pressure measurements (right arm) are recommended to detect/confirm arterial hypertension (24-h mean systolic >130 mmHg and/or diastolic >80 mmHg).
• Other findings consist of a suprasternal thrill (proximal obstruction), an interscapular (systolic) murmur, or continuous murmurs
(due to collateral vessels). In the case of a pinpoint CoA, murmurs may be completely absent.
• Chest X-ray findings may be characterized by rib notching of the third and fourth (to the eighth) ribs due to the collaterals.
• Echocardiography provides information regarding site, structure,
and extent of CoA, LV function and LVH, associated cardiac abnormalities, and aortic and supra-aortic vessel diameters.
Doppler gradients are not useful for quantification, neither in native nor in post-operative coarctation. In the presence of extensive collateral arteries, gradients are not reliable and are often underestimated. After surgical repair or stenting, increased systolic flow rates may develop, even in the absence of significant narrowing, due to decreased/absent aortic compliance and
Recommendations for intervention in subaortic stenosis
Recommendations
Classa
Levelb
In symptomatic patients (spontaneous or on exercise test) with a mean Doppler gradient
>_40 mmHgc or severe AR, surgery is recommended.
I
C
Asymptomatic patients should be considered for surgery when one or more of the following
ﬁndings are present:
• Mean gradient <40 mmHg but LVEF <50%.
• AR is severe and LVESD >50 mm
(or 25 mm/m2 BSA) and/or EF <50%d.
• Mean Doppler gradient is >_40 mmHgc and marked LVH present.
• Mean Doppler gradient is >_40 mmHgc and there is a fall in blood pressure below baseline on exercise.
IIa
C
Asymptomatic patients may be considered for surgery when one or more of the following ﬁndings are present:
• Mean Doppler gradient is >_40 mmHg,c LV is normal (EF >50% and no LVH), exercise testing is normal, and surgical risk is low.
• Progression of AR is documented and AR
becomes more than mild (to prevent further progression).
IIb
C
AR = aortic regurgitation; BSA = body surface area; EF = ejection fraction; ESC =
European Society of Cardiology; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end systolic diameter; LVH =
left ventricular hypertrophy.
aClass of recommendation.
bLevel of evidence.
cDoppler-derived gradients may overestimate the obstruction and may need conﬁrmation by cardiac catheterization.
dSee 2017 ESC Guidelines on the management of valvular heart disease.25
ESC Guidelines
603


<!-- PAGE 42 -->

### Page 42

...................................................................
Doppler-related pressure recovery. The gradient is then overestimated. A diastolic tail in the descending aorta and diastolic forward flow in the abdominal aorta are findings of significant
(re-)CoA.
• CMR and CCT, including 3D reconstruction, are the preferred non-invasive techniques to evaluate the entire aorta in adolescents and adults. Both depict site, extent, and degree of the aortic narrowing, the aortic arch and head and neck vessels, the preand post-stenotic aorta, and collaterals. Both methods detect complications such as aneurysms, false aneurysms, restenosis, or residual stenosis.184
• Imaging of intracerebral vessels is indicated in the case of symptoms and/or clinical manifestations of aneurysms/rupture.
• Cardiac catheterization with manometry (a peak-to-peak gradient >_20 mmHg) indicates a haemodynamically significant CoA
in the absence of well-developed collaterals and is performed in the setting of interventional treatment. It should be noted that, in patients under general anaesthesia, invasive measurement of gradient may be underestimated.
4.6.4
Surgical/catheter interventional treatment
Indications for intervention are summarized in the Recommendations for intervention in coarctation and re-coarctation of the aorta table and in
Figure 6.
In native CoA, as well as re-coarctation with appropriate anatomy,
stenting has become the first-choice treatment in many ACHD
centres.185 The use of covered stents is preferred because of lower short- and long-term complication rates.186 Biodegradable stents are in development but are mainly applied in children when the aorta is still expected to grow.
Balloon angioplasty in adults is only indicated for re-dilatation of previously stented aortas.
While paediatric surgical techniques include resection and end-toend anastomosis, resection and extended end-to-end anastomosis,
prosthetic patch aortoplasty, subclavian flap aortoplasty, interposition of a (tube) graft, and bypass tube (jump) grafts, only the latter two are generally feasible in adults. Ascending-to-descending aorta conduits may be preferable in adults with difficult anatomy. Although the surgical risk in simple CoA may currently be <1%, it increases significantly beyond the age of 3040 years. Spinal cord injury has become extremely rare.187
As coarctation is not a localized disease of the aorta, associated lesions that may require structural interventions have to be considered:
• Associated significant aortic valve stenosis or regurgitation
(BAV).
• Aneurysm of the ascending aorta with a diameter >50 mm or rapid progression of diameter.
• Aneurysm and false aneurysms at the previous CoA site.
• Symptomatic or large aneurysms of the circle of Willis.
Treatment should be performed in centres with extensive experience in the treatment of CHD.
4.6.5
Follow-up recommendations
Residua, sequelae, and complications are listed below:
• Arterial hypertension at rest or during exercise is common, even after successful treatment, and is an important risk factor for premature CAD, ventricular dysfunction, and rupture of aortic or cerebral aneurysms.188
• The geometry of the arch (gothic, crenel, normal) and smaller aortic size in the stented region may play a role in the development of hypertension. Right arm 24-h ambulatory blood pressure measurement better detects hypertension than a one-off measurement.189 The significance of isolated, exercise-induced hypertension is a matter of debate.
• An increased pressure gradient (systolic >_20 mmHg) between upper and lower extremities indicates re-coarctation and warrants invasive assessment for confirmation and treatment.
• Medical treatment of arterial hypertension should follow the
2018 ESC/ESH Guidelines.190
• Recurring or residual CoA may induce or aggravate systemic arterial hypertension and its complications.
• Aneurysms of the ascending aorta or at the intervention site present a risk of rupture and death. Patch repairs (e.g. with
Dacron) are at particular risk of repair-site aneurysms, while
Recommendations for intervention in coarctation and re-coarctation of the aorta
Recommendations
Classa
Levelb
Repair of coarctation or re-coarctation (surgically or catheter based) is indicated in hypertensive patientsc with an increased non-invasive gradient between upper and lower limbs conﬁrmed with invasive measurement (peak-topeak >_20 mmHg) with preference for catheter treatment (stenting), when technically feasible.
I
C
Catheter treatment (stenting) should be considered in hypertensive patientsc with >_50% narrowing relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient is <20 mmHg, when technically feasible.
IIa
C
Catheter treatment (stenting) should be considered in normotensive patientsc with an increased non-invasive gradient conﬁrmed with invasive measurement (peak-to-peak >_20
mmHg), when technically feasible.
IIa
C
Catheter treatment (stenting) may be considered in normotensive patientsc with >_50% narrowing relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient is <20 mmHg, when technically feasible.
IIb
C
aClass of recommendation.
bLevel of evidence.
cRight arm ambulatory blood pressure monitoring should be considered for the diagnosis of hypertension.


<!-- PAGE 43 -->

### Page 43

.............................................................................
interposition grafts are at particular risk of false aneurysms,191
and both should be imaged on a regular basis.
• Attention is required for BAV, mitral valve disease, premature
CAD, and berry aneurysms of the circle of Willis (routine screening in asymptomatic patients is not recommended).
All CoA patients require regular follow-up at least every year. Imaging of the aorta (preferably with CMR) is required to document post-repair or post-interventional anatomy and complications (restenosis, aneurysm,
false aneurysm formation). Recommended imaging intervals are commonly every 35 years but also depend on baseline pathology.
4.6.6
Additional considerations
• Exercise/sports: patients without residual obstruction, who are normotensive at rest and with exercise, can usually lead normally active lives without restriction. Patients with arterial hypertension, residual obstruction, or other complications should avoid heavy isometric exercises in proportion to the severity of their problems.
• Pregnancy: after successful treatment of CoA, many women tolerate pregnancy without major problems.43 In particular, women with unrepaired CoA  but also those after repair with arterial hypertension, residual CoA, or aortic aneurysms  have an increased risk of aortic rupture and rupture of a cerebral aneurysm during pregnancy and delivery. An excess of miscarriages and hypertensive disorders has been reported192 (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.7 Aortopathies
4.7.1
Marfan syndrome and related heritable thoracic aortic diseases
4.7.1.1 Introduction and background
Marfan syndrome is the prototype of syndromic HTAD entities,
comprising a clinically and genetically heterogeneous group of disorders with aneurysm or dissection of the thoracic aorta as the common denominator. Both syndromic and non-syndromic (or isolated)
forms of HTAD are part of the clinical spectrum, with notable clinical overlap between the various entities.
For more details on the various syndromes, please refer to the
other syndromes are mentioned in case of important differences from Marfan syndrome.
©ESC 2020
Figure 6 Management of coarctation and re-coarctation of the aorta.
CoA = coarctation of the aorta.
aRight arm ambulatory blood pressure should be considered for diagnosis.
bInvasively confirmed measurement.
cRelative to the aortic diameter at the diaphragm.
ESC Guidelines
605


<!-- PAGE 44 -->

### Page 44

.......................................................................................................................................................................
4.7.1.2 Clinical presentation and natural history
Although thoracic aortic disease  either aneurysms detected by screening or dissection in an emergency setting  is the principal characteristic in Marfan syndrome /HTAD, extra-aortic features in the skeletal/ocular organ system may be the key to diagnosis in some patients.
Prognosis in all HTAD entities is mainly determined by progressive dilation of the aorta, leading to aortic dissection or rupture.
Prognosis varies according to the underlying genetic defect. The average age at death in untreated Marfan syndrome patients is
<40 years, but can approach that of the general population in patients in whom the diagnosis is known and who are properly managed.29,194 More rare cardiovascular causes of death include heart failure and SCD.29
In Marfan syndrome, the major determinant of type A aortic dissection is the aortic root diameter with increased risk of rupture >_50
mm.195 Other risk factors include family history of aortic dissection at low diameter,193 aortic root growth rate, pregnancy, and hypertension. Increasing evidence for gene-based differences in aortic risk are emerging and need to be considered. Other parts of the aorta 
or in the case of some entities, major branching vessels  may also dilate or dissect.
The presence of significant aortic, tricuspid, or mitral regurgitation  usually related to valve prolapse  may lead to symptoms of ventricular volume overload. However, LV disease may also occur independently of valvular dysfunction and this may be associated with arrhythmia. Mitral valve prolapse in patients with
Marfan syndrome manifests early and progresses to severe regurgitation, need for surgery, and IE earlier than idiopathic mitral valve prolapse.196
4.7.1.3 Diagnostic work-up
Early identification and establishment of the correct diagnosis is critical since prophylactic surgery can prevent aortic dissection and rupture. This requires a multidisciplinary team approach with integration of clinical and genetic findings.197 The diagnosis of Marfan syndrome is based on the Ghent criteria, with aortic root aneurysm/dissection and ectopia lentis as cardinal features.198 Criteria for the other
HTAD entities are less well defined.
Gene panel testing is meaningful for confirmation of the diagnosis and to guide management. Mutation pick-up rate in syndromic forms is higher (>90%) than in non-syndromic entities (2030%).199 Once a pathogenic variant is identified, presymptomatic genetic screening of family members is mandatory to allow early and appropriate management.
• Echocardiographic assessment of the aortic root should include measurements at the annulus, sinus, sinotubular junction, distal ascending, arch, and descending thoracic aortic levels. In adults, measurement at end diastole using the leadingto-leading edge principle is recommended.
The values obtained should be corrected for the individual’s age, sex, and body size using standardized nomograms.200,201 Valvular morphology (mitral valve prolapse, BAV) and function must be assessed, as well as the presence of a PDA. LV dimension and function should be addressed according to standard recommendations.
• CMR or CCT angiography from head to pelvis should be performed in every patient at baseline, providing imaging of the entire aorta and branching vessels. In addition to measuring aortic diameters, information on aortic/vertebral artery tortuosity is important for diagnostic and prognostic purposes.202,203
• Holter monitoring should be performed in symptomatic patients,
as ventricular arrhythmias, conduction disturbances, and SCD
can occur.
4.7.1.4 Medical therapy
Although no reduction in mortality or dissection rate has been established in any trial, beta blockers remain the mainstay for medical treatment in Marfan/HTAD patients, reducing wall shear stress and aortic growth rate.204 Rigorous antihypertensive medical treatment aimed at a 24-h ambulatory systolic blood pressure
<130 mmHg (110 mmHg in patients with aortic dissection) is important, although there are no data to establish outright blood pressure thresholds. ARBs did not prove to have a superior effect when compared with beta blockers or in addition to beta blockers in several trials, but may be considered as an alternative in patients intolerant to beta blockers.205,206 Medical treatment should be continued after surgery.
Ongoing meta-analyses of medical treatment trials may help define subgroups  based on genetic and clinical data  who benefit from specific treatment.207 Since no medical trials have been conducted in non-Marfan HTAD, medical treatment is usually adopted from
Marfan data.
4.7.1.5 Surgical treatment
Indications for intervention are summarized in the
Recommendations for aortic surgery in aortopathies table.
Prophylactic aortic root surgery is the only definitive treatment for the prevention of aortic dissection in Marfan syndrome and related HTADs. In patients with anatomically normal aortic valves and low-grade regurgitation, a valve-sparing aortic root replacement by a Dacron prosthesis and reimplantation of the coronary arteries into the prosthesis (David procedure) has become the preferred surgical procedure with good long-term outcome,
including in Marfan patients.193,208 Composite graft replacement,
usually with a mechanical valve, is a more durable alternative but does require lifelong anticoagulation. The decision on which technique to use should be made on an individual basis, and patient preferences and surgical experience should be taken into account.209
Marfan and related HTADs are associated with a risk of redissection and recurrent aneurysm in the distal aorta, especially in patients with previous dissection.210,211 With improved life expectancy, these complications now occur more frequently. Open aortic surgery remains the reference method for treatment of distal aortic disease, although hybrid procedures with endovascular stenting 
where proximal and distal landing is possible in a Dacron tube 
could be considered in selected cases.


<!-- PAGE 45 -->

### Page 45

............................................................................................................................................................
4.7.1.6 Follow-up recommendations
Lifelong and regular multidisciplinary follow-up at an expert centre is required. Echocardiography and CCT/CMR are the principal examinations.
4.7.1.7 Additional considerations
• Exercise/sports: patients should be advised to avoid exertion at maximal capacity, competitive, contact, and isometric sports.
Risk estimation based on aortic size has been suggested by Budts et al.24
• Pregnancy: in genetically confirmed Marfan/HTAD, there is a
50% transmission risk for both men and women. Proper and timely genetic counselling is needed. Women with an aortic root diameter >45 mm are strongly discouraged from becoming pregnant without prior repair because of the increased risk of dissection.43 An aortic root diameter <40 mm rarely presents a problem, although a completely safe diameter does not exist. With an aortic root 4045 mm, previous aortic growth and family history are important factors when considering repair prior to pregnancy. After repair of the ascending aorta, Marfan patients remain at risk for dissection of the residual aorta (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.7.2
Bicuspid aortic disease
Depending on the reported series, 2084% of patients with a BAV
will develop ascending aortic dilatation,212 indicating that BAV should be regarded as part of a spectrum of valvluo-aortopathy and that bicuspid aortic disease may be a more appropriate term. Although the relative contribution of intrinsic/genetic wall abnormalities and altered haemodynamics remains debated, both factors are probably involved.
In the absence of significant valvular dysfunction, aortic dilatation in the setting of bicuspid aortic disease typically evolves asymptomatically. With increasing diameters, however, the risk for acute aortic dissection rises. Compared with the general population,
the dissection incidence in bicuspid aortic disease patients is eight times higher, which is in absolute numbers still a low risk (31/100 000 patient years)172,176,213 and much lower than in Marfan/HTAD. Observational studies indicate that the clinical outcome in bicuspid aortic disease patients is more similar to that of the general population with aneurysms and represents a
more benign aortopathy than
Marfan/
HTAD.176,214
CoA is associated with an increased risk for dissection.215
For diagnostic work-up see section 4.7.1.3.
To this date, no evidence for medical treatment of aortic dilatation in the setting of bicuspid aortic disease is available, but it may be reasonable to consider beta blockers or ARBs as first-line treatment for arterial hypertension.
Indications for intervention are summarized in the
Recommendations for aortic surgery in aortopathies table.
Familial occurrence of BAV has clearly been established with rates of 510% in first-degree relatives in various studies.216
Echocardiographic screening in first-degree relatives of BAV
patients is recommended and may be appropriate,
particularly in boys, in athletes, and if hypertension is present.
Rare pathogenic variants in a number of genes account for <5%
of all bicuspid aortic disease cases and routine genetic testing in this setting is not indicated but may be considered in familial cases.140
There are no data on the risk for dissection related to pregnancy in women with a dilated aorta. According to the 2018 ESC
Guidelines for the management of cardiovascular disease during pregnancy,43 women should be counselled against pregnancy when the aortic diameter is >50 mm.
For treatment of AR, see 2017 ESC/EACTS Guidelines on the management of valvular heart disease.25
4.7.3
Turner syndrome
Turner syndrome is caused by a partial or complete monosomy of the X-chromosome and occurs in 1 in 2500 live-born females.217
Turner syndrome is associated with short stature, delayed puberty, ovarian dysgenesis, hypergonadotropic hypogonadism, infertility, congenital malformations of the heart, diabetes mellitus,
osteoporosis, and autoimmune disorders. CHD, occurring in approximately 50% of women with Turner syndrome, includes a high incidence of BAV, CoA, partial anomalous pulmonary venous connection, left SVC, elongated transverse aortic arch, dilatation of the brachiocephalic arteries, and aortic dilatation. Given this high prevalence of abnormalities, every woman with Turner syndrome should be seen by a cardiologist at least once.217 Even in the absence of CHD, all individuals with Turner syndrome have a generalized arteriopathy and Turner syndrome alone is an independent risk factor for thoracic aortic dilation. Aortic dissection
(both type A and type B) occurs in approximately 40 per 100 000
person-years compared with 6 per 100 000 person-years in the general population.218
For diagnostic work-up see section 4.7.1.3.
Indications for intervention are summarized in the
Recommendations for aortic surgery in aortopathies table.
With advances in assisted reproductive technology and oocyte donation, an increasing number of women with Turner syndrome are now able to become pregnant. The presence of aortic dilatation and CHD increases the risks of pregnancy and Turner syndrome women are also at increased risk of hypertensive disorders, including pre-eclampsia. All women with Turner syndrome should be counselled about the increased cardiovascular risk of pregnancy and fertility treatment.43
ESC Guidelines
607


<!-- PAGE 46 -->

### Page 46

.............................................................................................................................................................................
4.8 Right ventricular outflow tract obstruction
4.8.1
Introduction and background
RVOTO can occur at the sub-infundibular, infundibular, valvular, or supravalvular levels.
• Sub-infundibular stenosis, or DCRV, is commonly associated with a VSD. It is caused by narrowing between prominent and hypertrophied muscle bands or ridges that separate the hypertrophied, high-pressure inlet and apical portions from a lowpressure, non-hypertrophied and non-obstructive infundibular portion of the RV.219
• Infundibular stenosis usually occurs in combination with other lesions, particularly VSD, TOF, and secondary to valvular pulmonary stenosis (PS) (reactive myocardial hypertrophy). At the infundibular level, and to some extent the sub-infundibular level,
the obstruction tends to be dynamic, meaning that the orifice narrows during systole.
• Valvular PS is usually an isolated lesion. Mainly due to intrinsic wall abnormalities, and independent of haemodynamics, dilation of the PA may occur. Most often, there is a typical dome-shaped pulmonary valve with a narrow central opening but a preserved mobile valve base. A dysplastic pulmonary valve, with poorly mobile cusps and myxomatous thickening, is less common
(1520%; even less in untreated adults) and frequently part of
Noonan syndrome. In adults, a stenotic pulmonary valve may calcify late in life.
• Supravalvular PS, or pulmonary arterial stenosis, is caused by narrowing of the main pulmonary trunk, pulmonary arterial bifurcation, or pulmonary branches. It seldom occurs in isolation, and may occur in WilliamsBeuren syndrome, Noonan syndrome, congenital rubella syndrome, or Alagille syndrome.
The stenosis may be located in the main branches or more peripherally; it may be discrete or diffuse (hypoplastic) or there may be frank occlusion, and it may occur as single or multiple stenoses. Stenosis may be secondary to previous placement of a PA band or at a previous shunt site. A diameter narrowing >_50% is usually considered to be significant and would be expected to have a pressure gradient and result in hypertension in the proximal PA.
4.8.2
Clinical presentation and natural history
• Sub-infundibular/infundibular: adult patients with DCRV may be asymptomatic or they may present with dyspnoea, chest discomfort, dizziness, or syncope during exertion. The degree of obstruction is progressive over time.220
• Valvular: patients with mild-to-moderate valvular PS are usually asymptomatic. Mild valvular PS in unoperated adults is usually not progressive.221 Moderate PS can progress at the valvular level (calcification) or at the subvalvular level due to reactive myocardial hypertrophy. Patients with severe stenosis may present with dyspnoea and reduced exercise capacity and have a worse prognosis.
• Supravalvular: patients may be asymptomatic or have symptoms of dyspnoea and reduced exercise capacity. They are usually recognized in the context of certain syndromes or in patients referred for suspicion of PH. Peripheral PA stenosis may progress in severity.
Recommendations for aortic surgery in aortopathies
Recommendations
Classa
Levelb
Marfan syndrome and HTAD
Aortic valve repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young patients with
Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves,
when performed by experienced surgeons.
I
C
Surgery is indicated in patients with Marfan syndrome who have aortic root disease with a maximal aortic sinus diameter >_50 mm.c
I
C
Surgery should be considered in patients with
Marfan syndrome who have aortic root disease with maximal aortic sinus diameter >_45
mmc and additional risk factors.d
IIa
C
Surgery should be considered in patients with a TGFBR1 or TGFBR2 mutation (including
LoeysDietz syndrome) who have aortic root disease with maximal aortic sinus diameter >_45mm.c
IIa
C
Bicuspid aortic disease
Aortic surgery should be considered if the ascending aorta is:
• >_50 mm in the presence of a bicuspid valve with additional risk factorse or coarctation.
• >_55 mm for all other patients.
IIa
C
Turner syndrome
Elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered for women with Turner syndrome who are >16 years of age, have an ascending aortic size index >25 mm/m2, and have associated risk factors for aortic dissection.f
IIa
C
Elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women with Turner syndrome who are >16 years of age, have an ascending aortic size index >25 mm/m2, and do not have associated risk factors for aortic dissection.f
IIb
C
AR = aortic regurgitation; BAV = bicuspid aortic valve; ECG = electrocardiogram;
BSA = body surface area; CoA = coarctation of the aorta; HTAD = heritable thoracic aortic disease.
aClass of recommendation.
bLevel of evidence.
cAt the extreme ends of the BSA range, recommended cut-offs may require appropriate adjustment.
dFamily history of aortic dissection at a low diameter (or personal history of spontaneous vascular dissection), progressive AR, desire for pregnancy, uncontrolled hypertension, and/or aortic size increase >3 mm/year (on repeated measurements using the same ECG-gated imaging technique measured at the same level of the aorta with side-by-side comparison and conﬁrmed by another technique).
eFamily history of dissection at a low diameter, desire for pregnancy, systemic hypertension, and/or size increase >3 mm/year (on repeated measurements using the same ECG-gated imaging technique, measured at the same level of the aorta with side-by-side comparison and conﬁrmed by another technique).
fBAV, elongation of the transverse aorta, CoA, and/or hypertension.


<!-- PAGE 47 -->

### Page 47

............................................
4.8.3
Diagnostic work-up
See section 3.3 for general principles.
Clinical findings include a harsh systolic murmur across the obstruction and wide splitting of the second heart sound. In peripheral PS, the systolic murmur is typically heard over the lung fields.
• Echocardiography: size, shape, and function of the RV can be assessed and the exact position/level of the RVOTO can be visualized, as well as pulmonary valve, main PA, and proximal PA
branches. For quantification of RV sizes, volumes, and EF, CMR is a more robust and more reliable technique. Doppler ultrasound is used for measurements of flow velocities across an obstruction to assess severity. Correlation between flow velocities and pressure gradients is only good in the case of discrete stenosis, e.g.
isolated valvular PS. In the presence of normal RV function and normal transvalvular flow, RVOTO is considered mild when the peak gradient across the obstruction is <36 mmHg, moderate if
3664 mmHg, and severe when the gradient is >64 mmHg. If the narrowing is elongated, or if more than one stenosis is present in series (e.g. subvalvular and valvular), application of the
Bernoulli equation will lead to an overestimation of the pressure gradient. Doppler flow velocity of TR then gives a more reliable estimation of RV pressures  and with that, severity of the
RVOTO  than the flow velocity across the RVOTO. Gradients only represent severity of an obstruction if a good systolic RV
function is present. In a low-flow, low-gradient situation, it is very difficult to assess severity of a RVOTO.222
• CMR and CCT frequently provide additional important information identifying the level(s) of obstruction, including at the subinfundibular (DCRV), conduit, or branch PA levels, and assessment of RV volumes, pulmonary annulus, outflow tract and artery dimensions, and differential pulmonary blood flow. CMR
and CCT are the methods of choice for visualization of pulmonary dilation and peripheral PS.
• Cardiac catheterization may be required to confirm the extent,
severity, and level of obstruction (e.g. DCRV).
4.8.4
Surgical/catheter interventional treatment
Catheter-based balloon valvotomy is recommended for patients with non-dysplastic valvular PS and with peripheral PS (often with stent implantation).223 Surgery is recommended for patients with sub-infundibular or infundibular PS and hypoplastic pulmonary annulus, with dysplastic pulmonary valves, and for patients with associated lesions which need a surgical approach, such as severe pulmonary regurgitation (PR) or severe TR. Peripheral PS can rarely be addressed with surgery.
Both surgical and catheter interventions should only be performed in centres specialized in CHD.
In patients with subvalvular, valvular, and supravalvular PS, a markedly dilated pulmonary trunk may be present. Rupture is extremely rare in these low-pressure, highly elastic vessels and these pulmonary aneurysms generally do not require intervention.224
For RVPA conduit, see section 4.14.
Indications for intervention are summarized in the
Recommendations for intervention in right ventricular outflow tract obstruction table and in Figure 7.
4.8.5
Follow-up recommendations
Patients with RVOTO need lifelong follow-up with regular echocardiographic imaging. The frequency of follow-up depends on the severity of the lesion, but most patients will need a yearly visit, including evaluation in specialized ACHD centres except for patients with mild or well repaired valvular stenosis. After surgical or catheter intervention, a residual PR may need reintervention later in life for patients who become symptomatic or when progressive RV dilatation or dysfunction occurs (see section 4.10). Patients with mild valvular or mild residual PS need to be seen only once in 5 years.
4.8.6
Additional considerations
• Exercise/sports: no restrictions for patients with mild (residual)
PS. Patients with moderate PS should avoid high-intensity and
Recommendations for intervention in right ventricular outﬂow tract obstruction
Recommendations
Classa
Levelb
In valvular PS, balloon valvuloplasty is the intervention of choice, if anatomically suitable.
I
C
Provided that no valve replacement is required,
RVOTO intervention at any level is recommended regardless of symptoms when the stenosis is severe (Doppler peak gradient is >64 mmHgc).
I
C
If surgical valve replacement is the only option, it is indicated in patients with severe stenosis who are symptomatic.d
I
C
If surgical valve replacement is the only optiond in patients with severe stenosis who are asymptomatic, it is indicated in the presence of one or more of the following.
• Objective decrease in exercise capacity.
• Decreasing RV function and/or progression of
TR to at least moderate.
• RVSP >80 mmHg.
• RL shunting via an ASD or VSD.
I
C
Intervention in patients with a Doppler peak gradient <64 mmHg should be considered in the presence of one or more of the following.
• Symptoms related to PS.
• Decreasing RV function and/or progressive TR
to at least moderate.
• RL shunting via an ASD or VSD.
IIa
C
Peripheral PS, regardless of symptoms, should be considered for catheter interventional treatment if
>50% diameter narrowing, and RVSP >50 mmHg,
and/or related reduced lung perfusion is present.
IIa
C
ASD = atrial septal defect; PS = pulmonary stenosis; RL = right-to-left; RV =
right ventricle/ventricular; RVOTO = right ventricular outﬂow tract obstruction;
RVSP = right ventricular systolic pressure; TR = tricuspid regurgitation; VSD =
ventricular septal defect.
aClass of recommendation.
bLevel of evidence.
cRVSP estimated from TR velocity should conﬁrm severe PS.
dThe threshold for intervention is higher when a valve substitute is required because long-term risks, such as endocarditis and re-intervention for prosthetic valve failure, need to be taken into account.
ESC Guidelines
609


<!-- PAGE 48 -->

### Page 48

....................................................................
static sports. Patients with severe PS should be restricted to lowintensity sports.
• Pregnancy: well tolerated unless the RVOTO is extremely severe or unless RV failure is a major issue. Transcatheter balloon valvotomy can be performed during pregnancy but is rarely necessary (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.9 Ebstein anomaly
4.9.1
Introduction and background
Ebstein anomaly is characterized by abnormally formed and apically displaced leaflets of the TV. The anterior leaflet usually originates at the annular level but is enlarged and sail-like, while the septal and posterior leaflets are displaced towards the RV apex and often tethered to the endocardium.
The apical displacement of the TV means that the right heart consists of a morphological RA, an atrialized portion of the RV, and the remaining functional RV; the TV is often regurgitant.
The most frequently associated anomalies include a shunt at the atrial level [secundum ASD or patent foramen ovale (PFO)] and
(concealed) accessory pathways, including Mahaim-type pathways.
Multiple accessory pathways in conjunction with AT and AF are associated with SCD. Ebstein-like anomaly of the systemic TV is present in one-third of ccTGA.
Haemodynamic changes depend on the severity of the TV dysfunction, the degree of atrialization of the RV, contractility of the remaining functional RV and the systemic ventricle, type and severity of concomitant anomalies, and arrhythmias.
The pathophysiology is characterized by systolic regurgitation of blood from the functional RV, across the TV, and into the atrialized ventricle or RA, which tend to dilate. An interatrial connection permits a LR shunt or, especially during exercise, a RL shunt.
Ebstein anomaly may result in a chronically low systemic cardiac output.
4.9.2
Clinical presentation and natural history
The clinical presentation ranges from trivial symptoms to the presentation of a profound cyanotic heart defect. Patients with mild forms can be asymptomatic over decades until they are diagnosed. Typical complications include high-grade TR, RV dysfunction, RV failure, liver cirrhosis, cerebral abscesses, paradoxical embolism, pulmonary embolism, tachyarrhythmias, SCD, and IE. Key symptoms are arrhythmias [atrioventricular reentrant tachycardia (AVRT) is most
©ESC 2020
Figure 7 Management of right ventricular outflow tract obstruction.
ASD = atrial septal defect; PS = pulmonary stenosis; RL = right-to-left; RV = right ventricle/ventricular; RVOTO = right ventricular outflow tract obstruction; RVSP = right ventricular systolic pressure; TR = tricuspid regurgitation; VSD = ventricular septal defect.
aIn peripheral PS, regardless of symptoms, catheter interventional treatment should be considered if >50% diameter narrowing and RVSP >50 mmHg and/
or related reduced lung perfusion is present.
bIn valvular PS, balloon valvuloplasty is the intervention of choice if anatomically suitable.


<!-- PAGE 49 -->

### Page 49

.......................................
common], dyspnoea, fatigue, poor exercise tolerance, chest pain, and peripheral and/or central cyanosis.
4.9.3
Diagnostic work-up
See section 3.3 for general principles.
Clinical findings may include cyanosis and hepatomegaly.
Auscultation findings include a widely split first sound and second sound, serial clicks, third and fourth sound, and a systolic murmur from TR. ECG may show RA hypertrophy, a prolonged PR
interval, right bundle branch block (often with a splintered QRS complex), deep Q in II, III, aVF, and V1V4, pre-excitation, low voltage,
multiple pathways (AVRT), and supraventricular and ventricular arrhythmias.
• Chest X-ray is helpful to follow changes in the heart’s size.
• Echocardiography provides information on: anatomy and function of the TV; apical distal displacement of the septal or posterior leaflet (in adults >_0.8 cm/m2 BSA); size of the anterior leaflet;
tethering of the septal or posterior TV leaflet on the septum or ventricular wall; size and function of the different cardiac sections
(RA, atrialized ventricle, remaining functional RV, and LV); and
RVOTO and associated lesions.
• CMR has value with regards to prognostication225, and for evaluation before and after surgery, as it offers unrestricted views for assessment and quantification of the dilated right heart, RV function, and TV function.
4.9.4
Surgical/catheter interventional treatment
Clinical symptoms determine the treatment. Conservative therapy can alleviate symptoms temporarily and create a beneficial basis for the following operation.226 Oral anticoagulation is recommended for patients with a history of paradoxical embolism or AF. In the presence of an increased thromboembolic risk or a RL shunt, oral anticoagulation may be considered. Symptomatic rhythm disorders can be treated conservatively or, preferably, with EP intervention.227 Transcatheter access to right-sided accessory pathways and the slow pathway in AV
node reentry may be hindered by TV surgery, such that it may be reasonable to assess for arrhythmia substrates and proceed with catheter ablation, if identified, before surgery. Occasionally, there may be an indication to close the atrial communication in isolation. However, this needs to be discussed carefully, as it may lead to a further increase in right heart pressures and a decrease in systemic cardiac output.
Surgical repair remains challenging and should only be performed by surgeons with specific experience in this lesion. TV repair, if feasible, is preferred over TV replacement (with closure of an associated interatrial communication). If the RV is too small for repair or RV dysfunction has developed, an additional bidirectional cavopulmonary (Glenn)
anastomosis may be considered in adults with preserved LV function when LA pressure and LV end diastolic pressure are not elevated.228
In patients with failed repair, or in severe biventricular dysfunction,
heart transplantation may be the only option.
The previously high operative mortality (>25%) has fallen to <6%
in specialized centres. Over 90% of patients operated on by an experienced surgeon survive >10 years, many in functional class I or II.
Late fatalities are probably due to arrhythmias. In a large series, survival free of late reoperation was 86%, 74%, 62%, and 46% at 5, 10,
15, and 20 years, respectively.229
4.9.5
Follow-up recommendations
Regular follow-up (at least yearly) is required in all patients in specialized ACHD centres. Typical post-operative residual anomalies to look for are persisting or new TR, the usual complications after valve replacement, failure of RV or LV, residual atrial shunts, arrhythmias,
and higher-grade AV blocks.
Reintervention may become necessary for recurrent TR and failure of prosthetic valves.
4.9.6
Additional considerations
• Exercise/sports: patients without residual anomalies can usually lead normally active lives without restriction, except for extensive static
Recommendations for intervention in Ebstein anomaly
Recommendations
Classa
Levelb
Indications for surgery
Surgical repair is recommended in patients with severe TR and symptoms or objective deterioration of exercise capacity.
I
C
It is recommended that surgical repair is performed by a congenital surgeon with speciﬁc experience in Ebstein surgery.
I
C
If there is an indication for TV surgery, ASD/
PFO closure is recommended at the time of valve repair if it is expected to be haemodynamically tolerated.
I
C
Surgical repair should be considered regardless of symptoms in patients with progressive right heart dilation or reduction of RV systolic function.
IIa
C
Indications for catheter intervention
In patients with symptomatic arrhythmias, or pre-excitation on the ECG, electrophysiologic testing followed by ablation therapy, if feasible,
or surgical treatment of the arrhythmias in the case of planned heart surgery is recommended.
I
C
In the case of documented systemic embolism,
probably caused by paradoxical embolism, isolated device closure of ASD/PFO should be considered but requires careful evaluation before intervention to exclude induction of RA pressure increase or fall in cardiac output.
IIa
C
If cyanosis (oxygen saturation at rest <90%) is the leading problem, isolated device closure of
ASD/PFO may be considered but requires careful evaluation before intervention to exclude induction of RA pressure increase or fall in cardiac output.
IIb
C
ASD = atrial septal defect; ECG = electrocardiogram; PFO = patent foramen ovale; RA = right atrium/atrial; RV = right ventricle/ventricular; TR = tricuspid regurgitation; TV = tricuspid valve.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
611


<!-- PAGE 50 -->

### Page 50

.............................................................................................................................................................................
sports. Patients with more than mild TR, ventricular dysfunction,
shunting, arrhythmias, or other complications should avoid heavy isometric exercises, in proportion to the severity of their problems.
• Pregnancy: asymptomatic females with good ventricular function may tolerate pregnancy well. There is a certain risk of RV failure,
arrhythmia, and paradoxical embolism. Pregnancy will be of higher risk in the presence of significant cyanosis, serious arrhythmia, and right heart failure (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.10 Tetralogy of Fallot
4.10.1
Introduction and background
TOF is characterized by the following four features: a nonrestrictive VSD; overriding aorta (but <50%); infundibular, valvular, supravalvular RVOTO and/or branch PA stenosis; and consequent RV hypertrophy (RVH). TOF populations can be subdivided into syndromic patients (20%, such as: microdeletion 22q11,
trisomy 21, Alagille, Noonan, Williams, and Klippel Feil) and nonsyndromic patients (which represent the vast majority).230 The standardized mortality rate among patients with repaired TOF is almost twice as high as among patients with simple defects (ASD
and VSD).231
4.10.2
Clinical presentation and natural history
Surgical repair of TOF has evolved over time, with relief of the
RVOTO usually involving infundibulotomy, resection of obstructive muscle bundles, and the use of a patch to enlarge the pathway from the RV to the PAs. In some patients, a palliative shunt procedure  in order to increase pulmonary blood flow  has been performed before repair. Common complications in adulthood are:
• PR: significant PR is almost always encountered following a transannular patch repair. PR is usually well tolerated for years. Severe chronic PR, however, eventually leads to symptomatic RV dilation and dysfunction.232 The severity of PR and its deleterious long-term effects are augmented by co-existing distal PA stenoses or PAH.
• Residual RVOTO can occur at the infundibulum, at the level of the pulmonary valve and main pulmonary trunk, and into the branches of the left and right PA. Elevated RV pressure and RVH have been described as independent risk factors for poor outcome and a decreased exercise performance, despite smaller RV volumes233.
• Residual VSD can be due to partial patch dehiscence or failure of complete closure at the time of surgery; it may lead to LV volume overload.
• Aortic complications may occur many years after the initial surgical repair and include progressive aortic dilation and AR (rarely aortic dissection). The underlying mechanism is incompletely understood, and may include ascending aorta dilation, abnormal aortic elasticity, or type of surgical repair234.
• RV and LV dysfunction/heart failure: RV dilation is usually due to residual longstanding free PR ± RVOTO. Significant TR may occur as a consequence of RV dilation, which begets more RV
dilation. LV dilatation may result from longstanding palliative arterial shunts, residual VSDs, and/or AR. Both RV and LV dysfunction may be due to longstanding cyanosis before repair and/or inadequate myocardial protection during repair,
adverse ventricularventricular interactions, electromechanical dyssynchrony,235,236 and coronary artery abnormalities. A reduced LV
free wall longitudinal strain has been reported despite preserved
LVEF.237 The incidence of clinical heart failure, with its typical signs and symptoms,
increases significantly with age.238
Underlying mechanisms may also be: damage to myocardium,
sequelae from surgical repair strategies, or electrical conduction abnormalities. Management strategies effective in acquired heart disease are frequently applied in these patients, although its effectiveness for RV failure remains uncertain.239
• Atrial/ventricular arrhythmias and SCD: arrhythmias and sudden death are important late complications. The estimated lifetime prevalence of atrial arrhythmias is 20%. IART involving the cavotricuspid isthmus and RA incision are related to RA
enlargement, whereas AF is facilitated by LA dilatation.
Ventricular arrythmias encompass polymorphic VT/VF, typically related to severely impaired RV and LV function, and monomorphic sustained VT, which are particularly relevant in rTOF.34 Although both polymorphic VT/VF and monomorphic VT can lead to SCD, with a reported frequency of
13.5% in retrospective studies,32 the different underlying ventricular arrhythmia substrates need to be recognized for risk stratification and treatment. LV systolic or diastolic dysfunction, and ventricular and atrial tachyarrhythmias are predictive of death and sustained VT in adults with rTOF.240
Possible risk factors associated with any ventricular arrhythmia and SCD in rTOF are QRS duration >_180 ms, LV systolic or diastolic dysfunction, and inducible VT at EP testing. Older age at PVRep and pre-PVRep RVH and dysfunction may be predictive of shorter time to post-operative death and sustained ventricular arrhythmia.241 The dominant substrates for monomorphic VT are anatomically defined isthmuses, bordered by unexcitable tissue. Isthmus dimension and conduction properties can be evaluated by catheter mapping and likely determine susceptibility to arrhythmias. Targeting the anatomical isthmuses by catheter ablation has been highly effective to control VT.242 Whether catheter mapping can contribute to individualized risk stratification requires further investigation.
• Endocarditis can be encountered after both surgical and percutaneous PVRep. Valve-containing prosthetics are an important independent risk factor for IE in the short- and long-term after implantation, whereas non-valve-containing prosthetics are a risk factor only during the first 6 months after implantation.76
A schematic overview of long-term complications after repair of
TOF is provided in Figure 8.
4.10.3
Diagnostic work-up of repaired patients
See section 3.3 for general principles.
• Clinical findings mostly include a wide split in the second heart sound. A low-pitched early ending diastolic murmur suggests severe PR. A long, loud ejection systolic murmur indicates
RVOTO, a high-pitched diastolic murmur indicates AR, and a pansystolic murmur indicates a residual VSD.


<!-- PAGE 51 -->

### Page 51

..............................................................................
• ECG often shows complete right bundle branch block dependent on the surgical approach. The QRS width may also be influenced by the degree of RV dilation.
• Echocardiography provides assessment of residual RVOTO and
PR, residual VSD, RV and LV size and function,241 TR, RV pressure, aortic root size, and AR. Strain measurements are helpful in quantifying the degree of electromechanical dyssychrony.243
• CMR is the method of choice for assessment of RV volume and function; PR; size, shape, and expansion of the PAs; infundibulum;
the ascending aorta; the position of great vessels or conduits in relation to the sternum (resternotomy); and evaluation for residual shunt (Qp:Qs). Late gadolinium enhancement demonstrates fibrosis, the extent of which relates to other risk factors for VT
and SCD.244 T1 mapping may have an emerging role.
• CCT provides information on coronary arteries (particularly important for the assessment of the spatial relationship with the RVOT
prior to TPVI or surgery), the extent of conduit calcification (percutaneous valve anchoring), and the presence of major aortic pulmonary collaterals (MAPCAs). CCT may also be considered as an alternative for RV quantification in patients unable to undergo CMR.
• CPET assists timing of reintervention and provides prognostic information.23
• Holter monitoring, event recorder, and EP evaluation are required for selected patients (high risk, suspected or clinical arrhythmia, and/or before RVOT reoperation). Inducible sustained VT carries prognostic value for clinical VT and SCD.245
• Cardiac catheterization should be restricted to patients undergoing catheter-based interventions (i.e. relief of distal PA stenosis,
transcatheter valve implantation) and when non-invasive evaluation is inconclusive. Before surgery, coronary angiography may visualize the coronary arteries, which is important to assess the spatial relationship with the RVOT prior to TPVI.
4.10.4
Late surgical/catheter interventional treatment
PVRep and/or relief of RVOTO can be performed with low mortality risk in patients without heart failure and/or advanced ventricular dysfunction.246 PR is the most frequent reason for consideration of surgery. Optimal timing remains challenging.
Longitudinal data are more important than single measurements to assist timing for reintervention.247 Normalization of RV size after reintervention becomes unlikely as soon as the end systolic index exceeds 80 mL/m2 and the end diastolic volume index exceeds 160 mL/m2,248250 but this cut-off for reintervention may not correlate with clinical benefit. A recent meta-analysis demonstrated that PVRep can improve symptoms and reduce RV volume, but a survival benefit still needs to be shown.251
Distal PA stenosis must be addressed, either at the time of surgery
(including intra-operative stenting) or with a percutaneous approach.
A biological pulmonary valve (xenograft or homograft) seems to have a mean lifespan of 1020 years,248,252,253 and future replacement could be performed by transcatheter valve-in-valve
©ESC 2020
Figure 8 Management of repaired tetralogy of Fallot: long-term complications to address during follow-up.
Ao = aorta; LV = left ventricle; RV = right ventricle; PA = Pulmonary artery; TV = tricuspid valve; RA = right atrium; RV = right ventricular; LA = left atrium;
PA = pulmonary artery; PS = pulmonary stenosis; SCD = sudden cardiac death; VSD = ventricular septal defect.
ESC Guidelines
613


<!-- PAGE 52 -->

### Page 52

..............................
procedures. There is little experience with mechanical valves in this setting and there is concern about adequate anticoagulation.
Indications for TV annuloplasty, closure of residual VSDs, and/or aortic root dilation/AR surgery should also be addressed at the time of surgery. The indication for aortic root surgery does not differ from the general population.254
TPVI techniques have become an alternative to open heart surgery primarily in patients with RVOT conduit stenosis/regurgitation, but also in selected patients with native RVOT regurgitation/stenosis.
TPVI, when technically feasible, provides outcomes comparable to surgical PVRep and is intended to extend the lifetime of a conduit,
hence reducing the number of reoperations during a patient’s lifetime.255 Stent fracture  the initially most common complication 
has become less of a problem with careful preparation of the ‘landing zone’ using additional stents. Best long-term results were reported when a residual gradient of <15 mmHg could be achieved.256
Uncommon complications, occurring in <2% of patients, include conduit rupture and coronary artery compression. The risk of endocarditis after TPVI remains a concern with an annual incidence rate of
23%.257,258 Since coronary artery compression may be lifethreatening, a balloon test to exclude potential coronary artery compression must be performed prior to TPVI, although this test carries a risk for conduit rupture. In case of severe circumscript conduit calcification, TPVI should only be performed if a CCT scan shows sufficient distance between the conduit and the coronary arteries. The strong link between slowly conducting anatomical isthmuses and sustained monomorphic VT, and the potential loss of accessibility to the anatomical isthmus by catheter ablation after surgical PVRep or after transcutaneous insertion of valves in patch augmented RVOTs, has important implications for patients who undergo reinterventions.259
Whether pre-interventional mapping and preventive ablation of slowly conducting anatomical isthmuses before or during intervention in patients without documented spontaneous sustained VT is beneficial is under investigation.
4.10.5
Indications for electrophysiological testing and implantable cardioverter defibrillator
An ICD should be implanted for secondary prevention of SCD
(patients with cardiac arrest or sustained VT) (IC recommendation).
ICD implantation for primary prevention remains controversial, and no ideal risk stratification scheme has so far been developed. Patients with unexplained syncope and impaired ventricular function or other risk factors for SCD should undergo haemodynamic and EP evaluation. In the absence of a reversible cause, ICD implantation should be considered (see section 3.4.2).260,261
Recommendations for intervention after repair of tetralogy of Fallot
Recommendations
Classa
Levelb
PVRep is recommended in symptomatic patients with severe PRc and/or at least moderate
RVOTO.d
I
C
In patients with no native outﬂow tract,e catheter intervention (TPVI) should be preferred if anatomically feasible.
I
C
PVRep should be considered in asymptomatic patients with severe PR and/or RVOTO when one of the following criteria is present.
• Decrease in objective exercise capacity.
• Progressive RV dilation to RVESVi >_80 mL/
m2, and/or RVEDVi >_160 mL/m2 f, and/or progression of TR to at least moderate.
• Progressive RV systolic dysfunction.
• RVOTO with RVSP >80 mmHg.
IIa
C
Continued
VSD closure should be considered in patients with residual VSD and signiﬁcant LV volume overload or if the patient is undergoing pulmonary valve surgery.
IIa
C
In patients with sustained VT who are undergoing surgical PVRep or transcutaneous valve insertion, pre-operative catheter mapping and transsection of VT-related anatomical isthmuses before or during the intervention should be considered.
IIa
C
Electrophysiologic evaluation, including programmed electrical stimulation, should be considered for risk stratiﬁcation for SCD in patients with additional risk factors (LV/RV dysfunction;
non-sustained, symptomatic VT; QRS duration
>_180 ms, extensive RV scarring on CMR).
IIa
C
ICD implantation should be considered in selected TOF patients with multiple risk factors for SCD, including LV dysfunction, non-sustained, symptomatic VT, QRS duration >_180
ms, extensive RV scarring on CMR, or inducible
VT at programmed electrical stimulation.
IIa
C
Catheter ablation or concomitant surgical ablation for symptomatic monomorphic sustained
VT may be considered in those with a preserved biventricular function as an alternative to ICD
therapy, provided that the procedure is performed in highly experienced centres and that established ablation endpoints have been reached (e.g. non-inducibility, conduction block across ablation lines).
IIb
C
CMR = cardiovascular magnetic resonance; ICD = implantable cardioverter deﬁbrillator; LV = left ventricle/ventricular; PR = pulmonary regurgitation; PVRep
= pulmonary valve replacement; RV = right ventricle/ventricular; RVESVi = right ventricular end systolic volume indexed; RVEDVi = right ventricular end diastolic volume indexed; RVOT = right ventricular outﬂow tract; RVOTO = right ventricular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; SCD =
sudden cardiac death; TOF = tetralogy of Fallot; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgitation; VSD = ventricular septal defect;
VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cRegurgitant fraction by CMR >3040%.
dPeak velocity >3 m/s.
ePatients with previous RVOT surgery using homografts, bovine jugular vein grafts, bioprostheses/conduits.
fConﬁrmed by repeated measurements.


<!-- PAGE 53 -->

### Page 53

....................................................................................................................................................................
4.10.6
Follow-up recommendations
All patients with TOF should have periodic cardiac follow-up in a specialized ACHD centre, which  in most patients  should be done annually. Follow-up evaluation needs to look for the complications listed in section 4.10.2. All patients should have CMR at regular intervals, dependent on the pathology found.
4.10.7
Additional considerations
• Exercise/sports: there are no restrictions in asymptomatic repaired patients with good haemodynamics. Patients at high risk for clinical arrhythmia/SCD, patients with advanced biventricular dysfunction, and patients with marked ascending aortopathy should be limited to low-intensity activity/sports and avoid isometric exercise.
• Pregnancy: in unrepaired patients constitutes a considerable risk of maternal and foetal complications and death. The risk of pregnancy in repaired patients depends on their haemodynamic status (low in patients with good haemodynamics). In patients with significant residual lesions, there is a risk of arrhythmia and right heart failure. Pregnancy is unlikely to have an adverse long-term effect on cardiovascular function262 (see section 3.5.7).
• IE prophylaxis: recommended only for high-risk patients (see section 3.4.6).
4.11 Pulmonary atresia with ventricular septal defect
4.11.1
Introduction and background
Adult patients with pulmonary atresia with VSD are a heterogeneous population in terms of underlying anatomy, physiology, and previous interventions. Pulmonary atresia þ VSD patients share the intracardiac anatomy of TOF but lack a direct communication between the
RV and PAs. Microdeletion 22q11.2 is common (facial anomalies,
nasal speech, and developmental delay).263 PA supply varies in pulmonary atresia þ VSD, and determines both clinical presentation and management (the complexity of the pulmonary vascular bed may make repair unattractive or impossible).
Patients with discordant cardiac connections and/or a single ventricle physiology and their management will be discussed in the appropriate sections.
There are three patterns of PAs:
• Unifocal with confluent, good-sized PAs supplied by a PDA.
• Multifocal, with confluent but hypoplastic PAs (‘seagull’ appearance) supplied by multiple MAPCAs.
• Multifocal with non-confluent or absent PAs supplied by
MAPCAs.
Surgical management is a heavily debated topic due to the lack of consensus on the optimal treatment.
Patients with confluent, good-sized PAs and a pulmonary trunk
(usually with valvular atresia) are suitable for a Fallot-like repair using a transannular patch. Patients with good-sized PAs but without a pulmonary trunk should undergo repair with a RVPA conduit. Patients with confluent but hypoplastic PAs often require an arterial shunt or reconstruction of the RVOT (without VSD closure), which may enhance PA growth, and then be reviewed at a later stage for repair using a valved conduit. Patients with non-confluent PAs with adequate, but not excessive, pulmonary blood flow in infancy can survive into adulthood without surgery. There are proponents of a staged unifocalization approach for this latter challenging group of infants, ultimately aiming for a conduit repair.264
4.11.2
Clinical presentation and natural history
At adult age, clinical presentation for repaired patients is similar to those with TOF (see sections 4.10 and 4.14). Unrepaired patients present with exertional dyspnoea, fatigue, and progressive chronic cyanosis, due to decreased pulmonary blood flow from collateral stenosis, PA stenosis, increased PVR, or increasing ventricular end diastolic pressures.265 Cyanosis will eventually lead to multiorgan involvement (see section 3.4.8). A number of complications may occur in unrepaired patients:
• Haemoptysis may be due to rupture of usually small collateral vessels and/or small PA thrombosis.
• Chronic heart failure is usually multifactorial and may be due to chronic cyanosis, early excessive pulmonary blood flow,
increased PVR, RV dysfunction, AR, and other causes.
• Progressive dilation of the ascending aorta with increasing AR
(rarely aortic dissection).
• Endocarditis can be particularly compromising in patients with limited cardiovascular reserve and those with significant cyanosis.
• Arrhythmia and SCD are not uncommon.
• Segmental PAH.46
4.11.3
Diagnostic work-up
See section 3.3 for general principles.
• Clinical findings: cyanosis in unrepaired patients may be profound,
even with minimal physical effort. Continuous murmurs at the back suggest MAPCAs. ECG findings include right-axis deviation and RVH. Chest X-ray may show a boot-shaped cardiac contour
(‘empty PA bay’) with abnormal, decreased pulmonary vascularity (alternating with some areas of increased vascularity through large MAPCAs).
• Echocardiography: findings in repaired patients depend on the type of repair (see sections 4.10 and 4.14). For unrepaired patients, absence of direct flow from the RV to PA, with continuous flow on multiple sites on colour Doppler from the MAPCAs,
may be seen. 3D echocardiography can further aid in delineating anatomic pathology and biventricular size and function. TOE is useful in certain patients to evaluate valve anatomy when transthoracic imaging is challenging or when IE is suspected.266
• CMR, CCT, and cardiac catheterization are required to determine sources of pulmonary blood supply and size of PAs, to assess MAPCAs, and obtain haemodynamics. In repaired patients,
CMR is used for requirements similar to patients with TOF [for
RV volumes and function, PR, size, shape, and expansion of the
PAs, and the size of the ascending aorta, and for residual shunt
(Qp:Qs)]. 3D rotational angiography and 3D overlay imaging, as
ESC Guidelines
615


<!-- PAGE 54 -->

### Page 54

......................................................................................................................................................................
well as X-ray and magnetic resonance imaging fusion, aid in precision assessment.267
4.11.4
Surgical/catheter interventional treatment
For follow-up and intervention in patients with Fallot-like repair with transannular patch, see section 4.10; for patients with repair using a valved RVPA conduit, see section 4.14.
Patients with pulmonary atresia þ VSD surviving unrepaired to adulthood, or with previous palliative procedures, may actually benefit from modern surgical or interventional procedures.268,269 Patients with good-sized confluent PAs and those with large MAPCAs anatomically suitable for unifocalization, who have not developed severe
PVD due to protecting stenosis, should be considered for surgery.
Many unrepaired patients may, however, not be suitable for further surgery, mainly because of the complexity of their pulmonary vasculature. It is important to appreciate that while cardiac surgery may improve clinical status or prognosis (the latter is purely speculative),
it is also a major cause of mortality.
Catheter intervention may include balloon dilation/stenting of collateral vessels to enhance pulmonary blood flow.270 On the other hand, patients with severe haemoptysis may require coiling of ruptured collateral vessels.
Survival depends on the complexity of the pulmonary malformations and the results of surgical repair. Survival in palliated patients is significantly lower and has been reported as 60% at 20-year followup. Heart-lung transplantation could possibly be an option for highly selected individuals.
4.11.5
Follow-up recommendations
Patients with pulmonary atresia þ VSD should have periodic followup in a specialized ACHD centre (at least once a year). For the management of cyanosis-related multiorgan involvement, see section
3.4.8.
Patients with segmental PAH may be considered for targeted PAH
therapy; see section 3.4.3.271,272
Symptoms such as dyspnoea, increasing cyanosis, change in the shunt murmur, heart failure, or arrhythmias warrant special attention and should necessitate an earlier review and assessment for intervention.
4.11.6
Additional considerations
• Exercise/sports: those with excellent haemodynamics should be encouraged to exercise regularly, avoiding only extreme isometric exercise. Those with less optimal haemodynamics will be more functionally limited. Extremes of exertion should be avoided, but regular low-intensity physical activity (walking, swimming, even cycling) should be encouraged.
• Pregnancy: the risk of pregnancy in repaired patients with good haemodynamics and no history of arrhythmias is low. The risk increases with hypoxaemia, PAH, ventricular dysfunction, heart failure symptoms, and arrhythmias (see section 3.5.7). As microdeletion 22q11 is fairly common with this defect, patients should be checked before pregnancy.
• IE prophylaxis: recommended only for high-risk patients (including all unrepaired patients; see section 3.4.6).
4.12 Transposition of the great arteries
4.12.1
Introduction and background
TGA is characterized by AV concordance and ventriculo-arterial discordance: the aorta originates from the RV, the PA from the LV.
TGA is called simple in the absence of associated congenital anomalies; TGA is called complex in the presence of associated anomalies:
VSD (45%), LVOTO (25%), and CoA (5%). Long-term outcome of complex TGA is, regardless of the type of surgical repair,
worse than that of simple TGA.
The aetiology of TGA is unknown and the pathogenesis is controversial. Familial occurrence exists but is very rare. There is a 2:1 male preponderance.
Natural history is extremely poor and survival to adult life without surgical repair is the exception. Surgical techniques have evolved:
atrial switch transitioned to arterial switch procedure, and complex
TGAs are often operated upon using a Rastelli-type repair.
A schematic overview of surgical techniques and their long-term complications in TGA is provided in Figure 9.
4.12.2
Atrial switch operation
4.12.2.1 Clinical presentation after atrial switch
Older adults with a simple TGA have a Mustard or Senning atrial switch procedure. The most common complications are:
• Systemic RV dysfunction and failure.
• Secondary progressive TR (systemic AV valve).
• Bradycardia and chronotropic incompetence due to loss of sinus rhythm; AV conduction is usually intact.
• Supraventricular tachyarrhythmia,
typically cavotricuspid isthmus-dependent flutter, followed by macro-reentry circuit related to surgical incisions/scars; AF may occur at older age.
High heart rates are often haemodynamically poorly tolerated because of the inability to increase preload, a consequence of the
(restrictive) atrial baffles. Bradycardia due to SND can promote
AT.
• Ventricular tachyarrhythmias: primary polymorphic VT or VF
due to poor ventricular function and heart failure-related mechanism, or monomorphic VT due to scar/incision/patch-related reentry in repaired complex TGA; secondary VT or VF, preceded by supraventricular tachycardia (SVT) with rapid conduction and consecutive myocardial ischaemia due to the very low stroke volume associated with the SVT.
• Baffle stenosis, either superior baffle (most common) or inferior baffle obstruction.
• Baffle leakage, with either LR shunt giving rise to pulmonary overflow or RL shunting in the presence of distal flow obstruction, with cyanosis or paradoxical embolism.
• Pulmonary veins/venous atrial obstruction, most often at the site where the pulmonary veins connect to the pulmonary venous atrium/RA.


<!-- PAGE 55 -->

### Page 55

©ESC 2020
Figure 9 Management of transposition of the great arteries: long-term complications to address during follow-up.
Ao = aorta; AV = atrioventricular; IVC = inferior caval vein; LA = left atrium; LV = left ventricle; LVOT = left ventricular (subpulmonary) outflow tract; PS
= pulmonary stenosis (supravalvular/pulmonary artery branch); PV = pulmonary vein; PVA = pulmonary venous atrium; RA = right atrium; RV = right ventricle; SCD = sudden cardiac death; SN-dysf. = sinus node dysfunction; SVA = systemic venous atrium; SVC = superior vena cava; TV = tricuspid valve.
ESC Guidelines
617


<!-- PAGE 56 -->

### Page 56

........................................................................................................................................................................
• LVOTO can develop due to bulging of the interventricular septum towards the low-pressure subpulmonic LV, frequently associated with systolic anterior motion of the mitral valve.
• PH can become manifest, sometimes decades after the atrial switch procedure; it is usually post-capillary273 but PAH may be present too.
• Death due to heart failure or sudden death, probably caused by arrhythmia.
In larger series with follow-up of up to 40 years, survival is
6075%.274,275 Event-free survival is as low as 20%.276,277 Exercise capacity is usually reduced by inadequate increase in cardiac output:
chronotropic incompetence, reduced preload resulting from the relatively narrowed and/or non-compliant baffles  inherent to the atrial switch operation  and diminished RV function.
4.12.2.2 Diagnostic work-up
See section 3.3 for general principles.
Clinical evaluation must include looking for signs of venous congestion. A swollen head and neck are a sign of superior baffle obstruction. Oedema of the legs, varices, hepatomegaly, and liver cirrhosis are seen in inferior baffle obstruction. Stenosis, even complete obstruction, can be asymptomatic due to an effective bypass circulation provided by the azygos or hemiazygos vein.
An ejection-type systolic murmur suggests subpulmonary outflow tract obstruction, and a systolic regurgitant-type murmur suggests regurgitation of the systemic TV. ECG findings include RVH
and, not uncommonly, narrow QRS escape rhythm, without visible P
waves.
• Echocardiography is the first-line diagnostic modality, providing information on size and systolic function of the subpulmonic and systemic ventricles, subpulmonary outflow tract obstruction, TR,
leakage or obstruction of the atrial baffles, and assessment of pulmonary venous return. Signs of PH are often subtle  decreased flattening of the interventricular septum in systole and an abnormally wide PA  and can be difficult to recognize. Suspicion of
PH dictates diagnostic heart catheterization to exclude/confirm
PH as it may impact management. Contrast echocardiography can demonstrate baffle leakage  present in up to 50% in nonselected and asymptomatic patients  or baffle obstruction.278
Injection of contrast into the upper limbs frequently misses a leak in the inferior systemic venous baffle; this can only be excluded by injection into one of the femoral veins. TOE is useful for evaluation of baffles.
• CMR provides more reliable and more robust quantitative assessment of systemic RV systolic function than echocardiography, and of patency of the atrial baffles. Size of the great arteries can be measured reliably; an abnormally wide PA and/or large subpulmonary LV may indicate PH. Shunt related to baffle leak can be quantified (Qp:Qs). Small baffle leaks not leading to a relevant shunt are difficult to detect with CMR (contrast echocardiography is superior). Late gadolinium enhancement in the systemic RV predicts clinical outcome.279
• Exclusion of superior baffle stenosis or baffle leak (and treatment) is essential before PM/ICD implantation or placing new/
additional pacemaker wires through the superior baffle. An alternative to CMR and CCT for assessment of the superior baffle is contrast injection in the right arm and fluoroscopy.
• CPET is important in longitudinal follow-up for serial assessment of exercise capacity and chronotropic incompetence. It also can
‘unmask’ baffle leakage (desaturation) that is asymptomatic at rest.
• Holter monitoring, event recorder, and EP testing are indicated for selected patients if bradycardia and/or tachyarrhythmias are suspected.
• Cardiac catheterization is indicated when non-invasive assessment is inconclusive or when suspicion of PH requires evaluation
(see section 3.3.5).
4.12.2.3 Medical treatment
• Systemic RV systolic dysfunction: there are no data to support the hypothesis that ACE inhibitors, ARBs, beta blockers, or aldosterone antagonists  alone or in combination  improve outcome.280 No solid recommendation can currently be made.
• Systemic RV failure: in the case of overt heart failure, diuretics relieve symptoms. Although no benefit has been demonstrated for conventional heart failure medical therapy in patients with systemic RVs, more symptomatic patients may benefit from prescription of ‘classical’ heart failure medication.
• Arrhythmia: drugs that lower heart rate should be used with caution, since after atrial switch, patients are prone to bradycardia and SND.
• PH: the exact mechanism of PH must be elucidated before consideration of medical treatment. Post-capillary PH late after atrial switch operation seems to be most common, with the consequence that specific pulmonary vasodilator therapy is contraindicated but pre-capillary PH may be present, too. Thus, careful haemodynamic evaluation is crucial.
4.12.2.4 Surgical/catheter interventional treatment
Electrophysiology testing, ablation, cardiac resynchronization therapy, and implantable cardioverter defibrillators.
General principles, also valid for patients with the atrial switch procedure, are discussed in section 3.4.2.32,37
• EP studies and interventions are complicated because baffles interfere with normal access to the atria. The dominant mechanism of supraventricular arrhythmias is cavotricuspid isthmus atrial flutter, often requiring baffle puncture to achieve isthmus block. Alternatively, remote magnetic navigation can be used for retrograde access to the pulmonary venous atrium.
Conventional retrograde transaortic route access in adults is usually not successful to achieve isthmus block. TOE guidance is recommended when puncture of a baffle is indicated. Programmed electrical stimulation for risk stratification is not useful.
• Pacemakers: see section 3.4.2.
Indications for intervention are summarized in the
Recommendations for surgical and catheter intervention in TGA after atrial switch operation table.


<!-- PAGE 57 -->

### Page 57

.............................................................................................................................................................................
4.12.3
Arterial switch operation
4.12.3.1 Clinical presentation after arterial switch
Young adults with a simple TGA will probably have had an arterial switch operation. The most common complications are:
• Neo-aortic root dilatation, resulting in AR.
• Supravalvular PS and pulmonary branch stenosis (unilaterally or bilaterally), a consequence of the position of the pulmonary bifurcation anterior to the ascending aorta in the Lecompte technique and the dilatation of the neo-aortic root.
• LV dysfunction and ventricular arrhythmias are rare but may occur; both may be related to problems with the coronary arteries,281 which were reimplanted in the neo-aorta.
• Acute angle of the aortic arch, which may lead to functional obstruction and hypertension.
Survival up to 30 years is excellent (>90% of hospital survivors282)
and event-free survival is fair (6080%283285). A large majority of these patients are asymptomatic. As a rule, exercise capacity is mildly reduced, but it can be normal. The incidence of late coronary arteryrelated problems is reported to be very low,286,287 which makes it questionable whether routine screening of coronary arteries is justified.
4.12.3.2 Diagnostic work-up
See section 3.3 for general principles. Clinical findings of AR or PS may be present.
• Echocardiography is the key diagnostic modality, providing information on LV function (global and regional); stenosis at the arterial anastomotic sites, most commonly PS; neo-aortic valve regurgitation; dimension of the neo-aortic root and proximal ascending aorta; and the acute angulation of the aortic arch. RV
systolic function can be assessed and, if possible, peak RV systolic pressure (RVSP) should be measured (TR velocity). Due to its position: far anteriorly and just behind the sternum, echocardiographic visualization of the bifurcation and both branches is rarely possible.
• Stress echocardiography is used to assess stress-induced wallmotion abnormalities.
• CMR provides more reliable quantitative assessment of ventricular volumes, EF, and neo-aortic dilatation or regurgitation.
Pulmonary trunk and branches can be visualized, together with their relation to the (dilated) neo-aortic root. Flow distribution between left and right lung can be calculated. Stress CMR is an alternative technique to assess myocardial perfusion and possible coronary artery compromise, where clinically indicated.
• CCT is the preferred technique for non-invasive imaging of coronary arteries, including the ostia, when stenosis is suspected. The reported low incidence of coronary-related problems makes it questionable whether routine screening for coronary artery pathologies (with whatever modality) can be justified.286,287
• Nuclear techniques are no longer used as first-choice imaging modality but may still have a role if other techniques are not available or lead to inconclusive or contradictory results.
• Cardiac catheterization, including coronary angiography, is indicated in the case of LV dysfunction and suspicion of myocardial ischaemia. In the case of severe pulmonary branch stenosis and
Recommendations for intervention in transposition of the great arteries after atrial switch operation
Recommendations
Classa
Levelb
Indications for surgical intervention
In symptomatic patients with pulmonary venous atrium obstruction, surgical repair
(catheter intervention rarely possible) is recommended.
I
C
In symptomatic patients with bafﬂe stenosis not amenable to catheter intervention, surgical repair is recommended.
I
C
In symptomatic patients with bafﬂe leaks not amenable to catheter-based closure, surgical repair is recommended.
I
C
In patients with severe systemic (tricuspid) AV
valve regurgitation, without signiﬁcant ventricular systolic dysfunction (EF >40%), valve repair or replacement should be considered,
regardless of symptoms.
IIa
C
PA banding in adults, as LV training with subsequent arterial switch procedure, is not recommended.
III
C
Indications for catheter intervention
In symptomatic patients with bafﬂe stenosis,
stenting is recommended when technically feasible.
I
C
In symptomatic patients with bafﬂe leaks and cyanosis at rest or during exercise, or with strong suspicion of paradoxical emboli, stenting (covered) or device closure is recommended when technically feasible.
I
C
In patients with bafﬂe leaks and symptoms due to LR shunt, stenting (covered) or device closure is recommended when technically feasible.
I
C
In asymptomatic patients with bafﬂe leaks with substantial ventricular volume overload due to
LR shunt, stenting (covered) or device closure should be considered when technically feasible.
IIa
C
In patients with a bafﬂe leak who require a
PM/ICD, closure of the bafﬂe leak with a covered stent should be considered, when technically feasible, prior to insertion of transvenous leads.
IIa
C
In asymptomatic patients with bafﬂe stenosis,
stenting may be considered when technically feasible.
IIb
C
AV = atrioventricular; EF = ejection fraction; ICD = implantable cardioverter deﬁbrillator; LR = left-to-right; LV = left ventricle/ventricular; PA = pulmonary artery; PM = pacemaker.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
619


<!-- PAGE 58 -->

### Page 58

.............................................................................................................................................................................
inconclusive non-invasive assessment or suspected PAH, cardiac catheterization is indicated.
4.12.3.3 Surgical/catheter interventional treatment
Indications for intervention are summarized in the Recommendations for interventions in TGA after arterial switch operation table.
RVOTO can be subvalvular, valvular (both rare), or supravalvular
(most common). Indications for treatment are similar to those described in section 4.8, but different anatomies may require different approaches.
4.12.4
Rastelli-type operation
4.12.4.1 Clinical presentation after Rastelli-type repair
Adults with TGA, VSD, and PS (complex transposition) have often had a Rastelli-type repair. The VSD patch directs blood from the LV
to the aorta and the RV is connected to the PA with a valved conduit.
Variants of the Rastelli technique, sharing the same principle, are the re´paration a l’etage ventriculaire and Nikaidoh techniques.
Common complications are:
• Stenosis or regurgitation of the valved conduit between the RV
and the PA.
• LVOTO, i.e. obstruction of the flow from the LV to the aorta.
• Residual VSD.
• AR.
• LV dysfunction.
• Arrhythmias, both ventricular and supraventricular.
• Endocarditis of the valved conduit.
• Death, either sudden (arrhythmia) or due to heart failure.
The few long-term outcome studies report 20-year survival <60%
and 20-year event-free survival 2030%. Replacement of the conduit between the RV and PA is the most common indication for reoperation. Relief of LVOTO is the second most common, followed by closure of a residual VSD.288 Endocarditis of the valved conduit is relatively common.
Exercise capacity is mildly to substantially diminished. Repeat reintervention, surgical or percutaneous, is the fate of most patients with a Rastelli-type repair.
4.12.4.2 Diagnostic work-up
See section 3.3 for general principles.
Clinical findings may suggest conduit stenosis, residual VSD, TR,
mitral regurgitation, or AR.
• Echocardiography: the connection between the posteriorly positioned LV and the anteriorly positioned (due to the TGA) aortic valve, aortic valve function, and aortic root diameters should be assessed. The anatomy and function of the conduit between the
RV and the pulmonary trunk must be visualized and assessed with Doppler interrogation. RV pressure assessed with Doppler measurement of TR jet velocity is of particular importance because the Doppler technique often overestimates the pressure gradient across the RVPA conduit.
• CMR provides a more robust quantification of LV and RV volumes, aortic diameters, and EF. The RVPA conduit, often difficult to visualize by echocardiogram, and peripheral PAs can be readily seen and measured with CMR. In the presence of a residual VSD, Qp:Qs can be calculated.
• Cardiac catheterization may be required for haemodynamic assessment of conduit stenosis. Angiography can be helpful for assessing the level of stenosis and peripheral PA stenosis.
4.12.4.3 Surgical/catheter interventional treatment
For indications for treatment of conduit stenosis, see section 4.14.
If LR shunting through a residual VSD causes symptoms or substantial LV volume overload, surgical/catheter treatment should be performed (IC recommendation).
4.12.5
Follow-up recommendations (irrespective of type of repair)
All patients with TGA, regardless of the type of operation, should be seen at least annually in a specialized ACHD centre, with attention given to the specific issues previously described (see sections 4.12.2.1,
4.12.3.1 and 4.12.4.1).
4.12.6
Additional considerations (irrespective of type of repair)
• Exercise/pregnancy/IE prophylaxis: see sections 3.4.6, 3.5.5 and
3.5.7.
4.13 Congenitally corrected transposition of the great arteries
4.13.1
Introduction and background ccTGA, or discordant atrio-ventricular and ventriculo-arterial connections, is uncommon. The ventricles are inverted, with the aorta arising anteriorly from the RV (usually on the left side) and the PA
arising posteriorly from the LV (usually on the right side). The abnormal connections in ‘double’ discordance may be present in hearts
Recommendations for intervention in transposition of the great arteries after arterial switch operation
Recommendations
Classa
Levelb
Stenting or surgery (depending on substrate) is recommended for coronary artery stenosis causing ischaemia.
I
C
Neo-aortic root surgery should be considered when the neo-aortic root is >55 mm, providing average adult stature (for neo-aortic valve replacement for severe neo-aortic AR see valvular heart disease guidelines with special considerationsc).
IIa
C
Stenting should be considered for PA branch stenosis, regardless of symptoms, if >50% diameter narrowing and RVSP >50 mmHg and/or related reduced lung perfusion are present.
IIa
C
AR = aortic regurgitation; ESC = European Society of Cardiology; PA = pulmonary artery; RVSP = right ventricular systolic pressure.
aClass of recommendation.
bLevel of evidence.
cWhen applying the 2017 ESC/EACTS valvular heart disease Guidelines25 for the decision to operate, it has to be taken into account that this is a reoperation and technically more difﬁcult.


<!-- PAGE 59 -->

### Page 59

.....................................................................................................
with usual or mirror-image atrial arrangement. Abnormal base-apex orientation, especially dextrocardia (apex of the heart pointed to the right), is common (20%). Associated lesions are common (8090%):
VSD (70%), PS (40%), dysplastic systemic TV (e.g. Ebstein-like malformation).
The position of the AV node (sometimes multiple AV nodes), and the course of the bundle of His, are often abnormal and lead to AV
conduction abnormalities. The anterior and lateral displacement of a fragile His bundle is important to recognize during EP studies and catheter interventions.
4.13.2
Clinical presentation and natural history
The natural history and clinical presentation are determined by associated malformations. Patients with associated lesions reaching adulthood have either been operated upon [closure of VSD, relief of PS
or (rarely) TV repair or replacement] or have a balanced physiology.
Patients with isolated ccTGA rarely develop complications before adulthood.
Late complications are:
• Systemic RV dysfunction and failure.
• Progressive TR (systemic AV valve).
• LVOTO.
• Complete AV block (2% loss of AV conduction per year); it is more common after VSD repair and/or TV replacement and may occur during pregnancy.
• VTs (extremely rare).
Life expectancy is reduced: 50% of patients with associated lesions were alive at the age of 40 years; without associated lesions,
50% of patients were alive at the age of 60 years. Patients die from congestive heart failure or die suddenly, presumably due to VT/VF,
regardless of the presence of advanced heart failure.
4.13.3
Diagnostic work-up
See section 3.3 for general principles.
• Clinical findings may include murmurs of TR, VSD, and/or PS.
• ECG may reveal a prolonged PR interval or a complete heart block.
Early septal activation from right to left may cause deep Q waves in
II, III, aVF, and V1V3. Reversal of the normal precordial progression may be seen as a QR pattern in V1 and rS in V6. Wolff
ParkinsonWhite syndrome is present in 24% of patients.
• Chest X-ray may show an abnormally straight left heart border due to the leftward and anterior position of the ascending aorta,
dextroposition with apex to the right (20%), or mesocardia (relatively common).
• Echocardiography is the key diagnostic modality, demonstrating double discordance and identifying associated anomalies
(Ebstein-like malformation of the TV and TR, VSD, LVOTO, and
PS). Systolic RV and LV function and severity of TR can be qualitatively assessed.
• CMR provides intracardiac and great vessel anatomy and is indicated for quantification of ventricular volumes, mass, and EF,
especially since echocardiographic assessment of systolic function in systemic RVs is difficult and less reliable.
• Holter monitoring, event recorder, and EP testing may be indicated for detection of arrhythmias, progressive AV block, and for risk assessment for SCD.
• Cardiac catheterization is indicated when non-invasive assessment is inconclusive, or PH requires evaluation (see section
3.4.5).
4.13.4
Medical treatment
There are no data to support the hypothesis that
ACE
inhibitors, ARBs, beta blockers or aldosterone antagonists, alone or in combination, improve outcome.280 Routine prescription of these medications to prevent heart failure/improve outcome is not recommended.
• Diuretics may provide relief of symptoms if overt heart failure is present. Although there is no proven benefit from heart failure medical therapy, in terms of outcome in patients with systemic
RVs, ‘classical’ heart failure medications or ARBs may provide some benefit in more symptomatic patients.289 A systemic RV
morphology is not a contraindication for a ventricular assist device. The coarse trabecularization of the RV apex may deserve special consideration, since it may block the inflow cannula.
Selective myomectomy should be considered.
4.13.5
Surgical/catheter interventional treatment
Catheter intervention may be recommended for PA stenosis or conduit stenosis, which can be dilated or stented. However, a residual
LVOTO may have a beneficial effect on the dilated subaortic RV and subaortic AV (tricuspid) valve regurgitation because of the septal shift. If complete heart block occurs, AV sequential pacing is the standard. Fixation of the pacemaker wire in the smooth-walled LV is difficult and requires a screw-in electrode. There are some data suggesting that biventricular pacing with a second ventricular wire through the (normally connecting) coronary sinus behind the subaortic RV may lead to a better preservation of RV systolic function than LV pacing alone.290
Recommendations for intervention in congenitally corrected transposition of the great arteries
Recommendations
Classa
Levelb
In symptomatic patients with severe TR and preserved or mildly impaired systemic RV systolic function (EF >40%), TV replacement is indicated.
I
C
In asymptomatic patients with severe TR and progressive systemic RV dilatation and/or mildly impaired systemic RV systolic function (EF >40%),
TV replacement should be considered.
IIa
C
Biventricular pacing should be considered in case of complete AV block or >40% ventricular pacing requirement.
IIa
C
In symptomatic patients with severe TR and more than mildly reduced systemic RV systolic function
(EF <_40%), TV replacement may be considered.
IIb
C
AV = atrioventricular; EF = ejection fraction; RV = right ventricle/ventricular; TR
= tricuspid regurgitation; TV = tricuspid valve.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
621


<!-- PAGE 60 -->

### Page 60

..............................................................................
The most challenging questions are TR, RV dysfunction, and when to implant a TV and/or an ICD. In contrast to the situation in the paediatric age group, in which double switch is an established treatment option in case of systemic RV failure, this approach is very rarely successful in adults.
Systemic AV valve (tricuspid) regurgitation is frequently the focus of surgical treatment. Repair is rarely feasible and, as a rule, valve replacement is the treatment of choice. Pre-operative systemic RVEF
<_40%, PAP >50 mmHg, AF, and New York Heart Association
(NYHA) class III to IV are associated with late mortality.291
4.13.6
Follow-up recommendations
Patients with ccTGA need lifelong follow-up in a specialized ACHD
centre at annual intervals, particularly because of conduction disturbances and subaortic ventricular and subaortic AV valve dysfunction.
For arrhythmias, see section 3.4.2.
4.13.7
Additional considerations
• Exercise/sports: symptomatic patients with ccTGA and preserved RVEF should avoid high-intensity sports and preferably not do more than moderate-static and moderate-intensity sports. Patients with significant associated lesions and/or decreased subaortic RV function should be restricted to lowstatic and low-intensity sports.
• Pregnancy: risk depends on functional status, ventricular function,
systemic AV valve function, presence of arrhythmias (especially
AV block), and associated lesions (see section 3.5.7).
4.14 Right ventricular to pulmonary artery conduit
4.14.1
Introduction and background
Conduits establish the continuity between the RV and the PA in complex defects when the native outflow tract is not amenable to reconstruction, including pulmonary atresia, common arterial trunk, TOF,
absent pulmonary valve syndrome, Rastelli procedure, and Ross operation.
Types of conduits include valved [pulmonary or aortic homograft,
bioprosthetic valves, bovine jugular vein conduits (Contegra)] and non-valved conduits. There is no ideal conduit. Limited durability implicates early reoperation. Predictors for conduit failure are sterilization/preservation process, smaller conduit, conduit type, younger age at implantation, PA stenosis, and diagnosis of transposition.269,292,293 Freedom from reoperation for conduit failure at 20
years was reported at 32% and 40%.269,292
Complications include outgrowth, progressive obstruction with and without regurgitation,
endocarditis,
and aneurysms or pseudoaneurysms.
Clinical presentation may include exertional dyspnoea, palpitations, syncope, and SCD.
4.14.2
Diagnostic work-up
See section 3.3 for general principles.
Clinical findings may include a precordial thrill, prominent A wave of the jugular veins, and systolic murmur. Conduit calcification may be seen on chest X-ray.
• Echocardiography is the first-line diagnostic tool providing size,
shape, and function of both ventricles, PR, TR, and associated lesions. Gradients across the conduit may be difficult to measure and unreliable. RV pressure derived from TR velocity should be used to assess conduit stenoses.
• CMR is used to quantify conduit stenosis and/or regurgitation,
RV volumes and mass, and to assess PAs.
• CMR/CCT is helpful for coronary artery anatomy and proximity of the RV/conduit, and other structures to the retro sternum.
• Catheterization with haemodynamic assessment is always required if intervention is considered. Angiography provides information on the level of stenosis, peripheral PA stenoses, and coronary anatomy (anomalies/abnormal course).
4.14.3
Surgical/catheter interventional treatment
Balloon dilation/stent implantation have been reported to be safe and to prolong the lifespan of failing conduits.294,295 Percutaneous pulmonary valve implantation has now become the treatment of choice for dysfunctional valves, if technically feasible. Current exclusions for
TPVI include occluded systemic veins, active infection, unsuitable outflow tract morphology, and unfavourable coronary anatomy (compression by the expanded implant). Surgery is preferred when additional interventions are considered (tricuspid annuloplasty).
Longitudinal data are more important for timing of reintervention than single measurements.
Recommendations for intervention in right ventricular to pulmonary artery conduits
Recommendations
Classa
Levelb
Symptomatic patients with RVSP >60 mmHg
(may be lower in case of reduced ﬂow) and/or severe PRc should undergo intervention with preference for catheter intervention (TPVI) if anatomically feasible.
I
C
Asymptomatic patients with severe RVOTO and/
or severe PR should be considered for intervention, preferably catheter intervention (TPVI) if anatomically feasible, when at least one of the following criteria is present:
• Decrease in objective exercise capacity
(CPET).
• Progressive RV dilation to RVESVi
>_80 mL/m2, and/or RVEDVi >_160 mL/m2, and/
or progression of TR to at least moderate.
• Progressive RV systolic dysfunction.
• RVSP >80 mmHg.
IIa
C
CPET = cardiopulmonary exercise testing; CMR = cardiovascular magnetic resonance; PR = pulmonary regurgitation; RV = right ventricle/ventricular; RVEDVi =
right ventricular end diastolic volume indexed; RVESVi = right ventricular end systolic volume indexed; RVOTO = right ventricular outﬂow tract obstruction;
RVSP = right ventricular systolic pressure; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgitation.
aClass of recommendation.
bLevel of evidence.
cRegurgitant fraction by CMR >3040%.


<!-- PAGE 61 -->

### Page 61

.............................................................................................................................................................................
4.14.4
Follow-up recommendations
Regular follow-up in a specialized ACHD centre at least every year is recommended. Special attention should be given to exercise capacity
(CPET), RVSP (conduit gradient), RV function, TR, and arrhythmias.
4.14.5
Additional considerations
• Exercise/sports: no restrictions are required in asymptomatic patients with mild obstruction. High-risk patients with high RV
pressure must limit themselves to low-intensity activity/sports and avoid isometric exercise. Other patients should limit themselves according to symptoms.
• Pregnancy: maternal and foetal risks are driven by the underlying congenital heart defect and severity of RVOTO, arrhythmia, and heart failure (see section 3.5.7).
• IE prophylaxis: recommended in all patients (see section 3.4.6).
4.15 Univentricular heart
This section deals with unoperated and palliated univentricular heart
(UVH). For patients after Fontan operation see section 4.16.
4.15.1
Introduction and background
The term ‘UVH’ summarizes a variety of malformations where either the RV or LV is missing or, if present, is hypoplastic and thus not amenable for biventricular repair, such as:
• Tricuspid atresia.
• Hypoplastic right heart syndrome variants, e.g. pulmonary atresia with intact ventricular septum variants.
• Hypoplastic left heart syndrome (HLHS) variants, including mitral atresia.
• Double-inlet LV.
• Double-inlet RV.
• Extreme forms of unbalanced complete AV septal defects.
• Single ventricle with undefined morphology.
These malformations are always associated with additional intraand/or extracardiac lesions such as:
• ASD, VSD, AVSD, PDA.
• AS (valvular, subvalvular).
• Aortic arch anomalies: hypoplasia, interruption, coarctation.
• PS (valvular, subvalvular), pulmonary atresia.
• PA anomalies: peripheral stenosis, hypoplasia, one-sided absence.
• Discordant connections, malposition of the great arteries.
• AV valve stenosis, regurgitation, overriding, straddling.
• LA or RA isomerism, abnormal systemic or pulmonary venous connections.
• Left SVC, absent innominate vein, absent right SVC, absent infrahepatic IVC with azygos or hemiazygos continuity.
• Aortic-to-pulmonary collateral arteries.
• Polysplenia or asplenia.
Detailed anatomic description is beyond the scope of these guidelines and can be found in textbooks. Owing to the lack of data, recommendations are mainly based on expert consensus.296300 When presenting as adults, the vast majority of patients with these conditions will have undergone previous palliation with some type of systemic-to-PA shunt, cavopulmonary connection (Glenn), or now preferably a Fontan operation or one of its modifications; the latter is covered in section 4.16.
Two different haemodynamic situations can be identified:
• No anatomic restriction to pulmonary blood flow: if pulmonary circulation remains unmodified (i.e. no surgery), many patients will die in childhood due to intractable heart failure. Those who survive this period will have developed severe PVD. This will be a main determinant of long-term outcome. Many will have had pulmonary banding to restrict pulmonary blood flow in early childhood. An effective banding will protect against PVD, while allowing enough pulmonary blood flow to limit the degree of cyanosis. A banding that is too loose will result in pulmonary overflow and PVD despite the banding. If the banding is too tight,
pulmonary blood flow will be extremely limited, resulting in severe cyanosis.
• Obstruction to pulmonary blood flow (frequently valvular and/or subvalvular PS or atresia): sometimes the obstruction is such that the pulmonary circulation is adequate (not excessive, thus avoiding development of PH, and not too restricted, thus without extreme cyanosis). These balanced situations are the exception but allow survival into adulthood without having surgery. Most patients have a very restricted pulmonary blood flow, necessitating a systemic-to-PA shunt operation in childhood  most commonly BlalockTaussig (subclavian to PA), rarely Waterston or
Potts (ascending or descending aorta to PA, respectively). If a systemic-to-PA shunt is too large, pulmonary overflow will result in PVD at adult age. If the shunt is too small, patients will be extremely cyanotic. Beyond infancy, an anastomosis between the
SVC and PA is a possibility: the classical Glenn anastomosis to the right PA (historical) or an end-to-side anastomosis with the PA,
creating a
bidirectional cavopulmonary anastomosis.
An adequate shunt will lead to a balanced situation.
4.15.2
Clinical presentation and natural history
Depending on the extent of pulmonary blood flow, presence or absence of PVD, and ventricular function, patients may present with various degrees of cyanosis and congestive heart failure. Exercise ability is generally substantially reduced (with exceptions); complete AV
block, arrhythmias (supraventricular, but also ventricular, SCD not unusual), stroke, brain abscess, and thromboembolism can occur.
Endocarditis is relatively common in this population. For more details, see section 3.4.8.
Cyanosis is typically present in patients with UVH without a
Fontan operation. Arterial oxygen saturation commonly ranges from
7585% but may, in exceptional cases with ideally balanced circulations, reach values >90%.
Patients may present with progressive obstruction towards the aorta. This will lead to ventricular hypertrophy and, eventually, to reduced cardiac output. Progressive obstruction towards the PA will cause progressive cyanosis. In Glenn patients, worsening cyanosis may also be due to development of pulmonary arteriovenous malformations or IVC-to-SVC collaterals.
The UVH has to accommodate both systemic and pulmonary venous return. This chronic volume overload will lead to a high likelihood of ventricular failure relatively early in life. AV valve regurgitation may develop or progress, if present previously. The already
ESC Guidelines
623


<!-- PAGE 62 -->

### Page 62

.........................................................
diminished exercise capacity will deteriorate further. Eventually,
overt heart failure may develop, in addition to the cyanosis.
In rare cases, with a well-balanced haemodynamic situation, ventricular dysfunction does not develop, and survival until the fifth, sixth,
and even seventh decade has been reported.
4.15.3
Diagnostic work-up
See section 3.3 for general principles.
Clinical findings include central cyanosis, clubbing of fingers and toes, and often an asymmetric chest with a precordial heave at the side where the heart lies in the chest. Scoliosis is a common problem. The second heart sound is typically single, but the rest of the auscultation depends on the associated abnormalities. ECG may reveal rhythm or conduction disturbances. Atrial reentrant tachycardia with 2:1 block and only modest tachycardia may be easily overlooked.
• TTE is the key diagnostic technique, providing information on anatomy and monitoring of cardiac function during follow-up. The segmental approach is required in the echocardiographic examination; UVHs are always complex and can present with a wide range of abnormalities in situs, orientation, and connections.
Fundamental TTE parameters/issues/items in the diagnosis of
UVHs are:
- Abdominal and atrial situs.
- Position of the heart in the chest and position of the apex.
- Veno-atrial, AV, and ventriculo-arterial connections.
- Morphological and haemodynamic information has to be obtained on the entire heart.
- Exact anatomy of the ventriculo-arterial connection and its functional status has to be assessed, with special focus on obstruction towards the aorta or pulmonary vascular bed.
- AV valve function should be evaluated, with special focus on regurgitation.
- Ventricular function/hypertrophy.
- ASD/VSD type, size, number, location.
- Ascending aorta, aortic arch, and descending aorta; detect/
exclude coarctation.
- PAs  common trunk, branches, and sources of pulmonary blood supply.
- Visualization of shunts (BlalockTaussig, Waterston, etc.).
TOE may be indicated in cases of inadequate TTE images.
• CMR is the imaging modality of choice for extracardiac anatomy,
including veno-atrial and ventriculo-arterial connections (CCT is an alternative). Detailed morphological information of intracardiac anatomy can also be obtained. CMR is also the method of choice for quantification of ventricular volumes, EF, and relative distribution of blood flow in the left and right lungs.
• Cardiac catheterization is required when intervention is considered for haemodynamic assessment, in particular PAP and transpulmonary gradient (PVR is often difficult to assess in this setting). It is mandatory when patients are evaluated for a Fontan operation. Evaluation of systemic-to-PA or Glenn shunts  and their sequelae (stenosis of the pulmonary branches) and other vascular anomalies (arteriovenous collateral vessels, fistulas, etc.)
 may also require catheterization.
Interventional treatment, such as pulmonary valvotomy to increase pulmonary blood flow in cases of severe PS, is debatable.
If the clinical situation is stable, the (frequently high) risk of any type of surgical intervention should be weighed very carefully against the possible benefit.
A Fontan operation can only be considered in very well selected patients (see section 4.16). For patients with severe cyanosis, with decreased pulmonary blood flow without elevated
PVR, a bidirectional Glenn shunt (SVC-to-PA) can be an option.
If a systemic-to-pulmonary shunt (e.g. arteriovenous axillary fistula or systemic artery pulmonary shunt) is the only option
(bidirectional Glenn shunt not sufficient or PAP not low enough for this shunt), the benefit of increased pulmonary blood flow should be weighed against increased volume load to the systemic ventricle.
For transplantation,
previous sternotomies/thoracotomies,
aorto-pulmonary collaterals, and the multisystem nature of cyanotic CHD are technical and medical challenges and limit the outcome.
Special considerations and recommendations for intervention in univentricular heart
Recommendations
Classa
Levelb
It is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres, including multimodality imaging as well as invasive work-up to decide whether they may beneﬁt from surgical or interventional procedures.
I
C
Only well-selected symptomatic cyanotic patients, after careful evaluation [low pulmonary vascular resistances, adequate function of the
AV valve(s), preserved ventricular function],
should be considered candidates for a Fontan circulation.
IIa
C
Patients with increased pulmonary blood ﬂow
 unlikely at adult age  should be considered for PA banding or tightening of a previously placed band.
IIa
C
Patients with severe cyanosis and decreased pulmonary blood ﬂow, but without elevated PVR
or PAP, should be considered for a bidirectional
Glenn shunt.
IIa
C
Patients with severe cyanosis and decreased pulmonary blood ﬂow not suitable for a Glenn shunt may be considered for a systemic-to-PA
shunt.
IIb
C
Heart transplantation and heart-lung transplantation should be considered when there is no conventional surgical option in patients with poor clinical status.
IIa
C
AV = atrioventricular; PA = pulmonary artery; PAP = pulmonary artery pressure;
PVR = pulmonary vascular resistance; UVH = univentricular heart.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 63 -->

### Page 63

..................................................................................................................................................................
4.15.4
Conservative management
See sections 3.4.3 and 3.4.8 for haematological management and the role of targeted therapy in PVD.
4.15.5
Follow-up recommendations
Regular evaluation is required in a specialized ACHD centre.
Frequency is individualized, but at least yearly, with physical examination, measurement of oxygen saturation, laboratory tests (haematological indices, iron status, liver function, kidney function, etc.),
ECG, X-ray, and echocardiography (see also section 3.4.8).
CMR and an exercise test are required at least once at adult age and at further intervals timed according to baseline findings.
4.15.6
Additional considerations
• Exercise/sports: as a rule, patients do not have an elevated risk of death during exercise, but they do have a substantially reduced exercise capacity. Recreational sports can be considered at a symptom-limited level.
• Pregnancy: contraindicated in patients with severely reduced pulmonary blood flow or with severe PVD, or if ventricular function is poor. Cyanosis poses a significant risk to the foetus, with a live birth unlikely (<12%) if oxygen saturation is <85%106 (see section
3.5.7).
• For contraception, a combined oral contraceptive pill must be avoided because of the risk of thrombogenicity and thromboembolism. Progestogen-only pills and progestogen-eluting intrauterine devices or implantation systems provide safe contraception with a smaller cardiovascular risk.
• IE prophylaxis: indicated in all patients (see section 3.4.6).
4.16 Patients after Fontan operation
4.16.1
Introduction and background
The Fontan operation was introduced in 1968 and has become the definitive treatment for suitable patients with a range of cardiac malformations characterized by a single functional ventricle (see section
4.15). Surgery consists of the separation of the systemic and pulmonary venous returns without a subpulmonary ventricle and restores them to being ‘in series’. Since its introduction, a number of modifications have been made to the original procedure, designed to streamline the systemic venous return to the PAs. Currently, the total cavopulmonary connection has replaced the atriopulmonary connection (RA appendage to PA), with either an intracardiac or extracardiac conduit between the IVC and the PA, together with an SVC-toPA anastomosis (bidirectional Glenn).301 This circulation is frequently established in two stages. Adults with HLHS remain a small but expanding group of patients. The first data in adulthood describe a considerable prevalence of major adverse cardiovascular events and it appears that HLHS patients are more prone to complications than general
Fontan patients,
warranting closer follow-up and assessment.302
The natural history and outcome of other palliations for hearts with a ‘single ventricle’ are poor, so that the Fontan is usually undertaken in all patients in whom the haemodynamics are suitable.
It is now appreciated that the operative mortality and subsequent outcome depend on the suitability of the circulation and adherence to defined criteria. Strict selection gives the best early and late results,
with operative mortality of <5% in modern series and includes low
PVR and PAP (mean <15 mmHg), preserved ventricular function,
adequate PA size, no relevant AV valve regurgitation, and normal rhythm. A ‘fenestration’ has been performed in selected or all cases by some centres to allow for shunting of deoxygenated blood to the systemic circulation at atrial level, aiming to improve the cardiac output at the expense of cyanosis.303 Fontan operation, when considered late in adults, is not always the palliation of choice because of the limited long-term outcome.
4.16.2
Clinical presentation and natural history
The lack of a subpulmonary ventricle results in chronic systemic venous hypertension, markedly altered pulmonary haemodynamics,
and a chronically ‘preload-deprived’ ventricle. A number of important problems have emerged during long-term follow-up. Although 10year survival may approach 90%, it should be appreciated that a premature decline in cardiovascular performance, with reduced survival,
is inevitable even in the best Fontan patients.304 Important haemodynamic issues contributing to late Fontan failure include a progressive decline in systemic ventricular function, AV valve regurgitation, a rise in PVR, atrial enlargement, pulmonary venous obstruction, progressively restrictive subaortic VSD, and the consequences of chronic systemic venous hypertension including hepatic congestion and dysfunction.305 Further complications include atrial and PA thrombus formation, development of pulmonary arteriovenous malformations,
systemic arterial-to-pulmonary venous or systemic arterial-topulmonary arterial connection, and systemic-to-pulmonary venous collaterals.
After the Fontan operation, the majority of patients do well during childhood and adolescence, although exercise capacity is reduced when measured objectively. However, clinical complications may subsequently develop, with a progressive decline in exercise performance and heart failure, cyanosis, chronic venous insufficiency,
and development of important arrhythmias, especially in patients with a classical Fontan operation.306 By 10 years after a Fontan operation, 20% of patients have supraventricular tachyarrhythmias
(including typically IART and atrial flutter, but also AF and focal
AT).307 Bradycardia due to SND may facilitate occurrence of AT.
The incidence of AT is lower after total cavopulmonary connection than atriopulmonary connection, and lower after extracardiac conduit than intracardiac conduit.308 Atrial tachyarrythmias with rapid conduction are associated with SCD.
The spectrum of Fontan-associated liver disease is wide and includes both hepatic congestion and severe fibrosis, with signs of portal hypertension and hyperenhancing nodules as well as hepatocellular carcinoma.309
Protein-losing enteropathy is a rare but important complication and results in peripheral oedema, pleural effusions, and ascites. It can be diagnosed by documentation of low serum albumin and elevated
ESC Guidelines
625


<!-- PAGE 64 -->

### Page 64

....................................................................................................................................................................
a1-antitrypsin levels in the stool.310 It has traditionally been associated with a very poor prognosis (5-year survival <50%) but a more recent study reported a 5-year survival of 88%; however, treatment remains challenging.311 Plastic bronchitis and lymphatic system dysfunction may further complicate prognosis.
For more details, see a recently published extensive review.312
4.16.3
Diagnostic work-up
See section 3.3 for general principles.
Clinical findings include commonly mild, non-pulsatile jugular venous distension. Significant jugular venous distension and hepatomegaly, however, raise suspicion of Fontan obstruction or ventricular failure. ECG frequently shows junctional rhythm or atrial arrhythmias.
Pleural effusion on chest X-ray raises suspicion of protein-losing enteropathy.
• Echocardiography is the first-line diagnostic tool, providing information on ventricular and valve function. To image the Fontan pathway, TOE or other imaging modalities are generally required.
• Annual blood tests should include haematology, serum albumin,
and liver and renal function. When protein losing enteropathy is suspected, a1-antitrypsin clearance must be calculated.
• CMR is helpful for evaluation of the Fontan pathway, collaterals,
and pulmonary veins (e.g. right pulmonary vein obstruction by enlarged RA) and for thrombus, all of which CCT can also provide. CCT requires experience to mitigate streaming artefact and false positive diagnosis of thrombus. CMR is regularly performed for ventricular volumes, Fontan pathway patency and flows, to evaluate AV valve regurgitation, subaortic obstruction, myocardial fibrosis, and for detection of thrombus.
• As liver dysfunction, liver cirrhosis, and hepatocellular carcinoma have been recognized as typical complications in this setting, regular liver imaging (ultrasound, computed tomography, magnetic resonance) and laboratory assessment should be performed.
• Cardiac catheterization should be performed at a low threshold in cases of unexplained oedema, exercise deterioration, newonset arrhythmia, cyanosis, and haemoptysis. It provides information on ventricular and valvular function, haemodynamics including PVR, and Fontan obstruction and anomalous vascular connections (see section 4.16.2). Integration with CMR for flows
(cardiac output) may allow more precise measurement of PVR.
4.16.4
Medical treatment
• Anticoagulation: right atrial blood stasis and disturbed coagulation may predispose to thrombosis. The potential for subclinical,
recurrent pulmonary embolism (eventually leading to a rise in
PVR) and systemic embolism have led to a recommendation, by some, for lifelong anticoagulation. There is, however, no evidence of benefit, and practice varies between centres. Anticoagulation is indicated in the presence, or with a history, of atrial thrombus,
atrial arrhythmias, or thromboembolic events. Although NOACs have been reported to be safe in selected Fontan patients,79
robust prospective efficacy data are lacking and thus these drugs cannot currently be recommended as standard therapy.
• Antiarrhythmic therapy: loss of sinus rhythm may precipitate rapid haemodynamic decline and atrial arrhythmias. Sustained atrial arrhythmia with rapid AV conduction should be considered a medical emergency. Electrical cardioversion is the mainstay of treatment, as drug therapy is often ineffective. Amiodarone may be effective in preventing recurrence, but it has many long-term side effects. Sotalol can be an alternative. There should be a low threshold for radiofrequency ablation, although these are difficult arrhythmias to treat in the catheterization laboratory.313
Antitachycardia atrial PMs may assist. If AV pacing is required, this will need an epicardial approach. Occurrence of arrhythmias should prompt haemodynamic evaluation. In addition, a proactive approach of EP evaluation and ablation therapy (where appropriate) should be considered, including Fontan conversion with concomitant arrhythmia surgery. ICD therapy may be considered in selected patients. See section 3.4.2.
• Therapy of protein losing enteropathy: medical therapy remains challenging and various treatments have been proposed (after exclusion of haemodynamic problems) including salt restriction,
high protein diet, diuretics, ACE inhibitors (may be poorly tolerated), steroids, albumin infusion, chronic subcutaneous heparin,
creation of a fenestration (by interventional catheter), and eventually, consideration of transplantation.
• Pulmonary vasodilators: ERAs and PDE-5 inhibitors may be considered in selected patients with elevated pulmonary pressure/
resistance in the absence of elevated ventricular end diastolic pressure. Data on the routine use of these medications in Fontan patients are limited at present. A randomized trial of the ERA
bosentan has demonstrated significantly improved cardiopulmonary exercise capacity in 75 adults with Fontan physiology.314
4.16.5
Surgical/interventional treatment
Patients with a ‘failing Fontan’ (with a combination of intractable arrhythmia, right atrial dilation, worsening AV valve regurgitation,
deterioration of ventricular function, and/or atrial thrombus) should be considered for surgery.315 While patients with failing systemic ventricular function may benefit from heart transplantation (performed in experienced settings), patients with preserved systemic ventricular function, atrial arrhythmia, and impaired flow dynamics in the Fontan pathway may benefit from conversion to extracardiac total cavopulmonary connection and concomitant cryoablation.316
The latter has provided good early results in a very experienced setting, but is associated with surgical mortality and ongoing morbidity,
with the need for both continued drug therapy and pacemaker implantation in the majority of cases.317 If performed late, conversion may be less likely to result in a good outcome, and cardiac transplantation may be required. However, the best timing for a conversion remains a matter of uncertainty. In selected adult patients, it may be appropriate to consider device closure of a fenestration if there is significant cyanosis, but this may also worsen the patient’s condition.
Catheter intervention may also be required in the case of flow obstruction, or anomalous vascular connections.


<!-- PAGE 65 -->

### Page 65

.............................................................................................................................................................................
4.16.6
Follow-up recommendations
As a result of these many complex issues, the care of Fontan patients is one of the major challenges for ACHD practitioners. All Fontan patients should be followed in specialized ACHD centres, usually at least annually, with echocardiography, ECG, blood tests, and exercise testing. Intervals for CMR and hepatic ultrasound (or computed tomography) must be decided on an individual basis. For adults, it appears reasonable to perform a baseline hepatic assessment with magnetic resonance imaging at the first visit to guide the frequency and mode of follow-up based on the degree of pre-existing hepatic changes. In addition, yearly follow-up hepatic assessments including,
for example, liver ultrasound and alpha-fetoprotein measurement,
should be considered after consultation with local hepatology services.
Comprehensive assessment is mandatory for patients with manifestations of the ‘failing Fontan’ complex, with particular care to exclude even minor obstructions to cavopulmonary flow and pulmonary venous return, which may have a major haemodynamic impact.
4.16.7
Additional considerations
• Exercise/sports: after Fontan operation, patients have significantly reduced exercise capacity as part of their circulation. However,
moderate symptom-limited aerobic exercise is to be recommended according to current recommendations to improve musculatory strength and quality of life.24
• Pregnancy: patients with a Fontan circulation and any complication should be advised against pregnancy. Successful pregnancy is possible in selected patients, although with significant maternal morbidity, especially heart failure and arrhythmia, but also thromboembolic complications. Therapeutic anticoagulants should be considered, balanced against the risk of bleeding, which is also higher in these patients. Intensive monitoring, including after delivery, is mandatory. There is a high miscarriage rate of
2755% and a high rate of prematurity and intrauterine growth restriction. Whether pregnancy with its volume loading has an adverse effect on the long-term outcome of women with a single ventricle remains to be elucidated.
• IE prophylaxis: only recommended in patients with a recent redo
Fontan (<6 months), cyanosis, a prosthetic valve, residual patch leak, or prior endocarditis.
4.17 Coronary anomalies
4.17.1
Introduction and background
Coronary anomalies include anomalous aortic origin of a coronary artery (AAOCA), anomalous coronary artery from the PA
(ACAPA), and coronary fistulae.
4.17.1.1 Anomalous coronary artery from the pulmonary artery
Although many congenital coronary anomalies are benign, natural history studies of anomalous left coronary artery from the PA
(ALCAPA) document poor outcome if untreated.318 ACAPA results in low oxygen levels in the coronary artery, coronary steal syndrome,
and myocardial ischaemia. ALCAPA can present as a silent or symptomatic myocardial infarction, LV dysfunction, VTs, or even SCD.
Patients may also primarily present with volume overload due to
LR shunt causing heart failure symptoms. However, anomalous right coronary artery from the PA (ARCAPA) has frequently been diagnosed incidentally. Dual coronary system repair, including coronary button transfer with or without an interposition graft, is preferred. A coronary artery bypass graft (CABG) with closure of the
ACAPA should be reserved for those in whom coronary transfer is not feasible.
4.17.1.2 Anomalous aortic origin of a coronary artery
Natural history studies are lacking regarding untreated patients with
AAOCA. The debate about management is ongoing, in particular in patients with an interarterial course of an anomalous coronary artery.
Risk assessment for SCD is difficult because of the lack of data.
Autopsy series show that most patients are young (<35 years) and die during, or shortly after, exercise. Myocardial fibrosis has been demonstrated, suggesting myocardial ischaemia may play a role. Left coronary artery arising from the opposite (right) sinus is less
Special considerations and recommendations for intervention after Fontan operation
Recommendations
Classa
Levelb
Sustained atrial arrhythmia with rapid AV conduction is a medical emergency and should be promptly treated with electrical cardioversion.
I
C
Anticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic events.
I
C
It is recommended that women with a Fontan circulation and any complication are counselled against pregnancy.
I
C
Cardiac catheterization is recommended at a low threshold in cases of unexplained oedema,
exercise deterioration, new-onset arrhythmia,
cyanosis, and haemoptysis.
I
C
In patients with arrhythmias, a proactive approach of electrophysiologic evaluation and ablation (where appropriate) should be considered.
IIa
C
Regular liver imaging (ultrasound, computed tomography, magnetic resonance) should be considered.
IIa
C
Endothelin receptor antagonists and phosphodiesterase-5 inhibitors may be considered in selected patients with elevated pulmonary pressure/resistance in the absence of elevated ventricular end diastolic pressure.
IIb
C
In selected patients with signiﬁcant cyanosis,
device closure of a fenestration may be considered but requires careful evaluation before intervention to exclude induction of systemic venous pressure increase or fall in cardiac output.
IIb
C
AV = atrioventricular.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
627


<!-- PAGE 66 -->

### Page 66

........................................................................................
common, but more malignant than the right coronary artery from the left sinus. High orifice, ostial stenosis, slit-like/fish-mouth-shaped orifice, acute-angle take-off, intramural course and its length, or interarterial course and hypoplasia of the proximal coronary artery have been associated with myocardial ischaemia and have all been proposed as risk factors.319322
Risk stratification must also include age (<35 years) and level of exercise (e.g. competitive sports). There is very limited evidence that surgery in asymptomatic middle-aged patients provides any survival benefit or modifies the SCD risk.323,324
4.17.1.3 Coronary artery fistulae
A coronary artery fistula, whether congenital or acquired, is an abnormal connection between a coronary artery and cardiac chamber or vessel. Small fistulae have a good prognosis without treatment.
Medium or large fistulae are associated with long-term complications
(angina, myocardial infarction, arrhythmias, heart failure, and endocarditis). The presence of symptoms, complications, and a significant shunt are the main indications for percutaneous or surgical closure.
4.17.2
Diagnostic evaluation
CCT is the preferred technique for the evaluation of high-risk anatomy, including features such as an intramural course and orifice anomalies (slit-like orifice, acute-angle take-off, orifice >1 cm above the sinotubular junction).
Assessment of physical stress-induced ischaemia using advanced imaging modalities is the key to decision making.
4.17.3
Surgical treatment
Indications for surgery are summarized in the Recommendations for the management of patients with anomalous coronary arteries table.
5 Quality indicators
The overall aim of this new edition of the ESC Clinical Practice
Guidelines for ACHD is to assist caregivers in their daily practice for the benefit of patients. In a next step, it is important to analyse the adaptation of, and the adherence to, these Guidelines in practice, a process that can be envisaged using Quality Indicators (QIs).
QIs are sets of measures that enable the quantification of adherence to Guideline recommendations and provide a mechanism for measuring opportunities to improve cardiovascular care and outcomes.325 QIs show important differences from Clinical Practice
Guidelines. For instance, the latter are recommendations for care to apply prospectively to individual patients, whereas QIs are applied retrospectively to a group of patients to assess if a care process was delivered or not.325
QIs are derived from evidence, feasible, concretely interpretable, and usable.326 The goal of QIs is to improve quality of health care, and they have been increasingly used by health authorities,
professional organisations, healthcare payers, as well as the public.327329
The process of development and defining QIs for the management of specific ACHD items has been initiated during the Guideline writing process and results will be published later in a dedicated document.
Recommendations for the management of patients with anomalous coronary arteries
Recommendations
Classa
Levelb
Non-pharmacological functional imaging
(e.g. nuclear study, echocardiography, or
CMR with physical stress) is recommended in patients with coronary anomalies to conﬁrm/exclude myocardial ischaemia.
I
C
Anomalous coronary arteries from the pulmonary artery
Surgery is recommended in patients with
ALCAPA.
I
C
Surgery is recommended in patients with
ARCAPA and symptoms attributable to anomalous coronary artery.
I
C
Surgery should be considered for ARCAPA
in asymptomatic patients with ventricular dysfunction, or myocardial ischaemia attributable to coronary anomaly.
IIa
C
Anomalous aortic origin of the coronary artery
Surgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced myocardial ischaemia in a matching territory or high-risk anatomy.c
I
C
Continued
Surgery should be considered in asymptomatic patients with AAOCA (right or left)
and evidence of myocardial ischaemia.
IIa
C
Surgery should be considered in asymptomatic patients with AAOLCA and no evidence of myocardial ischaemia but a highrisk anatomy.c
IIa
C
Surgery may be considered for symptomatic patients with AAOCA even if there is no evidence of myocardial ischaemia or highrisk anatomy.c
IIb
C
Surgery may be considered for asymptomatic patients with AAOLCA without myocardial ischaemia and without high-risk anatomyc when they present at young age (<35 years).
IIb
C
Surgery is not recommended for AAORCA in asymptomatic patients without myocardial ischaemia and without high-risk anatomy.c
III
C
AAOCA = anomalous aortic origin of a coronary artery; AAOLCA = anomalous aortic origin of the left coronary artery; AAORCA = anomalous aortic origin of the right coronary artery; ALCAPA = anomalous left coronary artery from the pulmonary artery; ARCAPA = anomalous right coronary artery from the pulmonary artery; CMR = cardiovascular magnetic resonance.
aClass of recommendation.
bLevel of evidence.
cHigh-risk anatomy includes features such as an intramural course and oriﬁce anomalies (slit-like oriﬁce, acute-angle take-off, oriﬁce >1 cm above the sinotubular junction).


<!-- PAGE 67 -->

### Page 67

.............................................................................................................................................................................
6 Gaps in evidence
6.1 General aspects
6.1.1
Organization of care and patient evaluation
• Congenital heart defects are arbitrarily classified into lesions of different complexities (mild, moderate, severe; Table 4). The validity of this classification for clinical management and risk stratification remains to be investigated in large registries.
• Minimal volumes of patients under care at each ACHD expert centre, and the necessary staff resources for an optimal outcome,
need to be defined.
• Relevant outcome measures, over and above mortality, need to be determined to measure quality of care.
• The role of neurohormones to estimate disease severity and timing of interventions is not yet fully established and needs to be defined.
6.1.2
Heart failure
• The pathophysiology/mechanism of heart failure, especially in those with a systemic RV and Fontan circulation, is incompletely understood and needs further study to find better ways for prevention and treatment.
• Indications for application of standard heart failure treatment in both acute and chronic settings need to be better defined.
• The prediction and course of heart failure needs to be better defined to improve indications and timing of ventricular assist device/transplantation.
• Large-scale collaborative international prospective registries on medical and device therapy in ACHD are needed and support for the set up and practical implementation is required.
6.1.3
Arrhythmia
• Dedicated scoring systems to assess the indication for anticoagulation in the setting of atrial arrhythmias are needed for moderate and complex CHD.
• Targeting slow-conducting anatomical isthmuses by catheter ablation has been highly effective to control monomorphic VT in repaired tetralogy of Fallot. Whether catheter mapping can contribute to individualized risk stratification in patients without spontaneous VTs in repaired tetralogy of Fallot and related defects requires further research.
• The potential loss of accessibility to slow-conducting anatomical isthmuses by catheter ablation after re-valving rTOF and related defects is of concern. Whether patients without documented VT
benefit from preventive ablation before or during re-valving should be studied.
• Indications for pacing and CRT in ACHD patients are mainly derived from adults with anatomically normal hearts with ischaemic or dilated cardiomyopathy and are not adapted to the diversity of structural and functional CHD substrates. The selection of
CRT candidates, CRT application, and optimal pacing sites for the different CHD substrates requires further research.
6.1.4
Pulmonary arterial hypertension
• The impact of medical PAH therapy on survival of patients with
Eisenmenger syndrome requires further study.
• The role of upfront combination therapy in PAH-CHD requires further attention.
• Limited experience is available for prostacyclin therapy in patients with PAH-CHD and needs further investigation.
6.1.5
Cyanotic patients
• The benefit of routine anticoagulation, in the absence of any strong risk factor for thromboembolic complications (e.g. atrial arrhythmias), is controversial and requires further study.
6.2 Specific lesions
6.2.1
Shunt lesions
• Late outcome after device closure requires further study, particularly of arrhythmias.
• The impact of shunt closure on long-term outcome of patients with PAH remains an area of uncertainty; further research is required to better define the thresholds for treatment recommendations.
6.2.2
Left ventricular outflow tract obstruction and coarctation
• The optimal timing of intervention in asymptomatic severe
LVOTO requires further study.
• Transcatheter aortic valve implantation is rapidly evolving; its role in ACHD needs further refinement.
• According to the 2018 ESC Guidelines for the management of arterial hypertension,190 definitions of hypertension in patients with repaired CoA are the same as in general arterial hypertension and patients should be managed according to the general guidelines: evidence for this strategy is lacking and prospective studies are required.
6.2.3
Aortopathies
• Estimation of the risk for aortic dissection and definition of the threshold for prophylactic surgery in HTAD based on diameter alone is suboptimal and calls for a more personalized approach.
Whether the type of underlying gene defect is helpful in this stratification requires further study.
• Current prophylactic treatment regimens in
HTAD
patients include beta blockers and ARBs. Either in monotherapy or combined, neither one prevents further growth of the aorta. The search for new and better treatment targets should continue.
6.2.4
Right ventricular outflow tract obstruction
• Criteria for concomitant TV repair at the time of RVOT surgery require refinement.
• The identification of patients with low-gradient RVOTO who have severe stenosis and would benefit from intervention requires improvement.
• The criteria for identification of RVOTO patients who would benefit from reintervention for residual PR requires further research.
• The role of an EP study for risk stratification for SCD is controversial in patients with rTOF and needs further study.
ESC Guidelines
629


<!-- PAGE 68 -->

### Page 68

.............................................................................................................................................................................
6.2.5
Ebstein anomaly
• The identification of asymptomatic Ebstein patients with severe
TR who would benefit from TV surgery requires further improvement.
• The identification of Ebstein patients at risk for late lifethreatening arrhythmias needs to be improved.
6.2.6
Tetralogy of Fallot
• Optimal timing of PVRep for asymptomatic patients with significant PR needs to be further improved.
• Long-term follow-up studies after TPVI are required to increase knowledge about valve durability, consequences of stent fractures, and occurrence of endocarditis.
• The identification of rTOF patients at risk for late life-threatening arrhythmias, who would benefit from ICD implantation as primary prevention, needs to be improved.
• The effect of medical treatment on RV dilatation and/or dysfunction in rTOF patients needs to be established.
6.2.7
Transposition of the great arteries
• The potential benefit of classical heart failure medical therapy and biventricular pacing in patients with a systemic RV after an atrial switch procedure requires further study.
• Risk stratification for SCD and indications for primary ICD
implantation after atrial switch require refinement.
• After an arterial switch procedure, the risk of dissection/rupture of neo-aortic root aneurysms requires further study to refine the recommendations for prophylactic surgery.
• Long-term follow-up after arterial switch is required to study the risk for development of CAD after reimplantation of the coronary arteries into the neo-aortic root.
6.2.8
Congenitally corrected transposition of the great arteries
• The definition of optimal timing for TV replacement in patients with severe asymptomatic TR requires more data.
• The potential benefit of pulmonary banding for the preservation of systemic ventricular function requires further study.
6.2.9
Univentricular heart and Fontan operation
• The role of medication, including pulmonary vasodilators, in
Fontan patients is not clear and requires further study.
• The effects of pregnancy on long-term maternal outcome must be better established.
• Physiological determinants of long-term outcome in Fontan patients, including the role of the lymphatic system, requires more research.
6.2.10
Coronary anomalies
• Identification of adult patients with coronary anomalies
(AAOCA, ACAPA) who are at risk for SCD, and for whom surgery provides benefit at adult age, requires further research.
7 Key messages
7.1 General aspects
7.1.1
Organization of care and patient evaluation
• Special structural and organizational healthcare requirements are necessary to meet the needs of ACHD patients.
• Multimodality imaging is key for adequate assessment of overall anatomy and ventricular and valvular function, and quantification of blood flow, including perfusion distribution.
• Objective exercise testing is an important tool for determining the timing of interventions and reinterventions.
• Cardiac catheterization remains key for the assessment of haemodynamics, in particular, PAP and vascular resistance.
7.1.2
Heart failure
• The key treatment for heart failure in ACHD patients remains its prevention by optimizing haemodynamics and heart rhythm. This requires systematic follow-up in specialized centres to facilitate timely intervention.
• In a biventricular circulation, standard heart failure treatment can be extrapolated to ACHD patients with a systemic LV and may be applied in patients with a systemic RV, although it remains uncertain whether the known benefits of treating a failing LV can be expected. Pathophysiology of patients with an atrial switch,
and especially with a UVH and Fontan palliation, differs markedly from a ‘regular circulation’ and standard heart failure therapy has to be applied cautiously.
• Timely referral and consultation with ACHD and heart failure specialists in a centre with a transplant service and ACHD expertise is recommended, especially in those with moderate and severe complexity CHD.
7.1.3
Arrhythmia
• In all patients, evaluation for a reversible cause of an arrhythmia and for new or residual haemodynamic abnormalities should be performed.
• Maintenance of sinus rhythm is the aim in most ACHD patients.
• For optimal chronic arrhythmia management, referral to a centre with a multidisciplinary team and expertise in ACHD-related arrhythmias is mandatory.
• Patients with documented arrhythmias or at high risk for postprocedural arrhythmias considered for percutaneous or surgical
(re)interventions should be discussed in a multidisciplinary team with expertise in interventions and invasive treatment of arrhythmias.
7.1.4
Pulmonary arterial hypertension
• PAH in CHD is a progressive disease with poor prognosis.
• High suspicion of PAH, and regular assessment for the presence of PAH in patients with shunt lesions, after defect closure is recommended.
• Proactive treatment is required in all PAH patients, including those with Eisenmenger syndrome.
• Women with CHD and confirmed pre-capillary PH should be counselled against pregnancy.


<!-- PAGE 69 -->

### Page 69

.............................................................................................................................................................................
7.1.5
Cyanotic patients
• Cyanotic patients present with a multisystem disorder and are at risk for both bleeding and thrombotic complications, causing a therapeutic dilemma.
• Routine phlebotomies must be avoided as they put patients at risk for iron-deficient anaemia and cerebrovascular complications. Therapeutic phlebotomy is only indicated in the presence of moderate/severe hyperviscosity symptoms.
• Cyanotic patients have a very balanced, but fragile, pathophysiology and any intervention puts the patient at high risk; all interventions must therefore be performed in an ACHD expert centre.
• Prophylactic measures are the mainstay of care to prevent and avoid complications.
7.2 Specific lesions
7.2.1
Shunt lesions
• Treatment decisions require careful evaluation of ventricular volume overload and pulmonary circulation.
• In patients with non-invasive signs of elevated PAP, heart catheterization with assessment of PVR is mandatory.
• In the presence of PVR >_5 WU, ASD closure should be avoided.
VSD and PDA closure may only be considered in selected patients with significant shunt after careful evaluation in an
ACHD and PH expert centre.
• Device closure is the treatment of choice when technically feasible.
7.2.2
Left ventricular outflow tract obstruction
• The strongest indications for surgery remain symptoms and LV
dysfunction.
• Exercise testing should be performed in patients with severe obstruction who do not report symptoms in order to confirm asymptomatic status.
• In congenital valvular AS, associated aortic disease (ascending aortic dilatation and/or CoA) needs to be excluded.
7.2.3
Aortic coarctation
• Correct blood pressure measurement (right arm, ambulatory) is essential in the follow-up of patients with CoA.
• The decision to (re)intervene depends on blood pressure, gradient, and stenosis morphology.
• Stenting is the treatment of choice when technically feasible.
7.2.4
Aortopathies
• Lifelong surveillance is essential in all HTAD patients and should include imaging of the entire aorta, as well as assessment of valvular and myocardial function.
• The aortic diameter at which surgery should be performed depends on the underlying disease and presence of risk factors.
7.2.5
Right ventricular outflow tract obstruction
• RVOTO may be overestimated by the flow velocity across the obstruction, particularly when the narrowing is elongated, or stenosis is present in series (e.g. subvalvular and valvular).
Therefore, cross-checking with RV pressure estimated from TR
velocity is required.
• Catheter intervention is the treatment of choice for patients with non-dysplastic valvular PS (balloon valvuloplasty) and with peripheral PS (often with stent implantation).
• The indication for intervention is more restrictive whenever a valve substitute is required because of its long-term implications for complications and requirement for reintervention.
7.2.6
Ebstein anomaly
• Timing of surgery remains challenging and this operation should only be performed by surgeons with specific experience in this lesion.
• Valve repair is the preferred technique whenever feasible.
7.2.7
Tetralogy of Fallot
• Significant PR and/or RVOTO, RV and LV dysfunction, and arrhythmias are common long-term complications.
• Possible risk factors associated with any ventricular arrhythmia and SCD in rTOF are QRS duration >180 ms, LV systolic or diastolic dysfunction, RV dysfunction, inducible VT at programmed electrical stimulation, and history of atrial arrhythmia.
• The optimal timing for intervention in asymptomatic severe PR
remains challenging. Normalization of RV size becomes unlikely when the end diastolic volume index exceeds 160 mL/m2, but this cut-off for reintervention may not correlate with clinical benefit.
• TPVI has become the treatment of choice for RVOT reintervention when anatomically feasible.
7.2.8
Transposition of the great arteries
• Systemic ventricular failure, secondary systemic AV valve regurgitation, arrhythmia, and baffle stenosis and/or leakage are common long-term complications that need to be addressed after atrial switch operation.
• Outcome of morbidity has markedly improved with introduction of the arterial switch operation. Dilatation of the neo-aortic root with or without significant regurgitation of the neo-aortic valve,
supravalvular PS, and pulmonary branch stenosis mostly occur during infancy, but may need reintervention during adulthood.
• New LV systolic dysfunction and/or arrhythmias after arterial switch require full evaluation, including exclusion of ostial/proximal stenoses of the reimplanted coronary arteries.
• Failure of the RV-to-PA conduit (stenosis, regurgitation, or both)
is the predominant long-term complication requiring reintervention after the Rastelli operation.
7.2.9
Congenitally corrected transposition of the great arteries
• Systemic RV failure, systemic AV valve regurgitation, AV block,
and atrial arrhythmia are common late complications.
• Systemic AV valve regurgitation is an important driver of late outcome and, when severe, should be addressed before systemic
RV function becomes impaired.
ESC Guidelines
631


<!-- PAGE 70 -->

### Page 70

..............................................
...
7.2.10
Univentricular heart and Fontan operation
• Although quality of life is well preserved in many Fontan patients,
all require regular intensive follow-up at an ACHD expert centre as they are at risk of developing multiple severe complications including arrhythmia, heart failure, hepatic disease, and proteinlosing enteropathy.
• Low pulmonary artery pressure is mandatory for a good functioning Fontan circulation and a low threshold for invasive haemodynamic assessment is recommended when dysfunction is suspected, or complications occur.
• Arrhythmias are poorly tolerated and require immediate action.
• Pregnancy is feasible in selected patients with well-functioning
Fontan circulation but there is a high risk of miscarriage and pregnancy should be managed in an ACHD expert centre.
• Surveillance for liver problems is mandatory in all Fontan patients.
7.2.11
Coronary anomalies
• CCT is the preferred technique for the evaluation of high-risk anatomy including features such as an intramural course and orifice anomalies (slit-like orifice, acute-angle take-off, orifice >1 cm above the sinotubular junction).
• Assessment of stress-induced ischaemia, by means of advanced imaging modalities with physical stress, is the key for decision making.
• In patients with coronary fistulae, the presence of symptoms,
complications, and a significant shunt are the main indications for percutaneous or surgical closure.
8 ‘What to do’ and ‘what not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Treatment of arrhythmias in adult congenital heart disease
In patients with moderate and severe CHD complexity (Table 4) and documented arrhythmias, referral to a centre with a multidisciplinary team and expertise in ACHD patients and ACHD-related arrhythmia is indicated.
I
C
In CHD patients with documented arrhythmias or at high risk for post-procedural arrhythmias (e.g. ASD closure at older age)
considered for percutaneous or surgical (re)interventions, referral to a centre with a multidisciplinary team with expertise in these interventions and in invasive treatment of arrhythmias is indicated.
I
C
In mild CHD, catheter ablation is recommended over long-term medical therapy for symptomatic, sustained recurrent SVT
(AVNRT, AVRT, AT, and IART), or if SVT is potentially related to SCD (Table 7).
I
C
Catheter ablation is indicated as adjunctive therapy to ICDs in patients who present with recurrent monomorphic VT, incessant VT, or electrical storm not manageable by medical therapy or ICD reprogramming.
I
C
ICD implantation is indicated in adults with CHD who are survivors of an aborted cardiac arrest due to VF or haemodynamically untolerated VT after evaluation to deﬁne the cause of the event and exclusion of reversible causes.
I
C
ICD implantation is indicated in adults with CHD and sustained VT after haemodynamic evaluation and repair when indicated.
EP evaluation is required to identify patients in whom catheter ablation or surgical ablation may be beneﬁcial as adjunctive treatment or in whom it may offer a reasonable alternative.
I
C
Treatment of pulmonary arterial hypertension associated with congenital heart disease
It is recommended that patients with CHD and conﬁrmed pre-capillary PH are counselled against pregnancy.
I
C
Risk assessment is recommended in all patients with PAH-CHD.
I
C
In low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or sequential combination therapy is recommended and high-risk patients should be treated with initial combination therapy including parenteral prostanoids.
I
A
Atrial septal defect (native and residual)
In patients with evidence of RV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs) or LV disease, ASD closure is recommended regardless of symptoms.
I
B
Device closure is recommended as the method of choice for secundum ASD closure when technically suitable.
I
C
In elderly patients not suitable for device closure, it is recommended to carefully weigh the surgical risk against the potential beneﬁt of ASD closure.
I
C
In patients with non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory.
I
C
In patients with LV disease, it is recommended to perform balloon testing and carefully weigh the beneﬁt of eliminating LR
shunt against the potential negative impact of ASD closure on outcome due to an increase in ﬁlling pressure (taking closure,
fenestrated closure, and no closure into consideration).
I
C
ASD closure is not recommended in patients with Eisenmenger physiology, patients with PAH and PVR >_5 WU despite targeted PAH treatment, or desaturation on exercise.
III
C
Continued


<!-- PAGE 71 -->

### Page 71

Ventricular septal defect (native and residual)
In patients with evidence of LV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs), VSD closure is recommended regardless of symptoms.
I
C
VSD closure is not recommended in patients with Eisenmenger physiology and patients with severe PAH (PVR >_5 WU) presenting with desaturation on exercise.
III
C
Atrioventricular septal defect
Surgical repair is not recommended in patients with Eisenmenger physiology and patients with PAH (PVR >_5 WU) presenting with desaturation on exercise.
III
C
Surgical closure is recommended in patients with signiﬁcant RV volume overload and should only be performed by a congenital cardiac surgeon.
I
C
Valve surgery, preferably AV valve repair, is recommended in symptomatic patients with moderate to severe AV valve regurgitation and should be performed by a congenital cardiac surgeon.
I
C
In asymptomatic patients with severe left-sided AV valve regurgitation, valve surgery is recommended when LVESD >_45 mm and/or LVEF <_60% provided other causes of LV dysfunction are excluded.
I
C
Patent ductus arteriosus
In patients with evidence of LV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs), PDA closure is recommended regardless of symptoms.
I
C
Device closure is recommended as the method of choice when technically suitable.
I
C
PDA closure is not recommended in patients with Eisenmenger physiology and patients with lower limb desaturation on exercise.
III
C
Valvular aortic stenosis
Intervention is recommended in all symptomatic patients with severe high-gradient AS (mean gradient >_40 mmHg).
I
B
Intervention is indicated in patients with severe low-ﬂow, low-gradient (mean gradient <40 mmHg) AS with reduced EF and evidence of ﬂow (contractile) reserve excluding pseudosevere AS.
I
C
Intervention is indicated in asymptomatic patients with severe AS and an abnormal exercise test showing symptoms on exercise clearly related to AS.
I
C
Intervention is indicated in asymptomatic patients with severe AS and systolic LV dysfunction (LVEF <50%) not due to another cause.
I
C
Surgery is recommended when patients with severe AS undergo surgery of the ascending aorta or of another valve, or
CABG.
I
C
Supravalvular aortic stenosis
In patients with symptoms (spontaneous or on exercise test) and mean Doppler gradient >_40 mmHg, surgery is recommended.
I
C
In patients with mean Doppler gradient <40 mmHg, surgery is recommended when one or more of the following ﬁndings are present:
• Symptoms attributable to obstruction (exertional dyspnoea, angina, syncope).
• LV systolic dysfunction (EF <50% without other explanation).
• Surgery required for signiﬁcant CAD or valvular disease.
I
C
Subaortic stenosis
In symptomatic patients (spontaneous or on exercise test) with a mean Doppler gradient >_40 mmHg or severe AR, surgery is recommended.
I
C
Coarctation and re-coarctation of the aorta
Repair of coarctation or re-coarctation (surgically or catheter based) is indicated in hypertensive patients with an increased non-invasive gradient between upper and lower limbs conﬁrmed with invasive measurement (peak-to-peak >_20 mmHg) with preference for catheter treatment (stenting) when technically feasible.
I
C
Aortic surgery in aortopathies
Aortic valve repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young patients with Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves when performed by experienced surgeons.
I
C
Surgery is indicated in patients with Marfan syndrome who have aortic root disease with a maximal aortic sinus diameter >_50 mm.
I
C
Continued
ESC Guidelines
633


<!-- PAGE 72 -->

### Page 72

Right ventricular outﬂow tract obstruction
In valvular PS, balloon valvuloplasty is the intervention of choice, if anatomically suitable.
I
C
Provided that no valve replacement is required, RVOTO intervention at any level is recommended regardless of symptoms when the stenosis is severe (Doppler peak gradient is >64 mmHg).
I
C
If surgical valve replacement is the only option, it is indicated in patients with severe stenosis who are symptomatic.
I
C
If surgical valve replacement is the only option in patients with severe stenosis who are asymptomatic, it is indicated in the presence of one or more of the following:
 Objective decrease in exercise capacity.
 Decreasing RV function and/or progression of TR to at least moderate.
 RVSP >80 mmHg.
 RL shunting via an ASD or VSD.
I
C
Ebstein anomaly
Surgical repair is recommended in patients with severe TR and symptoms or objective deterioration of exercise capacity.
I
C
It is recommended that surgical repair is performed by a congenital surgeon with speciﬁc experience in Ebstein surgery.
I
C
If there is an indication for TV surgery, ASD/PFO closure is recommended at the time of valve repair if it is expected to be haemodynamically tolerated.
I
C
In patients with symptomatic arrhythmias or pre-excitation on the ECG, electrophysiologic testing followed by ablation therapy, if feasible, or surgical treatment of the arrhythmias in the case of planned heart surgery is recommended.
I
C
After repair of tetralogy of Fallot
PVRep is recommended in symptomatic patients with severe PR and/or at least moderate RVOTO.
I
C
In patients with no native outﬂow tract, catheter intervention (TPVI) should be preferred if anatomically feasible.
I
C
Transposition of the great arteries after atrial switch operation
In symptomatic patients with pulmonary venous atrium obstruction, surgical repair (catheter intervention rarely possible) is recommended.
I
C
In symptomatic patients with bafﬂe stenosis not amenable to catheter intervention, surgical repair is recommended.
I
C
In symptomatic patients with bafﬂe leaks not amenable to catheter-based closure, surgical repair is recommended.
I
C
PA banding in adults, as LV training with subsequent arterial switch procedure, is not recommended.
III
C
In symptomatic patients with bafﬂe stenosis, stenting is recommended when technically feasible.
I
C
In symptomatic patients with bafﬂe leaks and cyanosis at rest or during exercise, or with strong suspicion of paradoxical emboli, stenting (covered) or device closure is recommended when technically feasible.
I
C
In patients with bafﬂe leaks and symptoms due to LR shunt, stenting (covered) or device closure is recommended when technically feasible.
I
C
Transposition of the great arteries after arterial switch operation
Stenting or surgery (depending on substrate) is recommended for coronary artery stenosis causing ischaemia.
I
C
Congenitally corrected transposition of the great arteries
In symptomatic patients with severe TR and preserved or mildly impaired systemic RV systolic function (EF >40%), TV replacement is indicated.
I
C
Right ventricular to pulmonary artery conduits
Symptomatic patients with RVSP >60 mmHg (may be lower in case of reduced ﬂow) and/or severe PR should undergo intervention with preference for catheter intervention (TPVI) if anatomically feasible.
I
C
Univentricular heart
It is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres, including multimodality imaging as well as invasive work-up to decide whether they may beneﬁt from surgical or interventional procedures.
I
C
After Fontan operation
Sustained atrial arrhythmia with rapid AV conduction is a medical emergency and should be promptly treated with electrical cardioversion.
I
C
Anticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic events.
I
C
It is recommended that women with a Fontan circulation and any complication are counselled against pregnancy.
I
C
Cardiac catheterization is recommended at a low threshold in cases of unexplained oedema, exercise deterioration, newonset arrhythmia, cyanosis, and haemoptysis.
I
C
Continued


<!-- PAGE 73 -->

### Page 73

...............................................................................................
9 Appendix
Author/Task Force Member Affiliations:
Sonya V. Babu-Narayan, NHLI, Imperial College London, Royal
Brompton and Harefield NHS Foundation Trust, London, United
Kingdom; Werner Budts, Congenital and Structural Cardiology,
UZ Leuven and Department of Cardiovascular Sciences, KU Leuven,
Leuven, Belgium; Massimo Chessa, ACHD Unit, Paediatric and
Adult Congenital Heart Centre, IRCCS Policlinico San Donato, San
Donato Milanese, Milan, Italy; Gerhard-Paul Diller, Department of
Cardiology III, Adult Congenital and Valvular Heart Disease,
University
Hospital,
Muenster,
Germany;
Bernard
Iung,
Cardiology,
Bichat
Hospital,
Paris,
France;
Jolanda
Kluin,
Cardiothoracic
Surgery,
Amsterdam
UMC,
University of
Amsterdam, Amsterdam, Netherlands; Irene M. Lang, Cardiology,
Medical University of Vienna, Vienna, Austria; Folkert Meijboom,
Cardiology,
University
Medical
Centre
Utrecht,
Utrecht,
Netherlands; Philip Moons, Department of Public Health and
Primary Care, KU Leuven, Leuven, Belgium, and Institute of Health and Care Sciences, University of Gothenburg, Gothenburg, Sweden and Department of Paediatrics and Child Health, University of Cape
Town, Cape Town, South Africa; Barbara J. M. Mulder,
Cardiology, Amsterdam University Medical Center, Amsterdam,
Netherlands; Erwin Oechslin, Medicine, Division of Cardiology,
Peter Munk Cardiac Centre, University Health Network and
University of Toronto, Toronto, Ontario, Canada; Jolien W. RoosHesselink, Cardiology, Erasmus MC, Rotterdam, Netherlands;
Markus Schwerzmann, Center for Congenital Heart Disease,
Department of Cardiology, University Hospital Inselspital, University of Bern, Bern, Switzerland; Lars Sondergaard, Cardiology,
Rigshospitalet, Copenhagen, Denmark; Katja Zeppenfeld, Leiden
University Medical Centre, Leiden, Netherlands.
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Colin Baigent (United Kingdom), Jean-Philippe Collet (France),
Veronica Dean (France), Victoria Delgado (Netherlands), Donna
Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom),
Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway),
Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni
(Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany),
Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S.
Lewis
(Israel),
Be´la
Merkely
(Hungary),
Christian
Mueller
(Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia
Petronio
(Italy),
Dimitrios
J.
Richter
(Greece),
Marco
Roffi
(Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A.
Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Rhian M.
Touyz (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2020 ESC Guidelines for the management of adult congenital heart disease.
Algeria: Algerian Society of Cardiology, Naima Hammoudi;
Armenia:
Armenian
Cardiologists
Association,
Svetlana
V.
Grigoryan; Austria: Austrian Society of Cardiology, Johannes Mair;
Azerbaijan: Azerbaijan Society of Cardiology, Galib Imanov;
Belarus: Belorussian Scientific Society of Cardiologists, Jouri
Chesnov; Belgium: Belgian Society of Cardiology, Antoine Bondue;
Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, Naser Nabil; Bulgaria: Bulgarian Society of
Cardiology, Anna Kaneva; Croatia: Croatian Cardiac Society,
Anomalous coronary arteries
Non-pharmacological functional imaging (e.g. nuclear study, echocardiography, or CMR with physical stress) is recommended in patients with coronary anomalies to conﬁrm/exclude myocardial ischaemia.
I
C
Anomalous coronary arteries from the pulmonary artery
Surgery is recommended in patients with ALCAPA.
I
C
Surgery is recommended in patients with ARCAPA and symptoms attributable to anomalous coronary artery.
I
C
Anomalous aortic origin of the coronary artery
Surgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced myocardial ischaemia in a matching territory or high-risk anatomy.
I
C
Surgery is not recommended for AAORCA in asymptomatic patients without myocardial ischaemia and without high-risk anatomy.
III
C
AAOCA = anomalous aortic origin of a coronary artery; AAORCA anomalous aortic origin of the right coronary artery; ACHD = adult congenital heart disease; ALCAPA =
anomalous left coronary artery from the pulmonary artery; ARCAPA = anomalous right coronary artery from the pulmonary artery; AR = aortic regurgitation; AS = aortic stenosis; ASD = atrial septal defect; AT = atrial tachycardia; AV = atrioventricular; AVNRT = atrioventricular node reentrant tachycardia; AVRT = atrioventricular reentrant tachycardia; AVSD = atrioventricular septal defect; CABG = coronary artery bypass graft; CAD = coronary artery disease; CHD = congenital heart disease; CMR = cardiovascular magnetic resonance; ECG = electrocardiogram; EF = ejection fraction; EP = electrophysiology/electrophysiological; HTAD = heritable thoracic aortic disease; IART=
intraatrial reentrant tachycardia; ICD = implantable cardioverter deﬁbrillator; LR = left-to-right; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction;
LVESD = left ventricular end systolic diameter; PAH = pulmonary arterial hypertension; PAP = pulmonary arterial pressure; PAH-CHD = pulmonary arterial hypertension associated with congenital heart disease; PDA = patent ductus arteriosus; PFO = patent foramen ovale; PH = pulmonary hypertension; PR = pulmonary regurgitation; PS = pulmonary stenosis; PVR = pulmonary vascular resistance; PVRep = pulmonary valve replacement; RL = right-to-left; RV = right ventricle/ventricular; RVOTO = right ventricular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; SCD = sudden cardiac death; SVT = supraventricular tachycardia; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgitation; TV = tricuspid valve; UVH = univentricular heart; VF = ventricular ﬁbrillation; VSD = ventricular septal defect; VT = ventricular tachycardia; WU = Wood units;
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
635


<!-- PAGE 74 -->

### Page 74

.............................................................................................................................................................................
Margarita Brida; Cyprus: Cyprus Society of Cardiology, Ourania
Hadjisavva; Czech Republic: Czech Society of Cardiology, Jana
Rubackova-Popelova; Denmark: Danish Society of Cardiology,
Dorte Guldbrand Nielsen; Egypt: Egyptian Society of Cardiology,
Maiy Hamdy El Sayed; Estonia: Estonian Society of Cardiology, Raili
Ermel; Finland: Finnish Cardiac Society, Juha Sinisalo; France: French
Society of Cardiology, Jean-Benoit Thambo; Georgia: Georgian
Society of Cardiology, Zviad Bakhutashvili; Germany: German
Cardiac Society, Claudia Walther; Greece: Hellenic Society of
Cardiology, George Giannakoulas; Hungary: Hungarian Society of
Cardiology, Olga Hajnalka Balint; Ireland: Irish Cardiac Society,
Christopher J. Lockhart; Israel: Israel Heart Society, Amiram Nir;
Italy: Italian Federation of Cardiology, Adriano Murrone; Kosovo
(Republic of): Kosovo Society of Cardiology, Artan Ahmeti;
Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegova; Latvia:
Latvian Society of Cardiology, Ainars Rudzitis; Lebanon: Lebanese
Society of Cardiology, Zakhia Saliba; Lithuania: Lithuanian Society of
Cardiology, Lina Gumbiene; Luxembourg: Luxembourg Society of
Cardiology, Kerstin Wagner; Malta: Maltese Cardiac Society,
Maryanne
Caruana;
Montenegro:
Montenegro
Society of
Cardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of
Cardiology, Rachida Amri; Netherlands: Netherlands Society of
Cardiology, Berto J. Bouma; North Macedonia: North Macedonian
Society of Cardiology, Elizabeta Srbinovska-Kostovska; Norway:
Norwegian Society of Cardiology, Mette-Elise Estensen; Poland:
Polish Cardiac Society, Lidia Tomkiewicz-Pajak; Romania: Romanian
Society of Cardiology, Ioan Mircea Coman; Russian Federation:
Russian Society of Cardiology, Olga Moiseeva; San Marino: San
Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology
Society of Serbia, Anastazija Stojsic-Milosavljevic; Slovakia: Slovak
Society of Cardiology, Iveta Simkova; Slovenia: Slovenian Society of
Cardiology, Katja Prokselj; Spain: Spanish Society of Cardiology,
Pastora Gallego; Sweden: Swedish Society of Cardiology, Bengt
Johansson; Switzerland: Swiss Society of Cardiology, Matthias
Greutmann; Tunisia: Tunisian Society of Cardiology and CardioVascular Surgery, Essia Boughzela; Ukraine: Ukrainian Association of
Cardiology, Yuriy Sirenko; United Kingdom of Great Britain and
Northern Ireland: British Cardiovascular Society, Louise Coats.
10 References
1. Camm AJ, Lu¨scher TF, Maurer G, Serruys PW, European Society of Cardiology.
The ESC Textbook of Cardiovascular Medicine. 3rd ed. Oxford/New York: Oxford
University Press; 2019.
2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg
JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011;58:22412247.
3. Liu Y, Chen S, Zuhlke L, Black GC, Choy MK, Li N, Keavney BD. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol 2019;48:455463.
4. Lytzen R, Vejlstrup N, Bjerre J, Petersen OB, Leenskjold S, Dodd JK, Jorgensen FS,
Sondergaard L. Live-born major congenital heart disease in Denmark: incidence,
detection rate, and termination of pregnancy rate from 1996 to 2013. JAMA
Cardiol 2018;3:829837.
5. Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to
1992 in Belgium. Circulation 2010;122:22642272.
6. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to
2010. Circulation 2014;130:749756.
7. Moons P, Meijboom FJ, Baumgartner H, Trindade PT, Huyghe E, Kaemmerer H,
Working ESC Group on Grown-up Congenital Heart Disease. Structure and activities of adult congenital heart disease programmes in Europe. Eur Heart J
2010;31:13051310.
8. Baumgartner H, Budts W, Chessa M, Deanfield J, Eicken A, Holm J, Iserin L,
Meijboom F, Stein J, Szatmari A, Trindade PT, Walker F, Working Group on
Grown-up Congenital Heart Disease of the European Society of Cardiology.
Recommendations for organization of care for adults with congenital heart disease and for training in the subspecialty of ‘Grown-up Congenital Heart Disease’ in
Europe: a position paper of the Working Group on Grown-up Congenital Heart
Disease of the European Society of Cardiology. Eur Heart J 2014;35:686690.
9. Deanfield J, Thaulow E, Warnes C, Webb G, Kolbel F, Hoffman A, Sorenson K,
Kaemmer H, Thilen U, Bink-Boelkens M, Iserin L, Daliento L, Silove E, Redington
A, Vouhe P, Priori S, Alonso MA, Blanc JJ, Budaj A, Cowie M, Deckers J,
Fernandez BE, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth O,
Trappe HJ, Klein W, Blomstrom-Lundqvist C, de Backer G, Hradec J, Mazzotta G,
Parkhomenko A, Presbitero P, Torbicki A. Management of grown up congenital heart disease. Eur Heart J 2003;24:10351084.
10. Moons P, Hilderson D, Van Deyk K. Implementation of transition programs can prevent another lost generation of patients with congenital heart disease. Eur J
Cardiovasc Nurs 2008;7:259263.
11. Thomet C, Moons P, Budts W, De Backer J, Chessa M, Diller G, Eicken A,
Gabriel H, Gallego P, Giamberti A, Roos-Hesselink J, Swan L, Webb G,
Schwerzmann M, ESC Working Group on Grown-up Congenital Heart Disease.
Staffing, activities, and infrastructure in 96 specialised adult congenital heart disease clinics in Europe. Int J Cardiol 2019;292:100105.
12. Kovacs AH, Sears SF, Saidi AS. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. Am Heart J 2005;150:
193201.
13. Moons P, De Geest S, Budts W. Comprehensive care for adults with congenital heart disease: expanding roles for nurses. Eur J Cardiovasc Nurs 2002;1:2328.
14. Gratz A, Hess J, Hager A. Self-estimated physical functioning poorly predicts actual exercise capacity in adolescents and adults with congenital heart disease.
Eur Heart J 2009;30:497504.
15. Uretsky S, Gillam L, Lang R, Chaudhry FA, Argulian E, Supariwala A, Gurram S,
Jain K, Subero M, Jang JJ, Cohen R, Wolff SD. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol 2015;65:10781088.
16. Li W, West C, McGhie J, van den Bosch AE, Babu-Narayan SV, Meijboom F,
Mongeon FP, Khairy P, Kimball TR, Beauchesne LM, Ammash NM, Veldtman GR,
Oechslin
E,
Gatzoulis
MA,
Webb
G.
Consensus recommendations for echocardiography in adults with congenital heart defects from the International
Society of
Adult
Congenital
Heart
Disease
(ISACHD).
Int
J
Cardiol
2018;272:7783.
17. Mertens L, Friedberg MK. Systolic ventricular function. In:
Echocardiography in
Pediatric and Congenital Heart Disease: From Fetus to Adult; 2016, Hoboken, US:
Wiley-Blackwell, p.96131.
18. Di Salvo G, Miller O, Babu Narayan S, Li W, Budts W, Valsangiacomo Buechel
ER, Frigiola A, van den Bosch AE, Bonello B, Mertens L, Hussain T, Parish V,
Habib G, Edvardsen T, Geva T, Baumgartner H, Gatzoulis MA, EACVI Scientific
Documents Committee. Imaging the adult with congenital heart disease: a multimodality imaging approach-position paper from the EACVI. Eur Heart J Cardiovasc
Imaging 2018;19:10771098.
19. European Medicines Agency. EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://www.ema.europa.eu/en/docu ments/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restric tions-use-linear-gadolinium-agents_en.pdf (28 January 2020).
20. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt
OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW,
Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Zamorano JL,
Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C,
Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti
P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo
JL, Tendera M, Torbicki A, Wijns W, Windecker S, Kirchhof P, BlomstromLundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P,
Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le
Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske
B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC
Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task
Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart
Rhythm Association (EHRA). Eur Heart J 2013;34:22812329.
21. Kilner P, Nichol E, Rubens M. The roles of CT and CMR in Adult Congenital
Heart Disease. In: ESC Textbook of Cardiovascular Imaging. 2nd ed, Oxford:
Oxford University Press; 2015, p. 563600.


<!-- PAGE 75 -->

### Page 75

.............................................................................................................................................................................
22. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F,
Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak
E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I,
Zamorano JL, ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of
Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by:
European Association for Cardio-Thoracic Surgery (EACTS), the European
Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:30753128.
23. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS,
Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA.
Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005;112:828835.
24. Budts W, Borjesson M, Chessa M, van Buuren F, Trigo Trindade P, Corrado D,
Heidbuchel H, Webb G, Holm J, Papadakis M. Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription. Eur
Heart J 2013;34:36693674.
25. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti
P, Lansac E, Rodriguez Munoz D, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian
A, Walther T, Wendler O, Windecker S, Zamorano JL, ESC Scientific Document
Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:27392791.
26. Baggen VJ, van den Bosch AE, Eindhoven JA, Schut AW, Cuypers JA, Witsenburg
M, de Waart M, van Schaik RH, Zijlstra F, Boersma E, Roos-Hesselink JW.
Prognostic value of N-terminal pro-B-type natriuretic peptide, troponin-T, and growth-differentiation factor 15 in adult congenital heart disease. Circulation
2017;135:264279.
27. Van De Bruaene A, Hickey EJ, Kovacs AH, Crean AM, Wald RM, Silversides CK,
Redington AN, Ross HJ, Alba AC, Billia F, Nair K, Benson L, Horlick E, Osten M,
Colman J, Heggie J, Oechslin EN, Roche SL. Phenotype, management and predictors of outcome in a large cohort of adult congenital heart disease patients with heart failure. Int J Cardiol 2018;252:8087.
28. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2004;109:28722877.
29. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, BabuNarayan S, Wort SJ, Dimopoulos K, Gatzoulis MA. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 2015;132:21182125.
30. Budts W, Roos-Hesselink J, Radle-Hurst T, Eicken A, McDonagh TA, Lambrinou
E, Crespo-Leiro MG, Walker F, Frogoudaki AA. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of
Grown-Up Congenital Heart Disease and the Heart Failure Association of the
European Society of Cardiology. Eur Heart J 2016;37:14191427.
31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,
Gonzalez-Juanatey
JR,
Harjola
VP,
Jankowska
EA,
Jessup
M,
Linde
C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:21292200.
32. Hernandez-Madrid A, Paul T, Abrams D, Aziz PF, Blom NA, Chen J, Chessa M,
Combes N, Dagres N, Diller G, Ernst S, Giamberti A, Hebe J, Janousek J, Kriebel
T, Moltedo J, Moreno J, Peinado R, Pison L, Rosenthal E, Skinner JR, Zeppenfeld
K, ESC Scientific Document Group. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European
Society of Cardiology (ESC) Working Group on Grown-up Congenital Heart
Disease,
endorsed by
HRS,
PACES,
APHRS,
and
SOLAECE.
Europace
2018;20:17191753.
33. Van De Bruaene A, Meier L, Droogne W, De Meester P, Troost E, Gewillig M,
Budts W. Management of acute heart failure in adult patients with congenital heart disease. Heart Fail Rev 2018;23:114.
34. Zeppenfeld K, Schalij MJ, Bartelings MM, Tedrow UB, Koplan BA, Soejima K,
Stevenson WG. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 2007;116:22412252.
35. Kapel GF, Reichlin T, Wijnmaalen AP, Piers SR, Holman ER, Tedrow UB, Schalij
MJ, Stevenson WG, Zeppenfeld K. Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ
Arrhythm Electrophysiol 2015;8:102109.
36. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res 2004;61:208217.
37. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, Daniels CJ, Deal
BJ, Dearani JA, Groot N, Dubin AM, Harris L, Janousek J, Kanter RJ, Karpawich
PP, Perry JC, Seslar SP, Shah MJ, Silka MJ, Triedman JK, Walsh EP, Warnes CA.
PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES,
HRS, the American College of Cardiology (ACC), the American Heart
Association (AHA), the European Heart Rhythm Association (EHRA), the
Canadian Heart Rhythm Society (CHRS), and the International Society for Adult
Congenital Heart Disease (ISACHD). Heart Rhythm 2014;11:e102e165.
38. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,
Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur
Heart J 2016;37:28932962.
39. Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC. Mode of death in adults with congenital heart disease. Am J Cardiol 2000;86:11111116.
40. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, Budts
W, Zwinderman AH, Van Gelder IC, Mulder BJ. Sudden cardiac death in adult congenital heart disease. Circulation 2012;126:19441954.
41. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J,
Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH,
Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen
DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the
Management of Patients with Ventricular Arrhythmias and the Prevention of
Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur
Heart J 2015;36:27932867.
42. Engelfriet PM, Duffels MG, Moller T, Boersma E, Tijssen JG, Thaulow E,
Gatzoulis MA, Mulder BJ. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease.
Heart 2007;93:682687.
43. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
Cifkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM,
Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T,
Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J
2018;39:31653241.
44. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G,
Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA,
Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA,
Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the
Diagnosis and Treatment of Pulmonary Hypertension of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by:
Association for
European
Paediatric and
Congenital
Cardiology
(AEPC),
International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J
2016;37:67119.
45. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M,
Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913.
46. Dimopoulos K, Diller GP, Opotowsky AR, D’Alto M, Gu H, Giannakoulas G,
Budts W, Broberg CS, Veldtman G, Swan L, Beghetti M, Gatzoulis MA.
Definition and Management of segmental pulmonary hypertension. J Am Heart
Assoc 2018;7:e008587.
47. van Riel AC, Schuuring MJ, van Hessen ID, Zwinderman AH, Cozijnsen L,
Reichert CL, Hoorntje JC, Wagenaar LJ, Post MC, van Dijk AP, Hoendermis ES,
Mulder BJ, Bouma BJ. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification.
Int J Cardiol 2014;174:299305.
48. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J
2014;35:716724.
49. Vanderpool RR, Naeije R. Hematocrit-corrected pulmonary vascular resistance.
Am J Respir Crit Care Med 2018;198:305309.
50. Diller GP, Korten MA, Bauer UM, Miera O, Tutarel O, Kaemmerer H, Berger F,
Baumgartner H, German Competence Network for Congenital Heart Defects
Investigators. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. Eur Heart J
2016;37:14491455.
51. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ,
Gatzoulis MA. Improved survival among patients with Eisenmenger syndrome
ESC Guidelines
637


<!-- PAGE 76 -->

### Page 76

...........................................................................................................................................................................
receiving advanced therapy for pulmonary arterial hypertension. Circulation
2010;121:2025.
52. Rondelet B, Dewachter C, Kerbaul F, Kang X, Fesler P, Brimioulle S, Naeije R,
Dewachter L. Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of right ventricular failure. Eur Heart J 2012;33:10171026.
53. Gabriels C, De Meester P, Pasquet A, De Backer J, Paelinck BP, Morissens M,
Van De Bruaene A, Delcroix M, Budts W. A different view on predictors of pulmonary hypertension in secundum atrial septal defect.
Int
J
Cardiol
2014;176:833840.
54. Goetschmann S, Dibernardo S, Steinmann H, Pavlovic M, Sekarski N, Pfammatter
JP. Frequency of severe pulmonary hypertension complicating "isolated" atrial septal defect in infancy. Am J Cardiol 2008;102:340342.
55. Akagi S, Kasahara S, Sarashina T, Nakamura K, Ito H. Treat-and-repair strategy is a feasible therapeutic choice in adult patients with severe pulmonary arterial hypertension associated with a ventricular septal defect: case series. Eur Heart J
Case Rep 2018;2:17.
56. Bush A, Busst CM, Haworth SG, Hislop AA, Knight WB, Corrin B, Shinebourne
EA. Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J 1988;59:480485.
57. Kannan BR, Sivasankaran S, Tharakan JA, Titus T, Kumar Ajith Francis, VK
Krishnamoorthy, B Harikrishnan, KM Padmakumar, S Nair, R K. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Heart J 2003;55:161166.
58. Lopes AA, O’Leary PW. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009;19:431435.
59. Neutze JM, Ishikawa T, Clarkson PM, Calder AL, Barratt-Boyes BG, Kerr AR.
Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. Am J Cardiol 1989;63:327331.
60. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive diseaselong-term follow-up and prediction of outcome after surgical correction. Circulation 1987;76:10371042.
61. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A metaanalysis of randomized controlled trials in pulmonary arterial hypertension. Eur
Heart J 2009;30:394403.
62. Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S,
Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med 2016;4:291305.
63. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV,
Peacock AJ, Simonneau G, Vachiery JL, Grunig E, Oudiz RJ, Vonk-Noordegraaf A,
White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION
Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834844.
64. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper
MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J,
Moiseeva O, Zeng X, Simonneau G, McLaughlin VV. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:25222533.
65. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P,
Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon
O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN
Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809818.
66. Skoro-Sajer N, Gerges C, Balint OH, Kohalmi D, Kaldararova M, Simkova I,
Jakowitsch J, Gabriel H, Baumgartner H, Gerges M, Sadushi-Kolici R, Celermajer
DS, Lang IM. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart 2018;104:11951199.
67. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E,
Landzberg M, Bosentan Randomized Trial of Endothelin Antagonist Therapy-5
(BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Circulation 2006;114:4854.
68. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, He J,
Papadakis K, Pulido T, Galie N, MAESTRO Study Investigators. Evaluation of macitentan in patients with Eisenmenger syndrome. Circulation 2019;139:5163.
69. D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A,
Scognamiglio G, Russo MG, Calabro R. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and
Eisenmenger physiology. Int J Cardiol 2012;155:378382.
70. Fuller SM, He X, Jacobs JP, Pasquali SK, Gaynor JW, Mascio CE, Hill KD, Jacobs
ML, Kim YY. estimating mortality risk for adult congenital heart surgery: an analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database. Ann
Thorac Surg 2015;100:17281735; discussion 17351726.
71. O’Brien SM, Clarke DR, Jacobs JP, Jacobs ML, Lacour-Gayet FG, Pizarro C,
Welke KF, Maruszewski B, Tobota Z, Miller WJ, Hamilton L, Peterson ED,
Mavroudis C, Edwards FH. An empirically based tool for analyzing mortality associated with congenital heart surgery.
J
Thorac
Cardiovasc
Surg
2009;138:11391153.
72. Horer J, Roussin R, LeBret E, Ly M, Abdullah J, Marzullo R, Pabst von Ohain J,
Belli E. Validation of the grown-ups with congenital heart disease score. Heart
2018;104:10191025.
73. Karamlou T, Diggs BS, Person T, Ungerleider RM, Welke KF. National practice patterns for management of adult congenital heart disease: operation by pediatric heart surgeons decreases in-hospital death. Circulation 2008;118:23452352.
74. Chessa M, Baumgartner H, Michel-Behnke I, Berger F, Budts W, Eicken A,
Sondergaard L, Stein J, Wiztsemburg M, Thomson J. ESC Working Group
Position Paper: transcatheter adult congenital heart disease interventions: organization of care - recommendations from a Joint Working Group of the European
Society of Cardiology (ESC), European Association of Pediatric and Congenital
Cardiology (AEPC), and the European Association of Percutaneous Cardiac
Intervention (EAPCI). Eur Heart J 2019;40:10421048.
75. Haas NA, Bach S, Vcasna R, Laser KT, Sandica E, Blanz U, Jakob A, Dietl M,
Fischer M, Kanaan M, Lehner A. The risk of bacterial endocarditis after percutaneous and surgical biological pulmonary valve implantation. Int J Cardiol
2018;268:5560.
76. Kuijpers JM, Koolbergen DR, Groenink M, Peels KCH, Reichert CLA, Post MC,
Bosker HA, Wajon E, Zwinderman AH, Mulder BJM, Bouma BJ. Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart disease:
focus on the use of prosthetic material. Eur Heart J 2017;38:20482056.
77. Ostergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason G, Torp-Pedersen C,
Bruun NE, Sondergaard L, Kober L, Fosbol EL. Incidence of infective endocarditis among patients considered at high risk. Eur Heart J 2018;39:623629.
78. Thornhill MH, Jones S, Prendergast B, Baddour LM, Chambers JB, Lockhart PB,
Dayer MJ. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. Eur Heart J 2018;39:586595.
79. Pujol C, Niesert AC, Engelhardt A, Schoen P, Kusmenkov E, Pittrow D, Ewert P,
Kaemmerer H. Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol 2016;117:450455.
80. Yang H, Bouma BJ, Dimopoulos K, Khairy P, Ladouceur M, Niwa K, Greutmann
M, Schwerzmann M, Egbe A, Scognamiglio G, Budts W, Veldtman G, Opotowsky
AR, Broberg CS, Gumbiene L, Meijboom FJ, Rutz T, Post MC, Moe T, Lipczynska
M, Tsai SF, Chakrabarti S, Tobler D, Davidson W, Morissens M, van Dijk A,
Buber J, Bouchardy J, Skoglund K, Christersson C, Kronvall T, Konings TC,
Alonso-Gonzalez R, Mizuno A, Webb G, Laukyte M, Sieswerda GTJ, Shafer K,
Aboulhosn J, Mulder BJM. Non-vitamin K antagonist oral anticoagulants
(NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol 2019;299:123130
81. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler
KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R,
Camm AJ, Heidbuchel H, ESC Scientific Document Group. The 2018 European
Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Eur
Heart
J
2018;39:13301393.
82. Oechslin E. Hematological management of the cyanotic adult with congenital heart disease. Int J Cardiol 2004;97 (Suppl 1):109115.
83. Oechslin E. Management of adults with cyanotic congenital heart disease. Heart
2015;101:485494.
84. Broberg CS, Bax BE, Okonko DO, Rampling MW, Bayne S, Harries C, Davidson
SJ, Uebing A, Khan AA, Thein S, Gibbs JS, Burman J, Gatzoulis MA. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006;48:356365.
85. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca HP.
Systemic endothelial dysfunction in adults with cyanotic congenital heart disease.
Circulation 2005;112:11061112.
86. Perloff JK. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol
Clin 1993;11:689699.
87. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilen U,
Kaemmerer H, Moons P, Meijboom F, Popelova J, Laforest V, Hirsch R, Daliento
L, Thaulow E, Mulder B. The spectrum of adult congenital heart disease in
Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart
Survey on adult congenital heart disease. Eur Heart J 2005;26:23252333.
88. Hjortshoj CMS, Kempny A, Jensen AS, Sorensen K, Nagy E, Dellborg M,
Johansson B, Rudiene V, Hong G, Opotowsky AR, Budts W, Mulder BJ,
Tomkiewicz-Pajak L, D’Alto M, Prokselj K, Diller GP, Dimopoulos K, Estensen
ME, Holmstrom H, Turanlahti M, Thilen U, Gatzoulis MA, Sondergaard L. Past and current cause-specific mortality in Eisenmenger syndrome. Eur Heart J
2017;38:20602067.
89. Kempny A, Hjortshoj CS, Gu H, Li W, Opotowsky AR, Landzberg MJ, Jensen AS,
Sondergaard L, Estensen ME, Thilen U, Budts W, Mulder BJ, Blok I, TomkiewiczPajak L, Szostek K, D’Alto M, Scognamiglio G, Prokselj K, Diller GP, Dimopoulos


<!-- PAGE 77 -->

### Page 77

..........................................................................................................................................................................
K, Wort SJ, Gatzoulis MA. Predictors of death in contemporary adult patients with
Eisenmenger syndrome:
a multicenter study.
Circulation
2017;135:14321440.
90. Sakazaki H, Niwa K, Echigo S, Akagi T, Nakazawa M. Predictive factors for longterm prognosis in adults with cyanotic congenital heart diseaseJapanese multicenter study. Int J Cardiol 2007;120:7278.
91. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996;28:768772.
92. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R,
Vachiery
JL,
Paelinck
B,
Morissens
M,
Budts
W.
Iron deficiency is associated with adverse outcome in
Eisenmenger patients.
Eur
Heart
J
2011;32:27902799.
93. Diller
GP,
Alonso-Gonzalez
R,
Kempny
A,
Dimopoulos
K,
Inuzuka
R,
Giannakoulas G, Castle L, Lammers AE, Hooper J, Uebing A, Swan L, Gatzoulis
M, Wort SJ. B-type natriuretic peptide concentrations in contemporary
Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart 2012;98:736742.
94. Reardon LC, Williams RJ, Houser LS, Miner PD, Child JS, Aboulhosn JA.
Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome. Am J Cardiol 2012;110:15231526.
95. Cantor WJ, Harrison DA, Moussadji JS, Connelly MS, Webb GD, Liu P,
McLaughlin PR, Siu SC. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol 1999;84:677681.
96. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone
S. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart
J 1998;19:18451855.
97. Jensen AS, Idorn L, Thomsen C, von der Recke P, Mortensen J, Sorensen KE,
Thilen U, Nagy E, Kofoed KF, Ostrowski SR, Sondergaard L. Prevalence of cerebral and pulmonary thrombosis in patients with cyanotic congenital heart disease. Heart 2015;101:15401546.
98. Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults:
ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol
1999;34:223232.
99. Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003;92:182187.
100. Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J.
Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol
2003;42:19821987.
101. Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE, Davidson SJ, Bouzas B,
Gibbs
JS,
Burman
J,
Gatzoulis
MA.
Pulmonary arterial thrombosis in
Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007;50:634642.
102. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation 1993;87:19541959.
103. Wand O, Guber E, Guber A, Epstein Shochet G, Israeli-Shani L, Shitrit D.
Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial. Chest 2018;154:13791384.
104. Broberg CS, Uebing A, Cuomo L, Thein SL, Papadopoulos MG, Gatzoulis MA.
Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart 2007;93:15991603.
105. Harinck E, Hutter PA, Hoorntje TM, Simons M, Benatar AA, Fischer JC, de
Bruijn D, Meijboom EJ. Air travel and adults with cyanotic congenital heart disease. Circulation 1996;93:272276.
106. Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F.
Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus.
Circulation 1994;89:26732676.
107. Engelfriet P, Mulder BJ. Gender differences in adult congenital heart disease.
Neth Heart J 2009;17:414417.
108. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution.
Circulation 2007;115:163172.
109. Oliver JM, Gallego P, Gonzalez AE, Garcia-Hamilton D, Avila P, Alonso A, RuizCantador J, Peinado R, Yotti R, Fernandez-Aviles F. Impact of age and sex on survival and causes of death in adults with congenital heart disease. Int J Cardiol
2017;245:119124.
110. Zomer AC, Ionescu-Ittu R, Vaartjes I, Pilote L, Mackie AS, Therrien J,
Langemeijer MM, Grobbee DE, Mulder BJ, Marelli AJ. Sex differences in hospital mortality in adults with congenital heart disease: the impact of reproductive health. J Am Coll Cardiol 2013;62:5867.
111. Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, Vliegen
HW, van Dijk AP, Bouma BJ, Grobbee DE, Mulder BJ. Gender and outcome in adult congenital heart disease. Circulation 2008;118:2632.
112. D’Alto M, Budts W, Diller GP, Mulder B, Egidy Assenza G, Oreto L, Ciliberti P,
Bassareo PP, Gatzoulis MA, Dimopoulos K. Does gender affect the prognosis and risk of complications in patients with congenital heart disease in the modern era? Int J Cardiol 2019;290:156161.
113. Meijboom LJ, Timmermans J, Zwinderman AH, Engelfriet PM, Mulder BJ. Aortic root growth in men and women with the Marfan’s syndrome. Am J Cardiol
2005;96:14411444.
114. Sluman MA, Zomer AC, Vaartjes I, Bouma BJ, Mulder BJ. Congenital heart disease may hurt men more than women in job participation. Int J Cardiol
2014;172:230232.
115. Goossens E, Stephani I, Hilderson D, Gewillig M, Budts W, Van Deyk K, Moons
P, SWITCH(2) Investigators. Transfer of adolescents with congenital heart disease from pediatric cardiology to adult health care: an analysis of transfer destinations. J Am Coll Cardiol 2011;57:23682374.
116. Larsson L, Johansson B, Sandberg C, Apers S, Kovacs AH, Luyckx K, Thomet C,
Budts W, Enomoto J, Sluman MA, Wang JK, Jackson JL, Khairy P, Cook SC,
Alday L, Eriksen K, Dellborg M, Berghammer M, Rempel G, Menahem S,
Caruana M, Tomlin M, Soufi A, Fernandes SM, White K, Callus E, Kutty S,
Moons
P,
APPROACH-IS
Consortium;
International
Society for
Adult
Congenital Heart Disease (ISACHD). Geographical variation and predictors of physical activity level in adults with congenital heart disease. Int J Cardiol Heart
Vasc 2019;22:2025.
117. van der Bom T, Mulder BJ, Meijboom FJ, van Dijk AP, Pieper PG, Vliegen HW,
Konings TC, Zwinderman AH, Bouma BJ. Contemporary survival of adults with congenital heart disease. Heart 2015;101:19891995.
118. Afilalo J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Marelli AJ. Geriatric congenital heart disease: burden of disease and predictors of mortality. J Am
Coll Cardiol 2011;58:15091515.
119. Tutarel O, Kempny A, Alonso-Gonzalez R, Jabbour R, Li W, Uebing A,
Dimopoulos K, Swan L, Gatzoulis MA, Diller GP. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J 2014;35:725732.
120. Bhatt AB, Foster E, Kuehl K, Alpert J, Brabeck S, Crumb S, Davidson WR, Jr.,
Earing MG, Ghoshhajra BB, Karamlou T, Mital S, Ting J, Tseng ZH, American
Heart Association Council on Clinical Cardiology. Congenital heart disease in the older adult: a scientific statement from the American Heart Association.
Circulation 2015;131:18841931.
121. Greutmann M, Tobler D, Colman JM, Greutmann-Yantiri M, Librach SL, Kovacs
AH. Facilitators of and barriers to advance care planning in adult congenital heart disease. Congenit Heart Dis 2013;8:281288.
122. Troost E, Roggen L, Goossens E, Moons P, De Meester P, Van De Bruaene A,
Budts W. Advanced care planning in adult congenital heart disease: transitioning from repair to palliation and end-of-life care. Int J Cardiol 2019;279:5761.
123. Gibbs JS, McCoy AS, Gibbs LM, Rogers AE, Addington-Hall JM. Living with and dying from heart failure: the role of palliative care. Heart 2002;88 (Suppl
2):ii36ii39.
124. Crossland DS, Jackson SP, Lyall R, Hamilton JR, Hasan A, Burn J, O’Sullivan JJ.
Life insurance and mortgage application in adults with congenital heart disease.
Eur J Cardiothorac Surg 2004;25:931934.
125. Pickup L, Bowater S, Thorne S, Clift P, Hudsmith L. Travel insurance in adult congenital heart disease - do they declare their condition? Int J Cardiol
2016;223:316317.
126. Sluman MA, Apers S, Bouma BJ, van Melle JP, Peels CH, Post MC, Waskowsky
WM, Moons P, Mulder BJ. Uncertainties in insurances for adults with congenital heart disease. Int J Cardiol 2015;186:9395.
127. Sluman MA, Apers S, Sluiter JK, Nieuwenhuijsen K, Moons P, Luyckx K, Kovacs
AH, Thomet C, Budts W, Enomoto J, Yang HL, Jackson JL, Khairy P, Cook SC,
Subramanyan R, Alday L, Eriksen K, Dellborg M, Berghammer M, Mattsson E,
Mackie AS, Menahem S, Caruana M, Gosney K, Soufi A, Fernandes SM, White
KS, Callus E, Kutty S, Bouma BJ, Mulder BJM, APPROACH-IS consortium tISfACHDI. Education as important predictor for successful employment in adults with congenital heart disease worldwide.
Congenit
Heart
Dis
2019;14:362371.
128. Opic P, Utens EM, Cuypers JA, Witsenburg M, van den Bosch A, van Domburg
R, Bogers AJ, Boersma E, Pelliccia A, Roos-Hesselink JW. Sports participation in adults with congenital heart disease. Int J Cardiol 2015;187:175182.
129. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D,
Biffi A, Borjesson M, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A,
Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A,
Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A,
Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D,
Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T,
Senden J, Spataro A, Thiene G, Study Group of Sports Cardiology of the
Working Group of Cardiac Rehabilitation and Exercise Physiology, Working
Group of Myocardial and Pericardial Diseases of the European Society of
Cardiology. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of
ESC Guidelines
639


<!-- PAGE 78 -->

### Page 78

.............................................................................................................................................................................
Sports Cardiology of the Working Group of Cardiac Rehabilitation and
Exercise Physiology and the Working Group of Myocardial and Pericardial
Diseases of the
European
Society of
Cardiology.
Eur
Heart
J
2005;26:14221445.
130. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I,
Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B,
Kjeldsen KP, Longrois D, Luscher TF, Pierard L, Pocock S, Price S, Roffi M,
Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C. 2014 ESC/ESA
Guidelines on non-cardiac surgery: cardiovascular assessment and management:
The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European
Society of Anaesthesiology (ESA). Eur Heart J 2014;35:23832431.
131. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM,
Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A,
Valente AM, Van Hare GF. 2018 AHA/ACC Guideline for the Management of
Adults With Congenital Heart Disease. Circulation 2018:CIR0000000000000603.
132. van Hagen IM, Boersma E, Johnson MR, Thorne SA, Parsonage WA, Escribano
Subias P, Lesniak-Sobelga A, Irtyuga O, Sorour KA, Taha N, Maggioni AP, Hall
R, Roos-Hesselink JW, ROPAC investigators and EORP team. Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the
European
Society of
Cardiology.
Eur
J
Heart
Fail
2016;18:523533.
133. Sliwa K, van Hagen IM, Budts W, Swan L, Sinagra G, Caruana M, Blanco MV,
Wagenaar LJ, Johnson MR, Webb G, Hall R, Roos-Hesselink JW, ROPAC investigators. Pulmonary hypertension and pregnancy outcomes: data from the
Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail 2016;18:11191128.
134. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G,
Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A,
Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of
Pregnancy And Cardiac Disease (ROPAC). Eur Heart J 2019;40:38483855.
135. van Hagen IM, Roos-Hesselink JW, Donvito V, Liptai C, Morissens M, Murphy
DJ, Galian L, Bazargani NM, Cornette J, Hall R, Johnson MR. Incidence and predictors of obstetric and fetal complications in women with structural heart disease. Heart 2017;103:16101618.
136. Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR.
Contraception and cardiovascular disease. Eur Heart J 2015;36:17281734,
1734a1734b.
137. Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K,
Frattarelli JL, Tarlatzis BC, Fatemi HM, Lutjen P, Stegmann BJ. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod 2016;31:19972004.
138. Kametas NA, McAuliffe F, Krampl E, Chambers J, Nicolaides KH. Maternal cardiac function in twin pregnancy. Obstet Gynecol 2003;102:806815.
139. Opic P, Roos-Hesselink JW, Cuypers JA, Witsenburg M, van den Bosch A, van
Domburg RT, Bogers AJ, Utens EM. Sexual functioning is impaired in adults with congenital heart disease. Int J Cardiol 2013;168:38723877.
140. De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, Loeys B,
Pena ML, Teixido-Tura G, van de Laar I, Verstraeten A, Roos Hesselink J.
Genetic counselling and testing in adults with congenital heart disease: a consensus document of the ESC Working Group of Grown-Up Congenital Heart
Disease, the ESC Working Group on Aorta and Peripheral Vascular Disease and the
European
Society of
Human
Genetics.
Eur
J
Prev
Cardiol
2019:2047487319854552.
141. Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, Mital S,
Priest JR, Pu WT, Roberts A, Ware SM, Gelb BD, Russell MW, American Heart
Association Council on Cardiovascular Disease in the Young, Council on
Cardiovascular and Stroke Nursing, Council on Genomic and Precision Medicine.
Genetic basis for congenital heart disease: revisited: a scientific statement from the American Heart Association. Circulation 2018;138:e653e711.
142. Nyboe C, Karunanithi Z, Nielsen-Kudsk JE, Hjortdal VE. Long-term mortality in patients with atrial septal defect: a nationwide cohort-study. Eur Heart J
2018;39:993998.
143. Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med
1999;340:839846.
144. Murphy JG, Gersh BJ, McGoon MD, Mair DD, Porter CJ, Ilstrup DM, McGoon
DC, Puga FJ, Kirklin JW, Danielson GK. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med
1990;323:16451650.
145. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH,
Utens EM, Bogers AJ, Simoons ML. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur Heart J
2003;24:190197.
146. Attie F, Rosas M, Granados N, Zabal C, Buendia A, Calderon J. Surgical treatment for secundum atrial septal defects in patients >40 years old. A randomized clinical trial. J Am Coll Cardiol 2001;38:20352042.
147. Oster M, Bhatt AB, Zaragoza-Macias E, Dendukuri N, Marelli A. Interventional therapy versus medical therapy for secundum atrial septal defect: a systematic review (part 2) for the 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines. Circulation 2019;139:e814e830.
148. Butera G, Carminati M, Chessa M, Youssef R, Drago M, Giamberti A, Pome G,
Bossone E, Frigiola A. Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications. Am Heart J
2006;151:228234.
149. Fischer G, Stieh J, Uebing A, Hoffmann U, Morf G, Kramer HH. Experience with transcatheter closure of secundum atrial septal defects using the
Amplatzer septal occluder: a single centre study in 236 consecutive patients.
Heart 2003;89:199204.
150. Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS.
Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 2004;63:496502.
151. Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, Sievert
H. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am
Coll Cardiol 2004;43:302309.
152. Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K, Investigators
Amplatzer. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol 2002;39:18361844.
153. Humenberger M, Rosenhek R, Gabriel H, Rader F, Heger M, Klaar U, Binder T,
Probst P, Heinze G, Maurer G, Baumgartner H. Benefit of atrial septal defect closure in adults: impact of age. Eur Heart J 2011;32:553560.
154. Tadros VX, Asgar AW. Atrial septal defect closure with left ventricular dysfunction. EuroIntervention 2016;12 (Suppl X):X13X17.
155. Yong G, Khairy P, De Guise P, Dore A, Marcotte F, Mercier LA, Noble S,
Ibrahim R. Pulmonary arterial hypertension in patients with transcatheter closure of secundum atrial septal defects: a longitudinal study. Circ Cardiovasc Interv
2009;2:455462.
156. D’Alto M, Romeo E, Argiento P, Correra A, Santoro G, Gaio G, Sarubbi B,
Calabro R, Russo MG. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol 2013;168:37973801.
157. Lopez L, Houyel L, Colan SD, Anderson RH, Beland MJ, Aiello VD, Bailliard F,
Cohen MS, Jacobs JP, Kurosawa H, Sanders SP, Walters HL, 3rd, Weinberg PM,
Boris JR, Cook AC, Crucean A, Everett AD, Gaynor JW, Giroud J, Guleserian
KJ, Hughes ML, Juraszek AL, Krogmann ON, Maruszewski BJ, St Louis JD, Seslar
SP, Spicer DE, Srivastava S, Stellin G, Tchervenkov CI, Wang L, Franklin RCG.
Classification of ventricular septal defects for the Eleventh Iteration of the
International Classification of Diseases-striving for consensus: a report from the
International Society for Nomenclature of Paediatric and Congenital Heart
Disease. Ann Thorac Surg 2018;106:15781589.
158. Miyake T, Shinohara T, Fukuda T, Ikeoka M, Takemura T. Spontaneous closure of perimembranous ventricular septal defect after school age. Pediatr Int
2008;50:632635.
159. Gabriel HM, Heger M, Innerhofer P, Zehetgruber M, Mundigler G, Wimmer M,
Maurer G, Baumgartner H. Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am
Coll Cardiol 2002;39:10661071.
160. Neumayer U, Stone S, Somerville J. Small ventricular septal defects in adults.
Eur Heart J 1998;19:15731582.
161. Menting ME, Cuypers JA, Opic P, Utens EM, Witsenburg M, van den Bosch AE,
van Domburg RT, Meijboom FJ, Boersma E, Bogers AJ, Roos-Hesselink JW. The unnatural history of the ventricular septal defect: outcome up to 40 years after surgical closure. J Am Coll Cardiol 2015;65:19411951.
162. Meijboom F, Szatmari A, Utens E, Deckers JW, Roelandt JR, Bos E, Hess J.
Long-term follow-up after surgical closure of ventricular septal defect in infancy and childhood. J Am Coll Cardiol 1994;24:13581364.
163. Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, O’Fallon WM, Pieroni
DR, Wolfe RR, Weidman WH. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects.
Circulation 1993;87(2 Suppl):I38151.
164. Gatzoulis MA, Hechter S, Webb GD, Williams WG. Surgery for partial atrioventricular septal defect in the adult. Ann Thorac Surg 1999;67:504510.
165. El-Najdawi EK, Driscoll DJ, Puga FJ, Dearani JA, Spotts BE, Mahoney DW,
Danielson GK. Operation for partial atrioventricular septal defect: a fortyyear review.
J
Thorac
Cardiovasc
Surg
2000;119:880889;
discussion
889890.


<!-- PAGE 79 -->

### Page 79

.............................................................................................................................................................................
166. Malhotra SP, Lacour-Gayet F, Mitchell MB, Clarke DR, Dines ML, Campbell
DN. Reoperation for left atrioventricular valve regurgitation after atrioventricular septal defect repair.
Ann
Thorac
Surg
2008;86:147151;
discussion
151142.
167. Drenthen W, Pieper PG, van der Tuuk K, Roos-Hesselink JW, Voors AA,
Mostert B, Mulder BJ, Moons P, Ebels T, van Veldhuisen DJ, Investigators
Zahara. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J
2005;26:25812587.
168. Fisher RG, Moodie DS, Sterba R, Gill CC. Patent ductus arteriosus in adults-
long-term follow-up: nonsurgical versus surgical treatment. J Am Coll Cardiol
1986;8:280284.
169. Harrison DA, Benson LN, Lazzam C, Walters JE, Siu S, McLaughlin PR.
Percutaneous catheter closure of the persistently patent ductus arteriosus in the adult. Am J Cardiol 1996;77:10941097.
170. John S, Muralidharan S, Jairaj PS, Mani GK, Babuthaman, Krishnaswamy S,
Sukumar IP, Cherian G. The adult ductus: review of surgical experience with
131 patients. J Thorac Cardiovasc Surg 1981;82:314319.
171. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G,
Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis.
N Engl J Med 2000;343:611617.
172. Tzemos N, Therrien J, Yip J, Thanassoulis G, Tremblay S, Jamorski MT, Webb
GD,
Siu
SC.
Outcomes in adults with bicuspid aortic valves.
JAMA
2008;300:13171325.
173. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S,
Lancellotti P, LeFevre M, Miller F, Jr., Otto CM. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the
European Association of Cardiovascular Imaging and the American Society of
Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:254275.
174. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard
AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN,
Wang D, Pocock S, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl
J Med 2010;363:15971607.
175. Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, Szeto
WY, Dewey TM, Guyton RA, Bavaria JE, Babaliaros V, Gammie JS, Svensson L,
Williams M, Badhwar V, Mack MJ. Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015;99:5561.
176. Michelena HI, Della Corte A, Prakash SK, Milewicz DM, Evangelista A,
Enriquez-Sarano M. Bicuspid aortic valve aortopathy in adults: incidence, etiology, and clinical significance. Int J Cardiol 2015;201:400407.
177. Urban Z, Zhang J, Davis EC, Maeda GK, Kumar A, Stalker H, Belmont JW, Boyd
CD, Wallace MR. Supravalvular aortic stenosis: genetic and molecular dissection of a complex mutation in the elastin gene. Hum Genet 2001;109:512520.
178. Summers RM, Andrasko-Bourgeois J, Feuerstein IM, Hill SC, Jones EC, Busse
MK, Wise B, Bove KE, Rishforth BA, Tucker E, Spray TL, Hoeg JM. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia. Circulation 1998;98:509518.
179. Greutmann M, Tobler D, Sharma NC, Vonder Muhll I, Mebus S, Kaemmerer H,
Schuler PK, Deanfield JE, Beauchesne L, Salehian O, Hoffmann A, Golovatyuk V,
Oechslin EN, Silversides CK. Cardiac outcomes in adults with supravalvar aortic stenosis. Eur Heart J 2012;33:24422450.
180. Aboulhosn J, Child JS. Echocardiographic evaluation of congenital left ventricular outflow obstruction. Echocardiography 2015;32 Suppl 2:S140S147.
181. Roemers R, Kluin J, de Heer F, Arrigoni S, Bokenkamp R, van Melle J, Ebels T,
Hazekamp M. Surgical correction of supravalvar aortic stenosis: 52 years’ experience. World J Pediatr Congenit Heart Surg 2018;9:131138.
182. van der Linde D, Takkenberg JJ, Rizopoulos D, Heuvelman HJ, Budts W, van
Dijk AP, Witsenburg M, Yap SC, Bogers AJ, Silversides CK, Oechslin EN, RoosHesselink JW. Natural history of discrete subaortic stenosisin adults: a multicentre study. Eur Heart J 2013;34:15481556.
183. Choudhary P, Canniffe C, Jackson DJ, Tanous D, Walsh K, Celermajer DS. Late outcomes in adults with coarctation of the aorta. Heart 2015;101:11901195.
184. Padang R, Dennis M, Semsarian C, Bannon PG, Tanous DJ, Celermajer DS,
Puranik R. Detection of serious complications by MR imaging in asymptomatic young adults with repaired coarctation of the aorta.
Heart
Lung
Circ
2014;23:332338.
185. Ringel RE, Vincent J, Jenkins KJ, Gauvreau K, Moses H, Lofgren K, Usmani K.
Acute outcome of stent therapy for coarctation of the aorta: results of the coarctation of the aorta stent trial. Catheter Cardiovasc Interv 2013;82:503510.
186. Taggart NW, Minahan M, Cabalka AK, Cetta F, Usmani K, Ringel RE, COAST II
Investigators. Immediate outcomes of covered stent placement for treatment or prevention of aortic wall injury associated with coarctation of the aorta
(COAST II). JACC Cardiovasc Interv 2016;9:484493.
187. Ungerleider RM, Pasquali SK, Welke KF, Wallace AS, Ootaki Y, Quartermain
MD, Williams DA, Jacobs JP. Contemporary patterns of surgery and outcomes for aortic coarctation: an analysis of the Society of Thoracic Surgeons
Congenital
Heart
Surgery
Database.
J
Thorac
Cardiovasc
Surg
2013;145:150157; discussion 157158.
188. Hager A, Kanz S, Kaemmerer H, Schreiber C, Hess J. Coarctation Long-term
Assessment (COALA): significance of arterial hypertension in a cohort of 404
patients up to 27 years after surgical repair of isolated coarctation of the aorta,
even in the absence of restenosis and prosthetic material. J Thorac Cardiovasc
Surg 2007;134:738745.
189. Morgan GJ, Lee KJ, Chaturvedi R, Bradley TJ, Mertens L, Benson L. Systemic blood pressure after stent management for arch coarctation implications for clinical care. JACC Cardiovasc Interv 2013;6:192201.
190. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement
DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J,
Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH,
McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C,
Aboyans V, Desormais I, ESC Scientific Document Group. 2018 ESC/ESH
Guidelines for the management of arterial hypertension.
Eur
Heart
J
2018;39:30213104.
191. Troost E, Gewillig M, Daenen W, Meyns B, Bogaert J, Van Deyk K, Budts W.
Behaviour of polyester grafts in adult patients with repaired coarctation of the aorta. Eur Heart J 2009;30:11361141.
192. Siegmund AS, Kampman MAM, Bilardo CM, Balci A, van Dijk APJ, Oudijk MA,
Mulder BJM, Roos-Hesselink JW, Sieswerda GT, Koenen SV, Sollie-Szarynska
KM, Ebels T, van Veldhuisen DJ, Pieper PG, ZAHARA investigators. Pregnancy in women with corrected aortic coarctation: uteroplacental Doppler flow and pregnancy outcome. Int J Cardiol 2017;249:145150.
193. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H,
Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung
B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U,
Sirnes PA, Allmen RS, Vrints CJ, ESC Committee for Practice Guidelines. 2014
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic
Diseases of the
European
Society of
Cardiology
(ESC).
Eur
Heart
J
2014;35:28732926.
194. Attias D, Stheneur C, Roy C, Collod-Beroud G, Detaint D, Faivre L, Delrue
MA, Cohen L, Francannet C, Beroud C, Claustres M, Iserin F, Khau Van Kien P,
Lacombe D, Le Merrer M, Lyonnet S, Odent S, Plauchu H, Rio M, Rossi A, Sidi
D, Steg PG, Ravaud P, Boileau C, Jondeau G. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in
Marfan syndrome and related disorders. Circulation 2009;120:25412549.
195. Jondeau G, Detaint D, Tubach F, Arnoult F, Milleron O, Raoux F, Delorme G,
Mimoun L, Krapf L, Hamroun D, Beroud C, Roy C, Vahanian A, Boileau C.
Aortic event rate in the Marfan population: a cohort study. Circulation
2012;125:226232.
196. Rybczynski M, Treede H, Sheikhzadeh S, Groene EF, Bernhardt AM,
Hillebrand M, Mir TS, Kuhne K, Koschyk D, Robinson PN, Berger J,
Reichenspurner H, Meinertz T, von Kodolitsch Y. Predictors of outcome of mitral valve prolapse in patients with the Marfan syndrome. Am J Cardiol
2011;107:268274.
197. von Kodolitsch Y, Rybczynski M, Vogler M, Mir TS, Schuler H, Kutsche K,
Rosenberger G, Detter C, Bernhardt AM, Larena-Avellaneda A, Kolbel T,
Debus ES, Schroeder M, Linke SJ, Fuisting B, Napp B, Kammal AL, Puschel K,
Bannas P, Hoffmann BA, Gessler N, Vahle-Hinz E, Kahl-Nieke B, Thomalla G,
Weiler-Normann C, Ohm G, Neumann S, Benninghoven D, Blankenberg S,
Pyeritz RE. The role of the multidisciplinary health care team in the management of patients with Marfan syndrome. J Multidiscip Healthc 2016;9:587614.
198. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB,
Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller
PD, Wordsworth P, De Paepe AM. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476485.
199. Arnaud P, Hanna N, Benarroch L, Aubart M, Bal L, Bouvagnet P, Busa T, Dulac
Y, Dupuis-Girod S, Edouard T, Faivre L, Gouya L, Lacombe D, Langeois M,
Leheup B, Milleron O, Naudion S, Odent S, Tchitchinadze M, Ropers J, Jondeau
G, Boileau C. Genetic diversity and pathogenic variants as possible predictors of severity in a French sample of nonsyndromic heritable thoracic aortic aneurysms and dissections (nshTAAD). Genet Med 2019;21:20152024.
200. Campens L, Demulier L, De Groote K, Vandekerckhove K, De Wolf D, Roman
MJ, Devereux RB, De Paepe A, De Backer J. Reference values for echocardiographic assessment of the diameter of the aortic root and ascending aorta spanning all age categories. Am J Cardiol 2014;114:914920.
201. Devereux RB, de Simone G, Arnett DK, Best LG, Boerwinkle E, Howard BV,
Kitzman D, Lee ET, Mosley TH, Jr., Weder A, Roman MJ. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic
ESC Guidelines
641


<!-- PAGE 80 -->

### Page 80

.............................................................................................................................................................................
root dimensions in persons
>/=15
years of age.
Am
J
Cardiol
2012;110:11891194.
202. Franken R, El Morabit A, de Waard V, Timmermans J, Scholte AJ, van den Berg
MP, Marquering H, Planken NR, Zwinderman AH, Mulder BJ, Groenink M.
Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome. Int J Cardiol 2015;194:712.
203. Morris SA, Orbach DB, Geva T, Singh MN, Gauvreau K, Lacro RV. Increased vertebral artery tortuosity index is associated with adverse outcomes in children and young adults with connective tissue disorders.
Circulation
2011;124:388396.
204. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl
J Med 1994;330:13351341.
205. Teixido-Tura G, Forteza A, Rodriguez-Palomares J, Gonzalez Mirelis J,
Gutierrez L, Sanchez V, Ibanez B, Garcia-Dorado D, Evangelista A. Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome. J Am Coll Cardiol 2018;72:16131618.
206. Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D,
Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N,
Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent
S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G. Marfan Sartan: a randomized,
double-blind,
placebo-controlled trial.
Eur
Heart
J
2015;36:21602166.
207. Pitcher A, Emberson J, Lacro RV, Sleeper LA, Stylianou M, Mahony L, Pearson
GD, Groenink M, Mulder BJ, Zwinderman AH, De Backer J, De Paepe AM,
Arbustini E, Erdem G, Jin XY, Flather MD, Mullen MJ, Child AH, Forteza A,
Evangelista A, Chiu HH, Wu MH, Sandor G, Bhatt AB, Creager MA, Devereux
RB, Loeys B, Forfar JC, Neubauer S, Watkins H, Boileau C, Jondeau G, Dietz
HC, Baigent C. Design and rationale of a prospective, collaborative metaanalysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: a report from the Marfan
Treatment Trialists’ Collaboration. Am Heart J 2015;169:605612.
208. David TE, Feindel CM, David CM, Manlhiot C. A quarter of a century of experience with aortic valve-sparing operations.
J
Thorac
Cardiovasc
Surg
2014;148:872879; discussion 879880.
209. Groenink M, Mulder BJ. How to treat Marfan syndrome: an update. Eur Heart J
2016;37:986987.
210. Isselbacher EM, Bonaca MP, Di Eusanio M, Froehlich J, Bassone E, Sechtem U,
Pyeritz R, Patel H, Khoynezhad A, Eckstein HH, Jondeau G, Ramponi F, Abbasi
M, Montgomery D, Nienaber CA, Eagle K, Lindsay ME, International Registry of
Aortic Dissection Investigators. Recurrent aortic dissection: observations from the
International
Registry of
Aortic
Dissection.
Circulation
2016;134:10131024.
211. Mimoun L, Detaint D, Hamroun D, Arnoult F, Delorme G, Gautier M, Milleron
O, Meuleman C, Raoux F, Boileau C, Vahanian A, Jondeau G. Dissection in
Marfan syndrome: the importance of the descending aorta. Eur Heart J
2011;32:443449.
212. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J
Med 2014;370:19201929.
213. Michelena HI, Desjardins VA, Avierinos JF, Russo A, Nkomo VT, Sundt TM,
Pellikka PA, Tajik AJ, Enriquez-Sarano M. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation 2008;117:27762784.
214. Detaint D, Michelena HI, Nkomo VT, Vahanian A, Jondeau G, Sarano ME.
Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy. Heart
2014;100:126134.
215. Oliver JM, Alonso-Gonzalez R, Gonzalez AE, Gallego P, Sanchez-Recalde A,
Cuesta E, Aroca A, Lopez-Sendon JL. Risk of aortic root or ascending aorta complications in patients with bicuspid aortic valve with and without coarctation of the aorta. Am J Cardiol 2009;104:10011006.
216. Galian-Gay L, Carro Hevia A, Teixido-Tura G, Rodriguez Palomares J,
Gutierrez-Moreno L, Maldonado G, Gonzalez-Alujas MT, Sao-Aviles A, Gallego
P, Calvo-Iglesias F, Bermejo J, Robledo-Carmona J, Sanchez V, Saura D, Sevilla
T, Burillo-Sanz S, Guala A, Garcia-Dorado D, Evangelista A, BICUSPID investigators. Familial clustering of bicuspid aortic valve and its relationship with aortic dilation in first-degree relatives. Heart 2019;105:603608.
217. Silberbach M, Roos-Hesselink JW, Andersen NH, Braverman AC, Brown N,
Collins RT, De Backer J, Eagle KA, Hiratzka LF, Johnson WH, Jr., Kadian-Dodov
D, Lopez L, Mortensen KH, Prakash SK, Ratchford EV, Saidi A, van Hagen I,
Young LT, American Heart Association Council on Cardiovascular Disease in the Young, Council on Genomic and Precision Medicine, Council on Peripheral
Vascular Disease. Cardiovascular health in Turner syndrome: a scientific statement from the
American
Heart
Association.
Circ
Genom
Precis
Med
2018;11:e000048.
218. Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome:
report of the international Turner syndrome aortic dissection registry.
Circulation 2012;126:22202226.
219. McElhinney DB, Goldmuntz E. Double-chambered right ventricle. In: Diagnosis and
Management
Of
Adult
Congenital
Heart
Disease.
London:
Churchill
Livingstone; 2003. p305311.
220. Oliver JM, Garrido A, Gonzalez A, Benito F, Mateos M, Aroca A, Sanz E. Rapid progression of midventricular obstruction in adults with double-chambered right ventricle. J Thorac Cardiovasc Surg 2003;126:711717.
221. Hayes CJ, Gersony WM, Driscoll DJ, Keane JF, Kidd L, O’Fallon WM, Pieroni
DR, Wolfe RR, Weidman WH. Second natural history study of congenital heart defects. Results of treatment of patients with pulmonary valvar stenosis.
Circulation 1993;87 (2 suppl):I28137.
222. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K,
Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of
Echocardiography endorsed by the European Association of Echocardiography,
a registered branch of the European Society of Cardiology, and the Canadian
Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685713; quiz
786688.
223. Voet A, Rega F, de Bruaene AV, Troost E, Gewillig M, Van Damme S, Budts W.
Long-term outcome after treatment of isolated pulmonary valve stenosis. Int J
Cardiol 2012;156:1115.
224. Duijnhouwer AL, Navarese EP, Van Dijk AP, Loeys B, Roos-Hesselink JW, De
Boer MJ. Aneurysm of the pulmonary artery, a systematic review and critical analysis of current literature. Congenit Heart Dis 2016;11:102109.
225. Rydman R, Shiina Y, Diller GP, Niwa K, Li W, Uemura H, Uebing A, Barbero U,
Bouzas B, Ernst S, Wong T, Pennell DJ, Gatzoulis MA, Babu-Narayan SV. Major adverse events and atrial tachycardia in Ebstein’s anomaly predicted by cardiovascular magnetic resonance. Heart 2018;104:3744.
226. Chauvaud S, Berrebi A, d’Attellis N, Mousseaux E, Hernigou A, Carpentier A.
Ebstein’s anomaly: repair based on functional analysis. Eur J Cardiothorac Surg
2003;23:525531.
227. Shivapour JK, Sherwin ED, Alexander ME, Cecchin F, Mah DY, Triedman JK,
Marx GR, del Nido PJ, Walsh EP. Utility of preoperative electrophysiologic studies in patients with Ebstein’s anomaly undergoing the Cone procedure.
Heart Rhythm 2014;11:182186.
228. Raju V, Dearani JA, Burkhart HM, Grogan M, Phillips SD, Ammash N, Pike RP,
Johnson JN, O’Leary PW. Right ventricular unloading for heart failure related to Ebstein malformation. Ann Thorac Surg 2014;98:167173; discussion
173164.
229. Brown ML, Dearani JA, Danielson GK, Cetta F, Connolly HM, Warnes CA, Li
Z, Hodge DO, Driscoll DJ. Functional status after operation for Ebstein anomaly: the Mayo Clinic experience. J Am Coll Cardiol 2008;52:460466.
230. Morgenthau A, Frishman WH. Genetic origins of Tetralogy of Fallot. Cardiol Rev
2018;26:8692.
231. Wu MH, Lu CW, Chen HC, Kao FY, Huang SK. Adult congenital heart disease in a nationwide population 2000-2014: epidemiological trends, arrhythmia, and standardized mortality ratio. J Am Heart Assoc 2018;7:e007907.
232. Samad MD, Wehner GJ, Arbabshirani MR, Jing L, Powell AJ, Geva T, Haggerty
CM, Fornwalt BK. Predicting deterioration of ventricular function in patients with repaired tetralogy of Fallot using machine learning. Eur Heart J Cardiovasc
Imaging 2018;19:730738.
233. Freling HG, Willems TP, van Melle JP, van Slooten YJ, Bartelds B, Berger RM,
van Veldhuisen DJ,, Pieper PG. Effect of right ventricular outflow tract obstruction on right ventricular volumes and exercise capacity in patients with repaired tetralogy of Fallot. Am J Cardiol 2014;113:719723.
234. Ordovas KG, Keedy A, Naeger DM, Kallianos K, Foster E, Liu J, Saloner D,
Hope MD. Dilatation of the ascending aorta is associated with presence of aortic regurgitation in patients after repair of tetralogy of Fallot. Int J Cardiovasc
Imaging 2016;32:12651272.
235. Lumens J, Fan CS, Walmsley J, Yim D, Manlhiot C, Dragulescu A, GrosseWortmann L, Mertens L, Prinzen FW, Delhaas T, Friedberg MK. Relative impact of right ventricular electromechanical dyssynchrony versus pulmonary regurgitation on right ventricular dysfunction and exercise intolerance in patients after repair of tetralogy of Fallot. J Am Heart Assoc 2019;8:e010903.
236. Jalal Z, Sacher F, Fournier E, Cochet H, Derval N, Haissaguerre M, Fernandez
ET, Iriart X, Denis A, Ploux S, Pillois X, Bordachar P, Thambo JB. right ventricular electrical activation in patients with repaired tetralogy of Fallots. Circ
Arrhythm Electrophysiol 2019;12:e007141.
237. Nakamura A, Horigome H, Seo Y, Ishizu T, Sumazaki R. Right ventricular remodeling due to pulmonary regurgitation is associated with reduced left ventricular free wall strain in surgically repaired tetralogy of fallot. Circ J
2014;78:19601966.


<!-- PAGE 81 -->

### Page 81

.............................................................................................................................................................................
238. Wald RM, Valente AM, Marelli A. Heart failure in adult congenital heart disease:
emerging concepts with a focus on tetralogy of Fallot. Trends Cardiovasc Med
2015;25:422432.
239. Bokma JP, Winter MM, van Dijk AP, Vliegen HW, van Melle JP, Meijboom FJ,
Post MC, Berbee JK, Boekholdt SM, Groenink M, Zwinderman AH, Mulder
BJM, Bouma BJ. effect of losartan on right ventricular dysfunction: results from the double-blind, randomized REDEFINE trial (Right Ventricular Dysfunction in
Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in adults with repaired tetralogy of Fallot. Circulation 2018;137:14631471.
240. Valente AM, Gauvreau K, Assenza GE, Babu-Narayan SV, Schreier J, Gatzoulis
MA, Groenink M, Inuzuka R, Kilner PJ, Koyak Z, Landzberg MJ, Mulder B,
Powell AJ, Wald R, Geva T. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart 2014;100:247253.
241. Geva T, Mulder B, Gauvreau K, Babu-Narayan SV, Wald RM, Hickey K, Powell
AJ, Gatzoulis MA, Valente AM. preoperative predictors of death and sustained ventricular tachycardia after pulmonary valve replacement in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Circulation
2018;138:21062115.
242. Kapel GF, Sacher F, Dekkers OM, Watanabe M, Blom NA, Thambo JB, Derval
N, Schalij MJ, Jalal Z, Wijnmaalen AP, Zeppenfeld K. Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping are the substrate for ventricular tachycardia in repaired Tetralogy of Fallot. Eur Heart J 2017;38:268276.
243. Huntgeburth M, Germund I, Geerdink LM, Sreeram N, Udink Ten Cate FEA.
Emerging clinical applications of strain imaging and three-dimensional echocardiography for the assessment of ventricular function in adult congenital heart disease. Cardiovasc Diagn Ther 2019;9:S326S345.
244. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, Khan M,
Ho SY, Pennell DJ, Gatzoulis MA. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation 2006;113:405413.
245. Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marcon F,
Alexander ME, Walsh EP. Value of programmed ventricular stimulation after tetralogy of Fallot repair: a multicenter study. Circulation 2004;109:19942000.
246. Babu-Narayan SV, Diller GP, Gheta RR, Bastin AJ, Karonis T, Li W, Pennell DJ,
Uemura H, Sethia B, Gatzoulis MA, Shore DF. Clinical outcomes of surgical pulmonary valve replacement after repair of tetralogy of Fallot and potential prognostic value of preoperative cardiopulmonary exercise testing. Circulation
2014;129:1827.
247. Bokma JP, Geva T, Sleeper LA, Babu Narayan SV, Wald R, Hickey K, Jansen K,
Wassall R, Lu M, Gatzoulis MA, Mulder BJ, Valente AM. A propensity scoreadjusted analysis of clinical outcomes after pulmonary valve replacement in tetralogy of Fallot. Heart 2018;104:738744.
248. Oosterhof T, Meijboom FJ, Vliegen HW, Hazekamp MG, Zwinderman AH,
Bouma BJ, van Dijk AP, Mulder BJ. Long-term follow-up of homograft function after pulmonary valve replacement in patients with tetralogy of Fallot. Eur Heart
J 2006;27:14781484.
249. Heng EL, Gatzoulis MA, Uebing A, Sethia B, Uemura H, Smith GC, Diller GP,
McCarthy KP, Ho SY, Li W, Wright P, Spadotto V, Kilner PJ, Oldershaw P,
Pennell DJ, Shore DF, Babu-Narayan SV. Immediate and midterm cardiac remodeling after surgical pulmonary valve replacement in adults with repaired tetralogy of Fallot: a prospective cardiovascular magnetic resonance and clinical study. Circulation 2017;136:17031713.
250. Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG,
Koolbergen DR, Groenink M, Mulder BJ, Bouma BJ. Preoperative thresholds for mid-to-late haemodynamic and clinical outcomes after pulmonary valve replacement in tetralogy of Fallot. Eur Heart J 2016;37:829835.
251. Mongeon FP, Ben Ali W, Khairy P, Bouhout I, Therrien J, Wald RM, Dallaire F,
Bernier PL, Poirier N, Dore A, Silversides C, Marelli A. Pulmonary valve replacement for pulmonary regurgitation in adults with tetralogy of Fallot: a meta-analysisa report for the writing committee of the 2019 update of the
Canadian Cardiovascular Society Guidelines for the management of adults with congenital heart disease. Can J Cardiol 2019;35:17721783.
252. Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG,
Koolbergen DR, Groenink M, Mulder BJ, Bouma BJ. Individualised prediction of pulmonary homograft durability in tetralogy of
Fallot.
Heart
2015;101:17171723.
253. Abbas JR, Hoschtitzky JA. Which is the best tissue valve used in the pulmonary position, late after previous repair of tetralogy of Fallot? Interact Cardiovasc
Thorac Surg 2013;17:854860.
254. Egbe AC, Crestanello J, Miranda WR, Connolly HM. Thoracic aortic dissection in tetralogy of Fallot: a review of the national inpatient sample database. J Am
Heart Assoc 2019;8:e011943.
255. Daily JA, Tang X, Angtuaco M, Bolin E, Lang SM, Collins RT, 2nd. Transcatheter versus surgical pulmonary valve replacement in repaired tetralogy of Fallot. Am
J Cardiol 2018;122:498504.
256. Georgiev S, Ewert P, Tanase D, Hess J, Hager A, Cleuziou J, Meierhofer C,
Eicken A. A low residual pressure gradient yields excellent long-term outcome after percutaneous pulmonary valve implantation. JACC Cardiovasc
Interv
2019;12:15941603.
257. Abdelghani M, Nassif M, Blom NA, Van Mourik MS, Straver B, Koolbergen DR,
Kluin J, Tijssen JG, Mulder BJM, Bouma BJ, de Winter RJ. Infective endocarditis after melody valve implantation in the pulmonary position: a systematic review.
J Am Heart Assoc 2018;7:e008163.
258. McElhinney DB, Sondergaard L, Armstrong AK, Bergersen L, Padera RF, Balzer
DT, Lung TH, Berger F, Zahn EM, Gray RG, Hellenbrand WE, Kreutzer J,
Eicken A, Jones TK, Ewert P. Endocarditis After transcatheter pulmonary valve replacement. J Am Coll Cardiol 2018;72:27172728.
259. Bergersen L, Benson LN, Gillespie MJ, Cheatham SL, Crean AM, Hor KN,
Horlick EM, Lung TH, McHenry BT, Osten MD, Powell AJ, Cheatham JP.
Harmony feasibility trial: acute and short-term outcomes with a self-expanding transcatheter pulmonary valve. JACC Cardiovasc Interv 2017;10:17631773.
260. Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA,
Fernandes SM, Beauchesne L, Therrien J, Chetaille P, Gordon E, Vonder Muhll I,
Cecchin
F.
Implantable cardioverter-defibrillators in tetralogy of
Fallot.
Circulation 2008;117:363370.
261. Koyak Z, de Groot JR, Bouma BJ, Van Gelder IC, Budts W, Zwinderman AH,
Mulder BJ. Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int J Cardiol 2013;167:15321535.
262. Cauldwell M, Quail MA, Smith GS, Heng EL, Ghonim S, Uebing A, Swan L, Li
W, Patel RR, Pennell DJ, Steer PJ, Johnson MR, Gatzoulis MA, Babu-Narayan
SV. Effect of pregnancy on ventricular and aortic dimensions in repaired tetralogy of Fallot. J Am Heart Assoc 2017;6:e005420.
263. Bassett AS, Chow EW, Husted J, Weksberg R, Caluseriu O, Webb GD,
Gatzoulis MA. Clinical features of 78 adults with 22q11 Deletion Syndrome. Am
J Med Genet A 2005;138:307313.
264. Reddy VM, McElhinney DB, Amin Z, Moore P, Parry AJ, Teitel DF, Hanley FL.
Early and intermediate outcomes after repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries: experience with 85 patients. Circulation 2000;101:18261832.
265. Bull K, Somerville J, Ty E, Spiegelhalter D. Presentation and attrition in complex pulmonary atresia. J Am Coll Cardiol 1995;25:491499.
266. Valente AM, Cook S, Festa P, Ko HH, Krishnamurthy R, Taylor AM, Warnes
CA, Kreutzer J, Geva T. Multimodality imaging guidelines for patients with repaired tetralogy of
Fallot:
a report from the
American
Society of
Echocardiography:
developed in collaboration with the
Society for
Cardiovascular Magnetic Resonance and the Society for Pediatric Radiology. J
Am Soc Echocardiogr 2014;27:111141.
267. Presnell LB, Blankenship A, Cheatham SL, Owens GE, Staveski SL. An overview of pulmonary atresia and major aortopulmonary collateral arteries. World J
Pediatr Congenit Heart Surg 2015;6:630639.
268. Belli E, Mace L, Ly M, Dervanian P, Pineau E, Roussin R, Lebret E, Serraf A.
Surgical management of pulmonary atresia with ventricular septal defect in late adolescence and adulthood. Eur J Cardiothorac Surg 2007;31:236241.
269. Dearani JA, Danielson GK, Puga FJ, Schaff HV, Warnes CW, Driscoll DJ,
Schleck CD, Ilstrup DM. Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac Surg 2003;75:399410; discussion 410411.
270. Redington AN, Somerville J. Stenting of aortopulmonary collaterals in complex pulmonary atresia. Circulation 1996;94:24792484.
271. Giannakoulas G, Gatzoulis MA. Pulmonary arterial hypertension in congenital heart disease: current perspectives and future challenges. Hellenic J Cardiol
2016;57:218222.
272. Schuuring MJ, Bouma BJ, Cordina R, Gatzoulis MA, Budts W, Mullen MP, Vis JC,
Celermajer D, Mulder BJ. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol 2013;164:106110.
273. Van De Bruaene A, Toh N, Hickey EJ, Benson L, Horlick E, Granton JT,
Williams WG, Roche SL. Pulmonary hypertension in patients with a subaortic right ventricle:
prevalence,
impact and management.
Heart
2019;105:14711478.
274. Gelatt M, Hamilton RM, McCrindle BW, Connelly M, Davis A, Harris L, Gow
RM, Williams WG, Trusler GA, Freedom RM. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol
1997;29:194201.
275. Raissadati A, Nieminen H, Sairanen H, Jokinen E. Outcomes after the Mustard,
Senning and arterial switch operation for treatment of transposition of the great arteries in Finland: a nationwide 4-decade perspective. Eur J Cardiothorac
Surg 2017;52:573580.
276. Cuypers JA, Eindhoven JA, Slager MA, Opic P, Utens EM, Helbing WA,
Witsenburg M, van den Bosch AE, Ouhlous M, van Domburg RT, Rizopoulos
D, Meijboom FJ, Bogers AJ, Roos-Hesselink JW. The natural and unnatural
ESC Guidelines
643


<!-- PAGE 82 -->

### Page 82

.............................................................................................................................................................................
history of the Mustard procedure: long-term outcome up to 40 years. Eur
Heart J 2014;35:16661674.
277. Vejlstrup N, Sorensen K, Mattsson E, Thilen U, Kvidal P, Johansson B, Iversen K,
Sondergaard L, Dellborg M, Eriksson P. Long-term outcome of Mustard/Senning correction for transposition of the great arteries in Sweden and Denmark.
Circulation 2015;132:633638.
278. De Pasquale G, Bonassin Tempesta F, Lopes BS, Babic D, Oxenius A,
Seeliger T, Gruner C, Tanner FC, Biaggi P, Attenhofer Jost C, Greutmann M.
High prevalence of baffle leaks in adults after atrial switch operations for transposition of the great arteries.
Eur
Heart
J
Cardiovasc
Imaging
2017;18:531535.
279. Rydman R, Gatzoulis MA, Ho SY, Ernst S, Swan L, Li W, Wong T, Sheppard M,
McCarthy KP, Roughton M, Kilner PJ, Pennell DJ, Babu-Narayan SV. Systemic right ventricular fibrosis detected by cardiovascular magnetic resonance is associated with clinical outcome, mainly new-onset atrial arrhythmia, in patients after atrial redirection surgery for transposition of the great arteries. Circ
Cardiovasc Imaging 2015;8:e002628.
280. Zaragoza-Macias E, Zaidi AN, Dendukuri N, Marelli A. Medical therapy for systemic right ventricles: a systematic review (part 1) for the 2018 AHA/ACC
Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association
Task
Force on
Clinical
Practice
Guidelines.
J
Am
Coll
Cardiol
2019;73:15641578.
281. Ou P, Khraiche D, Celermajer DS, Agnoletti G, Le Quan Sang KH, Thalabard
JC, Quintin M, Raisky O, Vouhe P, Sidi D, Bonnet D. Mechanisms of coronary complications after the arterial switch for transposition of the great arteries. J
Thorac Cardiovasc Surg 2013;145:12631269.
282. Losay J, Touchot A, Serraf A, Litvinova A, Lambert V, Piot JD, Lacour-Gayet F,
Capderou A, Planche C. Late outcome after arterial switch operation for transposition of the great arteries. Circulation 2001;104:I-121 I-126.
283. Kempny A, Wustmann K, Borgia F, Dimopoulos K, Uebing A, Li W, Chen SS,
Piorkowski A, Radley-Smith R, Yacoub MH, Gatzoulis MA, Shore DF, Swan L,
Diller GP. Outcome in adult patients after arterial switch operation for transposition of the great arteries. Int J Cardiol 2013;167:25882593.
284. Khairy P, Clair M, Fernandes SM, Blume ED, Powell AJ, Newburger JW,
Landzberg MJ, Mayer JE, Jr. Cardiovascular outcomes after the arterial switch operation for
D-transposition of the great arteries.
Circulation
2013;127:331339.
285. Tobler D, Williams WG, Jegatheeswaran A, Van Arsdell GS, McCrindle BW,
Greutmann M, Oechslin EN, Silversides CK. Cardiac outcomes in young adult survivors of the arterial switch operation for transposition of the great arteries.
J Am Coll Cardiol 2010;56:5864.
286. Tobler D, Motwani M, Wald RM, Roche SL, Verocai F, Iwanochko RM,
Greenwood JP, Oechslin EN, Crean AM. Evaluation of a comprehensive cardiovascular magnetic resonance protocol in young adults late after the arterial switch operation for d-transposition of the great arteries. J Cardiovasc Magn
Reson 2014;16:98.
287. van Wijk SWH, van der Stelt F, Ter Heide H, Schoof PH, Doevendans PAFM,
Meijboom FJ, Breur JMPJ. Sudden death due to coronary artery lesions longterm after the arterial switch operation: a systematic review. Can J Cardiol
2017;33:11801187.
288. Hazekamp MG, Gomez AA, Koolbergen DR, Hraska V, Metras DR, Mattila IP,
Daenen W, Berggren HE, Rubay JE, Stellin G, European Congenital Heart
Surgeons Association. Surgery for transposition of the great arteries, ventricular septal defect and left ventricular outflow tract obstruction:
European
Congenital Heart Surgeons Association multicentre study. Eur J Cardiothorac
Surg 2010;38:699706.
289. van Dissel AC, Winter MM, van der Bom T, Vliegen HW, van Dijk APJ, Pieper
PG, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJM, Bouma
BJ. Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: follow-up of a multicenter randomized controlled trial. Int J Cardiol
2019;278:8487.
290. Hofferberth SC, Alexander ME, Mah DY, Bautista-Hernandez V, del Nido PJ,
Fynn-Thompson F. Impact of pacing on systemic ventricular function in L-transposition of the great arteries. J Thorac Cardiovasc Surg 2016;151:131138.
291. Mongeon FP, Connolly HM, Dearani JA, Li Z, Warnes CA. Congenitally corrected transposition of the great arteries ventricular function at the time of systemic atrioventricular valve replacement predicts long-term ventricular function. J Am Coll Cardiol 2011;57:20082017.
292. Caldarone CA, McCrindle BW, Van Arsdell GS, Coles JG, Webb G, Freedom
RM, Williams WG. Independent factors associated with longevity of prosthetic pulmonary valves and valved conduits.
J
Thorac
Cardiovasc
Surg
2000;120:10221030; discussion 1031.
293. Mohammadi S, Belli E, Martinovic I, Houyel L, Capderou A, Petit J, Planche C,
Serraf A. Surgery for right ventricle to pulmonary artery conduit obstruction:
risk factors for further reoperation. Eur J Cardiothorac Surg 2005;28:217222.
294. Peng LF, McElhinney DB, Nugent AW, Powell AJ, Marshall AC, Bacha EA, Lock
JE. Endovascular stenting of obstructed right ventricle-to-pulmonary artery conduits: a 15-year experience. Circulation 2006;113:25982605.
295. Sugiyama H, Williams W, Benson LN. Implantation of endovascular stents for the obstructive right ventricular outflow tract. Heart 2005;91:10581063.
296. Gatzoulis MA, Munk MD, Williams WG, Webb GD. Definitive palliation with cavopulmonary or aortopulmonary shunts for adults with single ventricle physiology. Heart 2000;83:5157.
297. Gilljam T, McCrindle BW, Smallhorn JF, Williams WG, Freedom RM.
Outcomes of left atrial isomerism over a 28-year period at a single institution. J
Am Coll Cardiol 2000;36:908916.
298. Hashmi A, Abu-Sulaiman R, McCrindle BW, Smallhorn JF, Williams WG,
Freedom RM. Management and outcomes of right atrial isomerism: a 26-year experience. J Am Coll Cardiol 1998;31:11201126.
299. Khairy
P,
Poirier
N,
Mercier
LA.
Univentricular heart.
Circulation
2007;115:800812.
300. Ro PS, Rychik J, Cohen MS, Mahle WT, Rome JJ. Diagnostic assessment before
Fontan operation in patients with bidirectional cavopulmonary anastomosis: are noninvasive methods sufficient? J Am Coll Cardiol 2004;44:184187.
301. de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. J Thorac Cardiovasc Surg
1988;96:682695.
302. Wilson WM, Valente AM, Hickey EJ, Clift P, Burchill L, Emmanuel Y, Gibson P,
Greutmann M, Grewal J, Grigg LE, Gurvitz M, Hickey K, Khairy P, Mayer JE, Jr.,
Teo E, Vonder Muhll I, Roche SL, Silversides CK, Wald RM. Outcomes of patients with hypoplastic left heart syndrome reaching adulthood after Fontan palliation: multicenter study. Circulation 2018;137:978981.
303. Kim SJ, Kim WH, Lim HG, Lee JY. Outcome of 200 patients after an extracardiac Fontan procedure. J Thorac Cardiovasc Surg 2008;136:108116.
304. Fontan F, Kirklin JW, Fernandez G, Costa F, Naftel DC, Tritto F, Blackstone EH.
Outcome after a "perfect" Fontan operation. Circulation 1990;81:15201536.
305. Khairy P, Fernandes SM, Mayer JE, Jr., Triedman JK, Walsh EP, Lock JE,
Landzberg MJ. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 2008;117:8592.
306. Giardini A, Hager A, Pace Napoleone C, Picchio FM. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann Thorac Surg
2008;85:818821.
307. Durongpisitkul K, Porter CJ, Cetta F, Offord KP, Slezak JM, Puga FJ, Schaff HV,
Danielson GK, Driscoll DJ. Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation. Circulation 1998;98:10991107.
308. Ben Ali W, Bouhout I, Khairy P, Bouchard D, Poirier N. Extracardiac versus lateral tunnel Fontan: a meta-analysis of long-term results. Ann Thorac Surg
2019;107:837843.
309. Munsterman ID, Duijnhouwer AL, Kendall TJ, Bronkhorst CM, Ronot M, van
Wettere M, van Dijk APJ, Drenth JPH, Tjwa E, Nijmegen Fontan Initiative. The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort. Eur Heart J 2019;40:10571068.
310. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998;115:10631073.
311. John AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. J Am Coll Cardiol 2014;64:5462.
312. Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH, Hsia TY,
Hsu DT, Kovacs AH, McCrindle BW, Newburger JW, Pike NA, Rodefeld M,
Rosenthal DN, Schumacher KR, Marino BS, Stout K, Veldtman G, Younoszai
AK, d’Udekem Y, American Heart Association Council on Cardiovascular
Disease in the Young and Council on Cardiovascular and Stroke Nursing.
Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the
American
Heart
Association.
Circulation
2019:CIR0000000000000696.
313. Abrams DJ, Earley MJ, Sporton SC, Kistler PM, Gatzoulis MA, Mullen MJ, Till JA,
Cullen S, Walker F, Lowe MD, Deanfield JE, Schilling RJ. Comparison of noncontact and electroanatomic mapping to identify scar and arrhythmia late after the Fontan procedure. Circulation 2007;115:17381746.
314. Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K,
Sorensen KE, Sondergaard L. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With
Endothelin Receptor Antagonist in Fontan Patients, a Randomized, PlaceboControlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
Circulation 2014;130:20212030.
315. Huddleston CB. The failing Fontan: options for surgical therapy. Pediatr Cardiol
2007;28:472476.
316. van Melle JP, Wolff D, Horer J, Belli E, Meyns B, Padalino M, Lindberg H, Jacobs
JP, Mattila IP, Berggren H, Berger RM, Pretre R, Hazekamp MG, Helvind M,


<!-- PAGE 83 -->

### Page 83

..................................................................
Nosal M, Tlaskal T, Rubay J, Lazarov S, Kadner A, Hraska V, Fragata J, Pozzi M,
Sarris G, Michielon G, di Carlo D, Ebels T. Surgical options after Fontan failure.
Heart 2016;102:11271133.
317. Mavroudis C,
Deal BJ, Backer CL, Stewart RD, Franklin WH, Tsao S, Ward
KM, DeFreitas RA. J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg 2007;84:14571465; discussion 14651466.
318. Yau JM, Singh R, Halpern EJ, Fischman D. Anomalous origin of the left coronary artery from the pulmonary artery in adults: a comprehensive review of 151
adult cases and a new diagnosis in a 53-year-old woman. Clin Cardiol
2011;34:204210.
319. Opolski MP, Pregowski J, Kruk M, Witkowski A, Kwiecinska S, Lubienska E,
Demkow M, Hryniewiecki T, Michalek P, Ruzyllo W, Kepka C. Prevalence and characteristics of coronary anomalies originating from the opposite sinus of
Valsalva in 8,522 patients referred for coronary computed tomography angiography. Am J Cardiol 2013;111:13611367.
320. Mainwaring RD, Reddy VM, Reinhartz O, Petrossian E, MacDonald M, Nasirov
T, Miyake CY, Hanley FL. Anomalous aortic origin of a coronary artery:
medium-term results after surgical repair in 50 patients. Ann Thorac Surg
2011;92:691697.
321. Frommelt PC, Sheridan DC, Berger S, Frommelt MA, Tweddell JS. Ten-year experience with surgical unroofing of anomalous aortic origin of a coronary artery from the opposite sinus with an interarterial course. J Thorac Cardiovasc
Surg 2011;142:10461051.
322. Jegatheeswaran A, Devlin PJ, McCrindle BW, Williams WG, Jacobs ML,
Blackstone EH, DeCampli WM, Caldarone CA, Gaynor JW, Kirklin JK, Lorber
RO, Mery CM, St Louis JD, Molossi S, Brothers JA. Features associated with myocardial ischemia in anomalous aortic origin of a coronary artery: a
Congenital
Heart
Surgeons’
Society study.
J
Thorac
Cardiovasc
Surg
2019;158:822834 e823.
323. Grani C, Benz DC, Steffen DA, Clerc OF, Schmied C, Possner M, Vontobel J,
Mikulicic F, Gebhard C, Pazhenkottil AP, Gaemperli O, Hurwitz S, Kaufmann
PA, Buechel RR. Outcome in middle-aged individuals with anomalous origin of the coronary artery from the opposite sinus: a matched cohort study. Eur Heart
J 2017;38:20092016.
324. Krasuski RA, Magyar D, Hart S, Kalahasti V, Lorber R, Hobbs R, Pettersson G,
Blackstone E. Long-term outcome and impact of surgery on adults with coronary arteries originating from the opposite coronary cusp.
Circulation
2011;123:154162.
325. Spertus JA, Eagle KA, Krumholz HM, Mitchell KR, Normand S-LT. American
College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. Circulation 2005;111:17031712.
326. National Quality Forum. Measure evaluation criteria. http://www.qualityforum.
org/Measuring_Performance/Submitting_Standards/Measure_Evaluation_
Criteria.aspx#comparison. (25 March 2020).
327. Bhatt DL, Drozda JP, Shahian DM, Chan PS, Fonarow GC,
Heidenreich PA,
Jacobs JP, Masoudi FA, Peterson ED, Welke KF. ACC/AHA/STS statement on the future of registries and the performance measurement enterprise. J Am Coll
Cardiol 2015;66:22302245.
328. Lindauer PK, Remus D, Roman S, Rothberg MB, Banjamin EM, Ma A, Bratzler
DW. Public reporting and pay for performance in hospital quality improvement. N Engl J Med 2007;356:486496.
329. Raleigh VS, Foot C. Getting the Measure of Quality. Opportunities and Challenges.
London: The King’s Fund; 2010.
ESC Guidelines
645


<!-- PAGE 84 -->

### Page 84

Downloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 28 April 2025

<!-- 2020_Atrial_Fibrillation.md -->

# ESC Guidelines: Atrial Fibrillation (2020)

**Source**: `2020_Atrial_Fibrillation.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 126

---

## Table of Contents

- [l](#l) *(p. 7)*
- [l](#l) *(p. 7)*
- [l](#l) *(p. 7)*
- [tblfn2](#tblfn2) *(p. 11)*
- [ehaa612-T23](#ehaa612-t23) *(p. 11)*
- [l](#l) *(p. 7)*
- [tblfn150](#tblfn150) *(p. 13)*
- [ehaa612-T24](#ehaa612-t24) *(p. 13)*
- [tblfn67](#tblfn67) *(p. 13)*
- [ehaa612-3.2](#ehaa612-32) *(p. 14)*
- [ehaa612-3.3](#ehaa612-33) *(p. 14)*
- [l](#l) *(p. 7)*
- [tblfn68](#tblfn68) *(p. 14)*
- [tblfn69](#tblfn69) *(p. 14)*
- [tblfn70](#tblfn70) *(p. 14)*
- [ehaa612-4.2](#ehaa612-42) *(p. 16)*
- [l](#l) *(p. 7)*
- [tblfn3](#tblfn3) *(p. 18)*
- [l](#l) *(p. 7)*
- [tblfn68a](#tblfn68a) *(p. 19)*
- [tblfn69a](#tblfn69a) *(p. 19)*
- [tblfn70a](#tblfn70a) *(p. 19)*
- [l](#l) *(p. 7)*
- [l](#l) *(p. 7)*
- [tblfn1](#tblfn1) *(p. 22)*
- [l](#l) *(p. 7)*
- [ehaa612-8](#ehaa612-8) *(p. 23)*
- [tblfn74](#tblfn74) *(p. 23)*
- [tblfn75](#tblfn75) *(p. 23)*
- [tblfn76](#tblfn76) *(p. 23)*
- [tblfn77](#tblfn77) *(p. 23)*
- [tblfn4](#tblfn4) *(p. 24)*
- [tblfn5](#tblfn5) *(p. 24)*
- [tblfn6](#tblfn6) *(p. 24)*
- [tblfn7](#tblfn7) *(p. 25)*
- [tblfn8](#tblfn8) *(p. 25)*
- [tblfn9](#tblfn9) *(p. 25)*
- [ehaa612-9](#ehaa612-9) *(p. 26)*
- [ehaa612-9](#ehaa612-9) *(p. 26)*
- [ehaa612-9](#ehaa612-9) *(p. 26)*
- [l](#l) *(p. 7)*
- [ehaa612-10.1.1](#ehaa612-1011) *(p. 29)*
- [tblfn10](#tblfn10) *(p. 29)*
- [tblfn11](#tblfn11) *(p. 29)*
- [tblfn12](#tblfn12) *(p. 29)*
- [ehaa612-10.1.2](#ehaa612-1012) *(p. 30)*
- [tblfn78](#tblfn78) *(p. 30)*
- [tblfn13](#tblfn13) *(p. 31)*
- [tblfn80](#tblfn80) *(p. 31)*
- [tblfn81](#tblfn81) *(p. 31)*
- [tblfn82](#tblfn82) *(p. 31)*
- [tblfn83](#tblfn83) *(p. 31)*
- [tblfn84](#tblfn84) *(p. 31)*
- [l](#l) *(p. 7)*
- [tblfn14](#tblfn14) *(p. 32)*
- [tblfn15](#tblfn15) *(p. 32)*
- [tblfn16](#tblfn16) *(p. 32)*
- [tblfn17](#tblfn17) *(p. 32)*
- [l](#l) *(p. 7)*
- [tblfn18](#tblfn18) *(p. 33)*
- [l](#l) *(p. 7)*
- [tblfn19](#tblfn19) *(p. 34)*
- [tblfn20](#tblfn20) *(p. 34)*
- [tblfn21](#tblfn21) *(p. 34)*
- [l](#l) *(p. 7)*
- [ehaa612-10.2](#ehaa612-102) *(p. 37)*
- [ehaa612-10.2.1](#ehaa612-1021) *(p. 37)*
- [tblfn22](#tblfn22) *(p. 37)*
- [tblfn23](#tblfn23) *(p. 37)*
- [tblfn24](#tblfn24) *(p. 37)*
- [tblfn25](#tblfn25) *(p. 37)*
- [ehaa612-10.2.1](#ehaa612-1021) *(p. 37)*
- [tblfn26](#tblfn26) *(p. 39)*
- [tblfn27](#tblfn27) *(p. 39)*
- [tblfn28](#tblfn28) *(p. 39)*
- [tblfn29](#tblfn29) *(p. 39)*
- [tblfn30](#tblfn30) *(p. 39)*
- [tblfn31](#tblfn31) *(p. 40)*
- [tblfn32](#tblfn32) *(p. 40)*
- [tblfn33](#tblfn33) *(p. 40)*
- [tblfn34](#tblfn34) *(p. 40)*
- [tblfn35](#tblfn35) *(p. 40)*
- [ehaa612-10.2](#ehaa612-102) *(p. 37)*
- [ehaa612-10.2.2.2.2](#ehaa612-102222) *(p. 42)*
- [ehaa612-10.2.2.2](#ehaa612-10222) *(p. 42)*
- [tblfn36](#tblfn36) *(p. 42)*
- [tblfn37](#tblfn37) *(p. 42)*
- [tblfn38](#tblfn38) *(p. 42)*
- [ehaa612-10.2.2.3](#ehaa612-10223) *(p. 44)*
- [tblfn39](#tblfn39) *(p. 44)*
- [tblfn40](#tblfn40) *(p. 44)*
- [tblfn41](#tblfn41) *(p. 44)*
- [tblfn42](#tblfn42) *(p. 44)*
- [tblfn43](#tblfn43) *(p. 44)*
- [ehaa612-10.2.2.3](#ehaa612-10223) *(p. 44)*
- [tblfn44](#tblfn44) *(p. 45)*
- [tblfn45](#tblfn45) *(p. 45)*
- [tblfn46](#tblfn46) *(p. 45)*
- [tblfn47](#tblfn47) *(p. 45)*
- [ehaa612-10.2.2.3.3](#ehaa612-102233) *(p. 47)*
- [ehaa612-10.2.2.3](#ehaa612-10223) *(p. 44)*
- [tblfn48](#tblfn48) *(p. 47)*
- [ehaa612-10.2.2.3](#ehaa612-10223) *(p. 44)*
- [ehaa612-10.2.2.3.6](#ehaa612-102236) *(p. 48)*
- [tblfn49](#tblfn49) *(p. 48)*
- [ehaa612-10.2](#ehaa612-102) *(p. 37)*
- [tblfn50](#tblfn50) *(p. 49)*
- [tblfn51](#tblfn51) *(p. 49)*
- [tblfn52](#tblfn52) *(p. 49)*
- [ehaa612-10.2](#ehaa612-102) *(p. 37)*
- [tblfn53](#tblfn53) *(p. 50)*
- [tblfn54](#tblfn54) *(p. 50)*
- [tblfn55](#tblfn55) *(p. 50)*
- [ehaa612-10.2.2.6](#ehaa612-10226) *(p. 51)*
- [tblfn56](#tblfn56) *(p. 51)*
- [tblfn57](#tblfn57) *(p. 51)*
- [tblfn58](#tblfn58) *(p. 51)*
- [ehaa612-10.2.2.6](#ehaa612-10226) *(p. 51)*
- [ehaa612-10.2](#ehaa612-102) *(p. 37)*
- [tblfn59](#tblfn59) *(p. 52)*
- [tblfn60](#tblfn60) *(p. 52)*
- [tblfn61](#tblfn61) *(p. 52)*
- [tblfn62](#tblfn62) *(p. 52)*
- [tblfn63](#tblfn63) *(p. 52)*
- [tblfn64](#tblfn64) *(p. 52)*
- [ehaa612-10.2](#ehaa612-102) *(p. 37)*
- [tblfn66](#tblfn66) *(p. 53)*
- [tblfn65](#tblfn65) *(p. 53)*
- [tblfn85](#tblfn85) *(p. 55)*
- [tblfn87](#tblfn87) *(p. 55)*
- [tblfn88](#tblfn88) *(p. 56)*
- [ehaa612-10.2](#ehaa612-102) *(p. 37)*
- [ehaa612-10.3](#ehaa612-103) *(p. 57)*
- [tblfn89](#tblfn89) *(p. 57)*
- [tblfn90](#tblfn90) *(p. 57)*
- [tblfn91](#tblfn91) *(p. 57)*
- [ehaa612-10.3.2.4](#ehaa612-10324) *(p. 58)*
- [ehaa612-10.3](#ehaa612-103) *(p. 57)*
- [ehaa612-11.1](#ehaa612-111) *(p. 59)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [tblfn92](#tblfn92) *(p. 59)*
- [tblfn93](#tblfn93) *(p. 59)*
- [tblfn94](#tblfn94) *(p. 59)*
- [tblfn95](#tblfn95) *(p. 59)*
- [tblfn96](#tblfn96) *(p. 59)*
- [tblfn97](#tblfn97) *(p. 59)*
- [ehaa612-11.3](#ehaa612-113) *(p. 60)*
- [tblfn98](#tblfn98) *(p. 62)*
- [tblfn99](#tblfn99) *(p. 62)*
- [tblfn100](#tblfn100) *(p. 62)*
- [tblfn101](#tblfn101) *(p. 62)*
- [tblfn102](#tblfn102) *(p. 62)*
- [tblfn103](#tblfn103) *(p. 62)*
- [tblfn104](#tblfn104) *(p. 62)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [ehaa612-11.4.3](#ehaa612-1143) *(p. 64)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [tblfn105](#tblfn105) *(p. 64)*
- [tblfn106](#tblfn106) *(p. 64)*
- [tblfn107](#tblfn107) *(p. 64)*
- [tblfn108](#tblfn108) *(p. 64)*
- [tblfn109](#tblfn109) *(p. 65)*
- [tblfn110](#tblfn110) *(p. 65)*
- [tblfn111](#tblfn111) *(p. 65)*
- [tblfn112](#tblfn112) *(p. 65)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [ehaa612-11.6](#ehaa612-116) *(p. 67)*
- [ehaa612-11.7](#ehaa612-117) *(p. 67)*
- [tblfn113](#tblfn113) *(p. 67)*
- [tblfn114](#tblfn114) *(p. 67)*
- [tblfn115](#tblfn115) *(p. 67)*
- [tblfn116](#tblfn116) *(p. 67)*
- [tblfn117](#tblfn117) *(p. 67)*
- [tblfn118](#tblfn118) *(p. 67)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [tblfn119](#tblfn119) *(p. 70)*
- [tblfn120](#tblfn120) *(p. 70)*
- [tblfn121](#tblfn121) *(p. 70)*
- [ehaa612-11](#ehaa612-11) *(p. 59)*
- [ehaa612-11.19](#ehaa612-1119) *(p. 71)*
- [tblfn122](#tblfn122) *(p. 71)*
- [tblfn123](#tblfn123) *(p. 71)*
- [tblfn124](#tblfn124) *(p. 71)*
- [tblfn125](#tblfn125) *(p. 71)*
- [tblfn126](#tblfn126) *(p. 71)*
- [tblfn127](#tblfn127) *(p. 71)*
- [tblfn128](#tblfn128) *(p. 71)*
- [tblfn129](#tblfn129) *(p. 71)*
- [tblfn130](#tblfn130) *(p. 71)*
- [tblfn131](#tblfn131) *(p. 71)*
- [tblfn132](#tblfn132) *(p. 71)*
- [tblfn133](#tblfn133) *(p. 71)*
- [ehaa612-11.19](#ehaa612-1119) *(p. 71)*
- [l](#l) *(p. 7)*
- [tblfn134](#tblfn134) *(p. 73)*
- [tblfn135](#tblfn135) *(p. 73)*
- [tblfn136](#tblfn136) *(p. 73)*
- [l](#l) *(p. 7)*
- [ehaa612-16](#ehaa612-16) *(p. 74)*
- [tblfn137](#tblfn137) *(p. 74)*
- [tblfn138](#tblfn138) *(p. 74)*
- [tblfn139](#tblfn139) *(p. 74)*
- [tblfn143](#tblfn143) *(p. 74)*
- [tblfn144](#tblfn144) *(p. 74)*
- [tblfn145](#tblfn145) *(p. 74)*
- [tblfn140](#tblfn140) *(p. 75)*
- [tblfn141](#tblfn141) *(p. 75)*
- [tblfn142](#tblfn142) *(p. 75)*
- [l](#l) *(p. 7)*
- [tblfn146](#tblfn146) *(p. 77)*
- [tblfn147](#tblfn147) *(p. 77)*
- [tblfn148](#tblfn148) *(p. 77)*
- [l](#l) *(p. 7)*
- [l](#l) *(p. 7)*
- [tblfn149](#tblfn149) *(p. 84)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for
Cardio-Thoracic Surgery (EACTS)
The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)
Developed with the special contribution of the European Heart
Rhythm Association (EHRA) of the ESC
Authors/Task Force Members: Gerhard Hindricks* (Chairperson) (Germany),
Tatjana Potpara* (Chairperson) (Serbia), Nikolaos Dagres (Germany), Elena Arbelo
(Spain), Jeroen J. Bax (Netherlands), Carina Blomstro¨m-Lundqvist (Sweden),
Giuseppe Boriani (Italy), Manuel Castella1 (Spain), Gheorghe-Andrei Dan
(Romania), Polychronis E. Dilaveris (Greece), Laurent Fauchier (France),
Gerasimos Filippatos (Greece), Jonathan M. Kalman (Australia), Mark La Meir1
(Belgium), Deirdre A. Lane (United Kingdom), Jean-Pierre Lebeau (France),
* Corresponding authors: The two chairpersons contributed equally to the document.
Gerhard Hindricks, University Clinic of Cardiology, Heart Center Leipzig, Department of Cardiology and Electrophysiology, Leipzig Heart Institute, Stru¨mpellstr. 39, 04289
Leipzig, Germany. Tel: þ49 34 1865 1410, Fax: þ49 34 1865 1460, Email: gerhard.hindricks@helios-gesundheit.de
Tatjana Potpara, School of Medicine, Belgrade University, dr Subotica 8, 11000 Belgrade, Serbia, and Cardiology Clinic, Clinical Centre of Serbia, Visegradska 26, 11000 Belgrade,
Serbia. Tel: þ38 11 1361 6319, Email: tatjana.potpara@med.bg.ac.rs
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers, and Author/Task Force Member afﬁliations: listed in the Appendix.
1Representing the European Association for Cardio-Thoracic Surgery (EACTS)
ESC entities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European
Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council on Stroke, Council on Valvular Heart Disease.
Working Groups: Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, e-Cardiology, Thrombosis.
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
V
C The European Society of Cardiology 2020. All rights reserved. For permissions please email: journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehaa612


<!-- PAGE 2 -->

### Page 2

................................................
Maddalena Lettino (Italy), Gregory Y. H. Lip (United Kingdom), Fausto J. Pinto
(Portugal), G. Neil Thomas (United Kingdom), Marco Valgimigli (Switzerland),
Isabelle C. Van Gelder (Netherlands), Bart P. Van Putte1 (Netherlands),
Caroline L. Watkins (United Kingdom)
Document Reviewers: Paulus Kirchhof (CPG Review Coordinator) (United Kingdom/Germany), Michael
Ku¨ hne (CPG Review Coordinator) (Switzerland), Victor Aboyans (France), Anders Ahlsson1 (Sweden),
Pawel Balsam (Poland), Johann Bauersachs (Germany), Stefano Benussi1 (Italy), Axel Brandes (Denmark),
Frieder Braunschweig (Sweden), A. John Camm (United Kingdom), Davide Capodanno (Italy), Barbara
Casadei (United Kingdom), David Conen (Canada), Harry J. G. M. Crijns (Netherlands), Victoria Delgado
(Netherlands), Dobromir Dobrev (Germany), Heinz Drexel (Austria), Lars Eckardt (Germany), Donna
Fitzsimons (United Kingdom), Thierry Folliguet (France), Chris P. Gale (United Kingdom), Bulent Gorenek
(Turkey), Karl Georg Haeusler (Germany), Hein Heidbuchel (Belgium), Bernard Iung (France), Hugo A.
Katus (Germany), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Christophe Leclercq
(France), Basil S. Lewis (Israel), Julia Mascherbauer (Austria), Jose Luis Merino (Spain), Be´la Merkely
(Hungary), Lluıs Mont (Spain), Christian Mueller (Switzerland), Klaudia V. Nagy (Hungary), Jonas Oldgren
(Sweden), Nikola Pavlovic (Croatia), Roberto F. E. Pedretti (Italy), Steffen E. Petersen (United Kingdom),
Jonathan P. Piccini (United States of America), Bogdan A. Popescu (Romania), Helmut Pu¨ rerfellner
(Austria), Dimitrios J. Richter (Greece), Marco Rofﬁ(Switzerland), Andrea Rubboli (Italy), Daniel Scherr
(Austria), Renate B. Schnabel (Germany), Iain A. Simpson (United Kingdom), Evgeny Shlyakhto (Russia),
Moritz F. Sinner (Germany), Jan Steffel (Switzerland), Miguel Sousa-Uva (Portugal), Piotr Suwalski1
(Poland), Martin Svetlosak (Slovakia), Rhian M. Touyz (United Kingdom)
The disclosure forms of all experts involved in the development of these guidelines are available on the
ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the Guidelines see European Heart Journal online.
Click here to access the corresponding chapter in section 41- Atrial ﬁbrillation
...................................................................................................................................................................................................
Keywords
Guidelines • atrial ﬁbrillation • anticoagulation • vitamin K antagonists • non-vitamin K antagonist oral anticoagulants • left atrial appendage occlusion • rate control • rhythm control • cardioversion • antiarrhythmic drugs • catheter ablation • pulmonary vein isolation • left atrial ablation • AF surgery • upstream therapy
• ABC pathway • screening • stroke • recommendations
Table of contents
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380
2.1 What is new in the 2020 Guidelines? . . . . . . . . . . . . . . . . . . . . . . . . . 381
3 Definition and diagnosis of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . 385
3.1 Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385
3.2 Diagnostic criteria for atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . 386
3.3 Diagnosis of atrial high-rate episodes/subclinical atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
4 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
4.1 Prediction of incident atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . 388
4.2 Pathophysiology of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . 388
5 Clinical features of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388
6 Atrial fibrillation subtypes, burden, and progression . . . . . . . . . . . . . . . 388
6.1 Classification of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388
6.2 Definition and assessment of atrial fibrillation burden . . . . . . . . . 391
6.3 Atrial fibrillation progression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392
6.4 Atrial cardiomyopathy: definition, classification, clinical implications, and diagnostic assessment . . . . . . . . . . . . . . . . . . . . . . . . . . 392
7 Screening for atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392
7.1 Screening tools . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392
7.2 Screening types and strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394
7.3 Benefits from and risks of screening for atrial fibrillation . . . . . . . 394
7.4 Cost-effectiveness of screening for atrial fibrillation . . . . . . . . . . . 394
7.5 Screening in high-risk populations . . . . . . . . . . . . . . . . . . . . . . . . . . . 395
7.5.1 Elderly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 395
8 Diagnostic assessment in atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . 395
8.1 Symptoms and quality of life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 395
8.2 Substrate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 395
9 Integrated management of patients with atrial fibrillation . . . . . . . . . . 398


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
9.1 Definitions and components of integrated management of atrial fibrillation patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 398
9.2 Multidisciplinary atrial fibrillation teams . . . . . . . . . . . . . . . . . . . . . . 398
9.2.1 Role of healthcare systems and budget constraints . . . . . . . 398
9.3 Patient involvement and shared decision making . . . . . . . . . . . . . . 398
9.3.1 Patient values and preferences . . . . . . . . . . . . . . . . . . . . . . . . . . 398
9.3.2 Patient education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399
9.4 Healthcare professional education . . . . . . . . . . . . . . . . . . . . . . . . . . . 399
9.5 Adherence to treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399
9.6 Technology tools supporting atrial fibrillation management . . . 399
9.7 Advantages of integrated management of atrial fibrillation patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
9.8 Measures (or approaches) for implementation of integrated management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
9.9 Treatment burden . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
9.10 Patient-reported outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
10 Patient management: the integrated ABC pathway . . . . . . . . . . . . . . 401
10.1 ‘A’  Anticoagulation/Avoid stroke . . . . . . . . . . . . . . . . . . . . . . . . 401
10.1.1 Stroke risk assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
10.1.2 Bleeding risk assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
10.1.3 Absolute contraindications to oral anticoagulants . . . . . . . 404
10.1.4 Stroke prevention therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . 404
10.1.4.1 Vitamin K antagonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404
10.1.4.2 Non-vitamin K antagonist oral anticoagulants . . . . . . . 405
10.1.4.3 Other antithrombotic drugs . . . . . . . . . . . . . . . . . . . . . . . 405
10.1.4.4 Combination therapy with oral anticoagulant and antiplatelet drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406
10.1.4.5 Left atrial appendage occlusion and exclusion . . . . . . . 406
10.1.4.5.1 Left atrial appendage occlusion devices . . . . . . . . . 406
10.1.4.5.2 Surgical left atrial appendage occlusion or exclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406
10.1.4.6 Long-term oral anticoagulation per atrial fibrillation burden . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407
10.1.4.7 Long-term oral anticoagulation per symptom control strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407
10.1.5 Management of anticoagulation-related bleeding risk . . . . 407
10.1.5.1 Strategies to minimize the risk of bleeding . . . . . . . . . . 407
10.1.5.2 High-risk groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407
10.1.6 Decision-making to avoid stroke . . . . . . . . . . . . . . . . . . . . . . . 407
10.2 ‘B’  Better symptom control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409
10.2.1 Rate control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409
10.2.1.1 Target/optimal ventricular rate range . . . . . . . . . . . . . . 409
10.2.1.2 Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409
10.2.1.3 Acute rate control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410
10.2.1.4 Atrioventricular node ablation and pacing . . . . . . . . . . 410
10.2.2 Rhythm control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413
10.2.2.1 Indications for rhythm control . . . . . . . . . . . . . . . . . . . . . 413
10.2.2.2 Cardioversion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
10.2.2.2.1 Immediate cardioversion/elective cardioversion . . 414
10.2.2.2.2 Electrical cardioversion . . . . . . . . . . . . . . . . . . . . . . . 414
10.2.2.2.3 Pharmacological cardioversion
(including ‘pill in the pocket’) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
10.2.2.2.4 Follow-up after cardioversion . . . . . . . . . . . . . . . . . 414
10.2.2.3 Atrial fibrillation catheter ablation . . . . . . . . . . . . . . . . . . 417
10.2.2.3.1 Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 417
10.2.2.3.2 Techniques and technologies . . . . . . . . . . . . . . . . . . 419
10.2.2.3.3 Complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419
10.2.2.3.4 AF catheter ablation outcome and impact of modifiable risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419
10.2.2.3.5 Follow-up after atrial fibrillation ablation . . . . . . . 420
10.2.2.3.7 Risk assessment for recurrence of AF post catheter ablation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420
10.2.2.4 Surgery for atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . 421
10.2.2.4.1 Concomitant surgery for atrial fibrillation:
indications, outcome, complications . . . . . . . . . . . . . . . . . . . . . 422
10.2.2.4.2 Stand-alone surgery for atrial fibrillation:
indications, outcome, complications . . . . . . . . . . . . . . . . . . . . . 422
10.2.2.5 Hybrid surgical/catheter ablation procedures . . . . . . . 422
10.2.2.6 Peri-procedural stroke risk management in patients undergoing rhythm control interventions . . . . . . . . . . 423
10.2.2.6.1 Management of stroke risk and oral anticoagulant therapy in atrial fibrillation patients undergoing cardioversion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423
10.2.2.6.2 Management of stroke risk and oral anticoagulant therapy in atrial fibrillation patients undergoing atrial fibrillation catheter ablation . . . . . . . . . . . . 424
10.2.2.6.3 Postoperative anticoagulation after surgery for atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424
10.2.2.7 Long-term antiarrhythmic drug therapy for rhythm control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424
10.2.2.7.1 Antiarrhythmic drugs . . . . . . . . . . . . . . . . . . . . . . . . . 424
10.3 ‘C  Cardiovascular risk factors and concomitant diseases: detection and management . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
10.3.1 Lifestyle interventions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
10.3.1.1 Obesity and weight loss . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
10.3.1.2 Alcohol and caffeine use . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
10.3.1.3 Physical activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
10.3.2 Specific cardiovascular risk factors/comorbidities . . . . . . . 430
10.3.2.1 Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
10.3.2.2 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
10.3.2.3 Coronary artery disease . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
10.3.2.4 Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
10.3.2.5 Sleep apnoea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
11 The ABC pathway in specific clinical settings/conditions/
patient populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431
11.1 Atrial fibrillation with haemodynamic instability . . . . . . . . . . . . . 431
11.2 First-diagnosed (new-onset) atrial fibrillation . . . . . . . . . . . . . . . . 431
11.3 Acute coronary syndromes, percutaneous coronary intervention, and chronic coronary syndromes in patients with atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 432
11.4 Acute stroke or intracranial haemorrhage in patients with atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
11.4.1 Patients with atrial fibrillation and acute ischaemic stroke or transient ischaemic attack . . . . . . . . . . . . . . . . . . . . . . . . . . 435
11.4.2 Cryptogenic stroke/embolic stroke with undetermined source . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
11.4.3 Post-stroke patients without known atrial fibrillation . . . . 436
11.4.4 Management of patients with atrial fibrillation postintracranial haemorrhage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436
11.5 Active bleeding on anticoagulant therapy: management and reversal drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438
11.6 Atrial fibrillation and heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . 439
11.7 Atrial fibrillation and valvular heart disease . . . . . . . . . . . . . . . . . . 439
11.8 Atrial fibrillation and chronic kidney disease . . . . . . . . . . . . . . . . . 440
ESC Guidelines
375


<!-- PAGE 4 -->

### Page 4

.............................................................................................................................................................................
11.9 Atrial fibrillation and peripheral artery disease . . . . . . . . . . . . . . . 440
11.10 Atrial fibrillation and endocrine disorders . . . . . . . . . . . . . . . . . . 440
11.11 Atrial fibrillation and gastrointestinal disorders . . . . . . . . . . . . . 440
11.12 Atrial fibrillation and haematological disorders . . . . . . . . . . . . . 441
11.13 The elderly and frail with atrial fibrillation . . . . . . . . . . . . . . . . . . 441
11.14 Patients with cognitive impairment/dementia . . . . . . . . . . . . . . 441
11.15 Atrial fibrillation and congenital heart disease . . . . . . . . . . . . . . 441
11.16 Atrial fibrillation in inherited cardiomyopathies and primary arrhythmia syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 442
11.17 Atrial fibrillation during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . 442
11.18 Atrial fibrillation in professional athletes . . . . . . . . . . . . . . . . . . . 443
11.19 Postoperative atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443
11.19.1 Prevention of postoperative AF . . . . . . . . . . . . . . . . . . . . . . . 444
11.19.2 Prevention of thrombo-embolic events . . . . . . . . . . . . . . . 444
12 Prevention of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 445
12.1 Primary prevention of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . 445
12.2 Secondary prevention of atrial fibrillation . . . . . . . . . . . . . . . . . . . 445
13 Sex-related differences in atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . 445
14 Implementation of the atrial fibrillation guidelines . . . . . . . . . . . . . . . . 446
15 Quality measures and clinical performance indicators in the management of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 446
16 Epidemiology, clinical implications, and management of atrial high-rate episodes/subclinical atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . 446
17 Atrial fibrillation and other atrial tachyarrhythmias (atrial flutter and atrial tachycardias) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449
18 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449
19 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450
20 ‘What to do’ and ‘what not to do’ messages from the
Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 452
21 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 456
22 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 456
23 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457
List of recommendations
New recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381
Changes in the recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383
Recommendations for diagnosis of AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
Recommendations for structured characterization of AF . . . . . . . . . . . 391
Recommendations for screening to detect AF . . . . . . . . . . . . . . . . . . . . . . 395
Recommendations for diagnostic evaluation of patients with AF . . . . 397
Recommendations about integrated AF management . . . . . . . . . . . . . . 401
Recommendations for the prevention of thrombo-embolic events in AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 408
Recommendations for ventricular rate control in patients with AF . . 412
Recommendations for rhythm control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
Recommendations for cardioversion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 417
Recommendations for rhythm control/catheter ablation of AF . . . . . . 421
Recommendations for surgical ablation of AF . . . . . . . . . . . . . . . . . . . . . . 422
Recommendations for stroke risk management peri-cardioversion . . 423
Recommendations for stroke risk management peri-catheter ablation . . 424
Recommendations for postoperative anticoagulation after
AF surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424
Recommendations for long-term antiarrhythmic drugs . . . . . . . . . . . . . 429
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with AF . . . . . . . . . . . 431
Recommendations for management of AF with haemodynamic instability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431
Recommendations for patients with AF and an ACS, PCI, or CCS . . . 434
Recommendations for the search for AF in patients with cryptogenic stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436
Recommendations for secondary stroke prevention in AF
patients after acute ischaemic stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
Recommendations for stroke prevention in AF patients after intracranial haemorrhage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
Recommendations for the management of active bleeding on OAC . . . 439
Recommendations for patients with valvular heart disease and AF . . . 439
Recommendations for the management of AF in patients with congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 442
Recommendations for the management of AF during pregnancy . . . . 443
Recommendations for sports activity in patients with AF . . . . . . . . . . . 443
Recommendations for postoperative AF . . . . . . . . . . . . . . . . . . . . . . . . . . . 445
Recommendations pertaining to sex-related differences in AF . . . . . . 446
Recommendations for quality measures in patients with AF . . . . . . . . . 446
Recommendations for management of patients with AHRE . . . . . . . . . 449
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380
Table 3 Definition of atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385
Table 4 Classification of AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390
Table 5 Sensitivity and specificity of various AF screening tools considering the 12-lead ECG as the gold standard . . . . . . . . . . . . . . . . . . 394
Table 6 EHRA symptom scale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 396
Table 7 Stroke risk factors in patients with AF . . . . . . . . . . . . . . . . . . . . . . 402
Table 8 CHA2DS2-VASc score . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403
Table 9 Risk factors for bleeding with OAC and antiplatelet therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403
Table 10 Clinical risk factors in the HAS-BLED score . . . . . . . . . . . . . . . 404
Table 11 Dose selection criteria for NOACs . . . . . . . . . . . . . . . . . . . . . . . 405
Table 12 Antithrombotic therapy after left atrial appendage occlusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406
Table 13 Drugs for rate control in AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411
Table 14 Antiarrhythmic drugs used for restoration of sinus rhythm . . 416
Table 15 Goals of follow-up after cardioversion of AF . . . . . . . . . . . . . . 417
Table 16 Procedure-related complications in catheter ablation and thoracoscopic ablation of AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419
Table 17 Key issues in follow-up after AF catheter ablation . . . . . . . . . 420
Table 18 Principles of antiarrhythmic drug therapy . . . . . . . . . . . . . . . . . 425
Table 19 Rules to initiate antiarrhythmic drugs for long-term rhythm control in AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425
Table 20 AADs used for long-term maintenance of sinus rhythm in AF patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 426
Table 21 Non-antiarrhythmic drugs with antiarrhythmic properties (upstream therapy) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
Table 22 Summary of quality indicators for the diagnosis and management of AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
List of figures
Figure 1 Diagnosis of AHRE/subclinical AF . . . . . . . . . . . . . . . . . . . . . . . . . 386


<!-- PAGE 5 -->

### Page 5

............................................................................................................................................................................
Figure 2 Epidemiology of AF: prevalence; and lifetime risk and projected rise in the incidence and prevalence . . . . . . . . . . . . . . . . . . . . . 387
Figure 3 Summary of risk factors for incident AF . . . . . . . . . . . . . . . . . . . . 388
Figure 4 Clinical presentation of AF and AF-related outcomes . . . . . . 389
Figure 5 4S-AF scheme as an example of structured characterization of AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391
Figure 6 Systems used for AF screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393
Figure 7 Potential benefits from and risks of screening for AF . . . . . . . . 394
Figure 8 Diagnostic work-up and follow-up in AF patients . . . . . . . . . . . 396
Figure 9 Imaging in AF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 397
Figure 10 Components of integrated AF management . . . . . . . . . . . . . . 398
Figure 11 Integrated AF management team (an example) . . . . . . . . . . . 399
Figure 12 ‘A’ - Anticoagulation/Avoid stroke:
The ‘AF 3-step’ pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 408
Figure 13 Outline of rate control therapy . . . . . . . . . . . . . . . . . . . . . . . . . . 410
Figure 14 Choice of rate control drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412
Figure 15 Rhythm control strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413
Figure 16 Flowchart for decision making on cardioversion of AF
depending on clinical presentation, AF onset, oral anticoagulation intake, and risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415
Figure 17 Indications for catheter ablation of symptomatic AF . . . . . . . 418
Figure 18 Risk factors for AF contributing to the development of an abnormal substrate translating into poorer outcomes with rhythm control strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420
Figure 19 Long-term rhythm control therapy . . . . . . . . . . . . . . . . . . . . . . . 428
Figure 20 Post-procedural management of patients with AF
and ACS/PCI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433
Figure 21 (Re-) initiation of anticoagulation post-intracranial bleeding . . 437
Figure 22 Management of active bleeding in patients receiving anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438
Figure 23 Management of postoperative AF . . . . . . . . . . . . . . . . . . . . . . . . 444
Figure 24 Progression of atrial high-rate episode burden and stroke rates according to AHRE daily burden and CHA2DS2-VASc score . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448
Figure 25 Proposed management of AHRE/subclinical AF . . . . . . . . . . . 448
Central Illustration. Management of AF. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451
List of boxes
Box 1 About post-procedural management of patients with AF
and ACS and/or PCI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 432
Box 2 About acute ischaemic stroke in patients with AF . . . . . . . . . . . . 435
Abbreviations and acronyms
Abbreviations and acronyms
4S-AF
Stroke risk, Symptom severity, Severity of AF
burden, Substrate severity
AAD
Antiarrhythmic drug
ABC
Atrial ﬁbrillation Better Care [includes A (avoid stroke), B (better symptom control), and C
(cardiovascular risk factors and comorbid conditions management)]
ABC-bleeding
Age, Biomarkers (haemoglobin, cTnT hs T,
GDF-15), and Clinical history (prior bleeding)
ABC-stroke
Age, Biomarkers, Clinical history (stroke risk score)
ACS
Acute coronary syndromes
ACTIVE W
Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events trial
AF
Atrial ﬁbrillation
AFFIRM
Atrial Fibrillation Follow-up Investigation of
Rhythm Management
AFL
Atrial ﬂutter
AHRE
Atrial high-rate episode
AMICA
Atrial Fibrillation Management in Congestive
Heart Failure With Ablation
ARCADIA
AtRial Cardiopathy and Antithrombotic Drugs In
Prevention After Cryptogenic Stroke
ARISTOTLE
Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation
ARREST-AF
Aggressive Risk Factor Reduction Study 
Implication for AF
AST
Aspartate aminotransferase
ATRIA
Anticoagulation and Risk Factors in Atrial
Fibrillation (score)
ATTICUS
Apixaban for treatment of embolic stroke of undetermined source
AVERROES
Apixaban Versus Acetylsalicylic Acid (ASA) to
Prevent Stroke in Atrial Fibrillation Patients Who
Have Failed or Are Unsuitable for Vitamin K
Antagonist Treatment b.i.d.
bis in die (twice a day)
BP
Blood pressure bpm
Beats per minute
C2HEST
CAD/COPD (1 point each), Hypertension (1
point), Elderly ( >_75 years, 2 points), Systolic heart failure (2 points), and Thyroid disease
(hyperthyroidism, 1 point) (score)
CABANA
Catheter ABlation vs. ANtiarrhythmic Drug
Therapy for Atrial Fibrillation
CAD
Coronary artery disease
CAPTAF
Catheter Ablation compared with
Pharmacological Therapy for Atrial Fibrillation
CASTLE-AF
Catheter Ablation vs. Standard conventional
Treatment in patients with LEft ventricular dysfunction and Atrial Fibrillation
CATCH-ME
Characterizing AF by Translating its Causes into
Health Modiﬁers in the Elderly
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome
CHA2DS2VASc
Congestive heart failure, Hypertension, Age >_75
years, Diabetes mellitus, Stroke, Vascular disease,
Age 6574 years, Sex category (female)
CHADS2
CHF history, Hypertension history, Age >_75 y,
Diabetes mellitus history, Stroke or TIA
symptoms previously
CHF
Congestive heart failure
CI
Conﬁdence interval
CIED
Cardiac implantable electronic device
CKD
Chronic kidney disease
COP-AF
Colchicine For The Prevention Of Perioperative
Atrial Fibrillation In Patients Undergoing
Thoracic Surgery
ESC Guidelines
377


<!-- PAGE 6 -->

### Page 6

..........................................................................................................................................................................
COPD
Chronic obstructive pulmonary disease
CPAP
Continuous positive airway pressure
CrCl
Creatinine clearance
CRT
Cardiac resynchronization therapy
CT
Computed tomography
CTI
Cavotricuspid isthmus cTnT-hs
High-sensitivity troponin T
DAPT
Dual antiplatelet therapy
EAST
Early treatment of Atrial ﬁbrillation for Stoke prevention Trial
ECG
Electrocardiogram
EHRA
European Heart Rhythm Association
ELAN
Early versus Late initiation of direct oral
Anticoagulants in post-ischaemic stroke patients with atrial ﬁbrillatioN
ENGAGE
AF-TIMI 48
Effective aNticoaGulation with factor XA next
GEneration in Atrial Fibrillation-Thrombolysis In
Myocardial Infarction 48
ENTRUSTAF PCI
Edoxaban Treatment Versus Vitamin K
Antagonist in Patients With Atrial Fibrillation
Undergoing Percutaneous Coronary Intervention
ESC
European Society of Cardiology
GARFIELD-AF
Global Anticoagulant Registry in the FIELD -
Atrial Fibrillation
GDF-15
Growth differentiation factor-15
HAS-BLED
Hypertension, Abnormal renal/liver function,
Stroke, Bleeding history or predisposition, Labile
INR, Elderly (>65 years), Drugs/alcohol concomitantly
HCM
Hypertrophic cardiomyopathy
HF
Heart failure
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HR
Hazard ratio i.v.
intravenous
ICH
Intracranial haemorrhage
IMPACT-AF
Integrated Management Program Advancing
Community Treatment of Atrial Fibrillation
INR
International normalized ratio
LA
Left atrium/atrial
LAA
Left atrial appendage
LEGACY
Long-term Effect of Goal-directed weight management on an Atrial ﬁbrillation Cohort: a 5Year follow-up study
LGE-CMR
Late gadolinium contrast-enhanced cardiac magnetic resonance
LMWH
Low-molecular-weight heparin
LV
Left ventricular
LVEF
Left ventricular ejection fraction
LVH
Left ventricular hypertrophy mAFA
Mobile AF App
MANTRA-PAF
Medical Antiarrhythmic Treatment or
Radiofrequency Ablation in Paroxysmal Atrial
Fibrillation
MRI
Magnetic resonance imaging
NDCC
Non-dihydropyridine calcium channel blocker
NOAC
Non-vitamin K antagonist oral anticoagulant
NSAID
Non-steroidal anti-inﬂammatory drug
NYHA
New York Heart Association o.d.
omni die (once daily)
OAC
Oral anticoagulant
OPTIMAS
OPtimal TIMing of Anticoagulation after Stroke
OSA
Obstructive sleep apnoea
PACES
Anticoagulation for New-Onset Post-Operative
Atrial Fibrillation After CABG
PAD
Peripheral artery disease
PCI
Percutaneous coronary intervention
PCORI
Patient-Centred Outcomes Research Institute
PIONEER
AF-PCI
OPen-Label, Randomized, Controlled,
Multicenter Study ExplorIng TwO TreatmeNt
StratEgiEs of Rivaroxaban and a Dose-Adjusted
Oral Vitamin K Antagonist Treatment Strategy in
Subjects with Atrial Fibrillation who Undergo
Percutaneous Coronary Intervention
PREVAIL
Watchman LAA Closure Device in Patients With
Atrial Fibrillation Versus Long Term Warfarin
Therapy
PRO
Patient-reported outcome
PROTECT AF
Watchman Left Atrial Appendage System for
Embolic Protection in Patients With Atrial
Fibrillation
PVI
Pulmonary vein isolation
QoL
Quality of life
QRS
QRS interval
QTc
Corrected QT interval
RACE
Race Control Efﬁcacy in Permanent Atrial
Fibrillation
RCT
Randomized controlled trial
RE-DUAL
Randomized Evaluation of Dual Antithrombotic
Therapy with Dabigatran vs. Triple Therapy with
Warfarin in Patients with Nonvalvular Atrial
Fibrillation Undergoing Percutaneous Coronary
Intervention
RE-CIRCUIT
Randomized Evaluation of dabigatran etexilate
Compared to warfarIn in pulmonaRy vein ablation: assessment of different periproCedUral antIcoagulation sTrategies
REHEARSE-AF
REmote HEArt Rhythm Sampling using the
AliveCor hear monitor to scrEen for Atrial
Fibrillation
RE-LY
Randomized Evaluation of Long Term
Anticoagulant Therapy
ROCKET AF
Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation
SAMe-TT2R2
Sex (female), Age (<60 years), Medial history,
Treatment, Tobacco use, Race (non-Caucasian)
(score)
SBP
Systolic blood pressure
START
Optimal Delay Time to Initiate Anticoagulation
After Ischemic Stroke in AF


<!-- PAGE 7 -->

### Page 7

........................................................................................................
STEMI
ST-segment elevation myocardial infarction
TIA
Transient ischaemic attack
TOE
Transoesophageal echocardiography
TTR
Time in therapeutic range
UFH
Unfractionated heparin
US
United States of America
VHD
Valvular heart disease
VKA
Vitamin K antagonist
WOEST
What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESCGuidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the ESC
carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world,
based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded, in some of its guidelines, a set of quality indicators (QIs) which are tools to evaluate the level of implementation of the Guidelines and may be used by the ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes,
alongside the key messages from the Guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
guidelines). This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
Table 1
Classes of recommendations
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
©ESC 2020
ESC Guidelines
379


<!-- PAGE 8 -->

### Page 8

.......................................................................................................
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task
Force. The finalized document is approved by the CPG for publication in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions,
summary slides, booklets with essential messages, summary cards for non-specialists, and an electronic version for digital applications
(smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access the full text version of the Guidelines, which is freely available via the ESC
website and hosted on the EHJ website. The National Cardiac
Societies of the ESC are encouraged to endorse, adopt, translate,
and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
2 Introduction
Atrial fibrillation (AF) poses significant burden to patients, physicians,
and healthcare systems globally. Substantial research efforts and resources are being directed towards gaining detailed information about the mechanisms underlying AF, its natural course and effective treatments (see also the ESC Textbook of Cardiovascular Medicine:
CardioMed) and new evidence is continuously generated and published.
The complexity of AF requires a multifaceted, holistic, and multidisciplinary approach to the management of AF patients, with their active involvement in partnership with clinicians. Streamlining the care of patients with AF in daily clinical practice is a challenging but essential requirement for effective management of AF. In recent years, substantial progress has been made in the detection of AF and its management,
and new evidence is timely integrated in this third edition of the ESC
guidelines on AF. The 2016 ESC AF Guidelines introduced the concept of the five domains to facilitate an integrated structured approach to AF
care and promote consistent, guideline-adherent management for all patients. The Atrial Fibrillation Better Care (ABC) approach in the 2020
ESC AF Guidelines is a continuum of this approach, with the goal to further improve the structured management of AF patients, promote patient values, and finally improve patient outcomes.
Reflecting the multidisciplinary input into the management of patients with AF and interpretation of new evidence, the Task Force includes cardiologists with varying subspecialty expertise, cardiac surgeons, methodologists, and specialist nurses amongst its members.
Further to adhering to the standards for generating recommendations that are common to all ESC guidelines (see preamble), this Task
Force discussed each draft recommendation during web-based conference calls dedicated to specific chapters, followed by consensus modifications and an online vote on each recommendation. Only recommendations that were supported by at least 75% of the Task
Force members were included in the Guidelines.
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2020


<!-- PAGE 9 -->

### Page 9

#### 2.1 What is new in the 2020 Guidelines?

New recommendations
Recommendations
Classa
Recommendations for diagnosis of AF
ECG documentation is required to establish the diagnosis of AF.
A standard 12-lead ECG recording or a single-lead ECG tracing of >_30 s showing heart rhythm with no discernible repeating P waves and irregular RR intervals (when atrioventricular conduction is not impaired) is diagnostic of clinical AF.
I
Recommendations for structured characterization of AF
Structured characterization of AF, which includes clinical assessment of stroke risk, symptom status, burden of AF, and evaluation of substrate, should be considered in all AF patients, to streamline the assessment of AF patients at different healthcare levels, inform treatment decision making, and facilitate optimal management of AF patients.
IIa
Recommendations for screening to detect AF
When screening for AF it is recommended that:
• The individuals undergoing screening are informed about the signiﬁcance and treatment implications of detecting AF.
• A structured referral platform is organized for screen-positive cases for further physician-led clinical evaluation to conﬁrm the diagnosis of AF and provide optimal management of patients with conﬁrmed AF.
• Deﬁnite diagnosis of AF in screen-positive cases is established only after the physician reviews the single-lead ECG recording of >_30 s or 12-lead ECG and conﬁrms that it shows AF.
I
Recommendations about integrated AF management
It is recommended to routinely collect PROs to measure treatment success and improve patient care.
I
Recommendations for the prevention of thrombo-embolic events in AF
For a formal risk-score-based assessment of bleeding risk, the HAS-BLED score should be considered to help address modiﬁable bleeding risk factors, and to identify patients at high risk of bleeding (HAS-BLED score >_3) for early and more frequent clinical review and followup.
IIa
Stroke and bleeding risk reassessment at periodic intervals is recommended to inform treatment decisions (e.g. initiation of OAC in patients no longer at low risk of stroke) and address potentially modiﬁable bleeding risk factors
I
In patients with AF initially at low risk of stroke, ﬁrst reassessment of stroke risk should be made 4 - 6 months after the index evaluation.
IIa
Estimated bleeding risk, in the absence of absolute contraindications to OAC, should not in itself guide treatment decisions to use OAC
for stroke prevention.
III
Clinical pattern of AF (i.e. ﬁrst detected, paroxysmal, persistent, long-standing persistent, permanent) should not condition the indication to thromboprophylaxis.
III
Recommendations for cardioversion
Pharmacological cardioversion of AF is indicated only in a haemodynamically stable patient, after consideration of the thrombo-embolic risk.
I
For patients with sick-sinus syndrome, atrioventricular conduction disturbances or prolonged QTc (>500 ms), pharmacological cardioversion should not be attempted unless risks for proarrhythmia and bradycardia have been considered.
III
Recommendations for rhythm control/catheter ablation of AF
General recommendations
For the decision on AF catheter ablation, it is recommended to take into consideration the procedural risks and the major risk factors for AF recurrence following the procedure and discuss them with the patient.
I
Repeated PVI procedures should be considered in patients with AF recurrence provided the patient’s symptoms were improved after the initial PVI.
IIa
AF catheter ablation after antiarrhythmic drug therapy failure
AF catheter ablation for PVI should be considered for rhythm control after one failed or intolerant to beta-blocker treatment to improve symptoms of AF recurrences in patients with paroxysmal and persistent AF.
IIa
First-line therapy
AF catheter ablation for PVI should/may be considered as ﬁrst-line rhythm control therapy to improve symptoms in selected patients with symptomatic:
• Paroxysmal AF episodes, or
IIa
• Persistent AF without major risk factors for AF recurrence as an alternative to AAD class I or III, considering patient choice, beneﬁt,
and risk.
IIb
Continued
ESC Guidelines
381


<!-- PAGE 10 -->

### Page 10

Techniques and technologies
Use of additional ablation lesions beyond PVI (low voltage areas, lines, fragmented activity, ectopic foci, rotors, and others) may be considered but is not well established.
IIb
Lifestyle modiﬁcation and other strategies to improve outcomes of ablation
Strict control of risk factors and avoidance of triggers are recommended as part of rhythm control strategy.
I
Recommendations for stroke risk management peri-cardioversion
It is recommended that the importance of adherence and persistence to NOAC treatment both before and after cardioversion is strongly emphasized to patients.
I
In patients with AF duration of >24 h undergoing cardioversion, therapeutic anticoagulation should be continued for at least 4 weeks even after successful cardioversion to sinus rhythm (beyond 4 weeks, the decision about long-term OAC treatment is determined by the presence of stroke risk factors).
IIa
In patients with a deﬁnite duration of AF <_24 h and a very low stroke risk (CHA2DS2-VASc of 0 in men or 1 in women) post-cardioversion anticoagulation for 4 weeks may be omitted.
IIb
Recommendations for stroke risk management peri-catheter ablation
In AF patients with stroke risk factors not taking OAC before ablation, it is recommended that pre-procedural management of stroke risk includes initiation of anticoagulation and:
• Preferably, therapeutic OAC for at least 3 weeks before ablation, or
• Alternatively, the use of TOE to exclude LA thrombus before ablation.
I
IIa
For patients undergoing AF catheter ablation who have been therapeutically anticoagulated with warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban, performance of the ablation procedure without OAC interruption is recommended.
I
Recommendations for long-term AADs
In AF patients treated with sotalol, close monitoring of QT interval, serum potassium levels, CrCl, and other proarrhythmia risk factors is recommended.
I
In AF patients treated with ﬂecainide for long-term rhythm control, concomitant use of an atrioventricular nodal-blocking drug (if tolerated) should be considered.
IIa
Sotalol may be considered for long-term rhythm control in patients with normal LV function or with ischaemic heart disease if close monitoring of QT interval, serum potassium levels, CrCl, and other proarrhythmia risk factors is provided.
IIb
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in AF
Identiﬁcation and management of risk factors and concomitant diseases is recommended as an integral part of treatment in AF patients.
I
Modiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.
I
Opportunistic screening for AF is recommended in hypertensive patients.
I
Opportunistic screening for AF should be considered in patients with OSA.
IIa
Recommendations for patients with AF and an ACS, PCI, or CCS
Recommendations for AF patients with ACS
In AF patients with ACS undergoing an uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with an
OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 12 months is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis, irrespective of the type of stent used.
I
Recommendations in AF patients with a CCS undergoing PCI
After uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with OAC for up to 6 months and clopidogrel is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis, irrespective of the type of stent used.
I
Recommendations for the management of active bleeding on OAC
Four-factor prothrombin complex concentrates should be considered in AF patients on VKA who develop a severe bleeding complication.
IIa
Recommendations for the management of AF during pregnancy
Acute management
In pregnant women with HCM, cardioversion should be considered for persistent AF.
IIa
Ibutilide or ﬂecainide i.v. may be considered for termination of AF in stable patients with structurally normal hearts.
IIb
Long-term management (oral administration of drugs)
Flecainide, propafenone, or sotalol should be considered to prevent AF if atrioventricular nodal-blocking drugs fail.
IIa
Digoxin or verapamil should be considered for rate control if beta-blockers fail.
IIa
Continued


<!-- PAGE 11 -->

### Page 11

Recommendations for postoperative AF
Long-term OAC therapy to prevent thrombo-embolic events should be considered in patients at risk for stroke with postoperative AF
after non-cardiac surgery, considering the anticipated net clinical beneﬁt of OAC and informed patient preferences.
IIa
Beta-blockers should not be used routinely for the prevention of postoperative AF in patients undergoing non-cardiac surgery.
III
Recommendations pertaining to sex-related differences in AF
Women with symptomatic paroxysmal or persistent AF should be offered timely access to rhythm control therapies, including AF catheter ablation, when appropriate for medical reasons.
IIa
Recommendations for quality measures in AF
The introduction of tools to measure quality of care and identify opportunities for improved treatment quality and AF patient outcome should be considered by practitioners and institutions.
IIa
AAD = antiarrhythmic drug; ACS = acute coronary syndrome; AF = atrial ﬁbrillation; CCS = chronic coronary syndrome; CHA2DS2-VASc = Congestive heart failure,
Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 6574 years, Sex category (female); CrCl = creatinine clearance; ECG = electrocardiogram;
HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs/alcohol concomitantly; HCM =
hypertrophic cardiomyopathy; i.v. = intravenous; LA = left atrium/atrial; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; OSA = obstructive sleep apnoea; PCI = percutaneous coronary intervention; PRO = patient-reported outcome; PVI = pulmonary vein isolation; QTc = corrected QT interval; TOE = transoesophageal echocardiography; VKA = vitamin K antagonist therapy.
aClass of recommendation.
Changes in the recommendations
Recommendations about integrated AF management
2020
Classa
2016
Classa
To optimize shared decision making about speciﬁc AF treatment option(s) in consideration, it is recommended that:
• Physicians inform the patient about advantages/limitations and beneﬁt/risks associated with considered treatment option(s);
and
• Discuss the potential burden of the treatment with the patient and include the patient’s perception of treatment burden in the treatment decision.
I
Placing patients in a central role in decision making should be considered in order to tailor management to patient preferences and improve adherence to long-term therapy
IIa
Recommendations for the prevention of thrombo-embolic events in AF
For bleeding risk assessment, a formal structured risk-scorebased bleeding risk assessment is recommended to help identify non-modiﬁable and address modiﬁable bleeding risk factors in all
AF patients, and to identify patients potentially at high risk of bleeding who should be scheduled for early and more frequent clinical review and follow-up.
I
Bleeding risk scores should be considered in AF patients on oral anticoagulation to identify modiﬁable risk factors for major bleeding.
IIa
In patients on VKAs with low time in INR therapeutic range (e.g.
TTR<70%), recommended options are:
• Switching to a NOAC but ensuring good adherence and persistence with therapy; or
• Efforts to improve TTR (e.g. education/counselling and more frequent INR checks).
I
AF patients already on treatment with a VKAs may be considered for NOAC treatment if TTR is not well controlled despite good adherence, or if patient preference without contraindications to
NOAC (e.g. prosthetic valve).
IIb
IIa
Recommendations for rhythm control/catheter ablation of AF
AF catheter ablation after drug therapy failure
AF catheter ablation for PVI is recommended for rhythm control after one failed or intolerant class I or III AAD, to improve symptoms of AF recurrences in patients with:
• Paroxysmal AF, or
• Persistent AF without major risk factors for AF recurrence, or
• Persistent AF with major risk factors for AF recurrence.
I
Catheter or surgical ablation should be considered in patients with symptomatic persistent or long-standing persistent AF refractory to AAD therapy to improve symptoms, considering patient choice,
beneﬁt and risk, supported by an AF Heart Team.
IIa
Continued
ESC Guidelines
383


<!-- PAGE 12 -->

### Page 12

First-line therapy
AF catheter ablation:
• Is recommended to reverse LV dysfunction in AF patients when tachycardia-induced cardiomyopathy is highly probable,
independent of their symptom status.
I
AF ablation should be considered in symptomatic patients with AF
and HFrEF to improve symptoms and cardiac function when tachycardiomyopathy is suspected.
IIa
• Should be considered in selected AF patients with HFrEF to improve survival and reduce HF hospitalization.
IIa
Techniques and technologies
Complete electrical isolation of the pulmonary veins is recommended during all AF catheter-ablation procedures.
I
Catheter ablation should target isolation of the pulmonary veins using radiofrequency ablation or cryothermy balloon catheters.
IIa
If patient has a history of CTI-dependent atrial ﬂutter or if typical atrial ﬂutter is induced at the time of AF ablation, delivery of a
CTI lesion may be considered.
IIb
Ablation of common atrial ﬂutter should be considered to prevent recurrent ﬂutter as part of an AF ablation procedure if documented or occurring during the AF ablation
IIa
Lifestyle modiﬁcation and other strategies to improve outcomes of ablation
Weight loss is recommended in obese patients with AF, particularly those who are being evaluated to undergo AF ablation.
I
In obese patients with AF, weight loss together with management of other risk factors should be considered to reduce AF burden and symptoms.
IIa
Recommendations for stroke risk management peri-cardioversion
In patients with AF undergoing cardioversion, NOACs are recommended with at least similar efﬁcacy and safety as warfarin.
I
Anticoagulation with heparin or a NOAC should be initiated as soon as possible before every cardioversion of AF or atrial ﬂutter.
IIa
Recommendations for stroke risk management peri-catheter ablation
After AF catheter ablation, it is recommended that:
• Systemic anticoagulation with warfarin or a NOAC is continued for at least 2 months post ablation, and
• Long-term continuation of systemic anticoagulation beyond 2
months post ablation is based on the patient’s stroke risk proﬁle and not on the apparent success or failure of the ablation procedure.
I
All patients should receive oral anticoagulation for at least 8 weeks after catheter ablation.
IIa
Recommendations for long-term antiarrhythmic drugs
Amiodarone is recommended for long-term rhythm control in all
AF patients, including those with HFrEF. However, owing to its extracardiac toxicity, other AADs should be considered ﬁrst whenever possible.
I
Amiodarone is more effective in preventing AF recurrences than other AAD, but extracardiac toxic effects are common and increase with time. For this reason, other AAD should be considered ﬁrst.
IIa
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with AF
Attention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and bleeding.
I
BP control in anticoagulated patients with hypertension should be considered to reduce the risk of bleeding
IIa
Physical activity should be considered to help prevent AF incidence or recurrence, with the exception of excessive endurance exercise, which may promote AF.
IIa
Moderate regular physical activity is recommended to prevent AF,
while athletes should be counselled that long-lasting intense sports participation can promote AF
I
Optimal management of OSA may be considered, to reduce AF
incidence, AF progression, AF recurrences, and symptoms.
IIb
OSA treatment should be optimized to reduce AF recurrences and improve AF treatment results.
IIa
Recommendations for stroke prevention in AF patients after ICH
In AF patients at high risk of ischaemic stroke, (re-)initiation of
OAC, with preference for NOACs over VKAs in NOAC-eligible patients, should be considered in consultation with a neurologist/
stroke specialist after:
• A trauma-related ICH
• Acute spontaneous ICH (which includes subdural, subarachnoid, or intracerebral haemorrhage), after careful consideration of risks and beneﬁts
IIa
After ICH oral anticoagulation in patients with AF may be reinitiated after 48 weeks provided the cause of bleeding or the relevant risk factor has been treated or controlled.
IIb
Continued


<!-- PAGE 13 -->

### Page 13

3 Definition and diagnosis of atrial fibrillation
3.1 Definition
Recommendations for postoperative AF
Long-term OAC therapy to prevent thrombo-embolic events may be considered in patients at risk for stroke with postoperative AF after cardiac surgery, considering the anticipated net clinical beneﬁt of OAC therapy and informed patient preferences.
IIb
Long-term anticoagulation should be considered in patients with
AF after cardiac surgery at risk for stroke, considering individual stroke and bleeding risk.
IIa
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; BP = blood pressure; CTI = cavotricuspid isthmus; HFrEF = heart failure with reduced ejection fraction; ICH = intracranial haemorrhage; INR = international normalized ratio; LV = left ventricular; LVEF = left ventricular ejection fraction; NOAC = non-vitamin K antagonist oral anticoagulant; OAC
= oral anticoagulant or oral anticoagulation; PVI = pulmonary vein isolation; TTR = time in therapeutic range; VKA = vitamin K antagonist.
aClass of recommendation.
Table 3
Deﬁnition of atrial ﬁbrillation
Definition
AF
A supraventricular tachyarrhythmia with uncoordinated atrial electrical activation and consequently ineffective atrial contraction.
Electrocardiographic characteristics of AF include:
• Irregularly irregular R-R intervals (when atrioventricular conduction is not impaired),
• Absence of distinct repeating P waves, and
• Irregular atrial activations.
Currently used terms
Clinical AF
Symptomatic or asymptomatic AF that is documented by surface ECG.
The minimum duration of an ECG tracing of AF required to establish the diagnosis of clinical AF is at least 30 seconds, or entire 12-lead ECG.1,2
AHRE, subclinical AF
Refers to individuals without symptoms attributable to AF, in whom clinical AF is NOT previously detected (that is, there is no surface
ECG tracing of AF), see also section 3.3.
AHRE - events fulﬁlling programmed or speciﬁed criteria for AHRE that are detected by CIEDs with an atrial lead allowing automated continuous monitoring of atrial rhythm and tracings storage. CIED-recorded AHRE need to be visually inspected because some AHRE may be electrical artefacts/false positives.
Subclinical AF includes AHRE conﬁrmed to be AF, AFL, or an AT, or AF episodes detected by insertable cardiac monitor or wearable monitor and conﬁrmed by visually reviewed intracardiac electrograms or ECG-recorded rhythm.
Device-programmed rate criterion for AHRE is >_175 bpm, whereas there is no speciﬁc rate limit for subclinical AF.
The criterion for AHRE duration is usually set at >_5 min (mainly to reduce the inclusion of artefacts), whereas a wide range of subclinical AF duration cutoffs (from 10 - 20 seconds to >24 hours) is reported in studies of the association of subclinical AF with thromboembolism. The reported duration refers to either the longest single episode or, more commonly, total duration of AHRE/subclinical AF during the speciﬁed monitoring period.
Although not completely identical, the terms AHRE and subclinical AF are often used interchangeably (in this document the amalgamated term AHRE/subclinical AF will be used for practicality).35 Whereas a large body of high-quality evidence from RCTs informing the management of AF patients pertains exclusively to ‘clinical’ AF (that is, the ECG documentation of AF was a mandatory inclusion criterion in those RCTs), data on optimal management of AHRE
and subclinical AF are lacking. For this reason, AF is currently described as either ‘clinical’ or ‘AHRE/subclinical’, until the results of several ongoing RCTs expected to inform the management of AHRE and ‘subclinical’ AF are available.
AHRE = atrial high-rate episode; AF = atrial ﬁbrillation; ECG = electrocardiogram; AFL = atrial ﬂutter; AT = atrial tachycardia; bpm = beats per minute; CIED = cardiac implantable electronic device; ECG = electrocardiogram; RCT = randomized controlled trial.
ESC Guidelines
385


<!-- PAGE 14 -->

### Page 14

...........................................................
3.2 Diagnostic criteria for atrial fibrillation
The diagnosis of AF requires rhythm documentation with an electrocardiogram (ECG) tracing showing AF. By convention, an episode lasting at least 30 s is diagnostic for clinical AF.6
3.3 Diagnosis of atrial high-rate episodes/
subclinical atrial fibrillation
Various implanted devices and wearable monitors allow detection of atrial high-rate episodes (AHRE) /subclinical AF (Figure 1).3
Owing to a short monitoring, detection of AHRE/subclinical AF via external ECG is less likely.7
When AHRE/subclinical AF is detected by a device/wearable,
inspection of the stored electrograms/ECG rhythm strips is recommended to exclude artefacts or other causes of inappropriate detection.8,9
4 Epidemiology
Worldwide, AF is the most common sustained cardiac arrhythmia in adults10 (Figure 2, upper panel). AF is associated with substantial morbidity and mortality, thus portending significant burden to patients,
societal health, and health economy (Figure 2, lower panel)
(Supplementary section 1).
Recommendations for diagnosis of AF
Recommendations
Classa
Levelb
ECG documentation is required to establish the diagnosis of AF.
• A standard 12-lead ECG recording or a single-lead ECG tracing of >_30 s showing heart rhythm with no discernible repeating P waves and irregular RR intervals (when atrioventricular conduction is not impaired) is diagnostic of clinical AF.6
I
B
AF = atrial ﬁbrillation; ECG = electrocardiogram.
aClass of recommendation.
bLevel of evidence.
©ESC 2020
Pacemaker/implantable defibrillator
Figure 1 Diagnosis of AHRE/subclinical AF. CIEDs with an atrial lead can monitor atrial rhythm and store the tracings. ICMs have no intracardiac leads but continuously monitor cardiac electrical activity by recording and analysing a single-lead bipolar surface ECG based on a specific algorithm. Left-bottom image: pacemaker with a right atrial lead, and a ventricular lead in the right ventricular apex. In addition to pacing at either site, these leads can sense activity in the respective cardiac chamber. The device can also detect pre-programmed events, such as AHRE. Right-bottom image: subcutaneous ICM: these devices have no intra-cardiac leads and essentially record a single, bipolar, surface ECG, with inbuilt algorithms for detection of AHRE or AF. AF = atrial fibrillation; AHRE = atrial high rate episode; CIED = cardiac implantable electronic device; ECG = electrocardiogram; ICM = insertable cardiac monitor; RCT =
randomized clinical trial.


<!-- PAGE 15 -->

### Page 15

Figure 2 Epidemiology of AF: prevalence (upper panel)1020; and lifetime risk and projected rise in the incidence and prevalence (lower panel).19,2134
AF = atrial fibrillation; AFL = atrial flutter; BP = blood pressure; CI = confidence interval; EU = European Union. aSmoking, alcohol consumption, body mass index, BP, diabetes mellitus (type 1 or 2), and history of myocardial infarction or heart failure. bRisk profile: optimal - all risk factors are negative or within the normal range; borderline - no elevated risk factors but >1 borderline risk factor; elevated - >1 elevated risk factor.
ESC Guidelines
387


<!-- PAGE 16 -->

### Page 16

............................................................................................
The currently estimated prevalence of AF in adults is between 2%
and 4%,10 and a 2.3-fold rise11 is expected,12,13 owing to extended longevity in the general population and intensifying search for undiagnosed AF.15 Increasing age is a prominent AF risk factor, but increasing burden of other comorbidities including hypertension, diabetes mellitus, heart failure (HF), coronary artery disease (CAD), chronic kidney disease (CKD),21 obesity, and obstructive sleep apnoea
(OSA) is also important;2226 modifiable risk factors are potent contributors to AF development and progression27,28 (Figure 3). The ageadjusted incidence, prevalence, and lifetime risk of AF are lower in women vs. men and in non-Caucasian vs. Caucasian cohorts.10,1420
A previous lifetime AF risk estimate of 1 in 4 individuals29,30 was recently revised to 1 in 3 individuals of European ancestry at index age of 55 years.31,32 The AF lifetime risk depends on age, genetic, and
(sub)clinical factors.10,33,34 The observed impact of clinical risk factor burden/multiple comorbidity on AF risk (Figure 3, lower panel31) suggests that an early intervention and modifiable risk factor control could reduce incident AF.
4.1 Prediction of incident atrial fibrillation
Identifying individuals at higher risk of developing AF in the community could facilitate targeting of preventive interventions and screening programmes for early AF detection, for example in high-risk subgroups such as post-stroke patients.73 Various predictive scores for new-onset AF have been proposed (Supplementary Table 2), but none has been widely used in clinical practice.
4.2 Pathophysiology of atrial fibrillation
A complex interplay of triggers, perpetuators, and substrate development eventually resulting in AF occurrence is shown in Supplementary
Figure 1.
5 Clinical features of atrial fibrillation
Clinical presentation of AF and AF-related outcomes are shown in Figure 4 (see also Supplementary section 2 and Supplementary
Box 1).
6 Atrial fibrillation subtypes,
burden, and progression
6.1 Classification of atrial fibrillation
Different AF classifications have been proposed but, traditionally, five patterns of AF are distinguished, based on presentation,
duration,
and spontaneous termination of
AF
episodes
(Table 4).143
In patients experiencing both paroxysmal and persistent AF episodes, the more common type should be used for classification.
However, clinically determined AF patterns do not correspond well to the
AF
burden measured by long-term
ECG
monitoring.144146
Other classifications of AF reflect the presence of symptoms
(asymptomatic AF is diagnosed with an opportune 12-lead ECG or rhythm strip in asymptomatic patients) or underlying cause of AF
©ESC 2020
Figure 3 Summary of risk factors for incident AF10,22,33,3572 (Supplementary Table 1 for full list). AF = atrial fibrillation; COPD = chronic obstructive pulmonary disease.


<!-- PAGE 17 -->

### Page 17

©ESC 2020
Figure 4 Clinical presentation of AF and AF-related outcomes.10,31,74140 AF = atrial fibrillation; HF = heart failure; HR = Hazard Ratio; LV = left ventricle; MI = myocardial infarction; QoL = quality of life.
Patients with AF may have various symptoms92,108,109,128,131 but 50- 87% are initially asymptomatic,75,82,88,111,117,120,125,127 with possibly a less favourable prognosis.79,82,87,88,117,119,127,134,139 First-onset AF symptoms are less well studied,92,105,108,109,,127 may change with treatment119 and AF recurrences are commonly asymptomatic.113
Stroke/systolic embolism: annual AF-related stroke risk in AF patients depends on comorbidities.78,84,85,91,106,112 Cardioembolic strokes associated with AF are usually severe, highly recurrent, often fatal, or with permanent disability.10,83,115 In a population-based registry, patients with new-onset AF also had increased rates of systemic embolism.89
ESC Guidelines
389


<!-- PAGE 18 -->

### Page 18

.........................
(e.g. postoperative AF, see section 11.19). Classifying AF by underlying drivers could inform management, but the evidence in support of the clinical use of such classification is lacking (Supplementary Table 3).
Terms that should no longer be used to describe AF are listed in
Table 4.
Recommendations for AF management are not based on the temporal
AF
patterns,
except for the restoration of sinus rhythm.143,149,150 It is very unlikely that a simple but comprehensive
AF classification will be proposed, given the multiplicity of factors relevant for its management, advances in AF monitoring, multiplicity of risk assessment tools, evolving treatments, and complexity of AF
itself. Indeed, a paradigm shift from classification towards a structured characterization of AF, addressing specific domains with treatment and prognostic implications has been recently proposed.151 Such a scheme would streamline the assessment of AF patients at any healthcare level, thus facilitating communication among physicians,
Figure 4 Continued
Left ventricular (LV) dysfunction and HF: multiple AF-associated mechanisms/myocardial alterations may lead to LV dysfunction and HF,102,138 resulting in a high prevalence and incidence of HF among AF patients. Sharing common risk factors, AF and HF often coexist, or may precipitate/exacerbate each other, resulting in significantly greater mortality than either condition alone.140
Hospitalization: approximately 30% of AF patients have at least one, and 10% have >_2, hospital admissions annually,99,110,129 being twice as likely to be hospitalized as ageand sex-matched non-AF individuals (37.5% vs. 17.5%, respectively).98 In a nationwide cohort, AF was the main cause for admission in 14% of hospitalized patients but their inhospital mortality was <1%.101 The most common reasons for hospitalization of AF patients were cardiovascular disorders (49%), non-cardiovascular causes (43%) and bleeding
(8%).129
Quality of life (QoL) and functional status: >60% of AF patients have significantly impaired QoL/exercise tolerance,81,88,136 but only 17% have disabling symptoms.88
QoL is significantly lower in women,81,107,114,124 young individuals, and those with comorbidities.118 AF burden100 may also affect QoL, but only psychological functioning consistently predicted symptoms and QoL.136 Patients with AF more often developed anxiety disorders,126 had a higher burden of depressive symptoms,123 and poorer QoL with a
Distressed personality type (Type D).103 Key symptom and QoL drivers are important to identify optimal AF treatment. It is also important to confirm that symptoms are related to AF or, if absent, to exclude a subconscious adaptation to living with suboptimal physical capacity by asking for breathlessness or fatigue on exertion and recording possible improvements after cardioversion.
Cognitive impairment/dementia: AF may lead to cognitive impairment ranging from mild dysfunction to dementia97,104,141 via clinically apparent or silent stroke or insufficiently understood stroke-independent pathways.94,96,97,122 Magnetic resonance imaging (MRI) studies have shown that AF is associated with a greater than twofold increase in the odds of having silent cerebral ischaemia.90,121,142 A recent expert consensus paper summarized the available data.86
Mortality: AF is independently associated with a twofold increased risk of all-cause mortality in women and a 1.5-fold increase in men,77,80,130,137 with an overall 3.5-fold mortality risk increase.31 Whereas the mechanistic explanation for this association is multifaceted, associated comorbidities play an important role.95 In a recent study, the most common causes of death among AF patients were HF (14.5%), malignancy (23.1%), and infection/sepsis (17.3%), whereas stroke-related mortality was only 6.5%.76 These and other recent data indicate that, in addition to anticoagulation and HF treatment, comorbid conditions need to be actively treated in the endeavour to reduce AF-related mortality.77,93,116,133
Table 4
Classiﬁcation of AF
AF pattern
Deﬁnition
First diagnosed
AF not diagnosed before, irrespective of its duration or the presence/severity of AF-related symptoms.
Paroxysmal
AF that terminates spontaneously or with intervention within 7 days of onset.
Persistent
AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion)
after >_7 days
Long-standing persistent
Continuous AF of >12 months’ duration when decided to adopt a rhythm control strategy.
Permanent
AF that is accepted by the patient and physician, and no further attempts to restore/maintain sinus rhythm will be undertaken.
Permanent AF represents a therapeutic attitude of the patient and physician rather than an inherent pathophysiological attribute of AF, and the term should not be used in the context of a rhythm control strategy with antiarrhythmic drug therapy or AF ablation. Should a rhythm control strategy be adopted, the arrhythmia would be re-classiﬁed as ‘long-standing persistent AF’.
Terminology that should be abandoned
Lone AF
A historical descriptor. Increasing knowledge about the pathophysiology of AF shows that in every patient a cause is present. Hence, this term is potentially confusing and should be abandoned.147
Valvular/nonvalvular AF
Differentiates patients with moderate/severe mitral stenosis and those with mechanical prosthetic heart valve(s) from other patients with AF, but may be confusing148 and should not be used.
Chronic AF
Has variable deﬁnitions and should not be used to describe populations of AF patients.
AF = atrial ﬁbrillation.


<!-- PAGE 19 -->

### Page 19

..........................................................................................
treatment decision making, and optimal management of AF patients,
and should become a standard in clinical practice when reporting an
AF case.
The proposed 4S-AF scheme (Stroke risk, Symptom severity,
Severity of AF burden, Substrate severity) includes four AF-related domains (Figure 5).151 The currently used assessment tools/classifications pertinent to specific domains (e.g. stroke risk scores, symptom scores, clinical factors, imaging modalities, etc.) can be easily fitted in,
but the 4S-AF has great potential for future refinements guided by advances in technology, and the most appropriate descriptors of AF
domains are yet to be defined. Given the descriptors of AF included in the 4S-AF scheme, the structured characterization of AF patients using 4S-AF could also provide prognostic information, but the clinical utility and prognostic value of the 4S-AF scheme needs extensive validation in different AF cohorts and clinical settings.
6.2 Definition and assessment of atrial fibrillation burden
The term ‘burden’ refers to various AF aspects (e.g. epidemiological,
economic).144 Regarding continuous device-based monitoring, ‘AF
burden’ is currently defined as the overall time spent in AHRE/subclinical AF during a specified monitoring period (e.g. 1 day). Both the time in AF and the monitoring period should be acknowledged when reporting AF burden (most studies reported the maximum time spent in AF over a 24-h period), but optimal measures are yet to be determined.152 The term ‘AF burden’ is different from ‘burden of AF’,
the latter referring to AF consequences.
Clinical AF burden is routinely determined by AF temporal pattern146 (Table 4) and intermittent ECG monitoring,153 neither corresponding well to the long-term ECG monitoring. The relationship of clinical AF burden with specific outcomes is not well characterized,154
but may be associated with higher risk of incident HF155 and all-cause mortality,156 while the association with quality of life (QoL) is complex and data about cognitive impairment/dementia are lacking.86 Recent randomized controlled trial (RCT) data consistently showed significantly lower residual thrombo-embolic risk among anticoagulated patients with paroxysmal vs. persistent AF,156159 whereas earlier trial-based160 and observational data161,162 are contradictory. Among non-anticoagulated patients, stroke risk was lower with paroxysmal than non-paroxysmal AF,156 and a greater total AF burden (but not the longest AF episode) was independently associated with higher thrombo-embolic event rates.163 Clinical AF burden may influence the response to rhythm control therapy.164,165 The presence of >6 h of AF
per week (especially when progressing to >24 h weekly) was associated with increased mortality, especially in women.166
©ESC 2020
Figure 5 4S-AF scheme as an example of structured characterization of AF.151 AF = atrial fibrillation; CHA2DS2-VASc = Congestive heart failure,
Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65- 74 years, Sex category (female); CT = computed tomography; EHRA =
European Heart Rhythm Association; LA = left atrium; MRI = magnetic resonance imaging; QoL = quality of life; TOE = transoesophageal echocardiography; TTE = transthoracic echocardiography.
Recommendations for structured characterization of AF
Recommendations
Classa
Levelb
Structured characterization of AF, which includes clinical assessment of stroke risk, symptom status, burden of AF, and evaluation of substrate, should be considered in all AF patients,
to streamline the assessment of AF patients at different healthcare levels, inform treatment decision-making, and facilitate optimal management of AF patients.151
IIa
C
AF = atrial ﬁbrillation aClass of recommendation.
bLevel of evidence.
ESC Guidelines
391


<!-- PAGE 20 -->

### Page 20

.............................................................................................................................................................................
Available evidence on the association of AF burden with AFrelated outcomes is insufficient to guide treatment and should not be a major factor in treatment decisions. Comprehensive management of modifiable cardiovascular risk factors/comorbidity reduces AF burden (section 10.3).
6.3 Atrial fibrillation progression
Transition from paroxysmal to non-paroxysmal AF (or from subclinical to clinical AF)154,167169 is often characterized by advancing atrial structural remodelling or worsening of atrial cardiomyopathy.170,171
Assessment of AF progression depends on duration of rhythm monitoring and underlying substrate.172,173 Reported annual rates of paroxysmal AF progression range from <1% to 15% (up to 27- 36%
in studies with >_10-year follow-up).169,174 Risk factors for AF progression include age, HF, hypertension, CKD, chronic pulmonary diseases, diabetes mellitus, previous stroke, and left atrial (LA) size,167
whereas the added predictive value of biomarkers is presently not well defined. Older age is associated with permanent AF,82,117,154 and various triggers may also play a role, with different progression patterns resulting from their interaction with substrate remodelling.171
Progression to persistent/permanent AF is associated with adverse cardiovascular events, hospitalizations, and death,166 but it is unclear whether AF progression is a determinant of adverse prognosis or rather a marker of an underlying progressive disease/substrate.175,176
The true impact of different therapeutic interventions at different disease stages on AF progression and associated outcomes is also less well defined.
6.4 Atrial cardiomyopathy: definition,
classification, clinical implications, and diagnostic assessment
Important progress in understanding AF mechanisms and thrombogenicity reconsiders the role of atrial cardiomyopathy (i.e. atrial structural, architectural, contractile, or electrophysiological changes with potentially relevant clinical manifestations).170
Clinical classification of atrial cardiomyopathy should be based on the atrial structure, morphology, electrical and mechanical function,
and the diagnosis could be based on easily accessible parameters (e.g.
aetiology, the prothrombotic state,177 and abnormal LA volume/
function).178 Major clinical issues in AF (i.e. prevention of thromboembolic complications and AF progression) are influenced by atrial remodelling; and, importantly, AF is not only a risk factor for but also a marker of atrial cardiomyopathy, which could explain the lack of temporal relationship between detected AF and stroke.179
The diagnostic algorithm for atrial cardiomyopathy should follow a stepwise approach, identifying risk factors for atrial cardiomyopathy,170 atrial electrical and mechanical dysfunction,180 and increased thrombotic risk.181 More data are needed to define prognostic and treatment implications of different atrial cardiomyopathy morphofunctional forms.
7 Screening for atrial fibrillation
Multiple factors (i.e. increasing AF prevalence, previously unknown
AF detection in about 10% of all ischaemic strokes,4,182 high prevalence of asymptomatic AF,117 potential to prevent AF-related strokes with appropriate treatment and increasing availability of AF detection tools) have fuelled international initiatives to implement screening for
AF in clinical practice.172
Asymptomatic clinical AF has been independently associated with increased risk of stroke and mortality compared with symptomatic
AF.82,117,127,183 Data derived from studies of incidentally detected asymptomatic AF are the closest possible approximation of the risk of stroke and death in screen-detected AF subjects, because delaying treatment to discern a natural history would be unethical.
Observational data suggest that screen-detected AF responds to treatment similarly to AF detected by routine care,183 thus favouring
AF screening.
Although AF fulfils many of the criteria for disease screening184
(Supplementary Figure 2), RCT data to confirm the health benefits from screening for AF and inform the choice of optimal screening programmes and strategies for its implementation are scarce.185,186
Advances in wearable technology will likely yield inexpensive and practical options for AF detection and AF burden assessment in the near future.
7.1 Screening tools
The systems used for AF screening are shown in Table 5 and
Figure 6.173,187
Mobile health technologies are rapidly developing for AF detection and other purposes (>100 000 mHealth apps and >_400 wearable activity monitors are currently available).197 Caution is needed in their clinical use, as many are not clinically validated. Several studies evaluated AF detection using smartwatches,198,199 thus opening new perspectives for AF detection targeting specific populations at risk.
Machine learning and artificial intelligence may be capable of identifying individuals with previous AF episodes from a sinus rhythm ECG
recording,200 which would be a major technological breakthrough in
AF detection.200
The Apple Heart study201 included 419 297 self-enrolled smartwatch app users (mean age 40 years) in the United States of America
(USA), of whom 0.5% received an irregular pulse notification (0.15%
of those aged <40 years, 3.2% among those aged >65 years).
Subsequent (notification-triggered) 1-week ECG patch monitoring revealed AF in 34% of monitored participants. The Huawei Heart study202 included 187 912 individuals (mean age 35 years, 86.7%
male), of whom 0.23% received a ‘suspected AF’ notification. Of those effectively followed up, 87.0% were confirmed as having AF,
with the positive predictive value of photoplethysmography signals being 91.6% [95% confidence interval (CI) 91.5- 91.8]. Of those with identified AF, 95.1% entered an integrated AF management programme using a mobile AF App (mAFA).
When AF is detected by a screening tool, including mobile or wearable devices, a single-lead ECG tracing of >_30 s or 12-lead ECG
showing AF analysed by a physician with expertise in ECG rhythm interpretation is necessary to establish a definitive diagnosis of AF
(devices capable of ECG recording enable direct analysis of the device-provided tracings). When AF detection is not based on an
ECG recording (e.g. with devices using photoplethysmography) or in case of uncertainty in the interpretation of device-provided ECG
tracing, a confirmatory ECG diagnosis has to be obtained using additional ECG recording (e.g. 12-lead ECG, Holter monitoring, etc.)


<!-- PAGE 21 -->

### Page 21

©ESC 2020
Figure 6 Systems used for AF screening. Pulse palpation, automated BP monitors, single-lead ECG devices, PPG devices, other sensors (using seismocardiography, accelerometers, and gyroscopes, etc.) used in applications for smartphones, wrist bands, and watches. Intermittent smartwatch detection of AF
is possible through PPG or ECG recordings. Smartwatches and other ‘wearables’ can passively measure pulse rate from the wrist using an optical sensor for PPG and alerting the consumer of a pulse irregularity (based on a specific algorithm for AF detection analysing pulse irregularity and variability).172,173,188196 AF = atrial fibrillation; BP = blood pressure; ECG = electrocardiogram; PPG = photoplethysmography.
ESC Guidelines
393


<!-- PAGE 22 -->

### Page 22

........................................................................
The data reported in Table 5 should be interpreted with caution,
as assessment of sensitivity and specificity in many studies was based on small observational cohorts, with a substantial risk of bias due to signal selection. Moreover, there is a continuous evolution of algorithms and technologies available in commercial devices.
Two recent meta-analyses reported that screening for AF using an
ECG would not detect more cases than would screening with pulse palpation.215
7.2 Screening types and strategies
Commonly used AF screening types and strategies172,173,216 include opportunistic or systematic screening of individuals above a certain age (usually >_65 years) or with other characteristics suggestive of increased stroke risk, using intermittent single-point or repeated 30-s
ECG recording over 2 weeks. The appropriate frequency of monitoring using smartphones or watches is undefined. Primary care, pharmacies, or community screening during special events is a good setting for AF screening.172,173 Overall, there was no significant difference between systematic vs. opportunistic or general practice vs.
community screening in a meta-analysis, but repeated heart rhythm monitoring was associated with significantly better effectiveness compared with single assessment.215 Importantly, a structured referral of screen-detected or suspected AF cases for further clinical evaluation should be organized, to provide an appropriate management.
7.3 Benefits from and risks of screening for atrial fibrillation
Potential advantages and disadvantages of detecting a previously undiagnosed AF through screening are shown in Figure 7.173
Screening can also highlight cases of known suboptimally managed
AF.217 Intermittent ECG recording increased new AF detection fourfold.217 In the REHEARSE-AF (REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation) controlled study using a smartphone/tablet-based single-lead ECG
system twice weekly over 12 months vs. routine care resulted in a
3.9-fold increase in AF detection in patients aged >_65 years.218
Appropriate patient information and screening programme organization with rapid ECG clarification may reduce anxiety induced by suspicion of abnormality.
7.4 Cost-effectiveness of screening for atrial fibrillation
Higher AF-related medical costs justify strategies to identify and treat undiagnosed AF.219 Opportunistic AF screening is associated with lower costs than systematic screening.173 Appropriate choice of the screening tool and setting is important,220 and a favourable cost-effectiveness profile has been estimated for screening programmes based on pulse palpation, hand-held ECG devices, and
Table 5
Sensitivity and speciﬁcity of various AF screening tools considering the 12-lead ECG as the gold standard173
Sensitivity
Specificity
Pulse taking203
87 - 97%
70 - 81%
Automated BP monitors204207
93 - 100%
86 - 92%
Single lead ECG208211
94 - 98%
76 - 95%
Smartphone apps188,189,191,195,212,213
91.5 - 98.5%
91.4 - 100%
Watches196,198,213,214
97 - 99%
83 - 94%
AF = atrial ﬁbrillation; BP = blood pressure; ECG = electrocardiogram.
©ESC 2020
Figure 7 Potential benefits from and risks of screening for AF. AF = atrial fibrillation; ECG = electrocardiogram; OAC = oral anticoagulant; SE =systemic embolism.


<!-- PAGE 23 -->

### Page 23

.......................................................................................................................................................................
smartphones with pulse photoplethysmography algorithms.172
Both systematic and opportunistic screening are more costeffective than routine practice for patients >_65 years, with opportunistic screening more likely to be cost-effective than systematic population screening.1491
7.5 Screening in high-risk populations
7.5.1
Elderly
The risk of AF (often asymptomatic) and stroke increase with age,82,127,221 thus justifying AF screening in the elderly. Opportunistic
AF screening seems to be cost-effective in elderly populations (>_65
years)222 and among 75- 76-year-old individuals undergoing a 2week intermittent ECG screening.223
Pulse palpation and/or short-term ECG among the elderly (>_65
years) yielded an AF prevalence of 4.4%, with previously undiagnosed
AF in 1.4%, suggesting a number needed to screen of 70.224 Repeated hand-held ECG recordings over 2 weeks in an unselected population aged 75 - 76 years increased the detection of asymptomatic AF up to
7.4% in subjects with >_2 stroke risk factors.225
8 Diagnostic assessment in atrial fibrillation
Often occurring in patients with cardiovascular risk factors/comorbidities, AF may sometimes be a marker of undiagnosed conditions.
Hence, all AF patients will benefit from a comprehensive cardiovascular assessment (Figure 8).
The ‘standard package’ for diagnostic evaluation of AF patients should include complete medical history and assessment of concomitant conditions, AF pattern, stroke risk, AF-related symptoms,
thrombo-embolism, and LV dysfunction.143 A 12-lead ECG is recommended in all AF patients, to establish the diagnosis of AF, assess ventricular rate during AF, and check for the presence of conduction defects, ischaemia, or signs of structural heart disease. Laboratory tests (thyroid and kidney function, serum electrolytes, full blood count) and transthoracic echocardiography (LV size and function, LA
size, valvular disease, and right heart size and systolic function) are needed to guide treatment. Based on the patient’s characteristics,
specific additional information can be obtained. Most AF patients need regular follow-up (primary care) to ensure continued optimal management.
8.1 Symptoms and quality of life
As symptoms related to AF may range from none to disabling, and rhythm control treatment decisions (including catheter ablation) are influenced by symptom severity, symptom status should be characterized using the European Heart Rhythm Association (EHRA) symptom scale228 (Table 6), and the relation of symptoms (especially if non-specific, such as shortness of breath, fatigue, chest discomfort,
etc.) to AF should be elucidated because symptoms may also result from undiagnosed or suboptimally managed concomitant cardiovascular risk factors or pathological conditions.229
In selected AF patients, long-term ECG monitoring is recommended to assess the adequacy of rate control or to relate symptoms with AF episodes. Sometimes the association of symptoms with
AF can be established only retrospectively, after successful rhythm control intervention. In selected patients, a trial of sinus rhythm using cardioversion and a quantified patient perception of symptoms using a validated assessment tool (Supplementary Table 4) may inform the decision about subsequent AF catheter ablation (section 10.2).
Symptomatic and functional improvement with rhythm control therapies (cardioversion,232234 antiarrhythmic medications, and AF
catheter-ablation procedures235242) largely depends on sinus rhythm maintenance243; however, QoL may improve despite AF
recurrences, unless AF burden is high244 (e.g. >2 h daily100) owing to optimized management of cardiovascular risk factors or comorbidities245 or a treatment expectancy effect. The effect of AF treatment246,247 is supported by reports of persistently improved QoL 10
years after paroxysmal AF catheter ablation in patients with a low AF
progression rate.248
8.2 Substrate
The substrate for AF relates to LA dilation and fibrosis with subsequent LA dysfunction and delay in electromechanical conduction.
Recommendations for screening to detect AF
Recommendation
Classa
Levelb
Opportunistic screening for AF by pulse taking or ECG rhythm strip is recommended in patients >_65 years of age.188,211,223,225
I
B
It is recommended to interrogate pacemakers and implantable cardioverter deﬁbrillators on a regular basis for AHRE.c224,226
I
B
When screening for AF it is recommended that:217,218
• The individuals undergoing screening are informed about the signiﬁcance and treatment implications of detecting AF.
• A structured referral platform is organized for screen-positive cases for further physician-led clinical evaluation to conﬁrm the diagnosis of
AF and provide optimal management of patients with conﬁrmed AF.
• Deﬁnite diagnosis of AF in screen-positive cases is established only after physician reviews the single-lead ECG recording of
>_30 s or 12-lead ECG and conﬁrms that it shows AF.
I
B
Systematic ECG screening should be considered to detect AF in individuals aged >_75 years, or those at high risk of stroke.212,224,227
IIa
B
AF
=
atrial
ﬁbrillation;
AHRE
=
atrial high-rate episode;
ECG
=
electrocardiogram.
aClass of recommendation.
bLevel of evidence.
cSee sections 3.2 and 3.3 for diagnostic criteria for AF and AHRE, and section 16
for the management of patients with AHRE.
ESC Guidelines
395


<!-- PAGE 24 -->

### Page 24

................
Non-invasive, multimodality imaging can provide all needed information (Figure 9).249,250
In selected patients, transoesophageal echocardiography (TOE)
can be used to evaluate valvular heart disease (VHD) or left atrial appendage (LAA) thrombus; CT coronary angiography can be performed for assessment of CAD; CT/MRI of the brain can be performed when stroke is suspected. Specific predictors of stroke have been suggested: LA dilation, spontaneous LA contrast, reduced LA
strain, LAA thrombus, low peak LAA velocity (<20 cm/s), and LAA
non-chicken wing configuration (on CT).250
©ESC 2020
Figure 8 Diagnostic work-up and follow-up in AF patients. AF = atrial fibrillation; BNP = B-type natriuretic peptide; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65- 74 years, Sex category (female); CAD = coronary artery disease;
CRP = C-reactive protein; CT = computed tomography; CTA = computed tomography angiography; cTnT-hs = high-sensitivity cardiac troponin T; ECG
= electrocardiogram; LAA = left atrial appendage; LGE-CMR = late gadolinium contrast-enhanced cardiac magnetic resonance; MRI = magnetic resonance imaging; NT-ProBNP = N-terminal (NT)-prohormone B-type natriuretic peptide.
Table 6
EHRA symptom scale
Score
Symptoms
Description
1
None
AF does not cause any symptoms
2a
Mild
Normal daily activity not affected by symptoms related to AF
2b
Moderate
Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms
3
Severe
Normal daily activity affected by symptoms related to AF
4
Disabling
Normal daily activity discontinued
Six symptoms, including palpitations, fatigue, dizziness, dyspnoea, chest pain, and anxiety during AF, are evaluated with regard to how it affects the patient’s daily activity, ranging from none to symptom frequency or severity that leads to a discontinuation of daily activities.
To measure treatment effects, QoL and symptom questionnaires should be sensitive to changes in AF burden. The EHRA symptom scale is a physician-assessed tool for quantiﬁcation of AF-related symptoms that is used to guide symptom-driven AF treatment decisions,228 and has been related to adverse outcomes in more symptomatic patients
(score 3 - 4) versus those with a score of 1 - 2.228,230 However, it does not consider the symptom dimensions such as anxiety, treatment concerns, and medication adverse effects that are captured by general QoL scales,230 or the patient-reported symptom-related outcomes. As discrepancies between patient-reported and physician-assessed outcomes are frequently observed,231 the AF-related treatment decisions also need to be informed by a quantiﬁed patient perception of symptoms, but further research is needed to identify optimal tool(s) for capturing this information.
AF = atrial ﬁbrillation; EHRA = European Heart Rhythm Association; QoL = quality of life.


<!-- PAGE 25 -->

### Page 25

©ESC 2020
Figure 9 Imaging in AF. Anatomical imaging provides the LA size, shape, and fibrosis. Most accurate assessment of LA dilation is obtained by CMR or
CT. For routine assessment, two-dimensional (2D) or (preferably) three-dimensional (3D) transthoracic echocardiography is used. The 3D echocardiographic normal volume values are 15- 42 mL/m2 for men and 15- 39 mL/m2 for women.250 Assessment of LA fibrosis with LGE-CMR has been described but only rarely applied in clinical practice.251 Functional imaging includes TDI and strain. TDI measures the velocities of the myocardium in diastole and systole, whereas LA strain reflects active LA contraction. The PA-TDI interval reflects the atrial electromechanical delay (total LA conduction time, the time interval between the P-wave on the ECG and the A’ [atrial peak velocity] on TDI) and reflects LA strain.252 LA wall infiltration by epicardial fat is a potential early marker of inflammation and can be detected with CT or cardiac MRI.253 Before AF ablation, the pulmonary vein anatomy can be visualized with CT
or CMR. AF = atrial fibrillation; CT = computed tomography; EP = electrophysiology; LA = left atrium; LAA = left atrial appendage; LV = left ventricular;
LGE-CMR = late gadolinium contrast-enhanced cardiac magnetic resonance; MRI = magnetic resonance imaging; TDI = tissue doppler imaging; TOE =
transoesophageal echocardiography; TTE = transthoracic echocardiography.
Recommendations for diagnostic evaluation of patients with AF
Recommendation
Classa
Levelb
In patients with AF, it is recommended to:
• Evaluate AF-related symptoms (including fatigue, tiredness, exertional shortness of breath, palpitations, and chest pain) and quantify the patient symptom status using the modiﬁed EHRA symptom scale before and after initiation of treatment.230,232
• Evaluate AF-related symptoms before and after cardioversion of persistent AF to aid rhythm control treatment decisions.230,232
I
C
AF = atrial ﬁbrillation; EHRA = European Heart Rhythm Association.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
397


<!-- PAGE 26 -->

### Page 26

..............................................................................
9 Integrated management of patients with atrial fibrillation
9.1 Definitions and components of integrated management of atrial fibrillation patients
Integrated management of AF patients requires a coordinated and agreed patient-individualized care pathway to deliver optimized treatment (Figure 10) by an interdisciplinary team (Figure 11). Central to this approach is the patient; treatment options should be discussed,
and the management plan agreed in discussion with healthcare professionals. Treatment is subject to change over time with the development of new risk factors, symptoms, disease progression, and the advent of new treatments.
9.2 Multidisciplinary atrial fibrillation teams
Integrated AF management requires a coordinated multidisciplinary team (Figure 11) composed according to individual patient needs and local availability of services. Complex patients would benefit from a multidisciplinary team that includes relevant specialists, as well as their primary care physician (for post-discharge care) and their family/carer. Involvement of patient and family/carers is integral to the success of AF management.
9.2.1
Role of healthcare systems and budget constraints
Optimized AF treatment requires a well-structured healthcare system and significant financial resources.254 Allocation of resources will vary due to differing healthcare system structures and budget constraints in diverse geographies. The significant inequalities in the access to AF management-related resources are documented in the recent ESC Atlas on Cardiovascular Disease.255 It is important to consider optimizing use of available resources to reduce stroke,
improve symptoms, and treat comorbidities.
9.3 Patient involvement and shared decision making
9.3.1
Patient values and preferences
Exploring patient’s values, goals, and preferences should be the first step of shared decision making.256,257 Qualitative research demonstrates recurring discordance between caregivers reporting shared decision making and patients experiencing a paternalistic model,109,258261 and a misperception that many prefer not to be involved in decision making, rather deferring to their physician.259,262266 For shared decision making,261 the importance attached by the patient to stroke prevention and rhythm control and the respective risk of death, stroke, and major bleeding, as well as the burden of treatment,
should be thoroughly assessed and respected.257,264,266268
©ESC 2020
Figure 10 Components of integrated AF management. AF = atrial fibrillation; HCP = healthcare professional; MDT = multidisciplinary team.


<!-- PAGE 27 -->

### Page 27

..........................................................................
9.3.2
Patient education
Patient knowledge about AF and its management is often limited257,269272 particularly when first diagnosed, when the majority of treatment decisions are discussed and made.
Information on useful resources to help educate AF patients273
can be found in the ESC Textbook of Cardiovascular Medicine, but education alone is often insufficient to produce and maintain medication adherence and lifestyle modifications.
9.4 Healthcare professional education
A mixed-methods approach has been used when targeting healthcare professionals including individual needs assessment followed by bespoke education and training, whether by smart technology,
online resources, or upskilling face-to-face workshops or a combination.274 The mAFA, integrating clinical-decision support and education for healthcare professionals, has been successfully piloted and subsequently tested in an outcome RCT.275 Education alone is insufficient to change healthcare-professional behaviour.276 In the Integrated Management Program Advancing
Community Treatment of Atrial Fibrillation (IMPACT-AF) trial,277
a multifaceted educational intervention including healthcareprofessional education and feedback resulted in a significant increase in the proportion of patients treated with oral anticoagulant (OAC) therapy.
9.5 Adherence to treatment
Factors affecting adherence to treatment can be grouped into patientrelated (e.g. demographics, comorbidities, cognitive impairment,
polypharmacy, treatment side-effects, psychological health, patient understanding of the treatment regimen), physician-related (knowledge, awareness of guidelines, expertise, multidisciplinary team approach), and healthcare system-related (work-setting, access to treatments, cost) factors.278
Ensuring patients are appropriately informed about treatment options, how to adhere to treatment, potential consequences of non-adherence, in addition to managing patient’s expectations of treatment goals, are crucial to promote adherence. Regular review by any member of the multidisciplinary team is important to identify non-adherence and implement strategies to improve adherence where appropriate.
9.6 Technology tools supporting atrial fibrillation management
Clinical decision support systems are intelligent systems that digitize and provide evidence-based guidelines, clinical pathways, and algorithms facilitating personalized,
timely,
and evidence-based treatment.
The
MobiGuide project279
and several applications280283
(Supplementary Tables 5 and 6) have been used to enhance patient
©ESC 2020
Figure 11 Integrated AF management team (an example). The figure gives an example on the potential composition of AF teams showing a variety of different specialists supporting individual patients as needed. AF = atrial fibrillation. aAccording to local standards, this could be a general cardiologist with special interest in arrhythmias/AF or an electrophysiologist.
ESC Guidelines
399


<!-- PAGE 28 -->

### Page 28

.............................................................................................................................................................
education, improve communication between patients and healthcare professionals, and encourage active patient involvement. The ESC/
CATCH-ME (Characterizing AF by Translating its Causes into Health
Modifiers in the Elderly) consortium also has a smartphone/tablet app281 for AF patients, but this is yet to be tested prospectively. A
Cochrane review284 demonstrated that patient decision-support aids reduce decision conflict.285288
Nevertheless,
contradictory results277,289,290 illustrate the need for more carefully designed studies, including assessment of the intervention’s effect on clinical events.
9.7 Advantages of integrated management of atrial fibrillation patients
Limited evidence exists on the effectiveness of integrated management of AF. Available intervention studies vary widely in number and content of ‘integrated care’ employed. Six studies—one cluster
RCT,291 four RCTs,277,292295 and one before-and-after study294—
of integrated AF management have demonstrated mixed findings
(Supplementary Table 7). Two studies292,294 and one meta-analysis296
report significantly lower rates of cardiovascular hospitalization and death with nurse-led, integrated care, whereas others reported no effect of integrated care on these outcomes. One multifaceted study277 demonstrated improved OAC rates in the intervention group at 12 months. The IMPACT-AF study277 found no significant difference in the composite efficacy outcome (unplanned emergency department visit or cardiovascular hospitalization) or the primary safety outcome of major bleeding between intervention and usual care.
9.8 Measures (or approaches) for implementation of integrated management
Integrated management of AF requires a change in the current approach to patient care, to focus on moving from a multidisciplinary team to interdisciplinary working, including behaviour change for all
AF team members and key stakeholders including patients and their family297,298 (Supplementary Figure 3).
To understand whether integrated AF management has been implemented into clinical practice and had an impact on important outcomes (mortality, stroke, hospitalization, QoL, symptom reduction, etc.), a specific international standard set of outcome measures should be collected (Supplementary Figure 4).299 This would also highlight areas requiring further development.
9.9 Treatment burden
Patient-perceived treatment burden300 is defined as the workload imposed by healthcare on patients and its effect on patient functioning and well-being apart from specific treatment side-effects.301,302 It includes everything patients do for their health (drug management,
self-monitoring, visits to the doctor, laboratory tests, lifestyle changes) and healthcare impact on their social relationships, potentially affecting adherence to treatment,303,304 QoL, and outcomes
(e.g. hospitalization and survival).305,306 Patient-perceived treatment burden is influenced by their knowledge about disease.302 Patients with similar treatment regimens may have very different treatment burden,307 with only a weak agreement between patient’s and physicians’ treatment burden evaluation, suggesting that the patient’s experience is not shared in depth during consultations.302,308,309
Treatment burden can be overwhelming for patients with multiple chronic conditions301 (e.g. those with three chronic conditions would have to take 6 - 12 medications daily, visit a healthcare giver
1.2 - 5.9 times per month, and spend 49.6 - 71.0 h monthly in healthcare-related activities310). Treatment burden in AF patients is largely unknown. In a single-centre prospective study, AF
patient-perceived total treatment burden was higher than in patients with other chronic conditions (27.6% vs. 24.3%, P =0.011),
and 1 in 5 AF patients reported a high treatment burden that could question the sustainability of their treatment. Notably, AF patients attributed the highest proportion of treatment burden to healthcare system-related aspects (e.g. attending appointments etc.) and lifestyle modification requirements. Female sex and younger age were independently significantly associated with a higher treatment burden, whereas non-vitamin K antagonist oral anticoagulants (NOACs) and rhythm control reduced the odds for high treatment burden by >50%.311
The discussion of treatment burden should be an integral part of shared, informed treatment decision making, and treatment burden can be assessed using a validated questionnaire.312
9.10 Patient-reported outcomes
There is increasing advocacy for including patient-reported outcomes
(PROs)
as endpoints in clinical trials313
and their routine collection314316 to improve care and assess treatment success from the patient’s perspective. Patients’ experience of AF and its management is highly subjective; AF management has become increasingly complex, potentially resulting in significant treatment burden and poorer health-related QoL.
Measuring outcomes that are important to patients, in addition to
‘hard’ clinical endpoints (death, stroke, major bleeding, etc.), can inform AF management. An international consortium of AF patients and healthcare professionals has identified the following PROs as important to measure for AF: health-related QoL, physical and emotional functioning, cognitive function, symptom severity, exercise tolerance, and ability to work (Supplementary Figure 4)299; PRO
measures can be used to assess these factors and the international standard set of AF outcome measures proposes some tools for assessing PROs.299 Health informatics systems could help capture
PRO data. Despite increasing support for the role of PRO measures in healthcare management, few studies and registries report collecting PRO data using validated tools.313 Implementation of PRO measures in the management of AF patients is addressed in a dedicated expert consensus paper developed in collaboration with patient representatives by the EHRA.317


<!-- PAGE 29 -->

### Page 29

............................................................................................................................
10 Patient management: the integrated ABC pathway
The simple Atrial fibrillation Better Care (ABC) holistic pathway (’A’
Anticoagulation/Avoid stroke; ‘B’ Better symptom management; ‘C’
Cardiovascular and Comorbidity optimization318) streamlines integrated care of AF patients across all healthcare levels and among different specialties. Compared with usual care, implementation of the
ABC pathway has been significantly associated with lower risk of allcause death, composite outcome of stroke/major bleeding/cardiovascular death and first hospitalization,319 lower rates of cardiovascular events,320,321 and lower health-related costs.322 In the prospective,
randomized mAFA-II trial, the composite outcome was significantly lowered with ABC pathway management intervention compared with usual care [1.9% vs. 6.0%; hazard ratio (HR) 0.39; 95% CI
0.22- 0.67; P <0.001].323
10. 1 ‘A’  Anticoagulation/Avoid stroke
This section refers to AF in the absence of severe mitral stenosis or prosthetic heart valves (for AF with concomitant VHD see section
11.7).148
10.1.1
Stroke risk assessment
Overall, AF increases the risk of stroke five-fold, but this risk is not homogeneous, depending on the presence of specific stroke risk factors/modifiers. Main clinical stroke risk factors have been identified from non-anticoagulated arms of the historical RCTs conducted >20
years ago, notwithstanding that these trials only randomized <10% of patients screened, whereas many common risk factors were not recorded or consistently defined.324 These data have been supplemented by evidence from large observational cohorts also studying patients who would not have been included in the RCTs.
Subsequently, various imaging, blood, and urine biological markers
(biomarkers) have been associated with stroke risk (Table 7).324,325 In addition, non-paroxysmal AF is associated with an increase in thrombo-embolism (multivariable adjusted
HR 1.38; 95%
CI
1.19- 1.61; P <0.001) compared with paroxysmal AF.156 Notably,
many of the risk factors for AF-related complications are also risk factors for incident AF.33
Common stroke risk factors are summarized in the clinical risk-factor-based CHA2DS2-VASc [Congestive heart failure, Hypertension,
Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age
6574 years, Sex category (female)] score (Table 8).334
Stroke risk scores have to balance simplicity and practicality against precision.354356 As any clinical risk-factor-based score, CHA2DS2VASc performs only modestly in predicting high-risk patients who will sustain thrombo-embolic events, but those identified as low-risk
[CHA2DS2-VASc 0 (males), or score of 1 (females)] consistently have low ischaemic stroke or mortality rates (<1%/year) and do not need any stroke prevention treatment.
Female sex is an age-dependent stroke risk modifier rather than a risk factor per se.357,358 Observational studies showed that women with no other risk factors (CHA2DS2-VASc score of 1) have a low stroke risk, similar to men with a CHA2DS2-VASc score of 0.359 The simplified CHA2DS2-VA score could guide the initial decision about
OAC in AF patients, but not considering the sex component would underestimate stroke risk in women with AF.360,361 In the presence of >1 non-sex stroke risk factor, women with AF consistently have significantly higher stroke risk than men.353,362
Many clinical stroke risk factors (e.g. renal impairment, OSA, LA
dilatation291,326,363365) are closely related to the CHA2DS2-VASc components, and their consideration does not improve its predictive value (the relationship of smoking or obesity to stroke risk in
AF is also contentious).366 Various biomarkers [e.g. troponin,
natriuretic peptides, growth differentiation factor (GDF)-15, von
Willebrand factor]
have shown improved performance of biomarker-based over clinical scores in the assessment of residual stroke risk among anticoagulated AF patients329,367; notwithstanding, many of these biomarkers (as well as some clinical risk factors)
are predictive of both stroke and bleeding329 or non-AF and noncardiovascular conditions, often (non-specifically) reflecting simply a sick heart or patient.
More complex clinical scores [e.g. Global Anticoagulant Registry in the FIELD - Atrial Fibrillation (GARFIELD-AF)]368 and those inclusive of biomarkers [e.g. Anticoagulation and Risk Factors in Atrial
Fibrillation (ATRIA),369,370 Intermountain Risk Score,371ABC-stroke
(Age, Biomarkers, Clinical history)]372 improve stroke risk prediction modestly but statistically significantly. The ABC-stroke risk score that considers age, previous stroke/transient ischaemic attack (TIA), highsensitivity troponin T (cTnT-hs) and N-terminal (NT)-prohormone
Recommendations about integrated AF management
Recommendations
Classa
Levelb
To optimize shared decision making about speciﬁc AF treatment option(s) in consideration, it is recommended that physicians:
• Inform the patient about the advantages/limitations and beneﬁt/risks associated with the treatment option(s) being considered;
and
• Discuss the potential burden of the treatment with the patient and include the patient’s perception of treatment burden in the treatment decision.
I
C
It is recommended to routinely collect PROs to measure treatment success and improve patient care.
I
C
Integrated management with a structured multidisciplinary approach including healthcare professionals, patients, and their family/
carers, should be used in all AF patients to improve clinical outcomes.277,292294,296,297
IIa
B
AF = atrial ﬁbrillation; PRO = patient-reported outcome.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
401


<!-- PAGE 30 -->

### Page 30

.............................................................................................................
B-type natriuretic peptide has been validated in the cohorts of landmark NOAC trials.373375 A biomarker score-guided treatment strategy to reduce stroke and mortality in AF patients is being evaluated in an ongoing RCT (the ABC-AF Study, NCT03753490).
Whereas the routine use of biomarker-based risk scores currently would not substantially add to initial stroke prevention treatment decisions in patients already qualifying for treatment based on the
CHA2DS2-VASc score (and a limited practicality would be accompanied by increased healthcare costs),355,376,377 biomarkers could further refine stroke risk differentiation among patients initially classified as low risk and those with a single non-sex CHA2DS2-VASc risk factor.378
Studies of the CHA2DS2-VASc score report a broad range of stroke rates depending on study setting (community vs. hospital),
methodology (e.g. excluding patients subsequently treated with
OAC would bias stroke rates towards lower levels), ethnicity, and prevalence of specific stroke risk factors in the study population (different risk factors carry different weight, and age thresholds for initiating NOACs may even differ for patients with a different single non-sex stroke risk factor, as follows: age 35 years for HF, 50 years for hypertension or diabetes, and 55 years for vascular disease).379,380
No RCT has specifically addressed the need for OAC in patients with a single non-sex CHA2DS2-VASc risk factor (to obtain high event rates and timely complete the study, anticoagulation trials have preferentially included high-risk patients), but an overview of subgroup analyses and observational data suggests that OAC use in such patients confers a positive net clinical benefit when balancing the reduction in stroke against the potential for harm with serious bleeding.339,381
For many risk factors (e.g. age), stroke risk is a continuum rather than an artificial low-, moderate-, or high-risk category. Risk factors are dynamic and, given the elderly AF population with multiple (often changing) comorbidities, stroke risk needs to be re-evaluated at each clinical review. Recent studies have shown that patients with a change in their risk profile are more likely to sustain strokes.382,383 Many initially low-risk patients (>15%) would have >_1 non-sex CHA2DS2VASc risk factor at 1 year after incident AF,384386 and 90% of new comorbidities were evident at 4.4 months after AF was diagnosed.387
A Patient-Centred Outcomes Research Institute (PCORI)-commissioned systematic review of 61 studies compared diagnostic accuracy and impact on clinical decision making of available clinical and imaging tools and associated risk factors for predicting thromboembolic and bleeding risk in AF patients.388 The authors concluded that the CHADS2 (CHF history, Hypertension history, Age >_75 y,
Diabetes mellitus history, Stroke or TIA symptoms previously),
CHA2DS2-VASc, and ABC risk scores have the best evidence for predicting thrombo-embolic risk (moderate strength of evidence for limited prediction ability of each score).
10.1.2
Bleeding risk assessment
When initiating antithrombotic therapy, potential risk for bleeding also needs to be assessed. Non-modifiable and partially modifiable bleeding risks (Table 9) are important drivers of bleeding events in synergy with modifiable factors.389 Notably, a history of falls is not an independent predictor of bleeding on OAC (a modelling study estimated that a patient would need to fall 295 times per year for the benefits of ischaemic stroke reduction with OAC to be outweighed by the potential for serious bleeding).390
Modifiable and non-modifiable bleeding risk factors have been used to formulate various bleeding risk scores,368,391395 generally with a modest predictive ability for bleeding events.396,397 Studies comparing specific bleeding risk scores provided conflicting findings.393,394,398 Various biomarkers have been proposed as bleeding risk predictors, but many have been studied in anticoagulated trial cohorts (while bleeding risk assessment is needed at all parts of the patient pathway—when initially not using OAC, if taking aspirin, and,
subsequently, on OAC). Additionally, biomarkers are non-specifically predictive of stroke, death, HF, etc.399,400 or even non-cardiovascular conditions (e.g. glaucoma),401 and the availability of some biomarkers is limited in routine clinical practice.
The biomarker-based ABC-bleeding risk score [Age, Biomarkers
(GDF-15,
cTnT-hs,
haemoglobin)
and
Clinical history
(prior
Table 7
Stroke risk factors in patients with AF
Most commonly studied clinical risk factors
(a systematic review)324
Positive studies/All studies
Other clinical risk factors325
Imaging biomarkers291,326328
Blood/urine biomarkers329332
Stroke/TIA/systemic embolism
15/16
Impaired renal function/
CKD
Echocardiography
Cardiac troponin T and I
Natriuretic peptides
Cystatin C
Proteinuria
CrCl/eGFR
CRP
IL-6
GDF-15
von Willebrand factor
D-dimer
Hypertension
11/20
OSA
LA dilatation
Spontaneous contrast or thrombus in LA
Low LAA velocities
Complex aortic plaque
Ageing (per decade)
9/13
HCM
Structural heart disease
9/13
Amyloidosis in degenerative cerebral and heart diseases
Diabetes mellitus
9/14
Hyperlipidaemia
Vascular disease
6/17
Smoking
Cerebral imaging
CHF/LV dysfunction
7/18
Metabolic syndrome333
Small-vessel disease
Sex category (female)
8/22
Malignancy
CHF = congestive heart failure; CKD = chronic kidney disease; CrCl = creatinine clearance; CRP = C-reactive protein; eGFR = estimated glomerular ﬁltration rate; GDF-15 =
growth differentiation factor-15; IL-6 = interleukin 6; LA = left atrium; LAA = left atrial appendage; LV = left ventricular; OSA = obstructive sleep apnoea; TIA = transient ischaemic attack.


<!-- PAGE 31 -->

### Page 31

Table 8
CHA2DS2-VASc score334
CHA2DS2-VASc score
Risk factors and definitions
Points awarded
Comment
C
Congestive heart failure
Clinical HF, or objective evidence of moderate to severe
LV dysfunction, or HCM
1
Recent decompensated HF irrespective of LVEF (thus incorporating HFrEF or HFpEF), or the presence (even if asymptomatic) of moderate-severe LV systolic impairment on cardiac imaging335; HCM confers a high stroke risk336 and OAC is beneﬁcial for stroke reduction.337
H
Hypertension or on antihypertensive therapy
1
History of hypertension may result in vascular changes that predispose to stroke, and a wellcontrolled BP today may not be well-controlled over time.324 Uncontrolled BP - the optimal BP
target associated with the lowest risk of ischaemic stroke, death, and other cardiovascular outcomes is 120 - 129/<80 mmHg.338
A
Age 75 years or older
2
Age is a powerful driver of stroke risk, and most population cohorts show that the risk rises from age 65 years upwards.339 Age-related risk is a continuum, but for reasons of simplicity and practicality, 1 point is given for age 65 - 74 years and 2 points for age >_75 years.
D
Diabetes mellitus
Treatment with oral hypoglycaemic drugs and/or insulin or fasting blood glucose
>125 mg/dL (7 mmol/L)
1
Diabetes mellitus is a well-established risk factor for stroke, and more recently stroke risk has been related to duration of diabetes mellitus (the longer the duration of diabetes mellitus, the higher the risk of thromboembolism340) and presence of diabetic target organ damage, e.g. retinopathy.341 Both type 1 and type 2 diabetes mellitus confer broadly similar thromboembolic risk in AF, although the risk may be slightly higher in patients aged <65 years with type 2 diabetes mellitus compared to patients with type 1 diabetes mellitus.342
S
StrokePrevious stroke, TIA, or thromboembolism
2
Previous stroke, systemic embolism, or TIA confers a particularly high risk of ischaemic stroke,
hence weighted 2 points. Although excluded from RCTs, AF patients with ICH (including haemorrhagic stroke) are at very high risk of subsequent ischaemic stroke, and recent observational studies suggest that such patients would beneﬁt from oral anticoagulation.343345
V
Vascular disease
Angiographically signiﬁcant
CAD, previous myocardial infarction, PAD, or aortic plaque
1
Vascular disease (PAD or myocardial infarction) confers a 17 - 22% excess risk, particularly in
Asian patients.346348 Angiographically signiﬁcant CAD is also an independent risk factor for ischaemic stroke among AF patients (adjusted incidence rate ratio 1.29, 95% CI 1.08 - 1.53).349
Complex aortic plaque on the descending aorta, as an indicator of signiﬁcant vascular disease, is also a strong predictor of ischaemic stroke.350
A
Age 65 2 74 years
1
See above. Recent data from Asia suggest that the risk of stroke may rise from age 50 - 55 years upwards and that a modiﬁed CHA2DS2-VASc score may be used in Asian patients.351,352
Sc
Sex category (female)
1
A stroke risk modiﬁer rather than a risk factor.353
Maximum score
9
AF = atrial ﬁbrillation; BP = blood pressure; CAD = coronary artery disease; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus,
Stroke, Vascular disease, Age 65-74 years, Sex category (female); CI = conﬁdence interval; EF = ejection fraction; HCM = hypertrophic cardiomyopathy; HF = heart failure;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; ICH = intracranial haemorrhage; LV = left ventricular; LVEF = left ventricular ejection fraction; OAC = oral anticoagulant; PAD = peripheral artery disease; RCT = randomized controlled trial; TIA = transient ischaemic attack.
Table 9
Risk factors for bleeding with OAC and antiplatelet therapy
Non-modifiable
Potentially modifiable
Modifiable
Biomarkers
Age >65 years
Previous major bleeding
Severe renal impairment (on dialysis or renal transplant)
Severe hepatic dysfunction (cirrhosis)
Malignancy
Genetic factors (e.g. CYP 2C9 polymorphisms)
Previous stroke, small-vessel disease, etc.
Diabetes mellitus
Cognitive impairment/dementia
Extreme frailty ± excessive risk of fallsa
Anaemia
Reduced platelet count or function
Renal impairment with CrCl <60
mL/min
VKA management strategyb
Hypertension/elevated SBP
Concomitant antiplatelet/NSAID
Excessive alcohol intake
Non-adherence to OAC
Hazardous hobbies/occupations
Bridging therapy with heparin
INR control (target 2.0 - 3.0), target
TTR >70%c
Appropriate choice of OAC and correct dosingd
GDF-15
Cystatin C/CKD-EPI
cTnT-hs von Willebrand factor (þ
other coagulation markers)
CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; CrCl = creatinine clearance; cTnT-hs = high-sensitivity troponin T; CYP = cytochrome P; GDF-15 = growth differentiation factor-15; INR = international normalized ratio; NSAID = non-steroidal anti-inﬂammatory drug; OAC = oral anticoagulant; SBP = systolic blood pressure; TTR =
time in therapeutic range; VKA = vitamin K antagonist.
aWalking aids; appropriate footwear; home review to remove trip hazards; neurological assessment where appropriate.
bIncreased INR monitoring, dedicated OAC clinicals, self-monitoring/self-management, educational/behavioural interventions.
cFor patients receiving VKA treatment.
dDose adaptation based on patient’s age, body weight, and serum creatinine level.
ESC Guidelines
403


<!-- PAGE 32 -->

### Page 32

...........................................................................................
bleeding)]375,402 reportedly outperformed clinical scores, but in another study there was no long-term advantage of ABC-bleeding over HAS-BLED score (Table 10), whereas HAS-BLED was better in identifying patients at low risk of bleeding (HAS-BLED 0 - 2).403 In the
PCORI-commissioned systematic review,388 encompassing 38 studies of bleeding risk prediction, the HAS-BLED score had the best evidence for predicting bleeding risk (moderate strength of evidence),
consistent with other systematic reviews and meta-analyses comparing bleeding risk prediction approaches.404406
A high bleeding risk score should not lead to withholding OAC, as the net clinical benefit of OAC is even greater amongst such patients.
However, the formal assessment of bleeding risk informs management of patients taking OAC, focusing attention on modifiable bleeding risk factors that should be managed and (re)assessed at every patient contact, and identifying high-risk patients with non-modifiable bleeding risk factors who should be reviewed earlier (for instance in
4 weeks rather than 4 - 6 months) and more frequently.389,407
Identification of ‘high bleeding risk’ patients is also needed when determining the antithrombotic strategy in specific AF patient groups,
such as those undergoing percutaneous coronary intervention (PCI).
Overall, bleeding risk assessment based solely on modifiable bleeding risk factors is an inferior strategy compared with formal bleeding risk assessment using a bleeding risk score,408410 thus also considering the interaction between modifiable and non-modifiable bleeding risk factors. Bleeding risk is dynamic, and attention to the change in bleeding risk profile is a stronger predictor of major bleeding events compared with simply relying on baseline bleeding risk. In a recent study, there was a 3.5-fold higher risk of major bleeding in the first 3
months amongst patients who had a change in their bleeding risk profile.389
In the mAFA-II trial, prospective dynamic monitoring and reassessment using the HAS-BLED score (together with holistic App-based management) was associated with fewer major bleeding events, mitigated modifiable bleeding risk factors, and increased OAC uptake; in contrast,
bleeding rates were higher and OAC use overall decreased by 25% in the ‘usual care’ arm when comparing baseline with 12 months.411
10.1.3
Absolute contraindications to oral anticoagulants
The few absolute contraindications to OAC include active serious bleeding (where the source should be identified and treated), associated comorbidities (e.g. severe thrombocytopenia <50 platelets/lL,
severe anaemia under investigation, etc.), or a recent high-risk bleeding event such as intracranial haemorrhage (ICH). Non-drug options may be considered in such cases (section 11.4.3).
10.1.4
Stroke prevention therapies
10.1.4.1 Vitamin K antagonists
Compared with control or placebo, vitamin K antagonist (VKA) therapy (mostly warfarin) reduces stroke risk by 64% and mortality by
26%,412 and is still used in many AF patients worldwide. VKAs are currently the only treatment with established safety in AF patients with rheumatic mitral valve disease and/or an artificial heart valve.
The use of VKAs is limited by the narrow therapeutic interval, necessitating frequent international normalized ratio (INR) monitoring and dose adjustments.413 At adequate time in therapeutic range [(TTR) >70%],
VKAs are effective and relatively safe drugs. Quality of VKA management
(quantified using the TTR based on the Rosendaal method, or the percentage of INRs in range) correlates with haemorrhagic and thrombo-
..................................................................................................................................................................
Table 10
Clinical risk factors in the HAS-BLED score395
Risk factors and definitions
Points awarded
H
Uncontrolled hypertension
SBP >160 mmHg
1
A
Abnormal renal and/or hepatic function
Dialysis, transplant, serum creatinine >200 mmol/L, cirrhosis, bilirubin >  2 upper limit of normal,
AST/ALT/ALP >3  upper limit of normal
1 point for each
S
Stroke
Previous ischaemic or haemorrhagica stroke
1
B
Bleeding history or predisposition
Previous major haemorrhage or anaemia or severe thrombocytopenia
1
L
Labile INRb
TTR <60% in patient receiving VKA
1
E
Elderly
Aged >65 years or extreme frailty
1
D
Drugs or excessive alcohol drinking
Concomitant use of antiplatelet or NSAID; and/or excessivec alcohol per week
1 point for each
Maximum score
9
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; SBP = systolic blood pressure; INR = international normalized ratio; NSAID =
Non-steroidal anti-inﬂammatory drug; TTR = time in therapeutic range; VKA = vitamin K antagonist.
aHaemorrhagic stroke would also score 1 point under the ‘B’ criterion.
bOnly relevant if patient receiving a VKA.
cAlcohol excess or abuse refers to a high intake (e.g. >14 units per week), where the clinician assesses there would be an impact on health or bleeding risk.


<!-- PAGE 33 -->

### Page 33

...............................................................................................................................
embolic rates.414 At high TTR values, the efficacy of VKAs in stroke prevention may be similar to NOACs, whereas the relative safety benefit with NOACs is less affected by TTR, with consistently lower serious bleeding rates (e.g. ICH) seen with NOACs compared with warfarin,
notwithstanding that the absolute difference is small.415,416
Numerous factors (including genetics, concomitant drugs, etc.) influence the intensity of VKA anticoagulant effect; the more common ones have been used to derive and validate the SAMe-TT2R2 fSex [female],
Age [<60 years], Medical history of >_2 comorbidities [hypertension,
diabetes mellitus, CAD/myocardial infarction, peripheral artery disease
(PAD), HF, previous stroke, pulmonary disease, and hepatic or renal disease], Treatment [interacting drugs, e.g. amiodarone], Tobacco use,
Race [non-Caucasian]g score,417 which can help to identify patients who are less likely to achieve a good TTR on VKA therapy (score >2)
and would do better with a NOAC. If such patients with SAMeTT2R2>2 are prescribed a VKA, greater efforts to improve TTR, such as more intense regular reviews, education/counselling, and frequent
INR monitoring are needed or, more conveniently, the use of a NOAC
should be reconsidered.418
10.1.4.2 Non-vitamin K antagonist oral anticoagulants
In four pivotal RCTs, apixaban, dabigatran, edoxaban, and rivaroxaban have shown non-inferiority to warfarin in the prevention of stroke/systemic embolism.419422 In a meta-analysis of these RCTs, NOACs were associated with a 19% significant stroke/systemic embolism risk reduction, a 51% reduction in haemorrhagic stroke,423 and similar ischaemic stroke risk reduction compared with VKAs, but NOACs were associated with a significant 10% reduction in all-cause mortality
(Supplementary Table 8). There was a non-significant 14% reduction in major bleeding risk, significant 52% reduction in ICH, and 25% increase in gastrointestinal bleeding with NOACs vs. warfarin.423
The major bleeding relative risk reduction with NOACs was significantly greater when INR control was poor (i.e. centre-based
TTR<66%). A meta-analysis of the five NOAC trials [RE-LY
(Randomized Evaluation of Long Term Anticoagulant Therapy),
ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation), J-ROCKET AF,
ARISTOTLE
(Apixaban for
Reduction in
Stroke and
Other
Thromboembolic Events in Atrial Fibrillation), and ENGAGE AF TIMI
48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial
FibrillationThrombolysis in Myocardial Infarction 48)] showed that,
compared with warfarin, standard-dose NOACs were more effective and safer in Asians than in non-Asians.424 In the AVERROES [Apixaban
Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial
Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K
Antagonist Treatment] trial of AF patients who refused or were deemed ineligible for VKA therapy, apixaban 5 mg b.i.d. (twice a day)
significantly reduced the risk of stroke/systemic embolism with no significant difference in major bleeding or ICH compared with aspirin.425
Post-marketing observational data on the effectiveness and safety of dabigatran,426,427 rivaroxaban,428,429 apixaban,430 and edoxaban431
vs. warfarin show general consistency with the respective RCT.
Given the compelling evidence about NOACs, AF patients should be informed of this treatment option.
Persistence to NOAC therapy is generally higher than to VKAs,
being facilitated by a better pharmacokinetic profile of NOACs432
(Supplementary Table 9) and favourable safety and efficacy, especially amongst vulnerable patients including the elderly, those with renal dysfunction or previous stroke, and so on.433 Whereas patients with end-stage renal dysfunction were excluded from the pivotal RCTs,
reduced dose regimens of rivaroxaban, edoxaban, and apixaban are feasible options for severe CKD [creatinine clearance (CrCl)
15 - 30
mL/min using the
Cockcroft-Gault equation].434,435
Considering that inappropriate dose reductions are frequent in clinical practice,436 thus increasing the risks of stroke/systemic embolism,
hospitalization, and death, but without decreasing bleeding risk,437
NOAC therapy should be optimized based on the efficacy and safety profile of each NOAC in different patient subgroups (Table 11).
10.1.4.3 Other antithrombotic drugs
In the ACTIVE W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) trial, dual antiplatelet therapy
(DAPT) with aspirin and clopidogrel was less effective than warfarin for prevention of stroke, systemic embolism, myocardial infarction,
and vascular death (the annual risk of events was 5.6% vs. 3.9%,
P =0.0003), with a similar rate of major bleeding.438 In the ACTIVE-A
trial, patients unsuitable for anticoagulation had a lower rate of thrombo-embolic complications when clopidogrel was added to aspirin compared with aspirin alone, but with a significant increase in major bleeding.439 Aspirin monotherapy was ineffective for stroke prevention compared with no antithrombotic treatment and was
Table 11
Dose selection criteria for NOACs
Dabigatran
Rivaroxaban
Apixaban
Edoxaban
Standard dose
150 mg b.i.d.
20 mg o.d.
5 mg b.i.d.
60 mg o.d.
Lower dose
110 mg b.i.d.
Reduced dose
15 mg o.d.
2.5 mg b.i.d.
30 mg o.d.
Dose-reduction criteria
Dabigatran 110 mg b.i.d. in patients with:
• Age >_80 years
• Concomitant use of verapamil, or
• Increased bleeding risk
CrCl 15 - 49 mL/min
At least 2 of 3 criteria:
• Age >_80 years,
• Body weight <_60 kg, or
• Serum creatinine
>_1.5 mg/dL (133 lmol/L)
If any of the following:
• CrCl 15 - 50 mL/min,
• Body weight <_60 kg,
• Concomitant use of dronedarone,
ciclosporine, erythromycin, or ketoconazole b.i.d. = bis in die (twice a day); CrCl = creatinine clearance; o.d. = omni die (once daily).
ESC Guidelines
405


<!-- PAGE 34 -->

### Page 34

.....................................................................................................................
associated with a higher risk of ischaemic stroke in elderly patients.440
Overall, antiplatelet monotherapy is ineffective for stroke prevention and is potentially harmful, (especially amongst elderly AF
patients),441,442 whereas DAPT is associated with a bleeding risk similar to OAC therapy. Hence, antiplatelet therapy should not be used for stroke prevention in AF patients.
10.1.4.4 Combination therapy with oral anticoagulant and antiplatelet drugs
The use of antiplatelet therapy remains common in clinical practice,
often in patients without an indication (e.g. PAD, CAD, or cerebrovascular disease) beyond AF.443 There is limited evidence to support the combination therapy solely for stroke prevention in AF, with no effect on reductions in stroke, myocardial infarction, or death, but with a substantial increase in the risk of major bleeding and
ICH.441,442
10.1.4.5 Left atrial appendage occlusion and exclusion
10.1.4.5.1
Left atrial appendage occlusion devices.
Only the
Watchman device has been compared with VKA therapy in RCTs
[the PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) and
PREVAIL (Watchman LAA Closure Device in Patients With Atrial
Fibrillation Versus Long Term Warfarin Therapy)],444446 where
LAA occlusion was non-inferior to VKA stroke prevention treatment in AF patients with moderate stroke risk, with a possibility of lower bleeding rates on longer follow-up.447 The LAA occlusion may also reduce stroke risk in patients with contraindications to OAC.448,449
A large European registry reported a high implantation success rate (98%), with an acceptable procedure-related complication rate of 4% at 30 days.450 Nevertheless, the implantation procedure can cause serious complications (higher event rates have been reported in real-world analyses compared with industry-sponsored studies,
possibly identifying some reporting bias) and device-related thrombosis may not be a benign finding.451454 Antithrombotic management after LAA occlusion has never been evaluated in a randomized manner and is based on historical studies, at least including aspirin
(Table 12). For patients who do not tolerate any antiplatelet therapy,
either an epicardial catheter approach (e.g. Lariat system) or thoracoscopic clipping of the LAA may be an option.455,456
Notably, the non-inferiority of LAA occlusion to VKA treatment was mostly driven by the prevention of haemorrhagic stroke, with a trend for more ischaemic strokes. The limitations of LAA occlusion as a strategy to reduce the risk of stroke associated with AF also include the consideration that AF acts as a risk marker of stroke.
Withholding OAC after LAA occlusion is likely to result in undertreating the overall risk of stroke related to atrial cardiomyopathy.
10.1.4.5.2 Surgical left atrial appendage occlusion or exclusion. Multiple observational studies indicate the feasibility and safety of surgical LAA
occlusion/exclusion, but only limited controlled trial data are available.457459 Residual LAA flow or incomplete LAA occlusion may be associated with an increased risk of stroke.460 In most studies,
LAA occlusion/exclusion was performed during other open heart surgery, and in more recent years in combination with surgical ablation of AF459,461 or as an isolated thoracoscopic procedure. A large
RCT in patients with an associated cardiac surgical procedure is ongoing.462
The most common justification for LAA occlusion/exclusion in clinical practice is a perceived high bleeding risk or, less often, contraindications for OAC.450 However, LAA occluders have not been randomly tested in such populations. Most patients who some years ago would be considered unsuitable for OAC therapy with VKA now seem to do relatively well on NOAC,433,463,464 and LAA occluders have not been compared with NOAC therapy in patients at risk for bleeding, or with surgical LAA occlusion/exclusion. Long-term aspirin is a common strategy in these patients,465 and one may question whether a NOAC would not be a better strategy if aspirin is tolerated. There is the need for adequately powered trials to define the best indications of LAA occlusion/exclusion compared with NOAC
therapy in patients with relative or absolute contraindications for anticoagulation, in those suffering from an ischaemic stroke on anticoagulant therapy, and for assessment of the appropriate antithrombotic therapy after LAA occlusion.
Table 12
Antithrombotic therapy after left atrial appendage occlusion
Device/patient
Aspirin
OAC
Clopidogrel
Comments
Watchman/low bleeding risk
75 - 325 mg/day indeﬁnitely
Start warfarin after procedure (target INR 2 - 3) until 45 days or continue until adequate LAA sealing is conﬁrmeda by TOE. NOAC is a possible alternative
Start 75 mg/day when OAC
stopped, continue until 6 months after the procedure
Some centres do not withhold
OAC at the time of procedure (no data to support/deny this approach)
Watchman/high bleeding risk
75 - 325 mg/day indeﬁnitely
None
75 mg/day for 1 - 6 months while ensuring adequate LAA sealinga
Clopidogrel often given for shorter time in very high-risk situations
ACP/Amulet
75 - 325 mg/day indeﬁnitely
None
75 mg/day for 1 - 6 months while ensuring adequate LAA sealinga
Clopidogrel may replace long-term aspirin if better tolerated
ACP = AmplatzerTM Cardiac Plug; INR = international normalized ratio; LAA = left atrial appendage; LMWH = low-molecular-weight heparin; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant ; TOE = transoesophageal echocardiography.
Note: Load aspirin or clopidogrel before procedure if untreated. Heparin with activated clotting time >250 seconds before or immediately after trans-septal punctures for all patients, followed by LMWH when warfarin needed.
aLess than 5 mm leak.


<!-- PAGE 35 -->

### Page 35

.......................................................................................................................................................................
10.1.4.6 Long-term oral anticoagulation per atrial fibrillation burden
Although the risk of ischaemic stroke/systemic embolism is higher with non-paroxysmal vs. paroxysmal AF, and AF progression is associated with an excess of adverse outcomes,169,466 the clinically determined temporal pattern of AF should not affect the decision regarding long-term OAC, which is driven by the presence of stroke risk factors.156 Management of patients with AHRE/subclinical AF is reviewed in section 16. Stroke risk in AHRE patients may be lower than in patients with diagnosed AF,467 and strokes often occur without a clear temporal relationship with AHRE/subclinical AF,179,226
underscoring its role as a risk marker rather than a stroke risk factor.4,172 Whether AHRE and subclinical AF have the same therapeutic requirements as clinical AF7 is presently unclear, and the net clinical benefit of OAC for AHRE/subclinical AF>24 h is currently being studied in several RCTs.4
Notably, patients with subclinical AF/AHRE may develop atrial tachyarrhythmias lasting more than 24 h468 or clinical AF; hence careful monitoring of these patients is recommended, even considering remote monitoring, especially with longer AHRE and higher risk profile.469 Given the dynamic nature of AF as well as stroke risk, a recorded duration in one monitoring period would not necessarily be the same in the next.
10.1.4.7 Long-term oral anticoagulation per symptom control strategy
Symptom control focuses on patient-centred and symptom-directed approaches to rate or rhythm control. Again, symptom control strategy should not affect the decision regarding long-term OAC, which is driven by the presence of stroke risk factors, and not the estimated success in maintaining sinus rhythm.
10.1.5
Management of anticoagulation-related bleeding risk
10.1.5.1 Strategies to minimize the risk of bleeding
Ensuring good quality of VKA treatment (TTR>70%) and selecting the appropriate dose of a NOAC (as per the dose reduction criteria specified on the respective drug label) are important considerations to minimize bleeding risk. As discussed in section 10.1.2, attention to modifiable bleeding risk factors should be made at every patient contact, and formal bleeding risk assessment is needed to help identify high-risk patients who should be followed up or reviewed earlier (e.g. 4 weeks rather than 4- 6 months).407 Concomitant regular administration of antiplatelet drugs or non-steroidal anti-inflammatory drug (NSAID) should be avoided in anticoagulated patients. Bleeding risk is dynamic, and attention to the change in bleeding risk profile is a stronger predictor of major bleeding events, especially in the first 3 months.389
10.1.5.2 High-risk groups
Certain high-risk AF populations have been under-represented in
RCTs, including the extreme elderly (>_90 years), those with cognitive impairment/dementia, recent bleeding or previous ICH, end-stage renal failure, liver impairment, cancer, and so on. Observational data suggest that such patients are at high risk for ischaemic stroke and death, and many would benefit from OAC.
Patients with liver function abnormalities may be at higher risk of bleeding on VKA, possibly less so on NOACs. Observational data in cirrhotic patients suggest that ischaemic stroke reduction may outweigh bleeding risk.470472
In patients with a recent bleeding event, attention should be directed towards addressing the predisposing pathology (e.g. bleeding ulcer or polyp in a patient with gastrointestinal bleeding), and the reintroduction of OAC as soon as feasible, as part of a multidisciplinary team decision. Consideration should be made for drugs such as apixaban or dabigatran 110 mg b.i.d., which are not associated with an excess of gastrointestinal bleeding compared with warfarin.
Where OAC is not reintroduced, there is a higher risk of stroke and death compared with restarting OAC, although the risk of rebleeding may be higher.473 Similarly, thromboprophylaxis in cancer may require a multidisciplinary team decision balancing stroke reduction against serious bleeding, which may be dependent on cancer type, site(s), staging, anti-cancer therapy and so on.
Thromboprophylaxis in specific high-risk groups is discussed in detail throughout section 11.
10.1.6
Decision making to avoid stroke
In observational population cohorts, both stroke and death are relevant endpoints, as some deaths could be due to fatal strokes (given that endpoints are not adjudicated in population cohorts, and cerebral imaging or post-mortems are not mandated). As OAC significantly reduces stroke (by 64%) and all-cause mortality (by 26%)
compared with control or placebo,412 the endpoints of stroke and/or mortality are relevant in relation to decision making for thromboprophylaxis.
The threshold for initiating OAC for stroke prevention, balancing ischaemic stroke reduction against the risk of ICH and associated
QoL, has been estimated to be 1.7%/year for warfarin and 0.9%/year for a NOAC (dabigatran data were used for the modelling analysis).474 The threshold for warfarin may be even lower, if good-quality anticoagulation control is achieved, with average TTR>70%.475
Given the limitations of clinical risk scores, the dynamic nature of stroke risk, the greater risk of stroke and death among AF patients with >_1 non-sex stroke risk factor, and the positive net clinical benefit of OAC among such patients, we recommend a risk-factorbased approach to stroke prevention rather than undue focus on (artificially defined) ‘high-risk’ patients. As the default is to offer stroke prevention unless the patient is low risk, the CHA2DS2VASc score should be applied in a reductionist manner, to decide on OAC or not.476
Thus, the first step in decision making (‘A’ Anticoagulation/Avoid stroke) is to identify low-risk patients who do not need antithrombotic therapy. Step 2 is to offer stroke prevention (i.e. OAC) to those with >_1 non-sex stroke risk factors (the strength of evidence differs,
with multiple clinical trials for patients with >_2 stroke risk factors,
and subgroups from trials/observational data on patients with 1 nonsex stroke risk factor). Step 3 is the choice of OAC—a NOAC (given their relative effectiveness, safety and convenience, these drugs are generally first choice as OAC for stroke prevention in AF) or VKA
(with good TTR at >70%). This ‘AF 3-step’ patient pathway182,477 for stroke risk stratification and treatment decision making is shown in
Figure 12.
ESC Guidelines
407


<!-- PAGE 36 -->

### Page 36

©ESC 2020
Figure 12 ‘A’ - Anticoagulation/Avoid stroke: The ‘AF 3-step’ pathway. AF = atrial fibrillation; CHA2DS2-VASc = Congestive heart failure,
Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65- 74 years, Sex category (female); HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs/alcohol concomitantly; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; SAMe-TT2R2 = Sex (female), Age (<60 years), Medical history,
Treatment (interacting drug(s)), Tobacco use, Race (non-Caucasian) (score); TTR = time in therapeutic range; VKA = vitamin K antagonist.
aIf a VKA being considered, calculate SAMe-TT2R2 score: if score 02, may consider VKA treatment (e.g. warfarin) or NOAC; if score >2, should arrange regular review/frequent INR checks/ counselling for VKA users to help good anticoagulation control, or reconsider the use of NOAC instead; TTR ideally
>70%.
Recommendations for the prevention of thrombo-embolic events in AF
Recommendations
Classa
Levelb
For stroke prevention in AF patients who are eligible for OAC, NOACs are recommended in preference to VKAs (excluding patients with mechanical heart valves or moderate-to-severe mitral stenosis).423,424
I
A
For stroke risk assessment, a risk-factor-based approach is recommended, using the CHA2DS2-VASc clinical stroke risk score to initially identify patients at ‘low stroke risk’ (CHA2DS2-VASc score = 0 in men, or 1 in women) who should not be offered antithrombotic therapy.334,388
I
A
OAC is recommended for stroke prevention in AF patients with CHA2DS2-VASc score >_2 in men or >_3 in women.412
I
A
OAC should be considered for stroke prevention in AF patients with a CHA2DS2-VASc score of 1 in men or 2 in women.
Treatment should be individualized based on net clinical beneﬁt and consideration of patient values and preferences.338,378,380
IIa
B
For bleeding risk assessment, a formal structured risk-score-based bleeding risk assessment is recommended to help identify nonmodiﬁable and address modiﬁable bleeding risk factors in all AF patients, and to identify patients potentially at high risk of bleeding who should be scheduled for early and more frequent clinical review and follow-up.388,395,404,406
I
B
Continued


<!-- PAGE 37 -->

### Page 37

...........................................................................
10.2 ‘B’  Better symptom control
10.2.1
Rate control
Rate control is an integral part of AF management, and is often sufficient to improve AF-related symptoms. Very little robust evidence exists to inform the best type and intensity of rate control treatment.484486
10.2.1.1 Target/optimal ventricular rate range
The optimal heart-rate target in AF patients is unclear. In the RACE
(Race Control Efficacy in Permanent Atrial Fibrillation) II RCT of permanent AF patients, there was no difference in a composite of clinical events, New York Heart Association (NYHA) class, or hospitalizations between the strict [target heart rate <80 beats per minute
(bpm) at rest and <110 bpm during moderate exercise] and lenient
(heart-rate target <110 bpm) arm,487,488 similar to an analysis from the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm
Management) and RACE trials.489 Therefore, lenient rate control is an acceptable initial approach, regardless of HF status (with the exception of tachycardia-induced cardiomyopathy), unless symptoms call for stricter rate control (Figure 13).
10.2.1.2 Drugs
Pharmacological rate control can be achieved with beta-blockers,
digoxin, diltiazem, and verapamil, or combination therapy (Table 13).
Some antiarrhythmic drugs (AADs) also have rate-limiting properties
(e.g. amiodarone, dronedarone, sotalol) but generally they should be used only for rhythm control. The choice of rate control drugs depends on symptoms, comorbidities, and potential side-effects
(Table 13).
Beta-blockers are often first-line rate-controlling agents, largely based on better acute rate control. Interestingly, the prognostic benefit of beta-blockers seen in HF with reduced ejection fraction
(HFrEF) patients with sinus rhythm has been questioned in patients with AF.491
Non-dihydropyridine calcium channel blockers (NDCC)
verapamil and diltiazem provide reasonable rate control492 and can improve AF-related symptoms486 compared with betablockers. In one small trial of patients with preserved LVEF, NDCC
preserved exercise capacity and reduced
B-type natriuretic peptide.493,494
Digoxin and digitoxin are not effective in patients with increased sympathetic drive. Observational studies have associated digoxin use with excess mortality in AF patients.495497 This finding was likely due to selection and prescription biases rather than harm caused by digoxin,498501 particularly as digoxin is commonly prescribed to sicker patients.502 Lower doses of digoxin may be associated with
For a formal risk-score-based assessment of bleeding risk, the HAS-BLED score should be considered to help address modiﬁable bleeding risk factors, and to identify patients at high risk of bleeding (HAS-BLED score >_3) for early and more frequent clinical review and follow-up.388,395,404,406
IIa
B
Stroke and bleeding risk reassessment at periodic intervals is recommended to inform treatment decisions (e.g. initiation of OAC
in patients no longer at low risk of stroke) and address potentially modiﬁable bleeding risk factors.c389,478,479
I
B
In patients with AF initially at low risk of stroke, ﬁrst reassessment of stroke risk should be made at 4 - 6 months after the index evaluation.385387
IIa
B
If a VKA is used, a target INR of 2.0 - 3.0 is recommended, with individual TTR>_70%.414
I
B
In patients on VKAs with low time in INR therapeutic range (e.g. TTR<70%), recommended options are:
• Switching to a NOAC but ensuring good adherence and persistence with therapy415,416; or
I
B
• Efforts to improve TTR (e.g. education/counselling and more frequent INR checks).480
IIa
B
Antiplatelet therapy alone (monotherapy or aspirin in combination with clopidogrel) is not recommended for stroke prevention in AF.440,441,480,481
III
A
Estimated bleeding risk, in the absence of absolute contraindications to OAC, should not in itself guide treatment decisions to use
OAC for stroke prevention.
III
A
Clinical pattern of AF (i.e. ﬁrst detected, paroxysmal, persistent, long-standing persistent, permanent) should not condition the indication to thromboprophylaxis.160
III
B
Recommendations for occlusion or exclusion of the LAA
LAA occlusion may be considered for stroke prevention in patients with AF and contraindications for long-term anticoagulant treatment (e.g. intracranial bleeding without a reversible cause).448,449,481,482
IIb
B
Surgical occlusion or exclusion of the LAA may be considered for stroke prevention in patients with AF undergoing cardiac surgery.459,483
IIb
C
AF = atrial ﬁbrillation; BP = blood pressure; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65 - 74
years, Sex category (female); HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs/alcohol concomitantly; INR = international normalized ratio; LAA = left atrial appendage; NOAC = non-vitamin K antagonist oral anticoagulant; NSAID = non-steroidal anti-inﬂammatory drug; OAC = oral anticoagulant ; TTR = time in therapeutic range; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cIncluding uncontrolled BP; labile INRs (in a patient taking VKA); alcohol excess; concomitant use of NSAIDs or aspirin in an anticoagulated patient; bleeding tendency or predisposition (e.g. treat gastric ulcer, optimize renal or liver function, etc.).
ESC Guidelines
409


<!-- PAGE 38 -->

### Page 38

....................................................................
better prognosis.502 An ongoing RCT is addressing digitoxin use in patients with HFrEF.503
Amiodarone can be useful as a last resort when heart rate cannot be controlled with combination therapy in patients who do not qualify for non-pharmacological rate control, i.e. atrioventricular node ablation and pacing, notwithstanding the extracardiac adverse effects of the drug504 (Table 13).
10.2.1.3 Acute rate control
In acute settings, physicians should always evaluate underlying causes,
such as infection or anaemia. Beta-blockers and diltiazem/verapamil are preferred over digoxin because of their rapid onset of action and effectiveness at high sympathetic tone.507511 The choice of drug
(Table 13 and Figure 14) and target heart rate will depend on the patient characteristics, symptoms, LVEF value, and haemodynamics,
but a lenient initial rate control approach seems acceptable
(Figure 13). Combination therapy may be required. In patients with
HFrEF, beta-blockers, digitalis, or their combination should be used.512,513 In critically ill patients and those with severely impaired
LV systolic function, i.v. amiodarone can be used.504,514,515 In unstable patients, urgent cardioversion should be considered (section 11.1).
10.2.1.4 Atrioventricular node ablation and pacing
Ablation of the atrioventricular node and pacemaker implantation can control ventricular rate when medication fails. The procedure is relatively simple and has a low complication rate and low long-term mortality risk,516,517 especially when the pacemaker is implanted a few weeks before the atrioventricular node ablation and the initial pacing rate after ablation is set at 7090 bpm.518,519 The procedure does not worsen LV function520 and may even improve LVEF in selected patients.521523 Most studies have included older patients with limited life expectancy. For younger patients, ablation of the atrioventricular node should only be considered if there is urgent need for rate control and all other pharmacological and nonpharmacological treatment options have been carefully considered.
The choice of pacing therapy (right ventricular or biventricular pacing) will depend on patient characteristics.524,525 His-bundle pacing after atrioventricular node ablation may evolve as an attractive alternative pacing mode,526 as currently tested in ongoing clinical trials
(NCT02805465, NCT02700425).
In severely symptomatic patients with permanent AF and at least one hospitalization for HF, atrioventricular node ablation combined with cardiac resynchronization therapy (CRT) may be preferred. In a small RCT, the primary composite outcome (death
Figure 13 Outline of rate control therapy.490 AF = atrial fibrillation; AVN = atrioventricular node; bpm = beats per minute; BV = biventricular; CRT =
cardiac resynchronization therapy; CRT-D: cardiac resynchronization therapy defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; ECG
= electrocardiogram; LV = left ventricular; SR = sinus rhythm.


<!-- PAGE 39 -->

### Page 39

..........
or hospitalization for HF, or worsening HF) was significantly less common in the ablation þ CRT group vs. the drug arm (P =0.013),
and ablation þ CRT patients showed a 36% decrease in symptoms and physical limitations at 1-year follow-up (P =0.004).527
Emerging evidence suggest that His-bundle pacing could be an alternative in these patients.528
Table 13
Drugs for rate control in AFa
Intravenous administration
Usual oral maintenance dose
Contraindicated
Beta-blockersb
Metoprolol tartrate
2.5 - 5 mg i.v. bolus; up to 4 doses
25 - 100 mg b.i.d.
In case of asthma use beta-1blockers
Contraindicated in acute HF and history of severe bronchospasm
Metoprolol XL (succinate)
N/A
50 - 400 mg o.d.
Bisoprolol
N/A
1.25 - 20 mg o.d.
Atenololc
N/A
25 - 100 mg o.d.
Esmolol
500 mg/kg i.v. bolus over 1 min; followed by
50 - 300 mg/kg/min
N/A
Landiolol
100 mg/kg i.v. bolus over 1 min, followed by
10 - 40 mg/kg/min; in patients with cardiac dysfunction: 1 - 10 mg/kg/min
N/A
Nebivolol
N/A
2.5 - 10 mg o.d.
Carvedilol
N/A
3.125 - 50 mg b.i.d.
Non-dihydropyridine calcium channel antagonists
Verapamil
2.5 - 10 mg i.v. bolus over 5 min
40 mg b.i.d. to 480 mg (extended release) o.d.
Contraindicated in HFrEF
Adapt doses in hepatic and renal impairment
Diltiazem
0.25 mg/kg i.v. bolus over 5 min, then 5 - 15
mg/h
60 mg t.i.d. to 360 mg (extended release) o.d.
Digitalis glycosides
Digoxin
0.5 mg i.v. bolus (0.75 - 1.5 mg over 24
hours in divided doses)
0.0625 - 0.25 mg o.d.
High plasma levels associated with increased mortality
Check renal function before starting and adapt dose in CKD patients
Digitoxin
0.4 - 0.6 mg
0.05 - 0.1 mg o.d.
High plasma levels associated with increased mortality
Other
Amiodarone
300 mg i.v. diluted in 250 mL 5% dextrose over 30 - 60 min (preferably via central venous cannula), followed by 900 - 1200
mg i.v. over 24 hours diluted in 500 - 1000
mL via a central venous cannula
200 mg o.d. after loading
3  200 mg daily over 4 weeks,
then 200 mg daily536 d(reduce other rate controlling drugs according to heart rate)
In case of thyroid disease, only if no other options
AF = atrial ﬁbrillation; b.i.d. = bis in die (twice a day); CKD = chronic kidney disease; HF = heart failure; HFrEF = HF with reduced ejection fraction; i.v. = intravenous; min =
minutes; N/A = not available or not widely available; o.d. = omni die (once daily); t.i.d. = ter in die (three times a day).
aAll rate control drugs are contraindicated in Wolff-Parkinson-White syndrome, also i.v. amiodarone.
bOther beta-blockers are available but not recommended as speciﬁc rate control therapy in AF and therefore not mentioned here (e.g. propranolol and labetalol).
cNo data on atenolol; should not be used in HFrEF.
dLoading regimen may vary; i.v. dosage should be considered when calculating total load.
ESC Guidelines
411


<!-- PAGE 40 -->

### Page 40

©ESC 2020
Figure 14 Choice of rate control drugs.490 AF = atrial fibrillation; AFL = atrial flutter; COPD = chronic obstructive pulmonary disease; CRT-D = cardiac resynchronization therapy defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; HFpEF = heart failure with preserved ejection fraction; HFrEF =
heart failure with reduced ejection fraction; NDCC = Non-dihydropyridine calcium channel blocker. aClinical reassessment should be focused on evaluation of resting heart rate, AF/AFL-related symptoms and quality of life. In case suboptimal rate control (resting heart rate >110 bpm), worsening of symptoms or quality of life consider 2nd line and, if necessary, 3rd line treatment options. bCareful institution of beta-blocker and NDCC, 24-hour Holter to check for bradycardia.
Recommendations for ventricular rate control in patients with AFa
Recommendations
Classb
Levelc
Beta-blockers, diltiazem, or verapamil are recommended as ﬁrst-choice drugs to control heart rate in AF patients with
LVEF>_40%.492,507,511,529
I
B
Beta-blockers and/or digoxin are recommended to control heart rate in AF patients with LVEF<40%.486,491,502,512,530532
I
B
Combination therapy comprising different rate controlling drugsd should be considered if a single drug does not achieve the target heart rate.533,534
IIa
B
A resting heart rate of <110 bpm (i.e. lenient rate control) should be considered as the initial heart rate target for rate control therapy.488
IIa
B
Atrioventricular node ablation should be considered to control heart rate in patients unresponsive or intolerant to intensive rate and rhythm control therapy, and not eligible for rhythm control by LA ablation, accepting that these patients will become pacemaker dependent.516,523,535,536
IIa
B
In patients with haemodynamic instability or severely depressed LVEF, intravenous amiodarone may be considered for acute control of heart rate.504,514,515
IIb
B
AF = atrial ﬁbrillation; bpm = beats per minute; ECG = electrocardiogram; LA = left atrial; LVEF = left ventricular ejection fraction.
aSee section 11 for ventricular rate control in various concomitant conditions and AF populations bClass of recommendation.
cLevel of evidence.
dCombining beta-blocker with verapamil or diltiazem should be performed with careful monitoring of heart rate by 24-h ECG to check for bradycardia.488


<!-- PAGE 41 -->

### Page 41

...................................................
10.2.2
Rhythm control
The ‘rhythm control strategy’ refers to attempts to restore and maintain sinus rhythm, and may engage a combination of treatment approaches, including cardioversion,164,234 antiarrhythmic medication,233,537,538 and catheter ablation,539541 along with an adequate rate control, anticoagulation therapy (section 10.2.2.6) and comprehensive cardiovascular prophylactic therapy (upstream therapy,
including lifestyle and sleep apnoea management) (Figure 15).
10.2.2.1 Indications for rhythm control
Based on the currently available evidence from RCTs, the primary indication for rhythm control is to reduce AF-related symptoms and improve QoL (Figure 15). In case of uncertainty, an attempt to restore sinus rhythm in order to evaluate the response to therapy may be a rational first step. Factors that may favour an attempt at rhythm control should be considered542,543 (Figure 15).
As AF progression is associated with a decrease in QoL544 and,
with time, becomes irreversible or less amenable to treatment,176
rhythm control may be a relevant choice, although currently there is no substantial evidence that this may result in a different outcome.
Reportedly, rates of AF progression were significantly lower with rhythm control than rate control.545 Older age, persistent AF, and previous stroke/TIA independently predicted AF progression,545
which may be considered when deciding the treatment strategy. For many patients, an early intervention to prevent AF progression may be worth considering,546 including optimal risk-factor management.245 Ongoing trials in patients with newly diagnosed symptomatic AF will assess whether early rhythm control interventions such as AF catheter ablation offer an opportunity to halt the progressive patho-anatomical changes associated with AF.547 However, there is evidence that, at least in some patients, a successful rhythm control strategy with AF catheter ablation may not affect atrial substrate
©ESC 2020
Figure 15 Rhythm control strategy. AAD = antiarrhythmic drug; AF = atrial fibrillation; CMP = cardiomyopathy; CV = cardioversion; LAVI = left atrial volume index; PAF = paroxysmal atrial fibrillation; PVI = pulmonary vein isolation; QoL = quality of life; SR = sinus rhythm. aConsider cardioversion to confirm that the absence of symptoms is not due to unconscious adaptation to reduced physical and/or mental capacity.
ESC Guidelines
413


<!-- PAGE 42 -->

### Page 42

.............................................................................................................................................................................
development.548 Important evidence regarding the effect of early rhythm control therapy on clinical outcomes are expected in 2020
from the ongoing EAST (Early treatment of Atrial fibrillation for
Stoke prevention Trial) trial.549
General recommendations regarding active informed patient involvement in shared decision making (section 9) also apply for rhythm control strategies. The same principles should be applied in female and male AF patients when considering rhythm control therapy.550
10.2.2.2 Cardioversion
10.2.2.2.1
Immediate cardioversion/elective cardioversion.
Acute rhythm control can be performed as an emergency cardioversion in a haemodynamically unstable AF patient or in a non-emergency situation. Synchronized direct current electrical cardioversion is the preferred choice in haemodynamically compromised AF patients as it is more effective than pharmacological cardioversion and results in immediate restoration of sinus rhythm.554,555 In stable patients, either pharmacological cardioversion or electrical cardioversion can be attempted; pharmacological cardioversion is less effective but does not require sedation. Of note, pre-treatment with AADs can improve the efficacy of elective electrical cardioversion.556 A RCT
showed maximum fixed-energy electrical cardioversion was more effective than an energy-escalation strategy.557
In a RCT, a wait-and-watch approach with rate control medication only and cardioversion when needed within 48 h of symptom onset was as safe as and non-inferior to immediate cardioversion of paroxysmal AF, which often resolves spontaneously within 24 h.558
Elective cardioversion refers to the situation when cardioversion can be planned beyond the nearest hours. Observational data243
showed that cardioversion did not result in improved AF-related
QoL or halted AF progression, but many of these patients did not receive adjunctive rhythm control therapies.243 Other studies reported significant QoL improvement in patients who maintain sinus rhythm after electrical cardioversion and the only variable independently associated with a moderate to large effect size was sinus rhythm at 3 months.232
Factors associated with an increased risk for AF recurrence after elective cardioversion include older age, female sex, previous cardioversion, chronic obstructive pulmonary disease (COPD), renal impairment, structural heart disease, larger LA volume index, and
HF.164,559,560 Treatment of potentially modifiable conditions should be considered before cardioversion to facilitate maintenance of sinus rhythm (Figure 15).245 In case of AF recurrence after cardioversion in patients with persistent AF, an early re-cardioversion may prolong subsequent duration of sinus rhythm.561
Non-emergency cardioversion is contraindicated in the presence of known LA thrombus. Peri-procedural thrombo-embolic risk should be evaluated and peri-procedural and long-term OAC use considered irrespective of cardioversion mode (i.e. pharmacological cardioversion or electrical cardioversion) (section 10.2.2.6). A flowchart for decision making on cardioversion is shown in Figure 16.
10.2.2.2.2 Electrical cardioversion. Electrical cardioversion can be performed safely in sedated patients treated with i.v. midazolam and/or propofol or etomidate.562 BP monitoring and oximetry during the procedure should be used routinely. Skin burns may occasionally be observed. Intravenous atropine or isoproterenol, or temporary transcutaneous pacing, should be available in case of post-cardioversion bradycardia. Biphasic defibrillators are standard because of their superior efficacy compared with monophasic defibrillators.563,564 Anterior
posterior electrode positions restore sinus rhythm more effectively,554,555 while other reports suggest that specific electrical pad positioning is not critically important for successful cardioversion.565
10.2.2.2.3 Pharmacological cardioversion (including ‘pill in the pocket’).
Pharmacological cardioversion to sinus rhythm is an elective procedure indicated in haemodynamically stable patients. Its true efficacy is biased by the spontaneous restoration of sinus rhythm within 48 h of hospitalization in 76 - 83% of patients with recent onset AF (10 - 18%
within first 3 h, 55- 66% within 24 h, and 69% within 48 h).566568
Therefore, a ‘wait-and-watch’ strategy (usually for <24 h) may be considered in patients with recent-onset AF as a non-inferior alternative to early cardioversion.558
The choice of a specific drug is based on the type and severity of associated heart disease (Table 14), and pharmacological cardioversion is more effective in recent onset AF. Flecainide (and other class
Ic agents), indicated in patients without significant LV hypertrophy
(LVH), LV systolic dysfunction, or ischaemic heart disease, results in prompt (3- 5 h) and safe569 restoration of sinus rhythm in >50% of patients,570574 while i.v. amiodarone, mainly indicated in HF patients,
has a limited and delayed effect but can slow heart rate within
12 h.570,575577 Intravenous vernakalant is the most rapidly cardioverting drug, including patients with mild HF and ischaemic heart disease, and is more effective than amiodarone578583 or flecainide.584
Dofetilide is not used in Europe and is rarely used outside Europe.
Ibutilide is effective to convert atrial flutter (AFL) to sinus rhythm.585
In selected outpatients with rare paroxysmal AF episodes, a selfadministered oral dose of flecainide or propafenone is slightly less effective than in-hospital pharmacological cardioversion but may be preferred (permitting an earlier conversion), provided that the drug safety and efficacy has previously been established in the hospital setting.586 An atrioventricular node-blocking drug should be instituted in patients treated with class Ic AADs (especially flecainide) to avoid transformation to AFL with 1:1 conduction.587
10.2.2.2.4 Follow-up after cardioversion. The goals of follow-up after cardioversion are shown in Table 15. When assessing the efficacy of a rhythm control strategy, it is important to balance symptoms and
AAD side-effects. Patients should be reviewed after cardioversion to detect whether an alternative rhythm control strategy including AF
catheter ablation, or a rate control approach is needed instead of current treatment.
Recommendations for rhythm control
Recommendations
Classa
Levelb
Rhythm control therapy is recommended for symptom and QoL improvement in symptomatic patients with AF.551553
I
A
AF = atrial ﬁbrillation; QoL = quality of life.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 43 -->

### Page 43

©ESC 2020
Figure 16 Flowchart for decision making on cardioversion of AF depending on clinical presentation, AF onset, oral anticoagulation intake, and risk factors for stroke. AF = atrial fibrillation; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age
65- 74 years, Sex category (female); cardioversion = cardioversion; ECV = electrical cardioversion; h = hour; LA = left atrium; LAA = left atrial appendage;
LMWH = low-molecular-weight heparin; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; TE = thromboembolism; TOE
= transoesophageal echocardiography; UFH = unfractionated heparin; VKA = vitamin K antagonist.
ESC Guidelines
415


<!-- PAGE 44 -->

### Page 44

.............................................................................................................................................................................
................................................................................................................................................................................................................................................................................................
Table 14
Antiarrhythmic drugs used for restoration of sinus rhythm
Antiarrhythmic drugs for restoration of sinus rhythm (pharmacological cardioversion)
Drug
Administration route
Initial dose for cardioversion
Further dosing for cardioversion
Acute success rate and expected time to sinus rhythm
Contraindications/precautions/comments
Flecainidea
Oralb i.v.
200300 mg
2 mg/kg over 10 min
-
Overall: 5978%
(51% at 3 h, 72% at 8 h)
• Should not be used in ischaemic heart disease and/or signiﬁcant structural heart disease
• May induce hypotension, AFL with 1:1 conduction (in
3.5 - 5.0% of patients)
• Flecainide may induce mild QRS complex widening
• Do NOT use for pharmacological cardioversion of AFL
Propafenonea
Oralb i.v.
450600 mg
1.5 - 2 mg/kg over 10 min
-
Oral: 4555% at 3 h,
6978% at 8 h;
i.v.: 4389%
Up to 6 h
Vernakalantc i.v.
3 mg/kg over 10 min
2 mg/kg over 10 min
(10 - 15 min after the initial dose)
<1 h (50% conversion within 10 min)
• Should not be used in patients with arterial hypotension (SBP
<100 mmHg), recent ACS (within 1 month), NYHA III or IV
HF, prolonged QT, or severe aortic stenosis
• May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia
Amiodaronea i.v.
5 - 7 mg/kg over 1 - 2 h
50 mg/h (maximum 1.2 g for
24 h)
44%
(812 h to several days)
• May cause phlebitis (use a large peripheral vein, avoid i.v.
administration >24 hours and use preferably volumetric pump)
• May cause hypotension, bradycardia/atrioventricular block,
QT prolongation
• Only if no other options in patients with hyperthyroidism
(risk of thyrotoxicosis)
Ibutilidec i.v.
1 mg over 10 min
0.01 mg/kg if body weight <60 kg
1 mg over 10 min
(10 - 20 min after the initial dose)
3151% (AF)
6373% (AFL)
1 h
• Effective for conversion of AFL
• Should not be used in patients with prolonged QT, severe
LVH, or low LVEF
• Should be used in the setting of a cardiac care unit as it may cause QT prolongation, polymorphic ventricular tachycardia
(torsades de pointes)
• ECG monitoring for at least 4 hours after administration to detect a proarrhythmic event
AAD = antiarrhythmic drug; ACS = acute coronary syndrome; AF = atrial ﬁbrillation; AFL = atrial ﬂutter; b.i.d. ¼ bis in die (twice a day); CrCl = creatinine clearance; CYP2D6 = cytochrome P450 2D6; ECG = electrocardiogram; EHRA =
European Heart Rhythm Association; HCM = hypertrophic cardiomyopathy; HF = heart failure; i.v. = intravenous; LV = left ventricular; LVEF = left ventricular ejection fraction; LVH = LV hypertrophy; NYHA = New York Heart
Association; QRS = QRS interval; QT = QT interval; SA = sinoatrial; SBP = systolic blood pressure; VKA = vitamin K antagonist.
aMost frequently used for cardioversion of AF, available in most countries.
bMay be self-administered by selected outpatients as a ‘pill-in-the-pocket’ treatment strategy.
cNot available in some countries.
For more details regarding pharmacokinetic or pharmacodynamic properties refer to EHRA AADsclinical use and clinical decision making: a consensus document.568


<!-- PAGE 45 -->

### Page 45

###### 10.2.2.3 Atrial fibrillation catheter ablation

AF catheter ablation is a well-established treatment for the prevention of AF recurrences.1,602604 When performed by appropriately trained operators, AF catheter ablation is a safe and superior alternative to AADs for maintenance of sinus rhythm and symptom improvement.165,235242,246,247,605618 It is advised to discuss the efficacy and complication rates of AF catheter ablation and AADs with the patient once rhythm control as long-term management has been selected.
10.2.2.3.1 Indications. In the following section, indications for AF catheter ablation are presented for paroxysmal and persistent AF in patients with and without risk factors for post-ablation AF recurrence. Differentiation of persistent and long-standing persistent AF
was omitted because the latter only expresses the duration of persistent AF above an arbitrary and artificial cut-off at 12 months’ duration. The significance of such a cut-off as a single measure has never been substantially proven.
A number of risk factors for AF recurrence after AF ablation have been identified, including LA size, AF duration, patient age, renal dysfunction, and substrate visualization by means of MRI.619625 Recent systematic reviews on prediction models for AF recurrence after catheter ablation showed the potential benefits of risk predictions,
but a more robust evaluation of such models is desirable.167,626 The model variables can be measured before ablation; therefore models could be used pre-procedurally to predict the likelihood of recurrence.627635 However, no single score has been presently identified as consistently superior to others. Thus, at present, for an improved and more balanced indication for ablation in patients with persistent AF and risk factors for recurrence, the most intensely evaluated risk predictors (including duration of AF) should be considered,
and adjusted to the individual patient’s situation including their preferences. Notably, patients must also be explicitly informed about the importance of treating modifiable risk factors to reduce risk of recurrent AF.621,636652
The indications for AF catheter ablation are summarized in
Figure 17. AF catheter ablation is effective in maintaining sinus rhythm in patients with paroxysmal and persistent AF.165,235242,605616 The main clinical benefit of AF catheter ablation is the reduction of arrhythmia-related symptoms.246,247,603,604,607,617,653,654
This has been confirmed in a recent RCT showing that the improvement in
QoL was significantly higher in the ablation vs. medical therapy group,
Table 15
Goals of follow-up after cardioversion of AF
Goals
Early recognition of AF recurrence by ECG recording after cardioversion
Evaluation of the efﬁcacy of rhythm control by symptom assessment
Monitoring of risk for proarrhythmia by regular control of PR, QRS, and QTc intervals in patients on Class I or III AADs
Evaluation of balance between symptoms and side-effects of therapy considering QoL and symptoms
Evaluation of AF-related morbidities and AAD-related side-effects on concomitant cardiovascular conditions and LV function
Optimization of conditions for maintenance of sinus rhythm including cardiovascular risk management (BP control, HF treatment, increasing cardiorespiratory ﬁtness, and other measures, see section 11).
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; BP = blood pressure; ECG = electrocardiogram; HF = heart failure; LV = left ventricular; PR = PR interval; QoL = quality of life; QRS = QRS interval; QTc = corrected QT interval.
Recommendations for cardioversion
Recommendations
Classa
Levelb
For pharmacological cardioversion of recentonset AF, i.v. vernakalant (excluding patients with recent ACS or severe HF) or ﬂecainide or propafenone (excluding patients with severe structural heart disease) is recommended.569,573,579,582,588590
I
A
Intravenous amiodarone is recommended for cardioversion of AF in patients with HF or structural heart disease, if delayed cardioversion is consistent with clinical situation.515,591,592
I
A
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent AF as part of rhythm control therapy.232,233,593,594
I
B
Pharmacological cardioversion of AF is indicated only in a haemodynamically stable patient, after consideration of the thromboembolic risk.595
I
B
Pre-treatment with amiodarone, ﬂecainide, ibutilide, or propafenone should be considered to facilitate the success of electrical cardioversion.556,596599
IIa
B
In selected patients with infrequent and recentonset AF and no signiﬁcant structural or ischaemic heart disease, a single self-administered oral dose of ﬂecainide or propafenone (‘pill in the pocket’ approach) should be considered for patient-led cardioversion, but only following efﬁcacy and safety assessment.574,586,600,601
IIa
B
For patients with sick-sinus syndrome, atrioventricular conduction disturbances or prolonged
QTc (>500 ms), pharmacological cardioversion should not be attempted unless risks for proarrhythmia and bradycardia have been considered.
III
C
ACS = acute coronary syndrome; AF = atrial ﬁbrillation; HF = heart failure; ms =
milliseconds; i.v. = intravenous; QTc = corrected QT interval. Note: For cardioversion in various speciﬁc conditions and AF populations see section 11.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
417


<!-- PAGE 46 -->

### Page 46

............................................................................................
as was the associated reduction in AF burden.246 Symptom improvement has also been confirmed in the recent large CABANA
(Catheter ABlation vs. ANtiarrhythmic Drug Therapy for Atrial
Fibrillation) RCT,655 but the trial showed that the strategy of AF catheter ablation did not significantly reduce the primary composite outcome of death, disabling stroke, serious bleeding, or cardiac arrest compared with medical therapy.617 As no RCT has yet demonstrated a significant reduction in all-cause mortality, stroke, or major bleeding with AF catheter ablation in the ’general’ AF population, the indications for the procedure have not been broadened beyond symptom relief,617 and AF catheter ablation is generally not indicated in asymptomatic patients. Further important evidence regarding the impact of ablation on major cardiovascular events is expected from the EAST
trial.656
In selected patients with HF and reduced LVEF, two RCTs have shown a reduction in all-cause mortality and hospitalizations with AF
catheter ablation,611,657 although combined mortality and HF hospitalization was a primary endpoint only in the CASTLE-AF (Catheter
Ablation vs. Standard conventional Treatment in patients with LEft ventricular dysfunction and Atrial Fibrillation) trial.657 The generalizability of the trial has recently been evaluated in a large HF patient population.658 This analysis showed that only a small number of patients met the trial inclusion criteria (<10%) and patients who met the CASTLE-AF inclusion criteria had a significant benefit from treatment as demonstrated in the trial.658 The smaller AMICA (Atrial
Fibrillation Management in Congestive Heart Failure With Ablation)
RCT, which included patients with more advanced HFrEF, did not show benefits gained by AF catheter ablation at 1-year follow-up,659
whereas a recent CABANA subgroup analysis supported the benefits of AF catheter ablation in patients with HFrEF, showing a significant reduction in the study primary endpoint (death, stroke, bleeding, cardiac arrest) and reduced mortality in the ablation group.617,660
Overall, AF catheter ablation in patients with HFrEF results in higher rates of preserved sinus rhythm and greater improvement in LVEF,
exercise performance, and QoL compared with AAD and rate control.611,657,661671 Accordingly, ablation should be considered in patients with HFrEF who have been selected for rhythm control treatment to improve QoL and LV function, and to reduce HF hospitalization and, potentially, mortality.
When AF-mediated tachycardia-induced cardiomyopathy (i.e. ventricular dysfunction secondary to rapid and/or asynchronous/irregular myocardial contraction, partially or completely reversed after treatment of the causative arrhythmia) is highly suspected, AF catheter ablation is recommended to restore LV function.672676
Ablation is recommended, in general, as a second-line therapy after failure (or intolerance) of class I or class III AADs. This recommendation is based on the results of multiple RCTs showing superiority of AF catheter ablation vs. AADs regarding freedom from recurrent arrhythmia or improvement in symptoms, exercise capacity,
and
QoL
after medication failure.235239,246,247,605607,609,611,613617
Clinical trials considering AF catheter ablation before any AAD
suggest that AF catheter ablation is more effective in maintaining sinus rhythm, with comparable complication rates in experienced centres.240242,614 The 5-year follow-up in the MANTRA-PAF (Medical
Antiarrhythmic
Treatment or
Radiofrequency
Ablation in
Paroxysmal Atrial Fibrillation) trial showed a significantly lower AF
burden in the ablation arm that did not, however, translate into improved QoL compared with AAD treatment,615 whereas the
CAPTAF (Catheter Ablation compared with Pharmacological
©ESC 2020
Figure 17 Indications for catheter ablation of symptomatic AF. The arrows from AAD to ablation indicate failed drug therapy. AAD = antiarrhythmic drug; AF = atrial fibrillation; EF = ejection fraction; LA = left atrial. aSignificantly enlarged LA volume, advanced age, long AF duration, renal dysfunction, and other cardiovascular risk factors. bIn rare individual circumstances, catheter ablation may be carefully considered as first-line therapy. cRecommended to reverse LV dysfunction when tachycardiomyopathy is highly probable. dTo improve survival and reduce hospitalization.


<!-- PAGE 47 -->

### Page 47

.....................................................................................................................
Therapy for Atrial Fibrillation) study showed that, in AF patients mostly naive to class I and III AADs, the greater improvement in QoL
in the ablation arm was directly associated with greater reduction in
AF burden compared with the AAD arm.246 Based on these studies and patient preferences, AF catheter ablation should be considered before a trial of AAD in patients with paroxysmal AF episodes (class
IIa), or may be considered in patients with persistent AF without risk factors for recurrence (class IIb).
10.2.2.3.2 Techniques and technologies. The cornerstone of AF catheter ablation is the complete isolation of pulmonary veins by linear lesions around their antrum,
either using point-by-point radiofrequency ablation or single-shot ablation devices.235,237,239,607609,612,613,654,677686 Unfortunately, persistent pulmonary vein electrical isolation is difficult to achieve (pulmonary vein reconnection rates of >70% are reported683,687697, but could be significantly lower with the newer generation of catheters698700).
Particularly in persistent and long-standing persistent AF, more extensive ablation has been advocated. This may include linear lesions in the atria, isolation of the LAA or of the superior vena cava,
ablation of complex fractionated electrograms,
rotors,
nonpulmonary foci, or ganglionated plexi, fibrosis-guided voltage and/or
MRI-mapping, or ablation of high dominant frequency sites.701710
However, additional benefit vs. pulmonary vein isolation (PVI) alone,
justifying its use during the first procedure, is yet to be confirmed.677,680,711730 A RCT-based data suggest improved outcome with targeting extrapulmonary (particularly the LAA) foci and selective ablation of low-voltage areas as adjunct to PVI.708,725 In patients with documented cavotricuspid isthmus (CTI)-dependent flutter undergoing AF catheter ablation, right isthmus ablation may be considered.731734 In case of non-CTI-dependent atrial tachycardia, the ablation technique depends on the underlying mechanism and tachycardia focus or circuit.1,614
Several RCTs and observational studies have compared point-bypoint radiofrequency and cryoballoon ablation, mostly in the first procedure for paroxysmal AF.612,681,735755 They reported broadly similar arrhythmia-free survival and overall complications with either technique, with slightly shorter procedure duration but longer fluoroscopy time with cryoballoon ablation.612,681,735755 However,
some studies showed reduced hospitalization and lower complication rates with cryoballoon ablation.746,756,757 The choice of energy source may depend on centre availability, operator preference/experience, and patient preference. Alternative catheter designs and energy sources have been developed in an attempt to simplify the ablation procedure and improve outcomes,613,755,758761 but further evidence is required before changing current recommendations.
10.2.2.3.3 Complications. Prospective, registry-based data show that approximately 4 - 14% of patients undergoing AF catheter ablation experience complications, 2 - 3% of which are potentially life-threatening.602604,762765 In the recent CABANA trial, mostly including experienced high-volume centres, complications occurred in the lower range of these rates.617 Complications occur mostly within the first 24 h after the procedure, but some may appear 1 - 2 months after ablation1,602604 (Table 16 and Supplementary Table 10). Periprocedural death is rare (<0.2%) and usually related to cardiac tamponade.603,604,766770
10.2.2.3.4 AF catheter ablation outcome and impact of modifiable risk factors. Multiple RCTs have compared AADs with AF catheter ablation using different technologies/energy sources, either as ‘first-line’
therapy or after AAD failure, showing superiority of AF catheter ablation in arrhythmia-free survival.165,235242,605616 However, many patients require several procedures and late recurrences are not infrequent.248,639,772780
Key outcomes include
QoL,
HF,
stroke,
and mortality.539541,608,781,782 Compared with AADs, AF catheter ablation was associated with significant and sustained improvement in QoL scores in several RCTs and meta-analyses.1,235,239242,246,247,539541,783,784
To date, there is no RCT sufficiently large to properly evaluate a reduction in stroke by catheter ablation.
Several factors,
including
AF
type and duration,235237,239,607,609,612,613,654,680,682,785 and the presence of comorbidities such as hypertension,621,639641
obesity,638,639,643,646,772,786791
metabolic syndrome,792794
and sleep apnoea643645,647652 may influence the outcome of catheter
..................................................................................
Table 16
Procedure-related complications in catheter ablation and thoracoscopic ablation of AF771
Complication severity
Complication type
Complication rate
Catheter ablation
Thoracoscopic ablation
Life-threatening complications
Periprocedural death
<0.1%
<0.1%
Oesophageal perforation/ﬁstula
<0.5%
N/A
Periprocedural thromboembolic event
<1.0%
<1.5%
Cardiac tamponade
1%
<1.0%
Severe complications
Pulmonary vein stenosis
<1.0%
N/A
Persistent phrenic nerve palsy
<1.0%
N/A
Vascular complications
2-4%
N/A
Conversion to sternotomy
N/A
<1.7%
Pneumothorax
N/A
<6.5%
Moderate or minor complications
Various
1 - 2%
1 - 3%
Complications of unknown signiﬁcance
Asymptomatic cerebral embolism
5 - 15%
N/A
NA = not available.
ESC Guidelines
419


<!-- PAGE 48 -->

### Page 48

.............................................................................
ablation (Figure 18 and Supplementary Box 2). Prospective cohort studies suggest that aggressive control of modifiable risk factors may improve arrhythmia-free survival after catheter ablation.636
10.2.2.3.5 Follow-up after atrial fibrillation ablation. AF catheter ablation is a complex procedure that may be associated with a range of specific post-procedural complications
(section
10.2.2.3.3)603,604,766770. Although mostly rare, potentially catastrophic complications may initially present with non-specific symptoms and signs to which managing physicians should be attuned. Key issues in follow-up are shown in Table 17.
10.2.2.3.6 Risk assessment for recurrence of atrial fibrillation post catheter ablation. Recurrence of AF after catheter ablation is driven by the complex interaction of various factors. These include increasing
AF duration, age, and LA size,619624 and structural factors such as the abundance of epicardial fat tissue807810 and the presence of atrial substrate as evident from electrical or morphological markers.811 A number of risk-prediction scores have been evaluated
(for detailed description see
Supplementary
Table
11
and
Supplementary Box 2). Whereas these scores only moderately predict
AF recurrence, one of the strongest predictors is early recurrent AF,
indicating the need for further refinement of these scoring systems.629
©ESC 2020
Figure 18 Risk factors for AF contributing to the development of an abnormal substrate translating into poorer outcomes with rhythm control strategies. AF = atrial fibrillation; BMI = body mass index; CPAP =
continuous positive airway pressure; HbA1C = haemoglobin A1c; OSA =
obstructive sleep apnoea. Several AF risk factors may contribute to the development of LA substrates and thus affect the outcome of AF catheter ablation, predisposing to a higher recurrence rate. Aggressive control of modifiable risk factors may reduce recurrence rate.
Table 17
Key issues in follow-up after AF catheter ablation
Key issues
Recognition and management of complications
• Patients must be fully informed about the clinical signs and symptoms of rare but potentially dangerous ablation-related complications that may occur after hospital discharge (e.g. atrio-oesophageal ﬁstula, pulmonary vein stenosis).
Follow-up monitoring:
Useful to assess procedural success and correlate symptom status with rhythm.795,796 Recurrences beyond the ﬁrst month post-ablation are generally predictive of late recurrences,797,798 but recurrent symptoms may be due to ectopic beats or other non-sustained arrhythmia640,799,800; conversely the presence of asymptomatic AF after ablation is well described.801803
Monitoring may be performed with intermittent ECG, Holter, Patch recordings, external or implanted loop recorder, or smart phone monitor (although the latter has not been validated for such use). Patients should be ﬁrst reviewed at a minimum of 3 months and annually thereafter.1
Management of antiarrhythmic medication and treatment of AF recurrences a. Continuing AAD treatment for 6 weeks to 3 months may reduce early AF recurrences, rehospitalizations and cardioversions during this period.797,804
Clinical practice regarding routine AAD treatment after ablation varies and there is no convincing evidence that such treatment is routinely needed.
b. Subsequently, AADs may be weaned, ceased, or continued according to symptoms and rhythm status. Recent ﬁndings suggest that in AAD-treated patients remaining free of AF at the end of the blanking period, AAD continuation beyond the blanking period reduces arrhythmia recurrences.805
Management of anticoagulation therapy a. In general, OAC therapy is continued for 2 months following ablation in all patients.1,806 Beyond this time, a decision to continue OAC is determined primarily by the presence of CHA2DS2-VASc stroke risk factors rather than the rhythm status (section 10.2.2.6).
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age
65 - 74 years, Sex category (female); ECG=electrocardiogram; OAC = oral anticoagulant.


<!-- PAGE 49 -->

### Page 49

.........................
10.2.2.4 Surgery for atrial fibrillation
With development of the maze procedure for surgical cure from AF,
Cox et al. opened up a new window of therapeutic opportunities for
AF patients.822 The classical cut-and-sew maze procedure underwent several modifications and various device-based surgical ablation procedures have been developed.823,824 More than 200 publications documented the application of these techniques and technologies in various clinical scenarios.825 Most studies are retrospective and/or observational, but some RCTs and meta-analyses have also been published.771,826828 While the effects of surgical ablation on rhythm outcome (i.e. restoration of sinus rhythm/freedom from AF) have been clearly demonstrated, the effects on endpoints such as QoL,
hospitalization,
stroke,
and mortality are not well established.461,827,829,830 The only RCT with longer follow-up has shown a significant reduction in stroke risk at 5 years and a greater likelihood of maintaining sinus rhythm although the trial was underpowered for
Recommendations for rhythm control/catheter ablation of AF
Recommendations
Classa
Levelb
General recommendations
For the decision on AF catheter ablation, it is recommended to take into consideration the procedural risks and the major risk factors for AF recurrence following the procedure and discuss them with the patient.235237,239,607,609,612,613,636,638,652,654,680,682,785,789
I
B
Repeated PVI procedures should be considered in patients with AF recurrence provided the patient’s symptoms were improved after the initial PVI.812814
IIa
B
AF catheter ablation after failure of drug therapy
AF catheter ablation for PVI is recommended for rhythm control after one failed or intolerant class I or III AAD, to improve symptoms of AF recurrences in patients with235238,247,605609,612,613,615617,654,677,678,680,682,685,758,779,780,815:
I
• Paroxysmal AF, or
A
• Persistent AF without major risk factors for AF recurrence, or
A
• Persistent AF with major risk factors for AF recurrence.
B
AF catheter ablation for PVI should be considered for rhythm control after one failed or intolerant to beta-blocker treatment to improve symptoms of AF recurrences in patients with paroxysmal and persistent AF.246
IIa
B
First-line therapy
AF catheter ablation for PVI should/may be considered as ﬁrst-line rhythm control therapy to improve symptoms in selected patients with symptomatic:
• Paroxysmal AF episodes,240242,614,615 or
IIa
B
• Persistent AF without major risk factors for AF recurrence.253255,264,598601,609,610,633,636,641,724,745,746,832
IIb
C
as an alternative to AAD class I or III, considering patient choice, beneﬁt, and risk.
AF catheter ablation:
• Is recommended to reverse LV dysfunction in AF patients when tachycardia-induced cardiomyopathy is highly probable, independent of their symptom status.666,675,676
I
B
• Should be considered in selected AF patients with HF with reduced LVEF to improve survival and reduce HF
hospitalization.612,659,662666,668671,817826
IIa
B
AF catheter ablation for PVI should be considered as a strategy to avoid pacemaker implantation in patients with AF-related bradycardia or symptomatic pre-automaticity pause after AF conversion considering the clinical situation.816818
IIa
C
Techniques and technologies
Complete electrical isolation of the pulmonary veins is recommended during all AF catheter-ablation procedures.235237,239,606,608610,613,614,678,679,681,683,684,686,713,731,759,780
I
A
If patient has history of CTI-dependent AFL or if typical AFL is induced at the time of AF ablation, delivery of a CTI lesion may be considered.731733,819821
IIb
B
Use of additional ablation lesions beyond PVI (low voltage areas, lines, fragmented activity, ectopic foci, rotors, and others) may be considered but is not well established.677,680,708,711730
IIb
B
Lifestyle modiﬁcation and other strategies to improve outcomes of ablation
Weight loss is recommended in obese patients with AF, particularly those who are being evaluated to undergo AF
ablation.636,638,639,643,646,772,786791
I
B
Strict control of risk factors and avoidance of triggers are recommended as part of a rhythm control strategy.636,637
I
B
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; AFL = atrial ﬂutter; CTI = cavotricuspid isthmus; HF = heart failure; LV = left ventricular; LVEF = left ventricular ejection fraction; PVI = pulmonary vein isolation.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
421


<!-- PAGE 50 -->

### Page 50

..............................................................................
stroke risk assessment.828 The largest registry published, from the
Polish National Health Service, describes better survival when ablation is performed concomitant to mitral or coronary surgery.831,832
Close cooperation between cardiac surgeons and electrophysiologists (heart team) for proper patient selection and postoperative management, especially for handling of arrhythmia recurrences,
seems advisable for high-standard quality care.
10.2.2.4.1 Concomitant surgery for atrial fibrillation: indications, outcome, complications. Most trials of concomitant AF ablation have been based mainly on patients undergoing mitral valve repair or replacement.
While surgical PVI has been shown to be effective for maintaining sinus rhythm,833 the most effective ablation treatment for AF isolates the pulmonary veins and the LA posterior wall, creates ablation lines that impede electrical impulses around the most important structures
(mitral and tricuspid annuli, venae cavae and appendages), and excludes the LAA. Most evidence supports bipolar radiofrequency clamps and cryothermy to perform a maze.834 For non-paroxysmal AF, a biatrial lesion pattern is more effective than left-sided only, performed by sternotomy or minimally invasive techniques.826
In general, the same preoperative risk factors for AF recurrence after concomitant AF surgery as for AF catheter ablation have been identified. These include LA size, patient age, AF duration, HF/
reduced LVEF, and renal dysfunction.379,636,835841 The significant positive effects of concomitant surgical ablation on freedom from atrial arrhythmias is clearly documented. Most RCTs with 1-year follow-up show no effect on QoL, stroke, and mortality,842845 but some reported reduced event rates.828,830,846
Surgical AF ablation concomitant to other cardiac surgery significantly increases the need for pacemaker implantation with biatrial
(but not left-sided) lesions,827 being reported from 6.8% to 21.5%,
while other complications are not increased.827830,846,847
10.2.2.4.2 Stand-alone surgery for atrial fibrillation: indications, outcome, complications. Thoracoscopic radiofrequency ablation targets the pulmonary veins, LA posterior wall, and LAA closure in AF patients with no structural heart disease. Freedom from AF after the procedure is well documented, but only a few studies have reported improved
QoL.844,845,848850 A recent meta-analysis of three RCTs showed a significantly higher freedom from atrial tachyarrhythmia and less need for repeat ablations after thoracoscopic ablation compared with AF catheter ablation for paroxysmal or persistent AF.851 The FAST trial randomized patients who were prone to AF catheter-ablation failure
(i.e. failed previous ablation or LA dilatation and hypertension) and reported common but substantially lower recurrence after thoracoscopic compared with AF catheter ablation (56% vs. 87%) at long-term follow-up (mean 7 years).849 Hospitalization was longer and complication rates of surgical ablation were higher compared with catheter ablation771 (Table 16). A systematic safety analysis of thoracoscopic ablation showed a 30-day complication rate of 11.3%, mainly selflimiting, whereas it was significantly lower (3.6%) in a multicentre registry.456 In RCTs, thoracoscopic ablation proved more effective in rhythm control than catheter ablation; however, surgical ablation is more invasive, with higher complication rates and longer hospitalization.461,852 Because of this risk-benefit ratio of surgical vs. catheter ablation, it seems reasonable to consider thoracoscopic surgery preferentially in patients with previous failed catheter ablation or with a high risk of catheter-ablation failure. There are no convincing data on the effects on stroke of surgical ablation as a stand-alone procedure or in combination with LAA occlusion or exclusion. Hence, OAC therapy should be continued after the procedure regardless of rhythm outcome in AF patients with stroke risk factors.
10.2.2.5 Hybrid surgical/catheter ablation procedures
Hybrid AF procedures combine a minimally invasive epicardial nonsternotomy ablation not using cardiopulmonary bypass with a percutaneous endocardial approach. They can be performed as a single intervention or sequentially, when the endocardial catheter mapping and, if needed,
additional ablations are done within 6 months after the epicardial procedure.853 There are no studies comparing these two hybrid strategies.
A systematic review on rhythm outcome and complications with a hybrid procedure or AF catheter ablation in patients with persistent or long-standing persistent AF showed that at 12 months or longer, a hybrid procedure achieved a significantly higher rate of freedom from atrial arrhythmias with and without the use of AAD compared with
AF catheter ablation. Although the overall complication rate was low for both strategies, hybrid ablations had more complications (13.8%
vs. 5.9%).854 The difference in outcome could be explained by a longlasting isolation of the pulmonary veins after bipolar radiofrequency clamping of the pulmonary veins, epicardial clipping of the LAA, and the add-on possibility of an endocardial touch-up.855,856
Recommendations for surgical ablation of AF
Recommendations
Classa
Levelb
Concomitant AF ablation should be considered in patients undergoing cardiac surgery, balancing the beneﬁts of freedom from atrial arrhythmias and the risk factors for recurrence (left atrial dilatation, years in AF, age, renal dysfunction, and other cardiovascular risk factors).461,843,857859
IIa
A
Thoracoscopic—including hybrid surgical ablation—procedures should be considered in patients who have symptomatic paroxysmal or persistent AF refractory to AAD therapy and have failed percutaneous AF ablation, or with evident risk factors for catheter ablation failure,
to maintain long-term sinus rhythm. The decision must be supported by an experienced team of electrophysiologists and surgeons.860,861
IIa
B
Thoracoscopic—including hybrid surgical ablation—procedures may be considered in patients with persistent AF with risk factors for recurrence, who remain symptomatic during AF
despite at least one failed AAD and who prefer further rhythm control therapy.
IIb
C
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 51 -->

### Page 51

###### 10.2.2.6 Peri-procedural stroke risk management in patients undergoing rhythm control interventions

10.2.2.6.1 Management of stroke risk and oral anticoagulant therapy in atrial fibrillation patients undergoing cardioversion. Patients undergoing cardioversion of AF are at increased risk of stroke and thromboembolism, especially in the absence of OAC and if AF has been present for >_12 h.860862 The exact duration of an AF episode before cardioversion may be difficult to ascertain, as many patients develop AF asymptomatically, seeking help only when symptoms or complications occur. If there is uncertainty over the exact onset of
AF (i.e. unknown duration of AF), peri-cardioversion anticoagulation is managed as for AF of >12 h to 24 h. Mechanisms of the increased propensity to peri-cardioversion thrombo-embolism include the presence of pre-existing thrombus (especially if not anticoagulated),
change in the atrial mechanical function with restoration of sinus rhythm, atrial stunning post-cardioversion, and a transient prothrombotic state.863
No RCT has evaluated anticoagulation vs. no anticoagulation in AF
patients undergoing cardioversion with a definite duration of
AF<48 h. Observational data suggest that the risk of stroke/
thrombo-embolism is very low (0- 0.2%) in patients with a definite
AF duration of <12 h and a very low stroke risk (CHA2DS2-VASc 0
in men, 1 in women),860,864,865 in whom the benefit of 4-week anticoagulation after cardioversion is undefined and the prescription of anticoagulants can be optional, based on an individualized approach.
Peri-cardioversion anticoagulation with a VKA results in a significant decrease of stroke and thrombo-embolism,863 but achieving the necessary therapeutic anticoagulation (INR 2.0- 3.0) for a minimum of 3 weeks before cardioversion may be difficult. This 3-week period is arbitrary, based on the time presumably needed for endothelialization or resolution of pre-existing AF thrombus. To shorten this time,
TOE-guided cardioversion was introduced. If there is no atrial thrombus on TOE, cardioversion is performed after administration of heparin, and OAC is continued post-cardioversion.866,867
As NOACs act rapidly, cardioversion can be scheduled 3 weeks after NOAC initiation, provided that patients are counselled about the need for compliance to NOAC therapy868870; NOACs have at least comparable efficacy and safety to warfarin in AF patients undergoing cardioversion.871874 A review of the three largest prospective trials (n =5203 patients) showed that the composite primary outcome
(stroke/systemic embolism,
myocardial infarction,
or cardiovascular death) was significantly reduced with NOACs compared with VKA.873
Long-term OAC therapy after cardioversion should not be based on successful restoration of sinus rhythm, but on the stroke risk profile (using the CHA2DS2-VASc score), balanced against bleeding risk
(e.g. HAS-BLED score).
For patients in whom a thrombus is identified on TOE, effective anticoagulation for at least 3 weeks before reassessment for cardioversion is recommended. A repeat TOE to ensure thrombus resolution should be considered before cardioversion.875 Antithrombotic management for these patients is challenging and decided on an individual basis based on the efficacy (or inefficacy) of previous treatments.
Recommendations for stroke risk management pericardioversion
Recommendations
Classa
Levelb
In patients with AF undergoing cardioversion,
NOACs are recommended with at least similar efﬁcacy and safety to warfarin.868873
I
A
For cardioversion of AF/AFL, effective anticoagulation is recommended for a minimum of 3
weeks before cardioversion.866870
I
B
TOE is recommended to exclude cardiac thrombus as an alternative to 3-week pre-procedural anticoagulation when early cardioversion is planned.866,868870,875
I
B
In patients at risk of stroke, it is recommended that OAC therapy is continued long term after cardioversion according to the long-term anticoagulation recommendations, irrespective of the method of cardioversion, the apparent maintenance of sinus rhythm, or characterization of AF
as a ‘ﬁrst-diagnosed episode’.412,872,876
I
B
When thrombus is identiﬁed on TOE, effective anticoagulation is recommended for at least 3
weeks before cardioversion of AF.875
I
B
It is recommended that the importance of adherence and persistence to NOAC treatment both before and after cardioversion is strongly emphasized to patients.
I
C
Effective anticoagulation should be initiated as soon as possible before every cardioversion of
AF or AFL.866870
IIa
B
Early cardioversion can be performed without
TOE in patients with an AF duration of <48 h.866
IIa
B
In patients with AF duration of >24 h undergoing cardioversion, therapeutic anticoagulation should be continued for at least 4 weeks, even after successful cardioversion to sinus rhythm
(beyond 4 weeks, the decision about long-term
OAC treatment is determined by the presence of stroke risk factors).860,861
IIa
B
When thrombus is identiﬁed on TOE, a repeat
TOE to ensure thrombus resolution should be considered before cardioversion.875
IIa
C
In patients with a deﬁnite duration of AF <_24 h and a very low stroke risk (CHA2DS2-VASc of 0
in men or 1 in women) post-cardioversion anticoagulation for 4 weeks may be omitted.871,876
IIb
C
AF = atrial ﬁbrillation; AFL = atrial ﬂutter; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease,
Age 65 - 74 years, Sex category (female); NOAC = non-vitamin K antagonist oral anticoagulant;
OAC
=
oral anticoagulant;
TOE
=
transoesophageal echocardiography.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
423


<!-- PAGE 52 -->

### Page 52

........................................
10.2.2.6.2 Management of stroke risk and oral anticoagulant therapy in atrial fibrillation patients undergoing atrial fibrillation catheter ablation.
Although there is some variability in the peri-procedural OAC
management in patients undergoing AF ablation, more recently operators have moved towards a strategy of performing the ablation under uninterrupted VKA or NOAC treatment, provided the
INR is within therapeutic range. In non-anticoagulated patients, initiating therapeutic anticoagulation 3 - 4 weeks before ablation may be considered.1
In a meta-analysis of 12 studies,877 uninterrupted anticoagulation using NOACs vs. VKAs for AF catheter ablation was associated with low rates of stroke/TIA (NOACs, 0.08%; VKA, 0.16%) and similar rates of silent cerebral embolic events (8.0% vs 9.6%). However,
major bleeding was significantly reduced with uninterrupted NOACs
(0.9%) compared with VKAs (2%).
In the largest RCT comparing peri-procedural NOAC vs. warfarin
[the RE-CIRCUIT trial (Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of different peri-proCedUral antIcoagulation sTrategies)],878 the incidence of major bleeding events during and up to 8 weeks after ablation was significantly lower with dabigatran vs. warfarin (1.6% vs.
6.9%). Other RCTs (VENTURE-AF with rivaroxaban,879 AXAFA-AF
NET 5 with apixaban,880 and ELIMINATE-AF with edoxaban881) also showed similar event rates under uninterrupted NOACs vs. VKAs.
Overall, uninterrupted peri-procedural NOACs were associated with a low incidence of stroke/TIA and a significant reduction in major bleeding compared with uninterrupted VKAs in patients undergoing AF catheter ablation. In contrast, heparin bridging increases the bleeding risk and should be avoided.
Frequently, the term ‘uninterrupted’ is used in clinical practice for the description of regimens where one or two NOAC doses are omitted before ablation, whereas in the RCTs comparing uninterrupted NOACs vs. warfarin, NOAC administration before ablation was truly uninterrupted.869,878 Hence, there is no reason to recommend omitting one or two NOAC doses before ablation. After the procedure, administration of the first dose the evening after ablation or the next morning (if this corresponds to the timing of the next dose according to the patient’s previous OAC regimen) appears to be safe.878,881
10.2.2.6.3 Postoperative anticoagulation after surgery for atrial fibrillation. Owing to endothelial damage during ablation, OAC is advisable in all patients after AF surgery, starting as soon as possible (balancing the risk of postoperative bleeding). There are no RCT data regarding interruption of OAC over the long term. Non-randomized studies with longer follow-up have shown better long-term freedom from stroke in patients with persistent sinus rhythm, but not in those with
AF despite LAA exclusion.824 Therefore, long-term OAC is recommended in all patients at risk of stroke despite a successful maze surgery and appendage closure.
10.2.2.7 Long-term antiarrhythmic drug therapy for rhythm control
10.2.2.7.1 Antiarrhythmic drugs. The aim of AAD therapy is to improve AF-related symptoms.484,882,883 Hence, the decision to initiate long-term AAD therapy needs to balance symptom burden,
possible adverse drug reactions, and patient preferences. The principles of AAD therapy are shown in Tables 18 and 19.
Compared with no therapy, AAD therapy approximately doubles sinus rhythm maintenance,883 but it is difficult to draw firm
Recommendations for stroke risk management peri-catheter ablation
Recommendations
Classa
Levelb
In AF patients with stroke risk factors not taking OAC before ablation, it is recommended that pre-procedural management of stroke risk includes initiation of anticoagulation and:
• Preferably, therapeutic OAC for at least 3 weeks before ablation, or
• Alternatively, the use of TOE to exclude LA thrombus before ablation.
I
C
IIa
C
For patients undergoing AF catheter ablation who have been therapeutically anticoagulated with warfarin, dabigatran, rivaroxaban,
apixaban, or edoxaban, performance of the ablation procedure without OAC interruption is recommended.878,879,881
I
A
After AF catheter ablation, it is recommended that:
• Systemic anticoagulation with warfarin or a NOAC is continued for at least 2 months post ablation, and
• Long-term continuation of systemic anticoagulation beyond 2 months post ablation is based on the patient’s stroke risk proﬁle and not on the apparent success or failure of the ablation procedure.
I
C
AF = atrial ﬁbrillation; LA = left atrial; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant therapy; TOE=transoesophageal echocardiography.
aClass of recommendation bLevel of evidence
Recommendations for postoperative anticoagulation after AF surgery
Recommendations
Classa
Levelb
Long-term OAC therapy is recommended in patients after AF surgery and appendage closure,
based on the patient’s thrombo-embolic risk assessed with the CHA2DS2-VASc score.
I
C
AF = atrial ﬁbrillation; CHA2DS2-VASc = Congestive heart failure, Hypertension,
Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65 - 74 years, Sex category (female); OAC = oral anticoagulant.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 53 -->

### Page 53

................................................................................
conclusions from existing trials on their comparative efficacy.884 In general, AAD therapy is less effective than AF catheter ablation,114,611,615 but previously ineffective AADs can be continued after
PVI, to reduce recurrent AF.805 A shorter duration of AAD therapy would likely reduce the risk of side-effects883,885 but late recurrences may occur.595 Short-term AAD therapy is also used to prevent early
AF recurrences after catheter ablation,886 although the benefit is still debated797,887; this strategy may be reasonable in patients deemed at increased risk of AAD side-effects or in those with a low perceived risk of recurrent AF. Concomitant management of underlying cardiovascular conditions is pivotal to reduce AF symptom burden and facilitate the maintenance of sinus rhythm.245,636,888,889
10.2.2.7.1 Available antiarrhythmic drugs. Several AADs have been shown to reduce AF recurrences (Table 20).890 Class Ia (quinidine and disopyramide) and sotalol have been associated with increased overall mortality.884 Again, safety should dictate both the initiation and continuation of AADs.
A flow chart for use of AADs for long-term rhythm control,
depending on the underlying disease, is given in Figure 19.
10.2.2.7.2 Non-antiarrhythmic drugs with antiarrhythmic properties
(upstream therapy). Either resulting from, or being a marker of structural atrial remodelling, AF is closely related to atrial cardiomyopathy.
Drugs that affect the atrial-remodelling process could prevent newonset AF acting as non-conventional AADs (i.e. upstream therapy)
(Table 21).
Recently, the RACE 3 study245 confirmed the importance of assessing underlying conditions and targeted upstream therapy for intense risk-factor control in AF patients with mild or moderate HF
in optimizing rhythm control. The results showed that targeted therapy of underlying conditions improves maintenance of sinus rhythm in patients with persistent AF.
A list of new investigational antiarrhythmic drugs is provided in
Supplementary Box 3.
Table 19
Rules to initiate antiarrhythmic drugs for long-term rhythm control in AF
Consideration
Criteria
Indication for AAD
• Is the patient symptomatic?
• Are AF symptoms severe enough (EHRA class) to justify AAD use?
• Are there associated conditions predicting poor tolerance of AF episodes?
When to start AAD
• Usually not for the ﬁrst episode, but it may enhance efﬁcacy of cardioversion
How to choose among AADs
• Minimize proarrhythmic risk and organ toxicity
Evaluate for:
• basal ECG abnormalities (QRS duration, PR, QTc) and possible interference with AAD
• impact on LV function
• important pharmacokinetic and pharmacodynamic interactions (i.e. antithrombotic drugs)
• Risk factors for proarrhythmia may be dynamic and change over time
How to minimize proarrhythmic risk
• Evaluate ECG after the treatment, as indicated in these Guidelines
• Evaluate periodically for organ toxicity (amiodarone)
• Long-term Holter monitoring and exercise test in selected cases
• Avoid AAD combinations
How to verify efﬁcacy
• Estimate AF burden under therapy (ask patient for noting episodes)
• If the patient is already on AAD and it was effective but was stopped because of intolerance,
choose preferably from the same class
Adjuvant interventions and hybrid therapy
• In patients with atrioventricular conduction abnormalities and/or sinus node dysfunction,
pacemaker implantation should be considered if AAD therapy is deemed necessary
• Short-term AAD therapy could prevent early recurrences after AF ablation
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; ECG = electrocardiogram; EHRA = European Heart Rhythm Association; LV = left ventricular; PR = PR interval; QRS =
QRS interval; QTc = corrected QT interval.
Table 18
Principles of antiarrhythmic drug therapy143
Principles
AAD therapy aims to reduce AF-related symptoms
Efﬁcacy of AADs to maintain sinus rhythm is modest
Clinically successful AAD therapy may reduce rather than eliminate AF
recurrences
If one AAD ‘fails’, a clinically acceptable response may be achieved by another drug
Drug-induced proarrhythmia or extracardiac side-effects are frequent
Safety rather than efﬁcacy considerations should primarily guide the choice of AAD
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation.
ESC Guidelines
425


<!-- PAGE 54 -->

### Page 54

Table 20
Antiarrhythmic drugs used for long-term maintenance of sinus rhythm in AF patients890
Drug
Administration route
Dose
Contraindications/precautions/comments
Amiodarone233,506,891896
Oral
3  200 mg daily over
4 weeks, then 200 mg daily506
• The most effective AAD890,897
• RCTs showed lower AF recurrence compared with sotalol and dronedarone884
• Also reduces ventricular rate (for 10 - 12 bpm), safe in patients with
HF898900
• Concomitant use with other QT-prolonging drugs with caution
• Concomitant use with VKAs or digitalis (their dose should be reduced)
• Increased risk of myopathy when used with statins
• Requires regular surveillance for liver, lung, and thyroid toxicity
• Has atrioventricular nodal-slowing properties, but should not be used as ﬁrst intention for rate control
• QT prolongation is common but rarely associated with torsades de pointes (<0.5%)901
• Torsades de pointes occurs infrequently during treatment with amiodarone (the proarrhythmia caution requires QT-interval and TUwave monitoring)902
• Should be discontinued in case of excessive QT prolongation
(>500 ms)
• ECG at baseline, after 4 weeks
• Contraindicated in manifest hyperthyroidism
• Numerous and frequent extracardiac side-effects may warrant discontinuation of amiodarone, thus making it a second-line treatment when other choices are possible903907
Flecainide
Flecainide slow release896,908,909
Oral
100 - 200 mg b.i.d., or
200 mg once daily (ﬂecainide slow release)
• Effective in preventing recurrence of AF891,908,910
• Should not be used in patients with CrCl <35 mL/min/1.73 m2 and signiﬁcant liver disease
• Both are contraindicated in patients with ischaemic heart disease or reduced LVEF911913
• Should be discontinued in case of QRS widening >25% above baseline and patients with left bundle-branch block or any other conduction block >120 ms
• Caution when sinoatrial/atrioventricular conduction disturbances presenta
• CYP2D6 inhibitors increase concentration
• May increase AFL cycle length, thus promoting 1:1 atrioventricular conduction and increasing ventricular rate.914 This risk can be reduced by concomitant administration of an atrioventricular nodalblocking drug such as a beta-blocker or NDCC
• In patients properly screened for propensity to proarrhythmias, both
ﬂecainide and propafenone are associated with a low proarrhythmic risk915
• ECG at baseline, after 1 - 2 weeks
Propafenone
Propafenone slow release895,896,916922
Oral
150 - 300 mg three times daily, or
225 - 425 mg b.i.d.
(propafenone slow release)
• Should not be used in patients with signiﬁcant renal or liver disease,
ischaemic heart disease, reduced LV systolic function, or asthma
• Should be discontinued in case of QRS widening >25% above baseline and in patients left bundle-branch block and any other conduction block >120 ms
• Caution when sinoatrial/atrioventricular conduction disturbances presenta
• Increases concentration of warfarin/acenocoumarin and digoxin when used in combination
• May increase AFL cycle length, thus promoting 1:1 atrioventricular conduction and increasing ventricular rate
• ECG at baseline and after 1 - 2 weeks
Continued


<!-- PAGE 55 -->

### Page 55

Table 20
Continued
Drug
Administration route
Dose
Contraindications/precautions/comments
Dronedarone923927
Oral
400 mg b.i.d.
• Less effective than amiodarone in rhythm control but has very few extracardiac side-effects925,928930
• Reduces cardiovascular hospitalizations and death in patients with paroxysmal or persistent AF or AFL and cardiovascular comorbidity923,931
• Associated with increased mortality in patients with recent decompensated HF927 or permanent AF932
• Dronedarone has the most solid safety data and may thus be a preferable ﬁrst choice,933,934 however not indicated in patients with HF
and permanent AF935,936
• Should not be used in NYHA class III or IV or unstable HF, in combination with QT-prolonging drugs or with strong CYP3A4 inhibitors
(e.g. verapamil, diltiazem) and in patients with CrCl <30 mL/min
• Concomitant use with dabigatran is contraindicated
• Combination with digoxin may signiﬁcantly increase digoxin serum concentration
• When used with digitalis or beta-blockers their doses should be reduced
• Should be discontinued in case of excessive QT prolongation
(>500 ms or >60 ms increase)
• A modest increase in serum creatinine is common and reﬂects druginduced reduction in CrCl rather than a decline in renal function937
• Has atrioventricular nodal-slowing properties
• ECG at baseline and after 4 weeks
Sotalol (d,l racemic mixture)233,891,894,895,920,938940
Oral
80 - 160 mg b.i.d.
• Only class III effects if dosing >160 mg daily
• Considering its safety and efﬁcacy and potential drug alternatives,
sotalol should be used with a caution
• Should not be used in patients with HFrEF, signiﬁcant LVH, prolonged QT, asthma, hypokalaemia, or CrCl <30 mL/min
• Dose-related torsades de pointes may occur in >2% of patients941
• Should be discontinued in case of excessive QT prolongation
(>500 ms or >60 ms increase)
• The potassium channel-blocking effect increases with increasing dose and, consequently, the risk of ventricular proarrhythmia (torsades de pointes) increases
• Observational data and a recent meta-analysis revealed a correlation with an increased all-cause mortality890,897,934 , whereas a nationwide registry analysis and two RCTs found no evidence for increased safety concerns with sotalol233,933,942,943
• ECG at baseline, after 1 day and after 1 - 2 weeks
Disopyramide944946
Oral
100 - 400 mg two or t.i.d. (maximum 800 mg/
24 h)
• Associated with signiﬁcantly increased mortality890,947, and rarely used for rhythm control in AF.948,949 Should not be used in patients with a structural heart disease. Rarely used for rhythm control in AF
patients, due to increased mortality and frequent intolerance to sideeffects
• May be useful in ‘vagal’ AF occurring in athletes or during sleep901
• Reduces LV outﬂow obstruction and symptoms in patients with
HCM950
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; AFL = atrial ﬂutter; b.i.d. = bis in die (twice a day); bpm = beats per minute; CrCl = creatinine clearance; CYP2D6 = cytochrome P450 2D6; CYP34A = cytochrome 34A; ECG=electrocardiogram; HCM = hypertrophic cardiomyopathy; HF = heart failure; HFrEF = HF with reduced ejection fraction; LV = left ventricular; LVEF = LV ejection fraction; LVH = LV hypertrophy; NDCC = non-dihydropyridinecalcium-channel blocker; NYHA = New York Heart Association;
QRS = QRS interval; QT = QT interval; RCT=randomized controlled trial; SBP = systolic blood pressure; t.i.d. = ter in die (three times a day); VKA = vitamin K antagonist.
aCaution is needed when using any AAD in patients with conduction-system disease (e.g. sinoatrial or atrioventricular node disease).
ESC Guidelines
427


<!-- PAGE 56 -->

### Page 56

©ESC 2020
Figure 19 Long-term rhythm control therapy. ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; CAD=coronary artery disease; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LV =
left ventricular; LVH = left ventricular hypertrophy; MRA=mineralocorticoid receptor antagonist.
Table 21
Non-antiarrhythmic drugs with antiarrhythmic properties (upstream therapy)
Drugs
Comment
ACEi, ARBs
Activated renin-angiotensin-aldosterone system is up-regulated in AF.951,952 ACEi and ARBs showed encouraging results in preventing
AF in preclinical studies.953
As suggested by retrospective analyses and studies where AF was a prespeciﬁed secondary endpoint, ACEi/ARBs could prevent newonset AF in patients with LV dysfunction, LVH, or hypertension.954961
As initial treatment, ACEi and ARBs seem to be superior to other antihypertensive regimens,962 but ARBs did not reduce AF burden in patients without structural heart disease.963 Despite several positive small-scale prospective studies and retrospective analyses,
larger RCTs have shown controversial results and failed to conﬁrm the role of ACEi or ARBs in secondary (post-cardioversion) prevention of AF.964 The multifactorial pathways for AF promotion and study design could explain these negative results and should not discourage the use of ACEi or ARB to AAD in patients with structural heart disease.
MRAs
Aldosterone is implicated in inducibility and perpetuation of AF.965967 Evidence from RCTs showed that MRAs reduced new-onset atrial arrhythmias in patients with HFrEF in parallel with improvement of other cardiovascular outcomes.968,969
Recently, the positive impact of MRAs was also shown in patients with HFpEF970 irrespective of baseline AF status. Regarding other renin-angiotensin-aldosterone system inhibitors, the role of MRAs as upstream therapy in rhythm control strategy for patients with
HF and AF has not been clariﬁed. As AF is a marker of HF severity, the beneﬁcial antiarrhythmic effect could be driven indirectly,
through improvement of HF. A recent meta-analysis showed that MRAs signiﬁcantly reduced new-onset AF and recurrent AF, but not postoperative AF.971
Beta-blockers
Several small studies suggested a lower AF recurrence rate with beta-blockers, with a comparable efﬁcacy with sotalol.939,972,973
However, most evidence pleads against a signiﬁcant role of beta-blockers in preventing AF.890 The observed beneﬁcial effect could also result from transformation of clinically manifested AF to silent AF, because of the rate control with beta-blockers.
Statins
Statins are attractive candidates for upstream therapy, as the role of inﬂammation in AF is well established. However, in an adequately designed RCT,974 statins failed to show a beneﬁcial effect, and their preventive effect was not conﬁrmed in other settings.975,976
Speciﬁc patient groups in whom statins could induce reverse remodelling are not identiﬁed yet, but ﬁndings from the CARAF registry suggested that AF patients already on beta-blockers could beneﬁt from statin therapy.977 Polyunsaturated fatty acids also failed to show convincing beneﬁt in preventing AF.978982
AAD = antiarrhythmic drug; ACEi = angiotensin converting enzyme inhibitor; AF = atrial ﬁbrillation; ARB=angiotensin receptor blocker; CARAF = Canadian Registry of Atrial
Fibrillation; HF = heart failure; HFrEF = HF with reduced ejection fraction; HFpEF = HF with preserved ejection fraction; LV = left ventricular; LVH = LV hypertrophy; MRA =
mineralocorticoid receptor antagonist; RCT = randomized controlled trial.


<!-- PAGE 57 -->

### Page 57

.................................................................................................
10.2.2.7.3 Assessment and long-term monitoring of the risk of proarrhythmia with antiarrhythmic drugs. A variety of clinical, echocardiographic, and ECG criteria have been associated with a higher risk of proarrhythmia.986989 Increasing age, female sex, impaired renal and/
or liver function, and known CAD have been variously identified as associated with higher risk.890,990992 Concomitant AAD use, hypokalaemia, or family history of sudden death have also been implicated.990 Proarrhythmic events tend to cluster shortly after drug initiation, especially if a loading dose or a change in usual dosage is prescribed.568 For quinidine, the risk is idiosyncratic independent of dosage. Impaired LV function and LVH are echocardiographic markers of increased proarrhythmic risk. Sotalol has a proarrhythmic risk even in the absence of structural heart disease. On the 12-lead
ECG, prolonged corrected QT interval (QTc), widened QRS, and prolonged
PR
interval have all been associated with proarrhythmia.993995 Significant ion-channel mutations have been detected in only a minority of cases of drug-induced torsade.996
Periodic ECG analysis for proarrhythmia signs has been used successfully in recent AAD trials594,.997 Specifically, ECG monitoring was used systematically on days 13 in patients receiving flecainide, propafenone, or sotalol to identify those at risk of proarrhythmia233,594,.998
The role of routine use of exercise stress testing in patients commencing 1C drugs who had no evidence of structural heart disease is still debatable915,.999
10.3 ‘C’  Cardiovascular risk factors and concomitant diseases: detection and management
Cardiovascular risk-factor burden and comorbidities, including lifestyle factors and borderline conditions, significantly affect the lifetime risk for AF development (Supplementary Figure 5). The continuum of unhealthy lifestyle, risk factor(s), and cardiovascular disease can contribute to atrial remodelling/cardiomyopathy and development of AF
that commonly results from a combined effect of multiple interacting factors (often without specific threshold values).
The ‘C’ component of the ABC pathway includes identification and management of concomitant diseases, cardiometabolic risk factors, and unhealthy lifestyle factors. Management of risk factors and cardiovascular disease complements stroke prevention and reduces
AF burden and symptom severity. In a recent RCT, for example, targeted therapy of underlying conditions significantly improved maintenance of sinus rhythm in patients with persistent AF and HF.245
Whereas strategies on comprehensive risk-factor modification and interventions targeting underlying conditions have shown reduction of AF burden and recurrence, studies addressing isolated management of specific conditions alone (e.g. hypertension) yielded inconsistent findings,1000 likely because the condition was not a sole contributor to AF.
10.3.1
Lifestyle interventions
10.3.1.1 Obesity and weight loss
Obesity increases the risk for AF progressively according to body mass index.366,10011005 It may also increase the risk for ischaemic stroke, thrombo-embolism, and death in AF patients,366 notwithstanding an obesity paradox in AF patients, especially regarding allcause and cardiovascular death, with an inverse relationship between overweight/obesity and better cardiovascular prognosis in long-term follow-up.1006
Intense weight reduction with comprehensive management of concomitant cardiovascular risk factors resulted in fewer AF recurrences and symptoms than general advice in obese patients with
AF636,888,.889 Achieving a healthy weight may reduce blood pressure
(BP), dyslipidaemia, and risk of developing type 2 diabetes mellitus,
Recommendations for long-term antiarrhythmic drugs
Recommendations
Classa
Levelb
Amiodarone is recommended for long-term rhythm control in all AF patients, including those with HFrEF. However, owing to its extracardiac toxicity, other AADs should be considered ﬁrst whenever possible.233,570,884,942,983,985
I
A
Dronedarone is recommended for long-term rhythm control in AF patients with:
• Normal or mildly impaired (but stable) LV function, or
• HFpEF, ischaemic, or VHD.884,923,925,985
I
A
Flecainide or propafenone is recommended for long-term rhythm control in AF patients with normal LV function and without structural heart disease, including signiﬁcant LVH and myocardial ischaemia.594,884,910,942,983,984
I
A
In AF patients treated with sotalol, close monitoring of QT interval, serum potassium levels, CrCl, and other proarrhythmia risk factors is recommended.884,942
I
B
In AF patients treated with ﬂecainide for long-term rhythm control, concomitant use of an atrioventricular nodal-blocking drug (if tolerated) should be considered.
IIa
C
Sotalol may be considered for long-term rhythm control in patients with normal LV function or with ischaemic heart disease if close monitoring of QT interval, serum potassium levels, CrCl, and other proarrhythmia risk factors is provided.233,983
IIb
A
AAD therapy is not recommended in patients with permanent AF under rate control and in patients with advanced conduction disturbances unless antibradycardia pacing is provided.
III
C
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; CrCl = Creatinine clearance; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LV = left ventricular; LVH = LV hypertrophy; VHD = valvular heart disease.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
429


<!-- PAGE 58 -->

### Page 58

.............................................................................................................................................................................
thus improving the cardiovascular risk profile.1007 Obesity may increase AF recurrence rates after AF catheter ablation (with OSA as a potential confounder).638,643,789,1008 It has also been linked to a higher radiation dose and complication rate during AF ablation,1009,1010 whereas symptom improvement after AF catheter ablation seems comparable in obese and normal-weight patients.1008
Given the potential to reduce AF episodes by weight reduction, AF
catheter ablation should be offered to obese patients in conjunction with lifestyle modifications for weight reduction (Figure 18).
10.3.1.2 Alcohol and caffeine use
Alcohol excess is a risk factor for incident AF10111014 and bleeding395 in anticoagulated patients (mediated by poor adherence, liver disease, variceal bleeding, and risk of major trauma), and high alcohol intake may be associated with thrombo-embolism or death.1015 In a recent RCT, alcohol abstinence reduced arrhythmia recurrence in regular drinkers with AF.1016
By contrast, it is unlikely that caffeine consumption causes or contributes to AF.47 Habitual caffeine consumption might be associated with lower risk of AF, but caffeine intake may increase symptoms of palpitations unrelated to AF.
10.3.1.3 Physical activity
Many studies have demonstrated beneficial effects of moderate exercise/physical activity on cardiovascular health.10171019 Nevertheless,
the incidence of AF appears to be increased among elite athletes, and multiple small studies reported a relationship between AF and vigorous physical activity, mainly related to long-term or endurance sport participation.10201023 A non-linear relationship between physical activity and AF seems likely. Based on these data, patients should be encouraged to undertake moderate-intensity exercise and remain physically active to prevent AF incidence or recurrence, but maybe avoid chronic excessive endurance exercise (such as marathons and long-distance triathlons, etc.), especially if aged >50 years. Owing to few randomized patients and outcomes, the effect of exercise-based cardiac rehabilitation on mortality or serious adverse events is uncertain.1024
10.3.2
Specific cardiovascular risk factors/comorbidities
10.3.2.1 Hypertension
Hypertension is the most common aetiological factor associated with the development of AF, and patients with hypertension have a 1.7-fold higher risk of developing AF compared with normotensives.26,1025
Hypertension also adds to the complications of AF, particularly stroke, HF, and bleeding risk. AF patients with a longer hypertension duration or uncontrolled systolic BP (SBP) levels should be categorized as ‘high-risk’, and strict BP control in addition to OAC is important to reduce the risk of ischaemic stroke and ICH.
Given the importance of hypertension as a precipitating factor for
AF, which should be regarded as a manifestation of hypertension target-organ damage, treatment of hypertension consistent with current BP guidelines1026 is mandatory in AF patients, aiming to achieve
BP<_130/80 mmHg to reduce adverse outcomes.338,1027,1028 A recent randomized trial in patients with paroxysmal AF and hypertension reported fewer recurrences in patients undergoing renal denervation in addition to PVI compared with patients undergoing PVI only.1029
Sotalol should not be used in the presence of hypertensive LVH or renal impairment, owing to the risk of proarrhythmia. There is some evidence of angiotensin converting enzyme or angiotensin receptor blocker use to improve outcomes in AF or reduce progression of the arrhythmia26,.1025 Other lifestyle changes, including obesity management, alcohol reduction, and attention to OSA, may also help in patients with AF and hypertension.
10.3.2.2 Heart failure
The interactions between AF and HF and the optimal management of patients with both AF and HF are discussed in section 11.6.
10.3.2.3 Coronary artery disease
The interactions between AF and CAD and the optimal management of patients with both AF and CAD are discussed in section 11.3.
10.3.2.4 Diabetes mellitus
In addition to shared risk factors (e.g. hypertension and obesity),1004,1030 diabetes is an independent risk factor for AF, especially in young patients.1031 Silent AF episodes are favoured by concurrent autonomic dysfunction,1032 thus suggesting an opportunity for routine screening for AF in diabetes mellitus patients. The prevalence of AF is at least two-fold higher in patients with diabetes compared with people without diabetes,1033 and AF incidence rises with increasing severity of microvascular complications (retinopathy, renal disease).1034 Both type
1 and type 2 diabetes mellitus are the risk factors for stroke.342,1035
Intensive glycaemic control does not affect the rate of new-onset
AF,1036 but metformin and pioglitazone could be associated with lower long-term risk of AF in patients with diabetes,1037 while this was not confirmed for rosiglitazone.1038 Currently there is no evidence that glucagon-like peptide-1 agonists, sodium glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors affect the development of AF.1039
Previous meta-analyses showed no significant interaction between diabetes mellitus and NOAC effects in AF patients,423,1040 but vascular mortality was lower in patients with diabetes treated with
NOACs than in those on warfarin.1040 Bleeding risk reduction with
NOACs was similar in diabetic and non-diabetic patients except for apixaban, where a lower reduction in haemorrhagic complications was reported in the AF patients with diabetes compared with AF
patients without diabetes.1041 Regarding potential side-effects of
OAC, there is no evidence that bleeding risk is increased in patients with diabetes and retinopathy.341
Optimal glycaemic control in 12 months before AF catheter ablation was associated with significant reduction in recurrent AF after ablation.1042
10.3.2.5 Sleep apnoea
The most common form of sleep-disordered breathing, OSA, is highly prevalent in patients with AF, HF, and hypertension, and is associated with increased risk of mortality or major cardiovascular events.1043 In a prospective analysis, approximately 50% of AF
patients had OSA compared with 32% of controls.1044 The mechanisms facilitating AF include intermittent nocturnal hypoxemia/hypercapnia, intrathoracic pressure shifts, sympathovagal imbalance,
oxidative stress, inflammation, and neurohumoral activation.1045
OSA has been shown to reduce success rates of AADs, electrical cardioversion, and catheter ablation in AF.1045


<!-- PAGE 59 -->

### Page 59

..............................................................................................................
Continuous positive airway pressure (CPAP) is the therapy of choice for OSA, and may ameliorate OSA effects on AF recurrences.1046,1047 Observational studies and meta-analyses showed that appropriate CPAP treatment of OSA may improve rhythm control in AF patients.648,649,10471051
It seems reasonable to test for OSA before the initiation of rhythm control therapy in symptomatic AF patients, with the aim to reduce symptomatic AF recurrences (Figure 18). In the ARREST-AF
(Aggressive Risk Factor Reduction Study  Implication for AF) and
LEGACY (Long-term Effect of Goal-directed weight management on an Atrial fibrillation Cohort: a 5-Year follow-up study) studies, an aggressive risk-factor reduction programme focusing on weight management, hyperlipidaemia, OSA, hypertension, diabetes, smoking cessation, and alcohol-intake reduction significantly reduced AF burden after PVI.636,1052 However, it remains unclear how and when to test for OSA and implement OSA management in the standard work-up of AF patients.
11 The ABC pathway in specific clinical settings/conditions/patient populations
In this section, the management of AF in patient populations with specific conditions is described. The principles of the ABC pathway apply in these settings as well. Additionally, specific considerations are given for each of these special conditions and populations.
11.1 Atrial fibrillation with haemodynamic instability
Acute haemodynamic instability (i.e. syncope, acute pulmonary oedema, ongoing myocardial ischaemia, symptomatic hypotension,
or cardiogenic shock) in AF patients presenting with a rapid ventricular rate requires prompt intervention. In severely compromised patients, emergency electrical cardioversion should be attempted without delay, and anticoagulation should be started as soon as possible.
In critically ill patients and those with severely impaired LV systolic function, AF is often precipitated/exacerbated by increased sympathetic tone, inotropes, and vasopressors, and rhythm control is often unsuccessful. It is important to identify and correct precipitating factors and secondary causes and optimize background treatment.
Owing to their rate-controlling effect during exertion and increased sympathetic tone, rather than only at rest, beta-blockers are preferred over digitalis glycosides for ventricular rate control in AF.490
Beta-blockers and NDCC antagonists may exert a negative inotropic effect (the latter are contraindicated in HFrEF). Digoxin is often unsuccessful due to the increased sympathetic tone in these patients.
As conventional therapy is often ineffective or not well-tolerated,490 electrical cardioversion should always be considered, even as initial therapy, whereas intravenous amiodarone may be instituted for rate control (or potential cardioversion to sinus rhythm), with or without electrical cardioversion.504,514,515 Intravenous administration of amiodarone may lead to a further decrease in BP.
11.2 First-diagnosed (new-onset) atrial fibrillation
First-diagnosed or new-onset AF is a working diagnosis in a patient without a history of AF, until the pattern of AF can be defined more
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with AF
Recommendations
Classa
Levelb
Identiﬁcation and management of risk factors and concomitant diseases is recommended as an integral part of treatment in AF patients.888
I
B
Modiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.245,636,887,889,1016,1052
I
B
Opportunistic screening for AF is recommended in hypertensive patients.26,172,222
I
B
Attention to good BP control is recommended in
AF patients with hypertension to reduce AF recurrences and risk of stroke and bleeding.26,1035
I
B
In obese patients with AF, weight loss together with management of other risk factors should be considered to reduce AF incidence, AF progression, AF recurrences, and symptoms.898,899,1011
IIa
B
Advice and management to avoid alcohol excess should be considered for AF prevention and in
AF patients considered for OAC
therapy.324,1012,1014,1016
IIa
B
Physical activity should be considered to help prevent AF incidence or recurrence, with the exception of excessive endurance exercise,
which may promote AF.10271033,1063
IIa
C
Opportunistic screening for AF should be considered in patients with OSA.172
IIa
C
Optimal management of OSA may be considered, to reduce AF incidence, AF progression,
AF recurrences, and symptoms.650,651,10471051
IIb
C
AF = atrial ﬁbrillation; BP = blood pressure; OAC = oral anticoagulant; OSA =
obstructive sleep apnoea.
aClass of recommendation.
bLevel of evidence.
Recommendations for management of AF with haemodynamic instability
Recommendations
Classa
Levelb
Emergency electrical cardioversion is recommended in AF patients with acute or worsening haemodynamic instability.1053,1054
I
B
In AF patients with haemodynamic instability,
amiodarone may be considered for acute control of heart rate.503,511,512
IIb
B
AF = atrial ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
431


<!-- PAGE 60 -->

### Page 60

precisely. Although the clinical profile and outcome of patients with first-diagnosed AF in AF registries were less favourable than those with paroxysmal AF, rather resembling permanent AF,1055,1056 OAC
prescription rates were the lowest in patients with first-diagnosed
AF.1057 In patients with first-diagnosed AF, the ABC pathway should resemble all steps outlined in the Central Illustration.
11.3 Acute coronary syndromes,
percutaneous coronary intervention, and chronic coronary syndromes in patients with atrial fibrillation
The incidence of AF in acute coronary syndromes (ACS) ranges from
2 - 23%,1058 the risk of new-onset AF is increased by 60- 77%1059 in myocardial infarction patients, and AF per se may be associated with an increased risk of ST-segment elevation myocardial infarction
(STEMI) or non-STEMI ACS.381,10601063 Overall, 10 - 15% of AF
patients undergo PCI for CAD.1064 In observational studies, patients with AF and ACS were less likely to receive appropriate antithrombotic therapy1065 and more likely to experience adverse outcomes1066 than ACS patients without AF.
Peri-procedural management of patients with an ACS or undergoing PCI is detailed in the respective ESC Guidelines on myocardial revascularization1067 and chronic coronary syndromes (CCS).1068
Post-procedural management of atrial fibrillation patients with acute coronary syndrome and/or percutaneous coronary intervention
In AF patients having an ACS or undergoing PCI, concomitant risks of ischaemic stroke/systemic embolism, coronary ischaemic events, and antithrombotic treatment-related bleeding need to be carefully balanced when considering the use and duration of combined antithrombotic therapy.1069 Overall, dual antithrombotic therapy including
OAC (preferably NOAC) and a P2Y12 inhibitor (preferably clopidogrel) is associated with significantly less major bleeding (and ICH) than triple therapy. However, available evidence suggests that at least a short course of triple therapy (e.g. <_1 week) would be desirable in some AF patients after a recent ACS or undergoing PCI, especially in those at increased risk of ischaemic events1070,1071 (Figure 20).
Box 1 About post-procedural management of patients with AF and ACS and/
or PCI
Shorter courses of triple therapy (OAC þ DAPT) may be safe in post-ACS/PCI patients requiring OAC.1076 Observational data1077
and the WOEST trial with warfarin (a safety RCT, underpowered for ischaemic outcomes)1078 suggested better safety and similar efficacy with dual (OAC þ clopidogrel) vs. triple therapy.
RCTs of NOACs in AF patients after a recent ACS/PCI
Four RCTs compared dual therapy with a P2Y12 inhibitor (mostly clopidogrel) plus a NOAC—dabigatran 110 mg or 150 mg b.i.d. (REDUAL PCI),1079 rivaroxaban 15 mg o.d. (PIONEER AF-PCI),1080 apixaban 5 mg b.i.d. (AUGUSTUS),1081 or edoxaban 60 mg o.d.
(ENTRUST-AF PCI)1082 —vs. triple therapy with a VKA in AF
patients with a recent ACS or undergoing PCI. The two-by-two factorial AUGUSTUS trial design enabled the comparison of aspirin vs. placebo (see Supplementary Table 12 for detailed information about these studies). All four trials had a primary safety endpoint (i.e. bleeding) and were underpowered to assess ischaemic outcomes.
Despite some heterogeneity among these trials, all have consistently:
• Included a proportion of patients with an ACS/PCI (37- 52%);
nevertheless, the highest risk patients (e.g. previous stent thrombosis or a complex PCI with stent-in-stent placement) were largely under-represented;
• Used triple therapy during PCI and until randomization (1- 14
days post PCI);
• Most commonly used the P2Y12 inhibitor clopidogrel (overall,
>90%); and
• Reported a significant reduction of major/clinically significant bleeding, comparable rates of ischaemic stroke, similar or non-significantly higher rates of myocardial infarction and stent thrombosis,
and a
neutral effect on trial-defined major adverse cardiovascular events and all-cause mortality with dual (NOAC
þ P2Y12) vs. triple (VKA þ P2Y12 þ aspirin) therapy.
In AUGUSTUS,1081 both placebo (vs. aspirin) and apixaban (vs. VKA)
regimens were associated with significant reduction in bleeding, and apixaban (vs. VKA) was associated with significantly lower rates of stroke, death, or hospitalization.
Meta-analyses of RCTs
• Bleeding outcomes: Meta-analyses1070,1071,1083,1084 consistently showed a significant reduction in major bleeding with dual vs. triple and NOAC- vs. VKA-based therapies (NOAC-based treatments were also associated with a significant reduction in ICH).
• Ischaemic events: Stroke rates were similar across all treatment arms, but the rates of myocardial infarction and stent thrombosis were numerically higher with dual vs. triple therapy.
In two meta-analyses1070,,1071 stent thrombosis was statistically significantly increased on dual (i.e. no aspirin) vs. triple therapy.
Also, the risk of myocardial infarction or stent thrombosis was slightly higher with dabigatran 110 mg but not dabigatran 150 mg.
• The trial-defined major adverse cardiovascular events and mortality rates were similar in all treatment arms, suggesting that the benefit from major bleeding and ICH reduction is counterbalanced by a higher risk for coronary (mainly stent-related) ischaemic events with dual therapy.
ACS = acute coronary syndromes; AF = atrial fibrillation; b.i.d. = bis in die
(twice a day); DAPT = dual antiplatelet therapy; ENTRUST-AF PCI =
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial
Fibrillation Undergoing Percutaneous Coronary Intervention; ICH = intracranial haemorrhage; NOAC = non-vitamin K antagonist oral anticoagulant; OAC =
oral anticoagulant; o.d. = omni die (once daily); PCI = percutaneous coronary intervention; PIONEER AF-PCI = (OPen-Label, Randomized, Controlled,
Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a
Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with
Atrial Fibrillation who Undergo Percutaneous Coronary Intervention; RCT =
randomized controlled trial; RE-DUAL PCI = Randomized Evaluation of Dual
Antithrombotic Therapy with Dabigatran vs. Triple Therapy with Warfarin in
Patients with
Nonvalvular
Atrial
Fibrillation
Undergoing
Percutaneous
Coronary Intervention; VKA = vitamin K antagonist; WOEST = What is the
Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing.


<!-- PAGE 61 -->

### Page 61

©ESC 2020
Figure 20 Post-procedural management of patients with AF and ACS/PCI (full-outlined arrows represent a default strategy; graded/dashed arrows show treatment modifications depending on individual patient’s ischaemic and bleeding risks).
Pretreatment with a P2Y12 inhibitor is recommended in STEMI patients or when coronary anatomy is known; it should be withheld in non-STEMI ACS
until the time of coronary angiography in case of an early invasive strategy within 24 hours. Observational studies indicate that PCI on uninterrupted VKAs is generally safe compared with OAC interruption and heparin-bridging therapy,1073 particularly with radial artery access; in contrast, studies on NOACs are conflicting, predominantly discouraging a PCI on fully uninterrupted NOAC therapy.1074,1075 If urgent PCI is needed, administration of a parenteral anticoagulant (UFH, LMWH, or bivalirudin) is suggested, with temporary withdrawal of NOAC at least for the initial post-procedural period (e.g. 24 h)
depending on the patient’s thrombotic and bleeding risk profile. Where thrombolysis is being considered in a patient with STEMI, the initial step should be to assess the anticoagulation status (e.g. INR in a patient taking VKA; with a NOAC, assessing, for example, activated partial thromboplastin time on dabigatran or anti-factor Xa activity on factor Xa inhibitors). Thrombolytic therapy may be associated with an increased risk of bleeding in systemically anticoagulated patients, especially if parenteral heparin and antiplatelet drugs are coadministered. A balance between the potential benefit (e.g. large anterior myocardial infarction) and harm (e.g. ICH) is needed, as well as the reassessment of urgent transfer to a PCI centre. If the supposedly anticoagulated patient does not have evidence of a therapeutic anticoagulation effect (e.g. INR <2.0 on warfarin; or no NOAC anticoagulant effect detected), systemic thrombolysis may be considered if no access to primary PCI is possible.
ACS = acute coronary syndromes; ASA = acetylsalicylic acid; CAD = coronary artery disease; CCS = chronic coronary syndromes; CKD = chronic kidney disease; DAPT = dual antithrombotic therapy; eGFR = estimated glomerular filtration rate; ICH = intracranial haemorrhage; INR = international normalized ratio; LMWH = low-molecular-weight heparin; MI = myocardial infarction; NOAC = non-vitamin K antagonist oral anticoagulant; NSAID = non-steroidal anti-inflammatory drug; OAC = oral anticoagulant; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; PPI = proton-pump inhibitor; STEMI = ST-segment elevation myocardial infarction; UFH = unfractionated heparin; VKA = vitamin K antagonist.
ESC Guidelines
433


<!-- PAGE 62 -->

### Page 62

............................................................
Whichever initial treatment plan was chosen, dual therapy with OAC
and an antiplatelet drug (preferably clopidogrel) is recommended for the first 12 months after PCI for ACS, or 6 months after PCI in patients with CCS.1067 Thereafter, OAC monotherapy is to be continued (irrespective of the stent type) provided that there were no recurrent ischaemic events in the interim. In 1-year event-free (i.e. ‘stable’) AF
patients with CAD and no PCI, OAC monotherapy is also recommended.1072
Use of prasugrel or ticagrelor has been associated with a greater risk of major bleeding compared with clopidogrel10851089 and should be avoided in ACS patients with AF. In the RE-DUAL PCI (Randomized
Evaluation of Dual Antithrombotic Therapy with Dabigatran vs. Triple
Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation
Undergoing Percutaneous Coronary Intervention) trial, 12% of patients received ticagrelor with dabigatran, but experience with ticagrelor or prasugrel was minimal in PIONEER-AF (OPen-Label, Randomized,
Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of
Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist
Treatment Strategy in Subjects with Atrial Fibrillation who Undergo
Percutaneous Coronary Intervention), AUGUSTUS, and ENTRUSTAF PCI (Edoxaban Treatment Versus Vitamin K Antagonist in Patients
With
Atrial
Fibrillation
Undergoing
Percutaneous
Coronary
Intervention). In patients at potential risk of gastrointestinal bleeding,
concomitant use of proton-pump inhibitors is reasonable.1084
In AF patients treated with surgical coronary revascularization,
OAC should be resumed as soon as bleeding is controlled, possibly in combination with clopidogrel, and triple therapy should be avoided.
Poor ventricular rate control during AF may exacerbate symptoms of myocardial ischaemia and precipitate or worsen HF. Appropriate treatment may include a beta-blocker or rate-limiting calcium antagonist. In haemodynamic instability, acute cardioversion may be indicated. Vernakalant, flecainide, and propafenone should not be used for rhythm control in patients with known CAD (section 10.2.2.2).
In all AF patients with an ACS/CCS, optimized management of risk factors is needed, and cardiovascular prevention strategies such as good BP control,338 lipid management, and other cardiovascular prevention interventions1007 should be implemented as needed, once the acute presentation is stabilized.
Recommendations for patients with AF and an ACS, PCI, or CCS1068
General recommendations for patients with AF and an indication for concomitant antiplatelet therapy
Classa
Levelb
In AF patients eligible for NOACs, it is recommended to use a NOACc in preference to a VKA in combination with antiplatelet therapy.1079,1081
I
A
In patients at high bleeding risk (HAS-BLED >_3), rivaroxaban 15 mg o.d. should be considered in preference to rivaroxaban 20 mg o.d. for the duration of concomitant single or DAPT, to mitigate bleeding risk.1080
IIa
B
In patients at high bleeding risk (HAS-BLED >_3), dabigatran 110 mg b.i.d. should be considered in preference to dabigatran 150 mg b.i.d. for the duration of concomitant single or DAPT, to mitigate bleeding risk.1079
IIa
B
In AF patients with an indication for a VKA in combination with antiplatelet therapy, the VKA dosing should be carefully regulated with a target INR of 2.0 - 2.5 and TTR>70%.1094,1095,1104,1105
IIa
B
Recommendations for AF patients with ACS
In AF patients with ACS undergoing an uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with an
OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 12 months is recommended if the risk of stent thrombosisd is low or if concerns about bleeding riske prevail over concerns about risk of stent thrombosis,d irrespective of the type of stent used.1090,10921095
I
A
Triple therapy with aspirin, clopidogrel, and an OACf for longer than 1 week after an ACS should be considered when risk of stent thrombosisd outweighs the bleeding risk,e with the total duration (<_1 month) decided according to assessment of these risks, and the treatment plan should be clearly speciﬁed at hospital discharge.
IIa
C
Recommendations in AF patients with a CCS undergoing PCI
After uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with OAC for up to 6 months and clopidogrel is recommended if the risk of stent thrombosisd is low or if concerns about bleeding riske prevail over concerns about risk of stent thrombosis,d irrespective of the type of stent used.1076,10781081
I
A
Triple therapy with aspirin, clopidogrel, and an OACf for longer than 1 week should be considered when risk of stent thrombosisd outweighs the bleeding risk,e with the total duration (<_1 month) decided according to assessment of these risks, and the treatment plan should be clearly speciﬁed at hospital discharge.
IIa
C
ACS = acute coronary syndrome; AF = atrial ﬁbrillation; b.i.d. = bis in die (twice a day); CCS = chronic coronary syndrome; CKD = chronic kidney disease; DAPT = Dual antiplatelet therapy; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs/alcohol concomitantly; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral anticoagulant; o.d. = omni die (once daily); OAC = oral anticoagulant; PCI=percutaneous coronary intervention; TTR = time in therapeutic range; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cSee summary of product characteristics for reduced doses or contraindications for each NOAC in patients with CKD, body weight <60 kg, age >75 - 80 years, and/or drug interactions.
dRisk of stent thrombosis encompasses: (i) risk of thrombosis occurring, and (ii) risk of death should stent thrombosis occur, both of which relate to anatomical, procedural,
and clinical characteristics. Risk factors for CCS patients include: stenting of left main stem or last remaining patent artery; suboptimal stent deployment; stent length >60 mm;
diabetes mellitus; CKD; bifurcation with two stents implanted; treatment of chronic total occlusion; and previous stent thrombosis on adequate antithrombotic therapy.
eBleeding risk in AF patients may be assessed using the HAS-BLED score (section 10.1.2), which draws attention to modiﬁable bleeding risk factors; those at high risk (score >_3)
can have more frequent or early review and follow-up. Bleeding risk is highly dynamic and does not remain static, and relying on modiﬁable bleeding risk factors alone is an inferior strategy to evaluate bleeding risk.389
fWhen dabigatran is used in triple therapy, dabigatran 110 mg b.i.d may be used instead of 150 mg b.i.d, but the evidence is insufﬁcient.


<!-- PAGE 63 -->

### Page 63

....................................................................................
11.4 Acute stroke or intracranial haemorrhage in patients with atrial fibrillation
11.4.1
Patients with atrial fibrillation and acute ischaemic stroke or transient ischaemic attack
Management of acute stroke in AF patients is beyond the scope of this document. In AF patients presenting with acute ischaemic stroke while taking OAC, acute therapy depends on the treatment regimen and intensity of anticoagulation. Patients on VKA with an
INR<1.7 are eligible for thrombolysis according to the neurological indication (if presenting with a clinically relevant neurological deficit within the appropriate time window and ICH is excluded with cerebral imaging). In patients taking NOACs, measurement of activated partial thromboplastin time or thrombin time (for dabigatran), or antifactor Xa levels (for factor Xa inhibitors) will provide information on whether the patient is systemically anticoagulated. Whenever possible, the time when the last NOAC dose was taken should be elucidated (generally, thrombolysis is considered to be safe in patients with last NOAC intake being >_48 h,
assuming normal renal function).1090
If the patient is systemically anticoagulated, thrombolysis should not be performed due to the risk of haemorrhage, and endovascular treatment should be considered. In patients taking dabigatran, systemic thrombolysis may be performed after reversal of the dabigatran action by idarucizumab.1091
Secondary prevention of stroke/systemic embolism in patients after acute AF-related ischaemic stroke or TIA includes early prevention of recurrent ischaemic stroke in the 2 weeks after the index event and long-term prevention thereafter.
Whereas infarct size/stroke severity is used clinically to guide timing of OAC initiation,1090 the usefulness of such an approach in estimating the net benefit of early treatment may be limited. Robust data to inform optimal timing for (re)initiation of OAC after acute stroke are lacking. From the cardiological perspective, OAC should be
(re)initiated as soon as considered possible from the neurological perspective (in most cases within the first 2 weeks). A multidisciplinary approach with involvement of stroke specialists, cardiologists,
and patients is considered appropriate.
In AF patients who presented with acute ischaemic stroke despite taking OAC, optimization of OAC therapy is of key importance—if on VKA, optimize TTR (ideally >70%) or switch to a NOAC; if on
NOAC, ensure appropriate dosing and good adherence to treatment. Inappropriate NOAC under-dosing using lower or reduced doses of specific NOACs has been associated with increased risk of stroke/systemic embolism, hospitalization, and deaths without appreciable reduction in major bleeding.1107
11.4.2
Cryptogenic stroke/embolic stroke with undetermined source
Currently available evidence including two recently completed
RCTs1108,1109 does not support routine OAC use in patients with acute ischaemic stroke of uncertain aetiology (cryptogenic stroke)
or acute embolic stroke of undetermined source in patients without documented AF (Supplementary Box 4). Of note, subgroup
Box 2 About acute ischaemic stroke in patients with AF
AF-related ischaemic strokes are often fatal or disabling 106 , with increased risk of early recurrence within 48 h 1092 to 2 weeks,10921095 or haemorrhagic transformation,1096 especially in the first days after large cardio-embolic lesions and acute recanalization therapy.1097,1098 Notably, ICH is generally associated with higher mortality and morbidity than recurrent ischaemic stroke.
Timing of OAC (re)initiation after acute ischaemic stroke
• Early anticoagulation after acute ischaemic stroke might cause parenchymal haemorrhage, with potentially serious clinical consequences1097,.1099 Using UFH,
LMWH, heparinoids, or VKAs <48 h after acute ischaemic stroke was associated with an increased risk of symptomatic ICH, without significant reduction in recurrent ischaemic stroke.1095
• Reportedly, the 90-day risk of recurrent ischaemic stroke outweighs the risk of symptomatic ICH in AF patients receiving a NOAC 4- 14 days after the acute event11001102 (ischaemic stroke recurrence rates after mild/moderate ischaemic stroke significantly increased with a later NOAC administration,1101 e.g. >14
days).1100 In a small RCT, rivaroxaban use within 5 days after mild ischaemic stroke in AF patients was associated with similar event rates compared with VKA.1103
As high-quality RCT-derived evidence to inform optimal timing of anticoagulation after acute ischaemic stroke is lacking, OAC use in the early post-stroke period is currently based on expert consensus.505 Several ongoing RCTs [ELAN (NCT03148457), OPTIMAS (EudraCT, 2018-003859-3), TIMING (NCT02961348), and
START (NCT03021928)] are investigating early (<1 week) vs. late NOAC initiation in patients with AF-related ischaemic stroke (first results are not expected before 2021).
Long-term secondary stroke prevention
• There is no evidence that the addition of aspirin to OAC or supratherapeutic INRs would improve outcomes in secondary stroke prevention.
• Compared with VKAs, NOACs were associated with better efficacy in secondary stroke prevention and better safety regarding ICH in a meta-analysis of landmark NOAC AF trial.1104
• Good adherence to OAC treatment is essential for effective secondary stroke prevention.
There is some evidence to support that strokes can induce AF through neurogenic mechanisms1105,.1106 The first study showed that damage to the insula increases the odds of AF detection after ischaemic stroke and is more prevalent in patients with AF diagnosed after stroke than among those without AF.1105
The second study explained the reason why AFDAS detected soon after ischaemic stroke is associated with a low risk of ischaemic stroke recurrence.1106
AF = atrial fibrillation; ELAN = Early versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With AF; ICH = intracranial haemorrhage; INR = international normalized ratio; LMWH = low-molecular-weight heparin; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; OPTIMAS = OPtimal TIMing of Anticoagulation after Stroke; RCT = randomized controlled trial; START = Optimal Delay Time to Initiate
Anticoagulation After Ischemic Stroke in AF; TIMING = TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With AF; UFH = unfractionated heparin; VKA = vitamin K antagonist.
ESC Guidelines
435


<!-- PAGE 64 -->

### Page 64

...........................................................................................................................................................
analyses of those two RCTs suggested that certain subgroups (i.e.
age >_75 years, impaired renal function,1109 or enlarged LA1110)
could benefit from OAC, but more data are needed to inform optimal use of NOACs among patients with a cryptogenic stroke.
Two ongoing trials will study the use of apixaban in this setting
[ATTICUS (Apixaban for treatment of embolic stroke of undetermined source)]1111 and ARCADIA [(AtRial Cardiopathy and
Antithrombotic Drugs In Prevention After Cryptogenic Stroke)
(NCT03192215)].
Efforts to improve detection of AF are needed in such patients
(see also section 8). Clinical risk scores fe.g. C2HEST [CAD/COPD
(1 point each), Hypertension (1 point), Elderly ( >_75 years, 2 points),
Systolic heart failure (2 points), and Thyroid disease (hyperthyroidism, 1 point) (score)]g have been proposed for identification of ‘highrisk’ patients for AF diagnosis1112 and facilitation of prolonged monitoring.
11.4.3
Post-stroke patients without known atrial fibrillation
Detection of previously unknown AF after stroke has important implications for secondary prevention. Several RCTs have established the effectiveness of ECG monitoring for post-stroke AF detection,
with numbers needed to screen of 814.1117,1118
Looking harder and longer and using more sophisticated monitoring may generally improve AF detection. In a meta-analysis1118
of 50 post-stroke studies, the proportion of patients with poststroke AF was 7.7% in the emergency room using admission ECG;
5.1% in the wards using serial ECG, continuous inpatient ECG
monitoring/cardiac telemetry, and in-hospital Holter monitoring;
10.7% in the first ambulatory period using ambulatory Holter; and,
after discharge, 16.9% using mobile cardiac outpatient telemetry and external or implantable loop recording. The overall poststroke AF detection after all phases of cardiac monitoring reached
23.7%.1118
In patients with ischaemic stroke/TIA, monitoring for AF is recommended by short-term ECG recording followed by continuous ECG
monitoring for at least 72 h, also considering a tiered longer ECG
monitoring approach1113 and insertion of an intracardiac monitor in case of cryptogenic stroke.1114,1119 Post-stroke ECG monitoring is likely cost-effective1120,1121; however, RCTs have not been powered to assess the effect of prolonged ECG monitoring and subsequent prescription of OAC on stroke or mortality in patients with detected
AF.
11.4.4
Management of patients with atrial fibrillation post-intracranial haemorrhage
As ICH is the most feared, often lethal, complication of anticoagulant and antiplatelet therapy, there is a considerable reluctance to (re)initiate OAC in AF patients who survived an ICH, despite their high estimated risk of AF-related ischaemic stroke.
Patients with a history of recent ICH were excluded from RCTs of stroke prevention in AF, but available observational data suggest than many AF patients would benefit from (re)institution of OAC,
depending on the cause(s) of ICH and findings on brain CT and MRI
(Supplementary Box 5).
Treatment decision to (re)start OAC in AF patients after an ICH
requires multidisciplinary-team input from cardiologists, stroke specialists, neurosurgeons, patients, and their family/carers. After acute spontaneous ICH (which includes epidural, subdural, subarachnoid,
or intracerebral haemorrhage), OAC may be considered after careful assessment of risks and benefits, and cerebral imaging may help. The risk of recurrent ICH may be increased in the presence of specific risk factors, shown in Figure 21. Of note, the risk of OAC-related ICH
is increased especially in Asian patients.1122
Compared with VKAs, the use of NOACs in patients without previous ICH is associated with an approximately 50% lower risk of
ICH,423 whereas the size and outcome of OAC-related ICH is similar with NOACs and VKAs.1124 Hence, NOACs should be preferred in
NOAC-eligible ICH survivors with AF although there is no RCT to prove this.
The optimal timing of anticoagulation after ICH is unknown, but should be delayed beyond the acute phase, probably for at least 4
weeks; in AF patients at very high risk of recurrent ICH, LAA occlusion may be considered. Ongoing RCTs of NOACs and LAA occlusion may inform decision making in the future.
Recommendations for the search for AF in patients with cryptogenic stroke
Recommendations
Classa
Levelb
In patients with acute ischaemic stroke or TIA
and without previously known AF, monitoring for AF is recommended using a short-term ECG
recording for at least the ﬁrst 24 h, followed by continuous ECG monitoring for at least 72 h whenever possible.11131116
I
B
In selectedc stroke patients without previously known AF, additional ECG monitoring using long-term non-invasive ECG monitors or insertable cardiac monitors should be considered, to detect AF.1112
IIa
B
AF = atrial ﬁbrillation; C2HEST = CAD/COPD (1 point each), Hypertension (1
point), Elderly ( >_75 years, 2 points), Systolic heart failure (2 points), and Thyroid disease (hyperthyroidism, 1 point) (score); ECG=electrocardiogram; LA = left atrial; TIA=transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
cNot all stroke patients would beneﬁt from prolonged ECG monitoring; those deemed at risk of developing AF (e.g. elderly, with cardiovascular risk factors or comorbidities, indices of LA remodelling, high C2HEST score, etc.) or those with cryptogenic stroke and stroke characteristics suggestive of an embolic stroke should be scheduled for prolonged ECG monitoring.


<!-- PAGE 65 -->

### Page 65

©ESC 2020
Figure 21 (Re-) initiation of anticoagulation post-intracranial bleeding.
A pooled analysis of individual patient data from cohort studies (n=20 322 patients; 38 cohorts; >35 225 patient-years) showed that although cerebral microbleeds can inform regarding the risk for ICH in patients with recent ischaemic stroke/TIA treated with antithrombotic therapy, the absolute risk of ischaemic stroke is substantially higher than that of ICH, regardless of the presence, burden, or location of cerebral microbleeds.505,1123
IS = ischaemic stroke;ACS = acute coronary syndrome; CMB = cerebral microbleeds; ICH = intracranial haemorrhage; LAA = left atrial appendage; LDL
= low-density lipoprotein; LoE = level of evidence; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; PCI = percutaneous coronary intervention; RCT = randomized controlled trial; TIA = transient ischaemic attack.
Recommendations for secondary stroke prevention in AF patients after acute ischaemic stroke
Classa
Levelb
In AF patients with an ischaemic stroke or TIA, long-term secondary prevention of stroke using OAC is recommended if there is no strict contraindication to OAC use, with a preference for NOACs over VKAs in NOAC-eligible patients.11251130
I
A
In AF patients presenting with acute ischaemic stroke, very early anticoagulation (<48 h) using UFH, LMWH, or VKAs is not recommended.1095
III
B
Recommendations for stroke prevention in AF patients after intracranial haemorrhage
In AF patients at high risk of ischaemic stroke, (re-)initiation of OAC, with preference for NOACs over VKAs in NOAC-eligible patients, should be considered in consultation with a neurologist/stroke specialist after:
• A trauma-related ICH
• Acute spontaneous ICH (which includes subdural, subarachnoid, or intracerebral haemorrhage), after careful consideration of risks and beneﬁts.c
IIa
C
AF = atrial ﬁbrillation; ICH = intracranial haemorrhage; LMWH = low-molecular-weight heparin; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; TIA = transient ischaemic attack; UFH = unfractionated heparin; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cA more favourable net beneﬁt is likely with deep ICH or without neuroimaging evidence of cerebral amyloid angiopathy or microbleeds.
ESC Guidelines
437


<!-- PAGE 66 -->

### Page 66

..................................................................................
11.5 Active bleeding on anticoagulant therapy: management and reversal drugs
Management of patients with active bleeding while on OAC is shown in Figure 22. General assessment should include detection of the bleeding site, assessment of bleeding severity, and evaluation of the time-point of last OAC intake. Concomitant antithrombotic drugs and other factors influencing bleeding risk (alcohol abuse, renal function) should be explored. Laboratory tests, such as INR, are useful in case of VKA therapy. More specific coagulation tests for NOACs include diluted thrombin time, ecarin clotting time, or ecarin chromogenic assay for dabigatran, and chromogenic anti-factor Xa assay for rivaroxaban, apixaban, and edoxaban.1131 However, these tests or measurement of NOAC plasma levels are not always readily available in practice and are often unnecessary for bleeding management.1132
An overview of reversal drugs for NOACs is given in Supplementary
Table 13 and Supplementary Figure 6.
Notably, the time of last drug ingestion combined with assessment of renal function, haemoglobin, haematocrit, and platelet count enable appropriate clinical decision making in most of the cases.
Minor bleeding events should be treated with supportive measures such as mechanical compression or minor surgery to achieve haemostasis. Withdrawal of VKAs is not associated with a prompt reduction of anticoagulant effect, while NOACs have a short plasma half-life and haemostasis can be expected within 12 - 24 h after an omitted dose.
Treatment of moderate bleeding events may require blood transfusions and fluid replacement. If the last intake of NOACs was less than 2 - 4 h before bleeding assessment, charcoal administration and/
or gastric lavage will reduce further exposure. Specific diagnostic and treatment interventions to identify and manage the cause of bleeding
(e.g. gastroscopy) should be performed promptly. Dialysis is effective in reducing dabigatran concentration and has been associated with reduction in the duration and/or severity of associated bleeding.1133
Severe or life-threatening bleeding requires immediate reversal of the antithrombotic effect of OACs. For VKAs, administration of fresh frozen plasma restores coagulation more rapidly than vitamin K, but prothrombin complex concentrates achieve even faster blood coagulation1134 and are first-line therapy for VKA reversal.1135 Specific reversal drugs are available for NOACs: idarucizumab (for dabigatran) and andexanet alfa (for factor Xa inhibitors) effectively reverse the anticoagulation action of NOACs and restore physiological haemostasis.1136,1137 However, their use is often associated with subsequent non-reinitiation of OAC and increased rates of thrombotic events. These drugs can be effectively applied in case of severe lifethreatening bleeding or urgent surgery, but their use is only very rarely necessary in daily clinical practice. Ciraparantag is an investigational synthetic drug that binds and inhibits direct factor Xa inhibitors,
dabigatran, and heparin. The use of four-factor prothrombin complex concentrates may be considered as an alternative treatment for reversing the anticoagulant effect of rivaroxaban, apixaban, and edoxaban, although scientific evidence is very limited in this context and is frequently from healthy volunteers.11381140
©ESC 2020
Figure 22 Management of active bleeding in patients receiving anticoagulation (institutions should have an agreed procedure in place).143 FFP = fresh frozen plasma; INR = international normalized ratio; i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation therapy; PCC = prothrombin complex concentrates; VKA = vitamin K antagonist.


<!-- PAGE 67 -->

### Page 67

........................................................................................................................
11.6 Atrial fibrillation and heart failure
Both AF and HF facilitate the occurrence and aggravate the prognosis of each other, and often coexist (see also sections 4.2 and 5.3); HF is also a thrombo-embolic risk factor in AF. The efficacy and safety of
NOACs do not seem to differ in AF patients with and without
HF.1141,1142
The management of patients with AF and HF is often challenging
(section 10.2). The optimal heart-rate target in AF patients with HF
remains unclear, but a rate of <100 - 110 bpm is usually recommended.11431145 Pharmacological rate control strategies are different for patients with heart failure with preserved ejection fraction
(HFpEF) and HFrEF. Beta-blockers, diltiazem, verapamil, and digoxin are all viable options in HFpEF, while beta-blockers and digoxin can be used in those with HFrEF. Amiodarone may be considered for rate control in both forms of HF, but only in the acute setting.
Atrioventricular-node ablation and pacing can control ventricular rate when medication fails (section 10.2.1.). However, in an observation study, rhythm control strategies showed a lower 1-year all-cause death over rate control in older patients (>_65 years) with HFpEF.1146
Haemodynamic instability or worsening of HF may require emergency or immediate electrical cardioversion of AF, whereas pharmacological cardioversion using i.v. amiodarone may be attempted if a delayed cardioversion is consistent with the clinical situation (section
10.2.2.2.2). AF catheter ablation has been shown to improve symptoms, exercise capacity, QoL, and LVEF in AF patients with HF,661
whereas the recent CASTLE-AF RCT showed a reduction in allcause mortality and hospitalization for worsening HF after AF catheter ablation in patients with HFrEF657 (section 10.2.2.3).
All patients with HF and AF should receive guideline-adherent HF
therapy.1145 The benefit of beta-blocker therapy in reducing mortality in AF patients with HFrEF has been questioned by some meta-analyses,491 although this is not a universal finding, especially with some real-world studies supporting an improved prognosis.1147,1148
11.7 Atrial fibrillation and valvular heart disease
VHD is independently associated with AF1149 and more than onethird of patients with AF have some form of VHD.512
Among patients with severe VHD, including those undergoing surgical and transcatheter aortic or mitral valve intervention, AF is associated with less favourable clinical outcomes.11501155 Compared to
AF patients without VHD, the risk of thrombo-embolism and stroke is increased among AF patients with VHD other than mitral stenosis and mechanical heart prostheses, mostly owing to older age and more frequent comorbidities.1156,1157 While patients with moderateto-severe mitral stenosis and mechanical prosthetic heart valves require anticoagulation with VKAs,1158 there is no evidence that the presence of other VHDs including aortic stenosis/regurgitation,
mitral regurgitation, bioprostheses, or valve repair should modify the choice of OAC.1156,1159 In a meta-analysis of the four pivotal RCTs comparing NOACs with VKAs, the effects of NOACs vs. VKAs in terms of stroke/systemic embolism and bleeding risk in patients with
VHD other than mitral stenosis and mechanical prosthetic heart valves were consistent with those in the main RCTs.1160 In an observational study, NOACs were associated with better outcomes, with reduced rates of ischaemic stroke and major bleeding compared to warfarin in AF patients with mitral stenosis.1161
Recently, a functional categorization of VHD in relation to OAC
use was introduced, categorizing patients with moderate-severe or rheumatic mitral stenosis as type 1 and all other VHD as type
2.148,1157,1162 There are gaps in evidence on NOAC use in AF
patients with rheumatic mitral valve disease, and during the first
3 months after surgical or transcatheter implantation of a bioprosthesis, and observational data regarding NOACs use after transcatheter aortic valve implantation are conflicting.1163 An RCT in non-AF
patients comparing rivaroxaban 10 mg daily with aspirin after transcatheter aortic valve implantation was stopped early due to higher risks of death or thrombo-embolic complications and bleeding in the rivaroxaban arm.1164
Recommendations for the management of active bleeding on OAC
Classa
Levelb
In an AF patient with severe active bleeding, it is recommended to:
• Interrupt OAC until the cause of bleeding is identiﬁed and active bleeding is resolved; and
• Promptly perform speciﬁc diagnostic and treatment interventions to identify and manage the cause(s) and source(s) of bleeding.
I
C
Four-factor prothrombin complex concentrates should be considered in AF patients on VKA
who develop a severe bleeding complication.
IIa
C
AF = atrial ﬁbrillation; OAC = oral anticoagulant; VKA=vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
Recommendations for patients with valvular heart disease and AF
Recommendations
Classa
Levelb
NOACs are contraindicated in patients with a prosthetic mechanical valve.1165
III
B
Use of NOACs is not recommended in patients with AF and moderate-to-severe mitral stenosis.
III
C
AF = atrial ﬁbrillation; NOAC = non-vitamin K antagonist oral anticoagulant.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
439


<!-- PAGE 68 -->

### Page 68

.............................................................................................................................................................................
11.8 Atrial fibrillation and chronic kidney disease
Independently of AF, CKD is a prothrombotic and prohaemorrhagic condition (Supplementary Figure 7),1166,1167,1168 and AF may accelerate CKD progression. Coexisting in 1520% of CKD patients,1169
AF is associated with increased mortality,1170 whereas CKD may be present in 40 - 50% of AF patients.1171 In AF patients, renal function can deteriorate over time,1172 and worsening CrCl is a better independent predictor of ischaemic stroke/systemic embolism and bleeding than renal impairment per se.1172 In RCTs of OAC for stroke prevention in AF, renal function was usually estimated using the
CockcroftGault formula for CrCl, and a CrCl cut-off of <50 mL/
min was used to adapt NOAC dosage.
In patients with mild-to-moderate CKD (CrCl 30 - 49 mL/min),
the safety and efficacy of NOACs vs. warfarin was consistent with patients without CKD in landmark NOAC trials11731176, hence the same considerations for stroke risk assessment and choice of OAC
may apply.
In patients with CrCl 15- 29 mL/min, RCT-derived data on the effect of VKA or NOACs are lacking. These patients were essentially excluded from the major RCTs. The evidence for the benefits of
OAC in patients with end-stage kidney disease with CrCl<_15 mL/
min or on dialysis is even more limited, and to some extent controversial. There are no RCTs, whereas observational data question the benefit of OAC in this patient population. Data from observational studies suggest possible bleeding risk reduction in patients with endstage kidney disease taking a NOAC compared with VKA,435,1177 but there is no solid evidence for a reduction in embolic events with either NOACs or VKAs, as recently shown in a systematic review.1178 Notably, NOACs have not been approved in Europe for patients with CrCl <_15 mL/min or on dialysis.
Several RCTs are currently assessing OAC use and comparing
NOACs with VKAs in patients with end-stage renal disease
(NCT02933697, NCT03987711). The RENAL-AF trial, investigating apixaban vs. warfarin in AF patients on haemodialysis, was terminated early with inconclusive data on relative stroke and bleeding rates.1179
There are no RCT data on OAC use in patients with AF after kidney transplantation. The prescription and dosing of NOACs should be guided by the estimated glomerular filtration rate of the transplanted kidney and taking into account potential interactions with concomitant medication.
Particular attention must be given to the dosing of NOACs in patients with CKD (Supplementary Table 9).
11.9 Atrial fibrillation and peripheral artery disease
Patients with AF often have atherosclerotic vascular disease. With the inclusion of asymptomatic ankle-brachial index<_0.90 in the definition PAD, the prevalence of vascular disease increased significantly.1180 In a systematic review and meta-analysis, the presence of
PAD was significantly associated with a 1.3- to 2.5-fold increased risk of stroke.347 Complex aortic plaque in the descending aorta, as identified on TOE, is also a significant vascular stroke risk factor (section
10.1.1).
In patients with asymptomatic PAD, the risk of cardiovascular events progressively increases with increasing vascular disease burden.470 Therefore, PAD patients should be opportunistically screened for AF. Patients with AF and PAD should be prescribed
OAC, unless contraindicated. Those with stable vascular disease
(arbitrarily defined as no new vascular event in the past 12 months)
should be managed with OAC alone (section 11.3), as concomitant use of antiplatelet therapy has not been shown to reduce stroke or other cardiovascular events, but may increase serious bleeds, including ICH.
The principles of rate and rhythm control outlined in section 10.2
also apply for AF patients with PAD. Special considerations include possibly limited exercise capacity in these patients, owing to intermittent claudication. Beta-blockers may exacerbate PAD symptoms in some patients, in whom NDCC blockers may be more appropriate for rate control.
11.10 Atrial fibrillation and endocrine disorders
Electrolyte disturbances and altered glucose and/or hormone levels in endocrine disorders such as thyroid disorders, acromegaly, pheochromocytoma, diseases of adrenal cortex, parathyroid disease, or pancreas dysfunction including diabetes mellitus may contribute to development of AF. Data on management of AF in these settings are limited.3 Diabetes is discussed in section 10.3.2.4. Stroke prevention should follow the same principles as in other AF patients, with risk stratification using the CHA2DS2-VASc score.3,1181 In AF patients with hyperthyroidism, spontaneous conversion of AF often occurs once a euthyroid state is achieved.1182 Withdrawal of amiodarone is mandatory in hyperthyroidism. AF catheter ablation should be performed under stable electrolytic and metabolic conditions and should not be carried out during active hyperthyroidism.
11.11 Atrial fibrillation and gastrointestinal disorders
While gastrointestinal lesions can lead to bleeding events in anticoagulated AF patients, some gastrointestinal conditions such as active inflammatory bowel disease increase the risk of AF and stroke.1183
Gastrointestinal bleeding is a well-known complication of OAC.
Overall, NOAC use is associated with an increased risk of gastrointestinal bleeding,1184,1185 but in patients treated with apixaban or dabigatran 110 mg the risk is similar to warfarin.419,421 Bleeding lesions can be identified in more than 50% of cases of major gastrointestinal bleeding.1186 After correction of the bleeding source, OAC
should be restarted, as this strategy has been associated with decreased risks of thrombo-embolism and death.1187
Patients treated with dabigatran may experience dyspepsia (about
11% in the RE-LY trial, and 2% discontinued the drug because of gastrointestinal symptoms419). After-meal ingestion of dabigatran and/or the addition of proton-pump inhibitors improves symptoms.1188
Management of AF patients with liver disease is challenging, owing to increased bleeding risk (associated with decreased hepatic synthetic function in advanced liver disease, thrombocytopenia, and gastrointestinal variceal lesions), as well as increased ischaemic risk1189,1190). Patients with hepatic dysfunction were generally excluded from the RCTs,1191 especially those with abnormal clotting tests, as such patients may be at higher risk of bleeding on VKA, possibly less so on NOACs. Despite the paucity of data, observational


<!-- PAGE 69 -->

### Page 69

.............................................................................................................................................................................
studies did not raise concerns regarding the use of NOACs in advanced hepatic disease.1192 In a recent study, AF patients with liver fibrosis had no increase in bleeding on NOACs compared with
VKAs.470 Other reassuring data for NOACs come from a large nationwide cohort.472 A number of patients may be started on a
NOAC while having unrecognized significant liver damage and, in cirrhotic patients, ischaemic stroke reduction may outweigh bleeding risk.471 NOACs are contraindicated in patients within ChildTurcotte-Pugh C hepatic dysfunction, and rivaroxaban is not recommended for patients in the Child-Turcotte-Pugh B or C category.1193
11.12 Atrial fibrillation and haematological disorders
Anaemia is an independent predictor of OAC-related major bleeding.393,402 In a population-based AF cohort, anaemia was associated with major bleeding and lower TTR, whereas OAC use in AF patients with moderate or severe anaemia was associated with more major bleeding but no reduction in thrombo-embolic risk.1194
Thrombocytopenia is also associated with increased bleeding risk.
Before and during anticoagulation treatment, both anaemia and thrombocytopenia should be investigated and corrected, if possible.
Decision making on OAC use in patients with platelet counts <100/
mL requires a multidisciplinary approach including haematologists,
balancing thrombotic and bleeding risks and addressing modifiable bleeding risk factors. Some chemotherapeutic drugs may increase the risk of incident AF (e.g. ibrutinib, melphalan, anthracyclines)11951197
or impair platelet function, thus increasing the risk of bleeding (e.g.
ibrutinib).1198,1199
11.13 The elderly and frail with atrial fibrillation
The prevalence of AF increases progressively with age67,12001206,
and age is an independent risk factor for adverse outcomes in
AF.372,1200,1207,1208
Older people are less likely to receive
OAC12091216 despite sufficient evidence supporting the use of
OAC in this population. Frailty, comorbidities, and increased risk of falls12171219 do not outweigh the benefits of OAC given the small absolute risk of bleeding in anticoagulated elderly patients.339,390,391,12201223 Evidence from RCTs,441,1224 meta-analyses423,1225 and large registries339,433,1209,1226 support the use of OAC
in this age group. Antiplatelets are neither more effective nor safer than warfarin and may even be harmful,433 whereas NOACs appear to have a better overall riskbenefit profile compared with warfarin.423,433,441,1035,1225,12271236 Prescribing a reduced dose of
OAC
is less effective in preventing
AF
adverse outcomes.1107,1211,1237,1238
Rate control is traditionally the preferred strategy, but evidence informing the choice between rate and rhythm control in the elderly is insufficient.12391242 Limited evidence on other AF treatments supports the use of all rate and rhythm control options, including cardioversion, pacemaker implantation, and AF catheter ablation without any age discrimination. AF catheter ablation may be an effective and safe option in selected older individuals with success rates comparable to younger patients12431255 and acceptable complication rates.1243,12451247,12491260
Nevertheless, age was a predictor of complications in AF catheter ablation in some studies12611263 and longer follow-up studies suggested an age-related increase in multivariable-adjusted risk for AF/AFL recurrence, death, and major adverse cardiac events.1257
11.14 Patients with cognitive impairment/dementia
Evidence regarding effective prevention of cognitive impairment in
AF is derived mainly from observational studies, suggesting that OAC
could play a protective role in AF patients with stroke risk factors,
not only for stroke prevention but also for prevention of cognitive decline.1264 The quality of anticoagulation with VKAs (i.e. TTR) seems to play an additional role: low TTR and supratherapeutic INR values were associated with higher risk of dementia.1265,1266 Limited evidence suggests that NOACs may be superior to VKA for preventing cognitive impairment in some,1267,1268 but not all, studies.1269 Recent observational data indicate a protective effect of OAC even in lowrisk AF patients who do not need OAC for stroke prevention.1270 A
number of RCTs with cognitive function as an endpoint are ongoing and will provide more insights into the role of anticoagulation
(NOACs and VKAs) for prevention of cognitive impairment in AF.86
Conversely, cognitive impairment can influence treatment adherence,1271,1272 thus affecting outcomes in AF patients. After AF catheter ablation, silent brain lesions are detected by MRI, but this has not led to cognitive impairment in the AXAFAAFNET 5 trial, although underpowered.880
11.15 Atrial fibrillation and congenital heart disease
Survival of patients with congenital heart disease has increased over time, but robust data on the management of AF are missing and available evidence is derived mainly from observational studies and/or extrapolation from large clinical trials.
In patients with AF (or AFL or intra-atrial re-entrant tachycardia)
and congenital heart disease, OAC treatment is recommended for all patients with intracardiac repair, cyanotic congenital heart disease,
Fontan palliation, or systemic right ventricle.1273 Patients with AF and other congenital heart diseases should follow the general risk stratification for OAC use in AF. Notably, NOACs are contraindicated in patients with mechanical heart valves,1165 whereas they seem safe in those with a valvular bioprosthesis.1274,1275
Rate control drugs such as beta-blockers, verapamil, diltiazem, and digitalis can be used with caution due to the risk of bradycardia and hypotension. Rhythm control strategies (i.e. amiodarone) may be effective. In Fontan patients, sodium-channel blockers suppress half of the atrial arrhythmias, but caution is needed for proarrhythmia.
When cardioversion is planned, both 3 weeks of anticoagulation and
TOE may be considered as thrombi are common in patients with congenital heart disease and atrial tachyarrhythmias.1276,1277
In patients with atrial septal defect, closure may be considered before the fourth decade of life to decrease the risk of AF or AFL.1278
Patients with stroke who underwent closure of the patent foramen ovale may have an increased risk of AF,1279 but in patients with patent foramen ovale and AF, closure is not recommended for stroke prevention; and OAC use should be decided using the conventional stroke risk assessment tool. In patients with a history of AF, AF surgery or AF catheter ablation should be considered at the time of
ESC Guidelines
441


<!-- PAGE 70 -->

### Page 70

.............................................................................................................................................................................
closure of the septal defect.12801282 AF catheter ablation of late atrial arrhythmias is likely to be effective after surgical atrial septal defect closure.1283
11.16 Atrial fibrillation in inherited cardiomyopathies and primary arrhythmia syndromes
A higher incidence and prevalence of AF have been described in patients with inherited cardiomyopathies and primary arrhythmia syndromes.12841318 Sometimes AF is the presenting or only clinically overt feature,13191323 is often associated with adverse clinical outcomes,1292,1299,1301,1307,1308,1310,13241329
and has important implications:
• The use of AADs may be challenging. In congenital long QT syndrome, many drugs are contraindicated owing to increased risk of QT prolongation and torsade de pointes (http://www.credible meds.org/); in Brugada syndrome, class I drugs are contraindicated (http://www.brugadadrugs.org/). Owing to its long-term adverse effects, chronic use of amiodarone is problematic in these typically young individuals.
• In patients with an implantable cardioverter defibrillator, AF is a common cause of inappropriate shocks.1307,1311,13301333
Programming a single high-rate ventricular fibrillation zone
>_210 - 220 bpm with long detection time is safe,1295,1296,1334 and is recommended in patients without documented slow monomorphic ventricular tachycardia. Implantation of an atrial lead may be considered in case of significant bradycardia under betablocker treatment.
Supplementary Table 14 summarizes the main clinical features of AF
in patients with inherited cardiac diseases.
Patients with Wolff-Parkinson-White syndrome and AF are at risk of fast ventricular rates resulting from rapid conduction of atrial electrical activity to the ventricles via the accessory pathway, and at increased risk of ventricular fibrillation and sudden death.1335,1336
Electrical cardioversion should be readily available for haemodynamically compromised patients with pre-excited AF, and atrioventricular node-modulating drugs (e.g. verapamil, beta-blockers, digoxin) should be avoided.1337,1338 Pharmacological cardioversion can be attempted using ibutilide,1339 whereas AADs class Ia (procainamide) and Ic
(propafenone, flecainide) should be used with caution owing to their effect on the atrioventricular node.13401343 Amiodarone may not be safe in pre-excited AF as it may enhance pathway conduction.1343
11.17 Atrial fibrillation during pregnancy
AF is one of the most frequent arrhythmias during pregnancy,1344
especially in women with congenital heart disease1345,1346 and in older gravidae,1344,1347,1348 and is associated with increased risk of death.1344 Rapid atrioventricular conduction may have serious haemodynamic consequences for mother and foetus.
Pregnancy is associated with a hypercoagulable state and increased thrombo-embolic risk. Given the lack of specific data, the same rules for stroke risk assessment should be used as in non-pregnant women.1349 Detailed practical recommendations on oral and parenteral anticoagulation regimens depending on the pregnancy trimester,
such as low- and high-dose VKA use during the second and third trimesters, timing of low-molecular-weight heparin (LMWH) to unfractionated heparin (UFH) relative delivery, and control of therapeutic effects are given in the recent ESC Pregnancy Guidelines.1349
Immediate anticoagulation is required in clinically significant mitral stenosis, using LMWH at therapeutic doses in the first and last trimesters, and VKA with the usual INR targets or LMWH for the second trimester. Use of NOACs is prohibited during pregnancy.
Vaginal delivery should be advised for most women but is contraindicated while the mother is on VKAs because of the risk of foetal intracranial bleeding.1349
Intravenous beta-blockers are recommended for acute rate control.
Beta-1 selective blockers (e.g. metoprolol and bisoprolol) are generally safe and are recommended as the first choice.1349 If beta-blockers fail,
digoxin and verapamil should be considered for rate control.
Rhythm control should be considered the preferred strategy during pregnancy. Electrical cardioversion is recommended if there is haemodynamic instability or considerable risk for mother or foetus.
It can be performed safely without compromising foetal blood flow1350 and the consequent risk for foetal arrhythmias or preterm
Recommendations for the management of AF in patients with congenital heart disease
Recommendations
Classa
Levelb
• Oral anticoagulation should be considered in all adult patients with intracardiac repair, cyanosis, Fontan palliation, or systemic right ventricle and a history of AF, AFL, or intra-atrial re-entrant tachycardia.1273
• In patients with AF and other congenital heart diseases, anticoagulation should be considered in the presence of one or more non-sex stroke risk factor(s).1273
IIa
C
Surgery for AF should be considered in patients:
• Who need surgical closure of an atrial septal defect and who have a history of symptomatic atrial arrhythmia (atrial ablation should be considered at the time of surgical closure).12801282
• Cox maze surgery should be considered in patients with symptomatic AF and an indication for corrective repair of congenital heart defects. The surgery should be done in experienced centres.12801282
IIa
C
AF catheter ablation of atrial arrhythmias associated with congenital heart defects may be considered when performed in experienced centres.1283
IIb
C
In patients with congenital heart disease, TOE
may be considered together with 3-week anticoagulation therapy before cardioversion.1292,1293
IIb
C
AF
=
atrial
ﬁbrillation;
AFL
=
atrial
ﬂutter;
TOE
=
transoesophageal echocardiography.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 71 -->

### Page 71

......................................................................
labour is low.1351,1352 The fetal heart rate should routinely be controlled after cardioversion.1353 Cardioversion should generally be preceded by anticoagulation (section 10.2.2.6).1349 In haemodynamically stable patients without structural heart disease, i.v. ibutilide or flecainide may be considered for termination of AF but experience is limited.1354,1355 Flecainide, propafenone, or sotalol should be considered to prevent AF if atrioventricular nodal-blocking drugs fail. AF
catheter ablation has no role during pregnancy.
11.18 Atrial fibrillation in professional athletes
Moderate physical activity improves cardiovascular health and prevents AF, whereas intense sports activity increases the risk of
AF.35,1357 Athletes have an approximate five-fold increased lifetime risk of AF compared with sedentary individuals despite a lower prevalence of conventional AF risk factors.35,1020 Risk factors for AF
in athletes include male sex, middle age, endurance sports, tall stature,
and total lifetime exercise dose exceeding
1500 - 2000 hours.1020,13581361 Endurance sports such as running,
cycling, and cross-country skiing35,1362 carry the highest risk.
In the absence of RCTs, recommendations for AF management in athletes are based largely on evidence in non-athletes, observational data, and expert consensus.143 The need for anticoagulation is determined by clinical risk factors. Sports with direct bodily contact or prone to trauma should be avoided in patients on OAC. As athletes have a high prevalence of sinus bradycardia and sinus pauses, medical therapy is frequently contraindicated or poorly tolerated.1021,1363
Digoxin and verapamil are often ineffective for rate control during exertional AF, whereas beta-blockers may not be well tolerated or are sometimes prohibited. Pill-in-the-pocket therapy has been used,
but sports activity should be avoided after ingestion of flecainide or propafenone until AF ceases and two half-lives of the drug have elapsed.586 AF catheter ablation is often preferred by athletes and was similarly efficacious in both the athletic and non-athletic populations in small studies.1364,1365
11.19 Postoperative atrial fibrillation
Perioperative AF describes the onset of the arrhythmia during an ongoing intervention. This is most relevant in patients undergoing cardiac surgery. While multiple strategies to reduce the incidence of perioperative AF with pretreatment or acute drug treatment have been described, there is lack of evidence from large RCTs.
Amiodarone is the most frequently used drug for prevention of perioperative AF.1369
Postoperative AF, defined as new-onset AF in the immediate postoperative period, is a clinically relevant problem,1370,1371 occurring in
20 - 50% of patients after cardiac surgery,1372,1373 10- 30% after noncardiac thoracic surgery,1374 and in 5 - 10% after vascular or large colorectal surgery,1375 with peak incidence between postoperative day
2 and 4.1376 Intra- and postoperative changes affecting AF triggers and pre-existing atrial substrate may increase atrial vulnerability to
AF. Many episodes of postoperative AF are self-terminating and some are asymptomatic, but postoperative AF has been associated with a four- to five-fold risk of recurrent AF in the next 5
years.1377,1378 It has also been shown to be a risk factor for stroke,
Recommendations for the management of AF during pregnancy
Recommendations
Classa
Levelb
Acute management
Immediate electrical cardioversionc is recommended in case of haemodynamic instability or pre-excited AF.1350,1351,1354
I
C
In pregnant women with HCM, cardioversionc should be considered for persistent AF.882
IIa
C
Ibutilide or ﬂecainide i.v. may be considered for termination of AF in stable patients with structurally normal hearts.1355
IIb
C
Long-term management (oral administration of drugs)
Therapeutic anticoagulation with heparin or
VKA according to the stage of pregnancy is recommended for patients with AF.1349
I
C
Beta-selective blockers are recommended for rate control in AF.d
I
C
Flecainide,e propafenone,e or sotalolf should be considered to prevent AF if atrioventricular nodal-blocking drugsf fail.
IIa
C
Digoxing or verapamilg should be considered for rate control if beta-blockers fail.
IIa
C
AF = atrial ﬁbrillation; ECG = electrocardiogram; US FDA = United States Food and Drug Administration; i.v. = intravenous; LV = left ventricular; HCM = hypertrophic cardiomyopathy; QTc = corrected QT interval; VKA = vitamin K
antagonist.
aClass of recommendation.
bLevel of evidence.
cCardioversion of AF should generally be preceded by anticoagulation.
dAtenolol has been associated with higher rates of foetal growth retardation and is not recommended.1356
eFlecainide and propafenone should be combined with atrioventricular nodalblocking drugs, but structural heart disease, reduced LV function, and bundle branch block should be excluded.
fClass III drugs should not be used in prolonged QTc.
gAtrioventricular nodal-blocking drugs should not be used in patients with preexcitation on resting ECG or pre-excited AF.
Note that the former A to X categories of drugs—the classiﬁcation system for counselling of pregnant women requiring drug therapy—was replaced by the
Pregnancy and Lactation Labelling Rule, which provides a descriptive risk summary and detailed information on animal and clinical data, by the US FDA in June
2015.
Recommendations for sports activity in patients with
AF
Recommendation
Classa
Levelb
It is recommended to counsel professional athletes that long-lasting intense sports participation may promote AF, while moderate physical activity is recommended to prevent
AF.35,38,1020,1360,13661368
I
B
AF = atrial ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
443


<!-- PAGE 72 -->

### Page 72

............................................................................
myocardial infarction, and death compared with non-postoperative
AF patients.1379,1380
Other adverse consequences of postoperative AF include haemodynamic instability, prolonged hospital stay, infections, renal complications, bleeding, increased in-hospital death, and greater healthcare costs.1371,1381,1382 Management of postoperative AF is shown in
Figure 23.
11.19.1
Prevention of postoperative AF
Preoperative beta-blocker (propranolol, carvedilol plus N-acetyl cysteine) use in cardiac and non-cardiac surgery is associated with a reduced incidence of postoperative AF,13831386 but not major adverse events such as death, stroke, or acute kidney injury.1387
Notably, in non-cardiac surgery, perioperative metoprolol was associated with increased risk of death in a large RCT.1388 In a metaanalysis, amiodarone (oral or i.v.), and beta-blockers were equally effective in reducing postoperative AF,1389 but their combination was better than beta-blockers alone.1390 Lower cumulative doses of amiodarone (<3000 mg) could be effective, with fewer adverse events.13911393 Data for other interventions such as statins974,,1394 magnesium,1395
sotalol,1385
colchicine,1396
posterior pericardiotomy,1397,1398 (bi)atrial pacing,1385 and corticosteroids1399
are not robust. Two large RCTs showed no significant effect of i.v.
steroids on the incidence of postoperative AF after cardiac surgery,1400,1401 and colchicine is currently being investigated in the prevention of postoperative AF [COP-AF (Colchicine For The
Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing
Thoracic Surgery): NCT03310125].
11.19.2
Prevention of thrombo-embolic events
In a large meta-analysis, patients with postoperative AF had a 62%
higher odds of early and 37% higher risk of long-term stroke compared with those without postoperative AF (>_1-year stroke rates were 2.4% vs. 0.4%, respectively), as well as 44% higher odds of early and 37% higher risk of long-term mortality; long-term stroke risk was substantially higher with non-cardiac than cardiac postoperative AF
(HR 2.00; 95% CI 1.702.35 for non-cardiac vs. HR 1.20; 95% CI
1.071.34 for cardiac postoperative AF; P for subgroup difference
<0.0001).1379
Nevertheless, the evidence on OAC effects in patients with postoperative AF is not very robust.1382,14021407 Observational data1408
suggest that although coronary artery bypass graft-related postoperative AF might not be equivalent to non-surgery AF regarding the long-term risk of adverse outcomes, OAC use during follow-up was associated with a significantly lower risk of thrombo-embolic events in both postoperative AF and non-surgery AF compared with no
OAC.1408 Reportedly, postoperative AF occurring after non-cardiac surgery was associated with a similar long-term thrombo-embolic risk to non-surgery AF, and OAC therapy was associated with comparably lower risk of thrombo-embolic events and all-cause death in
©ESC 2020
Figure 23 Management of postoperative AF. AAD = antiarrhythmic drug; bpm = beats per minute; CCB = calcium channel blocker; ECV = electrical cardioversion; LVEF = left ventricular ejection fraction; Mg2þ magnesium; OAC = oral anticoagulation; PCV = pharmacological cardioversion;
PUFA=polyunsaturated fatty acid.


<!-- PAGE 73 -->

### Page 73

.............................................................................................................................................................................
both groups.1409 Ongoing RCTs in cardiac [PACES (Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG);
NCT04045665] and non-cardiac (ASPIRE-AF; NCT03968393) surgery will inform optimal long-term OAC use among patients developing postoperative AF.
In haemodynamically unstable patients with postoperative AF,
emergency electrical cardioversion (or i.v. administration of amiodarone1385 or vernakalant,583 if consistent with the clinical situation) is indicated. In a recent RCT of postoperative AF patients after cardiac surgery, neither rate nor rhythm control showed net clinical advantage over each other.1373 Hence, rate or rhythm control treatment decisions should be based on symptoms, and non-emergency cardioversion should follow the principles of peri-cardioversion anticoagulation outlined in section 10.2.
12 Prevention of atrial fibrillation
12.1 Primary prevention of atrial fibrillation
Primary prevention of AF refers to the implementation of preventive measures in patients at risk but without previous documentation of
AF. This strategy relies on the identification and management of risk factors and comorbidities predisposing to AF, before the development of atrial remodelling and fibrosis964,.1411 Upstream therapy refers to the use of non-AADs that modify the atrial substrate or target-specific mechanisms of AF to prevent the occurrence or recurrence of the arrhythmia. The key targets of upstream therapy are structural changes in the atria (e.g. fibrosis, hypertrophy, inflammation, oxidative stress), but effects on atrial ion channels, gap junctions, and calcium handling are also evident.964
Adequate management of hypertension and HF may prevent AF
by reducing atrial stretch, but inhibition of the renin-angiotensinaldosterone system may exert an additional protective role by suppressing electrical and structural cardiac remodelling.964,1411,1412
Large RCTs and meta-analyses have yielded equivocal results, either in favour14131416 or against14171421 statin use for primary prevention of AF. Controversial results have also been reported for the effects of fish oils on primary prevention of AF.1422
For primary prevention of postoperative AF after cardiac and noncardiac surgery, see section 11.19.
12.2 Secondary prevention of atrial fibrillation
For secondary AF prevention see section 11.3 and Supplementary section 12.
13 Sex-related differences in atrial fibrillation
Female patients are generally under-represented in RCTs, including
AF trials. Sex-related differences in the epidemiology, pathophysiology, clinical presentation, and prognosis of AF that are consistently reported19,107,124,1423,1424 may influence the effectiveness of AF treatment, and hence should be considered in a personalized, individual patient-centred approach to AF management in clinical practice.1425
Understanding the underlying pathophysiological mechanisms and biology may help to improve personalized treatments. Adequate representation of women in future AF trials is recommended, as well as the identification and resolution of sex-specific barriers to implementation of guideline-recommended treatments for AF.
Women presenting with AF are older, have a higher prevalence of hypertension, VHD, and HFpEF, and a lower prevalence of CAD
compared with men. Women with AF are more often symptomatic than men with AF, with greater symptom severity.1423,1426
Female sex is a stroke risk modifier that increases the risk of AFassociated stroke in the presence of other stroke risk factors.353
Women with AF have a greater stroke severity and permanent disability than men with AF.1427 Anticoagulation with warfarin may be less well controlled in women, and they have a greater residual stroke risk even with well-controlled VKAs.1428 The efficacy and safety of
NOACs in landmark RCTs were consistent in both sexes, but women were largely under-represented.423
In women with AF, the use of AADs for rhythm control is associated with significantly higher rates of life-threatening adverse events
(e.g. acquired long QT syndrome with class Ia or III AADs)1429,1430 or sinus-node disease/bradyarrhythmia requiring pacemaker implantation19 compared with male patients. Women with AF are less likely to undergo electrical cardioversion,1426 and are referred for AF catheter ablation later than men, possibly reflecting AF occurrence later in life among women.107,1431,1432 The result of PVI may be less favourable in women,1431,1432 with higher rates of procedure-related complications.1431 Women are more likely to undergo atrioventricular nodal ablation for AF than men.124 Sex-specific data on cardiovascular risk management in women with AF are lacking. Principles outlined in section 11.3 apply to women with AF.
Recommendations for postoperative AF
Recommendations
Classa
Levelb
Perioperative amiodarone or beta blocker therapy is recommended for the prevention of postoperative AF after cardiac surgery.1390,1492
I
A
Long-term OAC therapy to prevent thromboembolic events should be considered in patients at risk for stroke with postoperative AF after non-cardiac surgery, considering the anticipated net clinical beneﬁt of OAC therapy and informed patient preferences.1404,1405,1408,1409
IIa
B
Long-term OAC therapy to prevent thromboembolic events may be considered in patients at risk for stroke with postoperative AF after cardiac surgery, considering the anticipated net clinical beneﬁt of OAC therapy and informed patient preferences.1404,1405,1408,1409
IIb
B
Beta-blockers should not be used routinely for the prevention of postoperative AF in patients undergoing non-cardiac surgery.1410
III
B
AF = atrial ﬁbrillation; OAC = oral anticoagulant.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
445


<!-- PAGE 74 -->

### Page 74

............................................
14 Implementation of the atrial fibrillation guidelines
Guideline-adherent care (i.e. the implementation of guidelinerecommended management to individual AF patients) aims to improve patient outcomes and reduce healthcare costs,1238,1434,1435
but adherence to guidelines is modest worldwide.124,14361439,1440,1441
Reportedly,
the adoption of
NOACs as first-line therapy has been associated with increasing guideline-adherent stroke prevention.1442,1443
Guideline non-adherence is multifactorial,1215,1444,1445 including physician/healthcare professional- and healthcare system-related factors.1446 Integrated AF management may facilitate adherence to guidelines. Various educational interventions280,284,290,1447,1448 based on guideline-provided recommendations284 and tailored to close specific knowledge gaps among healthcare professionals and/or AF
patients1446 may facilitate the implementation of guideline-based AF
management to improve patient outcomes.277,14491452 Further research is needed to identify the cost-effective intervention type(s)
that would more effectively improve patient clinical outcomes, medication adherence, and QoL.
15 Quality measures and clinical performance indicators in the management of atrial fibrillation
Measurable service quality has been identified as a cornerstone for optimal AF management and is a mandatory step towards valuebased healthcare. Quality and performance indicator sets should provide practitioners and institutions with the tools to measure the quality of care (e.g. adherence to guideline class I recommendations upon discharge/end of visit, complications after procedures, access/waiting list times) and identify opportunities for improvement. They should capture important aspects of care quality, including structure, process, outcome measures, and patient-centrednes, while the reporting burden for hospitals, practices, and practitioners should be kept to a minimum.658,14531455
A collaborative effort involving the ESC, EHRA, Asia Pacific Heart
Rhythm Society, Heart Rhythm Society, and Latin American Heart
Rhythm Society was put in place to develop quality indicators for the diagnosis and management of AF; a summary form of these quality indicators is provided in Table 22, with the full set published separately.317 The ESC quality indicators are intended for quality improvement and performance measurement through meaningful surveillance, as well as for integration within registries that specifically aim to identify areas for improvement in clinical practice and are not intended for ranking healthcare professionals/providers or payment incentives.
16 Epidemiology, clinical implications, and management of atrial high-rate episodes/
subclinical atrial fibrillation
The incidence of AHRE/subclinical AF in patients with a pacemaker/
implanted device is 3070%, but it may be lower in the general population.1458 Very short episodes (<_10- 20 s/day) are considered clinically irrelevant, as they are not significantly associated with longer episodes or an increased risk of stroke or systemic embolism.1459
However, longer episodes of AHRE/subclinical AF (minimum of 5 - 6
min) are associated with an increased risk of clinical AF,467,469 ischaemic stroke,168,467 major adverse cardiovascular events,1460 and cardiovascular death.1461
Overall, the absolute risk of stroke associated with AHRE/subclinical AF may be lower than with clinical AF.160,168,226,467 The temporal dissociation from acute stroke suggests that AHRE/subclinical AF
may represent a marker rather than a risk factor for stroke4,7,1462
(Supplementary Box 6).
Whereas current data were obtained mostly from pacemakers/
implantable cardioverter defibrillators or post-stroke patients,
AHRE/subclinical AF is increasingly reported in a variety of patients undergoing cardiac monitoring. Clinical AF will reportedly develop in
1 in 5 - 6 of patients within 2.5 years after diagnosing AHRE/subclinical AF.168 Notwithstanding that more high-quality evidence is needed to inform optimal management of these patients, more intense
Recommendations pertaining to sex-related differences in AF
Recommendation
Classa
Levelb
It is recommended that women and men with
AF are equally offered diagnostic assessment and therapies to prevent stroke and other AFrelated complications.423,1433
I
A
Women with symptomatic paroxysmal or persistent AF should be offered timely access to rhythm control therapies, including AF catheter ablation, when appropriate for medical reasons.1448,1451
IIa
B
AF = atrial ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
Recommendations for quality measures in patients with
AF
Recommendations
Classa
Levelb
The introduction of tools to measure quality of care and identify opportunities for improved treatment quality and AF patient outcome should be considered by practitioners and institutions.317
IIa
B
AF = atrial ﬁbrillation.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 75 -->

### Page 75

..................
follow-up and monitoring to detect clinical AF early is prudent (preferably with the support of remote monitoring). Notably, the AHRE/
subclinical AF burden is not static but may change on daily basis,469
hence should be regularly reassessed—the greater the AHRE/subclinical AF burden at diagnosis, the higher the risk of subsequent progression to longer episodes469 (Figure 24).
Whereas available evidence is insufficient to justify routine OAC
use in patients with AHRE/subclinical AF, modifiable stroke risk factors should be identified and managed in each patient.
The use of OAC may be considered in selected patients with longer durations of AHRE/subclinical AF (>_24 h) and an estimated high individual risk of stroke,4,1462 accounting for the anticipated net
Table 22
Summary of quality indicators for the diagnosis and management of AF
Domain: Patient assessment (at baseline and follow-up)
Main quality indicator: CHA2DS2-VASc cardioembolic risk assessment.
Main quality indicator: bleeding risk assessment using a validated method such as the HAS-BLED score.
Numerator: Number of AF patients who have their respective score documented at the time of diagnosis and at every follow-up appointment.
Denominator: Number of AF patients.
Domain: Anticoagulation
Main quality indicator: inappropriate prescription of anticoagulation to patients with a CHA2DS2-VASc score of 0 for men and 1 for women.
Numerator: number of AF patients with CHA2DS2-VASc score of 0 for men and 1 for women, who are inappropriately prescribed anticoagulation.
Denominator: number of AF patients with CHA2DS2-VASc score of 0 for men and 1 for women who do not have other indication for anticoagulation.
Main quality indicator: proportion of patients with a CHA2DS2-VASc score of >_1 for men and >_2 for women who are prescribed anticoagulation.
Numerator: Number of AF patients with CHA2DS2-VASc score of >_1 for men and >_2 for women who are prescribed anticoagulation.
Denominator: Number of AF patients with CHA2DS2-VASc score of >_1 for men and >_2 for women who are eligible for anticoagulation with no contraindication or refusal.
Domain: rate control
Main quality indicator: inappropriate prescription of AADsa to patients with permanent AF (i.e. where no attempt to restore sinus rhythm is planned).
Numerator: Number of patients with permanent AF who are prescribed one or more AADsa for rhythm control.
Denominator: Number of patients with permanent AF.
Domain: rhythm control
Main quality indicator: inappropriate prescription of class IC AADs to patients with structural heart disease.
Numerator: number of AF patients with structural heart disease who are inappropriately prescribed class IC AADs.
Denominator: number of AF patients with structural heart disease.
Main quality indicator: proportion of patients with symptomatic paroxysmal or persistent AF who are offered AF catheter ablation after failure of/intolerance to one class I or class III AAD.
Numerator: Number of patients with paroxysmal or persistent AF who are offered catheter ablation after the failure of, or intolerance to, at least one class I
or class III AAD.
Denominator: Number of patients with paroxysmal or persistent AF with no contraindications (or refusal) to catheter ablation who remain symptomatic on,
or intolerant to at least one class I or class III AAD.
Domain: risk factor management
Main quality indicator: Proportion of patients who have their modiﬁable risk factors identiﬁed.
Numerator: number of AF patients who have their modiﬁable risk factors (e.g. BP, obesity, OSA, alcohol excess, lack of exercise, poor glycaemic control and smoking) identiﬁed
Denominator: number of AF patients.
Domain: outcomes
Main quality indicator: ischaemic stroke or TIA.
Main quality indicator: life-threatening or major bleeding events.b
Numerator: number of AF patients who have a documented ischaemic or bleeding event
Denominator: number of AF patients or number of patients prescribed an OAC, respectively.
AAD = antiarrhythmic drug; AF = atrial ﬁbrillation; BP = blood pressure; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke,
Vascular disease, Age 65-74 years, Sex category (female); HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR,
Elderly (>65 years), Drugs/alcohol concomitantly; OAC = oral anticoagulant; OSA = obstructive sleep apnoea; TIA = transient ischaemic attack.
aFlecainide, propafenone, amiodarone, dronedarone, sotalol and disopyramide.
bUsing the deﬁnitions of the International Society of Thrombosis and Haemostasis.1456,1457
ESC Guidelines
447


<!-- PAGE 76 -->

### Page 76

............
clinical benefit and informed patient’s preferences (Figures 24 and 25).
In the recent trials, OAC was initiated in 76.4% and 56.3% of patients with >_2 clinical stroke risk factors and insertable cardiac monitordetected physician-confirmed AF>_6 min, but follow-up bleeding rates were not reported.1463,1464 In a large retrospective cohort study using remote monitoring data about daily AF burden, there was large practice variation in OAC initiation. Across increasing AF burden strata (from >6 min to >24 h) the risk of stroke in untreated
©ESC 2020
Figure 25 Proposed management of AHRE/subclinical AF. AF = atrial fibrillation; AHRE = atrial high-rate episode; CKD = chronic kidney disease;
CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65- 74 years, Sex category
(female); f = female; LA = left atrium; LoE = level of evidence; m = male; OAC = oral anticoagulant; SCAF = subclinical atrial fibrillation. aHighly selected patients (e.g. with previous stroke and/or age >_75 years, or >_3 CHA2DS2-VASc risk factors, and additional non-CHA2DS2-VASc stroke factors such as
CKD, elevated blood biomarkers, spontaneous echo contrast in dilated LA, etc); selected patients (e.g. with previous stroke and/or age >_75 years, or >_3
CHA2DS2-VASc risk factors , etc).
©ESC 2020
Figure 24 Progression of atrial high-rate episode burden (left panel) and stroke rates according to AHRE daily burden and CHA2DS2-VASc score (right panel). AHRE = atrial high-rate episodes; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65- 74 years, Sex category (female); OAC = oral anticoagulant. aThe higher the burden at diagnosis, the greater the incidence of progression in the next 6 months and thereafter. bStroke rates above the threshold for OAC are shown in red.


<!-- PAGE 77 -->

### Page 77

.............................................................................................................................................................................
patients increased numerically, and the strongest association of OAC
with reduction in stroke was observed among patients with devicedetected AF episodes of >24 h.5
17 Atrial fibrillation and other atrial tachyarrhythmias (atrial flutter and atrial tachycardias)
Although AFL may exist as a solitary atrial arrhythmia, a significant proportion of patients will subsequently develop AF.14661470
Typical AFL may occur in those taking class IC AADs or amiodarone.1467,1468,1471 The ABC pathway for integrated AF management largely applies to patients with AFL. It is recommended that strokeprevention strategies in patients with solitary AFL, including periprocedural management of stroke risk, follow the same principles as in patients with AF.1472
Rate control should be the first step in symptom management.
However, cardioversion to sinus rhythm may be more effective,
especially electrical cardioversion or (where feasible) high-rate stimulation.1473,1474 Of note, the class III AADs dofetilide and ibutilide i.v.
are very effective in interrupting AFL, whereas the class Ic drugs flecainide and propafenone14751478 should not be used in the absence of atrioventricular-blocking drugs as they may slow the atrial rate,
thus facilitating 1 : 1 atrioventricular conduction with a rapid ventricular rate.1479,1480 AF catheter ablation of the CTI is the most effective rhythm control treatment for CTI-dependent AFL.732,1481,1482 When typical AFL develops in AF patients during treatment with class Ic drugs or amiodarone, CTI ablation should be considered to ensure that AADs can be continued for AF rhythm control.732,1481
Atypical AFL (i.e. macro re-entrant atrial tachycardia) most commonly occurs in diseased or scarred atrial myocardium. Clinical management of atypical AFL/macro re-entrant atrial tachycardia broadly follows the principles of typical AFL management, but the use of AADs is often limited by significant structural heart disease,
and ablation is more complex.1336
Notably, the intervention to treat atrial tachycardias (AFL/macro re-entrant atrial tachycardia) occurring early after AF catheter ablation (or surgery) should be delayed, and initial rate control or the use of AADs should be considered instead, as some of these tachyarrhythmias are transient and cease after maturation of the lesions deployed by the index procedure.14831485 For additional details about AFL, see Supplementary Box 7 and the 2019 ESC Guidelines on supraventricular tachycardias.1336
18 Key messages
(1)
The diagnosis of AF needs to be confirmed by a conventional 12lead ECG tracing or rhythm strip showing AF for >_30 s.
(2)
Structured characterization of AF, including stroke risk, symptom severity, severity of AF burden, and AF substrate, helps improve personalized treatment of AF patients.
(3)
Novel tools and technologies for screening and detection of AF
such as (micro-)implants and wearables substantially add to the diagnostic opportunities in patients at risk for AF. However,
appropriate management pathways based on such tools are still incompletely defined.
(4)
Integrated holistic management of AF patients is essential to improving their outcomes.
(5)
Patient values need to be considered in treatment decision making and incorporated into the AF management pathways; the structured assessment of PRO measures is an important element to document and measure treatment success.
(6)
The ABC pathway streamlines integrated care of AF patients across healthcare levels and among different specialties.
(7)
Structured, clinical, risk-score-based assessment of individual thrombo-embolic risk, using the CHA2DS2-VASc score, should be performed as the first step in optimal thrombo-embolic risk management in AF patients.
(8)
Patients with AF and risk factors for stroke need to be treated with OAC for stroke prevention. In NOAC-eligible patients,
NOACs are preferred over VKAs.
(9)
A formal structured risk-score-based bleeding risk assessment using,
for example, the HAS-BLED score, helps to identify non-modifiable and address modifiable bleeding risk factors in AF patients.
(10)
An elevated bleeding risk should not automatically lead to withholding OAC in patients with AF and stroke risk. Instead, modifiable bleeding risk factors should be addressed, and high-risk patients scheduled for a more frequent clinical review and follow-up.
(11)
Rate control is an integral part of AF management and is often sufficient to improve AF-related symptoms.
(12)
The primary indication for rhythm control using cardioversion,
AADs, and/or catheter ablation is reduction in AF-related symptoms and improvement of QoL.
(13)
The decision to initiate long-term AAD therapy needs to balance symptom burden, possible adverse drug reactions, particularly drug-induced proarrhythmia or extracardiac side-effects, and patient preferences.
Recommendations for management of patients with
AHRE
Recommendations
Classa
Levelb
In patients with AHRE/subclinical AF detected by
CIED or insertable cardiac monitor, it is recommended to conduct:
• Complete cardiovascular evaluation with ECG
recording, clinical risk factors/comorbidity evaluation, and thrombo-embolic risk assessment using the CHA2DS2-VASc score.469
• Continued patient follow-up and monitoring
(preferably with the support of remote monitoring) to detect progression to clinical AF,
monitor the AHRE/subclinical AF burden
(especially transition to >_24 h), and detect changes in underlying clinical conditions.469
I
B
AF = atrial ﬁbrillation; AHRE = atrial high-rate episode; CIED = cardiac implantable electronic device; ECG = electrocardiogram.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
449


<!-- PAGE 78 -->

### Page 78

.............................................................................................................................................................................
(14)
Catheter ablation is a well-established treatment for prevention of
AF recurrences. When performed by appropriately trained operators, catheter ablation is a safe and superior alternative to AADs for maintenance of sinus rhythm and symptom improvement.
(15)
Major risk factors for AF recurrence should be assessed and considered in the decision making for interventional therapy.
(16)
In patients with AF and normal LVEF, catheter ablation has not been shown to reduce total mortality or stroke. In patients with
AF and tachycardia-induced cardiomyopathy, catheter ablation reverses LV dysfunction in most cases.
(17)
Weight loss, strict control of risk factors, and avoidance of triggers for
AF are important strategies to improve outcome of rhythm control.
(18)
Identification and management of risk factors and concomitant diseases is an integral part of the treatment of AF patients.
(19)
In AF patients with ACS undergoing uncomplicated PCI, an early discontinuation of aspirin and switch to dual antithrombotic therapy with OAC and a P2Y12 inhibitor should be considered.
(20)
Patients with AHRE should be regularly monitored for progression to clinical AF and changes in the individual thrombo-embolic risk
(i.e. change in CHA2DS2-VASc score). In patients with longer
AHRE (especially >24 h) and a high CHA2DS2-VASc score, it is reasonable to consider the use of OAC when a positive net clinical benefit from OAC is anticipated in a shared, informed, treatment decision-making process.
19 Gaps in evidence
Whereas some progress has been made since publication of the 2016
ESC AF Guidelines, major gaps identified in those guidelines persist in
2020, calling for more intense research. In 2019, the EHRA published a white paper that covers major gaps in the field of AF in detail.1486 The following bullet-list gives the most important knowledge gaps:
h Major health modifiers causing atrial fibrillation
Mechanisms of AF are not yet fully understood. Improvement in understanding of these mechanisms in individual patients, e.g. patients with cardiac structural remodelling or HF, would allow better selection of treatments including the best rate and rhythm control strategies and OAC.
It is uncertain how educational interventions translate into actual behavioural change (patients and physicians) that leads to improvements in clinical management and outcomes, especially in the multimorbid AF patient.
h Implementation of digital technologies for screening,
diagnosis, and risk stratification in the atrial fibrillation patient
New techniques for digital ECG analysis (e.g. machine learning and artificial intelligence) and new technologies (e.g. wearables and injectables) have opened up potentially significant opportunities for the detection and diagnosis of AF. These innovations may help to personalize therapy and risk stratification. Studies are needed to evaluate such opportunities and to define for which groups of patients this is worthwhile.
h Type of atrial fibrillation
There is a gap in knowledge regarding classification of AF. Recent data suggest that paroxysmal AF is not one entity. According to the pattern, type of therapy and outcome may differ.1487 More studies are needed.
h How much atrial fibrillation constitutes a mandate for therapy?
The threshold of AF burden at which to initiate OAC therapy needs to be defined more clearly. This knowledge gap has resulted in substantial variation in physician attitudes and practice patterns.5
We are still waiting for the results of two ongoing RCTs in subclinical
AF patients who are detected with cardiac implantable electronic device
(CIED) [(Apixaban for the Reduction of Thrombo-Embolism in Patients
With
Device-Detected
Sub-Clinical
Atrial
Fibrillation)
(NCT
01938248) and NOAH (Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) (NCT 02618577)].
h Role of biomarkers in atrial fibrillation management
Although some studies have demonstrated an effective role of biomarkers (including natriuretic peptides and troponin) in AF risk assessment, there is uncertainty over the exact time point of biomarker assessment, optimal cut-offs, and the effect on management decision making based on changes in biomarker levels over time,
especially with increasing age and incident comorbidities.
h Stroke risk in specific populations
Some studies have tested the effect of biomarkers in predicting risk of AF-related complications, including stroke, in specific populations.
However, it is unknown if biomarkers and biomarker-based scores practically help physicians in refining stroke risk, especially in prospective non-anticoagulated cohorts, particularly given the dynamic nature of stroke risk and how many current biomarkers are nonspecific for AF or AF-related outcomes.
There is uncertainty of actual stroke risk in AHRE, compared with actual stroke risk in overt AF, in properly matched cohorts in similar settings, and the effect of appropriate management pathways.
The effect of sex in AF patients has been more investigated. Men with AF are less likely to have hypertension or VHD vs. women.1488
Women often present with atypical symptoms related to AF. Further comparative studies are needed in different settings and ethnic groups on the effect of different stroke risk factors and female sex on stroke and bleeding risks.
h Anticoagulant therapy in specific patients
There is a gap in knowledge regarding optimal NOAC dosing in specific groups, including those with mild-to-moderate CKD, with very low/high body mass index, and patients receiving medications with a high risk of metabolic interaction.1489
In patients with CrCl <_25 mL/min, RCT-derived data on the effect of
VKA or NOACs is still lacking, due to the exclusion of these patients from the major RCTs. However, two RCTs (NCT02933697,
NCT03987711) are currently assessing OAC use and comparing
NOACs with VKAs in patients with end-stage renal disease.
h Anticoagulation in patients with heart valve diseases
There are gaps in evidence on NOAC use in AF patients with rheumatic mitral valve disease and during the first 3 months after surgical or transcatheter implantation of a bioprosthesis; observational data regarding the use of NOACs after transcatheter aortic valve implantation are conflicting.1163
h Anticoagulation in atrial fibrillation patients after a bleeding or stroke event
As high-quality RCT-derived evidence to inform optimal timing of anticoagulation after acute ischaemic stroke is lacking, OAC use in the early post-stroke period is currently based on expert consensus.
Several ongoing
RCTs
[ELAN
(NCT03148457),
OPTIMAS


<!-- PAGE 79 -->

### Page 79

©ESC 2020
1. Identify l f
ow-risk patients
CHA2DS2-V
- A
V Sc 0(m), 1(f)
CHA2DS2VA
V Sc ≥1(m), 2(f)
Assess bleeding risk, address
3. Choose OAC (NOAC or VKA
with well-managed TTR)
R
Assess symptoms,
QoL and patient’s prefef rences
Optimize rate control
Consider a rhythm control strategy
Comorbidities and cardiovascular risk 
faf ctors
Lifef style changes
(obesi
(
ty reduction,
regular exercise,
reduction of alcohol use,
etc.)
Treat AF: The ABC pathway
A
Anticoagulation/
Avoid stroke
B
Better symptom control
C
Comorbidities/
Cardiovascular 
risk factor management
Symptom severity (Sy)
(e.g., EHRA symptom score)
Severity of AF burden (Sb)
(duration, spontaneous termination)
Stroke risk (St)
(e.g., CHA2DS2-VASc score)
Substrate severity (Su)
(age, comorbidities,
C
CC To ABC
Characterise AF (the 4S-AF scheme)
A 12-lead ECG or a rhythm strip showing AF pattern for ≥30 s
(CV, AADs, ablation)
Central Illustration Management of AF. AAD = antiarrhythmic drug; AF = atrial fibrillation; ECG = electrocardiogram; EHRA = European Heart
Rhythm Association; CHA2DS2-VASc = Congestive HF, Hypertension, Age >_75 years, diabetes mellitus, Stroke, Vascular disease, Age 65- 74 years, Sex category (female); CV = cardioversion; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; TTR = time in therapeutic range;
VKA = vitamin K antagonist.
ESC Guidelines
451


<!-- PAGE 80 -->

### Page 80

..................................................................................................................
(EudraCT, 2018-003859-3), TIMING (NCT02961348), and START
(NCT03021928)] will try to assess the differences between the two approaches, including early (<1 week) vs. late NOAC initiation in patients with AF-related ischaemic stroke.
h Left atrial appendage occlusion for stroke prevention
More studies have been conducted in this field. There is clearer evidence of the safety and possible complications of the LAA closure procedure.450454 However, there are still knowledge gaps to be addressed: (i) antithrombotic management after LAA occlusion has not been evaluated in a randomized manner; and (ii) the efficacy and safety of
LAA closure vs. OAC therapy needs to be assessed in randomized trials.
LAA occluders have not been compared with NOAC therapy in patients at risk for bleeding, or with surgical LAA occlusion/
exclusion.
h Surgical exclusion of Left atrial appendage
Only limited RCT data are available457459 on surgical exclusion of the LAA. Although a large RCT in patients with an associated cardiac surgical procedure is ongoing,462 adequately powered RCTs are needed.
There is the need for adequately powered trials to define the best indications for LAA occlusion/exclusion compared with NOAC therapy in patients with relative or absolute contraindications for anticoagulation, in those with an ischaemic stroke on anticoagulant therapy,
and for assessment of the appropriate antithrombotic therapy after
LAA occlusion.
h Atrial fibrillation catheter ablation technique
The best approach to safely and expeditiously achieve permanent
PVI in a single procedure is still one of the knowledge gaps in relation to emerging technologies for catheter ablation of AF. Moreover, it remains unknown if ablating additional targets will improve the outcomes of AF catheter ablation.1490
h Outcome of atrial fibrillation catheter ablation
The following issues need to be addressed in further studies:
• The value of early AF ablation to prevent AF progression.
• The optimal outcome measure (AF 30 s, AF burden, etc.) for AFrelated outcome.
• How much reduction in AF burden is needed to achieve an effect on hard endpoints, including survival, stroke, and comorbidity.
• The main mechanism of PVI translating into freedom of AF.
• The potential effect of cardiac structure and function on the likelihood of success of AF ablation.
Despite the publication of CABANA and CASTLE-AF, more data are needed on the effect of AF catheter ablation on clinical outcomes,
including death, stroke, serious bleeding, AF recurrence, QoL, and cardiac arrest.
The relationship between the degree of atrial dilation/fibrosis and successful ablation of AF needs to be addressed. Additionally, the impact of specific components of structural heart disease, including
LA structure/function, LV structure, etc., on the success of AF catheter ablation and the likelihood of recurrence requires further investigation.
h Who may benefit less from atrial fibrillation catheter ablation
There are gaps in knowledge about subgroups of patients who may benefit less from AF catheter ablation, including (i) persistent and long-standing persistent AF; (ii) patients with enlarged atrial size and/
or atrial fibrosis; (iii) patients with atypical AFL; and (iv) patients with risk factors for AF recurrence, including obesity or sleep apnoea.
h Thoracoscopic ‘stand-alone’ atrial fibrillation surgery
There are no convincing data on the effects on stroke of surgical ablation as a stand-alone procedure or in combination with LAA occlusion or exclusion on various outcomes including QoL, stroke, and death.
h Personalized therapy
The arrhythmia phenotype may differ among patients. Improved assessment of the pathophysiological process involved in the individual patient by using clinical characteristics, blood biomarkers, and non-invasive substrate determination (echo/MRI/CT) may improve personalized therapy (e.g. selection of rhythm control, yes or no;
treatment of risk factors and comorbidities; type of antiarrhythmic drug; atrial ablation; and which type/techniques used for AF).
Recommendations
Classa
Levelb
Recommendations for diagnosis of AF
ECG documentation is required to establish the diagnosis of AF.
• A standard 12-lead ECG recording or a single-lead ECG tracing of >_30 s showing heart rhythm with no discernible repeating P
waves and irregular RR intervals (when atrioventricular conduction is not impaired) is diagnostic of clinical AF.
I
B
Recommendations for screening of AF
Opportunistic screening for AF by pulse taking or ECG rhythm strip is recommended in patients >_65 years of age.
I
B
It is recommended to interrogate pacemakers and implantable cardioverter deﬁbrillators on a regular basis for AHRE.
I
B
When screening for AF it is recommended that:
• The individuals undergoing screening are informed about the signiﬁcance and treatment implications of detecting AF.
• A structured referral platform is organized for screen-positive cases for further physician-led clinical evaluation to conﬁrm the diagnosis of AF and provide optimal management of patients with conﬁrmed AF.
• Deﬁnite diagnosis of AF in screen-positive cases is established only after the physician reviews the single-lead ECG recording of
>_30 s or 12-lead ECG and conﬁrms that it shows AF.
I
B
Continued
20 ‘What to do’ and ‘what not to do’ messages from the Guidelines


<!-- PAGE 81 -->

### Page 81

Recommendations for diagnostic evaluation of patients with AF
In patients with AF, it is recommended to:
• Evaluate AF-related symptoms (including fatigue, tiredness, exertional shortness of breath, palpitations, and chest pain) and quantify the patient symptom status using the modiﬁed EHRA symptom scale before and after initiation of treatment.
• Evaluate AF-related symptoms before and after cardioversion of persistent AF to aid rhythm control treatment decisions.
I
C
In patients with AHRE/subclinical AF detected by CIED or insertable cardiac monitor, it is recommended to conduct:
• Complete cardiovascular evaluation with ECG recording, clinical risk factors/comorbidity evaluation, and thrombo-embolic risk assessment using the CHA2DS2-VASc score.
• Continued patient follow-up and monitoring (preferably with the support of remote monitoring) to detect progression to clinical AF, monitor the AHRE/subclinical AF burden (especially transition to >_24 h), and detect changes in underlying clinical conditions.
I
B
Recommendations about integrated AF management
To optimize shared decision making about speciﬁc AF treatment option(s) in consideration, it is recommended that physicians:
• Inform the patient about the advantages/limitations and beneﬁt/risks associated with the treatment option(s) being considered;
and
• Discuss the potential burden of the treatment with the patient and include the patient’s perception of treatment burden in the treatment decision.
I
C
It is recommended to routinely collect PROs to measure treatment success and improve patient care.
I
C
Recommendations for the prevention of thrombo-embolic events in AF
For stroke prevention in AF patients who are eligible for OAC, NOACs are recommended in preference to VKAs (excluding patients with mechanical heart valves or moderate-to-severe mitral stenosis).
I
A
For stroke risk assessment, a risk-factor-based approach is recommended, using the CHA2DS2-VASc clinical stroke risk score to initially identify patients at ‘low stroke risk’ (CHA2DS2-VASc score = 0 in men, or 1 in women) who should not be offered antithrombotic therapy.
I
A
OAC is recommended for stroke prevention in AF patients with CHA2DS2-VASc score >_2 in men or >_3 in women.
I
A
For bleeding risk assessment, a formal structured risk-score-based bleeding risk assessment is recommended to help identify nonmodiﬁable and address modiﬁable bleeding risk factors in all AF patients, and to identify patients potentially at high risk of bleeding who should be scheduled for early and more frequent clinical review and follow-up.
I
B
Stroke and bleeding risk reassessment at periodic intervals is recommended to inform treatment decisions (e.g. initiation of OAC
in patients no longer at low risk of stroke) and address potentially modiﬁable bleeding risk factors.
I
B
If a VKA is used, a target INR of 2.0 - 3.0 is recommended, with individual TTR>_70%.
I
B
In patients on VKAs with low time in INR therapeutic range (e.g. TTR<70%), switching to a NOAC but ensuring good adherence and persistence with therapy is recommended.
I
B
Antiplatelet therapy alone (monotherapy or aspirin in combination with clopidogrel) is not recommended for stroke prevention in AF.
III
A
Estimated bleeding risk, in the absence of absolute contraindications to OAC, should not in itself guide treatment decisions to use
OAC for stroke prevention.
III
A
Clinical pattern of AF (i.e. ﬁrst detected, paroxysmal, persistent, long-standing persistent, permanent) should not condition the indication to thromboprophylaxis.
III
B
Recommendations for stroke risk management peri-cardioversion
In patients with AF undergoing cardioversion, NOACs are recommended with at least similar efﬁcacy and safety as warfarin.
I
A
For cardioversion of AF/AFL, effective anticoagulation is recommended for a minimum of 3 weeks before cardioversion.
I
B
TOE is recommended to exclude cardiac thrombus as an alternative to 3-week pre-procedural anticoagulation when early cardioversion is planned.
I
B
In patients at risk of stroke, it is recommended that OAC therapy is continued long term after cardioversion according to the long-term anticoagulation recommendations, irrespective of the method of cardioversion, the apparent maintenance of sinus rhythm, or characterization of AF as a ‘ﬁrst-diagnosed episode’.
I
B
When thrombus is identiﬁed on TOE, effective anticoagulation is recommended for at least 3 weeks before cardioversion of AF.
I
B
It is recommended that the importance of adherence and persistence to NOAC treatment both before and after cardioversion is strongly emphasized to patients.
I
C
Recommendations for stroke risk management peri-catheter ablation
In AF patients with stroke risk factors not taking OAC before ablation, it is recommended that pre-procedural management of stroke risk includes initiation of anticoagulation and, preferably, therapeutic OAC for at least 3 weeks before ablation.
I
C
Continued
ESC Guidelines
453


<!-- PAGE 82 -->

### Page 82

For patients undergoing AF catheter ablation who have been therapeutically anticoagulated with warfarin, dabigatran, rivaroxaban,
apixaban, or edoxaban, performance of the ablation procedure without OAC interruption is recommended.
I
A
After AF catheter ablation, it is recommended that:
• Systemic anticoagulation with warfarin or a NOAC is continued for at least 2 months post ablation, and
• Long-term continuation of systemic anticoagulation beyond 2 months post ablation is based on the patient’s stroke risk proﬁle and not on the apparent success or failure of the ablation procedure.
I
C
Recommendations for postoperative anticoagulation after AF surgery
Long-term OAC is recommended in patients after AF surgery and appendage closure, based on the patient’s thrombo-embolic risk assessed with the CHA2DS2-VASc score.
I
C
Recommendations for patients with AF and an ACS, PCI, or CCS
In AF patients eligible for NOACs, it is recommended to use a NOAC in preference to a VKA in combination with antiplatelet therapy.
I
A
In AF patients with ACS undergoing an uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with an OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 12 months is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis, irrespective of the type of stent used.
I
A
After uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with OAC for up to 6 months and clopidogrel is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis, irrespective of the type of stent used.
I
A
Recommendations for secondary stroke prevention in AF patients after acute ischaemic stroke
In AF patients with an ischaemic stroke or TIA, long-term secondary prevention of stroke using OAC is recommended if there is no strict contraindication to OAC use, with a preference for NOACs over VKAs in NOAC-eligible patients.
I
A
In AF patients presenting with acute ischaemic stroke, very early anticoagulation (<48 h) using UFH, LMWH, or VKAs is not recommended.
III
B
Recommendations for patients with valvular heart disease and AF
NOACs are contraindicated in patients with a prosthetic mechanical valve.
III
B
Use of NOACs is not recommended in patients with AF and moderate-to-severe mitral stenosis.
III
C
Recommendations for the management of AF during pregnancy
Therapeutic anticoagulation with heparin or VKA according to the stage of pregnancy is recommended for patients with AF.
I
C
Recommendations for the management of active bleeding on OAC
In an AF patient with severe active bleeding, it is recommended to:
• Interrupt OAC until the cause of bleeding is identiﬁed and active bleeding is resolved; and
• Promptly perform speciﬁc diagnostic and treatment interventions to identify and manage the cause(s) and source(s) of bleeding.
I
C
Recommendations for ventricular rate control in patients with AF
Beta-blockers, diltiazem, or verapamil are recommended as ﬁrst-choice drugs to control heart rate in AF patients with
LVEF>_40%.
I
B
Beta-blockers and/or digoxin are recommended to control heart rate in AF patients with LVEF<40%.
I
B
Recommendations for the management of AF during pregnancy
Beta-selective blockers are recommended for rate control in AF.
I
C
Recommendations for rhythm control
Rhythm control therapy is recommended for symptom and QoL improvement in symptomatic patients with AF.
I
A
Recommendations for cardioversion
For pharmacological cardioversion of new-onset AF, i.v. vernakalant (excluding patients with recent ACS or severe HF) or ﬂecainide or propafenone (excluding patients with severe structural heart disease) is recommended.
I
A
Intravenous amiodarone is recommended for cardioversion of AF in patients with HF or structural heart disease, if delayed cardioversion is consistent with clinical situation.
I
A
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent or longstanding persistent AF as part of rhythm control therapy.
I
B
Pharmacological cardioversion of AF is indicated only in a haemodynamically stable patient, after consideration of the thromboembolic risk.
I
B
Continued


<!-- PAGE 83 -->

### Page 83

Emergency electrical cardioversion is recommended in AF patients with acute or worsening haemodynamic instability.
I
B
For patients with sick-sinus syndrome, atrioventricular conduction disturbances or prolonged QTc (>500 ms), pharmacological cardioversion should not be attempted unless risks for proarrhythmia and bradycardia have been considered.
III
C
Recommendations for the management of AF during pregnancy
Immediate electrical cardioversion is recommended in case of haemodynamic instability or pre-excited AF.
I
C
Recommendations for rhythm control/catheter ablation of AF
For the decision on AF catheter ablation, it is recommended to take into consideration the procedural risks and the major risk factors for AF recurrence following the procedure and discuss them with the patient.
I
B
AF catheter ablation after failure of drug therapy
AF catheter ablation for PVI is recommended for rhythm control after one failed or intolerant class I or III AAD, to improve symptoms of AF recurrences in patients with:
I
• Paroxysmal AF, or
A
• Persistent AF without major risk factors for AF recurrence, or
A
• Persistent AF with major risk factors for AF recurrence.
B
First-line therapy
AF catheter ablation is recommended to reverse LV dysfunction in AF patients when tachycardia-induced cardiomyopathy is highly probable, independent of their symptom status.
I
B
Techniques and technologies
Complete electrical isolation of the pulmonary veins is recommended during all AF catheter-ablation procedures.
I
A
Lifestyle modiﬁcation and other strategies to improve outcomes of ablation
Weight loss is recommended in obese patients with AF, particularly those who are being evaluated to undergo AF ablation.
I
B
Strict control of risk factors and avoidance of triggers are recommended as part of a rhythm control strategy.
I
B
Recommendations for long-term antiarrhythmic drugs
Flecainide or propafenone are recommended for long-term rhythm control in AF patients with normal LV function and without structural heart disease, including signiﬁcant LVH and myocardial ischaemia.
I
A
Dronedarone is recommended for long-term rhythm control in AF patients with:
• Normal or mildly impaired (but stable) LV function, or
• HFpEF, ischaemic, or VHD.
I
A
Amiodarone is recommended for long-term rhythm control in all AF patients, including those with HFrEF. However, owing to its extracardiac toxicity, other AADs should be considered ﬁrst whenever possible.
I
A
In AF patients treated with sotalol, close monitoring of QT interval, serum potassium levels, CrCl, and other proarrhythmia risk factors is recommended.
I
B
AAD therapy is not recommended in patients with permanent AF under rate control and in patients with advanced conduction disturbances unless antibradycardia pacing is provided.
III
C
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with AF
Identiﬁcation and management of risk factors and concomitant diseases is recommended as an integral part of treatment in AF
patients.
I
B
Modiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.
I
B
Opportunistic screening for AF is recommended in hypertensive patients.
I
B
Attention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and bleeding.
I
B
Recommendations for sports activity in patients with AF
It is recommended to counsel professional athletes that long-lasting intense sports participation may promote AF, while moderate physical activity is recommended to prevent AF.
I
B
Recommendations for postoperative AF
Perioperative amiodarone or beta blocker therapy is recommended for the prevention of postoperative AF after cardiac surgery.
I
A
Beta-blockers should not be used routinely for the prevention of postoperative AF in patients undergoing non-cardiac surgery.
III
B
Continued
ESC Guidelines
455


<!-- PAGE 84 -->

### Page 84

.........................................................................................................................................
21 Supplementary data
Supplementary Data with additional Supplementary Figures, Tables,
and text complementing the full text are available on the European
Heart Journal website and via the ESC website at www.escardio.org/
guidelines.
22 Appendix
Author/Task Force Member Affiliations: Nikolaos Dagres,
Department of Electrophysiology, Heart Center Leipzig at the
University of Leipzig, Leipzig, Germany; Elena Arbelo, Arrhythmia
Department, Cardiovascular Institute, Hospital Clinic de Barcelona,
Barcelona, Catalonia, Spain; Jeroen J. Bax, Cardiology, Leiden
University
Medical
Center,
Leiden,
Netherlands;
Carina
Blomstro¨m-Lundqvist, Department of Medical Science and
Cardiology,
Medicine,
Uppsala,
Sweden;
Giuseppe
Boriani,
Cardiology Division, Department of Biomedical, Metabolic and
Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy; Manuel Castella,1 Cardiovascular
Surgery, Hospital Clınic, University of Barcelona, Barcelona, Spain;
Gheorghe-Andrei
Dan,
Cardiology
Department,
Internal
Medicine Clinic, ‘Carol Davila’ University of Medicine, Colentina
University Hospital, Bucharest, Romania; Polychronis E. Dilaveris,
1st University Department of Cardiology, National & Kapodistrian
University of Athens School of Medicine, Athens, Attica, Greece;
Laurent Fauchier, Department of Cardiology, Centre Hospitalier
Universitaire Trousseau and University of Tours, Tours, France;
Gerasimos
Filippatos,
Department of
Cardiology,
Attikon
University Hospital, National and Kapodistrian University of Athens,
Athens, Greece; Jonathan M. Kalman, Department of Cardiology,
Royal Melbourne Hospital and University of Melbourne, Melbourne,
Australia; Mark La Meir,1 Cardiac surgery, UZ Brussel, Brussels,
Belgium; Deirdre A. Lane, Liverpool Centre for Cardiovascular
Science, University of Liverpool and Liverpool Heart & Chest
Hospital, Liverpool, United Kingdom, and Department of Clinical
Medicine, Aalborg University, Aalborg, Denmark; Jean-Pierre
Lebeau, Department of General Practice, University of Tours,
Tours, France; Maddalena Lettino, Cardiovascular, San Gerardo
Hospital, ASST-Monza, Monza, Italy; Gregory Y. H. Lip, Liverpool
Centre for Cardiovascular Science, University of Liverpool and
Liverpool Heart & Chest Hospital, Liverpool, United Kingdom, and
Department of Clinical Medicine, Aalborg University, Aalborg,
Denmark; Fausto J. Pinto, Cardiology, CCUL, Faculdade de
Medicina, Universidade de Lisboa, Lisbon, Portugal; G. Neil
Thomas, Institute of Applied Health Research, University of
Birmingham, Birmingham, United Kingdom; Marco Valgimigli,
Cardiocentro Ticino, Lugano, Switzerland; Isabelle C. Van
Gelder, Department of Cardiology, University of Groningen,
University Medical Center Groningen, Groningen, Netherlands; Bart
P. Van Putte,1 Cardiothoracic Surgery, St Antonius Hospital,
Nieuwegein, Netherlands; Caroline L. Watkins, Faculty of Health and Wellbeing, University of Central Lancashire, Preston, United
Kingdom.
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Colin Baigent (United Kingdom), Jean-Philippe Collet (France),
Veronica Dean (France), Victoria Delgado (Netherlands), Donna
Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom),
Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway),
Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni
(Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany),
Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S.
Lewis
(Israel),
Be´la
Merkely
(Hungary),
Christian
Mueller
(Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia
Petronio
(Italy),
Dimitrios
J.
Richter
(Greece),
Marco
Roffi
(Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A.
Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Rhian M.
Touyz (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation.
Algeria: Algerian Society of Cardiology, Tahar Delassi; Armenia:
Armenian Cardiologists Association, Hamayak S. Sisakian; Austria:
Austrian Society of Cardiology, Daniel Scherr; Belarus: Belorussian
Scientific Society of Cardiologists, Alexandr Chasnoits; Belgium:
Belgian Society of Cardiology, Michel De Pauw; Bosnia and
Herzegovina:
Association of
Cardiologists of
Bosnia and
Herzegovina,
Elnur
Smajic;
Bulgaria:
Bulgarian
Society of
Cardiology, Tchavdar Shalganov; Cyprus: Cyprus Society of
Cardiology,
Panayiotis Avraamides; Czech
Republic:
Czech
Society of Cardiology, Josef Kautzner; Denmark: Danish Society of
Cardiology,
Christian
Gerdes;
Egypt:
Egyptian
Society of
Cardiology, Ahmad Abd Alaziz; Estonia: Estonian Society of
Cardiology, Priit Kampus; Finland: Finnish Cardiac Society, Pekka
Raatikainen; France: French Society of Cardiology, Serge Boveda;
Recommendations pertaining to sex-related differences in AF
It is recommended that women and men with AF are equally offered diagnostic assessment and therapies to prevent stroke and other AF-related complications.
I
A
AAD = antiarrhythmic drug; ACS = acute coronary syndrome; AF = atrial ﬁbrillation; AFL = atrial ﬂutter; AHRE = atrial high-rate episodes; BP = blood pressure; CCS = chronic coronary syndrome; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years, Diabetes mellitus, Stroke, Vascular disease, Age 6574 years, Sex category
(female); CIED = cardiac implantable electronic device; CrCl = creatinine clearance; ECG = electrocardiogram; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; i.v. = intravenous; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricular; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; PCI
= percutaneous coronary intervention; PRO = patient-reported outcome; PVI = pulmonary vein isolation; QoL = quality of life; TIA = transient ischaemic attack; TOE = transoesophageal echocardiography; TTR = time in therapeutic range; UFH = unfractionated heparin; VHD = Valvular heart disease; VKA = vitamin K antagonist.


<!-- PAGE 85 -->

### Page 85

...........................................................................................................................................................................
Georgia: Georgian Society of Cardiology, Giorgi Papiashvili;
Germany: German Cardiac Society, Lars Eckardt; Greece:
Hellenic Society of Cardiology, Vassilios P. Vassilikos; Hungary:
Hungarian Society of Cardiology, Zoltan Csanadi; Iceland: Icelandic
Society of Cardiology, David O. Arnar; Ireland: Irish Cardiac
Society, Joseph Galvin; Israel: Israel Heart Society, Alon Barsheshet;
Italy:
Italian
Federation of
Cardiology,
Pasquale
Caldarola;
Kazakhstan: Association of Cardiologists of Kazakhstan, Amina
Rakisheva; Kosovo (Republic of): Kosovo Society of Cardiology,
Ibadete Bytyc¸i; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina
Kerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;
Lebanon:
Lebanese
Society of
Cardiology,
Mario
Njeim;
Lithuania: Lithuanian Society of Cardiology, Aras Puodziukynas;
Luxembourg:
Luxembourg
Society of
Cardiology,
Laurent
Groben; Malta: Maltese Cardiac Society, Mark A. Sammut;
Moldova (Republic of): Moldavian Society of Cardiology, Aurel
Grosu; Montenegro: Montenegro Society of Cardiology, Aneta
Boskovic; Morocco: Moroccan Society of Cardiology, Abdelhamid
Moustaghfir; Netherlands: Netherlands Society of Cardiology,
Natasja de Groot; North Macedonia: North Macedonian Society of Cardiology, Lidija Poposka; Norway: Norwegian Society of
Cardiology, Ole-Gunnar Anfinsen; Poland: Polish Cardiac Society,
Przemyslaw
P.
Mitkowski;
Portugal:
Portuguese
Society of
Cardiology, Diogo Magalh~aes Cavaco; Romania: Romanian Society of Cardiology, Calin Siliste; Russian Federation: Russian Society of
Cardiology, Evgeny N. Mikhaylov; San Marino: San Marino Society of Cardiology, Luca Bertelli; Serbia: Cardiology Society of Serbia,
Dejan Kojic; Slovakia: Slovak Society of Cardiology, Robert Hatala;
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain:
Spanish Society of Cardiology, Fernando Arribas; Sweden: Swedish
Society of Cardiology, Tord Juhlin; Switzerland: Swiss Society of
Cardiology, Christian Sticherling; Tunisia: Tunisian Society of
Cardiology and Cardio-Vascular Surgery, Leila Abid; Turkey:
Turkish Society of Cardiology, Ilyas Atar; Ukraine: Ukrainian
Association of Cardiology, Oleg Sychov; United Kingdom of
Great Britain and Northern Ireland: British Cardiovascular
Society, Matthew G. D. Bates; Uzbekistan: Association of
Cardiologists of Uzbekistan, Nodir U. Zakirov.
23 References
1. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG,
Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis
AB, Davies DW, Day JD, d’Avila A, de Groot N, Di Biase L, Duytschaever M,
Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP,
Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM,
Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD,
Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel
S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M,
Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/
EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace 2018;20:157208.
2. Charitos EI, Stierle U, Ziegler PD, Baldewig M, Robinson DR, Sievers HH, Hanke T. A
comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. Circulation 2012;126:806814.
3. Gorenek B, Boriani G, Dan GA, Fauchier L, Fenelon G, Huang H, Kudaiberdieva
G, Lip GYH, Mahajan R, Potpara T, Ramirez JD, Vos MA, Marin F, ESC Scientific
Document Group. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm
Society (LAHRS). Europace 2018;20:895896.
4. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS.
Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017;14:701714.
5. Perino AC, Fan J, Askari M, Heidenreich PA, Keung E, Raitt MH, Piccini JP, Ziegler
PD, Turakhia MP. Practice variation in anticoagulation prescription and outcomes after device-detected atrial fibrillation. Circulation 2019;139:25022512.
6. Steinberg JS, O’Connell H, Li S, Ziegler PD. Thirty-second gold standard definition of atrial fibrillation and its relationship with subsequent arrhythmia patterns: analysis of a
large prospective device database.
Circ
Arrhythm
Electrophysiol
2018;11:e006274.
7. Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G,
Diener HC, Kirchhof P. Atrial high-rate episodes and stroke prevention. Europace
2017;19:169179.
8. Pollak WM, Simmons JD, Interian A, Jr., Atapattu SA, Castellanos A, Myerburg RJ,
Mitrani RD. Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol 2001;24:424429.
9. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH,
Brandes A, Crystal E, Costantini O, Sandhu RK, Parkash R, Connolly SJ,
Hohnloser SH, Healey JS; ASSERT Steering Committee and Investigators. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:12411246.
10. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP,
Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind
MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL,
Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS,
Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O’Flaherty M,
Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM,
Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW,
Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS, American Heart
Association Council on Epidemiology and Prevention Statistics Committee and
Stroke Statistics Subcommittee. Heart disease and stroke statistics  2019
update:
a report from the
American
Heart
Association.
Circulation
2019;139:e56e528.
11. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum
RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA,
Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global
Burden of Disease 2010 Study. Circulation 2014;129:837847.
12. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol 2013;112:11421147.
13. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC,
Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the
European
Union,
from
2000
to
2060.
Eur
Heart
J
2013;34:27462751.
14. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among
Asians, Hispanics, blacks, and whites. Circulation 2013;128:24702477.
15. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology,
pathophysiology, and clinical outcomes. Circ Res 2017;120:15011517.
16. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ,
Folsom AR. Incidence of atrial fibrillation in whites and African Americans: the
Atherosclerosis
Risk in
Communities
(ARIC)
study.
Am
Heart
J
2009;158:111117.
17. Chao TF, Liu CJ, Tuan TC, Chen TJ, Hsieh MH, Lip GYH, Chen SA. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study. Chest
2018;153:453466.
18. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 2015;147:109119.
19. Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M, Baldereschi
M, Cattarinussi A, D’Alfonso MG, Gradia C, Sgherzi B, Pracucci G, Piccardi B,
Polizzi B, Inzitari D, National Research Program: Progetto FAI. La Fibrillazione
Atriale in Italia. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI
Project. Europace 2019;21:14681475.
20. Mou L, Norby FL, Chen LY, O’Neal WT, Lewis TT, Loehr LR, Soliman EZ,
Alonso A. Lifetime risk of atrial fibrillation by race and socioeconomic status:
ARIC study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol
2018;11:e006350.
21. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, Lane DA, La Manna
G, Morton J, Mitjans AM, Vos MA, Turakhia MP, Lip GY. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making  a position paper of the European
Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia
Pacific Heart Rhythm Society. Europace 2015;17:11691196.
ESC Guidelines
457


<!-- PAGE 86 -->

### Page 86

............................................................................................................................................................................
22. Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus,
blood glucose and the risk of atrial fibrillation: a systematic review and metaanalysis of cohort studies. J Diabetes Complications 2018;32:501511.
23. Cadby G, McArdle N, Briffa T, Hillman DR, Simpson L, Knuiman M, Hung J.
Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest 2015;148:945952.
24. Hobbelt AH, Siland JE, Geelhoed B, Van Der Harst P, Hillege HL, Van Gelder IC,
Rienstra M. Clinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND study. Europace
2017;19:226232.
25. Nalliah CJ, Sanders P, Kalman JM. The impact of diet and lifestyle on atrial fibrillation. Curr Cardiol Rep 2018;20:137.
26. Lip GYH, Coca A, Kahan T, Boriani G, Manolis AS, Olsen MH, Oto A, Potpara
TS, Steffel J, Marin F, de Oliveira Figueiredo MJ, de Simone G, Tzou WS, Chiang
CE, Williams B, Reviewers, Dan GA, Gorenek B, Fauchier L, Savelieva I, Hatala R,
van Gelder I, Brguljan-Hitij J, Erdine S, Lovic D, Kim YH, Salinas-Arce J, Field M.
Hypertension and cardiac arrhythmias: a consensus document from the
European Heart Rhythm Association (EHRA) and ESC Council on Hypertension,
endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm
Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y
Electrofisiologia (SOLEACE). Europace 2017;19:891911.
27. Gallagher C, Hendriks JML, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME,
Mahajan R, Lau DH, Sanders P. Alcohol and incident atrial fibrillation  a systematic review and meta-analysis. Int J Cardiol 2017;246:4652.
28. Ricci C, Gervasi F, Gaeta M, Smuts CM, Schutte AE, Leitzmann MF. Physical activity volume in relation to risk of atrial fibrillation. A non-linear meta-regression analysis. Eur J Prev Cardiol 2018;25:857866.
29. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH,
Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J 2006;27:949953.
30. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino
RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:10421046.
31. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njolstad I,
Vartiainen E, Sans S, Pasterkamp G, Hughes M, Costanzo S, Donati MB, Jousilahti
P, Linneberg A, Palosaari T, de Gaetano G, Bobak M, den Ruijter HM, Mathiesen
E, Jorgensen T, Soderberg S, Kuulasmaa K, Zeller T, Iacoviello L, Salomaa V,
Schnabel RB, BiomarCaRE Consortium. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation 2017;136:15881597.
32. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, McManus DD, Ko
D, Weng LC, Lunetta KL, Frost L, Benjamin EJ, Trinquart L. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors:
cohort study based on longitudinal data from the Framingham Heart Study. BMJ
2018;361:k1453.
33. Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, Perel P,
Morley K, Banerjee A, Hemingway H. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants.
Thromb Haemost 2017;117:837850.
34. Feghaly J, Zakka P, London B, MacRae CA, Refaat MM. Genetics of atrial fibrillation. J Am Heart Assoc 2018;7:e009884.
35. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population?
A
systematic review and meta-analysis.
Europace
2009;11:11561159.
36. Alonso A, Jensen PN, Lopez FL, Chen LY, Psaty BM, Folsom AR, Heckbert SR.
Association of sick sinus syndrome with incident cardiovascular disease and mortality: the Atherosclerosis Risk in Communities Study and Cardiovascular Health
Study. PLoS One 2014;9:e109662.
37. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ,
Astor BC, Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.
Circulation 2011;123:29462953.
38. Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K,
Sundstrom J. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 2013;34:36243631.
39. Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with incident atrial fibrillation independent of gender: a meta-analysis. J Cardiovasc
Electrophysiol 2018;29:725732.
40. Aune D, Sen A, Schlesinger S, Norat T, Janszky I, Romundstad P, Tonstad S,
Riboli E, Vatten LJ. Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol 2017;32:181192.
41. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, Katz R,
Kestenbaum
B, Mathew J, Robinson-Cohen
C, Sarnak
MJ,
Shlipak MG,
Sotoodehnia N, Young B, Heckbert SR. eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the
Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J
Am Soc Nephrol 2017;12:13861398.
42. Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC,
Cappola AR, Heckbert SR, Ceresini G, Gussekloo J, den Elzen WPJ, Peeters RP,
Luben R, Volzke H, Dorr M, Walsh JP, Bremner A, Iacoviello M, Macfarlane P,
Heeringa J, Stott DJ, Westendorp RGJ, Khaw KT, Magnani JW, Aujesky D,
Rodondi N, Thyroid Studies Collaboration. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation
2017;136:21002116.
43. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA.
Independent risk factors for atrial fibrillation in a population-based cohort. The
Framingham Heart Study. JAMA 1994;271:840844.
44. Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ, Jacobs V,
Mallender C, Muhlestein JB, Osborn JS, Weiss JP, Day JD. Long-term natural history of adult Wolff-Parkinson-White syndrome patients treated with and without catheter ablation. Circ Arrhythm Electrophysiol 2015;8:14651471.
45. Chang SH, Kuo CF, Chou IJ, See LC, Yu KH, Luo SF, Huang LH, Zhang W,
Doherty M, Wen MS, Kuo CT, Yeh YH. Association of a family history of atrial fibrillation with incidence and outcomes of atrial fibrillation: a population-based family cohort study. JAMA Cardiol 2017;2:863870.
46. Chen LY, Leening MJ, Norby FL, Roetker NS, Hofman A, Franco OH, Pan W,
Polak JF, Witteman JC, Kronmal RA, Folsom AR, Nazarian S, Stricker BH,
Heckbert SR, Alonso A. Carotid intima-media thickness and arterial stiffness and the risk of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC)
study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study. J
Am Heart Assoc 2016;5.
47. Cheng M, Hu Z, Lu X, Huang J, Gu D. Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies. Can J Cardiol
2014;30:448454.
48. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, Benjamin
EJ, Vasan RS, Wang TJ. Long-term outcomes in individuals with prolonged PR
interval or first-degree atrioventricular block. JAMA 2009;301:25712577.
49. Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine consumption and incident atrial fibrillation in women. Am J Clin Nutr 2010;92:509514.
50. Desai R, Patel U, Singh S, Bhuva R, Fong HK, Nunna P, Zalavadia D, Dave H,
Savani S, Doshi R. The burden and impact of arrhythmia in chronic obstructive pulmonary disease: insights from the National Inpatient Sample. Int J Cardiol
2019;281:4955.
51. Eaker ED, Sullivan LM, Kelly-Hayes M, D’Agostino RB Sr, Benjamin EJ. Anger and hostility predict the development of atrial fibrillation in men in the Framingham
Offspring Study. Circulation 2004;109:12671271.
52. Fox CS, Parise H, D’Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ, Levy
D, Wolf PA, Benjamin EJ. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:28512855.
53. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM.
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health
Study). Am J Cardiol 1994;74:236241.
54. Giacomantonio NB, Bredin SS, Foulds HJ, Warburton DE. A systematic review of the health benefits of exercise rehabilitation in persons living with atrial fibrillation. Can J Cardiol 2013;29:483491.
55. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U,
Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L,
Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M,
Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N,
Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia
M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A,
Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C,
Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P,
Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options  a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart
Rhythm Association consensus conference. Europace 2012;14:827.
56. Ko D, Benson MD, Ngo D, Yang Q, Larson MG, Wang TJ, Trinquart L, McManus
DD, Lubitz SA, Ellinor PT, Vasan RS, Gerszten RE, Benjamin EJ, Lin H.
Proteomics profiling and risk of new-onset atrial fibrillation: Framingham Heart
Study. J Am Heart Assoc 2019;8:e010976.
57. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical activity and incidence of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol
2014;177:467476.
58. Lip GYH, Collet JP, de Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F,
Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N,


<!-- PAGE 87 -->

### Page 87

.............................................................................................................................................................................
Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association
(EHRA) and European Society of Cardiology Working Group on Thrombosis,
Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac
Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS),
Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart)
Association and
Sociedad
Latinoamericana de
Estimulacion
Cardiaca y
Electrofisiologia (SOLEACE). Thromb Haemost 2017;117:22152236.
59. Loomba RS, Buelow MW, Aggarwal S, Arora RR, Kovach J, Ginde S. Arrhythmias in adults with congenital heart disease: what are risk factors for specific arrhythmias?Pacing Clin Electrophysiol 2017;40:353361.
60. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, Villalon ML, Vasan
RS, Pencina MJ, Levy D, Larson MG, Ellinor PT, Benjamin EJ. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation.
JAMA
2010;304:22632269.
61. May AM, Blackwell T, Stone PH, Stone KL, Cawthon PM, Sauer WH, Varosy PD,
Redline S, Mehra R, Sleep MrOS (Outcomes of Sleep Disorders in Older Men)
Study Group. Central sleep-disordered breathing predicts incident atrial fibrillation in older men. Am J Respir Crit Care Med 2016;193:783791.
62. Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J.
Patients with atrial fibrillation and coronary artery disease  double trouble. Adv
Med Sci 2018;63:3035.
63. Monrad M, Sajadieh A, Christensen JS, Ketzel M, Raaschou-Nielsen O,
Tjonneland A, Overvad K, Loft S, Sorensen M. Long-term exposure to trafficrelated air pollution and risk of incident atrial fibrillation: a cohort study. Environ
Health Perspect 2017;125:422427.
64. O’Neal WT, Efird JT, Qureshi WT, Yeboah J, Alonso A, Heckbert SR, Nazarian
S, Soliman EZ. Coronary artery calcium progression and atrial fibrillation:
the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging 2015;8:pii:
e003786.
65. Qureshi WT, Alirhayim Z, Blaha MJ, Juraschek SP, Keteyian SJ, Brawner CA, AlMallah MH. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the
Henry
Ford
Exercise
Testing
(FIT)
Project.
Circulation
2015;131:18271834.
66. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA,
Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE.
Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction.
Circulation
2016;133:484492.
67. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, NewtonCheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS,
Benjamin EJ, Levy D. 50-Year trends in atrial fibrillation prevalence, incidence,
risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet
2015;386:154162.
68. Shen J, Johnson VM, Sullivan LM, Jacques PF, Magnani JW, Lubitz SA, Pandey S,
Levy D, Vasan RS, Quatromoni PA, Junyent M, Ordovas JM, Benjamin EJ. Dietary factors and incident atrial fibrillation: the Framingham Heart Study. Am J Clin Nutr
2011;93:261266.
69. Svensson T, Kitlinski M, Engstrom G, Melander O. Psychological stress and risk of incident atrial fibrillation in men and women with known atrial fibrillation genetic risk scores. Sci Rep 2017;7:42613.
70. Tung P, Levitzky YS, Wang R, Weng J, Quan SF, Gottlieb DJ, Rueschman M,
Punjabi NM, Mehra R, Bertisch S, Benjamin EJ, Redline S. Obstructive and central sleep apnea and the risk of incident atrial fibrillation in a community cohort of men and women. J Am Heart Assoc 2017;6:pii.
71. Walkey AJ, Greiner MA, Heckbert SR, Jensen PN, Piccini JP, Sinner MF, Curtis
LH, Benjamin EJ. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J 2013;165:949955.e3.
72. Zoller B, Ohlsson H, Sundquist J, Sundquist K. High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. J Am
Heart Assoc 2012;2:e003384.
73. Lip GYH, Skjoth F, Nielsen PB, Larsen TB. Evaluation of the C2HEST risk score as a possible opportunistic screening tool for incident atrial fibrillation in a healthy population (from a nationwide Danish cohort study). Am J Cardiol
2020;125:4854.
74. Yiin GSC, Li L, Bejot Y, Rothwell PM. Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation. Stroke 2018:STROKEAHA118022249.
75. Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji
H, Furuke K; Fushimi AFRegistry Investigators. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the
Fushimi AF Registry. J Cardiol 2013;61:260266.
76. An Y, Ogawa H, Yamashita Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H,
Wada H, Hasegawa K, Abe M, Lip GYH, Akao M. Causes of death in Japanese patients with atrial fibrillation: the Fushimi Atrial Fibrillation Registry. Eur Heart J
Qual Care Clin Outcomes 2019;5:3542.
77. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM,
Edvardsson N, Poci D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 19952008: a Swedish nationwide long-term case-control study. Eur Heart J 2013;34:10611067.
78. Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke:
what progress has been made?Neuroepidemiology 2013;40:227239.
79. Bakhai A, Darius H, De Caterina R, Smart A, Le Heuzey JY, Schilling RJ,
Zamorano JL, Shah M, Bramlage P, Kirchhof P. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the
PREFER in AF registry. Eur Heart J Qual Care Clin Outcomes 2016;2:299305.
80. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation
1998;98:946952.
81. Blum S, Muff C, Aeschbacher S, Ammann P, Erne P, Moschovitis G, Di Valentino
M, Shah D, Schlapfer J, Fischer A, Merkel T, Kuhne M, Sticherling C, Osswald S,
Conen D. Prospective assessment of sex-related differences in symptom status and health perception among patients with atrial fibrillation. J Am Heart Assoc
2017;6:e005401.
82. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH,
Sinagra G, Petrescu L, Tavazzi L, Maggioni AP, Lip GY. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot
General Registry. Am J Med 2015;128:509518.e2.
83. Ceornodolea AD, Bal R, Severens JL. Epidemiology and management of atrial fibrillation and stroke: review of data from four European countries. Stroke Res
Treat 2017;2017:8593207.
84. Chao TF, Lip GY, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW,
Hu YF, Chen TJ, Chiang CE, Chen SA. Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study. Stroke 2016;47:24622469.
85. Chao T-F, Liu C-J, Wang K-L, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, Tuan T-C,
Chen T-J, Lip GY. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?J Am Coll
Cardiol 2015;65:635642.
86. Dagres N, Chao T-F, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ,
Chen LY, Chen S-A, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J,
Kalra L, Kim Y-H, Lane DA, Lip GYH, Lubitz SA, Marquez MF, Potpara T, Pozzer
DL, Ruskin JN, Savelieva I, Teo WS, Tse H-F, Verma A, Zhang S, Chung MK,
Bautista-Vargas W-F, Chiang C-E, Cuesta A, Dan G-A, Frankel DS, Guo Y,
Hatala R, Lee YS, Murakawa Y, Pellegrini CN, Pinho C, Milan DJ, Morin DP,
Nadalin E, Ntaios G, Prabhu MA, Proietti M, Rivard L, Valentino M, Shantsila A.
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia
Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society
(LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?EP Europace 2018;20:13991421.
87. Esato M, Chun YH, An Y, Ogawa H, Wada H, Hasegawa K, Tsuji H, Abe M, Lip
GYH, Akao M. Clinical impact of asymptomatic presentation status in patients with paroxysmal and sustained atrial fibrillation: the Fushimi AF Registry. Chest
2017;152:12661275.
88. Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM,
Kowey PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP;
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Investigators. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed
Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes
2015;8:393402.
89. Frost L, Engholm G, Johnsen S, Moller H, Henneberg EW, Husted S. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation.
Arch Intern Med 2001;161:272276.
90. Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, Bergamasco
L, Boffano C, Valentini MC, Cesarani F, Scaglione M. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J Am Coll Cardiol 2013;62:19901997.
91. Garcia-Fernandez A, Roldan V, Rivera-Caravaca JM, Lip GYH, Marin F.
Applicability of the modified CHA2DS2-VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. Eur J Intern Med 2017;38:e21e22.
92. Gleason KT, Nazarian S, Dennison Himmelfarb CR. Atrial fibrillation symptoms and sex, race, and psychological distress: a literature review. J Cardiovasc Nurs
2018;33:137143.
93. Gomez-Outes A, Lagunar-Ruiz J, Terleira-Fernandez AI, Calvo-Rojas G, SuarezGea ML, Vargas-Castrillon E. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2016;68:25082521.
94. Graves KG, May HT, Jacobs V, Bair TL, Stevens SM, Woller SC, Crandall BG,
Cutler MJ, Day JD, Mallender C, Osborn JS, Peter Weiss J, Jared Bunch T. Atrial fibrillation incrementally increases dementia risk across all CHADS2 and
ESC Guidelines
459


<!-- PAGE 88 -->

### Page 88

.............................................................................................................................................................................
CHA2DS2VASc strata in patients receiving long-term warfarin. Am Heart J
2017;188:9398.
95. John RM, Michaud GF, Stevenson WG. Atrial fibrillation hospitalization, mortality,
and therapy. Eur Heart J 2018;39:39583960.
96. Kalantarian S, Ruskin JN. Atrial fibrillation and cognitive decline: phenomenon or epiphenomenon?Cardiol Clin 2016;34:279285.
97. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 2013;158:33846.
98. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
Circ Cardiovasc Qual Outcomes 2011;4:313320.
99. Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K,
Meinertz T, ATRIUM Study Group. Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry.
Clin Cardiol 2014;37:277284.
100. Kochhauser S, Joza J, Essebag V, Proietti R, Koehler J, Tsang B, Wulffhart Z,
Pantano A, Khaykin Y, Ziegler PD, Verma A. The impact of duration of atrial fibrillation recurrences on measures of health-related quality of life and symptoms. Pacing Clin Electrophysiol 2016;39:16672.
101. Konig S, Ueberham L, Schuler E, Wiedemann M, Reithmann C, Seyfarth M,
Sause A, Tebbenjohanns J, Schade A, Shin DI, Staudt A, Zacharzowsky U,
Andrie R, Wetzel U, Neuser H, Wunderlich C, Kuhlen R, Tijssen JGP, Hindricks
G, Bollmann A. In-hospital mortality of patients with atrial arrhythmias: insights from the German-wide Helios hospital network of 161 502 patients and 34 025
arrhythmia-related procedures. Eur Heart J 2018;39:39473957.
102. Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M.
Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 2016;68:22172228.
103. Kupper N, van den Broek K, Haagh E, van der Voort P, Widdershoven J,
Denollet J. Type D personality affects health-related quality of life in patients with lone atrial fibrillation by increasing symptoms related to sympathetic activation. J Psychosom Res 2018;115:4452.
104. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology
2011;76:914922.
105. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, Sebaoun A.
Characterization of different subsets of atrial fibrillation in general practice in
France: the ALFA study. The College of French Cardiologists. Circulation
1999;99:30283035.
106. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino
RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke
1996;27:17601764.
107. Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M, Kalarus Z,
Rasmussen LH, Popescu MI, Tica O, Hellum CF, Mortensen B, Tavazzi L,
Maggioni AP. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro
Observational Research Programme Pilot Survey on Atrial Fibrillation. Europace
2015;17:2431.
108. McCabe PJ, Rhudy LM, DeVon HA. Patients’ experiences from symptom onset to initial treatment for atrial fibrillation. J Clin Nurs 2015;24:786796.
109. McCabe PJ, Schumacher K, Barnason SA. Living with atrial fibrillation: a qualitative study. J Cardiovasc Nurs 2011;26:336344.
110. Meyre P, Blum S, Berger S, Aeschbacher S, Schoepfer H, Briel M, Osswald S,
Conen D. Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis. Can J Cardiol 2019;35:13321343.
111. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW,
Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ; European
Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur
Heart J 2005;26:24222434.
112. Overvad TF, Nielsen PB, Lip GY. Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score. Eur Heart J
Cardiovasc Pharmacother 2017;3:3741.
113. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994;89:224227.
114. Piccini
JP,
Fauchier
L.
Rhythm control in atrial fibrillation.
Lancet
2016;388:829840.
115. Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The epidemiology of atrial fibrillation and stroke. Cardiol Clin 2016;34:255268.
116. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL,
Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD,
Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering
Committee Investigators. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET
AF. J Am Heart Assoc 2016;5:e002197.
117. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J
Cardiol 2013;168:47444749.
118. Randolph TC, Simon DN, Thomas L, Allen LA, Fonarow GC, Gersh BJ, Kowey
PR, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson ED, Piccini JP;
ORBIT AF Investigators. Patient factors associated with quality of life in atrial fibrillation. Am Heart J 2016;182:135143.
119. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, Van Gelder
IC, Ellinor PT, Benjamin EJ. Symptoms and functional status of patients with atrial fibrillation: state-of-the-art and future research opportunities. Circulation
2012;125:29332943.
120. Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC; RACE
Investigators. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm 2014;11:939945.
121. Rivard L, Khairy P. Mechanisms, clinical significance, and prevention of cognitive impairment in patients with atrial fibrillation.
Can
J
Cardiol
2017;33:15561564.
122. Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M,
Horton R, Burkhardt JD, Lakkireddy D, Reddy YM, Casella M, Dello Russo A,
Tondo C, Natale A. Atrial fibrillation and the risk of incident dementia: a metaanalysis. Heart Rhythm 2012;9:17611768.
123. Schnabel RB, Michal M, Wilde S, Wiltink J, Wild PS, Sinning CR, Lubos E, Ojeda
FM, Zeller T, Munzel T, Blankenberg S, Beutel ME. Depression in atrial fibrillation in the general population. PLoS One 2013;8:e79109.
124. Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, Darius
H, Kotecha D, Caterina R, Kirchhof P. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart 2017;103:10241030.
125. Senoo K, Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa
Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita
T. Distribution of first-detected atrial fibrillation patients without structural heart diseases in symptom classifications. Circ J 2012;76:10201023.
126. Serpytis R, Navickaite A, Serpytiene E, Barysiene J, Marinskis G, Jatuzis D,
Petrulioniene Z, Laucevicius A, Serpytis P. Impact of atrial fibrillation on cognitive function, psychological distress, quality of life, and impulsiveness. Am J Med
2018;131:703.e1-703e5.
127. Siontis KC, Gersh BJ, Killian JM, Noseworthy PA, McCabe P, Weston SA, Roger
VL, Chamberlain AM. Typical, atypical, and asymptomatic presentations of newonset atrial fibrillation in the community: characteristics and prognostic implications. Heart Rhythm 2016;13:14181424.
128. Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter
T, Merioua I, Murin J, Naditch-Brule L, Ponikowski P, Rosenqvist M, SilvaCardoso J, Zharinov O, Brette S, Neill JO; RealiseAF investigators. Symptoms,
functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry.
Heart 2012;98:195201.
129. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey
KW, Gersh BJ, Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED,
Piccini JP. Drivers of hospitalization for patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation (ORBIT-AF). Am Heart J 2014;167:735742.e2.
130. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the
Renfrew/Paisley study. Am J Med 2002;113:359364.
131. Streur M, Ratcliffe SJ, Ball J, Stewart S, Riegel B. Symptom clusters in adults with chronic atrial fibrillation. J Cardiovasc Nurs 2017;32:296303.
132. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest 2007;132:12591264.
133. Ugowe FE, Jackson LRn. Atrial fibrillation and mortality risk: seeing the big picture. Eur Heart J Qual Care Clin Outcomes 2019;5:67.
134. Vermond RA, Crijns HJ, Tijssen JG, Alings AM, Van den Berg MP, Hillege HL,
Van Veldhuisen DJ, Van Gelder IC, Rienstra M; RACE II investigators. Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace 2014;16:14171425.
135. Walters TE, Wick K, Tan G, Mearns M, Joseph SA, Morton JB, Sanders P,
Bryant C, Kistler PM, Kalman JM. Psychological distress and suicidal ideation in patients with atrial fibrillation: prevalence and response to management strategy. J Am Heart Assoc 2018;7:e005502.
136. Walters TE, Wick K, Tan G, Mearns M, Joseph SA, Morton JB, Sanders P,
Bryant C, Kistler PM, Kalman JM. Symptom severity and quality of life in patients with atrial fibrillation: psychological function outweighs clinical predictors. Int J
Cardiol 2019;279:8489.
137. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB, Larson MG,
Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart
Study. JAMA 2003;290:10491056.


<!-- PAGE 89 -->

### Page 89

.............................................................................................................................................................................
138. Wijesurendra
RS,
Casadei
B.
Atrial fibrillation:
effects beyond the atrium?Cardiovasc Res 2015;105:238247.
139. Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: a systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol 2015;191:172177.
140. Ziff OJ, Carter PR, McGowan J, Uppal H, Chandran S, Russell S, Bainey KR,
Potluri R. The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: insights from the United Kingdom ACALM registry.
Int J Cardiol 2018;252:117121.
141. Sepehri Shamloo A, Dagres N, Mussigbrodt A, Stauber A, Kircher S, Richter S,
Dinov B, Bertagnolli L, Husser-Bollmann D, Bollmann A, Hindricks G, Arya A.
Atrial fibrillation and cognitive impairment: new insights and future directions.
Heart Lung Circ 2020;29:6985.
142. Conen D, Rodondi N, Muller A, Beer JH, Ammann P, Moschovitis G, Auricchio
A, Hayoz D, Kobza R, Shah D, Novak J, Schlapfer J, Di Valentino M,
Aeschbacher S, Blum S, Meyre P, Sticherling C, Bonati LH, Ehret G, Moutzouri
E, Fischer U, Monsch AU, Stippich C, Wuerfel J, Sinnecker T, Coslovsky M,
Schwenkglenks M, Kuhne M, Osswald S, Swiss AFSI. Relationships of overt and silent brain lesions with cognitive function in patients with atrial fibrillation. J Am
Coll Cardiol 2019;73:989999.
143. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,
Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
Popescu BA, Schotten U, Van Putte B, Vardas P, ESC Scientific Document
Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:28932962.
144. Boriani G, Diemberger I, Ziacchi M, Valzania C, Gardini B, Cimaglia P,
Martignani C, Biffi M. AF burden is important  fact or fiction?Int J Clin Pract
2014;68:444452.
145. Boriani G, Pettorelli D. Atrial fibrillation burden and atrial fibrillation type: clinical significance and impact on the risk of stroke and decision making for longterm anticoagulation. Vascul Pharmacol 2016;83:2635.
146. Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195
patients continuously monitored with implantable devices. J Am Coll Cardiol
2014;63:28402848.
147. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S,
Schotten U, Rienstra M. Lone atrial fibrillation: does it exist?J Am Coll Cardiol
2014;63:17151723.
148. Lip GYH, Collet JP, Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F,
Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N,
Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B, ESC Scientific
Document Group. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart
Rhythm Association (EHRA) and European Society of Cardiology Working
Group on Thrombosis, endorsed by the ESC Working Group on Valvular
Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart
Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South
African Heart (SA Heart) Association and Sociedad Latinoamericana de
Estimulacion
Cardiaca y
Electrofisiologia
(SOLEACE).
Europace
2017;19:17571758.
149. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Jr., Ellinor
PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB,
Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused update of the 2014 AHA/
ACC/HRS Guideline for the management of patients with atrial fibrillation.
Circulation 2019;;140:e125e151.
150. NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger D,
Amerena J, Attia J, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C,
Hall T, Haqqani H, Hendriks J, Hespe C, Hung J, Kalman JM, Sanders P,
Worthington J, Yan TD, Zwar N. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical
Guidelines for the diagnosis and management of atrial fibrillation 2018. Heart
Lung Circ 2018;27:12091266.
151. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC,
Heidbuchel H, Hindricks G, Camm AJ. The 4S-AF scheme (Stroke Risk;
Symptoms; Severity of Burden; Substrate): A novel approach to in-depth characterization (rather than Classification) of atrial fibrillation. Thromb Haemost
2020; doi: 10.1055/s-0040-1716408.
152. Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P,
Noseworthy PA, Perez MV, Turakhia MP,American Heart Association
Council on Clinical Cardiology, Council on Cardiovascular and Stroke
Nursing, Council on Quality of Care and Outcomes Research, and Stroke
Council. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation
2018;137:e623e644.
153. Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006;3:14451452.
154. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T,
Dan GA, Kalarus Z, Diemberger I, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF
Long-Term General Registry Investigators Steering Committee (National
Coordinators). Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research
Programme on Atrial Fibrillation (EORP-AF) long-term general registry.
Europace 2018;20:747757.
155. Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, Kowey PR, Mahaffey
KW, Hylek E, Peterson ED, Piccini JP, Fonarow GC; ORBIT-AF Investigators and Patients. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC Heart Fail 2017;5:4452.
156. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders
P, McGavigan AD. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur
Heart J 2016;37:15911602.
157. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz
J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:24642471.
158. Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE,
Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI
48 Investigators. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective
Anticoagulation With Factor Xa Next Generation in Atrial FibrillationThrombolysis in
Myocardial
Infarction
48).
Circ
Arrhythm
Electrophysiol
2017;10:e004267.
159. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ,
Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD,
Mahaffey KW, Fox KA, Califf RM, Piccini JP; ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs.
paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J
2015;36:288296.
160. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL.
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll
Cardiol 2000;35:183187.
161. Takabayashi K, Hamatani Y, Yamashita Y, Takagi D, Unoki T, Ishii M, Iguchi M,
Masunaga N, Ogawa H, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe
M, Lip GY, Akao M. Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation: the Fushimi Atrial Fibrillation Registry. Stroke
2015;46:33543361.
162. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, Lip GY,
Crijns HJ; Euro Heart Survey Investigators. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?Eur
Heart J 2008;29:915922.
163. Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, Harrison TN, Liu TI,
Solomon MD. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM Study.
JAMA Cardiol 2018;3:601608.
164. Ecker V, Knoery C, Rushworth G, Rudd I, Ortner A, Begley D, Leslie SJ. A
review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation. Clin Cardiol 2018;41:862870.
165. Nyong J, Amit G, Adler AJ, Owolabi OO, Perel P, Prieto-Merino D, Lambiase P,
Casas JP, Morillo CA. Efficacy and safety of ablation for people with nonparoxysmal atrial fibrillation. Cochrane Database Syst Rev 2016;11:CD012088.
166. Piccini JP, Passman R, Turakhia M, Connolly AT, Nabutovsky Y, Varma N. Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices.
Europace
2019;21:404413.
167. Deng H, Bai Y, Shantsila A, Fauchier L, Potpara TS, Lip GYH. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. Clin Res Cardiol 2017;106:813823.
168. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau
CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES,
Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120129.
169. Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic
MC, Lip GYH. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the
Belgrade Atrial Fibrillation Study. Chest 2012;141:339347.
170. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS,
Corradi D, D’Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R,
Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM,
Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner DR, Nattel S. EHRA/
HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition,
characterization, and clinical implication. Europace 2016;18:14551490.
ESC Guidelines
461


<!-- PAGE 90 -->

### Page 90

.............................................................................................................................................................................
171. Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL, Conroy JM,
Al-Khatib SM, Hess PL, Kirchhof P, De Bono J, Lip GY, Banerjee A, Ruskin J,
Blendea D, Camm AJ. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014;35:14481456.
172. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM,
Anderson CS, Antoniou S, Benjamin EJ, Boriani G, Brachmann J, Brandes A,
Chao TF, Conen D, Engdahl J, Fauchier L, Fitzmaurice DA, Friberg L, Gersh BJ,
Gladstone DJ, Glotzer TV, Gwynne K, Hankey GJ, Harbison J, Hillis GS, Hills
MT, Kamel H, Kirchhof P, Kowey PR, Krieger D, Lee VWY, Levin LA, Lip GYH,
Lobban T, Lowres N, Mairesse GH, Martinez C, Neubeck L, Orchard J, Piccini
JP, Poppe K, Potpara TS, Puererfellner H, Rienstra M, Sandhu RK, Schnabel RB,
Siu CW, Steinhubl S, Svendsen JH, Svennberg E, Themistoclakis S, Tieleman
RG, Turakhia MP, Tveit A, Uittenbogaart SB, Van Gelder IC, Verma A, Wachter
R, Yan BP, SCREEN CollaboratorsAF-. Screening for atrial fibrillation: a report of the
AF-SCREEN
International
Collaboration.
Circulation
2017;135:18511867.
173. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, Banerjee A,
Gorenek B, Brachmann J, Varma N, Glotz de Lima G, Kalman J, Claes N, Lobban T,
Lane D, Lip GYH, Boriani G, ESC Scientific Document Group. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society
(APHRS),
and
Sociedad
Latinoamericana de
Estimulacion
Cardiaca y
Electrofisiologia (SOLAECE). Europace 2017;19:15891623.
174. Padfield GJ, Steinberg C, Swampillai J, Qian H, Connolly SJ, Dorian P, Green
MS, Humphries KH, Klein GJ, Sheldon R, Talajic M, Kerr CR. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian
Registry of Atrial Fibrillation. Heart Rhythm 2017;14:801807.
175. Vidal-Perez R, Otero-Ravina F, Lado-Lopez M, Turrado-Turrado V, RodriguezMoldes E, Gomez-Vazquez JL, de Frutos-de Marcos C, de Blas-Abad P, BesadaGesto R, Gonzalez-Juanatey JR; BARBANZA Investigators. The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study. Int J Cardiol
2013;168:21462152.
176. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den
Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis.
J
Am
Coll
Cardiol
2010;55:725731.
177. Hobbelt AH, Spronk HM, Crijns H, Ten Cate H, Rienstra M, Van Gelder IC.
Prethrombotic state in young very low-risk patients with atrial fibrillation. J Am
Coll Cardiol 2017;69:19901992.
178. Habibi M, Samiei S, Ambale Venkatesh B, Opdahl A, Helle-Valle TM, Zareian M,
Almeida AL, Choi EY, Wu C, Alonso A, Heckbert SR, Bluemke DA, Lima JA.
Cardiac magnetic resonance-measured left atrial volume and function and incident atrial fibrillation:
results from
MESA
(Multi-Ethnic
Study of
Atherosclerosis). Circ Cardiovasc Imaging 2016;9:e004299.
179. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP,
Van Gelder IC, Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH,
Halytska M, Deng WQ, Israel CW, Healey JS; ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation
2014;129:20942099.
180. Guichard JB, Nattel S. Atrial Cardiomyopathy: A useful notion in cardiac disease management or a passing fad?J Am Coll Cardiol 2017;70:756765.
181. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy,
atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol 2015;65:22392251.
182. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet
2016;388:806817.
183. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost
2014;112:276286.
184. Wilson JM, Jungner YG. [Principles and practice of mass screening for disease].
Bol Oficina Sanit Panam 1968;65:281393.
185. Welton NJ, McAleenan A, Thom HH, Davies P, Hollingworth W, Higgins JP,
Okoli G, Sterne JA, Feder G, Eaton D, Hingorani A, Fawsitt C, Lobban T,
Bryden P, Richards A, Sofat R. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis.
Health
Technol
Assess
2017;21:1236.
186. Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS,
Carter C, Baca-Motes K, Felicione E, Sarich T, Topol EJ. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA 2018;320:146155.
187. Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J,
Brandes A, Bustamante A, Casadei B, Crijns H, Doehner W, Engstrom G,
Fauchier L, Friberg L, Gladstone DJ, Glotzer TV, Goto S, Hankey GJ, Harbison
JA, Hobbs FDR, Johnson LSB, Kamel H, Kirchhof P, Korompoki E, Krieger DW,
Lip GYH, Lochen ML, Mairesse GH, Montaner J, Neubeck L, Ntaios G, Piccini
JP, Potpara TS, Quinn TJ, Reiffel JA, Ribeiro ALP, Rienstra M, Rosenqvist M,
Sakis T, Sinner MF, Svendsen JH, Van Gelder IC, Wachter R, Wijeratne T, Yan
B. Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN
International Collaboration. Circulation 2019;140:18341850.
188. Yan BP, Lai WHS, Chan CKY, Chan SC, Chan LH, Lam KM, Lau HW, Ng CM,
Tai LY, Yip KW, To OTL, Freedman B, Poh YC, Poh MZ. Contact-free screening of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic signals. J Am Heart Assoc 2018;7.
189. Orchard J, Lowres N, Freedman SB, Ladak L, Lee W, Zwar N, Peiris D,
Kamaladasa Y, Li J, Neubeck L. Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph
(iECG): a feasibility study. Eur J Prev Cardiol 2016;23:1320.
190. Lampert R. Screening for atrial fibrillation using smartphone-based technology and layperson volunteers: high-tech meets community participatory research for the best of both worlds. Heart Rhythm 2018;15:13121313.
191. Lahdenoja O, Hurnanen T, Iftikhar Z, Nieminen S, Knuutila T, Saraste A,
Kiviniemi T, Vasankari T, Airaksinen J, Pankaala M, Koivisto T. Atrial fibrillation detection via accelerometer and gyroscope of a smartphone. IEEE J Biomed
Health Inform 2018;22:108118.
192. Freedman B. Screening for atrial fibrillation using a smartphone: is there an app for that?J Am Heart Assoc 2016;5.
193. Chan NY, Choy CC. Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. Heart 2017;103:2431.
194. Chan PH, Wong CK, Poh YC, Pun L, Leung WW, Wong YF, Wong MM, Poh
MZ, Chu DW, Siu CW. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J Am Heart Assoc 2016;5.
195. Brasier N, Raichle CJ, Dorr M, Becke A, Nohturfft V, Weber S, Bulacher F,
Salomon L, Noah T, Birkemeyer R, Eckstein J. Detection of atrial fibrillation with a smartphone camera: first prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace 2019;21:4147.
196. Tison GH, Sanchez JM, Ballinger B, Singh A, Olgin JE, Pletcher MJ, Vittinghoff E,
Lee ES, Fan SM, Gladstone RA, Mikell C, Sohoni N, Hsieh J, Marcus GM. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA
Cardiol 2018;3:409416.
197. Li KHC, White FA, Tipoe T, Liu T, Wong MC, Jesuthasan A, Baranchuk A, Tse
G, Yan BP. The current state of mobile phone apps for monitoring heart rate,
heart rate variability, and atrial fibrillation: narrative review. JMIR Mhealth
Uhealth 2019;7:e11606.
198. Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K,
Lindsay BD, Wazni OM, Tarakji KG. Smartwatch algorithm for automated detection of atrial fibrillation. J Am Coll Cardiol 2018;71:23812388.
199. Wasserlauf J, You C, Patel R, Valys A, Albert D, Passman R. Smartwatch performance for the detection and quantification of atrial fibrillation. Circ Arrhythm
Electrophysiol 2019;12:e006834.
200. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh
BJ, Carter RE, Yao X, Rabinstein AA, Erickson BJ, Kapa S, Friedman PA.
Anartificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet 2019;394:861867.
201. Turakhia MP, Desai M, Hedlin H, Rajmane A, Talati N, Ferris T, Desai S, Nag D,
Patel M, Kowey P, Rumsfeld JS, Russo AM, Hills MT, Granger CB, Mahaffey
KW, Perez MV. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. Am Heart J
2019;207:6675.
202. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, Liu
Y, Liu F, Feng M, Chen Y, Lip GYH; MAFA II Investigators. Mobile photoplethysmographic technology to detect atrial fibrillation.
J
Am
Coll
Cardiol
2019;74:23652375.
203. Harris K, Edwards D, Mant J. How can we best detect atrial fibrillation?J R Coll
Physicians Edinb 2012;42 Suppl 18:522.
204. Wiesel J, Wiesel D, Suri R, Messineo FC. The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients. Pacing Clin Electrophysiol
2004;27:639643.
205. Wiesel J, Fitzig L, Herschman Y, Messineo FC. Detection of atrial fibrillation using a
modified microlife blood pressure monitor.
Am
J
Hypertens
2009;22:848852.
206. Stergiou GS, Karpettas N, Protogerou A, Nasothimiou EG, Kyriakidis M.
Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. J Hum Hypertens 2009;23:654658.
207. Willits I, Keltie K, Craig J, Sims A. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension:
aNICE
Medical
Technology
Guidance.
Appl
Health
Econ
Health
Policy
2014;12:255265.
208. Desteghe L, Raymaekers Z, Lutin M, Vijgen J, Dilling-Boer D, Koopman P,
Schurmans J, Vanduynhoven P, Dendale P, Heidbuchel H. Performance of


<!-- PAGE 91 -->

### Page 91

.............................................................................................................................................................................
handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace 2017;19:2939.
209. Kaasenbrood F, Hollander M, Rutten FH, Gerhards LJ, Hoes AW, Tieleman RG.
Yield of screening for atrial fibrillation in primary care with a hand-held, singlelead electrocardiogram device during influenza vaccination.
Europace
2016;18:15141520.
210. Wiesel J, Abraham S, Messineo FC. Screening for asymptomatic atrial fibrillation while monitoring the blood pressure at home: trial of regular versus irregular pulse for prevention of stroke
(TRIPPS
2.0).
Am
J
Cardiol
2013;111:15981601.
211. Jacobs MS, Kaasenbrood F, Postma MJ, van Hulst M, Tieleman RG. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld,
single-lead electrocardiogram device in the
Netherlands.
Europace
2018;20:1218.
212. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, Bennett AA,
Briffa T, Bauman A, Martinez C, Wallenhorst C, Lau JK, Brieger DB, Sy RW,
Freedman SB. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The
SEARCH-AF study. Thromb Haemost 2014;111:11671176.
213. William AD, Kanbour M, Callahan T, Bhargava M, Varma N, Rickard J,
Saliba W, Wolski K, Hussein A, Lindsay BD, Wazni OM, Tarakji KG.
Assessing the accuracy of an automated atrial fibrillation detection algorithm using smartphone technology: the iREAD Study. Heart Rhythm
2018;15:15611565.
214. Nemati S, Ghassemi MM, Ambai V, Isakadze N, Levantsevych O, Shah A,
Clifford GD. Monitoring and detecting atrial fibrillation using wearable technology. Conf Proc IEEE Eng Med Biol Soc 2016;2016:33943397.
215. Petryszyn P, Niewinski P, Staniak A, Piotrowski P, Well A, Well M, Jeskowiak I,
Lip G, Ponikowski P. Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. PLoS One 2019;14:e0213198.
216. Orchard J, Lowres N, Neubeck L, Freedman B. Atrial fibrillation: is there enough evidence to recommend opportunistic or systematic screening?Int J
Epidemiol 2018;47:1361.
217. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation
2015;131:21762184.
218. Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, Gravenor
MB. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF Study. Circulation
2017;136:17841794.
219. Turakhia MP, Shafrin J, Bognar K, Goldman DP, Mendys PM, Abdulsattar Y,
Wiederkehr D, Trocio J. Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States. Am J Cardiol 2015;116:733739.
220. Fay MR, Fitzmaurice DA, Freedman B. Screening of older patients for atrial fibrillation in general practice: current evidence and its implications for future practice. Eur J Gen Pract 2017;23:246253.
221. Boriani G, Valzania C, Biffi M, Diemberger I, Ziacchi M, Martignani C.
Asymptomatic lone atrial fibrillation  how can we detect the arrhythmia?Curr
Pharm Des 2015;21:659666.
222. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J,
Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The
SAFE study. Health Technol Assess 2005;9:iii-iv, ix-x, 174.
223. Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, FrykmanKull V, Levin LA. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 2015;17:10231029.
224. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213222.
225. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention.
Circulation 2013;127:930937.
226. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M,
Lewalter T, Camm JA, Singer DE. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35:508516.
227. Lowres N, Krass I, Neubeck L, Redfern J, McLachlan AJ, Bennett AA, Freedman
SB. Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. Int J Clin Pharm 2015;37:11111120.
228. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D.
The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace
2014;16:965972.
229. De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH,
Alings M, Tijssen JGP, Brugemann J, Geelhoed B, Hillege HL, Tukkie R, Hemels
ME, Tieleman RG, Ranchor AV, Van Veldhuisen DJ, Crijns H, Van Gelder IC.
Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. Europace
2019;21:563571.
230. Schnabel RB, Pecen L, Rzayeva N, Lucerna M, Purmah Y, Ojeda FM, De
Caterina R, Kirchhof P. Symptom burden of atrial fibrillation and its relation to interventions and outcome in Europe. J Am Heart Assoc 2018;7.
231. Bjo¨rkenheim A, Brandes A, Magnuson A, Chemnitz A, Svedberg L, Edvardsson
N, Poc¸i D. Assessment of atrial fibrillation  specific symptoms before and 2
years after atrial fibrillation ablation: do patients and physicians differ in their perception of symptom relief?JACC: Clinical Electrophysiology 2017;3:11681176.
232. Sandhu RK, Smigorowsky M, Lockwood E, Savu A, Kaul P, McAlister FA. Impact of electrical cardioversion on quality of life for the treatment of atrial fibrillation. Can J Cardiol 2017;33:450455.
233. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD,
Sharma SC, Atwood JE, Jacobson AK, Lewis HD, Jr., Raisch DW, Ezekowitz
MD;
Sotalol
Amiodarone
Atrial
Fibrillation
Efficacy
Trial
Investigators.
Amiodarone versus sotalol for atrial fibrillation.
N
Engl
J
Med
2005;352:18611872.
234. Gilbert KA, Hogarth AJ, MacDonald W, Lewis NT, Tan LB, Tayebjee MH.
Restoration of sinus rhythm results in early and late improvements in the functional reserve of the heart following direct current cardioversion of persistent
AF: FRESH-AF. Int J Cardiol 2015;199:121125.
235. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, Hocini M,
Extramiana F, Sacher F, Bordachar P, Klein G, Weerasooriya R, Clementy J,
Haissaguerre M. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:24982505.
236. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F, Jr., Bates ER,
Lehmann MH, Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady
F. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J
Med 2006;354:934941.
237. Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal
A, Arribas F, Fernandez-Lozano I, Bodegas A, Cobos A, Matia R, PerezVillacastin J, Guerra JM, Avila P, Lopez-Gil M, Castro V, Arana JI, Brugada J;
SARA investigators. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA
study). Eur Heart J 2014;35:501507.
238. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, De Sanctis V,
Pappalardo A, Laurenzi F, Avella A, Casella M, Dello Russo A, Romeo F,
Pelargonio G, Tondo C. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol
2009;20:2228.
239. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L,
Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu
CY, Berry SM, Berry DA; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation:
a randomized controlled trial.
JAMA
2010;303:333340.
240. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash
D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D,
Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale A.
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:26342640.
241. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns
LD, Beresh H, Healey JS, Natale A; RAAFT Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014;311:692700.
242. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H,
Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS, Hansen PS.
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl
J Med 2012;367:15871595.
243. Pokorney SD, Kim S, Thomas L, Fonarow GC, Kowey PR, Gersh BJ, Mahaffey
KW, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators. Cardioversion and subsequent quality of life and natural history of atrial fibrillation. Am Heart J 2017;185:5966.
244. Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, Novak P, Calzolari V,
Khaykin Y, Guerra PG, Nair G, Torrecilla EG, Verma A. Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: substudy of the STAR AF randomized trial. Can J Cardiol
2013;29:12111217.
245. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J,
Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns H,
Van Gelder IC; RACE Investigators. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation:
results of the RACE 3 trial. Eur Heart J 2018;39:29872996.
ESC Guidelines
463


<!-- PAGE 92 -->

### Page 92

.............................................................................................................................................................................
246. Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L,
Kenneback G, Rubulis A, Malmborg H, Raatikainen P, Lonnerholm S, Hoglund
N, Mortsell D. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial.
JAMA 2019;321:10591068.
247. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels
MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL; CABANA
Investigators. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial.
JAMA 2019.
248. Gaita F, Scaglione M, Battaglia A, Matta M, Gallo C, Galata M, Caponi D, Di
Donna P, Anselmino M. Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of followup?Europace 2018;20:443450.
249. Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M,
Mondillo S, Edvardsen T, Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A,
Potpara TS, Van Gelder IC, Gorenek B, Mabo P, Lancellotti P, Kuck KH,
Popescu BA, Hindricks G, Habib G, Cardim NM, Cosyns B, Delgado V, Haugaa
KH, Muraru D, Nieman K, Boriani G, Cohen A. EACVI/EHRA Expert
Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation.
Eur
Heart
J
Cardiovasc
Imaging
2016;17:355383.
250. Delgado V, Di Biase L, Leung M, Romero J, Tops LF, Casadei B, Marrouche N,
Bax JJ. Structure and function of the left atrium and left atrial appendage: AF
and stroke implications. J Am Coll Cardiol 2017;70:31573172.
251. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ,
Rao SN, DiBella EV, Segerson NM, Daccarett M, Windfelder J, McGann CJ,
Parker D, MacLeod RS, Marrouche NF. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119:17581767.
252. Cameli M, Lisi M, Righini FM, Massoni A, Natali BM, Focardi M, Tacchini D,
Geyer A, Curci V, Di Tommaso C, Lisi G, Maccherini M, Chiavarelli M, Massetti
M, Tanganelli P, Mondillo S. Usefulness of atrial deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgitation secondary to mitral valve prolapse.
Am J Cardiol 2013;111:595601.
253. Nakamori S, Nezafat M, Ngo LH, Manning WJ, Nezafat R. Left atrial epicardial fat volume is associated with atrial fibrillation: a prospective cardiovascular magnetic resonance 3D Dixon Study. J Am Heart Assoc 2018;7.
254. Murphy A, Banerjee A, Breithardt G, Camm AJ, Commerford P, Freedman B,
Gonzalez-Hermosillo JA, Halperin JL, Lau CP, Perel P, Xavier D, Wood D,
Jouven X, Morillo CA. The World Heart Federation roadmap for nonvalvular atrial fibrillation. Glob Heart 2017;12:273284.
255. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos
EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L,
Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S,
Wright L, Vardas P. European Society of Cardiology: Cardiovascular Disease
Statistics 2019. Eur Heart J 2020;41:1285.
256. Charles C, Whelan T, Gafni A. What do we mean by partnership in making decisions about treatment?BMJ 1999;319:780782.
257. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT,
Hylek EM, LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS,
Pisters R, Stewart S, Wood K, Potpara TS, Gorenek B, Conti JB, Keegan R,
Power S, Hendriks J, Ritter P, Calkins H, Violi F, Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their management: the
European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society
(APHRS),
and
Sociedad
Latinoamericana de
Estimulacion
Cardiaca y
Electrofisiologia (SOLEACE). Europace 2015;17:17471769.
258. Bergtun S, Oterhals K, Fridlund B. Patients’ experiences 1-6 months after atrial fibrillation ablation: an holistic perspective. J Adv Nurs 2019;75:150160.
259. Borg Xuereb C, Shaw RL, Lane DA. Patients’ and physicians’ experiences of atrial fibrillation consultations and anticoagulation decision-making: a multiperspective IPA design. Psychol Health 2016;31:436455.
260. Loewen PS, Ji AT, Kapanen A, McClean A. Patient values and preferences for antithrombotic therapy in atrial fibrillation. A narrative systematic review.
Thromb Haemost 2017;117:10071022.
261. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation: where we are and where we should be going. Circulation 2014;129:704710.
262. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers.
Med J Aust 2007;186:175180.
263. Hess EP, Knoedler MA, Shah ND, Kline JA, Breslin M, Branda ME, Pencille LJ, Asplin
BR, Nestler DM, Sadosty AT, Stiell IG, Ting HH, Montori VM. The chest pain choice decision aid: a randomized trial. Circ Cardiovasc Qual Outcomes 2012;5:251259.
264. Lane DA, Meyerhoff J, Rohner U, Lip GYH. Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: results of a conjoint analysis. Clin
Cardiol 2018;41:855861.
265. Lindberg T, Sanmartin Berglund J, Elmstahl S, Bohman DM. Older individuals’
need for knowledge and follow-up about their chronic atrial fibrillation, lifelong medical treatment and medical controls. Scand J Caring Sci 2017;31:10221030.
266. Palacio AM, Kirolos I, Tamariz L. Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence 2015;9:133138.
267. Lane DA, Lip GY. Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation.
Thromb Haemost 2014;111:381383.
268. MacLean S, Mulla S, Akl EA, Jankowski M, Vandvik PO, Ebrahim S, McLeod S,
Bhatnagar N, Guyatt GH. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e1Se23S.
269. Desteghe L, Engelhard L, Raymaekers Z, Kluts K, Vijgen J, Dilling-Boer D,
Koopman P, Schurmans J, Dendale P, Heidbuchel H. Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire. Int J
Cardiol 2016;223:906914.
270. Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 Survey of atrial fibrillation and stroke: gaps in knowledge and perspective, opportunities for improvement. J Stroke Cerebrovasc Dis 2015;24:1691700.
271. Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J
Cardiol 2006;110:354358.
272. McCabe PJ, Schad S, Hampton A, Holland DE. Knowledge and self-management behaviors of patients with recently detected atrial fibrillation. Heart Lung
2008;37:7990.
273. Ihara M, Washida K. Linking atrial fibrillation with Alzheimer’s disease: epidemiological,
pathological,
and mechanistic evidence.
J
Alzheimers
Dis
2018;62:6172.
274. Lip GYH, Lane DA, Sarwar S. Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation. Eur Heart J
2017;38:29802982.
275. Guo Y, Lane DA, Wang L, Chen Y, Lip GYH; mAF-App II Trial investigators.
Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: the mAFA (mAF-App)
II randomised trial. Int J Clin Pract 2019:e13352.
276. Franchi C, Antoniazzi S, Ardoino I, Proietti M, Marcucci M, Santalucia P,
Monzani V, Mannucci PM, Nobili A, Collaborators S-A. Simulation-based education for physicians to increase oral anticoagulants in hospitalized elderly patients with atrial fibrillation. Am J Med 2019;132:e634e647.
277. Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian
Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O,
Tajer C, de Barros ESPGM, Roettig ML, Huo Y, Granger CB; IMPACT-AF
Investigators. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation
(IMPACT-AF):
an international,
clusterrandomised trial. Lancet 2017;390:17371746.
278. Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on nonvitamin K antagonist oral anticoagulants. Thromb Haemost 2017;117:209218.
279. Parimbelli E, Sacchi L, Budasu R, Napolitano C, Peleg M, Quaglini S. The role of nurses in e-health: the MobiGuide project experience. Stud Health Technol
Inform 2016;225:153157.
280. Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF App trial. Am J Med 2017;130:13881396.e6.
281. Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P,
Heidbuchel H, Dean V, Kirchhof P, European Society of Cardiology (ESC)
Atrial Fibrillation Guidelines Taskforce, the CATCH ME consortium, and the
European Heart Rhythm Association (EHRA). European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. Europace 2018;20:225233.
282. Lee J-A, Evangelista LS, Moore AA, Juth V, Guo Y, Gago-Masague S, Lem
CG, Nguyen M, Khatibi P, Baje M, Amin AN. Feasibility study of a mobile health intervention for older adults on oral anticoagulation therapy.
Gerontol Geriatr Med 2016;2. doi:10.1177/2333721416672970. Published
2016 Oct 7.
283. Stephan LS, Dytz Almeida E, Guimaraes RB, Ley AG, Mathias RG, Assis MV,
Leiria TL. Processes and recommendations for creating mHealth apps for lowincome populations. JMIR Mhealth Uhealth 2017;5:e41.
284. Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.
Cochrane Database Syst Rev 2017;4:CD008600.


<!-- PAGE 93 -->

### Page 93

.............................................................................................................................................................................
285. Man-Son-Hing M, Laupacis A, O’Connor AM, Biggs J, Drake E, Yetisir E, Hart
RG. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation:
a randomized controlled trial.
JAMA
1999;282:737743.
286. McAlister FA, Man-Son-Hing M, Straus SE, Ghali WA, Anderson D, Majumdar
SR, Gibson P, Cox JL, Fradette M; Decision Aid in Atrial Fibrillation
Investigators. Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation:
a cluster randomized trial.
CMAJ
2005;173:496501.
287. Thomson RG, Eccles MP, Steen IN, Greenaway J, Stobbart L, Murtagh MJ, May
CR. A patient decision aid to support shared decision-making on antithrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care 2007;16:216223.
288. Eckman MH, Costea A, Attari M, Munjal J, Wise RE, Knochelmann C, Flaherty
ML, Baker P, Ireton R, Harnett BM, Leonard AC, Steen D, Rose A, Kues J.
Shared decision-making tool for thromboprophylaxis in atrial fibrillation  a feasibility study. Am Heart J 2018;199:1321.
289. Eckman MH, Lip GY, Wise RE, Speer B, Sullivan M, Walker N, Kissela B,
Flaherty ML, Kleindorfer D, Baker P, Ireton R, Hoskins D, Harnett BM, Aguilar
C, Leonard AC, Arduser L, Steen D, Costea A, Kues J. Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation. Am
Heart J 2016;176:1727.
290. Karlsson LO, Nilsson S, Bang M, Nilsson L, Charitakis E, Janzon M. A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: a cluster-randomized trial in a Swedish primary care setting (the CDS-AF study). PLoS Med
2018;15:e1002528.
291. Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros ESPGM, Atar
D, Wallentin
L, Granger CB, Alexander JH; ARISTOTLE
Investigators.
Echocardiographic risk factors for stroke and outcomes in patients with atrial fibrillation anticoagulated with apixaban or warfarin.
Stroke
2017;48:32663273.
292. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA,
Blaauw Y, Tieleman RG. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J
2012;33:26922699.
293. Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C,
Abhayaratna WP, Chan YK, Esterman A, Thompson DR, Scuffham PA,
Carrington MJ. Standard versus atrial fibrillation-specific management strategy
(SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet 2015;385:775784.
294. Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S, Sapp JL, Gray
C, Abdelwahab A, Parkash R. An integrated management approach to atrial fibrillation. J Am Heart Assoc 2016;5.
295. Wijtvliet E, Tieleman RG, van Gelder IC, Pluymaekers NAHA, Rienstra M,
Folkeringa RJ, Bronzwaer P, Elvan A, Elders J, Tukkie R, Luermans JGLM, Van
Asselt ADIT, Van Kuijk SMJ, Tijssen JG, Crijns HJGM; RACE Investigators.
Nurse-led vs. usual-care for atrial fibrillation. Eur Heart J 2020;41:634641.
296. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R,
Lau DH, Sanders P, Hendriks JML. Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart 2017;103:19471953.
297. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci
2011;6:42.
298. Lip GYH, Lane DA, Potpara TS. Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Eur Heart J 2018;39:14041406.
299. Seligman WH, Das-Gupta Z, Jobi-Odeneye AO, Arbelo E, Banerjee A,
Bollmann A, Caffrey-Armstrong B, Cehic DA, Corbalan R, Collins M,
Dandamudi G, Dorairaj P, Fay M, Van Gelder IC, Goto S, Granger CB, Gyorgy
B, Healey JS, Hendriks JM, Hills MT, Hobbs FDR, Huisman MV, Koplan KE, Lane
DA, Lewis WR, Lobban T, Steinberg BA, McLeod CJ, Moseley S, Timmis A,
Yutao G, Camm AJ. Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International
Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. Eur Heart J 2020;41:11321140.
300. Dobler CC, Harb N, Maguire CA, Armour CL, Coleman C, Murad MH.
Treatment burden should be included in clinical practice guidelines. BMJ
2018;363:k4065.
301. Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR,
Montori VM. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat
Outcome Meas 2012;3:3949.
302. Tran VT, Montori VM, Eton DT, Baruch D, Falissard B, Ravaud P. Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions. BMC Med
2012;10:68.
303. Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 2005;20:479482.
304. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm
Ther 2001;26:331342.
305. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF,
Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.
Arch
Intern
Med
2006;166:18361841.
306. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177186.
307. May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ
2009;339:b2803.
308. Wilcox AR, Dragnev MC, Darcey CJ, Siegel CA. A new tool to measure the burden of Crohn’s disease and its treatment: do patient and physician perceptions match?Inflamm Bowel Dis 2010;16:645650.
309. Bohlen K, Scoville E, Shippee ND, May CR, Montori VM. Overwhelmed patients: a videographic analysis of how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters.
Diabetes Care 2012;35:4749.
310. Buffel du Vaure C, Ravaud P, Baron G, Barnes C, Gilberg S, Boutron I.
Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. BMJ Open
2016;6:e010119.
311. Potpara TS, Mihajlovic M, Zec N, Marinkovic M, Kovacevic V, Simic J, Kocijancic
A, Vajagic L, Jotic A, Mujovic N, Stankovic G. Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants and implications for integrated holistic management of the arrhythmia. Europace 2020;
doi:10.1093/europace/euaa210.
312. Tran VT, Harrington M, Montori VM, Barnes C, Wicks P, Ravaud P. Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform. BMC Med 2014;12:109.
313. Steinberg BA, Dorian P, Anstrom KJ, Hess R, Mark DB, Noseworthy PA,
Spertus JA, Piccini JP. Patient-reported outcomes in atrial fibrillation research:
results of a Clinicaltrials.gov analysis. JACC Clin Electrophysiol 2019;5:599605.
314. Calvert M, Kyte D, Price G, Valderas JM, Hjollund NH. Maximising the impact of patient reported outcome assessment for patients and society. BMJ
2019;364:k5267.
315. Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors happier

the potential of patient-reported outcomes.
N
Engl
J
Med
2017;377:13091312.
316. Van Der Wees PJ, Nijhuis-Van Der Sanden MW, Ayanian JZ, Black N, Westert
GP, Schneider EC. Integrating the use of patient-reported outcomes for both clinical practice and performance measurement: views of experts from 3 countries. Milbank Q 2014;92:754775.
317. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT,
Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban T,
Pak H-N, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres N.
Quality indicators for the care and outcomes of adults with atrial fibrillation.
Task Force for the development of quality indicators in Atrial Fibrillation of the
European Heart Rhythm Association (EHRA) and of the European Society of
Cardiology (ESC): Developed in collaboration with the Heart Rhythm Society
(HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin-American
Heart Rhythm Society (LAHRS). Europace 2020;doi:10.1093/europace/euaa253.
318. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017;14:627628.
319. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple
ABC
(Atrial
Fibrillation
Better
Care)
Pathway.
Am
J
Med
2018;131:13591366.e6.
320. Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN,
Lee MH, Joung B, Lip GYH. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial
Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. Thromb Haemost 2019;19:16951703.
321. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the
ABC (Atrial fibrillation Better Care) pathway in the ATHERO-AF study cohort.
Mayo Clin Proc 2019;94:12611267
322. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation
Better Care) pathway and healthcare costs in atrial fibrillation: the ATHEROAF study. Am J Med 2019;132:856861.
ESC Guidelines
465


<!-- PAGE 94 -->

### Page 94

.............................................................................................................................................................................
323. Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, Wen J, Xing Y, Wu F,
Xia Y, Liu T, Wu F, Liang Z, Liu F, Zhao Y, Li R, Li X, Zhang L, Guo J, Burnside
G, Chen Y, Lip GYH; mAF-App II Trial Investigators. Mobile health technology to improve care for patients with atrial fibrillation. J Am Coll Cardiol
2020;75:15231534.
324. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012;76:22892304.
325. Szymanski FM, Lip GY, Filipiak KJ, Platek AE, Hrynkiewicz-Szymanska A, Opolski
G. Stroke risk factors beyond the CHA(2)DS(2)-VASc score: can we improve our identification of ‘high stroke risk’ patients with atrial fibrillation?Am J Cardiol
2015;116:17811788.
326. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158:13161320.
327. Ntaios G, Lip GY, Lambrou D, Papavasileiou V, Manios E, Milionis H, Spengos
K, Makaritsis K, Vemmos K. Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation. Neurology 2015;84:12131219.
328. Esteve-Pastor MA, Roldan V, Rivera-Caravaca JM, Ramirez-Macias I, Lip GYH,
Marin F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019;119:19011919.
329. Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem 2017;63:152164.
330. Yaghi S, Kamel H. Stratifying stroke risk in atrial fibrillation: beyond clinical risk scores. Stroke 2017;48:26652670.
331. Ioannou A, Papageorgiou N, Falconer D, Rehal O, Sewart E, Zacharia E,
Toutouzas K, Vlachopoulos C, Siasos G, Tsioufis C, Tousoulis D. Biomarkers associated with stroke risk in atrial fibrillation.
Curr
Med
Chem
2019;26:803823.
332. Sepehri Shamloo A, Bollmann A, Dagres N, Hindricks G, Arya A. Natriuretic peptides: biomarkers for atrial fibrillation management. Clin Res Cardiol
2020;109:957966.
333. Decker JJ, Norby FL, Rooney MR, Soliman EZ, Lutsey PL, Pankow JS, Alonso A,
Chen LY. Metabolic syndrome and risk of ischemic stroke in atrial fibrillation:
ARIC Study. Stroke 2019;50:30453050.
334. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
Chest 2010;137:263272.
335. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L.
Ejection fraction and outcomes in patients with atrial fibrillation and heart failure:
the
Loire
Valley
Atrial
Fibrillation
Project.
Eur
J
Heart
Fail
2012;14:295301.
336. Jung H, Sung JH, Yang PS, Jang E, Yu HT, Kim TH, Pak HN, Lee MH, Joung B,
Lip GYH. Stroke risk stratification for atrial fibrillation patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2018;72:24092411.
337. Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH,
Joung B, Lip GYH. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy:
a nationwide cohort study. Chest 2019;155:354363.
338. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, Yu HT, Uhm JS, Kim JY, Pak
HN, Lee MH, Joung B, Lip GYH. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol 2018;72:12331245.
339. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged >/=75 years with atrial fibrillation: the
Loire Valley Atrial Fibrillation Project. Stroke 2015;46:14350.
340. Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH, Larsen
TB. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke 2015;46:216874.
341. Lip GYH, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation:
the
Loire
Valley
Atrial
Fibrillation
Project.
Chest
2015;147:11031110.
342. Fangel MV, Nielsen PB, Larsen TB, Christensen B, Overvad TF, Lip GYH,
Goldhaber SZ, Jensen MB. Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study. Int J
Cardiol 2018;268:137142.
343. Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC,
Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:15401547.
344. Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjoth F, Rasmussen LH,
Lip GYH. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest 2015;147:16511658.
345. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY.
Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 2015;132:517525.
346. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, Chen PC, Lin JL. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation

a nation-wide database analysis.
Atherosclerosis
2011;217:292295.
347. Anandasundaram B, Lane DA, Apostolakis S, Lip GY. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients:
a systematic review.
J
Thromb
Haemost
2013;11:975987.
348. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the
Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:15001510.
349. Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen
SD, Botker HE, Lip GYH, Maeng M. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A
report from the
Western
Denmark
Heart
Registry.
Thromb
Haemost
2018;118:21622170.
350. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG.
Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III
Investigators. J Am Coll Cardiol 1998;31:16221626.
351. Kim TH, Yang PS, Yu HT, Jang E, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip
GYH. Age threshold for ischemic stroke risk in atrial fibrillation. Stroke
2018;49:18721879.
352. Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung
FP, Liao JN, Chen TJ, Chiang CE, Lip GY, Chen SA. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol 2015;66:13391347.
353. Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a
CHA2DS2-VA score rather than CHA2DS2-VASc?Circulation 2018;137:832840.
354. Killu AM, Granger CB, Gersh BJ. Risk stratification for stroke in atrial fibrillation:
a critique. Eur Heart J 2019;40:12941302.
355. Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, Valdes M, Vicente V, Lip
GYH, Marin F. Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-Stroke and CHA2DS2-VASc scores. J Am Heart
Assoc 2017;6: pii: JAHA.117.006490. doi: 10.1161/JAHA.117.006490.
356. Alkhouli M, Friedman PA. Ischemic stroke risk in patients with nonvalvular atrial fibrillation:
JACC
review topic of the week.
J
Am
Coll
Cardiol
2019;74:30503065.
357. Wu VC, Wu M, Aboyans V, Chang SH, Chen SW, Chen MC, Wang CL, Hsieh
IC, Chu PH, Lin YS. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart 2020;106:534540.
358. Tomasdottir M, Friberg L, Hijazi Z, Lindback J, Oldgren J. Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation. Clin Cardiol 2019;42:10031009.
359. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study.
BMJ 2012;344:e3522.
360. Overvad TF, Potpara TS, Nielsen PB. Stroke risk stratification: CHA2DS2-VA
or CHA2DS2-VASc?Heart Lung Circ 2019;28:e14e15.
361. Nielsen PB, Overvad TF. Female sex as a risk modifier for stroke risk in atrial fibrillation: using CHA2DS2-VASc versus CHA2DS2-VA for stroke risk stratification in atrial fibrillation: a note of caution. Thromb Haemost 2020. doi:
10.1055/s-0040-1710014. Epub ahead of print.
362. Marzona I, Proietti M, Farcomeni A, Romiti GF, Romanazzi I, Raparelli V, Basili
S, Lip GYH, Nobili A, Roncaglioni MC. Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: a systematic review and meta-analysis of 993,600 patients. Int J Cardiol 2018;269:182191.
363. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study.
Eur Heart J 2015;36:297306.
364. Poli M, Philip P, Taillard J, Debruxelles S, Renou P, Orgogozo JM, Rouanet F,
Sibon I. Atrial fibrillation is a major cause of stroke in apneic patients: a prospective study. Sleep Med 2017;30:251254.
365. Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice
DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K,
Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF
Investigators. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One 2018;13:e0191592.
366. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J
Med 2013;126:640.e9-17.


<!-- PAGE 95 -->

### Page 95

...........................................................................................................................................................................
367. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von
Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006;37:22942300.
368. Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA,
Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG,
Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELDAF Investigators. Improved risk stratification of patients with atrial fibrillation:
an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open 2017;7:e017157.
369. Zhu W, Fu L, Ding Y, Huang L, Xu Z, Hu J, Hong K. Meta-analysis of ATRIA
versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol 2017;227:436442.
370. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N,
Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am
Heart Assoc 2013;2:e000250.
371. Graves KG, May HT, Knowlton KU, Muhlestein JB, Jacobs V, Lappe DL,
Anderson JL, Horne BD, Bunch TJ. Improving CHA2DS2-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart 2018;5:e000907.
372. Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD,
Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L;
ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016;37:158290.
373. Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindback J, Granger CB, Alexander
JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin
L. Repeated measurements of cardiac biomarkers in atrial fibrillation and validation of the ABC stroke score over time. J Am Heart Assoc 2017;6.
374. Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW,
Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S,
Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation
2016;134:16971707.
375. Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF,
Antman EM, Braunwald E, Morrow DA. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation 2019;139:760771.
376. Rivera-Caravaca JM, Marin F, Vilchez JA, Galvez J, Esteve-Pastor MA, Vicente V,
Lip GYH, Roldan V. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores.
Stroke
2019;50:13721379.
377. Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Vicente V, Valdes M, Marin F,
Lip GY. Long-term bleeding risk prediction in ‘real world’patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores.
Thromb Haemost 2017;117:18481858.
378. Shin SY, Han SJ, Kim JS, Im SI, Shim J, Ahn J, Lee EM, Park YM, Kim JH, Lip GYH,
Lim HE. Identification of markers associated with development of stroke in
‘clinically low-risk’ atrial fibrillation patients. J Am Heart Assoc 2019;8:e012697.
379. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung
FP, Chen TJ, Chen SA. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation:
insights into the optimal assessment of age and incident comorbidities. Eur
Heart J 2019;40:15041514.
380. Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep 2016;6:27410.
381. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, Lip GY.
Should atrial fibrillation patients with only 1 nongender-related CHA2DS2VASc risk factor be anticoagulated?Stroke 2016;47:18311836.
382. Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN,
Chung FP, Chen TJ, Chen SA. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation.
J
Am
Coll
Cardiol
2018;71:122132.
383. Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH,
Lip GYH, Joung B. Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in Asian patients with atrial fibrillation: a nationwide cohort study. Thromb Haemost 2018;118:12961304.
384. Chao TF, Chiang CE, Chen TJ, Lip GYH, Chen SA. Reassessment of risk for stroke during follow-up of patients with atrial fibrillation. Ann Intern Med
2019;170:663664.
385. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY.
Reliable identification of ‘truly low’ thromboembolic risk in patients initially diagnosed with ‘lone’ atrial fibrillation: the Belgrade Atrial Fibrillation Study. Circ
Arrhythm Electrophysiol 2012;5:319326.
386. Weijs B, Dudink E, de Vos CB, Limantoro I, Tieleman RG, Pisters R, Cheriex
EC, Luermans J, Crijns H. Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study. Neth Heart J
2019;27:487497.
387. Chao TF, Liao JN, Tuan TC, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP, Chen
TJ, Lip GYH, Chen SA. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk’ patients. Thromb Haemost
2019;119:11621170.
388. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, Sharan L,
Allen LaPointe NM, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, AlKhatib SM, Sanders GD. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb
Haemost 2018;118:21712187.
389. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung
FP, Chen TJ, Chen SA. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline,
follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018;118:768777.
390. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern
Med 1999;159:677685.
391. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford
MJ. Clinical classification schemes for predicting hemorrhage: results from the
National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713719.
392. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer
DE. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA
(Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol
2011;58:395401.
393. O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR,
Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The
ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36:32583264.
394. Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, Schilling R,
Kotecha D, Lucerna M, Huber K, De Caterina R, Kirchhof P. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events  European Registry in Atrial Fibrillation (PREFER in AF). BMJ
Open 2019;9:e022478.
395. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:10931100.
396. Mori N, Sotomi Y, Hirata A, Hirayama A, Sakata Y, Higuchi Y. External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian data from the
DIRECT registry). Am J Cardiol 2019;124:10441048.
397. Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, Abraham NS,
Noseworthy PA. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED,
ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol
2017;120:15491556.
398. Rutherford OW, Jonasson C, Ghanima W, Holst R, Halvorsen S. New score for assessing bleeding risk in patients with atrial fibrillation treated with
NOACs. Open Heart 2018;5:e000931.
399. Thomas MR, Lip GY. Novel risk markers and risk assessments for cardiovascular disease. Circ Res 2017;120:133149.
400. Khan AA, Lip GYH. The prothrombotic state in atrial fibrillation: pathophysiological and management implications. Cardiovasc Res 2019;115:3145.
401. Ban N, Siegfried CJ, Lin JB, Shui YB, Sein J, Pita-Thomas W, Sene A, Santeford
A, Gordon M, Lamb R, Dong Z, Kelly SC, Cavalli V, Yoshino J, Apte RS. GDF15
is elevated in mice following retinal ganglion cell death and in glaucoma patients.
JCI Insight 2017;2:pii: 91455. doi: 10.1172/jci.insight.91455.
402. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW,
Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB,
Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based
ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016;387:23022311.
403. Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Vicente V, Valdes M, Marin F,
Lip GYH. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The
Murcia Atrial Fibrillation Project. Thromb Haemost 2017;117:18481858.
404. Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the
HAS-BLED
high bleeding-risk category,
compared to
ATRIA
and
HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2014;40:277284.
ESC Guidelines
467


<!-- PAGE 96 -->

### Page 96

.............................................................................................................................................................................
405. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015;38:555561.
406. Chang G, Xie Q, Ma L, Hu K, Zhang Z, Mu G, Cui Y. Accuracy of HAS-BLED
and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a network meta-analysis. J Thromb Haemost 2020;18:791801.
407. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores.
J
Thromb
Haemost
2016;14:17111714.
408. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung
FP, Chen TJ, Chen SA. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int
J Cardiol 2018;254:157161.
409. Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med 2018;131:185192.
410. Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldan V, Lip GYH, Marin
F. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED
score. The AMADEUS trial. Thromb Haemost 2017;117:22612266.
411. Guo Y, Lane DA, Chen Y, Lip GYH; mAF-App II Trial investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial. Am J Med 2020:pii: S0002-9343(20)30274-6.
412. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med
2007;146:857867.
413. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F,
Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen
LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease:
current status and perspectives (Section III). Position paper of the ESC working group on thrombosis  Task Force on anticoagulants in heart disease. Thromb
Haemost 2013;110:10871107.
414. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu
Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:8491.
415. Sjalander S, Sjogren V, Renlund H, Norrving B, Sjalander A. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res
2018;167:113118.
416. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.
Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF,
and RE-LY trials. J Thromb Thrombolysis 2014;38:150159.
417. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the
SAMe-TT(2)R(2) score. Chest 2013;144:15551563.
418. Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score.
Eur Heart J Cardiovasc Pharmacother 2015;1:150152.
419. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J,
Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R,
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering
Committee Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:11391151.
420. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz
SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883891.
421. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, AlKhalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz
JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo
AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL,
Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE
Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981992.
422. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL,
Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y,
Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM;
ENGAGE AF-TIMI Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:20932104.
423. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz
MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet
2014;383:955962.
424. Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation:
meta-analysis. Stroke 2015;46:25552561.
425. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G,
Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A,
Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van
Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans
AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S;
AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806817.
426. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K
antagonists. Thromb Haemost 2016;116:754763.
427. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ,
Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Bartels DB, Lip GYH; GLORIAAF Investigators. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation:
Global
Registry on
Long-Term
Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF)
registry. Am Heart J 2018;198:5563.
428. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M,
Turpie AG; XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:11451153.
429. Martinez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL,
Ziadeh NS, Turpie AGG; XANTUS Investigators. XANTUS-EL: a real-world,
prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin
America. Egypt Heart J 2018;70:307313.
430. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X,
Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘real-world’
clinical practice. A propensity-matched analysis of 76,940 patients. Thromb
Haemost 2017;117:10721082.
431. Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Edoxaban in Asian patients with atrial fibrillation:
effectiveness and safety.
J
Am
Coll
Cardiol
2018;72:838853.
432. Ingrasciotta Y, Crisafulli S, Pizzimenti V, Marciano I, Mancuso A, Ando G,
Corrao S, Capranzano P, Trifiro G. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol
2018;14:10571069.
433. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP,
Chen TJ, Lip GYH, Chen SA. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 2018;138:3747.
434. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment.
Pharmacotherapy 2017;37:412419.
435. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack
AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK.
Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138:15191529.
436. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey
PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP;
ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am
Coll Cardiol 2016;68:25972604.
437. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K
antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017;69:27792790.
438. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart
R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the
Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular
Events
(ACTIVE
W):
a randomised controlled trial.
Lancet
2006;367:19031912.
439. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M,
Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:20662078.
440. Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014;16:631638.
441. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E;
BAFTA investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged
Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493503.
442. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev
Cardiol 2011;8:602606.


<!-- PAGE 97 -->

### Page 97

.............................................................................................................................................................................
443. Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar
D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F,
Pieper
KS,
van
Eickels
M,
Kakkar
AK;
GARFIELD-AF
Investigators.
Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELDAF registry. Eur Heart J 2018;39:464473.
444. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin
CM, Sick P; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534542.
445. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL,
Holmes D; PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic
Protection in
Patients with
Atrial
Fibrillation)
trial.
Circulation
2013;127:720729.
446. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K,
Reddy VY. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:112.
447. Holmes DR, Jr., Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano
M, Reddy VY. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll
Cardiol 2015;65:26142623.
448. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P,
Sievert H. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix
Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J
Am Coll Cardiol 2013;61:25512556.
449. Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E,
Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW, on behalf of the
EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the
EWOLUTION registry. Eur Heart J 2016;37:24652474.
450. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T,
Meincke F, Protopopov AV, Betts T, Foley D, Sievert H, Mazzone P, De Potter
T, Vireca E, Stein K, Bergmann MW, for the EWOLUTION Investigators.
Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year followup outcome data of the
EWOLUTION
trial.
Heart
Rhythm
2017;14:13021308.
451. Badheka AO, Chothani A, Mehta K, Patel NJ, Deshmukh A, Hoosien M, Shah
N, Singh V, Grover P, Savani GT, Panaich SS, Rathod A, Patel N, Arora S,
Bhalara V, Coffey JO, O’Neill W, Makkar R, Grines CL, Schreiber T, Di Biase L,
Natale A, Viles-Gonzalez JF. Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the
United States: influence of hospital volume. Circ Arrhythm Electrophysiol
2015;8:4248.
452. Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C;
Scientific Initiative Committee EHRA. Left atrial appendage closure-indications,
techniques, and outcomes: results of the European Heart Rhythm Association
Survey. Europace 2015;17:642646.
453. Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A, Burkhardt
JD, Pershad A, Byrne TJ, Gidney B, Aragon JR, Goldstein J, Moulton K, Patel T,
Knight B, Lin AC, Valderrabano M. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the US transcatheter LAA ligation consortium. J Am Coll Cardiol 2014;64:565572.
454. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, Fatemi M,
Franceschi F, Guedeney P, Jacon P, Paziaud O, Venier S, Deharo JC, Gras D,
Klug D, Mansourati J, Montalescot G, Piot O, Defaye P. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J
Am Coll Cardiol 2018;71:15281536.
455. Lakkireddy D, Afzal MR, Lee RJ, Nagaraj H, Tschopp D, Gidney B, Ellis C,
Altman E, Lee B, Kar S, Bhadwar N, Sanchez M, Gadiyaram V, Evonich R,
Rasekh A, Cheng J, Cuoco F, Chandhok S, Gunda S, Reddy M, Atkins D,
Bommana S, Cuculich P, Gibson D, Nath J, Ferrell R, Matthew E, Wilber D.
Short and long-term outcomes of percutaneous left atrial appendage suture ligation:
results from a
US
multicenter evaluation.
Heart
Rhythm
2016;13:10301036.
456. van Laar C, Verberkmoes NJ, van Es HW, Lewalter T, Dunnington G, Stark S,
Longoria J, Hofman FH, Pierce CM, Kotecha D, van Putte BP. Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis.
JACC
Clin
Electrophysiol 2018;4:893901.
457. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I,
Abouzahr L, Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E,
Connolly SJ. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.
Am
Heart
J
2005;150:288293.
458. Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R, Devereaux PJ,
Teoh K, Lamy A, Connolly SJ, Yusuf S, Carrier M, Healey JS. Left Atrial
Appendage Occlusion Study II (LAAOS II). Can J Cardiol 2013;29:14431447.
459. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg 2015;47:847854.
460. Aryana A, Singh SK, Singh SM, O’Neill PG, Bowers MR, Allen SL, Lewandowski
SL, Vierra EC, d’Avila A. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization.
Heart
Rhythm
2015;12:14311437.
461. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P,
Ailawadi G, Bouchard D, Smith PK, Mack MJ, Acker MA, Mullen JC, Rose EA,
Chang HL, Puskas JD, Couderc JP, Gardner TJ, Varghese R, Horvath KA, Bolling
SF, Michler RE, Geller NL, Ascheim DD, Miller MA, Bagiella E, Moquete EG,
Williams P, Taddei-Peters WC, O’Gara PT, Blackstone EH, Argenziano M;
CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015;372:13991409.
462. Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A, Shah P, Guo Y,
Alings M, Folkeringa RJ, Paparella D, Colli A, Meyer SR, Legare JF, Lamontagne
F, Reents W, Boning A, Connolly S. Rationale and design of the Left Atrial
Appendage Occlusion Study (LAAOS) III. Ann Cardiothorac Surg 2014;3:4554.
463. Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB.
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017;356:j510.
464. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
BMJ 2016;353:i3189.
465. Tilz RR, Potpara T, Chen J, Dobreanu D, Larsen TB, Haugaa KH, Dagres N. Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
Survey. Europace 2017;19:17371742.
466. Ogawa H, An Y, Ikeda S, Aono Y, Doi K, Ishii M, Iguchi M, Masunaga N, Esato
M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF
Registry Investigators. Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. Stroke 2018;49:23012308.
467. Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA, Khokhar
KB, Thiyagarajah A, Middeldorp ME, Nalliah CJ, Hendriks JML, Kalman JM, Lau
DH, Sanders P. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J 2018;39:14071415.
468. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR, Capucci
A, Lau CP, Morillo CA, Hobbelt AH, Rienstra M, Connolly SJ. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in
ASSERT. Eur Heart J 2017;38:13391344.
469. Boriani G, Glotzer TV, Ziegler PD, De Melis M, Mangoni di SSL, Sepsi M,
Landolina M, Lunati M, Lewalter T, Camm AJ. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm
2018;15:376383.
470. Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci
R, Grifoni E, Pignatelli P, Violi F, ATHERO-AF study group. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol
2018;264:5863.
471. Kuo L, Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN,
Chung FP, Chen TJ, Lip GYH, Chen SA. Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?J Am Heart Assoc 2017;6.
472. Lee SR, Lee HJ, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll
Cardiol 2019;73:32953308.
473. Staerk L, Lip GY, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN, Gundlund A,
Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ
2015;351:h5876.
474. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual
Outcomes 2011;4:1421.
475. Proietti M, Lip GY. Major outcomes in atrial fibrillation patients with one risk factor: impact of time in therapeutic range observations from the SPORTIF trials. Am J Med 2016;129:11101116.
ESC Guidelines
469


<!-- PAGE 98 -->

### Page 98

..........................................................................................................................................................................
476. Lip GY, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) be anticoagulated? Yes:
even
1
stroke risk factor confers a
real risk of stroke.
Circulation
2016;133:14981503; discussion 1503.
477. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review.
JAMA 2015;313:19501962.
478. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M,
Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB,
Wallentin L. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the
ARISTOTLE randomized clinical trial. JAMA Cardiol 2016;1:451460.
479. Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA,
Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC,
Hijazi Z, Wallentin L. Changes in renal function in patients with atrial fibrillation:
an analysis from the RE-LY trial. J Am Coll Cardiol 2015;65:24812493.
480. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 2013;8:e74037.
481. Teiger E, Thambo JB, Defaye P, Hermida JS, Abbey S, Klug D, Juliard JM, Pasquie
JL, Rioufol G, Lepillier A, Elbaz M, Horvilleur J, Brenot P, Pierre B, Le
Corvoisier P. Percutaneous left atrial appendage closure is a reasonable option for patients with atrial fibrillation at high risk for cerebrovascular events. Circ
Cardiovasc Interv 2018;11:e005841.
482. Saw J, Fahmy P, Azzalini L, Marquis JF, Hibbert B, Morillo C, Carrizo A, Ibrahim
R. Early Canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure. J Cardiovasc Electrophysiol 2017;28:396401.
483. Martin Gutierrez E, Castano M, Gualis J, Martinez-Comendador JM, Maiorano P,
Castillo L, Laguna G. Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients. Eur J Cardiothorac Surg
2020;57:252262.
484. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong
DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders
GD. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014;160:760773.
485. Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol
Clin 2004;22:3545.
486. Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J 2009;85:303312.
487. Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen
JG, Hillege HL, Tuininga YS, Van Veldhuisen DJ, Ranchor AV, Van Gelder IC;
RACE II Investigators. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 2011;58:17951803.
488. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM,
Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van
Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation.
N
Engl
J
Med
2010;362:13631373.
489. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE,
Crijns HJ; RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE
and AFFIRM studies. Europace 2006;8:935942.
490. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet 2016;388:818828.
491. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY,
Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G,
Shibata MC, Rigby A, Flather MD. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.
Lancet 2014;384:22352243.
492. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen
H, Gjesdal K, Tveit A. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013;111:225230.
493. Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A.
Calcium channel blockers improve exercise capacity and reduce N-terminal
Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 2014;35:517524.
494. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, Hilgers R.
Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy.
Results of the
Diltiazem in
Dilated
Cardiomyopathy trial. Circulation 1996;94:346352.
495. Hallberg P, Lindback J, Lindahl B, Stenestrand U, Melhus H, group R-H. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin
Pharmacol 2007;63:959971.
496. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, Schmitt
S, Holmes TH, Frayne SM, Phibbs CS, Yang F, Hoang DD, Ho PM, Heidenreich
PA. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol
2014;64:660668.
497. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J,
Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai
R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ,
Elayi CS. Increased mortality among patients taking digoxin  analysis from the
AFFIRM study. Eur Heart J 2013;34:14811488.
498. Andrey JL, Romero S, Garcia-Egido A, Escobar MA, Corzo R, GarciaDominguez G, Lechuga V, Gomez F. Mortality and morbidity of heart failure treated with digoxin.
A
propensity-matched study.
Int
J
Clin
Pract
2011;65:12501258.
499. Flory JH, Ky B, Haynes K, S MB, Munson J, Rowan, C, Strom BL, Hennessy S.
Observational cohort study of the safety of digoxin use in women with heart failure. BMJ Open 2012;2:e000888.
500. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein
AE, Patel K, Aban IB, Aronow WS, Anker SD, Ahmed A. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J
2013;34:14891497.
501. Aguirre Davila L, Weber K, Bavendiek U, Bauersachs J, Wittes J, Yusuf S, Koch
A. Digoxin-mortality: randomized vs. observational comparison in the DIG trial.
Eur Heart J 2019;40:33363341.
502. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend
J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.
503. Bavendiek U, Berliner D, Davila LA, Schwab J, Maier L, Philipp SA, Rieth A,
Westenfeld R, Piorkowski C, Weber K, Hanselmann A, Oldhafer M, Schallhorn
S, von der Leyen H, Schroder C, Veltmann C, Stork S, Bohm M, Koch A,
Bauersachs J; DIGIT-HF Investigators and Committees. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.
Eur J Heart Fail 2019;21:676684.
504. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594598.
505. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Korv J, Lal A, Putaala J, Werring
DJ. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. Eur
Stroke J 2019;4:198223.
506. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Lowdose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:32893293.
507. Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron
B, McGrath L, Innes G. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med 2013;20:222230.
508. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg
Med 1997;29:135140.
509. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson
K, Yu D, Bass EB. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000;49:4759.
510. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation.
Crit
Care
Med
2009;37:21742179; quiz 2180.
511. Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, Paone
G, Frank DM, Borzak S. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery.
Am Heart J 1998;135:739747.
512. Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation 2012;125:945957.
513. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do?Eur
Heart J 2015;36:32503257.
514. Delle
Karth
G,
Geppert
A,
Neunteufl
T,
Priglinger
U,
Haumer
M,
Gschwandtner M, Siostrzonek P, Heinz G. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med
2001;29:11491153.
515. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study.
Eur Heart J 1995;16:521528.


<!-- PAGE 99 -->

### Page 99

.............................................................................................................................................................................
516. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R.
Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT
trial. Europace 2007;9:498505.
517. Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited:
long term survival and predictors of permanent atrial fibrillation. Heart
2003;89:10351038.
518. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction.
Pacing Clin Electrophysiol 1997;20:343348.
519. Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF, Munger
TM, Jahangir A, Srivathsan K, Shen WK. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation.
Heart
Rhythm
2013;10:696701.
520. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK,
Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 2012;5:6876.
521. Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation. Clin
Pharmacol Ther 2007;81:284287.
522. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA,
Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation.
N
Engl
J
Med
2001;344:10431051.
523. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation
2000;101:11381144.
524. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt
OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW,
Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ,
Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW,
Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P,
Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns
W, Windecker S, Document R, Kirchhof P, Blomstrom-Lundqvist C, Badano
LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert
JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis
H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L,
Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology
(ESC).
Developed in collaboration with the
European
Heart
Rhythm
Association (EHRA). Eur Heart J 2013;34:22812329.
525. Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP.
Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs.
right ventricular pacing mode.
Eur
J
Heart
Fail
2012;14:661667.
526. Huang W, Su L, Wu S. Pacing treatment of atrial fibrillation patients with heart failure: His bundle pacing combined with atrioventricular node ablation. Card
Electrophysiol Clin 2018;10:519535.
527. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E,
Quartieri F, Calo L, Ungar A, Mont L; APAF-CRT Investigators. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur
Heart J 2018;39:39994008.
528. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Ellenbogen KA. Benefits of permanent His bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ventricular ejection fraction. J Am Heart Assoc 2017;6.
529. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.
J
Am
Coll
Cardiol
1999;33:304310.
530. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?J Am Coll Cardiol 2003;42:19441951.
531. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9:777781.
532. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M,
Rienstra M, Van den Berg MP, Van Gelder IC. Digoxin in patients with permanent atrial fibrillation:
data from the
RACE
II
study.
Heart
Rhythm
2014;11:15431550.
533. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986;73:316324.
534. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979;44:13781382.
535. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D,
Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M. The
Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial
(AIRCRAFT). J Am Coll Cardiol 2003;41:16971702.
536. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. Europace 2017;19:iv10iv16.
537. Shiga T, Yoshioka K, Watanabe E, Omori H, Yagi M, Okumura Y, Matsumoto
N, Kusano K, Oshiro C, Ikeda T, Takahashi N, Komatsu T, Suzuki A, Suzuki T,
Sato Y, Yamashita T; AF-QOL study investigators. Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: a crossover study of flecainide and pilsicainide. J Arrhythm 2017;33:310317.
538. Capucci A, Piangerelli L, Ricciotti J, Gabrielli D, Guerra F. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. Europace
2016;18:16981704.
539. Shi LZ, Heng R, Liu SM, Leng FY. Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: a meta-analysis of randomized controlled trials.
Exp Ther Med 2015;10:816822.
540. Siontis KC, Ioannidis JPA, Katritsis GD, Noseworthy PA, Packer DL, Hummel
JD, Jais P, Krittayaphong R, Mont L, Morillo CA, Nielsen JC, Oral H, Pappone C,
Santinelli V, Weerasooriya R, Wilber DJ, Gersh BJ, Josephson ME, Katritsis DG.
Radiofrequency ablation versus antiarrhythmic drug therapy for atrial fibrillation: meta-analysis of quality of life, morbidity, and mortality. JACC Clin
Electrophysiol 2016;2:170180.
541. Kim YG, Shim J, Choi JI, Kim YH. Radiofrequency catheter ablation improves the quality of life measured with a short form-36 questionnaire in atrial fibrillation patients:
a systematic review and meta-analysis.
PLoS
One
2016;11:e0163755.
542. Bayes de Luna A, Platonov P, Cosio FG, Cygankiewicz I, Pastore C, Baranowski
R, Bayes-Genis A, Guindo J, Vinolas X, Garcia-Niebla J, Barbosa R, Stern S,
Spodick D. Interatrial blocks. A separate entity from left atrial enlargement: a consensus report. J Electrocardiol 2012;45:445451.
543. Jadidi A, Muller-Edenborn B, Chen J, Keyl C, Weber R, Allgeier J, MorenoWeidmann Z, Trenk D, Neumann FJ, Lehrmann H, Arentz T. The duration of the amplified sinus-p-wave identifies presence of left atrial low voltage substrate and predicts outcome after pulmonary vein isolation in patients with persistent atrial fibrillation. JACC Clin Electrophysiol 2018;4:531543.
544. Dudink E, Erkuner O, Berg J, Nieuwlaat R, de Vos CB, Weijs B, Capucci A,
Camm AJ, Breithardt G, Le Heuzey JY, Luermans J, Crijns H. The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart
Survey. Europace 2018;20:929934.
545. Zhang YY, Qiu C, Davis PJ, Jhaveri M, Prystowsky EN, Kowey P, Weintraub
WS. Predictors of progression of recently diagnosed atrial fibrillation in
REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial
Fibrillation (RecordAF)  United States cohort. Am J Cardiol 2013;112:7984.
546. Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, Osborn JS,
Anderson JL, Muhlestein JB, Lappe DL, Day JD. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm 2013;10:12571262.
547. Andrade JG, Champagne J, Deyell MW, Essebag V, Lauck S, Morillo C, Sapp J,
Skanes
A,
Theoret-Patrick
P,
Wells
GA,
Verma
A;
EARLY-AF
Study
Investigators. A randomized clinical trial of early invasive intervention for atrial fibrillation
(EARLY-AF)

methods and rationale.
Am
Heart
J
2018;206:94104.
548. Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ, Morton JB, Sanders
P, Kalman JM. Long-term effects of catheter ablation for lone atrial fibrillation:
progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm 2012;9:473480.
549. Aliot E, Brandes A, Eckardt L, Elvan A, Gulizia M, Heidbuchel H, Kautzner J,
Mont L, Morgan J, Ng A, Szumowski L, Themistoclakis S, Van Gelder IC,
Willems S, Kirchhof P. The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for
Stroke prevention Trial. Eur Heart J 2015;36:255256.
550. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: ten years later. Gend Med 2010;7:206217.
551. Sethi NJ, Feinberg J, Nielsen EE, Safi S, Gluud C, Jakobsen JC. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis.
PLoS One 2017;12:e0186856.
552. Ha AC, Breithardt G, Camm AJ, Crijns HJ, Fitzmaurice GM, Kowey PR, Le
Heuzey JY, Naditch-Brule L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C,
ESC Guidelines
471


<!-- PAGE 100 -->

### Page 100

..........................................................................................................................................................................
Weintraub WS, Dorian P. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes
2014;7:896904.
553. Bulkova V, Fiala M, Havranek S, Simek J, Sknouril L, Januska J, Spinar J,
Wichterle D. Improvement in quality of life after catheter ablation for paroxysmal versus long-standing persistent atrial fibrillation: a prospective study with 3year follow-up. J Am Heart Assoc 2014;3.
554. Kirchhof P, Monnig G, Wasmer K, Heinecke A, Breithardt G, Eckardt L, Bocker
D. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation
(MOBIPAPA).
Eur
Heart
J
2005;26:12921297.
555. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Bocker D,
Breithardt G, Haverkamp W, Borggrefe M. Anterior-posterior versus anteriorlateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002;360:12751279.
556. Um KJ, McIntyre WF, Healey JS, Mendoza PA, Koziarz A, Amit G, Chu VA,
Whitlock RP, Belley-Cote EP. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace 2019;21:856863.
557. Schmidt AS, Lauridsen KG, Torp P, Bach LF, Rickers H, Lofgren B. Maximumfixed energy shocks for cardioverting atrial fibrillation.
Eur
Heart
J
2020;41:626631.
558. Pluymaekers N, Dudink E, Luermans J, Meeder JG, Lenderink T, Widdershoven
J, Bucx JJJ, Rienstra M, Kamp O, Van Opstal JM, Alings M, Oomen A, Kirchhof
CJ, Van Dijk VF, Ramanna H, Liem A, Dekker LR, Essers BAB, Tijssen JGP, Van
Gelder IC, Crijns H; RACE ACWAS Investigators. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med 2019;380:14991508.
559. Baranchuk A, Yeung C. Advanced interatrial block predicts atrial fibrillation recurrence across different populations: learning Bayes syndrome. Int J Cardiol
2018;272:221222.
560. Toufan M, Kazemi B, Molazadeh N. The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion.
J Cardiovasc Thorac Res 2017;9:5459.
561. Voskoboinik A, Kalman E, Plunkett G, Knott J, Moskovitch J, Sanders P, Kistler
PM, Kalman JM. A comparison of early versus delayed elective electrical cardioversion for recurrent episodes of persistent atrial fibrillation: a multi-center study. Int J Cardiol 2019;284:3337.
562. Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart
2015;101:15261530.
563. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz
SM, Slotwiner DJ, Scheiner MA, Lerman BB. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000;101:12821287.
564. Inacio JF, da Rosa Mdos S, Shah J, Rosario J, Vissoci JR, Manica AL, Rodrigues
CG. Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation:
systematic review and network meta-analysis.
Resuscitation
2016;100:6675.
565. Kirkland S, Stiell I, AlShawabkeh T, Campbell S, Dickinson G, Rowe BH. The efficacy of pad placement for electrical cardioversion of atrial fibrillation/flutter:
a systematic review. Acad Emerg Med 2014;21:717726.
566. Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs
2004;64:27412762.
567. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol
1998;31:588592.
568. Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, van
Gelder I, Gorenek B, Kaski JC, Kjeldsen K, Lip GYH, Merkely B, Okumura K,
Piccini JP, Potpara T, Poulsen BK, Saba M, Savelieva I, Tamargo JL, Wolpert C,
ESC Scientific Document Group. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm
Association (EHRA) and European Society of Cardiology (ESC) Working
Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm
Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International
Society of
Cardiovascular
Pharmacotherapy
(ISCP).
Europace
2018;20:731732.
569. Markey GC, Salter N, Ryan J. Intravenous flecainide for emergency department management of acute atrial fibrillation. J Emerg Med 2018;54:320327.
570. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P.
Amiodarone versus placebo and class Ic drugs for cardioversion of recentonset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003;41:255262.
571. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, Fontana G,
Magnani B. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:6972.
572. Donovan KD, Dobb GJ, Coombs LJ, Lee KY, Weekes JN, Murdock CJ, Clarke
GM. Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J
Cardiol 1992;70:50A-54A; discussion 54A-55A.
573. Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T, Niemeth
C, Aicher F, Grander W, Heinze G, Kuhn P, Siostrzonek P. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur
Heart J 2004;25:13181324.
574. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121128.
575. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D, SolerSoler J. Intravenous amiodarone in treatment of recent-onset atrial fibrillation:
results of a
randomized,
controlled study.
J
Am
Coll
Cardiol
1996;27:10791082.
576. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN,
Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest
2000;117:15381545.
577. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern
Med 2003;163:777785.
578. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R,
Mwamburi M. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
Cardiovasc Drugs Ther 2012;26:167179.
579. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal
B, Beatch G; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313321.
580. Akel T, Lafferty J. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: a meta-analysis. Ann Noninvasive
Electrocardiol 2018;23:e12508.
581. Beatch GN, Mangal B. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. BMC
Cardiovasc Disord 2016;16:113.
582. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T,
Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ; Atrial
Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
Circulation 2008;117:15181525.
583. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J,
Sobczyk
D,
Bochenek
A,
Toft
E;
Atrial
Arrhythmia
Conversion
Trial
Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652659.
584. Pohjantahti-Maaroos H, Hyppola H, Lekkala M, Sinisalo E, Heikkola A,
Hartikainen J. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. Eur Heart J Acute
Cardiovasc Care 2019;8:114120.
585. Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, Perry KT,
Touboul P, Steinbeck G, Wellens HJ. Superiority of ibutilide (a new class III
agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The
Ibutilide/Sotalol Comparator Study Group. Heart 1998;79:568575.
586. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari
M, Solano A, Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the
‘pill-in-the-pocket’
approach.
N
Engl
J
Med
2004;351:23842391.
587. Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Terrier de la Chaise A,
Louis P. Predictors of atrial flutter with 1:1 conduction in patients treated with class
I
antiarrhythmic drugs for atrial tachyarrhythmias.
Int
J
Cardiol
2001;80:715.
588. Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation.
Int J Clin Pract 2005;59:13951400.
589. Conde D, Costabel JP, Caro M, Ferro A, Lambardi F, Corrales Barboza A,
Lavalle Cobo A, Trivi M. Flecainide versus vernakalant for conversion of recentonset atrial fibrillation. Int J Cardiol 2013;168:24232425.
590. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez
JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone,
and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J
Cardiol 2000;86:950953.
591. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN.
Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans


<!-- PAGE 101 -->

### Page 101

.............................................................................................................................................................................
affairs congestive heart failure survival trial of antiarrhythmic therapy (CHFSTAT).
The
Department of
Veterans
Affairs
CHF-STAT
Investigators.
Circulation 1998;98:25742579.
592. Hofmann R, Steinwender C, Kammler J, Kypta A, Wimmer G, Leisch F.
Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. Wien Klin Wochenschr
2004;116:744749.
593. Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martin A, Ponikowski
P, Rosenqvist M, Sanders P, Scanavacca M, Bash LD, Chazelle F, Bernhardt A,
Gitt AK, Lip GY, Le Heuzey JY. Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int J Cardiol
2014;172:588594.
594. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens
U, Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012;380:238246.
595. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJ.
Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol 1999;84:147R151R.
596. Climent VE, Marin F, Mainar L, Gomez-Aldaravi R, Martinez JG, Chorro FJ,
Roman P, Sogorb F. Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation. Pacing Clin
Electrophysiol 2004;27:368372.
597. Mussigbrodt A, John S, Kosiuk J, Richter S, Hindricks G, Bollmann A.
Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace 2016;18:5156.
598. Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial.
Heart Rhythm 2009;6:152155.
599. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F.
Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999;340:18491854.
600. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation.
J
Am
Coll
Cardiol
2001;37:542547.
601. Alboni P, Botto GL, Boriani G, Russo G, Pacchioni F, Iori M, Pasanisi G, Mancini
M, Mariconti B, Capucci A. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment. Heart 2010;96:546549.
602. Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P, Anselme F,
Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse G, Perez-Villacastin
J, Riahi S, Taborsky M, Theodorakis G, Trines S; Atrial Fibrillation Ablation Pilot
Study Investigators. ESC-EURObservational Research Programme: the Atrial
Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm
Association. Europace 2012;14:10941103.
603. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, Laroche C,
Anselme F, Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse GH,
Perez-Villacastin J, Riahi S, Taborsky M, Theodorakis G, Trines SA; Atrial
Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur
Heart J 2014;35:14661478.
604. Arbelo
E,
Brugada
J,
Blomstrom-Lundqvist
C,
Laroche
C,
Kautzner J,
Pokushalov E, Raatikainen P, Efremidis M, Hindricks G, Barrera A, Maggioni A,
Tavazzi L, Dagres N, on the behalf of the ESC EHRA Atrial Fibrillation Ablation
Long-term Registry Investigators. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J
2017;38:13031316.
605. Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C,
Pooranawattanakul S, Punlee K, Kangkagate C. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 2003;86 Suppl
1:S816.
606. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, Turco P,
Pascotto P, Fazzari M, Vitale DF. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur
Heart J 2006;27:216221.
607. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, Paglino G,
Mazzone P, Sora N, Greiss I, Santagostino A, LiVolsi L, Pappone N, Radinovic
A, Manguso F, Santinelli V. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation:
the APAF Study. J Am Coll Cardiol 2006;48:23402347.
608. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ,
Sledge I. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ
Arrhythm Electrophysiol 2009;2:349361.
609. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, Dubuc
M, Reddy V, Nelson L, Holcomb RG, Lehmann JW, Ruskin JN; STOP AF
Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP
AF) pivotal trial. J Am Coll Cardiol 2013;61:17131723.
610. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T,
Roberts-Thomson KC, Sanders P. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc
2013;2:e004549.
611. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy
M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci
ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S,
Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A.
Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the
AATAC multicenter randomized trial. Circulation 2016;133:16371644.
612. Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A,
Arentz T, Bestehorn K, Pocock SJ, Albenque JP, Tondo C; FIRE AND ICE
Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016;374:22352245.
613. Sohara H, Ohe T, Okumura K, Naito S, Hirao K, Shoda M, Kobayashi Y,
Yamauchi Y, Yamaguchi Y, Kuwahara T, Hirayama H, YeongHwa C, Kusano K,
Kaitani K, Banba K, Fujii S, Kumagai K, Yoshida H, Matsushita M, Satake S,
Aonuma K. HotBalloon ablation of the pulmonary veins for paroxysmal AF: a multicenter randomized trial in Japan. J Am Coll Cardiol 2016;68:27472757.
614. Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs.
antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace 2015;17:370378.
615. Nielsen JC, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Pehrson
SM, Englund A, Hartikainen J, Mortensen LS, Hansen PS; MANTRA-PAF
Investigators. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial.
Heart 2017;103:368376.
616. Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, Dai J, Xu X, Mao W. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. J Interv Card Electrophysiol 2018;52:918.
617. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE,
Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov
E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ,
Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV,
Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA
Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation:
the CABANA randomized clinical trial. JAMA 2019;321:12611274.
618. Noseworthy PA, Gersh BJ, Kent DM, Piccini JP, Packer DL, Shah ND, Yao X.
Atrial fibrillation ablation in practice: assessing CABANA generalizability. Eur
Heart J 2019;40:12571264.
619. Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ, Sparks PB, Morton
JB, Kalman JM. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. J Cardiovasc
Electrophysiol 2012;23:232238.
620. D’Ascenzo F, Corleto A, Biondi-Zoccai G, Anselmino M, Ferraris F, di Biase L,
Natale A, Hunter RJ, Schilling RJ, Miyazaki S, Tada H, Aonuma K, Yenn-Jiang L,
Tao H, Ma C, Packer D, Hammill S, Gaita F. Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. Int J Cardiol 2013;167:19841989.
621. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M, Vidal B,
Arriagada G, Mendez F, Matiello M, Molina I, Brugada J. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007;28:836841.
622. Nedios S, Kosiuk J, Koutalas E, Kornej J, Sommer P, Arya A, Richter S, Rolf S,
Husser D, Hindricks G, Bollmann A. Comparison of left atrial dimensions in CT
and echocardiography as predictors of long-term success after catheter ablation of atrial fibrillation. J Interv Card Electrophysiol 2015;43:237244.
623. Njoku A, Kannabhiran M, Arora R, Reddy P, Gopinathannair R, Lakkireddy D,
Dominic P. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis. Europace 2018;20:3342.
624. Costa FM, Ferreira AM, Oliveira S, Santos PG, Durazzo A, Carmo P, Santos KR,
Cavaco D, Parreira L, Morgado F, Adragao P. Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation. Int J Cardiol 2015;184:5661.
ESC Guidelines
473


<!-- PAGE 102 -->

### Page 102

.............................................................................................................................................................................
625. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F,
Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann
T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P,
Brachmann J. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA
2014;311:498506.
626. Kosich F, Schumacher K, Potpara T, Lip GY, Hindricks G, Kornej J. Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation. Clin Cardiol 2019;42:320329.
627. Kornej J, Hindricks G, Shoemaker MB, Husser D, Arya A, Sommer P, Rolf S,
Saavedra P, Kanagasundram A, Patrick Whalen S, Montgomery J, Ellis CR,
Darbar D, Bollmann A. The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. Clin Res
Cardiol 2015;104:871876.
628. Kornej J, Hindricks G, Arya A, Sommer P, Husser D, Bollmann A. The APPLE
score  a novel score for the prediction of rhythm outcomes after repeat catheter ablation of atrial fibrillation. PLoS One 2017;12:e0169933.
629. Kornej J, Schumacher K, Dinov B, Kosich F, Sommer P, Arya A, Husser D,
Bollmann A, Lip GYH, Hindricks G. Prediction of electro-anatomical substrate and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER scores in patients with atrial fibrillation undergoing catheter ablation.
Sci
Rep
2018;8:12686.
630. Kosiuk J, Dinov B, Kornej J, Acou WJ, Schonbauer R, Fiedler L, Buchta P, Myrda
K, Gasior M, Polonski L, Kircher S, Arya A, Sommer P, Bollmann A, Hindricks
G, Rolf S. Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. Heart
Rhythm 2015;12:22072212.
631. Mujovic N, Marinkovic M, Markovic N, Shantsila A, Lip GY, Potpara TS.
Prediction of very late arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation: the MB-LATER clinical score. Sci Rep 2017;7:40828.
632. Mesquita J, Ferreira AM, Cavaco D, Moscoso Costa F, Carmo P, Marques H,
Morgado F, Mendes M, Adragao P. Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure  ATLAS score. Europace 2018;20:f428f435.
633. Winkle RA, Jarman JW, Mead RH, Engel G, Kong MH, Fleming W, Patrawala
RA. Predicting atrial fibrillation ablation outcome: the CAAP-AF score. Heart
Rhythm 2016;13:21192125.
634. Canpolat U, Aytemir K, Yorgun H, Sahiner L, Kaya EB, Oto A. A proposal for a new scoring system in the prediction of catheter ablation outcomes: promising results from the Turkish Cryoablation Registry. Int J Cardiol 2013;169:201206.
635. Wojcik M, Berkowitsch A, Greiss H, Zaltsberg S, Pajitnev D, Deubner N,
Hamm CW, Pitschner HF, Kuniss M, Neumann T. Repeated catheter ablation of atrial fibrillation: how to predict outcome?Circ J 2013;77:22712279.
636. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D,
Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP,
Sanders P. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll
Cardiol 2014;64:22222231.
637. Trines SA, Stabile G, Arbelo E, Dagres N, Brugada J, Kautzner J, Pokushalov E,
Maggioni AP, Laroche C, Anselmino M, Beinart R, Traykov V, BlomstromLundqvist C. Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Pacing Clin Electrophysiol 2019;42:13651373.
638. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, Twomey
D, Ganesan AN, Rangnekar G, Roberts-Thomson KC, Lau DH, Sanders P.
Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol
2015;1:139152.
639. Wokhlu A, Hodge DO, Monahan KH, Asirvatham SJ, Friedman PA, Munger TM,
Cha YM, Shen WK, Brady PA, Bluhm CM, Haroldson JM, Hammill SC, Packer
DL. Long-term outcome of atrial fibrillation ablation: impact and predictors of very late recurrence. J Cardiovasc Electrophysiol 2010;21:10711078.
640. Arya A, Hindricks G, Sommer P, Huo Y, Bollmann A, Gaspar T, Bode K, Husser
D, Kottkamp H, Piorkowski C. Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. Europace 2010;12:173180.
641. Santoro F, Di Biase L, Trivedi C, Burkhardt JD, Paoletti Perini A, Sanchez J,
Horton R, Mohanty P, Mohanty S, Bai R, Santangeli P, Lakkireddy D, Reddy M,
Elayi CS, Hongo R, Beheiry S, Hao S, Schweikert RA, Viles-Gonzalez J, Fassini
G, Casella M, Dello Russo A, Tondo C, Natale A. Impact of uncontrolled hypertension on atrial fibrillation ablation outcome. JACC Clin Electrophysiol
2015;1:164173.
642. Letsas KP, Weber R, Burkle G, Mihas CC, Minners J, Kalusche D, Arentz T. Preablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 2009;11:158163.
643. Jongnarangsin K, Chugh A, Good E, Mukerji S, Dey S, Crawford T, Sarrazin
JF, Kuhne M, Chalfoun N, Wells D, Boonyapisit W, Pelosi F, Jr., Bogun F,
Morady F, Oral H. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation.
J
Cardiovasc
Electrophysiol
2008;19:668672.
644. Patel D, Mohanty P, Di Biase L, Shaheen M, Lewis WR, Quan K, Cummings JE,
Wang P, Al-Ahmad A, Venkatraman P, Nashawati E, Lakkireddy D, Schweikert
R, Horton R, Sanchez J, Gallinghouse J, Hao S, Beheiry S, Cardinal DS,
Zagrodzky J, Canby R, Bailey S, Burkhardt JD, Natale A. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol
2010;3:445451.
645. Matiello M, Nadal M, Tamborero D, Berruezo A, Montserrat J, Embid C, Rios J,
Villacastin J, Brugada J, Mont L. Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace 2010;12:10841089.
646. Chilukuri K, Dalal D, Gadrey S, Marine JE, Macpherson E, Henrikson CA,
Cheng A, Nazarian S, Sinha S, Spragg D, Berger R, Calkins H. A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation.
J
Cardiovasc
Electrophysiol
2010;21:521525.
647. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011;108:4751.
648. Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y, Ito Y, Kuroki
K, Machino T, Yamasaki H, Igarashi M, Sekiguchi Y, Sato A, Aonuma K.
Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy.
Heart
Rhythm
2013;10:331337.
649. Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y, Guo WH, Jiang CX, Ma CS.
Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment:
a meta-analysis of observational studies. Europace 2014;16:13091314.
650. Kawakami H, Nagai T, Fujii A, Uetani T, Nishimura K, Inoue K, Suzuki J, Oka Y,
Okura T, Higaki J, Ogimoto A, Ikeda S. Apnea-hypopnea index as a predictor of atrial fibrillation recurrence following initial pulmonary vein isolation: usefulness of type-3 portable monitor for sleep-disordered breathing. J Interv Card
Electrophysiol 2016;47:237244.
651. Congrete S, Bintvihok M, Thongprayoon C, Bathini T, Boonpheng B, Sharma K,
Chokesuwattanaskul R, Srivali N, Tanawuttiwat T, Cheungpasitporn W. Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis. J Evid Based Med 2018;11:145151.
652. Deng F, Raza A, Guo J. Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis. Sleep Med 2018;46:511.
653. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM,
Bradley DJ, Bluhm CM, Haroldson JM, Packer DL. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 2010;55:23082316.
654. Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J, Shah D,
Michaud G, Wharton M, Harari D, Mahapatra S, Lambert H, Mansour M.
Randomized, controlled trial of the safety and effectiveness of a contact forcesensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation
(TOCCASTAR) Study. Circulation 2015;132:907915.
655. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels
MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:12751285.
656. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider
K. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J
2013;166:442448.
657. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L,
Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J,
Bansch D; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417427.
658. Noseworthy PA, Van Houten HK, Gersh BJ, Packer DL, Friedman PA, Shah
ND, Dunlay SM, Siontis KC, Piccini JP, Yao X. Generalizability of the CASTLEAF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm 2020;17:10571065.
659. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, Tilz RR, Piorkowski
C, Geller L, Kleemann T, Hindricks G. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure:
the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12:e007731.
660. Packer DL, Monahan KH, Al-KhalidiHR, Silverstein AP, Poole JP, Bahnson TD,
Mark DB, Lee KL. Ablation of Atrial Fibrillation in Heart Failure Patients:
Additional outcomes of the CABANATrial. Heart Rhythm 2019;16(suppl):S35.


<!-- PAGE 103 -->

### Page 103

.............................................................................................................................................................................
661. Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J,
Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert
R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello
Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, Raviele
A, Haissaguerre M, Natale A; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med
2008;359:17781785.
662. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M,
Denvir
M,
Bhagra
S,
Small
S,
Martin
W,
McMurray
JJ,
Petrie
MC.
Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011;97:740747.
663. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL,
McDonagh TA, Underwood SR, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:18941903.
664. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F,
Sawhney V, Duncan E, Page SP, Ullah W, Unsworth B, Mayet J, Dhinoja M,
Earley MJ, Sporton S, Schilling RJ. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the
CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:3138.
665. Al Halabi S, Qintar M, Hussein A, Alraies MC, Jones DG, Wong T, MacDonald
MR, Petrie MC, Cantillon D, Tarakji KG, Kanj M, Bhargava M, Varma N,
Baranowski B, Wilkoff BL, Wazni O, Callahan T, Saliba W, Chung MK. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. JACC Clin Electrophysiol 2015;1:200209.
666. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A,
Sugumar H, Lockwood SM, Stokes MB, Pathik B, Nalliah CJ, Wong GR,
Azzopardi SM, Gutman SJ, Lee G, Layland J, Mariani JA, Ling LH, Kalman JM,
Kistler PM. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction:
the
CAMERA-MRI
study.
J
Am
Coll
Cardiol
2017;70:19491961.
667. Elgendy AY, Mahmoud AN, Khan MS, Sheikh MR, Mojadidi MK, Omer M,
Elgendy IY, Bavry AA, Ellenbogen KA, Miles WM, McKillop M. Meta-analysis comparing catheter-guided ablation versus conventional medical therapy for patients with atrial fibrillation and heart failure with reduced ejection fraction.
Am J Cardiol 2018;122:806813.
668. Briceno DF, Markman TM, Lupercio F, Romero J, Liang JJ, Villablanca PA, Birati
EY, Garcia FC, Di Biase L, Natale A, Marchlinski FE, Santangeli P. Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol 2018;53:1929.
669. Ma Y, Bai F, Qin F, Li Y, Tu T, Sun C, Zhou S, Liu Q. Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2018;18:165.
670. Kheiri B, Osman M, Abdalla A, Haykal T, Ahmed S, Bachuwa G, Hassan M,
Bhatt DL. Catheter ablation of atrial fibrillation with heart failure: an updated meta-analysis of randomized trials. Int J Cardiol 2018;269:170173.
671. Khan SU, Rahman H, Talluri S, Kaluski E. The clinical benefits and mortality reduction associated with catheter ablation in subjects with atrial fibrillation: a systematic review and meta-analysis. JACC Clin Electrophysiol 2018;4:626635.
672. Martin CA, Lambiase PD. Pathophysiology, diagnosis and treatment of tachycardiomyopathy. Heart 2017;103:15431552.
673. Raymond-Paquin A, Nattel S, Wakili R, Tadros R. Mechanisms and clinical significance of arrhythmia-induced cardiomyopathy.
Can
J
Cardiol
2018;34:14491460.
674. Brembilla-Perrot B, Ferreira JP, Manenti V, Sellal JM, Olivier A, Villemin T,
Beurrier D, De Chillou C, Louis P, Brembilla A, Juilliere Y, Girerd N. Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of
1269
patients undergoing atrial flutter ablation.
Eur
J
Heart
Fail
2016;18:394401.
675. Dagres N, Varounis C, Gaspar T, Piorkowski C, Eitel C, Iliodromitis EK, Lekakis
JP, Flevari P, Simeonidou E, Rallidis LS, Tsougos E, Hindricks G, Sommer P,
Anastasiou-Nana M. Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis. J Card
Fail 2011;17:964970.
676. Prabhu S, Costello BT, Taylor AJ, Gutman SJ, Voskoboinik A, McLellan AJA,
Peck KY, Sugumar H, Iles L, Pathik B, Nalliah CJ, Wong GR, Azzopardi SM, Lee
G, Mariani J, Kaye DM, Ling LH, Kalman JM, Kistler PM. Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy of the
CAMERA MRI trial. JACC Clin Electrophysiol 2018;4:9991007.
677. Tamborero D, Mont L, Berruezo A, Matiello M, Benito B, Sitges M, Vidal B, de
Caralt TM, Perea RJ, Vatasescu R, Brugada J. Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: a prospective randomized study. Circ Arrhythm Electrophysiol
2009;2:3540.
678. Natale A, Reddy VY, Monir G, Wilber DJ, Lindsay BD, McElderry HT, Kantipudi
C, Mansour MC, Melby DP, Packer DL, Nakagawa H, Zhang B, Stagg RB, Boo
LM, Marchlinski FE. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll
Cardiol 2014;64:647656.
679. McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S, Wong MC,
Walters TE, Lee JM, Looi KL, Halloran K, Stiles MK, Lever NA, Fynn SP, Heck
PM, Sanders P, Morton JB, Kalman JM, Kistler PM. A minimal or maximal ablation strategy to achieve pulmonary vein isolation for paroxysmal atrial fibrillation: a prospective multi-centre randomized controlled trial (the Minimax study). Eur Heart J 2015;36:18121821.
680. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L,
Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E,
Novak P, Sanders P; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015;372:18121822.
681. Luik A, Radzewitz A, Kieser M, Walter M, Bramlage P, Hormann P, Schmidt K,
Horn N, Brinkmeier-Theofanopoulou M, Kunzmann K, Riexinger T, Schymik
G, Merkel M, Schmitt C. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective,
randomized,
controlled,
noninferiority
FreezeAF
study.
Circulation
2015;132:13111319.
682. Dukkipati SR, Cuoco F, Kutinsky I, Aryana A, Bahnson TD, Lakkireddy D,
Woollett I, Issa ZF, Natale A, Reddy VY; HeartLight Study Investigators.
Pulmonary vein isolation using the visually guided laser balloon: a prospective,
multicenter, and randomized comparison to standard radiofrequency ablation. J
Am Coll Cardiol 2015;66:13501360.
683. Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt
L, Lewalter T, Breithardt G, Willems S; Gap-AFAFNET 1 Investigators.
Impact of complete versus incomplete circumferential lines around the pulmonary veins during catheter ablation of paroxysmal atrial fibrillation: results from the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1
trial. Circ Arrhythm Electrophysiol 2016;9:e003337.
684. Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczotka A, Sadek MM,
Green MS, Wells G, Birnie DH. Relationship between pulmonary vein reconnection and atrial fibrillation recurrence: a systematic review and meta-analysis.
JACC Clin Electrophysiol 2016;2:474483.
685. Bassiouny M, Saliba W, Hussein A, Rickard J, Diab M, Aman W, Dresing T, Tt
Callahan, Bhargava M, Martin DO, Shao M, Baranowski B, Tarakji K, Tchou PJ,
Hakim A, Kanj M, Lindsay B, Wazni O. Randomized study of persistent atrial fibrillation ablation: ablate in sinus rhythm versus ablate complex-fractionated atrial electrograms in atrial fibrillation.
Circ
Arrhythm
Electrophysiol
2016;9:e003596.
686. Hindricks G, Sepehri Shamloo A, Lenarczyk R, Kalarus Z, Arya A, Kircher S,
Darma A, Dagres N. Catheter ablation of atrial fibrillation: current status, techniques, outcomes and challenges. Kardiol Pol 2018;76:16801686.
687. Nanthakumar K, Plumb VJ, Epstein AE, Veenhuyzen GD, Link D, Kay GN.
Resumption of electrical conduction in previously isolated pulmonary veins:
rationale for a different strategy?Circulation 2004;109:12261229.
688. Verma A, Kilicaslan F, Pisano E, Marrouche NF, Fanelli R, Brachmann J,
Geunther J, Potenza D, Martin DO, Cummings J, Burkhardt JD, Saliba W,
Schweikert RA, Natale A. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation 2005;112:627635.
689. Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT, Schaumann A,
Chun J, Falk P, Hennig D, Liu X, Bansch D, Kuck KH. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation 2005;111:127135.
690. Cheema A, Dong J, Dalal D, Marine JE, Henrikson CA, Spragg D, Cheng A,
Nazarian S, Bilchick K, Sinha S, Scherr D, Almasry I, Halperin H, Berger R,
Calkins H. Incidence and time course of early recovery of pulmonary vein conduction after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol
2007;18:387391.
691. Pratola C, Baldo E, Notarstefano P, Toselli T, Ferrari R. Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm?Circulation 2008;117:136143.
692. Rajappan K, Kistler PM, Earley MJ, Thomas G, Izquierdo M, Sporton SC,
Schilling RJ. Acute and chronic pulmonary vein reconnection after atrial fibrillation ablation: a prospective characterization of anatomical sites. Pacing Clin
Electrophysiol 2008;31:15981605.
693. Bansch D, Bittkau J, Schneider R, Schneider C, Wendig I, Akin I, Nienaber CA.
Circumferential pulmonary vein isolation: wait or stop early after initial successful pulmonary vein isolation?Europace 2013;15:183188.
ESC Guidelines
475


<!-- PAGE 104 -->

### Page 104

.............................................................................................................................................................................
694. Nakamura K, Naito S, Kaseno K, Tsukada N, Sasaki T, Hayano M, Nishiuchi S,
Fuke E, Miki Y, Sakamoto T, Nakamura K, Kumagai K, Kataoka A, Takaoka H,
Kobayashi Y, Funabashi N, Oshima S. Optimal observation time after completion of circumferential pulmonary vein isolation for atrial fibrillation to prevent chronic pulmonary vein reconnections. Int J Cardiol 2013;168:53005310.
695. Neuzil P, Reddy VY, Kautzner J, Petru J, Wichterle D, Shah D, Lambert H,
Yulzari A, Wissner E, Kuck KH. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: results from the
EFFICAS I study. Circ Arrhythm Electrophysiol 2013;6:327333.
696. Jiang RH, Po SS, Tung R, Liu Q, Sheng X, Zhang ZW, Sun YX, Yu L, Zhang P, Fu
GS, Jiang CY. Incidence of pulmonary vein conduction recovery in patients without clinical recurrence after ablation of paroxysmal atrial fibrillation: mechanistic implications. Heart Rhythm 2014;11:969976.
697. Kim TH, Park J, Uhm JS, Joung B, Lee MH, Pak HN. Pulmonary vein reconnection predicts good clinical outcome after second catheter ablation for atrial fibrillation. Europace 2017;19:961967.
698. Bordignon S, Furnkranz A, Perrotta L, Dugo D, Konstantinou A, Nowak B,
Schulte-Hahn B, Schmidt B, Chun KR. High rate of durable pulmonary vein isolation after second-generation cryoballoon ablation: analysis of repeat procedures. Europace 2015;17:725731.
699. Ullah W, McLean A, Tayebjee MH, Gupta D, Ginks MR, Haywood GA, O’Neill
M, Lambiase PD, Earley MJ, Schilling RJ, Group UKMT. Randomized trial comparing pulmonary vein isolation using the SmartTouch catheter with or without real-time contact force data. Heart Rhythm 2016;13:17611767.
700. Phlips T, Taghji P, El Haddad M, Wolf M, Knecht S, Vandekerckhove Y,
Tavernier R, Duytschaever M. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the ‘CLOSE’-protocol.
Europace 2018;20:f419f427.
701. Shah D, Haissaguerre M, Jais P, Hocini M. Nonpulmonary vein foci: do they exist?Pacing Clin Electrophysiol 2003;26:16311635.
702. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul
T, Khunnawat C, Ngarmukos T. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol
2004;43:20442053.
703. Haissaguerre M, Sanders P, Hocini M, Takahashi Y, Rotter M, Sacher F, Rostock
T, Hsu LF, Bordachar P, Reuter S, Roudaut R, Clementy J, Jais P. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. J Cardiovasc Electrophysiol 2005;16:11251137.
704. Haissaguerre M, Hocini M, Sanders P, Sacher F, Rotter M, Takahashi Y, Rostock
T, Hsu LF, Bordachar P, Reuter S, Roudaut R, Clementy J, Jais P. Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. J Cardiovasc Electrophysiol 2005;16:11381147.
705. Jaı¨s P, O’Neill MD, Takahashi Y, Jo¨nsson A, Hocini M, Sacher F, Sanders P,
Kodali S, Rostock T, Rotter M, Cle´menty J, Haı¨ssaguerre M. Stepwise catheter ablation of chronic atrial fibrillation:importance of discrete anatomic sites for termination. J Cardiovasc Electrophysiol 2006;17:S28S36.
706. Atienza F, Almendral J, Jalife J, Zlochiver S, Ploutz-Snyder R, Torrecilla EG,
Arenal A, Kalifa J, Fernandez-Aviles F, Berenfeld O. Real-time dominant frequency mapping and ablation of dominant frequency sites in atrial fibrillation with left-to-right frequency gradients predicts long-term maintenance of sinus rhythm. Heart Rhythm 2009;6:3340.
707. Stavrakis S, Nakagawa H, Po SS, Scherlag BJ, Lazzara R, Jackman WM. The role of the autonomic ganglia in atrial fibrillation.
JACC
Clin
Electrophysiol
2015;1:113.
708. Di Biase L, Burkhardt JD, Mohanty P, Mohanty S, Sanchez JE, Trivedi C, Gunes
M, Gokoglan Y, Gianni C, Horton RP, Themistoclakis S, Gallinghouse GJ, Bailey
S, Zagrodzky JD, Hongo RH, Beheiry S, Santangeli P, Casella M, Dello Russo A,
Al-Ahmad A, Hranitzky P, Lakkireddy D, Tondo C, Natale A. Left atrial appendage isolation in patients with longstanding persistent af undergoing catheter ablation: BELIEF trial. J Am Coll Cardiol 2016;68:19291940.
709. Gianni C, Mohanty S, Di Biase L, Metz T, Trivedi C, Gokoglan Y, Gunes MF, Bai
R, Al-Ahmad A, Burkhardt JD, Gallinghouse GJ, Horton RP, Hranitzky PM,
Sanchez JE, Halbfass P, Muller P, Schade A, Deneke T, Tomassoni GF, Natale A.
Acute and early outcomes of focal impulse and rotor modulation (FIRM)-guided rotors-only ablation in patients with nonparoxysmal atrial fibrillation. Heart
Rhythm 2016;13:830835.
710. Santangeli P, Zado ES, Hutchinson MD, Riley MP, Lin D, Frankel DS, Supple GE,
Garcia FC, Dixit S, Callans DJ, Marchlinski FE. Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial fibrillation. Heart
Rhythm 2016;13:374382.
711. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS,
Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol
2013;62:23182325.
712. Arbelo E, Guiu E, Ramos P, Bisbal F, Borras R, Andreu D, Tolosana JM,
Berruezo A, Brugada J, Mont L. Benefit of left atrial roof linear ablation in paroxysmal atrial fibrillation: a prospective, randomized study. J Am Heart Assoc
2014;3:e000877.
713. Da Costa A, Levallois M, Romeyer-Bouchard C, Bisch L, Gate-Martinet A, Isaaz
K. Remote-controlled magnetic pulmonary vein isolation combined with superior vena cava isolation for paroxysmal atrial fibrillation: a prospective randomized study. Arch Cardiovasc Dis 2015;108:163171.
714. Wong KC, Paisey JR, Sopher M, Balasubramaniam R, Jones M, Qureshi N,
Hayes CR, Ginks MR, Rajappan K, Bashir Y, Betts TR. No benefit of complex fractionated atrial electrogram ablation in addition to circumferential pulmonary vein ablation and linear ablation: Benefit of Complex Ablation Study. Circ
Arrhythm Electrophysiol 2015;8:13161324.
715. Vogler J, Willems S, Sultan A, Schreiber D, Luker J, Servatius H, Schaffer B,
Moser J, Hoffmann BA, Steven D. Pulmonary vein isolation versus defragmentation: the CHASE-AF clinical trial. J Am Coll Cardiol 2015;66:27432752.
716. Faustino M, Pizzi C, Agricola T, Xhyheri B, Costa GM, Flacco ME, Capasso L,
Cicolini G, Di Girolamo E, Leonzio L, Manzoli L. Stepwise ablation approach versus pulmonary vein isolation in patients with paroxysmal atrial fibrillation:
randomized controlled trial. Heart Rhythm 2015;12:19071915.
717. Scott PA, Silberbauer J, Murgatroyd FD. The impact of adjunctive complex fractionated atrial electrogram ablation and linear lesions on outcomes in persistent atrial fibrillation: a meta-analysis. Europace 2016;18:359367.
718. Driessen AHG, Berger WR, Krul SPJ, van den Berg NWE, Neefs J, Piersma FR,
Chan Pin Yin D, de Jong J, van Boven WP, de Groot JR. Ganglion plexus ablation in advanced atrial fibrillation: the AFACT study. J Am Coll Cardiol
2016;68:11551165.
719. Qin M, Liu X, Wu SH, Zhang XD. Atrial substrate modification in atrial fibrillation: targeting GP or CFAE? Evidence from meta-analysis of clinical trials. PLoS
One 2016;11:e0164989.
720. Hu X, Jiang J, Ma Y, Tang A. Is there still a role for additional linear ablation in addition to pulmonary vein isolation in patients with paroxysmal atrial fibrillation? An updated meta-analysis of randomized controlled trials. Int J Cardiol
2016;209:266274.
721. Wynn GJ, Panikker S, Morgan M, Hall M, Waktare J, Markides V, Hussain W,
Salukhe T, Modi S, Jarman J, Jones DG, Snowdon R, Todd D, Wong T, Gupta
D. Biatrial linear ablation in sustained nonpermanent AF: results of the substrate modification with ablation and antiarrhythmic drugs in nonpermanent atrial fibrillation (SMAN-PAF) trial. Heart Rhythm 2016;13:399406.
722. Zhang Z, Letsas KP, Zhang N, Efremidis M, Xu G, Li G, Liu T. Linear ablation following pulmonary vein isolation in patients with atrial fibrillation: a meta-analysis. Pacing Clin Electrophysiol 2016;39:623630.
723. Fink T, Schluter M, Heeger CH, Lemes C, Maurer T, Reissmann B, Riedl J,
Rottner L, Santoro F, Schmidt B, Wohlmuth P, Mathew S, Sohns C, Ouyang F,
Metzner A, Kuck KH. Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation:
the randomized Alster-Lost-AF trial (Ablation at St. Georg Hospital for longstanding persistent atrial fibrillation). Circ Arrhythm Electrophysiol 2017;10.
724. Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN. Does additional electrogram-guided ablation after linear ablation reduce recurrence after catheter ablation for longstanding persistent atrial fibrillation? A prospective randomized study. J Am Heart Assoc 2017;6:e004811.
725. Kircher S, Arya A, Altmann D, Rolf S, Bollmann A, Sommer P, Dagres N,
Richter S, Breithardt OA, Dinov B, Husser D, Eitel C, Gaspar T, Piorkowski C,
Hindricks G. Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study.
Europace 2018;20:17661775.
726. Ammar-Busch S, Bourier F, Reents T, Semmler V, Telishevska M, Kathan S,
Hofmann M, Hessling G, Deisenhofer I. Ablation of complex fractionated electrograms with or without ADditional LINEar Lesions for Persistent Atrial
Fibrillation (the ADLINE trial). J Cardiovasc Electrophysiol 2017;28:636641.
727. Blandino A, Bianchi F, Grossi S, Biondi-Zoccai G, Conte MR, Gaido L, Gaita F,
Scaglione M, Rametta F. Left atrial substrate modification targeting low-voltage areas for catheter ablation of atrial fibrillation: a systematic review and metaanalysis. Pacing Clin Electrophysiol 2017;40:199212.
728. Yang B, Jiang C, Lin Y, Yang G, Chu H, Cai H, Lu F, Zhan X, Xu J, Wang X,
Ching CK, Singh B, Kim YH, Chen M; STABLE-SR Investigators. STABLE-SR
(Electrophysiological Substrate Ablation in the Left Atrium During Sinus
Rhythm) for the treatment of nonparoxysmal atrial fibrillation: a prospective,
multicenter randomized clinical trial. Circ Arrhythm Electrophysiol 2017;10:pii:
e005405.
729. Yu HT, Shim J, Park J, Kim IS, Kim TH, Uhm JS, Joung B, Lee MH, Kim YH, Pak
HN. Pulmonary vein isolation alone versus additional linear ablation in patients with persistent atrial fibrillation converted to paroxysmal type with


<!-- PAGE 105 -->

### Page 105

.............................................................................................................................................................................
antiarrhythmic drug therapy: a multicenter, prospective, randomized study. Circ
Arrhythm Electrophysiol 2017;10:pii: e004915.
730. Wang YL, Liu X, Zhang Y, Jiang WF, Zhou L, Qin M, Zhang DL, Zhang XD, Wu
SH, Xu K. Optimal endpoint for catheter ablation of longstanding persistent atrial fibrillation:
a randomized clinical trial.
Pacing
Clin
Electrophysiol
2018;41:172178.
731. Perez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA, Wood MA. Longterm outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol 2009;2:393401.
732. Natale A, Newby KH, Pisano E, Leonelli F, Fanelli R, Potenza D, Beheiry S,
Tomassoni G. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll
Cardiol 2000;35:18981904.
733. Wazni O, Marrouche NF, Martin DO, Gillinov AM, Saliba W, Saad E, Klein A,
Bhargava M, Bash D, Schweikert R, Erciyes D, Abdul-Karim A, Brachman J,
Gunther J, Pisano E, Potenza D, Fanelli R, Natale A. Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation.
Circulation 2003;108:24792483.
734. Shah DC, Sunthorn H, Burri H, Gentil-Baron P. Evaluation of an individualized strategy of cavotricuspid isthmus ablation as an adjunct to atrial fibrillation ablation. J Cardiovasc Electrophysiol 2007;18:926930.
735. Neumann T, Kuniss M, Conradi G, Janin S, Berkowitsch A, Wojcik M, Rixe J,
Erkapic D, Zaltsberg S, Rolf A, Bachmann G, Dill T, Hamm CW, Pitschner HF.
MEDAFI-Trial (Micro-embolization during ablation of atrial fibrillation): comparison of pulmonary vein isolation using cryoballoon technique vs. radiofrequency energy. Europace 2011;13:3744.
736. Herrera Siklody C, Deneke T, Hocini M, Lehrmann H, Shin DI, Miyazaki S,
Henschke S, Fluegel P, Schiebeling-Romer J, Bansmann PM, Bourdias T, Dousset
V,
Haissaguerre
M,
Arentz
T.
Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol
2011;58:681688.
737. Herrera Siklody C, Arentz T, Minners J, Jesel L, Stratz C, Valina CM, Weber R,
Kalusche D, Toti F, Morel O, Trenk D. Cellular damage, platelet activation, and inflammatory response after pulmonary vein isolation: a randomized study comparing radiofrequency ablation with cryoablation.
Heart
Rhythm
2012;9:189196.
738. Pokushalov E, Romanov A, Artyomenko S, Baranova V, Losik D, Bairamova S,
Karaskov A, Mittal S, Steinberg JS. Cryoballoon versus radiofrequency for pulmonary vein re-isolation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2013;24:274279.
739. Schmidt M, Dorwarth U, Andresen D, Brachmann J, Kuck KH, Kuniss M,
Lewalter T, Spitzer S, Willems S, Senges J, Junger C, Hoffmann E. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German
Ablation Registry. J Cardiovasc Electrophysiol 2014;25:17.
740. Perez-Castellano N, Fernandez-Cavazos R, Moreno J, Canadas V, Conde A,
Gonzalez-Ferrer JJ, Macaya C, Perez-Villacastin J. The COR trial: a randomized study with continuous rhythm monitoring to compare the efficacy of cryoenergy and radiofrequency for pulmonary vein isolation.
Heart
Rhythm
2014;11:814.
741. Hunter RJ, Baker V, Finlay MC, Duncan ER, Lovell MJ, Tayebjee MH, Ullah W,
Siddiqui MS, Mc LA, Richmond L, Kirkby C, Ginks MR, Dhinoja M, Sporton S,
Earley MJ, Schilling RJ. Point-by-point radiofrequency ablation versus the cryoballoon or a novel combined approach: a randomized trial comparing 3 methods of pulmonary vein isolation for paroxysmal atrial fibrillation (the Cryo
Versus RF trial). J Cardiovasc Electrophysiol 2015;26:13071314.
742. Squara F, Zhao A, Marijon E, Latcu DG, Providencia R, Di Giovanni G, Jauvert
G, Jourda F, Chierchia GB, De Asmundis C, Ciconte G, Alonso C, Grimard C,
Boveda S, Cauchemez B, Saoudi N, Brugada P, Albenque JP, Thomas O.
Comparison between radiofrequency with contact force-sensing and secondgeneration cryoballoon for paroxysmal atrial fibrillation catheter ablation: a multicentre European evaluation. Europace 2015;17:718724.
743. Straube F, Dorwarth U, Ammar-Busch S, Peter T, Noelker G, Massa T, Kuniss
M, Ewertsen NC, Chun KR, Tebbenjohanns J, Tilz R, Kuck KH, Ouarrak T,
Senges J, Hoffmann E; Freeze Cohort Investigators. First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs. cryoballoon pulmonary vein isolation. Europace 2016;18:368375.
744. Schmidt M, Dorwarth U, Andresen D, Brachmann J, Kuck K, Kuniss M, Willems
S, Deneke T, Tebbenjohanns J, Gerds-Li JH, Spitzer S, Senges J, Hochadel M,
Hoffmann E. German ablation registry: cryoballoon vs. radiofrequency ablation in paroxysmal atrial fibrillation  one-year outcome data. Heart Rhythm
2016;13:836844.
745. Boveda S, Providencia R, Defaye P, Pavin D, Cebron JP, Anselme F, Halimi F,
Khoueiry Z, Combes N, Combes S, Jacob S, Albenque JP, Sousa P. Outcomes after cryoballoon or radiofrequency ablation for persistent atrial fibrillation: a multicentric propensity-score matched study.
J
Interv
Card
Electrophysiol
2016;47:133142.
746. Kuck KH, Furnkranz A, Chun KR, Metzner A, Ouyang F, Schluter M, Elvan A,
Lim HW, Kueffer FJ, Arentz T, Albenque JP, Tondo C, Kuhne M, Sticherling C,
Brugada J; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization,
and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J
2016;37:28582865.
747. Buist TJ, Adiyaman A, Smit JJJ, Ramdat Misier AR, Elvan A. Arrhythmia-free survival and pulmonary vein reconnection patterns after second-generation cryoballoon and contact-force radiofrequency pulmonary vein isolation. Clin Res
Cardiol 2018;107:498506.
748. Gunawardene MA, Hoffmann BA, Schaeffer B, Chung DU, Moser J, Akbulak
RO, Jularic M, Eickholt C, Nuehrich J, Meyer C, Willems S. Influence of energy source on early atrial fibrillation recurrences: a comparison of cryoballoon vs.
radiofrequency current energy ablation with the endpoint of unexcitability in pulmonary vein isolation. Europace 2018;20:4349.
749. Mortsell D, Arbelo E, Dagres N, Brugada J, Laroche C, Trines SA, Malmborg H,
Hoglund N, Tavazzi L, Pokushalov E, Stabile G, Blomstrom-Lundqvist C; ESCEHRA
Atrial
Fibrillation
Ablation
Long-Term
Registry
Investigators.
Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. Europace 2019;21:581589.
750. Akkaya E, Berkowitsch A, Zaltsberg S, Greiss H, Hamm CW, Sperzel J,
Neumann T, Kuniss M. Ice or fire? Comparison of second-generation cryoballoon ablation and radiofrequency ablation in patients with symptomatic persistent atrial fibrillation and an enlarged left atrium. J Cardiovasc Electrophysiol
2018;29:375384.
751. Murray MI, Arnold A, Younis M, Varghese S, Zeiher AM. Cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Res Cardiol 2018;107:658669.
752. Chen CF, Gao XF, Duan X, Chen B, Liu XH, Xu YZ. Comparison of catheter ablation for paroxysmal atrial fibrillation between cryoballoon and radiofrequency: a meta-analysis. J Interv Card Electrophysiol 2017;48:351366.
753. Buiatti A, von Olshausen G, Barthel P, Schneider S, Luik A, Kaess B, Laugwitz
KL, Hoppmann P. Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies.
Europace 2017;19:378384.
754. Cardoso R, Mendirichaga R, Fernandes G, Healy C, Lambrakos LK, VilesGonzalez JF, Goldberger JJ, Mitrani RD. Cryoballoon versus radiofrequency catheter ablation in atrial fibrillation: a meta-analysis. J Cardiovasc Electrophysiol
2016;27:11511159.
755. Kabunga P, Phan K, Ha H, Sy RW. Meta-analysis of contemporary atrial fibrillation ablation strategies: irrigated radiofrequency versus duty-cycled phased radiofrequency versus cryoballoon ablation.
JACC
Clin
Electrophysiol
2016;2:377390.
756. Bollmann A, Ueberham L, Schuler E, Wiedemann M, Reithmann C, Sause A,
Tebbenjohanns J, Schade A, Shin DI, Staudt A, Zacharzowsky U, Ulbrich M,
Wetzel U, Neuser H, Bode K, Kuhlen R, Hindricks G. Cardiac tamponade in catheter ablation of atrial fibrillation: German-wide analysis of 21 141 procedures in the Helios atrial fibrillation ablation registry (SAFER). Europace
2018;20:19441951.
757. Ueberham L, Schuler E, Hindricks G, Kuhlen R, Bollmann A. SAFER. Eur Heart J
2018;39:20232024.
758. Hummel J, Michaud G, Hoyt R, DeLurgio D, Rasekh A, Kusumoto F, Giudici M,
Dan D, Tschopp D, Calkins H, Boersma L; TTOP-AF Investigators. Phased RF
ablation in persistent atrial fibrillation. Heart Rhythm 2014;11:202209.
759. Boersma
LV,
van der Voort
P, Debruyne
P,
Dekker
L, Simmers
T,
Rossenbacker T, Balt J, Wijffels M, Degreef Y. Multielectrode pulmonary vein isolation versus single tip wide area catheter ablation for paroxysmal atrial fibrillation: a multinational multicenter randomized clinical trial. Circ Arrhythm
Electrophysiol 2016;9:e003151.
760. Nagashima K, Okumura Y, Watanabe I, Nakahara S, Hori Y, Iso K, Watanabe R,
Arai M, Wakamatsu Y, Kurokawa S, Mano H, Nakai T, Ohkubo K, Hirayama A.
Hot balloon versus cryoballoon ablation for atrial fibrillation: lesion characteristics and middle-term outcomes. Circ Arrhythm Electrophysiol 2018;11:e005861.
761. Ucer E, Janeczko Y, Seegers J, Fredersdorf S, Friemel S, Poschenrieder F, Maier
LS, Jungbauer CG. A RAndomized Trial to compare the acute reconnection after pulmonary vein ISolation with Laser-BalloON versus radiofrequency
Ablation: RATISBONA trial. J Cardiovasc Electrophysiol 2018;29:733739.
762. De Greef Y, Stroker E, Schwagten B, Kupics K, De Cocker J, Chierchia GB, de
Asmundis C, Stockman D, Buysschaert I. Complications of pulmonary vein isolation in atrial fibrillation: predictors and comparison between four different ablation techniques: results from the Middelheim PVI-registry.
Europace
2018;20:12791286.
ESC Guidelines
477


<!-- PAGE 106 -->

### Page 106

.............................................................................................................................................................................
763. Steinbeck G, Sinner MF, Lutz M, Muller-Nurasyid M, Kaab S, Reinecke H.
Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for
Germany in 2014. Eur Heart J 2018;39:40204029.
764. Fink T, Metzner A, Willems S, Eckardt L, Ince H, Brachmann J, Spitzer SG,
Deneke T, Schmitt C, Hochadel M, Senges J, Rillig A. Procedural success, safety and patients satisfaction after second ablation of atrial fibrillation in the elderly:
results from the
German ablation registry.
Clin
Res
Cardiol
2019;108:13541363.
765. Szegedi N, Szeplaki G, Herczeg S, Tahin T, Sallo Z, Nagy VK, Osztheimer I,
Ozcan EE, Merkely B, Geller L. Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation. Europace 2019;21:732737.
766. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein
G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:3238.
767. Lee G, Sparks PB, Morton JB, Kistler PM, Vohra JK, Medi C, Rosso R, Teh A,
Halloran K, Kalman JM. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol 2011;22:163168.
768. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, Grover P, Singh
V, Vallurupalli S, Savani GT, Badheka A, Tuliani T, Dabhadkar K, Dibu G, Reddy
YM, Sewani A, Kowalski M, Mitrani R, Paydak H, Viles-Gonzalez JF. In-hospital complications associated with catheter ablation of atrial fibrillation in the
United States between 2000 and 2010: analysis of 93 801 procedures.
Circulation 2013;128:21042112.
769. Tripathi B, Arora S, Kumar V, Abdelrahman M, Lahewala S, Dave M, Shah M,
Tan B, Savani S, Badheka A, Gopalan R, Shantha GPS, Viles-Gonzalez J,
Deshmukh A. Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: an update from
Nationwide Inpatient Sample database (20112014). J Cardiovasc Electrophysiol
2018;29:715724.
770. Voskoboinik A, Sparks PB, Morton JB, Lee G, Joseph SA, Hawson JJ, Kistler PM,
Kalman JM. Low rates of major complications for radiofrequency ablation of atrial fibrillation maintained over 14 years: a single centre experience of 2750
consecutive cases. Heart Lung Circ 2018;27:976983.
771. Berger WR, Meulendijks ER, Limpens J, van den Berg NWE, Neefs J, Driessen
AHG, Krul SPJ, van Boven WJP, de Groot JR. Persistent atrial fibrillation: a systematic review and meta-analysis of invasive strategies.
Int
J
Cardiol
2019;278:137143.
772. Shah AN, Mittal S, Sichrovsky TC, Cotiga D, Arshad A, Maleki K, Pierce WJ,
Steinberg JS. Long-term outcome following successful pulmonary vein isolation:
pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol
2008;19:661667.
773. Sawhney N, Anousheh R, Chen WC, Narayan S, Feld GK. Five-year outcomes after segmental pulmonary vein isolation for paroxysmal atrial fibrillation. Am J
Cardiol 2009;104:366372.
774. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Kokturk B,
Konstantinidou M, Metzner A, Fuernkranz A, Kuck KH. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year followup. Circulation 2010;122:23682377.
775. Bertaglia E, Tondo C, De Simone A, Zoppo F, Mantica M, Turco P, Iuliano A,
Forleo G, La Rocca V, Stabile G. Does catheter ablation cure atrial fibrillation?
Single-procedure outcome of drug-refractory atrial fibrillation ablation: a 6-year multicentre experience. Europace 2010;12:181187.
776. Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F, Lellouche N,
Knecht S, Wright M, Nault I, Miyazaki S, Scavee C, Clementy J, Haissaguerre M,
Jais P. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?J Am Coll Cardiol 2011;57:160166.
777. Medi C, Sparks PB, Morton JB, Kistler PM, Halloran K, Rosso R, Vohra JK,
Kumar S, Kalman JM. Pulmonary vein antral isolation for paroxysmal atrial fibrillation:
results from long-term follow-up.
J
Cardiovasc
Electrophysiol
2011;22:137141.
778. Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA, Luker
J, Berner I, Schaffer B, Wegscheider K, Lezius S, Willems S, Steven D. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol
2015;8:308317.
779. Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB,
Ramoul K, Komatsu Y, Roten L, Jadidi A, Linton N, Pedersen M, Daly M,
O’Neill M, Knecht S, Weerasooriya R, Rostock T, Manninger M, Cochet H,
Shah AJ, Yeim S, Denis A, Derval N, Hocini M, Sacher F, Haissaguerre M, Jais P.
Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a
procedural endpoint.
Circ
Arrhythm
Electrophysiol 2015;8:1824.
780. Bertaglia E, Senatore G, De Michieli L, De Simone A, Amellone C, Ferretto S,
La Rocca V, Giuggia M, Corrado D, Zoppo F, Stabile G. Twelve-year follow-up of catheter ablation for atrial fibrillation: a prospective, multicenter, randomized study. Heart Rhythm 2017;14:486492.
781. Skelly A, Hashimoto R, Al-Khatib S, et alet alCatheter Ablation for Treatment of
Atrial Fibrillation [Internet]. Rockville, MD: Agency for Healthcare Research and
Quality (US). Available from https://www.ncbi.nlm.nih.gov/books/NBK305763/
(accessed 20 April 2015).
782. Zheng YR, Chen ZY, Ye LF, Wang LH. Long-term stroke rates after catheter ablation or antiarrhythmic drug therapy for atrial fibrillation: a meta-analysis of randomized trials. J Geriatr Cardiol 2015;12:507514.
783. Reynolds MR, Walczak J, White SA, Cohen DJ, Wilber DJ. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circ
Cardiovasc Qual Outcomes 2010;3:615623.
784. Walfridsson H, Walfridsson U, Nielsen JC, Johannessen A, Raatikainen P, Janzon
M, Levin LA, Aronsson M, Hindricks G, Kongstad O, Pehrson S, Englund A,
Hartikainen J, Mortensen LS, Hansen PS. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace 2015;17:215221.
785. De Greef Y, Schwagten B, Chierchia GB, de Asmundis C, Stockman D,
Buysschaert I. Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI registry. Europace 2018;20:589595.
786. Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G, Leong
DP,
Lau
DH,
Middeldorp
ME,
Roberts-Thomson
KC,
Wittert
GA,
Abhayaratna WP, Worthley SG, Sanders P. Pericardial fat is associated with atrial fibrillation severity and ablation outcome.
J
Am
Coll
Cardiol
2011;57:17451751.
787. Kang JH, Lee DI, Kim S, Kim MN, Park YM, Ban JE, Choi JI, Lim HE, Park SW,
Kim YH. Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. J Cardiovasc
Electrophysiol 2012;23:11651170.
788. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JPM, Finnie JW,
Samuel CS, Royce SG, Twomey DJ, Thanigaimani S, Kalman JM, Sanders P.
Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol 2015;66:111.
789. Winkle RA, Mead RH, Engel G, Kong MH, Fleming W, Salcedo J, Patrawala RA.
Impact of obesity on atrial fibrillation ablation: patient characteristics, long-term outcomes, and complications. Heart Rhythm 2017;14:819827.
790. De Maat GE, Mulder B, Berretty WL, Al-Jazairi MIH, Tan YES, Wiesfeld ACP,
Mariani MA, Van Gelder IC, Rienstra M, Blaauw Y. Obesity is associated with impaired long-term success of pulmonary vein isolation: a plea for risk factor management before ablation. Open Heart 2018;5:e000771.
791. Glover BM, Hong KL, Dagres N, Arbelo E, Laroche C, Riahi S, Bertini M,
Mikhaylov EN, Galvin J, Kiliszek M, Pokushalov E, Kautzner J, Calvo N,
Blomstrom-Lundqvist C, Brugada J; ESC-EHRA Atrial Fibrillation Ablation LongTerm Registry Investigators. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart 2019;105:244250.
792. Chang SL, Tuan TC, Tai CT, Lin YJ, Lo LW, Hu YF, Tsao HM, Chang CJ, Tsai
WC, Chen SA. Comparison of outcome in catheter ablation of atrial fibrillation in patients with versus without the metabolic syndrome. Am J Cardiol
2009;103:6772.
793. Tang RB, Dong JZ, Liu XP, Long DY, Yu RH, Kalifa J, Ma CS. Metabolic syndrome and risk of recurrence of atrial fibrillation after catheter ablation. Circ J
2009;73:438443.
794. Mohanty S, Mohanty P, Di Biase L, Bai R, Pump A, Santangeli P, Burkhardt D,
Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Zagrodzky J, Natale A. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J Am Coll Cardiol 2012;59:12951301.
795. Mulder AA, Wijffels MC, Wever EF, Kelder JC, Boersma LV. Arrhythmia detection after atrial fibrillation ablation: value of incremental monitoring time. Pacing
Clin Electrophysiol 2012;35:164169.
796. Steven D, Rostock T, Lutomsky B, Klemm H, Servatius H, Drewitz I, Friedrichs
K, Ventura R, Meinertz T, Willems S. What is the real atrial fibrillation burden after catheter ablation of atrial fibrillation? A prospective rhythm analysis in pacemaker patients with continuous atrial monitoring.
Eur
Heart
J
2008;29:10371042.
797. Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, Morishima I,
Miura F, Watanabe T, Masuda M, Naito M, Fujimoto H, Nishida T, Furukawa Y,
Shirayama T, Tanaka M, Okajima K, Yao T, Egami Y, Satomi K, Noda T,
Miyamoto K, Haruna T, Kawaji T, Yoshizawa T, Toyota T, Yahata M, Nakai K,
Sugiyama H, Higashi Y, Ito M, Horie M, Kusano KF, Shimizu W, Kamakura S,
Morimoto T, Kimura T, Shizuta S; EAST-AF Trial Investigators. Efficacy of
Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial
Fibrillation (EAST-AF) trial. Eur Heart J 2016;37:610618.


<!-- PAGE 107 -->

### Page 107

.............................................................................................................................................................................
798. Willems S, Khairy P, Andrade JG, Hoffmann BA, Levesque S, Verma A,
Weerasooriya R, Novak P, Arentz T, Deisenhofer I, Rostock T, Steven D,
Rivard L, Guerra PG, Dyrda K, Mondesert B, Dubuc M, Thibault B, Talajic M,
Roy D, Nattel S, Macle L, ADVICE Trial Investigators. Redefining the blanking period after catheter ablation for paroxysmal atrial fibrillation: insights from the ADVICE (Adenosine Following Pulmonary Vein Isolation to Target
Dormant Conduction Elimination) trial. Circ Arrhythm Electrophysiol 2016;9:
e003909.
799. Klemm HU, Ventura R, Rostock T, Brandstrup B, Risius T, Meinertz T, Willems
S. Correlation of symptoms to ECG diagnosis following atrial fibrillation ablation. J Cardiovasc Electrophysiol 2006;17:146150.
800. Vasamreddy CR, Dalal D, Dong J, Cheng A, Spragg D, Lamiy SZ, Meininger G,
Henrikson CA, Marine JE, Berger R, Calkins H. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J
Cardiovasc Electrophysiol 2006;17:134139.
801. Oral H, Veerareddy S, Good E, Hall B, Cheung P, Tamirisa K, Han J, Fortino J,
Chugh A, Bogun F, Pelosi F Jr, Morady F. Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J
Cardiovasc Electrophysiol 2004;15:920924.
802. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C,
Kottkamp H. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation
2005;112:307313.
803. Senatore G, Stabile G, Bertaglia E, Donnici G, De Simone A, Zoppo F, Turco P,
Pascotto P, Fazzari M. Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol 2005;45:873876.
804. Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S,
Riley M, Russo AM, Hutchinson MD, Cooper J, Verdino R, Patel V, Joy PS,
Gerstenfeld EP. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study).
Circulation 2009;120:10361040.
805. Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P,
Knecht S, Tavernier R, Vandekerckhove Y, De Potter T. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J 2018;39:14291437.
806. Mardigyan V, Verma A, Birnie D, Guerra P, Redfearn D, Becker G, Champagne
J, Sapp J, Gula L, Parkash R, Macle L, Crystal E, O’Hara G, Khaykin Y, Sturmer
M, Veenhuyzen GD, Greiss I, Sarrazin JF, Mangat I, Novak P, Skanes A, Roux JF,
Chauhan V, Hadjis T, Morillo CA, Essebag V. Anticoagulation management preand post atrial fibrillation ablation: a survey of Canadian centres. Can J Cardiol
2013;29:219223.
807. Nakahara S, Hori Y, Kobayashi S, Sakai Y, Taguchi I, Takayanagi K, Nagashima K,
Sonoda K, Kogawa R, Sasaki N, Watanabe I, Okumura Y. Epicardial adipose tissue-based defragmentation approach to persistent atrial fibrillation: its impact on complex fractionated electrograms and ablation outcome. Heart Rhythm
2014;11:13431351.
808. Chao TF, Hung CL, Tsao HM, Lin YJ, Yun CH, Lai YH, Chang SL, Lo LW, Hu
YF, Tuan TC, Chang HY, Kuo JY, Yeh HI, Wu TJ, Hsieh MH, Yu WC, Chen SA.
Epicardial adipose tissue thickness and ablation outcome of atrial fibrillation.
PLoS One 2013;8:e74926.
809. Masuda M, Mizuno H, Enchi Y, Minamiguchi H, Konishi S, Ohtani T, Yamaguchi
O, Okuyama Y, Nanto S, Sakata Y. Abundant epicardial adipose tissue surrounding the left atrium predicts early rather than late recurrence of atrial fibrillation after catheter ablation. J Interv Card Electrophysiol 2015;44:3137.
810. Sepehri Shamloo A, Dagres N, Dinov B, Sommer P, Husser-Bollmann D,
Bollmann A, Hindricks G, Arya A. Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis. Int
J Cardiol Heart Vasc 2019;22:132138.
811. Blanche C, Tran N, Rigamonti F, Burri H, Zimmermann M. Value of P-wave signal averaging to predict atrial fibrillation recurrences after pulmonary vein isolation. Europace 2013;15:198204.
812. Bhargava M, Di Biase L, Mohanty P, Prasad S, Martin DO, Williams-Andrews M,
Wazni OM, Burkhardt JD, Cummings JE, Khaykin Y, Verma A, Hao S, Beheiry S,
Hongo R, Rossillo A, Raviele A, Bonso A, Themistoclakis S, Stewart K, Saliba
WI, Schweikert RA, Natale A. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm 2009;6:14031412.
813. Winkle RA, Mead RH, Engel G, Patrawala RA. Long-term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation. Am Heart J 2011;162:193200.
814. Mohanty S, Mohanty P, DIB L, Bai R, Trivedi C, Santangeli P, Santoro F, Hongo
R, Hao S, Beheiry S, Burkhardt D, Gallinghouse JG, Horton R, Sanchez JE, Bailey
S, Hranitzky PM, Zagrodzky J, Natale A. Long-term outcome of catheter ablation in atrial fibrillation patients with coexistent metabolic syndrome and obstructive sleep apnea: impact of repeat procedures versus lifestyle changes. J
Cardiovasc Electrophysiol 2014;25:930938.
815. Ejima K, Shoda M, Arai K, Suzuki A, Yagishita D, Yagishita Y, Yashiro B, Sato T,
Manaka T, Ashihara K, Hagiwara N. Impact of diastolic dysfunction on the outcome of catheter ablation in patients with atrial fibrillation. Int J Cardiol
2013;164:8893.
816. Hocini M, Sanders P, Deisenhofer I, Jais P, Hsu LF, Scavee C, Weerasoriya R,
Raybaud F, Macle L, Shah DC, Garrigue S, Le Metayer P, Clementy J,
Haissaguerre M. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation
2003;108:11721175.
817. Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY, Yu RH, Tang RB, Guo XY,
Yan XL, Nie JG, Du X, Dong JZ, Ma CS. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome?Pacing
Clin Electrophysiol 2014;37:403411.
818. Inada K, Yamane T, Tokutake K, Yokoyama K, Mishima T, Hioki M, Narui R, Ito
K, Tanigawa S, Yamashita S, Tokuda M, Matsuo S, Shibayama K, Miyanaga S,
Date T, Sugimoto K, Yoshimura M. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up. Europace 2014;16:208213.
819. Cummings JE, Schweikert R, Saliba W, Hao S, Martin DO, Marrouche NF,
Burkhardt JD, Kilicaslan F, Verma A, Beheiry S, Belden W, Natale A. Left atrial flutter following pulmonary vein antrum isolation with radiofrequency energy:
linear lesions or repeat isolation. J Cardiovasc Electrophysiol 2005;16:293297.
820. Schneider R, Lauschke J, Tischer T, Schneider C, Voss W, Moehlenkamp F,
Glass A, Diedrich D, Bansch D. Pulmonary vein triggers play an important role in the initiation of atrial flutter: initial results from the prospective randomized
Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial. Heart Rhythm
2015;12:865871.
821. Patel NJ, Deshmukh A, Pau D, Goyal V, Patel SV, Patel N, Agnihotri K,
Asirvatham S, Noseworthy P, Di Biase L, Natale A, Viles-Gonzalez JF.
Contemporary utilization and safety outcomes of catheter ablation of atrial flutter in the United States: analysis of 89,638 procedures. Heart Rhythm
2016;13:13171325.
822. Cox JL, Schuessler RB, Boineau JP. The development of the maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000;12:214.
823. Melby SJ, Zierer A, Bailey MS, Cox JL, Lawton JS, Munfakh N, Crabtree TD,
Moazami N, Huddleston CB, Moon MR, Damiano RJ Jr. A new era in the surgical treatment of atrial fibrillation: the impact of ablation technology and lesion set on procedural efficacy. Ann Surg 2006;244:583592.
824. Badhwar V, Rankin JS, Damiano RJ, Jr., Gillinov AM, Bakaeen FG, Edgerton JR,
Philpott JM, McCarthy PM, Bolling SF, Roberts HG, Thourani VH, Suri RM,
Shemin RJ, Firestone S, Ad N. The Society of Thoracic Surgeons 2017 Clinical
Practice Guidelines for the surgical treatment of atrial fibrillation. Ann Thorac
Surg 2017;103:329341.
825. Belley-Cote EP, Singal RK, McClure G, Devereaux K, Brady K, An K, Healey JS,
Connolly SJ, Whitlock RP. Perspective and practice of surgical atrial fibrillation ablation:
an international survey of cardiac surgeons.
Europace
2019;21:445450.
826. Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis. J Thorac Cardiovasc Surg 2006;131:10291035.
827. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, Spence J,
Healey J, Singal RK, Whitlock RP. Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace
2018;20:14421450.
828. Osmancik P, Budera P, Talavera D, Hlavicka J, Herman D, Holy J, Cervinka P,
Smid J, Hanak P, Hatala R, Widimsky P. Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 study. Heart Rhythm
201916:13341340.
829. Sharples L, Everett C, Singh J, Mills C, Spyt T, Abu-Omar Y, Fynn S, Thorpe B,
Stoneman V, Goddard H, Fox-Rushby J, Nashef S. Amaze: a double-blind, multicentre randomised controlled trial to investigate the clinical effectiveness and cost-effectiveness of adding an ablation device-based maze procedure as an adjunct to routine cardiac surgery for patients with pre-existing atrial fibrillation. Health Technol Assess 2018;22:1132.
830. Bagge L, Probst J, Jensen SM, Blomstrom P, Thelin S, Holmgren A, BlomstromLundqvist C. Quality of life is not improved after mitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: a substudy of the double blind randomized SWEDish Multicentre Atrial
Fibrillation study (SWEDMAF). Europace 2018;20:f343f350.
831. Suwalski P, Kowalewski M, Jasinski M, Staromlynski J, Zembala M, Widenka K,
Brykczynski M, Skiba J, Zembala MO, Bartus K, Hirnle T, Dziembowska I, Deja
M, Tobota Z, Maruszewski BJ. Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery. Eur J Cardiothorac Surg 2019.
ESC Guidelines
479


<!-- PAGE 108 -->

### Page 108

.............................................................................................................................................................................
832. Suwalski P, Kowalewski M, Jasinski M, Staromlynski J, Zembala M, Widenka K,
Brykczynski M, Skiba J, Zembala MO, Bartus K, Hirnle T, Dziembowska I,
Tobota Z, Maruszewski BJ; KROK Investigators. Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis from the Polish National
Registry of Cardiac Surgery Procedures (KROK). J Thorac Cardiovasc Surg 2018;
doi: 10.1016/j.jtcvs.2018.07.099.
833. Gillinov AM, Bakaeen F, McCarthy PM, Blackstone EH, Rajeswaran J, Pettersson
G, Sabik JF 3rd, Najam F, Hill KM, Svensson LG, Cosgrove DM, Marrouche N,
Natale A. Surgery for paroxysmal atrial fibrillation in the setting of mitral valve disease: a role for pulmonary vein isolation? Ann Thorac Surg 2006;81:1926;
discussion 2728.
834. Basu S, Nagendran M, Maruthappu M. How effective is bipolar radiofrequency ablation for atrial fibrillation during concomitant cardiac surgery?Interact
Cardiovasc Thorac Surg 2012;15:741748.
835. Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG, Navia JL,
Pettersson BG, Sabik JF, 3rd, Smedira NG, Mihaljevic T, McCarthy PM,
Shewchik J, Natale A. Surgery for permanent atrial fibrillation: impact of patient factors and lesion set. Ann Thorac Surg 2006;82:502513; discussion 513514.
836. Beukema WP, Sie HT, Misier AR, Delnoy PP, Wellens HJ, Elvan A. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified maze procedure. Eur J Cardiothorac Surg 2008;34:771775.
837. Lee SH, Kim JB, Cho WC, Chung CH, Jung SH, Choo SJ, Lee JW. The influence of age on atrial fibrillation recurrence after the maze procedure in patients with giant left atrium. J Thorac Cardiovasc Surg 2011;141:10151019.
838. Damiano RJ Jr, Schwartz FH, Bailey MS, Maniar HS, Munfakh NA, Moon MR,
Schuessler RB. The Cox maze IV procedure: predictors of late recurrence. J
Thorac Cardiovasc Surg 2011;141:113121.
839. Sunderland N, Maruthappu M, Nagendran M. What size of left atrium significantly impairs the success of maze surgery for atrial fibrillation?Interact
Cardiovasc Thorac Surg 2011;13:332338.
840. Bakker RC, Akin S, Rizopoulos D, Kik C, Takkenberg JJ, Bogers AJ. Results of clinical application of the modified maze procedure as concomitant surgery.
Interact Cardiovasc Thorac Surg 2013;16:151156.
841. Ad N, Holmes SD. Prediction of sinus rhythm in patients undergoing concomitant Cox maze procedure through a median sternotomy. J Thorac Cardiovasc
Surg 2014;148:881886.
842. Blomstrom-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM, Thelin S,
Holmgren A, Edvardsson N, Kallner G, Blomstrom P. A randomized doubleblind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial
Fibrillation study (SWEDMAF). Eur Heart J 2007;28:29022908.
843. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM,
Malaisrie SC. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database Syst Rev 2016:CD011814.
844. Budera P, Straka Z, Osmancik P, Vanek T, Jelinek S, Hlavicka J, Fojt R, Cervinka
P, Hulman M, Smid M, Maly M, Widimsky P. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. Eur Heart J
2012;33:26442652.
845. Wang JG, Xin M, Han J, Li Y, Luo TG, Wang J, Meng F, Meng X. Ablation in selective patients with long-standing persistent atrial fibrillation: medium-term results of the Dallas lesion set. Eur J Cardiothorac Surg 2014;46:213220.
846. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM,
McCarthy PM, Thourani VH, Suri RM, Jacobs JP, Cox JL. Surgical ablation of atrial fibrillation in the United States: trends and propensity matched outcomes.
Ann Thorac Surg 2017;104:493500.
847. Joshibayev S, Bolatbekov B. Early and long-term outcomes and quality of life after concomitant mitral valve surgery, left atrial size reduction, and radiofrequency surgical ablation of atrial fibrillation. Anatol J Cardiol 2016;16:797803.
848. Driessen AHG, Berger WR, Bierhuizen MFA, Piersma FR, van den Berg NWE,
Neefs J, Krul SPJ, van Boven WP, de Groot JR. Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: results of the
Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic
Surgery (AFACT) study. J Thorac Cardiovasc Surg 2018;155:972980.
849. Castella M, Kotecha D, van Laar C, Wintgens L, Castillo Y, Kelder J, Aragon D,
Nunez M, Sandoval E, Casellas A, Mont L, van Boven WJ, Boersma LVA, van
Putte BP. Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. Europace 2019;21:746753.
850. Osmancik P, Budera P, Talavera D, Herman D, Vesela J, Prochazkova R, Rizov
V, Kacer P. Improvement in the quality of life of patients with persistent or long-standing persistent atrial fibrillation after hybrid ablation. J Interv Card
Electrophysiol 2020;57:435442.
851. Kim HJ, Kim JS, Kim TS. Epicardial thoracoscopic ablation versus endocardial catheter ablation for management of atrial fibrillation: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2016;22:729737.
852. Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr, O’Brien
SM, Griffith BP, Peterson ED. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National Cardiac Database. Ann Thorac Surg
2008;85:909914.
853. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ,
Damiano RJ, Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz
MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais
P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K,
Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F,
Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C,
Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D.
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528606.
854. van der Heijden CAJ, Vroomen M, Luermans JG, Vos R, Crijns H, Gelsomino S,
La Meir M, Pison L, Maesen B. Hybrid versus catheter ablation in patients with persistent and longstanding persistent atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2019;56:433443.
855. Velagic V, DEA C, Mugnai G, Irfan G, Hunuk B, Stroker E, Hacioglu E, Umbrain
V, Beckers S, Czapla J, Wellens F, Nijs J, Brugada P, M LAM, Chierchia GB.
Repeat procedures after hybrid thoracoscopic ablation in the setting of longstanding persistent atrial fibrillation: electrophysiological findings and 2-year clinical outcome. J Cardiovasc Electrophysiol 2016;27:4150.
856. Osmancik
P,
Budera
P,
Zdarska
J,
Herman
D,
Petr
R,
Straka
Z.
Electrophysiological findings after surgical thoracoscopic atrial fibrillation ablation. Heart Rhythm 2016;13:12461252.
857. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, Han H. A prospective randomized trial of the cut-and-sew maze procedure in patients undergoing surgery for rheumatic mitral valve disease. J Thorac Cardiovasc Surg 2018;155:
608617.
858. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS,
Damiano RJ Jr. A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay. J Thorac
Cardiovasc Surg 2014;148:955961.
859. Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL, Damiano RJ
Jr. The Cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ Arrhythm Electrophysiol 2012;5:814.
860. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA
2014;312:647649.
861. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F,
Hartikainen JE. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol
2013;62:11871192.
862. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH,
Hansen J, Kober L, Husted S, Torp-Pedersen C. Thromboembolic risk in 16
274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 2015;17:1823.
863. Lip GY. Cardioversion of atrial fibrillation. Postgrad Med J 1995;71:457465.
864. Garg A, Khunger M, Seicean S, Chung MK, Tchou PJ. Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset. JACC Clin Electrophysiol
2016;2:487494.
865. Tampieri A, Cipriano V, Mucci F, Rusconi AM, Lenzi T, Cenni P. Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk.
Intern
Emerg
Med
2018;13:8793.
866. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW,
Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF;
Assessment of
Cardioversion
Using
Transesophageal
Echocardiography
Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:14111420.
867. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P,
Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA, Group
ACES. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004;109:9971003.
868. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic
M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL,
Wildgoose P, van Eickels M, Hohnloser SH; X-VERT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J
2014;35:33463355.
869. Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S,
Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P. Apixaban


<!-- PAGE 109 -->

### Page 109

.............................................................................................................................................................................
compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion:
the
EMANATE
trial.
Eur
Heart
J
2018;39:29592971.
870. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri
MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S,
Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY; ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Lancet 2016;388:19952003.
871. Telles-Garcia N, Dahal K, Kocherla C, Lip GYH, Reddy P, Dominic P. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis. Int J
Cardiol 2018;268:143148.
872. Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M.
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation:
an updated meta-analysis.
J
Thromb
Thrombolysis
2018;45:550556.
873. Kotecha D, Pollack CV Jr, De Caterina R, Renda G, Kirchhof P. Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin. J Am Coll Cardiol 2018;72:19841986.
874. Itainen S, Lehto M, Vasankari T, Mustonen P, Kotamaki M, Numminen A,
Lahtela H, Bah A, Hartikainen J, Hekkala AM, Airaksinen JKE. Non-vitamin K
antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace 2018;20:565568.
875. Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, van Eickels M,
Cohen A; X-TRA study and CLOT-AF Registry Investigators. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 2016;178:126134.
876. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell
WB, Havranek E, Murray K, Olshansky B, O’Neill G, Sami M, Schmidt S, Storm
R, Zabalgoitia M, Miller J, Chandler M, Nasco EM, Greene HL. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study. Circulation 2004;109:19731980.
877. Cardoso R, Knijnik L, Bhonsale A, Miller J, Nasi G, Rivera M, Blumer V, Calkins
H. An updated meta-analysis of novel oral anticoagulants versus vitamin K
antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm 2018;15:107115.
878. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH,
Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M;
RE-CIRCUIT Investigators. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:16271636.
879. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ,
Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De
Chillou C, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators.
Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:18051811.
880. Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van
Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR,
Massaro T, Mont L, Nielsen JC, Nolker G, Piccini JP, De Potter T, Scherr D,
Schotten U, Themistoclakis S, Todd D, Vijgen J, Di Biase L. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
Eur
Heart
J
2018;39:29422955.
881. Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Mont L, Morillo
CA, Abozguia K, Grimaldi M, Rauer H, Reimitz PE, Smolnik R, Monninghoff C,
Kautzner J. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J 2019;40:30133021.
882. European Heart Rhythm Association, European Association for CardioThoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst
S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri
O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A,
Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P,
Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology
(ESC). Eur Heart J 2010;31:23692429.
883. Lafuente-Lafuente
C,
Longas-Tejero
MA,
Bergmann
JF,
Belmin
J.
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012:CD005049.
884. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, LafuenteLafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2019;9:CD005049.
885. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A,
Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423434.
886. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, Svendsen
JH. Recurrence of arrhythmia following short-term oral AMIOdarone after
CATheter ablation for atrial fibrillation: a double-blind, randomized, placebocontrolled study (AMIO-CAT trial). Eur Heart J 2014;35:33563364.
887. Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R,
Dixit S, Riley M, Hutchinson MD, Cooper J, Russo AM, Verdino R, Gerstenfeld
EP. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol 2011;4:1114.
888. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME,
Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM,
Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:20502060.
889. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX,
Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Longterm effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:21592169.
890. Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane
Database Syst Rev 2015;3:CD005049.
891. Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis
EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent,
symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart
2000;84:251257.
892. Galperin J, Elizari MV, Chiale PA, Molina RT, Ledesma R, Scapin AO, Vazquez
Blanco M; GEFCA Investigators-GEMA Group. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J
Cardiovasc Pharmacol Ther 2001;6:341350.
893. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, Muthusamy
R, Rhoden WE, Saeed BT, Batin P, Brooksby WP, Wilson I, Grant S. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25:144150.
894. Singh SN, Singh BN, Reda DJ, Fye CL, Ezekowitz MD, Fletcher RD, Sharma SC,
Atwood JE, Jacobson AK, Lewis HD Jr, Antman EM, Falk RH, Lopez B, Tang
XC. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation
Efficacy Trial [Safe-T]). Am J Cardiol 2003;92:468472.
895. Kochiadakis GE, Igoumenidis NE, Hamilos ME, Tzerakis PG, Klapsinos NC,
Chlouverakis GI, Vardas PE. Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. Am J Cardiol 2004;94:15631566.
896. Gulizia M, Mangiameli S, Orazi S, Chiaranda G, Piccione G, Di Giovanni N,
Colletti A, Pensabene O, Lisi F, Vasquez L, Grammatico A, Boriani G;
PITAGORA Study Investigators. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for
Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J
2008;155:100107.e1.
897. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone,
for the management of atrial fibrillation.
Europace
2011;13:329345.
898. Cadrin-Tourigny J, Wyse DG, Roy D, Blondeau L, Levesque S, Talajic M,
Andrade JG, Dubuc M, Thibault B, Guerra PG, Macle L, Rivard L, Khairy P.
Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. J
Cardiovasc Electrophysiol 2014;25:13061313.
899. Massie BM, Fisher SG, Radford M, Deedwania PC, Singh BN, Fletcher RD, Singh
SN. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation
1996;93:21282134.
900. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie
BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995;333:7782.
901. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation
2012;125:381389.
902. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol
2009;54:143149.
903. Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66:865869.
ESC Guidelines
481


<!-- PAGE 110 -->

### Page 110

.............................................................................................................................................................................
904. Lai SW, Lin CL, Liao KF, Lin CY. Amiodarone use and risk of acute pancreatitis:
a population-based case-control study. Heart Rhythm 2015;12:163166.
905. Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr, Murphy EJ, Goldschlager
N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med 2016;129:468475.
906. Basaria
S,
Cooper
DS.
Amiodarone and the thyroid.
Am
J
Med
2005;118:706714.
907. Colby
R,
Geyer
H.
Amiodarone-induced pulmonary toxicity.
JAAPA
2017;30:2326.
908. Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI.
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol
1989;64:13171321.
909. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK,
Hawkinson RW, Pritchett EL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A
multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
Circulation 1989;80:15571570.
910. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J
Cardiol 1997;79:418423.
911. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH,
Arensberg D, Baker A, Friedman L, Greene HL, et alet alMortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac
Arrhythmia Suppression Trial. N Engl J Med 1991;324:781788.
912. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG.
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The
Stroke
Prevention in
Atrial
Fibrillation
Investigators.
J
Am
Coll
Cardiol
1992;20:527532.
913. Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study
Group. Am J Cardiol 1996;78:430434.
914. Brembilla-Perrot B, Laporte F, Sellal JM, Schwartz J, Olivier A, Zinzius PY,
Manenti V, Beurrier D, Andronache M, Louis P, Selton O, de la Chaise AT, De
Chillou C. 1: 1 atrial-flutter. Prevalence and clinical characteristics. Int J Cardiol
2013;168:32873290.
915. Gao X, Guha A, Buck B, Patel D, Snider MJ, Boyd M, Afzal M, Badin A, Godara
H, Liu Z, Tyler J, Weiss R, Kalbfleisch S, Hummel J, Augostini R, Houmsse M,
Daoud EG. Initiation and outcomes with Class Ic antiarrhythmic drug therapy.
Indian Pacing Electrophysiol J 2018;18:6872.
916. Richiardi E, Gaita F, Greco C, Gaschino G, Comba Costa G, Rosettani E,
Brusca A. [Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation]. Cardiologia 1992;37:123127.
917. Chimienti M, Cullen MT, Jr., Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation:
report from theFlecainide and
Propafenone
Italian
Study
Investigators. Am J Cardiol 1996;77:60A75A.
918. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol
1993;71:558563.
919. Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter.
The
Flecainide
AF
French
Study
Group.
Am
J
Cardiol
1996;77:66A71A.
920. Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, Dabizzi
RP. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001;88:640645.
921. Meinertz T, Lip GY, Lombardi F, Sadowski ZP, Kalsch B, Camez A, Hewkin A,
Eberle S; ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The
European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J
Cardiol 2002;90:13001306.
922. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G; Rythmol Atrial
Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol
2003;92:941946.
923. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C,
Connolly SJ; Athena Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668678.
924. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A shortterm, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation:
the
DIONYSOS
study.
J
Cardiovasc
Electrophysiol
2010;21:597605.
925. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot
EM, Hohnloser SH, for the EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med
2007;357:987999.
926. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH.
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur
Heart J 2003;24:14811487.
927. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J,
Carlsen J, Dronedarone Study G. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:26782687.
928. Wu C, Tcherny-Lessenot S, Dai W, Wang Y, Kechemir H, Gandhi S, Lin S,
Juhaeri J. Assessing the risk for peripheral neuropathy in patients treated with dronedarone compared with that in other antiarrhythmics.
Clin
Ther
2018;40:450455.e1.
929. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF.
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
J
Am
Coll
Cardiol
2009;54:10891095.
930. Gao S, Dai W, Zhang L, Juhaeri J, Wang Y, Caubel P. Risk of cardiovascular events, stroke, congestive heart failure, interstitial lung disease, and acute liver injury: dronedarone versus amiodarone and other antiarrhythmics. J Atr
Fibrillation 2013;6:890.
931. Pisters R, Hohnloser SH, Connolly SJ, Torp-Pedersen C, Naditch-Brule L, Page
RL, Crijns HJ; ATHENA Investigators. Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace 2014;16:174181.
932. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D,
Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK,
Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian
P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H,
Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan
C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S,
Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D,
Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S,
Chrolavicius S, Afzal R, Hohnloser SH;PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:22682276.
933. Friberg L. Safety of dronedarone in routine clinical care. J Am Coll Cardiol
2014;63:23762384.
934. Friberg L. Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. Am Heart J 2018;205:118127.
935. Khan MH, Rochlani Y, Aronow WS. Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation.
Expert
Opin
Drug
Saf
2017;16:14071412.
936. Vamos M, Hohnloser SH. Amiodarone and dronedarone: an update. Trends
Cardiovasc Med 2016;26:597602.
937. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C,
Biollaz J. Effect of dronedarone on renal function in healthy subjects. Br J Clin
Pharmacol 2007;64:785791.
938. Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA,
Harcombe AA, Linker NJ, Stewart MJ, Davies A, de Belder MA. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am
Heart J 2006;151:863.e1-6.
939. Capucci A, Botto G, Molon G, Spampinato A, Favale S, Proclemer A, Porfilio A,
Marotta T, Vimercati M, Boriani G; DAPHNE Study Investigators. The Drug
And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. Am Heart J 2008;156:373.e1-8.
940. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932199.
941. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44A50A.
942. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert
J, Dubuc M, Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J
Med 2000;342:913920.
943. Andersen SS, Hansen ML, Gislason GH, Schramm TK, Folke F, Fosbol E,
Abildstrom SZ, Madsen M, Kober L, Torp-Pedersen C. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace
2009;11:886891.
944. Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation:
a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther
1996;10:145152.


<!-- PAGE 111 -->

### Page 111

...........................................................................................................................................................................
945. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation.
A double-blind study comparing quinidine, disopyramide and placebo. S Afr Med
J 1984;65:367369.
946. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation.
A placebo-controlled one-year follow-up study. Eur Heart J 1988;9:284290.
947. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A
meta-analysis of randomized control trials. Circulation 1990;82:11061116.
948. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM,
Mairesse G, Crijns HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L,
Maggioni AP. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management:
baseline results of
EURObservational Research Programme Atrial Fibrillation (EORP-AF) pilot general registry. Europace 2014;16:308319.
949. Dagres N, Lewalter T, Lip GY, Pison L, Proclemer A, Blomstrom-Lundqvist C,
Scientific Initiatives Committee EHRA. Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: the European Heart
Rhythm Association survey. Europace 2013;15:478481.
950. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S,
Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
J
Am
Coll
Cardiol
2005;45:12511258.
951. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein
HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am
Coll Cardiol 2000;35:16691677.
952. Thanigaimani S, Lau DH, Agbaedeng T, Elliott AD, Mahajan R, Sanders P.
Molecular mechanisms of atrial fibrosis: implications for the clinic. Expert Rev
Cardiovasc Ther 2017;15:247256.
953. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:21972204.
954. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE.
Prevention of atrial fibrillation by renin-angiotensin system inhibition a metaanalysis. J Am Coll Cardiol 2010;55:22992307.
955. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly
SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:
a meta-analysis.
J
Am
Coll
Cardiol
2005;45:18321839.
956. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni
AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM) program. Am Heart J
2006;152:8692.
957. McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle
S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM
Investigators. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006;151:985991.
958. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H,
Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II
receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in
Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712719.
959. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of reninangiotensin system prevents new-onset atrial fibrillation.
Am
Heart
J
2006;152:217222.
960. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S,
Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlof B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
JAMA
2006;296:12421248.
961. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ,
Puu M, Yusuf S, Pfeffer MA; CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol
2006;47:19972004.
962. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation:
a nationwide study.
Eur
Heart
J
2014;35:12051214.
963. Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG, Klein HU,
Steinbeck G, Wegscheider K, Meinertz T. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012;5:4351.
964. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for
European Society of Cardiology guidelines. Part II: secondary prevention.
Europace 2011;13:610625.
965. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, Munz BM, Muller P,
Steendijk P, Reil GH, Allessie MA, Bohm M, Neuberger HR. Aldosterone promotes atrial fibrillation. Eur Heart J 2012;33:20982108.
966. Reil JC, Tauchnitz M, Tian Q, Hohl M, Linz D, Oberhofer M, Kaestner L, Reil
GH,
Thiele
H,
Steendijk
P,
Bohm
M,
Neuberger
HR,
Lipp
P.
Hyperaldosteronism induces left atrial systolic and diastolic dysfunction. Am J
Physiol Heart Circ Physiol 2016;311:H1014H1023.
967. Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, Wu CK, Yu CC, Wang YC,
Lai LP, Lin JL. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol
2010;55:758770.
968. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R,
Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:13091321.
969. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent
J, Pitt B; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild
Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll
Cardiol 2012;59:15981603.
970. Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, Anand IS, O’Meara
E, Rouleau JL, Sweitzer NK, Fang JC, Saksena S, Pitt B, Pfeffer MA, Solomon SD.
Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT
trial. JACC Heart Fail 2018;6:689697.
971. Neefs J, van den Berg NW, Limpens J, Berger WR, Boekholdt SM, Sanders P, de
Groot JR. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2017;231:155161.
972. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am
Coll Cardiol 2000;36:139146.
973. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J 2007;28:13511357.
974. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill
M, Chen Z, Collins R, Casadei B. Perioperative rosuvastatin in cardiac surgery.
N Engl J Med 2016;374:17441753.
975. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V,
Macfarlane PW, PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011;342:d1250.
976. Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal 2014;20:12681285.
977. Humphries KH, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, Kerr CR;
CARAF Investigators. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007;154:908913.
978. Bianconi L, Calo L, Mennuni M, Santini L, Morosetti P, Azzolini P, Barbato G,
Biscione F, Romano P, Santini M. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace
2011;13:174181.
979. Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ,
Latini R, Libby P, Lombardi F, O’Gara PT, Page RL, Tavazzi L, Tognoni G;
OPERA Investigators. Fish oil and postoperative atrial fibrillation: the Omega-3
Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA)
randomized trial. JAMA 2012;308:20012011.
980. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T,
Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T,
Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M,
Mitamura H, Yamazaki T, Watanabe E, Ogawa S; J-RHYTHM II Investigators.
Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011;13:473479.
981. Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra
R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators. Omega-3 fatty
ESC Guidelines
483


<!-- PAGE 112 -->

### Page 112

.............................................................................................................................................................................
acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the
Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll
Cardiol 2013;61:463468.
982. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation:
a randomized controlled trial.
JAMA
2010;304:23632372.
983. Kochiadakis GE, Marketou ME, Igoumenidis NE, Chrysostomakis SI, Mavrakis
HE, Kaleboubas MD, Vardas PE. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?Pacing Clin
Electrophysiol 2000;23:18831887.
984. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, Della Casa S,
Sanguinetti M, Magnani B. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized,
controlled trial. Ann Intern Med 1997;126:621625.
985. Ehrlich JR, Look C, Kostev K, Israel CW, Goette A. Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany. Int J Cardiol 2019;278:126132.
986. Camm AJ. Hopes and disappointments with antiarrhythmic drugs. Int J Cardiol
2017;237:7174.
987. De Vecchis R. Long-term antiarrhythmic drug treatment after atrial fibrillation ablation: does a too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients?Eur
Heart
J
Cardiovasc
Pharmacother
2019;5:117118.
988. Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. Basic Clin
Pharmacol Toxicol 2010;106:263268.
989. Reimold FR, Reynolds MR. Proarrhythmia and death with antiarrhythmic drugs for atrial fibrillation, and the unfulfilled promise of comparative effectiveness research. Am Heart J 2018;205:128130.
990. Coughtrie AL, Behr ER, Layton D, Marshall V, Camm AJ, Shakir SAW. Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open 2017;7:e016627.
991. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C,
Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of
Cardiology. Eur Heart J 2000;21:12161231.
992. Milan DJ, Saul JP, Somberg JC, Molnar J. Efficacy of intravenous and oral sotalol in pharmacologic conversion of atrial fibrillation: a systematic review and metaanalysis. Cardiology 2017;136:5260.
993. Agusala K, Oesterle A, Kulkarni C, Caprio T, Subacius H, Passman R. Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
Pacing
Clin
Electrophysiol
2015;38:490498.
994. Lin CY, Lin YJ, Lo LW, Chen YY, Chong E, Chang SL, Chung FP, Chao TF, Hu
YF, Tuan TC, Liao JN, Chang Y, Chien KL, Chiou CW, Chen SA. Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. Heart Rhythm
2015;12:14901500.
995. Kaab S, Hinterseer M, Nabauer M, Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome  a case-control pilot study using i.v. sotalol. Eur Heart J 2003;24:649657.
996. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H.
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007;4:603607.
997. Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R,
Opolski G, Muller HW, Meinertz T; SOPAT Investigators. Suppression of paroxysmal atrial tachyarrhythmias  results of the SOPAT trial. Eur Heart J
2004;25:13951404.
998. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L,
Trappe HJ, Treese N, Breithardt G; Prevention of Atrial Fibrillation after
Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion:
results of the PAFAC trial. Eur Heart J 2004;25:13851394.
999. Vallurupalli S, Pothineni NV, Deshmukh A, Paydak H. Utility of routine exercise testing to detect rate-related QRS widening in patients without structural heart disease on class Ic antiarrhythmic agents (flecainide and propafenone). Am J
Cardiol 2015;116:730732.
1000. Parkash R, Wells GA, Sapp JL, Healey JS, Tardif J-C, Greiss I, Rivard L, Roux JF, Gula L, Nault I. Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure
Control]). Circulation 2017;135:17881798.
1001. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso
A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the
Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol
2014;7:620625.
1002. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Longterm cardiovascular consequences of obesity: 20-year follow-up of more than
15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J
2006;27:96106.
1003. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS.
Atrial fibrillation and obesity  results of a meta-analysis. Am Heart J
2008;155:310315.
1004. Wang TJ, Parise H, Levy D, D’Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ.
Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:24712477.
1005. Baek YS, Yang PS, Kim TH, Uhm JS, Park J, Pak HN, Lee MH, Joung B.
Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc 2017;6.
1006. Proietti M, Guiducci E, Cheli P, Lip GY. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of nonvitamin K antagonist oral anticoagulant trials. Stroke 2017;48:857866.
1007. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney
MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen
ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar
N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM,
Binno S, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the
European
Association for
Cardiovascular
Prevention
&
Rehabilitation
(EACPR). Eur Heart J 2016;37:23152381.
1008. Cha YM, Friedman PA, Asirvatham SJ, Shen WK, Munger TM, Rea RF, Brady
PA, Jahangir A, Monahan KH, Hodge DO, Meverden RA, Gersh BJ, Hammill
SC, Packer DL. Catheter ablation for atrial fibrillation in patients with obesity.
Circulation 2008;117:25832590.
1009. Ector J, Dragusin O, Adriaenssens B, Huybrechts W, Willems R, Ector H,
Heidbuchel H. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol
2007;50:234242.
1010. Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M,
Stubblefield T, Rytlewski J, Parvathaneni S, Nagarakanti R, Roden DM,
Saavedra P, Ellis C, Whalen SP, Darbar D. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. Am J Cardiol 2013;111:368373.
1011. Ettinger PO, Wu CF, De La Cruz C Jr, Weisse AB, Ahmed SS, Regan TJ.
Arrhythmias and the ‘holiday heart’: alcohol-associated cardiac rhythm disorders. Am Heart J 1978;95:555562.
1012. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: how much is too much?J Am Coll Cardiol 2014;64:290292.
1013. Liang Y, Mente A, Yusuf S, Gao P, Sleight P, Zhu J, Fagard R, Lonn E, Teo KK;
ONTARGET and TRANSCEND Investigators. Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease.
CMAJ 2012;184:E857866.
1014. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol
2014;64:281289.
1015. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA, Lip
GY, Larsen TB. Alcohol intake and prognosis of atrial fibrillation. Heart
2013;99:10931099.
1016. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S,
Prabhu S, Stub D, Azzopardi S, Vizi D, Wong G, Nalliah C, Sugumar H, Wong
M, Kotschet E, Kaye D, Taylor AJ, Kistler PM. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 2020;382:2028.
1017. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc 2009;84:373383.
1018. Mont L. Arrhythmias and sport practice. Heart 2010;96:398405.
1019. Menezes AR, Lavie CJ, De Schutter A, Milani RV, O’Keefe J, DiNicolantonio JJ,
Morin DP, Abi-Samra FM. Lifestyle modification in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis 2015;58:117125.
1020. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 1998;316:17841785.
1021. Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, Jenni
R, Oechslin E, Luthi P, Scharf C, Marti B, Attenhofer Jost CH. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J 2008;29:7178.
1022. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J, Rebato C,
Elosua R. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace 2008;10:618623.


<!-- PAGE 113 -->

### Page 113

.............................................................................................................................................................................
1023. Nielsen JR, Wachtell K, Abdulla J. The relationship between physical activity and risk of atrial fibrillation  a systematic review and meta-analysis. J Atr
Fibrillation 2013;5:789.
1024. Risom SS, Zwisler AD, Johansen PP, Sibilitz KL, Lindschou J, Gluud C, Taylor
RS, Svendsen JH, Berg SK. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. Cochrane Database Syst Rev 2017;2:CD011197.
1025. Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial fibrillation and hypertension. Hypertension 2017;70:854861.
1026. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M,
Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F,
Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S,
Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E,
Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. 2018
ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J
2018;39:30213104.
1027. Kim TH, Yang PS, Yu HT, Jang E, Shin H, Kim HY, Uhm JS, Kim JY, Sung JH,
Pak HN, Lee MH, Joung B, Lip GYH. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. Eur Heart J 2019;40:809819.
1028. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007;28:752759.
1029. Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E,
Polyakov K, Ptaszynski P, Keweloh B, Yao CJ, Pokushalov EA, Romanov AB.
Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF
randomized clinical trial. JAMA
2020;323:248255.
1030. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M,
Cooper M, Harrap S, Hamet P, Poulter N, Lip GY, Patel A, Group AC. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE
study. Eur Heart J 2009;30:11281135.
1031. Pallisgaard JL, Schjerning AM, Lindhardt TB, Procida K, Hansen ML, TorpPedersen C, Gislason GH. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev Cardiol 2016;23:621627.
1032. Rizzo MR, Sasso FC, Marfella R, Siniscalchi M, Paolisso P, Carbonara O,
Capoluongo MC, Lascar N, Pace C, Sardu C, Passavanti B, Barbieri M, Mauro
C, Paolisso G. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 2015;29:8892.
1033. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105:315318.
1034. Lee SR, Choi EK, Rhee TM, Lee HJ, Lim WH, Kang SH, Han KD, Cha MJ, Cho
Y, Oh IY, Oh S. Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: a nationwide population-based study. Int
J Cardiol 2016;223:953957.
1035. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de
Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela
BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB,
McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K,
Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ,
Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh
RW, Turner MB, American Heart Association Statistics Committee and
Stroke Statistics Subcommittee. Heart disease and stroke statistics  2015
update:
a report from the
American
Heart
Association.
Circulation
2015;131:e29322.
1036. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T,
Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the
Action to Control Cardiovascular Risk in Diabetes study). Am J Cardiol
2014;114:12171222.
1037. Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, Wen MS, Chen WJ, Yeh
YH, See LC. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014;13:123.
1038. Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, Meng L, Li
G, Liu T. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord 2017;17:96.
1039. Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab
2019;21:210217.
1040. Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K
antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes
Metab Res Rev 2017;33.
1041. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM,
Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB.
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin:
the
ARISTOTLE
trial
(Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:21412147.
1042. Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, Baranowski
B, Hussein A, Saliba W, Wazni O. Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. JACC Clin Electrophysiol 2019;5:897903.
1043. Linz D, Baumert M, Catcheside P, Floras J, Sanders P, Levy P, Cowie MR,
Doug McEvoy R. Assessment and interpretation of sleep disordered breathing severity in cardiology: clinical implications and perspectives. Int J Cardiol
2018;271:281288.
1044. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, Malouf JF,
Ammash NM, Friedman PA, Somers VK. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004;110:364367.
1045. Goudis CA, Ketikoglou DG. Obstructive sleep and atrial fibrillation: pathophysiological mechanisms and therapeutic implications.
Int
J
Cardiol
2017;230:293300.
1046. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K,
Rogers R, Schwab RJ, Weaver EM, Weinstein MD, Adult Obstructive Sleep
Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009;5:263276.
1047. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Levy P, Kalman JM, Sanders
P. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiol 2018;3:532540.
1048. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K, Kramer DB,
Zimetbaum PJ, Buxton AE, Josephson ME, Anter E. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013;62:300305.
1049. Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP, Michaud GF,
van der Geest R, Blankstein R, Steigner M, John RM, Jerosch-Herold M,
Malhotra A, Kwong RY. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart
Assoc 2013;2:e000421.
1050. Qureshi WT, Nasir UB, Alqalyoobi S, O’Neal WT, Mawri S, Sabbagh S,
Soliman EZ, Al-Mallah MH. Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea. Am J Cardiol
2015;116:17671773.
1051. Shukla A, Aizer A, Holmes D, Fowler S, Park DS, Bernstein S, Bernstein N,
Chinitz L. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. JACC Clin Electrophysiol 2015;1:4151.
1052. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R,
Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P.
Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese
Individuals With Atrial Fibrillation: the CARDIO-FIT study. J Am Coll Cardiol
2015;66:985996.
1053. Bonfanti L, Annovi A, Sanchis-Gomar F, Saccenti C, Meschi T, Ticinesi A,
Cervellin G. Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience. Clin Exp Emerg Med 2019;6:6469.
1054. Scheuermeyer FX, Grafstein E, Stenstrom R, Innes G, Heslop C, MacPhee J,
Pourvali R, Heilbron B, McGrath L, Christenson J. Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause. Ann Emerg Med 2012;60:755765.e2.
1055. Boriani G, Proietti M, Laroche C, Diemberger I, Popescu MI, Riahi S, Shantsila
A, Dan GA, Tavazzi L, Maggioni AP, Lip GYH; EORP-A Pilot General Registry
Investigators. Changes to oral anticoagulant therapy and risk of death over a
3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on
Atrial
Fibrillation
(EORP-AF)
pilot general registry.
Int
J
Cardiol
2018;271:6874.
1056. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH,
Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GY. ‘Real-world’ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation
(EORP-AF) general pilot registry. Europace 2016;18:648657.
1057. Gulizia MM, Cemin R, Colivicchi F, De Luca L, Di Lenarda A, Boriani G, Di
Pasquale G, Nardi F, Scherillo M, Lucci D, Fabbri G, Maggioni AP; BLITZ-AF
Investigators. Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. Europace 2019;21:230238.
1058. Gonzalez-Pacheco H, Marquez MF, Arias-Mendoza A, Alvarez-Sangabriel A,
Eid-Lidt G, Gonzalez-Hermosillo A, Azar-Manzur F, Altamirano-Castillo A,
Briseno-Cruz JL, Garcia-Martinez A, Mendoza-Garcia S, Martinez-Sanchez C.
ESC Guidelines
485


<!-- PAGE 114 -->

### Page 114

.............................................................................................................................................................................
Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without
ST elevation. J Cardiol 2015;66:148154.
1059. Krijthe BP, Leening MJ, Heeringa J, Kors JA, Hofman A, Franco OH, Witteman
JC, Stricker BH. Unrecognized myocardial infarction and risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol 2013;168:14531457.
1060. Chao TF, Huang YC, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu
YF, Tuan TC, Chen TJ, Hsieh MH, Lip GY, Chen SA. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1:
a nationwide cohort study. Heart Rhythm 2014;11:19411947.
1061. Sanclemente C, Yeste M, Suarez C, Coll R, Aguilar E, Sahuquillo JC, Lerma R,
Monreal M; FRENA Investigators. Predictors of outcome in stable outpatients with peripheral artery disease. Intern Emerg Med 2014;9:6977.
1062. Soliman EZ, Lopez F, O’Neal WT, Chen LY, Bengtson L, Zhang ZM, Loehr L,
Cushman M, Alonso A. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2015;131:18431850.
1063. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA,
Thacker EL, Judd S, Howard VJ, Howard G, Herrington DM, Cushman M.
Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med
2014;174:107114.
1064. Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 2011;6:e24964.
1065. Guimaraes PO, Zakroysky P, Goyal A, Lopes RD, Kaltenbach LA, Wang TY.
Usefulness of antithrombotic therapy in patients with atrial fibrillation and acute myocardial infarction. Am J Cardiol 2019;123:1218.
1066. Erez A, Goldenberg I, Sabbag A, Nof E, Zahger D, Atar S, Pollak A, DobreckyMerye I, Beigel R, Matetzky S, Glikson M, Beinart R. Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome: real-world data from the Acute Coronary Syndrome Israeli Survey
(ACSIS), 20002013. Clin Cardiol 2017;40:275280.
1067. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U,
Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen
SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker
S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS
Guidelines on myocardial revascularization. Eur Heart J 2019;40:87165.
1068. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen
T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip
J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document
Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407477.
1069. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S,
Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF,
Valgimigli M, Huber K, ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of
Cardiology
Working
Group on
Thrombosis,
European
Association of
Percutaneous
Cardiovascular
Interventions
(EAPCI),
and
European
Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm
Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America
Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern
Africa (CASSA). Europace 2019;21:192193.
1070. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli
M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019;40:37573767.
1071. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, Valgimigli
M, Heidbuchel H, Lip GYH. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace
2020;22:3346.
1072. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K,
Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators.
Antithrombotic therapy for atrial fibrillation with stable coronary disease. N
Engl J Med 2019;381:11031113.
1073. Karjalainen PP, Vikman S, Niemela M, Porela P, Ylitalo A, Vaittinen MA,
Puurunen M, Airaksinen TJ, Nyman K, Vahlberg T, Airaksinen KE. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008;29:10011010.
1074. Vranckx P, Leebeek FW, Tijssen JG, Koolen J, Stammen F, Herman JP, de
Winter RJ, van THAW, Backx B, Lindeboom W, Kim SY, Kirsch B, van Eickels
M, Misselwitz F, Verheugt FW. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease.
The X-PLORER trial. Thromb Haemost 2015;114:258267.
1075. Vranckx P, Verheugt FW, de Maat MP, Ulmans VA, Regar E, Smits P, ten Berg
JM, Lindeboom W, Jones RL, Friedman J, Reilly P, Leebeek FW. A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention 2013;8:10521060.
1076. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D,
Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T,
Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:16191629.
1077. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM,
Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML.
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981989.
1078. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,
Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ’t Hof
AW, ten Berg JM, for the WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:11071115.
1079. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M,
Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J,
Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering
Committee Investigators. Dual antithrombotic therapy with dabigatran after
PCI in atrial fibrillation. N Engl J Med 2017;377:15131524.
1080. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,
Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip
GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing
PCI.
N
Engl
J
Med
2016;375:24232434.
1081. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman
SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj
A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D,
Granger CB, Alexander JH; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med
2019;380:15091524.
1082. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin
V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R,
Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Lancet 2019;394:13351343.
1083. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J,
Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. Eur Heart J 2018;39:17261735a.
1084. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger
CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Gibson CM, Alexander JH.
Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol 2019:pii:2735647.
1085. Andreou I, Briasoulis A, Pappas C, Ikonomidis I, Alexopoulos D. Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: a systematic review and meta-analysis. Cardiovasc Drugs Ther 2018;32:287294.
1086. Fu A, Singh K, Abunassar J, Malhotra N, Le May M, Labinaz M, Glover C,
Marquis JF, Froeschl M, Dick A, Hibbert B, Chong AY, So DY; CAPITAL
Investigators. Ticagrelor in triple antithrombotic therapy: predictors of ischemic and bleeding complications. Clin Cardiol 2016;39:1923.
1087. Jackson LR, 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, Baker
BA, Effron M, Peterson ED, Wang TY. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. JACC Cardiovasc Interv
2015;8:18801889.
1088. Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A.
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
J Am Coll Cardiol 2013;61:20602066.
1089. Verlinden NJ, Coons JC, Iasella CJ, Kane-Gill SL. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary


<!-- PAGE 115 -->

### Page 115

.............................................................................................................................................................................
intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. J
Cardiovasc Pharmacol Ther 2017;22:546551.
1090. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L,
Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P,
Collins R, Camm AJ, Heidbuchel H, ESC Scientific Document Group. The
2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur
Heart J 2018;39:13301393.
1091. Pikija S, Sztriha LK, Sebastian Mutzenbach J, Golaszewski SM, Sellner J.
Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase: a systematic review of the available evidence. CNS Drugs
2017;31:747757.
1092. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke
2001;32:23332337.
1093. Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke 1983;14:688693.
1094. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation:
a double-blind randomised study. HAEST Study Group. Heparin in Acute
Embolic Stroke Trial. Lancet 2000;355:12051210.
1095. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007;38:423430.
1096. von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD,
Treurniet KM, Majoie CB, Marquering HA, Mazya MV, San Roman L, Saver JL,
Strbian D, Whiteley W, Hacke W. The Heidelberg Bleeding Classification:
classification of bleeding events after ischemicstroke and reperfusion therapy.
Stroke 2015;46:29812986.
1097. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, Caso V,
Micheli S, Bertolani L, Venti M, Palmerini F, Biagini S, Comi G, Previdi P,
Silvestrelli G. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008;39:22492256.
1098. Kablau M, Kreisel SH, Sauer T, Binder J, Szabo K, Hennerici MG, Kern R.
Predictors and early outcome of hemorrhagic transformation after acute ischemic stroke. Cerebrovasc Dis 2011;32:334341.
1099. Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ, Engelter
ST, Fischer U, Norrving B. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol 2019;18:117126.
1100. Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C,
Chondrogianni M, Bovi P, Carletti M, Cappellari M, Zedde M, Ntaios G,
Karagkiozi E, Athanasakis G, Makaritsis K, Silvestrelli G, Lanari A, Ciccone A,
Putaala J, Tomppo L, Tatlisumak T, Abdul-Rahim AH, Lees KR, Alberti A,
Venti M, Acciarresi M, D’Amore C, Becattini C, Mosconi MG, Cimini LA,
Soloperto R, Masotti L, Vannucchi V, Lorenzini G, Tassi R, Guideri F, Acampa
M, Martini G, Sohn SI, Marcheselli S, Mumoli N, De Lodovici ML, Bono G,
Furie KL, Tadi P, Yaghi S, Toni D, Letteri F, Tassinari T, Kargiotis O, Lotti EM,
Flomin Y, Mancuso M, Maccarrone M, Giannini N, Bandini F, Pezzini A, Poli L,
Padovani A, Scoditti U, Denti L, Consoli D, Galati F, Sacco S, Carolei A, Tiseo
C, Gourbali V, Orlandi G, Giuntini M, Chiti A, Giorli E, Gialdini G, Corea F,
Ageno W, Bellesini M, Colombo G, Monaco S, Maimone Baronello M,
Karapanayiotides T, Caso V. Early Recurrence and Major Bleeding in Patients
With Acute Ischemic Stroke and Atrial Fibrillation Treated With NonVitamin-K Oral Anticoagulants (RAF-NOACs) study. J Am Heart Assoc 2017;6.
1101. Seiffge DJ, Traenka C, Polymeris A, Hert L, Peters N, Lyrer P, Engelter ST,
Bonati LH, De Marchis GM. Early start of DOAC after ischemic stroke: risk of intracranial hemorrhage and recurrent events. Neurology 2016;87:18561862.
1102. Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K, Yamagami H,
Terasaki T, Yoshimura S, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S,
Okada Y, Nagakane Y, Kameda T, Hasegawa Y, Shibuya S, Ito Y, Nakashima T,
Takamatsu K, Nishiyama K, Matsuki T, Homma K, Takasugi J, Tokunaga K, Sato
S, Kario K, Kitazono T, Toyoda K; SAMURAI Study Investigators. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the
SAMURAI-Nonvalvular
Atrial
Fibrillation
(NVAF)
study.
Int
J
Stroke
2016;11:565574.
1103. Hong KS, Kwon SU, Lee SH, Lee JS, Kim YJ, Song TJ, Kim YD, Park MS, Kim
EG, Cha JK, Sung SM, Yoon BW, Bang OY, Seo WK, Hwang YH, Ahn SH,
Kang DW, Kang HG, Yu KH, Phase 2 exploratory clinical study to assess the effects of xarelto versus warfarin on ischemia B, hospital stay in acute cerebral infarction patients with non-valvular atrial fibrillation study G. Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a randomized clinical trial. JAMA Neurol 2017;74:12061215.
1104. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-Kantagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials.
Int
J
Stroke
2017;12:589596.
1105. Gonzalez ME, Klein FR, Riccio PM, Cassara FP, Munoz Giacomelli F, Racosta
JM, Roberts ES, Sposato, LA. Atrial fibrillation detected after acute ischemic stroke: evidence supporting the neurogenic hypothesis. J Stroke Cerebrovasc Dis
2013;22:e486491.
1106. Sposato LA, Cerasuolo JO, Cipriano LE, Fang J, Fridman S, Paquet M, Saposnik
G. Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence. Neurology 2018;90:e924e931.
1107. Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS,
Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW,
Naccarelli GV, Reiffel JA, Singer, DE, Peterson ED, Piccini, JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) II Investigators.
Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants:
results from ORBIT-AF II (the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 2018;7:e007633.
1108. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD,
Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik
R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J,
Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ,
Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M,
Muir KW, Bornstein N, Ozturk S, O’Donnell MJ, De Vries Basson MM, Pare
G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh
A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS
Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of
Undetermined Source. N Engl J Med 2018;378:21912201.
1109. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S,
Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M,
Donnan G, Ferro JM, Grond M, Kallmunzer B, Krupinski J, Lee BC, Lemmens
R, Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K; RESPECT ESUS Steering Committee Investigators. Dabigatran for prevention of stroke after embolic stroke of undetermined source.
N Engl J Med
2019;380:19061917.
1110. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE,
Haeusler KG, Mikulik R, Kasner SE, Toni D, Arauz A, Ntaios G, Hankey GJ,
Perera K, Pagola J, Shuaib A, Lutsep H, Yang X, Uchiyama S, Endres M, Coutts
SB, Karlinski M, Czlonkowska A, Molina CA, Santo G, Berkowitz SD, Hart RG,
Connolly SJ. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE
ESUS randomized clinical trial. JAMA Neurol 2019.
1111. Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nagele T, Brachmann J,
Jung W, Gahn G, Schmid E, Baezner H, Keller T, Petzold GC, Schrickel JW,
Liman J, Wachter R, Schon F, Schabet M, Lindner A, Ludolph AC, Kimmig H,
Jander S, Schlegel U, Gawaz M, Ziemann U. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke 2017;12:985990.
1112. Li Y-G, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, Wang
Y-T, Lip GYH, Fauchier L. C2HEST score and prediction of incident atrial fibrillation in poststroke patients: a French nationwide study. J Am Heart Assoc
2019;8:e012546.
1113. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H,
O’Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski
V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S,
Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K,
Aviv R, Kapral MK, Mamdani M; EMBRACE Investigators and Coordinators.
Atrial fibrillation in patients with cryptogenic stroke.
N
Engl
J
Med
2014;370:24672477.
1114. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA,
Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J; CRYSTAL
AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J
Med 2014;370:24782486.
1115. Wachter R, Groschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, Seegers
J, Wasser K, Schulte A, Jurries F, Messerschmid A, Behnke N, Groschel S,
Uphaus T, Grings A, Ibis T, Klimpe S, Wagner-Heck M, Arnold M, Protsenko
E, Heuschmann PU, Conen D, Weber-Kruger M; Find-AF(randomised)
Investigators and
Coordinators.
Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol 2017;16:282290.
1116. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M,
Weimar C, Kohrmann M, Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:33573364.
1117. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014;45:520526.
ESC Guidelines
487


<!-- PAGE 116 -->

### Page 116

.............................................................................................................................................................................
1118. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V.
Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015;14:377387.
1119. Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA,
Diener HC, Di Lazzaro V, Rymer MM, Hogge L, Rogers TB, Ziegler PD, Assar
MD. Predictors for atrial fibrillation detection after cryptogenic stroke: results from CRYSTAL AF. Neurology 2016;86:261269.
1120. Levin LA, Husberg M, Sobocinski PD, Kull VF, Friberg L, Rosenqvist M,
Davidson T. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Europace 2015;17:207214.
1121. Yong JH, Thavorn K, Hoch JS, Mamdani M, Thorpe KE, Dorian P, Sharma M,
Laupacis A, Gladstone DJ, on behalf of the EMBRACE Steering Committee.
Potential cost-effectiveness of ambulatory cardiac rhythm monitoring after cryptogenic stroke. Stroke 2016;47:23802385.
1122. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am
Coll Cardiol 2007;50:309315.
1123. Wilson D, Ambler G, Lee KJ, Lim JS, Shiozawa M, Koga M, Li L, Lovelock C,
Chabriat H, Hennerici M, Wong YK, Mak HKF, Prats-Sanchez L, MartinezDomeno A, Inamura S, Yoshifuji K, Arsava EM, Horstmann S, Purrucker J, Lam
BYK, Wong A, Kim YD, Song TJ, Schrooten M, Lemmens R, Eppinger S,
Gattringer T, Uysal E, Tanriverdi Z, Bornstein NM, Assayag EB, Hallevi H,
Tanaka J, Hara H, Coutts SB, Hert L, Polymeris A, Seiffge DJ, Lyrer P, Algra A,
Kappelle J, Al-Shahi Salman R, Jager HR, Lip GYH, Mattle HP, Panos LD, Mas
JL, Legrand L, Karayiannis C, Phan T, Gunkel S, Christ N, Abrigo J, Leung T,
Chu W, Chappell F, Makin S, Hayden D, Williams DJ, Kooi ME, van DamNolen DHK, Barbato C, Browning S, Wiegertjes K, Tuladhar AM, Maaijwee N,
Guevarra
C,
Yatawara
C,
Mendyk
AM,
Delmaire
C,
Kohler
S,
van
Oostenbrugge R, Zhou Y, Xu C, Hilal S, Gyanwali B, Chen C, Lou M, Staals J,
Bordet R, Kandiah N, de Leeuw FE, Simister R, van der Lugt A, Kelly PJ,
Wardlaw JM, Soo Y, Fluri F, Srikanth V, Calvet D, Jung S, Kwa VIH, Engelter
ST, Peters N, Smith EE, Yakushiji Y, Orken DN, Fazekas F, Thijs V, Heo JH,
Mok V, Veltkamp R, Ay H, Imaizumi T, Gomez-Anson B, Lau KK, Jouvent E,
Rothwell PM, Toyoda K, Bae HJ, Marti-Fabregas J, Werring DJ. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet
Neurol 2019;18:653665.
1124. Murthy SB, Gupta A, Merkler AE, Navi BB, Mandava P, Iadecola C, Sheth KN,
Hanley DF, Ziai WC, Kamel H. Restarting anticoagulant therapy after intracranial hemorrhage:
a systematic review and meta-analysis.
Stroke
2017;48:15941600.
1125. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier
D, Di Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:11571163.
1126. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L,
Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH,
Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol
2012;11:503511.
1127. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener
HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B,
Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA,
Hacke W; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol
2012;11:315322.
1128. Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD,
Silverman S, Singhal AB, Nicolau JC, SomaRaju B, Mercuri MF, Antman EM,
Braunwald E. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective
Anticoagulation With Factor Xa Next Generation in Atrial FibrillationThrombolysis in Myocardial Infarction 48). Stroke 2016;47:20752082.
1129. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O’Donnell
M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012;11:225231.
1130. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study
Group. Lancet 1993;342:12551262.
1131. Cuker A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 2016;41:241247.
1132. Salmonson T, Dogne JM, Janssen H, Garcia Burgos J, Blake P. Non-vitamin-K
oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc
Pharmacother 2017;3:4247.
1133. Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M.
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 2015;13:17901798.
1134. Anderson I, Cifu AS. Management of bleeding in patients taking oral anticoagulants. JAMA 2018;319:20322033.
1135. Milling TJ Jr, Refaai MA, Sarode R, Lewis B, Mangione A, Durn BL, Harman A,
Lee ML, Goldstein JN. Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med 2016;23:466475.
1136. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA,
Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy
JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L,
Weitz JI. Idarucizumab for dabigatran reversal  full cohort analysis. N Engl J
Med 2017;377:431441.
1137. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence
JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J,
Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J,
Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM,
Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA Investigators.
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:13261335.
1138. Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ,
Raghoebar M, Patel MR, Weitz JI, Levy JH. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost
2014;12:14281436.
1139. Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK.
Reversibility of apixaban anticoagulation with a four-factor prothrombin complex concentrate in healthy volunteers. Clin Transl Sci 2016;9:176180.
1140. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner
A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015;131:8290.
1141. Isnard R, Bauer F, Cohen-Solal A, Damy T, Donal E, Galinier M, Hagege A,
Jourdain P, Leclercq C, Sabatier R, Trochu JN, Cohen A. Non-vitamin K antagonist oral anticoagulants and heart failure. Arch Cardiovasc Dis 2016;109:641650.
1142. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015;17:11921200.
1143. Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A,
Giannetti N, Grzeslo A, Hamilton PG, Heckman GA, Howlett JG, Koshman
SL, Lepage S, McKelvie RS, Moe GW, Rajda M, Swiggum E, Virani SA, Zieroth
S, Al-Hesayen A, Cohen-Solal A, D’Astous M, De S, Estrella-Holder E, Fremes
S, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH,
Masoudi FA, Ross HJ, Roussin A, Sussex B. 2017 comprehensive update of the
Canadian Cardiovascular Society Guidelines for the management of heart failure. Can J Cardiol 2017;33:13421433.
1144. Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I,
Kistler PM, Briffa T, Wong J, Abhayaratna W, Thomas L, Audehm R, Newton
P, O’Loughlin J, Branagan M, Connell C. National Heart Foundation of
Australia and Cardiac Society of Australia and New Zealand: Guidelines for the prevention, detection, and management of heart failure in Australia 2018.
Heart Lung Circ 2018;27:11231208.
1145. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,
Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group.
ESC. Eur Heart J 2016;37:21292200.
1146. Kelly JP, DeVore AD, Wu J, Hammill BG, Sharma A, Cooper LB, Felker GM,
Piccini JP, Allen LA, Heidenreich PA, Peterson ED, Yancy CW, Fonarow GC,
Hernandez AF. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from Get
With The Guidelines-Heart Failure. J Am Heart Assoc 2019;8:e011560.
1147. Filippatos G, Farmakis D. How to use beta-blockers in heart failure with reduced ejection fraction and atrial fibrillation.
J
Am
Coll
Cardiol
2017;69:28972900.


<!-- PAGE 117 -->

### Page 117

.............................................................................................................................................................................
1148. Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjoth F, Lip GY. beta-Blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study. Circ Heart Fail 2016;9:e002597.
1149. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano
M. Burden of valvular heart diseases: a population-based study. Lancet
2006;368:10051011.
1150. Barbash IM, Minha S, Ben-Dor I, Dvir D, Torguson R, Aly M, Bond E, Satler LF,
Pichard AD, Waksman R. Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015;85:468477.
1151. Eguchi K, Ohtaki E, Matsumura T, Tanaka K, Tohbaru T, Iguchi N, Misu K,
Asano R, Nagayama M, Sumiyoshi T, Kasegawa H, Hosoda S. Pre-operative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J 2005;26:18661872.
1152. Maan A, Heist EK, Passeri J, Inglessis I, Baker J, Ptaszek L, Vlahakes G, Ruskin
JN, Palacios I, Sundt T, Mansour M. Impact of atrial fibrillation on outcomes in patients who underwent transcatheter aortic valve replacement. Am J Cardiol
2015;115:220226.
1153. Ngaage DL, Schaff HV, Barnes SA, Sundt TM 3rd, Mullany CJ, Dearani JA, Daly
RC, Orszulak TA. Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic valve replacement: is there an argument for concomitant arrhythmia surgery?Ann Thorac Surg 2006;82:13921399.
1154. Ngaage DL, Schaff HV, Mullany CJ, Barnes S, Dearani JA, Daly RC, Orszulak
TA, Sundt TM 3rd. Influence of preoperative atrial fibrillation on late results of mitral repair:
is concomitant ablation justified?Ann
Thorac
Surg
2007;84:434442.
1155. Lim E, Barlow CW, Hosseinpour AR, Wisbey C, Wilson K, Pidgeon W,
Charman S, Barlow JB, Wells FC. Influence of atrial fibrillation on outcome following mitral valve repair. Circulation 2001;104:I5963.
1156. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty
D, Angoulvant D, Lip GY, Fauchier L. Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease:
the Loire Valley Atrial Fibrillation Project. Eur Heart J 2015;36:18221830.
11547. Lip GYH, Jensen M, Melgaard L, Skjoth F, Nielsen PB, Larsen TB. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating ‘valvular heart disease’ in a nationwide cohort study.
Europace 2019;21:3340.
1158. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964;1:12091212.
1159. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A,
Angoulvant D, Babuty D, Lip GY, Fauchier L. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis.
The
Loire
Valley
Atrial
Fibrillation
Project.
Thromb
Haemost
2016;115:10561063.
1160. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves:
a meta-analysis.
Circulation
2017;135:714716.
1161. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, Jang SW, Oh YS, Lee MY,
Rho TH. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol 2019;73:11231131.
1162. Bisson A, Bodin A, Clementy N, Bernard A, Babuty D, Lip GYH, Fauchier L.
Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. Int J Cardiol
2018;260:9398.
1163. Seeger J, Gonska B, Rodewald C, Rottbauer W, Wohrle J. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC
Cardiovasc Interv 2017;10:6674.
1164. Dangas GD, Tijssen JGP, Wohrle J, Sondergaard L, Gilard M, Mollmann H,
Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimaraes
AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schafer U,
Seeger J, Tchetche D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC,
Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R,
Windecker S, for the GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement.
N
Engl
J
Med
2020;382:120129.
1165. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack
MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y,
Lobmeyer MT, Maas H, Voigt JU, Simoon ML, Van de Werf,
F; RE-ALIGN
Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:12061214.
1166. Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 2018;14:337351.
1167. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY.
Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke 2013;44:13291336.
1168. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J,
Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625635.
1169. Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol
2013;29:S7178.
1170. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM.
Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis.
Nephrol
Dial
Transplant
2012;27:38163822.
1171. Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM, Lip
GYH. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation
Project. Chest 2014;145:13701382.
1172. Fauchier L, Bisson A, Clementy N, Vourc’h P, Angoulvant D, Babuty D, Halimi
JM, Lip GYH. Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. Am Heart J 2018;198:3945.
1173. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM,
Braunwald E. Impact of renal function on outcomes with edoxaban in the
ENGAGE AF-TIMI 48 trial. Circulation 2016;134:2436.
1174. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW,
Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term
Anticoagulation Therapy) trial analysis. Circulation 2014;129:961970.
1175. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF,
Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J
2011;32:23872394.
1176. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai
M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J
2012;33:28212830.
1177. Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke AK, Baker
WL. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis.
Am
J
Med
2019;132:10781083.
1178. Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, Jardine MJ, Sood
MM, Garg AX, Palmer SC, Mark PB, Wheeler DC, Jha V, Freedman B, Johnson
DW, Perkovic V, Badve SV. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. Ann Intern
Med 2019;171:181189.
1179. Pokorney SD. RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF). Presentation at the American Heart
Association Annual Scientific Sessions (AHA 2019), Philadelphia, PA, 16
November 2019.
1180. Violi F, Davi G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M,
Pignatelli P, Vestri AR, Basili S; ARAPACIS Study Investigators. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation:
implications for risk and therapy. J Am Coll Cardiol 2013;62:22552256.
1181. Bruere H, Fauchier L, Bernard Brunet A, Pierre B, Simeon E, Babuty D,
Clementy N. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. Am J Med 2015;128:3037.
1182. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982;72:903906.
1183. Kristensen SL, Lindhardsen J, Ahlehoff O, Erichsen R, Lamberts M, Khalid U,
Torp-Pedersen C, Nielsen OH, Gislason GH, Hansen PR. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease:
a nationwide study. Europace 2014;16:477484.
1184. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013;145:105112.e15.
1185. Caldeira D, Barra M, Ferreira A, Rocha A, Augusto A, Pinto FJ, Costa J,
Ferreira JJ. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Aliment
Pharmacol Ther 2015;42:12391249.
1186. Kolb JM, Flack KF, Chatterjee-Murphy P, Desai J, Wallentin LC, Ezekowitz M,
Connolly S, Reilly P, Brueckmann M, Ilgenfritz J, Aisenberg J. Locations and mucosal lesions responsible for major gastrointestinal bleeding in patients on warfarin or dabigatran. Dig Dis Sci 2018;63:18781889.
1187. Chai-Adisaksopha
C,
Hillis
C,
Monreal
M,
Witt
DM,
Crowther
M.
Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost
2015;114:819825.
ESC Guidelines
489


<!-- PAGE 118 -->

### Page 118

.............................................................................................................................................................................
1188. O’Dea D, Whetteckey J, Ting N. A prospective, randomized, open-label study to evaluate two management strategies for gastrointestinal symptoms in patients newly on treatment with dabigatran. Cardiol Ther 2016;5:187201.
1189. Lai HC, Chien WC, Chung CH, Lee WL, Wu TJ, Wang KY, Liu CN, Liu TJ.
Atrial fibrillation, liver disease, antithrombotics and risk of cerebrovascular events: a population-based cohort study. Int J Cardiol 2016;223:829837.
1190. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke,
Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly) score. J Am Coll Cardiol 2011;57:173180.
1191. Potpara TS, Lip GY. Drug-induced liver injury with oral anticoagulants: a threat or not?Heart 2017;103:809811.
1192. Hoolwerf EW, Kraaijpoel N, Buller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis:
a systematic review.
Thromb
Res
2018;170:102108.
1193. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W.
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin
Pharmacol 2013;76:8998.
1194. Bonde AN, Blanche P, Staerk L, Gerds TA, Gundlund A, Gislason G, TorpPedersen C, Lip GYH, Hlatky MA, Olesen JB. Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. Eur
Heart J 2019.
1195. Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL,
Sanchorawala V, Varga C. The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation:
experience at a
single institution.
Bone
Marrow
Transplant
2017;52:13491351.
1196. Yuan M, Tse G, Zhang Z, Han X, Wu WKK, Li G, Xia Y, Liu T. The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and metaanalysis. Cardiovasc Ther 2018;36:e12475.
1197. Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG,
Mahmood SS, Barac A, Groarke JD, Hayek SS, Dani S, Venesy D, Patten R,
Nohria
A.
Ibrutinib-associated atrial fibrillation.
JACC
Clin
Electrophysiol
2018;4:14911500.
1198. Boriani G, Corradini P, Cuneo A, Falanga A, Foa R, Gaidano G, Ghia PP,
Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M,
Pinto A, Tedeschi A, Vitolo U, Zinzani PL. Practical management of ibrutinib in the real life:
focus on atrial fibrillation and bleeding.
Hematol
Oncol
2018;36:624632.
1199. Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma
Leuk 2017;17:3137.e13.
1200. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469473.
1201. Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am
Heart Assoc 2017;6:e005155.
1202. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward
JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted
County, Minnesota, 1980 to 2000,and implications on the projections for future prevalence. Circulation 2006;114:119125.
1203. Ohlmeier C, Mikolajczyk R, Haverkamp W, Garbe E. Incidence, prevalence,
and antithrombotic management of atrial fibrillation in elderly Germans.
Europace 2013;15:14361444.
1204. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE.
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk
Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:23702375.
1205. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald
U, Bauersachs R, Breithardt G. Incidence and prevalence of atrial fibrillation:
an analysis based on 8.3 million patients. Europace 2013;15:486493.
1206. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213220.
1207. Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am
Coll Cardiol 2010;56:827837.
1208. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology
2007;69:546554.
1209. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson
M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C,
Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Circulation 2015;131:157164.
1210. Biteker M, Basaran O, Dogan V, Altun I, Ozpamuk Karadeniz F, Tekkesin AI,
Cakilli Y, Turkkan C, Hamidi M, Demir V, Gursoy MO, Tek Ozturk M, Aksan
G, Seyis S, Balli M, Alici MH, Bozyel S. Real-world clinical characteristics and treatment patterns of individuals aged 80 and older with nonvalvular atrial fibrillation: results from the ReAl-life Multicenter Survey Evaluating Stroke
Study. J Am Geriatr Soc 2017;65:16841690.
1211. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford
MJ. Adverse outcomes and predictors of underuse of antithrombotic therapy in
Medicare beneficiaries with chronic atrial fibrillation.
Stroke
2000;31:822827.
1212. Ghaswalla PK, Harpe SE, Slattum PW. Warfarin use in nursing home residents:
results from the 2004 national nursing home survey. Am J Geriatr Pharmacother
2012;10:2536.e2.
1213. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol
2016;203:660666.
1214. Oqab Z, Pournazari P, Sheldon RS. What is the impact of frailty on prescription of anticoagulation in elderly patients with atrial fibrillation? A systematic review and meta-analysis. J Atr Fibrillation 2018;10:1870.
1215. Proietti M, Laroche C, Opolski G, Maggioni AP, Boriani G, Lip GYH, on behalf of the AF Gen Pilot Investigators. ‘Real-world’ atrial fibrillation management in
Europe: observations from the 2-year follow-up of the EURObservational
Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace
2017;19:722733.
1216. Singh P, Arrevad PS, Peterson GM, Bereznicki LR. Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities.
J
Clin
Pharm
Ther
2011;36:166171.
1217. Annoni G, Mazzola P. Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?J Geriatr Cardiol 2016;13:226232.
1218. Deandrea S, Bravi F, Turati F, Lucenteforte E, La Vecchia C, Negri E. Risk factors for falls in older people in nursing homes and hospitals. A systematic review and meta-analysis. Arch Gerontol Geriatr 2013;56:407415.
1219. Phelan EA, Mahoney JE, Voit JC, Stevens JA. Assessment and management of fall risk in primary care settings. Med Clin North Am 2015;99:281293.
1220. Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, Aujesky D. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med
2012;125:773778.
1221. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother 2008;42:
523532.
1222. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation.
Ann
Intern
Med
2007;147:590592.
1223. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother 2009;7:159166.
1224. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation
(WASPO).
Age
Ageing
2007;36:151156.
1225. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc
2014;62:857864.
1226. Siu CW, Tse HF. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:300306.
1227. Alnsasra H, Haim M, Senderey AB, Reges O, Leventer-Roberts M, Arnson Y,
Leibowitz M, Hoshen M, Avgil-Tsadok M. Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: experience from the real world. Heart Rhythm 2019;16:3137.
1228. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J,
Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K,
Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial. Circulation 2011;123:23632372.
1229. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR,
Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC,
Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee
Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban
Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K


<!-- PAGE 119 -->

### Page 119

.............................................................................................................................................................................
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
(ROCKET AF). Circulation 2014;130:138146.
1230. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB,
Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W,
Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35:18641872.
1231. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S,
Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S,
Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban vs. warfarin in
Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J
2014;78:13491356.
1232. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F,
Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman, EM.
Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the
ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2016;5:e003432.
1233. Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, Pak HN. Non-vitamin K
antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiol 2018;72:105112.
1234. Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, Lanas
F, Yusuf S, Hart RG. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing
2016;45:7783.
1235. Ruiz Ortiz M, Muniz J, Rana Miguez P, Roldan I, Marin F, Asuncion EstevePastor M Cequier A, Martinez-Selles M, Bertomeu V, Anguita M; FANTASIIA
Study Investigators. Inappropriate doses of direct oral anticoagulants in realworld clinical practice: prevalence and associated factors. A subanalysis of the
FANTASIIA Registry. Europace 2018;20:15771583.
1236. Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander
N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves
AB, Yuce H, Lip GYH. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J Am Geriatr Soc 2019;67:16621671.
1237. Dillinger JG, Aleil B, Cheggour S, Benhamou Y, Bejot Y, Marechaux S, Delluc
A, Bertoletti L, Lellouche N. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: why we should not underdose our patients. Arch Cardiovasc Dis 2018;111:8594.
1238. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, Meeder
JG, Prins MH, Levy S, Crijns HJ; Euro Heart Survey Investigators. Guidelineadherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The
Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007;153:10061012.
1239. Fumagalli S, Said SAM, Laroche C, Gabbai D, Marchionni N, Boriani G,
Maggioni AP, Popescu MI, Rasmussen LH, Crijns H, Lip GYH; EORP-AF
Investigators. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in europe: the EORP-AF General Pilot
Registry (EURObservational Research Programme-Atrial Fibrillation). JACC Clin
Electrophysiol 2015;1:326334.
1240. Paciullo F, Proietti M, Bianconi V, Nobili A, Pirro M, Mannucci PM, Lip GYH,
Lupattelli G; REPOSI Investigators. Choice and outcomes of rate control versus rhythm control in elderly patients with atrial fibrillation: a report from the
REPOSI Study. Drugs Aging 2018;35:365373.
1241. Shariff N, Desai RV, Patel K, Ahmed MI, Fonarow GC, Rich MW, Aban IB,
Banach M, Love TE, White M, Aronow WS, Epstein AE, Ahmed A. Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med 2013;126:887893.
1242. Purmah Y, Proietti M, Laroche C, Mazurek M, Tahmatzidis D, Boriani G, Novo
S, Lip GYH; EORP-AF General Pilot Registry Investigators. Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation.
Europace 2018;20:243252.
1243. Abdin A, Yalin K, Lyan E, Sawan N, Liosis S, Meyer-Saraei R, Elsner C, Lange
SA, Heeger CH, Eitel C, Eitel I, Tilz RR. Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in elderly patients. Clin Res Cardiol
2019;108:167174.
1244. Bhargava M, Marrouche NF, Martin DO, Schweikert RA, Saliba W, Saad EB,
Bash D, Williams-Andrews M, Rossillo A, Erciyes D, Khaykin Y, Burkhardt JD,
Joseph G, Tchou PJ, Natale A. Impact of age on the outcome of pulmonary vein isolation for atrial fibrillation using circular mapping technique and cooled-tip ablation catheter. J Cardiovasc Electrophysiol 2004;15:813.
1245. Bulava A, Hanis J, Dusek L. Clinical outcomes of radiofrequency catheter ablation of atrial fibrillation in octogenarians-10-year experience of a one highvolume center. J Geriatr Cardiol 2017;14:575581.
1246. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL,
Lappe DL, Muhlestein JB, Nelson J, Day JD. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing Clin
Electrophysiol 2010;33:146152.
1247. Heeger CH, Bellmann B, Fink T, Bohnen JE, Wissner E, Wohlmuth P, Rottner
L, Sohns C, Tilz RR, Mathew S, Reissmann B, Lemes C, Maurer T, Luker J,
Sultan A, Plenge T, Goldmann B, Ouyang F, Kuck KH, Metzner I, Metzner A,
Steven D, Rillig A. Efficacy and safety of cryoballoon ablation in the elderly: a multicenter study. Int J Cardiol 2019;278:108113.
1248. Kis Z, Noten AM, Martirosyan M, Hendriks AA, Bhagwandien R, Szili-Torok T.
Comparison of long-term outcome between patients aged <65 years vs. >/
=65 years after atrial fibrillation ablation. J Geriatr Cardiol 2017;14:569574.
1249. Lim T, Day D, Weiss P, Crandall BG, May HAT, Bair TL, Osborn JS, Anderson
JL, Muhlestein JB, Lappe DL, Mahapatra S, Bunch TJ. More aggressive left atrial ablation in elderly patients does not increase procedural complications. J Innov
Card Rhythm Manag 2011;2:206211.
1250. Lin T, Du X, Bai R, Chen YW, Yu RH, Long DY, Tang RB, Sang CH, Li SN, Ma
CS, Dong JZ. Long-term results of single-procedure catheter ablation for atrial fibrillationin preand post-menopausal women.
J
Geriatr
Cardiol
2014;11:120125.
1251. Lioni L, Letsas KP, Efremidis M, Vlachos K, Giannopoulos G, Kareliotis V,
Deftereos S, Sideris A. Catheter ablation of atrial fibrillation in the elderly. J
Geriatr Cardiol 2014;11:291295.
1252. Metzner I, Wissner E, Tilz RR, Rillig A, Mathew S, Schmidt B, Chun J,
Wohlmuth P, Deiss S, Lemes C, Maurer T, Fink T, Heeger C, Ouyang F, Kuck
KH, Metzner A. Ablation of atrial fibrillation in patients >/=75 years: longterm clinical outcome and safety. Europace 2016;18:543549.
1253. Santangeli P, Di Biase L, Mohanty P, Burkhardt JD, Horton R, Bai R, Mohanty
S, Pump A, Gibson D, Couts L, Hongo R, Beheiry S, Natale A. Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes. J Cardiovasc
Electrophysiol 2012;23:687693.
1254. Tan HW, Wang XH, Shi HF, Yang GS, Zhou L, Gu JN, Jiang WF, Liu X.
Efficacy, safety and outcome of catheter ablation for atrial fibrillation in octogenarians. Int J Cardiol 2010;145:147148.
1255. Zado E, Callans DJ, Riley M, Hutchinson M, Garcia F, Bala R, Lin D, Cooper J,
Verdino R, Russo AM, Dixit S, Gerstenfeld E, Marchlinski FE. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J
Cardiovasc Electrophysiol 2008;19:621626.
1256. Abugattas JP, Iacopino S, Moran D, De Regibus V, Takarada K, Mugnai G,
Stroker E, Coutino-Moreno HE, Choudhury R, Storti C, De Greef Y, Paparella
G, Brugada P, de Asmundis C, Chierchia GB. Efficacy and safety of the second generation cryoballoon ablation for the treatment of paroxysmal atrial fibrillation in patients over 75 years: a comparison with a younger cohort. Europace
2017;19:17981803.
1257. Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, Weiss JP,
Mallender C, Osborn JS, Anderson JL, Day JD. The impact of age on 5-year outcomes after atrial fibrillation catheter ablation. J Cardiovasc Electrophysiol
2016;27:141146.
1258. Guiot A, Jongnarangsin K, Chugh A, Suwanagool A, Latchamsetty R, Myles JD,
Jiang Q, Crawford T, Good E, Pelosi F Jr, Bogun F, Morady F, Oral H.
Anticoagulant therapy and risk of cerebrovascular events after catheter ablation of atrial fibrillation in the elderly.
J
Cardiovasc
Electrophysiol
2012;23:3643.
1259. Kusumoto F, Prussak K, Wiesinger M, Pullen T, Lynady C. Radiofrequency catheter ablation of atrial fibrillation in older patients: outcomes and complications. J Interv Card Electrophysiol 2009;25:3135.
1260. Liu Y, Huang H, Huang C, Zhang S, Ma C, Liu X, Yang Y, Cao K, Wu S, Wang
F; National Atrial Fibrillation Working Group of Chinese Society of Pacing and
Electrophysiology. Catheter ablation of atrial fibrillation in Chinese elderly patients. Int J Cardiol 2011;152:266267.
1261. Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol 2012;59:143149.
1262. Spragg DD, Dalal D, Cheema A, Scherr D, Chilukuri K, Cheng A, Henrikson
CA, Marine JE, Berger RD, Dong J, Calkins H. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol
2008;19:627631.
1263. Srivatsa UN, Danielsen B, Anderson I, Amsterdam E, Pezeshkian N, Yang Y,
White RH. Risk predictors of stroke and mortality after ablation for atrial fibrillation:
the
California experience
20052009.
Heart
Rhythm
2014;11:18981903.
1264. Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J 2018;39:453460.
1265. Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, Crandall BG,
Day JD, Johanning K, Long Y, Mallender C, Olson JL, Osborn JS, Weiss JP,
Bunch TJ. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia.
Heart
Rhythm
2014;11:22062213.
1266. Jacobs V, Woller SC, Stevens SM, May HT, Bair TL, Crandall BG, Cutler M,
Day JD, Weiss JP, Osborn JS, Mallender C, Anderson JL, Bunch TJ. Percent
ESC Guidelines
491


<!-- PAGE 120 -->

### Page 120

.............................................................................................................................................................................
time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia. J Cardiovasc
Electrophysiol 2015;26:11801186.
1267. Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Mallender C,
Osborn JS, Stevens SM, Weiss JP, Woller SC, Bunch TJ. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol 2016;118:210214.
1268. Zhang C, Gu ZC, Shen L, Pan MM, Yan YD, Pu J, Liu XY, Lin HW. Non-vitamin K antagonist oral anticoagulants and cognitive impairment in atrial fibrillation: insights from the meta-analysis of over 90,000 patients of randomized controlled trials and real-world studies. Front Aging Neurosci 2018;10:258.
1269. Sogaard M, Skjoth F, Jensen M, Kjaeldgaard JN, Lip GYH, Larsen TB, Nielsen
PB. Nonvitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients and risk of dementia: a nationwide propensity-weighted cohort study. J Am Heart Assoc 2019;8:e011358.
1270. Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J
2019;40:23272335.
121. Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community?Eur J Clin Pharmacol
2001;57:589594.
1272. Salas M, In’t Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker
BH. Impaired cognitive function and compliance with antihypertensive drugs in elderly:
the
Rotterdam
Study.
Clin
Pharmacol
Ther
2001;70:561566.
1273. Jensen AS, Idorn L, Norager B, Vejlstrup N, Sondergaard L. Anticoagulation in adults with congenital heart disease: the who, the when and the how?Heart
2015;101:424429.
1274. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am
Coll Cardiol 2017;69:13631371.
1275. Caldeira D, David C, Costa J, Ferreira JJ, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease:
systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother
2018;4:111118.
1276. Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA, Friedman
PA, Warnes CA, Asirvatham SJ. Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital heart disease. Int J Cardiol
2012;154:270274.
1277. Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol 1994;24:13651370.
1278. Roos-Hesselink J, Meijboom F, Spitaels S, van Domburg R, van Rijen E, Utens
E, Bogers A, Simoons M, Simoons ML. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 2133 years. Eur Heart J
2003;24:190197.
1279. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L,
Arquizan C, Bejot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C,
Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, RobinetBorgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M,
Reiner P, Lefebvre C, Guerin P, Piot C, Rossi R, Dubois-Rande JL, Eicher JC,
Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB,
Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A,
Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J
Med 2017;377:10111021.
1280. Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyarrhythmias and the Cox-maze procedure in congenital heart disease. Congenit Heart
Dis 2013;8:434439.
1281. Kobayashi J, Yamamoto F, Nakano K, Sasako Y, Kitamura S, Kosakai Y. Maze procedure for atrial fibrillation associated with atrial septal defect. Circulation
1998;98:II399402.
1282. Shim H, Yang JH, Park PW, Jeong DS, Jun TG. Efficacy of the maze procedure for atrial fibrillation associated with atrial septal defect. Korean J Thorac
Cardiovasc Surg 2013;46:98103.
1283. Sherwin ED, Triedman JK, Walsh EP. Update on interventional electrophysiology in congenital heart disease: evolving solutions for complex hearts. Circ
Arrhythm Electrophysiol 2013;6:10321040.
1284. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ.
Prevalence of early-onset atrial fibrillation in congenital long QT syndrome.
Heart Rhythm 2008;5:704709.
1285. Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J,
Steinbeck G, Kaab S, Haverkamp W, Fabritz L, Gradaus R, Breithardt G,
Schulze-Bahr E, Bocker D, Kirchhof P. Atrial arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J Cardiovasc
Electrophysiol 2009;20:401407.
1286. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S,
Richiardi E, Borggrefe M. Short QT syndrome: a familial cause of sudden death.
Circulation 2003;108:965970.
1287. Borggrefe M, Wolpert C, Antzelevitch C, Veltmann C, Giustetto C, Gaita F,
Schimpf
R.
Short
QT
syndrome.
Genotype-phenotype correlations.
J
Electrocardiol 2005;38:7580.
1288. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P,
Leone G, Maury P, Anttonen O, Haissaguerre M, Gaita F. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J
2006;27:24402447.
1289. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, Probst
V, Blanc JJ, Sbragia P, Dalmasso P, Borggrefe M, Gaita F. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011;58:587595.
1290. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 2011;57:802812.
1291. Bordachar P, Reuter S, Garrigue S, Cai X, Hocini M, Jais P, Haissaguerre M,
Clementy J. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004;25:879884.
1292. Kusano KF, Taniyama M, Nakamura K, Miura D, Banba K, Nagase S, Morita H,
Nishii N, Watanabe A, Tada T, Murakami M, Miyaji K, Hiramatsu S, Nakagawa
K, Tanaka M, Miura A, Kimura H, Fuke S, Sumita W, Sakuragi S, Urakawa S,
Iwasaki J, Ohe T. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll
Cardiol 2008;51:11691175.
1293. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll
Cardiol 2008;51:11491153.
1294. Rodriguez-Manero M, Namdar M, Sarkozy A, Casado-Arroyo R, Ricciardi D,
de Asmundis C, Chierchia GB, Wauters K, Rao JY, Bayrak F, Van Malderen S,
Brugada P. Prevalence, clinical characteristics and management of atrial fibrillation in patients with Brugada syndrome. Am J Cardiol 2013;111:362367.
1295. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, Marquie C,
Rosa A, Diallo A, Cassagneau R, Loizeau C, Martins R, Field ME, Derval N,
Miyazaki S, Denis A, Nogami A, Ritter P, Gourraud JB, Ploux S, Rollin A,
Zemmoura A, Lamaison D, Bordachar P, Pierre B, Jais P, Pasquie JL, Hocini M,
Legal F, Defaye P, Boveda S, Iesaka Y, Mabo P, Haissaguerre M. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome:
a multicenter study  part 2. Circulation 2013;128:17391747.
1296. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM, GomezJuanatey A, Berruezo A, Campuzano O, Sarquella-Brugada G, Mont L, Brugada
R, Brugada J. Patients with Brugada syndrome and implanted cardioverterdefibrillators: long-term follow-up. J Am Coll Cardiol 2017;70:19912002.
1297. Sumitomo N, Sakurada H, Taniguchi K, Matsumura M, Abe O, Miyashita M,
Kanamaru H, Karasawa K, Ayusawa M, Fukamizu S, Nagaoka I, Horie M,
Harada K, Hiraoka M. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia.
Circ J 2007;71:16061609.
1298. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, Leong-Sit P, Gow
RM, Green MS, Birnie DH, Krahn AD. Arrhythmia characterization and longterm outcomes in catecholaminergic polymorphic ventricular tachycardia.
Heart Rhythm 2011;8:864871.
1299. Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations,
and mortality in a large high-risk population. J Am Heart Assoc 2014;3:e001002.
1300. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014;100:465472.
1301. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H,
Estes NAM, Maron MS, Maron BJ. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 2017;136:24202436.
1302. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ.
Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy. Am J Cardiol 2017;119:18621865.
1303. van Velzen HG, Theuns DA, Yap SC, Michels M, Schinkel AF. Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy. Am J Cardiol 2017;119:100105.
1304. Klopotowski M, Kwapiszewska A, Kukula K, Jamiolkowski J, Dabrowski M,
Derejko P, Oreziak A, Baranowski R, Spiewak M, Marczak M, Klisiewicz A,
Szepietowska B, Chmielak Z, Witkowski A. Clinical and echocardiographic parameters as risk factors for atrial fibrillation in patients with hypertrophic cardiomyopathy. Clin Cardiol 2018;41:13361340.
1305. Choi YJ, Choi EK, Han KD, Jung JH, Park J, Lee E, Choe W, Lee SR, Cha MJ,
Lim WH, Oh S. Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: a nationwide population-based study. Int J Cardiol 2018;273:130135.


<!-- PAGE 121 -->

### Page 121

.............................................................................................................................................................................
1306. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia.
Am J Cardiol 2010;106:720722.
1307. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, te Riele AS, Judge
DP, Tandri H, Calkins H. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2013;10:16611668.
1308. Saguner AM, Ganahl S, Kraus A, Baldinger SH, Medeiros-Domingo A, Saguner
AR, Mueller-Burri SA, Wolber T, Haegeli LM, Krasniqi N, Tanner FC, Steffel J,
Brunckhorst C, Duru F. Clinical role of atrial arrhythmias in patients with arrhythmogenic right ventricular dysplasia. Circ J 2014;78:28542861.
1309. Bourfiss M, Te Riele AS, Mast TP, Cramer MJ, Van Der Heijden JF, Van Veen
TA, Loh P, Dooijes D, Hauer RN, Velthuis BK. Influence of genotype on structural atrial abnormalities and atrial fibrillation or flutter in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
J
Cardiovasc
Electrophysiol
2016;27:14201428.
1310. Mussigbrodt A, Knopp H, Efimova E, Weber A, Bertagnolli L, Hilbert S, Kosiuk
J, Dinov B, Bode K, Kircher S, Dagres N, Richter S, Sommer P, Husser D,
Bollmann A, Hindricks G, Arya A. Supraventricular arrhythmias in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy associate with long-term outcome after catheter ablation of ventricular tachycardias.
Europace 2018;20:11821187.
1311. Tonet JL, Castro-Miranda R, Iwa T, Poulain F, Frank R, Fontaine GH.
Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1991;67:1153.
1312. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP,
Edvardsen T, Haugaa KH. Lamin A/C cardiomyopathy: young onset, high penetrance,
and frequent need for heart transplantation.
Eur
Heart
J
2018;39:853860.
1313. van Rijsingen IA, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J,
Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP,
Grasso M, Serio A, Jenkins S, Rowland C, Richard P, Wilde AA, Perrot A,
Pankuweit S, Zwinderman AH, Charron P, Christiaans I, Pinto YM. Genderspecific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur J Heart Fail 2013;15:376384.
1314. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF,
Waintraub X, Charron P, Rollin A, Richard P, Stevenson WG, Macintyre CJ,
Ho CY, Thompson T, Vohra JK, Kalman JM, Zeppenfeld K, Sacher F, Tedrow
UB, Lakdawala NK. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol 2016;68:22992307.
1315. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, Mannarino S,
Gambarin F, Favalli V, Grasso M, Agozzino M, Campana C, Gavazzi A, Febo O,
Marini M, Landolina M, Mortara A, Piccolo G, Vigano M, Tavazzi L, Arbustini E.
Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am
Coll Cardiol 2008;52:12501260.
1316. Stollberger C, Blazek G, Winkler-Dworak M, Finsterer J. Atrial fibrillation in left ventricular noncompaction with and without neuromuscular disorders is associated with a poor prognosis. Int J Cardiol 2009;133:4145.
1317. Aras D, Tufekcioglu O, Ergun K, Ozeke O, Yildiz A, Topaloglu S, Deveci B,
Sahin O, Kisacik HL, Korkmaz S. Clinical features of isolated ventricular noncompaction in adults long-term clinical course,
echocardiographic properties,
and predictors of left ventricular failure.
J
Card
Fail
2006;12:726733.
1318. Li S, Zhang C, Liu N, Bai H, Hou C, Wang J, Song L, Pu J. Genotype-positive status is associated with poor prognoses in patients with left ventricular noncompaction cardiomyopathy. J Am Heart Assoc 2018;7:e009910.
1319. Pappone C, Radinovic A, Manguso F, Vicedomini G, Sala S, Sacco FM, Ciconte
G, Saviano M, Ferrari M, Sommariva E, Sacchi S, Ciaccio C, Kallergis EM,
Santinelli V. New-onset atrial fibrillation as first clinical manifestation of latent
Brugada syndrome:
prevalence and clinical significance.
Eur
Heart
J
2009;30:29852992.
1320. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in
KCNH2.
J
Cardiovasc
Electrophysiol
2005;16:394396.
1321. Peters S. Atrial arrhythmias in arrhythmogenic cardiomyopathy: at the beginning or at the end of the disease story?Circ J 2015;79:446.
1322. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J,
Vidaillet HJ, Jr., Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F,
Muehle G, Johnson W, McDonough B. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conductionsystem disease. N Engl J Med 1999;341:17151724.
1323. Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, Hedley PL,
Christiansen M, Olesen SP, Haunso S, Schmitt N, Jespersen T, Svendsen JH.
High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet 2012;5:450459.
1324. Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E,
Giachino D, Bianchi F, Barbonaglia L, Ferraro A. Atrial fibrillation in a large population with
Brugada electrocardiographic pattern:
prevalence, management, and correlation with prognosis. Heart Rhythm
2014;11:259265.
1325. Conte G, Dewals W, Sieira J, de Asmundis C, Ciconte G, Chierchia GB, Di
Giovanni G, Baltogiannis G, Saitoh Y, Levinstein M, La Meir M, Wellens F,
Pappaert G, Brugada P. Drug-induced Brugada syndrome in children: clinical features, device-based management, and long-term follow-up. J Am Coll Cardiol
2014;63:22722279.
1326. Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart
2017;103:14961501.
1327. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.
Circulation 2001;104:25172524.
1328. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ,
Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation
2000;102:858864.
1329. Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N,
Monteforte N, Memmi M, Gambelli P, Novelli V, Bloise R, Catalano O, Moro
G, Tibollo V, Morini M, Bellazzi R, Napolitano C, Bagnardi V, Priori SG.
Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol 2016;68:25402550.
1330. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:13191321.
1331. Roses-Noguer F, Jarman JW, Clague JR, Till J. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm
2014;11:5866.
1332. van der Werf C, Lieve KV, Bos JM, Lane CM, Denjoy I, Roses-Noguer F, Aiba
T, Wada Y, Ingles J, Leren IS, Rudic B, Schwartz PJ, Maltret A, Sacher F,
Skinner JR, Krahn AD, Roston TM, Tfelt-Hansen J, Swan H, Robyns T, Ohno S,
Roberts JD, van den Berg MP, Kammeraad JA, Probst V, Kannankeril PJ, Blom
NA, Behr ER, Borggrefe M, Haugaa KH, Semsarian C, Horie M, Shimizu W, Till
JA,
Leenhardt A,
Ackerman
MJ,
Wilde AA.
Implantable cardioverterdefibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur
Heart J 2019;40:29532961.
1333. Sugiyasu A, Oginosawa Y, Nogami A, Hata Y. A case with catecholaminergic polymorphic ventricular tachycardia unmasked after successful ablation of atrial tachycardias from pulmonary veins.
Pacing
Clin
Electrophysiol
2009;32:e2124.
1334. Veltmann C, Kuschyk J, Schimpf R, Streitner F, Schoene N, Borggrefe M,
Wolpert C. Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol 2010;99:3744.
1335. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ.
Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med
1979;301:10801085.
1336. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C,
Calkins H, Corrado D, Deftereos SG, Diller GP, Gomez-Doblas JJ, Gorenek B,
Grace A, Ho SY, Kaski JC, Kuck KH, Lambiase PD, Sacher F, Sarquella-Brugada
G, Suwalski P, Zaza A; ESC Scientific Document Group. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task
Force for the management of patients with supraventricular tachycardia of the
European Society of Cardiology (ESC). Eur Heart J 2020;41:655720.
1337. Morady F, DiCarlo LA, Jr., Baerman JM, De Buitleir M. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1987;10:492496.
1338. Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977;56:260267.
1339. Glatter KA, Dorostkar PC, Yang Y, Lee RJ, Van Hare GF, Keung E, Modin G,
Scheinman MM. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001;104:19331939.
1340. Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and longterm follow-up. J Am Coll Cardiol 1987;9:13571363.
1341. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol
1990;16:14081414.
1342. Crijns HJ, den Heijer P, van Wijk LM, Lie KI. Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome. Am Heart J 1988;115:13171321.
1343. Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.
Intern Emerg Med 2010;5:421426.
ESC Guidelines
493


<!-- PAGE 122 -->

### Page 122

.............................................................................................................................................................................
1344. Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, Billimoria Z,
Turakhia MP, Friedman PA, Madhavan M, Kapa S, Noseworthy PA, Cha YM,
Gersh B, Asirvatham SJ, Deshmukh AJ. Burden of arrhythmia in pregnancy.
Circulation 2017;135:619621.
1345. Drenthen W, Pieper PG, Roos-Hesselink JW, van Lottum WA, Voors AA,
Mulder BJ, van Dijk AP, Vliegen HW, Yap SC, Moons P, Ebels T, van
Veldhuisen DJ; Zahara Investigators. Outcome of pregnancy in women with congenital heart disease:
a literature review.
J
Am
Coll
Cardiol
2007;49:23032311.
1346. Opotowsky AR, Siddiqi OK, D’Souza B, Webb GD, Fernandes SM, Landzberg
MJ. Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart 2012;98:145151.
1347. Lee MS, Chen W, Zhang Z, Duan L, Ng A, Spencer HT, Kwan DM, Shen AY.
Atrial fibrillation and atrial flutter in pregnant women  a population-based study. J Am Heart Assoc 2016;5:e003182.
1348. Li JM, Nguyen C, Joglar JA, Hamdan MH, Page RL. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service.
Clin
Cardiol
2008;31:538541.
1349. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
Cifkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM,
Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini
T, Swan L, Warnes CA; ESC Scientific Document Group. 2018 ESC
Guidelines for the management of cardiovascular diseases during pregnancy.
Eur Heart J 2018;39:31653241.
1350. Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268269.
1351. Moore JS, Teefey P, Rao K, Berlowitz MS, Chae SH, Yankowitz J. Maternal arrhythmia: a case report and review of the literature. Obstet Gynecol Surv
2012;67:298312.
1352. Page
RL.
Treatment of arrhythmias during pregnancy.
Am
Heart
J
1995;130:871876.
1353. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 2002;109:14061407.
1354. Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME, Keegan
R, Kim YH, Knight BP, Kuck KH, Lane DA, Lip GYH, Malmborg H, Oral H,
Pappone C, Themistoclakis S, Wood KA, Blomstrom-Lundqvist C. European
Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS),
Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de
Estimulacion
Cardiaca y
Electrofisiologia
(SOLAECE).
Eur
Heart
J
2018;39:14421445.
1355. Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol 2007;18:545547.
1356. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol 1997;79:14361438.
1357. Heidbuchel H, Anne W, Willems R, Adriaenssens B, Van de Werf F, Ector H.
Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. Int J Cardiol 2006;107:6772.
1358. Calvo N, Ramos P, Montserrat S, Guasch E, Coll-Vinent B, Domenech M,
Bisbal F, Hevia S, Vidorreta S, Borras R, Falces C, Embid C, Montserrat JM,
Berruezo A, Coca A, Sitges M, Brugada J, Mont L. Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study. Europace 2016;18:5763.
1359. Crump C, Sundquist J, Winkleby MA, Sundquist K. Height, weight, and aerobic fitness level in relation to the risk of atrial fibrillation. Am J Epidemiol
2018;187:417426.
1360. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, Pare C, Azqueta
M, Sanz G. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J
2002;23:477482.
1361. Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M, Vidal B,
Scalise A, Tejeira A, Berruezo A, Brugada J; GIRAFA Investigators. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace 2008;10:1520.
1362. Guasch E, Mont L. Diagnosis, pathophysiology, and management of exerciseinduced arrhythmias. Nat Rev Cardiol 2017;14:88101.
1363. Stein R, Medeiros CM, Rosito GA, Zimerman LI, Ribeiro JP. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J
Am Coll Cardiol 2002;39:10331038.
1364. Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M, Andreu
D, Vidal B, Sitges M, Brugada J. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace 2010;12:3036.
1365. Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L,
Alzand B, Willems R, Heidbuchel H. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace 2011;13:13861393.
1366. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation.
Am
J
Cardiol
2009;103:15721577.
1367. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study.
Circulation 2008;118:800807.
1368. Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S,
Tverdal A, Nystad W. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women.
Heart 2013;99:17551760.
1369. O’Brien B, Burrage PS, Ngai JY, Prutkin JM, Huang CC, Xu X, Chae SH, Bollen
BA, Piccini JP, Schwann NM, Mahajan A, Ruel M, Body SC, Sellke FW, Mathew
J, Muehlschlegel JD. Society of Cardiovascular Anesthesiologists/European
Association of Cardiothoracic Anaesthetists practice advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery. J
Cardiothorac Vasc Anesth 2019;33:1226.
1370. Lubitz SA, Yin X, Rienstra M, Schnabel RB, Walkey AJ, Magnani JW, Rahman F,
McManus DD, Tadros TM, Levy D, Vasan RS, Larson MG, Ellinor PT, Benjamin
EJ. Long-term outcomes of secondary atrial fibrillation in the community: the
Framingham Heart Study. Circulation 2015;131:16481655.
1371. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol
2019;16:417436.
1372. Echahidi N, Pibarot P, O’Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol
2008;51:793801.
1373. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME,
Ailawadi G, Kirkwood KA, Perrault LP, Parides MK, Smith RL 2nd, Kern JA,
Dussault G, Hackmann AE, Jeffries NO, Miller MA, Taddei-Peters WC, Rose
EA, Weisel RD, Williams DL, Mangusan RF, Argenziano M, Moquete EG,
O’Sullivan KL, Pellerin M, Shah KJ, Gammie JS, Mayer ML, Voisine P, Gelijns
AC, O’Gara PT, Mack MJ, CTSN. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med 2016;374:19111921.
1374. Amar
D.
Postthoracotomy atrial fibrillation.
Curr
Opin
Anaesthesiol
2007;20:4347.
1375. Philip I, Berroeta C, Leblanc I. Perioperative challenges of atrial fibrillation. Curr
Opin Anaesthesiol 2014;27:344352.
1376. Lowres N, Mulcahy G, Jin K, Gallagher R, Neubeck L, Freedman B. Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta-analysis. Interact
Cardiovasc Thorac Surg 2018;26:504511.
1377. Lee SH, Kang DR, Uhm JS, Shim J, Sung JH, Kim JY, Pak HN, Lee MH, Joung
B. New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. Am Heart J 2014;167:593
600.e1.
1378. Konstantino Y, Zelnik Yovel D, Friger MD, Sahar G, Knyazer B, Amit G.
Postoperative atrial fibrillation following coronary artery bypass graft surgery predicts long-term atrial fibrillation and stroke.
Isr
Med
Assoc
J
2016;18:744748.
1379. Lin MH, Kamel H, Singer DE, Wu YL, Lee M, Ovbiagele B. Perioperative/postoperative atrial fibrillation and risk of subsequent stroke and/or mortality.
Stroke 2019;50:13641371.
1380. AlTurki A, Marafi M, Proietti R, Cardinale D, Blackwell R, Dorian P, Bessissow
A, Vieira L, Greiss I, Essebag V, Healey JS, Huynh T. Major adverse cardiovascular events associated with postoperative atrial fibrillation after noncardiac surgery: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol
2020;13:e007437.
1381. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH,
Mangano DT; Investigators of the Ischemia Research and Education Foundation,
Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:17201729.
1382. Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, Lopez JA, Rasekh
A, Wilson JM, Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004;43:742748.
1383. Cardinale D, Sandri MT, Colombo A, Salvatici M, Tedeschi I, Bacchiani G,
Beggiato M, Meroni CA, Civelli M, Lamantia G, Colombo N, Veglia F,
Casiraghi M, Spaggiari L, Venturino M, Cipolla CM. Prevention of Atrial
Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: the
PRESAGE Trial. Ann Surg 2016;264:244251.
1384. Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, Kitadani J,
Tabata H, Takeuchi A, Yamaue H. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg 2017;104:10031009.
1385. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock
RP. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013:CD003611.


<!-- PAGE 123 -->

### Page 123

.............................................................................................................................................................................
1386. Ozaydin M, Icli A, Yucel H, Akcay S, Peker O, Erdogan D, Varol E, Dogan A,
Okutan H. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J 2013;34:597604.
1387. O’Neal JB, Billings FTt, Liu X, Shotwell MS, Liang Y, Shah AS, Ehrenfeld JM,
Wanderer JP, Shaw AD. Effect of preoperative beta-blocker use on outcomes following cardiac surgery. Am J Cardiol 2017;120:12931297.
1388. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D,
Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga G, Avezum A,
Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:18391847.
1389. Zhu J, Wang C, Gao D, Zhang C, Zhang Y, Lu Y, Gao Y. Meta-analysis of amiodarone versus beta-blocker as a
prophylactic therapy against atrial fibrillation following cardiac surgery.
Intern
Med
J
2012;42:10781087.
1390. Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, Schwarz C, Lehner
E, Strasser U, Lassnig E, Lamm G, Eber B; Study of Prevention of
Postoperative Atrial Fibrillation. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized,
placebo-controlled trial. Am Heart J 2004;147:636643.
1391. Buckley MS, Nolan PE Jr, Slack MK, Tisdale JE, Hilleman DE, Copeland JG.
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: metaanalysis of dose response and timing of initiation.
Pharmacotherapy
2007;27:360368.
1392. Riber
LP,
Christensen
TD,
Jensen
HK,
Hoejsgaard
A,
Pilegaard
HK.
Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. Ann Thorac Surg 2012;94:339344; discussion 345346.
1393. Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV,
Kesler KA. A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg 2009;88:886893; discussion 894895.
1394. Yuan X, Du J, Liu Q, Zhang L. Defining the role of perioperative statin treatment in patients after cardiac surgery: a meta-analysis and systematic review of 20 randomized controlled trials. Int J Cardiol 2017;228:958966.
1395. Fairley JL, Zhang L, Glassford NJ, Bellomo R. Magnesium status and magnesium therapy in cardiac surgery: a systematic review and meta-analysis focusing on arrhythmia prevention. J Crit Care 2017;42:6977.
1396. Tabbalat RA, Hamad NM, Alhaddad IA, Hammoudeh A, Akasheh BF, Khader
Y. Effect of ColchiciNe on the InciDence of atrial fibrillation in open heart surgery patients: END-AF trial. Am Heart J 2016;178:102107.
1397. Ali-Hasan-Al-Saegh S, Mirhosseini SJ, Liakopoulos O, Sabashnikov A, Dehghan
HR, Sedaghat-Hamedani F, Kayvanpour E, Ghaffari N, Vahabzadeh V,
Aghabagheri M, Mozayan MR, Popov AF. Posterior pericardiotomy in cardiac surgery: systematic review and meta-analysis. Asian Cardiovasc Thorac Ann
2015;23:354362.
1398. Hu XL, Chen Y, Zhou ZD, Ying J, Hu YH, Xu GH. Posterior pericardiotomy for the prevention of atrial fibrillation after coronary artery bypass grafting: a meta-analysis of randomized controlled trials. Int J Cardiol 2016;215:252256.
1399. Wang W, Mei YQ, Yuan XH, Feng XD. Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation. J
Thorac Cardiovasc Surg 2016;151:8085.
1400. Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis
JC, Schepp RM, Boer C, Moons KG, van Herwerden LA, Tijssen JG, Numan
SC, Kalkman CJ, van Dijk D; Dexamethasone for Cardiac Surgery Study
Group. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 2012;308:17611767.
1401. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D,
Sessler DI, Karthikeyan G, Villar JC, Zuo Y, Avezum A, Quantz M, Tagarakis
GI, Shah PJ, Abbasi SH, Zheng H, Pettit S, Chrolavicius S, Yusuf S; SIRS
Investigators. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet
2015;386:12431253.
1402. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE.
Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting
(multicenter
Australian study of
19,497
patients).
Am
J
Cardiol
2012;109:219225.
1403. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson
WG, Tarazi R, Shroyer AL, Sethi GK, Grover FL, Hammermeister KE. Atrial fibrillation after cardiac surgery:
a major morbid event?Ann
Surg
1997;226:501511; discussion 511513.
1404. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, Kamel
H. Perioperative atrial fibrillation and the long-term risk of ischemic stroke.
JAMA 2014;312:616622.
1405. Horwich P, Buth KJ, Legare JF. New onset postoperative atrial fibrillation is associated with a long-term risk for stroke and death following cardiac surgery. J Card Surg 2013;28:813.
1406. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J
Cardiothorac Surg 2010;37:13531359.
1407. Rubin DA, Nieminski KE, Reed GE, Herman MV. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1987;94:331335.
1408. Butt JH, Xian Y, Peterson ED, Olsen PS, Rorth R, Gundlund A, Olesen JB,
Gislason GH, Torp-Pedersen C, Kober L, Fosbol EL. Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA
Cardiol 2018;3:417424.
1409. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason
GH, Torp-Pedersen C, Kober L, Fosbol EL. Risk of thromboembolism associated with atrial fibrillation following noncardiac surgery. J Am Coll Cardiol
2018;72:20272036.
1410. POISE Study group., Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar
JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga
G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extendedrelease metoprolol succinate in patients undergoing non-cardiac surgery
(POISE trial): a randomised controlled trial. Lancet 2008;371:18391847.
1411. Leonardi M, Bissett J. Prevention of atrial fibrillation. Curr Opin Cardiol
2005;20:417423.
1412. Roberts JD, Dewland TA, Glidden DV, Hoffmann TJ, Arking DE, Chen LY,
Psaty BM, Olgin JE, Alonso A, Heckbert SR, Marcus GM. Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. Am Heart J 2016;175:917.
1413. Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein,
statin therapy, and risks of atrial fibrillation: an exploratory analysis of the
JUPITER trial. Eur Heart J 2012;33:531537.
1414. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi
GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G; GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSIHF trial. Eur Heart J 2009;30:23272336.
1415. Zhou X, Du JL, Yuan J, Chen YQ. Statin therapy is beneficial for the prevention of atrial fibrillation in patients with coronary artery disease: a meta-analysis. Eur J Pharmacol 2013;707:104111.
1416. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin
Pharmacol 2012;74:744756.
1417. Macfarlane PW, Murray H, Sattar N, Stott DJ, Ford I, Buckley B, Jukema JW,
Westendorp RG, Shepherd J. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011;13:634639.
1418. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard
A; ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in
ALLHAT
(Antihypertensive and
Lipid-Lowering
Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54:
20232031.
1419. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) trial. Am Heart J 2011;161:993999.
1420. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol 2013;28:718.
1421. Yang Q, Qi X, Li Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials.
BMC
Cardiovasc
Disord
2014;14:99.
1422. Martino A, Pezzi L, Magnano R, Salustri E, Penco M, Calo L. Omega 3 and atrial fibrillation: where are we?World J Cardiol 2016;8:114119.
1423. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I,
Furokawa T, Gillis AM, Haugaa KH, Lip GYH, Van Gelder I, Malik M, Poole J,
Potpara T, Savelieva I, Sarkozy A; ESC Scientific Document Group. Sex differences in cardiac arrhythmia: a consensus document of the European Heart
Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific
Heart Rhythm Society. Europace 2018;20:15651565ao.
1424. Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM, Ostojic
MC, Lip GY. Gender-related differences in presentation, treatment and longterm outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart:
the
Belgrade atrial fibrillation study.
Int
J
Cardiol
2012;161:3944.
1425. Potpara TS, Blomstrom-Lundqvist C. Sex-related differences in atrial fibrillation: can we discern true disparities from biases?Heart 2017;103:979981.
ESC Guidelines
495


<!-- PAGE 124 -->

### Page 124

.............................................................................................................................................................................
1426. Piccini JP, Simon DN, Steinberg BA, Thomas L, Allen LA, Fonarow GC, Gersh
B, Hylek E, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson
ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Investigators and Patients. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF
registry. JAMA Cardiol 2016;1:282291.
1427. Lang C, Seyfang L, Ferrari J, Gattringer T, Greisenegger S, Willeit K, Toell T,
Krebs S, Brainin M, Kiechl S, Willeit J, Lang W, Knoflach M; Austrian Stroke
Registry Collaborators. Do women with atrial fibrillation experience more severe strokes? Results from the Austrian Stroke Unit Registry. Stroke
2017;48:778780.
1428. Sullivan RM, Zhang J, Zamba G, Lip GY, Olshansky B. Relation of genderspecific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control
(from
AFFIRM).
Am
J
Cardiol
2012;110:17991802.
1429. Rienstra M, Van Veldhuisen DJ, Hagens VE, Ranchor AV, Veeger NJ, Crijns HJ,
Van Gelder IC; RACE Investigators. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus
Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2005;46:12981306.
1430. Lehmann MH, Timothy KW, Frankovich D, Fromm BS, Keating M, Locati EH,
Taggart RT, Towbin JA, Moss AJ, Schwartz PJ, Vincent GM. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol
1997;29:9399.
1431. Zylla MM, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, Andresen D,
Willems S, Eckardt L, Tebbenjohanns J, Spitzer SG, Schumacher B, Hochadel
M, Senges J, Katus HA, Thomas D. Sex-related outcome of atrial fibrillation ablation:
insights from the
German
Ablation
Registry.
Heart
Rhythm
2016;13:18371844.
1432. Patel N, Deshmukh A, Thakkar B, Coffey JO, Agnihotri K, Patel A, Ainani N,
Nalluri N, Patel N, Patel N, Patel N, Badheka AO, Kowalski M, Hendel R,
Viles-Gonzalez J, Noseworthy PA, Asirvatham S, Lo K, Myerburg RJ, Mitrani
RD. Gender, race, and health insurance status in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2016;117:11171126.
1433. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M,
Odutayo AA. Atrialfibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016;532:h7013.
1434. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA,
Kalarus Z, Crijns HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G.
Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 2015;17:17771786.
1435. Proietti M, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GY; REPOSI
Investigators. Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI
study. Clin Res Cardiol 2016;105:912920.
1436. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling
RJ, Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation:
primary results of the PREvention oF thromboemolic events  European
Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:614.
1437. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L,
Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani
G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme 
Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur
Heart J 2014;35:33653376.
1438. Jortveit J, Pripp AH, Langorgen J, Halvorsen S. Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. Eur J Prev Cardiol 2019:2047487319841940.
1439. Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljugic Z, Manola S, Music L,
Musetescu R, Badila E, Mitic G, Paparisto V, Dimitrova ES, Polovina MM,
Petranov SL, Djergo H, Loncar D, Bijedic A, Brusich S, Lip GY; Balkan-AF
Investigators. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the
Balkan region:
the
BALKAN-AFSurvey.
Sci
Rep
2016;6:20432.
1440. Kim H, Kim TH, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS,
Kim J, Park HW, Choi EK, Kim JB, Kim C, Lee YS, Joung B. A prospective survey of atrial fibrillation management for real-world guideline adherence:
COmparison study of
Drugs for symptom control and complication prEvention of
Atrial
Fibrillation
(CODE-AF)
Registry.
Korean
Circ
J
2017;47:877887.
1441. Miyazawa K, Li YG, Rashed WA, Al Mahmeed W, Shehab A, Zubaid M, Lip
GYH. Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: insights from the Gulf Survey of
Atrial Fibrillation events (Gulf SAFE). Int J Cardiol 2019;274:126131.
1442. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F,
Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y,
Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK;
GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart 2017;103:307314.
1443. Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz
MD, Fonarow GC, Gersh BJ, Goldhaber S, Haas S, Hacke W, Kowey PR,
Ansell J, Mahaffey KW, Naccarelli G, Reiffel JA, Turpie A, Verheugt F, Piccini
JP, Kakkar A, Peterson ED, Fox KAA, Garfield AF; ORBIT-AF Investigators.
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF,
ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 2017;194:132140.
1444. Leef GC, Perino AC, Askari M, Fan J, Ho PM, Olivier CB, Longo L, Mahaffey
KW, Turakhia MP. Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation:
insights from the
Veterans
Health
Administration. J Pharm Pract 2019:897190019828270.
1445. Dupree L, DeLosSantos M, Smotherman C. Evaluation of adherence to guideline-directed antithrombotic therapy for atrial fibrillation at hospital discharge. J Cardiovasc Pharmacol Ther 2018;23:502508.
1446. Heidbuchel H, Dagres N, Antz M, Kuck KH, Lazure P, Murray S, Carrera C,
Hindricks G, Vahanian A. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. Europace 2018;20:19191928.
1447. Desteghe L, Germeys J, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J,
Delesie M, Dendale P, Heidbuchel H. Effectiveness and usability of an online tailored education platform for atrial fibrillation patients undergoing a direct current cardioversion or pulmonary vein isolation.
Int
J
Cardiol
2018;272:123129.
1448. Marquez-Contreras E, Martell-Claros N, Marquez-Rivero S, Hermida-Campa
E, Gracia-Diez C, Sanchez-Lopez E, Gil-Guillen V; Compliance and Inertia
Working Group, Spanish Society of Hypertension (SEH-LELHA). Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA
study). Curr Med Res Opin 2018;34:13011308.
1449. Piccini JP, Xu H, Cox M, Matsouaka RA, Fonarow GC, Butler J, Curtis AB,
Desai N, Fang M, McCabe PJ, Page Ii RL, Turakhia M, Russo AM, Knight BP,
Sidhu M, Hurwitz JL, Ellenbogen KA, Lewis WR; Get With The GuidelinesAFIB Clinical Working Group and Hospitals. Adherence to guideline-directed stroke prevention therapy for atrial fibrillation is achievable. Circulation
2019;139:14971506.
1450. Richardson KM, Singh J, Munoz D, Damp JB, Mendes LA. Improving practice guideline adherence through peer feedback: impact of an ambulatory cardiology curriculum. Teach Learn Med 2018;30:328336.
1451. Ferguson C, Hickman LD, Phillips J, Newton PJ, Inglis SC, Lam L, Bajorek BV.
An mHealth intervention to improve nurses’ atrial fibrillation and anticoagulation knowledge and practice: the EVICOAG study. Eur J Cardiovasc Nurs
2019;18:715.
1452. Siebenhofer
A,
Ulrich
LR,
Mergenthal
K,
Berghold
A,
Pregartner
G,
Kemperdick B, Schulz-Rothe S, Rauck S, Harder S, Gerlach FM, Petersen JJ.
Primary care management for patients receiving long-term antithrombotic treatment: a cluster-randomized controlled trial. PLoS One 2019;14:e0209366.
1453. Heidenreich PA, Solis P, Estes NAM 3rd, Fonarow GC, Jurgens CY, Marine JE,
McManus DD, McNamara RL. 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the
American College of Cardiology/American Heart Association Task Force on performance measures. J Am Coll Cardiol 2016;68:525568.
1454. Lewis WR, Piccini JP, Turakhia MP, Curtis AB, Fang M, Suter RE, Page RL, 2nd,
Fonarow GC. Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circ Cardiovasc Qual
Outcomes 2014;7:770777.
1455. Friedman DJ, Al-Khatib SM. Measuring quality in electrophysiology. J Interv
Card Electrophysiol 2016;47:510.
1456. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the
Scientific and Standardization Committee of the International Society on
Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb
Haemost 2005;3:692694.
1457. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W;
Subcommittee on Control of Anticoagulation of the Scientific and Standardization
Committee of the International Society on Thrombosis and Haemostasis.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202204.


<!-- PAGE 125 -->

### Page 125

....................................................................................................................................................................
1458. Diederichsen SZ, Haugan KJ, Brandes A, Lanng MB, Graff C, Krieger D,
Kronborg C, Holst AG, Kober L, Hojberg S, Svendsen JH. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll
Cardiol 2019;74:27712781.
1459. Swiryn S, Orlov MV, Benditt DG, DiMarco JP, Lloyd-Jones DM, Karst E,
Qu F, Slawsky MT, Turkel M, Waldo AL; RATE Registry Investigators.
Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the Registry of
Atrial
Tachycardia and
Atrial
Fibrillation
Episodes.
Circulation
2016;134:11301140.
1460. Pastori D, Miyazawa K, Li Y, Szekely O, Shahid F, Farcomeni A, Lip GYH.
Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices.
Clin
Res
Cardiol
2020;109:96102.
1461. Gonzalez M, Keating RJ, Markowitz SM, Liu CF, Thomas G, Ip JE, Lerman BB,
Cheung JW. Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers. Heart Rhythm
2014;11:22142221.
1462. Gorenek BC, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV, Healey JS,
Israel CW, Kudaiberdieva G, Levin LA, Lip GYH, Martin D, Okumura K,
Svendsen JH, Tse HF, Botto GLC-C; ESC Scientific Document Group. Devicedetected subclinical atrial tachyarrhythmias: definition, implications and management  an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm
Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y
Electrofisiologia (SOLEACE). Europace 2017;19:15561578.
1463. Nasir JM, Pomeroy W, Marler A, Hann M, Baykaner T, Jones R, Stoll R, Hursey
K, Meadows A, Walker J, Kindsvater S. Predicting determinants of atrial fibrillation or flutter for therapy elucidation in Patients at Risk for Thromboembolic
Events (PREDATE AF) study. Heart Rhythm 2017;14:955961.
1464. Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, Pouliot E,
Ziegler PD; REVEAL AF Investigators. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the
REVEAL AF study. JAMA Cardiol 2017;2:11201127.
1465. Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score.
Circulation 2019;140:16391646.
1466. Celikyurt U, Knecht S, Kuehne M, Reichlin T, Muehl A, Spies F, Osswald S,
Sticherling C. Incidence of new-onset atrial fibrillation after cavotricuspid isthmus ablation for atrial flutter. Europace 2017;19:17761780.
1467. Bertaglia E, Bonso A, Zoppo F, Proclemer A, Verlato R, Coro L, Mantovan R,
Themistoclakis S, Raviele A, Pascotto P; North-Eastern Italian Study on Atrial
Flutter Ablation Investigators. Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Pacing Clin Electrophysiol 2004;27:15071512.
1468. Nabar A, Rodriguez LM, Timmermans C, van Mechelen R, Wellens HJ. Class
IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart 2001;85:424429.
1469. Enriquez A, Sarrias A, Villuendas R, Ali FS, Conde D, Hopman WM, Redfearn
DP, Michael K, Simpson C, De Luna AB, Bayes-Genis A, Baranchuk A. Newonset atrial fibrillation after cavotricuspid isthmus ablation: identification of advanced interatrial block is key. Europace 2015;17:12891293.
1470. Maskoun W, Pino MI, Ayoub K, Llanos OL, Almomani A, Nairooz R, Hakeem
A, Miller J. Incidence of atrial fibrillation after atrial flutter ablation. JACC Clin
Electrophysiol 2016;2:682690.
1471. Reithmann C, Hoffmann E, Spitzlberger G, Dorwarth U, Gerth A, Remp T,
Steinbeck G. Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J 2000;21:565572.
1472. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen
TB. Atrial flutter and thromboembolic risk: a systematic review. Heart
2015;101:14461455.
1473. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol
1991;68:4146.
1474. Gillis AM, Unterberg-Buchwald C, Schmidinger H, Massimo S, Wolfe K,
Kavaney
DJ,
Otterness
MF,
Hohnloser
SH;
GEM
III
AT
Worldwide
Investigators. Safety and efficacy of advanced atrial pacing therapies for atrial tachyarrhythmias in patients with a new implantable dual chamber cardioverter-defibrillator. J Am Coll Cardiol 2002;40:16531659.
1475. Crijns HJ, Van Gelder IC, Kingma JH, Dunselman PH, Gosselink AT, Lie KI.
Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J 1994;15:14031408.
1476. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Jr., Meissner
MC, Zoble RG, Wakefield LK, Perry KT, Vanderlugt JT. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a doseresponse study. J Am Coll Cardiol 1996;28:130136.
1477. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III
antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter.
Intravenous
Dofetilide
Investigators.
J
Am
Coll
Cardiol
1997;29:385390.
1478. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB, Jr.
Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
Circulation 2000;102:23852390.
1479. Crozier IG, Ikram H, Kenealy M, Levy L. Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm.
Am
J
Cardiol
1987;59:607609.
1480. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, Qi A, Vorderbrugge S, Kerr CR.
Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J
Cardiol 1990;66:755757.
1481. Da Costa A, Thevenin J, Roche F, Romeyer-Bouchard C, Abdellaoui L,
Messier M, Denis L, Faure E, Gonthier R, Kruszynski G, Pages JM, Bonijoly S,
Lamaison D, Defaye P, Barthelemy JC, Gouttard T, Isaaz K; Loire-Arde`cheDroˆme-Ise`re-Puy-de-Doˆme Trial of Atrial Flutter Investigators. Results from the Loire-Arde`che-Droˆme-Ise`re-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter.
Circulation 2006;114:16761681.
1482. Schwartzman D, Callans DJ, Gottlieb CD,
Dillon SM, Movsowitz C,
Marchlinski FE. Conduction block in the inferior vena caval-tricuspid valve isthmus: association with outcome of radiofrequency ablation of type I atrial flutter. J Am Coll Cardiol 1996;28:15191531.
1483. Wasmer K, Monnig G, Bittner A, Dechering D, Zellerhoff S, Milberg P, Kobe J,
Eckardt L. Incidence, characteristics, and outcome of left atrial tachycardias after circumferential antral ablation of atrial fibrillation.
Heart Rhythm
2012;9:16601666.
1484. Satomi K, Bansch D, Tilz R, Chun J, Ernst S, Antz M, Greten H, Kuck KH,
Ouyang F. Left atrial and pulmonary vein macroreentrant tachycardia associated with double conduction gaps: a novel type of man-made tachycardia after circumferential pulmonary vein isolation. Heart Rhythm 2008;5:4351.
1485. Chugh A, Oral H, Lemola K, Hall B, Cheung P, Good E, Tamirisa K, Han J,
Bogun F, Pelosi F Jr, Morady F. Prevalence, mechanisms, and clinical significance of macroreentrant atrial tachycardia during and following left atrial ablation for atrial fibrillation. Heart Rhythm 2005;2:464471.
1486. Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H,
Camm AJ, Crijns H, Dagres N, Deharo JC, Dobrev D, Hatala R, Hindricks G,
Hohnloser SH, Leclercq C, Lewalter T, Lip GYH, Merino JL, Mont L, Prinzen
F, Proclemer A, Purerfellner H, Savelieva I, Schilling R, Steffel J, van Gelder
IC,
Zeppenfeld
K,
Zupan
I,
Heidbuchel
H.
EHRA
White
Paper:
knowledge gaps in arrhythmia management  status 2019. Europace 2019;
21:993994.
1487. De With RR, Marcos EG, Dudink E, Spronk HM, Crijns H, Rienstra M, Van
Gelder IC. Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study.
Europace 2020;22:352360.
1488. Andrade JG, Deyell MW, Lee AY, Macle L. Sex differences in atrial fibrillation.
Canadian J Cardiol 2018;34:429436.
1489. Potpara TS, Ferro C, Lip GYH, Dan GA, Lenarczyk R, Mallamaci F, Ortiz A,
Sarafidis P, Ekart R, Dagres N. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm
Association (EHRA) and European Renal Association/European Dialysis and
Transplantation Association (ERA/EDTA) physician-based survey. Europace
2020;22:496505.
1490. Al-Khatib SM, Benjamin EJ, Buxton AE, Calkins H, Chung MK, Curtis AB,
Desvigne-Nickens P, Jais P, Packer DL, Piccini JP, Rosenberg Y, Russo AM,
Wang PJ, Cooper LS, Go AS, Workshop C. Research needs and priorities for catheter ablation of atrial fibrillation: a report from a National Heart, Lung,
and Blood Institute Virtual Workshop. Circulation 2020;141:482492.
1491. Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A,
Boveda S, Dagres N, Di Toro D, Eckhardt LL, Ellenbogen K, Hardy C, Ikeda T,
ESC Guidelines
497


<!-- PAGE 126 -->

### Page 126

..................
Jaswal A, Kaufman E, Krahn A, Kusano K, Kutyifa V, Lim HS, Lip GYH, NavaTownsend S, Pak HN, RodrU´ guez Diez G, Sauer W, Saxena A, Svendsen JH,
Vanegas D, Vaseghi M, Wilde A, Bunch TJ; ESC Scientific Document Group,
Buxton AE, Calvimontes G, Chao TF, Eckardt L, Estner H, Gillis AM, Isa R,
Kautzner J, Maury P, Moss JD, Nam GB, Olshansky B, Pava Molano LF,
Pimentel M, Prabhu M, Tzou WS, Sommer P, Swampillai J, Vidal A, Deneke T,
Hindricks G, Leclercq C. European Heart Rhythm Association (EHRA)/Heart
Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin
American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace 2020;22:11471148.
1492. Blessberger H, Lewis SR, Pritchard MW, Fawcett LJ, Domanovits H, Schlager
O, Wildner B, Kammler J, Steinwender C. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery. Cochrane Database Syst Rev 2019 23;9:CD013435.

<!-- 2020_Sports_Cardiology.md -->

# ESC Guidelines: Sports Cardiology (2020)

**Source**: `2020_Sports_Cardiology.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 80

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC)
Authors/Task Force Members: Antonio Pelliccia* (Chairperson) (Italy),
Sanjay Sharma* (Chairperson) (United Kingdom), Sabiha Gati (United Kingdom),
Maria B€ack (Sweden), Mats Bo¨rjesson (Sweden), Stefano Caselli (Switzerland),
Jean-Philippe Collet (France), Domenico Corrado (Italy), Jonathan A. Drezner
(United States of America), Martin Halle (Germany), Dominique Hansen (Belgium),
Hein Heidbuchel (Belgium), Jonathan Myers (United States of America),
Josef Niebauer (Austria), Michael Papadakis (United Kingdom),
Massimo Francesco Piepoli (Italy), Eva Prescott (Denmark),
Jolien W. Roos-Hesselink (Netherlands), A. Graham Stuart (United Kingdom),
Rod S. Taylor (United Kingdom), Paul D. Thompson (United States of America),
Monica Tiberi (Italy), Luc Vanhees (Belgium), Matthias Wilhelm (Switzerland)
Document Reviewers: Marco Guazzi (CPG Review Coordinator) (Italy), Andre´ La Gerche (CPG Review
Coordinator) (Australia), Victor Aboyans (France), Paolo Emilio Adami (Italy), Johannes Backs
(Germany), Aaron Baggish (United States of America), Cristina Basso (Italy), Alessandro Bifﬁ(Italy),
Chiara Bucciarelli-Ducci (United Kingdom), A. John Camm (United Kingdom), Guido Claessen (Belgium),
Victoria Delgado (Netherlands), Perry M. Elliott (United Kingdom), Maurizio Galderisi† (Italy),
Chris P. Gale (United Kingdom), Belinda Gray (Australia), Kristina Hermann Haugaa (Norway),
Bernard Iung (France), Hugo A. Katus (Germany), Andre Keren (Israel), Christophe Leclercq (France),
* Corresponding authors: Antonio Pelliccia, Department of Medicine, Institute of Sport Medicine and Science, Rome, Italy. Tel: þ39 06 3275 9230, Email: antonio.pelliccia@coni.
it; ant.pelliccia@gmail.com.
Sanjay Sharma, Cardiology Clinical Academic Group, St George’s, University of London, London, United Kingdom. Tel: þ44 (0)20 8725 6878, Email: sasharma@sgul.ac.uk.
† We would like to pay tribute to Professor Galderisi who passed away in March 2020.
ESC Committee for Practice Guidelines (CPG), National Cardiac Societies document reviewers and Author/Task Force Member afﬁliations: listed in the Appendix.
ESC entities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of
Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Working Groups: Adult Congenital Heart Disease.
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
V
C The European Society of Cardiology 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehaa605


<!-- PAGE 2 -->

### Page 2

........................................................................................................
Basil S. Lewis (Israel), Lluis Mont (Spain), Christian Mueller (Switzerland), Steffen E. Petersen (United
Kingdom), Anna Sonia Petronio (Italy), Marco Rofﬁ(Switzerland), Kai Savonen (Finland), Luis Serratosa
(Spain), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Marta Sitges (Spain),
Erik Ekker Solberg (Norway), Miguel Sousa-Uva (Portugal), Emeline Van Craenenbroeck (Belgium),
Caroline Van De Heyning (Belgium), William Wijns (Ireland)
The disclosure forms of all experts involved in the development of these Guidelines are available on the
ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the Guidelines see European Heart Journal online.
Click here to access the corresponding chapter in ESC CardioMed - section 55 - Sports and heart disease
...................................................................................................................................................................................................
Keywords
Guidelines • adult congenital heart disease • aortopathies • arrhythmias • cancer • cardiomyopathy • cardiovascular risk factors • chronic coronary syndromes • exercise • heart failure • pregnancy • peripheral vascular disease • recommendations • risk stratiﬁcation • sport  special environments • valvular heart disease
Table of Contents
Abbreviations and acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3 Identification of cardiovascular disease and risk stratification in individuals participating in recreational and competitive sports . . . . . . . 25
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.2 Definitions of recreational and competitive athletes . . . . . . . . . . . 25
3.3 Exercise-related major adverse cardiovascular events . . . . . . . . . 25
3.4 Incidence of sudden cardiac death in athletes . . . . . . . . . . . . . . . . . 26
3.5 Aetiology of sudden cardiac death during exercise . . . . . . . . . . . . 26
3.6 Screening modalities for cardiovascular disease in young athletes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.7 Screening for cardiovascular disease in older athletes . . . . . . . . . . 26
4 Physical activity, leisure exercise, and competitive sports participation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
4.1 General introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
4.1.1 Definition and characteristics of exercise interventions . . . . 27
4.1.1.1 Type of exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
4.1.1.2 Exercise frequency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.1.1.3 Exercise intensity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.1.1.4 Training volume . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.1.1.5 Type of training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.1.2 Classification of exercise and sports . . . . . . . . . . . . . . . . . . . . . . 29
4.2 Exercise recommendations in individuals with cardiovascular risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
4.2.1 General introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
4.2.2 Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4.2.3 Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.2.4 Dyslipidaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.2.5 Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.2.5.1 Effect of exercise on diabetic control, risk factors and outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.2.5.2 Recommendations for participation in exercise in individuals with diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.2.5.3 Cardiac evaluation before exercise in individuals with diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.3 Exercise and sports in ageing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
4.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
4.3.2 Risk stratification, inclusion/exclusion criteria . . . . . . . . . . . . . 37
4.3.3 Exercise modalities and recommendations for exercise and sport in the elderly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
5 Exercise in clinical settings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
5.1 Exercise programmes for leisure-time and competitive sport participation in chronic coronary syndrome . . . . . . . . . . . . . . . . 38
5.1.1 Individuals at risk of atherosclerotic coronary artery disease and asymptomatic individuals in whom coronary artery disease is detected at screening . . . . . . . . . . . . . . . . . . . . . . . . . 39
5.1.1.1 Recommendations for sports participation . . . . . . . . . . . 39
5.1.2 Established (long-standing) chronic coronary syndrome . . . 40
5.1.2.1 Antithrombotic treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1.3 Myocardial ischaemia without obstructive disease in the epicardial coronary artery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1.4 Return to sport after acute coronary syndrome . . . . . . . . . . 42
5.1.4.1 Competitive athletes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1.4.2 Recreational athletes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1.5 Anomalous origin of coronary arteries . . . . . . . . . . . . . . . . . . . 42
5.1.5.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1.5.2 Eligibility for sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1.6 Myocardial bridging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.1.6.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.1.6.2 Eligibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.2 Exercise recommendations in individuals with chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.2.1 Background: rationale for exercise in chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.2.2 Risk stratification and preliminary evaluation . . . . . . . . . . . . . . 44


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
5.2.3 Exercise modalities and sports participation in heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
5.2.3.1 Aerobic/endurance exercise . . . . . . . . . . . . . . . . . . . . . . . . . 45
5.2.3.2 Resistance exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
5.2.3.3 Respiratory exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
5.2.3.4 Aquatic exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
5.2.4 Sports participation and return to sports . . . . . . . . . . . . . . . . . 46
5.2.4.1 Competitive sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5.2.4.2 Recreational sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5.2.5 Heart failure with preserved ejection fraction . . . . . . . . . . . . . 47
5.2.5.1 Exercise modalities and sports participation . . . . . . . . . . 47
5.2.6 Exercise in individuals after heart transplantation . . . . . . . . . . 47
5.2.6.1 Exercise modalities and sports participation . . . . . . . . . . 47
5.3 Exercise recommendations in individuals with valvular heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
5.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
5.3.1.1 General principles in assessment and risk stratification of individuals with valvular heart disease prior to leisure exercise or competitive sports . . . . . . . . . . . . . . 48
5.3.1.2 Surveillance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
5.3.2 Aortic valve stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
5.3.3 Aortic valve regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
5.3.4 Bicuspid aortic valve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
5.3.5 Primary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
5.3.5.1 Mitral valve prolapse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
5.3.6 Mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
5.3.7 Tricuspid regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
5.4 Exercise recommendations in individuals with aortopathy . . . . . 53
5.4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
5.4.2 Risk of dissection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
5.4.3 Sporting disciplines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
5.4.4 Effect on aortic diameter and wall stress . . . . . . . . . . . . . . . . . . 54
5.4.5 Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
5.5 Exercise recommendations in individuals with cardiomyopathies, myocarditis, and pericarditis . . . . . . . . . . . . . . . . . . . 55
5.5.1 Hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
5.5.1.1 Risk stratification in hypertrophic cardiomyopathy . . . . 55
5.5.1.2 Baseline assessment of patients with HCM . . . . . . . . . . . 55
5.5.1.3 History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
5.5.1.4 Resting and ambulatory ECG . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.1.5 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.1.6 Cardiac magnetic resonance imaging . . . . . . . . . . . . . . . . . 56
5.5.1.7 Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.1.8 Genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.1.9 ESC risk score in HCM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.1.10 Exercise recommendation . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.1.11 Special considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.1.12 Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.5.2 Arrhythmogenic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . 57
5.5.2.1 Risk stratification in arrhythmogenic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
5.5.2.2 Baseline assessment of patients with arrhythmogenic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
5.5.2.3 History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.2.4 Resting and ambulatory ECG . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.2.5 Echocardiography and cardiac magnetic resonance imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.2.6 Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.2.7 Genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.2.8 Exercise recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.2.9 Special considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.2.10 Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.5.3 Exercise recommendations in individuals with left ventricular non-compaction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.5.3.1 Risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.5.3.2 Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.5.4 Exercise recommendations in individuals with dilated cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.5.4.1 Baseline assessment of patients with dilated cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.5.4.2 Special considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.5.5 Exercise recommendations in individuals with myocarditis and pericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.5.5.1 Myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.5.5.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.5.5.3 Risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.5.5.4 Exercise recommendations for individuals with myocarditis
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.5.6 Pericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.5.6.1 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.5.6.2 Risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.5.6.3 Exercise recommendations for individuals with pericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
5.6 Exercise recommendations in individuals with arrhythmias and channelopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
5.6.1 A general management framework . . . . . . . . . . . . . . . . . . . . . . . 62
5.6.2 Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
5.6.2.1 Patients without atrial fibrillation . . . . . . . . . . . . . . . . . . . . . 62
5.6.2.2 Prognostic and symptomatic relevance of AF
during sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
5.6.2.3 Impact of continuing sport on the natural progression of atrial fibrillation after ablation . . . . . . . . . . . . . . . . 63
5.6.3 Supraventricular tachycardia and Wolff-ParkinsonWhite syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5.6.3.1 Prognostic and symptomatic relevance of paroxysmal supraventricular tachycardia without pre-excitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5.6.3.2 Prognostic and symptomatic relevance of pre-excitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5.6.4 Premature ventricular contractions and non-sustained ventricular tachycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.6.4.1 Relation between number of premature ventricular contractions and risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.6.4.2 Morphology of premature ventricular contractions . . . 65
5.6.4.3 Premature ventricular contractions: response to exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.6.4.4 Practical management of cardiac patients with premature ventricular contractions or non-sustained ventricular tachycardia who want to engage in sports . . . . . . . . 66
5.6.5 Long QT syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5.6.6 Brugada syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
5.6.7 Following device implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.6.7.1 Pacemakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.6.7.2 Implantable cardioverter defibrillators . . . . . . . . . . . . . . . 68
ESC Guidelines
19


<!-- PAGE 4 -->

### Page 4

.............................................................................................................................................................................
5.7 Exercise recommendations in individuals with adult congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.7.2 The increasing numbers of athletes with congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.7.3 Non-cardiac abnormalities in congenital heart disease and Paralympic sport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.7.4 General considerations in the congenital heart disease athlete . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.7.5 Sudden death during sport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.7.6 Exercise in athletes with congenital heart disease:
current guidelines and recommendations . . . . . . . . . . . . . . . . . . . . . . 70
5.7.7 Assessment of the athlete with congenital heart disease . . . 70
6 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
7 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
8 Sex differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
9 ‘What to do’ and ‘what not to do’ messages from the Guidelines . . . 75
10 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
11 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
12 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Table 3 Characteristics of exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Table 4 Indices of exercise intensity for endurance sports from maximal exercise testing and training zones . . . . . . . . . . . . . . . . . . . . . . . . . 30
Table 5 Cardiovascular risk categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Table 6 Potential risks for older people during exercise . . . . . . . . . . . . . 38
Table 7 Exercise prescription in the elderly . . . . . . . . . . . . . . . . . . . . . . . . . 38
Table 8 Exercise activities for older people according to exercise type and intensity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Table 9 Borderline or uninterpretable ECG findings . . . . . . . . . . . . . . . . . 39
Table 10 Factors determining risk of adverse events during intensive exercise and competitive sports in asymptomatic individuals with long-standing coronary artery disease . . . . . . . . . . . . . . . 40
Table 11 High-risk features for exercise-induced adverse cardiac events in patients with atherosclerotic coronary artery disease . . . . . . 40
Table 12 Optimal exercise training dose for patients with chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Table 13 Factors influencing decreased exercise capacity
(peak VO2) and reduced cardiac output in individuals with heart transplants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Table 14 Classification of risk to perform sports in patients with aortic pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Table 15 Findings during an invasive electrophysiological study
(with the use of isoprenaline) indicating an accessory pathway with increased risk of sudden death . . . . . . . . . . . . . . . . . . . . . . . . 48
Table 16 Baseline parameters for assessment in congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
List of figures
Figure Central illustration Moderate physical activity should be promoted in all individuals with cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . 24
Figure 1 Components for expression of physical fitness . . . . . . . . . . . . . 27
Figure 2 Sporting discipline in relation to the predominant component
(skill, power, mixed and endurance) and intensity of exercise. Intensity of exercise must be individualized after maximal exercise testing, field testing and/or after muscular strength testing . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Figure 3a and 3b SCORE charts for European populations of countries at HIGH and LOW cardiovascular disease risk . . . . . . . . . . . . 31
Figure 4 Proposed algorithm for cardiovascular assessment in asymptomatic individuals with risk factors for and possible subclinical chronic coronary syndrome before engaging in sports for individuals aged >35 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Figure 5 Clinical evaluation and recommendations for sports participation in individuals with established coronary artery disease . . . . 41
Figure 6 Schematic representation of the most frequent anomalous origin of coronary arteries and associated risk of sudden cardiac death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Figure 7 Schematic representation of a myocardial bridge . . . . . . . . . . . 44
Figure 8 Specific markers of increased risk of sudden cardiac death with mitral valve prolapse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Figure 9 Pre-participation assessment of individuals with congenital heart disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Tables of recommendations
General recommendations for exercise and sports in healthy individuals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Recommendations for cardiovascular evaluation and regular exercise in healthy individuals aged >35 years . . . . . . . . . . . . . . . . . . . . . . . 34
Special considerations for individuals with obesity, hypertension,
dyslipidaemia, or diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Recommendations for exercise in ageing individuals . . . . . . . . . . . . . . . . . 38
Recommendations for exercise in individuals at risk of atherosclerotic coronary artery disease and asymptomatic individuals in whom coronary artery disease is detected at screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Recommendations for exercise in individuals with long-standing chronic coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Recommendations for return to exercise after acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Recommendations for exercise in young individuals/athletes with anomalous origins of coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . 43
Recommendations for exercise/sports in individuals with myocardial bridging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Recommendations for exercise prescription in heart failure with reduced or mid-range ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 46
Recommendations for participation in sports in heart failure . . . . . . . . . 46
Recommendations for exercise and participation in sport in individuals with heart failure with preserved ejection fraction . . . . . . . . 47
Recommendations for exercise and participation in sport in heart transplant recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Recommendations for exercise and participation in recreational/
leisure-time sports in asymptomatic individuals with aortic stenosis . . . . 49
Recommendations for participation in competitive sports in asymptomatic individuals with aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . 49
Recommendations for participation in recreational/leisure-time sports in asymptomatic individuals with aortic regurgitation . . . . . . . . . 50
Recommendations for participation in competitive sports in asymptomatic individuals with aortic regurgitation . . . . . . . . . . . . . . . . . . 50


<!-- PAGE 5 -->

### Page 5

............................................................................................................................................................................
Recommendations for participation in recreational/leisure-time sports in asymptomatic individuals with mitral regurgitation . . . . . . . . . 51
Recommendations for participation in competitive sports in asymptomatic individuals with mitral regurgitation . . . . . . . . . . . . . . . . . . 51
Recommendations for participation in recreational/leisure-time sports in individuals with mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Recommendations for participation in competitive sports in asymptomatic individuals with mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . 53
Recommendations for exercise and participation in sports in individuals with aortic pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Recommendations for exercise and sports participation in individuals with hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . 57
Recommendations for exercise and sports participation in individuals with arrhythmogenic cardiomyopathy . . . . . . . . . . . . . . . . . . . 58
Recommendations for exercise in individuals with left ventricular non-compaction cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Recommendations for exercise in individuals with dilated cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Recommendations for exercise in individuals with myocarditis . . . . . . . 62
Recommendations for exercise and sports participation in individuals with pericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Recommendations for exercise in individuals with atrial fibrillation . . . 63
Recommendations for exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Recommendations for exercise in individuals with premature ventricular contractions or non-sustained ventricular tachycardia . . . . 66
Recommendations for exercise in long QT syndrome . . . . . . . . . . . . . . . 67
Recommendations for exercise in Brugada syndrome . . . . . . . . . . . . . . . 67
Recommendations for exercise in individuals with pacemakers and implantable cardioverter defibrillators . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Recommendations for exercise in individuals with congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Abbreviations and acronyms
ACE
Angiotensin-converting enzyme
ACHD
Adults with congenital heart disease
ACM
Arrhythmogenic cardiomyopathy
ACS
Acute coronary syndromes
AED
Automatic external deﬁbrillator
AHA
American Heart Association
AF
Atrial ﬁbrillation
AFL
Atrial ﬂutter
AMI
Acute myocardial infarction
AN-SUD
Autopsy-negative sudden unexplained death
AP
Accessory pathway
AOCA
Anomalous origin of coronary arteries
AR
Aortic valve regurgitation
ARVC
Arrhythmogenic right ventricular cardiomyopathy
AS
Aortic valve stenosis
ASI
Aortic size index
AVNRT
Atrioventricular nodal re-entrant tachycardia
AVRT
Atrioventricular re-entrant tachycardia
BAV
Bicuspid aortic valve
BMI
Body mass index
BP
Blood pressure
BrS
Brugada syndrome
CAC
Coronary artery calcium
CAD
Coronary artery disease
CCS
Chronic coronary syndrome
CCTA
Coronary computed tomography angiography
CHD
Congenital heart disease
CKD
Chronic kidney disease
CMD
Coronary microvascular dysfunction
CMR
Cardiac magnetic resonance
CPET
Cardiopulmonary exercise test
CPR
Cardiopulmonary resuscitation
CT
Computed tomography
CV
Cardiovascular
CVA
Cerebrovascular accident
CVD
Cardiovascular disease
DBP
Diastolic blood pressure
DCM
Dilated cardiomyopathy
EACPR
European Association for Cardiovascular Prevention and Rehabilitation
EAPC
European Association of Preventive Cardiology
ECV
Extracellular volume
ECG
Electrocardiogram
EDS
Ehlers Danlos syndrome
EF
Ejection fraction
EP
Electrophysiological
ESC
European Society of Cardiology
Ex-R
Exercise-related exCR
Exercise-based cardiac rehabilitation
FFR
Fractional ﬂow reserve
FITT
Frequency, intensity, time, and type
HCM
Hypertrophic cardiomyopathy
HDL
High-density lipoprotein
HF
Heart failure
HIIT
High-intensity interval training
HR
Heart rate
HFmrEF
Heart failure with mid-range ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HRmax
Maximal heart rate
HRR
Heart rate reserve
HTAD
Hereditary thoracic aortic disease
HTx
Heart transplant
ICD
Implantable cardioverter deﬁbrillator
IMT
Intimamedia thickness
INOCA
Ischaemic and non-obstructive coronary artery disease
LBBB
Left bundle branch block
LDL
Low-density lipoprotein
LEAD
Lower extremity artery disease
LGE
Late gadolinium enhancement
LV
Left ventricular
LVEDD
Left ventricular end-diastolic diameter
LVEF
Left ventricular ejection fraction
LVNC
Left ventricular non-compaction
LVOT
Left ventricular outﬂow tract
LQTS
Long QT syndrome
ESC Guidelines
21


<!-- PAGE 6 -->

### Page 6

...........................................................................................................................................................................
MACE
Major adverse cardiovascular events
MB
Myocardial bridge/bridging
MCE
Moderate continuous exercise
MET
Metabolic equivalent
MFS
Marfan syndrome
MI
Myocardial infarction
MR
Mitral regurgitation
MS
Mitral stenosis
MVA
Mitral valve area
MVP
Mitral valve prolapse
NSVT
Non-sustained ventricular tachycardia
NYHA
New York Heart Association
OAC
Oral anticoagulants
PA
Physical activity
PAD
Peripheral arterial disease
PAP
Pulmonary artery pressure
PCI
Percutaneous coronary intervention
PCSK-9
Proprotein convertase subtilisin/kexin type 9
PET
Positron emission tomography
PH
Pulmonary hypertension
PM
Pacemaker
PSVT
Paroxysmal supraventricular tachycardia
PVC
Premature ventricular contraction
PVI
Pulmonary vein isolation
RBBB
Right bundle branch block
RM
Repetition maximum
RPE
Rating of perceived exertion
RT-PCR
Reverse transcriptase polymerase chain reaction
RV
Right ventricular
RVOT
Right ventricular outﬂow tract
SBP
Systolic blood pressure
SCA
Sudden cardiac arrest
SCAD
Spontaneous coronary artery dissection
SCD
Sudden cardiac death
SCORE
Systematic Coronary Risk Evaluation sPAP
Systolic pulmonary artery pressure
SPECT
Single-photon emission computed tomography
TIA
Transient ischaemic attack
TR
Tricuspid regurgitation
T2DM
Type II diabetes mellitus
US
United States
VA
Ventricular arrhythmia
VAD
Ventricular assist device
VF
Ventricular ﬁbrillation
VT
Ventricular tachycardia
VO2
Oxygen consumption
VO2max
Maximum oxygen consumption
VO2peak
Peak oxygen consumption
WADA
World Anti-Doping Agency
WPW
Wolff-Parkinson-White
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-
Education/Clinical-Practice-Guidelines/Guidelines-development/Wri ting-ESC-Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded, in some of its guidelines, a set of quality indicators (QIs) which are tools to evaluate the level of implementation of the Guidelines and may be used by the ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the Guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/guidelines).
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC
and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the


<!-- PAGE 7 -->

### Page 7

..................................
experts involved in the Task Force. The finalized document is approved by the CPG for publication in the European Heart
Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions,
summary slides, booklets with essential messages, summary cards for non-specialists and an electronic version for digital applications
(smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the Guidelines, which is freely available via the ESC
website and hosted on the EHJ website. The National Cardiac
Societies of the ESC are encouraged to endorse, adopt, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic
Table 1
Classes of recommendations
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
©ESC 2020
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2020
ESC Guidelines
23


<!-- PAGE 8 -->

### Page 8

.............................................
or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
2. Introduction
Exercise recommendations and eligibility criteria for sports participation in competitive athletes with cardiovascular disease (CVD) were originally published by the Sports Cardiology Section of the
European Society of Cardiology (ESC) in 20051 and some aspects were subsequently updated in 2018 and 2019.2,3 The overarching aim of these recommendations was to minimize the risk of adverse events in highly trained athletes. It is important to recognize, however, that most of the exercising population engages in leisure sport and solo recreational exercise and, unlike elite athletes, these individuals have a higher prevalence of risk factors for atherosclerosis and established CVD.
Regular physical activity (PA), including systematic exercise, is an important component of therapy for most CVDs and is associated with reduced cardiovascular (CV) and all-cause mortality. In an era where there is an increasing trend towards a sedentary lifestyle and a rising prevalence of obesity and associated CVDs, the promotion of
PA and regular exercise is more crucial than ever and at the forefront of priorities for all scientific CV societies. Even during routine
©ESC 2020
Figure Central illustration Moderate physical activity should be promoted in all individuals with cardiovascular disease. Appropriate risk stratification and optimal therapy are essential for providing exercise prescription for more vigorous activity. Individuals should be involved in the decision making process and a record of the discussion and exercise plan should be documented in the medical records.


<!-- PAGE 9 -->

### Page 9

.............................................................................................................................................................................
consultations for other considerations, physicians are encouraged to promote exercise in all patients.
Although proportionately scarce, exercise may paradoxically trigger sudden cardiac arrest (SCA) in individuals with CVD, particularly those who were previously sedentary or have advanced CVD.4,5 In parallel with the drive to promote exercise in all individuals,6 it is anticipated that physicians will be confronted with an increasing number of enquiries from individuals with established risk factors for coronary artery disease (CAD) or established CVDs about participation in exercise programmes and recreational sports activities. Such consultations need to strike a balance between the multiple benefits of exercise, the small risk of sudden death, and the patient’s goals for cardiorespiratory fitness and ongoing participation in relatively strenuous exercise following a CV diagnosis.
The current Guidelines for exercise and sports participation in individuals with CVD are the first of a kind by the ESC. Sports cardiology is a relatively novel and emerging sub-speciality, therefore the evidence base for the natural history of disease progression or risk of death during intensive exercise and competitive sport among individuals with CVD is relatively sparse. This is reflected by the fact that a disproportionately large number of recommendations are reliant on the wisdom and vast experience of the consensus group rather than on large prospective studies. We acknowledge the inherent difficulties in formulating recommendations for all scenarios in a heterogeneous population with a diverse spectrum of CVDs in light of the limited availability of evidence. Therefore, these recommendations should not be considered as legally binding and should not discourage individual physicians from practising outside the remit of this document, based on their clinical experience in sports cardiology.
Where possible, the Guidelines have included the most up-to-date research in exercising individuals with CVD. The current Guidelines also draw upon existing ESC Guidelines for the investigation, risk assessment, and management of individuals with CVDs to aid physicians when prescribing exercise programmes or providing advice for sports participation. We hope that the document will serve as a useful clinical guide but also as an incentive for future research to challenge established wisdom.
In line with good clinical practice, the present document encourages shared decision making with the athlete patient and respects the autonomy of the individual after provision of detailed information about the impact of sports and the potential risks of complications and/or adverse events (Central illustration). Similarly, all exercise prescription and related discussions between the individual and the physician should be documented in the medical report.
3. Identification of cardiovascular disease and risk stratification in individuals participating in recreational and competitive sports
3.1 Introduction
Higher levels of PA and fitness are associated with lower all-cause mortality, lower rates of CVD, and lower prevalence of several known malignancies.716 Despite the substantial health benefits provided by regular PA, intense exercise may paradoxically act as a trigger for life-threatening ventricular arrhythmias (VAs) in the presence of underlying CVD. Indeed, sudden cardiac death (SCD) is the leading cause of sports and exercise-related mortality in athletes.1719 CV
safety during sports participation for individuals at all levels and ages is imperative to avoid catastrophic and often preventable SCD and has become a common goal among medical and sports governing organizations.2024
Pre-participation CV screening aimed at the detection of disorders associated with SCD is universally supported by major medical societies.2022,25,26 However, the best method for CV screening of young competitive athletes (<35 years old) remains controversial,
and limited data are available to guide recommendations in master athletes (>_35 years old)
Screening strategies must be tailored to the target population and the specific disorders with highest risk. SCD in young athletes is caused by a variety of structural and electrical disorders of the heart,
including cardiomyopathies, ion channel disorders, coronary anomalies, and acquired cardiac conditions.17,27,28 In adult and senior athletes, atherosclerotic CAD is the primary condition leading to major adverse cardiovascular events (MACE).28,29
3.2 Definitions of recreational and competitive athletes
The ESC defines an athlete as ‘an individual of young or adult age,
either amateur or professional, who is engaged in regular exercise training and participates in official sports competition’.1,30 Similarly,
the American Heart Association (AHA) and others define a competitive athlete as an individual involved in regular (usually intense) training in organized individual or team sports, with an emphasis on competition and performance.31,32 Athletes involved in competitive sports span the age spectrum and can compete at the youth, high school, academy, university, semi-professional, professional, national,
international, and Olympic levels. As a distinction, a recreational athlete engages in sports for pleasure and leisure-time activity, whereas a competitive athlete is highly trained with a greater emphasis on performance and winning. In a proposed classification of athletes based on the minimum volume of exercise, ‘elite’ athletes (i.e. national team, Olympians, and professional athletes) generally exercise >_10
h/week; ‘competitive’ athletes [i.e. high school, college, and older
(master) club level athletes] exercise >_6 h/week; and ‘recreational’
athletes exercise >_4 h/week.33 This distinction is somewhat arbitrary since some recreational athletes, such as long-distance cyclists and runners, engage in exercise at higher volumes than some professional athletes participating in skill sports.
3.3 Exercise-related major adverse cardiovascular events
Exercise-related MACE include SCA and SCD; acute coronary syndromes (ACS) such as myocardial ischaemia and myocardial infarction (MI); transient ischaemic attacks (TIA) and cerebrovascular accidents (CVA); and supraventricular tachyarrhythmias.
SCA is defined as an unexpected collapse due to a cardiac cause in which cardiopulmonary resuscitation (CPR) and/or defibrillation is provided in an individual regardless of the survival outcome.17,27,32
ESC Guidelines
25


<!-- PAGE 10 -->

### Page 10

.............................................................................................................................................................................
SCD is defined as a sudden unexpected death due to a cardiac cause,
or a sudden death in a structurally normal heart at autopsy with no other explanation for death and a history consistent with cardiacrelated death (i.e. requiring cardiac resuscitation).17,27,32 In order to compare previously reported data on SCA and SCD using variable definitions, the timing of the event should be categorized as occurring during the episode, within the first hour post-exercise, or between 1
to 24 h post-exercise.30 The activity at the time of the event can be further characterized as occurring during training or competition, at rest, or during sleep.30
Exercise-induced ACS are most likely to affect adult and senior athletes and result from atherosclerotic plaque disruption and coronary thrombosis in most cases.34,35 More than 50% of patients who experience acute MI (AMI) and SCA do not have pre-existing symptoms or a known history of CAD.36,37 In long-term endurance athletes, SCA and myocardial ischaemia can also occur from ‘demand’
ischaemia due to an imbalance between oxygen supply and demand resulting from stable calcified plaque and a fixed stenosis.38 In a study of United States (US) marathon and half-marathon races, none of the runners with SCA with serious (>80% coronary artery stenosis in a proximal left coronary artery or three-vessel disease) coronary atherosclerosis had angiographic evidence of acute plaque rupture or thrombus.38
3.4 Incidence of sudden cardiac death in athletes
Current estimates of the incidence of SCD in competitive athletes range from almost 1 in a million to 1 in 5000 athletes per year.17,39,40
Differences in current estimates are largely due to inconsistent study methodology and heterogeneous population comparisons.
Because reporting of SCD in athletes is not mandatory in most countries, studies risk underestimating the true incidence due to incomplete case ascertainment. For instance, studies using media reports as their main source to detect incidents of SCD identify only
5 - 56% of cases, even in high-profile competitive athletes.4144
Similarly, use of catastrophic insurance claims as the only method for case identification missed 83% of SCD cases and 92% of all SCA cases in Minnesota high school athletes.40,45
The athlete population being studied also needs to be precisely defined. Census population statistics, cross-sectional surveys, and self-reported athlete participation data all produce less reliable calculations. Other study details should also be considered. Does the study include all cases of SCA (survivors plus deaths) or only SCD?
Does the study include cases occurring at any time (i.e. during exercise, rest, or sleep), or only those that occur during sports? Studies indicate that 56 - 80% of SCA in young athletes occurs during exercise with the remainder non-exertional.17,18,46
Evidence supports that some athletes display a higher risk for SCA
based on sex, race, or sport.17,40,41,4550 Incidence rates are consistently higher in male athletes than in female athletes, with a relative risk ranging from 3: 1 to 9: 1 (male: female).17,45,4749,51,52 Black athletes of African Caribbean descent also have a higher risk than white athletes. In US college athletes, males had a higher risk than females
(1 in 38 000 vs. 1 in 122 000), and black athletes had a 3.2 times higher risk than white athletes (1 in 21 000 vs. 1 in 68 000).17 Male basketball players had the highest annual risk of SCD (1 in 9000), and male black basketball players had a risk of 1 in 5300.17 Based on available studies and a systematic review of the literature, a generally accepted annual incidence of all SCA is approximately 1 in 80 000 in high school-aged athletes and 1 in 50 000 in college-aged athletes.50 Male athletes,
black athletes, basketball (US) and soccer (Europe) athletes represent higher risk groups. Limited estimates are available for youth, professional, and master athletes.
3.5 Aetiology of sudden cardiac death during exercise
SCD in young athletes is usually caused by a genetic or congenital structural cardiac disorder.1719,42,53,54 However, autopsy-negative sudden unexplained death (AN-SUD), also referred to as sudden arrhythmic death syndrome, is reported on post-mortem examination in up to 44% of presumed SCD cases depending on the study population.17,28,42,5356 In apparently healthy young athletes the prevalence of cardiac disorders associated with SCD is approximately 0.3%, and this figure is supported by multiple studies using non-invasive evaluation tools to detect cardiac disorders at elevated risk of SCD.20,5765
In athletes >35 years of age, more than 80% of all SCD is due to atherosclerotic CAD, and vigorous physical exertion is associated with an increased risk of AMI and SCD.34,6670 The athletes at greatest risk are those with little or no background in systematic training.
3.6 Screening modalities for cardiovascular disease in young athletes
Most experts believe that early detection of potentially lethal disorders in athletes can decrease CV morbidity and mortality through risk stratification, disease-specific interventions, and/or exercise modifications.22,57,58,71 CV screening by history and physical examination or by electrocardiogram (ECG) presents unique challenges and limitations. Several studies have documented the low sensitivity and high positive response rate of pre-participation history questionnaires.64,65,7275 In CV screening studies in which experienced clinicians use contemporary ECG interpretation standards, ECG
screening outperforms history and physical examination in all statistical measures of performance.58,59,62,64,65,74,76
While echocardiography may identify additional structural disorders, there is insufficient evidence to recommend an echocardiogram for routine screening.77
3.7 Screening for cardiovascular disease in older athletes
The recommendations and evidence base for CV screening in athletes >35 years of age are limited. CV screening in adult and senior athletes must target the higher prevalence of atherosclerotic CAD.
However, routine screening for ischaemia with exercise testing in asymptomatic adults has a low positive predictive value and a high number of false-positive tests and is not recommended.7880
A screening ECG may still discover undiagnosed cardiomyopathies and primary electrical disorders in older athletes, and risk factor assessment for CVD may identify higher risk individuals who warrant additional testing. Thus, consistent with a 2017 ESC position paper on pre-participation CV screening, exercise ECG testing should be reserved for symptomatic athletes or those deemed at high risk of


<!-- PAGE 11 -->

### Page 11

.................................................................................................
CAD based on the ESC Systematic Coronary Risk Evaluation
(SCORE) system (see chapters 4 and 5).6,81
Exercise testing may also be useful to evaluate the blood pressure
(BP) response to exercise, the occurrence of exercise-induced arrhythmias, and to assess symptoms or physical performance and its relation to exercise training.81 In adult and elderly individuals, especially those naı¨ve to moderate to vigorous PA, exercise testing or cardiopulmonary exercise testing (CPET) is a useful means to assess overall CV health and performance, allowing individualized recommendations regarding sports and exercise type and intensity, as will be discussed in subsequent sections.82
4. Physical activity, leisure exercise, and competitive sports participation
4.1 General introduction
Recommendations for prescription of exercise require a basic knowledge of physiological responses to exercise, along with an understanding of concepts and characteristics of
PA,
exercise interventions,
and their implications for sports participation.
Although exercise and PA are often used interchangeably, it is important to recognize that these terms differ. PA is defined as any bodily movement produced by the skeletal muscle that results in energy expenditure. Exercise or exercise training, on the other hand, by definition, is PA that is structured, repetitive, and purposeful to improve or maintain one or more components of physical fitness.83
Physical fitness may be expressed by five major components
(Figure 1):83 a morphological component (body mass relative to height, body composition, subcutaneous fat distribution, abdominal visceral fat, bone density, and flexibility);84 a muscular component
(power or explosive strength, isometric strength, muscular endurance);85 a motor component (agility, balance, coordination, speed of movement);85 a cardiorespiratory component (endurance or submaximal exercise capacity, maximal aerobic power, heart function,
lung function, BP); and a metabolic component (glucose tolerance,
insulin sensitivity, lipid and lipoprotein metabolism, substrate oxidation characteristics).86
4.1.1 Definition and characteristics of exercise interventions
The basic tenets of exercise prescription have been described using the ‘FITT’ concept (frequency, intensity, time, and type). The mode of exercise (Table 3) is also an important characteristic. The following sections will describe each of these components related to aerobic exercise followed by components of strength exercise.
4.1.1.1 Type of exercise
Traditionally, different forms of exercise are classified in binary terms as endurance or resistance (strength) exercise. However, this classification is somewhat oversimplified. Further classifications of exercise are metabolically related (aerobic vs. anaerobic exercise) or those related to the type of muscle contraction: isotonic [contraction against resistance in which the length of the muscle shortens (concentric) or lengthens (eccentric)] and isometric (static or without change in length of the muscle).
Aerobic exercise refers to activity performed at an intensity that allows metabolism of stored energy to occur mainly through aerobic glycolysis. Besides the glycolytic pathway, fat metabolism (b-oxidation)
is also involved during aerobic exercise. Aerobic exercise involves large muscle groups performing dynamic activities, resulting in
©ESC 2020
Figure 1 Components for expression of physical fitness.
ESC Guidelines
27


<!-- PAGE 12 -->

### Page 12

........................................................................................................................................................................
substantial increases in heart rate and energy expenditure. Examples of aerobic exercise include cycling, running, and swimming performed at low to moderate intensity.84 In contrast, anaerobic exercise refers to movement performed at high intensity unsustainable by oxygen delivery alone and requiring metabolism of stored energy to be processed largely by anaerobic glycolysis. A sustained isometric muscle action that is not working maximally but does not necessarily depend entirely upon oxygen during the muscle contraction is an example of anaerobic exercise. Another example of anaerobic exercise is intermittent high-intensity exercise.85
4.1.1.2 Exercise frequency
Exercise frequency is usually expressed as the number of times an individual engages in exercise per week. Guidelines suggest that moderate exercise should be performed most days of the week, amounting to a minimum of 150 min/week.
4.1.1.3 Exercise intensity
Of all the basic elements of exercise prescription, exercise intensity is generally considered to be the most critical for achieving aerobic fitness and to have the most favourable impact on risk factors.86,87
Absolute intensity refers to the rate of energy expenditure during exercise and is usually expressed in kcal/min or metabolic equivalents
(METs).84,88 Relative exercise intensity refers to a fraction of an individual’s maximal power (load) that is maintained during exercise and is usually prescribed as a percentage of maximal aerobic capacity
(VO2max) on the basis of a CPET.88 Training intensity can also be expressed as a percentage of maximal heart rate (HRmax) recorded during an exercise test89 or predicted on the basis of the equation
[HRmax = 220 - age].90 The use of prediction equations for HRmax is not recommended, because there is a large standard deviation around the regression line between age and HRmax.91 Alternatively,
exercise intensity can be expressed relative to a percentage of a person’s HR reserve (HRR), which uses a percentage of the difference between HRmax and resting HR and adds it to the resting HR
(Karvonen formula).92 There are caveats to the use of HR for prescribing and evaluating exercise intensity in persons using beta-blockers.93 Ideally, the HR derived for training should only be used if functional capacity was determined (an exercise test was performed)
while taking the medication. Intensity is also commonly monitored using the rate of perceived exertion scale (e.g. 12- 14 on the Borg
6- 20 scale) or ‘talk test’, e.g. ‘to be able to talk while exercising’.91,94
General zones for various exercise intensities are shown in Table 4.
4.1.1.4 Training volume
Exercise intensity is inversely related to exercise time. Their product (in kcal or kJ) defines the volume of each training unit, which in turn multiplied by frequency provides an estimate of the energy expenditure of the training bout or session. The frequency of training sessions and the duration of the training period provide total energy expenditure of a training programme. Meeting the minimal activity guidelines equates to approximately 1000 kcal/
week or about 10 MET/h/week (the product of MET level and duration in hours per week). Training volume should increase weekly either by 2.5% in intensity95 or 2 mins’ duration,95 although the rate of progression should be individualized according to the biological adaptation of the individual. Training adaptation is also influenced by age, genetics,96 fitness, and environmental factors,
such as hydration, heat, cold, and altitude.97
4.1.1.5 Type of training
Aerobic training. Aerobic exercise training can either be continuous or interval based. There is a plethora of evidence and many guidelines on continuous aerobic exercise, but there is also strong evidence emerging about the benefits of interval-type training. The interval design involves the completion of short bouts of exercise at high intensities, interspersed with recovery periods. When compared with continuous training, this approach provides a greater challenge to the cardiopulmonary, peripheral, and metabolic systems and results in a more efficient training effect.98 Interval training has been reported to be motivating, since the traditional continuous training can often be tedious. Interval training should be employed only in stable cardiac patients because it places a higher stress on the CV system.99 Since intermittent training exposes subjects to near maximal effort, rest intervals of appropriate duration, preferably active ones,
are recommended.100 The exercise to rest ratio varies.101 There are a number of different approaches used, which should be individualized according to fitness and comorbidities.
Table 3
Characteristics of exercise
©ESC 2020
HR = heart rate; HRR = heart rate reserve; RM = repetition maximum; VO2 =
oxygen consumption; VO2peak = peak oxygen consumption.


<!-- PAGE 13 -->

### Page 13

...........................................................................................
Resistance training. Exercise intensity: The intensity of resistance exercise is typically prescribed in terms of one repetition maximum
(1 RM). One RM is defined as the maximum amount of weight a person can lift throughout a range of motion with one repetition. Even though the performance of 1 RM appears to be a safe approach for evaluating strength102 and no significant CV events have been reported using this approach,103 for convenience and compliance reasons the use of multiple (usually five) repetitions (5 RM) is suggested. Five RM is the maximum amount of weight that can be performed five times. It has been reported that 1 RM can be accurately estimated from multiple repetitions and that 5 RM is an appropriate reflection of maximal strength.104
Exercise training zones: Resistance training using less than 20% 1 RM is generally considered aerobic endurance training. With more than
20% 1 RM, the muscular capillaries become compressed during muscle contraction resulting in a hypoxic stimulus responsible for training effects. The number of repetitions should be inversely related to the training intensity. A moderate training intensity of 3050% 1
RM with 1530 repetitions is considered muscular endurance training. Higher training intensities of 5070% 1 RM with 815 repetitions are optimal for strength gains.
Training volume: Optimal strength gains occur when resistance training is performed 23 times per week. Approaches to resistance training often follow either a station or a circuit approach. In the former approach, individuals typically complete all of the sets for a given exercise per muscle group before moving to another exercise and muscle group. In the latter approach, individuals typically perform one set of a given muscle group and then rotate to another exercise and muscle group until the full set of exercises in completed per muscle group. One to three sets of 815
repetitions should be performed including flexion and extension of each muscle group. Multiple sets are superior to a single set.105
A variety of 810 resistance exercises should be prescribed to cover most of the muscular groups.88 Muscular power is best maintained when 35 min rest intervals are used instead of short rest intervals (<1 min).106
Mode of training: Resistance training can either be isometric (i.e.
unchanged muscle length without joint movement) or dynamic (contraction with change in length of the muscle and movement of the joint throughout a range of motion). Isometric (static) muscle actions may induce a Valsalva manoeuvre at moderate to high loads, if it is not intentionally prevented by regular breathing, and may lead to an unnecessary fluctuation of BP. Dynamic training may include constant or variable resistance through the range of motion using either free weights or weight machines. In both of these modes, the type of contraction and the velocity of movement vary throughout the range of motion. This type of muscle activity mirrors muscle loading faced in daily activity. Muscles can contract in a concentric fashion, in which muscle shortening is exhibited during the movement, or eccentric fashion, in which a lengthening of the muscle occurs. Resistance training is an advanced application in which participants carry out a series of rapid concentric and eccentric muscle actions often at a relatively high load.
4.1.2 Classification of exercise and sports
A precise classification of sports by using the different components of
FITT is difficult because of the differences in the type of muscular work, the mode, and the volume and intensity of exercise. Moreover,
most sports consist of an isotonic and isometric muscular
Figure 2 Sporting discipline in relation to the predominant component (skill, power, mixed, and endurance) and intensity of exercise. Intensity of exercise must be individualized after maximal exercise testing, field testing and/or after muscular strength testing (Table 2).
ESC Guidelines
29


<!-- PAGE 14 -->

### Page 14

.................................................................................................................
component. For example, resistance activities can be performed in a predominantly dynamic manner or a predominantly static manner.
Some sports require a high motor control component and level of skill, whereas other sports are performed at a low, moderate, high,
or very high intensity. These intensities can vary depending upon the type of sport or the professional, amateur, or recreational level of performing the sports.
When providing advice regarding an exercise programme or sports participation, the physician should indicate: (i) the type of sport; (ii) frequency and duration of the exercise programme; and (iii)
the intensity that appears most appropriate to the individual.
(1)
Regarding the choice of the most convenient sport, the physician may indicate the type of sport as illustrated in Figure 2 (skill, power,
mixed, or endurance), with specification of the frequency, duration,
and intensity of muscular work to be preferentially maintained during the exercise programme.
(2)
In order to adequately prescribe the individual intensity of an endurance or mixed type of exercise or sports, the individual should perform a maximal exercise test with 12-lead ECG recording or preferentially, if possible, with simultaneous measurement of respiratory gas exchange (CPET).
Knowing a person’s maximal exercise capacity allows the health professional to determine a personally tailored exercise programme that is safe and most likely to be effective. The exercise test permits the formulation of the appropriate exercise prescription based on well-recognized indices including heart rate reserve (HRR = HRmax -
HRrest), VO2 reserve, the ventilatory threshold, or percentage of work rate for a given individual.
The exercise test also permits an assessment of any abnormal CV
responses that might not otherwise be apparent during usual daily activities (including symptoms, ECG abnormalities, arrhythmias, or abnormal BP response). Based on the exercise testing results, the physician may indicate the intensity, mode, and duration of exercise that appears most suitable to the individual patient (see Table 4).
For power sports or resistance training, additionally maximal muscular testing is warranted in order to determine 1 RM or 5 RM.
Percentage of these values, number of repetitions, and number of series will enable determination of the CV and muscular demand.
Additionally, field tests will facilitate appropriate prescriptions, mainly for team sports.
When prescribing power sports for individuals with CVD, one should also consider the type of muscular work: isometric (static) or isotonic (dynamic) strength exercises. Additionally, the type and amount of exercise training, when preparing for a sport, is very important. The amount of exercise work should be adapted gradually according to the subject’s actual exercise tolerance and to the anticipated level of performance.
4.2 Exercise recommendations in individuals with cardiovascular risk factors
4.2.1 General introduction
Exercise has a positive effect on several risk factors for atherosclerosis.6 Regular exercise reduces the risk of many adverse health outcomes irrespective of age, sex, ethnicity, or the presence of comorbidities. Indeed, there is a doseeffect relationship between exercise and CV and all-cause mortality, with a 2030% reduction in adverse events compared with sedentary individuals.107,108
Consequently, European Guidelines recommend that healthy adults of all ages should perform a minimum of 150 min of moderateintensity endurance exercise training over 5 days or 75 min of vigorous exercise per week over 3 days, with additional benefit derived by doubling the amount to 300 min of moderate-intensity or 150 min of vigorous-intensity aerobic PA per week.6
While exercise is also beneficial in patients with established CVD,
the risk associated with vigorous exercise and sports in these individuals is increased. Importantly, CVD may be subclinical and unrecognized; therefore, consideration should be given to pre-participation assessment of risk in individuals with a higher likelihood of CVD.
Individuals with multiple risk factors are more likely to develop CVD.
Assessment of the individual likelihood of subclinical CVD may be performed by calculating the accumulated risk through established risk scores such as the SCORE risk charts (Figure 3) and considering
Table 4
Indices of exercise intensity for endurance sports from maximal exercise testing and training zones
©ESC 2020
HRmax = maximum heart rate; HRR = heart rate reserve; RPE = rate of perceived exertion; VO2max = maximum oxygen consumption.
aAdapted from refs 84,85 using training zones related to aerobic and anaerobic thresholds. Low-intensity exercise is below the aerobic threshold; moderate is above the aerobic threshold but not reaching the anaerobic zone; high intensity is close to the anaerobic zone; and very intense exercise is above the anaerobic threshold. The duration of exercise will also largely inﬂuence this division in intensity.


<!-- PAGE 15 -->

### Page 15

180
160
140
120
WOMEN
SCORE Cardiovascular Risk Chart
10-year risk of fatal CVD
High-risk regions of Europe
MEN
Total cholesterol (mmol/L) 
Age
70
65
60
55
50
Non-smoker
Smoker
15
8
9
7
7
8
9
40
4
<3%
5
6
7
4
5
6
7
Systolic blood pressure (mmHg) 
12
13
14
10
11
12
13
10
10
21
12
13
10
10
11
12
17
19
20
14
15
16
18
14
15
180
160
140
120
9
4
4
3
3
4
4
7
8
8
5
6
6
7
5
5
15
7
7
5
5
6
7
11
12
13
9
9
10
11
8
9
180
160
140
120
5
2
2
1
1
2
2
4
4
5
3
3
3
4
2
3
10
4
4
3
3
3
3
7
8
9
5
6
6
7
4
5
180
160
140
120
3
1
1
1
1
1
1
2
2
3
1
2
2
2
1
1
7
2
2
1
1
2
2
5
5
6
3
3
4
4
2
3
180
160
140
120
2
0
0
0
0
0
0
1
1
2
1
1
1
1
1
1
4
1
1
1
1
1
1
3
3
4
2
2
2
3
1
2
180
160
140
120
1
0
0
3–4%
5–9%
≥10%
0
0
0
0
0
0
1
0
0
0
0
0
0
2
0
0
0
0
0
1
1
2
1
1
1
1
0
1
Non-smoker
Smoker
33
16
18
13
15
17
20
4
5
6
7
4
5
6
7
24
26
30
20
22
25
28
21
24
45
23
26
19
22
25
28
33
36
40
27
31
34
39
29
33
23
9
11
7
8
10
11
15
17
20
12
14
16
18
12
14
34
14
16
11
13
15
17
23
26
30
18
21
24
27
19
22
15
5
6
4
4
5
6
10
11
13
7
8
10
11
7
8
25
9
10
6
7
9
10
16
19
22
12
14
16
19
12
14
10
3
3
2
2
3
3
6
7
9
4
5
6
7
4
5
18
5
6
4
4
5
6
11
13
16
8
9
11
13
7
9
7
2
2
1
1
1
2
4
5
6
2
3
3
4
2
3
13
3
4
2
2
3
4
8
9
11
5
6
7
9
5
6
3
0
1
0
0
0
1
2
2
2
1
1
1
2
1
1
7
1
1
1
1
1
4
4
5
2
2
3
4
2
2
0
1
©ESC 2020
Figure 3a SCORE charts for European populations at high cardiovascular disease (CVD) risk109. The 10-year risk of fatal CVD in populations at high CVD risk is based on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of total (fatal þ nonfatal) CVD, multiply by 3 in men and 4 in women, and slightly less in older people. Note: the SCORE chart is for use in people without overt CVD, diabetes (type 1 and
2), chronic kidney disease, familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high risk and need intensive risk factor advice. Cholesterol: 1 mmol/L ¼ 38.67 mg/dL. The SCORE risk charts presented above differ slightly from those in the 2016 ESC/EAS Guidelines for the management of dyslipidaemias and the 2016 European Guidelines on cardiovascular disease prevention in clinical practice, in that: (i) age has been extended from
65 to 70 years; (ii) the interaction between age and each of the other risk factors has been incorporated, thus reducing the overestimation of risk in older persons in the original SCORE charts; (iii) the cholesterol band of 8 mmol/L has been removed since such persons will qualify for further evaluation in any event.
SCORE = Systematic Coronary Risk Evaluation.
ESC Guidelines
31


<!-- PAGE 16 -->

### Page 16

180
160
140
120
WOMEN
SCORE Cardiovascular Risk Chart
10-year risk of fatal CVD
Low-risk regions of Europe
MEN
Total cholesterol (mmol/L) 
Age
70
65
60
55
50
Non-smoker
Smoker
9
5
5
4
4
5
5
40
4
<3%
5
6
7
4
5
6
7
Systolic blood pressure (mmHg) 
7
8
8
6
6
7
7
6
6
13
7
8
6
6
7
7
11
11
12
9
9
10
11
8
9
180
160
140
120
5
2
3
2
2
2
2
4
4
5
3
3
4
4
3
3
9
4
4
3
3
3
4
7
7
8
5
6
6
7
5
5
180
160
140
120
3
1
1
1
1
1
1
2
3
3
2
2
2
2
1
2
6
2
2
2
2
2
2
4
5
5
3
3
4
4
3
3
180
160
140
120
2
1
1
0
0
0
1
1
1
2
1
1
1
1
1
1
4
1
1
1
1
1
1
3
3
3
2
2
2
3
1
2
180
160
140
120
1
0
0
0
0
0
0
1
1
1
0
0
1
1
0
0
3
1
1
0
0
0
1
2
2
2
1
1
1
2
1
1
180
160
140
120
0
0
0
3–4%
5–9%
≥10%
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
1
1
0
0
0
1
0
0
Non-smoker
Smoker
17
8
9
7
8
9
10
4
5
6
7
4
5
6
7
12
14
15
10
11
13
14
10
12
24
12
13
10
11
12
14
18
20
22
15
16
18
20
15
17
12
5
5
3
4
5
5
8
9
10
6
7
8
9
6
7
18
7
8
5
6
7
8
12
14
16
9
11
12
14
9
11
8
3
3
2
2
2
3
5
6
7
4
4
5
5
3
4
13
4
5
3
4
4
5
8
10
11
6
7
8
9
6
7
5
1
2
1
1
1
2
3
4
4
2
2
3
3
2
2
9
3
3
2
2
2
3
6
7
8
4
4
5
6
3
4
3
1
1
0
1
1
1
2
2
3
1
1
2
2
1
1
6
1
2
1
1
1
2
4
5
5
2
3
3
4
2
3
1
0
0
0
0
0
0
1
1
1
0
0
1
1
0
0
3
1
1
0
0
0
2
2
3
1
1
1
2
1
1
0
1
©ESC 2020
Figure 3b SCORE chart for European populations at low cardiovascular disease (CVD) risk. The 10-year risk of fatal CVD in populations at low CVD
risk is based on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of total (fatal þ non-fatal) CVD, multiply by 3 in men and 4 in women, and slightly less in older people. Note: the SCORE chart is for use in people without overt CVD, diabetes (type 1 and 2), chronic kidney disease, familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high risk and need intensive risk factor advice. Cholesterol: 1 mmol/L = 38.67 mg/dL. The SCORE risk charts presented above differ slightly from those in the 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias and 2016 European Guidelines on cardiovascular disease prevention in clinical practice, in that: (i) age has been extended from 65 to 70 years; (ii) the interaction between age and each of the other risk factors has been incorporated, thus reducing the overestimation of risk in older persons in the original SCORE charts; (iii) the cholesterol band of 8 mmol/L has been removed since such persons will qualify for further evaluation in any event. SCORE = Systematic Coronary Risk Evaluation.


<!-- PAGE 17 -->

### Page 17

.......................................................................................
individual risk factors such as very high total cholesterol and lowdensity lipoprotein (LDL), diabetes mellitus, or a strong family history of CVD.6 Based on this assessment the individual CV risk can be categorized from low to very high risk (Table 5).
Preliminary evaluation should consist of a self-assessment relating to symptoms and calculation of SCORE. Individuals who are habitually active and at low or moderate risk should not have any restrictions for exercise including competitive sports. Sedentary individuals and individuals at high or very high risk may engage in low-intensity exercise without further evaluation. Sedentary individuals and/or those at high or very high risk planning to undertake high-intensity exercise as well as selected individuals planning to undertake moderate-intensity exercise should undergo a physical examination,
12-lead ECG, and exercise stress test. The aim of the exercise test is to identify prognostically important CAD and to assess the presence of exercise-induced arrhythmias. Individuals with symptoms, abnormal findings on physical examination, abnormal ECG, or abnormal exercise test should be investigated further according to current ESC
Guidelines for chronic coronary syndromes.110 Following normal investigations, there should be no restrictions to sports participation.
All individuals should, however, be thoroughly informed that development of symptoms during exercise should prompt reassessment.
While a normal exercise test and a high exercise capacity is associated with a good prognosis, the test has limited sensitivity in diagnosing mild to moderate obstructive CAD.111,112 Currently there is no evidence for incorporating routine cardiac imaging in preparticipation screening among asymptomatic individuals aged >35
years old with a normal exercise stress test. However, in asymptomatic adults considered to be at high risk or very high risk (diabetes,
strong family history of CAD, previous risk assessment suggesting high risk for CAD) a functional imaging test or coronary computed tomography angiography (CCTA) should be considered in the risk assessment (Figure 4).110 Identification of atherosclerotic CAD should prompt aggressive management of risk factors and preventive medical treatment. Among individuals with proven obstructive CAD, further assessment and treatment is indicated.
Table 5
Cardiovascular risk categories
©ESC 2020
General recommendations for exercise and sports in healthy individuals
Recommendations
Classa
Levelb
At least 150 min/week of moderate-intensity, or
75 min/week of vigorous-intensity aerobic exercise, or an equivalent combination thereof is recommended in all healthy adults.113118
I
A
A gradual increase in aerobic exercise to 300
min/week of moderate-intensity, or 150 min/
week of vigorous-intensity aerobic exercise, or an equivalent combination is recommended for additional beneﬁts in healthy adults.114,116
I
A
Regular assessment and counselling to promote adherence and, if necessary, to support an increase in exercise volume over time are recommended.119
I
B
Multiple sessions of exercise spread throughout the week, i.e. on 45 days a week and preferably every day of the week, are recommended.113,114
I
B
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
33


<!-- PAGE 18 -->

### Page 18

..........................................................................................
4.2.2 Obesity
A person with a body mass index (BMI) >30 kg/m2 or (preferentially)
a waist circumference >94 cm for males and >80 cm for females
(both for European Caucasians) is considered obese.120,121
European guidelines for obese individuals recommend that a minimum of 150 min/week of moderate-intensity endurance exercise training should be combined with three weekly sessions of resistance exercise.121 Such intervention leads to a reduction in intra-abdominal fat mass, increments in muscle and bone mass, attenuation in the weight loss-induced decline of resting energy expenditure, reduction in BP and chronic inflammation, and improvement in glucose tolerance, insulin sensitivity, lipid profile, and physical fitness.121,122 There is also a positive influence on the long-term maintenance of weight reduction, general well-being and self-esteem, and reduction in anxiety and depression.121 The impact of exercise intervention alone on fat mass is modest.123 According to a series of large randomized controlled trials a high endurance-type exercise volume, >225 min/week,
is required to maximize fat mass loss in obese individuals.124
A pre-participation CV assessment is warranted in obese individuals who intend to engage in high-intensity exercise (Figure 4),
due to associated comorbidities such as type 2 diabetes, hypertension, dyslipidaemia, and CV and respiratory diseases.121 Obese individuals with a normal CV assessment should not have any restrictions on exercise. There is evidence from healthy, nonobese and non-athletic individuals that running, and abrupt increases in training volume, contribute to musculoskeletal injuries.125127 Therefore, it may be reasonable to consider that obese individuals should limit high-volume weight-bearing exercises on a hard surface (i.e. <2 h/day) until a considerable
Recommendations for cardiovascular evaluation and regular exercise in healthy individuals aged >35 years
Recommendations
Classa
Levelb
Among individuals with low to moderate CVD
risk, the participation in all recreational sports should be considered without further CV
evaluation.
IIa
C
Cardiac screening with family history, symptoms,
physical examination, and 12-lead resting ECG
should be considered for competitive athletes.
IIa
C
Clinical evaluation, including maximal exercise testing, should be considered for prognostic purposes in sedentary people and individuals with high or very high CV risk who intend to engage in intensive exercise programmes or competitive sports.
IIa
C
In selected individuals without known CAD who have very high CVD risk (e.g. SCORE>10%, strong family history, or familial hypercholesterolaemia)
and want to engage in high- or very high-intensity exercise, risk assessment with a functional imaging test, coronary CCTA, or carotid or femoral artery ultrasound imaging may be considered.
IIb
B
CCTA = coronary computed tomography angiography; CV = cardiovascular;
CVD = cardiovascular disease; SCORE = Systematic Coronary Risk Evaluation.
aClass of recommendation.
bLevel of evidence.
©ESC 2020
Figure 4 Proposed algorithm for cardiovascular assessment in asymptomatic individuals aged >35-years-old with risk factors for cardiovascular disease and possible subclinical chronic coronary syndrome before engaging in sports. *Consider functional test or CCTA if exercise stress test is equivocal or the ECG is uninterpretable. aSee text for examples of functional imaging. bSingle-photon emission computed tomography: area of ischaemia >_10% of the left ventricular myocardium; stress echocardiography: >_3 of 16 segments with stress-induced hypokinesia or akinesia; stress cardiovascular magnetic resonance: >_2 of 16 segments with stress perfusion defects or >_3 dobutamine-induced dysfunctional segments; coronary computed tomography angiography (CCTA): three-vessel disease with proximal stenoses; left main disease; proximal left anterior descending disease.110 CVD = cardiovascular disease; ECG = electrocardiogram;
SCORE = Systematic Coronary Risk Evaluation.


<!-- PAGE 19 -->

### Page 19

..............................................................................................................................................................
reduction in body weight is achieved. Moreover, if high-volume exercise (>2 h/day) is desired, a sufficient recovery time should be allowed for between periods of exercise (optimally 48 h). It is important to emphasize that good physical and muscular fitness and neuromuscular coordination may protect obese individuals from musculoskeletal injuries, hence non-weight-bearing exercises such as cycling or swimming128 may be beneficial. Finally,
there is no compelling evidence that resistance training, when executed properly, will increase the risk for musculoskeletal injuries or provoke musculoskeletal symptoms in obese individuals.129
4.2.3 Hypertension
A person with a persistent systolic BP (SBP) >_140 mmHg and/or diastolic BP (DBP) >_90 mmHg is considered hypertensive.130,131
Hypertensive individuals should participate in at least 30 min of moderate-intense dynamic aerobic exercise (walking, jogging, cycling,
or swimming) for 57 days per week.132 Such exercise intervention is associated with a mean reduction in SBP of 7 mmHg and DBP of 5
mmHg.133 Additional resistance training is highly effective in reducing
BP further and resistance training 23 days per week is also advised.132 Indeed, the BP-lowering effect of resistance and isometric exercise may be comparable to, or even greater than, that of aerobic exercise.134
If high-intensity sports participation is desired, a pre-participation
CV assessment is warranted to identify athletes with exerciseinduced symptoms, excessive BP response to exercise130, and the presence of end organ damage. Individuals with symptoms suggestive of CAD require further assessment and optimization of medical therapy before participation in sports. If arterial hypertension is poorly controlled (resting SBP > 160 mmHg), a maximal exercise test should be postponed until the BP is controlled.
Non-pharmacological measures should be considered as the first step in the management of hypertension in athletes, including: restriction of salt intake and alcohol consumption, weight reduction if applicable, balanced diet (e.g. Mediterranean diet),
and cessation of smoking. Aerobic exercise programmes should herein complement the individual’s training schedule.131 If such lifestyle changes do not lower BP after 3 months, antihypertensive drugs should be commenced if SBP remains >140 mmHg.
Antihypertensive therapy alongside lifestyle intervention should be considered in all individuals aged >65 years but <80 years,
provided it is well tolerated.131,132 It is important to consider that beta-blockers are prohibited in certain competitive skill sports such as shooting [see World Anti-Doping Association
(WADA) for complete list135], and can induce bradycardia and/
or lower aerobic exercise capacity.131 Diuretics are prohibited in all competitive sports.135Angiotensin-converting enzyme (ACE)
inhibitors, angiotensin II receptor blockers, and calcium antagonists are the preferred drugs of choice in exercising individuals. It is noteworthy that the use of non-selective non-steroidal inflammatory drugs for musculoskeletal pain may contribute to raised BP.136
When BP is uncontrolled, temporary restriction from competitive sports is recommended, with the possible exception of skill sports.131
In individuals with a high-risk profile, including those with end organ damage [left ventricular (LV) hypertrophy, diastolic dysfunction,
ultrasound evidence of arterial wall thickening or atherosclerotic plaque, hypertensive retinopathy, increased serum creatinine (men
1.31.5 mg/dL, women 1.21.4 mg/dL), and/or microalbuminuria]
in whom BP is controlled, participation in all competitive sports is possible, with the exception of the most intensive power disciplines such as discus/javelin throwing, shot-putting, and weightlifting (see section 4.1).131
During sports participation, regular follow-up is recommended depending on the severity of hypertension and the category of risk. In individuals with borderline BP readings, regular ambulatory assessment of BP should be considered. In individuals with low or moderate
CV risk and well-controlled BP, there should be no restrictions to sports participation, however, intensive heavy weightlifting, especially when this includes substantial isometric (static) muscle work, can have a marked pressor effect and should be avoided. In this context, avoiding the Valsalva manoeuvre in particular is warranted because breath holding during muscular contraction is associated with a greater elevation in SBP and DBP.135 When executed correctly, high-intense dynamic resistance training (up to 80% of 1 RM),
with a low number of repetitions (n < 10) does not induce greater increments in BP compared with low-intense dynamic resistance training (<50% of 1 RM) with a high number of repetitions (n >_
20).137142
Some individuals who are normotensive at rest will have an exaggerated BP response to exercise. An exaggerated BP response to exercise increases the risk for incident hypertension in highly trained and normotensive athletes over a middle-term period.143 If SBP rises to >200 mmHg at a workload of 100 W during exercise testing,144
antihypertensive medical therapy should be optimized and clinical evaluation, including ECG and echocardiography, should be considered, even if the athlete is normotensive at rest.131 Moreover, in young Olympic athletes a peak SBP of >220 mmHg in males and
>200 mmHg in females measured during cycle ergometry are beyond the 95th percentile.131
4.2.4 Dyslipidaemia
Physical activity has favourable effects on lipid metabolism by reducing serum triglycerides by up to 50% and increasing high-density lipoprotein (HDL) cholesterol by 510%.85,145 Exercise may also reduce LDL cholesterol by up to 5% and shift the more atherogenic small, dense LDL fraction towards larger LDL particles in a dosedependent fashion.146 These metabolic improvements can be achieved through 3.5 - 7 h of moderately vigorous PA per week or
30 - 60 min of exercise on most days.
In individuals with hypertriglyceridaemia or hypercholesterolaemia, a higher intensity of exercise is recommended, as this may
ESC Guidelines
35


<!-- PAGE 20 -->

### Page 20

................................................................................................................................................................
improve the lipid profile and reduce CV risk. Before embarking on high-intensity exercise, a clinical assessment should be performed including symptomatic status, and a maximal exercise stress test,
functional imaging test, or CCTA may be considered in the risk assessment110 (Figure 4), particularly in individuals with familial hypercholesterolaemia. Among athletes with hypercholesterolaemia, regular exercise will rarely reduce LDL cholesterol to normal or nearnormal values; therefore, guidelines on pharmacological treatment in primary and secondary prevention should be followed strictly.
Individuals with dyslipidaemia should be assessed at least every 25
years for primary prevention and annually for secondary prevention.
Pharmacological intervention, particularly with statins, is superior to exercise and lifestyle intervention alone for reducing LDL cholesterol and improving prognosis.147 Despite the minor effects of endurance exercise on serum LDL cholesterol, the clinically beneficial relationship between increased physical fitness and reduced CV
events remains beyond the effects of statins.147,148
Physically active individuals with dyslipidaemia may experience muscle pain and soreness or tendinopathy accompanied by elevated muscle enzymes.149 In these cases, measures such as stopping medication temporarily followed by repeat challenge with another statin drug, with or without an alternate day regimen, or introducing other lipid-lowering agents such as ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors should be considered.109
Individuals who develop rhabdomyolysis due to a statin should be prescribed an alternative lipid-lowering agent.
4.2.5 Diabetes mellitus
Physical inactivity is a major cause of type 2 diabetes mellitus
(T2DM).150 The risk of developing T2DM is 5080% higher in individuals who are physically inactive compared to their active counterparts. However, exercise does not entirely compensate for the effect of obesity.151154 Diabetes is also independently associated with an accelerated decline in muscular strength and, partly because of hyperglycaemia, may lead to reduced joint mobility.
4.2.5.1 Effect of exercise on diabetic control, risk factors and outcomes
Aerobic exercise in patients with T2DM improves glycaemic control and reduces visceral fat and insulin resistance. Exercise also has beneficial effects on BP and lipid profile, and leads to modest weight loss.155,156 Both aerobic and resistance training promote prolonged adaptations in skeletal muscle, adipose tissue, and the liver associated with enhanced insulin action.157 Observational studies have shown lower mortality with exercise in both type 1 diabetes mellitus and
T2DM.158
In patients with pre-diabetes or metabolic syndrome, both aerobic and resistance exercise may prevent the development of overt diabetes.159162 Intensity of exercise seems to be of greater importance than the volume of exercise; individuals who exercise at moderate or high intensity have a lower risk of developing metabolic impairment compared with those who have a similar energy expenditure at a lower intensity.160,163
The effects on muscle insulin sensitivity are observed with a relatively low volume of exercise (400 kcal/week) in previously sedentary adults, but increase with higher volumes of exercise.164 The optimal combination of duration and intensity is not well established. Highintensity interval training may be superior to moderate aerobic training in achieving metabolic effects and improvement in exercise capacity; however, whether long-term results are superior is unknown.165,166
Diabetes is a cause of coronary microvascular dysfunction (CMD),
which is associated with lower exercise capacity and adverse outcomes167,168 and can be improved by exercise training.162,169171
Large randomized trials have confirmed the beneficial effect of exercise intervention on glycaemic control and risk factors, but this has not translated into a significant improvement in survival, partly because of suboptimal long-term maintenance of lifestyle changes.172
During an acute bout of exercise, glucose uptake in the muscles is increased for up to 2 h afterwards through mechanisms that are independent of insulin. The exercise-induced hypoglycaemic effect can be diminished by performing resistance training or interval training in patients with type 1 diabetes.173 There is a doseresponse relationship between intensity and volume of exercise and duration of glucose uptake by skeletal muscle that may last up to 48 h after exercise.
These factors must be considered in individuals with diabetes who are undertaking intensive exercise or competitive sports in order to avoid hypoglycaemia.
4.2.5.2 Recommendations for participation in exercise in individuals with diabetes mellitus
Both aerobic and resistance training are effective for glycaemic control, BP reduction, weight loss, peak exercise capacity, and dyslipidemia.174 A programme combining aerobic and resistance training has been shown to be superior in terms of glycaemic control, whereas the effect on other outcomes is unproven.174176
The ideal exercise programme to achieve the full potential of benefits in patients with diabetes is daily exercise of at least moderate intensity, e.g. brisk walking, for at least 30 min, resistance training for
15 min on most days, and lighter-intensity activities (standing, walking) every 30 min. This can be supplemented by flexibility and balance exercise, particularly in older individuals or patients with microvascular complications due to their diabetes.
4.2.5.3 Cardiac evaluation before exercise participation in individuals with diabetes mellitus
Individuals with diabetes have a priori a higher likelihood of subclinical
CAD; therefore, all individuals with diabetes should undergo CV
assessment as outlined in Figure 4 before taking up an exercise programme of high intensity. This should be supplemented by an evaluation of glycaemic status, including risk factors for hypoglycaemia,
history of hypoglycaemic episodes, presence of autonomic neuropathy, and antidiabetic treatment.177
Asymptomatic individuals with diabetes mellitus and a normal CV
assessment and maximal exercise test may engage in all sports but should be warned about the potential risk of iatrogenic


<!-- PAGE 21 -->

### Page 21

........................................................................................................................................................................
hypoglycaemia in the event of inadequate caloric intake. Importantly,
all patients with diabetes should be aware of warning symptoms and attention should be given to chest discomfort or unusual breathlessness during exercise as this may be indicative of CAD.
4.3 Exercise and sports in ageing
4.3.1 Introduction
The elderly are defined as adults aged above 65 years. Similar to the general population, higher exercise capacity in this age group is also associated with reduced mortality.179 A physically active lifestyle maintained through middle and older age translates into better health180 and longevity.181185 Commencing a new exercise regimen among sedentary elderly individuals has shown significant health improvements180,186 including cognitive capacity.187190 Moreover,
regular exercise exerts beneficial effects in reducing the risk of developing CV and metabolic disease through improved control of CV risk factors,191,192 also preserving cognitive function.187190 Importantly,
exercise helps to preserve neuromuscular competence,193,194 thus maintaining balance and coordination, which reduces the risk of falling.195,196
4.3.2 Risk stratification, inclusion/exclusion criteria
Moderate-intensity exercise is generally safe for older healthy people and medical consultation before starting or progressing the level of exercise programme is not usually required.81,197 The general recommendation for exercise implementation for the general population also applies to healthy elderly people.
Nevertheless, due to potential risks of exercising among the elderly (Table 6), the European Association of Preventive Cardiology
(EAPC) recommends self-assessment by a brief questionnaire81 to determine the need for advice from health professionals, but this approach has not been tested prospectively.
Community-dwelling frail or sedentary older adults may have a slightly increased risk of falls during exercise; however, there is no evidence of serious adverse outcomes,
injury,
or
CV
events.195,196,198,199 Exercise interventions to improve balance in those diagnosed with dementia bring numerous benefits without an increased risk of adverse outcomes.200 Resistance exercise in older adults is rarely associated with adverse events.201,202 No major risks have been reported in older individuals performing low- and moderate-intensity aerobic exercise, and even more intense aerobic activities are associated with a relatively small risk.203205 CV events during intense exercise occur at a rate of around 1 event per 100
years of vigorous activity.206 Risks are highest during the first few weeks of beginning vigorous exercise; therefore both exercise intensity and duration should be increased gently (for example, every 4
weeks).81,197,207210 Among older individuals who are well prepared and accustomed to intense exercise, participation in competitive vigorous sports does not confer higher risk compared with younger adults.38,211
4.3.3 Exercise modalities and recommendations for exercise and sport in the elderly
The physical exercises for elderly persons should be designed according to their biological age, exercise experience, functional capacity, safety, ageing trajectories, comorbidity, lifestyle habits, and previous experience of exercise.
Elderly people should perform endurance and strength exercise,
and specific exercises for flexibility and balance (Table 7).201,212,213
Endurance exercise exerts beneficial effects on the cardiorespiratory system and resistance exercise prevents the decrease in muscle mass and sarcopenia.192 Achieving >150 min/week moderate-intensity aerobic exercise (i.e. walking or other moderate intensity aerobicstype activities) is associated with at least 30% lower risk of morbidity,
mortality, disability, frailty, and dementia compared with being inactive.212,214,215 The strength exercises for the major muscle groups should be performed at least twice a week (810 different exercises,
1015 repetitions).
Accustomed senior athletes should continue performing exercise and sports activities, without any predetermined age limit.38,211,216
Sports activities for older people according to exercise type and intensity are reported in Table 8. Annual clinical assessment including a maximal exercise test (preferably with simultaneous CPET) is recommended in master athletes performing a high level of sports and exercise programmes.217
Special considerations for individuals with obesity,
hypertension, dyslipidaemia, or diabetes
Recommendations
Classa
Levelb
In obese individuals (BMI>_30 kg/m2 or a waist circumference >80 cm for females or >94 cm for males) resistance training >_3 times per week, in addition to moderate or vigorous aerobic exercise
(at least 30 min, 57 days per week) is recommended to reduce CVD risk.121
I
A
In individuals with well-controlled hypertension,
resistance training >_3 times per week in addition to moderate or vigorous aerobic exercise (at least 30
min, 57 days per week) is recommended to reduce blood pressure and CVD risk. 132
I
A
Among individuals with diabetes mellitus, resistance training >_3 times per week in addition to moderate or vigorous aerobic exercise (at least 30 min, 57
days per week) is recommended to improve insulin sensitivity and achieve a better CVD risk proﬁle.176,178
I
A
Among adults with well-controlled hypertension but high risk and/or target organ damage, high-intensity resistance exercise is not recommended.
III
C
In individuals with uncontrolled hypertension
(SBP>160 mmHg) high-intensity exercise is not recommended until blood pressure has been controlled.
III
C
CVD = cardiovascular disease; SBP = systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
37


<!-- PAGE 22 -->

### Page 22

............................................................ 5. Exercise in clinical settings
5.1 Exercise programmes for leisure-time and competitive sport participation in chronic coronary syndrome
Atherosclerotic CAD is the predominant cause of exercise-related
(Ex-R) cardiac events including ACS, AMI, and SCA in individuals with established chronic coronary syndrome (CCS), or SCD as a primary presentation in individuals >35 years of age.218 In addition to atherosclerotic CAD, other entities, including an anomalous origin of a coronary artery
(AOCA),219
myocardial bridge
(MB),220
and spontaneous coronary artery dissection (SCAD),221 are also associated with myocardial ischaemia, and potentially with Ex-R SCD.
Physical inactivity is a risk factor for CAD, but somewhat paradoxically, vigorous physical exertion transiently increases the risk for
AMI66 and SCD.216 Overall, the benefits of regular exercise greatly outweigh the Ex-R risk, even in individuals with CCS. Moderate- to vigorous-intensity exercise is strongly associated with a reduced
Table 6
Potential risks for older people during exercise
©ESC 2020
Table 7
Exercise prescription in the elderly
©ESC 2020
Recommendations for exercise in ageing individuals
Recommendations
Classa
Levelb
Among adults aged 65 years or older who are
ﬁt and have no health conditions that limit their mobility, moderate-intensity aerobic exercise for at least 150 min/week is recommended.212,214,215
I
A
In older adults at risk of falls, strength training exercises to improve balance and coordination on at least 2 days a week are recommended.201,212,214,215
I
B
A full clinical assessment including a maximal exercise test should be considered in sedentary adults aged 65 years or older who wish to participate in high-intensity activity.
IIa
C
Continuation of high- and very high-intensity activity, including competitive sports, may be considered in asymptomatic elderly athletes
(master athletes) at low or moderate CV risk.
IIb
C
CV = cardiovascular.
aClass of recommendation.
bLevel of evidence.
Table 8
Exercise activities for older people according to exercise type and intensity
©ESC 2020


<!-- PAGE 23 -->

### Page 23

.................................................................................................................................
incidence of adverse outcomes from CAD, but prolonged, highintensity endurance exercise has been associated with increased coronary artery calcium (CAC), a marker of atherosclerosis,58,222 and coronary plaques58 but without an increase in mortality112 in the medium term. Importantly, the diagnosis of myocardial injury is also more complex in athletes because intense exercise may increase serologic markers of myocardial injury, including cardiac troponin I
and T.223,224
5.1.1 Individuals at risk of atherosclerotic coronary artery disease and asymptomatic individuals in whom coronary artery disease is detected at screening
Athletes or individuals participating in sports or regular exercise training may have risk factors for CAD and/or subclinical CCS.225
Such individuals may be identified by routine pre-participation screening as recommended by the ESC21 or by pre-evaluation of master athletes, as suggested by the European Association for
Cardiovascular Prevention and Rehabilitation (EACPR) 2011207 and the AHA.226
In addition to the SCORE risk stratification described earlier
(Table 5), the increasing use of cardiac imaging techniques allows the identification of a greater number of individuals with asymptomatic
CCS,227 including competitive master athletes.227
Newer predictive measures, such as high-sensitive C-reactive protein and carotid intimamedia thickness (IMT) add little to the traditional risk factors.110 The exception is CAC, which provides additional predictive information in individuals with a moderate-risk profile,228 dividing them into low- or high-risk individuals. The most prudent and cost-effective method of utilizing CAC may thus be additive to the traditional risk factors,229 as suggested by the EAPC.230
Clinical evaluation of asymptomatic individuals with possible subclinical CCS should include (Figure 4):112
(1)
Assessment of risk of CVD110 (Table 5)
(2)
Consideration of intensity of intended exercise programme
(3)
Clinical evaluation, including maximal exercise stress test
(4)
Further diagnostic testing in selected individuals.
Many middle-aged individuals in the general population can be expected to have some level of subclinical CCS as assessed with imaging techniques. Anatomical coronary imaging alone does not provide information relating to the coronary flow and reserve, which is important in assessing the risk of Ex-R ischaemia or SCD/SCA;
therefore functional evaluation is necessary. Several methods of stress testing (e.g. cycle ergometry or treadmill testing), stress echocardiography, adenosine or dobutamine stress cardiac magnetic resonance (CMR), or positron emission tomography (PET)/single-photon emission computed tomography (SPECT), can be used to detect inducible myocardial ischaemia231. Exercise stress-echo is preferred in athletes because it is free from radiation and does not involve administration of drugs.
Exercise testing is the most widely available functional test, and provides information on exercise capacity, heart rate, and BP
response, and detection of exercise-induced arrhythmias,2 but has a lower specificity for myocardial ischaemia than other functional tests,
especially in asymptomatic and low-risk individuals. It is recommended that a truly maximal exercise test232 (with or without CPET)
should be performed when evaluating individuals with possible subclinical (or clinical) CCS who intend to or are participating in systematic exercise including recreational or competitive sports. Whether the initial exercise test includes imaging or not depends on factors such as the baseline ECG (Table 9) and feasibility of performing functional imaging tests in a given institute.
• If the clinical assessment, including a maximal exercise test is normal, the presence of ‘relevant CAD’ is assumed to be unlikely
(Figure 4).
• In the event of a borderline or uninterpretable exercise test result,
it is recommended that a more specific imaging stress test is performed such as stress-echocardiography, CMR perfusion imaging,
or SPECT. Maximal exercise SPECT and exercise echocardiography or nuclear perfusion techniques utilizing exercise rather than pharmacological stress may preferentially be used, depending on availability and local expertise.
• If the exercise test is positive, an invasive coronary angiogram should be performed to confirm the presence, extent, and severity of CAD (Figure 4).
5.1.1.1 Recommendations for sports participation
Individuals at risk of CAD and asymptomatic individuals in whom CAD
is detected at screening should have aggressive management of risk factors for atherosclerosis.6,131,132,202 Considering the benefits of exercise on primary and secondary prevention of CCS,6,234 individuals with risk factors should be restricted from competitive sport only when there is substantial risk of an adverse event, as indicated by functional tests, or when there is evidence of disease progression during serial evaluations.233 Exercise recommendations should be individually tailored based on the intensity of the exercise and the sporting discipline.
Participation in competitive endurance, power, and mixed disciplines
(see sections 4.2 and 5.1.3) generally requires vigorous effort and is more likely to induce myocardial ischaemia, whereas leisure sports or intentional recreational exercise allows for greater control of physical effort. Individuals with a high risk of atherosclerotic CAD and asymptomatic individuals in whom CAD is detected at screening who participate in intensive exercise should be assessed with a maximal exercise test or functional imaging test on an annual basis.
Table 9
Borderline or uninterpretable ECG ﬁndings
©ESC 2020
ESC Guidelines
39


<!-- PAGE 24 -->

### Page 24

...................................................................
5.1.2 Established (long-standing) chronic coronary syndrome
All individuals with established (long-standing) CCS should be encouraged to perform the minimal PA recommendations for general and CV health.235 This applies to individuals with stable angina,
asymptomatic and symptomatic individuals stabilized <1 year after
ACS, or individuals with recent revascularization, and asymptomatic and symptomatic individuals >1 year after initial diagnosis or revascularization.110 Advice on intensive exercise and participation in most competitive sports in asymptomatic individuals with long-standing
CCS should be based on several factors, which are determined through clinical history, exercise stress testing, or functional imaging and echocardiography (Table 10).
Individuals with long-standing CCS who do not show any abnormalities on a maximal exercise test or functional imaging test, or have unimpaired LV function, may be considered as low risk for an exerciseinduced adverse event236238 (Table 11). Such individuals may engage in all competitive sports on an individual basis (Figure 5). Some restrictions may apply for high-intensity power, mixed, and endurance sports
(see Figure 2, section 4.1.2) for older patients (>60 years old) with CCS.
This is due to the fact that age is an additional, strong predictor of adverse events during exercise. There are no restrictions in low-risk patients for skills sports regardless of age (Figure 2).
Individuals with inducible ischaemia during functional testing,
despite adequate treatment, should undergo coronary angiography;
those with high-risk lesions on coronary angiography (Table 11)
should have revascularization prior to considering high-intensity exercise programmes or competitive sport (Figure 5). Individuals with high-risk coronary features may gradually return to sport 36
months after successful revascularization pending a normal maximal exercise or functional imaging test.
When ischaemia cannot be treated despite adequate therapy,
including revascularization, the individual should be restricted from competitive sports, with the possible exception of individually recommended low-intensity skill sports. Such individuals may engage in regular recreational exercise of low and moderate intensity provided risk factors and symptoms are treated adequately and there is regular clinical surveillance. These individuals may also participate in leisure sports, 23 times/week, in selected cases, if the intended activity is below (around 10 beats) the ischaemic threshold and below the level of arrhythmias.231
5.1.2.1 Antithrombotic treatment
Individuals with CAD should receive conventional antithrombotic treatment for secondary prevention, according to published guidelines for the general population.233,239,240 Individuals taking dual antiplatelet agents should avoid sports with bodily collision, especially when they are combined with oral anticoagulants, due to the risk of haemorrhage.241
Recommendations for exercise in individuals at risk of atherosclerotic coronary artery disease and asymptomatic individuals in whom coronary artery disease is detected at screening
Recommendations
Classa
Levelb
Among individuals with asymptomatic CCS, deﬁned as CAD without inducible myocardial ischaemia on a functional imaging or conventional exercise stress test, 233 participation in all types of exercise, including competitive sports, should be considered based on individual assessment.
IIa
C
CAD = coronary artery disease; CCS = chronic coronary syndrome.
aClass of recommendation.
bLevel of evidence.
Table 10
Factors determining risk of adverse events during intensive exercise and competitive sports in asymptomatic individuals with long-standing coronary artery disease
©ESC 2020
Table 11
High-risk features for exercise-induced adverse cardiac events in patients with atherosclerotic coronary artery disease233
©ESC 2020
ACS = acute coronary syndrome; FFR = fractional ﬂow reserve; iFR = instant
ﬂow reserve; NSVT = non-sustained ventricular tachycardia; PCI = percutaneous coronary intervention.


<!-- PAGE 25 -->

### Page 25

©ESC 2020
Figure 5 Clinical evaluation and recommendations for sports participation in individuals with established coronary artery disease. CCS = chronic coronary syndrome; LAD = left anterior descending coronary artery; LM = left main coronary artery; LVEF = left ventricular ejection fraction. *With documented ischaemia or a haemodynamically relevant lesion defined by FFR <0.8 or iFR <0.9.
Recommendations for exercise in individuals with long-standing chronic coronary syndrome
Recommendations
Classa
Levelb
Risk stratiﬁcation for exercise-induced adverse events is recommended in individuals with established (long-standing) chronic coronary syndrome (CCS) prior to engaging in exercise.233
I
C
Regular follow-up and risk stratiﬁcation of patients with CCS is recommended.233
I
B
It is recommended that individuals at high risk of an adverse event from CAD are managed according to the current Guidelines on CCS.233
I
C
Competitive or leisure sports activities (with some exceptions such as older athletes and sports with extreme CV demands)
should be considered in individuals at low risk of exercise-induced adverse events (Table 11).233
IIa
C
Leisure-time exercise, below the angina and ischaemic thresholds, may be considered in individuals at high risk of exerciseinduced adverse events (Table 11), including those with persisting ischaemia.233
IIb
C
Competitive sports are not recommended in individuals at high risk of exercise-induced adverse events or those with residual ischaemia, with the exception of individually recommended skill sports.233
III
C
CAD = coronary artery disease; CCS = chronic coronary syndrome; CV = cardiovascular.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
41


<!-- PAGE 26 -->

### Page 26

....................................................................................................
5.1.3 Myocardial ischaemia without obstructive disease in the epicardial coronary artery
Ischaemia and non-obstructive CAD (INOCA) is an underrecognized entity associated with increased risk of adverse events242
that is usually detected during evaluation of anginal symptoms. Stress
CMR and PET can detect abnormal coronary flow reserve and suggest coronary microvascular dysfunction with non-critical lesions.
There are no established treatments for microvascular angina.
However, the panel suggests adhering to the same exercise recommendations as for long-standing CCS.
5.1.4 Return to sport after acute coronary syndrome
Exercise-based cardiac rehabilitation (exCR) reduces cardiac mortality, hospital readmission,234234 and anxiety.243 Individuals who have experienced an ACS, cardiac surgery, or percutaneous intervention should be referred to an early exCR
programme,235,242 soon after the discharge,6,235,244 for 812 weeks after the cardiac event.235,244 Every week that exercise is delayed requires an additional month of exercise to accomplish the same level of benefit.245
Exercising individuals with CAD may start performing low- to moderate-intensity recreational sporting activities in parallel with participation in the structured progressive exercise programmes. All types of sports activities may be considered, at an appropriate intensity level; however, careful attention should be paid to the development of new symptoms.218
In general, structured outpatient exercise programmes, for 36
months, are required to achieve the appropriate level of activity for sports participation in patients with CAD. In individuals with non-ST
segment elevation MI or CCS who have had complete revascularization and do not have residual ischaemia, exercise training can be progressed at a faster pace until the recommended exercise level is reached.
5.1.4.1 Competitive athletes
Careful individual evaluation is required before starting high-intensity competitive sports. In competitive athletes, an echocardiogram, maximal exercise test with 12-lead ECG recording or CPET is recommended for risk stratification before return to sports (see section
5.1.2). CPET specifically adds information on aerobic and anaerobic thresholds, guiding exercise intensity prescription and progression
(see section 4.2).
5.1.4.2 Recreational athletes
For individuals intending to participate in non-competitive, recreational sports and leisure-time activity, similar principles apply regarding risk stratification. A symptom-limited/maximal exercise test should precede the return to sports. Higher-risk patients with
CCS (Table 11) are not eligible for competitive sports (see section
5.1.2); however, low-intensity skill sports, such as golf, may be considered, at intensities below the angina threshold. If aerobic exercise is not tolerated, predominantly strength-related sports with a small amount of muscular work are recommended
(Figure 2, section 4.1.2).
5.1.5 Anomalous origin of coronary arteries
5.1.5.1 Background
The prevalence of AOCA (left and right coronary artery) is 0.44% in the general population of adolescents.246 AOCA is considered to be a common cause of SCD in young athletes17,18,247,248 but is rarely implicated in individuals >40 years of age.249,250
Chest pain, exertional syncope and SCD may be the first manifestation of AOCA,251 however, over two thirds of patients are asymptomatic.252 Mechanisms leading to SCD likely include repeated bursts of ischaemia with consequent increase in myocardial fibrosis and a proclivity to develop VAs during exercise.
Ischaemia may result from the compression of the anomalous vessel coursing between the aorta and the pulmonary artery and/or from the acute angled take-off from the aorta and/or the proximal intramural course of the anomalous vessel (Figure 6).253 Both left and right anomalous coronary origins have been implicated in ExR SCD, although the risk has traditionally been thought to be considerably higher with an anomalous left coronary artery origin.252
Exercise testing rarely reveals myocardial ischaemia and multislice contrast-enhanced CT, CCTA, or CMR are the mainstay of diagnosis.
5.1.5.2 Eligibility for sports
Eligibility for competitive sports is based on the anatomical type of AOCA and on the presence of ischaemia. A highly positive inotropic and positive chronotropic exercise stress test is the best approach to demonstrate or rule out ischaemia. AOCA
with acute angled take-off from the aorta resulting in a slit-like orifice with reduced lumen and anomalous coursing between the aorta and the pulmonary artery is associated with the greatest risk for SCA/SCD whether or not the anomalous artery originates from the left or right sinus of Valsalva, and strong consideration should be given to surgical correction of such an anomaly
Recommendations for return to exercise after acute coronary syndrome
Recommendations
Classa
Levelb
Exercise-based cardiac rehabilitation is recommended in all individuals with CAD to reduce cardiac mortality and rehospitalization.234
I
A
During the initial period, motivational and psychological support, and individualized recommendations on how to progress the amount and intensity of sports activities, should be considered in patients with CAD.
IIa
B
All sports activities should be considered, at an individually adapted intensity level in low-risk individuals with CCS.
IIa
C
CAD = coronary artery disease; CCS = chronic coronary syndrome.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 27 -->

### Page 27

.............
in symptomatic individuals. Prior to successful correction,
participation in sports, other than low-intensity skill sports, is discouraged regardless of symptoms.
We are unable to provide exercise or sport recommendations for older patients
(>40 years) with AOCA, due to the paucity of studies.
However, recreational exercise of moderate intensity seems reasonable, but a cautious approach is advised to more vigorous exercise.
©ESC 2020
Figure 6 Schematic representation of the most frequent anomalous origin of coronary arteries and associated risk of sudden cardiac death. RCA = right coronary artery; LMCA = left main coronary artery; LAD = left anterior descending artery; LCCA = left circumflex coronary artery.
Recommendations for exercise in young individuals/athletes with anomalous origins of coronary arteries
Recommendations
Classa
Levelb
When considering sports activities, evaluation with imaging tests to identify high-risk patterns and an exercise stress test to check for ischaemia should be considered in individuals with AOCA.
IIa
C
In asymptomatic individuals with an anomalous coronary artery that does not course between the large vessels, does not have a slitlike oriﬁce with reduced lumen and/or intramural course, competition may be considered, after adequate counselling on the risks,
provided there is absence of inducible ischaemia.
IIb
C
After surgical repair of an AOCA, participation in all sports may be considered, at the earliest 3 months after surgery, if they are asymptomatic and there is no evidence of inducible myocardial ischaemia or complex cardiac arrhythmias during maximal exercise stress test.
IIb
C
Participation in most competitive sports with a moderate and high cardiovascular demand among individuals with AOCA with an acutely angled take-off or an anomalous course between the large vessels is not recommended.c
III
C
AOCA = anomalous origin of coronary arteries.
aClass of recommendation.
bLevel of evidence.
cThis recommendation applies whether the anomaly is identiﬁed as a consequence of symptoms or discovered incidentally, and in individuals <40 years of age.
ESC Guidelines
43


<!-- PAGE 28 -->

### Page 28

.............................................................................................................
5.1.6 Myocardial bridging
5.1.6.1 Background
Myocardial bridging (MB) refers to a condition when some of the myocardium overlies a segment of an epicardial coronary artery
(referred to as a tunnelled artery) and most commonly affects the left anterior descending artery (Figure 7). The prevalence of MB varies from 0.512% and up to 575% according to diagnostic angiography or CT scan series.254 MBs are traditionally considered as benign;
however, the association between myocardial ischaemia and MBs has increased their clinical relevance. MB may be discovered at imaging after an abnormal exercise ECG and should also be suspected in individuals who present with exertional angina or syncope.
Coronary artery compression together with a Venturi (suction)
effect are the potential underlying mechanisms for exercise-induced ischaemia.248
Evaluation of individuals with MB aims primarily at assessing the morphologic characteristics of the anatomical anomaly (i.e. number of MB, depth and overall length of the tunnelled vessel) and the presence of inducible ischaemia. A positive inotropic and positive chronotropic stress test is the best approach to demonstrate myocardial ischaemia. MB without other underlying associated diseases [e.g.
hypertrophic cardiomyopathy (HCM)] and with no evidence of inducible myocardial ischaemia has a good prognosis.255 However, in adult/senior individuals, it has been shown that the arterial compression in MB may be directly related to the atherosclerotic burden,
proximal to the MB.256 These individuals should be considered in the same category as individuals with CAD and treated appropriately if necessary, although the vast majority of MB is clinically silent. Betablockers should be used when patients are symptomatic or myocardial ischaemia is established. Surgical repair may be considered, while coronary stenting is discouraged.255
5.1.6.2 Eligibility
Patients with MB and evidence of ischaemia should be restricted from participation in competitive sports and should receive appropriate advice regarding leisure-time activities.
5.2 Exercise recommendations in individuals with chronic heart failure
5.2.1 Background: rationale for exercise in chronic heart failure
Most of the evidence regarding exercise in chronic heart failure (HF)
is derived from studies implementing exercise training programmes that are considered safe and highly recommended in stable patients on optimal medical therapy.257260Meta-analyses of these studies have demonstrated a significant improvement in exercise tolerance and quality of life and a modest effect on all-cause and HF-specific mortality and hospitalization.261267
5.2.2 Risk stratification and preliminary evaluation
Exercise intervention should only be initiated in a clinically stable individual after medical therapy for HF has been optimized. Key components before commencing an exercise programme and sports participation include:
(1)
Exclusion of contraindications to exercise: Contraindications to initiating an exercise programme in chronic HF include hypotension or hypertension at rest or during exercise, unstable cardiac disease,
deteriorating symptoms of HF, myocardial ischaemia despite therapy (exercise may be permitted up to ischaemic threshold), or severe and suboptimally treated pulmonary disease.258
(2)
Performing a baseline assessment: A thorough cardiological evaluation is required, including assessment of comorbidities and HF severity
(e.g. by assessment of blood natriuretic peptides and echocardiography). A maximal exercise test (preferably CPET) is important to assess functional capacity, exercise-induced arrhythmias or haemodynamic abnormalities and for prescription of exercise intensity,
based on VO2peak, or on resting and maximal heart rate during exercise [e.g. HRR or Borg’s rating of perceived exertion (RPE)].265,266
(3)
Optimizing medical therapy: All individuals with HF should be treated according to current Guidelines,257 including device implantation when required.267
©ESC 2020
Figure 7 Schematic representation of a myocardial bridge. LAD = left anterior descending coronary artery.
Recommendations for exercise/sports in individuals with myocardial bridging
Recommendations
Classa
Levelb
Participation in competitive and leisure-time sports should be considered in asymptomatic individuals with myocardial bridging and without inducible ischaemia or ventricular arrhythmia during maximal exercise testing.
IIa
C
Competitive sports are not recommended in individuals with myocardial bridging and persistent ischaemia or complex cardiac arrhythmias during maximal exercise stress testing.
III
C
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 29 -->

### Page 29

..................................................................................
The exercise session should be individually tailored for several weeks, according to symptoms and objective findings during exercise testing such as maximal exercise capacity, heart rate response, or arrhythmias. In atrial fibrillation (AF), exercise can only be monitored by power or Borg’s RPE.
High-risk patients should be counselled more frequently during the initial phases. Ideally exercise should be supervised through an exercisebased cardiac rehabilitation programme while non-supervised homebased sessions should be gradually added.260 When all these measures are followed, the overall risk of exercise is low, even during higherintensity exercises and in patients with more severe HF.268,269
Follow-up examinations for exercise recommendations should be scheduled at least every 36 months. Intervals between examinations should depend on disease severity and comorbidities, setting of the sessions (supervised vs. home-based), patient’s age and adherence.
5.2.3 Exercise modalities and sports participation in heart failure
Following risk factor control and therapy optimization, the individual with HF should be encouraged to start exercise programmes without delay.242,244,270 Initially home-based exercise programmes may also be prescribed and monitored.270,271
In uncomplicated cases low to moderate-intensity recreational sporting activities may be considered in parallel to the structured exercise programme. When prescribed, maximal exercise intensities should be monitored, for example, by heart rate monitors. If monitoring does not reveal any exercise-induced arrhythmias or other abnormalities, then all types of recreational sports activities are permitted (see Figure 2, section 4.1.2).
5.2.3.1 Aerobic/endurance exercise
Aerobic exercise is recommended for stable patients [New York
Heart Association (NYHA) class IIII], because of its welldemonstrated efficacy and safety.260 Recommendations on optimal exercise dose have been previously described in ESC and AHA
Guidelines.242,270272 The most commonly evaluated exercise mode is moderate continuous exercise (MCE).242,270272 In patients in
NYHA functional class III, exercise intensity should be maintained at a lower intensity (<40% of VO2peak), according to perceived symptoms and clinical status during the first 12 weeks. This should be followed by a gradual increase in intensity to 5070% VO2peak, and if tolerated, up to 85% VO2peak as the primary aim.270,271
Recently, high-intensity interval training (HIIT) programmes have been considered as an alternative exercise modality for low-risk patients.269 The most recent meta-analysis showed that HIIT was superior to MCE in improving VO2peak in individuals with HF with reduced
(<40%) ejection fraction (HFrEF) in the short term.273 However, this superiority disappeared in subgroup analysis of isocaloric protocols. HITT programmes may be recommended initially to prepare low risk patients with stable HF who want to return to high intensity aerobic and mixed endurance sports (Figure 2, section 4.1.2).
5.2.3.2 Resistance exercise
Resistance exercise training may complement, but not substitute,
aerobic exercise training because it reverses skeletal muscle mass loss and deconditioning without excessive stress on the heart.270,274
The training intensity can preferably be set at the level of resistance at which the patient can perform 1015 repetitions at 15 on Borg’s
RPE scale (Table 12).242,270 In patients with altered skeletal muscle function and muscle wasting, exercise training should focus initially on increasing muscle mass by using resistance programmes.275,276
Resistance programmes may specifically be considered for lowrisk stable patients, who want to return to strength-related power sports, e.g. weightlifting (Figure 2, section 4.1.2). A meta-analysis showed that resistance exercise as a single intervention has the capacity to increase muscle strength, aerobic capacity, and quality of life in HFrEF patients who are unable to participate in aerobic exercise programmes.277 Also, in advanced HF or in patients with very low exercise tolerance, resistance exercise can be safely applied if small muscle groups are trained.270,277,278
5.2.3.3 Respiratory exercise
Inspiratory muscle training improves VO2peak, dyspnoea, and muscle strength,279282 and it typically involves several sessions per week with intensity ranging from 30% to 60% of maximal inspiratory pressure, and duration from 1530 min for an average of 1012
weeks.279 This training modality should be recommended to the most severely deconditioned individuals as an initial alternative who may then transition to conventional exercise training and sports participation, to optimize cardiopulmonary benefits.280
5.2.3.4 Aquatic exercise
Aquatic exercise has not been recommended for individuals with HF, due to concerns that the increase in central blood
Table 12
Optimal exercise training dose for patients with chronic heart failure
©ESC 2020
1 RM = one repetition maximum; RPE = rating of perceived exertion; VO2peak =
peak oxygen consumption.
ESC Guidelines
45


<!-- PAGE 30 -->

### Page 30

.................................................................................................
volume and cardiac preload as a consequence of hydrostatic pressure may not be tolerated.283 However, a recent meta-analysis has shown that aquatic exercise training may be safe and clinically effective.284
5.2.4 Sports participation and return to sports
In addition to risk stratification (section 5.2.3), the evaluation for participation in sports includes intensity and type of sports (competitive vs. recreational), and determining the individual fitness level.
5.2.4.1 Competitive sports
Participation in competitive sports may be considered in a group of selected low-risk individuals. A thorough individual evaluation using a maximal exercise test (or preferably CPET) is recommended before returning to sports, particularly before starting moderate- to high-intensity sports, mixed and power sports
(Figure 2, section 4.1.2).
Asymptomatic individuals with preserved (>_50%) EF (HFpEF) or with mid-range (>_4059%) EF (HFmrEF) who are optimally treated may be eligible to participate in some competitive sports in the absence of exercise-induced arrhythmias or exercise-induced hypotension. In such cases, a progressive increase in exercise dose is recommended. The duration of this process is dependent upon the functional capacity and perceived symptoms. Some restrictions may apply to high-intensity endurance, mixed and power sports with high demands, especially in older patients. No restrictions should apply for skill-related sports.
Asymptomatic patients with HFrEF who are optimally treated may only be considered safe to perform specific low-intensity skill sports at a competitive level (Figure 2). Higher-risk patients including those who are suboptimally treated, those that remain in
NYHA II or III despite optimal therapy, and those with exerciseinduced arrhythmias or exercise-induced hypotension should not participate in competitive sports, particularly those sports with moderate to high cardiopulmonary strain during training or competition.
5.2.4.2 Recreational sports
For patients intending to participate in recreational sports and leisure-time activity, similar principles apply regarding risk stratification. A progressive increase in exercise dose is recommended. Lowto moderate-intensity skill, power, mixed, and endurance sports may be considered in all asymptomatic individuals.
As with competitive sports, high-intensity recreational sports should only be considered in asymptomatic individuals with HFmrEF
(EF 4049%) who do not have exercise-induced arrhythmias or exercise-induced hypotension. Asymptomatic individuals with HFrEF
who are optimally treated may engage in low- to moderate-intensity skill-related recreational sports, and selectively in low-intensity endurance sports (Figure 2).
In patients with HFrEF with very low exercise tolerance, frequent decompensation,
or patients with
LV
assist devices
(see
Supplementary Data), participation in low-intensity skill-related sports is possible, if tolerated. Regular low-intensity endurance activities, e.g.
walking or cycling, should generally be recommended to improve basic exercise capacity.
Recommendations for exercise prescription in heart failure with reduced or mid-range ejection fraction
Recommendations
Classa
Levelb
Regular discussion about exercise participation and provision of an individualized exercise prescription is recommended in all individuals with heart failure.260,261,285
I
A
Exercise-based cardiac rehabilitation is recommended in all stable individuals to improve exercise capacity, quality of life, and to reduce the frequency of hospital readmission.260,261,285
I
A
Beyond annual cardiac assessment, clinical reassessment should be considered when the intensity of exercise is increased.
IIa
C
Motivational and psychological support and individualized recommendations on how to progress the amount and intensity of sports activities should be considered.
IIa
C
Low- to moderate-intensity recreational sporting activities and participation in structured exercise programmes may be considered in stable individuals.
IIb
C
High-intensity interval training programmes may be considered in low-risk patients who want to return to high-intensity aerobic and mixed endurance sports.
IIb
C
aClass of recommendation.
bLevel of evidence.
Recommendations for participation in sports in heart failure
Recommendations
Classa
Levelb
Before considering a sport activity, a preliminary optimization of heart failure risk factor control and therapy, including device implantation (if appropriate), is recommended.
I
C
Participation in sports activities should be considered in individuals with heart failure who are at low risk, based on a complete assessment and exclusion of all contraindications, in stable condition for at least 4 weeks, optimal treatment, and
NYHA functional class I status.
IIa
C
Non-competitive (low- to moderate-intensity recreational) skill, power, mixed, or endurance sports may be considered in stable, asymptomatic, and optimally treated individuals with HFmrEF.
IIb
C
High-intensity recreational sports, adapted to the capabilities of the individual patient, may be considered in selected stable, asymptomatic, and optimally treated individuals with HFmrEF with an age-matched exercise capacity beyond average.
IIb
C
Continued


<!-- PAGE 31 -->

### Page 31

.......................................................................................................................
5.2.5 Heart failure with preserved ejection fraction
Exercise-based cardiac rehabilitation programmes are a cornerstone in the holistic prevention and management of HFpEF.260,285 Exercise intervention for 1224 weeks increases functional capacity and quality of life.286292 The beneficial effects seem to be mediated by improvement in oxidative muscle metabolism and vascular function.293 In obese patients, weight reduction has been shown to have similar effects to exercise alone,288 therefore a stable weight reduction of 10% over 24 years is recommended.294
5.2.5.1 Exercise modalities and sports participation
Higher endurance intensities such as HIIT (4  4 min at 8590%
peak heart rate, with 3 min active recovery) have revealed positive effects on myocardial function, but data are limited to a small group of patients with diabetes.295 HIIT performed over 4 weeks significantly improved VO2peak and LV diastolic function.296 Higherintensity exercise should be limited to stable patients and could be gradually introduced after 4 weeks of MCE.
Exercise sessions should start with short phases of 10 min of endurance and 10 min of resistance exercises, which should gradually be extended in time over a period of 4 weeks. The final aim should be at least 3045 min for >_3 days per week. Depending on the patient’s symptomatic status and functional capacity, intervals of higher intensity may be introduced.
Duration of intervention seems to be important for inducing functional and structural CV changes in HFpEF. Interventions over 2 years in healthy individuals reversed early signs of diastolic dysfunction.297,298 Regarding sports participation refer to section 5.2.3.
5.2.6 Exercise in individuals after heart transplantation
The exercise capacity in heart transplantation (HTx) recipients is reduced by 5060% compared with healthy age and sex-matched individuals in the general population,300302 due to several factors
(Table
13).303
Exercise reduces
CV
risk induced by posttransplantation immunosuppressive medical therapy,304
and increases physical performance,305 enabling HTx patients to achieve levels comparable to age-matched controls.306 HTx recipients participating in exercise-based cardiac rehabilitation programmes reveal a favourable outcome with respect to hospital readmission and longterm survival.305,307,308
Improvements in exercise capacity are primarily dependent on the volume of exercise. Increased functional capacity is primarily due to peripheral adaptations in the skeletal muscle including increased oxidative capacity and capillary conductance. Cardiac allograft neural reinnervation also contributes to improved functional capacity in the first year.304,309,310 If these occur, training can be performed at high levels, enabling selected HTx patients to perform marathon runs or triathlons.304,309,310
5.2.6.1 Exercise modalities and sports participation
A combination of endurance and resistance exercise is considered to be the preferred exercise programme. Mean endurance exercise intensity should start at a moderate intensity (60% VO2peak),
which can later be increased to 80% of VO2peak, a regimen level applied in the majority of exercise intervention studies in HTx.305 In uncomplicated cases these intensities can be increased to maximum levels.
It is recommended that individuals should perform up to five bouts of 30 min of exercise per week; however, exercise duration and frequency have ranged from 30 min to 90 min for 2 to 5 times per week, in previous HTx studies.305,311 Both endurance and resistance training is included in these training sessions; however, an additional 23 sessions of resistance training may be performed each week.
Resistance exercise should focus on large muscle groups using own body weight exercises or exercises on weight machines. Upper body resistance exercise should start at least 3 months after surgery,
and intensity should gradually increase from low to moderate but can
Non-competitive (low-intensity recreational skill-related sports) may be considered (when tolerated) in stable, optimally treated individuals with HFrEF.
IIb
C
High-intensity power and endurance sports are not recommended in patients with HFrEF irrespective of symptoms.
III
C
HFmrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure with reduced ejection fraction; NYHA = New York Heart Association.
aClass of recommendation.
bLevel of evidence.
Recommendations for exercise and participation in sport in individuals with heart failure with preserved ejection fraction
Recommendations
Classa
Levelb
Moderate endurance and dynamic resistance exercise, together with lifestyle intervention and optimal treatment of cardiovascular risk factors
(i.e. arterial hypertension and type 2 diabetes)
are recommended.287,289292,299
I
C
Competitive sports may be considered in selected stable patients without abnormalities on maximal exercise testing.
IIb
C
aClass of recommendation.
bLevel of evidence.
Refer also to the recommendation in section 5.2.5.
Table 13
Factors inﬂuencing decreased exercise capacity
(peak VO2) and reduced cardiac output in individuals with heart transplants
©ESC 2020
ESC Guidelines
47


<!-- PAGE 32 -->

### Page 32

.............................................................................................................................................................................
also be performed up to submaximal intensities, in case of uncomplicated disease (see section 4.1.1).
A major limitation of endurance exercise is the reduced chronotropic response to exercise because of allograft denervation. Apart from chronotropic incompetence, other pathophysiological changes present after HTx should also be considered when prescribing and conducting an exercise programme (Table 13). Exercise-induced ischaemia from cardiac allograft vasculopathy should be considered,
particularly when performing higher-intensity exercise, which has been advocated to have some superior effects on improving exercise capacity in these patients.311,312
Feasibility and safety of sports participation in stable asymptomatic
HTx patients, after therapy optimization, has been reported.
Therefore, participation in competitive sports, avoiding high-intensity power and endurance disciplines, may be considered in selected individuals.
5.3 Exercise recommendations in individuals with valvular heart disease
5.3.1 Introduction
Valvular heart disease affects approximately 12% of young exercising individuals in the general population. Reports on the natural history of valvular heart disease in athletes are sparse; however,
there is a theoretical possibility that a large stroke volume, coupled with vigorous mechanical contractions of the heart, and an increased chronotropic state induced by exercise may accelerate valve dysfunction. The ensuing effects on chronic stenotic or regurgitant lesions may cause compensatory cardiac hypertrophy,
impaired ventricular function,
myocardial ischaemia, cardiac arrhythmias, and possibly SCD.
5.3.1.1 General principles in assessment and risk stratification of individuals with valvular heart disease prior to leisure exercise or competitive sports
There are no prospective studies examining the impact of exercise on the progression of valvular disease; therefore, general guidance presented in this section is based on consensus opinions and longterm follow-up studies from non-athletic populations. Most individuals with valvular heart disease are asymptomatic or mildly symptomatic and some may aspire to engage in regular exercise programmes including leisure and competitive sports. The management of these individuals requires assessment of the symptomatic status, functional capacity, the nature of the valvular lesion, and impact of the resulting loading conditions on cardiac structure and function. All individuals should be assessed with a clinical history,
physical examination, ECG, echocardiography, and exercise stress test. The clinical history should enquire about cardiac symptoms and functional capacity. Echocardiography should focus on the valve morphology and function with particular attention to the severity and the impact of cardiac chamber size and function. Exercise testing should resemble the intensity of the sport being engaged in and should focus on inducibility of symptoms, arrhythmias, myocardial ischaemia, and the haemodynamic (BP) response to exercise. Some individuals may require exercise echocardiography to assess the severity of the valve defect.
Asymptomatic individuals with mild to moderate valvular dysfunction who have preserved ventricular function and show good functional capacity without exercise-inducible myocardial ischaemia,
abnormal haemodynamic response, or arrhythmias are considered to be at low risk and may participate in all sports. Indeed, mild valvular regurgitation (mostly tricuspid and pulmonary) are common among trained athletes and likely represent a feature of the athlete’s heart.
Conversely, individuals with exertional symptoms, moderate or severe valvular dysfunction, left or right ventricular dysfunction, pulmonary hypertension, and exercise-induced cardiac arrhythmias or abnormal haemodynamic response are considered to be at high risk and should be considered for invasive intervention.
5.3.1.2 Surveillance
All individuals with valvular heart disease should be assessed on a regular basis. The frequency of the assessment may vary from 6 monthly to 2 yearly depending on symptomatic status and the severity of valve dysfunction.
5.3.2 Aortic valve stenosis
Aortic valve stenosis (AS) is most frequently the result of an agedependent degenerative process causing progressive thickening, calcification, and reduced mobility of the cusps.313 AS causes an increase in transvalvular pressure gradient and LV workload, with consequent
LV hypertrophy, fibrosis, and increased myocardial oxygen demand.
Left ventricular ejection fraction (LVEF) is usually preserved. Affected individuals may have a normal cardiac output at rest and even during exercise, therefore, some individuals with AS are capable of good exercise performance. Nonetheless, severe AS is associated with increased risk of heart failure and SCD from mechanical outflow obstruction, malignant VAs, or coronary hypoperfusion.18,314
The diagnosis and grading of AS during echocardiography is based on well-established criteria.315 Specifically, severe AS is defined by: (i)
Recommendations for exercise and participation in sport in heart transplant recipients
Recommendations
Classa
Levelb
Regular exercise through cardiac rehabilitation,
combining moderate-intensity aerobic and resistance exercise, is recommended to revert pathophysiology to pre-transplantation time, reduce cardiovascular risk induced by post-transplantation medical treatment, and improve clinical outcome.305312
I
B
Recreational (low-intensity recreational) sports participation should be considered and encouraged in stable, asymptomatic individuals after therapy optimization.
IIa
C
Eligibility for competitive sports involving lowand moderate-intensity exercise may be considered in selected, asymptomatic individuals with an uncomplicated follow-up.304,309,310
IIb
C
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 33 -->

### Page 33

.............................................................................................
a transvalvular Doppler velocity >_4.0 m/s; (ii) a mean gradient >_40
mmHg; and (iii) a calculated aortic valve area <1.0 cm2 or an indexed area (recommended in athletes) <0.6 cm2/m2.315 In cases with a low gradient (<40 mmHg) and calculated valve area <1.0 cm2, with EF <
50% and stroke volume index <35 mL/m2, low-dose dobutamine stress echocardiography is recommended to identify pseudo-severe
AS or true severe AS.315,316 Assessment of the aortic valve calcium score with CT can be useful in borderline cases where the severity of
AS remains unclear.313,316
Exercise testing is particularly important to assess the haemodynamic response in AS and to serve as a guide to exercise prescription in cases of asymptomatic moderate and severe AS. A progressive drop in SBP with exercise, or failure to increase SBP by at least 20
mmHg, identifies subjects at higher risk.317Exercise-induced ventricular tachycardia should also be considered a criterion for exercise restrictions.
Asymptomatic individuals with mild AS may participate in all sports. Asymptomatic athletes with severe AS should not participate in any competitive or leisure sports with the exception of lowintensity skill sports. However, low-intensity aerobic exercise could be encouraged in asymptomatic individuals to improve functional capacity and general well-being.
Individuals with symptomatic AS should not participate in any competitive sport or recreational sport/exercise and valve replacement is recommended. Mild exercise, that does not provoke symptoms, may be considered in these individuals for general health benefits.
5.3.3 Aortic valve regurgitation
Aortic valve regurgitation (AR) is usually caused by a congenitally abnormal valve (i.e. bicuspid valve), degeneration of a tricuspid valve,
or loss of coaptation due to aortic root enlargement.313,318 Less common causes of AR include infective endocarditis or aortic dissection.
The haemodynamic consequence of chronic AR is characterized by a pressure and volume overload that typically leads to a dilated and hypertrophied LV. To accommodate the concomitant forward flow from the mitral valve and the backward flow from the aortic valve during diastole, the LV progressively increases in size and mass.
This remodelling may occasionally be difficult to distinguish from cardiac adaptation in athletes, especially in males with a large body size who engage in endurance activities, and therefore LV size should be interpreted in the context of the sport participated in, and the gender and body surface area of the individual.319 Males with a LV enddiastolic diameter >35 mm/m2 or a LV end-systolic diameter >50
mm, and females with a LV end-diastolic diameter >40 mm/m2 or a
LV end-systolic diameter >40 mm, should be considered to have pathological LV enlargement, irrespective of the level of physical training. These individuals should be closely monitored for a progressive increase in LV end-systolic diameter.
In individuals with suboptimal echocardiographic images, CMR has the advantages of providing an accurate assessment of LV volume and EF, flow calculations and detecting the presence of myocardial scar,319 in individuals with severe AR. Furthermore, the whole thoracic aorta can be visualized during the same examination.
Asymptomatic individuals with mild and moderate AR may participate in all sports. Asymptomatic individuals with severe AR, moderately dilated LV, and good LV systolic function may participate in
Recommendations for exercise and participation in recreational/leisure-time sports in asymptomatic individuals with aortic stenosis
Aortic stenosisc
Recommendation
Classa
Levelb
Mild
Participation in all recreational sports, if desired, is recommended.
I
C
Moderate
Participation in all recreational sports involving low to moderate intensity, if desired, should be considered in individuals with
LVEF>_50%, good functional capacity, and normal exercise test.
IIa
C
Severe
Participation in all recreational sports/exercise involving low intensity, if desired, may be considered in individuals with LVEF>_50% and normal BP response during exercise.
IIb
C
Participation in competitive or recreational sports/exercise of moderate and high intensity is not recommended.
III
C
BP = blood pressure; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant lesion
(stenotic or regurgitant) should be followed.
Recommendations for participation in competitive sports in asymptomatic individuals with aortic stenosis
Aortic stenosisc
Recommendation
Classa
Levelb
Mild
Participation in all competitive sports, if desired, is recommended.
I
C
Moderate
Participation in all competitive sports involving low to moderate effort, if desired, may be considered in individuals with LVEF>_50%, good functional capacity, and normal BP
response during exercise.
IIb
C
Severe
Participation in low-intensity skill sports may be considered in a select group of individuals with LVEF>_50%.
IIb
C
Participation in sports or exercise of moderate or high intensity is not recommended.
III
C
BP = blood pressure; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant lesion should be followed.
ESC Guidelines
49


<!-- PAGE 34 -->

### Page 34

......................................................
sports involving low and moderate intensity and may be considered for more intensive exercise on an individual basis. Such individuals require more frequent surveillance on a 6-monthly basis to assess LV
function. In asymptomatic individuals with severe AR and reduced
LVEF, surgical valve replacement/repair is indicated, and they should not participate in competitive sports but may participate in leisure sports involving only low-intensity exercise. Surgery is recommended in symptomatic individuals with severe AR. These individuals should not participate in competitive or leisure sports; however, lowintensity aerobic exercise activity is encouraged to improve functional capacity and general well-being.
5.3.4 Bicuspid aortic valve
Bicuspid aortic valve (BAV) is a common congenital abnormality with a prevalence of 12% in the general population.320 BAV may be associated with AS or AR and increased risk for ascending aortic aneurysm or dissection, and SCD.28,321 Compared with Marfan syndrome, the risk of aortopathy is lower; nonetheless BAV is much more frequent, and the relative risk of aortic dissection has been reported to be eight times greater than with a tricuspid aortic valve.321 BAV may not be identified during physical examination in the absence of valve dysfunction;58,322 however, the outcome of young individuals without valvular dysfunction is good.323,324
It is unclear whether intensive exercise accelerates aortic dilatation in the long term. A previous study comparing athletes with BAV,
non-athletes with BAV, and athletes with a normal aortic valve reported that athletes with BAV showed a 0.11 ± 0.59 mm/year increase in aortic size at the sinuses of Valsalva and 0.21 ± 0.44 mm/
year for the proximal ascending aorta, which was not dissimilar to non-athletes with a BAV.325 Currently, expert consensus panels advise a cautious approach to sports activities when the ascending aorta is above the normal limits (see section 5.4). In the absence of aortopathy, exercise recommendations for individuals with BAV are identical to those in individuals with tricuspid aortic valve dysfunction.
Recommendations for participation in recreational/leisure-time sports in asymptomatic individuals with aortic regurgitation
Aortic regurgitationc
Recommendation
Classa
Levelb
Mild
Participation in all recreational sports, if desired, is recommended.
I
C
Moderate
Participation in all recreational sports, if desired, should be considered in asymptomatic individuals with a non-dilated LV with LVEF>50% and normal exercise stress test.
IIa
C
Severe
Participation in all recreational sports involving low and moderate intensity, if desired, may be considered with a mild or moderately dilated LV with LVEF>50% and normal exercise stress test.
IIb
C
Participation in any moderate- or high-intensity recreational exercise is not recommended with LVEF<_50% and/or exercise-induced arrhythmias.
III
C
LV = left ventricle; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant lesion should be followed.
Recommendations for participation in competitive sports in asymptomatic individuals with aortic regurgitation
Aortic regurgitationc
Recommendation
Classa
Levelb
Mild
Participation in all competitive sports, if desired, is recommended.
I
C
Moderate
Participation in all competitive sports, if desired, should be considered in individuals with
LVEF>50% and normal exercise test.
IIa
C
Severe
Participation in most competitive sports involving low to moderate intensity may be considered in individuals with a mild or moderately dilated LV with LVEF>50% and normal exercise stress test.
IIb
C
Participation in any moderate- or high-intensity competitive sports is not recommended in individuals with severe AR and/or LVEF<_50% and/or exercise-induced arrhythmias
III
C
AR = aortic regurgitation; LV = left ventricle; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant lesion should be followed.


<!-- PAGE 35 -->

### Page 35

.................................
5.3.5 Primary mitral regurgitation
Most individuals with mitral valve disease have primary mitral regurgitation (MR) from myxomatous disease.326 MR is confirmed and quantified by echocardiography. General recommendations regarding exercise and sports are based on symptomatic status, severity of MR,
LV function, systolic pulmonary artery pressure (sPAP), and the presence or absence of arrhythmias during exercise. Both athletic training and MR may be associated with an enlarged LV cavity; however, an enlarged LV that is disproportionate to the level of exercise may be suggestive of severe MR and an indication to refrain from competitive or leisure sports involving moderate- or high-intensity exercise.
Asymptomatic individuals with mild or moderate MR may compete in all sports if they have good functional capacity, preserved LV
function, sPAP < 50 mmHg and absence of complex arrhythmias during exercise. Individuals with symptomatic MR and reduced exercise capacity or individuals with MR with exercise-induced complex arrhythmias should not participate in competitive or leisure sport;
however, low-intensity aerobic exercise should be encouraged to improve functional capacity and general well-being. Individuals on long-term anticoagulation therapy for AF should not engage in contact/collision sport.
Recommendations for participation in recreational/leisure-time sports in asymptomatic individuals with mitral regurgitation
Mitral regurgitationc,d
Recommendation
Classa
Levelb
Mild
Participation in all sports, if desired, is recommended.
I
C
Moderate
Participation in all recreational sports, if desired, should be considered in individuals fulﬁlling the following:
• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women
• LVEF>_60%
• Resting sPAP<50 mmHg
• Normal exercise test
IIa
C
Severe
Participation in all recreational sports involving low and moderate intensity, if desired, may be considered in individuals fulﬁlling the following:
• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women
• LVEF>_60%
• Resting sPAP<50 mmHg
• Normal exercise test
IIb
C
LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; MR = mitral regurgitation; sPAP = systolic pulmonary artery pressure.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.
dNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.
Recommendations for participation in competitive sports in asymptomatic individuals with mitral regurgitation
Mitral regurgitationc,d
Recommendation
Classa
Levelb
Mild
Participation in all competitive sports, if desired, is recommended.
I
C
Moderate
Participation in all competitive sports, if desired, should be considered in individuals fulﬁlling the following:
• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women
• LVEF>_60%
• Resting sPAP<50 mmHg
• Normal exercise test
IIa
C
Severe
Participation in competitive sports involving low exercise intensity, if desired, may be considered in individuals fulﬁlling the following:
• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women
• LVEF>_60%
• Resting sPAP<50 mmHg
• Normal exercise test
IIb
C
Participation in competitive sports is not recommended in individuals with a LVEF<60%
III
C
LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; MR = mitral regurgitation; sPAP = systolic pulmonary artery pressure.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.
dNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.
ESC Guidelines
51


<!-- PAGE 36 -->

### Page 36

.................................................................................................
5.3.5.1 Mitral valve prolapse
Mitral valve prolapse (MVP) is characterized by fibro-myxomatous changes of the mitral valve leaflets and has a prevalence of
12.4%.328,329 The diagnosis of MVP is defined as >2 mm displacement of one or both leaflets of the mitral valve beyond the annulus within the left atrium in end-systole.330 MVP is generally benign with a 10-year mortality risk of 5%.331 The majority of individuals are identified incidentally during cardiac auscultation, or echocardiography.
The most common complication of MVP is the progression to chronic severe MR, in 510% of individuals with MVP. Other complications include HF from chronic MR, pulmonary hypertension, infective endocarditis, supraventricular and VAs, and, occasionally,
SCD.313 In the Italian cardiac pathology registry of 650 SCDs in young adults, 7% were attributed to MVP.332 Most decedents showed scarring in the infero-basal wall and papillary muscles and bi-leaflet prolapse. Myocardial scarring, mitral valve annular disjunction (i.e. an abnormal atrial displacement of the mitral valve leaflet hinge point during systole),333 T-wave inversion in the inferior leads and VAs arising from the LV [right bundle branch block (RBBB) morphology]
were high-risk features for SCD.334 The mechanical strain of MVP on papillary muscles and adjacent myocardium is thought to be responsible for the myocardial scarring, which may be a possible mechanism for life-threatening arrhythmias in some individuals.335,336
In general, exercising individuals with MVP have an excellent prognosis. In a recent Italian study of 7449 young competitive athletes,
MVP was identified in 2.9%. During a follow-up period of 8 ± 2 years there were no fatalities.337 Adverse events, including progressive MR
with LV dilatation, ischaemic stroke, and AF occurred at a rate of
0.5% per annum and were more common in older athletes with baseline mitral valve disjunction or VAs.
Individuals with MVP should be evaluated with an exercise test and
24-hour ECG. Individuals with inferior T-wave inversion or ventricular premature beats arising from the LV should undergo a
CMR imaging scan to check specifically for myocardial fibrosis affecting the infero-basal wall. Other potentially high-risk markers include evidence of mechanical dispersion detected by speckled tracking echocardiography,338 coexisting prolongation of the QT interval and mitral annular disjunction.333
Given the relatively benign nature of MVP, asymptomatic patients with mild or moderate MR can participate in all competitive sports and leisure sports in the absence of the aforementioned risk factors
(Figure 8). Asymptomatic patients with severe MR but none of the above high-risk markers may compete in low- to moderate-intensity sports after detailed discussion with their specialist in the presence of
LV end-diastolic diameter (LVEDD) <60 mm (or <35.5 mm/m2 in men and <40 mm/m2 in women) with LVEF >_ 60%, resting sPAP <
50 mmHg, and normal exercise test.
Symptomatic patients with MVP and any of the aforementioned high-risk features (Figure 8) should not participate in recreational or competitive sports; however, low-intensity aerobic exercise should be encouraged to improve functional capacity and general well-being.
5.3.6 Mitral stenosis
Although rheumatic valve disease is uncommon in the western world, the increase in emigration patterns means that cardiologists may encounter individuals with rheumatic mitral stenosis (MS) who aspire to exercise. Individuals with advanced MS are usually symptomatic and incapable of engaging in exercise regimens with a high CV
demand. The risk stratification of exercising individuals with MS is based largely on a detailed echocardiogram with specific interest in the severity of the lesion and accompanying systolic PAP. In addition,
assessment should include a maximal exercise stress test to identify concealed symptoms and functional capacity.
Figure 8 Specific markers of increased risk of sudden cardiac death (SCD) with mitral valve prolapse. LV = left ventricular; MR = mitral regurgitation;
MV = mitral valve. Adapted from Gati et al.336


<!-- PAGE 37 -->

### Page 37

........................................
Asymptomatic individuals with mild MS [mitral valve area (MVA)
1.52.0 cm2] and moderate MS (MVA 1.01.5 cm2) who are in sinus rhythm and demonstrate good functional capacity on exercise testing and a normal sPAP may participate in all competitive and leisure sports. Mildly symptomatic individuals with severe MS (MVA < 1.0
cm2) may only participate in leisure exercise involving physical effort of low intensity. Individuals with symptomatic MS should be referred for intervention and advised to abstain from participation in sports and recreational exercise of moderate or high intensity. Individuals with AF should be anticoagulated and avoid contact/collision sport. In cases of balloon mitral valvuloplasty with good results (i.e. MVA > 2.0
cm2) regular exercise and competitive sport may be considered in asymptomatic individuals with good functional capacity.
5.3.7 Tricuspid regurgitation
Tricuspid regurgitation (TR) is usually secondary to left heart disease,
pulmonary hypertension, or right ventricular (RV) dysfunction. In most patients with secondary TR, exercise limitations relate to the underlying pathology.
Mild TR is common in athletes and accompanied by physiological dilatation of the inferior vena cava, which is easily collapsible with inspiration. Severe TR is characterized by increasing tricuspid annular dilatation and RV remodelling that eventually leads to RV dysfunction and a non-reactive inferior vena cava. Individuals with severe TR may also have a reduced exercise capacity due to an impaired cardiac output response with exercise.339 Furthermore, they may experience increased right- and left-sided filling pressures during exercise, the latter being due to diastolic ventricular interaction.340
In general, asymptomatic patients with TR who have good functional capacity, non-dilated right ventricle, preserved ventricular function, sPAP<40 mmHg, and absence of complex arrhythmias may compete in all competitive and recreational sports.
5.4 Exercise recommendations in individuals with aortopathy
5.4.1 Introduction
Thoracic aortic aneurysms are largely asymptomatic until a sudden and catastrophic event, including aortic rupture or dissection, occurs,
Recommendations for participation in recreational/leisure-time sports in individuals with mitral stenosis
Mitral stenosisc,d
Recommendation
Classa
Levelb
Mild (MVA 1.52.0 cm2)
Participation in all recreational sports, if desired, is recommended in individuals with a resting sPAP<40 mmHg and normal exercise test.
I
C
Moderate (MVA 1.01.5 cm2)
Participation in all recreational sports involving low and moderate intensity, if desired, may be considered in individuals with resting sPAP<40 mmHg and a normal exercise test.
IIb
C
Severe (MVA<1 cm2)
Participation in leisure sports of moderate or high intensity is not recommended.
III
C
MVA = mitral valve area; sPAP = systolic pulmonary artery pressure.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.
dNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.
Recommendations for participation in competitive sports in asymptomatic individuals with mitral stenosis
Mitral stenosisc,d
Recommendation
Classa
Levelb
Mild (MVA 1.52.0 cm2)
Participation in all competitive sports, if desired, is recommended in individuals with a resting sPAP<40 mmHg and a normal exercise test.
I
C
Moderate (MVA 1.01.5 cm2)
Participation in all competitive sports involving low intensity may be considered in individuals with a resting sPAP<40 mmHg and normal exercise test.
IIb
C
Severe (MVA<1.0 cm2)
Participation in competitive sports is not recommended.
III
C
MVA = mitral valve area; sPAP = systolic pulmonary artery pressure.
aClass of recommendation.
bLevel of evidence.
cFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.
dNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.
ESC Guidelines
53


<!-- PAGE 38 -->

### Page 38

.............................................................................................................
which can be rapidly fatal. Advanced age, male sex, long-term history of arterial hypertension, and the presence of aortic aneurysm confer the greatest population attributable risk for aortic dissection.
However, patients with genetic connective tissue disorders such as
Marfan (MFS), Loeys Dietz, Turner, or Ehlers Danlos (EDS) syndromes, and patients with BAV are at increased risk at a much younger age. BAV has a prevalence of about 12% in the general population. These patients have a relatively low risk for aortic dissection in comparison with patients with hereditary thoracic aortic disease (HTAD). Having a family history of aortic dissection or sudden death is a risk factor and a larger diameter of the aorta carries a higher risk, although dissection can occur at any diameter and especially in
EDS
patients there is no clear association with aortic diameter.341343
A dilated aortic root (>40 mm) is not a feature of athlete’s heart,
with only a small minority of young athletes (0.3%) having an enlarged aortic root diameter.344347 During follow-up no progressive enlargement of the aortic diameter was observed in these athletes,
and no aortic events occurred during a 5-year period.347
5.4.2 Risk of dissection
Because of the increase in BP and wall stress associated with intensive exercise and sports, such activities are potentially associated with an enhanced risk of expansion of the aorta and acute aortic dissection.
However, daily exercise is important in maintaining an ideal BP, heart rate, and body weight and a sedentary lifestyle is an important modifiable risk factor for CV disease and mortality. Physical activity is advised in all patients with aortic pathology, even when the aorta is dilated.
There are no randomized controlled trials on competitive sports in patients with thoracic aortic disease, or any prospective data regarding the risks of competitive athletics in patients after surgical correction; however, even after aortic root replacement, patients with MFS and other HTAD remain at risk of aortic complications.
One small prospective cohort study evaluated the feasibility and effects of a 3-week rehabilitation training programme in 19 MFS
patients with a mean age of 47 years. During the 1-year follow-up,
there were no adverse events but there was improvement in physical fitness and reduction in psychological distress. These effects were detectable after 3 weeks of rehabilitation, and mostly persisted through the 1-year follow-up. Unfortunately, no information on aortic diameters was provided.348
5.4.3 Sporting disciplines
Exercise-related acute thoracic aortic dissections are described in the literature in a total of 49 case reports. Of these, 42 patients suffered Stanford type A thoracic aortic dissections. In the majority (26/
49)
weightlifting was associated with aortic dissection.349
Furthermore, a recently published retrospective cohort study of 615
patients with acute type A aortic dissection found that 4.1% cases were related to sports activities. The type of sports most often reported was golf (32%), but this was not corrected for the percentage of participants in the sport and probably reflects that golfers are frequently older with an increased risk of hypertension and hence the potential for dissection.350
5.4.4 Effect on aortic diameter and wall stress
One cross-sectional study, which included 58 competitive athletes with BAV, showed no correlation between aortic dimensions and duration of training.351 Two studies compared athletes and sedentary individuals with BAV and reported no difference in aortic growth rate between the two groups.
Two MFS mouse models investigating the effects of mildmoderate dynamic exercise on the aortic wall showed a reduction in the growth rate of the aortic diameter in mice with MFS that performed mild to moderate dynamic exercise compared to sedentary mice with MFS.352,353 Among exercising mice, the aortic wall became stronger and a larger mechanical stress was required to induce aortic rupture. An optimum protective effect was found at a training intensity level of 5565% of maximum oxygen uptake (VO2max).
Table 14
Classiﬁcation of risk to perform sports in patients with aortic pathology
©ESC 2020
ASI = aortic size index; BAV = bicuspid aortic valve; HTAD = hereditary thoracic aortic disease; MFS = Marfan syndrome.


<!-- PAGE 39 -->

### Page 39

.............................................................................................................................................................................
5.4.5 Recommendations
Regular exercise has a well-documented benefit for fitness, psychological well-being, and social interaction, as well as a positive effect on hypertension and concomitant future risk of dissection. Most individuals with aortic pathology benefit from a certain minimal exercise programme and can at least participate in recreational sports
(Table 14). Some lesions are not compatible with endurance training and athletic sports, due to their high risk of dissection or rupture.
Recommendations for exercise and sports should be individualized and based on the underlying diagnosis, the aortic diameter, family history for dissection or sudden death (risk factor), and the pre-existing fitness and experience. An exercise test with an assessment of blood pressure response is recommended before engaging in sports.
5.5 Exercise recommendations in individuals with cardiomyopathies,
myocarditis, and pericarditis
Cardiomyopathies are an important cause of SCD/SCA in young individuals and exercise has been implicated as a trigger for fatal arrhythmias.1719,28 The detection of a cardiomyopathy in an individual has important implications with respect to ongoing participation in exercise. The advent of preventive strategies for SCD has led to a significant expansion in the number of predominantly asymptomatic young patients with cardiomyopathies who aspire to exercise. When advising such individuals, it is essential to strike a balance between protecting patients from the potentially adverse effects of exercise and depriving them of the multiple benefits of exercise.
5.5.1 Hypertrophic cardiomyopathy
The diagnosis of HCM is based on the presence of unexplained LV
hypertrophy, defined as a maximum end-diastolic wall thickness >_15
mm, in any myocardial segment on echocardiography, CMR, or CT
imaging.355 HCM may also be considered in individuals with a lesser degree of LV hypertrophy (wall thickness >_13 mm) in the context of a family history of definite HCM or a positive genetic test.355
5.5.1.1 Risk stratification in hypertrophic cardiomyopathy
Circumstantial evidence and a large systematic collection of young
SCDs in sports in the US suggest that exercise increases the risk of
SCD/SCA in individuals with HCM.18 Consistently, previous consensus recommendations have restricted all athletes with HCM from competitive sports.1,356,357
More recently, relatively small longitudinal clinical studies indicate that the risk of SCD during exercise may be considerably lower than initially considered. Lampert et al. reported that individuals with
HCM who continued participating in sports after implantable cardioverter defibrillator (ICD) implantation did not reveal an increased number of shocks during exercise.358,359 In a cross-sectional study of
187 patients with HCM, vigorous exercise was not associated with the occurrence of VAs.358 Pelliccia et al. reported outcomes in a cohort of 35 athletes with HCM, engaged in training and competitions for 5 to 31 years (mean 15 ± 8). During a 9-year follow-up period, there were no differences in the incidence of symptoms or major events between athletes who ceased exercise (n = 20) compared with athletes who continued competitive sports (n = 15).360 In a post-mortem series, only 23% of 194 deaths from HCM occurred during sport, and affected males with a mean age of 30 years.361
Finally, individuals with HCM who participated in rehabilitation programmes demonstrated a significant improvement in functional capacity without adverse events.362,363
In conclusion, there is limited evidence to indicate that all individuals with HCM are vulnerable to fatal arrhythmias during exercise and sport participation. In this regard, systematic restriction from competitive sports in all affected individuals is probably unjustified and a more liberal approach to sports participation is reasonable in some individuals after careful evaluation.3 This is particularly important for the majority of individuals with HCM who wish to participate in amateur sports or leisure-time exercise to maintain their physical and psychological well-being.
5.5.1.2 Baseline assessment of patients with HCM
A systematic approach is required when assessing an individual with
HCM who requests exercise advice. The baseline evaluation should include a comprehensive personal and family history with consideration of the age of the individual and years of exercise prior to diagnosis, assessment of the severity of the HCM phenotype, and the presence of any conventional risk factors for SCD/SCA. In older patients with HCM, the physician should review the presence of cardiac comorbidities such as hypertension and ischaemic heart disease,
which may confer a worse prognosis in HCM.364,365
5.5.1.3 History
The presence of symptoms attributed to HCM should prompt more conservative exercise recommendations. Individuals with a history of cardiac arrest or unheralded syncope and individuals with exerciseRecommendations for exercise and participation in sports in individuals with aortic pathology
Recommendations
Classa
Levelb
Prior to engaging in exercise, risk stratiﬁcation,
with careful assessment including advanced imaging of the aorta (CT/CMR) and exercise testing with blood pressure assessment is recommended.
I
C
Regular follow-up including risk assessment is recommended.
I
C
Dynamic exercise should be considered more suitable than static exercise.
IIa
C
Participation in competitive or leisure-time sports activities (except power sports) should be considered in low-risk individuals (Table 14).
IIa
C
Participation in individualized leisure exercise programmes may be considered in high-risk individuals (Table 14).
IIb
C
Competitive sports are not recommended in individuals who are at high risk (Table 14).
III
C
CMR = cardiac magnetic resonance; CT = computed tomography.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
55


<!-- PAGE 40 -->

### Page 40

....................................................................................................................................................................
induced symptoms should be advised to engage in low-intensity recreational sports only.
5.5.1.4 Resting and ambulatory ECG
The resting 12-lead ECG has limited value in risk stratification.
Ambulatory ECG monitoring, preferably for 48 h, is important for detecting ventricular and supraventricular arrhythmias. The monitoring period should include an exercise session. Asymptomatic nonsustained ventricular tachycardia (NSVT) confers considerable risk of
SCD in younger individuals (<_35 years).355 Paroxysmal supraventricular arrhythmias may pose significant implications for functional capacity and, in the case of AF, for stroke prevention.366
5.5.1.5 Echocardiography
In relation to risk stratification for SCD the clinician should assess the following echocardiographic indices: (i) LV wall thickness; (ii) LV outflow tract (LVOT) gradient; and (iii) left atrial diameter.355 All individuals should have the LVOT gradient assessed at rest, during the
Valsalva manoeuvre, on standing suddenly, and after light exercise on the spot, such as repeated squats. By convention, LVOT obstruction is defined as a peak pressure gradient >_30 mmHg at rest or during physiological provocation. A gradient >_50 mmHg is considered to be haemodynamically important. Exercise stress echocardiography should be considered in individuals with exertional symptoms who have resting systolic anterior motion of the mitral valve leaflets but who do not reveal LVOT obstruction or show only mild to moderate
LVOT obstruction with the aforementioned manoeuvres.
5.5.1.6 Cardiac magnetic resonance imaging
CMR imaging is increasingly recognized as a necessary tool for confirming diagnosis and to assess risk stratification in individuals with
HCM. Late gadolinium enhancement (LGE), indicative of myocardial fibrosis, may be present in up to 75% of patients with HCM and, by itself, is a poor discriminator of outcomes. However, the presence of extensive (>_15% of LV myocardium) LGE may identify individuals at increased risk of ventricular tachyarrhythmias and SCD.367370
5.5.1.7 Exercise testing
Exercise testing (or CPET) should be part of the routine evaluation to assess functional capacity in an individual with HCM who intends to exercise. In addition, an abnormal BP response to exercise
(defined as <20 mmHg increase in SBP from baseline, or exerciseinduced hypotension)371,372 and the presence of exercise-induced symptoms or arrhythmias are markers of high risk and should result in more conservative exercise recommendations.
5.5.1.8 Genetic testing
Currently genetic testing is reserved for familial cascade screening. It does not inform decisions relating to the risk of SCD/SCA and should not be performed for exercise risk stratification.
5.5.1.9 ESC risk score in HCM
The ESC risk score uses seven variables (age, syncope, family history of SCD from HCM, maximal LV wall thickness, left atrial diameter, LV outflow obstruction, NSVT) to assess the risk of SCD of patients with HCM.355,373 This information can be inserted into an online calculator (https://doc2do.com/hcm/
webHCM.html) to estimate individualized 5-year risk to provide guidance on whether a prophylactic ICD is indicated. For the purposes of these Guidelines the risk of SCD is defined as low if <4%, moderate if between >_4% and <6%, and high if >_6% in
5 years.
5.5.1.10 Exercise recommendation
On completion of the baseline evaluation, the physician should consider: (i) the presence of symptoms; (ii) ESC risk score; (iii) presence of resting or inducible LVOT obstruction during exercise; (iv) the haemodynamic (BP) response to exercise; and (v) the presence of resting or exercise-induced arrhythmias before recommending the appropriate form and intensity of exercise.
Although these Guidelines advocate for a more liberal approach to sports participation, it is indisputable that even the absence of all major risk factors does not convey immunity to SCD.374 In addition, the ESC risk score relies on evidence derived from predominantly non-athletic cohorts.373 Whereas there are no data to suggest that this approach to risk estimation is less valid in athletic individuals, one has to consider that it may not accurately reflect the risk of SCD in individuals exposed to the haemodynamic and metabolic stresses of high-intensity sports. Therefore, when advising an individual with HCM regarding participation in high-intensity exercise programmes and competitive sports, this consideration should be an integral part of the discussion during the shared decision-making process.
5.5.1.11 Special considerations
The age of an individual may have an impact on risk. The mean age of death in the largest series of SCD from the US was 18 years,
with 65% of deaths occurring in athletes <_17 years.354 Although young age should not exclude an individual from high-intensity exercise in the absence of additional risk factors, it should be considered in the discussion with the individual and the parents or guardians. In addition, specific sports may pose a higher risk for
SCD, such as highly dynamic, startstop sports like basketball and football.17,58
Individuals who have a positive genotype but who do not reveal any phenotypic structural or arrhythmia features of HCM may engage in all sports. Such individuals should be assessed annually for phenotypic features and risk stratification purposes.
5.5.1.12 Follow-up
Annual follow-up is recommended for most individuals with HCM
who exercise on a regular basis. More frequent (6-monthly) followup should be considered in adolescent individuals and young adults whose phenotype, and therefore risk of SCD, may still be evolving and who are more vulnerable to exercise-related SCD.58,239Followup evaluation should focus on assessment of disease progression and risk stratification. New symptoms should prompt interruption of exercise and re-evaluation.


<!-- PAGE 41 -->

### Page 41

.............................................................................................................................................................................
5.5.2 Arrhythmogenic cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is defined pathologically by the presence of fibro-fatty replacement of the right ventricle and clinically by life-threatening VAs. The condition was initially recognized as a predominantly RV disease, and diagnosis is currently based on probabilistic Task Force Criteria that encompass electrophysiological, anatomical, functional, and clinical features of the disease.375 Since its first description, the concept of ARVC has evolved to include concealed or subclinical phenotypes and biventricular disease. It is now well established that both ventricles are affected in most cases.376378 This has led to the development of a new term, arrhythmogenic cardiomyopathy, that embraces an array of diagnostic terms for different (genetic and acquired) pathologies.
Although the definition of ‘arrhythmogenic cardiomyopathy’ is yet to be agreed, it can be considered as an umbrella term for a family of diseases that are characterized by biventricular myocardial abnormalities, including fibro-fatty infiltration and scarring, identified by pathological examination and/or cardiac imaging and VA.
The term arrhythmogenic cardiomyopathy (ACM) is used throughout these recommendations; however, it is important to recognize that most of the literature on the influence of exercise on disease progression and risk of SCD is derived from cohorts with classical ARVC. This is reflected in the recommendations provided in these Guidelines. It is possible therefore that the recommendations may not accurately reflect predominantly LV disease, which constitutes a small proportion of the disease spectrum where the impact of exercise on disease phenotype and risk is less clarified than the RV
variant. Where appropriate, guidance is provided for other conditions that can be reasonably considered under the umbrella of ACM
[including subtypes of dilated cardiomyopathy (DCM)].
5.5.2.1 Risk stratification in arrhythmogenic cardiomyopathy
ACM accounts for a significant proportion of SCDs in young and athletic individuals.28 Established risk factors for SCD that should prompt consideration for an ICD include aborted SCD, unheralded syncope, ventricular tachycardia, and impaired RV and/or LV systolic function.379 A novel risk prediction model for VAs has recently been proposed but is yet to be validated.380 Regular and high-intensity exercise programmes are associated with acceleration of the disease process and worse outcomes.381389
In an experimental model of heterozygous plakoglobin-deficient mice, exercise training accelerated RV dysfunction and arrhythmias.382 Similar results have been confirmed in human desmosomal mutation carriers participating in vigorous (>70% VO2max) endurance sports.384 Similar findings were reported in patients with ACM and asymptomatic gene-positive family members, despite a more conservative definition of athletic status (exercise with intensity >_6 METs for >_4 h/week for >_6 years).386 Recently, the results from the North
American multidisciplinary study reported that patients engaging in competitive sports were at two-fold increased risk of ventricular tachyarrhythmias or death and earlier presentation of symptoms,
compared with patients who participated in recreational sports and sedentary individuals.385 Among patients engaging in competitive sports, early age of sports initiation was associated with premature presentation of symptoms and adverse clinical profile. Reducing exercise intensity was associated with a substantial decrease in the risk of ventricular tachyarrhythmias or death, to the same level as inactive patients.385 Finally, in a multinational registry of 393 competitive athletes implanted with an ICD who continued to participate in regular competitions, 20% of athletes with ACM received a shock during exertion compared to 10% at rest, during a median follow-up of 44
months. The diagnosis of ACM was the only variable associated with receiving appropriate shocks during competition.359,389
5.5.2.2 Baseline assessment of patients with arrhythmogenic cardiomyopathy
A systematic approach is required when assessing individuals with
ACM who request exercise advice. The baseline evaluation should include a comprehensive history of symptoms and family history of
ACM or SCD, assessment of the severity of the ACM phenotype,
and the presence of any conventional risk factors for SCD/SCA.
Recommendations for exercise and sports participation in individuals with hypertrophic cardiomyopathy
Recommendations
Classa
Levelb
Exercise recommendations
Participation in high-intensity exercise/competitive sports, if desired (with the exception of those where occurrence of syncope may be associated with harm or death), may be considered for individuals who do not have any markers of increased riskc following expert assessment.
IIb
C
Participation in low- or moderate-intensity recreational exercise, if desired, may be considered for individuals who have any markers of increased riskc following expert assessment .
IIb
C
Participation in all competitive sports, if desired,
may be considered for individuals who are gene positive for HCM but phenotype negative.
IIb
C
Participation in high-intensity exercise (including recreational and competitive sports) is not recommended for individuals who have ANY markers of increased riskc.
III
C
Follow-up and further considerations relating to risk
Annual follow-up is recommended for individuals who exercise on a regular basis.
I
C
Six-monthly follow-up should be considered in adolescent individuals and young adults who are more vulnerable to exercise-related SCD.
IIa
C
Annual assessment should be considered for genotype-positive/phenotype-negative individuals for phenotypic features and risk stratiﬁcation purposes.
IIa
C
BP = blood pressure; ESC = European Society of Cardiology; HCM = hypertrophic cardiomyopathy; LVOT = left ventricular outﬂow tract obstruction cardiomyopathy; SCD = sudden cardiac death.
aClass of recommendation.
bLevel of evidence.
cMarkers of increased risk include: (i) cardiac symptoms or history of cardiac arrest or unexplained syncope; (ii) moderate ESC risk score (>_4%) at 5 years; (iii)
LVOT gradient at rest >30 mmHg; (iv) abnormal BP response to exercise; (v)
exercise-induced arrhythmias.
Refer to Table 4 for different indices of exercise intensity and training zones.
ESC Guidelines
57


<!-- PAGE 42 -->

### Page 42

................................................................
5.5.2.3 History
Syncope due to presumed arrhythmia is an important risk marker for SCD/SCA and a predictor of future appropriate ICD
therapies.390394 The presence of symptoms attributed to ACM
should reinforce the conservative exercise recommendations.
Individuals with a history of cardiac arrest or unheralded syncope and individuals with exercise-induced symptoms should be advised to engage only in low-intensity recreational exercise programmes.
5.5.2.4 Resting and ambulatory ECG
Apart from its diagnostic utility, the 12-lead ECG may provide useful information relating to risk stratification in ACM. The presence of extensive T-wave inversion affecting >_3 precordial leads or T-wave inversion in two of the three inferior leads confers some additional risk for SCD/
SCA.395,396
Ambulatory ECG monitoring is important for detecting VAs.
Every effort should be made for the monitoring period to include the proposed exercise session. The presence of NSVT or significant burden of ventricular ectopy (>_1000/24 h), even in asymptomatic individuals, confers an increased risk of fatal arrhythmias.392,393,397
5.5.2.5 Echocardiography and cardiac magnetic resonance imaging
In relation to risk stratification for SCD, the clinician should assess the severity of RV and LV involvement in terms of ventricular dilatation and systolic dysfunction. CMR imaging is more useful than echocardiography for assessing
RV
wall motion abnormalities and can also quantify the degree of myocardial fat infiltration and/or scar. The more extensive the disease the higher the arrhythmic risk.398,399
5.5.2.6 Exercise testing
Exercise testing should be part of the routine assessment of every individual with ACM who wishes to exercise, as it can provide information regarding functional capacity and risk stratification. Exercise testing in patients with ACM should not be performed during ‘hot phases’. The presence of exercise-induced symptoms or arrhythmias should result in more conservative recommendations.
5.5.2.7 Genetic testing
Genotype may also be of prognostic value. In the ARVC variant, a number of studies have reported that carriers of multiple pathogenic variants in the same desmosomal gene or mutations in >_2 genes may have an almost four-fold higher arrhythmic risk than those with a single mutation.400 Particular genotypes such as DSP and TMEM43, but also LMNA and FLNC, associated with other ACM phenotypes (see section 5.5.4) have a propensity for high arrhythmic burden that can pre-date the structural phenotype.401,402
5.5.2.8 Exercise recommendations
The overall scientific evidence supports the concept that in patients with ACM participation in high-intensity sports should be discouraged, because it is associated with accelerated disease progression,
greater risk of VAs and major events. This recommendation is also applicable to genetic carriers of pathogenic variants for ACM even in the absence of overt disease phenotype.
5.5.2.9 Special considerations
Young age of presentation and male sex are associated with increased risk of malignant arrhythmias in ACM.379 Although young age should not exclude an individual from moderate-intensity exercise in the absence of high-risk features, age should be considered in the discussion with the patient and the parents. In addition, one should consider that specific highly dynamic, startstop sports, such as basketball and football, may pose a higher risk of SCD particularly in athletes who compete at the highest level.17,365
5.5.2.10 Follow-up
An annual follow-up is recommended for most individuals with ACM who exercise on a regular basis. More frequent (6monthly) follow-up should be considered for adolescent and young adults whose ACM phenotype, and therefore risk of SCD,
may still be evolving, particularly if they engage in moderate- to high-intensity exercise. More frequent follow-up should also be considered in individuals with high arrhythmic risk genotypes such as DSP, TMEM43, and carriers of multiple pathogenic variants.
New symptoms should prompt interruption of exercise and reevaluation.
Recommendations for exercise and sports participation in individuals with arrhythmogenic cardiomyopathy
Recommendations
Classa
Levelb
Exercise recommendations
Participation in 150 min of low-intensity exercise per week should be considered for all individuals.
IIa
C
Participation in low- to moderate-intensity recreational exercise/sports, if desired, may be considered for individuals with no history of cardiac arrest/VA, unexplained syncope, minimal structural cardiac abnormalities, <500 PVCs/24 h and no evidence of exercise-induced complex VAs.
IIb
C
Participation in high-intensity recreational exercise/
sports or any competitive sports is not recommended in individuals with ACM, including those who are gene positive but phenotype negative.384,386
III
B
Follow-up and further considerations relating to risk
Annual follow-up is recommended for individuals who exercise on a regular basis.
I
C
Six-monthly follow-up should be considered in adolescent individuals and young adults who are more vulnerable to exercise-related SCD.
IIa
C
Annual assessment should be considered for genotype-positive/phenotype-negative individuals for phenotypic features and risk stratiﬁcation purposes.
IIa
C
Six-monthly follow-up should also be considered in individuals with high arrhythmic risk genotypes such as DSP, TMEM43, and carriers of multiple pathogenic variants.
IIa
C
ACM = arrhythmogenic cardiomyopathy; PVC = premature ventricular contraction; SCD = sudden cardiac death; VA = ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
Refer to Table 4 for different indices of exercise intensity and training zones.


<!-- PAGE 43 -->

### Page 43

.....................................................................................................
5.5.3 Exercise recommendations in individuals with left ventricular non-compaction
LV non-compaction (LVNC) is an unclassified cardiomyopathy characterized by prominent trabeculation and deep recesses that communicate with the LV cavity.403,404 Clinical presentation of LVNC
includes progressive LV systolic dysfunction, ventricular tachyarrhythmias, and thromboembolic events.404
Athletes often demonstrate LV hypertrabeculation and up to 8% fulfil the echocardiographic criteria for a diagnosis of LVNC.405 It is hypothesized that an increased cardiac preload may unmask LV trabecular morphology.406 Therefore, among athletic individuals, the suspicion of
LVNC should only be considered in those who fulfil echocardiographic criteria for LVNC but also have either LV systolic dysfunction (EF <
50%), symptoms suggestive of cardiac disease, or a positive family history of LVNC.407409 Additional echocardiographic criteria include a very thin compacted epicardial layer (5 mm in end-diastole on CMR, or
<8 mm in systole) and abnormal myocardial relaxation (average E’ < 9
cm/s on tissue Doppler imaging).404,405,410,411 Such athletes will require further assessment with CMR, exercise echocardiography, and Holter monitor to assess the presence of LV fibrosis, cardiac thrombi, contractile reserve, and exercise-induced complex arrhythmias.405,406
5.5.3.1 Risk stratification
The clinical outcomes of LVNC are determined by the presence of symptoms, severity of LV dysfunction, and the nature of the VAs.
There are no reported adverse cardiac events in the absence of LV
dysfunction regardless of the severity of LV trabeculation.405409
5.5.3.2 Follow-up
Regular follow-up is recommended for individuals with LVNC. New symptoms should prompt interruption of exercise and re-evaluation.
5.5.4 Exercise recommendations in individuals with dilated cardiomyopathy
DCM is characterized by LV or biventricular systolic dysfunction with or without dilatation that are not explained by abnormal loading conditions or CAD. Possible causes include genetic predisposition, myocarditis, drugs, toxins, peripartum cardiomyopathy, and, in some cases, the cumulative effect of more than one factor.412
The clinical spectrum of disease may range from a mild phenotypic expression characterized by absence of symptoms, isolated LV dilatation and normal or low-normal systolic function, to an overt disease phenotype with limiting symptoms and significant systolic dysfunction. Ventricular arrhythmias are common in DCM, particularly in individuals with previous myocarditis, or with lamin A/C mutations and filamin C mutations.413,414 The risk of SCD in DCM is 23% per year and increases with lower EF and higher NYHA class.415 Exercise training improves functional capacity, ventricular function, and quality of life in patients with DCM and should therefore be considered as an integral part of the management of affected individuals.416,417
However, intensive exercise and competitive sports are reported as a cause of SCD in DCM. 28,46,58,413,418
LV cavity enlargement in trained individuals that is not associated with systolic dysfunction and outside the context of a familial disease,
represents a benign physiological adaptation if it is consistent with the type of sports participated (usually, endurance sports) and the body size of the athlete. Conversely, a mildly reduced EF (4550%) in an athlete with an enlarged LV cavity should not merely be considered as a normal adaptation. In such cases assessment of LV function during exercise may provide important diagnostic clues.319 Failure to increase EF at peak exercise by >10% compared with the baseline value may suggest a pathological condition.319,419,420 The presence of diastolic dysfunction or reduced peak oxygen consumption on CPET may also provide supporting information for the differential diagnosis. CMR has emerged as an important tool for the diagnosis and risk stratification of DCM.
Recommendations for exercise in individuals with left ventricular non-compaction cardiomyopathy
Recommendation for diagnosis
Classa
Levelb
A diagnosis of LVNC in athletic individuals should be considered if they fulﬁl imaging criteria, in association with cardiac symptoms, family history of
LVNC or cardiomyopathy, LV systolic (EF<50%)
or diastolic (E’<9 cm/s) dysfunction, a thin compacted epicardial layer (<5 mm in end-diastole on
CMR, or <8 mm in systole on echocardiography),
or abnormal 12-lead ECG.404,405,410,411
IIa
B
Exercise recommendations
Participation in high-intensity exercise and all competitive sports, if desired, with the exception where syncope may cause serious harm or death,
may be considered in asymptomatic individuals with LVNC and LVEF>_50% and absence of frequent and/or complex VAs.
IIb
C
Participation in recreational exercise programmes of low to moderate intensity, if desired, may be considered in individuals with LVEF 4049% in the absence of syncope and frequent or complex VAs on ambulatory Holter monitoring or exercise testing.
IIb
C
Continued
Participation in high- or very high-intensity exercise including competitive sports, if desired, may be considered for individuals who are gene positive for LVNC but phenotype negative (with the exception of lamin A/C or ﬁlamin C carriers).
IIb
C
Participation in high-intensity exercise or competitive sports is not recommended in individuals with any of the following: symptoms, LVEF<40% and/or frequent and/or complex VAs on ambulatory
Holter monitoring or exercise testing.
III
C
Follow-up and further considerations
Annual assessment for risk stratiﬁcation is recommended for individuals with LVNC and genotypepositive/phenotype-negative individuals who exercise on a regular basis.
I
C
CMR = cardiac magnetic resonance; ECG = electrocardiogram; EF = ejection fraction; LV = left ventricular; LVEF = left ventricular ejection fraction; LVNC =
left ventricular non-compaction; VA = ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
59


<!-- PAGE 44 -->

### Page 44

.........................................................................
Specifically, the presence of LGE, with the typical mid-wall distribution,
has been associated with increased risk of VAs and SCD.319,419,421424
5.5.4.1 Baseline assessment of patients with dilated cardiomyopathy
Clinical evaluation of affected individuals who request exercise advice should aim to: (i) ascertain the potential aetiology; (ii) assess the clinical status including exercise history and functional capacity; (iii)
review the degree of LV dilatation and dysfunction; (iv) assess the haemodynamic response to exercise; and (v) assess the presence of exercise-induced symptoms or arrhythmias.
In general, symptomatic individuals with DCM should abstain from most competitive and leisure sports or recreational exercise associated with moderate or high exercise intensity. A select group of asymptomatic individuals with DCM who have mildly impaired LV function
(LVEF 4550%) without exercise-induced arrhythmias or significant myocardial fibrosis may participate in most competitive sports.
5.5.4.2 Special considerations
Although the natural history of most pathogenic variants is unknown, it would be reasonable to permit intensive exercise and competitive sports in most individuals with pathogenic variants implicated in DCM in the absence of overt features of DCM. Special consideration, however,
should be given to individuals with pathogenic variants that are associated with an increased risk of life-threatening arrhythmias such as lamin
A/C or filamin C mutations. There is emerging evidence that exercise may have an adverse effect on cardiac function and risk for potentially fatal arrhythmias in individuals harbouring pathogenic variants in lamin
A/C.425427 Affected individuals should not engage in any competitive sports or recreational exercise of high or very high intensity irrespective of the severity of LV dysfunction and dilatation.428,429
5.5.4.3 Follow-up.
Regular follow-up is recommended for most individuals with DCM. New symptoms should prompt interruption of exercise and re-evaluation
5.5.5 Exercise recommendations in individuals with myocarditis and pericarditis
5.5.5.1 Myocarditis
Myocarditis is a non-ischaemic inflammatory disease of the myocardium, which may cause cardiac dysfunction and arrhythmias.
Myopericarditis is defined as a primary pericarditis with associated myocardial inflammation and biomarker evidence of myocyte necrosis.430,431 The aetiology of myocarditis is heterogenous, but viral infection is the most common cause in the developed world.
Enterovirus, Coxsackie B virus, parvovirus B-19, and human herpesvirus 6 are the most frequently responsible infectious pathogens.432,433
In the context of young individuals, toxins such as cocaine and amphetamine-based supplements should also be evaluated in the clinical history.430
The clinical presentation is highly variable and the diagnosis can be challenging. The illness may be proceeded by coryzal symptoms and athletic individuals may present with non-specific features of general malaise, fatigue, or diarrhoea.430,431 At the other extreme, myocarditis may simulate MI or present with symptomatic supraventricular and
VAs unexplained by other causes, HF, cardiogenic shock, or SCD.
Approximately 50% of individuals reveal full resolution of LV function within 30 days, 25% show persistent cardiac dysfunction, and
1225% progress to fulminant HF. LV dysfunction is an important prognostic factor in the long term.28,434
Recommendations for exercise in individuals with dilated cardiomyopathy
Recommendations
Classa
Levelb
Participation in low- to moderate-intensity recreational exercise should be considered in all individuals with DCM, regardless of the EF, in the absence of limiting symptoms, and exercise-induced VAs.
IIa
C
Participation in high- or very high-intensity exercise including competitive sports (with the exception of those where occurrence of syncope may be associated with harm or death) may be considered in asymptomatic individuals who fulﬁl all of the following: (i) mildly reduced LV systolic function (EF 4550%); (ii) absence of frequent and/or complex VAs on ambulatory Holter monitoring or exercise testing; (iii) absence of LGE on CMR;
(iv) ability to increase EF by 1015% during exercise; and (v) no evidence of high-risk genotype
(lamin A/C or ﬁlamin C).
IIb
C
Continued
Participation in all competitive sports may be considered in individuals with DCM who are genotype positive and phenotype negative, with the exception of carriers of high-risk mutations (lamin
A/C or ﬁlamin C).
IIb
C
Participation in high- or very high-intensity exercise including competitive sports is not recommended for individuals with a DCM and any of the following: (i) symptoms or history of cardiac arrest or unexplained syncope; (ii) LVEF<45%; (iii)
frequent and/or complex VAs on ambulatory
Holter monitoring or exercise testing; (iv) extensive LGE (>20%) on CMR; or (v) high-risk genotype (lamin A/C or ﬁlamin C).
III
C
Follow-up recommendations
Annual follow-up is recommended for individuals with DCM who exercise on a regular basis.
I
C
Six-monthly follow-up should be considered in individuals with high-risk mutations and adolescent individuals and young adults whose DCM phenotype may still be evolving and who are more vulnerable to exercise-related SCD.
IIa
C
Annual assessment should be considered for genotype-positive/phenotype-negative individuals for phenotypic features and risk stratiﬁcation purposes.
IIa
C
CMR = cardiac magnetic resonance; DCM = dilated cardiomyopathy; EF = ejection fraction; LGE = late gadolinium enhancement; SCD = sudden cardiac death;
VA = ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 45 -->

### Page 45

..........................................................................................................................................................................
5.5.5.2 Diagnosis
Serum cardiac troponin is usually elevated in myopericarditis and is a sensitive marker of cardiac inflammation-induced myocyte necrosis.435
The ECG has low sensitivity and electrical anomalies are nonspecific. ECG patterns vary from non-specific T-wave and STchanges to ST-segment elevation mimicking MI, left bundle branch block (LBBB), or frequent and/or complex ventricular and supraventricular arrhythmias, or atrioventricular block, or low QRS voltages in the presence of a pericardial effusion.436
Recognized echocardiographic features of overt myocarditis include a non-dilated LV cavity with increased myocardial wall thickness (when oedema is present), or mildly dilated LV cavity with a thinned myocardial wall, usually with regional wall motion abnormalities.437 The global LV systolic function may range from being almost normal to severely depressed. Regional wall motion abnormalities may be present.438
CMR is the most useful diagnostic tool and has excellent sensitivity for detecting myocardial hyperaemia, inflammation, oedema and/or focal scar.439,440 The Lake Louise Criteria and LGE are now complemented by CMR techniques of T1/T2 mapping and extracellular volume fraction (ECV).440442 The extent and distribution of LGE with non-ischaemic pattern are independent predictors of CV events during follow-up.439,440,443447 Namely, a 10% increase of LGE volume conveys a 79% increase in the risk of major CV events.448,449
Endomyocardial biopsy is the gold standard for the diagnosis of myocarditis.450,451 A histological diagnosis allows distinction between the different types of inflammatory processes, (i.e. giant cell myocarditis), and guides treatment in life-threatening presentations.430,445,452 The diagnostic yield of endomyocardial biopsy can be improved by analysing the viral genome through DNARNA extraction and reverse transcriptase polymerase chain reaction (RT-PCR) amplification, which has the advantage of identifying the disease-causing pathogen.445
5.5.5.3 Risk stratification
Case series have established myocarditis as a risk factor for SCD,
which accounts for up to 220% of sudden death in athletes.17,18,28,430,453,454 Murine models have shown that daily exercise in mice infected with Coxsackie virus is associated with increased viral titres, fulminant myocarditis, and sudden death.455 These animal models provide some insight into the mechanisms of SCD with exercise, which appears to cause an accelerated and progressive inflammatory response.455458
5.5.5.4 Exercise recommendations for individuals with myocarditis
Athletic individuals with a probable or definitive diagnosis of recent myocarditis should be advised to abstain from competitive sports or leisure sports while active inflammation is present, regardless of age,
sex, or extent of LV systolic dysfunction.459,460
The duration of myocardial inflammation can be highly variable and may take several months for full resolution. Both the ESC and
AHA recommend abstinence from moderate- to high-intensity exercise for a period of 36 months,459,460 although the precise timing for return to competitive or recreational sports involving moderate- or high-intensity exercise may be guided by the presence of inflammation on T2-weighted images and LGE uptake on CMR.3,461
Individuals with myocarditis should have a comprehensive evaluation after complete recovery to assess the risk of exercise-related SCD.
Imaging studies, exercise stress test, and Holter monitor provide essential information for risk stratification. Depressed LV function, presence of LGE and complex VAs during exercise or Holter monitoring are recognized risk markers for adverse outcomes.455,462,463
Repeat evaluation should consist of measurement of troponin and biomarkers of inflammation, echocardiography, and prolonged ECG
monitoring. Individuals without evidence of ongoing inflammation should undergo an exercise stress test. A CMR should be repeated if myocardial oedema or LGE was present during the acute illness.
Return to sporting activities should be considered, in asymptomatic individuals, with normal troponin and biomarkers of inflammation,
normal LV systolic function on echocardiography and CMR, no evidence of ongoing inflammation or myocardial fibrosis on CMR, good functional capacity, and absence of complex arrhythmias during exercise on prolonged ECG monitoring .430,434,453,459,460,464
Individuals with previous myocarditis are at risk of recurrence and silent clinical progression, and the presence of LGE during the acute presentation is associated with increased incidence of major adverse cardiac events; therefore, periodic re-evaluation is advised on an annual basis.443,445,454,463
Among individuals with healed myocarditis with persistence of
LGE on CMR but no myocardial oedema at 36 months, those who are asymptomatic, with normal troponin and biomarkers of inflammation, normal LV systolic function, no evidence of ongoing inflammation on CMR, and absence of complex arrhythmias during exercise on prolonged ECG monitoring (48 h Holter ECG and exercise stress testing), should be evaluated on a case by case basis and may return to competitive sports on an individual basis. In contrast,
individuals with extensive myocardial scar (>20% LGE) and persistent
LV dysfunction should abstain from exercise programmes and sports activities involving moderate or high physical intensity.
5.5.6 Pericarditis
Pericarditis is defined as an inflammatory disorder of the pericardium,430,465 which may be preceded by upper respiratory or gastrointestinal symptoms. As with myocarditis, viral pathogens are the most commonly implicated pathogens in the western world.
5.5.6.1 Diagnosis
The ECG is non-specific but may reveal characteristic concave STsegment elevation in most leads and/or PQ depression in the acute phase. Echocardiography may reveal a pericardial effusion. CMR
should be considered in individuals with raised cardiac troponin levels to assess for concomitant myocardial inflammation. Furthermore,
CMR will identify active inflammation of the pericardium, thickened pericardial layers, and any signs of pericardial constriction.
5.5.6.2 Risk stratification
Pericarditis is generally associated with an excellent prognosis.430,465,466
However, there are a subset of patients who may be at greater risk of recurrence and these include individuals with a temperature >38C at
ESC Guidelines
61


<!-- PAGE 46 -->

### Page 46

...................................................................................................
presentation, large pericardial effusion, and those who are resistant to therapy with non-steroidal anti-inflammatory drugs.465,466
5.5.6.3 Exercise recommendations for individuals with pericarditis
Exercise should be avoided in individuals during active pericarditis.
Individuals can return to exercise after complete resolution of the active disease.467 Individuals with a milder clinical course and rapid resolution can return to sporting activities within 30 days. However,
in more severe cases, it may be necessary to wait for a period of 3
months for complete resolution followed by re-evaluation before returning to sports.
Asymptomatic individuals with a small pericardial effusion occasionally detected on echocardiography in the absence of clinical correlates should be monitored with periodic surveillance, but should not be restricted from sports participation. Competitive sports and/
or moderate- to high-intensity leisure-time activities should be avoided in individuals with constrictive pericarditis. Individuals with myopericarditis should be managed according to the recommendations for myocarditis.
5.6 Exercise recommendations in individuals with arrhythmias and channelopathies
5.6.1 A general management framework
When individuals with known arrhythmias or with a potentially arrhythmogenic condition want to engage in sports activity, three principle questions should guide management: (1) is there an increased risk for life-threatening arrhythmias?; (2) how does one control symptoms due to arrhythmias, during sports, but also at rest?; and (3) what is the impact of sports on the natural progression of the arrhythmogenic condition? The general view on the association between sports and arrhythmias is that exercise sets the stage for an arrhythmia in the context of an underlying and pre-existing condition, be it structural, electrical, inherited, or acquired. Moreover,
regular exercise programmes may induce or accelerate the progression of ARVC,382,384 even among those without underlying mutations.383,387,468 Conceptually, all the structural and functional cardiac adaptations to regular intensive exercise may contribute to the development of arrhythmias, at the atrial, nodal, and ventricular level.469
This concept explains why recommendations for sports participation in individuals with arrhythmogenic conditions are so complex.
5.6.2 Atrial fibrillation
5.6.2.1 Patients without atrial fibrillation
Moderate, regular PA is a cornerstone in the prevention of AF
through modifying many of its predisposing factors.297,470473
Patients at risk of AF should therefore be motivated to exercise (see section 4.2). Conversely, AF is more prevalent in active and former male master athletes and those performing high-intensity endurance sports, suggesting a U-shaped relationship between habitual exercise and AF.471,474477 478481 This association has not been confirmed in women.474
Recommendations for exercise in individuals with myocarditis
Recommendations
Classa
Levelb
Comprehensive evaluation, using imaging studies,
exercise stress test and Holter monitoring, is recommended following recovery from acute myocarditis to assess the risk of exercise-related
SCD.455,462,463
I
B
Return to all forms of exercise including competitive sports should be considered after 36
months in asymptomatic individuals, with normal troponin and biomarkers of inﬂammation, normal
LV systolic function on echocardiography and
CMR, no evidence of ongoing inﬂammation or myocardial ﬁbrosis on CMR, good functional capacity, and absence of frequent and/or complex
VAs on ambulatory Holter monitoring or exercise testing.430,434,453,459,460,464
IIa
C
Among individuals with a probable or deﬁnitive diagnosis of recent myocarditis, participation in leisure-time or competitive sports while active inﬂammation is present is not recommended.459,460
III
C
Participation in moderate- to high-intensity exercise for a period of 36 months after acute myocarditis is not recommended.459461,467
III
B
Participation in leisure exercise or competitive sports involving high intensity in individuals with residual myocardial scar and persistent LV dysfunction is not recommended.
III
C
CMR = cardiovascular magnetic resonance; LV = left ventricular; SCD = sudden cardiac death; VA = ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
Recommendations for exercise in individuals with pericarditis
Recommendations
Classa
Levelb
Return to all forms of exercise including competitive sports is recommended after 30 days to 3
months for individuals who have recovered completely from acute pericarditis, depending on clinical severity.459,460
I
C
Participation in leisure-time or competitive sports is not recommended for individuals with a probable or deﬁnitive diagnosis of recent pericarditis while active inﬂammation is present, regardless of age, sex, or extent of LV systolic dysfunction.459,460
III
C
Participation in moderate- to high-intensity exercise, including competitive sports, is not recommended for individuals with constrictive pericarditis.
III
C
LV = left ventricle.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 47 -->

### Page 47

###### 5.6.2.2 Prognostic and symptomatic relevance of AF during sports

Underlying structural heart disease or pre-excitation should always be excluded before advising sports activity in individuals with recognized AF. It is also important to exclude hyperthyroidism, alcohol abuse, and (illicit) drug use. Intensive sports participation should be temporarily stopped until an identified underlying cause is corrected.
Rapid atrioventricular nodal conduction of AF during exercise may lead to symptoms, including dizziness, syncope, fatigue, or impaired physical performance. Therefore, the individual should be instructed to stop PA on the emergence of symptoms and rate control should be optimized. Rapid 1: 1 conduction can occur, especially during atrial tachycardia or atrial flutter (AFL); therefore, if AFL has been documented, prophylactic cavo-tricuspid isthmus ablation should be considered. If there is evidence for adequate rate control while in AF through an exercise stress test or ECG monitoring during training or competition, all sports participation is possible in asymptomatic individuals.
Achieving adequate rate control can be difficult, however. Betablockers are the logical choice but may not be tolerated due to their impact on physical performance. Calcium-channel blockers and digitalis are usually not potent enough when used alone. Often a combination of individually titrated negatively chronotropic agents is needed, while avoiding sinus bradycardia at rest or chronotropic incompetence during exercise.
Rhythm control is equally complicated. Class III antiarrhythmic drugs are usually insufficient for control (sotalol) or relatively contraindicated in a young population (amiodarone). Although class I drugs may be able to prevent recurrences of AF, they should not be used in monotherapy,
since these may increase the propensity to develop AFL (‘class I AFL’),
which in the absence of adequate rate control may lead to 1: 1 atrioventricular conduction, high ventricular rates, and very profound intraventricular conduction slowing, with haemodynamic compromise.482,483
Therefore, prophylactic cavo-tricuspid-isthmus ablation should be considered if class I drugs are prescribed in monotherapy in athletes.
In patients with sporadic AF, class I drugs may be considered only for acute cardioversion, i.e. as a ‘pill-in-the-pocket’ approach. These patients should refrain from sports as long as AF persists, and until two half-lives of the antiarrhythmic drug have passed.484
Prescription of oral anticoagulants (OAC) depends on the clinical risk profile (mainly CHA2DS2-VASc score).485 Sports with direct bodily contact or prone to trauma should be avoided in patients on OAC.486
Catheter ablation by pulmonary vein isolation (PVI) should be considered if drug therapy fails or as first-line therapy if drug therapy is not desired.487 Several small series have shown that the outcome of PVI in athletes with paroxysmal AF is similar to that in non-athletic patients.488,489
5.6.2.3 Impact of sports continuation on the natural progression of atrial fibrillation after ablation
If there are no recurrences of AF within 1 month of a successful ablation procedure, sports activity may be resumed. It is unknown whether continuation of sports after successful PVI might progress the disease process and lead to recurrence of non-pulmonary veindependent AF in the future. Therefore, no firm recommendation can be made about the ‘safe’ dose of sports after ablation.
Recommendations for exercise in individuals with atrial
ﬁbrillation
Recommendations
Classa
Levelb
Regular physical activity is recommended to prevent AF.297,470473
I
A
Evaluation and management of structural heart disease, thyroid dysfunction, alcohol or drug abuse, or other primary causes of AF is recommended before engaging in sports.485
I
A
Counselling about the effect of long-lasting intense sports participation on (recurrence of) AF is recommended in individuals with AF who exercise vigorously for prolonged periods, especially in middle-aged men.471,475,481,490
I
B
AF ablation is recommended in exercising individuals with recurrent symptomatic AF, and/
or in those who do not want drug therapy,
given its impact on athletic performance.488,489
I
B
The ventricular rate while exercising with AF
should be considered in every exercising individual (by symptoms and/or by ECG monitoring), and titrated rate control should be instituted.
IIa
C
Participation in sports without antiarrhythmic therapy should be considered in individuals without structural heart disease, and in whom AF is well tolerated.
IIa
C
Cavo-tricuspid isthmus ablation should be considered in those with documented ﬂutter who want to engage in intensive exercise, to prevent atrial
ﬂutter 1 : 1 atrioventricular conduction.
IIa
C
Prophylactic cavo-tricuspid isthmus ablation to prevent ﬂutter should be considered in individuals with AF who want to engage in intensive exercise and in whom class I drug therapy is initiated.
IIa
C
The use of class I antiarrhythmic drugs as monotherapy, without proof of adequate rate control of AF/AFL during vigorous exercise, is not recommended.482,483
III
C
After ingestion of pill-in-the-pocket ﬂecainide or propafenone, participation in intensive sports is not recommended until two half-lives of the antiarrhythmic drug have elapsed (i.e. up to 2
days).484
III
C
Sports with direct bodily contact or prone to trauma are not recommended in exercising individuals with AF who are anticoagulated.485
III
A
AF = atrial ﬁbrillation; AFL = atrial ﬂutter; ECG = electrocardiogram.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
63


<!-- PAGE 48 -->

### Page 48

...................................................................................................................
5.6.3 Supraventricular tachycardia and Wolff-ParkinsonWhite syndrome
The term paroxysmal supraventricular tachycardia (PSVT) includes
(i) atrioventricular nodal re-entrant tachycardia (AVNRT; most common); (ii) atrioventricular re-entrant tachycardia (AVRT) involving an accessory pathway; or (iii) atrial tachycardia.
Ventricular pre-excitation on the resting ECG is due to an accessory pathway (AP) with antegrade conduction. The prevalence of pre-excitation in the general population varies from 0.10.3%.491,492
Wolff-Parkinson-White (WPW) syndrome is defined as the presence of paroxysmal arrhythmias in a patient with pre-excitation.
5.6.3.1 Prognostic and symptomatic relevance of paroxysmal supraventricular tachycardia without pre-excitation
PSVT without pre-excitation and without associated structural heart disease is not life-threatening, although the arrhythmia may result in dizziness and exhaustion that requires cessation of exercise. Syncope is uncommon. Pre-excitation, however, may be associated with sudden death (see later); therefore, it is important to exclude the presence of latent pre-excitation, by performing carotid sinus massage or an adenosine-test in sinus rhythm.493
Athletes with PSVT should stop exercise in the event of palpitations since rapid heart rates may cause (pre)syncope. Individuals with proven PSVT without pre-excitation should be educated on how to safely perform vagal manoeuvres (such as carotid sinus massage or,
preferably, Valsalva manoeuvre) to facilitate termination of the arrhythmia.494 Exercise may be resumed after termination of the arrhythmia. Prophylactic drug treatment with beta-blockers or calcium antagonists with atrioventricular nodal blocking properties can be considered, although it has limited efficacy. Class I drugs have no role in the management of PSVT, since they can cause lifethreatening arrhythmias (see earlier).
If competitive athletic activity is desired, curative treatment by ablation should be considered. Ablation outcome is equally safe and has similar acute success rates in athletes and non-athletes.495 If the
PSVT is only sporadic and transient and not associated with haemodynamic consequences, even when it develops during exercise, or in cases where ablation is not desired or unsuccessful, sports activity is permissible when there is no increased risk of a fatality from a potential loss of consciousness (such as motorsports drivers, parachute jumpers, divers, and so on).
5.6.3.2 Prognostic and symptomatic relevance of pre-excitation
It has been estimated that one third of patients with WPW syndrome may develop AF and, in such cases, rapid conduction over the AP can lead to ventricular fibrillation (VF) and sudden death. Given the fact that AF is more common in athletes, pre-excitation constitutes a prognostic concern in athletes. The risk for sudden death in patients with pre-excitation varies in population-based studies from
0.150.20%, and usually presents during exercise or emotional stress.496
Evaluation of the athlete with ventricular pre-excitation should exclude associated structural cardiac disease, such as HCM or Ebstein anomaly. Minimal or ‘latent’ pre-excitation can be unmasked on a 12lead ECG during sinus rhythm by vagal manoeuvres or intravenous administration of adenosine. Prolongation of the PR interval without a change in the QRS morphology, or transient atrioventricular block,
excludes non-intermittent latent pre-excitation. Pre-excitation may be intermittent, which usually indicates low risk properties of the pathway.
However, some accessory pathways may be potentiated by adrenergic stimuli. Therefore, exercise testing excluding pre-excitation at peak exercise is recommended before clearance for sports.
Ablation of the AP is recommended in competitive and recreational athletes with pre-excitation and documented arrhythmias. In the event of transient, infrequent well-tolerated arrhythmia (even during exercise), good anticipation of an ablation procedure with increased risk (e.g. anteroseptal AP), or reluctance of the athlete to undergo ablation, management should be guided by assessment of the antegrade conduction characteristics of the AP using either noninvasive tests or an invasive electrophysiological (EP) study.
Non-invasive investigation examines for intermittent preexcitation on ECG or Holter, for abrupt disappearance of preexcitation after administration of a low dose of class I drugs, or for its abrupt disappearance during an exercise test.497 In cases of a long refractory period and hence low risk for sudden death, continuation of sports activity is permitted without ablation on the understanding that sporting activity should be stopped in the event of recurrence of palpitations.
In competitive athletes with asymptomatic pre-excitation an EP
study is warranted to evaluate the risk for sudden death. In the event of a high-risk finding (Table 15), ablation of the AP is recommended.
For athletes who refuse ablation, or if the procedure is associated with high risk, such as an anteroseptal accessory pathway, participation in competitive sports activities can be discussed on an individual case by case basis including the use of pharmacological therapy,
although there are currently no data about its efficacy. Sports in which the potential loss of consciousness could be fatal should be discouraged.
In recreational athletes with asymptomatic pre-excitation, risk assessment may first be pursued via non-invasive testing.497 The sensitivity of non-invasive screening for AP properties that facilitate a fast ventricular response to AF/AFL is good, but its specificity is low.498
Of note, in children younger than 12 years, the risk of AF-induced
VF and sudden death is very low. Generally, a conservative approach
Table 15
Findings during an invasive electrophysiological study (with the use of isoprenaline) indicating an accessory pathway with increased risk of sudden death
©ESC 2020
AF = atrial ﬁbrillation; AVRT = atrioventricular re-entrant tachycardia.


<!-- PAGE 49 -->

### Page 49

.............................................................................................................................................................................
is recommended in this age group, although one study499 suggested that prophylactic assessment and ablation reduces the risk of sudden death. There is a knowledge gap in the benefit/risk ratio of this approach and large-scale studies are required to address the issue.
Leisure-time and low- to medium-intensity exercise programmes can generally be resumed 1 week after ablation if there is no particular risk of recurrence of arrhythmia.
Resuming competitive sports is possible after 13 months, with further ECG follow-up at 6 months and 1 year (given the very small risk for late recurrence of pre-excitation).
Although there may be an association between (type of) AVNRT
and history of sports, there are no data about higher recurrence rate post ablation when sports are resumed or not, and hence no reason to limit exercise programmes for such reason.
5.6.4 Premature ventricular contractions and non-sustained ventricular tachycardia
5.6.4.1 Relation between number of premature ventricular contractions and risk
Only a minority of athletes exhibit frequent or complex VA with a prevalence similar to that of their sedentary counterparts.502505
Premature ventricular contractions (PVCs) may be a marker of underlying heart disease, the presence of which would confer an unfavourable prognosis even in asymptomatic individuals. Specific characteristics of the PVCs, including morphology (origin from the apex or free wall of the LV or RV), high burden, complexity (e.g. couplets, triplets, or non-sustained runs), multifocal origin, and/or increasing frequency with exercise should alert to the possibility of electrical, ischaemic, or structural heart disease.505,506
There is no absolute threshold of the number of PVCs that can be used as a cut-off for underlying disease. One study has shown that in asymptomatic athletes with >2000 PVCs per day, there was a 30%
chance of finding an underlying structural or cardio-genetic disease.503
5.6.4.2 Morphology of premature ventricular contractions
The morphology of the PVCs may provide important prognostic information since some foci of origin are recognized as benign. The most prevalent entity in this respect are PVCs originating from the right or left ventricular outflow regions (RVOT/LVOT), showing a clear inferior axis with high voltages in the inferior limb leads. Early precordial transition (in V2, and certainly when V1 shows a right bundle branch morphology) suggests a left-sided origin.507 RVOT/LVOT
PVCs are thought to be the result of triggered activity, i.e. a local cellular cause, which has no negative prognostic implications. Although these RVOT/LVOT arrhythmias usually occur in structurally normal hearts, they may be the expression of subclinical arrhythmogenic cardiomyopathy. Cardiac imaging tests can help exclude structural heart disease in such athletes.
Less common locations of focal PVCs are around the mitral or tricuspid annulus, most often in a postero-septal location. These have a superior axis with LBBB or RBBB morphology. The PVCs originating from the His-Purkinje system typically have relatively narrow QRS
complex with RBBB morphology and either left anterior or left posterior hemi-block. Lastly, intramyocardial foci may occur, often related to the papillary muscles or moderator band.508
PVCs of differing morphologies from the RV (i.e., wide LBBB and superior axis) in individuals with normal LV function should prompt investigations to exclude arrhythmogenic cardiomyopathy or sarcoidosis. Similarly, wide RBBB pattern, with superior axis and multifocal
PVCs of LV origin should trigger investigations for non-ischaemic cardiomyopathy.
Very rarely, otherwise ‘benign’ PVCs arising from the Purkinje network may give rise to polymorphic ventricular tachycardia (VT) or
VF due to their short coupling interval.509,510 In such patients, the malignant electrical presentation mandates aggressive treatment.
Finally, frequent but otherwise benign PVCs (usually defined as
>1015% of the total number of beats per 24 h) can impair LV function over time (PVC-induced cardiomyopathy), which may be reversible with medical treatment or catheter ablation.511,512
5.6.4.3 Premature ventricular contractions: response to exercise
Reduction or resolution of PVCs with increasing exercise load is typical of idiopathic and benign VAs, particularly those with an outflow tract morphology.513,514 PVCs induced by exercise should be considered as a ‘red flag’, because VAs associated with heart diseases are often made worse by adrenergic stimulation.19,502,511,512,515520 A
higher prevalence of myocardial substrates (mainly mid-wall or subepicardial non-ischaemic LV scars) was found in a CMR study among athletes with exercise-induced PVCs compared to those with exercise-suppressed VAs (56% vs. 21%).516
Recommendations for exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation
Recommendations
Classa
Levelb
In individuals with palpitations, a comprehensive assessment to exclude (latent) pre-excitation,
structural heart disease, and VAs is recommended.500
I
B
Participation in all sports activities is recommended in individuals PSVT without preexcitation.500
I
C
Ablation of the accessory pathway is recommended in competitive and recreational athletes with pre-excitation and documented arrhythmias.500
I
C
In competitive/professional athletes with asymptomatic pre-excitation, an EP study is recommended to evaluate the risk for sudden death.497,500
I
B
In competitive athletes with PSVT but without pre-excitation, curative treatment by ablation should be considered.
IIa
C
EP = electrophysiological; PSVT = paroxysmal supraventricular tachycardia; VA =
ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
65


<!-- PAGE 50 -->

### Page 50

........................................................................................................................................................
Of note, exercise-induced isolated or repetitive PVCs with multiple morphologies, especially with beat-to-beat alternating morphologies (so-called ‘bi-directional’ pattern), may be the expression of catecholaminergic polymorphic VT, which can degenerate into
VF.518,521
5.6.4.4 Practical management of cardiac patients with premature ventricular contractions or non-sustained ventricular tachycardia who want to engage in sports
The most important task in individuals with PVCs or NSVT who want to engage in sports is to exclude underlying structural or familial arrhythmogenic conditions, since sports activity may trigger sustained
VT. It has been suggested that the presence of >_2 PVCs on a baseline
ECG (or even >_1 PVC in the case of high-endurance athletes) should prompt a more thorough evaluation.522Work-up includes a family history, assessment of the number, morphology, and complexity of
PVCs by Holter and 12-lead ECG, inducibility by exertion (via exercise test or long-term ECG recording during sports activities), and tailored additional imaging.1 Further diagnostic evaluation with molecular genetic testing may be indicated in selected cases if the suspicion for familial disease is high. Finally, repeat evaluation may be needed after 6 months to 2 years. Recommendations for sports participation of athletes with PVC should be individualized based on evaluation for underlying cardiac conditions as described earlier, and often requires shared decision making.
5.6.5 Long QT syndrome
The
QT
and corrected
QTc intervals vary by sex and physical training. Congenital long QT syndrome (LQTS) should be distinguished from acquired forms, i.e. due to circumstances, which can be reversed and prevented. Once acquired LQTS is established,
sports activity should be prohibited until the underlying cause is corrected.
A definitive diagnosis of congenital LQTS is often difficult.523
Congenital LQTS should be suspected on a routine ECG or 4 min into recovery after an exercise stress test,524 if the corrected QTc interval according to Bazett’s formula is >_470 ms or >_480 ms in asymptomatic male or female athletes, respectively.525 A QTc of
>_500 ms is diagnostic.526 In the case of a borderline long QTc interval and a negative personal and familial history, subclinical arrhythmias should be excluded by exercise testing and long-term
ECG recording.
Since the risk of cardiac events during sports activities is largely gene-specific, genetic testing and cascade screening of family members should be performed following a clinical diagnosis of LQTS. Individuals with LQT1 are at highest risk during stressful exercise.527,528
Symptomatic athletes should not engage in competitive sports.
Individuals with LQT1 should not engage in sports that involve diving into cold water since this is associated with increased risk of arrhythmias. General precautions include avoidance of QTprolonging drugs, dehydration, and electrolyte imbalance. Betablocker therapy is extremely effective in LQT1 and additional therapies are only needed to control more severe cases or specific genotypes.529
Survivors of SCA (certainly while taking beta-blocker therapy)
should be referred for an ICD. Similarly, individuals who have experienced sudden syncope despite beta-blocker therapy should also be referred for an ICD or sympathetic cardiac denervation.530 ICD
implantation does not constitute clearance for intensive or competitive sports. Continued sports participation with an ICD is possible,
but specific recommendations apply (see section 5.5.6). American guidelines are more lenient with respect to participation in competitive sport (except for LQT1), provided that precautions include the presence of an automatic external defibrillator (AED) ‘as part of the athlete’s personal sports safety gear’.531 We consider such obligation to be impractical (e.g. winter sports, water sports), and it places an added responsibility on clubs or other bystanders, which cannot be justified by a medical recommendation for an individual athlete.
Moreover, although LQTS-related cardiac arrest is uncommon, even during competitive sports,527 AED efficacy is not 100% in such cases.532
In asymptomatic LQTS mutation carriers without a prolonged QT
interval, i.e. <470 ms in men and <480 ms in women (‘genotype positive/phenotype negative’), shared decision making is required, balancing the risk for arrhythmias with psychological well-being. A negative exercise stress test has no predictive value.
Recommendations for exercise in individuals with premature ventricular contractions or non-sustained ventricular tachycardia
Recommendations
Classa
Levelb
In exercising individuals with >_2 PVCs on a baseline ECG (or >_1 PVC in the case of high-endurance athletes) thorough evaluation (including a detailed family history) to exclude underlying structural or arrhythmogenic conditions is recommended.503,522
I
C
Among individuals with frequent PVCs and nonsustained VT a thorough investigation with
Holter monitoring, 12-lead ECG, exercise test,
and suitable imaging is recommmended.503
I
C
It is recommended that all competitive and leisure-time sports activities are permitted, with periodic re-evaluation in individuals without familial or structural underlying disease.503
I
C
ECG = electrocardiogram; PVC = premature ventricular contractions; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 51 -->

### Page 51

..................................................................................
5.6.6 Brugada syndrome
The Brugada syndrome (BrS) is an inherited cardiac ion channel disorder with an elevated risk of VF and SCD in individuals with a structurally normal heart.533,534 Although BrS was initially described as a purely electrical disease, minor structural RV abnormalities have been described,535538 suggesting that the disease may be the result of early repolarization or delayed depolarization.509 The diagnosis is based on the presence of the type 1 Brugada pattern on the 12-lead
ECG (coved-type ST-segment elevation >_2 mm followed by a negative T-wave in >_1 mm of the right precordial leads positioned in the fourth, third, or second intercostal space), either spontaneously or following provocation by a sodium ion channel blocker.523,539,540
Most individuals with BrS remain asymptomatic throughout their lives. In the majority of cases, events occur during sleep or rest, during febrile states or, occasionally, from heat stroke.541549 Patients who have suffered a SCA or an arrhythmic syncope should undergo
ICD implantation.247,511 Risk stratification in the asymptomatic population with spontaneous type 1 ECG pattern is more challenging.247,511 There is controversial evidence that exercise testing showing an aggravating phenotype during exercise or early recovery,
or EP study, are efficient at detecting individuals at risk of SCD. In asymptomatic patients with only inducible type 1 Brugada ECG
pattern, preventive measures are recommended, such as avoidance of triggering drugs (www.brugadadrugs.org), electrolyte imbalance,
and increases in core temperature >39C (e.g. by minimizing immersion in hot tubs, saunas, and steam rooms; by avoiding sports in warm/humid conditions; or by abstaining from prolonged endurance events such as triathlons and marathons). During febrile illness, fever should be treated aggressively.247,511
One could speculate that an enhanced vagal reaction during recovery550 and a predominant vagal tone at rest551 may increase the susceptibility of highly trained individuals to develop arrhythmias during recovery or at rest. However, there are no reports directly linking exercise or sports training to cardiac events and there are no large prospective studies evaluating the effect of exercise and sports in
BrS.
Asymptomatic patients with the spontaneous type I BrS ECG pattern may compete in all sports except endurance sports associated with an increase in core temperature >39C (e.g. marathon running and triathlons). Similar rules apply to asymptomatic genotypepositive/phenotype-negative individuals and those with the concealed form of BrS.
If treated with an ICD, provided precautionary measures are taken and the patient has been asymptomatic for >_3 months, resumption of all sport, including competitive sport, may be considered, after shared decision making, and also taking into consideration the findings from the ICD registry (see later).
Recommendations for exercise in long QT syndrome
Recommendations
Classa
Levelb
It is recommended that all exercising individuals with LQTS with prior symptoms or prolonged
QTc be on therapy with beta-blockers at target dose.529
I
B
It is recommended that exercising individuals with LQTS should avoid QT prolonging drugs
(www.crediblemeds.org) and electrolyte imbalance such as hypokalaemia and hypomagnesaemia.529
I
B
Shared decision making should be considered regarding sports participation in patients with genotype-positive/phenotype-negative LQTS
(i.e. <470/480 ms in men/women). Type and setting of sports (individual vs. team), type of mutation, and extent of precautionary measures should be considered in this context.
IIa
C
Participation in high-intensity recreational and competitive sports, even when on beta-blockers,
is not recommended in individuals with a
QTc>500 ms or a genetically conﬁrmed LQTS
with a QTc>_470 ms in men or >_480 ms in women.
III
B
Participation in competitive sports (with or without ICD) is not recommended in individuals with
LQTS and prior cardiac arrest or arrhythmic syncope.
III
C
ICD = implantable cardioverter deﬁbrillator; LQTS = long QT syndrome.
aClass of recommendation.
bLevel of evidence.
Recommendations for exercise in Brugada syndrome
Recommendations
Classa
Levelb
ICD implantation is recommended in patients with BrS with episodes of arrhythmic syncope and/or aborted SCD.247
I
C
Following implantation of an ICD, resumption of leisure or competitive sports should be considered after shared decision making in individuals who have not experienced recurrent arrhythmias over 3 months after ICD implantation.
IIa
C
In asymptomatic individuals with BrS, asymptomatic mutation carriers and asymptomatic athletes with only an inducible ECG pattern,
participation in sports activities that are not associated with an increase in core temperature
>39C (e.g. endurance events under extremely hot and/or humid conditions) may be considered.
IIb
C
Prescription of drugs that may aggravate BrSc,
electrolyte abnormalities, and sports practice that increases core temperature >39
C are not recommended in individuals with overt BrS or phenotypically negative mutation carriers.
III
C
BrS = Brugada syndrome; ECG = electrocardiogram; ICD = implantable cardioverter deﬁbrillator; SCD = sudden cardiac death.
aClass of recommendation.
bLevel of evidence.
cFor example, www.brugadadrugs.org.
ESC Guidelines
67


<!-- PAGE 52 -->

### Page 52

................................................................................................................................................
5.6.7 Following device implantation
5.6.7.1 Pacemakers
Pacemaker (PM) implantation is common. Generally, individuals implanted with a PM have less severe disease and comorbidities than patients with an ICD. Moreover, there is less risk of malfunction for a
PM than for an ICD during sports.552 For all these reasons, recommendations for sports practice are more liberal in patients with a PM
than in patients with an ICD. Patients with a PM may participate in competitive or recreational sports in the absence of structural or other heart disease for which exercise may be prohibited.
In the first weeks after device implantation, sports activities that increase the risk of lead dislocation (e.g. strong upper extremity movements) should be avoided. Exercise testing and/or Holter monitoring during sports may improve individualized programming of the upper sensor and the tracking rate and exclude inappropriate rate acceleration in other circumstances (e.g. horse riding).553
For all patients with cardiac devices (PM, cardiac resynchronization therapy, and ICD), sports activities associated with a risk of chest trauma should be avoided.554557 Some sports such as soccer, basketball, and baseball may be possible while wearing appropriate padding. It is noteworthy that sports with pronounced arm movements such as volleyball, basketball, tennis, golf, and climbing may increase the risk for late lead damage due to subclavian crush (with insulation or conductor failure).554,558,559 Implantation on the contralateral side of the dominant arm, fixation within the pocket, or submuscular placement may improve durability of the system. It is not known whether subcostal or epicardial implant techniques provide longterm benefit. Electromagnetic interference is unlikely with modern devices, and no cases have been reported, but it should always be suspected and closely evaluated in specific athletic environments with electronic equipment (e.g. fencing). Myopotential inhibition may result in inhibition of pacing, a problem that is more common with unipolar electrodes, although it can usually be corrected with appropriate reprogramming of the device.560,561 Bipolar leads are less sensitive to this problem, but may have a reduced longevity.
5.6.7.2 Implantable cardioverter defibrillators
A large multinational ICD Sports Safety Registry has shown that after a median follow-up of 44 months, there were no deaths or arrhythmia or shock-related physical injury in 440 athletes who continued organized competitive or high-risk sports after ICD implantation.359,389 An additional analysis in 82 non-professional recreational athletes confirmed these reassuring outcomes,562 which is relevant for the many ICD recipients who want to continue recreational sports activities after implantation. Therefore, shared decision making is appropriate when deciding whether or not to continue sports and the level of participation with an ICD.
However, three important considerations come into play. First, if sport is contraindicated because it can contribute to the progression of the underlying disease (such as in arrhythmogenic cardiomyopathy or lamin A/C mutations),384,425 an ICD cannot be considered as a substitute for sports restriction, and participation in moderate- and high-intensity exercise should be discouraged. Recommendations in such circumstances should have a lifetime perspective and be based on the optimal preservation of structural cardiac integrity. The ICD,
however, may allow for light to moderate exercise without concerns about risk of arrhythmia or shocks, and may help individuals to regain autonomy and overcome fears relating to exercising unattended.
The second consideration is that ICD shocks in general, even when appropriate and safe, will have a psychological impact on the athlete; 3040% of the athletes who experienced shocks in the multinational ICD Sports Safety Registry stopped participation, at least temporarily, out of fear of repeat shocks.389 Moreover, the proportion of athletes with appropriate and inappropriate shocks during exercise was higher in competitive than in recreational sports,
emphasizing the known triggering effect of high-intensity exercise.562
Considering that ICD therapy is lifelong, where quality of life is not only dependent on the ability to perform sports activities, but also and mostly on continued trust in the device, physicians should be aware that their own belief in the effectiveness and safety of ICD
therapy during sports should not implicitly put pressure on the athlete to continue sports. Again, informed decision making needs to reevaluate all options of the athlete aftershocks, including continuing,
reducing, or stopping sports.563,564
Third, situations where loss of focus or loss of consciousness could cause harm to a third party or the athlete (such as in motor sports,
diving, mountain climbing, even cycling) should be avoided.
The athlete must be aware of the programmed detection rate cutoffs to be able to avoid reaching those during exercise. Conversely,
detection zones need to be programmed sufficiently high to allow for adequately high heart rates during the desired exercise levels. This practice proved safe and reduced the occurrence of shocks in the
ICD Sports Safety Database.565 The most common cause of inappropriate shocks in individuals with an ICD is the occurrence of sinus tachycardia and supraventricular arrhythmias.566,567 Underlying heart disease and endurance sport itself carries a higher risk for developing
AF.474,480,568 Implantation of a dual system ICD for the sole reason of atrial arrhythmia detection and discrimination is not warranted because it is usually not effective.565,569572 Given the fact that many of these athletes are young, there is a higher risk for long-term lead complications when more leads are implanted; therefore, implantation of more complex ICD systems, and their indication, should be weighed in every patient. Routine inclusion of athletes in remote monitoring programmes is highly recommended.


<!-- PAGE 53 -->

### Page 53

........................................................................................................................................................................
5.7 Exercise recommendations in individuals with adult congenital heart disease
5.7.1 Introduction
Congenital heart disease (CHD) has a prevalence of 89 per 1000
live births and is the most common birth defect.573 Most children with CHD survive to adulthood, including over 85% with complex disease. Regular exercise is important for adults with congenital heart disease (ACHD) and exercise participation should be discussed at every patient encounter.574 However, CHD represents a spectrum of conditions with widely varying physiological consequences.
Individualized assessment is essential before advising on sports participation. This requires detailed understanding of the congenital heart defect, its physiological consequences, and the effect of surgical or transcatheter intervention.
5.7.2 The increasing numbers of athletes with congenital heart disease
Athletes with CHD include those with minor unoperated lesions and palliated and repaired CHD. Some athletes will be diagnosed with
CHD
for the first time during pre-participation screening.
Approximately 1 in 150 adults have a congenital heart defect. This is an increase of over 50% in the last 10 years and reflects improved diagnosis and long-term survival.575 Overall 90% of adults with CHD are in
NYHA functional class I or II.576 The number of professional and recreational athletes with CHD is unknown but the elite athlete population is likely to be small. In a study of 2352 Olympian athletes, only nine
(0.4%) had a congenital heart defect.577 However, many more CHD
patients compete at a recreational level. It is likely that the number of athletes with CHD is increasing due to improved survival, better understanding of the benefits of exercise, and the increased number of professional athletes from countries where poorly developed healthcare systems are associated with under-diagnosis of CHD.573,574
5.7.3 Non-cardiac abnormalities in congenital heart disease and Paralympic sport
CHD has a multifactorial aetiology, but there is a significant genetic component and a recurrence risk of 25%.578 The genetic origin may be due to a chromosome anomaly, a heritable syndrome with
Mendelian pattern,
or sporadic with variable penetrance.578
Approximately 14% of patients with CHD have additional noncardiac abnormalities.579 Thus, 44% of ACHD patients have lung function abnormalities.580 This can make advising sports participation for the ACHD athlete more difficult. There is no specific classification for CHD in Paralympic sport.
5.7.4 General considerations in the congenital heart disease athlete
There is considerable variation in the haemodynamic consequences and prognosis of different CHD lesions. Furthermore, the consequences of any individual lesion can vary hugely between individuals. Thus,
Ebstein’s anomaly may present in infancy with pulmonary hypoplasia due to compression by a giant right atrium or may present in late middle age with supraventricular tachycardia and minimal haemodynamic consequences. Similarly, a ventricular septal defect may be small and asymptomatic, or large presenting with HF in infancy, or may present with extreme cyanosis, reduced exercise capacity, and Eisenmenger syndrome in the adult. Consequently, these recommendations are based on a physiological assessment rather than underlying anatomic diagnosis. An understanding of the range of severity and a lesion-based knowledge of potential complications is essential. The cardiologist should work in conjunction with a CHD specialist. Athletes with CHD
who participate in regular training and competitive sports should undergo a comprehensive annual assessment that includes clinical examination, ECG, echocardiogram, and exercise stress test, ideally
CPET.
Many athletes with CHD will have undergone corrective or palliative surgery. In young adults with post-surgical CHD, valve
Recommendations for exercise in individuals with pacemakers and implantable cardioverter deﬁbrillators
Recommendations
Classa
Levelb
It is recommended that individuals with implanted devices with/without resynchronization and underlying disease follow the recommendations pertaining to the underlying disease.384,425
I
B
Participation in sports and exercise (except collision sports) should be considered in individuals with pacemaker therapy who do not have pathological substrates for fatal arrhythmias.
IIa
C
Prevention of direct impact to the implanted device by adapting the site of lead and/or device implantation, padding, or restricting direct impact sports should be considered.
IIa
C
Holter recordings and device interrogation during and after resuming sports should be considered to allow appropriate tailoring of rateresponsive pacing parameters, exclusion of myopotential or electromagnetic inhibition, and detection of VAs.
IIa
C
Shared decision making should be considered during decisions relating to continuation of intensive or competitive sports participation in individuals with an ICD, taking into account the effect of sports on the underlying substrate, the fact that intensive sports will trigger more appropriate and inappropriate shocks, the psychological impact of shocks on the athlete/patient, and the potential risk for third parties.
IIa
C
An ICD is not recommended as a substitute for disease-related recommendations when these mandate sports restrictions.
III
C
ICD = implantable cardioverter deﬁbrillator; VA = ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
69


<!-- PAGE 54 -->

### Page 54

.............................................................................................................................................................................
incompetence and arrhythmias are common problems, but with increasing age arrhythmias and HF predominate. In master athletes,
problems related to previous corrective or palliative surgery become prevalent. These include cardiac arrhythmias, systemic ventricular dysfunction, valvar incompetence, and prosthetic conduit obstruction. Redo valve or conduit surgery and arrhythmia ablation due to re-entry arrhythmias (secondary to surgical scar) are frequent in this age group. In addition, with increasing age, acquired CVD may develop.581,582 This is of particular relevance in the assessment of the master athlete with CHD.
5.7.5 Sudden death during sport
SCD in CHD is rare (<0.1% per year)583 and only 8% of deaths occur during exercise.584 Many complex CHD patients at highest risk of
SCD have reduced exercise tolerance and cannot participate in significant athletic activity. However, some diagnostic groups, e.g. post tetralogy of Fallot repair, carry a risk of SCD but can still compete in elite sport.585 Other high-risk congenital lesions such as anomalous coronary origin, mitral valve prolapse, and aortopathy are described in sections 5.1, 5.3, and 5.4, respectively. In a large population-based study of SCD in CHD patients under 35 years, 87% of SCD was due to a presumed arrhythmia and 41% occurred in patients with undiagnosed CHD.586Activity-related SCD was more common in the undiagnosed group (18% vs. 4%), which supports the case for preparticipation athletic screening.586 It is not known whether exercise intensity is a risk factor for SCD in CHD. There is reasonable evidence that moderate to vigorous exercise is safe in most ACHD
patients even when symptomatic (NYHA IIIII).576,587,588 However,
cardiac arrhythmias are a common cause of hospital admission in
ACHD and extreme exercise may expose a latent arrhythmic substrate.589,590
5.7.6 Exercise in athletes with congenital heart disease:
current guidelines and recommendations
Regular structured exercise is safe and effective therapy for most patients with CHD. This is true for most diagnostic groups, including symptomatic patients, and includes aerobic and strength-based exercise.588,591596 Exercise intolerance in CHD is a strong predictor of both outcome and SCD.576 Specific precautions are necessary in extreme environments including underwater sports and this is considered below (see Supplementary Data, section 4). This is particularly true if there is a potential for a right to left shunt. Guidelines are available for exercise assessment and prescription in both children and adults with CHD, although these are not specifically designed for the athlete.597,598 The paediatric guidelines are based primarily on the underlying anatomical diagnosis, but the teenage and young adult
CHD guidelines have taken a functional approach based on underlying haemodynamics and arrhythmia risk. This latter approach is better suited for assessment of the ACHD athlete (Figure 9).
5.7.7 Assessment of the athlete with congenital heart disease
The guidelines for exercise prescription in adolescents and adults with CHD use a structured methodology described by Budts et al.597
This can be modified for use in the assessment of athletes with CHD.
Stage 1. A full history and physical examination are carried out.
This should include details of underlying CHD diagnosis, any transcatheter or surgical interventions, current medications and CV symptoms (at rest and on exercise). Attention should be paid to any associated non-cardiac diagnoses including pulmonary dysfunction. A
full exercise and sports participation history should be taken including precise details of current training schedule and any dietary supplements. Details of the planned or current sports activity should be established to include an assessment of the static component and intensity as described in section 4.1 (see Figure 2). If necessary, advice should be sought from a sports fitness coach or sports medicine specialist.
Stage 2. The following five baseline parameters should then be evaluated597 (Table 16).
(1)
Ventricular function
Assessment of ventricular function can usually be achieved using echocardiography. The aim is to establish whether function is reduced (EF < 55%), and if so, is it mild (4555%), moderate
(3045%), or severe (<30%). This is used for baseline assessment and subsequent monitoring of the effects of exercise training.
Echocardiography can also evaluate inflow and outflow abnormalities,
which may become more severe during acute exercise (e.g. LV outflow obstruction or systemic atrioventricular valve regurgitation).
CMR scanning may be a preferable modality in complex disease. This has the additional benefit of evaluating intracardiac scar, which may inform the assessment of arrhythmia risk.599,600
(2)
Pulmonary artery pressure
Pulmonary hypertension (PH) is diagnosed when the mean PAP is
>20 mmHg.601 PH may occur in the context of a chronic leftright shunt (e.g. atrial septal defect, ventricular septal defect, patent ductus arteriosus) that allows unrestricted volume/pressure overload.
Eventually this can result in supra-normal PAP with reversal of shunting and elevated pulmonary vascular resistance (Eisenmenger syndrome). An increased RV afterload limits the ability to increase cardiac output by increasing stroke volume and can impair LV function through disruption of normal RVLV interaction.
Few CHD patients with significant PH will take part in competitive sports due to reduced exercise capacity. However, some athletes with CHD will have mild elevation of pulmonary vascular resistance that may be exacerbated by factors such as altitude training.602 PAP
rises during exercise. This rise is accentuated with increasing age and may be exaggerated in CHD athletes due to elevated pulmonary vascular resistance.603 In addition, valvar pulmonary stenosis or distal stenoses in branch pulmonary arteries may cause exercise-related
RV hypertension. The non-invasive assessment of PH can be difficult and full assessment guidelines have been published.604,605 Further information can be gained by CPET and a VO2 of >25.2 mL/min/kg makes significant PH unlikely.606 As PH can also be a late postoperative complication after surgical correction of CHD607 the assessment of PAP should be part of every echocardiographic examination in athletes with CHD. Although exercise training is generally regarded as safe in PH, competitive sport is not recommended.1,608
(3)
Aortic assessment
Many CHD patients are at risk of aortic dilatation, in particular,
patients with tetralogy of Fallot, coarctation of the aorta and certain


<!-- PAGE 55 -->

### Page 55

syndromes such as 22q11 microdeletion and Turner syndrome.
However, aortic dissection is very rare in CHD.609 Athletes have mildly increased aortic dimensions in comparison to sedentary controls, but it is not known if this has a cumulative effect in CHD athletes with aortic dilatation.345 The presence of ascending aorta dilatation should lead to assessment for coarctation of the aorta as this can be associated with severe coarctation, which may be missed on clinical assessment but may cause severe exercise-related hypertension.610 Exercise risks in aortopathy are described in detail in section 5.4. Contact sports should be avoided in patients with dilated aortas >5 cm.
(4)
Arrhythmia assessment
Arrhythmias are responsible for 25% of CHD hospital admissions.
Over 80% are atrial but life-threatening VAs can occur.611
Independent risk factors include increasing age, male gender, double outlet right ventricle, atrioventricular septal defect, HF, obstructive sleep apnoea, transposition of the great arteries, congenitally corrected transposition, and tetralogy of Fallot.599 Assessment of the
CHD athlete should include a symptom history with evaluation of palpitations, presyncope and syncope, particularly during exercise.
©ESC 2020
Figure 9 Pre-participation assessment of individuals with congenital heart disease.598 CPET = cardiopulmonary exercise test; HR = heart rate; MHR =
maximum heart rate; RPE = rate of perceived exertion. AE represent pathways linking static and intensity components for each column. After assessment of CPET and the five variables (Table 16), an individual recommendation can be given (solid arrow). If a higher static level sport is chosen, then a lower intensity level is advised (dotted arrow).
Table 16
Baseline parameters for assessment in congenital heart disease
©ESC 2020
CMR = cardiac magnetic resonance; ECG = electrocardiogram.
ESC Guidelines
71


<!-- PAGE 56 -->

### Page 56

.......
Arrhythmias may be the first sign of underlying haemodynamic deterioration and new-onset arrhythmias should lead to a full haemodynamic assessment. Detailed guidelines for the assessment and treatment of arrhythmias in CHD are available.612 In the athlete,
arrhythmia therapy may be complicated by the need to minimize the negative chronotropic effects of antiarrhythmic treatment, which may affect performance. If symptomatic arrhythmias are present then an exercise ECG, prolonged ECG monitoring, loop recorder implantation, and even electrophysiology testing might be required. This should be coordinated by an electrophysiologist with expertise in
CHD.
(5)
Assessment of saturations/lung function
CHD athletes should be assessed for the potential of an underlying intracardiac right to left shunt. This can be assessed using pulse oximetry, but a resting saturation >95% does not exclude exerciserelated central cyanosis, and exercise assessment is essential. The potential for a pulmonary cause of cyanosis must be considered and lung function should be assessed as part of a cardiopulmonary exercise test. Even after surgical correction of the cardiac defect there may be residual intracardiac shunting.
Stage 3. Cardiopulmonary exercise testing
CPET is invaluable in risk stratifying the adult with CHD and can predict outcome.613,614 It is also extremely useful in the evaluation of the athlete with CHD as it allows an assessment of PAP, respiratory problems, cardiac output, exercise-related haemodynamics, and arrhythmias. This should be used in conjunction with an evaluation of effort such as the Borg scale.615 Normal CPET values are available for non-athlete CHD patients.616 CPET should be carried out in conjunction with a 12-lead ECG to allow detection of arrhythmias and evaluate chronotropic incompetence. Reduced VO2max and peak oxygen pulse may reflect reduced stroke volume and are found in complex CHD as well as in other forms of CHD, including repaired tetralogy of Fallot, aortic regurgitation, and coarctation of the aorta.
In CHD, ventilatory anaerobic threshold may be reduced and this impairs gas exchange efficiency in dynamic and endurance sports.
This may relate to previous thoracotomy or lung disease. Similarly,
there may be an elevated minute ventilation/carbon dioxide production (VE/VCO2) slope,601 indicating an inadequate pulmonary vascular bed.610,611,613616 Reduced skeletal muscle mass is common in adults with CHD and can contribute to decreased tissue oxygen uptake. The extent to which this is modified in athletes with CHD
has not been evaluated. However, even in complex disease, regular resistance exercise participation improves muscle mass and regular exercise participation is a dominant factor in determining long-term outcome.593,617
Stage 4. Exercise intensity and prescription
An assessment of the athlete’s sports and exercise participation should take place as discussed in the introduction (Table 16). This should include an assessment of the intensity, aerobic and resistance components (isometric and dynamic), and the overall volume of exercise, which should include training and competition. The haemodynamic consequences should be considered in light of an understanding of known lesion-specific consequences and individual athlete-specific changes identified on assessment.
Stage 5. Follow-up and repeat assessment
In the CHD athlete, serial assessment should be carried out—usually on an annual basis—while participating in sport. This recognizes the age-related changes that occur in the CHD athlete and the potential for onset of degenerative CVD.
6. Key messages
CV screening before participation in recreational and competitive sports is aimed at the detection of disorders associated with SCD
and has the potential to lower CV risk through disease-specific and individualized patient management.
CV screening in adult and senior athletes should target the higher prevalence of atherosclerotic CAD including an assessment of CVD
risk factors and exercise stress test. CAC scoring may be performed in asymptomatic athletes with a moderate atherosclerotic risk profile.
Healthy adults of all ages and individuals with known cardiac disease should exercise on most days, totalling at least 150 min/week of moderate-intensity exercise.
Individuals with CAD, at low risk for exercise-induced adverse events, should be considered eligible for competitive or leisure sports activities, with few exceptions.
Competitive sports are not recommended in individuals with
CAD, at high risk of exercise-induced adverse events or those with residual ischaemia, with the exception for individually low-intensity skill sports.
Exercise programmes in HF improve exercise tolerance and quality of life and have a modest effect on all-cause and HF-specific mortality, and all-cause hospitalization and HF-specific hospitalization.
Exercise recommendations for individuals with congenital heart disease
Recommendations
Classa
Levelb
Participation in regular moderate exercise is recommended in all individuals with
CHD.588,591594,619
I
B
A discussion on exercise participation and provision of an individualized exercise prescription is recommended at every CHD patient encounter.574,597,598,617
I
B
Assessment for ventricular function, pulmonary artery pressure, aortic size, and arrhythmia risk is recommended in all athletes with
CHD.342,348,573,597
I
C
Competitive sports participation should be considered for CHD athletes in NYHA class I or II
who are free from potentially serious arrhythmias after individual tailored evaluation and shared decision making.573,595,597,598
IIa
C
Competitive sports are not recommended for individuals with CHD who are in NYHA class
IIIIV or with potentially serious arrhythmias.605,608
III
C
CHD = congenital heart disease; NYHA = New York Heart Association.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 57 -->

### Page 57

.............................................................................................................................................................................
Asymptomatic individuals with mild valvular heart disease may participate in all sporting activities including competitive sports.
A select group of asymptomatic individuals with moderate valve disease who have good functional capacity and no evidence of myocardial ischaemia, complex arrhythmias, or haemodynamic compromise on a maximal exercise stress test may be considered for competitive sports after careful discussion with an expert cardiologist.
Implementation of healthy lifestyle behaviours including sports participation decreases the risk of CV events and mortality in individuals with aortopathies.
Individuals with acute myocarditis or pericarditis should abstain from all sports while active inflammation is present.
Individuals with cardiomyopathy or resolved myocarditis or pericarditis, who wish to participate in regular sports, should undergo comprehensive evaluation, including an exercise test, to assess the risk of exercise-induced arrhythmias.
Individuals who are genotype positive/phenotype negative or have a mild cardiomyopathy phenotype and absence of symptoms or any risk factors, may be able to participate in competitive sports. A notable exception is arrhythmogenic cardiomyopathy where highintensity exercise and competitive sports should be discouraged.
Managing sports participation in individuals with arrhythmogenic conditions is guided by three principles: (i) preventing life-threatening arrhythmias during exercise; (ii) symptom management to allow sports; and (iii) preventing sports-induced progression of the arrhythmogenic condition. In each case, these three basic questions need to be addressed.
Pre-excitation should be excluded in all athletes with PSVT, and ablation of the accessory pathway is recommended if present.
In individuals with PVCs who want to engage in sports, underlying structural or familial arrhythmogenic conditions must be excluded,
since sports activity may trigger more malignant arrhythmias if those underlying conditions are present.
Athletes with electrical abnormalities of genetic origin, such as the inherited ion channelopathies, require assessment and shared decision making in which cardiogeneticists are involved, given the complex interplay of genotype, phenotype, potential modifiers, and exercise.
Individuals with pacemakers should not be discouraged from participation in sport because of the device but need to tailor their sports participation according to the underlying disease.
Participation in leisure-time and competitive sport in patients with an ICD may be considered, but requires shared and individualized decision making, based on a higher likelihood of appropriate and inappropriate shocks during sports, and the potential consequences of short episodes of loss of consciousness.
Patients with CHD should be encouraged to exercise and should be given a personalized exercise prescription.
7. Gaps in evidence
Outcomes in exercising individuals with cardiovascular diseases. The natural history and absolute risk of conditions associated with SCD in athletes identified through CV screening is largely unknown, making it difficult to quantify short- and long-term risk.
Prospective outcomes data, including the occurrence of major CV
events and other CV morbidity, is needed to better guide risk stratification, management, and eligibility recommendations for athletes diagnosed with CVD.
Cardiovascular evaluation in master athletes. Current methods for screening individuals for atherosclerotic CAD are based on symptoms and a maximal exercise test; however, they do not identify individuals with mild to moderate atherosclerotic plaques.
More knowledge on the optimal pre-participation screening algorithm for identifying individuals at risk of adverse cardiac events during exercise is required.
Safety of high-intensity exercise in cardiovascular disease.
There are limited data on the safety of high-intensity exercise training and sports participation in healthy individuals with a high burden of risk factors; more information can be gained through high-quality prospective studies in the future.
Risk of anomalous origins of the coronary arteries in older individuals. Although AOCA from the opposite sinus of
Valsalva are a recognized cause of mortality in young athletes, more knowledge is required on the risk of high-intensity exercise in older individuals (>40 years old), with this congenital abnormality.
Risk of myocardial bridge. The precise significance of MB in causing MI or sudden death during exercise is unknown.
Benefit of regular exercise on survival in chronic heart failure. Although exercise improves functional capacity and quality of life in individuals with HF, strong evidence on the benefit of regular exercise on survival is still lacking.
Role of high-intensity exercise in chronic heart failure.
The impact of high-intensity exercise in asymptomatic individuals with HF with reduced and preserved systolic function is unknown and large multicentre studies are required to facilitate exercise prescription in the future.
Initiation of an exercise programme after decompensated heart failure. The start time of an exercise programme of moderate-high intensity and return to sports after an acute event in
HF is unknown.
Aquatic exercise in heart failure. The safety of aquatic exercise in HF needs to be confirmed by larger trials.
Effect of exercise on the natural history of valvular heart disease. There is a paucity data on the effects of regular intensive exercise in individuals with valvular heart disease. Large-scale longitudinal studies are required to provide more evidence-based guidelines on exercise prescription in individuals with valvular heart disease.
Effect of exercise on the natural history of aortopathies.
There is a lack of knowledge on the impact of sport on progression of aortic disease and risk of dissection or aortic rupture among individuals with aortopathy. The impact of beta-blockers on progression of aortic disease among individuals with aortopathy who participate in regular exercise is unknown and should be investigated in a randomized controlled trial.
Optimal safe exercise dose in cardiomyopathy. With an exception for arrhythmogenic cardiomyopathy, current practice relating to exercise recommendations in individuals with cardiomyopathy or following myopericarditis are largely based on circumstantial evidence. Large, adequately powered randomized prospective studies are necessary to provide evidence-based recommendations for optimal exercise prescription without compromising safety. Such
ESC Guidelines
73


<!-- PAGE 58 -->

### Page 58

.............................................................................................................................................................................
studies should also prove useful for validating current risk stratification protocols derived from a relatively sedentary population.
Exercise and atrial fibrillation. The threshold lifetime sports activity for increasing the risk of developing AF is unknown. It is also unknown whether ongoing participation in vigorous exercise at the same intensity after successful AF ablation is associated with a higher risk of AF recurrence.
Benefit of invasive electrophysiological studies in adolescents with accessory pathways. The benefit/risk ratio of early invasive EP evaluation of AP conduction properties in young athletes with asymptomatic pre-excitation (<1214 years old), and prophylactic ablation, remains unclear and requires large-scale studies for clarification.
Exercising with an implantable cardioverter defibrillator.
Although an international registry has shown absence of sportsrelated sudden death or injury in individuals with an ICD who perform competitive, high-intensive recreational or high-risk sports,
many data are sparse and have not examined specific athletic populations with reduced LV function, catecholaminergic polymorphic VT.
Moreover, the long-term physical and psychological impact of appropriate and inappropriate shocks, which become more frequent with increasing sports intensity, is unknown.
Arrhythmic risk of exercise in adult congenital heart disease. The relationship between intensity of exercise and risk of arrhythmias in individuals with CHD is unknown and further research is needed. Although exercise prescription is recommended in CHD
patients, further studies are necessary to identify the optimal method of improving adherence to an exercise prescription.
8. Sex differences
For many years sports participation, especially at the highest echelons, has been dominated by males, but the last four decades have witnessed an increasing number of females participating in a large variety of sporting disciplines at elite level. Females constituted 45%
of all athletes at the 2016 Rio Olympics and participated in 26 of the
28 different sporting disciplines including those that were traditionally considered to be ‘male sports’, such as footfall, rugby, and boxing.
Although the guidelines in this document are applicable to both sexes, there are some pertinent sex-based differences relative to exercise and sport including: (i) the incidence of SCD during exercise;
(ii) quantitative differences in CV adaptation to regular intensive exercise and the overlap with cardiomyopathy; (iii) the predilection of adverse events with specific CVDs in women; and (iv) the additive haemodynamic effects of exercise in pregnant women with a structurally abnormal heart.
Current evidence suggests a significantly lower prevalence of exercise-related SCD in females who represent a small minority of athletes dying suddenly with a male to female ratio ranging from 3 to
10: 1.17,18,46,49,52,620 This disproportionately lower incidence of SCD
among young competitive female athletes also holds true for older recreational athletes where deaths in males are 20-fold greater than in females.
Apart from a lower incidence of exercise-related SCD, there appear to be sex differences related to the diseases predisposing to
SCD. Unlike males, female athletes rarely succumb to SCD from
HCM. In the US National Registry, females comprised only 3% of the
302 individuals who died from HCM.621 Potential determinants of this disproportionate prevalence of death in males may include a lower absolute volume and intensity of training load in females, which could make them less susceptible to ventricular tachyarrhythmias.
However, it is also plausible that certain protective metabolic or hormonal mechanisms could reduce the arrhythmic risk during intense physical exertion in females with HCM. This observation is relevant to prescription of intensive exercise or competitive sports in HCM,
which is relatively conservative, but could be of less concern and more liberal in affected females in the future. The diagnosis of HCM
in an athlete is also relevant in this regard, because male athletes, particularly those competing in endurance sports, show quantitatively great structural changes within the heart including LV hypertrophy.
Approximately 2% of white male athletes and 13% of black male athletes show a LV wall thickness of 1215 mm that overlaps with morphologically mild HCM and can pose a diagnostic dilemma. In contrast female athletes rarely reveal a LV wall thickness >12 mm or concentric LV remodelling, hence the diagnosis of HCM is clear-cut.3
In contrast, a different scenario is represented in females with
MVP, where recommendation for participation in intensive exercise warrants a more detailed risk stratification. In the Italian pathology registry of 650 SCDs, 7% were attributed to MVP. Of these, the majority (60%) were female who presented a marked elongation of both leaflets due to an extensive myxomatous degeneration.332
It is also noteworthy that the majority of exercise-related SCDs in young females are associated with a structurally normal heart at autopsy. This observation from several registries suggests that genetic electrical diseases (namely, LQTS, Brugada syndrome, or catecholaminergic polymorphic VT) are likely responsible for a significant proportion of these deaths. Differences in cardiac repolarization between men and women have been reported in healthy subjects and in individuals with LQTS.622 Healthy females also have a longer
QTc interval compared with males. Therefore, they are more often clinically affected by the syndrome than men, despite the equal sex distribution of the disease genotype. Females are also at a higher risk than males of developing arrhythmias in response to QT-prolonging drugs,
and electrolyte disturbances compared with males.
Furthermore, female sex is an independent risk factor for cardiac events in LQTS.623 Unfortunately, little is known about the influence of sex hormones on cardiac repolarization, except that androgens may shorten the QTc interval. Based on these considerations, we recommend particular caution when advising competitive sports in women with a probable or definite diagnosis of LQTS.
Pregnancy is associated with a 50% increase in plasma volume and cardiac output. The stresses of exercise in pregnant women with structural heart disease have the potential to cause haemodynamic compromise. Moderate aerobic exercise is generally safe in all women and is associated with a lower prevalence of excessive weight gain, post-partum obesity, gestational diabetes, and pre-eclampsia.
Female athletes may continue training intensively during pregnancy,
although it is recommended that women do not exceed a heart rate of >90% of the maximum predicted for age to reduce the risk of foetal bradycardia. Pregnant women with known structural heart disease require evaluation before embarking on intensive exercise programmes. Exercise or sports involving forceful physical contact,
risk of falling or abdominal trauma, heavy lifting, scuba diving, and


<!-- PAGE 59 -->

### Page 59

.............
exercising at high altitude in an unacclimatized state are not recommended.
Finally, females represent the largest population of obese individuals worldwide and females with T2DM have a higher prevalence of cardiovascular complications and death compared with men. In this regard all women should be incentivized to engage in regular PA and exercise programmes irrespective of age, ethnicity, and CV
morbidities.
Recommendations: What to do and what not to do for exercise and sports in healthy individuals
Classa
Levelb
General recommendations for exercise and sports in healthy individuals
At least 150 min/week of moderate-intensity, or 75 min/week of vigorous-intensity aerobic exercise or an equivalent combination thereof is recommended in all healthy adults.
I
A
Regular assessment and counselling to promote adherence and, if necessary, to support an increase in exercise volume over time are recommended.
I
B
Multiple sessions of exercise spread throughout the week, i.e. on 45 days a week and preferably every day of the week, are recommended.
I
B
Special considerations for individuals with obesity, hypertension, dyslipidaemia, or diabetes
In obese individuals (BMI>_30 kg/m2 or a waist circumference >80 cm for females or >94 cm for males) resistance training >_3 times per week, in addition to moderate or vigorous aerobic exercise (at least 30 min, 57 days per week) is recommended to reduce
CVD risk.
I
A
In individuals with well-controlled hypertension, resistance training >_3 times per week in addition to moderate or vigorous aerobic exercise (at least 30 min, 57 days per week) is recommended to reduce blood pressure and CVD risk.
I
A
Among individuals with diabetes mellitus, resistance training >_3 times per week) in addition to moderate or vigorous aerobic exercise
(at least 30 min, 57 days per week) is recommended to improve insulin sensitivity and achieve a better CVD risk proﬁle.
I
A
In individuals with uncontrolled hypertension (SBP>160 mmHg) high-intensity exercise is not recommended until BP has been controlled.
III
C
Recommendations for exercise in ageing individuals
Among adults aged 65 years or older who are ﬁt and have no health conditions that limit their mobility, moderate-intensity aerobic exercise for at least 150 min/week is recommended.
I
A
In older adults at risk of falls, strength training exercises to improve balance and coordination on at least 2 days a week are recommended.
I
B
Recommendations for exercise in individuals with coronary artery disease
Recommendations for exercise in individuals with long-standing chronic coronary syndrome
Risk stratiﬁcation for exercise-induced adverse events is recommended in individuals with established (long-standing) CCS prior to engaging in exercise.
I
C
Competitive sports are not recommended in individuals at high risk of exercise-induced adverse events or those with residual ischaemia, with the exception of individually recommended skill sports.
III
C
Recommendations for return to exercise after acute coronary syndrome
Exercise-based cardiac rehabilitation is recommended in all individuals with CAD to reduce cardiac mortality and rehospitalization.
I
A
Recommendations for exercise in young individuals/athletes with anomalous origins of coronary arteries
Participation in most competitive sports with a moderate and high CV demand among individuals with AOCA with an acutely angled take-off or an anomalous course between the large vessels is not recommended.
III
C
Recommendations for exercise/sports in individuals with myocardial bridging
Competitive sports are not recommended in individuals with myocardial bridging and persistent ischaemia or complex cardiac arrhythmias during maximal exercise stress testing.
III
C
Recommendations for exercise in chronic heart failure
Recommendations for exercise prescription in heart failure with reduced or mid-range ejection fraction
Regular discussion about exercise participation and provision of an individualized exercise prescription is recommended in all individuals with HF.
I
A
Exercise-based cardiac rehabilitation is recommended in all stable individuals to improve exercise capacity and quality of life and to reduce the frequency of hospital readmission.
I
A
Continued
9. ‘What to do’ and ‘what not to do’ messages from the Guidelines
ESC Guidelines
75


<!-- PAGE 60 -->

### Page 60

Recommendations for participation in sports in heart failure
Before considering a sport activity, a preliminary optimization of HF risk factor control and therapy, including device implantation (if appropriate), is recommended.
I
C
High-intensity power and endurance sports are not recommended in patients with HFrEF irrespective of symptoms.
III
C
Recommendations for exercise and participation in sports in individuals with heart failure and preserved ejection fraction
Moderate endurance and dynamic resistance exercise, together with lifestyle intervention and optimal treatment of CV risk factors
(i.e. arterial hypertension and type 2 diabetes) are recommended.
I
C
Recommendations for exercise and participation in sports in individuals with heart transplant recipients
Regular exercise through cardiac rehabilitation combining moderate-intensity aerobic and resistance exercise is recommended to revert pathophysiology to pre-transplantation time, reduce CV risk induced by post-transplantation medical treatment, and improve clinical outcome.
I
B
Recommendations for exercise in asymptomatic individuals with valvular heart disease
Participation in competitive or recreational sports/exercise of moderate and high intensity is not recommended in individuals with severe aortic stenosis.
III
C
Participation in competitive or recreational sports/exercise of moderate and high intensity is not recommended in individuals with severe aortic regurgitation with LVEF<_50% and/or exercise-induced arrhythmias.
III
C
Participation in competitive sports is not recommended in individuals with severe mitral regurgitation with a LVEF<60%.
III
C
Participation in any competitive sport, or leisure sports/exercise of mild to moderate intensity, is not recommended in individuals with severe (MVA<1 cm2) mitral stenosis.
III
C
Recommendations for exercise in individuals with aortic pathology
Prior to engaging in exercise, risk stratiﬁcation, with careful assessment including advanced imaging of the aorta (CT/CMR) and exercise testing with BP assessment, is recommended.
I
A
Competitive sports are not recommended in individuals who are at high risk (Table 14).
III
C
Recommendations for exercise in individuals with cardiomyopathy
General recommendation
Annual assessment for risk stratiﬁcation is recommended in all individuals with cardiomyopathy who exercise regularly.
I
C
Recommendations for exercise and sports participation in individuals with hypertrophic cardiomyopathy
Participation in high-intensity exercise (including recreational and competitive sports) is not recommended in individuals who have
ANY markers of increased risk [(i) cardiac symptoms or history of cardiac arrest or unexplained syncope; (ii) moderate ESC risk score (>_4%) at 5 years; (iii) LVOT gradient at rest >30 mmHg; (iv) abnormal BP response to exercise; (v) exercise-induced arrhythmias].
III
C
Recommendations for exercise and sports participation in individuals with arrhythmogenic cardiomyopathy
Participation in high-intensity recreational exercise/sports or any competitive sports is not recommended in individuals with ACM
including those who are genotype positive and phenotype negative.
III
C
Recommendations for exercise and sports participation in individuals with left ventricular non-compaction cardiomyopathy
Participation in high-intensity exercise or competitive sports is not recommended in individuals with symptoms, LVEF<40% and/or frequent and/or complex VAs on ambulatory Holter monitoring or exercise testing.
III
C
Recommendations for exercise and sports participation in individuals with dilated cardiomyopathy
Participation in high- or very high-intensity exercise including competitive sports is not recommended for individuals with a DCM and any of the following: (i) symptoms or history of cardiac arrest or unexplained syncope; (ii) LVEF<45%; (iii) frequent and/or complex
VAs on ambulatory Holter monitoring or exercise testing; (iv) extensive LGE (>20%) on CMR; or (v) high-risk genotype (lamin A/C
or ﬁlamin C).
III
C
Recommendations for exercise in individuals with myocarditis and pericarditis
Comprehensive evaluation, using imaging studies, exercise stress test, and Holter monitoring, is recommended following recovery from acute myocarditis to assess the risk of exercise-related SCD.
I
B
Return to all forms of exercise including competitive sports is recommended after 30 days to 3 months of rest for individuals who have recovered completely from acute pericarditis, depending on clinical severity.
I
C
Among individuals with a probable or deﬁnitive diagnosis of recent myocarditis or pericarditis, participation in leisure-time or competitive sports while active inﬂammation is present is not recommended.
III
C
Participation in moderate- to high-intensity exercise for a period of 36 months after acute myocarditis is not recommended.
III
B
Participation in moderate- to high-intensity exercise, including competitive sports, is not recommended for individuals with constrictive pericarditis.
III
C
Continued


<!-- PAGE 61 -->

### Page 61

Recommendations for exercise in individuals with arrhythmias and implantable cardiac devices
Exercise recommendations in individuals with atrial ﬁbrillation
Regular physical activity is recommended to prevent AF.
I
A
Evaluation and management of structural heart disease, thyroid dysfunction, alcohol or drug abuse, or other primary causes of AF is recommended before engaging in sports.
I
A
AF ablation is recommended in exercising individuals with recurrent, symptomatic AF and/or in those who do not want drug therapy,
given its impact on athletic performance.
I
B
Sports with direct bodily contact or prone to trauma are not recommended in exercising individuals with AF who are anticoagulated.
III
C
Recommendations for exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation
In individuals with palpitations, a comprehensive assessment to exclude (latent) pre-excitation, structural heart disease, and VAs is recommended.
I
B
Ablation of the accessory pathway is recommended in competitive and recreational athletes with pre-excitation and documented arrhythmias.
I
C
In competitive/professional athletes with asymptomatic pre-excitation, an EP study is recommended to evaluate the risk for sudden death.
I
B
Exercise recommendations in individuals with premature ventricular contractions or non-sustained ventricular tachycardia
In exercising individuals with >_2 PVCs on a baseline ECG (or >_1 PVC in case of high-endurance athletes) a thorough evaluation
(including a detailed family history) to exclude underlying structural or arrhythmogenic conditions is recommended.
I
C
Among individuals with frequent PVCs and non-sustained VT a thorough investigation with Holter monitoring, 12-lead ECG, exercise test, and suitable imaging is recommended.
I
C
Exercise recommendations in long QT syndrome
It is recommended that all exercising individuals with LQTS with prior symptoms or prolonged QTc be on therapy with beta-blockers at target dose.
I
B
It is recommended that exercising individuals with LQTS should avoid QT-prolonging drugs (www.crediblemeds.org) and electrolyte imbalance such as hypokalaemia and hypomagnesaemia.
I
B
Participation in high-intensity recreational and competitive sports, even when on beta-blockers, is not recommended in individuals with a QTc>500 ms or a genetically conﬁrmed LQTS with a QTc>_470 ms in males or >_480 ms in females.
III
B
Participation in competitive sports (with or without ICD) is not recommended in individuals with LQTS and prior cardiac arrest or arrhythmic syncope.
III
C
Exercise recommendations in Brugada syndrome
ICD implantation is recommended in patients with BrS with episodes of arrhythmic syncope and/or aborted SCD.
I
C
Prescription of drugs that may aggravate BrS, electrolyte abnormalities, and sports practices that increase core temperature >39
C
are not recommended in individuals with overt BrS or phenotypically negative mutation carriers.
III
C
Exercise recommendations in individuals with implantable cardiac electronic devices
It is recommended that individuals with implanted devices with/without resynchronization and underlying disease follow the recommendations pertaining to the underlying disease.
I
B
An ICD is not recommended as a substitute for disease-related recommendations when these mandate sports restrictions.
III
C
Recommendations for patients with congenital heart disease
Participation in regular moderate exercise is recommended in all individuals with CHD.
I
B
A discussion on exercise participation and provision of an individualized exercise prescription is recommended at every CHD patient encounter.
I
B
Competitive sport is not recommended for individuals with CHD who are in NYHA class IIIIV or with potentially serious arrhythmias.
III
C
Recommendations for exercise in pregnancy
Among pregnant women without medical or obstetric contraindications, participation in at least 150 min/week of moderate-intensity aerobic exercise before, during, and after pregnancy is recommended.
I
B
Re-evaluation before continuing exercise or training is recommended in pregnant woman if they experience excessive shortness of breath, severe chest pain, dizziness or syncope, regular painful contractions, vaginal bleeding, or amniotic ﬂuid leakage.
I
A
Among women with CVD who were habitually engaged in strength training or power sport disciplines before pregnancy, discussing the option with the medical team before continuing and avoiding the Valsalva manoeuvre is recommended.
I
A
Exercise or sport involving forceful physical contact, risk of falling or abdominal trauma, heavy lifting, scuba diving, or exercising at high altitude when unacclimatized are not recommended.
III
C
Continued
ESC Guidelines
77


<!-- PAGE 62 -->

### Page 62

..................
10. Supplementary data
Supplementary Data with additional Supplementary Figures, Tables,
and text complementing the full text are available on the European
Heart Journal website and via the ESC website at www.escardio.org/
guidelines.
11. Appendix
Author/Task Force Member Affiliations: Sabiha Gati, Faculty of Medicine, National Heart & Lung Institute, Imperial College,
London, United Kingdom and Cardiology, Royal Brompton &
Harefield Hospital NHS Foundation Trust, London, United Kingdom;
Vigorous exercise associated with a maximal predicted heart rate >90% of the predicted heart rate is not recommended during pregnancy.
III
B
Exercising while lying supine on a hard surface is not recommended after the ﬁrst trimester due to the risk of decreased venous return and uterine blood ﬂow.
III
B
Recommendations for exercise in chronic kidney disease
Low- to moderate-intensity aerobic exercise training (up to 150 min/week), and low- to moderate-intensity resistance exercise training (2 day per week, 812 exercises, 1215 repetitions), and ﬂexibility exercises are recommended in all individuals with CKD.
I
A
Among patients with established osteodystrophy/osteoporosis, or coagulopathies, participation in contact sports is not recommended.
III
C
Participation in sport is not recommended in the following circumstances: electrolyte abnormalities, recent changes to the ECG,
excess inter-dialysis weight gain, changing or titration of medication regimen, pulmonary congestion, and increasing peripheral oedema.
III
C
Recommendations for exercise in individuals with cancer
Regular exercise during and after cancer therapy is recommended to reduce cancer-related fatigue, and improve quality of life, physical ﬁtness, and prognosis.
I
A
Among individuals treated with cardiotoxic medications, echocardiography before participation in high-intensity exercise is recommended.
I
A
Recommendations for exercise in individuals with spinal cord injury
In adults with spinal cord injury participation in 20 min of moderate- to vigorous-intensity aerobic exercise at least 3 times a week,
along with moderate-intensity resistance training 23 times per week, is recommended for cardiorespiratory ﬁtness, cardiometabolic health, and muscle strength beneﬁts.
I
A
Artiﬁcial methods of inducing autonomic dysreﬂexia by causing intentional pain to the lower half of the body (‘boosting’) through obstruction of an indwelling urinary catheter, overly tight leg straps and electrical shocks or other methods of pain to the genitalia or lower limbs can be life-threatening and are not recommended.
III
C
Recommendations for exercise in individuals with ventricular assist devices
Regular exercise, through cardiac rehabilitation, combining moderate-intensity aerobic and resistance exercise, is recommended in individuals with a ventricular assist device (VAD).
I
A
Sports that may potentially affect any of the VAD components (e.g. with body contact) are not recommended.
III
C
Physical activity and sports recommendations in patients and athletes with peripheral arterial disease
It is recommended that patients with atherosclerotic PAD perform regular exercise (at least 150 min/week of moderate aerobic exercise or 75 min/week of vigorous aerobic exercise or a combination thereof) as part of the secondary prevention strategy.
I
A
In patients with symptomatic LEAD, supervised exercise training programmes including walking to the maximal or submaximal distance for at least 3 h/week are indicated.
I
A
Continuation of competitive sports is recommended in athletes with traumatic or non-traumatic PAD following recovery after successful open surgery or percutaneous revascularization.
I
C
ACM = arrhythmogenic cardiomyopathy; AF = atrial ﬁbrillation; AOCA = anomalous origin of coronary arteries; BP = blood pressure; BMI = body mass index; BrS = Brugada syndrome; CAD = coronary artery disease; CCS = chronic coronary syndrome; CHD = congenital heart disease; CKD = chronic kidney disease; CMR, cardiovascular magnetic resonance; CT = computed tomography; CV = cardiovascular; CVD= cardiovascular disease; EEG = electrocardiogram; EP = electrophysiological; ESC = European Society of
Cardiology; EP = electrophysiological; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter deﬁbrillator; LEAD = lower extremity artery disease; LQTS = long QT syndrome; LVEF = left ventricular ejection fraction; LVOT = left ventricular outﬂow tract; MVA = mitral valve area; NYHA = New
York Heart Association; PAD = peripheral arterial disease; PVC = premature ventricular contractions; SCD = sudden cardiac death; SBP = systolic blood pressure; VA = ventricular arrhythmia; VAD = ventricular assist device; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 63 -->

### Page 63

.............................................................................................................................................................................
Maria B€ack, Unit of Physiotherapy, Department of Health,
Medicine and Caring Sciences, Linko¨ping University, Linko¨ping,
Sweden, and Department of Molecular and Clinical Medicine,
Institute of
Medicine,
Sahlgrenska
Academy,
University of
Gothenburg, and Sahlgrenska University Hospital, Gothenburg,
Sweden; Mats Bo¨rjesson, Department of Molecular and Clinical
Medicine, Institute of Medicine, Sahlgrenska Academy, University of
Gothenburg, and Sahlgrenska University Hospital, Gothenburg,
Sweden, and Center for Health and Performance, Department of
Food, Nutrition and Sports Science, Gothenburg University,
Gothenburg, Sweden; Stefano Caselli, Cardiovascular Center
Zurich, Hirslanden Klinik im Park, Zurich, Switzerland; JeanPhilippe Collet, Sorbonne Universite´, Institut de Cardiologie,
Hoˆpital
Pitie´-Salp^etrie`re
(APHP),
Paris,
France;
Domenico
Corrado, Cardiac, Thoracic and Vascular Sciences, University of
Padova, Padova, Italy; Jonathan A. Drezner, University of
Washington, Seattle, United States of America; Martin Halle,
Prevention and Sports Medicine, Klinikum rechts der Isar, Technical
University of Munich, Munich, Germany; Dominique Hansen,
Hasselt University, BIOMED/REVAL/Heart Centre Hasselt, Jessa
Hospital,
Hasselt,
Belgium;
Hein
Heidbuchel,
Cardiology,
University Hospital Antwerp and Antwerp University, Antwerp,
Belgium; Jonathan Myers, Cardiology Division, VA Palo Alto
Health Care System, Palo Alto, California, United States of America and Cardiology Division, Stanford University, Palo Alto, California,
United States of America; Josef Niebauer, University Institute of
Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical
University, Salzburg, Austria and Ludwig Boltzmann Institute for
Digital
Health and
Prevention,
Salzburg,
Austria;
Michael
Papadakis, Cardiology Clinical Academic Group, St George’s,
University of
London,
London,
United
Kingdom;
Massimo
Francesco Piepoli, Heart Failure Unit, Cardiology, Guglielmo da
Saliceto Hospital and University of Parma, Piacenza, Italy; Eva
Prescott,
Department of
Cardiology,
Bispebjerg
University
Hospital, Copenhagen, Denmark; Jolien W. Roos-Hesselink,
Department of Cardiology, Erasmus MC, Rotterdam, Netherlands;
A. Graham Stuart, Congenital Heart Unit, Bristol Heart Institute,
Bristol, United Kingdom; Rod S. Taylor, University of Glasgow,
Glasgow, Scotland, United Kingdom; Paul D. Thompson, Division of Cardiology, Hartford Hospital, Hartford, Connecticut, United
States of America; Monica Tiberi, Department of Health-Sport
Medicine, Azienda Unica Regionale Marche, Area Vasta 1, Pesaro,
Italy; Luc Vanhees, Rehabilitation Sciences, Kuleuven, Leuven,
Belgium; and Matthias Wilhelm, Department of Cardiology,
Inselspital, University Hospital Bern, University of Bern, Bern,
Switzerland.
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Colin Baigent (United Kingdom), Jean-Philippe Collet (France),
Veronica Dean (France), Victoria Delgado (Netherlands), Donna
Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom),
Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway),
Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni
(Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany),
Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S.
Lewis
(Israel),
Be´la
Merkely
(Hungary),
Christian
Mueller
(Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia
Petronio
(Italy),
Dimitrios
J.
Richter
(Greece),
Marco
Roffi
(Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A.
Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), and Rhian
M. Touyz (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2020 ESC Guidelines on Sports Cardiology and
Exercise in Patients with Cardiovascular Disease: Algeria: Algerian
Society of Cardiology, Mohamed Tahmi; Armenia: Armenian
Cardiologists Association, Parounak H. Zelveian; Austria: Austrian
Society of Cardiology, Thomas Berger; Azerbaijan: Azerbaijan
Society of Cardiology, Rahima Gabulova; Belarus: Belorussian
Scientific Society of Cardiologists, Svetlana Sudzhaeva; Belgium:
Belgian Society of Cardiology, Patrizio Lancellotti; Bosnia and
Herzegovina:
Association of
Cardiologists of
Bosnia and
Herzegovina, Sekib Sokolovic; Bulgaria: Bulgarian Society of
Cardiology, Ivan Gruev; Croatia: Croatian Cardiac Society, Vedran
Velagic; Cyprus: Cyprus Society of Cardiology, Evagoras Nicolaides;
Czech Republic: Czech Society of Cardiology, Vladimir Tuka;
Denmark: Danish Society of Cardiology, Hanne Rasmusen; Egypt:
Egyptian Society of Cardiology, Hazem Khamis; Estonia: Estonian
Society of Cardiology, Margus Viigimaa; Finland: Finnish Cardiac
Society, Jari A. Laukkanen; France: French Society of Cardiology,
Gilles
Bosser;
Germany:
German
Cardiac
Society,
Rainer
Hambrecht; Greece: Hellenic Society of Cardiology, Alexandros
Kasiakogias; Hungary: Hungarian Society of Cardiology, Be´la
Merkely; Iceland: Icelandic Society of Cardiology, Gunnar Thor
Gunnarsson; Ireland: Irish Cardiac Society, Brendan McAdam;
Israel: Israel Heart Society, Andre Keren; Italy: Italian Federation of
Cardiology, Pasquale Perrone-Filardi; Kosovo (Republic of):
Kosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan: Kyrgyz
Society of Cardiology, Erkin Mirrakhimov; Latvia: Latvian Society of
Cardiology, Sandra Rozenstoka; Lithuania: Lithuanian Society of
Cardiology,
Germanas
Marinskis;
Luxembourg:
Luxembourg
Society of Cardiology, Cristiana Banu; Malta: Maltese Cardiac
Society, Mark Abela; Moldova (Republic of): Moldavian Society of
Cardiology, Eleonora Vataman; Montenegro: Montenegro Society of Cardiology, Natasa Belada; Morocco: Moroccan Society of
Cardiology, Hasnaa Belghiti; Netherlands: Netherlands Society of
Cardiology, Harald Thune Jorstad; North Macedonia: North
Macedonian Society of Cardiology, Elizabeta Srbinovska Kostovska;
Norway: Norwegian Society of Cardiology, Kristina Haugaa;
Poland: Polish Cardiac Society, Renata Głowczynska; Portugal:
Portuguese Society of Cardiology, Helder Dores; Romania:
Romanian Society of Cardiology, Florin Mitu; Russian Federation:
Russian Society of Cardiology, Andrey Smolensky; San Marino: San
Marino Society of Cardiology, Marina Foscoli; Serbia: Cardiology
Society of Serbia, Ivana Nedeljkovic; Slovakia: Slovak Society of
Cardiology,
Stefan
Farsky;
Slovenia:
Slovenian
Society of
Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology,
Araceli Boraita; Sweden: Swedish Society of Cardiology, Peder
So¨renssen; Switzerland: Swiss Society of Cardiology, Christian
Schmied;
Syrian
Arab
Republic:
Syrian
Cardiovascular
Association, Walid Bsata; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Lilia Zakhama; Turkey: Turkish
Society of
Cardiology,
Mehmet
Uzun;
Ukraine:
Ukrainian
ESC Guidelines
79


<!-- PAGE 64 -->

### Page 64

...........................................................................................................................................................................
Association of Cardiology, Elena Nesukay; United Kingdom of
Great Britain and Northern Ireland: British Cardiovascular
Society, Dhrubo Rakhit.
12. References
1. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi
A, Borjesson M, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel
H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, vanBuuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson
M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J,
McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G.
Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the
Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005;26:14221445.
2. Borjesson M, Dellborg M. Exercise testing post-MI: still worthwhile in the interventional era. Eur Heart J 2005;26:105106.
3. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, La Gerche A,
Niebauer J, Pressler A, Schmied CM, Serratosa L, Halle M, Van Buuren F,
Borjesson M, Carre F, Panhuyzen-Goedkoop NM, Heidbuchel H, Olivotto I,
Corrado D, Sinagra G, Sharma S. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European
Association of Preventive Cardiology (EAPC). Eur Heart J 2019;40:1933.
4. Marijon E, Uy-Evanado A, Reinier K, Teodorescu C, Narayanan K, Jouven X,
Gunson K, Jui J, Chugh SS. Sudden cardiac arrest during sports activity in middle age. Circulation 2015;131:13841391.
5. Chugh SS, Weiss JB. Sudden cardiac death in the older athlete. J Am Coll Cardiol
2015;65:493502.
6. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen M-L,
Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N,
Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S.
2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J
2016;37:23152381.
7. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 2018;1:e183605.
8. Shiroma EJ, Lee I-M. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation
2010;122:743752.
9. Radford NB, DeFina LF, Leonard D, Barlow CE, Willis BL, Gibbons LW, Gilchrist
SC, Khera A, Levine BD. Cardiorespiratory fitness, coronary artery calcium, and cardiovascular disease events in a cohort of generally healthy middle-age men:
results from the
Cooper
Center
Longitudinal
Study.
Circulation
2018;137:18881895.
10. Shah RV, Murthy VL, Colangelo LA, Reis J, Venkatesh BA, Sharma R, Abbasi SA,
Goff DCJ, Carr JJ, Rana JS, Terry JG, Bouchard C, Sarzynski MA, Eisman A,
Neilan T, Das S, Jerosch-Herold M, Lewis CE, Carnethon M, Lewis GD, Lima
JAC. Association of fitness in young adulthood with survival and cardiovascular risk: the Coronary Artery Risk Development in Young Adults (CARDIA) study.
JAMA Intern Med 2016;176:8795.
11. Hussain N, Gersh BJ, Gonzalez Carta K, Sydo N, Lopez-Jimenez F, Kopecky SL,
Thomas RJ, Asirvatham SJ, Allison TG. Impact of cardiorespiratory fitness on frequency of atrial fibrillation, stroke, and all-cause mortality. Am J Cardiol
2018;121:4149.
12. Juraschek SP, Blaha MJ, Whelton SP, Blumenthal R, Jones SR, Keteyian SJ,
Schairer J, Brawner CA, Al-Mallah MH. Physical fitness and hypertension in a population at risk for cardiovascular disease: the Henry Ford ExercIse Testing
(FIT) Project. J Am Heart Assoc 2014;3:e001268.
13. Juraschek SP, Blaha MJ, Blumenthal RS, Brawner C, Qureshi W, Keteyian SJ,
Schairer J, Ehrman JK, Al-Mallah MH. Cardiorespiratory fitness and incident diabetes:
the
FIT
(Henry
Ford
ExercIse
Testing)
Project.
Diabetes
Care
2015;38:10751081.
14. Vainshelboim B, Muller J, Lima RM, Nead KT, Chester C, Chan K, Kokkinos P,
Myers J. Cardiorespiratory fitness and cancer incidence in men. Ann Epidemiol
2017;27:442447.
15. Powell KE, King AC, Buchner DM, Campbell WW, DiPietro L, Erickson KI,
Hillman CH, Jakicic JM, Janz KF, Katzmarzyk PT, Kraus WE, Macko RF, Marquez
DX, McTiernan A, Pate RR, Pescatello LS, Whitt-Glover MC. The Scientific
Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J Phys
Act Health 2018;111.
16. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman
JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJL,
Forouzanfar MH. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ
2016;354:i3857.
17. Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, Zigman
ML, Ellenbogen R, Rao AL, Ackerman MJ, Drezner JA. Incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: a decade in review. Circulation 2015;132:1019.
18. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 19802006.
Circulation 2009;119:10851092.
19. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll
Cardiol 2003;42:19591963.
20. Maron BJ, Friedman RA, Kligfield P, Levine BD, Viskin S, Chaitman BR, Okin PM,
Saul JP, Salberg L, Van Hare GF, Soliman EZ, Chen J, Matherne GP, Bolling SF,
Mitten MJ, Caplan A, Balady GJ, Thompson PD. Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in healthy general populations of young people (1225 years of age): a scientific statement from the American Heart Association and the American College of
Cardiology. J Am Coll Cardiol 2014;64:14791514.
21. Corrado D, Pelliccia A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M,
Panhuyzen-Goedkoop N, Deligiannis A, Solberg E, Dugmore D, Mellwig KP,
Assanelli D, Delise P, van-Buuren F, Anastasakis A, Heidbuchel H, Hoffmann E,
Fagard R, Priori SG, Basso C, Arbustini E, Blomstrom-Lundqvist C, McKenna WJ,
Thiene G. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus statement of the Study Group of Sport Cardiology of the
Working Group of Cardiac Rehabilitation and Exercise Physiology and the
Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005;26:516524.
22. Drezner JA, O’Connor FG, Harmon KG, Fields KB, Asplund CA, Asif IM, Price
DE, Dimeff RJ, Bernhardt DT, Roberts WO. AMSSM position statement on cardiovascular preparticipation screening in athletes: current evidence, knowledge gaps, recommendations and future directions. Br J Sports Med 2017;51:153167.
23. Ljungqvist A, Jenoure P, Engebretsen L, Alonso JM, Bahr R, Clough A, De Bondt
G, Dvorak J, Maloley R, Matheson G, Meeuwisse W, Meijboom E, Mountjoy M,
Pelliccia A, Schwellnus M, Sprumont D, Schamasch P, Gauthier J-B, Dubi C,
Stupp H, Thill C. The International Olympic Committee (IOC) Consensus
Statement on periodic health evaluation of elite athletes, March 2009. Br J Sports
Med 2009;43:631643.
24. Hainline B, Drezner JA, Baggish A, Harmon KG, Emery MS, Myerburg RJ,
Sanchez E, Molossi S, Parsons JT, Thompson PD. Interassociation consensus statement on cardiovascular care of college student-athletes. J Am Coll Cardiol
2016;67:29812995.
25. Preparticipation Physical Evaluation, 4th Edition [online]. American Academy of
Family Physicians et alet al; 2010. Available from: https://ebooks.aappublications.
org/content/9781581104882/9781581104882.
26. Maron BJ, Levine BD, Washington RL, Baggish AL, Kovacs RJ, Maron MS.
Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 2: Preparticipation screening for cardiovascular disease in competitive athletes: a scientific statement from the American
Heart Association. Circulation 2015;132:e26772.
27. Peterson DF, Siebert DM, Kucera KL, Thomas LC, Maleszewski JJ, LopezAnderson M, Suchsland MZ, Harmon KG, Drezner JA. Etiology of sudden cardiac arrest and death in US competitive athletes: a 2-year prospective surveillance study. Clin J Sport Med; doi:10.1097/JSM.0000000000000598. Published online ahead of print, 2018 Apr 9.
28. Finocchiaro G, Papadakis M, Robertus J-L, Dhutia H, Steriotis AK, Tome M,
Mellor G, Merghani A, Malhotra A, Behr E, Sharma S, Sheppard MN. Etiology of sudden death in sports: insights from a United Kingdom regional registry. J Am
Coll Cardiol 2016;67:21082115.
29. Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM,
Avedissian L, Pearse LA, Potter RN, Tremaine L, Gentlesk PJ, Huffer L, Reich SS,
Stevenson WG. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011;58:12541261.
30. Solberg EE, Borjesson M, Sharma S, Papadakis M, Wilhelm M, Drezner JA,
Harmon KG, Alonso JM, Heidbuchel H, Dugmore D, Panhuyzen-Goedkoop NM,
Mellwig K-P, Carre F, Rasmusen H, Niebauer J, Behr ER, Thiene G, Sheppard
MN, Basso C, Corrado D. Sudden cardiac arrest in sports  need for uniform registration: a position paper from the Sport Cardiology Section of the European


<!-- PAGE 65 -->

### Page 65

.............................................................................................................................................................................
Association for Cardiovascular Prevention and Rehabilitation. Eur J Prev Cardiol
2016;23:657667.
31. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R,
Douglas PS, Glover DW, Hutter AMJ, Krauss MD, Maron MS, Mitten MJ,
Roberts WO, Puffer JC. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes:
2007 update: a scientific statement from the American Heart Association Council on
Nutrition, Physical Activity, and Metabolism. Circulation 2007;115:14551643.
32. Drezner JA, Peterson DF, Siebert DM, Thomas LC, Lopez-Anderson M,
Suchsland MZ, Harmon KG, Kucera KL. Survival after exercise-related sudden cardiac arrest in young athletes: can we do better? Sports Health 2019;11:9198.
33. McKinney J, Velghe J, Fee J, Isserow S, Drezner JA. Defining athletes and exercisers. Am J Cardiol 2019;123:532535.
34. Giri S, Thompson PD, Kiernan FJ, Clive J, Fram DB, Mitchel JF, Hirst JA, McKay
RG, Waters DD. Clinical and angiographic characteristics of exertion-related acute myocardial infarction. JAMA 1999;282:17311736.
35. Thompson PD. Exercise prescription and proscription for patients with coronary artery disease. Circulation 2005;112:23542363.
36. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C,
Narayanan K, Gunson K, Jui J, Jouven X, Chugh SS. Warning symptoms are associated with survival from sudden cardiac arrest. Ann Intern Med 2016;164:2329.
37. Nehme Z, Bernard S, Andrew E, Cameron P, Bray JE, Smith K. Warning symptoms preceding out-of-hospital cardiac arrest: do patient delays matter?
Resuscitation 2018;123:6570.
38. Kim JH, Malhotra R, Chiampas G, d’Hemecourt P, Troyanos C, Cianca J, Smith
RN, Wang TJ, Roberts WO, Thompson PD, Baggish AL. Cardiac arrest during long-distance running races. N Engl J Med 2012;366:130140.
39. Drezner JA, Rao AL, Heistand J, Bloomingdale MK, Harmon KG. Effectiveness of emergency response planning for sudden cardiac arrest in United States high schools with automated external defibrillators. Circulation 2009;120:518525.
40. Roberts WO, Stovitz SD. Incidence of sudden cardiac death in Minnesota high school athletes 19932012 screened with a standardized pre-participation evaluation. J Am Coll Cardiol 2013;62:12981301.
41. Harmon KG, Asif IM, Klossner D, Drezner JA. Incidence of sudden cardiac death in
National
Collegiate
Athletic
Association athletes.
Circulation
2011;123:15941600.
42. Holst AG, Winkel BG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL,
Svendsen JH, Haunso S, Prescott E, Tfelt-Hansen J. Incidence and etiology of sports-related sudden cardiac death in Denmark  implications for preparticipation screening. Heart Rhythm 2010;7:13651371.
43. Risgaard B, Winkel BG, Jabbari R, Glinge C, Ingemann-Hansen O, Thomsen JL,
Ottesen GL, Haunso S, Holst AG, Tfelt-Hansen J. Sports-related sudden cardiac death in a competitive and a noncompetitive athlete population aged 12 to 49
years: data from an unselected nationwide study in Denmark. Heart Rhythm
2014;11:16731681.
44. Risgaard B, Tfelt-Hansen J, Winkel BG. Sports-related sudden cardiac death: how to prove an effect of preparticipation screening?
Heart
Rhythm
2016;13:15601562.
45. Drezner JA, Harmon KG, Marek JC. Incidence of sudden cardiac arrest in
Minnesota high school student athletes: the limitations of catastrophic insurance claims. J Am Coll Cardiol 2014;63:14551456.
46. Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-Ramos S. Incidence and causes of sudden death in
U.S.
college athletes.
J
Am
Coll
Cardiol
2014;63:16361643.
47. Maron BJ, Gohman TE, Aeppli D. Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes. J Am Coll Cardiol
1998;32:18811884.
48. Van Camp SP, Bloor CM, Mueller FO, Cantu RC, Olson HG. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc
1995;27:641647.
49. Maron BJ, Haas TS, Ahluwalia A, Rutten-Ramos SC. Incidence of cardiovascular sudden deaths in
Minnesota high school athletes.
Heart
Rhythm
2013;10:374377.
50. Harmon K, Asif I, Ellenbogen R, Drezner J. The incidence of sudden cardiac arrest and death in United States high school athletes. Br J Sports Med [Internet]
2014;48:605.
51. Toresdahl BG, Rao AL, Harmon KG, Drezner JA. Incidence of sudden cardiac arrest in high school student athletes on school campus. Heart Rhythm
2014;11:11901194.
52. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:10641075.
53. de Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN.
Aetiology of sudden cardiac death in athletes in the United Kingdom: a pathological study. Heart 2009;95:14091414.
54. Suarez-Mier MP, Aguilera B, Mosquera RM, Sanchez-de-Leon MS. Pathology of sudden death during recreational sports in
Spain.
Forensic
Sci
Int
2013;226:188196.
55. Ullal AJ, Abdelfattah RS, Ashley EA, Froelicher VF. Hypertrophic cardiomyopathy as a cause of sudden cardiac death in the young: a meta-analysis. Am J Med
2016;129:486496.e2.
56. Thiene G, Rizzo S, Schiavon M, Maron MS, Zorzi A, Corrado D, Maron BJ, Basso
C. Structurally normal hearts are uncommonly associated with sudden deaths in athletes and young people. J Am Coll Cardiol 2019;73:30313032.
57. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006;296:15931601.
58. Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P, Cowie C, Kenny
A, Mayet J, Oxborough D, Patel K, Pieles G, Rakhit D, Ramsdale D, Shapiro L,
Somauroo J, Stuart G, Varnava A, Walsh J, Yousef Z, Tome M, Papadakis M,
Sharma S. Outcomes of cardiac screening in adolescent soccer players. N Engl J
Med 2018;379:524534.
59. Fuller CM, McNulty CM, Spring DA, Arger KM, Bruce SS, Chryssos BE,
Drummer EM, Kelley FP, Newmark MJ, Whipple GH. Prospective screening of
5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc
1997;29:11311138.
60. Wilson MG, Basavarajaiah S, Whyte GP, Cox S, Loosemore M, Sharma S.
Efficacy of personal symptom and family history questionnaires when screening for inherited cardiac pathologies: the role of electrocardiography. Br J Sports Med
2008;42:207211.
61. Bessem B, Groot FP, Nieuwland W. The Lausanne recommendations: a Dutch experience. Br J Sports Med 2009;43:708715.
62. Hevia AC, Fernandez MM, Palacio JMA, Martin EH, Castro MG, Reguero JJR.
ECG as a part of the preparticipation screening programme: an old and still present international dilemma. Br J Sports Med 2011;45:776779.
63. Baggish AL, Hutter AMJ, Wang F, Yared K, Weiner RB, Kupperman E, Picard
MH, Wood MJ. Cardiovascular screening in college athletes with and without electrocardiography: a cross-sectional study. Ann Intern Med 2010;152:269275.
64. Fudge J, Harmon KG, Owens DS, Prutkin JM, Salerno JC, Asif IM, Haruta A, Pelto
H, Rao AL, Toresdahl BG, Drezner JA. Cardiovascular screening in adolescents and young adults: a prospective study comparing the Pre-participation Physical
Evaluation
Monograph
4th
Edition and
ECG.
Br
J
Sports
Med
2014;48:11721178.
65. Drezner JA, Prutkin JM, Harmon KG, O’Kane JW, Pelto HF, Rao AL, Hassebrock
JD, Petek BJ, Teteak C, Timonen M, Zigman M, Owens DS. Cardiovascular screening in college athletes. J Am Coll Cardiol 2015;65:23532355.
66. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE.
Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction
Onset Study Investigators. N Engl J Med 1993;329:16771683.
67. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med 1984;311:874877.
68. Waller BF, Roberts WC. Sudden death while running in conditioned runners aged 40 years or over. Am J Cardiol 1980;45:12921300.
69. Noakes TD, Opie LH, Rose AG, Kleynhans PH, Schepers NJ, Dowdeswell R.
Autopsy-proved coronary atherosclerosis in marathon runners. N Engl J Med
1979;301:8689.
70. Marijon E, Tafflet M, Celermajer DS, Dumas F, Perier M-C, Mustafic H, Toussaint
J-F, Desnos M, Rieu M, Benameur N, Le Heuzey J-Y, Empana J-P, Jouven X.
Sports-related sudden death in the general population.
Circulation
2011;124:672681.
71. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: preamble, principles,
and general considerations: a scientific statement from the American Heart
Association and
American
College of
Cardiology.
J
Am
Coll
Cardiol
2015;66:23432349.
72. Zeltser I, Cannon B, Silvana L, Fenrich A, George J, Schleifer J, Garcia M, Barnes
A, Rivenes S, Patt H, Rodgers G, Scott W. Lessons learned from preparticipation cardiovascular screening in a
state funded program.
Am
J
Cardiol
2012;110:902908.
73. Dunn TP, Pickham D, Aggarwal S, Saini D, Kumar N, Wheeler MT, Perez M,
Ashley E, Froelicher VF. Limitations of current AHA guidelines and proposal of new guidelines for the preparticipation examination of athletes. Clin J Sport Med
2015;25:472477.
74. Drezner JA, Owens DS, Prutkin JM, Salerno JC, Harmon KG, Prosise S, Clark A,
Asif IM. Electrocardiographic screening in national collegiate athletic association athletes. Am J Cardiol 2016;118:754759.
75. Williams EA, Pelto HF, Toresdahl BG, Prutkin JM, Owens DS, Salerno JC, Harmon
KG, Drezner JA. Performance of the American Heart Association (AHA) 14-point evaluation versus electrocardiography for the cardiovascular screening of high school athletes: a prospective study. J Am Heart Assoc 2019;8:e012235.
76. Price DE, McWilliams A, Asif IM, Martin A, Elliott SD, Dulin M, Drezner JA.
Electrocardiography-inclusive screening strategies for detection of cardiovascular abnormalities in high school athletes. Heart Rhythm 2014;11:442449.
ESC Guidelines
81


<!-- PAGE 66 -->

### Page 66

.............................................................................................................................................................................
77. Rizzo M, Spataro A, Cecchetelli C, Quaranta F, Livrieri S, Sperandii F, Cifra B,
Borrione P, Pigozzi F. Structural cardiac disease diagnosed by echocardiography in asymptomatic young male soccer players: implications for pre-participation screening. Br J Sports Med 2012;46:371373.
78. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg
JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD,
Williams MA. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 2013;128:873934.
79. Gianrossi R, Detrano R, Mulvihill D, Lehmann K, Dubach P, Colombo A,
McArthur D, Froelicher V. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989;80:8798.
80. Corrado D, Schmied C, Basso C, Borjesson M, Schiavon M, Pelliccia A, Vanhees
L, Thiene G. Risk of sports: do we need a pre-participation screening for competitive and leisure athletes? Eur Heart J 2011;32:934944.
81. Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Brugada Terradellas J, Carre
F, Guasch E, Heidbuchel H, La Gerche A, Lampert R, McKenna W, Papadakis M,
Priori SG, Scanavacca M, Thompson P, Sticherling C, Viskin S, Wilson M,
Corrado D, Lip GY, Gorenek B, Blomstrom Lundqvist C, Merkely B, Hindricks
G, Hernandez-Madrid A, Lane D, Boriani G, Narasimhan C, Marquez MF, Haines
D, Mackall J, Manuel Marques-Vidal P, Corra U, Halle M, Tiberi M, Niebauer J,
Piepoli M. Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: position paper from the EHRA and the EACPR, branches of the ESC. Eur J Prev Cardiol 2017;24:4169.
82. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, Arena R,
Fletcher GF, Forman DE, Kitzman DW, Lavie CJ, Myers J. EACPR/AHA scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 2012;126:22612274.
83. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health
Rep 1985;100:126131.
84. Vanhees L, De Sutter J, GeladaS N, Doyle F, Prescott E, Cornelissen V, Kouidi E,
Dugmore D, Vanuzzo D, Borjesson M, Doherty P. Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the
EACPR. Part I. Eur J Prev Cardiol 2012;19:670686.
85. Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, Cornelissen V,
Adamopoulos S, Prescott E, Borjesson M, Bjarnason-Wehrens B, Bjornstad HH,
Cohen-Solal A, Conraads V, Corrado D, De Sutter J, Doherty P, Doyle F,
Dugmore D, Ellingsen O, Fagard R, Giada F, Gielen S, Hager A, Halle M,
Heidbuchel H, Jegier A, Mazic S, McGee H, Mellwig KP, Mendes M, Mezzani A,
Pattyn N, Pelliccia A, Piepoli M, Rauch B, Schmidt-Trucksass A, Takken T, van
Buuren F, Vanuzzo D. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J
Prev Cardiol 2012;19:10051033.
86. Tjonna AE, Stolen TO, Bye A, Volden M, Slordahl SA, Odegard R, Skogvoll E,
Wisloff U. Aerobic interval training reduces cardiovascular risk factors more than a multitreatment approach in overweight adolescents. Clin Sci (Lond)
2009;116:317326.
87. Schjerve IE, Tyldum GA, Tjonna AE, Stolen T, Loennechen JP, Hansen HEM,
Haram PM, Heinrich G, Bye A, Najjar SM, Smith GL, Slordahl SA, Kemi OJ,
Wisloff U. Both aerobic endurance and strength training programmes improve cardiovascular health in obese adults. Clin Sci (Lond) 2008;115:283293.
88. Shephard
RJ,
Balady,
GJ.
Exercise as cardiovascular therapy.
Circulation
1999;99:963972.
89. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc 2009;84:373383.
90. Franckowiak SC, Dobrosielski DA, Reilley SM, Walston JD, Andersen RE.
Maximal heart rate prediction in adults that are overweight or obese. J Strength
Cond Res 2011;25:14071412.
91. Vanhees L, Stevens A. Exercise intensity: a matter of measuring or of talking? J
Cardiopulm Rehabil 2006;26:7879.
92. Myers J, Hadley D, Oswald U, Bruner K, Kottman W, Hsu L, Dubach P. Effects of exercise training on heart rate recovery in patients with chronic heart failure.
Am Heart J 2007;153:10561063.
93. Tabet J-Y, Meurin P, Ben Driss A, Thabut G, Weber H, Renaud N, Odjinkem N,
Solal AC. Determination of exercise training heart rate in patients on beta-blockers after myocardial infarction. Eur J Cardiovasc Prev Rehabil 2006;13:538543.
94. O’Donovan G, Blazevich AJ, Boreham C, Cooper AR, Crank H, Ekelund U, Fox
KR, Gately P, Giles-Corti B, Gill JMR, Hamer M, McDermott I, Murphy M, Mutrie
N, Reilly JJ, Saxton JM, Stamatakis E. The ABC of physical activity for health: a consensus statement from the British Association of Sport and Exercise
Sciences. J Sports Sci 2010;28:573591.
95. Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the evidence. CMAJ 2006;174:801809.
96. Thomaes T, Thomis M, Onkelinx S, Goetschalckx K, Fagard R, Lambrechts D,
Vanhees L. Genetic predisposition scores associate with muscular strength, size,
and trainability. Med Sci Sports Exerc 2013;45:14511459.
97. Gibson OR, Taylor L, Watt PW, Maxwell NS. Cross-adaptation: heat and cold adaptation to improve physiological and cellular responses to hypoxia. Sports
Med 2017;47:17511768.
98. Tjonna AE, Lee SJ, Rognmo O, Stolen TO, Bye A, Haram PM, Loennechen JP, AlShare QY, Skogvoll E, Slordahl SA, Kemi OJ, Najjar SM, Wisloff U. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation 2008;118:346354.
99. Arena R, Myers J, Forman DE, Lavie CJ, Guazzi M. Should high-intensity-aerobic interval training become the clinical standard in heart failure? Heart Fail Rev
2013;18:95105.
100. MacDonald MJ, Currie KD. Interval exercise is a path to good health, but how much, how often and for whom? Clin Sci (Lond) 2009;116:315316.
101. Helgerud J, Hoydal K, Wang E, Karlsen T, Berg P, Bjerkaas M, Simonsen T,
Helgesen C, Hjorth N, Bach R, Hoff J. Aerobic high-intensity intervals improve
VO2max more than moderate training. Med Sci Sports Exerc 2007;39:665671.
102. Ratamess NA, Falvo MJ, Mangine GT, Hoffman JR, Faigenbaum AD, Kang J. The effect of rest interval length on metabolic responses to the bench press exercise. Eur J Appl Physiol 2007;100:117.
103. Gordon NF, Kohl HW 3rd, Pollock ML, Vaandrager H, Gibbons LW, Blair SN.
Cardiovascular safety of maximal strength testing in healthy adults. Am J Cardiol
1995;76:851853.
104. Reynolds JM, Gordon TJ, Robergs RA. Prediction of one repetition maximum strength from multiple repetition maximum testing and anthropometry. J
Strength Cond Res 2006;20:584592.
105. Rhea MR, Alvar BA, Burkett LN. Single versus multiple sets for strength: a meta-analysis to address the controversy. Res Q Exerc Sport 2002;73:485488.
106. Peterson MD, Rhea MR, Alvar BA. Applications of the dose-response for muscular strength development: a review of meta-analytic efficacy and reliability for designing training prescription. J Strength Cond Res 2005;19:950958.
107. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Roberts N, Scarborough P.
Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc
2016;5:e002495.
108. Lear SA, Hu W, Rangarajan S, Gasevic D, Leong D, Iqbal R, Casanova A,
Swaminathan S, Anjana RM, Kumar R, Rosengren A, Wei L, Yang W, Chuangshi
W, Huaxing L, Nair S, Diaz R, Swidon H, Gupta R, Mohammadifard N, LopezJaramillo P, Oguz A, Zatonska K, Seron P, Avezum A, Poirier P, Teo K, Yusuf S.
The effect of physical activity on mortality and cardiovascular disease in 130
000 people from 17 high-income, middle-income, and low-income countries:
the PURE study. Lancet 2017;390:26432654.
109. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman
MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A,
Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS,
Taskinen M-R, Tokgozoglu L, Wiklund O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The
Task Force for the management of dyslipidaemias of the European Society of
Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J
2020;41:111188. doi: 10.1093/eurheartj/ehz455.
110. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen
T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip
J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European
Society of Cardiology (ESC). Eur Heart J 2020;41:407477.
111. Braber TL, Halle NHJPM, Velthuis SSBK. Cardiac imaging to detect coronary artery disease in athletes aged 35 years and older. A scoping review. Scand J
Med Sci Sports 2018;10361047.
112. DeFina LF, Radford NB, Barlow CE, Willis BL, Leonard D, Haskell WL, Farrell
SW, Pavlovic A, Abel K, Berry JD, Khera A, Levine BD. Association of all-cause and cardiovascular mortality with high levels of physical activity and concurrent coronary artery calcification. JAMA Cardiol 2019;4:174.
113. Arem H, Moore SC, Patel A, Hartge P, Berrington de Gonzalez A, Visvanathan
K, Campbell PT, Freedman M, Weiderpass E, Adami HO, Linet MS, Lee I-M,
Matthews
CE.
Leisure time physical activity and mortality:
a detailed pooled analysis of the dose-response relationship.
JAMA
Intern
Med
2015;175:959967.
114. Lee D-C, Pate RR, Lavie CJ, Sui X, Church TS, Blair SN. Leisure-time running reduces all-cause and cardiovascular mortality risk.
J
Am
Coll
Cardiol
2014;64:472481.
115. Lollgen H, Bockenhoff A, Knapp G. Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med
2009;30:213224.


<!-- PAGE 67 -->

### Page 67

.............................................................................................................................................................................
116. Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee I-M. Dose response between physical activity and risk of coronary heart disease: a metaanalysis. Circulation 2011;124:789795.
117. Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki
HA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur
SM, Hartge P, Lee I-M. Leisure time physical activity of moderate to vigorous intensity and mortality:
a large pooled cohort analysis.
PLoS
Med
2012;9:e1001335.
118. Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. Int J
Epidemiol 2011;40:13821400.
119. Elley CR, Kerse N, Arroll B, Robinson E. Effectiveness of counselling patients on physical activity in general practice: cluster randomised controlled trial. BMJ
2003;326:793.
120. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C,
Escaned J, Hammes H-P, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J,
Patrono C, Seferovic P, Uva MS, Taskinen M-R, Tendera M, Tuomilehto J,
Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ,
Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW,
Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P,
Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns
W, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon
L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, FunckBrentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev
E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N,
Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL,
Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the
EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboratio. Eur
Heart J 2013;34:30353087.
121. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H.
European
Guidelines for obesity management in adults.
Obes
Facts
2015;8:402424.
122. You T, Arsenis NC, Disanzo BL, Lamonte MJ. Effects of exercise training on chronic inflammation in obesity: current evidence and potential mechanisms.
Sports Med 2013;43:243256.
123. Keating SE, Johnson NA, Mielke GI, Coombes JS. A systematic review and meta-analysis of interval training versus moderate-intensity continuous training on body adiposity. Obes Rev 2017;18:943964.
124. Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Church TS. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis
2014;56:441447.
125. Almeida SA, Williams KM, Shaffer RA, Brodine SK. Epidemiological patterns of musculoskeletal injuries and physical training.
Med
Sci
Sports
Exerc
1999;31:11761182.
126. Gilchrist J, Jones BH, Sleet DA, Kimsey CD. Exercise-related injuries among women: strategies for prevention from civilian and military studies. MMWR
Recomm Rep 2000;49:1533.
127. Hootman JM, Macera CA, Ainsworth BE, Martin M, Addy CL, Blair SN.
Association among physical activity level, cardiorespiratory fitness, and risk of musculoskeletal injury. Am J Epidemiol 2001;154:251258.
128. Lisman PJ, de la Motte SJ, Gribbin TC, Jaffin DP, Murphy K, Deuster PA. A systematic review of the association between physical fitness and musculoskeletal injury risk:
Part
1-Cardiorespiratory endurance.
J
Strength
Cond
Res
2017;31:17441757.
129. Vincent HK, George SZ, Seay AN, Vincent KR, Hurley RW. Resistance exercise,
disability, and pain catastrophizing in obese adults with back pain. Med Sci Sports
Exerc 2014;46:16931701.
130. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens
T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma
T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM,
Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J,
Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E,
Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P,
Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton
C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh
P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes
PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL,
Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD,
Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA,
Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller
H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH,
Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L et alet al
2013 ESH/ESC Guidelines for the management of arterial hypertension: the
Task Force for the management of arterial hypertension of the European
Society of Hypertension (ESH) and of the European Society of Cardiology
(ESC). Eur Heart J 2013;34:21592219.
131. Niebauer J, Borjesson M, Carre F, Caselli S, Palatini P, Quattrini F, Serratosa L,
Adami PE, Biffi A, Pressler A, Schmied C, van Buuren F, Panhuyzen-Goedkoop
N, Solberg E, Halle M, La Gerche A, Papadakis M, Sharma S, Pelliccia A.
Recommendations for participation in competitive sports of athletes with arterial hypertension: a position statement from the sports cardiology section of the European Association of Preventive Cardiology (EAPC). Eur Heart J
2018;39:36643671.
132. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement
DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J,
Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH,
McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C,
Aboyans V, Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:30213104.
133. Wen H, Wang L. Reducing effect of aerobic exercise on blood pressure of essential hypertensive patients:
a meta-analysis.
Medicine
(Baltimore)
2017;96:e6150.
134. MacDonald HV, Johnson BT, Huedo-Medina TB, Livingston J, Forsyth KC,
Kraemer WJ, Farinatti PTV, Pescatello LS. Dynamic resistance training as standalone antihypertensive lifestyle therapy: a meta-analysis. J Am Heart Assoc
2016;5.
135. The World Anti-Doping Code International Standard, 2019. https://www.wadaama.org/sites/default/files/wada_2019_english_prohibited_list.pdf
136. Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Luscher
TF, Solomon DH, Husni ME, Graham DY, Davey DA, Wisniewski LM, Menon
V, Fayyad R, Beckerman B, Iorga D, Lincoff AM, Nissen SE. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis:
the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib
Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure
Measurement). Eur Heart J 2017;38:32823292.
137. de Sousa NMF, Magosso RF, Dipp T, Plentz RDM, Marson RA, Montagnolli AN,
Martins RAS, Perez SEA, Baldissera V. Continuous blood pressure response at different intensities in leg press exercise. Eur J Prev Cardiol 2014;21:13241331.
138. de Souza Nery S, Gomides RS, da Silva GV, de Moraes Forjaz CL, Mion DJ,
Tinucci T. Intra-arterial blood pressure response in hypertensive subjects during low- and high-intensity resistance exercise. Clinics (Sao Paulo) 2010;65:271277.
139. Lamotte M, Niset G, van de Borne P. The effect of different intensity modalities of resistance training on beat-to-beat blood pressure in cardiac patients. Eur J
Cardiovasc Prev Rehabil 2005;12:1217.
140. Sardeli AV, do Carmo Santos L, Ferreira MLV, Gaspari AF, Rodrigues B,
Cavaglieri CR, Chacon-Mikahil MPT. Cardiovascular responses to different resistance exercise protocols in elderly. Int J Sports Med 2017;38:928936.
141. Gjovaag T, Hjelmeland AK, Oygard JB, Vikne H, Mirtaheri P. Acute hemodynamic and cardiovascular responses following resistance exercise to voluntary exhaustion. Effects of different loadings and exercise durations. J Sports Med
Phys Fitness 2016;56:616623.
142. Hansen D, Abreu A, Doherty P, Voller H. Dynamic strength training intensity in cardiovascular rehabilitation: is it time to reconsider clinical practice? A systematic review.
Eur
J
Prev
Cardiol
2019;26:14831492.
doi:
10.1177/
2047487319847003. Epub 2 May 2019.
143. Caselli S, Serdoz A, Mango F, Lemme E, Vaquer Segui A, Milan A, Attenhofer
Jost C, Schmied C, Spataro A, Pelliccia A. High blood pressure response to exercise predicts future development of hypertension in young athletes. Eur
Heart J 2019;40:6268.
144. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens 2001;19:13431348.
145. Fletcher B, Berra K, Ades P, Braun LT, Burke LE, Durstine JL, Fair JM, Fletcher
GF, Goff D, Hayman LL, Hiatt WR, Miller NH, Krauss R, Kris-Etherton P, Stone
N, Wilterdink J, Winston M. Managing abnormal blood lipids: a collaborative approach. Circulation 2005;112:31843209.
146. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS,
Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med
2002;347:14831492.
147. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DDJ, DePalma
SM, Minissian MB, Orringer CE, Smith SCJ. 2017 Focused update of the
2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology
Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol
2017;70:17851822.
148. Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia:
a cohort study. Lancet 2013;381:394399.
ESC Guidelines
83


<!-- PAGE 68 -->

### Page 68

.............................................................................................................................................................................
149. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M,
Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM,
Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W,
Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg
HN. Statin-associated muscle symptoms: impact on statin therapy—European
Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:10121022.
150. Lee I-M, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012;380:219229.
151. Cloostermans L, Wendel-Vos W, Doornbos G, Howard B, Craig CL, Kivimaki
M, Tabak AG, Jefferis BJ, Ronkainen K, Brown WJ, Picavet SHSJ, Ben-Shlomo Y,
Laukkanen JA, Kauhanen J, Bemelmans WJE. Independent and combined effects of physical activity and body mass index on the development of Type 2 diabetes
 a meta-analysis of 9 prospective cohort studies. Int J Behav Nutr Phys Act
2015;12:147.
152. Ekelund U, Palla L, Brage S, Franks PW, Peters T, Balkau B, Diaz MJT, Huerta
JM, Agnoli C, Arriola L, Ardanaz E, Boeing H, Clavel-Chapelon F, Crowe F,
Fagherazzi G, Groop L, Fons Johnsen N, Kaaks R, Khaw KT, Key TJ, de LauzonGuillain B, May A, Monninkhof E, Navarro C, Nilsson P, Nautrup Ostergaard J,
Norat T, Overvad K, Palli D, Panico S, Redondo ML, Ricceri F, Rolandsson O,
Romaguera D, Romieu I, Sanchez Perez MJ, Slimani N, Spijkerman A, Teucher
B, Tjonneland A, Travier N, Tumino R, Vos W, Vigl M, Sharp S, Langeberg C,
Forouhi N, Riboli E, Feskens E, Wareham NJ. Physical activity reduces the risk of incident type 2 diabetes in general and in abdominally lean and obese men and women: the EPIC-InterAct Study. Diabetologia 2012;55:19441952.
153. Hjerkind KV, Stenehjem JS, Nilsen TIL. Adiposity, physical activity and risk of diabetes mellitus: prospective data from the population-based HUNT study,
Norway. BMJ Open 2017;7:e013142.
154. Rana JS, Li TY, Manson JE, Hu FB. Adiposity compared with physical inactivity and risk of type 2 diabetes in women. Diabetes Care 2007;30:5358.
155. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus.
Cochrane Database Syst Rev 2006;CD002968.
156. Zhang X, Devlin HM, Smith B, Imperatore G, Thomas W, Lobelo F, Ali MK,
Norris K, Gruss S, Bardenheier B, Cho P, Garcia de Quevedo I, Mudaliar U,
Jones CD, Durthaler JM, Saaddine J, Geiss LS, Gregg EW. Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: a systematic review and meta-analysis. PLoS One
2017;12:e0176436.
157. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M,
Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino
M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM,
Sousa-Uva M, Valensi P, Wheeler DC. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the
EASD. Eur Heart J 2020;41:255323.
158. Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, Tjonneland
A, Overvad K, Ostergaard JN, Amiano P, Ardanaz E, Bendinelli B, Pala V,
Tumino R, Ricceri F, Mattiello A, Spijkerman AMW, Monninkhof EM, May AM,
Franks PW, Nilsson PM, Wennberg P, Rolandsson O, Fagherazzi G, BoutronRuault M-C, Clavel-Chapelon F, Castano JMH, Gallo V, Boeing H, Nothlings U.
Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med 2012;172:12851295.
159. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med
2002;346:393403.
160. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman
AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program
Outcomes Study. Lancet 2009;374:16771686.
161. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K,
Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A,
Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:16731679.
162. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka
P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V,
Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:
13431350.
163. Hidalgo-Santamaria M, Fernandez-Montero A, Martinez-Gonzalez MA, MorenoGalarraga L, Sanchez-Villegas A, Barrio-Lopez MT, Bes-Rastrollo M. Exercise intensity and incidence of metabolic syndrome: the SUN Project. Am J Prev Med
2017;52:e95e101.
164. Dube JJ, Allison KF, Rousson V, Goodpaster BH, Amati F. Exercise dose and insulin sensitivity: relevance for diabetes prevention. Med Sci Sports Exerc
2012;44:793799.
165. da Silva DE, Grande AJ, Roever L, Tse G, Liu T, Biondi-Zoccai G, de Farias JM.
High-intensity interval training in patients with type 2 diabetes mellitus: a systematic review. Curr Atheroscler Rep 2019;21:8.
166. Magalhaes JP, Judice PB, Ribeiro R, Andrade R, Raposo J, Dores H, Bicho M,
Sardinha LB. Effectiveness of high-intensity interval training combined with resistance training versus continuous moderate-intensity training combined with resistance training in patients with type 2 diabetes: a one-year randomized controlled trial. Diabetes Obes Metab 2019;21:550559.
167. Mygind ND, Michelsen MM, Pena A, Frestad D, Dose N, Aziz A, Faber R, Host
N, Gustafsson I, Hansen PR, Hansen HS, Merz Bairey, Kastrup, CN, Prescott, J
E. Coronary microvascular function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: the iPOWER
Study. J Am Heart Assoc 2016;5:e003064.
168. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, Dorbala S,
Blankstein R, Di Carli MF. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation
2012;126:18581868.
169. Olsen RH, Pedersen LR, Jurs A, Snoer M, Haugaard SB, Prescott E. A randomised trial comparing the effect of exercise training and weight loss on microvascular function in coronary artery disease. Int J Cardiol 2015;185:229235.
170. Yoshinaga K, Beanlands RSB, Dekemp RA, Lortie M, Morin J, Aung M, McKelvie
R, Davies RF. Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease. Am Heart J 2006;151:1324.e118.
171. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler
G. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000;342:454460.
172. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis
JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW,
Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW,
Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ,
Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall
H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden
TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med
2013;369:145154.
173. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC,
Horton ES, Castorino K, Tate DF. Physical activity/exercise and diabetes: a position statement of the
American
Diabetes
Association.
Diabetes
Care
2016;39:20652079.
174. Pan B, Ge L, Xun Y-Q, Chen Y-J, Gao C-Y, Han X, Zuo L-Q, Shan H-Q, Yang
K-H, Ding G-W, Tian J-H. Exercise training modalities in patients with type 2
diabetes mellitus: a systematic review and network meta-analysis. Int J Behav
Nutr Phys Act 2018;15:72.
175. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud’homme D, Fortier M, Reid RD,
Tulloch H, Coyle D, Phillips P, Jennings A, Jaffey J. Effects of aerobic training,
resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007;147:357369.
176. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus
CR, Myers V, Nauta M, Rodarte RQ, Sparks L, Thompson A, Earnest CP.
Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type
2
diabetes:
a randomized controlled trial.
JAMA
2010;304:22532262.
177. Kemps H, Krankel N, Dorr M, Moholdt T, Wilhelm M, Paneni F, Serratosa L,
Ekker Solberg E, Hansen D, Halle M, Guazzi M. Exercise training for patients with type 2 diabetes and cardiovascular disease: what to pursue and how to do it. A position paper of the European Association of Preventive Cardiology
(EAPC). Eur J Prev Cardiol 2019;26:709727.
178. Umpierre D, Ribeiro PAB, Kramer CK, Leitao CB, Zucatti ATN, Azevedo MJ,
Gross JL, Ribeiro JP, Schaan BD. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011;305:17901799.
179. Feldman DI, Al-Mallah MH, Keteyian SJ, Brawner CA, Feldman T, Blumenthal
RS, Blaha MJ. No evidence of an upper threshold for mortality benefit at high levels of cardiorespiratory fitness. J Am Coll Cardiol 2015;65:629630.
180. Hamer M, Lavoie KL, Bacon SL. Taking up physical activity in later life and healthy ageing: the English longitudinal study of ageing. Br J Sports Med
2014;48:239243.
181. Manini TM, Everhart JE, Patel KV, Schoeller DA, Colbert LH, Visser M, Tylavsky
F, Bauer DC, Goodpaster BH, Harris TB. Daily activity energy expenditure and mortality among older adults. JAMA 2006;296:171179.
182. Stessman J, Hammerman-Rozenberg R, Cohen A, Ein-Mor E, Jacobs JM. Physical activity, function,
and longevity among the very old. Arch Intern Med
2009;169:14761483.
183. Sabia S, Singh-Manoux A, Hagger-Johnson G, Cambois E, Brunner EJ, Kivimaki
M. Influence of individual and combined healthy behaviours on successful aging.
CMAJ 2012;184:19851992.


<!-- PAGE 69 -->

### Page 69

.............................................................................................................................................................................
184. Sun Q, Townsend MK, Okereke OI, Franco OH, Hu FB, Grodstein F. Physical activity at midlife in relation to successful survival in women at age 70 years or older. Arch Intern Med 2010;170:194201.
185. Dugan SA, Gabriel KP, Lange-Maia BS, Karvonen-Gutierrez C. Physical activity and physical function: moving and aging. Obstet Gynecol Clin North Am
2018;45:723736.
186. Berk DR, Hubert HB, Fries JF. Associations of changes in exercise level with subsequent disability among seniors: a 16-year longitudinal study. J Gerontol A
Biol Sci Med Sci 2006;61:97102.
187. Thiel C, Vogt L, Tesky VA, Meroth L, Sahlender, Jakob M, Pantel, S Banzer, J W.
Cognitive intervention response is related to habitual physical activity in older adults. Aging Clin Exp Res 2012;24:4755.
188. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J,
Greenop KR, Almeida OP. Effect of physical activity on cognitive function in older adults at risk for
Alzheimer disease:
a randomized trial.
JAMA
2008;300:10271037.
189. Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, Guralnik J,
Hendrie HC, Jennings J, Katula J, Lopez OL, McDermott MM, Pahor M, Reid KF,
Rushing J, Verghese J, Rapp S, Williamson JD. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial. JAMA 2015;314:781790.
190. Loprinzi PD, Frith E, Edwards MK, Sng E, Ashpole N. The effects of exercise on memory function among young to middle-aged adults: systematic review and recommendations for future research. Am J Health Promot 2018;32:691704.
191. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol
2013;3:158.
192. Vigorito C, Giallauria F. Effects of exercise on cardiovascular performance in the elderly. Front Physiol 2014;5:51.
193. Power GA, Dalton BH, Behm DG, Vandervoort AA, Doherty TJ, Rice CL.
Motor unit number estimates in masters runners: use it or lose it? Med Sci
Sports Exerc 2010;42:16441650.
194. Power GA, Dalton BH, Behm DG, Doherty TJ, Vandervoort AA, Rice CL.
Motor unit survival in lifelong runners is muscle dependent. Med Sci Sports Exerc
2012;44:12351242.
195. Rubenstein LZ, Josephson KR, Trueblood PR, Loy S, Harker JO, Pietruszka FM,
Robbins AS. Effects of a group exercise program on strength, mobility, and falls among fall-prone elderly men. J Gerontol A Biol Sci Med Sci 2000;55:M31721.
196. Franco MR, Pereira LS, Ferreira PH. Exercise interventions for preventing falls in older people living in the community. Br J Sports Med 2014;48:867868.
197. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR,
Salem GJ, Skinner JS. American College of Sports Medicine position stand.
Exercise and physical activity for older adults.
Med
Sci
Sports
Exerc
2009;41:15101530.
198. Crocker T, Forster A, Young J, Brown L, Ozer S, Smith J, Green J, Hardy J,
Burns E, Glidewell E, Greenwood DC. Physical rehabilitation for older people in long-term care. Cochrane Database Syst Rev 2013;CD004294.
199. Bray NW, Smart RR, Jakobi JM, Jones GR. Exercise prescription to reverse frailty. Appl Physiol Nutr Metab 2016;41:11121116.
200. Forbes D, Thiessen EJ, Blake CM, Forbes SC, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev 2013;CD006489.
201. Liu C-J, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev 2009;CD002759.
202. Fragala MS, Cadore EL, Dorgo S, Izquierdo M, Kraemer WJ, Peterson MD, Ryan
ED. Resistance training for older adults: position statement from the National
Strength and
Conditioning
Association.
J
Strength
Cond
Res
2019;33:20192052.
203. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, Espeland
MA, Fielding RA, Gill TM, Groessl EJ, King AC, Kritchevsky SB, Manini TM,
McDermott MM, Miller ME, Newman AB, Rejeski WJ, Sink KM, Williamson JD.
Effect of structured physical activity on prevention of major mobility disability in older adults:
the
LIFE
study randomized clinical trial.
JAMA
2014;311:23872396.
204. Gill TM, Pahor M, Guralnik JM, McDermott MM, King AC, Buford TW,
Strotmeyer ES, Nelson ME, Sink KM, Demons JL, Kashaf SS, Walkup MP, Miller
ME. Effect of structured physical activity on prevention of serious fall injuries in adults aged 7089: randomized clinical trial (LIFE study). BMJ 2016;352:i245.
205. Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 2007;297:20812091.
206. Powell KE, Paluch AE, Blair SN. Physical activity for health: What kind? How much? How intense? On top of what? Annu Rev Public Health 2011;32:349365.
207. Borjesson M, Urhausen A, Kouidi E, Dugmore D, Sharma S, Halle M,
Heidbu¨chel H, Bjo¨rnstad HH, Gielen S, Mezzani A, Corrado D, Pelliccia A,
Vanhees L. Cardiovascular evaluation of middle-aged/senior individuals engaged in leisure-time sport activities: position stand from the Sections of Exercise
Physiology and
Sports
Cardiology of the
European
Association of
Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil
2011;18:446458.
208. Orkaby AR, Forman DE. Physical activity and CVD in older adults: an expert’s perspective. Expert Rev Cardiovasc Ther 2018;16:110.
209. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson
LM, Lamb SE. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012;CD007146.
210. Hamed A, Bohm S, Mersmann F, Arampatzis A. Follow-up efficacy of physical exercise interventions on fall incidence and fall risk in healthy older adults: a systematic review and meta-analysis. Sport Med - Open 2018;4:56.
211. Ganse B, Degens H, Drey M, Korhonen MT, McPhee J, Muller K, Johannes BW,
Rittweger J. Impact of age, performance and athletic event on injury rates in master athletics

first results from an ongoing prospective study. J
Musculoskelet Neuronal Interact 2014;14:148154.
212. Rogers NT, Marshall A, Roberts CH, Demakakos P, Steptoe A, Scholes S.
Physical activity and trajectories of frailty among older adults: evidence from the English Longitudinal Study of Ageing. PLoS One 2017;12:e0170878.
213. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA,
Castaneda-Sceppa C. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American
Heart Association. Med Sci Sports Exerc 2007;39:14351445.
214. Chou W-T, Tomata Y, Watanabe T, Sugawara Y, Kakizaki M, Tsuji I.
Relationships between changes in time spent walking since middle age and incident functional disability. Prev Med (Baltim) 2014;59:6872.
215. Tomata Y, Zhang S, Sugiyama K, Kaiho Y, Sugawara Y, Tsuji I. Changes in time spent walking and the risk of incident dementia in older Japanese people: the
Ohsaki Cohort 2006 Study. Age Ageing 2017;46:857860.
216. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE.
Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J
Med 2000;343:13551361.
217. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update:
clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J 2016;39:11441161.
218. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NAM 3rd,
Fulton JE, Gordon NF, Haskell WL, Link MS, Maron BJ, Mittleman MA, Pelliccia
A, Wenger NK, Willich SN, Costa F. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American
Heart Association Council on Nutrition, Physical Activity, and Metabolism and the
Council on Clinical Cardiology. Circulation 2007;115:23582368.
219. Penalver JM, Mosca RS, Weitz D, Phoon CKL. Anomalous aortic origin of coronary arteries from the opposite sinus: a critical appraisal of risk. BMC Cardiovasc
Disord 2012;12:83.
220. Gowd BMP, Thompson PD. Isolated myocardial bridging and exercise-related cardiac events. Int J Sports Med 2014;35:11451150.
221. Kalaga RV, Malik A, Thompson PD. Exercise-related spontaneous coronary artery dissection: case report and literature review. Med Sci Sports Exerc
2007;39:12181220.
222. Aengevaeren VL, Mosterd A, Braber TL, Prakken NHJ, Doevendans PA,
Grobbee DE, Thompson PD, Eijsvogels TMH, Velthuis BK. Relationship between lifelong exercise volume and coronary atherosclerosis in athletes.
Circulation 2017;136:138148.
223. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, Gaze D,
Thompson PD. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169176.
224. Aagaard P, Sahlen A, Braunschweig F. Performance trends and cardiac biomarkers in a 30-km cross-country race, 19932007. Med Sci Sports Exerc
2012;44:894899.
225. Collet J-P, Zeitouni M, Procopi N, Hulot J-S, Silvain J, Kerneis M, Thomas D,
Lattuca B, Barthelemy O, Lavie-Badie Y, Esteve J-B, Payot L, Brugier D, Lopes I,
Diallo A, Vicaut E, Montalescot G. Long-term evolution of premature coronary artery disease. J Am Coll Cardiol 2019;74:18681878.
226. Maron BJ, Araujo CG, Thompson PD, Fletcher GF, de Luna AB, Fleg JL, Pelliccia
A, Balady GJ, Furlanello F, Van Camp SP, Elosua R, Chaitman BR, Bazzarre TL.
Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes: an advisory for healthcare professionals from the working groups of the World Heart Federation, the International
Federation of
Sports
Medicine,
and the
American
Heart
Association
Committee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation
2001;103:327334.
227. Erbel R, Mohlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A,
Dragano N, Gronemeyer D, Seibel R, Kalsch H, Brocker-Preuss M, Mann K,
Siegrist J, Jockel K-H. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 2010;56:13971406.
ESC Guidelines
85


<!-- PAGE 70 -->

### Page 70

.............................................................................................................................................................................
228. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, Carr JJ,
Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
JAMA 2012;308:788795.
229. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210215.
230. Saad M, Pothineni NV, Thomas J, Parikh R, Kovelamudi S, Elsayed D, Nairooz R,
Feit F. Coronary artery calcium scoring in young adults: evidence and challenges. Curr Cardiol Rep 2018;20:10.
231. Borjesson M, Assanelli D, Carre F, Dugmore D, Panhuyzen-Goedkoop NM,
Seiler C, Senden J, Solberg EE. ESC Study Group of Sports Cardiology: recommendations for participation in leisure-time physical activity and competitive sports for patients with ischaemic heart disease. Eur J Cardiovasc Prev Rehabil
2006;13:137149.
232. Sirico F, Fernando F, Di Paolo F, Adami PE, Signorello MG, Sannino G, Bianco
A, Cerrone A, Baioccato V, Filippi N, Ferrari U, Tuzi M, Nurzynska D, Di
Meglio F, Castaldo C, D’Ascenzi F, Montagnani S, Biffi A. Exercise stress test in apparently healthy individuals  where to place the finish line? The Ferrari corporate wellness programme experience. Eur J Prev Cardiol 2019;26:731738.
233. Borjesson M, Dellborg M, Niebauer J, LaGerche A, Schmied C, Solberg EE,
Halle M, Adami E, Biffi A, Carre F, Caselli S, Papadakis M, Pressler A, Rasmusen
H, Serratosa L, Sharma S, van Buuren F, Pelliccia A. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J
2019;40:1318.
234. Anderson L, Thompson DR, Oldridge N, Zwisler A-D, Rees K, Martin N,
Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease.
Cochrane Database Syst Rev 2016;CD001800.
235. Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B,
Cupples M, Dendale P, Doherty P, Gaita D, Hofer S, McGee H, Mendes M,
Niebauer J, Pogosova N, Garcia-Porrero E, Rauch B, Schmid JP, Giannuzzi P.
Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the
European Association for Cardiovascular Prevention and Rehabilitation. Eur J
Prev Cardiol 2014;21:664681.
236. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LEJ, Friedman JD,
Hayes SW, Cohen I, Germano G, Berman DS. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011;32:10121024.
237. Hoffmann U, Ferencik M, Udelson JE, Picard MH, Truong QA, Patel MR, Huang
M, Pencina M, Mark DB, Heitner JF, Fordyce CB, Pellikka PA, Tardif J-C, Budoff
M, Nahhas G, Chow B, Kosinski AS, Lee KL, Douglas PS. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation 2017;135:23202332.
238. Newby DE, Adamsson PD, Berry C, Boon NA, Dweck MR, TFlather M, Forbes
J, Hunter A, Lewis S, MacLean S, Mills NL, Norrie J, Roditi G, Shah ASV, Timmis
AD, vanBeek EJR WM. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med 2018;379:924933.
239. Sousa-Uva M, Neumann F-J, Ahlsson A, Alfonso F, Banning AP, Benedetto U,
Byrne RA, Collet J-P, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen
SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker
S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2019;55:490.
240. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Juni P,
Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F-J, Petricevic M, Roffi M,
Steg PG, Windecker S, Zamorano JL. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed) 2018;71:42.
241. Albaladejo P, Samama C-M, Sie P, Kauffmann S, Memier V, Suchon P, Viallon A,
David JS, Gruel Y, Bellamy L, de Maistre E, Romegoux P, Thoret S, Pernod G,
Bosson J-L. Management of severe bleeding in patients treated with direct oral anticoagulants:
an observational registry analysis.
Anesthesiology
2017;127:111120.
242. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, Franklin B,
Sanderson B, Southard D. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American
Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee,
the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing,
Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism;
and the American Association of Cardiovascular and Pulmonary Rehabilitation.
Circulation 2007;115:26752682.
243. Verschueren S, Eskes AM, Maaskant JM, Roest AM, Latour CHM, Op Reimer
WS. The effect of exercise therapy on depressive and anxious symptoms in patients with ischemic heart disease: a systematic review. J Psychosom Res
2018;105:8091.
244. Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D,
McGee H, Mendes M, Niebauer J, Zwisler A-DO, Schmid J-P. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A
position paper from the Cardiac Rehabilitation Section of the European
Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc
Prev Rehabil 2010;17:117.
245. Haykowsky M, Scott J, Esch B, Schopflocher D, Myers J, Paterson I, Warburton
D, Jones L, Clark AM. A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: start early and go longer for greatest exercise benefits on remodeling. Trials 2011;12:92.
246. Angelini P, Cheong BY, Lenge De Rosen VV, Lopez JA, Uribe C, Masso AH, Ali
SW, Davis BR, Muthupillai R, Willerson JT. Magnetic resonance imaging-based screening study in a general population of adolescents. J Am Coll Cardiol
2018;71:579580.
247. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J,
Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van
Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task
Force for the Management of Patients with Ventricular Arrhythmias and the
Prevention of Sudden Cardiac Death of the European Society of Cardiology
(ESC). EP Europace 2015;17:16011687.
248. Lin S, Tremmel JA, Yamada R, Rogers IS, Yong CM, Turcott R, McConnell MV,
Dash R, Schnittger I. A novel stress echocardiography pattern for myocardial bridge with invasive structural and hemodynamic correlation. J Am Heart Assoc
2013;2:e000097.
249. Grani C, Benz DC, Steffen DA, Giannopoulos AA, Messerli M, Pazhenkottil AP,
Gaemperli O, Gebhard C, Schmied C, Kaufmann PA, Buechel RR. Sports behavior in middle-aged individuals with anomalous coronary artery from the opposite sinus of Valsalva. Cardiology 2018;139:222230.
250. Grani C, Benz DC, Steffen DA, Clerc OF, Schmied C, Possner M, Vontobel J,
Mikulicic F, Gebhard C, Pazhenkottil AP, Gaemperli O, Hurwitz S, Kaufmann
PA, Buechel RR. Outcome in middle-aged individuals with anomalous origin of the coronary artery from the opposite sinus: a matched cohort study. Eur Heart
J 2017;38:20092016.
251. Van Hare GF, Ackerman MJ, Evangelista J-AK, Kovacs RJ, Myerburg RJ, Shafer
KM, Warnes CA, Washington RL. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 4:
Congenital heart disease: a scientific statement from the American Heart
Association and
American
College of
Cardiology.
Circulation
2015;132:e28191.
252. Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol 2000;35:14931501.
253. Finocchiaro G, Behr ER, Tanzarella G, Papadakis M, Malhotra A, Dhutia H,
Miles C, Diemberger I, Sharma S, Sheppard MN. Anomalous coronary artery origin and sudden cardiac death: clinical and pathological insights from a national pathology registry. JACC Clin Electrophysiol 2019;5:516522.
254. Yamada R, Tremmel JA, Tanaka S, Lin S, Kobayashi Y, Hollak MB, Yock PG,
Fitzgerald PJ, Schnittger I, Honda Y. Functional versus anatomic assessment of myocardial bridging by intravascular ultrasound: impact of arterial compression on proximal atherosclerotic plaque. J Am Heart Assoc 2016;5:e001735.
255. Cerrato E, Barbero U, D’Ascenzo F, Taha S, Biondi-Zoccai G, Omede P, Bianco
M, Echavarria-Pinto M, Escaned J, Gaita F, Varbella F. What is the optimal treatment for symptomatic patients with isolated coronary myocardial bridge? A systematic review and pooled analysis.
J
Cardiovasc
Med
(Hagerstown)
2017;18:758770.
256. Dimitriu-Leen AC, van Rosendael AR, Smit JM, van Elst T, van Geloven N,
Maaniitty T, Jukema JW, Delgado V, Scholte AJHA, Saraste A, Knuuti J, Bax JJ.
Long-term prognosis of patients with intramural course of coronary arteries assessed with CT angiography. JACC Cardiovasc Imaging 2017;10:14511458.
257. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,
Gonzalez-Juanatey
JR, Harjola V-P, Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016;37:21292200.
258. Piepoli MF, Davos C, Francis DP, Coats AJS. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
259. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, O’Connor C,
Whellan D, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista


<!-- PAGE 71 -->

### Page 71

.............................................................................................................................................................................
L, Jolly K, Myers J, McKelvie RS, Nilsson BB, Passino C, Witham MD, Yeh GY,
Zwisler A-DO. Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials.
Eur
J
Heart
Fail
2018;20:17351743.
260. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, Dalal H, Rees K,
Singh SJ, Taylor RS. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
261. Rees K, Taylor RS, Singh S, Coats AJS, Ebrahim S. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2004;CD003331.
262. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, Whellan D,
O’Connor C, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista
LS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure:
individual participant meta-analysis. J Am Coll Cardiol 2019;73:14301443.
263. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B,
Drazner M, Berry J. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail
2015;8:3340.
264. Sagar VA, Davies EJ, Briscoe S, Coats AJS, Dalal HM, Lough F, Rees K, Singh S,
Taylor RS. Exercise-based rehabilitation for heart failure: systematic review and meta-analysis. Open Heart 2015;2:e000163.
265. Corra U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA,
Harjola V-P, Hill L, Lainscak M, Lund LH, Metra M, Ponikowski P, Riley J,
Seferovic PM, Piepoli MF. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise
Physiology and Training of the Heart Failure Association of the European
Society of Cardiology. Eur J Heart Fail 2018;20:315.
266. Scherr J, Wolfarth B, Christle JW, Pressler A, Wagenpfeil S, Halle M.
Associations between Borg’s rating of perceived exertion and physiological measures of exercise intensity. Eur J Appl Physiol 2013;113:147155.
267. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES,
Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL,
Schulman
KA,
McKelvie
RS, Zannad F,
Pi~na IL, for the
HF-ACTION
Investigators. Efficacy and safety of exercise training in patients with chronic heart failure:
HF-ACTION
randomized controlled trial.
JAMA
2009;301:14391450.
268. Rognmo O, Moholdt T, Bakken H, Hole T, Molstad P, Myhr NE, Grimsmo J,
Wisloff U. Cardiovascular risk of high- versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation 2012;126:14361440.
269. Ellingsen O, Halle M, Conraads V, Stoylen A, Dalen H, Delagardelle C, Larsen
A-I, Hole T, Mezzani A, Van Craenenbroeck EM, Videm V, Beckers P, Christle
JW, Winzer E, Mangner N, Woitek F, Hollriegel R, Pressler A, Monk-Hansen T,
Snoer M, Feiereisen P, Valborgland T, Kjekshus J, Hambrecht R, Gielen S,
Karlsen T, Prescott E, Linke A. High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation 2017;135:839849.
270. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T,
McMurray J, Pieske B, Piotrowicz E, Schmid J-P, Anker SD, Solal AC, Filippatos
GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure
Association and the European Association for Cardiovascular Prevention and
Rehabilitation. Eur J Heart Fail 2011;13:347357.
271. Corra U, Piepoli MF, Carre F, Heuschmann P, Hoffmann U, Verschuren M,
Halcox J, Giannuzzi P, Saner H, Wood D, Piepoli MF, Corra U, Benzer W,
Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J,
Zwisler A-DO, Schmid J-P. Secondary prevention through cardiac rehabilitation:
physical activity counselling and exercise training: key components of the position paper from the Cardiac Rehabilitation Section of the European Association of
Cardiovascular
Prevention and
Rehabilitation.
Eur
Heart
J
2010;31:19671974.
272. Gayda M, Ribeiro PAB, Juneau M, Nigam A. Comparison of different forms of exercise training in patients with cardiac disease: where does high-intensity interval training fit? Can J Cardiol 2016;32:485494.
273. Gomes Neto M, Duraes AR, Conceicao LSR, Saquetto MB, Ellingsen O,
Carvalho VO. High intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis. Int J
Cardiol 2018;261:134141.
274. Cornelis J, Beckers P, Taeymans J, Vrints C, Vissers D. Comparing exercise training modalities in heart failure: a systematic review and meta-analysis. Int J
Cardiol 2016;221:867876.
275. Conraads VM, Beckers PJ. Exercise training in heart failure: practical guidance.
Heart 2010;96:20252031.
276. Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin
BA, Gulanick M, Laing ST, Stewart KJ. Resistance exercise in individuals with and without cardiovascular disease:
2007
update:
a scientific statement from the American Heart Association Council on Clinical
Cardiology and Council on Nutrition, Physical Activity, and Metabolism.
Circulation 2007;116:572584.
277. Giuliano C, Karahalios A, Neil C, Allen J, Levinger I. The effects of resistance training on muscle strength, quality of life and aerobic capacity in patients with chronic heart failure  a meta-analysis. Int J Cardiol 2017;227:413423.
278. Alvarez P, Hannawi B, Guha A. Exercise and heart failure: advancing knowledge and improving care. Methodist Debakey Cardiovasc J 2016;12:110115.
279. Sadek Z, Salami A, Joumaa WH, Awada C, Ahmaidi S, Ramadan W. Best mode of inspiratory muscle training in heart failure patients: a systematic review and meta-analysis. Eur J Prev Cardiol 2018;25:16911701.
280. Smart NA, Giallauria F, Dieberg G. Efficacy of inspiratory muscle training in chronic heart failure patients: a systematic review and meta-analysis. Int J Cardiol
2013;167:15021507.
281. Neto MG, Martinez BP, Conceicao CS, Silva PE, Carvalho VO. Combined exercise and inspiratory muscle training in patients with heart failure: a systematic review and meta-analysis. J Cardiopulm Rehabil Prev 2016;36:395401.
282. Wu J, Kuang L, Fu L. Effects of inspiratory muscle training in chronic heart failure patients: a systematic review and meta-analysis. Congenit Heart Dis
2018;13:194202.
283. Tei C, Horikiri Y, Park JC, Jeong JW, Chang KS, Toyama Y, Tanaka N. Acute hemodynamic improvement by thermal vasodilation in congestive heart failure.
Circulation 1995;91:25822590.
284. Adsett JA, Mudge AM, Morris N, Kuys S, Paratz JD. Aquatic exercise training and stable heart failure: a systematic review and meta-analysis. Int J Cardiol
2015;186:2228.
285. Omar W, Pandey A, Haykowsky MJ, Berry JD, Lavie CJ. The evolving role of cardiorespiratory fitness and exercise in prevention and management of heart failure. Curr Heart Fail Rep 2018;15:7580.
286. Edelmann F, Gelbrich G, Dungen H-D, Frohling S, Wachter R, Stahrenberg R,
Binder L, Topper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Loffler M,
Hasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (exercise training in diastolic heart failure) pilot study. J Am Coll Cardiol 2011;58:17801791.
287. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE,
Eggebeen J, Nicklas BJ. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA
2016;315:3646.
288. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010;3:659667.
289. Alves AJ, Ribeiro F, Goldhammer E, Rivlin Y, Rosenschein U, Viana JL, Duarte
JA, Sagiv M, Oliveira J. Exercise training improves diastolic function in heart failure patients. Med Sci Sports Exerc 2012;44:776785.
290. Gary RA, Sueta CA, Dougherty M, Rosenberg B, Cheek D, Preisser J, Neelon
V, McMurray R. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure.
Heart
Lung
2004;33:210218.
291. Smart NA, Haluska B, Jeffriess L, Leung D. Exercise training in heart failure with preserved systolic function: a randomized controlled trial of the effects on cardiac function and functional capacity. Congest Heart Fail 2012;18:295301.
292. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de
Lemos JA, Berry JD. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 2015;132:17861794.
293. Adams V, Reich B, Uhlemann M, Niebauer J. Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium. Am J Physiol Heart Circ Physiol 2017;313:H72H88.
294. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX,
Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Longterm effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:21592169.
295. Hollekim-Strand SM, Bjorgaas MR, Albrektsen G, Tjonna AE, Wisloff U, Ingul
CB. High-intensity interval exercise effectively improves cardiac function in patients with type 2 diabetes mellitus and diastolic dysfunction: a randomized controlled trial. J Am Coll Cardiol 2014;64:17581760.
296. Angadi SS, Mookadam F, Lee CD, Tucker WJ, Haykowsky MJ, Gaesser GA.
High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: a pilot study. J Appl Physiol
2015;119:753758.
297. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R,
Hendriks JML, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P.
Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT Study. J Am Coll Cardiol
2015;66:985996.
ESC Guidelines
87


<!-- PAGE 72 -->

### Page 72

.............................................................................................................................................................................
298. Howden EJ, Sarma S, Lawley JS, Opondo M, Cornwell W, Stoller D, Urey MA,
Adams-Huet B, Levine BD. Reversing the cardiac effects of sedentary aging in middle age  a randomized controlled trial: implications for heart failure prevention. Circulation 2018;137:15491560.
299. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke
W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen H-D, Tschope
C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781791.
300. Givertz MM, Hartley LH, Colucci WS. Long-term sequential changes in exercise capacity and chronotropic responsiveness after cardiac transplantation.
Circulation 1997;96:232237.
301. Habedank D, Ewert R, Hummel M, Wensel R, Hetzer R, Anker SD. Changes in exercise capacity, ventilation, and body weight following heart transplantation.
Eur J Heart Fail 2007;9:310316.
302. Mandak JS, Aaronson KD, Mancini DM. Serial assessment of exercise capacity after heart transplantation. J Heart Lung Transplant 1995;14:468478.
303. Grupper A, Gewirtz H, Kushwaha S. Reinnervation post-heart transplantation.
Eur Heart J 2018;39:17991806.
304. Tucker WJ, Beaudry RI, Samuel TJ, Nelson MD, Halle M, Baggish AL,
Haykowsky MJ. Performance limitations in heart transplant recipients. Exerc
Sport Sci Rev 2018;46:144151.
305. Anderson L, Nguyen TT, Dall CH, Burgess L, Bridges C, Taylor RS. Exercisebased cardiac rehabilitation in heart transplant recipients. Cochrane Database
Syst Rev 2017;4:CD012264.
306. Esefeld K, Fricke H, Haykowsky M, Halle M. Ultra-endurance exercise in a heart transplant athlete: influence on myocardial function and biomarkers. Eur J Prev
Cardiol 2020;27:885887. doi: 10.1177/2047487318808636. Epub 2018 Nov 5.
307. Rosenbaum AN, Kremers WK, Schirger JA, Thomas RJ, Squires RW, Allison
TG, Daly RC, Kushwaha SS, Edwards BS. Association between early cardiac rehabilitation and long-term survival in cardiac transplant recipients. Mayo Clin
Proc 2016;91:149156.
308. Bachmann JM, Shah AS, Duncan MS, Greevy RAJ, Graves AJ, Ni S, Ooi HH,
Wang TJ, Thomas RJ, Whooley MA, Freiberg MS. Cardiac rehabilitation and readmissions after heart transplantation.
J
Heart
Lung
Transplant
2018;37:467476.
309. Haykowsky MJF, Riess KJ, Baggish AL. Heart transplant recipient finishes the
118th Boston Marathon 27 years post-surgery. J Heart Lung Transplant
2014;33:1197.
310. Haykowsky MJ, Halle M, Baggish A. Upper limits of aerobic power and performance in heart transplant recipients: legacy effect of prior endurance training.
Circulation 2018;137:650652.
311. Nytrøen K, Gullestad L. Exercise after heart transplantation: an overview.
World J Transplant 2013;3:7890.
312. Rustad LA, Nytrøen K, Amundsen BH, Gullestad L, Aakhus S. One year of highintensity interval training improves exercise capacity, but not left ventricular function in stable heart transplant recipients: a randomised controlled trial. Eur J
Prev Cardiol 2012;21:181191.
313. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B,
Lancellotti P, Lansac E, Rodriguez Mu~noz D, Rosenhek R, Sjo¨gren J, Tornos Mas
P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. 2017 ESC/
EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2017;38:27392791.
314. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M,
Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:22382244.
315. Baumgartner HC, Hung JC-C, Bermejo J, Chambers JB, Edvardsen T, Goldstein
S, Lancellotti P, LeFevre M, Miller FJ, Otto CM. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the
European Association of Cardiovascular Imaging and the American Society of
Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:254275.
316. Clavel M-A, Burwash IG, Pibarot P. Cardiac imaging for assessing low-gradient severe aortic stenosis. JACC Cardiovasc Imaging 2017;10:185202.
317. Morise AP. Exercise testing in nonatherosclerotic heart disease: hypertrophic cardiomyopathy,
valvular heart disease,
and arrhythmias.
Circulation
2011;123:216225.
318. Lee JKT, Franzone A, Lanz J, Siontis GCM, Stortecky S, Grani C, Roost E,
Windecker S, Pilgrim T. Early detection of subclinical myocardial damage in chronic aortic regurgitation and strategies for timely treatment of asymptomatic patients. Circulation 2018;137:184196.
319. Pelliccia A, Caselli S, Sharma S, Basso C, Bax JJ, Corrado D, D’Andrea A,
D’Ascenzi F, Di Paolo FM, Edvardsen T, Gati S, Galderisi M, Heidbuchel H,
Nchimi A, Nieman K, Papadakis M, Pisicchio C, Schmied C, Popescu BA, Habib
G, Grobbee D, Lancellotti P. European Association of Preventive Cardiology
(EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete’s heart. Eur Heart J
2018;39:19491969.
320. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J
Med 2014;370:19201929.
321. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM,
Eidem B, Edwards WD, Sundt TM 3rd, Enriquez-Sarano M. Incidence of aortic complications in patients with bicuspid aortic valves.
JAMA
2011;306:11041112.
322. Harris KM, Tung M, Haas TS, Maron BJ. Under-recognition of aortic and aortic valve disease and the risk for sudden death in competitive athletes. J Am Coll
Cardiol 2015;65:860862.
323. Spataro A, Pelliccia A, Rizzo M, Biffi A, Masazza G, Pigozzi F. The natural course of bicuspid aortic valve in athletes. Int J Sports Med 2008;29:8185.
324. Tzemos N, Therrien J, Yip J, Thanassoulis G, Tremblay S, Jamorski MT, Webb
GD,
Siu
SC.
Outcomes in adults with bicuspid aortic valves.
JAMA
2008;300:13171325.
325. Boraita A, Morales-Acuna F, Marina-Breysse M, Heras M-E, Canda A, Fuentes
M-E, Chacon A, Diaz-Gonzalez L, Rabadan M, Parra Laca B, Perez de Isla L,
Tunon J. Bicuspid aortic valve behaviour in elite athletes. Eur Heart J Cardiovasc
Imaging 2019;20:772780.
326. Bonow RO, Nishimura RA, Thompson PD, Udelson JE. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 5: Valvular heart disease: a scientific statement from the
American Heart Association and American College of Cardiology. Circulation
2015;132:e292e297.
327. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete’s heart in women.
Echocardiographic characterization of highly trained elite female athletes. JAMA
1996;276:211215.
328. Delling FN, Rong J, Larson MG, Lehman B, Osypiuk E, Stantchev P,
Slaugenhaupt SA, Benjamin EJ, Levine RA, Vasan RS. Familial clustering of mitral valve prolapse in the community. Circulation 2015;131:263268.
329. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B,
Benjamin EJ. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J
Med 1999;341:17.
330. Jeresaty RM. Mitral valve prolapse: definition and implications in athletes. J Am
Coll Cardiol 1986;7:231236.
331. Avierinos J-F, Gersh BJ, Melton LJ 3rd, Bailey KR, Shub C, Nishimura RA, Tajik
AJ, Enriquez-Sarano M. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002;106:13551361.
332. Basso C, Perazzolo Marra M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, Frigo
AC, Rigato I, Migliore F, Pilichou K, Bertaglia E, Cacciavillani L, Bauce B,
Corrado D, Thiene G, Iliceto S. Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation 2015;132:556566.
333. Dejgaard LA, Skjolsvik ET, Lie OH, Ribe M, Stokke MK, Hegbom F, Scheirlynck
ES, Gjertsen E, Andresen K, Helle-Valle TM, Hopp E, Edvardsen T, Haugaa KH.
The mitral annulus disjunction arrhythmic syndrome. J Am Coll Cardiol
2018;72:16001609.
334. Perazzolo Marra M, Basso C, De Lazzari M, Rizzo S, Cipriani A, Giorgi B,
Lacognata C, Rigato I, Migliore F, Pilichou K, Cacciavillani L, Bertaglia E, Frigo
AC, Bauce B, Corrado D, Thiene G, Iliceto S. Morphofunctional abnormalities of mitral annulus and arrhythmic mitral valve prolapse. Circ Cardiovasc Imaging
2016;9:e005030.
335. Cristina B, Sabino I, Gaetano T, Martina PM. Mitral valve prolapse, ventricular arrhythmias, and sudden death. Circulation 2019;140:952964.
336. Gati S, Malhotra A, Sharma S. Exercise recommendations in patients with valvular heart disease. Heart 2019;105:106110.
337. Caselli S, Mango F, Clark J, Pandian NG, Corrado D, Autore C, Pelliccia A.
Prevalence and clinical outcome of athletes with mitral valve prolapse.
Circulation 2018;137:20802082.
338. Ermakov S, Gulhar R, Lim L, Bibby D, Fang Q, Nah G, Abraham TP, Schiller
NB, Delling FN. Left ventricular mechanical dispersion predicts arrhythmic risk in mitral valve prolapse. Heart 2019;105:10631069.
339. Groves PH, Lewis NP, Ikram S, Maire R, Hall RJ. Reduced exercise capacity in patients with tricuspid regurgitation after successful mitral valve replacement for rheumatic mitral valve disease. Br Heart J 1991;66:295301.
340. Andersen MJ, Nishimura RA, Borlaug BA. The hemodynamic basis of exercise intolerance in tricuspid regurgitation. Circ Heart Fail 2014;7:911917.
341. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo R Di, Eggebrecht H,
Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung
B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U,
Sirnes PA, Allmen RS von, Vrints CJM. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of
Cardiology (ESC). Eur Heart J 2014;35:28732926.


<!-- PAGE 73 -->

### Page 73

.............................................................................................................................................................................
342. Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and Disqualification
Recommendations for
Competitive
Athletes
With
Cardiovascular
Abnormalities: Task Force 7: Aortic diseases, including Marfan syndrome: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015;66:23982405.
343. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DEJ, Eagle KA,
Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW,
Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010
ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the
American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. Circulation 2010;121:e266369.
344. Boraita A, Heras M-E, Morales F, Marina-Breysse M, Canda A, Rabadan M,
Barriopedro M-I, Varela A, de la Rosa A, Tunon J. Reference values of aortic root in male and female white elite athletes according to sport. Circ Cardiovasc
Imaging 2016;9:e005292.
345. Iskandar A, Thompson PD. A meta-analysis of aortic root size in elite athletes.
Circulation 2013;127:791798.
346. Pelliccia A, Di Paolo FM, De Blasiis E, Quattrini FM, Pisicchio C, Guerra E,
Culasso F, Maron BJ. Prevalence and clinical significance of aortic root dilation in highly trained competitive athletes. Circulation 2010;122:698706.
347. Gati S, Malhotra A, Sedgwick C, Papamichael N, Dhutia H, Sharma R, Child AH,
Papadakis M, Sharma S. Prevalence and progression of aortic root dilatation in highly trained young athletes. Heart 2019;105:920925.
348. Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J,
Schroeder F, Vogler M, Hoberg E. Inpatient rehabilitation for adult patients with Marfan syndrome: an observational pilot study. Orphanet J Rare Dis
2017;12:127.
349. Thijssen CGE, Bons LR, Go¨kalp AL, Van Kimmenade RRJ, Mokhles MM, Pelliccia
A, Takkenberg JJM, Roos-Hesselink JW. Exercise and sports participation in patients with thoracic aortic disease: a review. Expert Rev Cardiovasc Ther
2019;17:251266.
350. Itagaki R, Kimura N, Itoh S, Yamaguchi A, Adachi H. Acute type a aortic dissection associated with a sporting activity. Surg Today 2017;47:11631171.
351. Stefani L, Galanti G, Toncelli L, Manetti P, Vono MC, Rizzo M, Maffulli N.
Bicuspid aortic valve in competitive athletes. Br J Sports Med 2008;42:315; discussion 35.
352. Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, Cui JZ, van
Breemen C, Broderick TL, Vallejo-Elias J, Esfandiarei M. Mild aerobic exercise blocks elastin fiber fragmentation and aortic dilatation in a mouse model of
Marfan syndrome associated aortic aneurysm. J Appl Physiol 2017;123:147160.
353. Mas-Stachurska A, Siegert A-M, Batlle M, Blanco Gorbenko Del, Meirelles, D,
Rubies, T, Bonorino, C, Serra-Peinado, F, Bijnens, C, Baudin, B, Sitges, J, Mont,
M, Guasch, L Egea, E G. Cardiovascular benefits of moderate exercise training in Marfan syndrome: insights from an animal model. J Am Heart Assoc
2017;6:pii:e006438.
354. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes analysis of 1866 deaths in the United States, 19802006.
Circulation 2009;119:10851092.
355. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P,
Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J,
Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH,
Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology
(ESC). Eur Heart J 2014;35:27332779.
356. Maron BJ, Chaitman BR, Ackerman MJ, Baye´s de Luna A, Corrado D, Crosson
JE, Deal BJ, Driscoll DJ, Estes NAM, Araujo CGS, Liang DH, Mitten MJ,
Myerburg RJ, Pelliccia A, Thompson PD, Towbin JA VCS. Working Groups of the American Heart Association Committee on Exercise Cardiac Rehabilitation and Prevention, Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Recommendations for physical activity and recreational sports participation. Circulation 2004;109:28072816.
357. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE.
Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005;45:13401345.
358. Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, Berge KE,
Edvardsen T, Haugaa KH. Vigorous exercise in patients with hypertrophic cardiomyopathy. Int J Cardiol 2018;250:157163.
359. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M,
Calkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL,
Zipes DP, Berul CI, Cheng A, Jordaens L, Law I, Loomis M, Willems R, Barth C,
Broos K, Brandt C, Dziura J, Li F, Simone L, Vandenberghe K, Cannom D.
Safety of sports for athletes with implantable cardioverter-defibrillators: longterm results of a
prospective multinational registry.
Circulation
2017;135:23102312.
360. Pelliccia A, Lemme E, Maestrini V, Di Paolo FM, Pisicchio C, Di Gioia G, Caselli
S. Does sport participation worsen the clinical course of hypertrophic cardiomyopathy? Clinical outcome of hypertrophic cardiomyopathy in athletes.
Circulation 2018;137:531533.
361. Finocchiaro G, Papadakis M, Tanzarella G, Dhutia H, Miles C, Tome M, Behr
ER, Sharma S, Sheppard MN. Sudden death can be the first manifestation of hypertrophic cardiomyopathy: data from a United Kingdom Pathology Registry.
JACC Clin Electrophysiol 2019;5:252254.
362. Klempfner R, Kamerman T, Schwammenthal E, Nahshon A, Hay I, Goldenberg
I, Dov F, Arad M. Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. Eur J Prev Cardiol 2015;22:1319.
363. Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A,
Concannon M, Dries AM, Shmargad Y, Salisbury H, Kumar S, Herrera JJ, Myers
J, Helms AS, Ashley EA, Day SM. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial. JAMA 2017;317:13491357.
364. Sheikh N, Papadakis M, Panoulas VF, Prakash K, Millar L, Adami P, Zaidi A, Gati
S, Wilson M, Carr-White G, Tome´ MTE, Behr ER, Sharma S. Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the
UK. Heart 2016;102:17971804.
365. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003;108:23422348.
366. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:697704.
367. Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, Kanj M,
Flamm SD, Thamilarasan M, Popovic ZB, Lever HM, Desai MY. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol 2018;72:857870.
368. Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, He Y. Prognostic value of
LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 2016;9:13921402.
369. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR,
Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F,
Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore
C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS.
Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484495.
370. Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, Das B, Khwaja J,
Alpendurada FD, Wage R, Roughton M, McKenna WJ, Moon JC, Varnava A,
Shakespeare C, Cowie MR, Cook SA, Elliott P, O’Hanlon R, Pennell DJ, Prasad
SK. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.
Heart
2014;100:18511858.
371. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a communitybased patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol
1999;33:20442051.
372. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ.
Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:29872991.
373. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E,
Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy
(HCM risk-SCD). Eur Heart J 2014;35:20102020.
374. Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, Bongioanni S,
Semsarian C, Devoto E, Musumeci B, Lai F, Yeates L, Conte MR, Rapezzi C,
Boni L, Maron BJ. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J
Cardiol 2014;113:15501555.
375. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H,
Corrado D, Cox MGPJ, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A,
Picard MH, Protonotarios N, Saffitz JE, Sanborn DMY, Steinberg JS, Tandri H,
Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:15331541.
376. Miles C, Finocchiaro G, Papadakis M, Gray B, Westaby J, Ensam B, Basu J, ParryWilliams G, Papatheodorou E, Paterson C, Malhotra A, Robertus JL, Ware JS,
Cook SA, Asimaki A, Witney A, Chis Ster I, Tome M, Sharma S, Behr ER,
Sheppard MN. Sudden death and left ventricular involvement in arrhythmogenic cardiomyopathy. Circulation 2019;139:17861797.
377. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, Pennell
DJ, McKenna WJ. Left-dominant arrhythmogenic cardiomyopathy: an underrecognized clinical entity. J Am Coll Cardiol 2008;52:21752187.
ESC Guidelines
89


<!-- PAGE 74 -->

### Page 74

.............................................................................................................................................................................
378. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A,
Asimaki A, Basso C, Bauce B, Brunckhorst C, Bucciarelli-Ducci C, Duru F,
Elliott P, Hamilton RM, Haugaa KH, James CA, Judge D, Link MS, Marchlinski FE,
Mazzanti A, Mestroni L, Pantazis A, Pelliccia A, Marra MP, Pilichou K, Platonov
PGA, Protonotarios A, Rampazzo A, Saffitz JE, Saguner AM, Schmied C, Sharma
S, Tandri H, Te Riele ASJM, Thiene G, Tsatsopoulou A, Zareba W, Zorzi A,
Wichter T, Marcus FI, Calkins H. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur
Heart J 2020;41:14141429.
379. Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation 2017;136:20682082.
380. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A,
Bourfiss M, Fortier A, Lie ØH, Saguner AM, Svensson A, Andorin A, Tichnell C,
Murray B, Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn
AD, Talajic M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge
DP, Yap S-C, van der Heijden JF, Tandri H, Jongbloed JDH, Guertin M-C, van
Tintelen JP, Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins
H, te Riele ASJM, James CA. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.
Eur
Heart
J
2019;40:18501858.
381. Maupain C, Badenco N, Pousset F, Waintraub X, Duthoit G, Chastre T,
Himbert C, Hebert J-L, Frank R, Hidden-Lucet F, Gandjbakhch E. Risk stratification in arrhythmogenic right ventricular cardiomyopathy/dysplasia without an implantable cardioverter-defibrillator. JACC Clin Electrophysiol 2018;4:757768.
382. Kirchhof P, Fabritz L, Zwiener M, Witt H, Schafers M, Zellerhoff S, Paul M,
Athai T, Hiller K-H, Baba HA, Breithardt G, Ruiz P, Wichter T, Levkau B. Ageand training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice.
Circulation
2006;114:17991806.
383. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif J-C, Brugada J,
Nattel S, Mont L. Cardiac arrhythmogenic remodeling in a rat model of longterm intensive exercise training. Circulation 2011;123:1322.
384. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ,
Judge DP, Calkins H. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62:12901297.
385. Ruwald A-C, Marcus F, Estes NAM 3rd, Link M, McNitt S, Polonsky B, Calkins
H, Towbin JA, Moss AJ, Zareba W. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopath.
Eur
Heart
J
2015;36:17351743.
386. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith H-J,
Ribe M, Holst AG, Edvardsen T, Haugaa KH. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members.
Eur
J
Heart
Fail
2014;16:13371344.
387. Sawant AC, Bhonsale A, te Riele ASJM, Tichnell C, Murray B, Russell SD,
Tandri H, Tedford RJ, Judge DP, Calkins H, James CA. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/
cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc
2014;3:e001471.
388. Lie OH, Dejgaard LA, Saberniak J, Rootwelt C, Stokke MK, Edvardsen T,
Haugaa KH. Harmful effects of exercise intensity and exercise duration in patients with arrhythmogenic cardiomyopathy.
JACC
Clin
Electrophysiol
2018;4:744753.
389. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M,
Calkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL,
Zipes DP, Berul CI, Cheng A, Law I, Loomis M, Barth C, Brandt C, Dziura J, Li
F, Cannom D. Safety of sports for athletes with implantable cardioverterdefibrillators:
results of a
prospective,
multinational registry.
Circulation
2013;127:20212030.
390. Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, Roguin A, Tichnell C,
James C, Russell SD, Judge DP, Abraham T, Spevak PJ, Bluemke DA, Calkins H.
Arrhythmogenic right ventricular dysplasia: a
United
States experience.
Circulation 2005;112:38233832.
391. Gupta R, Tichnell C, Murray B, Rizzo S, Te Riele A, Tandri H, Judge DP, Thiene
G, Basso C, Calkins H, James CA. Comparison of features of fatal versus nonfatal cardiac arrest in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol 2017;120:111117.
392. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward
D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NAM
3rd, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/
dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 2010;122:11441152.
393. Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, Kamel
IR, Zimmerman SL, Judge DP, Crosson J, Tandri H, Calkins H. Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular dysplasia/
cardiomyopathy: predictors of appropriate therapy, outcomes, and complications. J Am Heart Assoc 2017;6.
394. Sadjadieh G, Jabbari R, Risgaard B, Olesen MS, Haunso S, Tfelt-Hansen J,
Winkel BG. Nationwide (Denmark) study of symptoms preceding sudden death due to arrhythmogenic right ventricular cardiomyopathy.
Am
J
Cardiol
2014;113:12501254.
395. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D,
Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll
Cardiol 2011;58:14851496.
396. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, Marcus F, Estes
NAM 3rd. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. J Am Coll Cardiol
2014;64:119125.
397. Piccini JP, Dalal D, Roguin A, Bomma C, Cheng A, Prakasa K, Dong J, Tichnell
C, James C, Russell S, Crosson J, Berger RD, Marine JE, Tomaselli G, Calkins H.
Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. Heart Rhythm 2005;2:11881194.
398. Saguner AM, Vecchiati A, Baldinger SH, Rueger S, Medeiros-Domingo A,
Mueller-Burri AS, Haegeli LM, Biaggi P, Manka R, Luscher TF, Fontaine G,
Delacretaz E, Jenni R, Held L, Brunckhorst C, Duru F, Tanner FC. Different prognostic value of functional right ventricular parameters in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Circ
Cardiovasc
Imaging
2014;7:230239.
399. Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TDT,
Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Bocker D.
Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation 2004;109:15031508.
400. Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E, Migliore F,
Marra MP, Lorenzon A, De Bortoli M, Calore M, Nava A, Daliento L, Gregori
D, Iliceto S, Thiene G, Basso C, Corrado D. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ
Cardiovasc Genet 2013;6:533542.
401. Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical diagnosis,
imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:784804.
402. Merner ND, Hodgkinson KA, Haywood AFM, Connors S, French VM,
Drenckhahn J-D, Kupprion C, Ramadanova K, Thierfelder L, McKenna W,
Gallagher
B,
Morris-Larkin
L,
Bassett
AS,
Parfrey
PS,
Young
T-L.
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant,
lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene.
Am J Hum Genet 2008;82:809821.
403. Dhutia H, Malhotra A, Yeo TJ, Ster IC, Gabus V, Steriotis A, Dores H, Mellor
G, Garcıa-Corrales C, Ensam B, Jayalapan V, Ezzat VA, Finocchiaro G, Gati S,
Papadakis M, Tome-Esteban M, Sharma S. Inter-rater reliability and downstream financial implications of electrocardiography screening in young athletes. Circ
Cardiovasc Qual Outcomes 2017;10:e003881.
404. Gati S, Rajani R, Carr-White GS, Chambers JB. Adult left ventricular noncompaction: reappraisal of current diagnostic imaging modalities. JACC Cardiovasc
Imaging 2014;7:12661275.
405. Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF, Ghani S, Sheikh
N, Zaidi A, Wilson M, Papadakis M, Carre´ F, Sharma S. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes? Heart 2013;99:401408.
406. Gati S, Papadakis M, Papamichael ND, Zaidi A, Sheikh N, Reed M, Sharma R,
Thilaganathan B, Sharma S. Reversible de novo left ventricular trabeculations in pregnant women: implications for the diagnosis of left ventricular noncompaction in low-risk populations. Circulation 2014;130:475483.
407. Zemrak F, Ahlman MA, Captur G, Mohiddin SA, Kawel-Boehm N, Prince MR,
Moon JC, Hundley WG, Lima JAC, Bluemke DA, Petersen SE. The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5year follow-up: the MESA study. J Am Coll Cardiol 2014;64:19711980.
408. Caselli S, Ferreira D, Kanawati E, Di Paolo F, Pisicchio C, Attenhofer Jost C,
Spataro A, Jenni R, Pelliccia A. Prominent left ventricular trabeculations in competitive athletes: a proposal for risk stratification and management. Int J Cardiol
2016;223:590595.
409. Caselli S, Attenhofer Jost CH, Jenni R, Pelliccia A. Left ventricular noncompaction diagnosis and management relevant to pre-participation screening of athletes. Am J Cardiol 2015;116:801808.


<!-- PAGE 75 -->

### Page 75

.............................................................................................................................................................................
410. Gati S, Merghani A, Sharma S. Increased left ventricular trabeculation does not necessarily equate to left ventricular noncompaction in athletes. JAMA Intern
Med 2015;175:1247.
411. Gati S, Sharma S. The dilemmas in diagnosing left ventricular non-compaction in athletes. Eur Heart J 2015;36:891893.
412. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, Duboc D,
Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli
G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S,
Zamorano JL, Caforio ALP, Charron P. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016;37:18501858.
413. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP,
Edvardsen T, Haugaa KH. Lamin A/C cardiomyopathy: young onset, high penetrance,
and frequent need for heart transplantation.
Eur
Heart
J
2018;39:853860.
414. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent
V, Padron-Barthe L, Duro-Aguado I, Jimenez-Jaimez J, Hidalgo-Olivares VM,
Garcia-Campo E, Lanzillo C, Suarez-Mier MP, Yonath H, Marcos-Alonso S,
Ochoa JP, Santome JL, Garcia-Giustiniani D, Rodriguez-Garrido JL, Dominguez
F, Merlo M, Palomino J, Pena ML, Trujillo JP, Martin-Vila A, Stolfo D, Molina P,
Lara-Pezzi E, Calvo-Iglesias FE, Nof E, Calo L, Barriales-Villa R, Gimeno-Blanes
JR, Arad M, Garcia-Pavia P, Monserrat L. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll
Cardiol 2016;68:24402451.
415. Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future.
Circulation 2017;136:215231.
416. Holloway CJ, Dass S, Suttie JJ, Rider OJ, Cox P, Cochlin LE, Jackson H, Fast AM,
Johnson AW, Karamitsos TD, Neubauer S, Clarke K. Exercise training in dilated cardiomyopathy improves rest and stress cardiac function without changes in cardiac high energy phosphate metabolism. Heart 2012;98:10831090.
417. Stolen KQ, Kemppainen J, Ukkonen H, Kalliokoski KK, Luotolahti M, Lehikoinen
P, Hamalainen H, Salo T, Airaksinen KEJ, Nuutila P, Knuuti J. Exercise training improves biventricular oxidative metabolism and left ventricular efficiency in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:460467.
418. Harmon KG, Drezner JA, Maleszewski JJ, Lopez-Anderson M, Owens D,
Prutkin JM, Asif IM, Klossner D, Ackerman MJ. Pathogeneses of sudden cardiac death in national collegiate athletic association athletes.
Circ
Arrhythm
Electrophysiol 2014;7:198204.
419. Claessen G, Schnell F, Bogaert J, Claeys M, Pattyn N, De Buck F, Dymarkowski
S, Claus P, Carre F, Van Cleemput J, La Gerche A, Heidbuchel H. Exercise cardiac magnetic resonance to differentiate athlete’s heart from structural heart disease. Eur Heart J Cardiovasc Imaging 2018;19:10621070.
420. Millar LM, Fanton Z, Finocchiaro G, Sanchez-Fernandez G, Dhutia H, Malhotra
A, Merghani A, Papadakis M, Behr ER, Bunce N, Oxborough D, Reed M,
O’Driscoll J, Tome Esteban MT, D’Silva A, Carr-White G, Webb J, Sharma R,
Sharma S. Differentiation between athlete’s heart and dilated cardiomyopathy in athletic individuals. Heart 2020;106:10591065.
421. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown
TDH, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y,
O’Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR,
Assomull RG, Pennell DJ, Prasad SK. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.
JAMA 2013;309:896908.
422. Neilan TG, Coelho-Filho OR, Danik SB, Shah RV, Dodson JA, Verdini DJ,
Tokuda M, Daly CA, Tedrow UB, Stevenson WG, Jerosch-Herold M,
Ghoshhajra BB, Kwong RY. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc
Imaging 2013;6:944954.
423. Masci PG, Doulaptsis C, Bertella E, Del Torto A, Symons R, Pontone G,
Barison A, Droogne W, Andreini D, Lorenzoni V, Gripari P, Mushtaq S, Emdin
M, Bogaert J, Lombardi M. Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure.
Circ Heart Fail 2014;7:448456.
424. Perazzolo Marra M, De Lazzari M, Zorzi A, Migliore F, Zilio F, Calore C, Vettor
G, Tona F, Tarantini G, Cacciavillani L, Corbetti F, Giorgi B, Miotto D, Thiene
G, Basso C, Iliceto S, Corrado D. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm
2014;11:856863.
425. Cattin M-E, Ferry A, Vignaud A, Mougenot N, Jacquet A, Wahbi K, Bertrand
AT, Bonne G. Mutation in lamin A/C sensitizes the myocardium to exerciseinduced mechanical stress but has no effect on skeletal muscles in mouse.
Neuromuscul Disord 2016;26:490499.
426. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, Mannarino S,
Gambarin F, Favalli V, Grasso M, Agozzino M, Campana C, Gavazzi A, Febo O,
Marini M, Landolina M, Mortara A, Piccolo G, Vigano M, Tavazzi L, Arbustini E.
Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am
Coll Cardiol 2008;52:12501260.
427. Skjølsvik ET, Hasselberg NE, Dejgaard LA, Lie ØH, Andersen K, Holm T,
Edvardsen T, Haugaa KH. Exercise is associated with impaired left ventricular systolic function in patients with lamin A/C genotype. J Am Heart Assoc
2020;9:e012937.
428. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal J-M, Androulakis AFA,
Waintraub X, Charron P, Rollin A, Richard P, Stevenson WG, Macintyre CJ, Ho
CY, Thompson T, Vohra JK, Kalman JM, Zeppenfeld K, Sacher F, Tedrow UB,
Lakdawala NK. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/
C mutation carriers. J Am Coll Cardiol 2016;68:22992307.
429. van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Pilotto A, Pasotti M, Jenkins S,
Rowland C, Aslam U, Wilde AAM, Perrot A, Pankuweit S, Zwinderman AH,
Charron P, Pinto YM. Risk factors for malignant ventricular arrhythmias in lamin
A/C
mutation carriers:
a
European cohort study.
J
Am
Coll
Cardiol
2012;59:493500.
430. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu
M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W,
Mogensen J, Pinto YM, Ristic A, Schultheiss H-P, Seggewiss H, Tavazzi L, Thiene
G, Yilmaz A, Charron P, Elliott PM. Current state of knowledge on aetiology,
diagnosis, management, and therapy of myocarditis: a position statement of the
European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2013;34:26362648.
431. Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bartunek J, Merlo M.
Myocarditis in clinical practice. Mayo Clin Proc 2016;91:12561266.
432. Breinholt JP, Moulik M, Dreyer WJ, Denfield SW, Kim JJ, Jefferies JL, Rossano
JW, Gates CM, Clunie SK, Bowles KR, Kearney DL, Bowles NE, Towbin JA.
Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant 2010;29:739746.
433. Yilmaz A, Klingel K, Kandolf R, Sechtem U. A geographical mystery: do cardiotropic viruses respect national borders? J Am Coll Cardiol 2008;52:82; author reply 8283.
434. Magnani JW, Danik HJS, Dec GWJ, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J 2006;151:463470.
435. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I
associated with myocarditis. Experimental and clinical correlates. Circulation
1997;95:163168.
436. Morgera T, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, Silvestri F,
Chersevani D, Camerini F. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J
1992;124:455467.
437. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, Camerini F.
Echocardiographic findings in myocarditis. Am J Cardiol 1988;62:285291.
438. Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A,
Carturan E, Iliceto S, Thiene G, Daliento L. A prospective study of biopsyproven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:13261333.
439. Schnell F, Claessen G, La Gerche A, Bogaert J, Lentz P-A, Claus P, Mabo P,
Carre F, Heidbuchel H. Subepicardial delayed gadolinium enhancement in asymptomatic athletes: let sleeping dogs lie? Br J Sports Med 2016;50:111117.
440. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT,
White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy J-P, Paterson I,
Filipchuk NG, Kumar A, Pauschinger M, Liu P. Cardiovascular magnetic resonance in myocarditis:
a
JACC
white paper.
J
Am
Coll
Cardiol
2009;53:14751487.
441. Radenkovic D, Weingartner S, Ricketts L, Moon JC, Captur G. T1 mapping in cardiac MRI. Heart Fail Rev 2017;22:415430.
442. Nadjiri J, Nieberler H, Hendrich E, Greiser A, Will A, Martinoff S, Hadamitzky
M. Performance of native and contrast-enhanced T1 mapping to detect myocardial damage in patients with suspected myocarditis: a head-to-head comparison of different cardiovascular magnetic resonance techniques. Int J Cardiovasc
Imaging 2017;33:539547.
443. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe
A, Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra
M, Barison A, Di Bella G. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study. J Am Coll
Cardiol 2017;70:19771987.
444. Mewton N, Dernis A, Bresson D, Zouaghi O, Croisille P, Flocard E, Douek P,
Bonnefoy-Cudraz E. Myocardial biomarkers and delayed enhanced cardiac
ESC Guidelines
91


<!-- PAGE 76 -->

### Page 76

.............................................................................................................................................................................
magnetic resonance relationship in clinically suspected myocarditis and insight on clinical outcome. J Cardiovasc Med (Hagerstown) 2015;16:696703.
445. Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert E-M,
Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Long-term followup of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012;59:16041615.
446. Schumm J, Greulich S, Wagner A, Grun S, Ong P, Bentz K, Klingel K, Kandolf R,
Bruder O, Schneider S, Sechtem U, Mahrholdt H. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J
Cardiovasc Magn Reson 2014;16:14.
447. van de Schoor FR, Aengevaeren VL, Hopman MTE, Oxborough DL, George
KP, Thompson PD, Eijsvogels TMH. Myocardial fibrosis in athletes. Mayo Clin
Proc 2016;91:16171631.
448. Ammirati E, Moroni F, Sormani P, Peritore A, Milazzo A, Quattrocchi G,
Cipriani M, Oliva F, Giannattasio C, Frigerio M, Roghi A, Camici PG, Pedrotti P.
Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. Int J Cardiol 2017;231:216221.
449. Gr€ani C, Eichhorn C, Bie`re L, Kaneko K, Murthy VL, Agarwal V, Aghayev A,
Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY. Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis. J Cardiovasc
Magn Reson 2019;21:14.
450. Matthias H, Alexander N, Uwe K, Michel N, Wolfgang P, Wolfgang H, Andreas
M, Bernhard W, Carsten T, Heinz-Peter S, Matthias P. Complication rate of right ventricular endomyocardial biopsy via the femoral approach. Circulation
2008;118:17221728.
451. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A,
Hill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Bohm M,
Sechtem U. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation
2010;122:900909.
452. Cooper LTJ, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC,
Menon S, Mullen GM, Jaski B, Bailey KR,, Cunningham MW, Dec GW.
Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol
2008;102:15351539.
453. Bohm P, Scharhag J, Meyer T. Data from a nationwide registry on sportsrelated sudden cardiac deaths in Germany. Eur J Prev Cardiol 2016;23:649656.
454. Phillips M, Robinowitz M, Higgins JR, Boran KJ, Reed T, Virmani R. Sudden cardiac death in Air Force recruits. A 20-year review. JAMA 1986;256:26962699.
455. Kiel RJ, Smith FE, Chason J, Khatib R, Reyes MP. Coxsackievirus B3 myocarditis in C3H/HeJ mice: description of an inbred model and the effect of exercise on virulence. Eur J Epidemiol 1989;5:348350.
456. Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the virulence of murine
Coxsackie-virus
B-3
myocardiopathy by exercise.
J
Exp
Med
1970;131:11211136.
457. Ilback NG, Fohlman J, Friman G. Exercise in Coxsackie B3 myocarditis: effects on heart lymphocyte subpopulations and the inflammatory reaction. Am Heart J
1989;117:12981302.
458. Cabinian AE, Kiel RJ, Smith F, Ho KL, Khatib R, Reyes MP. Modification of exercise-aggravated Coxsackie virus B3 murine myocarditis by T lymphocyte suppression in an inbred model. J Lab Clin Med 1990;115:454462.
459. Pelliccia A, Corrado D, Bjornstad HH, Panhuyzen-Goedkoop N, Urhausen A,
Carre F, Anastasakis A, Vanhees L, Arbustini E, Priori S. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil
2006;13:876885.
460. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM
3rd, Cooper LTJ, Link MS, Maron MS. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force
3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. A scientific statement from the American Heart Association and American College of Cardiology.
Circulation 2015;132:e273280.
461. Gati S, Sharma S, Pennell D. The role of cardiovascular magnetic resonance imaging in the assessment of highly trained athletes. JACC Cardiovasc Imaging
2018;11:13271339.
462. Enrico A, Manlio C, Claudio M, Claudia R, Daniela P, Paola S, Riccardo M,
Marisa V, Patrizia P, Cristina C, Antonio M, Aurelia G, Daniele B, Silvia G, PG
B., Stefania C, CS I., Cristina G, Alberto M, Valentina C, Marco M, Carlo L,
Jeness C, Piergiuseppe A, Giovanni P, Laura S, Annalisa T, Giuseppe DT, Carlo
C, Armando B, Fabrizio M, Andrea M, Antonio C, Michele S, Antonello G,
Maria F, Fabrizio O, CP G., null null. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis.
Circulation
2018;138:10881099.
463. Alessandro Z, Martina PM, Ilaria R, Manuel DL, Angela S, Alice N, Kalliopi P,
Federico M, Stefania R, Benedetta G, Giorgio DC, Patrizio S, Luis S, Giampiero
P, Elia DM, Antonio P, Cristina B, Maurizio S, Barbara B, Sabino I, Gaetano T,
Domenico C. Nonischemic left ventricular scar as a substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. Circ
Arrhythmia Electrophysiol 2016;9:e004229.
464. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, Salvi A,
Perkan A, Di Lenarda A, Bussani R, Bartunek J, Sinagra G. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation
2013;128:23842394.
465. Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA 2015;314:14981506.
466. Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation 2010;121:916928.
467. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, La Gerche A,
Niebauer J, Pressler A, Schmied CM, Serratosa L, Halle M, Van Buuren F,
Borjesson M, Carre` F, Panhuyzen-Goedkoop NM, Heidbuchel H, Olivotto I,
Corrado D, Sinagra G, Sharma S. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis,
and pericarditis: position statement of the Sport Cardiology Section of the
European
Association of
Preventive
Cardiology
(EAPC).
Eur
Heart
J
2018;40:1933.
468. La Gerche A, Robberecht C, Kuiperi C, Nuyens D, Willems R, de Ravel T,
Matthijs G, Heidbuchel H. Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventricular origin. Heart 2010;96:12681274.
469. Heidbuchel H. The athlete’s heart is a proarrhythmic heart, and what that means for clinical decision making. EP Europace 2018;20:14011411.
470. Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease? J Am Coll Cardiol
2017;69:19681982.
471. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study.
Circulation 2008;118:800807.
472. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J,
Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns H,
Van Gelder IC IR. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the
RACE 3 trial. Eur Hear J 2018;39:29872996.
473. Elliott AD, Maatman B, Emery MS, Sanders P. The role of exercise in atrial fibrillation prevention and promotion: finding optimal ranges for health. Heart
Rhythm 2017;14:17131720.
474. Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K,
Sundstrom J. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 2013;34:36243631.
475. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009;103:15721577.
476. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical activity and incidence of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol
2014;177:467476.
477. La Gerche A, Schmied CM. Atrial fibrillation in athletes and the interplay between exercise and health. Eur Heart J 2013;34:35993602.
478. Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E, Brugada J,
Marrugat J. Sport practice and the risk of lone atrial fibrillation: a case-control study. Int J Cardiol 2006;108:332337.
479. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, Pare C, Azqueta
M, Sanz G. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J
2002;23:477482.
480. Heidbuchel H, Anne W, Willems R, Adriaenssens B, Van de Werf F, Ector H.
Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. Int J Cardiol 2006;107:6772.
481. Morseth B, Graff-Iversen S, Jacobsen BK, Jorgensen L, Nyrnes A, Thelle DS,
Vestergaard P, Lochen M-L. Physical activity, resting heart rate, and atrial fibrillation: the Tromso Study. Eur Heart J 2016;37:23072313.
482. Kawabata M, Hirao K, Horikawa T, Suzuki K, Motokawa K, Suzuki F, Azegami K,
Hiejima K. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. J Electrocardiol 2001;34:6572.
483. Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Terrier de la Chaise A,
Louis P. Predictors of atrial flutter with 1: 1 conduction in patients treated with class
I
antiarrhythmic drugs for atrial tachyarrhythmias.
Int
J
Cardiol
2001;80:715.
484. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari
M, Solano A, Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the
“pill-in-the-pocket”
approach.
N
Engl
J
Med
2004;351:23842391.
485. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,
Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron
Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R,


<!-- PAGE 77 -->

### Page 77

.............................................................................................................................................................................
Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B,
Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J,
Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P,
Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL,
Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with
EACTS.
Eur
J
Cardiothorac
Surg
2016;50:e1e88.
486. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler
KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R,
Camm AJ, Heidbuchel H. The 2018 European Heart Rhythm Association
Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:13301393.
487. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, Akar JG,
Badhwar V, Brugada J, Camm J, Chen P-S, Chen S-A, Chung MK, Nielsen JC,
Curtis AB, Davies DW, Day JD, d’Avila A, de Groot NMSN, Di Biase L,
Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G,
Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM,
Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R,
Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF,
Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E,
Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao H-M, Verma
A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart
Rhythm 2017;14:e275e444.
488. Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M,
Andreu D, Vidal B, Sitges M, Brugada J. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes.
Europace
2010;12:3036.
489. Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L,
Alzand B, Willems R, Heidbuchel H. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace 2011;13:13861393.
490. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. EP Europace
2009;11:11561159.
491. Sorbo MD, Buja GF, Miorelli M, Nistri S, Perrone C, Manca S, Grasso F,
Giordano GM, Nava A. [The prevalence of the Wolff-Parkinson-White syndrome in a
population of
116,542
young males].
G
Ital
Cardiol
1995;25:681687.
492. Sano S, Komori S, Amano T, Kohno I, Ishihara T, Sawanobori T, Ijiri H, Tamura
K. Prevalence of ventricular preexcitation in Japanese schoolchildren. Heart
1998;79:374378.
493. Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A,
Wellens HJ. Aborted sudden death in the Wolff-Parkinson-White syndrome.
Am J Cardiol 1995;76:492494.
494. Waxman MB, Wald RW, Sharma AD, Huerta F, Cameron DA. Vagal techniques for termination of paroxysmal supraventricular tachycardia. Am J Cardiol
1980;46:655664.
495. Miljoen H, Ector J, Garweg C, Saenen J, Huybrechts W, Sarkozy A, Willems R
HH. Differential presentation of AV nodal reentrant tachycardia in athletes and non-athletes. EP Europace 2019;21:944949.
496. Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes
AC, Yee R, Gula LJ, Klein GJ. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation:
a meta-analysis.
Circulation
2012;125:23082315.
497. Wellens HJ, Rodriguez LM, Timmermans C, Smeets JP. The asymptomatic patient with the
Wolff-Parkinson-White electrocardiogram.
Pacing
Clin
Electrophysiol 1997;20:20822086.
498. Gaita F, Giustetto C, Riccardi R, Mangiardi L, Brusca A. Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. Am J Cardiol 1989;64:487490.
499. Pappone C, Manguso F, Santinelli R, Vicedomini G, Sala S, Paglino G, Mazzone
P, Lang CC, Gulletta S, Augello G, Santinelli O, Santinelli V. Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome. N
Engl J Med 2004;351:11971205.
500. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C,
Calkins H, Corrado D, Deftereos SG, Diller G-P, Gomez-Doblas JJ, Gorenek B,
Grace A, Ho SY, Kaski J-C, Kuck K-H, Lambiase PD, Sacher F, SarquellaBrugada G, Suwalski P, Zaza A. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of
Cardiology (ESC). Eur Heart J 2019;41:655720.
501. Bjornstad H, Storstein L, Meen HD, Hals O. Ambulatory electrocardiographic findings in top athletes, athletic students and control subjects. Cardiology
1994;84:4250.
502. Zorzi A, Mastella G, Cipriani A, Berton G, Del Monte A, Gusella B, Nese A,
Portolan L, Sciacca F, Tikvina S, Tollot S, Trovato D, Iliceto S, Schiavon M,
Corrado D. Burden of ventricular arrhythmias at 12-lead 24-hour ambulatory
ECG monitoring in middle-aged endurance athletes versus sedentary controls.
Eur J Prev Cardiol 2018;25:20032011.
503. Biffi A, Pelliccia A, Verdile L, Fernando F, Spataro A, Caselli S, Santini M, Maron
BJ. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol 2002;40:446452.
504. Palatini P, Maraglino G, Sperti G, Calzavara A, Libardoni M, Pessina AC, Dal
Palu C. Prevalence and possible mechanisms of ventricular arrhythmias in athletes. Am Heart J 1985;110:560567.
505. Lee V, Perera D, Lambiase P. Prognostic significance of exercise-induced premature ventricular complexes: a systematic review and meta-analysis of observational studies. Heart Asia 2017;9:1424.
506. Lin C-Y, Chang S-L, Chung F-P, Chen Y-Y, Lin Y-J, Lo L-W, Hu Y-F, Tuan T-C,
Chao T-F, Liao J-N, Chang Y-T, Lin C-H, Allamsetty S, Walia R, Te ALD,
Yamada S, Chiang S-J, Tsao H-M, Chen S-A. Long-term outcome of nonsustained ventricular tachycardia in structurally normal hearts. PLoS One
2016;11:e0160181.
507. Hutchinson MD, Garcia FC. An organized approach to the localization, mapping, and ablation of outflow tract ventricular arrhythmias. J Cardiovasc
Electrophysiol 2013;24:11891197.
508. Luebbert J, Auberson D, Marchlinski F. Premature ventricular complexes in apparently normal hearts. Card Electrophysiol Clin 2016;8:503514.
509. Haissaguerre M, Nademanee K, Hocini M, Cheniti G, Duchateau J, Frontera A,
Sacher F, Derval N, Denis A, Pambrun T, Dubois R, Jais P, Benoist D, Walton
RD, Nogami A, Coronel R, Potse M, Bernus O. Depolarization versus repolarization abnormality underlying inferolateral J-wave syndromes: new concepts in sudden cardiac death with apparently normal hearts.
Heart
Rhythm
2019;16:781790.
510. Leenhardt A, Glaser E, Burguera M, Nurnberg M, Maison-Blanche P, Coumel P.
Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias.
Circulation
1994;89:206215.
511. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB,
Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill
SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017
AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm
2018;15:e190e252.
512. Latchamsetty R, Bogun F. Premature ventricular complexes and premature ventricular complex induced cardiomyopathy.
Curr
Probl
Cardiol
2015;40:379422.
513. Morshedi-Meibodi A, Evans JC, Levy D, Larson MG, Vasan RS. Clinical correlates and prognostic significance of exercise-induced ventricular premature beats in the community:
the
Framingham
Heart
Study.
Circulation
2004;109:24172422.
514. Selzman KA, Gettes LS. Exercise-induced premature ventricular beats: should we do anything differently? Circulation 2004;109:23742375.
515. Zorzi A, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A,
Pilichou K, Migliore F, Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L,
Patrizi G, De Maria E, Pelliccia A, Basso C, Schiavon M, Bauce B, Iliceto S,
Thiene G, Corrado D. Nonischemic left ventricular scar as a substrate of lifethreatening ventricular arrhythmias and sudden cardiac death in competitive athletes.
Circ
Arrhythm
Electrophysiol
2016;9:e004229.
doi:
10.1161/
CIRCEP.116.004229. Originally published July 7, 2016.
516. Cipriani A, Zorzi A, Sarto P, Donini M, Rigato I, Bariani R, De Lazzari M,
Pilichou K, Thiene G, Iliceto S, Basso C, Corrado D, Perazzolo Marra M, Bauce
B. Predictive value of exercise testing in athletes with ventricular ectopy evaluated by cardiac magnetic resonance. Heart Rhythm 2019;16:239248.
517. Gimeno JR, Tome-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B,
Lambiase P, McKenna WJ, Elliott PM. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Eur Heart J 2009;30:25992605.
518. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M,
DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FES, Vignati G, Benatar
A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:6974.
519. Heidbuchel H, Hoogsteen J, Fagard R, Vanhees L, Ector H, Willems R, Van
Lierde J. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. Eur Heart J 2003;24:14731480.
520. Sofi F, Capalbo A, Pucci N, Giuliattini J, Condino F, Alessandri F, Abbate R,
Gensini GF, Califano S. Cardiovascular evaluation, including resting and exercise electrocardiography, before participation in competitive sports: cross sectional study. BMJ 2008;337:a346.
ESC Guidelines
93


<!-- PAGE 78 -->

### Page 78

.............................................................................................................................................................................
521. Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen O-G, Fruh
A, Edvardsen T, Kongsgard E, Leren TP, Amlie JP. High prevalence of exerciseinduced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
Europace 2010;12:417423.
522. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, La
Gerche A, Ackerman MJ, Borjesson M, Salerno JC, Asif IM, Owens DS, Chung
EH, Emery MS, Froelicher VF, Heidbuchel H, Adamuz C, Asplund CA, Cohen
G, Harmon KG, Marek JC, Molossi S, Niebauer J, Pelto HF, Perez MV, Riding
NR, Saarel T, Schmied CM, Shipon DM, Stein R, Vetter VL, Pelliccia A, Corrado
D. International recommendations for electrocardiographic interpretation in athletes. Eur Heart J 2018;39:14661480.
523. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini
A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:18661874.
524. Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin
M, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ,
Wilde AA, Krahn AD. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands.
Circulation 2011;124:21872194.
525. Chandra N, Bastiaenen R, Papadakis M, Panoulas VF, Ghani S, Duschl J, Foldes
D, Raju H, Osborne R, Sharma S. Prevalence of electrocardiographic anomalies in young individuals: relevance to a nationwide cardiac screening program. J Am
Coll Cardiol 2014;63:20282034.
526. Basavarajaiah S, Wilson M, Whyte G, Shah A, Behr E, Sharma S. Prevalence and significance of an isolated long QT interval in elite athletes. Eur Heart J
2007;28:29442949.
527. Johnson JN, Ackerman MJ. Return to play? Athletes with congenital long QT
syndrome. Br J Sports Med 2013;47:2833.
528. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C,
Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink
P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V,
Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann
MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.
Circulation 2001;103:8995.
529. Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J 2013;34:31093116.
530. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, Crotti L,
Piippo K, Lupoglazoff J-M, Villain E, Priori SG, Napolitano C, Zhang L. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment
“failures”. Circulation 2009;119:215221.
531. Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task
Force 10: The cardiac channelopathies: a scientific statement from the
American Heart Association and American College of Cardiology. Circulation
2015;132:e3269.
532. Drezner JA, Rogers KJ. Sudden cardiac arrest in intercollegiate athletes: detailed analysis and outcomes of resuscitation in nine cases.
Heart
Rhythm
2006;3:755759.
533. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:13911396.
534. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present status of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol
2018;72:10461059.
535. Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, Sanna T,
Bellocci F, Russo MA. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation 2005;112:36803687.
536. Frustaci A, Russo MA, Chimenti C. Structural myocardial abnormalities in asymptomatic family members with Brugada syndrome and SCN5A gene mutation. Eur Heart J 2009;30:1763.
537. Catalano O, Antonaci S, Moro G, Mussida M, Frascaroli M, Baldi M, Cobelli F,
Baiardi P, Nastoli J, Bloise R, Monteforte N, Napolitano C, Priori SG. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. Eur Heart J 2009;30:22412248.
538. van Hoorn F, Campian ME, Spijkerboer A, Blom MT, Planken RN, van Rossum
AC, de Bakker JMT, Wilde AAM, Groenink M,, Tan HL. SCN5A mutations in
Brugada syndrome are associated with increased cardiac dimensions and reduced contractility. PLoS One 2012;7:e42037.
539. Baranchuk A, Nguyen T, Ryu MH, Femenia F, Zareba W, Wilde AAM, Shimizu
W, Brugada P, Perez-Riera AR. Brugada phenocopy: new terminology and proposed classification. Ann Noninvasive Electrocardiol 2012;17:299314.
540. Bayes de Luna A, Brugada J, Baranchuk A, Borggrefe M, Breithardt G,
Goldwasser D, Lambiase P, Riera AP, Garcia-Niebla J, Pastore C, Oreto G,
McKenna W, Zareba W, Brugada R, Brugada P. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol
2012;45:433442.
541. Chockalingam P, Rammeloo LA, Postema PG, Hruda J, Clur S-AB, Blom NA,
Wilde AA. Fever-induced life-threatening arrhythmias in children harboring an
SCN5A mutation. Pediatrics 2011;127:e239e244. doi: 10.1542/peds.2010-1688.
542. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with
Brugada syndrome. J Am Coll Cardiol 1996;27:10611070.
543. Mizumaki K, Fujiki A, Tsuneda T, Sakabe M, Nishida K, Sugao M, Inoue H. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004;15:667673.
544. Matsuo K, Kurita T, Inagaki M, Kakishita M, Aihara N, Shimizu W, Taguchi A,
Suyama K, Kamakura S, Shimomura K. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J
1999;20:465470.
545. Probst V, Denjoy I, Meregalli PG, Amirault J-C, Sacher F, Mansourati J, Babuty
D, Villain E, Victor J, Schott J-J, Lupoglazoff J-M, Mabo P, Veltmann C, Jesel L,
Chevalier P, Clur S-AB, Haissaguerre M, Wolpert C, Le Marec H, Wilde AAM.
Clinical aspects and prognosis of Brugada syndrome in children. Circulation
2007;115:20422048.
546. Takigawa M, Noda T, Shimizu W, Miyamoto K, Okamura H, Satomi K, Suyama
K, Aihara N, Kamakura S, Kurita T. Seasonal and circadian distributions of ventricular fibrillation in patients with
Brugada syndrome.
Heart
Rhythm
2008;5:15231527.
547. Michowitz Y, Milman A, Sarquella-Brugada G, Andorin A, Champagne J,
Postema PG, Casado-Arroyo R, Leshem E, Juang JJM, Giustetto C, Tfelt-Hansen
J, Wijeyeratne YD, Veltmann C, Corrado D, Kim S-H, Delise P, Maeda S,
Gourraud J-B, Sacher F, Mabo P, Takahashi Y, Kamakura T, Aiba T, Conte G,
Hochstadt A, Mizusawa Y, Rahkovich M, Arbelo E, Huang Z, Denjoy I,
Napolitano C, Brugada R, Calo L, Priori SG, Takagi M, Behr ER, Gaita F, Yan GX, Brugada J, Leenhardt A, Wilde AAM, Brugada P, Kusano KF, Hirao K, Nam
G-B, Probst V, Belhassen B. Fever-related arrhythmic events in the multicenter survey on arrhythmic events in
Brugada syndrome.
Heart
Rhythm
2018;15:13941401.
548. Rossenbacker T, Carroll SJ, Liu H, Kuiperi C, de Ravel TJL, Devriendt K,
Carmeliet P, Kass RS, Heidbuchel H. Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and
Brugada syndrome to sudden cardiac death. Heart Rhythm 2004;1:610615.
549. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, Shoda M,
Toyoshima Y, Hosoda S. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease.
Circulation
1997;95:22772285.
550. Arai Y, Saul JP, Albrecht P, Hartley LH, Lilly LS, Cohen RJ, Colucci WS.
Modulation of cardiac autonomic activity during and immediately after exercise.
Am J Physiol 1989;256:H13241.
551. Smith ML, Hudson DL, Graitzer HM, Raven PB. Exercise training bradycardia:
the role of autonomic balance. Med Sci Sports Exerc 1989;21:4044.
552. Deharo JC, Bongiorni MG, Rozkovec A, Bracke F, Defaye P, Fernandez-Lozano
I, Golzio PG, Hansky B, Kennergren C, Manolis AS, Mitkowski P, Platou ES.
Pathways for training and accreditation for transvenous lead extraction: a
European
Heart
Rhythm
Association position paper.
Europace
2012;14:124134.
553. Lamas GA, Keefe JM. The effects of equitation (horseback riding) on a motion responsive DDDR pacemaker. Pacing Clin Electrophysiol 1990;13:
13711373.
554. Deering JA, Pederson DN. Pacemaker lead fracture associated with weightlifting: a report of two cases. Mil Med 1993;158:833834.
555. Gould L, Betzu R, Taddeo M, Judge JD, Lee J. Pulse generator failure due to blunt trauma. Clin Cardiol 1988;11:581582.
556. Grieco JG, Scanlon PJ, Pifarre R. Pacing lead fracture after a deceleration injury.
Ann Thorac Surg 1989;47:453454.
557. Schuger CD, Mittleman R, Habbal B, Wagshal A, Huang SK. Ventricular lead transection and atrial lead damage in a young softball player shortly after the insertion of a
permanent pacemaker.
Pacing
Clin
Electrophysiol
1992;15:12361239.
558. Altun A, Erdogan O. Pacemaker lead failure suggestive of crush injury. Cardiol
Rev 2003;11:256.
559. Noble SL, Burri H, Sunthorn H. Complete section of pacemaker lead due to subclavian crush. Med J Aust 2005;182:643.
560. Exner DV, Rothschild JM, Heal S, Gillis AM. Unipolar sensing in contemporary pacemakers: using myopotential testing to define optimal sensitivity settings. J
Interv Card Electrophysiol 1998;2:3340.
561. Jain P, Kaul U, Wasir HS. Myopotential inhibition of unipolar demand pacemakers: utility of provocative manoeuvres in assessment and management. Int J
Cardiol 1992;34:3339.


<!-- PAGE 79 -->

### Page 79

.............................................................................................................................................................................
562. Heidbuchel H, Willems R, Jordaens L, Olshansky B, Carre F, Fernandez Lozano
I, Wilhelm M, Mussigbrodt A, Huybrechts W, Morgan J, Anfinsen OG, Prior D,
Mont L, Mairesse GH, Boveda S, Duru F, Kautzner J, Viskin S, Geelen P,
Cygankiewicz I, Hoffman E, Vanden LR. Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: results from the
European cohort. Eur J Prev Cardiol 2019;26:764775.
563. Barry MJ, Edgman-Levitan S. Shared decision making  pinnacle of patientcentered care. N Engl J Med 2012;366:780781.
564. Rahman B, Macciocca I, Sahhar M, Kamberi S, Connell V, Duncan RE.
Adolescents with implantable cardioverter defibrillators: a patient and parent perspective. Pacing Clin Electrophysiol 2012;35:6272.
565. Olshansky B, Atteya G, Cannom D, Heidbuchel H, Saarel EV, Anfinsen O-G,
Cheng A, Gold MR, Mussigbrodt A, Patton KK, Saxon LA, Wilkoff BL, Willems
R, Dziura J, Li F, Brandt C, Simone L, Wilhelm M, Lampert R. Competitive athletes with implantable cardioverter-defibrillators  how to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. Heart Rhythm
2019;16:581587.
566. Auricchio A, Schloss EJ, Kurita T, Meijer A, Gerritse B, Zweibel S, AlSmadi FM,
Leng CT, Sterns LD. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms:
PainFree
SST
trial primary results.
Heart
Rhythm
2015;12:926936.
567. Theuns DAMJ, Brouwer TF, Jones PW, Allavatam V, Donnelley S, Auricchio A,
Knops RE, Burke MC. Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2018;15:15151522.
568. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, te Riele ASJM, Judge
DP, Tandri H, Calkins H. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2013;10:16611668.
569. Zeitler EP, Sanders GD, Singh K, Greenfield RA, Gillis AM, Wilkoff BL, Piccini
JP, Al-Khatib SM. Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. Europace
2018;20:16211629.
570. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J,
Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Estes
NAM 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz
JL, Keegan R, Kolb C, Kuck K-H, Marinskis G, Martinelli M, Mcguire M, Molina
LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS,
Uribe W, Viskin S, Wang C-C, Zhang S. 2015 HRS/EHRA/APHRS/SOLAECE
expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. EP Europace 2016;18:159183.
571. Sinha A-M, Stellbrink C, Schuchert A, Mox B, Jordaens L, Lamaison D, Gill J,
Kaplan A, Merkely B. Clinical experience with a new detection algorithm for differentiation of supraventricular from ventricular tachycardia in a dual-chamber defibrillator. J Cardiovasc Electrophysiol 2004;15:646652.
572. Deisenhofer I, Kolb C, Ndrepepa G, Schreieck J, Karch M, Schmieder S,
Zrenner B, Schmitt C. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc
Electrophysiol 2001;12:134142.
573. van der Linde D, Konings EEM, Slager MA, Witsenburg M, Helbing WA,
Takkenberg JJM, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol
2011;58:22412247.
574. Longmuir PE, Brothers JA, de Ferranti SD, Hayman LL, Van Hare GF, Matherne
GP, Davis CK, Joy EA, McCrindle BW. Promotion of physical activity for children and adults with congenital heart disease: a scientific statement from the
American Heart Association. Circulation 2013;127:21472159.
575. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M.
Lifetime prevalence of congenital heart disease in the general population from
2000 to 2010. Circulation 2014;130:749756.
576. Inuzuka R, Diller G-P, Borgia F, Benson L, Tay ELW, Alonso-Gonzalez R, Silva
M, Charalambides M, Swan L, Dimopoulos K, Gatzoulis MA. Comprehensive use of cardiopulmonary exercise testing identifies adults with congenital heart disease at increased mortality risk in the medium term.
Circulation
2012;125:250259.
577. Pelliccia A, Adami PE, Quattrini F, Squeo MR, Caselli S, Verdile L, Maestrini V,
Di Paolo F, Pisicchio C, Ciardo R, Spataro A. Are Olympic athletes free from cardiovascular diseases? Systematic investigation in 2352 participants from
Athens 2004 to Sochi 2014. Br J Sports Med 2017;51:238243.
578. Pierpont ME, Basson CT, Benson DWJ, Gelb BD, Giglia TM, Goldmuntz E,
McGee G, Sable CA, Srivastava D, Webb CL. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart
Association Congenital Cardiac Defects Committee, Council on Cardiovascular
Disease in the Young. Circulation 2007;115:30153038.
579. Correia
JD,
da
Rosa
EB,
Silveira
DB,
Grapiglia
CG,
Canabarro
ST,
Waterkemper R, Zen PRG, Rosa RFM. Major extracardic malformations among patients with congenital heart defects. Int J Cardiol 2016;214:154156.
580. Lui GK, Saidi A, Bhatt AB, Burchill LJ, Deen JF, Earing MG, Gewitz M, Ginns J,
Kay JD, Kim YY, Kovacs AH, Krieger EV, Wu FM, Yoo S-J. Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the
American
Heart
Association.
Circulation
2017;136:e348e392.
581. Hacker A-L, Oberhoffer R, Hager A, Ewert P, Muller J. Age-related cardiovascular risk in adult patients with congenital heart disease.
Int
J
Cardiol
2019;277:9096.
582. Giannakoulas G, Ntiloudi D. Acquired cardiovascular disease in adult patients with congenital heart disease. Heart 2018;104:546547.
583. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, Budts
W, Zwinderman AH, Van Gelder IC, Mulder BJM. Sudden cardiac death in adult congenital heart disease. Circulation 2012;126:19441954.
584. Zomer AC, Vaartjes I, Uiterwaal CSPM, van der Velde ET, van den Merkhof
LFM, Baur LHB, Ansink TJM, Cozijnsen L, Pieper PG, Meijboom FJ, Grobbee
DE, Mulder BJM. Circumstances of death in adult congenital heart disease. Int J
Cardiol 2012;154:168172.
585. Scanlan S. Shaun White’s biggest fans are the ones that share his heart condition. USA Today, 2018. https://eu.usatoday.com/story/sports/olympics/2018/02/
13/shaun-whites-biggest-fans-ones-share-his-heart-condition/333985002/.
586. Lynge TH, Jeppesen AG, Winkel BG, Glinge C, Schmidt MR, Sondergaard L,
Risgaard B, Tfelt-Hansen J. Nationwide study of sudden cardiac death in people with congenital heart defects aged 0 to 35 years. Circ Arrhythm Electrophysiol
2018;11:e005757.
587. Tutarel O, Gabriel H, Diller G-P. Exercise: friend or foe in adult congenital heart disease? Curr Cardiol Rep 2013;15:416.
588. van Dissel AC, Blok IM, Hooglugt J-LQ, de Haan FH, Jorstad HT, Mulder BJM,
Bouma BJ, Winter MM. Safety and effectiveness of home-based, self-selected exercise training in symptomatic adults with congenital heart disease: a prospective, randomised, controlled trial. Int J Cardiol 2019;278:5964.
589. Eijsvogels TMH, Thompson PD, Franklin BA. The “extreme exercise hypothesis”: recent findings and cardiovascular health implications. Curr Treat Options
Cardiovasc Med 2018;20:84.
590. Kim JH, Baggish AL. Strenuous exercise and cardiovascular disease outcomes.
Curr Atheroscler Rep 2017;19:1.
591. Dua JS, Cooper AR, Fox KR, Graham Stuart A. Exercise training in adults with congenital heart disease: feasibility and benefits. Int J Cardiol 2010;138:
196205.
592. Duppen N, Takken T, Hopman MTE, ten Harkel ADJ, Dulfer K, Utens EMWJ,
Helbing WA. Systematic review of the effects of physical exercise training programmes in children and young adults with congenital heart disease. Int J Cardiol
2013;168:17791787.
593. Cordina RL, O’Meagher S, Karmali A, Rae CL, Liess C, Kemp GJ, Puranik R,
Singh N, Celermajer DS. Resistance training improves cardiac output, exercise capacity and tolerance to positive airway pressure in Fontan physiology. Int J
Cardiol 2013;168:780788.
594. Duppen N, Etnel JR, Spaans L, Takken T, van den Berg-Emons RJ, Boersma E,
Schokking M, Dulfer K, Utens EM, Helbing W, Hopman MT. Does exercise training improve cardiopulmonary fitness and daily physical activity in children and young adults with corrected tetralogy of Fallot or Fontan circulation? A
randomized controlled trial. Am Heart J 2015;170:606614.
595. Chaix M-A, Marcotte F, Dore A, Mongeon F-P, Mondesert B, Mercier L-A,
Khairy P. Risks and benefits of exercise training in adults with congenital heart disease. Can J Cardiol 2016;32:459466.
596. Muller J, Amberger T, Berg A, Goeder D, Remmele J, Oberhoffer R, Ewert P,
Hager A. Physical activity in adults with congenital heart disease and associations with functional outcomes. Heart 2017;103:11171121.
597. Budts W, Borjesson M, Chessa M, van Buuren F, Trigo Trindade P, Corrado D,
Heidbuchel H, Webb G, Holm J, Papadakis M. Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription.
Eur Heart J 2013;34:36693674.
598. Takken T, Giardini A, Reybrouck T, Gewillig M, Hovels-Gurich HH, Longmuir
PE, McCrindle BW, Paridon SM, Hager A. Recommendations for physical activity, recreation sport, and exercise training in paediatric patients with congenital heart disease: a report from the Exercise, Basic & Translational Research
Section of the European Association of Cardiovascular Prevention. Eur J Prev
Cardiol 2012;19:10341065.
599. Muscogiuri G, Secinaro A, Ciliberti P, Fuqua M, Nutting A. Utility of cardiac magnetic resonance imaging in the management of adult congenital heart disease. J Thorac Imaging 2017;32:233244.
600. Sparrow P, Merchant N, Provost Y, Doyle D, Nguyen E, Paul N. Cardiac MRI
and CT features of inheritable and congenital conditions associated with sudden cardiac death. Eur Radiol 2009;19:259270.
ESC Guidelines
95


<!-- PAGE 80 -->

### Page 80

..........................................................................................................
601. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka
M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913.
602. Moller T, Brun H, Fredriksen PM, Holmstrom H, Pettersen E, Thaulow E. Moderate altitude increases right ventricular pressure and oxygen desaturation in adolescents with surgically closed septal defect. Congenit Heart Dis 2010;5:556564.
603. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J
2009;34:888894.
604. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J,
Coghlan G, Kaye N, Oxborough D, Robinson S, Sandoval J, Rana BS, Siva A,
Nihoyannopoulos P, Howard LS, Fox K, Bhattacharyya S, Sharma V, Steeds RP,
Mathew T. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Res Pract
2018;5:G11G24.
605. Galie N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G,
Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA,
Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA,
Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J
2016;37:67119.
606. Muller J, Heck PB, Ewert P, Hager A. Noninvasive screening for pulmonary hypertension by exercise testing in congenital heart disease. Ann Thorac Surg
2017;103:15441549.
607. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 2014;35:691700.
608. Grunig E, Eichstaedt C, Barbera J-A, Benjamin N, Blanco I, Bossone E, Cittadini
A, Coghlan G, Corris P, D’Alto M, D’Andrea A, Delcroix M, de Man F, Gaine S,
Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jureviciene E, Kiely DG,
Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R,
Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S,
Vonk Noordegraaf A, Peacock AJ. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. Eur Respir J
2019;53:1800332.
609. Kuijpers JM, Koolbergen DR, Groenink M, Boekholdt SM, Meijboom FJ,
Jongbloed MRM, Hoendermis ES, Duijnhouwer AL, Mulder BJM, Bouma BJ.
Aortic dissection and prophylactic surgery in congenital heart disease. Int J
Cardiol 2019;274:113116.
610. Zhao Q, Shi K, Yang Z-G, Diao K-Y, Xu H-Y, Liu X, Guo Y-K. Predictors of aortic dilation in patients with coarctation of the aorta: evaluation with dualsource computed tomography. BMC Cardiovasc Disord 2018;18:124.
611. Loomba RS, Buelow MW, Aggarwal S, Arora RR, Kovach J, Ginde S.
Arrhythmias in adults with congenital heart disease: what are risk factors for specific arrhythmias? Pacing Clin Electrophysiol 2017;40:353361.
612. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, Daniels CJ,
Deal BJ, Dearani JA, Groot N de, Dubin AM, Harris L, Janousek J, Kanter RJ,
Karpawich PP, Perry JC, Seslar SP, Shah MJ, Silka MJ, Triedman JK, Walsh EP,
Warnes CA. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the
Pediatric and
Congenital
Electrophysiology
Society (PACES) and the Heart Rhythm Society (HRS). Can J Cardiol
2014;30:e1e63.
613. Diller G-P, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS,
Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis
MA. Exercise intolerance in adult congenital heart disease: comparative severity,
correlates,
and prognostic implication.
Circulation
2005;112:
828835.
614. Mantegazza V, Apostolo A, Hager A. Cardiopulmonary exercise testing in adult congenital heart disease. Ann Am Thorac Soc 2017;14:S93S101.
615. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil
Med 1970;2:9298.
616. Kempny A, Dimopoulos K, Uebing A, Moceri P, Swan L, Gatzoulis MA, Diller
G-P. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life  single centre experience and review of published data. Eur Heart J 2012;33:13861396.
617. d’Udekem Y. Cardiorespiratory fitness, not the severity of the condition, dictates late outcomes after
Fontan procedures.
J
Am
Coll
Cardiol
2017;69:27452747.
618. Evangelista A, Flachskampf FA, Erbel R, Antonini-Canterin F, Vlachopoulos C,
Rocchi G, Sicari R, Nihoyannopoulos P, Zamorano J, Pepi M, Breithardt O-A,
Plonska-Gosciniak E. Echocardiography in aortic diseases: EAE recommendations for clinical practice. Eur J Echocardiogr 2010;11:645658.
619. Ait Ali L, Pingitore A, Piaggi P, Brucini F, Passera M, Marotta M, Cadoni A,
Passino C, Catapano G, Festa P. Respiratory training late after Fontan intervention:
impact on cardiorespiratory performance.
Pediatr
Cardiol
2018;39:695704.
620. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996;276:199204.
621. Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF. Demographics and epidemiology of sudden deaths in young competitive athletes: from the United
States National Registry. Am J Med 2016;129:11701177.
622. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH,
Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall
WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry.
Circulation 1998;97:22372244.
623. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
JAMA 1993;270:25902597.
